<SEC-DOCUMENT>0000950170-22-004721.txt : 20220328
<SEC-HEADER>0000950170-22-004721.hdr.sgml : 20220328
<ACCEPTANCE-DATETIME>20220328074736
ACCESSION NUMBER:		0000950170-22-004721
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		107
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220328
DATE AS OF CHANGE:		20220328

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tango Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001819133
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39485
		FILM NUMBER:		22773212

	BUSINESS ADDRESS:	
		STREET 1:		100 BINNEY ST
		STREET 2:		SUITE 700
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		(857) 320-4900

	MAIL ADDRESS:	
		STREET 1:		100 BINNEY ST
		STREET 2:		SUITE 700
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BCTG Acquisition Corp.
		DATE OF NAME CHANGE:	20200723
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>tngx-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2022-03-28T06:44:58.2834+00:00 --><!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:tngx="http://www.tangotx.com/20211231" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_9ce82792-73b0-4614-be7e-852d5e09b293" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_8431d889-009a-406d-91d5-381ea4e8cc14">P1Y</ix:nonNumeric><ix:nonNumeric id="F_0d45bf5a-7214-4f2c-834c-80c05c0d1717" name="dei:AmendmentFlag" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82">false</ix:nonNumeric><ix:nonNumeric id="F_0efe7b5a-fdb1-48a8-a6db-c093dd913725" name="dei:EntityCentralIndexKey" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82">0001819133</ix:nonNumeric><ix:nonNumeric id="F_399dcbb6-a750-40fe-933f-1801b0071147" name="dei:DocumentFiscalPeriodFocus" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82">FY</ix:nonNumeric><ix:nonFraction id="F_589030a1-b1fe-41c2-9818-779e165f6c4e" name="us-gaap:CommitmentsAndContingencies" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_2d6d8938-d6e5-45f5-9e08-f42fea8356b9" name="us-gaap:RestrictedCashCurrent" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_0b637d1f-640c-496c-91b4-be2bae95b9b9" name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="C_3461b9bd-5e6d-4357-91f1-01033ae50263" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_ef89b0d7-d3bc-47bb-b18c-a3ef93b3d967" name="us-gaap:CommitmentsAndContingencies" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_a762df4b-f3ed-4d4a-a408-0c28875d2805" name="us-gaap:MoneyMarketFundsAtCarryingValue" contextRef="C_298c6bea-143e-4985-beea-3b429f7512a4" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_ee97281b-b16a-45ae-9ceb-0f63f2818525" name="dei:CurrentFiscalYearEndDate" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82">--12-31</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="tngx-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_eb62df54-f0e0-4a6d-9c99-33f08d82c127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBTrancheTwoRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce1e3322-9b6b-477f-bd0a-0c49d4aedd8b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b3962309-cf85-4622-8558-52f8101a1c1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tngx:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_acbb8224-ebbe-4c79-b11c-d87062900529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_088edbda-4c95-4fa9-9856-74af91d7facd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c17d0f8f-c6ae-43cd-9b51-09d002c47c3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_42c26e7c-eca8-426f-9a02-4c53841db8ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b6540ba0-6a70-4698-835b-62e3f28a76b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tngx:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16173712-f7d9-4b40-a745-785b1fd272f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:AmendedGileadAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d04e6201-772a-4ebf-bcb7-57256a6b7980"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e935a51c-44f5-45c0-8969-0acd3c8dce51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8431d889-009a-406d-91d5-381ea4e8cc14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:HundredBinneyStreetInCambridgeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f0761b4f-fae1-40c4-a58b-8ac4939b226c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBCommonSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02f13488-10b7-4401-9968-07685eb9a45e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesACommonSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bbbc1247-505e-469d-9e7c-232824266da5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4e0ebfbb-6d60-400e-82c5-2271bdc193d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">tngx:SpecifiedRegulatoryAndSalesMilestonesForGeneticContextMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tngx:AgreementAxis">tngx:MedivirAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_96e2833b-b37d-4d45-9d0e-e469973ab162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7736b799-fc9e-41cb-ac3c-ebefeef52eb3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:GileadAgreementBasedPerformanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tngx:LicenseRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3461b9bd-5e6d-4357-91f1-01033ae50263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe8c0009-60fd-45e6-bf12-78e38e33e502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a34864eb-c999-4a01-906e-ed6300c59215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d340cce-d3f4-48f6-8dc7-031a8c6e1628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBCommonSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-06</xbrli:startDate><xbrli:endDate>2020-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0494c044-9ff9-41c2-8ddb-c0be1c1a2795"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">tngx:ResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e188203d-bb78-4e16-8893-867ab9986a87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tngx:PublicSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-08</xbrli:startDate><xbrli:endDate>2020-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9157c232-bd25-4b99-8aaa-53493f84a8b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-10</xbrli:startDate><xbrli:endDate>2021-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b5f7538f-2233-432c-8332-5f9eee3f4625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:TwoThousandAndEighteenGileadAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_84b473ca-21a7-4595-869a-d3b15476e2cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e025e6fe-ae40-47de-b624-610d8a25ba64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tngx:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c5112e96-b096-400a-8231-13c5db592e8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tngx:MergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-13</xbrli:startDate><xbrli:endDate>2021-04-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_13789a54-6583-461f-ace8-50d596a0d9e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62d30997-cb59-4c36-9293-3ab9037d2139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d31393e-af6d-4a5d-92ee-02bb00706dea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tngx:BctgAcquisitionCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_43fb107b-c6af-4569-9ee5-f77bf1f34285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBOneRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_53e4d63e-21a6-43e4-9dcd-522040ca6553"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:TwoThousandAndEighteenGileadAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1f668a19-d708-4382-b6de-856bbfb1c08d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d651794e-8630-4ab5-a33f-7df95e076d4e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_afd5c297-0100-4e5c-a1d4-238c915c6ebd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tngx:TangoTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7055bdf6-8d9f-4ea6-913c-d9194c0435b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0c877e59-744f-49bd-b36b-26c23781fc80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-08</xbrli:startDate><xbrli:endDate>2020-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c46a5787-04cc-4ee6-8232-98fef420c001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-08</xbrli:startDate><xbrli:endDate>2020-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_764718f8-db6b-4222-a924-e17f308b9e1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_36f9a5bb-51f4-4c4c-a4a4-483900a01305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7d2bf4c6-5a88-4f48-9b87-0040ef400364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f301ea89-3456-4254-8f42-f5814959d712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tngx:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b961f57f-cd1e-4000-be3a-575c1acb8245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:HundredBinneyStreetInCambridgeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ff6e5760-462e-48b4-9885-3a1afb5a7028"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:AmendedGileadAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f01892b3-15ca-4460-8be5-0c673db5d09c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:HundredBinneyStreetInCambridgeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cf54194b-5ca8-4902-bc7c-8ad279e05960"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_102b7845-9bed-440d-ab31-e9a0c961e54f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesB1CommonSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23d38092-0393-490f-b401-5d223a840f61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f993a7f8-4d25-4be9-b713-6bb38ecf342b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_54d3a1d3-953e-4a0b-ad72-8cc7769a4e4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesACommonSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5bbc6677-f9f3-4cc3-b8fc-b7c1ac21c7d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_90016151-b8de-4c70-b40c-6a6565310359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_215089d0-d271-4311-98aa-2b60bca282f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesACommonSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ddf3c437-2a6f-4dfd-a511-55b637ea608a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_31658d1c-3873-4646-a06e-c5e4358d9429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e5ec8fe-aded-4985-ba52-0a77d0cc933c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:AmendedGileadAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_637f6044-163f-4ffe-baaa-808b1b634223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tngx:TangoTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-10</xbrli:startDate><xbrli:endDate>2021-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2ac7ee07-3d73-4617-8ee2-9f9c91ec3957"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d0e1ab2-5dfb-47e6-a9e8-b49f9f14bd25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2097a9ea-7fc6-47b9-9264-c5cfd08007fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_22555df1-4efe-4a08-bb1c-08f931ec7211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1efa7be9-29eb-4c8a-a7b7-04a5517b4c9c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBOneRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_511b1fab-19fa-4719-9e1a-7d2d78a9c251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:GileadAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46942445-32c3-4ade-9ca0-aa6a6b83839a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:HundredBinneyStreetInCambridgeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_709432d5-f52b-4cb9-a494-7b1bae2706a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201912Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_19df7953-ecc1-48a3-9c5b-5d80830b8fdb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tngx:TwoThousandAndTwentyOnePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c89c0bd3-61fe-4fe1-aaf8-04c333eb7930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3a91db9e-6734-413e-8e17-66bb5d8bf9ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cba5ebca-4842-4066-b09c-3a3e8776378b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:TheTwoHundredAndOneBrooklineAvenueLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b638cb65-3908-4aeb-bd7c-94437b4d77af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_44358ddc-7505-46e1-8119-f33db1fa516a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_27037302-4c51-4ed7-bedc-d4aef3c65de1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tngx:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:GileadAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2065fc3b-bae5-4c9b-8a8a-012ebcce2f51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02d11875-4147-4360-a8aa-e87bfd6290ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:HundredBinneyStreetInCambridgeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f6d997d2-d3a1-431e-a764-711fd76bb4c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c96d2de7-cf25-4b3d-9e34-1a5c2b302481"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBTrancheOneRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f0aee49e-cda1-49dc-bfc8-ca8549516a0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:TwoThousandAndEighteenGileadAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1788c8d9-b2a8-41ee-b8fb-f1e5436c41eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:AmendedGileadAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBOnePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9943303c-4c93-4a64-a1b1-6e1c309ffbd6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBTrancheTwoRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a373566-cfe9-4a8d-b52b-3ba1ff5a8bdc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_42915faf-8358-4b14-8b2d-d0e8b545540d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3c3e34d-cd50-4fb1-a2a9-829d2a4cfdc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBTrancheOneRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9325e76a-6e44-41b8-9985-b303b44f8869"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:HundredBinneyStreetInCambridgeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_541297f2-8d87-4855-8f1c-53e1e755ed5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c0c8b2a4-7004-44a5-89e9-321b90380e0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tngx:BctgAcquisitionCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-11</xbrli:startDate><xbrli:endDate>2021-08-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f8e74028-ee7b-40aa-bbb2-cc9236784ca2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a15ceae-2bb5-42b0-a18d-a0d58154057d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBOneRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_75a3203a-e21d-4b7a-bf56-5007b4cfa6c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:HundredBinneyStreetInCambridgeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cca1c772-6eb6-4c26-835c-7b92064cf842"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2a1ab7b1-38dd-41eb-9f72-c6425108c827"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fcb0c4a1-8080-44f5-9e53-5ea3f5e568e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5b4da818-3aaf-49ee-92af-9ab384f7fb73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tngx:RestrictedCommonStockAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dbf730ab-1e1d-4b66-831b-495fa57b10da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tngx:MergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-10</xbrli:startDate><xbrli:endDate>2021-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_278d8753-1cb2-473c-a8e0-50755d56d579"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_06dcd5da-541e-4c79-b858-c0104fee1630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:TheTwoHundredAndOneBrooklineAvenueLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5a4c4d12-3d56-4c37-9a9a-c58a9b3e58b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b17588f4-eb89-4f86-9706-bd7d2b333a9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tngx:AgreementAxis">tngx:MedivirAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_34a6b51f-9398-4a33-b000-f084738ed301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tngx:TwoThousandAndTwentyOnePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cab846a0-8d37-4a4b-ae82-af6adf0f78e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tngx:RestrictedCommonStockAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c15c2969-e6e9-437c-89f0-0a388a5877e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_91ba7dc3-6470-42de-a194-06f0b8e6a25d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tngx:AgreementAxis">tngx:HitgenAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4c74beb2-4bb1-4873-8bda-4048130ed6a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tngx:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6a066c6-0c2f-4fc7-b6b0-b827d92388ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c11f77a-567b-409b-b802-3c267191840f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee85dddd-830e-4471-966a-17bed0f1923f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ae71f40f-3665-48a2-9117-946f426ce1db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tngx:FoundersAndAdvisorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tngx:RestrictedCommonStockAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_407a2f79-30e9-41df-8dfa-8788fa29b7cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fc96726e-aa67-4543-82fb-ba75a0a854df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4dbe3a85-64de-49a0-bef8-5deb3b1b9ca7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7aee73e0-1a70-49bf-b3fe-767d20ffc569"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:HundredBinneyStreetInCambridgeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a669c96-a649-4a8a-b346-1cb396dbfc42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9229ee0f-56b0-498f-a9f5-422119379b39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50f18cbc-9bd3-450e-8121-9d1f8276ed3c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28c70236-1fd3-49b1-a137-9ccf19f5d150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4cfd2b0e-b7d6-48f4-ace9-bcb7b07f4adc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBOneRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_355ebba5-ee81-4e5b-b3ac-c79944317418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9c964121-e164-4d55-976f-d2ed2a2c4cf3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesACommonSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a752877b-c28d-4699-ba2c-e36a1efb2376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:AmendedGileadAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5dd62d57-3336-4d82-b4cc-8df9199613af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tngx:RestrictedCommonStockAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_adf61d0e-b654-4419-b270-224361ec9e78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_654a4524-3c9b-448c-a88c-7c276a239270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aa1ca7f9-0b3a-4f12-96b6-45a3b58f76db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">tngx:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cb1f4de9-e84a-4dfa-b4b7-550c176b4251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a908a175-5b6c-474d-a2f6-5ae2b7895667"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_68e2d926-73f9-4065-8798-88999cfc5071"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10b1dfb3-7e3e-4852-85ed-49f7cb670c71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_48837b32-a7ba-4536-82fb-eeef4e91837e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c654669a-ad97-4deb-8c23-e8cf0a2ed78f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_edcd82c0-9d7d-49ac-abb2-37406bcefb72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">tngx:SpecifiedClinicalMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tngx:AgreementAxis">tngx:MedivirAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bec60272-dcf8-4c0e-bcea-ea6c80078013"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBCommonSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f2607f6a-532b-425d-bef1-6f23ecb3ca7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:AmendedGileadAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_19209eb4-ef67-4899-926b-0331243cd6b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d621dea-8b02-473e-8bc5-76032a18426e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d8f1f3f0-246b-4352-862d-987a0d66c18f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tngx:LicenseRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5a10696c-6f1a-45a5-9a37-ea3703aed7cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_42860419-a9e3-4801-beb1-962b31b7feab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:HundredBinneyStreetInCambridgeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_50520bd5-264f-47a4-b3f4-8fbfc12d12ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:HundredBinneyStreetInCambridgeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_292501bc-d852-43e2-83eb-a3fe171ce656"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4fb87c77-49f5-455c-a642-6e57e4c31b2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_37b91a95-e41f-4fd5-94cf-030951f28c96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tngx:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_babc5d15-ca37-4230-bde3-b6ec0c32b755"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:HundredBinneyStreetInCambridgeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_58f962d5-8219-4b47-8029-390de4ce2191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe7f16a9-c541-41d8-939f-8739b8cdc7e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:AmendedGileadAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2a0dabb0-2512-43fe-b76a-9eb289d5c030"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:AmendedGileadAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_08368de2-8657-4cb0-a2d6-6c41c8497c13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ecff8a34-7794-4031-8fce-96f60d31dc7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tngx:BctgAcquisitionCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ab502c57-9eb1-4c1e-b776-cac4cbc580eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">tngx:SpecifiedRegulatoryApprovalAndSalesMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="tngx:AgreementAxis">tngx:MedivirAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86fa47f4-0478-4603-9095-4af7a4e6165d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9ce5d825-ac92-4a7e-80e6-cb453f08db17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBCommonSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a3730188-5277-496a-8a25-6d10f45c0e37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_568bffaa-6246-4bbc-8efb-5c5ca93b43f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tngx:MergerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e9180ff9-f174-4296-94c6-215c9a213af5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:AmendedGileadAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a1ba7f84-139b-48f6-aaf0-8e1842c93c6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesB1CommonSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-16</xbrli:startDate><xbrli:endDate>2020-08-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_939c93ab-b292-4ae8-9554-f6d1ea202292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBOnePreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_39540783-7152-4a82-98d0-fe1bcc069278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_274ae3eb-6528-4797-924a-99295d4ce141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_33f11eaf-355a-47f4-a2b2-89b65a3ddda0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-08</xbrli:startDate><xbrli:endDate>2020-09-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4b6a86ef-4245-48e0-8889-4c4163bca1a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_77f3de9c-11d0-45e7-b744-00f10cdd56b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1cb9353-41dd-47bf-b30c-2b16642be52c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1745945-8454-47c6-9623-cbfd040e27d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7b2e605f-e833-48d9-925e-ef6e94396041"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_767a7086-7e98-4669-a6a3-ba4e0f1c5fc1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_934e45d0-2851-4e4a-848b-28c197e06283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e7c0cdf-ecd0-49cb-bcb4-d8123eab2f15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tngx:BctgBusinessCombinationAndPipeFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d122636a-689d-4ab0-b872-bae54aeb140c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tngx:TwoThousandAndTwentyOnePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97c1afc9-4f65-4a11-89cf-32bdc6c820ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_46657909-6cf1-47fc-8643-1f04c29704bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">tngx:ResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_27a26b8d-6763-4206-ad2e-220eddc0e107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a1adf0bb-c238-43d9-ba7a-df912e357f96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_322de39d-6bc1-437f-9811-2ddb0203f034"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tngx:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bee96a77-f86f-42a4-a0c1-11fced7670fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a921be2-dfdf-4ce8-8e66-04b6835527ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tngx:BctgBusinessCombinationAndPipeFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ce0aba6c-cd66-4a8d-9e8d-6cfea6fd49bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea92a304-c585-4deb-947b-651b75dbc182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-11</xbrli:startDate><xbrli:endDate>2021-08-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1c301094-2824-489c-bf63-ea4093ace32f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:HundredBinneyStreetInCambridgeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10e2e047-49ac-448b-9f30-e2610064f1ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_23df1860-e6dc-439c-b62d-1e850c67c5c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:AmendedGileadAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_068a6be4-9f16-496f-98c5-0d1f32f3787e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_04267f13-0c83-44a3-836a-4da5571814a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aefe6aea-0fcf-40c7-a8cb-fa9395426cc3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tngx:BctgTrustAccountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_369296b3-0383-4744-8c6b-7b140def6872"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tngx:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c887ec60-971a-4690-a982-03a761ebe233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_34cc5401-52f8-4cad-9b24-31c1f9fae295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">tngx:ResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8312ce29-e29e-402c-b364-5d664fa10451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tngx:BctgAcquisitionCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-10</xbrli:startDate><xbrli:endDate>2021-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12217c4f-04a9-422a-9151-5c1ab378d58e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tngx:RestrictedCommonStockAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_443492d4-1dcb-460f-9785-b7dc5f094e40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c73c0fe0-50a5-469f-988c-1cd417a6095d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c520f9bc-41be-4b8e-a264-4f675e8eec11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tngx:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1561790-aba2-4710-8ff9-2107c95bfddb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d558a274-44e2-47f9-ba78-6254302f1b82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_282b9328-036d-4123-bd3c-893d0d979dbc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_539c3823-b618-476a-9106-5362f015288f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tngx:AgreementAxis">tngx:HitgenAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eafdff08-f1e7-45e0-b53f-598f4991a9f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:GileadLetterAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tngx:LicenseRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_79ee2c85-0407-439c-899d-6ad699fae605"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201815Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12c81343-6906-4a1c-8cc1-2e51478b9b44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesB1CommonSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2a0457d3-f3a5-4a7b-982f-ab2cbc2377f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cf39d22f-09b3-4d53-87d3-8d7dc1f67897"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:GileadAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ee792758-9f05-4175-9451-5b418924373a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tngx:CollaborationRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:GileadAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_df7e4b79-2a16-44a2-844e-a0a5c357c1b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tngx:BctgBusinessCombinationAndPipeFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ca4a9ca6-a360-4a08-9af0-9f6ec20dc073"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="tngx:AgreementAxis">tngx:MedivirAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_89ff1d64-5c59-4fe4-b302-72f7ae4dcbe5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:TwoThousandAndEighteenGileadAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_298c6bea-143e-4985-beea-3b429f7512a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc1dd469-9b82-45a6-89fd-03f80ff198f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_af91c863-9582-40c7-8c3d-51a5ac90d570"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0bd03243-27c2-444e-894b-d4ebc2dc9598"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8b242d70-f5a0-401d-9c7c-8f5525429c2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:ComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b25831a-e551-4e81-9130-6ba7264df810"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesB1CommonSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28f5ff88-be03-44d4-a0e8-fd39586ab708"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d451c16b-ca67-4909-afea-ed3cd220991d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tngx:BctgAcquisitionCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f25b4a33-16a9-486a-8c10-2233f7ee8a8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4941cdcd-9899-46a1-b43b-5fcbeb247365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_50e1ee41-b3b0-4fe2-b580-591e5b4ec3aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fdf14edc-6cd9-4108-8f54-a48f0e34f4c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_758f7c30-6f5d-40eb-bfbc-5d756f87d621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a530332-b4e5-472d-a36a-9992e15ee630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tngx:LicenseRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d6f8304a-f49a-468d-abae-98d9b92542a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:TheTwoHundredAndOneBrooklineAvenueLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8de344bc-88b0-4716-8a86-20e32b63eab2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a8a40a2-67af-41ac-a7da-247f61928fb4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:HundredBinneyStreetInCambridgeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-01</xbrli:startDate><xbrli:endDate>2017-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1018e487-acae-48dc-9a83-1bc597615eb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_165d6390-156d-4d13-94be-fad709b50c15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819133</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201813Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_Program"><xbrli:measure>tngx:Program</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>tngx:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_Milestone"><xbrli:measure>tngx:Milestone</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="border-top:2.250pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;">UNITED STATES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Washington, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">FORM </span><span style="font-size:18.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ba7b0cb5-45aa-4540-bea3-b985518e48d7" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> (Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fff4b08f-eda0-4a49-a1fc-eb24cbc2a230" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">For the fiscal year ended </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9122552a-02bc-4d75-b171-b1db30791f35" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">December 31, </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_66bc9990-a96a-470c-abbd-b2a081b8c718" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2021</span></ix:nonNumeric></span><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">OR</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_671c08ba-7325-465c-bd59-300fae09e21b" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:3.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">                     </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Commission File Number </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a5a4800f-ed18-4847-a7df-44c897dba5b2" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">001-39485</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:22.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1bb1c4ce-499b-4c90-8266-dfed10de8c3c" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:22.0pt;font-family:Times New Roman;">TANGO THERAPEUTICS, INC.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:22.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(Exact name of Registrant as specified in its Charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_47df2ec2-1e57-4ccb-81a1-faec27c93238" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d0836344-2143-4371-b621-5b8ca18dc53f" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">85-1195036</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b73bacbf-e265-43d7-82e5-169a6e6f4101" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">100 Binney St.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7d3d55f7-bc0d-4a64-83df-a5c97e64da4f" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Suite 700</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8aae4df2-c46b-4da8-a872-840a3539eaad" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cambridge</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_609f8dbb-64f3-4496-a8c0-3aa1175e9558" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:EntityAddressStateOrProvince"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">MA</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8abec050-c84a-4457-8b84-8a56f45b6b65" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">02142</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Registrant&#x2019;s telephone number, including area code: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_00098317-f604-42ba-b30d-4268539d340b" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">857</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">) </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dcfce07e-3eba-448d-868e-34216f0d6d65" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">320-4900</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:38.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Trading</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4874aff7-7b6d-4d6b-8cb1-e8da016cc682" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock, par value $0.001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cf7a0fcf-3f9b-4d00-8cd0-cc2879611e3f" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">TNGX</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_08f3de99-c093-48ab-82a1-cbf41afa9973" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">None</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES &#9744;     </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9f2739cb-05a1-4f90-a237-ed5f75db590e" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">N</span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">o</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  YES &#9744;     </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c452ca3d-201c-4da0-9ef0-eabc17456642" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">N</span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">o</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9fbaae15-947e-42eb-a4c9-8dd930374b1f" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Y</span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">es</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> &#9746;     NO &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f789cdae-d3c0-41e8-a6d3-b2dd01c98b6a" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Y</span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">es</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> &#9746;     NO &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:19.295%;"></td>
    <td style="width:0.724%;"></td>
    <td style="width:55.362%;"></td>
    <td style="width:1.178%;"></td>
    <td style="width:20.492%;"></td>
    <td style="width:0.724%;"></td>
    <td style="width:2.226%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_53b98046-8a98-4266-9dbd-04ce4f47a590" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0dcb5c0c-3d46-4a21-886e-cc4bcdc8bde7" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_65ae3668-f046-46e9-a540-b1dee5d1e5a0" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_af731a31-c150-403f-8632-b2bb7bc370ba" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b09b8af7-649c-4994-99b9-8d25edbe7df2" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  YES &#9744;     NO </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_611c3c3d-bfb3-4391-a152-02c9675be9ab" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:EntityShellCompany" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">As of June 30, 2021, the last business day of the registrant&#x2019;s most recently completed second fiscal quarter, the aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, based on the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">closing price </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">of the shares of common stock on The Nasdaq Stock Market LLC on June 30, 2021, was approximately $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dfc562a5-9f04-403e-8baf-288beefb38ed" contextRef="C_10b1dfb3-7e3e-4852-85ed-49f7cb670c71" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">189.8</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">As of M</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">arch 21, 2022, the registrant had </span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_850abd0b-dda8-4c85-aa93-7968f629b8e0" contextRef="C_4b6a86ef-4245-48e0-8889-4c4163bca1a6" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">87,707,499</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> shares of common stock, $0.001 par value per share, outstanding.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Table of Contents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.001%;"></td>
    <td style="width:81.996%;"></td>
    <td style="width:7.003%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Calibri;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PART I</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PART II</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">[Reserved]</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 7.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 7A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_and_qualitative"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">102</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 8.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">102</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_and_disagreements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">102</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_and_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">102</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9C.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PART III</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 10.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_officers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 11.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 12.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">119</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 13.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationships"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">121</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 14.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accounting_fees"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">126</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PART IV</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 15.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits_financial_statement"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibits and Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">128</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 16.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form_10_k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">130</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Summary of Material Risks Associated with Our Business</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our business is subject to numerous material and other risks that you should be aware of before making an investment decision. These risks are described more fully in Item 1A of this Annual Report on Form 10-K entitled &#x201c;Risk Factors.&#x201d; These risks include, among others, the following:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a precision oncology company with a limited operating history. We have no products approved for commercial sale, have not generated any revenue from product sales and may never become profitable.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.901%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:1.042%;"></td>
    <td style="width:91.042%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have incurred significant net losses since our inception and anticipate that we will continue to incur losses for the foreseeable future.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.94%;"></td>
    <td style="width:3.036%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.042%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will need to raise substantial additional funding. If we are unable to raise capital when needed or on terms acceptable to us, we would be forced to delay, reduce or eliminate some of our product development programs or commercialization efforts.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:2.996%;"></td>
    <td style="width:1.042%;"></td>
    <td style="width:91.042%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have never successfully completed any clinical trials and we may be unable to do so for any product candidates we develop. Certain of our programs are still in preclinical development and may never advance to clinical development.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.98%;"></td>
    <td style="width:2.996%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:91.022%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our programs are focused on the development of oncology therapeutics for patients with genetically defined or biomarker-driven cancers, which is a rapidly evolving area of science, and the approach we are taking to discover and develop drugs is novel and may never lead to approved or marketable products.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.98%;"></td>
    <td style="width:2.976%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:91.042%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are unable to successfully validate, develop and obtain regulatory approval for companion diagnostic tests for our product candidates that require or would commercially benefit from such tests, or experience significant delays in doing so, we may not realize the full commercial potential of these product candidates.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:2.976%;"></td>
    <td style="width:1.042%;"></td>
    <td style="width:91.062%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical product development involves a lengthy and expensive process, with an uncertain outcome.  Further, our current and potential future collaborations may not realize the anticipated benefits.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.98%;"></td>
    <td style="width:2.976%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:91.042%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interim, top-line, and preliminary data from our future clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to confirmation, audit and verification procedures that could result in material changes in the final data.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.98%;"></td>
    <td style="width:2.996%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.002%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Results from early preclinical studies of our programs and product candidates are not necessarily predictive of the results of later preclinical studies and clinical trials of our programs and product candidates. If we cannot replicate the results from our earlier preclinical studies of our programs and product candidates in our later preclinical studies and clinical trials, we may be unable to successfully develop, obtain regulatory approval for and commercialize our product candidates.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.901%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.101%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we experience delays or difficulties in the initiation or enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.98%;"></td>
    <td style="width:2.956%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:91.062%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our future clinical trials or those of our current or future collaborators may reveal significant adverse events not seen in our preclinical or nonclinical studies and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.96%;"></td>
    <td style="width:2.996%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.022%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Some of our product candidates modulate pathways for which there are currently no approved or effective therapies, and utilize novel binding locations, which may result in greater research and development expenses, regulatory issues that could delay or prevent approval, or discovery of unknown or unanticipated adverse effects.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.96%;"></td>
    <td style="width:2.976%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.042%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:3.036%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:91.042%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The on-going COVID-19 pandemic, or a similar pandemic, epidemic, or outbreak of an infectious disease, may materially and adversely affect our business and our financial results and could cause a disruption to the development of our product candidates.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.98%;"></td>
    <td style="width:2.976%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:91.042%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect to rely on third parties to conduct our future clinical trials, as well as investigator-sponsored clinical trials of our product candidates. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.96%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.042%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We contract with third parties for the manufacture of our product candidates for preclinical development and expect to continue to do so for clinical testing and commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.94%;"></td>
    <td style="width:2.996%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.042%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The third parties upon whom we rely for the supply of the active pharmaceutical ingredients and drug product to be used in our product candidates are our sole source of supply, and the loss of any of these suppliers could significantly harm our business.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note Regarding Forward-Looking Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">           This Annual Report on Form 10-K contains express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;). Words such as &#34;anticipates,&#34; &#34;continue,&#34; &#34;could,&#34; &#34;may,&#34; &#34;forecasts,&#34; &#34;expects,&#34; &#34;intends,&#34; &#34;plans,&#34; &#34;potentially,&#34; &#34;believes,&#34; &#34;seeks,&#34; &#34;estimates,&#34; &#34;predict,&#34; &#34;target,&#34; and variations of such words and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict; therefore, actual results may differ materially from those expressed or forecasted in any such statements. Such forward-looking statements are based on current expectations, estimates and projections about our industry and business, management's beliefs, and certain assumptions made by our management, and may include, but are not limited to, statements regarding:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.94%;"></td>
    <td style="width:3.036%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.002%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and our research and development programs;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.94%;"></td>
    <td style="width:3.036%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.002%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to discover and develop product candidates efficiently (including the advancement of development candidates on the timelines identified);</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.94%;"></td>
    <td style="width:3.036%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.002%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability and the potential to manufacture our drug substances and product candidates successfully for preclinical use, for clinical trials and on a larger scale for commercial use, if approved;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.94%;"></td>
    <td style="width:3.036%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.002%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ability and willingness of our third-party strategic collaborators to continue research and development activities relating to our development candidates and product candidates;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.94%;"></td>
    <td style="width:3.036%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.002%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to obtain funding for our operations necessary to complete further development and commercialization of our product candidates (and that existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements at least into the second half of 2024);</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.94%;"></td>
    <td style="width:3.036%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.002%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to obtain and maintain regulatory approval of our product candidates;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.94%;"></td>
    <td style="width:3.036%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.002%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to commercialize our products, if approved;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.94%;"></td>
    <td style="width:3.036%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.002%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the pricing and reimbursement of our product candidates, if approved;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.94%;"></td>
    <td style="width:3.036%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.002%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the implementation of our business model, and strategic plans for our business and product candidates;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.94%;"></td>
    <td style="width:3.036%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.002%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.94%;"></td>
    <td style="width:3.036%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.002%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">estimates of our future expenses, capital requirements, and our need for additional financing;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.94%;"></td>
    <td style="width:3.036%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.002%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the potential benefits of strategic collaboration agreements, our ability to enter into strategic collaborations or arrangements, and our ability to attract collaborators with development, regulatory and commercialization expertise;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.94%;"></td>
    <td style="width:3.036%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.002%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">future agreements with third parties in connection with the commercialization of product candidates and any other approved products;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.94%;"></td>
    <td style="width:3.036%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.002%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the size and growth potential of the markets for our product candidates, and our ability to serve those markets;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.94%;"></td>
    <td style="width:3.036%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.002%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our financial performance, including the expectation that we will continue to incur operating losses and negative cash flow;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.94%;"></td>
    <td style="width:3.036%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.002%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the rate and degree of market acceptance of our product candidates;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.94%;"></td>
    <td style="width:3.036%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.002%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory developments in the United States and foreign countries;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.94%;"></td>
    <td style="width:3.036%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.002%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.94%;"></td>
    <td style="width:3.036%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.002%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to produce our products or product candidates with advantages in turnaround times or manufacturing cost;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.94%;"></td>
    <td style="width:3.036%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.002%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the success of competing therapies that are or may become available;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.94%;"></td>
    <td style="width:3.036%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.002%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to attract and retain key scientific or management personnel;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.94%;"></td>
    <td style="width:3.036%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.002%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the impact of laws and regulations;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.94%;"></td>
    <td style="width:3.036%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.002%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">developments relating to our competitors and its industry;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.94%;"></td>
    <td style="width:3.036%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.002%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the effect of the on-going COVID-19 pandemic, including mitigation efforts and economic effects, on any of the foregoing or other aspects of our business operations, including but not limited to our preclinical studies and clinical trials and any future studies or trials; and</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.94%;"></td>
    <td style="width:3.036%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.002%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">other risks and uncertainties, including those listed in this Annual Report on Form 10-K under the section titled &#x201c;Risk Factors.&#x201d;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">           The forward-looking statements contained in this Annual Report on Form 10-K are based on current expectations and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.  These risks and uncertainties include, but are not limited to, those factors described under the heading &#x201c;Risk Factors&#x201d; in Item 1A of this Annual Report on Form 10-K. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Some of these risks and uncertainties may in the future be amplified by the COVID-19 outbreak and there may be additional risks that we consider immaterial or which are unknown. It is not possible to predict or identify all such risks. We do not undertake any obligation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Corporate Information</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We were formerly known as BCTG Acquisition Corp. (&#x201c;BCTG&#x201d;) and were incorporated in Delaware May 2020 as a special purpose acquisition company, formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business. On August 10, 2021, we consummated the merger pursuant to the Agreement and Plan of Merger, dated as of April 13, 2021, by and among BCTG, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">BCTG Merger Sub Inc. and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tango Therapeutics Sub, Inc. Upon the consummation of the merger, we changed our name to &#x201c;Tango Therapeutics, Inc.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits, proxy and information statements and amendments to those reports filed or furnished pursuant to Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, are available through the &#x201c;Investors&#x201d; portion of our website free of charge as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission (&#x201c;SEC&#x201d;).  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">W</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">e also make available, free of charge on our website, the reports filed with the SEC by our executive officers, directors and 10% stockholders pursuant to Section 16 under the Exchange Act as soon as reasonably practicable a</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">f</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ter copies of those filings are provided to us by those persons</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ccordingly, investors should monitor such portions of the company&#x2019;s website, in addition to following the company&#x2019;s press releases, SEC filings and public conference calls and webcasts. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Information on our website is not to be deemed to be incorporated by reference in, and is not part of, this Annual Report on Form 10-K or any of our other securities filings, unless specifically incorporated herein by reference, and should not be relied upon in making a decision as to whether or not to purchase our common stock. Our filings with the SEC may be accessed through the SEC&#x2019;s Interactive Data Electronic Applications system at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">http://www.sec.gov</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, the company intends to use its website </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">http://www.tangotx.com</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as a means of disclosing material non-public information and for complying with its disclosure obligations under the SEC Regulation FD. The information contained on, or that may be accessed through, the website is not part of, and is not incorporated into, this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our principal executive office is located at 100 Binney Street, Suite 700, Cambridge, Massachusetts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 1. Business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a precision oncology company leveraging our state-of-the-art target discovery platform to identify novel targets and develop new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. Tumor suppressor gene loss remains a largely untouched target space specifically because these genetic events cannot be directly targeted. Empowered by recent advances in CRISPR technology, we are now able to employ a unique functional genomics approach and apply the principles of synthetic lethality to target the loss of specific tumor suppressor genes at scale. We believe this will result in establishing a sustainable pipeline optimized to deliver meaningfully clinical benefit to patients. Our novel small molecules are designed to be selectively active in cancer cells with specific tumor suppressor gene loss, killing those cancer cells while being relatively inert in normal cells. We also are extending this target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss to include the discovery of novel targets that reverse the effects of tumor suppressor gene loss that prevent the immune system from recognizing and killing cancer cells (immune evasion). We believe this approach will provide the ability to deliver the deep, sustained target inhibition necessary for prolonged tumor regression and meaningful clinical benefit as a result of the unique ability of synthetic lethal targeting to spare normal cells. We believe our approach also opens possibilities of histology-agnostic treatments for patients harboring specific genome alternations, regardless of cancer type, in cases where a specific tumor suppressor gene loss is common to more than one subgroup of cancers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our first product candidate, TNG908, is a synthetic lethal, small molecule inhibitor of protein arginine methyltransferase 5, or PRMT5, designed to work selectively in cancer cells with a methylthioadenosine phosphorylase, or MTAP, deletion. MTAP-deletion occurs in approximately 10% to 15% of all human tumors, including non-small cell lung cancer (NSCLC), mesothelioma, pancreatic cancer, cholangiocarcinoma </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and glioblastoma (GBM)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In our preclinical studies, TNG908 has demonstrated 15-</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fold greater potency in MTAP-deleted cancer cells versus normal cells and robust anti-tumor effects </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> in vivo</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In the first quarter of 2022, the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application for the Phase 1/2 clinical trial and granted Fast Track designation to TNG908. We plan to initiate a Phase 1/2 clinical trial in the second quarter of 2022. We expect to have preliminary safety and efficacy data in the first half of 2023. Additionally, recent preclinical studies show that TNG908 crosses the blood-brain barrier in non-human primates therefore we plan to evaluate TNG908 in primary central nervous system cancers with MTAP deletion such as GBM as well as MTAP-deleted central nervous system (CNS) metastases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As part of our target discovery immune evasion platform, we are developing Target 3, an undisclosed synthetic lethal</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">target, that reverses the immune evasion effects of serine-threonine kinase 11 (STK11) loss-of-function mutations. STK11 loss-of-function mutations are present in approximately 15% of NSCLC, 15% of cervical cancers, 10% carcinoma of unknown primary, 5% of breast cancers and 3% of pancreatic cancers. Using an </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> CRISPR-based context discovery screen, we identified STK11 as a tumor suppressor gene responsible for mediating </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">immune evasion, manifest </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">as resistance to checkpoint inhibitor therapy, when deleted and subsequently ide</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ntified a drug target (Target 3) that reverses this effect when inhibited in preclinical studies. In a syngeneic tumor-bearing mice model, where STK11 mutations drive resistance to immune checkpoint blockade, Target 3 inhibition, in combination with an anti-PD1 antibody, resulted in near or complete tumor regressions in eight out of eight treated mice and the induction of immune memory against re-implantation of tumors. We expect to advance a development candidate in the second quarter of 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and file an IND in 2023. We expect the clinical development plan for this inhibitor in STK11-mutant cancers to be among the first to combine the power of genetically-based patient selection and checkpoint inhibitor therapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are developing a small-molecule, allosteric inhibitor of ubiquitin-specific protease 1 (USP1). USP1 is a synthetic lethal target that </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we discovered using a CRISPR-based target discovery screen for BRCA1-mutant breast cancer. Advan</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ced lead compounds that inhibit this target have strong in vitro and in vivo single agent activity in BRCA1-mutant breast cancer. Our lead molecules also have strong activity in BRCA2-mutant patient derived xenografts, including both BRCA1 and BRCA2 mutant models that are intrinsically resistant to PARP inhibition. Our preclinical data further demonstrate that U</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SP1 inhibition</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is synergistic with PARP inhibition in multiple PARP inhibitor sensitive and resistant cancer cell lines and  xenograft models. We believe that these data provides the basis for the future clinical trials of a USP1 inhibitor both as a single agent and in combination with PARP inhibitors. Further, we have demonstrated in vitro activity of our lead molecules in a panel on BRCA WT lung cancer cell lines and in vivo activity in a lung cancer cell line xenograft, and are evaluating potential patient selection biomarkers for this indication. BRCA1 or BRCA 2 mutations are present in approximately 15% of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ovarian cancers, 10% of breast cancers, 10% of prostate cancers, 5% of endometrial cancers and 5% of pancreatic cancers. We anticipate advancing a development candidate in the second half of 2022 and filing an IND for this program in 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2018, we entered into a collaboration agreement with Gilead Sciences Inc., or Gilead, and this collaboration was expanded in August 2020, or the Gilead Agreement. Our immune evasion platform is the foundation for our collaboration with Gilead. Under the Gilead Agreement, we and Gilead collaborate to identify and develop novel immune evasion targets by leveraging our proprietary functional genomics-based discovery platform. To date, Gilead has licensed two of our programs and has research-extended two programs. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our collaboration with Gilead excludes our lead program, TNG908, our undisclosed target (Target 3) in STK11-mutant cancers, USP1 as well as a growing pipeline of novel targets identified in our non-immune based target discovery screens. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We retain the right to identify and validate targets outside the scope of our collaboration with Gilea</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">d, which includes all cell autonomous targets ex</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cept those discovered in immune evasion contexts, and to develop and commercialize products directed to such targets on our own or in collaboration with third parties. See &#x201c;&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> Collaboration and License Agreements &#x2014; Collaboration and License Agreement with Gilead Sciences</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; for additional information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Pipeline</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are leveraging the power and productivity of our discovery engine to discover and validate multiple novel targets each year. Our growing pipeline consists of discovery programs for multiple cancer types with limited treatment options. Our pipeline is summarized in the table below:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img158215518_0.jpg" alt="img158215518_0.jpg" style="width:672px;height:227px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are pioneering novel approaches to the discovery and development of innovative precision oncology therapies. We leverage the following core strategic components, enabling bold thinking in pursuit of transformative therapies for patients with cancer:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Advance TNG908, our PRMT5 inhibitor that is synthetic lethal with MTAP deletion, into the clinic in multiple indications with high unmet need </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Bring one of the first immunotherapy program within genetically-defined patients into the clinic in STK11-mutant cancers with a Target 3 inhibitor</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Advance our USP1 inhibitor program into clinical development in mult</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">iple BRCA1/2-mutant cancers  </span><span style="background-color:rgba(255,255,0,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Discover and drug the next generation of synthetic lethal precision oncology targets to continue to grow our pipeline</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Opportunistically evaluate and maximize the value of our strategic collaboration to bring more medicines to patients, accelerate development timelines and explore combination therapy approaches for our product candidates</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">BACKGROUND</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Unmet need of cancers caused by tumor suppressor gene loss</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many genetic drivers of cancer have been well-characterized but have not been directly targeted due to their molecular structure (undruggable oncogenes) or functional loss (tumor suppressor genes). Tumor suppressor gene loss represents a significant portion of the many genetic alterations that drive the formation of cancers but it remains a largely untouched target space. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Targeting tumor suppressor gene loss directly is not possible because they are deleted or inactivated, and the immune evasion effects of tumor suppressor gene loss has only recently been described. We are using the concept of synthetic lethality to address the unmet medical need of these large groups of patients characterized by tumor suppressor gene loss and activation of immune evasion genes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Synthetic Lethality to address tumor suppressor gene loss</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Synthetic lethal therapies for cancer refers to pairs of genes where one is inactivated by a genetic alteration and the other is inhibited pharmacologically. While genetic alterations give rise to the development of cancer, they also create a unique vulnerability that can be exploited therapeutically. Biologically, such vulnerability can be the inability of cancer cells to respond to a specific signal, such as DNA damage or cell cycle arrest, or the inability to remodel chromatin or to maintain cellular homeostasis. The unique advantage of a synthetic lethal approach to cancer therapy is that normal cells are not vulnerable to the synthetic lethal drug target and are largely unaffected at drug doses where the mutant cancer cells are selectively killed, noted in Figure 2 below. The recent success of PARP inhibitors in BRCA-mutant breast, ovarian and prostate cancers is the first clinical example of using synthetic lethality to target tumor suppressor gene loss.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 2. In cancer cells, when a tumor suppressor gene is lost, it creates a genetic vulnerability that allows an inhibitor to target a synthetic lethal partner gene causing cell death. This selective killing only occurs in cancer cells with tumor suppressor loss, therefore largely sparing the normal cells. Therefore, these synthetic lethality targets inherently can offer a wide therapeutic index.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img158215518_1.jpg" alt="img158215518_1.jpg" style="width:449px;height:183px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, we plan to use the tumor suppressor gene loss as a patient selection marker for clinical trial enrollment to ensure we are enrolling the patients most likely to benefit from each new drug candidate. We believe this approach should enable efficient clinical development and increase the probability of success with maximum clinical benefit for the patient.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe our expertise, capabilities, and experience differentiate us from others and will enable the rapid development of impactful new cancer treatments by:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Defining upfront the genetic background of the cancer type and patient subgroups with specific tumor suppressor gene loss; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Identifying synthetic lethal targets that are selectively active in specific genetic contexts by using cell line and animal models that reflect the patient genomics in our CRISPR-based target discovery platform; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Discovering and optimizing molecules with superior biological and innovative chemical properties; and </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Selecting patients for clinical trials using the cancer genetic context employed during target discovery as patient selection biomarkers to maximize enrollment of the patients most likely to respond. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Immune Evasion Platform</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The synthetic lethal target discovery approach can be adapted to identify druggable targets that do not kill cancer cells directly, but rather attract immune cells to destroy them. We are addressing the unmet medical need of this large group of patients by identifying novel immune evasion genes that (i) are activated by tumor suppressor gene loss and (ii) the effects of which can be reversed through inhibition with a small molecule as illustrated in Figure 3 below. In the first step, we perform an </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> CRISPR-based screen using immune cell-mediated cell killing as the readout. This first step allows us to identify tumor suppressor genes linked to immune evasion. For the second step, we repeat the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> CRISPR screen in animals with an intact immune system looking for potential drug targets that reverse the immune evasion effects of the tumor suppressor gene deletion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 3. Discovery of novel drug targets that reverse the immune evasion effects of tumor suppressor gene loss requires two sequential in vivo CRISPR-based screens. In the first screen, a CRISPR library of several hundred known tumor suppressor genes is transfected into a syngeneic mouse tumor model, and tumor growth is measured under conditions of increasing immune pressure. &#x201c;Hits&#x201d; from this context discovery screen are tumor suppressor genes that are enriched in tumors that grow well even when exposed to anti-PD1 treatment. In the second screen, a CRISPR library of potential drug targets is introduced in a syngeneic mouse tumor model with and without a deletion of the tumor suppressor gene of interest and genes that when knocked out reverse the immune evasion effect of the known tumor suppressor gene are potential drug targets.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img158215518_2.jpg" alt="img158215518_2.jpg" style="width:617px;height:262px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">OUR PROGRAMS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">TNG908</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our lead development candidate, TNG908, is a potent and selective oral small molecule inhibitor of PRMT5 that is synthetic lethal with MTAP deletion. We believe this interaction is one of the strongest and most prevalent synthetic lethal interactions in human cancers and represents a subset of synthetic lethality termed collateral lethality. Collateral lethality occurs when a &#x201c;passenger&#x201d; gene adjacent to a tumor suppressor gene is lost along with the &#x201c;driver&#x201d; gene. In this case, MTAP is the &#x201c;passenger&#x201d; and is frequently co-deleted with the &#x201c;driver&#x201d; CDKN2A gene (p16). The interaction occurs because MTAP-deleted cells accumulate high levels of the PRMT5 inhibitory co-factor MTA. As a result, PRMT5 is partially inhibited in MTAP-deleted cells, making those cells more sensitive than normal cells to further inhibition of PRMT5 activity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Taking advantage of this unique interaction between PRMT5 inhibition and MTAP deletion requires a specific mechanism of inhibition called MTA cooperativity. TNG908 binds cooperatively with MTA to inhibit PRMT5 function by blocking access to the PRMT5 active site for both protein substrates and the activating PRMT5 co-factor S-adenosyl-L-methionine (SAM). This MTA-cooperative mechanism of inhibition selectively inhibits PRMT5 in tumor cells that have lost MTAP (MTAP-null) while being relatively inert in normal cells without MTAP deletion (MTAP WT). We believe TNG908 is differentiated from other non-MTAP selective PRMT5 inhibitors based on this mechanism and that it will have the potential for a large therapeutic window in patients with MTAP-deleted tumors, given that normal cells (without MTAP deletion) are largely spared, potentially limiting toxicity and allowing for deep and sustained target inhibition in tumor cells.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are developing TNG908 for the treatment of patients with solid tumors with MTAP deletion, which occurs in 10% to 15% of all human tumors, including NSCLC, mesothelioma, pancreatic cancer, cholangiocarcinoma</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and GBM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In preclinical studies, TNG908 has demonstrated 15X selectivity for MTAP-null cancer cells over MTAP WT normal cells, anti-tumor effects</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and pharmacokinetics that support its potential to be a leading PRMT5 inhibitor if approved</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In the first quarter of 2022, the FDA cleared the IND for the Phase 1/2 trial and granted Fast Track designation to TNG908. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We plan to initiate a Phase 1/2 clinical trial in the </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">second quarter of 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and have preliminary safety and efficacy data expected in the first half of 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">MTAP-deletion frequency in multiple solid tumors</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A partial deletion of chromosome 9p21, driven by loss of the tumor suppressor gene CDKN2A, is the most common homozygous deletion in human cancer. MTAP is immediately adjacent to CDKN2A and is lost along with it in 80-90% of tumors, thus MTAP is one of the most commonly deleted genes across all cancer types. Based on The Cancer Genome Atlas (TCGA) data and a 2014 publication by Lee et al, there are at least 15 cancer types where MTAP loss occurs in more than 10% of patients, including approximately 10% of non-squamous NSCLC, 20% of squamous NSCLC, 25% of bladder cancers, 30% to 50% of malignant peripheral nerve sheath tumors (MPNST) </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and 40% of GBM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Given that we believe this is a large and important opportunity for patients with cancer, we have multiple preclinical efforts ongoing to support the development of our lead product candidate, TNG908, including identification of clinical combinations therapies and potential resistance mechanisms, as well as the development of next generation inhibitors that we are designing to be more potent and selective for cells with MTAP deletion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 4. The frequency of MTAP deletion across tumor types as determined from analysis of TCGA and an indication specific publication</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img158215518_3.jpg" alt="img158215518_3.jpg" style="width:496px;height:439px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">PRMT5 mechanism of action</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PRMT5 has long been a therapeutic target of interest for cancer given its role in regulating proteins involved in multiple essential cellular functions, including RNA splicing, cell cycling, cell death, and metabolic signaling. PRMT5 is a protein arginine methyltransferase that modifies the activity of these proteins, which are critical for growth and viability of both normal and cancer cells.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PRMT5 methylates target proteins by removing a methyl group from SAM, the co-factor and methyl donor which is necessary for PRMT5 to modify its various substrates and transferring that methyl group to a specific residue on target proteins. This methyl modification, or &#x201c;mark&#x201d;, alters the function of the target protein, thereby regulating the cell processes for which the protein is important.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The function of PRMT5 is regulated in several ways, including by the endogenous inhibitor MTA. MTA directly competes with SAM for binding to the active site in PRMT5 but does not have a methyl donor, thus when present inhibits PRMT5 function.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">MTA-cooperative PRMT5 inhibition as a novel mechanism with synthetic lethality in cancers with MTAP-deletion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our differentiated approach with TNG908</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The challenge of PRMT5 inhibitors with mechanisms of action that are not synthetic lethal with MTAP-deletion is that they kill rapidly growing normal cells (bone marrow cells in particular) as effectively as cancer cells and therefore the level needed to kill cancer cells is reduced by on-target, dose-limiting bone marrow toxicity. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To address this problem, we designed TNG908 to be selectively active (synthetic lethal) in cancer cells that have a deletion of MTAP, which is not present in normal cells.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Calibri;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">TNG908 binds PRMT5 cooperatively with MTA, which is distinct from non-MTAP selective PRMT5 inhibitors that</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> compete with or cooperate with SAM.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> In normal, non-cancerous cells, MTA is degraded by the enzyme MTAP. When MTAP is lost in cancer cells intracellular MTA is elevated, but, importantly, MTA is not elevated in adjacent normal cells, as noted in Figure 5 below. TNG908 preferentially binds PRMT5 in the presence of MTA to cause inhibition of activity. As a result, TNG908 selectively kills MTAP-deleted tumor cells with high MTA levels while sparing normal cells (MTAP-WT).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 5. Schematic of PRMT5 and MTAP functions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><img src="img158215518_4.jpg" alt="img158215518_4.jpg" style="width:497px;height:260px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PRMT5 and SAM are required in every tissue and cell type, and we believe PRMT5 inhibition with a SAM cooperative or competitive approach is likely to have substantial on-target, dose limiting toxicity in normal cells, which limits therapeutic efficacy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 6. TNG908 has a MTA-cooperative mechanism of action that is distinct from non-MTAP selective PRMT5 inhibitors that target the SAM/PRMT5 complex.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img158215518_5.jpg" alt="img158215518_5.jpg" style="width:672px;height:191px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We compared the potency and selectivity of our development candidate TNG908 and a non-MTAP selective PRMT5 inhibitor, GSK3326595, in a panel of 200 cancer cell lines representing NSCLC, bladder cancer, pancreatic cancer, cancers of the central nervous system, leukemia and lymphoma. TNG908 demonstrated significant MTAP-selective inhibition of viability, while GSK3326595 showed no selectivity for MTAP-null cell lines over MTAP-WT.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 7. TNG908 inhibits viability selectively in MTAP-null cancer cell lines. Cellular viability was determined in a panel of 200 cancer cell lines treated for seven days with either TNG908 or GSK3326595. Cell lines are color-coded by MTAP-status as indicated, and the maximal viability effect (% Amax) is plotted on the y-axis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img158215518_6.jpg" alt="img158215518_6.jpg" style="width:608px;height:224px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further validation of our approach to selectively inhibit PRMT5 in MTAP-null cancer cells was achieved</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Xenograft models differing only in MTAP status (MTAP-WT or MTAP-null) were treated with TNG908. PRMT5 symmetrically di-methylates specific arginine residues (SDMA-modification) in its substrate proteins, a modification that can be detected and quantified by specific antibodies as a direct measurement of PRMT5 activity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preclinical data summary</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">TNG908 is highly selective for PRMT5 against a panel of 38 methyltransferases at 10 &#xb5;M, showing that TNG908 does not affect other biological processes regulated by these types of enzymes at concentrations well above the predicted clinical efficacious dose. We observed that TNG908 has excellent drug-like properties and is easily formulated for oral administration. Preclinical studies demonstrate that TNG908 has high passive permeability, low plasma protein binding, moderate clearance, and moderate oral bioavailability. Allometric scaling was performed to predict the human dose-exposure relationship and to estimate the human dose that would provide exposure associated with efficacy in mouse xenograft models. These analyses </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">suggest the effective human dose will be in the range of 200-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">500 mg twice-daily (BID).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To determine the cellular potency and selectivity of TNG908 in MTAP-null tumors, we developed assays using engineered isogenic cancer cell lines that differ only by the presence or absence of MTAP. To determine pharmacodynamic potency and selectivity, a HAP1 MTAP-isogenic cell line pair was treated with TNG908 for 24 hours and PRMT5 activity was measured</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">by SDMA quantification. TNG908 inhibits PRMT5 in the MTAP-null HAP1 cell line with an IC50 of 5 nM, with marked selectivity over the MTAP-WT cell line. See representative data in Figure 8 below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 8. PRMT5 inhibition by TNG908 is dose-dependent and MTAP-selective</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">In vitro in-cell western data demonstrating dose-dependent reduction of SDMA levels after 24 hours of TNG908 treatment in HAP1 MTAP-isogenic cancer cell lines.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img158215518_7.jpg" alt="img158215518_7.jpg" style="width:202px;height:227px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For comparison, PRMT5 inhibitors that are not MTA-cooperative, have not demonstrated MTAP-selective PRMT5 inhibition, as summarized in the table below. These data show that TNG908 is MTAP-selective, and that its activity is on-target. Though the GSK3326595, JNJ-64619178 and Prelude compounds inhibit cellular viability consistent with their inhibition of PRMT5, none have been shown to selectively target MTAP-null cells.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Table 9. TNG908 is differentiated from non-MTAP selective PRMT5 inhibitors in ability to selectively inhibit viability in MTAP-null cells. Average IC50s from in vitro cellular viability assay with HAP1 MTAP-isogenic cell lines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img158215518_8.jpg" alt="img158215518_8.jpg" style="width:369px;height:184px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Consistent with</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> in vitro</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> data, TN</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">G908 also demonstrates dose-dependent PRMT5 inhibition</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in an MTAP-null xenograft model. LN18 tumor-bearing mice were treated with TNG908 at 3, 10, 30 or 60 mg/kg BID for ten days. Plasma concentrations of TNG908 increased with dose, and tumoral SDMA-modified protein levels decreased in a dose-dependent manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 10. PRMT5 inhibition with TNG908 is dose-dependent</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">. LN18 (MTAP-null) tumor-bearing mice were dosed with TNG908 at 3, 10, 30, or 60 mg/kg BID for ten days. Tumors were harvested at the time points indicated, and the levels of a single SDMA-modified protein were determined by immunoblot. Tumors from the 3 mg/kg group were not harvested at 16 hours post-last dose.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img158215518_9.jpg" alt="img158215518_9.jpg" style="width:428px;height:231px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">TNG908 was evaluated in an engineered MTAP-null xenograft model, HCT116, a colon cancer cell line. Marked activity was observed at 90 mg/kg BID (Figure 11 below). In comparison, TNG908 had minimal effect on the HCT116 MTAP WT xenografts. Together with PK/PD data, these data demonstrate that TNG908 inhibition of PRMT5 suppresses tumor growth in an on-target and MTAP-selective manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Consistent with the inhibitory effects of MTA accumulation caused by MTAP-deletion, PRMT5 activity was reduced in MTAP-null tumors at baseline relative to MTAP-WT tumors. In Figure 11 below, HCT116 MTAP-isogenic xenograft models were generated by deleting endogenous MTAP to create an MTAP-null cell line. Tumor-bearing mice were dosed with TNG908 or vehicle at the indicated dose levels. SDMA-modified protein levels were determined by immunoblot analysis on tumors harvested eight hours after the last dose. When tumor-bearing mice were dosed with TNG908, &gt;90% PRMT5 inhibition was observed in the MTAP-null tumors while PRMT5 inhibition in MTAP-WT tumors remained above the threshold for lethality.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 11. TNG908 demonstrates strong, MTAP-selective anti-tumor activity in xenograft models. TNG908 selectively inhibits PRMT5 in MTAP-null cancer in vivo.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img158215518_10.jpg" alt="img158215518_10.jpg" style="width:672px;height:210px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Consistent with these findings, TNG908 demonstrated significant and dose-dependent anti-tumor activity in over 50 xenograft models representing multiple tumor lineages (sample data shown in Figure 12) that did not have a bias to specific indications. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tumor regressions of -44%, -78% and -96% were demonstrated in additional MTAP-null PDX models representing cholangiocarcinoma, NSCLC and bladder cancer, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 12. TNG908 demonstrates strong anti-tumor activity with regressions in MTAP-null xenograft models.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img158215518_11.jpg" alt="img158215518_11.jpg" style="width:672px;height:213px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, TNG908 induces strong tumor regressions in xenograft models representing GBM (Figure 13), and has exposure in the cerebrospinal fluid (CSF) equivalent to plasma exposure in non-human primate studies. We believe this uniquely positions TNG908 as a potential treatment option for patients with MTAP-deleted tumors of the central nervous system (CNS) including GBM and CNS metastases of other MTAP-deleted solid tumors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 13.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> TNG908 demonstrates strong anti-tumor activity with regressions in MTAP-null xenograft models in GBM</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img158215518_12.jpg" alt="img158215518_12.jpg" style="width:292px;height:179px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Planned clinical trials</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have designed our Phase 1/2 first-in-human trial to evaluate the oral administration of TNG908 monotherapy in patients with MTAP-deleted tumors (See Figure 14 below). Our planned indications reflect the unmet medical need for new therapies in prevalent histologies, including NSCLC, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">mesothelioma, cholangiocarcinoma and GBM,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as well as indications where there are limited treatment options with no standard of care such as MPNST. As TNG908 is designed to selectively work in cancers with MTAP loss, we intend to limit enrollment to patients with MTAP-deleted tumors using next generation sequencing (NGS).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The dose escalation phase will evaluate safety, pharmacokinetics, pharmacodynamics, a</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">nd efficacy</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in patients with locally advanced or metastatic cancer of any histology with an MTAP deletion. Following determination of the optimal efficacious dose, we will evaluate the efficacy of TNG908 in multiple histology-specific expansion arms including MPNST, NSCLC, mesothelioma, cholangiocarcinoma and GBM. In parallel, we will enroll a histology agnostic cohort to provide optionality for a registration strategy in all tumors regardless of hist</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ology if broad activity is observed. Given that MTAP deletion occurs in 10% to 15% of human cancers, we may expand into other histology-specific cohorts b</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ased on activity observed in the Phase 1/2 trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the first quarter of 2022, the FDA cleared the IND for the Phase 1/2 trial and granted Fast Track designation to TNG908. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We plan to initiate the Phase 1/2 clinical trial of TNG908 in the </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">second quarter of 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. We expect to report preliminary safety and efficacy data for TNG908 in the first half of 2023. This program is excluded from the Gilead Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 14. TNG908 First-in-human trial schema.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img158215518_13.jpg" alt="img158215518_13.jpg" style="width:485px;height:296px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Next-generation PRMT5 Inhibitors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Given the significant addressable patient population with MTAP-deleted cancers, we are investing additional resources in our PRMT5 franchise to progress a superior candidate with increased potency, MTAP-deletion selectivity and once daily dosing. We have next-generation PRMT5 inhibitor compounds in preclinical development that use the same mechanism of action as TNG908 but have demonstrated more potent and selective activity in our xenograft models to date. We believe additional potency may allow stronger target inhibition and thus clinical efficacy and additional selectivity for MTAP-null cells may provide a wider therapeutic index.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An exemplar from our next-generation lead series is sig</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">nificantly more potent and selective for MTAP-null cells relative to TNG908 and the non-MTAP selective PRMT5 inhibitor, GSK3326595. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In a cell line panel containing both MTAP WT and MTAP-null cell lines representing solid tumor lineages, the exemplar demonstrates 67 selectivity for MTAP-null cells over MTAP WT cells (Figure 15).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 15. Next-generation PRMT5 inhibitor exemplar compound data demonstrates strong MTAP selectivity in 128 cancer cell lines as compared to TNG908 or GSK3326595.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img158215518_14.jpg" alt="img158215518_14.jpg" style="width:535px;height:262px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe our next-generation compounds have the potential to be more effective than our lead PRMT5 inhibitor, TNG908, with a yet wider therapeutic index.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> If additional preclinical or clinical evaluation of our next-generation compounds supports this hypothesis, we may elect to promote a next-generation compound as our lead PRMT5 inhibitor, which would result in a delay to our development timeline of approximat</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ely 12 to 18 months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our early development programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Target 3</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Target 3 was developed using our target discovery immune evasion platform which identifies druggable targets that do not kill cancer cells directly, but rather attract immune cells to destroy them. We identify novel immune evasion genes that (i) are activated by tumor suppressor gene loss and (ii) the effects of which can be reversed through inhibition with a small molecule.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Using</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> CRISPR-based screens in syngeneic mouse tumor models, we identified serine-threonine kinase 11 (STK11) loss-of-function mutatio</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ns as a t</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">umor suppressor gene that when inactivated confers resistance to the efficacy of PD-1 immune checkpoint inhibitors. STK11 loss-of-function mutations occurs in approximately 15% of NSCLC, 15% of cervical cancers, 10% carcinoma of unknown primary, 5% of breast cancers and 3% of pancreatic cancers. STK11 loss-of-function mutations trigger complex changes in both cancer cell signaling and in the broader tumor microenvironment. Retrospective analysis of human clinical data by multiple academic centers, including by Dr. Ferdinandos Skoulidis and Dr. John Heymach (MD Anderson Cancer Center), subsequently identified STK11 as a marker for the lack of durable clinical benefit to pembrolizumab + chemotherapy in NSCLC patients, demonstrating that STK11 loss-of-function mutations correlate with primary resistance to anti-PD1 therapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have generated genetically engineered mouse tumor models that consistently recapitulate the immunosuppressive microenvironment caused by genetic STK11 loss-of-function mutations and have conducted several target discovery screens using these same models. These models are used to discover novel targets to reverse the immune evasion effect of this genetic alteration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our exemplar molecule d</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">emonstrated strong genetic and pharmacologic validation showing reprogramming of the tumor microenvironment and strong sensitization to anti-PD1 therapy in a STK11-mutant dependent manner. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In a syngeneic mouse tumor model, where STK11 mutations drive resistance to immune checkpoint blockade, Target 3 inhibition, in combination with an anti-PD1 antibody, resulted in near or complete tumor regressions in eight out of eight treated mice. Treatment was stopped on Day 32 and the six of eight mice that were completely tumor-free at that time remained tumor-free for 51 days with no further treatment.  Furthermore, when tumor cells were re-implanted in these mice on day 83, they were rejected, demonstrating the induction of immune memory (Figure 16).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figu</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">re 16: Pharmacologic proof-of-concept for Target 3 inhibition in ST</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">K11 mutant MC38 mice.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img158215518_15.jpg" alt="img158215518_15.jpg" style="width:402px;height:221px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect to advance a development candidate in the second quarter of 2022 and file an IND in 2023. The clinical development plan for this program in STK11-mutant cancers will combine the power of genetic patient selection for immunotherapy with a novel approach to reversing tumor-intrinsic immune evasion. This program is excluded from the Gilead Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">USP1</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We identified USP1 as a strong synthetic lethal target for BRCA1 loss-of-function using CRISPR-based screens in a panel of BRCA1-mutant versus wild-type cancer cell lines (see Figure 17 below). This discovery has since been independently reported by other groups, including Dr. Alan D&#x2019;Andrea (DFCI). Advanced lead compounds that inhibit this target have strong in vitro and in vivo activity in BRCA1-mutant breast cancer. Our lead molecules also have strong activity in BRCA2-mutant patient derived xenografts, including both BRCA1 and BRCA2 mutant models that are intrinsically resistant to PARP inhibition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to the single-agent activity observed with USP1 inhibition in vitro (Figure 18) and in vivo (Figure 19) our USP1 inhibitors demonstrate strong combination synergy with PARP inhibition in vitro and in vivo including several primary, PARP resistant PDX models. We believe these data provide the basis for the future clinical trials of a USP1 inhibitor both as a single agent and in combination with PARP inhibitors. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As such, USP1 has the potential to treat a patient population that is comparable in size to the PARP inhibitor market (BRCA1 and BRCA2). BRCA1 or BRCA2 mutations are present in approximately 15% of ovarian cancers, 10% of breast cancers, 10% of prostate cancers, 5% of endometrial cancers and 5% of pancreatic cancers. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect to advance a development candidate in the in the second half of 2022 and file an IND in 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preclinical data summary</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 17. Volcano plot shows analysis of CRISPR screens performed in a panel of BRCA1 WT vs. mut cell lines where knockout of USP1 using multiple independent single strand guide RNAs (sgRNAs) leads to selective killing of BRCA1 mutant tumor cells. The clinically proven PARP-BRCA interaction was also identified in this screen as expected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img158215518_16.jpg" alt="img158215518_16.jpg" style="width:295px;height:270px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USP1 is a deubiquitinating enzyme that facilitates DNA damage response (DDR) repair. Our preclinical pharmacology studies show that USP1 inhibition halt the proliferation of a</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> subset of breast and ovarian cancer cell lines with BRCA1 and BRCA2 mutations, as well as a subset of NSCLC cell lines that do not have BRCA1/2 mutations. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are currently conducting experiments to define patient selection markers for these </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">BRCA1/2 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">WT cell lines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our lead series demonstrate nanomolar potency against USP1, as measured by cytotoxicity in BRCA1 mutant cells, and upregulation of mono-ubiquitinated PCNA as exemplified in Figure 18. Consistent with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> data, our lead series also exhibit potent and dose-dependent anti-tumor activity in the MDA-MB-436 xenograft model (BRCA1 mutant breast cancer cell line) and in the</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> BRCA1/2 wildtype lung cancer xenograft model (NCI-H1792) as shown in Figure 19.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 18. Tango lead series USP1 inhibitor demonstrates selective viability effect and target engagement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img158215518_17.jpg" alt="img158215518_17.jpg" style="width:598px;height:239px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Left) In vitro assay demonstrating cellular viability effects in exemplar BRCA1 mutant but not WT cell line following ten days of compound treatment. (Right) In vitro assay demonstrating dose dependent increase in monoubiquitinated PCNA, a USP1 substrate, in BRCA1 mutant cell line following 24 hours of treatment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 19. Lead series USP1 inhibitor demonstrates in vivo anti-tumor activity in human breast and lung cancer xenograft models.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img158215518_18.jpg" alt="img158215518_18.jpg" style="width:672px;height:223px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The DNA damage repair (DDR) pathways regulated by USP1 are not currently targeted by any marketed drug. Moreover, we performed genome-wide CRISPR-Cas9 screens in the presence and absence of our USP1 inhibitors and confirmed that USP1 inhibition has a differentiated and novel mechanism of action relative to other DDR-based inhibitors, including PARP inhibitors. We expect this molecule to have both single agent activity in PARPi-na&#xef;ve and potentially some PARPi-resistant cancers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Preclinically, we have demonstrated strong synergy with PARP inhibitors in both </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vivo</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as shown in Figure 20 and Figure 21. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This program is excluded from the Gilead Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 20. USP1 inhibition sensitizes PARP inhibitor in BRCA1and BRCA2 mutant contexts</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img158215518_19.jpg" alt="img158215518_19.jpg" style="width:672px;height:254px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Figure 21. USP1 inhibition demonstrates significant combination benefit with PARP inhibitor in breast cancer and ovarian cancer PDX models.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img158215518_20.jpg" alt="img158215518_20.jpg" style="width:412px;height:232px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Collaboration and License Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Collaboration and License Agreement with Gilead Sciences</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2020, we entered into an amended and restated research collaboration and license agreement, which we refer to as the Gilead Agreement, with Gilead Sciences, Inc. The Gilead Agreement expanded our 2018 collaboration with Gilead, or the 2018 Gilead Agreement. Pursuant to the Gilead Agreement we use our proprietary functional genomics-based discovery platform to identify and develop novel immune evasion targets during a seven-year period ending in August 2027, or the Research Term. During the Research Term, Gilead has the option to obtain exclusive, worldwide licenses to develop and commercialize products directed to up to 15 targets validated in the collaboration. Prior to exercising its option for a program, Gilead may &#x201c;extend&#x201d; such program, in which case we will further collaborate with Gilead during the Research Term to discover and develop immuno-oncology treatments directed to such target(s), potentially through early clinical development and be eligible to receive research extension payments from Gilead. Gilead will retain its option rights to any such extended program. For up to five programs licensed by Gilead, we have the option to co-develop and co-promote the lead product for such program in the United States, subject to certain exceptions, and eligible to receive milestone payments and royalties on ex-U.S. sales.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the terms of the Gilead Agreement, we received an upfront payment of $125.0 million in addition to an upfront payment of $50.0 million received under the 2018 Gilead Agreement. We also received a $20.0 million equity investment in connection with the Gilead Agreement, and as of December 31, 2021, we received </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$21.1 million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in license fees and $14.0</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">million in option-extension fees. We are eligible to receive up to an additional $410.0 million per program in license, research extension, and clinical, regulatory and commercial milestone payments. We are also eligible to receive tiered royalties in the first decile on net sales by Gilead on a country-by-country and product-by-product basis until the later of (i) the expiration of the last valid claim of our patents or, in some instances, certain of Gilead&#x2019;s patents, in each case covering such product in such country or (ii) ten years after the first commercial sale of such product in such country. For those products that we opt to co-develop and co-promote in the United States, we and Gilead will equally split profits and losses from the sales of such products in the United States, as well as development costs for such products attributable to the United States. For such products, we will remain eligible to receive certain of the $410.0 million per program milestone payments related to clinical and regulatory milestones as well as commercial milestones and royalties in the first decile on net sales outside the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Either party may terminate the Gilead Agreement if the other party materially breaches the terms of such agreement, subject to specified notice and cure provisions, or enters into bankruptcy or insolvency proceedings. Additionally, Gilead may terminate the agreement for any or no reason, in its entirety or on a program-by-program basis, upon specified written notice. If we terminate the Gilead Agreement for Gilead&#x2019;s material breach, or Gilead terminates the Gilead Agreement without cause, then Gilead is obligated to negotiate with us in good faith for a specified period regarding the transfer by Gilead of certain assets and the provision by Gilead of certain assistance to enable us to continue the research, development and commercialization of products under any terminated programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, Gilead has licensed two of our programs and has research-extended two programs under the Gilead agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our collaboration with Gilead excludes our lead programs, PRMT5, Target 3, USP1 </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">as well as a growing pipeline of novel targets identified in our non-immune related target discovery screens</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. We also retain the right to identify and validate targets outside the scope of our collaboration with Gilead (all cell-autonomous targets, exclusive of those in immune evasion contexts), and to develop and commercialize products directed to such targets, on our own or in collaboration with third parties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License Agreement with Medivir AB</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2020, we entered into a license agreement, or the Medivir Agreement, with Medivir AB, or Medivir, pursuant to which we obtained a worldwide, royalty-bearing, exclusive license under certain current and/or future patents and know-how of Medivir, to research, develop and commercialize products that are covered by such licensed patents or otherwise modulate USP1.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the terms of the Medivir Agreement, we are obligated to pay Medivir in connection with development, regulatory and commercial activities. We have agreed to make certain milestone payments of (i) $1.4 million in the aggregate for the first licensed product that achieves specified clinical milestones plus $25.0 million for the first licensed product that achieves specified regulatory approval and sales milestones, in each case, in either of the first two specified genetic contexts and (ii) $0.7 million in the aggregate if that first licensed product achieves specified clinical milestones plus $5.0 million if that first licensed product achieves specified regulatory and sales milestones for a third genetic context or the second licensed product achieves such specified development, regulatory and sales milestones in either of the first two specified genetic contexts. We have the right to reduce these milestone payments by a specified amount in the event the licensed product is not covered by Medivir&#x2019;s patents or if payments are due to a third party for a license under such third party&#x2019;s intellectual property rights. We are also obligated to pay Medivir a low single-digit royalty on net sales of any product covered by a licensed patent.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payments in respect of net sales or sublicense in a country shall remain in force on a product-by-product, country-by-country basis, with respect to products that are not covered by a licensed patent or certain of our patents, for ten years from the date of first commercial sale in such country, and products that are covered by a licensed patent or certain of our patents, until the expiration date of the last to expire of the licensed patents covering such product or its manufacture or use in the applicable country. No milestones have been achieved to date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Medivir Agreement expires on the date of expiration of all royalty obligations. Either party may terminate the Medivir Agreement earlier upon an uncured material breach of the other party.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Manufacturing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our lead investigational products are small molecule inhibitors that can be readily manufactured without requiring any specialized equipment or processes. We do not own or operate, and currently have no plans to establish any manufacturing facilities. We rely, and expect to continue to rely, on third-party Contract Development and Manufacturing Organizations, or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CDMOs for the manufacturing, packaging, labeling and distribution of our investigational products for preclinical and clinical testing, as well as for commercial manufacturing if any of our investigational products obtain marketing approval. A team of internal experts and consultants oversees activities at contracted CDMOs with the goal of ensuring our investigational products are being manufactured under current good manufacturing practices, or cGMP. At present, we have signed manufacturing and supply agreements for drug substance and drug product to support the first-in-human study of our PRMT5 development candidate TNG908. Currently, all manufacturing of TNG908 drug substance and drug product to be used in our planned clinical trial in the U.S. is conducted by one manufacturer.  We believe that the contracted CDMO has the capacity to support our planned registrational studies, in addition to the first-in-human study for TNG908. We plan to expand and diversify our supply chain by identifying and contracting other CDMOs with the capacity and expertise to support TNG908 and other investigational products in our pipeline and to manufacture commercial supply of our drugs (if those therapies obtain regulatory approval).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially important to the development of our business and our product candidates, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. We also rely on trade secrets relating to our proprietary target discovery technology platform and on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of precision oncology that may be important for the development of our business and product candidates. We additionally may rely on regulatory protection afforded through data exclusivity, market exclusivity and patent term extensions, where available.  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patent rights and regulatory protections are key factors that determine the period of market exclusivity for products in our industry. It is during the period of market exclusivity that, we believe, our potential future products have their greatest commercial value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial success may depend in part on our ability to: obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business; defend and enforce our patents; preserve the confidentiality of our trade secrets; and operate without infringing the valid enforceable patents and proprietary rights of third parties. Our ability to limit third parties from making, using, selling, offering to sell, or importing our product candidates (and any future products that may be approved for marketing by regulatory authorities) may depend on the extent to which we have rights under valid and enforceable licenses, patents, or trade secrets that cover these activities. In some cases, enforcement of these rights may depend on third-party licensors. With respect to both licensed and company-owned intellectual property, we cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially useful in protecting our commercial products and methods of manufacturing the same and to the extent such patents are commercially useful in protecting our commercial products or methods of manufacturing, such patents may be challenged or invalidated or otherwise become less useful in protecting our commercial products and methods of manufacturing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because a significant portion of a pharmaceutical product&#x2019;s patent protection can elapse during the course of developing and obtaining regulatory approval of the product, certain countries, including the U.S., provide compensatory mechanisms to extend patent terms for pharmaceutical products.  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patent expiration dates noted in the following paragraphs refer to statutory expiration dates and do not take into account any potential patent term adjustment or extension that may be available, or any potential disclaimers that may be needed to obtain certain patents that may reduce the term of such patents to correspond to that of earlier-expiring patents.  There </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">is no guarantee that any of our product candidates would be eligible for patent term extensions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">PRMT5 inhibitors</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We exclusively own two patent families covering the composition of matter and methods of use for our product candidate TNG908 and other structurally related PRMT5 inhibitors.  Patent applications are pending in the United States, Patent Cooperation Treaty, Argentina, Pakistan and Taiwan in one of the families, and a provisional United States patent application is pending in the other.  No patents have yet been granted in either of the two families.  Any issued patents covering TNG908 would be expected to expire no earlier than 2041.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, we exclusively own six patent families covering other PRMT5 inhibitors and their methods of use with expiration dates ranging from 2039 to 2043.  A US patent has been granted in one of the families.  Patent Cooperation Treaty applications or United States provisional patent applications are pending in the others.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">USP1 inhibitors</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We own two patent families covering USP1 inhibitors and methods of use thereof. Any patents issuing from each of these two patent families are expected to expire no earlier than 2042.  One of the patent families is exclusively owned by us, and the remaining one is jointly owned by us and Medivir AB and exclusively licensed to us under the Medivir Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Target 3 Portfolio</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We exclusively own one patent family relating to Target 3, including composition of matter and methods of use thereof.  Any issued patents covering Target 3 composition of matter, or methods of use thereof, are expected to expire no earlier than 2042.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Government Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, clinical trials, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, recordkeeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of drugs. We, along with our vendors, contract research organizations, or CROs, clinical investigators and contract manufacturing organizations, or CMOs, will be required to navigate the various preclinical, clinical, manufacturing and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval of our product candidates. The process of obtaining regulatory approvals of drugs and ensuring subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States, the FDA regulates drug products under the Federal Food, Drug, and Cosmetic Act, or FD&amp;C Act, its implementing regulations, and other federal statutes and regulations. Drugs are also subject to other federal, state and local statutes and regulations. If we fail to comply with applicable FDA or other regulatory requirements at any time with respect to product development, clinical testing, approval or any other regulatory requirements relating to product manufacture, processing, handling, storage, quality control, safety, pharmacovigilance, marketing, advertising, promotion, packaging, labeling, export, import, distribution or sale, we may become subject to administrative or judicial sanctions or other legal consequences. These sanctions or consequences could include, among other things, the FDA&#x2019;s refusal to approve pending applications, issuance of clinical holds for ongoing studies, suspension or revocation of approved applications, warning or untitled letters, product withdrawals or recalls, product seizures, relabeling or repackaging, total or partial suspensions of manufacturing or distribution, injunctions, fines, civil penalties or criminal prosecution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product candidates must be approved for therapeutic indications by the FDA before they may be marketed in the United States. For drug product candidates regulated under the FD&amp;C Act, FDA must approve a New Drug Application, or NDA. The process generally involves the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with good laboratory practice, or GLP, requirements; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">completion of the manufacture, under cGMP conditions, of the drug substance and drug product to be used in human clinical trials along with required analytical and stability testing; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually and when certain changes are made (for example, we received clearance of our IND application for TNG908 in the first quarter of 2022); </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">approval by an institutional review board, or IRB, or independent ethics committee at each clinical trial site before each trial may be initiated at that site; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">performance of adequate and well-controlled clinical trials in accordance with applicable IND regulations, good clinical practice, or GCP, requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">preparation and submission to the FDA of an NDA; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a determination by the FDA within 60 days of its receipt of an NDA to file the application for review; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">satisfactory completion of one or more FDA pre-approval inspections of the manufacturing facility or facilities where the drug will be produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#x2019;s identity, strength, quality and purity; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">satisfactory completion of FDA audit of the clinical trial sites that generated the data in support of the NDA; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">payment of user fees for FDA review of the NDA; and </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FDA review and approval of the NDA, including, where applicable, consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug in the United States. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preclinical studies and clinical trials for drugs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Before testing any drug in humans, the product candidate must undergo rigorous preclinical testing. Preclinical studies include laboratory evaluations of product chemistry, formulation and stability, as well as</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and animal studies to assess safety and in some cases to establish the rationale for therapeutic use. The conduct of preclinical studies is subject to federal and state regulation and requirements, including GLP requirements for safety/toxicology studies. The results of the preclinical studies, together with manufacturing information and analytical data, must be submitted to the FDA as part of an IND.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An IND is a request for authorization from the FDA to administer an investigational product to humans and must  become effective before clinical trials may begin. An IND includes the general investigational plan and the protocol(s) for clinical studies, the results of animal and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. Some long-term preclinical testing may continue after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the conduct of the clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks, and imposes a full or partial clinical hold.  A clinical hold can also be imposed once a trial has already begun, thereby halting the trial until any safety concerns or deficiencies articulated by FDA are corrected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The clinical stage of development involves the administration of the product candidate to healthy volunteers or patients under the supervision of qualified investigators, who generally are physicians not employed by or under the trial sponsor&#x2019;s control, in accordance with GCP requirements, which include the requirements that all research subjects provide their informed consent for their participation in any clinical trial.  Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, inclusion and exclusion criteria and the parameters and criteria to be used in monitoring safety and evaluating effectiveness. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable compared to the anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. The FDA, the IRB, or the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trials to public registries. Information about clinical trials, including results for clinical trials other than Phase 1 investigations, must be submitted within specific timeframes for publication on</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> www.ClinicalTrials.gov</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, a clinical trials database maintained by the National Institutes of Health.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, FDA may nevertheless accept the results of the study in support of an NDA if the study was conducted in accordance with GCP requirements, and the FDA is able to validate the data through independent analysis and an onsite inspection if deemed necessary.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical trials to evaluate therapeutic indications to support NDAs for marketing approval are typically conducted in three sequential phases, which may overlap or be combined.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> &#x2014; Phase 1 clinical trials involve initial introduction of the investigational product in a limited population of healthy human volunteers or patients with the target disease or condition. These studies are typically designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, excretion, the side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness. </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> &#x2014; Phase 2 clinical trials typically involve administration of the investigational product to a limited patient population with a specified disease or condition to evaluate the drug&#x2019;s potential efficacy, to determine the optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> &#x2014; Phase 3 clinical trials typically involve administration of the investigational product to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval and physician labeling. Generally, two adequate and well-controlled Phase 3 trials are required by the FDA for approval of an NDA.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the first quarter of 2022, we received clearance of our IND application for TNG908 to initiate a Phase 1/2 clinical trial.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2018, the FDA released a draft guidance titled &#x201c;Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics,&#x201d; which outlines how drug developers can utilize an adaptive trial design commonly referred to as a seamless trial design in early stages of oncology drug development (i.e., the first-in-human clinical trial) to compress the traditional three phases of trials into one continuous trial called an expansion cohort trial. Information to support the design of individual expansion cohorts are included in IND applications and assessed by FDA. Expansion cohort trials can potentially bring efficiency to drug development and reduce development costs and time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Post-approval trials, sometimes referred to as Phase 4 clinical trials or post-marketing studies, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication and are commonly intended to generate additional safety data regarding use of the product in a clinical setting. In certain instances, the FDA may mandate the completion of Phase 4 clinical trials as a condition of NDA approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA. Written IND safety reports must be submitted to the FDA and the investigators 15 days after the trial sponsor determines the information qualifies for reporting for serious and unexpected suspected adverse events, findings from other studies or animal or</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> testing that suggest a significant risk for human volunteers and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must also notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction as soon as possible but in no case later than seven calendar days after the sponsor&#x2019;s initial receipt of the information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product candidate and finalize a process for manufacturing the drug product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and manufacturers must develop, among other things, methods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">U.S. marketing approval for drugs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, together with detailed information relating to the product&#x2019;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA package requesting approval to market the product for one or more indications. An NDA must contain proof of the drug&#x2019;s safety and efficacy for the requested indications and the marketing application is required to include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings, together with detailed information relating to the product&#x2019;s chemistry, manufacturing, controls, and proposed labeling, among other things. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#x2019;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational drug to the satisfaction of the FDA. The FDA must approve an NDA before a drug may be marketed in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA reviews all submitted NDAs to ensure they are sufficiently complete to permit substantive review before it accepts them for filing and may request additional information rather than accepting the NDA for filing. The FDA must make a decision on accepting an NDA for filing within 60 days of receipt, and such decision could include a refusal to file by the FDA. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the NDA. The FDA reviews an NDA to determine, among other things, whether the product is safe and effective for the indications sought and whether the facility in which it is manufactured, processed, packaged or held meets standards, including cGMP requirements, designed to assure and preserve the product&#x2019;s continued identity, strength, quality and purity. Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, the FDA targets ten months, from the filing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">date, in which to complete its initial review of a new molecular entity NDA and respond to the applicant, and 6 months from the filing date of a new molecular entity NDA for Priority Review. The FDA does not always meet its PDUFA goal dates for standard or priority NDAs, and the review process is often extended by FDA requests for additional information or clarification. Further, under PDUFA, as amended, each NDA must be accompanied by a substantial user fee.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA also may require submission of a Risk Evaluation and Mitigation Strategy, or REMS, if it believes that a risk evaluation and mitigation strategy is necessary to ensure that the benefits of the drug outweigh its risks. A REMS can include use of risk evaluation and mitigation strategies like medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, special monitoring or other risk-minimization tools.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, which reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and are adequate to assure consistent production of the product within required specifications.  Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP and other requirements and the integrity of the clinical data submitted to the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a Complete Response Letter. A Complete Response Letter indicates that the review cycle of the application is complete and the application is not ready for approval. A Complete Response Letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA.  The FDA may require additional clinical or preclinical testing or recommend other actions, such as requests for additional information or clarification, that the applicant might take in order for the FDA to reconsider the application. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#x2019;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for indications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a product&#x2019;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Orphan drug designation and exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is a disease or condition with either a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 individuals in the United States when there is no reasonable expectation that the cost of developing and making the product available in the United States for the disease or condition will be recovered from sales of the product. Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process, although companies developing orphan-designated products are eligible for certain incentives, including tax credits for qualified clinical testing and waiver of application fees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to a seven-year period of marketing exclusivity during which the FDA may not approve any other applications to market the same therapeutic agent for the same indication, except in limited circumstances,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">such as a subsequent product&#x2019;s showing of clinical superiority over the product with orphan exclusivity or where the original applicant cannot produce sufficient quantities of product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Competitors, however, may receive approval of different therapeutic agents for the indication for which the orphan product has exclusivity or obtain approval for the same therapeutic agent for a different indication than that for which the orphan product has exclusivity. Orphan product exclusivity could block the approval of one of our products for seven years if a competitor obtains approval for the same therapeutic agent for the same indication before we do, unless we are able to demonstrate that our product is clinically superior. If an orphan designated product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan exclusivity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expedited development and review programs for drugs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA maintains several programs intended to facilitate and expedite development and review of new drugs to address unmet medical needs in the treatment of serious or life-threatening diseases or conditions. These programs include Fast Track designation, Breakthrough Therapy designation, Priority Review and Accelerated Approval, and the purpose of these programs is to get important new drugs to patients more quickly than standard FDA review timelines typically permit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A new drug is eligible for Fast Track designation if it is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address unmet medical needs for such disease or condition. Fast track designation applies to the combination of the product candidate and the specific indication for which it is being studied. Fast Track designation provides increased opportunities for sponsor interactions with the FDA during preclinical and clinical development, in addition to the potential for rolling review once a marketing application is filed. Rolling review means that the FDA may review portions of the marketing application before the sponsor submits the complete application.  In February 2022, the FDA granted Fast Track designation for TNG-908.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, a new drug may be eligible for Breakthrough Therapy designation if it is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug, alone or in combination with one or more other drugs, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough Therapy designation provides all the features of Fast Track designation in addition to as well as more intensive FDA interaction and guidance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any product submitted to the FDA for approval, including a product with Fast Track or Breakthrough Therapy designation, may also be eligible for additional FDA programs intended to expedite the review and approval process, including Priority Review designation and Accelerated Approval. A product is eligible for Priority Review, once an NDA is submitted, if the product that is the subject of the marketing application has the potential to provide a significant improvement in safety or effectiveness in the treatment, diagnosis or prevention of a serious disease or condition. Under priority review, the FDA&#x2019;s goal date to take action on the marketing application is six months compared to ten months for a standard review. Products are eligible for Accelerated Approval if they can be shown to have an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or an effect on a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, which is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accelerated Approval is usually contingent on a sponsor&#x2019;s agreement to conduct, in a diligent manner, adequate and well-controlled post-approval confirmatory studies to verify and describe the product&#x2019;s clinical benefit.  The FDA may withdraw approval of a drug or an indication approved under Accelerated Approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, these FDA programs do not change the scientific or medical standards for approval or the quality of evidence necessary to support approval, though they may expedite the development or review process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Pediatric information and pediatric exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Pediatric Research Equity Act, or PREA, as amended, certain NDAs and NDA supplements must contain data that can be used to assess the safety and efficacy of the product candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of pediatric data or full or partial waivers. The FD&amp;C Act requires</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">that a sponsor who is planning to submit a marketing application for a product candidate that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan, or PSP, within 60 days of an end-of-Phase 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 study. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies. The FDA and the sponsor must reach an agreement on the PSP. Unless otherwise required by regulation, PREA does not apply to a drug for an indication for which orphan designation has been granted, except that PREA will apply to an original NDA for a new active ingredient that is orphan-designated if the drug is a molecularly targeted cancer product intended for the treatment of an adult cancer and is directed at a molecular target that FDA determines to be substantially relevant to the growth or progression of a pediatric cancer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A drug can also obtain pediatric exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity may be granted based on the voluntary completion of a pediatric study that adequately responds to an FDA-issued &#x201c;Written Request&#x201d; for such a study.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">U.S. post-approval requirements for drugs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Drugs manufactured or distributed pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, reporting of adverse experiences and promotion and advertising requirements.  FDA's advertising and promotion requirements include restrictions on promoting products for unapproved uses or patient populations (known as &#x201c;off-label use&#x201d;) and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe approved products for off-label uses, manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, including not only by company employees but also by agents of the company or those speaking on the company&#x2019;s behalf, and a company that is found to have improperly promoted off-label uses may be subject to significant liability, including investigation by federal and state authorities. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties, including liabilities under the False Claims Act where products obtain reimbursement under federal health care programs. Promotional materials for approved drugs must be submitted to the FDA in conjunction with their first use or first publication. Further, for certain modifications to the drug, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain prior FDA approval of an NDA supplement, which may require the development of additional data or preclinical studies and clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-market testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#x2019;s safety and effectiveness after commercialization. In addition, manufacturers and their subcontractors involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMPs, which impose certain procedural and documentation requirements on sponsors and their CMOs. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon the sponsor and any third-party manufacturers that a sponsor may use.  Manufacturers and other parties involved in the drug supply chain for prescription drug products must also comply with product tracking and tracking requirements and notify the FDA of counterfeit, diverted, stolen and intentionally adulterated products or products that are otherwise unfit for distribution in the United States.  Accordingly, manufacturers must continue to expend time money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. Failure to comply with statutory and regulatory requirements may subject a manufacturer to possible legal or regulatory action, such as warning letters, suspension of manufacturing, product seizures, injunctions, civil penalties or criminal prosecution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA may withdraw approval of a product if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, requirements for</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">post-market studies or clinical trials to assess new safety risks, or imposition of distribution or other restrictions under a REMS. Other potential consequences include, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fines, warning letters or holds on post-approval clinical trials; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">refusal of the FDA to approve applications or supplements to approved applications, or suspension or revocation of product approvals; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product seizure or detention, or refusal to permit the import or export of products; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">injunctions or the imposition of civil or criminal penalties; and </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; or mandated modification of promotional materials and labeling and issuance of corrective information. </span></div></div>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Regulation of companion diagnostics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Companion diagnostics provide information that is essential for the safe and effective use of a corresponding drug.  A companion diagnostic may be used to help identify patients who are most likely to benefit from a particular therapeutic product; identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product; or monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness. Companion diagnostics are regulated as medical devices by the FDA. In the United States, the FD&amp;C Act, and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption or FDA exercise of enforcement discretion applies, diagnostic tests generally require marketing clearance or approval from the FDA prior to commercialization. The two primary types of FDA marketing authorization applicable to a medical device are clearance of a premarket notification, or 510(k), and approval of a PMA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To obtain 510(k) clearance for a medical device, or for certain modifications to devices that have received 510(k) clearance, a manufacturer must submit a premarket notification demonstrating that the proposed device is substantially equivalent to a previously cleared 510(k) device or to a pre-amendment device that was in commercial distribution before May 28, 1976, or a predicate device, for which the FDA has not yet called for the submission of a PMA.  If the FDA determines that the subject device is substantially equivalent to the predicate device, the subject device may be cleared for marketing. The 510(k) premarket notification pathway generally takes from three to 12 months from the date the application is completed, but can take significantly longer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A PMA must be supported by valid scientific evidence, which typically requires extensive data, including technical, preclinical, clinical and manufacturing data, to demonstrate to the FDA&#x2019;s satisfaction the safety and effectiveness of the device. For diagnostic tests, a PMA typically includes data regarding analytical and clinical validation studies. As part of its review of the PMA, the FDA will conduct a pre-approval inspection of the manufacturing facility or facilities to ensure compliance with the quality system regulation, or QSR, which requires manufacturers to follow design, testing, control, documentation and other quality assurance procedures. The FDA&#x2019;s review of an initial PMA is required by statute to take between six to ten months, although the process typically takes longer, and may require several years to complete. If the FDA evaluations of both the PMA and the manufacturing facilities are favorable, the FDA will either issue an approval letter or an approvable letter, which usually contains a number of conditions that must be met in order to secure the final approval of the PMA. If the FDA&#x2019;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny the approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. Once granted, PMA approval may be withdrawn by the FDA if compliance with post-approval requirements, conditions of approval or other regulatory standards is not maintained or problems are identified following initial marketing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 31, 2014, the FDA issued a final guidance document addressing the development and approval process for &#x201c;In Vitro Companion Diagnostic Devices.&#x201d; According to the guidance document, for novel therapeutic products that depend on the use of a diagnostic test and where the diagnostic device could be essential for the safe and effective use of the corresponding therapeutic product, the companion diagnostic device should be developed and approved or cleared contemporaneously with</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the therapeutic, although the FDA recognizes that there may be cases when contemporaneous development may not be possible. However, in cases where a drug cannot be used safely or effectively without the companion diagnostic, the FDA&#x2019;s guidance indicates it will generally not approve the drug without the approval or clearance of the diagnostic device.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Once cleared or approved, the companion diagnostic device must adhere to post-marketing requirements including the requirements of the FDA&#x2019;s QSR, adverse event reporting, recalls and corrections along with product marketing requirements and limitations. Like drug makers, companion diagnostic makers are subject to unannounced FDA inspections at any time during which the FDA will conduct an audit of the product(s) and the company&#x2019;s facilities for compliance with its authorities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other regulatory matters</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Manufacturing, sales, promotion and other activities of product candidates following product approval, where applicable, or commercialization are also subject to regulation by numerous regulatory authorities in the United States in addition to the FDA, which may include the Centers for Medicare &amp; Medicaid Services, or CMS, other divisions of the HHS, the Department of Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety &amp; Health Administration, the Environmental Protection Agency and state and local governments and governmental agencies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other healthcare laws</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Healthcare providers, physicians, and third-party payors will play a primary role in the recommendation and prescription of any products for which we will seek to obtain marketing approval. Our business operations and any current or future arrangements with third-party payors, healthcare providers and physicians may expose us to certain liabilities and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we develop, market, sell and distribute any drugs for which we obtain marketing approval in the future. In the United States, these laws include, without limitation, state and federal anti-kickback, false claims, physician transparency, and patient data privacy and security laws and regulations, including but not limited to those described below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. A person or entity need not have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers, on the one hand, and prescribers, purchasers and formulary managers, on the other. In addition, the government may assert that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act. </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The federal civil and criminal false claims and civil monetary penalties laws, including the federal False Claims Act, or FCA, imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#x201c;cause&#x201d; the submission of false or fraudulent claims. </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The federal civil monetary penalties laws impose civil fines for, among other things, the offering or transfer or remuneration to a Medicare or state healthcare program beneficiary, if the person knows or should know it is likely to influence the beneficiary&#x2019;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state health care program, unless an exception applies. </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;display:inline-flex;font-size:1.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">HIPAA, which imposes criminal and civil liability for knowingly and willfully executing a scheme, or attempting to execute a scheme, to defraud any healthcare benefit program, including private payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, or falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">services. Similar to the federal Anti-Kickback Statute, a person or entity may be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, impose, among other things, specified requirements on covered entities and their respective business associates relating to the privacy and security of individually identifiable health information, including mandatory contractual terms and required implementation of technical safeguards of such information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates in some cases, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#x2019; fees and costs associated with pursuing federal civil actions. </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal price reporting laws, which require manufacturers to calculate and report complex pricing metrics to government programs, where such reported prices may be used in the calculation of reimbursement and/or discounts on approved products</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Physician Payments Sunshine Act, enacted as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, imposed new annual reporting requirements for certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#x2019;s Health Insurance Program, for certain payments and &#x201c;transfers of value&#x201d; provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors, as well as certain non-physician providers such as physician assistants and nurse practitioners) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members.  </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Analogous state and foreign laws and regulations, including, but not limited to, state anti-kickback and false claims laws, may be broader in scope than the provisions described above and may apply regardless of payor. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and relevant federal government compliance guidance; require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers; restrict marketing practices or require disclosure of marketing expenditures and pricing information. State and foreign laws may govern the privacy and security of health information in some circumstances. These data privacy and security laws may differ from each other in significant ways and often are not pre-empted by HIPAA, which may complicate compliance efforts. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other related governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, disgorgement, exclusion from government funded healthcare programs, such as Medicare and Medicaid, reputational harm, additional oversight and reporting obligations if we become subject to a corporate integrity agreement or similar settlement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Insurance Coverage and Reimbursement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage, and establish adequate reimbursement levels for, the product. In the United States, the principal decisions about reimbursement for new medicines are typically made by CMS. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. Coverage and reimbursement for drug products can differ significantly from payor to payor. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, which will require additional expenditure above and beyond the costs required to obtain FDA or other comparable regulatory approvals.  Some product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, our operations and financial condition (when a product candidate is approved for marketing). Levels of coverage and reimbursement for a product can differ significantly from payor to payor.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The containment of healthcare costs has become a priority of federal, state and foreign governments (and other third-party payers), and the prices of products have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#x2019;s revenue generated from the sale of any approved products. Coverage policies and third-party payor reimbursement rates may change at any time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the European Union do not follow price structures of the U.S. and generally prices tend to be significantly lower</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Current and future healthcare reform legislation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States and certain foreign jurisdictions, there have been, and likely will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system directed at broadening the availability of healthcare, improving the quality of healthcare, and containing or lowering the cost of healthcare. For example, in March 2010, the United States Congress enacted the ACA, which, among other things, includes changes to the coverage and payment for products under government health care programs. The ACA includes provisions of importance to our potential product candidates that:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">created an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic products, apportioned among these entities according to their market share in certain government healthcare programs; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#x2019;s Medicaid rebate liability; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expanded manufacturers&#x2019; rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate for both branded and generic drugs and revising the definition of &#x201c;average manufacturer price,&#x201d; or AMP, for calculating and reporting Medicaid drug rebates on outpatient prescription drug prices; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expanded the types of entities eligible for the 340B drug discount program; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">established the Medicare Part D coverage gap discount program by requiring manufacturers to provide point-of-sale-discounts off the negotiated price of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturers&#x2019; outpatient drugs to be covered under Medicare Part D; and </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since its enactment, there have been numerous judicial, administrative, executive, and  legislative challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court's decision, President Biden issued an Executive Order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The Executive Order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other healthcare reform measures of the Biden administrations or other efforts, if any, to challenge repeal or replace the ACA, will impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. On August 2, 2011, the U.S. Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic. Following the temporary suspension, a 1% payment reduction will occur beginning April 1, 2022 through June 30, 2022, and the 2% payment reduction will resume on July 1, 2022.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On January 2, 2013, the U.S. American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On April 13, 2017, CMS published a final rule that gives states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On May 30, 2018, the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On&#x202f;May 23, 2019, CMS published a final rule to allow Medicare Advantage Plans the option of using step therapy for Part B drugs beginning January 1, 2020.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On December 20, 2019, former President Trump signed into law the Further Consolidated Appropriations Act (H.R. 1865), which repealed the Cadillac tax, the health insurance provider tax, and the medical device excise tax.  It is impossible to determine whether similar taxes could be instated in the future.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to drug pricing practices.  Specifically, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, and review the relationship between pricing and manufacturer patient programs.  At the federal level, President Biden signed an Executive Order on July 9, 2021 affirming the administration&#x2019;s policy to (i) support legislative reforms that would lower the prices of prescription drug and biologics, including by allowing Medicare to negotiate drug prices, by imposing inflation caps, and, by supporting the development and market entry of lower-cost generic drugs and biosimilars; and (ii) support the enactment of a public health insurance option.  Additionally, on November 30, 2020, HHS published a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to court order, the removal and addition of the aforementioned safe harbors were delayed and recent legislation imposed a moratorium on implementation of the rule until January 1, 2026. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that they will continue to seek new legislative measures to control drug costs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. Federal Government will pay for healthcare drugs and services, which could result in reduced demand for our drug candidates or additional pricing pressures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain drug access and marketing cost disclosure and transparency measures designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our drugs (if approved for marketing) or put pressure on our drug pricing, which could negatively affect our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outside the United States, ensuring coverage and adequate payment for a product also involves challenges. Pricing of prescription pharmaceuticals is subject to government control in many countries. Pricing negotiations with government authorities can extend well beyond the receipt of regulatory approval for a product and may require a clinical trial that compares the cost-effectiveness of a product to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed upon. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies or so-called health technology assessments, in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its member states to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a product or may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other member states allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states, and parallel trade, i.e., arbitrage between low-priced and high-priced member states, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other United States environmental, health and safety laws and regulations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may be subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We maintain workers&#x2019; compensation insurance to cover us for costs and expenses that we may incur due to injuries to our employees, but this insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Government regulation of drugs outside of the United States</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy and governing, among other things, clinical trials, marketing authorization, manufacturing, commercial sales, promotion and distribution of our potential future products. For instance, in the United Kingdom and the European Economic Area, or the EEA (comprised of the 27 EU Member States plus Iceland, Liechtenstein and Norway), medicinal products must be authorized for marketing by using either the centralized authorization procedure or national authorization procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Centralized procedure</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> &#x2014; The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid throughout the EEA. Pursuant to Regulation (EC) No. 726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy products (gene therapy, somatic cell therapy and tissue engineered products) and products with a new active substance indicated for the treatment of certain diseases, which includes products for the treatment of cancer. For medicines that do not fall within one of the mandatory categories, an applicant still has the option of submitting an application for a centralized marketing authorization to the European Medicines Agency, or EMA, as long as the medicine concerned contains a new active substance not yet authorized in the EEA, is a significant therapeutic, scientific or technical innovation, or if its authorization would be in the interest of public health in the EEA. If pursuing marketing authorization of a product candidate for a therapeutic indication under the centralized procedure, the EMA&#x2019;s Committee for Medicinal Products for Human Use, or CHMP, is responsible for conducting an initial assessment of whether a product meets the required quality, safety and efficacy requirements, and whether a product has a positive benefit/risk ratio. Under the centralized procedure the maximum timeframe for the evaluation of a marketing authorization application, or MAA, by the EMA is 210 days, excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP. Clock stops may extend the timeframe of evaluation of a MAA considerably beyond 210 days. Where the CHMP gives a positive opinion, it provides the opinion together with supporting documentation to the European Commission, who make the final decision to grant a marketing authorization, which is issued within 67 days of receipt of the EMA&#x2019;s recommendation. Accelerated assessment might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of major public health interest, particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of a MAA under the accelerated assessment procedure is 150 days, excluding clock stops, but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that the application is no longer appropriate to conduct an accelerated assessment. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;display:inline-flex;font-size:1.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">National authorization procedures</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> &#x2014; There are also two other possible routes to authorize products for therapeutic indications in several countries, which are available for products that fall outside the scope of the centralized procedure:  </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Using the decentralized procedure, an applicant may apply for simultaneous authorization in more than one EEA Member State for a medicinal product that has not yet been authorized in any EEA Member State and that does not fall within the mandatory scope of the centralized procedure. </span></div></div>
  <div style="margin-left:9.065%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.989278055754109%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the mutual recognition procedure, a medicine is first authorized in one EEA Member State, in accordance with the national procedures of that country. Following this, additional marketing authorizations can be sought from other EEA Member States in a procedure whereby the countries concerned recognize the validity of the original, national marketing authorization. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In both cases, as with the centralized procedure, the competent authorities of the EEA Member States assess the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy before granting the marketing authorization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the EEA, new products for therapeutic indications that are authorized for marketing (i.e., innovator products) qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from referencing the preclinical and clinical trial data contained in the dossier of the innovator product when applying for a generic or biosimilar marketing authorization in the EEA during a period of eight years from the date on which the innovator product was first authorized in the EEA. The additional two-year period of market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EEA until ten years have elapsed from the initial authorization of the reference product in the European Union. The overall ten-year period can be extended to a maximum of eleven years if, during the first eight years of those ten years, the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical entity so that the innovator gains the prescribed period of data exclusivity, another company may market another version of the product if such company obtained marketing authorization based on a MAA with a complete independent data package of pharmaceutical tests, preclinical tests and clinical trials</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The criteria for designating an &#x201c;orphan medicinal product&#x201d; in the EEA are similar in principle to those in the United States. Under Article 3 of Regulation (EC) 141/2000, in the EEA a medicinal product may be designated as orphan if it meets the following criteria: (i) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; and (ii) either (a) such condition affects no more than five in 10,000 persons in the EEA when the application is made, or (b) it is unlikely that the product, without the benefits derived from orphan status, would generate sufficient return in the EEA to justify the investment needed for its development; and (iii) there exists no satisfactory method of diagnosis, prevention or treatment of such condition, or if such a method exists, the product will be of significant benefit to those affected by the condition. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten years of market exclusivity for the approved therapeutic indication. During this ten-year orphan market exclusivity period, no marketing authorization application shall be accepted, and no marketing authorization shall be granted for a similar medicinal product for the same indication, unless certain conditions are met. An orphan product can also obtain an additional two years of market exclusivity in the European Union for pediatric studies.  Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Similar to the United States, the various phases of non-clinical and clinical research in the European Union are subject to significant regulatory controls.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Clinical Trials Directive 2001/20/EC, the Directive 2005/28/EC on GCP and the related national implementing provisions of the individual EU Member States govern the system for the approval of clinical trials in the European Union. Under this system, an applicant must obtain prior approval from the national competent authority, or NCA, of the EU Member States in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial at a specific study site after the competent ethics committee, or EC, has issued a favorable opinion. The clinical trial application must be accompanied by, among other documents, an investigational medicinal product dossier (the Common Technical Document) with supporting information prescribed by applicable directives. All suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial have to be reported to the NCA and ECs of the Member State where they occurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Government regulation of data collection outside of the United States</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the event we conduct clinical trials in the European Union, we will be subject to additional privacy restrictions. The collection and use of personal health data in the European Economic Area, or EEA (being the European Union plus Norway, Iceland, and Liechtenstein), is governed by the General Data Protection Regulation, or the GDPR, which became effective on May 25, 2018. The GDPR applies to the processing of personal data by any company established in the EEA and to companies established outside the EEA to the extent they process personal data in connection with the offering of goods or services to data subjects in the EEA or the monitoring of the behavior of data subjects in the EEA. The GDPR enhances data protection obligations for data controllers of personal data, including stringent requirements relating to the consent of data subjects, expanded disclosures about how personal data is used, enhanced requirements for securing personal data, requirements to conduct privacy impact assessments for &#x201c;high risk&#x201d; processing, limitations on retention of personal data, mandatory data breach notification and &#x201c;privacy by design&#x201d; requirements, and creates direct obligations on service providers acting as processors. The GDPR also imposes strict rules on the transfer of personal data outside of the EEA to countries that do not ensure an adequate level of protection, like the United States. Failure to comply with the requirements of the GDPR and the related national data protection laws of the European Union Member States and Norway, Iceland and Liechtenstein, which may deviate slightly from the GDPR, may result in fines of up to 4% of a company&#x2019;s global revenue for the preceding financial year, or &#x20ac;20,000,000, whichever is greater. Moreover, the GDPR grants data subjects the right to claim material and non-material damages resulting from infringement of the GDPR. Given the breadth and depth of changes in data protection obligations, maintaining compliance with the GDPR will require significant time, resources and expense, and we will be required to put in place controls and processes ensuring compliance with the new data protection rules. There has been limited enforcement of the GDPR to date, particularly in biopharmaceutical development, so we face uncertainty as to the exact interpretation of the new requirements on any future trials and we may be unsuccessful in implementing all measures required by data protection authorities or courts in interpretation of the new law. Further, the United Kingdom&#x2019;s decision to leave the European Union, means that it has in force its own legislation which is aligned with the GDPR, known as the Data</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Protection Act 2018. The requirements are similar except that the United Kingdom is now regarded as a &#x201c;third country&#x201d; for the purposes of transfers of personal data from the EEA. Transfers continue to flow freely from the United Kingdom to the EEA; however, as part of the agreement between the United Kingdom and the European Union, the United Kingdom intends to obtain an adequacy decision from the European Commission to ensure personal data can continue to flow freely from the European Union to the United Kingdom.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Data protection authority activity differs across the European Union, with certain authorities applying their own agenda which shows there is uncertainty in the manner in which data protection authorities will seek to enforce compliance with GDPR. For example, it is not clear if the authorities will conduct random audits of companies doing business in the European Union, or if the authorities will wait for complaints to be filed by individuals who claim their rights have been violated. Enforcement uncertainty and the costs associated with ensuring GDPR compliance are onerous and may adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Should we utilize third-party distributors, compliance with such foreign governmental regulations would generally be the responsibility of such distributors, who may be independent contractors over whom we have limited control.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Competition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We face direct competition from pharmaceutical and biotechnology companies leveraging the principle of synthetic lethality as well as companies developing therapies for the same target pathway and the same indications. Well-established companies that are developing or may develop therapies based on synthetic lethality include AstraZeneca, GlaxoSmithKline, Bristol Myers Squibb, Merck KGaA and Pfizer. Smaller and earlier-stage companies focused on synthetic lethality include Artios Pharma, Cyteir Therapeutics, KSQ Therapeutics, Ideaya Biosciences, MetaboMed, Mirati Therapeutics and Repare Therapeutics.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our PRMT5 inhibitor program, which includes TNG908 as well as a next generation compound that is in development, will face direct competition from companies that have clinical-stage, MTA-cooperative PRMT5 inhibitors that are selective for MTAP-deleted cancers. We are aware that Mirati Therapeutics and Amgen have a clinical MTA-cooperative PRMT5 inhibitor program, using the same mechanism of action as TNG908. The INDs submitted by Tango, Mirati and Amgen have all received clearance by the FDA to commence clinical trials for their respective inhibitors. Currently, there are no MTA-cooperative PRMT5 inhibitors that are authorized for marketing by any regulatory authority.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Indirect competition may come from non-MTAP deletion selective PRMT5 programs or MAT2A inhibitor programs that are uniquely different than the TNG908 mechanism of action. Two companies have non-MTAP selective PRMT5 inhibitors in clinical development, including Prelude Therapeutics (PRT543 and PRT811) and Johnson &amp; Johnson (JNJ 64619178). GSK and Pfizer have recently discontinued the clinical development of their non-MTAP selective PRMT5 inhibitors. MAT2A is an enzyme upstream of PRMT5 essential for the metabolism of the PRMT5 co-factor SAM that acts on the same pathway as TNG908. Agios Pharmaceuticals (AG-270) and Ideaya Biosciences (IDE397) are the two clinical programs we are aware of competing in the MAT2A space. Agios announced the divestment of their oncology portfolio to Servier Pharmaceuticals, including the MAT2A program in December 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Competition for our preclinical USP1 inhibitor program comes from KSQ Therapeutics, which has a USP1 program in preclinical development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We face competition more broadly across the oncology market for safe, efficacious, and reimbursable cancer treatments. The most common methods of treating patients with cancer are surgery, radiation, and drug therapy, including chemotherapy, hormone therapy, biologic therapy (such as monoclonal and bispecific antibodies), immunotherapy, cell-based therapy and targeted therapy, or a combination of any such methods. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. While our product candidates, if any are approved, may compete with these existing drugs and other therapies, to the extent they are ultimately used in combination with or as an adjunct to these therapies, our product candidates may not be competitive with them. Some of these drugs are branded and subject to patent protection, and others are available on a generic basis. Insurers and other third-party payors may also encourage the use of generic products or specific branded products. As a result, obtaining market acceptance of, and gaining significant share of the market for, any of our product candidates that we successfully introduce to the market may pose challenges. In addition, many companies are developing new oncology therapeutics, and we cannot predict what the standard of care will be as our product candidates progress through clinical development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many of our competitors, either alone or with their collaborators, have significantly greater resources, expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement, and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific, sales, marketing and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove significant competitors, particularly through collaborative arrangements with large and established companies. Additionally, mergers and acquisitions may result in even more resources being concentrated in our competitors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Employees and Human Capital Resources</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Attracting and retaining qualified and experienced employees in research and development, clinical, manufacturing, quality and other positions is crucial to our ability to compete effectively.  Competition for these employees is intense in the pharmaceutical industry in which we operate. Our ability to recruit and retain such employees depends on a number of factors, including the growth of our organization, the culture and work environment we have created, our organizational values and goals and our corporate philosophy; talent development and career opportunities; and compensation and benefits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had 91 full-time employees, of which 42 have M.D. or Ph.D. degrees. Within our workforce, 67 employees are engaged in research and development and 24 are engaged in business development, finance, legal, and general management and administration. None of our employe</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">es are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Talent Acquisition and Employee Development</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our principal talent acquisition goal is to attract, retain, and develop the highest quality talent. As we build our organization beyond drug discovery and drug development, our goals have been extended to include establishing an employee base that will allow us to efficiently move our pipeline products through clinical trials, regulatory approvals and into the market where we can help patients and their families and, simultaneously, to have a workforce that provides diverse backgrounds and ideas, are trained to operate and act at the highest standards of ethics and integrity, and are dedicated to achieve the highest level of innovation and to advance oncology treatments through the use of synthetic lethality. To support our talent acquisition, our human resources programs are designed to develop talent to prepare them for leadership positions in the future; reward employees through competitive benefits programs, including competitive pay, incentive compensation, and an equity program that aligns the incentives of our employees with the interests of our shareholders; enhance our culture through efforts aimed at making the workplace more engaging and inclusive; and retain and develop talent that embody our core values.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Diversity:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While Tango is early in its corporate development, our employees represent a broad set of backgrounds, perspectives and experiences.  We attribute our early growth and success to the diversity that our employees bring with them to their professional roles.  We are committed to the goals of diversity, equity and inclusion, which is the foundation upon which we are building a leading synthetic lethality business that is pushing the advances in oncology care, all with the objective of benefiting patients.  We are building a work environment where employees can express themselves and have a voice in how we operate.  Among other things, members of our management meet in small group sessions with all employees throughout the year and the feedback in these meetings is used to drive our professional development programs, our compensation structure, our organizational development and our culture.  These and similar programs are important to develop a sense of belonging for all employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Employee Engagement:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We survey our employees on an annual basis to assess overall engagement of our workforce, and compare our engagement results against a set of benchmark companies. These companies are in the biotech sector and of similar size (number of employees).  We use these results, both our internal results and the comparative results against the benchmark companies, to assess our employee engagement performance during the preceding year and to determine areas of focus going forward.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In our most recent survey, conducted in late-2021, the results indicated improvements in almost all areas reviewed in the survey and the results were generally higher than our benchmark dataset, which supports our view that we have positive employee engagement. Every year, we take these results, and a task force is formed to enable actions that will further improve our engagement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">COVID-19</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The COVID-19 pandemic continues to present a substantial public health and economic challenge globally. While the impact of the COVID-19 pandemic to date on our business has not been material, it is continuously evolving and its future effects are difficult to predict with meaningful precision as the impact will depend on many factors beyond our control and knowledge at this point in time. As the pandemic continues and new variants of the COVID-19 virus presents itself, we are monitoring its impact on our business.  For example, we received FDA clearance of our IND application for TNG908 in the first quarter of 2022 and expect to commence clinical trials in the second quarter of 2022.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> We do not expect, at this time, that our clinical trial enrollment and progress will be materially delayed beyond our anticipated timeframe, but any adverse developments with respect to COVID-19 may cause unexpected delays in these trials, including as a result of our CRO or clinical trial sites not having sufficient resources and employees to conduct the trials in the anticipated timeframe.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">    </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 1A. Risk Factors.</span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investing in our securities involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with all other information in this Annual Report on Form 10-K, including our financial statements and the related notes and the &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations.&#x201d; The occurrence of one or more of the events or circumstances described in these risk factors, alone or in combination with other events or circumstances, may have a material adverse effect on our business, reputation, revenue, financial condition, results of operations and future prospects, in which event the market price of our common stock could decline, and you could lose part or all of your investment. Unless otherwise indicated, reference in this section and elsewhere in this Annual Report on Form 10-K to our business being adversely affected, negatively impacted or harmed will include an adverse effect on, or a negative impact or harm to, our business, reputation, financial condition, results of operations, revenue and our future prospects. The material and other risks and uncertainties summarized above and described below are not intended to be exhaustive and are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. This Annual Report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of a number of factors, including the risks described below. See also the section titled &#x201c;Note Regarding Forward-Looking Statements&#x201d; above.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Limited Operating History, Financial Position, and Capital Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are a precision oncology company with a limited operating history.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a precision oncology company with a limited operating history. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. Since the Company's inception, we have devoted substantially all of our efforts to organizing and staffing our company, acquiring and developing intellectual property, business planning, raising capital, conducting discovery, research and development activities, and providing general and administrative support for these operations. We have no products approved for commercial sale and therefore have never generated any revenue from product sales, and we do not expect to in the foreseeable future. We have not obtained regulatory approvals for any of our product candidates, and there is no assurance that we will obtain approvals in the future.  Our first investigational new drug, or IND, application, for TNG908, was cleared by the FDA in the first quarter of 2022.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other than TNG908, all of our product candidates are still in preclinical development. We expect to continue to incur significant expenses and operating losses over the next several years and for the foreseeable future. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on cash and cash equivalent holdings, our stockholders&#x2019; deficit and working capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have incurred significant net losses since our inception and anticipate that we will continue to incur losses for the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have incurred significant net losses since our inception. For the year ended December 31, 2021, our net loss was $58.2 million. As of December 31, 2021, we had an accumulated deficit of $161.3 million. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect our research and development expenses to increase significantly in connection with the commencement and continuation of clinical trials of our product candidates. In addition, if we obtain regulatory approval for our product candidates, we will incur significant sales, marketing and manufacturing expenses. As a result, we expect to continue to incur significant and increasing operating losses for the foreseeable future. Because of the numerous risks and uncertainties associated with developing pharmaceutical products, we are unable to predict the extent of any future losses or when we will become profitable, if at all. Even if we do become profitable, we may not be able to sustain or increase our profitability on a quarterly or annual basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The amount of our future losses is uncertain and our quarterly and annual operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline. Our quarterly and annual operating results may fluctuate significantly in the future due to a variety of factors, many of which are outside of our control and may be difficult to predict, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing and success or failure of future clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to obtain INDs for our pipeline product candidates, successfully open clinical trial sites and recruit and retain subjects for clinical trials, and any delays caused by difficulties in such efforts;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to obtain regulatory approval for our product candidates, and the timing and scope of any such approvals we may receive;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing and cost of, and level of investment in, research and development activities relating to our product candidates and any future product candidates and research-stage programs, which may change from time to time;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of manufacturing our product candidates and products, should they receive regulatory approval, which may vary depending on FDA and other comparable foreign regulatory requirements, the quantity of production and the terms of our agreements with manufacturers;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to attract, hire and retain qualified personnel;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expenditures that we will or may incur to develop additional product candidates;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the level of demand for our product candidates should they receive regulatory approval, which may vary significantly;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and existing and potential future therapeutics that compete with our product candidates;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the changing and volatile U.S. and global economic environments, including as a result of the COVID-19 pandemic; and</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">future accounting pronouncements or changes in our accounting policies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The individual or cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have no products approved for commercial sale and have not generated any revenue from product sales.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ability to become profitable depends upon our ability to generate revenue. To date, we have not generated any revenue from product sales, and we do not expect to generate any revenue from the sale of products in the near future. We do not expect to generate significant product revenue unless and until we obtain regulatory approval of, and begin to sell, one or more of our product candidates. Our ability to generate revenue depends on a number of factors, including, but not limited to, our ability to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">successfully complete our planned preclinical studies for our novel precision oncology development programs;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">timely file INDs for our other programs, and clearance of these INDs to allow for commencement of such future clinical trials;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">timely patient enrollment and patient dosing in our TNG908 clinical trial;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">successfully complete our TNG908 clinical trial and any future clinical trials;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">initiate and successfully complete all safety and efficacy studies required to obtain U.S. and foreign regulatory approval for our product candidates;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">make and maintain arrangements with third-party manufacturers for clinical supply and commercial manufacturing;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtain and maintain patent and trade secret protection or regulatory exclusivity for our product candidates;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">launch commercial sales of our products, if and when approved, whether alone or in collaboration with others;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtain and maintain acceptance of our products, if and when approved, by patients, the medical community and third-party payors;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">position our products to effectively compete with other therapies;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtain and maintain healthcare coverage and adequate reimbursement;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">enforce and defend intellectual property rights and claims;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">implement measures to help minimize the risk of COVID-19 to our employees as well as patients and subjects to be enrolled in our clinical trials; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">maintain a continued acceptable safety profile of our products following approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we do not achieve these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations or we may be required to sell or license assets to third parties on terms that are not favorable to us, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, our most advanced program is a PRMT5 inhibitor, TNG908.  We believe our next-generation compounds have the potential to be more effective than TNG908, with a yet wider therapeutic index. If additional preclinical or clinical</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">evaluation of our next-generation compounds supports this hypothesis, we may elect to promote a next-generation compound as our lead PRMT5 inhibitor, which would result in a delay to our development timeline of approximately 12 to 18 months.  If we elect to promote this next-generation compound, it may result in the delay in receiving potential revenue from product sales, if approved by regulatory authorities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We will need to raise substantial additional funding. If we are unable to raise capital when needed or on terms acceptable to us, we would be forced to delay, reduce or eliminate some of our product development programs or commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The development of pharmaceutical products is capital-intensive. We are currently advancing our precision oncology programs through clinical and preclinical development.  We received FDA clearance of our IND application for TNG908 in the first quarter of 2022 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and plan to initiate a Phase 1/2 clinical trial in the second quarter of 2022.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> We also plan to file INDs for our undisclosed target for STK11-mutant cancers (Target 3) and our USP1 inhibitor program in 2023. Consequently, we expect our expenses to significantly increase in connection with our ongoing activities, particularly as we continue the research and development of, initiate and complete clinical trials of, and seek regulatory approval for, our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, depending on the status of regulatory approval or, if we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. We may also need to raise additional funds sooner if we choose to pursue additional indications and/or geographies for our current or future product candidates or otherwise expand more rapidly than we presently anticipate. Furthermore, we have, and will continue to, incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate certain of our research and development programs or future commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.2%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect that our existing cash, cash equivalents and marketable securities will fund our projected operating requirements at least into the second half of 2024. However, our future capital requirements will depend on and could increase significantly as a result of many factors (which may result in exhausting such cash resources prior to the second half of 2024), including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope, progress, results and costs of product discovery, preclinical and clinical development, and clinical trials for our product candidates;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the potential additional expenses attributable to adjusting our development plans (including any supply related matters) to the COVID-19 pandemic;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope, prioritization and number of our research and development programs;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs, timing and outcome of regulatory review of our product candidates;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to establish and maintain additional collaborations on favorable terms, if at all;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the achievement of milestones or occurrence of other developments that trigger payments under our existing collaboration agreements or any additional collaboration agreements we may establish;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under future collaboration agreements, if any;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the extent to which we acquire or in-license other product candidates and technologies;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs of securing manufacturing arrangements for clinical and commercial production;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to hire and retain skilled scientific and operational personnel to meet our development, clinical and commercial objectives;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">costs related to the development of any companion diagnostics we may use in the future; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs of establishing or contracting for sales and marketing capabilities if we obtain regulatory approvals to market our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Identifying potential product candidates and conducting preclinical development testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenue, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. Disruptions in the financial markets in general and due to the ongoing COVID-19 pandemic may make equity and debt financing more difficult to obtain and may have a material adverse effect on our ability to meet our fundraising needs. We cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are unable to obtain funding on a timely basis or on acceptable terms, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any product that has received regulatory approval or be unable to expand our operations or otherwise capitalize on our business opportunities as desired, which could materially affect our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of private and public equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. The terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. To the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, the ownership interest of our existing common stockholders will be diluted, and the terms of those securities may include liquidation or other preferences that may materially adversely affect your rights as a common stockholder. Debt financing, if available, would increase our fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, acquiring, selling or licensing intellectual property rights, and making capital expenditures, declaring dividends, repurchase shares of our common stock, or other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to meet certain milestones in connection with debt financing and the failure to achieve such milestones by certain dates may force us to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us which could have a material adverse effect on our business, operating results and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also could be required to seek funds through arrangements with additional collaborators or otherwise at an earlier stage than otherwise would be desirable. If we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or product candidates, grant licenses on terms that may not be favorable to us or grant rights to develop and market our product candidates that we would otherwise prefer to develop and market ourselves, any of which may have a material adverse effect on our business, operating results and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to the Development of our Precision Oncology and Other Programs and Product Candidates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have never successfully completed any clinical trials and we may be unable to do so for any product candidates we develop. Certain of our programs are still in preclinical development and may never advance to clinical development.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have not yet demonstrated our ability to successfully register, initiate, enroll and complete clinical trials, including large-scale, pivotal clinical trials, obtain regulatory approvals, manufacture a commercial scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization.  We received FDA clearance of our IND application for TNG908 in the first quarter of 2022.  Other than TNG908, our programs are still in preclinical development and may never advance to clinical development. We also plan to file INDs for our undisclosed target for STK11-mutant cancers (Target 3) and our USP1 inhibitor program in 2023. We may not be able to file such INDs or INDs for any of our other product candidates on the timelines we expect, if at all.  Further, timelines for developing and filing INDs are subject to significant uncertainties and projected timelines can be improved upon or delayed.  For example, we extended the timeline for filing an IND for our USP1 inhibitor program as we continue to work on a development candidate that has improved pharmaceutical properties.  Moreover, we cannot be sure that submission of an IND will result in the U.S. Food and Drug Administration, or FDA, allowing clinical trials to begin, or that, once begun, issues will not arise that require us to suspend or terminate clinical trials. Any guidance we receive from the FDA or other regulatory authorities is subject to change. These regulatory authorities could change their position, including on the acceptability of our trial designs or the clinical endpoints selected, which may require us to complete additional clinical trials or result in the imposition of stricter approval conditions than we currently expect. Successful completion of our clinical trials is a prerequisite to submitting an NDA to the FDA, an MAA to the European Medicines Agency, or EMA, or other marketing applications to regulatory authorities in other jurisdictions, for each product candidate and, consequently, the regulatory</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">approval of each product candidate. We currently do not have any product candidates in clinical development. While the IND for our lead program, TNG908, was cleared by the FDA, it is possible that patients may not be enrolled and the study may not be completed (and preliminary, initial or final trial results may not be available) on time. Similarly, future clinical trials may not begin on time or be completed on schedule, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">             If we are required to conduct additional preclinical studies or clinical trials of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety and/or efficacy concerns, we may, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">be delayed in obtaining regulatory approval for our product candidates;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not obtain regulatory approval at all;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtain regulatory approval for indications or patient populations that are not as broad as intended or desired;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">continue to be subject to post-marketing testing requirements; or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">have the product removed from the market after obtaining regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our programs are focused on the development of oncology therapeutics for patients with genetically defined or biomarker-driven cancers, which is a rapidly evolving area of science, and the approach we are taking to discover and develop drugs is novel and may never lead to approved or marketable products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The discovery and development of oncology therapeutics for patients with genetically defined or biomarker-driven cancers is a rapidly evolving area, and the scientific discoveries that form the basis for our efforts to discover and develop product candidates are relatively new. Our unique functional genomics discovery approach is based on the genetic concept of synthetic lethality. The scientific evidence to support the feasibility of developing product candidates based on these discoveries is both preliminary and limited. Although we believe, based on our preclinical work, that the genetic markers targeted by our programs drive the formation and spread of certain cancers, clinical results may not confirm this hypothesis or may only confirm it for certain alterations or certain tumor types. The patient populations for our product candidates are limited to those with specific target alterations and may not be completely defined but are substantially smaller than the general treated cancer population, and we will need to screen and identify these patients with targeted alterations. Successful identification of patients is dependent on several factors, including achieving certainty as to how specific alterations respond to our product candidates and the ability to identify such alterations. Furthermore, even if we are successful in identifying patients with specific targets, we cannot be certain that the resulting patient populations with each mutation will be large enough to allow us to successfully obtain approval for each such mutation and commercialize our product candidates and achieve profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical product development involves a lengthy and expensive process, with an uncertain outcome.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our preclinical studies, our TNG908 clinical trial and future clinical trials may not be successful.  It is impossible to predict when or if any of our product candidates will prove effective and safe in humans or will receive regulatory approval. Before obtaining regulatory approval from regulatory authorities for the sale of any product candidate, we must complete preclinical studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and outcomes are uncertain. A failure of one or more clinical trials can occur at any stage of testing. The outcome of preclinical development testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results (or be indicative of safety and efficacy if commercialized and used in a broader population). Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain regulatory approval of their product candidates. Our preclinical studies and future clinical trials may not be successful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we are unable to successfully validate, develop and obtain regulatory approval for diagnostic tests for our product candidates that require or would commercially benefit from such tests, or experience significant delays in doing so, we may not realize the full commercial potential of these product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the clinical development of our product candidates for certain indications, we may engage third parties to develop or otherwise obtain access to in vitro companion diagnostic tests to identify patient subsets within a disease category who may derive selective and meaningful benefit from our product candidates. Such companion diagnostics may be used during our clinical trials as well as in connection with the commercialization of our products that receive regulatory approval. To be successful, we or our collaborators will need to address a number of scientific, technical, regulatory and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">logistical challenges. The FDA and comparable foreign regulatory authorities regulate</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> in vitro</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> companion diagnostics as medical devices and, under that regulatory framework, will likely require the conduct of clinical trials to demonstrate the safety and effectiveness of any diagnostics we or third parties may develop, which we expect will require separate regulatory clearance or approval prior to commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We intend to rely on third parties for the design, development and manufacture of companion diagnostic tests for our therapeutic product candidates that may require such tests. If we enter into such collaborative agreements, we will be dependent on the sustained cooperation and effort of our future collaborators in developing and obtaining approval for these companion diagnostics. It may be necessary to resolve issues such as selectivity/specificity, analytical validation, reproducibility, or clinical validation of companion diagnostics during the development and regulatory approval processes. Moreover, even if data from preclinical studies and early clinical trials appear to support development of a companion diagnostic for a product candidate, data generated in later clinical trials may fail to support the analytical and clinical validation of the companion diagnostic. We and our future collaborators may encounter difficulties in developing, obtaining regulatory clearance or approval for, manufacturing and commercializing companion diagnostics similar to those we face with respect to our therapeutic product candidates themselves, including issues with achieving regulatory clearance or approval, production of sufficient quantities at commercial scale and with appropriate quality standards, and in gaining market acceptance. If we are unable to successfully develop companion diagnostics for these therapeutic product candidates, or experience delays in doing so, the development and commercialization of these therapeutic product candidates may be adversely affected, these therapeutic product candidates may not obtain regulatory approval, and we may not realize the full commercial potential of any of these therapeutic products that obtain regulatory approval. As a result, our business, results of operations and financial condition could be materially harmed. In addition, a diagnostic company with whom we contract may decide to discontinue selling or manufacturing the companion diagnostic test that we anticipate using in connection with development and commercialization of our product candidates or our relationship with such diagnostic company may otherwise terminate. We may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with the development and commercialization of our product candidates or do so on commercially reasonable terms, which could adversely affect and/or delay the development or commercialization of our therapeutic product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interim, top-line, and preliminary data from our future clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to confirmation, audit and verification procedures that could result in material changes in the final data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, we may publicly disclose interim, top-line or preliminary data from our current and future clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data.  For example, we may report responses in certain patients that are unconfirmed at the time and which do not ultimately result in confirmed responses to treatment after follow-up evaluations. We also may make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, top-line or preliminary results that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary, interim or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, preliminary, interim and top-line data should be viewed with caution until the final data are available.  In addition, we may report interim analyses of only certain endpoints rather than all endpoints. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available.  Adverse differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the price of our common stock to fluctuate or decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, regulatory agencies and others may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could adversely impact the potential of the particular program, the likelihood of obtaining regulatory approval of the particular product candidate, the scope of product label, and commercialization of any approved product. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is derived from information that is typically extensive, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the preliminary, interim or top-line data that we report differ from final or actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product candidates may be significantly impaired, which could materially harm our business, operating results, prospects or financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may incur additional costs or experience delays in initiating or completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may experience delays in initiating or completing our preclinical studies or clinical trials, including as a result of delays in obtaining, or failure to obtain, the FDA&#x2019;s clearance to initiate clinical trials under future INDs. Additionally, we cannot be certain that preclinical studies or clinical trials for our product candidates will not require redesign, will enroll an adequate number of subjects on time, or will be completed on schedule, if at all. We may experience numerous unforeseen events during, or as a result of, preclinical studies and clinical trials that could delay or prevent our ability to receive regulatory approval or commercialize our product candidates, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may receive feedback from regulatory authorities that require us to modify the design or implementation of our preclinical studies or clinical trials or to delay or terminate a clinical trial;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulators or institutional review boards, or IRBs, or ethics committees may delay or may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective clinical research organizations, or CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">preclinical studies or clinical trials of our product candidates may fail to show safety or efficacy or otherwise produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials, or we may decide to abandon product research or development programs;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">preclinical studies or clinical trials of our product candidates may not produce differentiated or clinically significant results across tumor types or indications;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials or fail to return for post-treatment follow-up at a higher rate than we anticipate;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our third-party contractors may fail to comply with regulatory requirements, fail to maintain adequate quality controls, be unable to provide us with sufficient product supply to conduct or complete preclinical studies or clinical trials, fail to meet their contractual obligations to us in a timely manner, or at all;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> our clinical trial sites or investigators may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may elect to, or regulators or IRBs or ethics committees may require us or our investigators to, suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants in our clinical trials are being exposed to unacceptable health risks;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of clinical trials of our product candidates may be greater than we anticipate;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">clinical trials of our product candidates may be delayed due to complications associated with the evolving COVID-19 pandemic;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or IRBs or ethics committees to suspend or terminate the trials, or reports may arise from preclinical or clinical testing of other cancer therapies that raise safety or efficacy concerns about our product candidates;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory developments with respect to our competitors&#x2019; products, including any developments, litigation or public concern about the safety of such products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions at which such trials are being conducted, by the Data Safety Monitoring Board, or DSMB, for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination or clinical hold due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, adverse findings upon an inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">denial of regulatory approval of our product candidates. Further, the FDA may disagree with our clinical trial design or our interpretation of data from clinical trials or may change the requirements for approval even after it has reviewed and commented on the design for our clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, principal investigators for our current or future clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected the interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site, and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of regulatory approval of one or more of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product development costs will also increase if we experience delays in testing or regulatory approvals. We do not know whether any of our current or future clinical trials will begin as planned, or whether any of our current or future clinical trials will need to be restructured or will be completed on schedule, if at all. Significant preclinical study or clinical trial delays, including those caused by the COVID-19 pandemic, also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which would impair our ability to successfully commercialize our product candidates and may significantly harm our business, operating results, financial condition and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be able to initiate clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or comparable foreign regulatory authorities, or as needed to provide appropriate statistical power for a given trial. In particular, because we are focused on patients with specific genetic mutations for the development of our precision oncology programs and because some of the indications we are pursuing are orphan indications that have small populations, our ability to enroll eligible patients may be limited or may result in slower enrollment than we anticipate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may experience difficulties with identifying specific patient populations for any biomarker-defined trial cohorts. The patient eligibility criteria defined in our trial protocols, including biomarker-driven identification, may limit the patient populations eligible for our clinical trials to a greater extent than competing clinical trials for the same indication that do not have biomarker-driven patient eligibility criteria. We will also rely on the willingness and ability of clinicians to screen their patients for biomarkers to indicate which patients may be eligible for enrollment in our clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, some of our competitors have ongoing clinical trials for product candidates that treat the same indications as do our product candidates, and patients who would otherwise be eligible for our clinical trials may choose instead to enroll in clinical trials of our competitors&#x2019; product candidates (for example, three INDs have been cleared by the FDA for clinical trials of MTA-cooperative PRMT5 inhibitors for the treatment of cancer patients). Furthermore, our ability to enroll patients may be significantly delayed by the ongoing COVID-19 pandemic (including due to lack of resources and personnel at trial sites), and we cannot accurately predict the extent and scope of such delays at this point.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to the competitive trial environment, the eligibility criteria of our future clinical trials will further limit the pool of available study participants as we will require that patients have specific characteristics that we can measure to assure their cancer is either severe enough or not too advanced to include them in a study. Additionally, the process of finding patients may prove costly. We also may not be able to identify, recruit or enroll a sufficient number of patients to complete our clinical studies because of the perceived risks and benefits of the product candidates under study, the availability and efficacy of competing therapies and clinical trials, the proximity and availability of clinical trial sites for prospective patients, and the patient referral practices of physicians. If patients are unwilling to participate in our studies for any reason, the timeline for recruiting patients, conducting studies, reporting preliminary and final trial results and obtaining regulatory approval of potential products may be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may also engage third parties to develop companion diagnostics for use in our clinical trials, but such third parties may not be successful in developing such companion diagnostics, limiting our ability to identify patients with the targeted genetic mutations for our clinical trials. Further, if we are required to develop companion diagnostics and are unable to include patients with the targeted genetic mutations, this could compromise our ability to seek designations under applicable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FDA expedited review and development programs, including Breakthrough Therapy Designation and Fast Track Designation (to the extent these are available to us), or otherwise seek to accelerate clinical development and regulatory timelines. Patient enrollment may be affected by other factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Symbol;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the severity of the disease under investigation;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the efforts to obtain and maintain patient consents and facilitate timely enrollment in clinical trials;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ability to monitor patients adequately during and after treatment;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the risk that patients enrolled in clinical trials will drop out of the clinical trials before clinical trial completion;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ability to recruit clinical trial investigators with the appropriate competencies and experience;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reporting of the preliminary results of any of our clinical trials; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">factors we may not be able to control, including the impacts of the COVID-19 pandemic, that may limit patients, principal investigators or staff or clinical site availability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We anticipate that certain of our current product candidates and future product candidates could be used in combination with third-party drugs or biologics, some of which are still in development, and we have limited or no control over the supply, regulatory status, or regulatory approval of such drugs or biologics.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain of our current product candidates and any future product candidates may have the potential to be administered in combination with existing standards of care such as checkpoint inhibitor immunotherapies, chemotherapies, targeted therapies or radiotherapy. Our ability to develop and ultimately commercialize our current programs and product candidates and any future programs or product candidates for use in combination with other therapies will depend on our ability to access such drugs or biologics on commercially reasonable terms for the clinical trials and their availability for use with our commercialized product, if approved. We cannot be certain that current or potential future commercial relationships will provide us with a steady supply of such drugs or biologics on commercially reasonable terms or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any failure to maintain or enter into new successful commercial relationships, or the expense of purchasing checkpoint inhibitor immunotherapies or other potential combination or comparator therapies in the market, may delay our development timelines, increase our costs and jeopardize our ability to develop our current product candidates and any future product candidates as commercially viable therapies. If any of these occur, our business, financial condition, operating results, stock price and prospects may be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, the development of product candidates for use in combination with another product or product candidate may present challenges that are not faced for single agent product candidates. The FDA or comparable foreign regulatory authorities may require us to use more complex clinical trial designs in order to evaluate the contribution of each product and product candidate to any observed effects. It is possible that the results of such trials could show that any positive previous trial results are attributable to the other therapy and not our current product candidates and any future product candidates. Moreover, following product approval, the FDA or comparable foreign regulatory authorities may require that products used in conjunction with each other be cross labeled for combined use. To the extent that we do not have rights to the other product, this may require us to work with a third party to satisfy such a requirement. Moreover, developments related to the other product may impact our clinical trials for the combination as well as our commercial prospects should we receive regulatory approval. Such developments may include changes to the other product&#x2019;s safety or efficacy profile, changes to the availability of the other product, quality, manufacturing and supply issues with respect to the other product, and changes to the standard of care.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the event that any future collaborator or supplier cannot continue to supply their products on commercially reasonable terms, we would need to identify alternatives for accessing potential combination or targeted therapies. Additionally, should the supply of products from any current or future collaborator or supplier be interrupted, delayed or otherwise be unavailable to us, our clinical trials may be delayed. In the event we are unable to source an alternative supply, or are unable to do so on commercially reasonable terms, our business, financial condition, operating results, stock price and prospects may be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Results from earlier preclinical studies of our programs and product candidates are not necessarily predictive of the results of later preclinical studies and clinical trials of our programs and product candidates. If we cannot replicate the results from our earlier preclinical studies of our programs and product candidates in our later preclinical studies and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">clinical trials, we may be unable to successfully develop, obtain regulatory approval for and commercialize our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any results from our earlier preclinical studies of our programs or our product candidates may not necessarily be predictive of the results from later preclinical studies and clinical trials. Similarly, even if we are able to complete our planned preclinical studies and clinical trials of our product candidates according to our current development timeline, the results from such preclinical studies and clinical trials of our product candidates may not be replicated in subsequent preclinical studies or clinical trial results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development, and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical and other nonclinical findings made while clinical trials were underway, or safety, pharmacokinetic or efficacy observations made in preclinical studies and clinical trials, including previously unreported adverse events. Moreover, preclinical, nonclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not be able to file INDs for our precision oncology and other programs to commence clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We received clearance of our IND application for TNG908 in the first quarter of 2022 and plan to initiate a Phase 1/2 clinical trial in the second quarter of 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Further, w</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">e expect to file INDs for our undisclosed target for STK11-mutant cancers (Target 3) and USP1 inhibitor program in 2023. However, we may not be able to file such INDs or INDs for future product candidates for our precision oncology or other programs on the timelines we expect.  We have, for example, extended the timeline for filing an IND for our USP1 inhibitor program as we continue to work on a development candidate that has improved pharmacologic properties.</span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, we may experience manufacturing delays or other delays with IND-enabling studies. Moreover, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate clinical trials. Additionally, even if the FDA agrees with the design and implementation of the clinical trials set forth in an IND, we cannot guarantee that it will not change its requirements in the future. These considerations also apply to new clinical trials we may submit as amendments to existing INDs or to a new IND. Any failure to file INDs on the timelines we expect or to obtain regulatory approvals for our planned clinical trials may prevent us from initiating or completing our clinical trials or commercializing our product candidates on a timely basis, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our current and future clinical trials or those of our current or future collaborators may reveal significant adverse events not seen in our preclinical or nonclinical studies and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Before obtaining regulatory approvals for the commercial sale of any products, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for use in each target indication. Clinical testing is expensive and can take many years to complete, and outcomes are inherently uncertain. Failure can occur at any time during the clinical trial process. Because our precision oncology programs and our product candidates are in an early stage of development, there is a high risk of failure, and we may never succeed in developing marketable products. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product candidates in later stages of clinical trials also may fail to show the desired safety and efficacy profile despite having progressed through nonclinical studies and initial clinical trials. If the results of our current and future preclinical studies and clinical trials are inconclusive with respect to the safety, pharmacokinetics or efficacy of our product candidates, if we do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with our product candidates, we may be prevented from, or delayed in, obtaining regulatory approval for such product candidates. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. There may be side effects experienced during clinical trials in connection with the use of oncology therapies. Results of our trials could reveal a high and unacceptable severity and prevalence of side effects as a result of the use of our therapy (or due to other factors). In such an event, our trials could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims (the latter can be expensive to defend and result in significant damages and harm to our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reputation).  While we do have insurance to cover certain product liability claims, including in connection with injury during clinical trials, the coverage may not be sufficient to cover all expenses related to any injury and we may be required to pay damages from our own resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, our product candidates could cause undesirable side effects in clinical trials related to on-target toxicity. If on-target toxicity is observed, or if our product candidates have characteristics that are unexpected, we may need to abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. In addition, our product candidates could cause undesirable side effects that we have not yet observed. Many compounds that initially showed promise in early-stage testing for treating cancer have later been found to cause side effects that prevented further development of the compound. Most product candidates that commence clinical trials are never approved as products, and there can be no assurance that any of our current or future clinical trials (including the TNG908 Phase 1/2 clinical trial that we expect to commence in the second quarter of 2022) will ultimately be successful or support further clinical development or regulatory approval of any of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may develop future product candidates in combination with one or more cancer therapies. The uncertainty resulting from the use of our product candidates in combination with other cancer therapies may make it difficult to accurately predict side effects in future clinical trials. As is the case with many treatments for cancer and rare diseases, it is likely that there may be side effects associated with the use of our product candidates. If significant adverse events or other side effects are observed in our clinical trial for TNG908 or in any of our other future clinical trials, we may have difficulty recruiting patients to our clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of one or more product candidates altogether. We, the FDA or other applicable regulatory authorities, or an IRB may suspend or terminate clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product from obtaining or maintaining regulatory approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability versus other therapies. Any of these developments could materially harm our business, operating results, financial condition and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:15.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Some of our product candidates modulate pathways for which there are currently no approved or effective therapies, and utilize novel binding locations, which may result in greater research and development expenses, regulatory issues that could delay or prevent approval, or discovery of unknown or unanticipated adverse effects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Some of our product candidates modulate pathways for which there are currently no approved or effective therapies, which may result in uncertainty regarding our current and future development efforts and ability to obtain regulatory approval for such candidates. We select programs for cancer driver targets based on what we believe is compelling biological rationale. We explore new programs based on extensive preclinical data analysis which sometimes cannot predict efficacy or safety in humans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Some of our product candidates utilize novel binding locations, which may result in greater research and development expenses, regulatory issues that could delay or prevent drug candidate development and approval, or discovery of unknown or unanticipated adverse effects. We utilize structural biology in tight integration with our medicinal chemistry and biology capabilities to predict and design the compounds that we believe will achieve the most desirable characteristics, including potency, selectivity, bioavailability, and drug-like properties. A disruption in any of these capabilities may have significant adverse effects in our ability to expand our pipeline of product candidates, and we cannot predict whether we will continue to have access to these capabilities in the future to support our pipeline development. In addition, there can be no assurance that we will be able to rapidly identify, design and synthesize the necessary compounds or that these or other problems related to the development of product candidates will not arise in the future, which may cause significant delays or raise problems we may not be able to resolve.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Regulatory approval of novel product candidates such as ours can be more expensive, riskier and take longer than for other, more well-known or extensively studied pharmaceutical or biopharmaceutical product candidates due to our and regulatory agencies&#x2019; lack of experience with them. The novelty of the mechanism of action of any of our product candidates may lengthen the regulatory review process, require us to conduct additional studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. The novel mechanism of action also means that fewer people are trained in or experienced with product candidates of this type, which may make it more difficult to find, hire and retain personnel for research, development and manufacturing positions. If our inhibitors utilize a novel mechanism of action that has not been the subject of extensive study compared to more well-known</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product candidates, there is also an increased risk that we may discover previously unknown or unanticipated adverse effects during our preclinical studies and clinical trials. Any such events could adversely impact our business prospects, operating results and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may in the future conduct clinical trials for our product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We plan to conduct certain clinical trials outside the United States, and these jurisdictions may include countries in Europe, Australia or other foreign jurisdictions. The acceptance of trial data from clinical trials conducted outside the United States by the FDA, or comparable foreign regulatory authorities, may be subject to certain conditions. In cases where data from clinical trials conducted outside the United States are intended to serve as the sole basis for regulatory approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the United States population and United States medical practices, (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">through on-site inspection or other appropriate means.  Additionally, the FDA&#x2019;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory bodies have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving regulatory approval or clearance for commercialization in the applicable jurisdiction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Although we intend to explore other therapeutic opportunities in addition to the programs and product candidates that we are currently developing, we may fail to identify viable new product candidates for clinical development for a number of reasons. If we fail to identify additional product candidates, our business could be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The ongoing success of businesses in the biopharmaceutical industry depend, to a large extent, on the ability to continue to introduce new products, especially as exclusivity rights to given therapies or indications expire.  Research programs to pursue the development of our existing and planned product candidates for new or additional indications and to identify new product candidates and disease targets require substantial technical, financial and human resources whether or not they are ultimately successful. Our screening technology and research programs may initially show promise in identifying potential indications and/or product candidates, yet fail to yield results for clinical development for a number of reasons, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Symbol;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the research methodology used may not be successful in identifying potential indications and/or product candidates (or the development of a chemical compound or formulation that has the desired effect cannot be developed);</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">potential product candidates may, after further study, be shown to have harmful adverse effects or other characteristics that indicate they are unlikely to be effective products; or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">it may take greater human and financial resources than we will possess to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, thereby limiting our ability to develop, diversify and expand our potential product portfolio.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because we have limited financial and human resources, we intend to initially focus on research programs and product candidates for a limited set of indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accordingly, there can be no assurance that we will ever be able to identify additional therapeutic opportunities for our product candidates or to develop suitable product candidates through internal research programs, which could materially adversely affect our future growth and prospects. We may focus our efforts and resources on potential product candidates or other potential programs that ultimately prove to be unsuccessful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates, we will not be able to commercialize, or will be delayed in commercializing, our product candidates, and our ability to generate revenue will be materially impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, distribution, import and export are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by comparable foreign regulatory authorities. Before we can commercialize any of our product candidates, we must obtain regulatory approval. We received clearance of our IND application for TNG908 in the first quarter of 2022 and plan to initiate a Phase 1/2 clinical trial in the second quarter of 2022, otherwise, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">all</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of our product candidates are in discovery or preclinical development.  We have not received approval to market any of our product candidates from regulatory authorities in any jurisdiction. It is possible that our product candidates, including any product candidates we may seek to develop in the future, will never obtain regulatory approval. We have limited experience in filing and supporting the applications necessary to gain regulatory approvals and expect to rely on third-party CROs and/or regulatory consultants to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the product candidate&#x2019;s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended pharmacokinetics, side effects, toxicities or other characteristics that may preclude our obtaining regulatory approval or prevent or limit commercial use. In addition, regulatory authorities may find fault with our manufacturing process or facilities or that of third-party contract manufacturers. We and our third-party manufacturers that we expect to rely on for commercial production of our therapies, if approved, may also face greater than expected difficulty in manufacturing our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The process of obtaining regulatory approvals, both in the United States and abroad, is expensive and often takes many years. If the FDA or a comparable foreign regulatory authority requires that we perform additional preclinical studies or clinical trials, approval may be delayed, if obtained at all. The length of such a delay varies substantially based upon a variety of factors, including the type, complexity and novelty of the product candidate involved. Changes in regulatory approval policies during the development period, changes in or enactment of additional statutes or regulations, or changes in regulatory review policies for each submitted NDA, premarket approval application, or PMA, or equivalent application types, may cause delays in the approval or rejection of an application. The FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies.  Our product candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may not be able to enroll a sufficient number of patients in our clinical studies;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication or a related companion diagnostic is suitable to identify appropriate patient populations;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be unable to demonstrate that a product candidate&#x2019;s clinical and other benefits outweigh its safety risks;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA, or other submission or to obtain regulatory approval in the United States or elsewhere;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or comparable foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change such that our clinical data are insufficient for approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we were to obtain regulatory approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, thereby narrowing the commercial potential of the product candidate. In addition, regulatory authorities may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we experience delays in obtaining, or if we fail to obtain, approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenue will be materially impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The COVID-19 pandemic, or a similar pandemic, epidemic, or outbreak of an infectious disease, may materially and adversely affect our business and our financial results and could cause a disruption to the development of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Public health crises such as pandemics or similar outbreaks could adversely impact our business. Beginning in 2020 and continuing through the date of this filing, a novel strain of a virus named SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), or coronavirus, which causes COVID-19 has spread to most countries across the world, including all 50 states within the United States, including Cambridge, Massachusetts, where our primary office and laboratory space is located. The coronavirus pandemic is evolving, and has led to the implementation of various responses, including government-imposed quarantines, travel restrictions and other public health safety measures. The extent to which the coronavirus impacts our operations or those of our third-party partners, including our preclinical studies and clinical trial operations, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak, new information that will emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. The continued spread of COVID-19 globally could adversely impact our preclinical or clinical trial operations in the United States and our future clinical trial sites in foreign jurisdictions, including our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in their geography. For example, similar to other biopharmaceutical companies, we may experience delays in initiating IND-enabling studies, protocol deviations, enrolling our clinical trials, or dosing of patients in our clinical trials as well as in activating new trial sites.  COVID-19 may also affect employees of third-party CROs located in affected geographies that we expect that we will rely upon to carry out our clinical trials. Any negative impact COVID-19 has to patient enrollment or treatment or the execution of our product candidates could cause costly delays to clinical trial activities, which could adversely affect our ability to obtain regulatory approval for and to commercialize our product candidates, increase our operating expenses, and have a material adverse effect on our financial results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, timely enrollment in planned clinical trials and the reporting of clinical trial results is dependent upon clinical trial sites which could be adversely affected by global health matters, such as pandemics. We plan to conduct clinical trials for our product candidates in geographies which are currently affected by the COVID-19 pandemic, including our clinical trial for TNG908, which we plan to initiate a Phase 1/2 clinical trial in the second quarter of 2022 in the United States (which, as noted above, may be impacted by the COVID-19 pandemic (see </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Item 1. Business - COVID-19</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> above)). Some factors from the COVID-19 pandemic that may delay or otherwise adversely affect enrollment in the clinical trials of our product candidates, including TNG908, as well as our business generally, include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Symbol;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the potential diversion of healthcare resources away from the conduct of clinical trials to focus on pandemic concerns, including the attention of physicians serving as our clinical trial investigators, hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our prospective clinical trials;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">limitations on travel that could interrupt key trial and business activities, such as clinical trial site initiations and monitoring, domestic and international travel by employees, contractors or patients to clinical trial sites, including any government-imposed travel restrictions or quarantines that will impact the ability or willingness of patients, employees or contractors to travel to our clinical trial sites or secure visas or entry permissions, a loss of face-to-face meetings and other interactions with potential partners, any of which could delay or adversely impact the conduct or progress of our prospective clinical trials;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the potential negative effect on the operations of our third-party manufacturers;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">interruption in global shipping affecting the transport of clinical trial materials, such as patient samples, investigational drug product and conditioning drugs and other supplies used in our prospective clinical trials;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7; </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">staffing shortages at clinical trial sites, both healthcare professionals (e.g. physicians, nurses) and support staff, caused by the COVID-19 pandemic and the challenges of finding replacements may adversely impact the timing and on-going performance of a clinical trial;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">business disruptions caused by potential workplace, laboratory and office closures and an increased reliance on employees working from home, disruptions to or delays in ongoing laboratory experiments;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">operations, staffing shortages, travel limitations, global supply chain delays or mass transit disruptions, any of which could adversely impact our business operations or delay necessary interactions with local regulators, ethics committees and other important agencies and contractors;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in local regulations as part of a response to the COVID-19 pandemic, which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue such clinical trials altogether; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our employees, including our lab personnel, are currently working at our headquarters office.  We have, in the past, taken temporary precautionary measures intended to help minimize the risk of the virus to our employees, including temporarily requiring certain of our employees to work remotely, suspending all non-essential travel worldwide for our employees, implementing COVID-19 testing policies for employees in certain instances and discouraging employee attendance at industry events and in-person work-related meetings, which could negatively affect our business (and certain of these measures remain in place). We cannot presently predict the scope and severity of the planned and potential shutdowns or disruptions of businesses and government agencies, such as the SEC or FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These and other factors arising from COVID-19 (and any future variant of the COVID-19 virus) could worsen in countries that are already afflicted with COVID-19 or could continue to spread to additional countries. Any of these factors, and other factors related to any such disruptions that are unforeseen, could have a material adverse effect on our business and our results of operations and financial condition and our clinical trials. Further, uncertainty around these and related issues could lead to adverse effects on the economy of the United States and other economies, which could impact our ability to raise the necessary capital needed to develop and commercialize our programs and product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Commercialization</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The development and commercialization of new products in the biopharmaceutical and related industries is highly competitive. We compete in the segments of the pharmaceutical, biotechnology, and other related markets that address structural biology-guided chemistry-based drug design to develop therapies in the fields of cancer and genetic diseases. There are other companies focusing on precision oncology to develop therapies in the fields of cancer and other diseases.  Specifically, with respect to TNG908 (for which we recently received FDA clearance of our IND application), we are aware that Mirati Therapeutics, Inc. and Amgen each have a clinical MTA-cooperative PRMT5 inhibitor program, using the same mechanism of action as TNG908 (and there are other indirect competitors in the PRMT5 inhibition space as well).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">W</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">e also compete more broadly across the market for cost-effective and reimbursable cancer treatments. Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach (as noted above), and others are based on entirely different approaches. These companies include divisions of large pharmaceutical companies and biotechnology companies of various sizes, such as Amgen. We face competition with respect to our current product candidates, and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any product candidates that we successfully develop and commercialize will compete with currently approved therapies and new therapies that may become available in the future from segments of the pharmaceutical, biotechnology and other related markets. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our products. We believe principal competitive factors to our business include, among other things, our ability to identify biomarkers, ability to successfully transition research programs into clinical development, ability to raise capital, and the scalability of the platform, pipeline, and business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many of the companies that we compete against or which we may compete against in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and marketing, promoting and selling approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">programs. If these or other barriers to entry do not remain in place, other companies may be able to more directly or effectively compete with us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we or our collaborators may develop. Our competitors also may obtain FDA or other regulatory approval for their products sooner than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we or our collaborators are able to enter the market. The key competitive factors affecting the success of all of our product candidates, if approved, are likely to be their efficacy, safety, convenience, price, level of generic competition and novel competition that utilize the same mechanism of action and availability of reimbursement from government and other third-party payors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If the market opportunities for our programs and product candidates are smaller than we estimate or if any regulatory approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability will be adversely affected, possibly materially.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The incidence and prevalence for target patient populations of our programs and product candidates have not been established with precision. Our lead product candidate, TNG908, is an oral small molecule inhibitor of PRMT5. We are developing TNG908 for the treatment of patients with solid tumors with MTAP deletion, a genetic alteration which occurs in 10% to 15% of all human tumors, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">including NSCLC, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">mesothelioma, cholangiocarcinoma, and GBM,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as well as indications where there are limited treatment options with no standard of care, including MPNST</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Additionally, our undisclosed Target 3 program is being developed for certain patients with STK11 loss-of-function mutations.  STK11 loss-of-function mutations are a genetic alteration in approximately 15% </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of NSCLC, 15% of cervical cancers, 10% carcinoma of unknown primary, 5% of breast cancers and 3% of pancreatic cancers. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USP1, is a strong synthetic lethal target for BRCA1/2-mutant, which are present in</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> approximately 15% of ovarian cancers, 10% of breast cancers, 10% of prostate cancers, 5% of endometrial cancers and 5% of pancreatic cancers. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our programs and product candidates, are based on our estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The total addressable market opportunity will ultimately depend upon, among other things, the diagnosis criteria included in the final label, the indications for which our product candidates are approved for sale, acceptance by the medical community and patient access, product pricing and reimbursement. The number of patients with the cancers and solid tumors for which our product candidates may be approved as treatment may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. We may not be successful in our efforts to identify additional product candidates. Due to our limited resources and capital, we must prioritize development of certain product candidates, which may prove to be the wrong choice and may adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If our current product candidates or any future product candidates do not achieve broad market acceptance, the revenue that we generate from their sales may be limited, and we may never become profitable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have never commercialized a product candidate for any indication. Even if our current product candidates and any future product candidates are approved by the appropriate regulatory authorities for marketing and sale, they may not gain acceptance among physicians, patients, third-party payors, and others in the medical community. If any product candidates for which we obtain regulatory approval do not gain an adequate level of market acceptance, we may not generate significant revenue and may not become profitable or may be significantly delayed in achieving profitability. Market acceptance of our current product candidates and any future product candidates by the medical community, patients and third-party payors will depend on a number of factors, some of which are beyond our control. For example, physicians are often reluctant to switch their patients, and patients may be reluctant to switch, from existing therapies even when new and potentially more effective or safer treatments enter the market. If public perception is influenced by claims that the use of certain precision oncology product candidates or immunotherapies and targeted therapies is unsafe, whether related to our or our competitors&#x2019; products, our potential future products may not be accepted by the general public or the medical community. Future adverse events in precision oncology, immuno-oncology or the biopharmaceutical industry could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approvals of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Efforts to educate the medical community and third-party payors on the benefits of our current product candidates and any future product candidates may require significant resources and may not be successful. If our current product candidates or any future product candidates are approved but do not achieve an adequate level of market acceptance, we could be</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">prevented from or significantly delayed in achieving profitability. The degree of market acceptance of any of our current product candidates and any future product candidates will depend on a number of factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the efficacy of our current product candidates and any future product candidates as single agents and in combination with marketed combination therapies or other therapies that are also pending regulatory approval;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the commercial success of the checkpoint blockade drugs with which certain of our products may be co-administered;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the prevalence and severity of adverse events associated with our current product candidates and any future product candidates or those products with which they may be co-administered;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the clinical indications for which our product candidates are approved and the approved claims that we may make for the products;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">limitations or warnings contained in the product&#x2019;s FDA-approved labeling or those of comparable foreign regulatory authorities, including potential limitations or warnings for our current product candidates and any future product candidates that may be more restrictive than other competitive products;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in the standard of care for the targeted indications of our current product candidates and any future product candidates, which could reduce the marketing impact of any claims that we could make following FDA approval or approval by comparable foreign regulatory authorities, if obtained;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the relative convenience and ease of administration of our current product candidates and any future product candidates (including the number of doses required in a given period) and any products with which they are co-administered;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of treatment compared with the economic and clinical benefit of alternative treatments or therapies;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the availability of adequate coverage or reimbursement by third-party payors, including government healthcare programs such as Medicare and Medicaid and other healthcare payors;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the price concessions required by third-party payors to obtain coverage;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the willingness of patients to pay out-of-pocket in the absence of adequate coverage and reimbursement;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the extent and strength of our marketing and distribution of our current product candidates and any future product candidates;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the safety, efficacy, and other potential advantages over, and availability of, alternative treatments already used or that may later be approved;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">distribution and use restrictions imposed by the FDA or comparable foreign regulatory authorities with respect to our current product candidates and any future product candidates or to which we agree as part of a risk evaluation and mitigation strategy, or REMS, or voluntary risk management plan;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing of market introduction of our current product candidates and any future product candidates, as well as competitive products;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to offer our current product candidates and any future product candidates for sale at competitive prices;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the extent and strength of our third-party manufacturer and supplier support;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the actions of companies that market any products with which our current product candidates and any future product candidates may be co-administered;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the approval of other new products;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adverse publicity about our current product candidates and any future product candidates or any products with which they are co-administered, or favorable publicity about competitive products; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">potential product liability claims.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Reliance on Third Parties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We expect to rely on third parties to conduct our future clinical trials, as well as investigator-sponsored clinical trials of our product candidates. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not have the ability to independently conduct clinical trials. We expect to rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct or otherwise support clinical trials for our product candidates, including our planned Phase 1/2 clinical trial of TNG908, and for any other product candidates that emerge from our precision oncology programs.  We may also rely on academic and private non-academic institutions to conduct and sponsor clinical trials relating to our product candidates. We will not control the design or conduct of the investigator-sponsored trials, and it is possible that the FDA or non-U.S. regulatory authorities will not view these investigator-sponsored trials as providing adequate support for future clinical trials, whether controlled by us or third parties, for any number of reasons, including elements of the design or execution of the trials or safety concerns or other trial results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are likely to have certain information rights with respect to the investigator-sponsored trials, including access to and the ability to use and reference the data, including for our own regulatory filings. However, we would not have control over the timing and reporting of the data from investigator-sponsored trials, nor would we own the data from the investigator-sponsored trials. If we are unable to confirm or replicate the results from the investigator-sponsored trials or if negative results are obtained, we would likely be further delayed or prevented from advancing further clinical development of our product candidates. Further, if investigators or institutions breach their obligations with respect to the clinical development of our product candidates, or if the data proves to be inadequate compared to the first-hand knowledge we might have gained had the investigator-sponsored trials been sponsored and conducted by us, then our ability to design and conduct any future clinical trials ourselves may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely and expect to continue to rely heavily on third parties for execution of clinical trials for our product candidates and control only certain aspects of their activities (and such control may be based on contractual provisions that may be breached by the third-party).  For example, for the planned Phase 1/2 clinical trial of TNG908, we expect to rely on one CRO for the conduct of the trial and one manufacturer to manufacture the study drug to be used during the course of the trial. We are responsible for ensuring that each of our clinical trials and the study drug is conducted and manufactured in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on a CRO or CDMO will not relieve us of our regulatory responsibilities. For any violations of laws and regulations during the conduct of our clinical trials, we could be subject to warning letters or enforcement action that may include civil penalties, suspension/hold or termination of trials and other penalties up to and including criminal prosecution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We, our principal investigators and our CROs are required to comply with regulations, including Good Clinical Practices, or GCPs, for conducting, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate, and that the trial patients are adequately informed of the potential risks of participating in clinical trials and their rights are protected. These regulations are enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area and comparable foreign regulatory authorities for any products in clinical development. The FDA enforces GCP regulations through periodic inspections of clinical trial sponsors, principal investigators and trial sites. If we, our principal investigators or our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, the FDA will determine that any of our future clinical trials will comply with GCPs. In addition, our clinical trials generally must be conducted with product candidates produced under current Good Manufacturing Practice, or cGMP, regulations. Our failure or the failure of our principal investigators, third party manufacturers or CROs to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process, significantly increase our expenditures and could also subject us to enforcement action. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we have designed our Phase 1/2 clinical trial of TNG908 and intend to design the future clinical trials for our product candidates, these trials will be conducted by CROs and we expect CROs will conduct all of our future clinical trials. As a result, many important aspects of our development programs, including their conduct and timing, are outside of our direct control. Our reliance on third parties to conduct future clinical trials also results in less direct control over the management of data developed through clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may have staffing difficulties, fail to comply with contractual obligations, experience regulatory compliance issues, undergo changes in priorities or become financially distressed or form relationships with other entities, some of which may be our competitors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These factors may materially adversely affect the willingness or ability of third parties to conduct our clinical trials and may subject us to unexpected cost increases that are beyond our control. If the principal investigators or CROs do not perform clinical trials in a satisfactory manner, breach their obligations to us or fail to comply with regulatory requirements, the development, regulatory approval and commercialization of our product candidates may be delayed, we may not be able to obtain regulatory approval and commercialize our product candidates or our development program may be materially and irreversibly harmed. If we are unable to rely on clinical data collected by our principal investigators or CROs, we could be required to repeat, extend the duration of, or increase the size of any clinical trials we conduct and this could significantly delay commercialization and require significantly greater expenditures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any of our relationships with these third-party principal investigators or CROs terminate, we may not be able to enter into arrangements with alternative CROs. If principal investigators or CROs do not successfully carry out their contractual obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, any clinical trials such principal investigators or CROs are associated with may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, our product candidates. As a result, we believe that our financial results and the commercial prospects for our product candidates in the subject indication would be harmed, our costs could increase and our ability to generate future revenue, if any, could be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have entered into collaborations and may enter into additional collaborations in the future, and we might not realize the anticipated benefits of such collaborations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research, development, commercialization and/or strategic collaborations, including the existing collaboration that we have with Gilead, are subject to numerous risks, which include the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Symbol;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may have significant control or discretion in determining the efforts and resources that they will apply to a collaboration, and might not commit sufficient efforts and resources or might misapply those efforts and resources;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may have limited influence or control over the approaches to research, development and/or commercialization of product candidates in the territories in which our collaboration partners lead research, development and/or commercialization;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators might not pursue research, development and/or commercialization of collaboration product candidates or might elect not to continue or renew research, development and/or commercialization programs based on nonclinical and/or clinical trial results, changes in their strategic focus, availability of funding or other factors, such as a business combination that diverts resources or creates competing priorities;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators might delay, provide insufficient resources to, or modify or stop research or clinical development for collaboration product candidates or require a new formulation of a product candidate for clinical testing;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators with sales, marketing and distribution rights to one or more product candidates might not commit sufficient resources to sales, marketing and distribution or might otherwise fail to successfully commercialize those product candidates;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators might not properly maintain or defend our intellectual property rights or might use our intellectual property improperly or in a way that jeopardizes our intellectual property or the potential commercial benefit of our product candidates or exposes us to potential liability;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaboration activities might result in the collaborator having intellectual property covering our activities or product candidates, which could limit our rights or ability to research, develop and/or commercialize our product candidates;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators might not be in compliance with laws applicable to their activities under the collaboration, which could impact the collaboration and us;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">disputes might arise between a collaborator and us that could cause a delay or termination of the collaboration or result in costly litigation that diverts management attention and resources; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborations might be terminated, which could result in a need for additional capital to pursue further research, development and/or commercialization of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, funding provided by a collaborator might not be sufficient to advance product candidates under the collaboration. For example, although Gilead provided us with $175.0 million upfront payments and a $20.0 million equity investment in connection with certain collaboration agreements with Gilead, we might need additional funding to advance product candidates prior to the completion of the clinical milestones of the collaboration agreement with Gilead.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If a collaborator terminates a collaboration or a program under a collaboration, including by failing to exercise a license or other option under the collaboration, whether because we fail to meet a milestone or otherwise, any potential revenue from the collaboration would be significantly reduced or eliminated. In addition, we will likely need to either secure other funding to advance research, development and/or commercialization of the relevant product candidate or abandon that program (or abandon a different program to allocate resources to the program rejected by the collaborator), the development of the relevant product candidate could be significantly delayed, and our cash expenditures could increase significantly if we are to continue research, development and/or commercialization of the relevant product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any one or more of these risks, if realized, could reduce or eliminate future revenue from product candidates under our collaborations, and could have a material adverse effect on our business, financial condition, results of operations and/or growth prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We contract with third parties for the manufacture of our product candidates for preclinical development and expect to continue to do so for clinical testing and commercialization. This reliance on third parties increases the risk that we will</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not currently own or operate, nor do we have any plans to establish in the future, any manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for preclinical development and clinical testing, as well as for the commercial manufacture of our products if any of our product candidates receive regulatory approval.  In some cases, we rely on one party to manufacture our preclinical and clinical products and we exercise limited direct control over this manufacturer (and it would be time consuming and expensive to move production to a new manufacturer, if we were able to do so at all). This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For example, we rely on a limited number of CROs to perform certain synthesis and other chemistry related work on our pre-clinical product candidates, and one of these CROs is located in Ukraine, which was invaded by Russia in February 2022.  This has the potential to disrupt their services on our behalf and delay development of our future product candidates, and such delay may materially impact the timing for moving products into development candidate stage and initiating IND-enabling studies, and ultimately the filing of an IND and the commencement of clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The facilities used by our contract manufacturers to manufacture our product candidates must be inspected by the FDA pursuant to pre-approval inspections that will be conducted after we submit our marketing applications to the FDA. We do not control the manufacturing process of, and will be completely dependent on, our contract manufacturers for compliance with cGMPs in connection with the manufacture of our product candidates. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to pass regulatory inspections and/or maintain regulatory compliance for their manufacturing facilities. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority finds deficiencies with or does not approve these facilities for the manufacture of our product candidates or if it finds deficiencies or withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any contract manufacturing organization, or CMO, with whom we contract fails to perform its obligations, we may be forced to enter into an agreement with a different CMO, which we may not be able to do on reasonable terms, if at all. In such scenario, our clinical trials supply could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our products or product candidates may be unique or proprietary to the original CMO and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product candidate according to the specifications previously submitted to the FDA or another regulatory authority. The delays associated with the verification of a new CMO could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. Furthermore, a CMO may possess technology related to the manufacture of our product candidate that such CMO owns independently. This would increase our reliance on such CMO or require us to obtain a license from such CMO in order to have another CMO manufacture our product candidates. In addition, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, our failure, or the failure of our third-party manufacturers to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, if approved, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect our business and supplies of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may be unable to establish any additional agreements with third-party manufacturers or do so on acceptable terms. Reliance on third-party manufacturers entails additional risks, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.2%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Symbol;">&#160;</span></p>
  <p style="text-indent:4.2%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reliance on the third party for regulatory compliance and quality assurance;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.2%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the possible breach of the manufacturing agreement by the third party;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.2%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.2%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product candidates and any products that we may develop may compete with other product candidates and approved products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Any performance failure on the part of our existing or future manufacturers could delay clinical development or regulatory approval. If our current contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers. We may incur added costs and delays in identifying and qualifying any such replacement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive regulatory approval on a timely and competitive basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The third parties upon whom we rely for the supply of the active pharmaceutical ingredients and drug product to be used in our product candidates are our sole source of supply, and the loss of any of these suppliers could significantly harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The active pharmaceutical ingredients, or API, and drug product we expect to use in all of our product candidates are supplied to us from single-source suppliers.  In some cases, both the API and drug product are manufactured and supplied by the same single-source (as is the case with respect to the supply of TNG908 for use in our planned Phase 1/2 clinical trial). Our ability to successfully develop our product candidates, and to ultimately supply our commercial products in quantities sufficient to meet the market demand (and to meet requirements in connection with our planned clinical trials), depends in part on our ability to obtain the API and drug product for these products in accordance with regulatory requirements and in sufficient quantities for clinical testing and commercialization. We are also unable to predict how changing global economic conditions or global health concerns such as the ongoing COVID-19 pandemic, as well as potential supply chain disruptions or cost increases related thereto, will affect our third-party suppliers and manufacturers. Any negative impact of such matters on our third-party suppliers and manufacturers may also have an adverse impact on our results of operations or financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For all of our product candidates, we intend to identify and qualify additional manufacturers to provide such API and drug product prior to submission of an NDA to the FDA and/or an MAA to the EMA. We are not certain, however, that our single-source suppliers will be able to meet our demand for their products, either because of the nature of our agreements with those suppliers, our limited experience with those suppliers or our relative importance as a customer to those suppliers. It may be difficult for us to assess their ability to timely meet our demand in the future based on past performance. While our suppliers have generally met our demand for their products on a timely basis in the past, they may subordinate our needs in the future to their other customers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Establishing additional or replacement suppliers for the API and drug product used in our product candidates, if required, may not be accomplished quickly (or at all). If we are able to find a replacement supplier, such replacement supplier would need to be qualified and may require additional regulatory inspection or approval, which could result in further delay. While we seek to maintain adequate inventory of the API and drug product used in our product candidates, any interruption or delay in the supply of components or materials, or our inability to obtain such API and drug product from alternate sources at acceptable prices in a timely manner could impede, delay, limit or prevent our development efforts, which could harm our business, results of operations, financial condition and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may seek to establish additional collaborations, and, if we are not able to establish them on commercially reasonable terms, or at all, we may have to alter our development and commercialization plans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. For some of our product candidates, we may decide to collaborate with additional pharmaceutical and biotechnology companies for the development and potential commercialization of those product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#x2019;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#x2019;s own evaluation of a potential collaboration. Factors a potential collaborator will use to evaluate a collaboration may include the design or results of clinical trials, the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">likelihood of approval by the FDA or comparable foreign regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry, and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. The terms of any additional collaborations or other arrangements that we may establish may not be favorable to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may also be restricted under collaboration agreements from entering into future agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be able to negotiate additional collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all and it may be difficult to recruit and retain the expertise needed to launch and commercialize a new drug therapy. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, any future collaborations that we enter into may not be successful. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations. Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the development process or commercializing the applicable product candidate and, in some cases, termination of the collaboration arrangement. These disagreements can be difficult to resolve if neither of the parties has final decision-making authority. Collaborations with pharmaceutical or biotechnology companies and other third parties often are terminated or allowed to expire by the other party. Any such termination or expiration would adversely affect us financially and could harm our business reputation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we are unable to obtain and maintain patent and other intellectual property protection for our technology and product candidates or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully commercialize our technology and drugs may be impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial success depends in part on our ability to obtain and maintain proprietary or intellectual property protection in the United States and other countries for our current or future product candidates, including our current lead product candidate, TNG908, and our other future product candidates, as well as for their respective compositions, formulations, methods used to manufacture them, and methods of treatment, in addition to successfully defending these patents against third-party challenges. We seek to protect our proprietary and intellectual property position by, among other methods, filing patent applications in the United States and abroad related to our proprietary technology, inventions, and improvements that are important to the development and implementation of our business. Our ability to stop unauthorized third parties from making, using, selling, offering to sell, or importing our product candidates is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property position.  As of the date of the filing of this Annual Report on Form 10-K, we have filed patent applications, but have no issued patents in the United States or elsewhere for our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. The degree of patent protection we require to successfully commercialize our current or future product candidates may be unavailable or severely limited in some cases and may not adequately protect our rights or permit us to gain or keep any competitive advantage. We cannot provide any assurances that any of our pending patent applications that mature into issued patents will include claims with a scope sufficient to protect TNG908 or our other current or future product candidates. In addition, if the breadth or strength of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">protection provided by our patent applications or any patents we may own or in-license is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, in jurisdictions outside the United States, a license may not be enforceable unless all the owners of the intellectual property agree or consent to the license. Accordingly, any actual or purported co-owner of our patent rights could seek monetary or equitable relief requiring us to pay it compensation for, or refrain from, exploiting these patents due to such co-ownership. Furthermore, patents have a limited lifespan. In the United States and most other jurisdictions in which we have undertaken patent filings, the natural expiration of a patent is generally twenty years after it is filed, assuming all maintenance fees are paid. Various extensions may be available, on a jurisdiction-by-jurisdiction basis; however, the life of a patent, and thus the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, patents we may own or in-license may not provide us with adequate and continuing patent protection sufficient to exclude others from commercializing drugs similar or identical to our current or future product candidates, including generic versions of such drugs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other parties have developed technologies that may be related or competitive to our own, and such parties may have filed or may file patent applications, or may have received or may receive patents, claiming inventions that may overlap or conflict with those claimed in our own patent applications or issued patents, with respect to either the same compounds, methods, formulations or other subject matter, in either case that we may rely upon to dominate our patent position in the market. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until at least 18 months after the earliest priority date of patent filing, or, in some cases, not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in patents we may own or in-license patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights cannot be predicted with any certainty.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. Further, with respect to certain pending patent applications covering our current or future product candidates, prosecution has yet to commence. Patent prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the relevant patent office(s) may be significantly narrowed by the time they issue, if they ever do. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we acquire patent protection that we expect should enable us to establish and/or maintain a competitive advantage, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. We may become involved in post-grant proceedings such as opposition, derivation, reexamination,</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> inter partes</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> review, post-grant review, or interference proceedings challenging our patent rights or the patent rights of others from whom we license or we may in the future obtain licenses to such rights, in the U.S. Patent and Trademark Office, or USPTO, the European Patent Office, or EPO, or in other countries. In addition, we may be subject to a third-party submission to the USPTO, the EPO, or elsewhere, that may reduce the scope or preclude the granting of claims from our pending patent applications. Competitors may allege that they invented the inventions claimed in our issued patents or patent applications prior to us, or may file patent applications before we do. Competitors may also claim that we are infringing their patents and that we therefore cannot practice our technology as claimed under our patents or patent applications. Competitors may also contest our patents by claiming to an administrative patent authority or judge that the invention was not patent-eligible, was not original, was not novel, was obvious, and/or lacked inventive step, and/or that the patent application filing failed to meet relevant requirements relating to description, basis, enablement, and/or support. In litigation, a competitor could claim that our patents, if issued, are not valid or are unenforceable for a number of reasons. If a court or administrative patent authority agrees, we would lose our protection of those challenged patents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we may in the future be subject to claims by our former employees or consultants asserting an ownership right in our patents or patent applications, as a result of the work they performed on our behalf. Although we generally require all of our employees, consultants and advisors and any other third parties who have access to our proprietary know-how, information or technology to assign or grant similar rights to the inventions they make in the course of their work to us,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we cannot be certain that we have executed such agreements with all parties who may have contributed to our intellectual property, nor can we be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An adverse determination in any such submission or proceeding may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and drugs, without payment to us, or could limit the duration of the patent protection covering our technology and current or future product candidates. Such challenges may also result in our inability to manufacture or commercialize our current or future product candidates without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if they are unchallenged, our issued patents and our pending patent applications, if issued, may not provide us with any meaningful protection or prevent competitors from designing around our patent claims to circumvent patents we may own or in-license by developing similar or alternative technologies or drugs in a non-infringing manner. For example, a third party may develop a competitive drug that provides benefits similar to one or more of our current or future product candidates but that has a different composition that falls outside the scope of our patent protection. If the patent protection provided by the patents and patent applications we hold or pursue with respect to our current or future product candidates is not sufficiently broad to impede such competition, our ability to successfully commercialize our current or future product candidates could be negatively affected, which would harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, even if we are able to issue patents with claims of valuable scope in one or more jurisdictions, we may not be able to secure such claims in all relevant jurisdictions, or in a sufficient number to meaningfully reduce competition. Our competitors may be able to develop and commercialize their products, including products identical to ours, in any jurisdiction in which we are unable to obtain, maintain, or enforce such patent claims.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, deadlines, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated if we fail to comply with these requirements. We may miss a filing deadline for patent protection on these inventions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The USPTO and foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process and after issuance of any patent. In addition, periodic maintenance fees, renewal fees, annuity fees and/or various other government fees are required to be paid periodically. While an inadvertent lapse can, in some cases, be cured by payment of a late fee, or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market with similar or identical products or platforms, which could have a material adverse effect on our business prospects and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we do not obtain patent term extension for our product candidates, our business may be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, one or more of our U.S. patents or those of our future licensors may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments). The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. A maximum of one patent may be extended per FDA approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of our product candidates. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. Further, if this occurs, our competitors may take</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If our trademarks and trade names for our products or company name are not adequately protected in one or more countries where we intend to market our products, we may delay the launch of product brand names, use different trademarks or tradenames in different countries, or face other potentially adverse consequences to building our product brand recognition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our trademarks or trade names may be challenged, infringed, diluted, circumvented or declared generic or determined to be infringing on other marks. We intend to rely on both registration and common law protection for our trademarks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest.  Further we have not, and may not, register for trademark protection in every potential jurisdiction where we may conduct business or sell products (if approved).  During the trademark registration process, we have in the past received and may in the future receive Office Actions from the USPTO or from comparable agencies in foreign jurisdictions objecting to the registration of our trademark. Although we may be given an opportunity to respond to those objections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and/or to seek the cancellation of registered trademarks. Opposition or cancellation proceedings may be filed against our trademark applications or registrations, and our trademark applications or registrations may not survive such proceedings. If we are unable to obtain a registered trademark, or do not seek registered trademarks, or establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we are unable to adequately protect and enforce our trade secrets, our business and competitive position would be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to the protection afforded by patents we may own or in-license, we seek to rely on trade secret protection, confidentiality agreements, and license agreements to protect proprietary know-how that may not be patentable, processes for which patents are difficult to enforce and any other elements of our product discovery and development processes that involve proprietary know-how, information, or technology that may not be covered by patents. Although we seek to require all of our employees, consultants, advisors, and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, trade secrets can be difficult to protect and we have limited control over the protection of trade secrets used by our collaborators and suppliers. We cannot be certain that we have or will obtain these agreements in all circumstances and we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, any of these parties might breach the agreements and intentionally or inadvertently disclose our trade secret information and we may not be able to obtain adequate remedies for such breaches. In addition, competitors may otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights and trade secrets to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property or proprietary information to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, financial condition, results of operations and future prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. If we choose to go to court to stop a third party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us.</span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual or entity during the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">course of the party&#x2019;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary technology by third parties. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. Although we require all of our employees to assign their inventions to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may initiate, become a defendant in, or otherwise become party to lawsuits to protect or enforce our intellectual property rights, which could be expensive, time-consuming, and unsuccessful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Competitors may infringe any patents we may own or in-license. In addition, any patents we may own or in-license also may become involved in inventorship, priority, validity or unenforceability disputes. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful (and we may not be able to prevent the commercialization of the competitor product). In addition, in an infringement proceeding, a court may decide that one or more of any patents we may own or in-license is not valid or is unenforceable or that the other party&#x2019;s use of our technology that may be patented falls under the safe harbor to patent infringement under 35 U.S.C. &#167; 271(e)(1). There is also the risk that, even if the validity of these patents is upheld, the court may refuse to stop the other party from using the technology at issue on the grounds that any patents we may own or in-license do not cover the technology in question or that such third party&#x2019;s activities do not infringe our patent applications or any patents we may own or in-license. An adverse result in any litigation or defense proceedings could put one or more of any patents we may own or in-license at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, patient support or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace and may negatively impact our stock price.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Post-grant proceedings provoked by third parties or brought by the USPTO may be necessary to determine the validity or priority of inventions with respect to our patent applications or any patents we may own or in-license. These proceedings are expensive and an unfavorable outcome could result in a loss of our current patent rights (or technology covered under current patent applications) and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. In addition to potential USPTO post-grant proceedings, we may become a party to patent opposition proceedings in the EPO, or similar proceedings in other foreign patent offices or courts where our patents may be challenged. The costs of these proceedings could be substantial, and may result in a loss of scope of some claims or a loss of the entire patent. An unfavorable result in a post-grant challenge proceeding may result in the loss of our right to exclude others from practicing one or more of our inventions in the relevant country or jurisdiction, which could have a material adverse effect on our business. Litigation or post-grant proceedings within patent offices may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be able to detect infringement against any patents we may own or in-license. Even if we detect infringement by a third party of any patents we may own or in-license, we may choose not to pursue litigation against or settlement with the third party. If we later sue such third party for patent infringement, the third party may have certain legal defenses available to it, which otherwise would not be available except for the delay between when the infringement was first</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">detected and when the suit was brought. Such legal defenses may make it impossible for us to enforce any patents we may own or in-license against such third party.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intellectual property litigation and administrative patent office patent validity challenges in one or more countries could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, patient support or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. As noted above, some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace, including compromising our ability to raise the funds necessary to initiate and continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development collaborations that would help us commercialize our current or future product candidates, if approved. Any of the foregoing events would harm our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be subject to damages or settlement costs resulting from claims that we or our employees have violated the intellectual property rights of third parties, or are in breach of our agreements. We may be accused of, allege or otherwise become party to lawsuits or disputes alleging wrongful disclosure of third-party confidential information by us or by another party, including current or former employees, contractors or consultants. In addition to diverting attention and resources to such disputes, such disputes could adversely impact our business reputation and/or protection of our proprietary technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The intellectual property landscape relevant to our product candidates and programs is crowded, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business. Our commercial success depends upon our ability to develop, manufacture, market and sell our current and future product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including derivation, interference, reexamination,</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> inter partes</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> review and post grant review proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We or any of our current or future licensors or strategic partners may be party to, exposed to, or threatened with, future adversarial proceedings or litigation by third parties having patent or other intellectual property rights alleging that our current or future product candidates and/or proprietary technologies infringe, misappropriate or otherwise violate their intellectual property rights. We cannot assure you that our current or future product candidates and other technologies that we have developed, are developing or may develop in the future do not or will not infringe, misappropriate or otherwise violate existing or future patents or other intellectual property rights owned by third parties. For example, many of our employees were previously employed at other biotechnology or pharmaceutical companies. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#x2019;s former employer. We may also be subject to claims that patents and applications we have filed to protect inventions of our employees, consultants and advisors, even those related to one or more of our current or future product candidates, are rightfully owned by their former or concurrent employer. Litigation may be necessary to defend against these claims.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While certain activities related to development and clinical testing of our current or future product candidates may be subject to safe harbor of patent infringement under 35 U.S.C. &#167;271(e)(1), upon receiving FDA approval for such candidates we or any of our future licensors or strategic partners may immediately become party to, exposed to, or threatened with, future adversarial proceedings or litigation by third parties having patent or other intellectual property rights alleging that such product candidates infringe, misappropriate or otherwise violate their intellectual property rights.  If such actions are successful, the third party may be able to, among other things, prevent launch of a product (which may happen only after the significant expense of development and clinical trials). Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our current or future product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our current or future product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties may allege they have patent rights encompassing our current or future product candidates, technologies or methods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If a third party claims that we infringe, misappropriate or otherwise violate its intellectual property rights, we may face a number of issues, including, but not limited to:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Symbol;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">infringement, misappropriation and other intellectual property claims which, regardless of merit, may be expensive and time-consuming to litigate and may divert our management&#x2019;s attention from our core business and may impact our reputation;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">substantial damages for infringement, misappropriation or other violations, which we may have to pay if a court decides that the product candidate or technology at issue infringes, misappropriates or violates the third party&#x2019;s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent owner&#x2019;s attorneys&#x2019; fees;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a court prohibiting us from developing, manufacturing, marketing or selling our current product candidate, including TNG908, or future product candidates, or from using our proprietary technologies, unless the third party licenses its product rights to us, which it is not required to do, on commercially reasonable terms or at all;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">if a license is available from a third party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant cross-licenses to intellectual property rights for our products, or the license to us may be non-exclusive, which would permit third parties to use the same intellectual property to compete with us;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">redesigning our current or future product candidates or processes so they do not infringe, misappropriate or violate third-party intellectual property rights, which may not be possible or may require substantial monetary expenditures and time; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. The occurrence of any of the foregoing could have a material adverse effect on our business, financial condition, results of operations or prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may choose to challenge the patentability of claims in a third party&#x2019;s U.S. patent by requesting that the USPTO review the patent claims in an ex-parte re-exam,</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> inter partes</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> review or post-grant review proceedings. These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third party&#x2019;s patent in patent opposition proceedings in the EPO or other foreign patent office. The costs of these opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed to litigation by a third party alleging that the patent may be infringed by our current or future product candidates or proprietary technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Third parties may assert that we are employing their proprietary technology without authorization. Patents issued in the United States by law enjoy a presumption of validity that can be rebutted in U.S. courts only with evidence that is &#x201c;clear and convincing,&#x201d; a heightened standard of proof. There may be issued third-party patents of which we are currently unaware with claims to compositions, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our current or future product candidates. Patent applications can take many years to issue. In addition, because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after their earliest priority filing date, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications covering our current or future product candidates or technology. If any such patent applications issue as patents, and if such patents have priority over our patent applications or patents we may own or in-license, we may be required to obtain rights to such patents owned by third parties which may not be available on commercially reasonable terms or at all, or may only be available on a non-exclusive basis. There may be currently pending third-party patent applications which may later result in issued patents that our current or future product candidates may infringe. It is also possible that patents owned by third parties of which we are aware, but which we do not believe are relevant to our current or future product candidates or other technologies, could be found to be infringed by our current or future product candidates or other technologies. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Moreover, we may fail to identify relevant patents or incorrectly conclude</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">that a patent is invalid, not enforceable, exhausted, or not infringed by our activities. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our current or future product candidates, molecules used in or formed during the manufacturing process, or any final product itself, the holders of any such patents may be able to block our ability to commercialize the product candidate unless we obtained a license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our current or future product candidates may be impaired or delayed, which could in turn significantly harm our business. Even if we obtain a license, it may be nonexclusive, thereby giving our competitors access to the same technologies licensed to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop, launch and commercialize our current or future product candidates. Defense of these claims, regardless of their merit, could involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement, misappropriation or other violation against us, we may have to pay substantial damages, including treble damages and attorneys&#x2019; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need or may choose to obtain licenses from third parties to advance our research or allow commercialization of our current or future product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our current or future product candidates, which could harm our business significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be unable to obtain patent or other intellectual property protection for our current or future product candidates or our future products, if any, in all jurisdictions throughout the world, and we may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be able to pursue patent coverage of our current or future product candidates in all countries. Filing, prosecuting and defending patents on current or future product candidates in all countries throughout the world would be prohibitively expensive, and intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but where intellectual property rights enforcement is not as strong as that in the United States. These products may compete with our current or future product candidates and in jurisdictions where we do not have any issued patents our patent applications or other intellectual property rights may not be effective or sufficient to prevent them from competing. Much of our patent portfolio is at the very early stage. We will need to decide whether and in which jurisdictions to pursue protection for the various inventions in our portfolio prior to applicable deadlines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to pharmaceutical products, which could make it difficult for us to stop the infringement of any patents we may own or in-license or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce any rights we may have in our patent applications or any patents we may own or in-license in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put any patents we may own or in-license at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents we may own or license that are relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not obtain or grant licenses or sublicenses to intellectual property rights in all markets on equally or sufficiently favorable terms with third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties. The licensing of third-party intellectual property rights is a competitive area, and more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. More established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to license such technology, or if we are forced to license such technology on unfavorable terms, our business could be materially harmed. If we are unable to obtain a necessary license, we may be unable to develop or commercialize the affected current or future product candidates, which could materially harm our business, and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. Any of the foregoing could harm our competitive position, business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we fail to comply with our obligations in any agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may from time to time be party to license and collaboration agreements with third parties to advance our research or allow commercialization of current or future product candidates. Such agreements may impose numerous obligations, such as development, diligence, payment, commercialization, funding, milestone, royalty, sublicensing, insurance, patent prosecution, enforcement and other obligations on us and may require us to meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the licenses. In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to develop and commercialize products and technologies covered by these license agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any termination of these licenses, or if the underlying patents fail to provide the intended exclusivity, could result in the loss of significant rights and could harm our ability to commercialize our current or future product candidates, and competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical to ours and we may be required to cease our development and commercialization of certain of our current or future product candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;"><br />&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope of rights granted under the license agreement and other interpretation-related issues;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">whether and the extent to which our technology and processes infringe, misappropriate or otherwise violate intellectual property rights of the licensor that is not subject to the licensing agreement;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our right to sublicense patent and other rights to third parties under collaborative development relationships;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our current or future product candidates, and what activities satisfy those diligence obligations;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the priority of invention of any patented technology; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our future licensors and us and our partners.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> 	In addition, the agreements under which we may license intellectual property or technology from third parties are likely to be complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we may license prevent or impair our ability to maintain future licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected current or future product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:15.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Any granted patents we may own or in-license covering our current or future product candidates or other valuable technology could be narrowed or found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad, including the USPTO and the EPO. A patent asserted in a judicial court could be found invalid or unenforceable during the enforcement proceeding. Administrative or judicial proceedings challenging the validity of our patents or individual patent claims could take months or years to resolve.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we or our licensors or strategic partners initiate legal proceedings against a third party to enforce a patent covering one of our current or future product candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of patentable subject matter, lack of written description, lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, in the process of obtaining the patent during patent prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination,</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> inter partes</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> review, post grant review and equivalent proceedings in foreign jurisdictions (such as opposition proceedings). Such proceedings could result in revocation or amendment to our patent applications or any patents we may own or in-license in such a way that they no longer cover our current or future product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, any rights we may have from our patent applications or any patents we may own or in-license, allow third parties to commercialize our current or future product candidates or other technologies and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in post-grant challenge proceedings, such as oppositions in a foreign patent office, that challenge our or our future licensors&#x2019; priority of invention or other features of patentability with respect to our patent applications and any patents we may own or in-license. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our current or future product candidates and other technologies. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we or our future licensing partners and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if we are otherwise unable to adequately protect our rights, we would lose at least part, and perhaps all, of the patent protection on our current or future product candidates. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and current or future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. If we are unsuccessful in any such proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of the current or future product candidates we may develop. The loss of exclusivity or the narrowing of our patent application claims could limit our ability to stop others from using or commercializing similar or identical technology and products. Any of the foregoing could have a material adverse effect on our business, results of operations, financial condition and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:15.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our current or future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act, or Leahy-Smith Act, signed into law on September 16, 2011, could increase those uncertainties and costs. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">inter partes</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> review, and derivation proceedings. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the Leahy-Smith Act has transformed the U.S. patent system into a &#x201c;first inventor to file&#x201d; system. The first-inventor-to-file provisions, however, only became effective on March 16, 2013. Accordingly, it is not yet clear what, if any, impact the Leahy-Smith Act will have on the operation of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Additionally, there have been recent proposals for additional changes to the patent laws of the United States and other countries that, if adopted, could impact our ability to obtain patent protection for our proprietary technology or our ability to enforce our proprietary technology. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our rights under patents that we might obtain in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might subject us to infringement claims or adversely affect our ability to develop and market our current or future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot guarantee that any of our or our licensors&#x2019; patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending patent application in the United States and abroad that is relevant to or necessary for the commercialization of our current or future product candidates in any jurisdiction. For example, U.S. patent applications filed before November 29, 2000 and certain U.S. patent applications filed after that date that will not be filed outside the United States remain confidential until patents issue. As mentioned above, patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our current or future product candidates could have been filed by third parties without our knowledge. Additionally, identification of third-party patent rights that may be relevant to our operations is difficult because patent searching is imperfect due to, for example, differences in terminology among patents or incomplete databases. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our current or future product candidates or the use of our current or future product candidates. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#x2019;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our current or future product candidates. We may incorrectly determine that our current or future product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#x2019;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our current or future product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our current or future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we fail to identify and correctly interpret relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay damages, which may be significant, we may be temporarily or permanently</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">prohibited from commercializing any of our current or future product candidates that are held to be infringing. We might, if possible, also be forced to redesign current or future product candidates so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business and could adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:15.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intellectual property rights do not guarantee commercial success of current or future product candidates or other business activities. Numerous factors may limit any potential competitive advantage provided by our intellectual property rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The degree of future protection afforded by our intellectual property rights, whether owned or in-licensed, is uncertain because intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors, or permit us to maintain our competitive advantage. Moreover, if a third party has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Symbol;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">patent applications that we own or may in-license may not lead to issued patents;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">patents, should they issue, that we may own or in-license, may not provide us with any competitive advantages, may be narrowed in scope, or may be challenged and held invalid or unenforceable;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">others may be able to develop and/or practice technology, including compounds that are similar to the chemical compositions of our current or future product candidates, that is similar to our technology or aspects of our technology but that is not covered by the claims of any patents we may own or in-license, should any patents issue;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">third parties may compete with us in jurisdictions where we do not pursue and obtain patent protection;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we, or our future licensors or collaborators, might not have been the first to make the inventions covered by a patent application that we own or may in-license;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we, or our future licensors or collaborators, might not have been the first to file patent applications covering a particular invention;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">others may independently develop similar or alternative technologies without infringing, misappropriating or otherwise violating our intellectual property rights;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and may then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may not be able to obtain and/or maintain necessary licenses on reasonable terms or at all;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">third parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights, or any rights at all, over that intellectual property;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such trade secrets or know-how;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may not be able to maintain the confidentiality of our trade secrets or other proprietary information;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may not develop or in-license additional proprietary technologies that are patentable; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the patents of others may have an adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Government Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assuming that our product candidates prove to be safe and effective in clinical trials, we expect that we will file for marketing approval for such product candidates in the United States and we may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or fail to receive applicable regulatory approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and future potential revenue may be less than expected by investors and analysts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants regulatory approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional nonclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In short, the foreign regulatory approval process involves all of the risks associated with FDA approval. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we may intend to charge for our products will also be subject to approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may seek priority review designation for one or more of our product candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster regulatory review or approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the FDA determines that a product candidate offers a treatment for a serious condition and, if approved, the product would provide a significant improvement in safety or effectiveness, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six months from the date of filing, rather than the standard review period of ten months. We may request priority review for our product candidates. The FDA has broad discretion with respect to whether or not to grant priority review status to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a priority review designation does not necessarily result in an expedited regulatory review or approval process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. Receiving priority review from the FDA does not guarantee approval within the six-month review cycle or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may seek orphan drug designation for certain of our product candidates, and we may be unsuccessful or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As part of our business strategy, we may seek orphan drug designation for certain of our product candidates, and we may be unsuccessful. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a product intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population of 200,000 or more in the United States where there is no reasonable expectation that the cost of developing the product will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Similarly, in Europe, the European Commission, upon the recommendation of the EMA&#x2019;s Committee for Orphan Medicinal Products, grants orphan drug designation to promote the development of drugs that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more than five in 10,000 persons in Europe and for which no satisfactory method of diagnosis, prevention, or treatment has been authorized (or the product would be a significant benefit to those affected). Additionally, designation is granted for drugs intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of the drug in Europe would be sufficient to justify the necessary investment in developing the drug. In Europe, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Generally, if a product with an orphan drug designation subsequently receives the first regulatory approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for the same product and indication for that time period, except in limited circumstances. The applicable period is seven years in the United States and ten years in the European Union. The exclusivity period in the European Union can be reduced to six years if a product no longer meets the criteria for orphan drug designation or if the product is sufficiently profitable so that market exclusivity is no longer justified.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we obtain orphan drug exclusivity for one of our product candidates, that exclusivity may not effectively protect our product candidate from competition because different products having different chemical compositions can be approved for the same condition and the same therapies can be approved for different conditions but used off-label. Even after an orphan drug is approved, the FDA can subsequently approve the same product for the same condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer, more effective or makes a major</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">contribution to patient care. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition or if another product with the same active moiety is determined to be safer, more effective, or represents a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a product nor gives the product any advantage in the regulatory review or approval process. While we may seek orphan drug designation for our product candidates, we may never receive such designations. Even if we do receive such designations, there is no guarantee that we will enjoy the benefits of those designations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:15.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">A breakthrough therapy designation and fast track designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development, regulatory review or approval process, and each designation does not increase the likelihood that any of our product candidates will receive regulatory approval in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may seek a breakthrough therapy designation for some of our product candidates. A breakthrough therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Product candidates designated as breakthrough therapies by the FDA may also be eligible for priority review and accelerated approval. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that such product candidates no longer meet the conditions for qualification and rescind the designation or decide that the time period for FDA review or approval will not be shortened.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may also seek fast track designation for some of our product candidates and, in the case of TNG908, we were granted fast track designation by the FDA in the first quarter of 2022. If a drug is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrates the potential to address unmet medical needs for this condition, the sponsor may apply for fast track designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive fast track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast track designation alone does not guarantee qualification for the FDA&#x2019;s priority review procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may seek accelerated approval of our current or future product candidates using the FDA&#x2019;s accelerated approval pathway.  Accelerated approval by the FDA, even if granted for our current or any other future product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may seek accelerated approval of our current or future product candidates using the FDA&#x2019;s accelerated approval pathway. A product may be eligible for accelerated approval if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA requires that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. These confirmatory trials must be completed with due diligence. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product. Even if we do receive accelerated approval, we may not experience a faster development or regulatory review or approval process, and receiving accelerated approval does not provide assurance of ultimate FDA approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:15.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The FDA, the EMA and other regulatory authorities may implement additional regulations or restrictions on the development and commercialization of our product candidates, and such changes can be difficult to predict.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA, the EMA and regulatory authorities in other countries have each expressed interest in further regulating biotechnology products. Agencies at both the federal and state level in the United States, as well as the U.S. Congressional committees and other governments or governing agencies, have also expressed interest in further regulating the biotechnology industry. Such action may delay or prevent commercialization of some or all of our product candidates. Adverse developments in clinical trials of products conducted by others may cause the FDA or other oversight bodies to change the requirements for conducting clinical trials or for approval of any of our product candidates. These regulatory review agencies and committees and the new requirements or guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies or trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory agencies and comply with applicable requirements and guidelines. If we fail to do so, we may be required to delay or discontinue development of such product candidates. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. Delays as a result of an increased or lengthier regulatory approval process or further restrictions on the development of our product candidates can be costly and could negatively impact our ability to complete clinical trials and commercialize our current and future product candidates in a timely manner, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:15.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Inadequate funding for the FDA, the SEC and other U.S. government agencies or the EMA or comparable foreign regulatory authorities, including from government shut downs, or other disruptions to these agencies&#x2019; operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The ability of the FDA, the EMA or comparable foreign regulatory authorities to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and enact statutory, regulatory and policy changes. Average review times at the FDA or other regulatory authorities have fluctuated in recent years as a result. Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Disruptions at the FDA, the EMA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Separately, since March 2020 when foreign and domestic inspections were largely placed on hold due to the COVID-19 pandemic, the FDA has been working to resume routine surveillance, bioresearch monitoring and pre-approval inspections on a prioritized basis.  Since April 2021, the FDA has conducted limited inspections and employed remote interactive evaluations, using risk management methods, to meet user fee commitments and goal dates. Ongoing travel restrictions and other uncertainties continue to impact oversight operations abroad and it is unclear when standard operational levels will resume. The FDA is continuing to complete mission-critical work, prioritize other higher-tiered inspectional needs (e.g., for-cause inspections), and carry out surveillance inspections using risk-based approaches for evaluating public health. Should the FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to be adequate, the agency has stated that it generally intends to issue, depending on the circumstances, a complete response letter or defer action on the application until an inspection can be completed.</span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2020 and in 2021, a number of companies announced receipt of complete response letters due to the FDA&#x2019;s inability to complete required inspections for their applications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in regulations, statutes or the interpretation of existing regulations and statutes could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall or discontinuation of our products; or (iv) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.  See section entitled &#x201c;</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Business &#x2013; Current and future healthcare reform legislation</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">            Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court's decision, President Biden issued an Executive Order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The Executive Order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other healthcare reform measures of the Biden administration or other efforts, if any, to challenge repeal or replace the ACA, will impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Separately, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or may not provide adequate payment for our product candidates. There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, there have been several changes to the 340B drug pricing program, which imposes ceilings on prices that drug manufacturers can charge for medications sold to certain health care facilities. On December 27, 2018, the District Court for the District of Columbia invalidated a reimbursement formula change under the 340B drug pricing program, and CMS subsequently altered the Fiscal Years 2019 and 2018 reimbursement formula on specified covered outpatient drugs, or SCODs. The court ruled this change was not an &#x201c;adjustment&#x201d; which was within the Secretary&#x2019;s discretion to make but was instead a fundamental change in the reimbursement calculation. However, most recently, on July 31, 2020, the U.S. Court of Appeals for the District of Columbia Circuit overturned the district court&#x2019;s decision and found that the changes were within the Secretary&#x2019;s authority. On September 14, 2020, the plaintiffs-appellees filed a Petition for Rehearing En Banc (i.e., before the full court), but was denied on October 16, 2020. It is unclear how these developments could affect covered hospitals who might purchase our future products and affect the rates we may charge such facilities for our approved products in the future, if any.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, former President Trump announced several executive orders related to prescription drug pricing that seek to implement several of the administration&#x2019;s proposals. In response, the FDA released a final rule on September 24, 2020, which went into effect on November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020 CMS issued an Interim Final Rule implementing the Most Favored Nation, or MFN, Model under which Medicare Part B reimbursement rates will be calculated for certain drugs and biologicals based on the lowest price drug manufacturers receive in Organization for Economic Cooperation and Development countries with a similar gross domestic product per capita. The MFN Model regulations mandate participation by identified Part B providers and will apply in all U.S. states and territories for a seven-year period beginning January 1,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021 and ending December 31, 2027. The Interim Final Rule has not been finalized and is subject to revision and challenge. Additionally, on November 20, 2020, DHHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Implementation of the amendments to the discount safe harbor have been delayed until at least January 1, 2023. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, Congress has indicated that it will continue to seek new legislative measures to control drug costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payers. In addition, individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These laws, and future state and federal healthcare reform measures may be adopted in the future, any of which may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. Additionally, we expect to experience pricing pressures in connection with the sale of any future approved product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, cost containment initiatives and additional legislative changes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational harm and diminished profits and future earnings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we do not currently have any products on the market, once we begin commercializing our product candidates, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal government and the states and foreign governments in which we conduct our business. Healthcare providers, physicians and third-party payors play a primary role in the recommendation and prescription of any product candidates for which we obtain regulatory approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our product candidates for which we obtain regulatory approval.  See section entitled &#x201c;</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Business &#x2013; Other healthcare laws</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ensuring that our future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations, including future sales of our product candidates (following regulatory approval of such therapy) by us or third-parties that we engage, were to be found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.  Further, defending against any such actions can be costly and time consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment. If any of the above occur, our ability to operate our business and our results of operations could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot, however, eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we maintain workers&#x2019; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to post-market study requirements, marketing and labeling restrictions, and even recall or market withdrawal if unanticipated safety issues are discovered following approval. In addition, we may be subject to penalties or other enforcement action if we fail to comply with regulatory requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any regulatory approvals that we receive for our product candidates will require surveillance to monitor the safety and efficacy of the product candidate.  If the FDA or a comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, labeling, packaging, distribution, import, export, adverse event reporting, storage, advertising, promotion, monitoring, and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and listing, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval and pharmacovigilance reporting obligations. Any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing studies, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product. The FDA may also require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">manufacturing delays and supply disruptions where regulatory inspections identify observations of noncompliance requiring remediation;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">revisions to the labeling, including limitation on approved uses or the addition of additional warnings, contraindications or other safety information, including boxed warnings;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">imposition of a REMS which may include distribution or use restrictions;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">requirements to conduct additional post-market clinical trials to assess the safety of the product;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">clinical trial holds;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fines, warning letters or other regulatory enforcement action;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of approvals;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product seizure or detention, or refusal to permit the import or export of products; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">injunctions or the imposition of civil or criminal penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:13.5pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA&#x2019;s and other regulatory authorities&#x2019; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any regulatory approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">European data collection is governed by restrictive regulations governing the use, processing and cross-border transfer of personal information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We plan to conduct clinical trials and enroll subjects in our planned or future clinical trials, and therefore we will be subject to additional privacy restrictions. The collection, use, storage, disclosure, transfer, or other processing of personal data regarding individuals in the European Union, including personal health data, is subject to the EU General Data Protection Regulation, or GDPR. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. While we have commenced the process of implementing procedures to comply with the GDPR, compliance with these regulations will be a rigorous and time-intensive process that we expect will increase our cost of doing business and require us to change certain of our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European activities. Further, many countries interpret the application of the provisions of the GDPR in different manner, making compliance in certain countries and across the European Union challenging.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain products outside of the United States and require us to develop and implement costly compliance programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we expand our operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#x2019;s accounting provisions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Relating to Employee Matters and Managing Anticipated Growth</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our future success depends on our ability to retain key executives and experienced scientists and to attract, retain and motivate qualified personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are highly dependent on many of our key employees and members of our executive management team as well as the other principal members of our management, scientific and clinical team. Although we have entered into employment letter agreements with certain of our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#x201c;key person&#x201d; insurance for any of our executives or other employees. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Recruiting and retaining qualified scientific, clinical, medical, manufacturing and sales and marketing personnel will also be critical to our success. The loss of the services of our executive officers or other key employees, including temporary loss due to illness, could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific, medical and clinical personnel from universities and research institutions. Failure to succeed in clinical trials may make it more challenging to recruit and retain qualified scientific personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In particular, we have experienced a very competitive hiring environment in Cambridge, Massachusetts, where we are headquartered. Many of the other pharmaceutical companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success with which we can discover and develop product candidates and our business will be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be unable to adequately protect our information systems from cyberattacks, which could result in the disclosure of confidential or proprietary information, including personal data, damage our reputation, and subject us to significant financial and legal exposure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely on information technology systems that we or our third-party providers operate to process, transmit and store electronic information in our day-to-day operations. In connection with our product discovery efforts, we collect and use a variety of personal data, such as names, mailing addresses, email addresses, phone numbers.  In addition, in connection with our planned Phase 1/2 clinical trial, which we expect to initiate in the second quarter of 2022, we will have access to, and may store, clinical and health information of the patients participating in the trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A successful cyberattack could result in the theft or destruction of intellectual property, data, or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and disrupt our operations. Cyberattacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyberattacks could include wrongful conduct by hostile foreign governments, industrial espionage, wire fraud and other forms of cyber fraud, the deployment of harmful malware, denial-of-service, social engineering fraud or other means to threaten data security, confidentiality, integrity and availability. A successful cyberattack could cause serious negative consequences for us, including, without limitation, the disruption of operations, the misappropriation of confidential business information, including financial information, trade secrets, financial loss and the disclosure of corporate strategic plans. Although we devote resources to protect our information systems, we realize that cyberattacks are a threat, and there can be no assurance that our efforts will prevent information security breaches that would result in business, legal, financial or reputational harm to us, or would have a material adverse effect on our results of operations and financial condition. Any failure to prevent or mitigate security breaches or improper access to, use of, or disclosure of our clinical data or patients&#x2019; personal data could result in significant liability under state (e.g., state breach notification laws), federal (e.g., HIPAA, as amended by HITECH), and international law (e.g., the GDPR) and may cause a material adverse impact to our reputation, affect our ability to conduct new studies and potentially disrupt our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely on our third-party providers to implement effective security measures and identify and correct for any such failures, deficiencies or breaches. If we or our third-party providers fail to maintain or protect our information technology systems and data integrity effectively or fail to anticipate, plan for or manage significant disruptions to our information technology systems, we or our third-party providers could have difficulty preventing, detecting and controlling such cyber-attacks and any such attacks could result in the losses described above as well as disputes with physicians, patients and our partners, regulatory sanctions or penalties, increases in operating expenses, expenses or lost revenue or other adverse consequences, any of which could have a material adverse effect on our business, results of operations, financial condition, prospects and cash flows. Any failure by such third parties to prevent or mitigate security breaches or improper access to or disclosure of such information could have similarly adverse consequences for us. If we are unable to prevent or mitigate the impact of such security or data privacy breaches, we could be exposed to litigation and governmental investigations, which could lead to a potential disruption to our business. By way of example, the California Consumer Privacy Act, or CCPA,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">which went into effect on January 1, 2020, creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal data. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability, and many similar laws have been proposed at the federal level and in other states.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">          Further, a new California privacy law, the California Privacy Rights Act, or CPRA, was passed by California voters on November 3, 2020. The CPRA will create additional obligations with respect to processing and storing personal information that are scheduled to take effect on January 1, 2023 (with certain provisions having retroactive effect to January 1, 2022). Additionally, some observers have noted that the CCPA and CPRA could mark the beginning of a trend toward more stringent privacy legislation in the U.S., which could increase our potential liability and adversely affect our business. Already, in the United States, we have witnessed significant developments at the state level. For example, on March 2, 2021, Virginia enacted the Consumer Data Protection Act (the &#x201c;CDPA&#x201d;) and, on July 8, 2021, Colorado&#x2019;s governor signed the Colorado Privacy Act (&#x201c;CPA&#x201d;), into law. The CDPA and the CPA will both become effective January 1, 2023. While the CDPA and CPA incorporate many similar concepts of the CCPA and CPRA, there are also several key differences in the scope, application, and enforcement of the law that will change the operational practices of regulated businesses. The new laws will, among other things, impact how regulated businesses collect and process personal sensitive data, conduct data protection assessments, transfer personal data to affiliates, and respond to consumer rights requests.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">          A number of other states have proposed new privacy laws, some of which are similar to the above discussed recently passed laws. Such proposed legislation, if enacted, may add additional complexity, variation in requirements, restrictions and potential legal risk, require additional investment of resources in compliance programs, impact strategies and the availability of previously useful data and could result in increased compliance costs and/or changes in business practices and policies. The existence of comprehensive privacy laws in different states in the country would make our compliance obligations more complex and costly and may increase the likelihood that we may be subject to enforcement actions or otherwise incur liability for noncompliance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">      By way of example regarding foreign laws and regulations with respect to data privacy and security, the GDPR went into effect in the European Union in May 2018 and introduces strict requirements for processing the personal data of EU data subjects. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#x20ac;20 million or 4% of the annual global revenue of the noncompliant company, whichever is greater. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, further to the U.K.&#x2019;s exit from the EU on January 31, 2020, the GDPR ceased to apply in the U.K. at the end of the transition period on December 31, 2020. However, as of January 1, 2021, the U.K.&#x2019;s European Union (Withdrawal) Act 2018 incorporated the U.K. GDPR into U.K. law. The U.K. GDPR and the U.K. Data Protection Act 2018 set out the U.K.&#x2019;s data protection regime, which is independent from but aligned to the EU&#x2019;s data protection regime. Non-compliance with the U.K. GDPR may result in monetary penalties of up to &#163;17.5 million or 4% of worldwide revenue, whichever is higher. Although the UK is regarded as a third country under the EU&#x2019;s GDPR, the European Commission has now issued a decision recognizing the UK as providing adequate protection under the EU GDPR and, therefore, transfers of personal data originating in the EU to the UK remain unrestricted. Like the EU GDPR, the UK GDPR restricts personal data transfers outside the UK to countries not regarded by the UK as providing adequate protection. The UK government has confirmed that personal data transfers from the UK to the EEA remain free flowing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">            To enable the transfer of personal data outside of the EEA or the UK, adequate safeguards must be implemented in compliance with European and UK data protection laws. On June 4, 2021, the EC issued new forms of standard contractual clauses for data transfers from controllers or processors in the EU/EEA (or otherwise subject to the GDPR) to controllers or processors established outside the EU/EEA (and not subject to the GDPR). The new standard contractual clauses replace the standard contractual clauses that were adopted previously under the EU Data Protection Directive. The UK is not subject to the EC&#x2019;s new standard contractual clauses but has published a draft version of a UK-specific transfer mechanism, which, once finalized, will enable transfers from the UK. We will be required to implement these new safeguards when conducting restricted data transfers under the EU and UK GDPR and doing so will require significant effort and cost.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">       Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. If we fail to comply with any such laws or regulations, we may face significant fines and penalties that could adversely affect our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we or third-party CMOs, CROs or other contractors or consultants fail to comply with U.S. and international data protection laws and regulations, it could result in government enforcement actions (which could include civil or criminal</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we, our CRO operating our trials, or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we or such third-party have violated individuals&#x2019; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had 91 full-time employees. We expect to experience significant growth in the number of our employees and the scope of our operations, particularly as we function as a public company and in the areas of product development, regulatory affairs and, if any of our product candidates receives regulatory approval, sales, medical affairs, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources, we may not be able to effectively manage the planned expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may acquire additional businesses or products, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure you that, following any such acquisition, we will achieve the expected synergies to justify the transaction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our executive officers, directors, principal stockholders and their affiliates own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on our common stock outstanding as of December 31, 2021, our executive officers, directors and their affiliates and our principal stockholders beneficially held, in the aggregate, approximately 40% of our outstanding voting stock. These stockholders, acting together, would be able to significantly influence all matters requiring stockholder approval. For example, these stockholders would be able to significantly influence elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. These stockholders may have interests, with respect to their common stock, that are different from those of other investors and the concentration of voting power among these stockholders may have an adverse effect on the price of our common stock. In addition, this concentration of ownership might adversely affect the market price of our common stock by delaying, deferring or preventing a change of control of us, impeding a merger, consolidation, takeover or other business combination involving us or discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under Sections 382 and 383 of the Internal Revenue Code, as amended, or the Code, if a corporation undergoes an &#x201c;ownership change&#x201d; (generally defined as a greater than 50 percentage point change (by value) in the ownership of its equity over a three-year period), the corporation&#x2019;s ability to use its pre-change net operating loss carryforwards and certain other pre-change tax attributes to offset its post-change income may be limited. We have experienced such ownership changes in the past, and we may experience ownership changes in the future as a result of shifts in our stock ownership, some of which are outside our control. The Company has performed an analysis of ownership changes through December 31, 2021, and determined that on February 6, 2017 and August 17, 2020, ownership changes had occurred. Based on this analysis, the Company&#x2019;s ability to use its pre-change tax attributes to offset federal and state taxable income are subject to annual limitations and a portion of the attributes generated prior to February 6, 2017, will expire unutilized, which could potentially result in an increased future tax liability. The Company has adjusted its deferred tax assets and valuation allowance balance for the affected tax attribute carryforwards to reflect the expiration of the attributes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal net operating loss carryforwards generated in taxable years beginning after December 31, 2017 will not be subject to expiration. However, any such net operating loss carryforwards may only offset 80% of our annual taxable income in taxable years beginning after December 31, 2020. There is also a risk that due to regulatory changes, such as suspensions on the use of net operating loss carryforwards or other unforeseen reasons, our existing net operating loss carryforwards could expire or otherwise be unavailable to offset future income tax liabilities, including for state tax purposes. In future years, if and when a net deferred tax asset is recognized related to our net operating loss carryforwards, the changes in the carryforward/carryback periods as well as the new limitation on use of net operating loss carryforwards may significantly impact our valuation allowance assessments for net operating loss carryforwards. For these reasons, we may not be able to utilize some portion of our net operating loss carryforwards, none of which are currently reflected on our balance sheet, even if we attain profitability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.2%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our certificate of incorporation and bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a requirement that special meetings of the stockholders may be called only by the board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office, and special meetings of stockholders may not be called by any other person or persons;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">advance notice requirements for stockholder proposals and nominations for election to our board of directors;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and then, in addition to any other vote required by law, only upon the approval of not less than 66 2/3% of all outstanding shares of our capital stock then entitled to vote in the election of directors;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">supermajority voting requirements to amend our bylaws by stockholder action (unless our board recommends that our stockholders approve such amendment(s)) and to amend specific provisions of our certificate of incorporation; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval, which preferred stock may include rights superior to the rights of the holders of common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These anti-takeover provisions and other provisions in our certificate of incorporation and bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our bylaws designate specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to our bylaws, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for any state law claims for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, or other employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the General Corporation Law of the State of Delaware, or the DGCL, or our certificate of incorporation or bylaws (including the interpretation, validity or enforceability thereof), or (iv) any action asserting a claim governed by the internal affairs doctrine. We refer to the foregoing provision as the Delaware Forum Provision. The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. Our bylaws further provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. We refer to such provision as the Federal Forum Provision. Our bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have notice of and consented to the Delaware Forum Provision and the Federal Forum Provision; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations thereunder.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Delaware Forum Provision and the Federal Forum Provision in our bylaws may impose additional litigation costs on stockholders in pursuing any such claims. Additionally, these forum selection clauses may limit our stockholders&#x2019; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage the filing of lawsuits against us and our directors, officers and employees, even though an action, if successful, might benefit our stockholders. While the Delaware Supreme Court and courts in other states have upheld federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The Federal Forum Provision may also impose additional litigation costs on us and/or our stockholders who assert that the provision is not enforceable or invalid. The Court of Chancery of the State of Delaware and the federal district courts of the United States may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Among other matters, U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, which are collectively referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors, and other partners and representatives from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect our non-U.S. activities to increase in time. We have, and we expect we will continue to, engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals and we can be held liable for the corrupt or other illegal activities of our personnel, agents, representatives or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our employees, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are exposed to the risk that our employees, principal investigators, CROs and consultants may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate the regulations of the FDA and other regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities; healthcare fraud and abuse laws and regulations in the United States and abroad; or laws that require the reporting of financial information or data accurately. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials or creating fraudulent data in our preclinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, imposition of a monitor, possible exclusion from participation in federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our stock price has been and is likely to continue to be volatile. The stock market in general, and the market for biopharmaceutical companies in particular, have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your common stock. The market price for our common stock may be influenced by many factors, including:</span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the success of competitive products or technologies;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">advancement of our preclinical programs, such as our targeted oncology programs, into clinical testing;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">results of clinical trials of our product candidates or those of our competitors;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory or legal developments in the United States and other countries;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the recruitment or departure of key personnel;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the level of expenses related to any of our programs and product candidates or preclinical and clinical development programs;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the results of our efforts to discover, develop, acquire or in-license additional product candidates or products;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">variations in our financial results or those of companies that are perceived to be similar to us;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in the structure of healthcare payment systems and third-party reimbursement decisions;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">market conditions in the pharmaceutical and biotechnology sectors;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">limited trading volume;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">future sales of common stock by our officers, directors and significant stockholders;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">general economic, industry and market conditions; and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;  </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the other factors described in this &#x201c;</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risk Factors</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; section.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a public company, and particularly after we are no longer an &#x201c;emerging growth company,&#x201d; we will incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act and rules subsequently implemented by the SEC and The Nasdaq Global Market, or Nasdaq, have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, these rules and regulations have made it more expensive for us to obtain director and officer liability insurance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to Section 404 of the Sarbanes-Oxley Act, we are required to furnish a report by our management on our internal control over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">internal control over financial reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. In addition, if we are not able to continue to meet these requirements, we may not be able to remain listed on Nasdaq.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The trading market for our common stock relies in part on the research and reports that industry or financial analysts publish about us or our business. We do not control these analysts. If one or more of the analysts covering our business downgrade their evaluations of our stock, the price target for our stock or publish inaccurate or unfavorable evaluations of our company or our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock or fail to publish reports covering our company regularly, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline. In addition, if we are the subject of negative publicity, whether from an analyst, academic, industry group or the general or financial press, our stock price may decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be subject to securities litigation, which is expensive and could divert management attention.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The market price of our common stock may be volatile. The stock market in general, and Nasdaq and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#x2019;s attention from other business concerns, which could seriously harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">General Risk Factors</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comprehensive tax reform legislation could adversely affect our business and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The tax regimes we are subject to or operate under are unsettled and may be subject to significant change. Changes in tax laws (including in response to the COVID-19 pandemic) or tax rulings, or changes in interpretations of existing laws, could cause us to be subject to additional income-based taxes and non- income taxes (such as payroll, sales, use, value-added, digital tax, net worth, property, and goods and services taxes), which in turn could materially affect our financial position and results of operations. Additionally, new, changed, modified, or newly interpreted or applied tax laws could increase our customers&#x2019; and our compliance, operating and other costs, as well as the costs of our products, if approved. As we expand the scale of our business activities, any changes in the U.S. taxation of such activities may increase our effective tax rate and harm our business, financial condition, and results of operations. For example, the change in administration and control of Congress in the United States following the 2020 elections may result in additional U.S. tax law changes that could have a material impact on our future effective tax rate, which could have a negative impact on our results of operations in the future. Complying with these tax laws is complex and the statutes and regulations can be subject to varying interpretation which can make compliance challenging.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. For example, in 2008, the global financial crisis caused extreme volatility and disruptions in the capital and credit markets and the current COVID-19 pandemic has caused significant volatility and uncertainty in U.S. and international</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including, weakened demand for our product candidates and our ability to raise additional capital when needed on acceptable terms, if at all. In addition, our business may be generally exposed to the impact of political or civil unrest or military action, including the current conflict between Russia and Ukraine (where a vendor that performs</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">chemistry related work on our pre-clinical product candidates is located) and, while we do not otherwise have direct exposure to Ukraine, our business and results of operations may be impacted based upon the events taking place there. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">An active trading market for our common stock may not be sustained, and you may not be able to resell your shares at the price you paid.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:5.133%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although our common stock is listed on The Nasdaq Global Market, an active trading market for our shares may not be sustained. In the absence of an active trading market for our common stock, investors may be unable to sell their shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 1B. Unresolved Staff Comments</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not Applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 2. Properties</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our corporate headquarters is located at 100 Binney Street, Cambridge, Massachusetts, where we lease and occupy approximately 22,383 square feet of office and laboratory space. The term of our amended lease with respect to this facility expires on October 15, 2022, however, under certain circumstances, this lease may terminate on an earlier date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2019, we entered into a new lease to move our corporate headquarters to 201 Brookline Avenue, Boston, Massachusetts, where we will lease and occupy approximately 64,805 square feet of office and laboratory space. The leased space is currently undergoing construction. The term of the new lease is ten years from the rent commencement date, which is expected to occur in the second half of 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Ite</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">m 3. Legal Proceedings</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, we may become involved in litigation or other legal proceedings. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 4. Mine Safety Disclosures</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5_market_for_registrants_common"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 5. Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Market Information</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our common stock currently trades on The Nasdaq Global Market under the symbol &#34;TNGX&#34;.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Holders of Common Stock</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of March 4, 2022, there were approximately 61 stockholders of record of our common stock. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain shares are held in &#x201c;street&#x201d; name and accordingly, the number of beneficial owners of such shares is not known or included in the foregoing number of stockholders of record.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Dividend Policy</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently intend to retain all available funds and future earnings, if any, to fund the development and expansion of our business. We have never declared or paid cash dividends on our common stock, and we do not expect to pay any cash dividends on our common stock in the foreseeable future. Payment of future dividends, if any, on our common stock will be at the discretion of our board of directors after taking into account various factors, including our financial condition, operating results, anticipated cash needs, and other factors that the board of directors may deem relevant.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Securities Authorized for Issuance Under Equity Compensation Plans</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by Item 5 of Form 10-K regarding equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Unregistered Sales of Equity Securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by Item 701 of Regulation S-K was previously included in our Quarterly Report on Form 10-Q filed on November 9, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Proceeds</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Of the gross proceeds received from the Initial Public Offering, including an additional 2,175,000 shares of common stock to cover the over-allotments, $166.8 million was placed in a trust account. The net proceeds of the Initial Public Offering were applied to fund the Business Combination and related expenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 6. [Reserved]</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7_managements_discussion"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 7. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes appearing at the end of this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#x201c;Risk Factors&#x201d; section of this Annual Report on Form 10-K, our actual results could differ materially from the results described in, or implied by, the forward-looking statements contained in the following discussion and analysis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Unless otherwise indicated, references in this Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations section to &#x201c;Tango,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our&#x201d; and other similar terms refer to our wholly-owned subsidiary Tango Therapeutics Sub, Inc. and its subsidiary prior to the closing of the business combination with BCTG Acquisition Corp. and to Tango Therapeutics, Inc. and its consolidated subsidiaries after giving effect to the Business Combination.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a precision oncology company leveraging our state-of-the-art target discovery platform to identify novel targets and develop new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. Tumor suppressor gene loss remains a largely untouched target space specifically because these genetic events cannot be directly targeted. Empowered by recent advances in CRISPR technology, we are now able to employ a unique functional genomics approach and apply the principles of synthetic lethality to target the loss of specific tumor suppressor genes at scale. We believe this will result in establishing a sustainable pipeline designed to deliver meaningfully clinical benefit to patients. Our novel small molecules are designed to be selectively active in cancer cells with specific tumor suppressor gene loss, killing those cancer cells while being relatively inert in normal cells. We also are extending this target space beyond the classic, cell-autonomous effects of tumor suppressor gene loss to include the discovery of novel targets that reverse the effects of tumor suppressor gene loss that prevent the immune system from recognizing and killing cancer cells (immune evasion). We believe this approach will provide the ability to deliver the deep, sustained target inhibition necessary for prolonged tumor regression and meaningful clinical benefit as a result of the unique ability of synthetic lethal targeting to spare normal cells.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our lead program, TNG908, a protein arginine methyl transferase 5, or PRMT5, inhibitor is synthetic lethal with MTAP deletion, is being developed as a treatment for cancers with MTAP deletions. MTAP deletions occur in 10% to 15% of all human cancers. In preclinical studies, TNG908 demonstrated 15-fold greater potency in cells with MTAP deletions than those without and showed strong regressions in multiple cancer types.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> In the first quarter of 2022, the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application for the Phase 1/2 clinical trial and granted Fast Track designation to TNG908. We plan to initiate a Phase 1/2 clinical trial in the second quarter of 2022. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our Target 3 program, an undisclosed synthetic lethal target, reverses the immune evasion effect of serine-threonine kinase 11 (STK11) loss-of-function mutations. In animal models, the combination of Target 3 with a PD1 inhibitor sustained strong tumor regressions and the induction of immune memory against re-implantation of tumo</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">rs. We expect to advance a development candidate in the second quarter of 2022 an</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">d file an IND in 2023. We are also developing a ubiquitin-specific protease 1, or USP1, inhibitor that is synthetic lethal with </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">BRCA1 and BRCA2-mutant tumors.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">In vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vivo </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">preclinical data for USP1 demonstrated potent anti-tumor activity. We expect this molecule to have both single agent activity in PARPi-na&#xef;ve and PARPi-resistant </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">BRCA1/2 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">mutant cancers and to synergize with PARP inhibitors. We anticipate declaring a development candidate in the second half of 2022 and filing an IND for this program in 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Business Combination</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On April 13, 2021, the Company, BCTG Merger Sub Inc., a Delaware corporation, and Tango Therapeutics, Inc. (now known as Tango Therapeutics Sub, Inc., or &#x201c;Old Tango&#x201d;) signed a definitive merger agreement, or the Merger Agreement, memorializing the terms of BCTG&#x2019;s acquisition of 100% of Old Tango&#x2019;s issued and outstanding equity securities in exchange for $550.0 million worth of consideration in the form of BCTG common stock, or the Business Combination.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Business Combination was approved on August 9, 2021 by shareholders of BCTG, resulting in BCTG acquiring 100% of our issued and outstanding equity securities on August 10, 2021. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon the closing of the Business Combination, BCTG Merger Sub Inc. merged with and into Tango, with Tango as the surviving company in the Merger, and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> BCTG changed its name to &#x201c;Tango Therapeutics, Inc.&#x201d;, or New Tango</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. For additional information on the Business Combination, see </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Note 3 </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">    </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We received gross proceeds of $167.1 million upon the closing of the Business Combination. Simultaneous with the closing of the Business Combination, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tango entered into agreements with certain investors, the PIPE Investors, pursuant to which these PIPE Investors purchased 18,610,000 shares of our common stock at $10.00 per share, for aggregate gross proceeds of $186.1 million, upon the closing of the PIPE financing.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  Total transaction costs and redemptions totaled $26.9 million, resulting in total net proceeds of $326.3 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Subject to the terms of the Merger Agreement, at the effective time of the Business Combination, each share of Old Tango redeemable convertible preferred stock issued and outstanding immediately prior to the effective time of the Business Combination was converted into a share of New Tango common stock. At the effective time of the Business Combination, each option to purchase Old Tango common stock became an option to purchase shares of New Tango common stock, subject to adjustment in accordance with the exchange ratio</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Financial Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since the Company's inception, we have focused primarily on organizing and staffing our company, business planning, raising capital, discovering product candidates, securing related intellectual property, and conducting research and development activities for our programs. Since our inception, we have funded our operations primarily through equity financings and from the proceeds received from our collaboration agreement with Gilead Sciences, Inc., or Gilead. Since inception, we have raised an aggregate of $166.9 million of gross proceeds from the sale of our preferred shares, $342.1 million in gross proceeds through the closing of the Business Combination and PIPE Financing transactions (as described below) and another</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> $212.1 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">million through our collaboration with Gilead.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that our existing cash, cash equivalents and marketable securities on hand as of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 of $485.3 million will ena</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ble us to fund our operating expenses and capital expenditure requirements at least into the second half of 2024. Since inception, we have incurred significant operating losses. For the years ended </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and 2020, our net losses</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> were $58.2 million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and $52.0 million, respectively. We had an accumulated deficit of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$161.3 million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">as of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> We expect to continue to incur significant and increasing expenses and operating losses for the foreseeable future, as we advance our product candidates through preclinical and clinical development and seek regulatory approvals, manufacture drug product and drug supply, maintain and expand our intellectual property portfolio, as well as hire additional personnel, pay for accounting, audit, legal, regulatory and consulting services, and pay costs associated with maintaining compliance with Nasdaq listing rules and the requirements of the U.S. Securities and Exchange Commission, or SEC, director and officer liability insurance, investor and public relations activities and other expenses associated with operating as a public company. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our preclinical studies, our clinical trials and our expenditures on other research and development activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not have any product candidates approved for sale and have not generated any revenue from product sales. We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for our product candidates, if ever. In addition, if we obtain regulatory approval for our product candidates and do not enter into a third-party commercialization partnership, we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing, manufacturing and distribution activities. As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity offerings and debt financings or other sources, such as potential collaboration agreements, strategic alliances and licensing arrangements. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on acceptable terms, or at all. Our failure to raise capital or enter into such agreements as, and when needed, could have a negative effect on our business, results of operations and financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because of the numerous risks and uncertainties associated with pharmaceutical development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate revenues from the sale of our therapies, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce our operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, we have not recognized any revenue from product sales, and we do not expect to generate any revenue from the sale of products in the next several years. If our development efforts for our product candidates are successful and result in regulatory approval, or license agreements with third parties, we may generate revenue in the future from product sales. However, there can be no assurance as to when we will generate such revenue, if at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Collaboration Agreements with Gilead Sciences</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2018, we entered into a collaboration agreement with Gilead, or the 2018 Gilead Agreement. Pursuant to the terms of the 2018 Gilead Agreement, we received an initial upfront payment of $50.0 million. The upfront payment was initially recorded as deferred revenue on our balance sheet and is recognized as revenue as or when the performance obligation under the contract is satisfied.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2019, Gilead licensed a program from us, and also separately contracted for additional services related to the program through a letter agreement. By December 2019, we had substantially completed our required obligations under the license and side letter agreement, and as a result, recognized $9.4 million of revenue. By December 2020, all remaining obligations under the license and side letter agreement were completed, resulting in the recognition of the remaining consideration of $0.7 million of revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2020, the 2018 Gilead Agreement was expanded into a broader collaboration via an amended and restated research collaboration and license agreement, or the Gilead Agreement. Pursuant to the terms of the Gilead Agreement, we received an upfront payment of $125.0 million. Consistent with the treatment of the previously received upfront payment, this upfront payment was recorded as deferred revenue on our balance sheet and is recognized as revenue as or when the performance obligation under the contract is satisfied.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020 and September 2021, Gilead elected to extend two programs for research extension fees totaling $24.0 million, which was added to our estimate of the transaction price to total $199.0 million. A total of $10.0 million of fees related to the research extensions have not been received as of December 31, 2021 as these were determined to be conditional upon the satisfaction of additional research obligations, and thus a contract asset, however, we determined that achievement of the entire research extension fees was probable and that a significant reversal in the amount of cumulative revenue recognized would not occur</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2021, Gilead licensed a program for an $11.0 million fee. The $11.0 million license fee was received and recognized as revenue in the second quarter of 2021 since we have no continued involvement in the advancement of the program, Gilead can benefit from the license on its own and the license is separately identifiable from the research service</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">s.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, $50.3 million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">has</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> been recognized as collaboration revenue related to the upfront and research extension payments from the Gilead Agreement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the years ended </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and 2020, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we recognized $26.0 million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $7.0 million, respectively, of collaboration revenue associated with the Gilead Agreements based on performance completed during each period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Refer to Note 2 and Note 4 to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K for additional information regarding our revenue recognition accounting policy and our collaboration agreement with Gilead.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses consist primarily of costs incurred for our research activities, including our drug discovery efforts and the development of our product candidates. We expense research and development costs as incurred, which include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">employee-related expenses, including salaries, bonuses, benefits, stock-based compensation, other related costs for those employees involved in research and development efforts; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">e</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">xternal research and development expenses incurred under agreements with contract research organizations, or CROs, as well as consultants that conduct our preclinical studies and development services</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">costs related to manufacturing material for our preclinical and clinical studies;   </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">laboratory supplies and research materials; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">costs to fulfill our obligations under the collaboration with Gilead; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">costs related to compliance with regulatory requirements; and </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent, utilities and insurance. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Costs for certain activities are recognized based on an evaluation of the progress to completion of specific tasks using data such as information provided to us by our vendors and analyzing the progress of our preclinical studies or other services performed. Significant judgment and estimates are made in determining the accrued expense balances at the end of any reporting period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our direct external research and development expenses consist primarily of fees paid to CROs and outside consultants in connection with our preclinical and clinical development and manufacturing activities. Our direct external research and development expenses also include fees incurred under license agreements. We track these external research and development costs on a program-by-program basis once we have identified a product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not allocate employee costs, costs associated with our target discovery efforts, laboratory supplies, and facilities, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We characterize research and development costs incurred prior to the identification of a product candidate as discovery costs. We use internal resources primarily to conduct our research and discovery activities as well as for managing our preclinical development and manufacturing activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our research and development expenses:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.478%;"></td>
    <td style="width:1.601%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:13.242%;"></td>
    <td style="width:0.636%;"></td>
    <td style="width:1.601%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:13.242%;"></td>
    <td style="width:0.636%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">TNG908 direct program expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,012</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,548</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">USP1 direct program expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,009</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,594</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Discovery direct program expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28,031</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,365</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unallocated research and development expenses:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Personnel related expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,276</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,937</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Facilities and other related expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,308</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,547</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77,636</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49,991</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The successful development of our product candidates is highly uncertain. We plan to substantially increase our research and development expenses for the foreseeable future as we continue the development of our product candidates and manufacturing processes and conduct discovery and research activities for our preclinical programs. We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical trials of our product candidates or the timing of regulatory filings in connection with clinical trials or regulatory approval, due to the inherently unpredictable nature of preclinical and clinical development. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments and our ongoing assessments as to each product candidate&#x2019;s commercial potential. Our clinical development costs are expected to increase significantly as we commence clinical trials. We anticipate that our expenses will increase substantially, particularly due to the numerous risks and uncertainties associated with developing product candidates, including the uncertainty of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope, rate of progress, and expenses of our ongoing research activities as well as any preclinical studies, clinical trials and other research and development activities; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">establishing an appropriate safety profile with IND enabling studies; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">successful enrollment in and completion of clinical trials; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">whether our product candidates show safety and efficacy in our clinical trials; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">receipt of marketing approvals from applicable regulatory authorities; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the progress of our collaboration with Gilead; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">commercializing product candidates, if and when approved, whether alone or in collaboration with others; and </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">continued acceptable safety profile of products following any regulatory approval. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any changes in the outcome of any of these variables with respect to the development of our product candidates in preclinical and clinical development could mean a significant change in the costs and timing associated with the development of these product candidates. We may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on other product candidates. For example, if the U.S. Food and Drug Administration, or FDA, European Medicines Agency, or EMA, or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development of that product candidate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expense consists primarily of employee related costs, including salaries, bonuses, benefits, stock-based compensation and other related costs. General and administrative expense also includes professional services, including legal, accounting and audit services and other consulting fees as well as facility costs not otherwise included in research and development expenses, insurance and other general administrative expenses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research activities and development of our product candidates. We also anticipate that we will incur significantly increased accounting, audit, legal, regulatory, compliance and director and officer insurance costs as well as investor and public relations expenses associated with operating as a public company</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other Income (Expense), Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Income</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income c</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">onsists of income earned and losses incurred in connection with our investments in money market funds, U.S. Treasury bills and U.S. government agency bonds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other (Expense) Income, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other (expense) income, net consists of miscellaneous income and expense unrelated to our core operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Provision for Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our provision for income tax </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">consists of an estimate for U.S. federal and state income taxes based on enacted rates, as adjusted for allowable credits, deductions, uncertain tax positions, changes in deferred tax assets and liabilities and changes in tax law. We have reco</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">rded a provision for income taxes in the</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> amount of $0.3 million for the year ended December 31, 2021. There was no provision for income taxes for the year ended December 31, 2020 because we have historically incurred net operating losses and maintain a full valuation allowance against our deferred tax assets</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Results of Operations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comparison of the Years Ended December 31, 2021 and 2020</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our results of operations for the years ended December 31, 2021 and 2020:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.715%;"></td>
    <td style="width:1.372%;"></td>
    <td style="width:1.272%;"></td>
    <td style="width:10.926%;"></td>
    <td style="width:0.865%;"></td>
    <td style="width:1.372%;"></td>
    <td style="width:1.272%;"></td>
    <td style="width:10.926%;"></td>
    <td style="width:0.865%;"></td>
    <td style="width:1.372%;"></td>
    <td style="width:1.272%;"></td>
    <td style="width:10.906%;"></td>
    <td style="width:0.865%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Collaboration revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26,042</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,972</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,070</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">License revenue</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,000</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">684</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,316</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37,042</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,656</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,386</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77,636</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49,991</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,645</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,596</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,865</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,731</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95,232</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59,856</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,376</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss from operations</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(58,190</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(52,200</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(5,990</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other income (expense), net:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">495</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">387</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other (expense) income, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(248</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(368</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total other income, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">247</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">228</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss before income taxes</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(57,943</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(51,972</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(5,971</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provision for income taxes</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(292</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(292</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(58,235</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(51,972</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(6,263</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss and comprehensive loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(59,017</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(51,965</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(7,052</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Collaboration Revenue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Collaboration revenue of $26.0 million and $7.0 million for the years ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and 2020, respectively, was derived from the Gilead collaboration. The increase of $</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.1 million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">is primarily due to the charge against revenue of $11.3 million in the third quarter of 2020 driven by a cumulative catch-up adjustment to the revenue previously recognized from the Gilead collaboration due to a change to the transaction price resulting from the execution of the Gilead Agreement as well as incremental costs incurred during the year ended December 31, 2021 resulting in greater collaboration revenue recognition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License Revenue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">License revenue of $11.0 million and $0.7 million for the years ended December 31, 2021 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and 2020, respectively, was derived from the Gilead collaboration. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The increase of $10.3 million is primarily due to Gilead licensing a program for $11.0 million during the second quarter of 2021 as compared to residual 2019 Gilead Letter Agreement revenue of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$0.7 million </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">recognized during the y</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ear ended December 31, 2020.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expense was $77.6 million for the year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> compared to $50.0 million for the year ended December 31, 2020.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The increase of $27.6 million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> w</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">as primarily due to a</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$18.6 million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">increase in external CRO expenses and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> lab supplies primarily relating to the advancement of our programs.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Additi</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">onally, personnel-related costs increased </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$6.8 million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">primarily due to an increase of share-based compensation expense and additional headcount to support our research and development activities, as well as a </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$2.5 million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">increase in IT spend, cons</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ulting and professional fees</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expense was $17.6 million for the year ended December 31, 2021 c</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ompared to $9.9 million for the year ended December 31, 2020.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The increase of $7.7 million was primarily d</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ue to a </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$4.8 million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">incr</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ease in personnel-related costs due to an increase in share-based compensation expense and additional headcount, as well as a $1.4 million increase in consulting and professional fees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Income</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income was $0.5 million for the year ended December 31, 2021 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">compared to $0.1 million for the year ended December 31, 2020.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The increase of $0.4 million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">was primarily due to an increase in cash invested and interest rates in 2021 as compared to 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other (Expense) Income, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other expense, net was $0.2 million for the year ended December 31, 2021 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">compared to other income of $0.1 million for the year ended December 31, 2020. Other (expense) income was not significant for both the years ended December 31, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Provision for Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provision for income taxes was $0.3 million for the year ended December 31, 2021 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">compared to $0 for the year ended December 31, 2020. The increase of $0.3 million is primarily attributable to taxable deferred revenue partially offset by the utilization of federal and state net operating losses and federal and state tax credits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liquidity and Capital Resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sources of Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since our inception, we have generated recurring net losses. We have not yet commercialized any product and we do not expect to generate revenue from sales of any products for several years, if at all. Since our inception, we have funded our operations primarily through proceeds from the issuance of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">equity in the form of stock and from the proceeds received from our collaboration with Gilead. To dat</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">e, we have raised an aggregate of $166.9 million of gross proceeds from the private placement of preferred shares, $342.1 million of gross proceeds from the Business Combination and PIPE Financing transactions, and </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$212.1 million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> thro</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ugh the collabo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ration and license agreement with Gilead. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had cash and cash equivalents and marketable securities of $485.3 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Funding Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that our existing cash, cash equivalents and marketa</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ble securities on hand as of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 of $485.3 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">million will enable us to fund our operating expenses and capital expenditure requirements at least into the second half of 2024. We have based this estimate on assumptions that may prove</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to be wrong, and we could expend our capital resources sooner than we expect</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comparison of the Years Ended December 31, 2021 and 2020</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our cash flows for each of the years presented:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.636%;"></td>
    <td style="width:1.372%;"></td>
    <td style="width:1.272%;"></td>
    <td style="width:10.945%;"></td>
    <td style="width:0.865%;"></td>
    <td style="width:1.372%;"></td>
    <td style="width:1.272%;"></td>
    <td style="width:10.945%;"></td>
    <td style="width:0.865%;"></td>
    <td style="width:1.372%;"></td>
    <td style="width:1.272%;"></td>
    <td style="width:10.945%;"></td>
    <td style="width:0.865%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash (used in) provided by operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(59,527</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70,074</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(129,601</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(183,434</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(145,466</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(37,968</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">357,325</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80,884</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">276,441</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net increase in cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114,364</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,492</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108,872</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash used in operating activities was $59.5 million for the year ended December 31, 2021 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">compared to net cash provided by operating activities of $70.1 million for the year ended December 31, 2020. The net cash used in operations for the year ended December 31, 2021 was primarily driven </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">by the net loss of $58.2 million as a direct result of higher operating expenses related to the advancement of our programs and personnel-related costs. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The net cash provided by operations for the year</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ended December 31, 2020 was primarily driven by a $125.0 million non-refundable upfront payment received from Gilead that was recorded as deferred revenue in 2020 and was partially offset by a net loss of $52.0 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash used in investing activities was $183.4 million for the year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> compared to net cash used in investing activities of $145.5 million for the year ended December 31, 2020. The increase in cash used in investing activities was primarily due to increased purchases of marketable securities and was partially offset by an increase in sales and maturities of marketable securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash provided by financing activities was $357.3 million for the year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> compared to net cash provided by financing activities of $80.9 million for the year ended December 31, 2020. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">e increase in net cash provided by</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> financing activities for the year ended December 31, 2021 was primarily due to net procee</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ds of $326.3 millio</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">n received upon the closing of the Business Combination and PIPE Financing in August 2021, as well as $30.0 million in proceeds related to the issuance of shares of redeemable convertible Series B preferred stock in March 2021. The net cash provided by financing activities for the year ended December 31, 2020 was primarily due to net proceeds of $30.0 million related to the issuance of shares of redeemable convertible Series B preferred stock in April 2020 and net proceeds of $51.2 million related to the issuance of shares of redeemable convertible Series-B-1 preferred stock in August 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Contractual Obligations and Commitments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our contractual obligations at December 31, 2021 and the effects that such obligations are expected to have on our liquidity and cash flows in future periods:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:43.951%;"></td>
    <td style="width:1.054%;"></td>
    <td style="width:1.272%;"></td>
    <td style="width:8.271%;"></td>
    <td style="width:0.636%;"></td>
    <td style="width:1.054%;"></td>
    <td style="width:1.272%;"></td>
    <td style="width:8.271%;"></td>
    <td style="width:0.636%;"></td>
    <td style="width:1.054%;"></td>
    <td style="width:1.272%;"></td>
    <td style="width:8.231%;"></td>
    <td style="width:0.636%;"></td>
    <td style="width:1.054%;"></td>
    <td style="width:1.272%;"></td>
    <td style="width:8.231%;"></td>
    <td style="width:0.636%;"></td>
    <td style="width:1.054%;"></td>
    <td style="width:1.272%;"></td>
    <td style="width:8.231%;"></td>
    <td style="width:0.636%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="18" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Payments Due by Period</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Less than<br />1 Year</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">1 &#x2013; 3 Years</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">3 &#x2013; 5 Years</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">More than<br />5 Years</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="18" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease commitments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,572</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,572</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,572</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,572</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The commitment amounts in the table above reflect the minimum payments due under our amended operating lease for office and laboratory space at our 100 Binney Street, Cambridge, Massachusetts location. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These commitments are also recognized as operating lease liabilities in our balance sheet at December 31, 2021. In November 2021, we entered into a lease termination agreement for our leased office and laboratory space at 100 Binney Street in Cambridge, Massachusetts. The lease termination agreement is a modification of the lease agreement for these premises that provides, among other things, the acceleration of the expiration of the original term of the lease from June 30, 2026 to an earlier lease termination date, for which the earlier date shall be no later than October 15, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Refer to Note 8 to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K for </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">additional discussion of the impact resulting from the lease termination agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The table does not include the minimum payments due under our new operating lease for office and laboratory space at the 201 Brookline Avenue, Boston, Massachusetts as we have not occupied the premises and the lease payments in connection with this lease are yet to commence as of December 31, 2021. Commitments pertaining to the 201 Brookline Avenue lease will be added to the table above, and also recognized as operating lease liabilities on our balance sheet upon achievement of the new lease commencement date. The fixed annual rent payable under the lease is </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$5.1 million, in</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">creasing by 3% annually from the rent commencement date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Purchase Obligations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the normal course of business, we enter into contracts with third parties for preclinical studies, clinical operations and research and development supplies. These contracts generally do not contain minimum purchase commitments and provide for termination on notice, and therefore are cancellable contracts. These payments are not included in the table above as the amount and timing of such payments are not known as of December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License Agreement Obligations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have also entered into license agreements under which we may be obligated to make milestone and royalty payments. We have not included future milestone or royalty payments under these agreements in the table above since the payment obligations are contingent upon future events, such as achieving certain development, regulatory, and commercial milestones or generating product sales. As of December 31, 2021 and December 31, 2020, we were unable to estimate the timing or likelihood of achieving these milestones or generating future product sales. Refer to Note 9 to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K for a description of our license agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Critical Accounting Policies and Significant Judgments and Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances and at the time these estimates are made, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis.  Some of the judgments and estimates we make can be subjective and complex.  Our actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts, and experience. The effects of material revisions in estimates, if any, will be reflected in the consolidated financial statements prospectively from the date of change in estimates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While our significant accounting policies are described in more detail in Note 2 to our audited consolidated financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The terms of our collaboration agreements may include consideration such as non-refundable up-front payments, license fees, research extension fees, and clinical, regulatory and sales-based milestones and royalties on product sales.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We recognize revenue under ASC Topic 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, or ASC 606, which applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. ASC 606 provides a five-step framework whereby revenue is recognized when control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of the revenue standard, we perform the following five steps: (i) identify the promised goods or services in the contract; (ii) determine whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measure the transaction price, including the constraint on variable consideration; (iv) allocate the transaction price to the performance obligations; and (v) recognize revenue when (or as) we satisfy each performance obligation. We only apply the five-step model to contracts when collectability of the consideration to which we are entitled in exchange for the goods or services we transfer to the customer is determined to be probable. At contract inception, once the contract is determined to be within the scope of ASC 606, we assess whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation. Goods and services that are determined not to be distinct are combined with other promised goods and services until a distinct bundle is identified. We then allocate the transaction price (the amount of consideration we expect to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognize the associated revenue when (or as) each performance obligation is satisfied. Our estimate of the transaction price for each contract includes all variable consideration to which we expect to be entitled.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We recognize the transaction price allocated to license payments as revenue upon delivery of the license to the customer and resulting ability of the customer to use and benefit from the license, if the license is determined to be distinct from the other performance obligations identified in the contract. If the license is considered to not be distinct from other performance obligations, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied (i) at a point in time, but only for licenses determined to be distinct from other performance obligations in the contract, or (ii) over time; and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> license payments. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We evaluate whether it is probable that the consideration associated with each milestone payment will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are considered constrained and excluded from the transaction price until they meet this threshold. Milestones tied to regulatory approval, and therefore not within our control, are considered constrained until such approval is received. Upfront and ongoing development milestones under our collaboration agreements are not subject to refund if the development activities are not successful. At the end of each subsequent reporting period, we re-evaluate the probability of a significant reversal of the cumulative revenue recognized for the milestones, and, if necessary, adjust the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues from collaborators in the period of adjustment. We exclude sales-based milestone payments and royalties from the transaction price until the sale occurs (or, if later, until the underlying performance obligation to which some or all of the royalty has been allocated has been satisfied or partially satisfied), because the license to our intellectual property is deemed to be the predominant item to which the royalties relate as it is the primary driver of value</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ASC 606 requires us to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in ASC 606 as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which we have sold the same performance obligation separately are not available, we are required to estimate the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Whenever we determine that multiple promises to a customer are not distinct and comprise a combined performance obligation that includes services, we recognize revenue over time using the cost-to-cost input method, based on the total estimated cost to fulfill the obligation. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which we are expected to complete our performance obligations under an arrangement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Consideration that does not meet the requirements to satisfy the above revenue recognition criteria is a contract liability and is recorded as deferred revenue in the consolidated balance sheets. We have recorded short-term and long-term deferred revenue on our consolidated balance sheets based on our best estimate of when such revenue will be recognized. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12 months. Amounts that we expect will not be recognized within the next 12 months are classified as long-term deferred revenue</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In certain instances, the timing of and total costs of satisfying these obligations under our collaboration agreement can be difficult to estimate. Accordingly, our estimates may change in the future. Such changes to estimates would result in a change in revenue recognition amounts. If these estimates and judgments change over the course of these agreements, it may affect the timing and amount of revenue that we will recognize and record in future periods</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under ASC 606, we will recognize revenue when we fulfill our performance obligations under the agreement with Gilead. As the required performance obligation is satisfied, we will recognize revenue for the portion satisfied and record a receivable for any fees that have not been received. Amounts are recorded as short-term collaboration receivables when our right to consideration is unconditional. A contract liability is recognized when a customer prepays consideration or owes payment to an entity in advance of our performance according to a contract. We do not assess whether a contract has a significant financing component if the expectation at contract inception is that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accrued Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. This process involves estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advance payments, which would be recorded as a prepaid expense in other assets, or if there is the right of offset, offset against our liability balance with the counterparty. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. At</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">each period end, we corroborate the accuracy of these estimates with the service providers and make adjustments, if necessary</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We record the expense and accrual related to research and development activities performed by our vendors based on our estimates of the services received and efforts expended considering a number of factors, including our knowledge of the progress towards completion of the research and development activities; invoicing to date under the contracts; communication from the vendors of any actual costs incurred during the period that have not yet been invoiced; and the costs included in the contracts and purchase orders. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We estimate the fair value of our stock option awards using the Black-Scholes method utilizing the &#x201c;simplified method,&#x201d; for determining the expected life of the award, which is based on the mid-point between the vesting date and the end of the contractual term as all options granted after becoming a public entity will be granted &#x201c;at-the-money.&#x201d; We determine the volatility for options granted based on an analysis of reported data for a peer group of companies. The expected volatility of granted options has been determined using a weighted-average of the historical volatility measures of this peer group of companies. We will continue to apply this method until a sufficient amount of historical information regarding the volatility of our own stock price becomes available. The fair value of each share of common stock underlying stock-based awards is based on the closing price of our common stock as reported by Nasdaq on the date of grant. The risk-free interest rate utilized in our calculations is based on a treasury instrument whose term is consistent with the expected life of the stock options. The expected dividend yield is assumed to be zero as we have never paid dividends and do not have current plans to pay any dividends on our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We measured stock-based awards granted to employees, non-employees and directors based on their fair value on the date of the grant using the Black-Scholes option-pricing model for options or the difference between the purchase price per share of the award, if any, and the fair value of our common stock for restricted common stock awards.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to the consummation of the Business Combination, as there was not a public market for our common stock prior to becoming publicly traded in August 2021, the estimated fair value of our common stock was determined by our board of directors as of the date of grant of each option or restricted stock award, considering our most recently available third-party valuations of common stock and our board of directors&#x2019; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#x2019; Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. Our common stock valuations were prepared using either an option pricing method, or OPM, or a hybrid method, both of which used market approaches to estimate our enterprise value. The OPM treats common stock and preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#x2019;s securities changes. Under this method, the common stock had value only if the funds available for distribution to stockholders exceed the value of the preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. The hybrid method was a probability-weighted expected return method, or PWERM, where the equity value in one or more scenarios is calculated using an OPM. The PWERM is a scenario-based methodology that estimated the fair value of common stock based upon an analysis of future values for the company, assuming various outcomes. The common stock value was based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class of stock. The future value of the common stock under each outcome was discounted back to the valuation date at an appropriate risk-adjusted discount rate and probability weighted to arrive at an indication of value for the common stock. A discount for lack of marketability of the common stock is then applied to arrive at an indication of value for the common stock. The Black-Scholes option-pricing model also uses as inputs the fair value of our common stock and assumptions we make for the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">volatility of our common stock, the expected term of our common stock options, the risk-free interest rate for a period that approximates the expected term of our common stock options, and our expected dividend yield.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Compensation expense for awards is recognized over the requisite service period, which is generally the vesting period of the respective award for employees and directors and the period during which services are performed for non-employees. We use the straight-line method to record the expense of awards with service-based vesting conditions</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe our methodologies are reasonable based upon our internal peer company analyses. If different assumptions had been made, equity-based compensation expense, consolidated net loss and consolidated net loss per share could have been significantly</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> different.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recently Adopted Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A description of recently issued accounting pronouncements that may potentially impact our financial position, results of operations or cash flows is disclosed in Note 2 to our audited consolidated financial statements and related notes appearing elsewhere in this </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">this Annual Report on Form 10-K</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:13.5pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Emerging Growth Company and Smaller Reporting Company Status</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are an &#x201c;emerging growth company,&#x201d; under the JOBS Act. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of delayed adoption of new or revised accounting standards and, therefore, we will be subject to the same requirements to adopt new or revised accounting standards as private entities. As an emerging growth company, we may take advantage of certain exemptions and reduced reporting requirements under the JOBS Act. Subject to certain conditions, as an emerging growth company</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may present only two years of audited financial statements and only two years of related Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations in our periodic reports and registration statements, including this Annual Report on Form 10-K; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may avail ourselves of the exemption from providing an auditor&#x2019;s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act; </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may provide reduced disclosure about our executive compensation arrangements; and </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may not require nonbinding advisory votes on executive compensation or stockholder approval of any golden parachute payments. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will remain an emerging growth company until the earliest of (i) December 31, 2025, (ii) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more, (iii) the last day of the fiscal year in which we are deemed to be a &#x201c;large accelerated filer&#x201d; as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such year, provided we have been subject to the Exchange Act for at least 12 calendar months and have filed at least one annual report pursuant to the Exchange Act or (iv) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period. We may choose to take advantage of some but not all of these exemptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are also a &#x201c;smaller reporting company,&#x201d; meaning that the market value of our stock held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7a_quantitative_and_qualitative"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Ite</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">m 7A. Quantitative and Qualitative Disclosures About Market Risk.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are exposed to certain market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Rate Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We had cash, cash equivalents and marketable securities of $485.3 million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and $190.3 million</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as of December 31, 2021 and December 31, 2020, respectively, which consisted of cash, money market funds, U.S. Treasury bills and U.S. government agency bonds. Interest income is sensitive to changes in the general level of interest rates; however, due to the nature of these investments, an immediate 1% change in interest rates would not have a material effect on the fair market value of our investment portfolio</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Foreign Currency Exchange Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our reporting and functional currency is the U.S. dollar. We currently do not have significant exposure to foreign currencies as we hold no foreign exchange contracts, option contracts, or other foreign hedging arrangements. Our operations may be subject to fluctuations in foreign currency exchange rates in the future</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Effects of Inflation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not believe that inflation has had a material effect on our business, financial condition or results of operations. Our operations may be subject to inflation in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_8_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Ite</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">m 8. Financial Statements and Supplementary Data.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our consolidated financial statements, together with the report of the independent registered public accounting firm, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">are appended to this Annual Report on Form 10-K and an index of those consolidated financial statements can be found </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">beginning on page F-1.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9_changes_in_and_disagreements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a_controls_and_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">I</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">tem 9A. Controls and Procedures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2021. Management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives. Our disclosure controls and procedures have been designed to provide reasonable assurance of achieving their objectives. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Changes in Internal Controls Over Financial Reporting</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There were no changes in the Company&#x2019;s internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 or 15d-15 that occurred during the quarter ended December 31, 2021 that materially affected, or were reasonably likely to materially affect, the Company&#x2019;s internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Management&#x2019;s Report on Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended. Our management, including our Chief</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Executive Officer and Chief Financial Officer, conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth in </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Internal Control-Integrated Framework (2013)</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> issued by the Committee of Sponsoring Organization of the Treadway Commission. Based on this assessment, management concluded that, as of December 31, 2021, our internal control over financial reporting was effective.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Annual Report on Form 10-K does not include an attestation report of the independent registered public accounting firm due to an exemption established by the JOBS Act for &#x201c;emerging growth companies.&#34;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9b_other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 9B. Other Information</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9c_disclosure_regarding_foreign"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART III</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;" id="item_10_directors_executive_officers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 10. Directors, Executive Officers and Corporate Governance</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Management</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following sets forth certain information, as of February 1, 2022, concerning our directors and executive officers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:0.05972222222222222in;border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:29.228%;"></td>
    <td style="width:1.136%;"></td>
    <td style="width:1.033%;"></td>
    <td style="width:2.66%;"></td>
    <td style="width:0.747%;"></td>
    <td style="width:0.399%;"></td>
    <td style="width:0.808%;"></td>
    <td style="width:1.074%;"></td>
    <td style="width:6.107%;"></td>
    <td style="width:55.775%;"></td>
    <td style="width:1.033%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Age</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Position</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:14.7pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Barbara Weber, M.D.</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(197,235,248,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">President, Chief Executive Officer and Class III Director</span></p></td>
   </tr>
   <tr style="height:13.8pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Daniella Beckman</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Financial Officer</span></p></td>
   </tr>
   <tr style="height:14.7pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Alan Huang, Ph.D.</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(197,235,248,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Scientific Officer</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Marc Rudoltz, M.D.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">                         </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Medical Officer</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Douglas Barry</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(197,235,248,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General Counsel, Chief Compliance Officer and Corporate Secretary</span></p></td>
   </tr>
   <tr style="height:13.8pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Alexis Borisy</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Class III Director and Chair</span></p></td>
   </tr>
   <tr style="height:13.8pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lesley Calhoun</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(197,235,248,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Class I Director</span></p></td>
   </tr>
   <tr style="height:14.7pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Aaron Davis</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Class III Director</span></p></td>
   </tr>
   <tr style="height:13.8pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reid Huber, Ph.D.</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(197,235,248,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Class I Director</span></p></td>
   </tr>
   <tr style="height:13.8pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Malte Peters, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Class II Director</span></p></td>
   </tr>
   <tr style="height:14.7pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Mace Rothenberg, M.D.</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(197,235,248,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Class II Director</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Executive Officers</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Barbara Weber, M.D.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> has served as our President and Chief Executive Officer since March 2017. Dr. Weber has been a Venture Partner at Third Rock Ventures since March 2015. Previously, Dr. Weber served as Senior Vice President, Oncology Translational Medicine, Novartis from 2009 to 2015, Vice President, Oncology, GSK from 2005 to 2009 and Professor, Medicine and Genetics, University of Pennsylvania from 1994 to 2005. Dr. Weber has served on the board of directors of Revolution Medicines, Inc. (NASDAQ: RVMD), a biotechnology company, since April 2018, Fog Pharma, a private biopharmaceutical company, since October 2018, and OPY Acquisition Corp. I (NASDAQ: OHAA), a special purpose acquisition company, since October 2021. Dr. Weber received a B.S. in Chemistry and an M.D. from the University of Washington, was a resident in internal medicine at Yale University and fellow in Medical Oncology at the Dana Farber Cancer Institute. We believe Dr. Weber qualifies to serve on our board based on her position as our President and Chief Executive Officer, her leadership experience and her extensive experience in the biopharmaceutical industry.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Daniella Beckman</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> has served as our Chief Financial Officer since September 2019 and served as our interim Chief Financial Officer from October 2016 to August 2019. Prior to joining us, she provided consulting and interim chief financial officer services for early-stage biotechnology companies since November 2015. Previously, Ms. Beckman was the Chief Financial Officer of Idenix Pharmaceuticals, Inc., a biopharmaceutical company, from June 2011 until it was acquired by Merck &amp; Co., Inc., a pharmaceutical company, in August 2014. Ms. Beckman has served on the board of directors of Translate Bio, Inc., a clinical-stage mRNA therapeutics company, since October 2017, and currently serves on the board of directors of Vor Biopharma Inc. (NASDAQ: VOR), a cell therapies company, since July 2020, on the board of directors of 5:01 Acquisition Corp (NASDAQ: FVAM), a special purpose acquisition company, since October 2020, and on the board of directors of Blueprint Medicines Corporation (NASDAQ: BPMC), a global precision therapy company, since December 2021. Ms. Beckman holds a B.S. in business administration-accounting from Boston University.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Alan Huang, Ph.D</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">., has served as our Chief Scientific Officer since April 2018. Before being appointed as Chief Scientific Officer, Dr. Huang served as Senior Vice President, Head of Biology. From 2016 to 2017, he served as a consultant at Third Rock Ventures. Previously, Dr. Huang was Senior Director and interim Global Head of Oncology Translational Research at Novartis Institute for Biomedical Research. Prior to joining Novartis, Dr. Huang was a senior scientist at Millennium Pharmaceuticals, Inc. Dr. Huang obtained his B.S. in biochemistry from Fudan University and his doctorate in biochemistry &amp; molecular biology from the University of South Alabama. He completed a postdoctoral fellowship at Schepen&#x2019;s Eye Research Institute of Harvard Medical School.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Marc Rudoltz, M.D. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">has served as our Chief Medical Officer since October 2021. From December 2012 through October 2021, Dr. Rudoltz was the founder and served as the principal of MSR Healthcare Consultants LLC, which provides </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">clinical,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory, business development, and organizational (executive) management support to companies in the pharmaceutical and biotechnology industry.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> In his capacity as principal at MSR Healthcare Consultants, Dr. Rudoltz served as interim Chief Medical Officer for a number of companies including Deciphera Pharmaceuticals, and Constellation Pharmaceuticals and as a clinical consultant for Blueprint Medicines.  Prior to December 2012, he worked in clinical development roles for several companies, including Novartis where he played a role in the development and commercialization of imatinib (Gleevec&#174;) and nilotinib (Tasigna&#174;). Dr. Rudoltz obtained his B.S. in Chemical Biology from the Massachusetts Institute of Technology and M.D. from SUNY-Upstate Medical University.  He completed his residency training in Radiation Oncology at Thomas Jefferson University followed by fellowship training in Cancer Biology at the University of Pennsylvania.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Douglas Barry</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> has served as our General Counsel, Chief Compliance Officer and Corporate Secretary since August 2021. Mr. Barry has been practicing law for over 20 years, and joins Tango from Alexion Pharmaceuticals, a biopharmaceutical company the develops and commercializes therapies that serve patients affected by certain rare diseases, where he served as Vice President of Corporate Law from May 2018 to July 2021. Prior to Alexion, he was Associate General Counsel at Alere Inc., a manufacturer and seller of point-of-care diagnostic equipment, from 2015 to March 2018 (Alere was acquired by Abbott Laboratories in 2018). Earlier in his career, Mr. Barry spent 10 years as an attorney in the corporate department at Wilmer Cutler Pickering Hale and Dorr LLP. Mr. Barry has a B.A. degree in Political Science from Hobart College, a Master&#x2019;s degree from University of Virginia in International Relations and a juris doctor from Northwestern University School of Law.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Non-Employee Directors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Alexis Borisy</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> has served as a member of our board of directors since our founding in 2017 and as the chairman of the board of directors since August 2021. Since June 2019, Mr. Borisy has served as Chief Executive Officer and Chairman of EQRx, Inc., a biotechnology company. From</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2010 to June 2019, Mr. Borisy was a partner at Third Rock Ventures, a series of venture capital funds investing in life science companies. Mr. Borisy co-founded Blueprint Medicines Corporation (NASDAQ: BPMC), a biopharmaceutical company, and served as its Interim Chief Executive Officer from 2013 to 2014 and has served as a member of its board of directors since 2011. Mr. Borisy co-founded Foundation Medicine, Inc. and served as its Interim Chief Executive Officer from 2009 to 2011 and served as a member of its board of directors from 2009 to July 2018, until its acquisition by Roche. In addition, during the past five years Mr. Borisy has served as a member of the board of directors of various public companies, including Relay Therapeutics, Inc. (NASDAQ: RLAY), Revolution Medicines, Inc. (NASDAQ: RVMD), Magenta Therapeutics, Inc. (NASDAQ: MGTA) and Editas Medicine, Inc. (NASDAQ: EDIT). Mr. Borisy received an A.B. in Chemistry from the University of Chicago and an A.M. in Chemistry and Chemical Biology from Harvard University. We believe Mr. Borisy&#x2019;s extensive experience as an executive of, and working with and serving on the boards of directors of, multiple biopharmaceutical and life sciences companies, his educational background and his experience working in the venture capital industry provide him with the qualifications and skills necessary to serve as a member of our board of directors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Lesley Ann Calhoun</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> has served as a member of our board of directors since March 2021. Since June 2020, Ms. Calhoun has served as Executive Vice President and Chief Financial Officer at Aligos Therapeutics, Inc., a clinical stage biopharmaceutical company. From August 2016 to June 2020, Ms. Calhoun served as Senior Vice President of Finance &amp; Administration and Chief Accounting Officer at Global Blood Therapeutics, Inc. From January 2013 to September 2015, Ms. Calhoun served as Vice President of Finance at Hyperion Therapeutics, Inc., a commercial pharmaceutical company, which was acquired by Horizon Pharma plc, a biopharmaceutical company, in May 2015. Prior to Horizon Pharma, Ms. Calhoun served as Senior Director of Finance and Corporate Controller at Theravance, Inc., a biopharmaceutical company, from August 2005 to January 2013. Prior to Theravance, Ms. Calhoun held various senior finance positions of increasing responsibility where she oversaw all aspects of finance and accounting operations for U.S. and multinational, publicly-traded and pre-IPO stage technology companies and in the biopharmaceutical industry. Earlier in her career, Ms. Calhoun was a member of the audit practice of Deloitte &amp; Touche LLP from 1989 to 2001. Ms. Calhoun holds a B.S. in business administration with a concentration in accounting from San Francisco State University and is a Certified Public Accountant (inactive). We believe that Ms. Calhoun&#x2019;s financial and accounting expertise and her experience in the finance and life sciences industries qualify her to serve as a member of our board of directors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Aaron Davis</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> has served as a member of our board of directors since April 2020. Mr. Davis is Co-Founder and Chief Executive Officer of Boxer Capital, LLC. After joining Tavistock Group as Portfolio Manager in 2005, Mr. Davis scaled Tavistock Group&#x2019;s public healthcare investing activities and founded Boxer Capital, LLC. Prior to the Business Combination, Mr. Davis was the Chairman and Chief Executive Officer of BCTG Acquisition Corp., our predecessor company. Mr. Davis is a Member of the Board of Directors of iTeos Therapeutics, Inc. (NASDAQ: ITOS), Mirati Therapeutics Inc. (NASDAQ: MRTX), and Rain Therapeutics Inc. (NASDAQ: RAIN). From 2006 to 2008, Mr. Davis served as a director of Kalypsys, Inc., and from 2000 to 2004, Mr. Davis worked in the Global Healthcare Investment Banking and Private Equity Group at</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">105</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">UBS Warburg, LLC. Mr. Davis received an M.A. degree in biotechnology from Columbia University and a B.B.A. degree in finance from Emory University. We believe that Mr. Davis is qualified to serve as a member of our board of directors because of his experience serving as a director of biotechnology companies and as a manager of funds specializing in the area of life sciences. We believe that Mr. Davis&#x2019;s experience serving as a director of multiple biotechnology companies and his knowledge of funds specializing in the area of life sciences makes him qualified to serve as a member of our board of directors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Reid M. Huber, Ph.D.,</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> has served as a member of our board of directors since July 2019. Dr. Huber has served as a Partner at Third Rock Ventures since December 2018. From April 2014 to December 2018, Dr. Huber served as Executive Vice President and Chief Scientific Officer at Incyte Corporation, a pharmaceutical company. From 2002 to 2014, Dr. Huber held various roles of increasing responsibility at Incyte. Prior to joining Incyte, Dr. Huber held scientific research positions at DuPont Pharmaceuticals and Bristol-Myers Squibb from 1997 to 2002. Dr. Huber has served on the board of directors of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) since October 2014 and also currently serves on the board of MOMA Therapeutics, Asher Bio, Insitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and The American Cancer Society. Dr. Huber received his Ph.D. in molecular genetics from the Washington University School of Medicine and held pre- and post-doctoral fellowships at the National Institutes of Health. We believe that Dr. Huber&#x2019;s extensive background in the pharmaceutical industry and senior management experience qualify him to serve on our board of directors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Malte Peters, M.D.,</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> has served on our board of directors since September 2018. Since March 2020, Dr. Peters has served as Chief Research and Development Officer of MorphoSys AG, a biopharmaceutical company, and prior to that served as its Chief Development Officer and member of its management board since March 2017. Prior to his time at MorphoSys, Dr. Peters served as the Global Head of Clinical Development of the Biopharmaceuticals Business Unit at Sandoz International. From 2004 to 2015, he served as Clinical Head and Site Head for Basel and East Hanover in the Department of Oncology Translational Medicine at Novartis. Dr. Peters has also held teaching appointments in Internal Medicine and Biochemistry at the University of Mainz, Germany, served as Research Scientist at the Amgen Research Institute in Toronto, Canada, as Director of Cancer Research at Merck KGaA and as Medical Director at Micromet AG. Dr. Peters received his Doctor of Medicine from the Freie Universit&#xe4;t Berlin, Germany, and was trained at the Universities of Padova, Italy, and Bochum and Berlin, Germany. After scientific work at different universities he habilitated in Internal Medicine at the University of Mainz, Germany. We believe Dr. Peters&#x2019; extensive knowledge of the biotechnology industry makes him qualified to serve on our board of directors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Mace Rothenberg, M.D., </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">has served on our board of directors since March 2021. Dr. Rothenberg was previously at Pfizer, Inc., a pharmaceutical company, where he served as Chief Medical Officer and Head of Worldwide Medical and Safety from 2019 to 2021, Chief Development Officer for Oncology from 2016 to 2018, and Senior Vice President for Clinical Development and Medical Affairs for Pfizer Oncology from 2008 to 2016. Prior to joining Pfizer, Dr. Rothenberg spent 25 years in academia, serving on the faculties of the University of Texas Health Science Center &#x2014; San Antonio and Vanderbilt University Medical Center. Dr. Rothenberg is a fellow of the American College of Physicians and the American Society of Clinical Oncology and is board-certified in Internal Medicine and Medical Oncology.  Dr. Rothenberg has been a member of the board of directors of Surrozen, Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, since May 2021 and Aulos Bioscience, a privately-held immuno-oncology company, since March 2021.  Dr. Rothenberg received his B.A. from the University of Pennsylvania, his M.D. from the New York University School of Medicine, completed his residency in Internal Medicine at Vanderbilt University and his fellowship in Medical Oncology at the National Cancer Institute. We believe Dr. Rothenberg&#x2019;s industry experience and life science expertise make him qualified to serve on our board of directors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Family Relationships</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There are no family relationships among any of our directors or executive officers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Board of Directors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our board of directors is divided into three staggered classes of directors, with each director assigned to one of the three classes. At each annual meeting of our stockholders, a class of directors will be elected for a three-year term to succeed the directors of the same class whose terms are then expiring. The terms of the directors will expire upon the election and qualification of successor directors at the annual meeting of stockholders to be held during the year 2022 for Class I directors, 2023 for Class II directors and 2024 for Class III directors. Lesley Calhoun and Reid Huber currently serve as our Class I directors, Malte Peters and Mace Rothenberg currently serve as our Class II directors and Alexis Borisy, Aaron Davis and Barbara Weber currently serve as our Class III directors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our certificate of incorporation and bylaws provide that the number of directors shall be fixed solely and exclusively by a resolution adopted from time to time by our board of directors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The division of our board of directors into staggered classes may delay or prevent stockholder efforts to effect a change of our management or a change in our control.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Committees of the Board of Directors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our board of directors has established three standing committees: an audit committee, a compensation committee and a nominating and corporate governance committee, each of which operates pursuant to a written charter adopted by our board of directors. The current members of our audit committee are Lesley Calhoun, Mace Rothenberg and Alexis Borisy, and Lesley Calhoun serves as the chairperson of the audit committee. The current members of our compensation committee are Malte Peters, Mace Rothenberg and Alexis Borisy, and Malte Peters is the chairperson of the compensation committee. The current members of our nominating and corporate governance committee are Reid Huber, Aaron Davis, and Lesley Calhoun, and Reid Huber is the chairperson of the nominating and corporate governance committee.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Audit Committee</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The audit committee currently consists of Lesley Calhoun, Mace Rothenberg and Alexis Borisy. Our board has determined that each member of our audit committee is independent under Nasdaq listing standards and Rule 10A-3(b)(1) under the Exchange Act. The chairperson of the audit committee is Lesley Calhoun. Our board has determined that Lesley Calhoun is an &#x201c;audit committee financial expert&#x201d; within the meaning of SEC regulations. Our board has also determined that each member of the audit committee has the requisite financial expertise required under the applicable requirements of Nasdaq. In arriving at this determination, our board has examined each audit committee member&#x2019;s scope of experience and the nature of their employment in the corporate finance sector.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The primary purpose of our audit committee is to discharge the responsibilities of our board of directors with respect to our accounting, financial, and other reporting and internal control practices and to oversee the independent registered accounting firm. Specific responsibilities of our audit committee include:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">helping our board of directors oversee corporate accounting and financial reporting processes;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">managing the selection, engagement and qualifications of a qualified firm to serve as the independent registered public accounting firm to audit our financial statements;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">helping to ensure the independence and performance of the independent registered public accounting firm;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">discussing the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and the independent accountants, our interim and year-end operating results;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">developing procedures for employees to submit concerns anonymously about questionable accounting or audit matters;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reviewing policies on financial risk assessment and financial risk management, as well as discussing with management the guidelines and policies that govern the process by which the Company's exposure to risk is assessed and managed by management;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reviewing related party transactions;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">107</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtaining and reviewing a report by the independent registered public accounting firm at least annually, that describes our internal quality-control procedures, any material issues with such procedures, and any steps taken to deal with such issues when required by applicable law; and</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">approving (or, as permitted, pre-approving) all audit and all permissible non-audit service to be performed by the independent registered public accounting firm.</span></p></td>
   </tr>
  </table>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Compensation Committee</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our compensation committee currently consists of Malte Peters, Mace Rothenberg and Alexis Borisy. Our board has determined each member of our compensation committee is a &#x201c;non-employee director&#x201d; as defined in Rule 16b-3 promulgated under the Exchange Act. The chairperson of the compensation committee is Malte Peters. The primary purpose of our compensation committee is to discharge the responsibilities of our board of directors to oversee our compensation policies, plans and programs and to review and determine the compensation to be paid to our executive officers, directors and other senior management, as appropriate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Specific responsibilities of our compensation committee include:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reviewing and approving, or recommending that our board approve, the compensation of our executive officers and senior management;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reviewing and recommending to our board the compensation of our directors;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">administering our stock and equity incentive plans;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">selecting independent compensation consultants and assessing whether there are any conflicts of interest with any of the committee&#x2019;s compensation advisors;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reviewing, approving, amending and terminating, or recommending that our board approve, amend or terminate, incentive compensation and equity plans, severance agreements, change-of-control protections and any other compensatory arrangements for our executive officers and other senior management, as appropriate;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reviewing and establishing general policies relating to compensation and benefits of our employees; and</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reviewing our overall compensation philosophy.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Compensation Committee Interlocks and Insider Participation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None of the members of our compensation committee has at any time during the prior three years been one of our officers or employees. None of our named executive officers currently serves, or in the past fiscal year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving on our board of directors or compensation committee.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Nominating and Corporate Governance Committee</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our nominating and corporate governance committee currently consists of Reid Huber, Aaron Davis, and Lesley Calhoun. Our board has determined each member is independent under Nasdaq listing standards. The chairperson of the nominating and corporate governance committee is Reid Huber.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Specific responsibilities of our nominating and corporate governance committee include:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">identifying, evaluating and selecting, or recommending that our board approve, nominees for election to our board;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">evaluating the performance of our board and of individual directors;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">evaluating the adequacy of our corporate governance practices and reporting;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reviewing management succession plans; and</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">developing and making recommendations to our board regarding corporate governance guidelines and matters.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Role of Our Board of Directors in Risk Oversight</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">One of the key functions of our board of directors is informed oversight of our risk management process. Our board does not have a standing risk management committee, but rather administers this oversight function directly through our board as a whole, as well as through various standing committees of our board that address risks inherent in their respective areas of oversight. In particular, our board is responsible for monitoring and assessing strategic risk exposure and our audit committee is responsible for considering and discussing our major financial risk exposures and the steps our management will take to monitor and control such exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. Our audit committee also monitors compliance with legal and regulatory requirements. Our compensation committee assesses and monitors whether our compensation plans, policies and programs comply with applicable legal and regulatory requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Code of Ethics</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have adopted a Code of Conduct that applies to all of our employees, officers and directors, including those officers responsible for financial reporting. The Code of Conduct is available on our website at https://www.tangotx.com under &#x201c;Investors &#x2013; Corporate Governance&#x201d;. Information contained on or accessible through such website is not a part of this Annual Report on Form 10-K, and the inclusion of the website address in this prospectus is an inactive textual reference only.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K regarding an amendment to, or waiver from, a provision of this Code of Conduct and disclose any amendments to the Code of Conduct by posting such information on our website, at the address and location specified above and, to the extent required by the listing standards of Nasdaq, by filing a Current Report on Form 8-K with the SEC, disclosing such information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Director Nomination Process</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In considering candidates for Board membership, the Nominating and Corporate Governance Committee considers recommendations by: Nominating and Corporate Governance Committee members and other Board members; management; our shareholders; third-party search firms; and any other appropriate sources. If a shareholder submits a nominee, the Nominating and Corporate Governance Committee will evaluate the qualifications of such shareholder nominee using the same selection criteria the Committee uses to evaluate other potential nominees. Our bylaws contain provisions addressing the process by which a shareholder may recommend a person for consideration as a nominee for director at an annual meeting.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our bylaws provide that stockholders seeking to nominate candidates for election as directors at our annual meeting of stockholders must provide timely notice of their intent in writing. To be timely, a stockholder&#x2019;s written notice will need to be delivered to our principal executive offices not later than the close of business on the 90th day nor earlier than the opening of business on the 120th day prior to the scheduled date of the annual meeting of stockholders. In the event that no annual meeting was held during the preceding year (as will be the case for our first annual meeting that will be held in 2022) or the annual meeting is advanced more than 30 days before, or more than 60 days after such anniversary date, a timely notice must be received not later than the close of business on the later of the 90th day prior to the scheduled date of such annual meeting</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">109</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">or the 10th day following the day on which public announcement of the date of such meeting is first made. Our bylaws also specify certain requirements as to the form and content of a stockholders&#x2019; notice. These provisions may preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the terms of its charter, the Nominating and Corporate Governance Committee requires the following qualifications to be satisfied by any nominee for a position on the Board:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">High standards of personal and professional ethics and integrity;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proven achievement and competence in the nominee&#x2019;s field and the ability to exercise sound business judgment;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Skills that are complementary to those of members of the existing Board;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The ability to assist and support management and make significant contributions to the Company&#x2019;s success; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An understanding of the fiduciary responsibilities required of a director and a commitment to devote the time and energy necessary to perform those responsibilities.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;" id="item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 11. Executive Compensation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Historically, our executive compensation program has reflected our growth and development-oriented corporate culture. To date, the compensation of our Chief Executive Officer and President and our other executive officers identified in the  Summary Compensation Table below, who we refer to as the named executive officers, has consisted of a combination of base salary, bonuses and long-term incentive compensation in the form of stock options to purchase shares of our common stock.  The Company awarded restricted stock to certain executives in 2017, and the restrictions on such awards have lapsed. Our named executive officers who are full-time employees, like all other full-time employees, are eligible to participate in our retirement and health and welfare benefit plans. As a publicly traded company, we plan to evaluate our compensation values and philosophy and compensation plans and arrangements as circumstances merit. At a minimum, we expect to review executive compensation annually with input from an independent compensation consultant. As part of this review process, we expect the board of directors and the compensation committee to apply our values and philosophy, while considering the compensation levels needed to ensure our executive compensation program remains competitive with our peers. In connection with our executive compensation program, we will also review whether we are meeting our retention objectives and the potential cost of replacing a key employee.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tango has assembled a team of highly experienced senior leaders and oncology drug developers who combine a flexible and adaptive approach to drug development that follows cutting-edge science with the proven expertise of large pharmaceutical company drug discovery and development. The management team and the employees at Tango are what, we believe, will be the ultimate differentiator that sets us apart from the competition as we move our products toward the market.  This is based on our innovative approach to target drug-discovery using synthetic lethality and our innovative capabilities and expertise in drug discovery, research and drug development. Building a management team to provide structure and direction will require retaining talent with proven leadership and results, extensive technical expertise, broad experience in building and constructing a drug development and commercialization organization, all the while establishing the broader vision of improving care and therapeutic options for cancer patients. Attracting, recruiting and hiring talent who have the requisite skill set, background and track record to lead and manage a growing business in a competitive environment is one of our primary goals.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Compensation Philosophy</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our compensation philosophy is focused on building a world-class research and development organization with deep experience and understanding in synthetic lethality in order that we may identify novel targets and develop new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need.  Attracting and retaining executives and employees that position Tango to meet these objectives, particularly as we move toward initiating a Phase 1/2 clinical trial for TNG908 in the second quarter of 2022 (following the FDA's clearance of the IND application in the first quarter of 2022), is a paramount goal of the Company's compensation program.  By building a talented and motivated organization around extraordinary leaders, we believe we can advance our product candidates, grow our pipeline and, ultimately, drive long-term and sustainable stockholder value creation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tango's compensation programs are designed by our Compensation Committee and our Board of Directors around the following imperatives:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Attract, Retain and Incentivize</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">:  We are committed to attracting and retaining industry-leading talented individuals and designing our compensation programs and pay-outs that incentivize our employees to achieve rigorous corporate and individual objectives that are important to our long-term business and success.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Performance-based compensation pay-outs</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">:  Rewarding performance is the keystone of our total compensation program.  In our annual bonus program, performance is measured by research and development advances, operating and strategic and individual contributions.  The amount actually earned is scaled with the achievement of these performance metrics.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Compensation structure competitive with peers</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">:  We believe that compensation paid by our peer companies matters when we determine overall compensation.  We evaluate the practices of our peers to validate that we are competitive with other companies with whom we compete for talent.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balanced combination of compensation components</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">:  We strive for an appropriate balance between cash and equity incentives.  The rationale being that annual cash incentive motivates individuals to successfully execute on short-term financial and strategic objectives and equity incentives focus executives on the long-term success of the organization and align the interests of our executives with those of our stockholders.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Named Executive Officer Compensation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table shows the total compensation awarded to, earned by, or paid to during the years ended December 31, 2021 and 2020 to (1) our principal executive officer, (2) our two next most highly compensated executive officers who earned more than $100,000 during the fiscal year ended December 31, 2021 and were serving as executive officers as of such date.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our named executive officers, or the NEOs, for 2021 who appear in the Summary Compensation Table are:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Barbara Weber, M.D., our President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Daniella Beckman, our Chief Financial Officer; and</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Alan Huang, Ph.D., our Chief Scientific Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021 Summary Compensation Table</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:21.881%;"></td>
    <td style="width:0.895%;"></td>
    <td style="width:0.447%;"></td>
    <td style="width:4.275%;"></td>
    <td style="width:0.447%;"></td>
    <td style="width:0.895%;"></td>
    <td style="width:1.799%;"></td>
    <td style="width:0.447%;"></td>
    <td style="width:6.412%;"></td>
    <td style="width:0.447%;"></td>
    <td style="width:2.287%;"></td>
    <td style="width:0.895%;"></td>
    <td style="width:1.799%;"></td>
    <td style="width:7.078%;"></td>
    <td style="width:1.491%;"></td>
    <td style="width:1.65%;"></td>
    <td style="width:0.447%;"></td>
    <td style="width:8.251%;"></td>
    <td style="width:0.447%;"></td>
    <td style="width:1.62%;"></td>
    <td style="width:1.67%;"></td>
    <td style="width:0.457%;"></td>
    <td style="width:9.484%;"></td>
    <td style="width:0.447%;"></td>
    <td style="width:1.183%;"></td>
    <td style="width:1.66%;"></td>
    <td style="width:0.457%;"></td>
    <td style="width:5.965%;"></td>
    <td style="width:0.457%;"></td>
    <td style="width:3.201%;"></td>
    <td style="width:0.895%;"></td>
    <td style="width:1.65%;"></td>
    <td style="width:0.447%;"></td>
    <td style="width:7.665%;"></td>
    <td style="width:0.447%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Name and Principal Position</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Year</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Salary(1) ($)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Bonus ($)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Option Awards(7) ($)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Non-Equity Incentive Plan Compensation (9)($)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">All Other Compensation ($)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Total ($)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Barbara Weber, M.D.(6)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">513,685</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(2)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">10,719,769</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">277,910</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">4,609</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(10)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">11,515,974</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;font-style:italic;">President, Chief Executive Officer and Director</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">491,617</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">227,622</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">226,194</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">12,788</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(11)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">958,221</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Daniella Beckman</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">377,945</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(3)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">2,630,841</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">164,562</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">3,317</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(12)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">3,176,664</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;font-style:italic;">Chief Financial Officer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">323,447</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(4)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">368,323</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(8)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">131,828</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">10,776</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(13)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">834,374</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Alan Huang, Ph.D.</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">394,793</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(5)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">1,649,121</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">168,347</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">3,396</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(14)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">2,215,657</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;font-style:italic;">Chief Scientific Officer</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">373,806</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">70,566</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">135,769</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">9,376</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(15)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">589,517</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1)    Salary amount represents actual amounts paid during year noted. See &#x201c;&#x2014; Narrative to the Summary Compensation Table &#x2014;Base Salaries&#x201d; below.</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2)    Dr. Weber earned a base salary of $506,479 for the period between January 1, 2021 and August 10, 2021. Upon the closing of Business Combination on August 10, 2021, her salary was increased to $526,000.</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(3)    Mrs. Beckman earned a base salary of $370,800 for the period between January 1, 2021 and August 10, 2021. Upon the closing of Business Combination on August 10, 2021, her salary was increased to $390,000.</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(4)    Mrs. Beckman earned a base salary of $288,000 for the period between January 1, 2020 and June 30, 2020, which reflected her part-time status. Upon her appointment to full-time on July 1, 2020, her salary was increased to $360,000. Her base salary and bonus were prorated to reflect her partial year of full-time employment from July 1, 2020 through December 31, 2020.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">111</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(5)    Mr. Huang earned a base salary of $385,107 for the period between January 1, 2021 and August 10, 2021. Upon the closing of Business Combination on August 10, 2021, his salary was increased to $411,000.</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(6)    Dr. Weber also serves as a member of our board of directors but does not receive any additional compensation for her service as a director.</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(7)    In accordance with SEC rules, this column reflects the aggregate grant date fair value of the option awards granted during fiscal years 2021 and 2020 computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, or ASC Topic 718, for share-based compensation transactions. These amounts do not reflect the actual economic value that will be realized by the named executive officer upon the vesting of the share options, the exercise of the share options or the sale of the common shares underlying such share options.</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(8)    The amounts reflected include an increase to Mrs. Beckman&#x2019;s stock options to reflect her appointment full-time status, effective on July 1, 2020.</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(9)    Reflects performance-based cash bonuses awarded to our named executive officers. See &#x201c;&#x2014; Non-Equity Incentive Plan Compensation&#x201d; below for a description of the material terms of the program pursuant to which this compensation was awarded.</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(10)  The amounts reported reflect $1,390 of commuter benefits and $3,219 for life &amp; disability premiums that our company paid for on behalf of Dr. Weber.</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(11)  The amounts reported reflect $4,320 of commuter benefits, $2,865 of health benefits and life &amp; disability insurance and $5,603 of expenses for phone services and home office expenses that our company paid for on behalf of Dr. Weber.</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(12)  The amounts reported reflect $1,390 of commuter benefits and $1,927 for life &amp; disability premiums that our company paid for on behalf of Mrs. Beckman.</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(13)  The amounts reported reflect $4,320 of commuter benefits, $1,684 for life &amp; disability premiums and $4,772 of expenses for phone services and home office expenses that our company paid for on behalf of Mrs. Beckman.</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(14)  The amounts reported reflect $1,390 of commuter benefits and $2,006 for life &amp; disability premiums that our company paid for on behalf of Mr. Huang.</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(15)  The amounts reported reflect $4,320 of commuter benefits, $1,684 for life &amp; disability premiums and $3,372 of expenses for phone services and home office expenses that our company paid for on behalf of Mr. Huang.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Narrative to the Summary Compensation Table</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">With respect to our 2021 compensation program, our board of directors reviewed compensation for all employees, including our named executive officers. In setting executive base salaries and bonuses and granting equity incentive awards, the board of directors considered compensation for comparable positions in the market, historical compensation level of our executives, individual performance as compared to our expectations and objectives, our desire to motivate employees to achieve short- and long-term results that are in the best interests of our stockholders and a long-term commitment to value creation for our company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our board of directors established a compensation committee, and delegated to such committee certain compensation-related functions for the Company in early 2021.  Prior to establishing the compensation committee, the board of directors made compensation decisions with respect to our named executive officers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">When setting named executive officer compensation, our board of directors, and now our compensation committee, targets a general competitive position, based on independent third-party benchmark analytics to inform the mix of compensation of base salary, bonus and long-term incentives.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our compensation committee is primarily responsible for determining the compensation for all of our executive officers. Our compensation committee reviews and discusses management&#x2019;s proposed compensation with our Chief Executive Officer for all executives other than the Chief Executive Officer. Based on those discussions and its discretion, taking into account the factors noted above, the compensation committee then sets the compensation for each executive officer</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> other than the Chief Executive Officer and recommends the compensation for the Chief Executive Officer to our board of directors for approval. Our board of directors discusses the compensation committee&#x2019;s recommendation and ultimately approves the compensation of our Chief Executive officer without the Chief Executive Officer present</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Our compensation committee has the authority to engage the services of a consulting firm or other outside advisor to assist it in designing our executive compensation programs and in making compensation decisions. During 2020 and 2021, the board of directors and the compensation committee retained the services of Pearl Meyer &amp; Partners, LLC as external compensation consultant to advise on executive compensation matters including our overall compensation program design and collection of market data to inform our compensation programs for our executive officers and members of our board of directors. Pearl Meyer &amp; Partners, LLC reports directly to our compensation committee. Prior to engaging Pearl Meyer &amp; Partners, LLC, our compensation committee assessed its independence consistent with Nasdaq listing standards and concluded that the engagement of such consultant did not raise any conflict of interest.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">112</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Base Salaries</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The annual base salaries of our named executive officers are generally determined, approved and reviewed periodically by our compensation committee in order to compensate our named executive officers for their satisfactory performance of duties to our company. Annual base salaries are intended to provide a fixed component of compensation to our named executive officers, reflecting their skill sets, experience, roles and responsibilities. Base salaries for our named executive officers have generally been set at levels deemed necessary to attract and retain individuals with superior talent.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:89.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.852%;"></td>
    <td style="width:5.376%;"></td>
    <td style="width:1.654%;"></td>
    <td style="width:0.715%;"></td>
    <td style="width:21.949%;"></td>
    <td style="width:0.715%;"></td>
    <td style="width:5.744%;"></td>
    <td style="width:1.654%;"></td>
    <td style="width:0.715%;"></td>
    <td style="width:20.91%;"></td>
    <td style="width:0.715%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020 Base Salary ($)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021 Base Salary ($)(2)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Barbara Weber, M.D.</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">491,617</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">526,000</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Daniella Beckman</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">360,000</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">390,000</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Alan Huang, Ph.D.</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">373,806</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">411,000</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1)    Mrs. Beckman transitioned to full-time employment on July 1, 2020 and her 2020 base salary was adjusted to reflect her employment status with our company.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2)    2021 Base Salary became effective upon the closing of the Business Combination on August 10, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The compensation committee determined that, in connection with the Business Combination and the Company becoming a publicly-traded company, the base salaries for each of the NEOs should be increased in order to reflect the additional responsibilities of each of these executive officers, as well as to align this fixed cash component of overall compensation at levels that are comparable to those companies in our compensation peer group.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Non-Equity Incentive Plan Compensation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our bonus program is intended to recognize and reward associates for achieving established objectives that are linked to the company&#x2019;s growth and success, with the goal of increasing the Company's intrinsic long-term value.  The program rewards performance based on corporate and individual accomplishments. The board endeavors to deliver a meaningful portion of total cash compensation in the form of performance-based annual cash incentives. Doing so, the board believes, is critical because the opportunity for a meaningful cash award will, together with strong management and accountability, drive executives to individually and collectively achieve and exceed our annual objectives.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The compensation committee and the board of directors established bonus metrics in connection with the 2021 bonus plan.  As with 2021 base salary, the target bonus percentage for each of the NEOs was increased in connection with the Business Combination and the Company becoming a publicly-traded company in order to reflect the additional responsibilities of each of these executive officers, as well as to align this variable portion of the cash component of overall compensation at levels that are comparable to those companies in our compensation peer group.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2021 corporate bonus plan provides for formula-based incentive payments based upon the achievement of certain corporate and individual performance goals and objectives approved by our compensation committee and board of directors.  These targets were established early in 2021 and communicated to the executives (and remained unchanged during the year).  Bonuses are targeted at a percentage of the executive officer&#x2019;s base salary during the year, and are expected to be paid out in the first quarter of the following year.  The following are the target percentages for the periods indicated:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.448%;"></td>
    <td style="width:2.714%;"></td>
    <td style="width:2.714%;"></td>
    <td style="width:17.348%;"></td>
    <td style="width:4.881%;"></td>
    <td style="width:2.972%;"></td>
    <td style="width:2.972%;"></td>
    <td style="width:17.348%;"></td>
    <td style="width:4.603%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020 Bonus Target (%)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021 Bonus Target (%)(1)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Barbara Weber, M.D.</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Daniella Beckman</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Alan Huang, Ph.D.</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The corporate bonus component of the 2021 bonus plan consisted of 5 separate metrics that were weighted as follows:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Target Discovery</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> - weighted 20%.  This target is designed to encourage our employees to identify validated targets to meet our goal of filing INDs in the future to establish an enhanced product pipeline.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Drug Discovery</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> - weighted 30%.  This target was established to incentivize our employees to continue to advance our identified programs into advanced drug discovery phases.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Preclinical Development </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">- weighted 30%.  This target is designed to meet our goal of filing an IND for TNG908 in the 4th quarter of 2021.  </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">113</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Corporate Strategy</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> - weighted 10%.  This target was established to incentivize our employees to meet budgetary and other important cash-based goals that are designed to allow for continued development of our product pipeline in the future.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">People</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> - weighted 10%.  This target was designed to reward results with respect to building out critical functions of our organization as we advanced our first product into clinical trials, and to reduce employee turnover in a competitive environment for talent.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the 2021 annual cash bonus program, all corporate targets were met at 110% of the established target, with the exception of: (i) corporate strategy, which was met at 150% of target and (ii) people, which was met at 115% of target.  These achievements, which were confirmed by our compensation committee, reflected, among other things, our continued advancements in drug discovery in the face of the COVID-19 pandemic, our continued advancement of our product candidates, including the acceleration of the Target 3 IND timeline, the hiring of our Chief Medical Officer, our successful IPO in August 2021 and our current strong cash position. As a result of this performance, which exceeded the objective goals set earlier in the year, the bonus payout was achieved at 115% of target. The following table reflects the target bonus as a percentage of base salary, the cash bonus payment at target and the actual bonus payout based on the success Tango achieved in 2021.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:38.173%;"></td>
    <td style="width:1.809%;"></td>
    <td style="width:14.47%;"></td>
    <td style="width:4.085%;"></td>
    <td style="width:2.266%;"></td>
    <td style="width:2.942%;"></td>
    <td style="width:0.646%;"></td>
    <td style="width:14.113%;"></td>
    <td style="width:0.646%;"></td>
    <td style="width:2.703%;"></td>
    <td style="width:2.276%;"></td>
    <td style="width:0.646%;"></td>
    <td style="width:14.58%;"></td>
    <td style="width:0.646%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021 Bonus Target (%)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021 Bonus Target ($)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021 Bonus Achieved ($)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Barbara Weber, M.D.</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">263,000</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">277,910</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Daniella Beckman</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">156,000</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">164,562</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Alan Huang, Ph.D.</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">164,400</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">168,347</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All final bonus payments to our named executive officers, if any, are determined by our compensation committee, which retains full discretion to adjust individual actual bonus awards based on the achievement of corporate and individual performance objectives, and may also adjust bonus awards based on other factors in their discretion. Individual performance objectives are generally related to each named executive officer&#x2019;s performance in his area of responsibility and his contributions to Tango.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Equity Incentive Compensation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our equity-based incentive awards granted to our named executive officers are designed to align their interests with those of our stockholders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have historically used share options as an incentive for long-term compensation to our executive officers because the share options allow our executive officers to profit from this form of equity compensation only if our share price increases relative to the share option&#x2019;s exercise price, which exercise price is set at the fair market value of our common shares on the date of grant. We may grant equity awards at such times as our board of directors or compensation committee determines appropriate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Along with the 2021 cash bonus program, stock options are a critical component of the variable portion of overall compensation that is designed to reward executive officer performance. Stock options align the interests of executives with those of our stockholders since the executive officers can only recognize increased compensation from these equity awards to the extent that our share price increases above the exercise price. These awards encourage our executives to focus on those corporate actions that drive increase in long-term value as reflected in the share price. Further, the four-year vesting schedule encourages executives to remain employed by the Company for an extended period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our executives generally are awarded an initial grant in the form of a share option in connection with their commencement of employment with us. Additional grants may occur periodically in order to specifically incentivize executives with respect to achieving corporate goals or to reward certain performance. Our stock options typically vest as to 25% of the underlying shares on the first anniversary of the vesting commencement date and in 36 equal monthly installments over the following three years, subject to the holder&#x2019;s continued employment with us. From time to time, the board of directors or compensation committee may also construct alternative vesting schedules as it determines are appropriate to motivate particular employees. All options are granted with an exercise price that is no less than the fair market value of our common shares on the date of such grant of such award.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Outstanding Equity Awards at 2021 Fiscal Year-End</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents information regarding all outstanding equity awards held by each of our named executive officers as of December 31, 2021.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.603%;"></td>
    <td style="width:1.56%;"></td>
    <td style="width:1.719%;"></td>
    <td style="width:10.325%;"></td>
    <td style="width:1.242%;"></td>
    <td style="width:2.047%;"></td>
    <td style="width:11.289%;"></td>
    <td style="width:1.401%;"></td>
    <td style="width:1.083%;"></td>
    <td style="width:0.517%;"></td>
    <td style="width:11.07%;"></td>
    <td style="width:0.517%;"></td>
    <td style="width:1.56%;"></td>
    <td style="width:1.083%;"></td>
    <td style="width:0.517%;"></td>
    <td style="width:8.685%;"></td>
    <td style="width:0.517%;"></td>
    <td style="width:3.955%;"></td>
    <td style="width:1.401%;"></td>
    <td style="width:2.007%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:5.058%;"></td>
    <td style="width:0.517%;"></td>
    <td style="width:1.56%;"></td>
    <td style="width:1.719%;"></td>
    <td style="width:9.043%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Name and Principal Position</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Grant Date</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Vesting Commencement Date</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Number of Securities Underlying Unexercised Options (#) (Exercisable)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Number of Securities Underlying Unexercised Options (#) (UnExercisable)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Option Exercise Price (1)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Option Expiration Date</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Barbara Weber, M.D.</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1/24/2019</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1/1/2019</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">159,793</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">59,358</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(2)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1.53</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1/23/2029</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">President,</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1/30/2020</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1/1/2020</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">105,005</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">114,145</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(2)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1.65</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1/29/2030</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">Chief Executive Officer</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1/28/2021</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1/1/2021</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1,284,065</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(2)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">3.50</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1/27/2031</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">and Director</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">8/12/2021</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">8/12/2021</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">961,404</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(2)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">9.56</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">8/11/2031</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Daniella Beckman</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">10/18/2019</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">9/10/2019</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">93,056</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">72,377</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(3)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1.53</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">10/17/2029</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">Chief Financial Officer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1/30/2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">11/1/2019</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">28,750</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">26,451</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(3)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1.65</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1/29/2030</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">10/1/2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">7/1/2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">24,114</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">43,994</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(3)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">3.21</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">9/30/2030</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1/28/2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1/1/2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">88,151</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(2)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">3.50</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1/27/2031</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">8/12/2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">8/12/2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">380,485</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(2)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">9.56</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">8/11/2031</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Alan Huang, Ph.D.</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">4/12/2018</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1/1/2018</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">83,155</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1,770</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(3)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1.38</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">4/11/2028</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">Chief Scientific Officer</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">4/12/2018</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">4/1/2018</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">101,201</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">9,201</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(3)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1.38</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">4/11/2028</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1/24/2019</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1/1/2019</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">49,532</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">18,407</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(2)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1.53</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1/23/2029</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1/30/2020</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1/1/2020</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">32,553</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">35,386</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(2)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1.65</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1/29/2030</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1/28/2021</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1/1/2021</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">163,054</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(2)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">3.50</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">1/27/2031</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">8/12/2021</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">8/12/2021</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">169,859</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(2)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">9.56</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">8/11/2031</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1)    All of the option awards listed in the table were granted with an exercise price per share that is no less than the fair market value of our common shares on the date of grant of such award. For information regarding the valuation of equity awards, see Note 2 and Note 12 to our audited financial statements contained in this Annual Report on Form 10-K for the year ended December 31, 2021.</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2)    25% vesting after 1st anniversary of the vesting commencement date and monthly vesting for 36 monthly installments thereafter, subject to continued employment with the company.</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(3)    Monthly vesting for 48 monthly installments following the vesting commencement date, subject to continued employment with our company.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Executive Compensation Arrangements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We initially entered into an offer letter with each of the named executive officers in connection with such officer&#x2019;s employment with us, which set forth the terms and conditions of this officer&#x2019;s employment, including base salary, target annual bonus opportunity, initial equity awards and standard employee benefit plan participation. Effective upon the closing of the Business Combination, we entered into an employment agreements with each of Dr. Weber, Ms. Beckman and Dr. Huang that replaced the offer letters and provide for specified payments and benefits in connection with a termination of employment in certain circumstances. Our goal in providing these severance and change in control payments and benefits is to offer sufficient cash continuity protection such that the named executive officers will focus their full time and attention on the requirements of the business rather than the potential implications for their respective positions. We prefer to have certainty regarding the potential severance amounts payable to the named executive officers, rather than negotiating severance at the time that a named executive officer&#x2019;s employment terminates. We have also determined that accelerated vesting provisions with respect to outstanding equity awards in connection with a qualifying termination of employment in certain circumstances are appropriate because they encourage our named executive officers to stay focused on the business in those circumstances, rather than focusing on the potential implications for them personally. The employment agreements with our named executive officers require the named executive officers to execute a separation agreement containing a general release of claims in favor of us to receive any severance payments and benefits. The material terms of the employment agreements with Dr. Weber, Ms. Beckman and Dr. Huang are summarized below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Barbara Weber, M.D.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effective upon the closing of the Business Combination, we entered into a new employment agreement with Dr. Weber. Under Dr. Weber&#x2019;s employment agreement, or the Weber Employment Agreement, Dr. Weber will serve as our Chief Executive Officer on an at-will basis. Dr. Weber&#x2019;s 2022 annual base salary is $575,000, which is subject to periodic review and adjustment, and she is eligible to earn an annual bonus with a target amount equal to 50% of her base salary. Dr. Weber is eligible to participate in the employee benefit plans available to our employees, subject to the terms of those plans.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">115</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Weber Employment Agreement, in the event that her employment is terminated by us without &#x201c;cause&#x201d; or Dr. Weber resigns for &#x201c;good reason&#x201d; (as each term is defined in the Weber Employment Agreement), subject to the execution and effectiveness of a separation agreement, including a general release of claims in our favor, (i) she will be entitled to receive base salary continuation for twelve (12) months following termination, (ii) she will be entitled to receive a prorated portion of her target annual cash incentive compensation for the year of termination, payable over the twelve (12) months following termination, (iii) subject to Dr. Weber&#x2019;s copayment of premium amounts at the applicable active employees&#x2019; rate and proper election to continue COBRA health coverage, we will cover the portion of the premium amount equal to the amount that we would have paid to provide health insurance to Dr. Weber had she remained employed with us until the earliest of (A) twelve (12) months following termination, (B) Dr. Weber&#x2019;s eligibility for group medical plan benefits under any other employer&#x2019;s group medical plan or (C) the end of Dr. Weber&#x2019;s COBRA health continuation period, and (iv) acceleration by 12 months of the unvested portion of all stock options and other stock-based awards subject solely to time-based vesting held by Dr. Weber.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In lieu of the payments and benefits described in the preceding sentence, in the event that Dr. Weber&#x2019;s employment is terminated by us without cause or Dr. Weber resigns for good reason on or within twelve (12) months following a &#x201c;change in control&#x201d; (as defined in the Weber Employment Agreement), subject to the execution and effectiveness of a separation agreement, including a general release of claims in our favor, (i) she will be entitled to receive a lump sum in cash equal to 1.5 times Dr. Weber&#x2019;s then-current annual base salary (or Dr. Weber&#x2019;s annual base salary in effect immediately prior to the change in control, if higher), (ii) she will be entitled to receive a lump sum in cash equal to 1.5 times Dr. Weber&#x2019;s target annual cash incentive compensation for the year of termination, (iii) she will be entitled to receive a lump sum in cash equal to a prorated portion of her target annual cash incentive compensation for the year of termination, (iv) subject to Dr. Weber&#x2019;s copayment of premium amounts at the applicable active employees&#x2019; rate and proper election to continue COBRA health coverage, we will cover the portion of the premium amount equal to the amount that we would have paid to provide health insurance to Dr. Weber had she remained employed with us until the earliest of (A) eighteen (18) months following termination, (B) Dr. Weber&#x2019;s eligibility for group medical plan benefits under any other employer&#x2019;s group medical plan or (C) the end of Dr. Weber&#x2019;s COBRA health continuation period, and (iv) 100% of all stock options and other stock-based awards subject solely to time-based vesting held by Dr. Weber shall be accelerated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Daniella Beckman</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effective upon the closing of the Business Combination, we entered into a new employment agreement with Ms. Beckman. Under Ms. Beckman&#x2019;s employment agreement, or the Beckman Employment Agreement, Ms. Beckman will serve as our Chief Financial Officer on an at-will basis. Ms. Beckman&#x2019;s 2022 annual base salary is $425,100, which is subject to periodic review and adjustment, and she is eligible to earn an annual bonus with a target amount equal to 40% of her base salary. Ms. Beckman is eligible to participate in the employee benefit plans available to our employees, subject to the terms of those plans.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Beckman Employment Agreement, in the event that her employment is terminated by us without &#x201c;cause&#x201d; or Ms. Beckman resigns for &#x201c;good reason&#x201d; (as each term is defined in the Beckman Employment Agreement), subject to the execution and effectiveness of a separation agreement, including a general release of claims in our favor, (i) she will be entitled to receive base salary continuation for twelve (12) months following termination, and (ii) subject to Ms. Beckman&#x2019;s copayment of premium amounts at the applicable active employees&#x2019; rate and proper election to continue COBRA health coverage, we will cover the portion of the premium amount equal to the amount that we would have paid to provide health insurance to Ms. Beckman had she remained employed with us until the earliest of (A) twelve (12) months following termination, (B) Ms. Beckman&#x2019;s eligibility for group medical plan benefits under any other employer&#x2019;s group medical plan or (C) the end of Ms. Beckman&#x2019;s COBRA health continuation period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In lieu of the payments and benefits described in the preceding sentence, in the event that Ms. Beckman&#x2019;s employment is terminated by us without cause or Ms. Beckman resigns for good reason on or within twelve (12) months following a &#x201c;change in control&#x201d; (as defined in the Beckman Employment Agreement), subject to the execution and effectiveness of a separation agreement, including a general release of claims in our favor, (i) she will be entitled to receive a lump sum in cash equal to 1.0 times Ms. Beckman&#x2019;s then-current annual base salary (or Ms. Beckman&#x2019;s annual base salary in effect immediately prior to the change in control, if higher), (ii) she will be entitled to receive a lump sum in cash equal to Ms. Beckman&#x2019;s target annual cash incentive compensation for the year of termination, (iii) subject to Ms. Beckman&#x2019;s copayment of premium amounts at the applicable active employees&#x2019; rate and proper election to continue COBRA health coverage, we will cover the portion of the premium amount equal to the amount that we would have paid to provide health insurance to Ms. Beckman had she remained employed with us until the earliest of (A) twelve (12) months following termination, (B) Ms. Beckman&#x2019;s eligibility for group medical plan benefits under any other employer&#x2019;s group medical plan or (C) the end of Ms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">116</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Beckman&#x2019;s COBRA health continuation period, and (iv) 100% of all stock options and other stock-based awards subject solely to time-based vesting held by Ms. Beckman shall be accelerated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Alan Huang, Ph.D.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effective upon the closing of the Business Combination, we entered into a new employment agreement with Dr. Huang. Under Dr. Huang&#x2019;s employment agreement, or the Huang Employment Agreement, Dr. Huang will serve as our Chief Scientific Officer on an at-will basis. Dr. Huang&#x2019;s 2022 annual base salary is $425,385, which is subject to periodic review and adjustment, and he is eligible to earn an annual bonus with a target amount equal to 40% of his base salary. Dr. Huang is eligible to participate in the employee benefit plans available to our employees, subject to the terms of those plans.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Huang Employment Agreement, in the event that his employment is terminated by us without &#x201c;cause&#x201d; or Dr. Huang resigns for &#x201c;good reason&#x201d; (as each term is defined in the Huang Employment Agreement), subject to the execution and effectiveness of a separation agreement, including a general release of claims in our favor, (i) he will be entitled to receive base salary continuation for twelve (12) months following termination, and (ii) subject to Dr. Huang&#x2019;s copayment of premium amounts at the applicable active employees&#x2019; rate and proper election to continue COBRA health coverage, we will cover the portion of the premium amount equal to the amount that we would have paid to provide health insurance to Dr. Huang had he remained employed with us until the earliest of (A) twelve (12) months following termination, (B) Dr. Huang&#x2019;s eligibility for group medical plan benefits under any other employer&#x2019;s group medical plan or (C) the end of Dr. Huang&#x2019;s COBRA health continuation period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In lieu of the payments and benefits described in the preceding sentence, in the event that Dr. Huang&#x2019;s employment is terminated by us without cause or Dr. Huang resigns for good reason on or within twelve (12) months following a &#x201c;change in control&#x201d; (as defined in the Huang Employment Agreement), subject to the execution and effectiveness of a separation agreement, including a general release of claims in our favor, (i) he will be entitled to receive a lump sum in cash equal to 1.0 times Dr. Huang&#x2019;s then-current annual base salary (or Dr. Huang&#x2019;s annual base salary in effect immediately prior to the change in control, if higher), (ii) he will be entitled to receive a lump sum in cash equal to Dr. Huang&#x2019;s target annual cash incentive compensation for the year of termination, (iii) subject to Dr. Huang&#x2019;s copayment of premium amounts at the applicable active employees&#x2019; rate and proper election to continue COBRA health coverage, we will cover the portion of the premium amount equal to the amount that we would have paid to provide health insurance to Dr. Huang had he remained employed with us until the earliest of (A) twelve (12) months following termination, (B) Dr. Huang&#x2019;s eligibility for group medical plan benefits under any other employer&#x2019;s group medical plan or (C) the end of Dr. Huang&#x2019;s COBRA health continuation period, and (iv) 100% of all stock options and other stock-based awards subject solely to time-based vesting held by Dr. Huang shall be accelerated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Other Elements of Compensation; Perquisites</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Health and Welfare Plans</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During their employment, our named executive officers are eligible to participate in our employee benefit plans and programs, including medical and dental benefits, life insurance &amp; disability benefits, to the same extent as our other full-time employees, subject to the terms and eligibility requirements of those plans.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Retirement Plan</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We maintain a 401(k) retirement savings plan for our employees, including our named executive officers, who satisfy certain eligibility requirements. The savings plan is intended to qualify for favorable tax treatment under Section 401(a) of the Code and contains a cash or deferred feature that is intended to meet the requirements of Section 401(k) of the Code. Participants may make pre-tax and certain after-tax (Roth) salary deferral contributions to the plan from their eligible earnings up to the statutorily prescribed annual limit under the Code. Participants who are 50 years of age or older may contribute additional amounts based on the statutory limits for catch-up contributions. Participant contributions are held in trust as required by law. Under this plan, we did not, during the year ended December 31, 2021 offer company matching contributions to participants in the 401(k) plan. Our named executive officers are eligible to participate in the 401(k) plan on the same terms as other full-time employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Compensation Risk Assessment</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that although a portion of the compensation provided to our executive officers and other employees is performance-based, our executive compensation program does not encourage excessive or unnecessary risk taking. Our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">117</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">compensation programs are designed to encourage our executive officers and other employees to remain focused on both short-term and long-term strategic goals. As a result, we do not believe that our compensation programs are reasonably likely to have a material adverse effect on the Company.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Non-Employee Director Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effective upon the closing of the Business Combination, we adopted a compensation program for our non-employee directors under which each non-employee director will receive the following amounts for their services on our board of directors.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An option to purchase 80,000 shares of our common stock upon the director&#x2019;s initial election or appointment to our board of directors that occurs after the Closing.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An annual option to purchase 40,000 shares of our common stock on the date of the annual meeting for such year (the first such annual option award is scheduled to be made in connection with the annual meeting to be held later in 2022). Directors who were elected in the 12 months preceding the annual grant receive a pro-rated portion of the annual grant based on the number of months of time in service on the board.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.921%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:0.982%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An annual director fee of $40,000,</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.901%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the director serves on a committee of our board of directors or in the other capacities stated below, an additional annual fee as follows:</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10.0%;"></td>
    <td style="width:2.917%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:86.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-executive chairperson, $30,000</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10.0%;"></td>
    <td style="width:2.917%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:86.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lead independent director, $15,000</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10.0%;"></td>
    <td style="width:2.917%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:86.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Audit committee chairperson, $15,000</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10.0%;"></td>
    <td style="width:2.917%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:86.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Audit committee member, $7,500</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10.0%;"></td>
    <td style="width:2.917%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:86.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Compensation committee chairperson, $10,000</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10.0%;"></td>
    <td style="width:2.917%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:86.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Compensation committee member, $5,000</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10.0%;"></td>
    <td style="width:2.917%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:86.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Nomination and governance committee chairperson, $8,000</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10.0%;"></td>
    <td style="width:2.917%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:86.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Nomination and governance committee member, $4,000</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options granted to our non-employee directors under the director compensation program will have an exercise price equal to the fair market value of our common stock on the date of grant and will expire not later than ten years after the date of grant. The options granted upon a director&#x2019;s initial election or appointment vest in 48 substantially equal monthly installments following the date of grant. In addition, all unvested options vest in full upon the occurrence of a change in control.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">118</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2021 Non-Employee Director</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Compensation Table</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The table below shows the cash fees paid to our directors in connection with their service on our board of directors, and the stock option awards granted, during the fiscal year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:35.527%;"></td>
    <td style="width:2.864%;"></td>
    <td style="width:3.351%;"></td>
    <td style="width:0.636%;"></td>
    <td style="width:12.081%;"></td>
    <td style="width:0.636%;"></td>
    <td style="width:3.112%;"></td>
    <td style="width:0.636%;"></td>
    <td style="width:14.318%;"></td>
    <td style="width:0.636%;"></td>
    <td style="width:4.236%;"></td>
    <td style="width:2.864%;"></td>
    <td style="width:3.977%;"></td>
    <td style="width:0.636%;"></td>
    <td style="width:13.851%;"></td>
    <td style="width:0.636%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fees Earned or Paid<br />In Cash ($)(1)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="4" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Option Awards ($)(2)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total ($)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Aaron Davis</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,444</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,444</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Alexis Borisy</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61,469</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61,469</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lesley Ann Calhoun</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45,028</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">419,900</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(3)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">464,928</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Mace Rothenberg</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39,353</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">419,900</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(3)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">459,253</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Malte Peters</span></p></td>
    <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44,292</span></p></td>
    <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44,292</span></p></td>
    <td style="background-color:rgba(204,236,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reid Huber</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,170</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,170</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1)    Amounts represent cash compensation earned and paid pursuant to our non-employee director compensation policy.</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2)    The amounts reported represent the aggregate grant-date fair value of stock options awarded to certain directors in 2021, calculated in accordance with Financial Accounting Standards Board, Accounting Standards Codification Topic 718, or ASC Topic 718. The amounts presented do not correspond to the actual value that may be recognized by the named director upon vesting of the applicable awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(3)    Ms. Calhoun and Dr. Rothenberg were each granted an option to purchase 84,925 shares of common stock on March 18, 2021, the date on which they were appointed to the board of directors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The table below shows the aggregate number of total stock option awards (exercisable and unexercisable) held as of December 31, 2021 by each non-employee director who was serving as of December 31, 2021.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:71.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:56.514%;"></td>
    <td style="width:4.903%;"></td>
    <td style="width:5.856%;"></td>
    <td style="width:1.037%;"></td>
    <td style="width:30.695%;"></td>
    <td style="width:0.995%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares Subject to <br />Outstanding Options</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Aaron Davis</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Alexis Borisy</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">131,463</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lesley Ann Calhoun</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84,925</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Mace Rothenberg</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84,925</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Malte Peters</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">118,895</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reid Huber</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;" id="item_12_security_ownership"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Equity Compensation Plan Information</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth information as of December 31, 2021 regarding shares of common stock that may be issued under our equity compensation plans, consisting of our 2021 Stock Option and Incentive Plan, or the 2021 Plan, and our 2021 Employee Stock Purchase Plan, or the ESPP. Upon the closing of the Business Combination in August 2021, the 2021 Plan replaced our previous 2017 Stock Option and Grant Plan. We do not have any non-stockholder approved equity compensation plans.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:34.45%;"></td>
    <td style="width:1.759%;"></td>
    <td style="width:0.646%;"></td>
    <td style="width:17.235%;"></td>
    <td style="width:0.636%;"></td>
    <td style="width:1.779%;"></td>
    <td style="width:1.431%;"></td>
    <td style="width:17.006%;"></td>
    <td style="width:1.551%;"></td>
    <td style="width:1.829%;"></td>
    <td style="width:17.911%;"></td>
    <td style="width:0.994%;"></td>
    <td style="width:2.773%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Plan Category</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of Shares of Common Stock to be Issued Upon Exercise of Outstanding Options (#)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-Average Exercise Price of Outstanding Options ($)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of Shares of Common Stock Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column) (#)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Equity compensation plans approved by stockholders(1)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,372,993</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.59</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,448,661</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Equity compensation plans not approved by security holders</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,372,993</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.59</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,448,661</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1)   </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2021 Plan provides that the number of shares reserved and available for issuance under the 2021 Plan will automatically increase each January 1, beginning on January 1, 2022, by 5.0% of the outstanding number of shares of Common Stock on the immediately preceding December 31, or such lesser amount as determined by the Board, or the</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">119</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="margin-left:4.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Annual Increase. This limit is subject to adjustment in the event of a reorganization, recapitalization, reclassification, stock split, stock dividend, reverse stock split or other similar change in the Company's capitalization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2)    Includes 949,873 shares available under the 2021 ESPP.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Security Ownership of Certain Beneficial Owners and Management</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth information, to the extent known by us or ascertainable from public filings, with respect to the beneficial ownership of our common stock as of February 1, 2022 by:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.901%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">each person, or group of affiliated persons, known by us to be the beneficial owner of more than 5% of Tango&#x2019;s outstanding Common Stock;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.901%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">each of Tango&#x2019;s executive officers and directors; and</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.901%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">all of Tango&#x2019;s executive officers and directors as a group.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she, or it possesses sole or shared voting or investment power over that security. Under those rules, beneficial ownership includes securities that the individual or entity has the right to acquire, such as through the exercise of stock options or the vesting of restricted stock awards, within 60 days of February 1, 2022. Shares subject to options that are currently exercisable or exercisable within 60 days of February 1, 2022, or subject to restricted stock awards that vest within 60 days of February 1, 2022, are considered outstanding and beneficially owned by the person holding such options or restricted stock awards for the purpose of computing the percentage ownership of that person but are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Except as noted by footnote, and subject to community property laws where applicable, based on the information provided to us, we believe that the persons and entities named in the table below have sole voting and investment power with respect to all shares shown as beneficially owned by them. Unless otherwise noted, the business address of each of our directors and executive officers is 100 Binney St, Suite 700, Cambridge, MA 02142. The percentage of beneficial ownership is calculated based on 87,649,385 shares of Common Stock outstanding as of February 1, 2022.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:65.729%;"></td>
    <td style="width:2.167%;"></td>
    <td style="width:2.177%;"></td>
    <td style="width:0.646%;"></td>
    <td style="width:14.859%;"></td>
    <td style="width:0.646%;"></td>
    <td style="width:2.356%;"></td>
    <td style="width:4.314%;"></td>
    <td style="width:0.646%;"></td>
    <td style="width:5.815%;"></td>
    <td style="width:0.646%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Name and Address of Beneficial Owner</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Number of Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Named Executive Officers and Directors:</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Barbara Weber, M.D.(1)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,070,184</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Daniella Beckman(2)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">257,947</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Alexis Borisy(3)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90,380</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lesley Calhoun(4)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,231</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Aaron Davis(8)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101,524</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Alan Huang, Ph.D.(5)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">475,572</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reid Huber Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Malte Peters, M.D.(6)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104,033</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Mace Rothenberg, M.D.(7)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,231</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Named Executive Officers and Directors as a group (eleven individuals)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,040,578</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.5</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">5% Stockholders:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#xfeff;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Entities affiliated with Boxer Capital, LLC(8)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,988,577</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16.0</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Casdin Partners Master Fund, L.P.(9)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,487,910</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gilead Sciences, Inc.(10)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,854,443</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Third Rock Ventures IV, L.P.(11)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,363,975</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cormorant Asset Management L.P.(12)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,899,184</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.6</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FMR LLC(13)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,182,188</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*       Less than one percent.</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1)    Consists of 1,367,592 shares of Common Stock and options to purchase 702,592 shares of Common Stock exercisable within 60 days of February 1, 2022.</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2)    Consists of 63,867 shares of Common Stock and options to purchase 189,675 shares of Common Stock exercisable within 60 days of February 1, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(3)    Consists of options to purchase 87,642 shares of Common Stock exercisable within 60 days of February 1, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(4)    Consists of options to purchase 21,231 shares of Common Stock exercisable within 60 days of February 1, 2022.</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(5)    Consists of 135,887 shares of Common Stock and options to purchase 331,157 shares of Common Stock exercisable within 60 days of February 1, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(6)    Consists of options to purchase 104,033 shares of Common Stock exercisable within 60 days of February 1, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(7)    Consists of options to purchase 21,231 shares of Common Stock exercisable within 60 days of February 1, 2022.</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(8)    This information is solely based on a Schedule 13D/A filed by Boxer Capital, LLC (&#x201c;Boxer Capital&#x201d;), Boxer Asset Management Inc. (&#x201c;Boxer Management&#x201d;), Joe Lewis, Aaron Davis, BCTG Holdings, LLC (&#x201c;BCTG Holdings&#x201d;), MVA Investors, LLC (&#x201c;MVA Investors&#x201d;), Braslyn Ltd. (&#x201c;Braslyn,&#x201d; together with Boxer Capital, Boxer Management, Joe Lewis, BCTG Holdings, MVA Investors and Aaron Davis, the &#x201c;Reporting Persons&#x201d;) with the SEC on January 4, 2022 Consists of 6,988,450 shares beneficially owned by BCTG Holdings, 6,871,642 shares beneficially owned by Boxer Capital and Boxer Management, 26,961 shares beneficially owned by Braslyn and 101,524 shares beneficially owned by MVA Investors. Boxer Capital, Boxer Management, and Joseph Lewis share voting and dispositive power over the shares held by Boxer Capital, and Aaron Davis has shared voting and dispositive power over the shares owned by MVA. Each of the individuals and entities listed above expressly disclaims beneficial interest of the shares listed above except to the extent of any pecuniary interest therein. The principal business address of the Reporting Persons is: 12860 El Camino Real, Suite 300, San Diego, CA 92130. The principal business address of Boxer Management, Braslyn and Joe Lewis is: c/o Cay House P.O. Box N-7776 E.P. Taylor Drive Lyford Cay, New Providence, Bahamas.  Aaron Davis serves as the Chief Executive Officer of MVA Investors. A board consisting of Aaron Davis, Christopher Fuglesang and Andrew Ellis makes voting and dispositive decisions with respect to securities owned by BCTG Holdings. Each of Aaron Davis, Christopher Fuglesang and Andrew Ellis disclaims any pecuniary interest in BCTG Holdings except to the extent of his beneficial interest in the securities owned by BCTG Holdings.</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(9)    This information is solely based on a Schedule 13G filed by Casdin Capital, LLC, Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC and Eli Casdin with the SEC on August 19, 2021. The general partner of Casdin Partners Master Fund, L.P. is Casdin Partners GP, LLC, or Casdin Partners GP. Casdin Capital, LLC is the investment manager of Casdin Master Fund, L.P. Eli Casdin is the managing member of Casdin Capital, LLC and makes the sole voting and investment decisions with respect to shares held by Casdin Master Fund, L.P. The address of Casdin Capital, LLC is 1350 Avenue of the Americas, Suite 2405, New York, NY 10019.</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(10)  This information is solely based on a Schedule 13G filed by Gilead Sciences, Inc. with the SEC on September 9, 2021. The address of Gilead Science, Inc. is 333 Lakeside Drive, Foster City, California 94404.</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(11)  This information is solely based on a Schedule 13G filed by Third Rock Ventures IV, L.P. (&#x201c;TRV IV&#x201d;), Third Rock Ventures GP IV, L.P. (&#x201c;TRV GP IV&#x201d;) and TRV GP IV, LLC (&#x201c;TRV GP IV LLC,&#x201d; and collectively with TRV IV and TRV GP IV, the &#x201c;Reporting Persons&#x201d;) with the SEC on August 19, 2021. The general partner of TRV IV is TRV GP IV. The general partner of TRV GP IV. is TRV GP IV LLC. Abbie Celniker, Ph.D., Robert Tepper, M.D., Craig Muir and Cary Pfeffer, M.D. are the managing members of TRV GP IV, LLC who collectively make voting and investment decisions with respect to shares held by TRV IV L.P. Dr. Huber is a partner at Third Rock Ventures, LLC, and a member of our board of directors. The address for each of the Reporting Persons is 29 Newbury Street, Suite 401, Boston, MA 02116.</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(12)  This information is solely based on a Schedule 13G filed by Cormorant Asset Management, LP with the SEC on February 14, 2022. Consists of 4,899,184 shares held for the benefit of private funds and a managed account for which Cormorant Asset Management, LP serves as investment manager. Bihua Chen serves as the general partner of Cormorant Asset Management, LP. The address of Cormorant Asset Management, LP is 200 Clarendon Street, 52nd Floor, Boston, MA 02116</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(13)  This information is based solely on a Schedule 13G filed by FMR LLC and its affiliates with the SEC on February 9, 2022, which reported ownership as of December 31, 2021. The address for FMR LLC is 245 Summer Street, Boston, MA 02210.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;" id="item_13_certain_relationships"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 13. Certain Relationships and Related Transactions, and Director Independence</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other than the compensation agreements and other arrangements described under the sections entitled &#x201c;Executive Compensation&#x201d; and &#x201c;Director Compensation&#x201d; in this Annual Report on Form 10-K and the transactions described below, since January 1, 2020, there has not been and there is not currently proposed, any transaction or series of similar transactions to which:</span><span style="background-color:rgba(255,255,0,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br /></span><span style="background-color:rgba(255,255,0,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.037%;"></td>
    <td style="width:3.035%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.906%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we were, or will be, a participant;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.037%;"></td>
    <td style="width:3.035%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.906%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the amount involved exceeded, or will exceed, $120,000; and</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">121</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.037%;"></td>
    <td style="width:3.035%;"></td>
    <td style="width:1.022%;"></td>
    <td style="width:91.906%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in which any director, executive officer, holder of 5% or more of any class of our capital stock or any member of the immediate family of, or entities affiliated with, any of the foregoing persons, had, or will have, a direct or indirect material interest.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Amended and Restated Registration and Shareholder Rights Agreement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On the Closing Date, we entered into an Amended and Restated Registration and Stockholder Rights Agreement, or the Amended and Restated Registration and Stockholder Rights Agreement, with BCTG Holdings, LLC, or the Sponsor, certain persons and entities holding securities of New Tango, and entities receiving Common Stock pursuant to the Merger Agreement (the foregoing persons and entities, together with other persons or entities who become party to the Amended and Restated Registration and Stockholder Rights Agreement collectively referred to as the Holders), pursuant to which we (i) agreed to register for resale (1) certain shares of Common Stock held by, or issuable upon exercise of options held by, the Holders and (2) any warrants, shares of capital stock or other securities of our company issued as a dividend or other distribution with respect to, or in exchange for or in replacement of the shares specified in clause (1) (the securities in clauses (1) and (2) collectively referred to as the Registrable Securities) and (ii) granted certain other registration rights to the Holders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In particular, the Amended and Restated Registration and Stockholder Rights Agreement provides for the following registration rights:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.901%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Shelf registration/demand registration rights.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;No later than 30 calendar days following the Closing Date, we were required to file with the SEC, a shelf registration statement registering the resale of the Registrable Securities, and use our commercially reasonable efforts to have such registration statement declared effective by the SEC within a specified period. At any time and from time to time when an effective shelf registration statement is on file with the SEC, a Holder may request to sell all or any portion of such Holder&#x2019;s Registrable Securities by means of an underwritten takedown off of the shelf registration statement, except that we are only obligated to effect such underwritten shelf takedown if such offering will include Registrable Securities proposed to be sold by the requesting Holder, either individually or together with other requesting Holders, with a total offering price reasonably expected to exceed, in the aggregate, $20.0 million. Additionally, we are not required to effect more than one underwritten shelf takedown in any six-month period.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.901%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Piggyback registration rights.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Subject to exceptions for certain offerings and registration statements, if at any time, we propose to file a registration statement under the Securities Act in connection with an offering of our equity securities or securities or other obligations exercisable or exchangeable for, or convertible into, our equity securities, either for our own account or for the account of our stockholders, the Holders are entitled to include their Registrable Securities in such registration statement.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.901%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expenses and indemnification</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The fees, costs and expenses of registrations pursuant to the registration rights granted to the Holders under the Amended and Restated Registration and Stockholder Rights Agreement will be borne by us, except that underwriting discounts and selling commissions, brokerage fees, and certain other incremental selling expenses will be borne by the holders of the shares being registered. The Amended and Restated Registration and Shareholder Rights Agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of Registrable Securities in the event of material misstatements or omissions in the registration statement attributable to us, and holders of Registrable Securities are obligated to indemnify Tango for material misstatements or omissions attributable to them.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our securities shall cease to be Registrable Securities when (i) a registration statement with respect to the sale of such securities shall have become effective under the Securities Act and such securities shall have been disposed of in accordance with such registration statement, (ii) such securities are freely saleable under Rule 144 under the Securities Act without any volume limitations or (iii) such securities shall have ceased to be outstanding.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Amended and Restated Registration and Stockholder Rights Agreement shall terminate on the earlier of (i) the 10th anniversary of the date of the agreement and (ii) with respect to any Holder, on the date that such Holder no longer holds any Registrable Securities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">122</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Lock-Up Agreements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Merger, on the Closing Date, we entered into lock-up agreements with our directors, officers and certain of our stockholders, or collectively, the Lockup Holders. The terms of the lock-up agreements provide for the Common Stock held by the Lockup Holders as of immediately after the effective time of the Business Combination to be subject to transfer restrictions for a period of 180 days after the Closing Date, subject to certain exceptions.  As of the date of this Annual Report on Form 10-K, such transfer restrictions in effect for such 180 days have lapsed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Certain Relationships and Related Person Transactions &#x2014; BCTG</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Founders Shares</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On June 4, 2020, BCTG issued 3,593,750 shares of common stock to the Sponsor in exchange for a payment of $25,000. We refer to such issued shares in this Annual Report on Form 10-K as the Founder Shares. On September 2, 2020, BCTG declared a dividend of 0.16 shares for each outstanding share of common stock (an aggregate of 575,000 shares), resulting in an aggregate of 4,168,750 Founder Shares outstanding. The Sponsor had agreed to forfeit up to an aggregate of 543,750 Founders Shares, so that the Founders Shares would represent 20% of BTCG&#x2019;s issued and outstanding shares after BCTG&#x2019;s initial public offering, to the extent the underwriters&#x2019; over-allotment option was not exercised in full or in part. On September 8, 2020, the underwriters exercised their 15% over-allotment option in full; thus, the Founders Shares were no longer subject to forfeiture.  The Sponsor currently owns an aggregate of 4,493,450 shares of our common stock, and its independent directors and advisors collectively own 208,800 shares of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The initial stockholders have agreed not to transfer, assign or sell any of their Founders Shares (except to certain permitted transferees) until the earlier of (i) one year after the date of the consummation of the Business Combination or (ii) the date on which the closing price of our common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any 20 trading days within any 30-trading day period commencing at least 150 days after the Business Combination, or earlier if, subsequent to the Business Combination, we consummate a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of our stockholders having the right to exchange their shares of common stock for cash, securities or other property.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Private Shares</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Concurrently with the closing of BCTG&#x2019;s initial public offering, the Sponsor purchased 533,500 Private Shares, at a price of $10.00 per share, in a private placement for an aggregate purchase price of approximately $5.3 million. The Private Shares are identical to the shares of common stock sold in BCTG&#x2019;s initial public offering, subject to certain limited exceptions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Related Party Loans</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On May 21, 2020 and June 10, 2020, the Sponsor agreed to loan BCTG up to $25,025 and $274,975, respectively, for an aggregate amount of $300,000 to be used for the payment of costs related to BCTG&#x2019;s initial public offering pursuant to a promissory note, or each, a Note, and collectively, the Notes. The Notes were non-interest bearing, unsecured and due upon the date BCTG consummated its initial public offering. BCTG borrowed approximately $127,000 under the Notes and repaid the Notes in full on September 10, 2020.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In order to fund working capital deficiencies or finance transaction costs in connection with the Business Combination, the initial stockholders, officers and directors and their affiliates could have, but were not obligated to, loan BCTG funds as may be required, or the Working Capital Loans. Each loan would be evidenced by a promissory note. The notes would either be paid upon consummation of the Business Combination, without interest, or, at the lender&#x2019;s discretion, up to $1.5 million of the notes may be converted upon consummation of the Business Combination into additional private placement shares at a conversion price of $10.00 per share. If BCTG did not complete a business combination, the loans would not be repaid. Such private placement shares would be identical to the Private Shares. BCTG did not have any borrowings under the Working Capital Loans.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Administrative Support Agreement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Commencing on September 2, 2020, BCTG agreed to pay an affiliate of the Sponsor a total of $10,000 per month for office space and certain office and secretarial services. Upon completion of the Business Combination, BCTG ceased paying these monthly fees. For the period from May 21, 2020 (inception) through the completion of the Business Combination, BCTG</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">123</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">incurred approximately $110,000 related to these services. As of the date hereof, no amounts are payable related to this agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Share Purchase Commitment</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Sponsor entered into an agreement to purchase an aggregate of at least 2,500,000 shares of BCTG&#x2019;s common stock for an aggregate purchase price of $25.0 million, or $10.00 per share, prior to, concurrently with, or following the closing of the Business Combination in a private placement. The funds from such private placement could be used as part of the consideration to the sellers in the Business Combination, and any excess funds from such private placement may be used for working capital in the post-transaction company.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">PIPE Financing</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At Closing, PIPE Investors subscribed for and purchased an aggregate of 18,610,000 shares of Common Stock at a price of $10.00 per share for aggregate gross proceeds of $186,100,000.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Certain Relationships and Related Person Transactions &#x2014; Old Tango</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Series B Preferred Stock Financing</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On April 7, 2020, Old Tango entered into a Series B Preferred Stock Purchase Agreement, or the Series B Purchase Agreement, pursuant to which Old Tango issued 45,372,050 shares of its Series B Preferred Stock for a per share price of $1.3224, for aggregate gross proceeds in the amount of $60.0 million in two closings. The first closing of the Series B Preferred Stock financing occurred on April 7, 2020, and the second closing of the Series B Preferred Stock financing occurred on March 11, 2021. The following holders of more than 5% of Old Tango&#x2019;s capital stock participated in the Series B Preferred Stock financing.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.91%;"></td>
    <td style="width:1.322%;"></td>
    <td style="width:2.088%;"></td>
    <td style="width:0.636%;"></td>
    <td style="width:12.824%;"></td>
    <td style="width:0.636%;"></td>
    <td style="width:1.432%;"></td>
    <td style="width:2.008%;"></td>
    <td style="width:0.636%;"></td>
    <td style="width:11.214%;"></td>
    <td style="width:0.636%;"></td>
    <td style="width:1.223%;"></td>
    <td style="width:1.988%;"></td>
    <td style="width:0.636%;"></td>
    <td style="width:12.496%;"></td>
    <td style="width:0.636%;"></td>
    <td style="width:1.432%;"></td>
    <td style="width:1.76%;"></td>
    <td style="width:0.636%;"></td>
    <td style="width:11.214%;"></td>
    <td style="width:0.636%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Name of 5% Tango Stockholder</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of Series B Preferred Stock Purchased &#x2013; First Closing</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate Purchase Price &#x2013; First Closing</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of Series B Preferred Stock Purchased &#x2013; Second Closing</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate Purchase Price &#x2013; Second Closing</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Boxer Capital, LLC and affiliated entities(1)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,507,260</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,250,000</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,507,260</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,250,000</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Casdin Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,890,502</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,499,999</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,890,502</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,499,999</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cormorant Asset Management and affiliated entities(2)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,781,004</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,999,999</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,781,004</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,999,999</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1)    Includes Boxer Capital LLC, which purchased 8,417,650 shares at the first closing and 8,417,650 shares at the second closing; and MVA Investors, LLC, which purchased 89,610 shares at the first closing and 89,610 shares at the second closing. Aaron Davis, a member of our board of directors, is Chief Executive Officer of Boxer Capital, LLC. Boxer Capital, LLC and Mr. Davis are each affiliated with BCTG and the Sponsor.</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2)    Includes Cormorant Private Healthcare Fund II, LP, which purchased 3,027,828 shares at the first closing and 3,027,828 shares at the second closing; Cormorant Global Healthcare Master Fund, LP, which purchased 707,048 shares at the first closing and 707,048 shares at the second closing; and CRMA SPV, LP, which purchased 46,128 shares at the first closing and 46,128 shares at the second closing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Series B-1 Preferred Stock Financing</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On August 17, 2020, Old Tango held the closing of its Series B-1 Preferred Stock financing, pursuant to its Series B-1 Preferred Stock Purchase Agreement, or the Series B-1 Purchase Agreement, at which Old Tango issued 27,152,255 shares of its Series B-1 Preferred Stock for a per share price of $1.885, for aggregate gross proceeds in the amount of $51.2 million. The following holders of more than 5% of Old Tango&#x2019;s capital stock participated in the Series B-1 Preferred Stock financing.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:52.902%;"></td>
    <td style="width:1.829%;"></td>
    <td style="width:1.67%;"></td>
    <td style="width:0.646%;"></td>
    <td style="width:18.684%;"></td>
    <td style="width:0.646%;"></td>
    <td style="width:2.326%;"></td>
    <td style="width:2.336%;"></td>
    <td style="width:0.646%;"></td>
    <td style="width:17.67%;"></td>
    <td style="width:0.646%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Name of 5% Tango Stockholder</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of Series B-1<br />Preferred Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate Purchase Price</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Boxer Capital, LLC and affiliated entities(1)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,511,769</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,519,685</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Casdin Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,957,852</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,000,551</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cormorant Asset Management and affiliated entities(2)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,560,786</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,942,082</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gilead Sciences, Inc.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,610,079</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,999,999</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">124</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1)    Includes Boxer Capital LLC, which purchased 3,392,141 shares; and MVA Investors, LLC, which purchased 119,628 shares. Aaron Davis, a member of our Board of Directors, is Chief Executive Officer of Boxer Capital, LLC. Boxer Capital, LLC and Mr. Davis are each affiliated with BCTG and the Sponsor.</span></p>
  <p style="text-indent:-4.167%;padding-left:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2)    Includes Cormorant Private Healthcare Fund II, LP, which purchased 1,235,518 shares; and Cormorant Global Healthcare Master Fund, LP, which purchased 325,268 shares.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gilead Collaboration Agreement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2018, we entered into a Collaboration and License Agreement with Gilead Sciences, Inc. which collaboration was amended and restated on August 17, 2020, concurrently with the closing of the Series B-1 Preferred Stock financing in which Gilead Sciences, Inc. participated. Gilead Sciences, Inc. holds 5% or more of our capital stock. See the section titled &#x201c;Business &#x2014; Collaboration and License Agreements &#x2014; Collaboration and License Agreement with Gilead Sciences&#x201d; for more information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Investors Rights Agreement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the initial closing of the Series B Preferred Stock financing, Old Tango entered into an Amended and Restated Investors Rights Agreement, or the Investors Rights Agreement with certain of its investors, including its 5% stockholders. Pursuant to the Investors Agreement, the investors were granted certain demand and registration rights as well as certain information rights. In connection with the Merger, the Investors Rights Agreement was terminated at the closing of the Business Combination.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Voting Agreement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the initial closing of the Series B Preferred Stock financing, Old Tango entered into an Amended and Restated Voting Agreement, or the Voting Agreement with certain of its investors, including its 5% stockholders. Pursuant to the Investors Agreement, certain investors were given the right to designate certain members of Old Tango&#x2019;s board of directors. In connection with the Merger, the Voting Agreement was terminated at the closing of the Business Combination.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Indemnification Agreements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are party to indemnity agreements with our directors and executive officers. These agreements, among other things, require us to indemnify these individuals for certain expenses (including attorneys&#x2019; fees), judgments, fines and settlement amounts reasonably incurred by such persons in any action or proceeding, including any action by or in our right, on account of any services undertaken by such person on behalf of our company or that person&#x2019;s status as a member of our board of directors to the maximum extent allowed under Delaware law.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Policies for Approval of Related Party Transactions</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our Audit Committee reviews and approves transactions with directors, officers and holders of 5% or more our capital stock and their affiliates, or each, related party. Prior to the transaction, the material facts as to the related party&#x2019;s relationship or interest in the transaction are disclosed to our Audit Committee prior to their consideration of such transaction, and the transaction is not considered approved unless approved by the Audit Committee. Further, when stockholders are entitled to vote on a transaction with a related party, the material facts of the related party&#x2019;s relationship or interest in the transaction are disclosed to the stockholders, who must approve the transaction in good faith.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Policies and Procedures for Related Party Transactions</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have adopted a written related person transaction policy that sets forth the following policies and procedures for the review and approval or ratification of related person transactions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A &#x201c;Related Person Transaction&#x201d; is a transaction, arrangement or relationship in which we or any our subsidiaries was, is or will be a participant, the amount of which involved exceeds $120,000, and in which any related person had, has or will have a direct or indirect material interest. A &#x201c;Related Person&#x201d; means:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.901%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any person who is, or at any time during the applicable period was, one of our officers, directors or director nominee;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.901%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any person who is known by us to be the beneficial owner of more than 5% of our voting stock;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.901%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any immediate family member of any of the foregoing persons, which means any child, stepchild, parent, stepparent, spouse, sibling, mother-in-law, father-in-law, daughter-in-law, brother-in-law or sister-in-law of a director, officer or a beneficial owner of more than 5% of its voting stock, and any person (other than a tenant or employee) sharing the household of such director, officer or beneficial owner of more than five percent 5% of our voting stock; and</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.901%;"></td>
    <td style="width:3.016%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:91.081%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#149;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any firm, corporation or other entity in which any of the foregoing persons is a partner or principal or in a similar position or in which such person has a ten percent 10% or greater beneficial ownership interest.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have policies and procedures designed to minimize potential conflicts of interest arising from any dealings we may have with our affiliates and to provide appropriate procedures for the disclosure of any real or potential conflicts of interest that may exist from time to time. The audit committee has the responsibility to review related party transactions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Director Independence</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The rules of the Nasdaq require that a majority of our board of directors be independent. An &#x201c;independent director&#x201d; is defined generally as a person other than an executive officer or employee of our company or any other individual having a relationship which, in the opinion of our board of directors, would interfere with the exercise of independent judgement in carrying out the responsibilities of a director. Our board of directors has determined that each individual who serves on our board, other than Dr. Weber, qualifies as an independent director under the rules of Nasdaq and the SEC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;" id="item_14_principal_accounting_fees"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Ite</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">m 14. Principal Accountant Fees and Services</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the fees of PricewaterhouseCoopers LLP billed to us for each of the last two fiscal years for audit services and billed to us in each of the last two fiscal years for other services:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:84.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:37.509%;"></td>
    <td style="width:4.511%;"></td>
    <td style="width:4.724%;"></td>
    <td style="width:0.758%;"></td>
    <td style="width:20.59%;"></td>
    <td style="width:0.758%;"></td>
    <td style="width:4.511%;"></td>
    <td style="width:4.914%;"></td>
    <td style="width:0.758%;"></td>
    <td style="width:20.211%;"></td>
    <td style="width:0.758%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fee Category</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Audit Fees</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,775,000</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">635,000</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Audit-Related Fees</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax Fees</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">170,000</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,200</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All Other Fees</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,409</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,956</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total Fees</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,949,409</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">668,156</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Audit Fees.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   Audit fees consist of fees billed for the audit of our annual consolidated financial statements, review of the interim consolidated financial statements, and the review of registration statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Tax Fees.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   Tax fees consist of aggregate fees for tax compliance and tax analysis related services.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">All Other Fees.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   All other fees consist of fees for accounting research tools.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Audit Committee Pre-Approval Policy and Procedures</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Audit Committee has adopted a policy (the &#x201c;Pre-Approval Policy&#x201d;) that sets forth the procedures and conditions pursuant to which audit and non-audit services proposed to be performed by the independent auditor may be pre-approved. The Pre-Approval Policy generally provides that we will not engage PricewaterhouseCoopers LLP to render any audit, audit-related, tax or permissible non-audit service unless the service is either (i) explicitly approved by the Audit Committee (&#x201c;specific pre-approval&#x201d;) or (ii) entered into pursuant to the pre-approval policies and procedures described in the Pre-Approval Policy (&#x201c;general pre-approval&#x201d;). Unless a type of service to be provided by PricewaterhouseCoopers LLP has received general pre-approval under the Pre-Approval Policy, it requires specific pre-approval by the Audit Committee or by a designated member of the Audit Committee to whom the committee has delegated the authority to grant pre-approvals. Any proposed services exceeding pre-approved cost levels or budgeted amounts will also require specific pre-approval. For both types of pre-approval, the Audit Committee will consider whether such services are consistent with the SEC&#x2019;s rules on auditor independence. The Audit Committee will also consider whether the independent auditor is best positioned to provide the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">126</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">most effective and efficient service, for reasons such as its familiarity with the Company&#x2019;s business, people, culture, accounting systems, risk profile and other factors, and whether the service might enhance the Company&#x2019;s ability to manage or control risk or improve audit quality. All such factors will be considered as a whole, and no one factor should necessarily be determinative. On an annual basis, the Audit Committee reviews and generally pre-approves the services (and related fee levels or budgeted amounts) that may be provided by PricewaterhouseCoopers LLP without first obtaining specific pre-approval from the Audit Committee. The Audit Committee may revise the list of general pre-approved services from time to time, based on subsequent determinations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">127</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART IV</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15_exhibits_financial_statement"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 15. Exhibits, Financial Statement Schedules.</span></p>
  <p style="text-indent:-4.603%;padding-left:4.4%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1)	Financial Statements</span></p>
  <p style="text-indent:-4.603%;padding-left:4.4%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See the Index to the Consolidated Financial Statements section beginning on page F-1 of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:-4.646%;padding-left:4.44%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2)	Financial Statement Schedules</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All financial statement schedules have been omitted as they are not required, not applicable, or the required information is included in the financial statements or notes to the financial statements.</span></p>
  <p style="text-indent:-4.646%;padding-left:4.44%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(3)	Exhibits</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The exhibits required by Item 601 of Regulation S-K and Item 15(b) of this Annual Report on Form 10-K are listed in the Exhibit Index below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">128</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit Index</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.001%;"></td>
    <td style="width:2.024%;"></td>
    <td style="width:86.975%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.1&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Agreement and Plan of Merger, dated as of April 13, 2021, by and among BCTG Acquisition Corp., BCTG Merger Sub Inc. and Tango Therapeutics, Inc. (incorporated by reference to Annex A to the Proxy Statement/ Prospectus) forming a part of the Registration Statement on Form S-4/A filed by the Registrant on July 15, 2021).</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Second Amended and Restated Certificate of Incorporation of Tango Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to the Registrant&#x2019;s registration statement on Form S-1 filed with the SEC on September 10, 2021).</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Bylaws of Tango Therapeutics, Inc. (incorporated by reference to Exhibit 4.2 to the Registrant&#x2019;s registration statement on Form S-8 filed with the SEC on October 14, 2021).</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Specimen Common Stock Certificate of the Registrant (incorporated by reference to Exhibit 4.5 to the Registration Statement on Form S-4/A filed by the Registrant on July 15, 2021).</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="tngx-ex4_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Description of Securities.</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Form of Subscription Agreement, dated as of April 13, 2021 by and among BCTG Acquisition Corp. and certain institutional and accredited investors (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Registrant on April 14, 2021).</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.2</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Form of Lock-Up Agreement (incorporated by reference to Exhibit D to Exhibit 2.1).</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.3</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Registration and Stockholder Rights Agreement, dated August 10, 2021, by and among Tango Therapeutics, Inc. and the stockholders party thereto (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed by the Registrant on August 13, 2021).</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.4&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Research Collaboration and License Agreement between Tango Therapeutics, Inc. and Gilead Sciences, Inc., dated August 17, 2020 (incorporated by reference to Exhibit 10.19 to the Registration Statement on Form S-4/A filed by the Registrant on June 17, 2021).</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.5&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">License Agreement between Tango Therapeutics, Inc. and Medivir AB, dated March 12, 2020 (incorporated by reference to Exhibit 10.20 to the Registration Statement on Form S-4/A filed by the Registrant on June 17, 2021).</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.6#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tango Therapeutics, Inc. 2021 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K filed by the Registrant on August 13, 2021).</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.7#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forms of Award Agreements under the Tango Therapeutics, Inc. 2021 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.5 to the Current Report on Form 8-K filed by the Registrant on August 13, 2021).</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.8#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tango Therapeutics, Inc. 2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.6 to the Current Report on Form 8-K filed by the Registrant on August 13, 2021).</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.9#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Form of Executive Employment Agreement (incorporated by reference to Exhibit 10.7 to the Current Report on Form 8-K filed by the Registrant on August 13, 2021).</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.10</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-Employee Director Compensation Policy (incorporated by reference to Exhibit 10.8 to the Current Report on Form 8-K filed by the Registrant on August 13, 2021).</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.11</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Form of Indemnification Agreement (Directors) (incorporated by reference to Exhibit 10.9 to the Current Report on Form 8-K filed by the Registrant on August 13, 2021).</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.12#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Form of Indemnification Agreement (Officers) (incorporated by reference to Exhibit 10.10 to the Current Report on Form 8-K filed by the Registrant on August 13, 2021).</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.13#</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Senior Executive Cash Annual Incentive Plan (incorporated by reference to Exhibit 10.11 to the Current Report on Form 8-K filed by the Registrant on August 13, 2021).</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.14</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="tngx-ex10_14.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Lease Agreement between the Company and ARE-MA Region No. 87 Tenant, LLC dated as of November 4, 2021</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Letter dated August 13, 2021 from Withum to the SEC (incorporated by reference to Exhibit 16.1 to the Current Report on Form 8-K filed by the Registrant on August 13, 2021).</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.1</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">List of subsidiaries of Tango Therapeutics, Inc. (incorporated by reference to Exhibit 4.5 to the Registration Statement on Form S-4/A filed by the Registrant on July 15, 2021).</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="tngx-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm of Tango Therapeutics, Inc.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Power of Attorney (included on signature page hereto).</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31.1*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="tngx-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">129</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.001%;"></td>
    <td style="width:2.024%;"></td>
    <td style="width:86.975%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31.2*</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="tngx-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32.1**</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="tngx-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32.2**</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="tngx-ex32_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.INS</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Instance Document &#x2013; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.SCH</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.CAL</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.DEF</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.LAB</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.PRE</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">*	Filed herewith.</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">&#134;        Portions of this exhibit (indicated by asterisks) have been omitted in accordance with Item 601(b)(10) of Regulation S-K.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">#	Indicates a management contract or any compensatory plan, contract or arrangement.</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">+	Portions of this exhibit (indicated by brackets and asterisks) have been omitted because the registrant has determined that the information is both not material and is the type that the registrant treats as private or confidential.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">**      The certifications furnished in Exhibit 32 hereto are deemed to be furnished with this Annual Report on Form 10-K and will not be deemed to be &#x201c;filed&#x201d; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference. <br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16_form_10_k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">It</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">em 16. Form 10-K Summary</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">130</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SIGNATURES</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.243%;"></td>
    <td style="width:2.823%;"></td>
    <td style="width:5.667%;"></td>
    <td style="width:46.267%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tango Therapeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 28, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Barbara Weber</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Barbara Weber, MD</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">POWER OF ATTORNEY</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Each person whose individual signature appears below hereby authorizes and appoints Barbara Weber, Daniella Beckman and Douglas Barry, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this annual report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.976%;"></td>
    <td style="width:1.042%;"></td>
    <td style="width:43.304%;"></td>
    <td style="width:1.042%;"></td>
    <td style="width:21.637%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Title</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Date</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Barbara Weber</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">President and Chief Executive Officer, Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 28, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Barbara Weber, MD</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;(Principal Executive Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Daniella Beckman</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Chief Financial Officer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;March 28, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Daniella Beckman</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;(Principal Financial Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Alexis Borisy</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Chairman of the Board of Directors</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;March 28, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Alexis Borisy</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Lesley Ann Calhoun</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;March 28, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Lesley Ann Calhoun</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Aaron Davis</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;March 28, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aaron Davis</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Reid Huber</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;March 28, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Reid Huber, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Malte Peters</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;March 28, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Malte Peters, MD</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Mace Rothenberg</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;March 28, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Mace Rothenberg, MD</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">131</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92.004%;"></td>
    <td style="width:7.996%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Page</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p><p style="border-top:1.000pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#auditorsreport"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Report of Independent Registered Public Accounting Firm (PCAOB ID </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8fbec538-8d0b-4847-bcf3-6870bd0b818d" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">238</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Balance Sheets</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_stmt_of_operations_and_com"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_redeemable"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#x2019; Equity (Deficit)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_of_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Cash Flows</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_consolidated_financial_stmts"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.100in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="auditorsreport"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Report of Independent Registered Public Accounting Firm</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the Board of Directors and Stockholders of Tango Therapeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Opinion on the Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have audited the accompanying consolidated balance sheets of Tango Therapeutics, Inc. and its subsidiaries (the &#x201c;Company&#x201d;) as of December 31, 2021 and 2020, and the related consolidated statements of operations and comprehensive loss, of redeemable convertible preferred stock and stockholders&#x2019; equity (deficit), and of cash flows for the years then ended, including the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis for Opinion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These consolidated financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on the Company&#x2019;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9ce67f27-0312-41e4-a1c4-2acc59f21dd1" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PricewaterhouseCoopers LLP</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_143a542d-ffc3-4459-a7f5-2aa932e0b155" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Boston, Massachusetts</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 28, 2022</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(255,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have served as the Company's auditor since 2017.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="fin118907_18"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">TANGO THERAPEUTICS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CONSOLIDATED </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">BALANCE SHEETS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(In thousands, except share and per share amounts)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:63.367%;"></td>
    <td style="width:1.759%;"></td>
    <td style="width:1.163%;"></td>
    <td style="width:14.609%;"></td>
    <td style="width:0.785%;"></td>
    <td style="width:1.759%;"></td>
    <td style="width:1.163%;"></td>
    <td style="width:14.609%;"></td>
    <td style="width:0.785%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Current assets:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_99a21c5d-22bf-4ddf-9b1a-9d4b17cfcf4c" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">142,745</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4e038a5d-62ec-4e38-b92f-e6931f914364" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,381</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Marketable securities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aa74e5c4-fa98-40ed-a75f-0b0029548dd5" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">342,510</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ee6627ee-f973-4ce0-a051-3a87c379d58f" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">161,939</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accounts receivable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_501e5a71-cc76-4e16-acdf-7ca6c9cd8269" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ec5bb0fc-2ac7-4134-95d8-c942d206bc5a" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Restricted cash</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0ffb221d-a52c-48f7-93d1-a7407dd0333f" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">567</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_2d6d8938-d6e5-45f5-9e08-f42fea8356b9;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_49e78aa5-8466-4f27-94fb-150f93f8dac9" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,516</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0f848ba7-c91a-4f84-84a2-43ca23fb56f8" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,312</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total current assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f1c3066e-21f8-4548-b162-269d054470c4" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">492,338</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_90b7cca5-5740-4e27-bd2f-c56ff548b1ae" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">193,632</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_933edb8d-7f7d-493e-85e7-2cf4a9907950" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,832</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1a29e774-85f5-48d0-8b35-9d8cea06ed1f" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,823</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Operating lease right-of-use assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_726d5781-3e32-4727-ae21-376a9d078d6a" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,254</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_879f780a-3d76-4c51-aa6b-d14bbc832c4e" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,480</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Restricted cash, net of current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_401ed779-421a-44ff-b31b-8648ef63311b" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,712</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_557cce34-0a38-4658-b089-8d89470049cd" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,279</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Other assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7410bb02-de3c-4e9e-8099-966a8bac6061" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_721e824a-51a9-46bc-a6b9-097a50b8c32d" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fa439791-cb6a-4b83-a450-686fce7feb15" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">500,155</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_52f35b99-45c2-4cf7-b4df-a0c48e923bd6" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">207,252</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Liabilities and Stockholders' Equity</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accounts payable</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_23c2de81-5e16-4fa2-9f7f-4d4308ba2573" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,226</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ed7c8c61-103a-4e64-b610-2c110fa00209" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,841</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accrued expenses and other current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_84299689-ee72-4a48-a64e-f981ac19b5ae" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="tngx:AccruedExpensesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,887</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_55c7a836-8fac-44bb-a7fa-f7a1bacffe45" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="tngx:AccruedExpensesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,140</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Operating lease liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_90cbf797-76f5-4bcb-b85d-3dc3d8adc0a3" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,503</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e604b740-66f3-4f04-ad89-3a8b43ec97fa" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">959</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Deferred revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e2f1f2ac-bf3a-42e9-a678-eb5cff847ebf" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,022</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f88c7b60-6091-4389-89f3-03fba2f9cf2a" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31,977</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Income tax payable</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_09660582-bd63-465e-86a8-f980b5003bd4" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:TaxesPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">52</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5074d751-7d32-41a0-9e38-808944bfee13" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,690</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ddcf1e87-0e41-4f7a-acb6-303f73fa5073" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,917</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Operating lease liabilities, net of current portion</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e5b74981-6b5d-4430-98fc-07bb818a1783" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,925</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Deferred revenue, net of current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c216d760-2f2a-4a2c-aaed-9c4cb004522c" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">114,718</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8e755994-7dfe-4b75-b9dc-f7218aaa9830" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">120,805</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Other long-term liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6797c562-9f21-408b-9e5b-b45f46d76fae" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6be0b411-a4d9-4012-aa17-444bae617be6" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">155,408</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cdcf267f-9b51-452a-8c13-564cb341e03a" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">168,652</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_ef89b0d7-d3bc-47bb-b18c-a3ef93b3d967;"><span style="-sec-ix-hidden:F_589030a1-b1fe-41c2-9818-779e165f6c4e;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Commitments and contingencies (Note 9)</span></span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Preferred stock, $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6913b509-fa90-44f8-909d-d71909c7bae7" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_be3a7f24-1aa9-4bd2-88fb-1936a36c5458" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;par value; </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_127afb8a-9d36-464f-9faa-9d9f177e0579" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_1d06ec31-91d8-4c3f-b876-0fbdeadfc749" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;shares authorized; </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_86dddb98-e5db-4eb3-8e23-1ee6d6054b31" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_bd3b4620-04fa-4caf-aa8e-a60880f9e910" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_cee1591d-4ed4-4712-aa56-2f2b786c8ea9" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_6bb264ef-fd30-4d5d-96b8-d2047af30d66" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;shares issued<br />&#160;&#160;&#160;and outstanding as of December 31, 2021 and 2020, respectively</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab66cb03-ff58-4982-8364-4b9878250c6e" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ebcb7f52-2f15-4f64-a75d-62fe80675fb5" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Stockholders' equity:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Common stock, $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_189e8340-441b-4fd4-976f-47b68e876119" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_f316d390-fc8a-4205-987c-f2e8c8d18dd1" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;par value; </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fda5f06c-359d-4375-8bda-0d4bb6079891" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;and </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2d24a0e6-6bdb-4e89-ad18-cca209afe94d" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">56,393,261</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;shares<br />&#160;&#160;&#160;authorized at December 31, 2021 and December 31, 2020, respectively;<br />&#160;&#160;&#160;</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2a8b96c7-f7d9-4b3c-9414-8f48e9d3cb4e" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_4b062acf-b302-434c-acf9-c60300fa9d97" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">87,598,184</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;and </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2416c1d1-9896-4bb9-af68-8f65c6f6d32b" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_b5d15bbb-56b9-4725-9204-03239102c6f7" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">40,372,133</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;shares issued and outstanding as of December 31,<br />&#160;&#160;&#160;2021 and 2020, respectively</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1792060f-df75-462c-8c22-e25a6273781e" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">88</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0e4ee8a6-0763-4eba-a333-cd51b81d5620" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_85ef8028-ae65-4a60-bc39-228a5af99ebd" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">506,760</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1bd5ab86-a1d1-403b-8ef5-7f8c4a093bc6" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">141,644</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accumulated other comprehensive (loss) income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f5ee2969-db63-4e91-a2b4-68e60d838e38" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">765</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9f48f0c3-f03c-49ba-972a-f6f11b595721" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3c0ae622-4a62-4876-802c-f127ea322c02" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">161,336</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ceb2fd35-762a-4e1a-996d-230c174ca901" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">103,101</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e8bbcfeb-3c87-4e52-8904-93c9e30a2d83" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">344,747</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9a0ff121-b7b0-47b6-a89e-3b89cde4eeb6" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,600</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total liabilities and stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ad906677-40d3-4014-919d-ee3117fb6767" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">500,155</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2c49d74c-9708-4987-9d7e-755600662159" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">207,252</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying notes are an integral part of the consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="fin118907_19"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">TANGO THERAPEUTICS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_stmt_of_operations_and_com"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CONSOLIDATED STATEMENTS OF OPE</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">RATIONS AND COMPREHENSIVE LOSS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands, except share and per share amounts)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:62.061%;"></td>
    <td style="width:1.7%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:15.406%;"></td>
    <td style="width:0.865%;"></td>
    <td style="width:1.7%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:14.839%;"></td>
    <td style="width:0.865%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Collaboration revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2ab7f0c2-0f14-4409-be73-46e2555c3ac7" contextRef="C_322de39d-6bc1-437f-9811-2ddb0203f034" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,042</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_04e0638d-c8f9-47bb-ba26-7a33a84adb1f" contextRef="C_37b91a95-e41f-4fd5-94cf-030951f28c96" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,972</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">License revenue</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_54afb518-f3e6-4410-8997-dbf365024ad9" contextRef="C_1a530332-b4e5-472d-a36a-9992e15ee630" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e85e39f5-6786-4d0a-ae73-645d7c10ff4b" contextRef="C_d8f1f3f0-246b-4352-862d-987a0d66c18f" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">684</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_686ea652-4ebd-4361-acf7-92a576da1616" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,042</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ee4fd431-8188-47c5-9589-aa727e78d388" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,656</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_184c89f0-6205-4597-b1d2-b25fd082ea0c" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">77,636</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d56846bc-01c2-4511-9579-74b172c32f40" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49,991</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dd02bcda-5574-45b2-b0be-0efa1747dd6f" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,596</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1fdf8e0a-8b15-4060-a090-ae50ffa37f44" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,865</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_db668361-2c70-48b3-a827-e73c33ecbb22" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">95,232</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e4390524-a0d7-4d92-8eae-fcd5f31b7038" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">59,856</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss from operations</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_06dc9e83-9991-4b16-bb8f-371138f1c269" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">58,190</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f74c2ad2-474b-4319-a3c0-0ccf0f0f12b7" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">52,200</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other income (expense):</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9324c653-1f1a-4631-bb99-46d73b10d75a" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:InterestIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">495</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9dc6ce5a-3982-47a4-ac02-f860a7cd46cb" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:InterestIncomeExpenseNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">108</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other (expense) income, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f966c34b-15bd-44e0-9cbb-e7d9abfbec66" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">248</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1f7f1844-dab5-4669-a43f-fe003fcef03d" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">120</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total other income, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d7bbd4fd-c3ed-4caf-ba01-a90144ee06ab" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">247</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9aeb3eed-c2a2-4de9-b586-f3d8258d0096" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">228</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss before income taxes</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1e7ab17f-5f60-4288-87eb-651652081dbc" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">57,943</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e1cc0fd9-fa89-4886-9a2f-88bc2d58190f" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">51,972</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provision for income taxes</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b8a3c093-cbd2-45ef-a658-d909718fcb5b" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">292</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cf6c785c-678d-4830-b62b-528219f9b376" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">58,235</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_754d6f30-a06a-4448-8057-645b07fdb836" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">51,972</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per common share &#x2013; basic and diluted</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_393522f9-9176-4ea1-bfd0-ccabb7b53b92" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">0.94</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_291e5ac9-f239-48a5-bb57-ab54621ea3cd" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">1.63</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted average number of common shares outstanding &#x2013; basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dfe6aacd-5426-4105-942e-78832d1b244d" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">62,108,032</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1df196de-b4c0-40ab-80b1-fe1ca48f4b4d" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">31,932,204</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d0f3052f-4c9d-498b-a151-eef4ec441902" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">58,235</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_10551165-37f4-4237-b548-2c9496afb2a9" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">51,972</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other comprehensive (loss) income:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unrealized (loss) gain on marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d2402e84-397b-4a8b-babf-5f166a6896e1" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">782</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_188b92a9-533d-4dfd-95af-4f7e066b90cb" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Comprehensive loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_20f432c1-e7f2-4b5f-afc1-bf9a0ffcf96f" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">59,017</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7083c7e9-1b77-4007-853b-1de24066be86" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">51,965</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying notes are an integral part of the consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="fin118907_20"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">TANGO THERAPEUTICS, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_of_redeemable"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> PREFERRED STOCK AND STOCKHOLDERS&#x2019; EQUITY (DEFICIT)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands, except share amounts)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:15.094%;"></td>
    <td style="width:0.725%;"></td>
    <td style="width:0.373%;"></td>
    <td style="width:5.453%;"></td>
    <td style="width:0.49%;"></td>
    <td style="width:0.725%;"></td>
    <td style="width:0.732%;"></td>
    <td style="width:5.036%;"></td>
    <td style="width:0.49%;"></td>
    <td style="width:0.725%;"></td>
    <td style="width:0.373%;"></td>
    <td style="width:5.453%;"></td>
    <td style="width:0.49%;"></td>
    <td style="width:0.725%;"></td>
    <td style="width:0.732%;"></td>
    <td style="width:5.036%;"></td>
    <td style="width:0.49%;"></td>
    <td style="width:0.725%;"></td>
    <td style="width:0.373%;"></td>
    <td style="width:5.453%;"></td>
    <td style="width:0.49%;"></td>
    <td style="width:0.725%;"></td>
    <td style="width:0.732%;"></td>
    <td style="width:5.036%;"></td>
    <td style="width:0.49%;"></td>
    <td style="width:0.351%;"></td>
    <td style="width:0.351%;"></td>
    <td style="width:0.373%;"></td>
    <td style="width:5.446%;"></td>
    <td style="width:0.49%;"></td>
    <td style="width:0.725%;"></td>
    <td style="width:0.732%;"></td>
    <td style="width:5.139%;"></td>
    <td style="width:0.373%;"></td>
    <td style="width:0.725%;"></td>
    <td style="width:0.732%;"></td>
    <td style="width:5.6%;"></td>
    <td style="width:0.373%;"></td>
    <td style="width:0.725%;"></td>
    <td style="width:0.805%;"></td>
    <td style="width:5.541%;"></td>
    <td style="width:0.49%;"></td>
    <td style="width:0.725%;"></td>
    <td style="width:0.739%;"></td>
    <td style="width:5.08%;"></td>
    <td style="width:0.49%;"></td>
    <td style="width:0.725%;"></td>
    <td style="width:0.769%;"></td>
    <td style="width:4.839%;"></td>
    <td style="width:0.49%;"></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="22" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">Redeemable Convertible Preferred Stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">Accumulated<br />Other</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">Series A</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">Series B</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">Series B-1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">Common Stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">Additional</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">Comprehensive</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">Total</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">Paid-in<br />Capital</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">Income<br />(Loss)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">Accumulated<br />Deficit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:Times New Roman;">Stockholders&#x2019;<br />Equity (Deficit)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Balance at December 31, 2019</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dcd1398a-cb95-4375-be6f-2608df362d36" contextRef="C_58f962d5-8219-4b47-8029-390de4ce2191" name="tngx:TemporaryEquitySharesOutstandingBeforeRetroactiveApplicationOfRecapitalization" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">55,700,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_da361afe-4d2a-459d-a8e5-b96c275a8f93" contextRef="C_58f962d5-8219-4b47-8029-390de4ce2191" name="tngx:TemporaryEquityBeforeRetroactiveApplicationOfRecapitalization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,700</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ac900e21-4726-4a7b-9ffa-60a3842533e9" contextRef="C_62d30997-cb59-4c36-9293-3ab9037d2139" name="tngx:SharesOutstandingBeforeRetroactiveApplicationOfRecapitalization" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,530,115</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a1bef661-e898-4612-9d89-75f43585febe" contextRef="C_62d30997-cb59-4c36-9293-3ab9037d2139" name="tngx:StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_67b57927-a9a3-4d22-b6cb-28e6251f2e78" contextRef="C_ce0aba6c-cd66-4a8d-9e8d-6cfea6fd49bf" name="tngx:StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,319</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aeaefe2c-2974-41e4-a210-8b2aace45478" contextRef="C_fe8c0009-60fd-45e6-bf12-78e38e33e502" name="tngx:StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_48ac2206-7b8f-44c9-8a25-b224d82a6162" contextRef="C_50e1ee41-b3b0-4fe2-b580-591e5b4ec3aa" name="tngx:StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">51,129</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4cbe3a95-d80b-4621-84a0-5b93c5f20e53" contextRef="C_4a669c96-a649-4a8a-b346-1cb396dbfc42" name="tngx:StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">47,795</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Retrospective application of recapitalization</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_391d0d8a-28d7-4582-8b8d-b3c3e1c52fe6" contextRef="C_58f962d5-8219-4b47-8029-390de4ce2191" name="tngx:TemporaryEquityRetroactiveApplicationOfRecapitalizationShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">55,700,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2faefb1c-ed4b-4968-a1d4-14e1e10f9104" contextRef="C_58f962d5-8219-4b47-8029-390de4ce2191" name="tngx:TemporaryEquityRetroactiveApplicationOfRecapitalization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,700</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_002f5faa-ed44-4f60-837d-1b5a0cb16be8" contextRef="C_62d30997-cb59-4c36-9293-3ab9037d2139" name="tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">18,922,317</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1c5b1ebe-8d9e-4919-a2eb-ee9e681e932e" contextRef="C_62d30997-cb59-4c36-9293-3ab9037d2139" name="tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_80878604-b602-4ea8-b400-79dd9c3372a3" contextRef="C_ce0aba6c-cd66-4a8d-9e8d-6cfea6fd49bf" name="tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,681</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0f9075bb-3603-4f8f-bdaa-5d6de311b41b" contextRef="C_4a669c96-a649-4a8a-b346-1cb396dbfc42" name="tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,700</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Recasted balance as of December 31, 2019</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b3b126ea-600e-49c7-b5a1-ae996ea7da92" contextRef="C_62d30997-cb59-4c36-9293-3ab9037d2139" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">23,452,432</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7e0a7387-cfed-4f4b-a1fa-f24bbc78aa95" contextRef="C_62d30997-cb59-4c36-9293-3ab9037d2139" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_428ada76-46ae-47ab-8de3-dd83b207960e" contextRef="C_ce0aba6c-cd66-4a8d-9e8d-6cfea6fd49bf" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">59,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_64cf6f47-177e-449e-8658-983f0da22745" contextRef="C_fe8c0009-60fd-45e6-bf12-78e38e33e502" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bb0e92cd-36f1-4cc1-9dc9-3a81b5ab2432" contextRef="C_50e1ee41-b3b0-4fe2-b580-591e5b4ec3aa" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">51,129</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2654a7a7-30ff-479a-8a9c-3d03b9899923" contextRef="C_4a669c96-a649-4a8a-b346-1cb396dbfc42" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,905</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Issuance of Series B redeemable convertible<br />&#160;&#160;&#160;preferred stock, net of issuance costs of less<br />&#160;&#160;&#160;than $</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a70e356e-aaa4-4717-b45a-7eb8f40e6861" contextRef="C_d04e6201-772a-4ebf-bcb7-57256a6b7980" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#160;million</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6998b12d-cec9-4499-9c31-921230e01a7a" contextRef="C_d04e6201-772a-4ebf-bcb7-57256a6b7980" name="tngx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">22,686,025</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b31c0c9d-9bfe-470f-8129-1196a5aaf6a6" contextRef="C_d04e6201-772a-4ebf-bcb7-57256a6b7980" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,761</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Retroactive application of recapitalization</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_96e42a81-0ba2-4de6-a172-dc010b4084ae" contextRef="C_d04e6201-772a-4ebf-bcb7-57256a6b7980" name="tngx:TemporaryStockRetroactiveApplicationOfRecapitalizationShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">22,686,025</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_678c0203-2493-42a8-a990-afa562b7b79b" contextRef="C_d04e6201-772a-4ebf-bcb7-57256a6b7980" name="tngx:TemporaryStockRetroactiveApplicationOfRecapitalization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,761</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c14c99fc-129d-4db9-b8a2-7e0ee3387cbf" contextRef="C_42c26e7c-eca8-426f-9a02-4c53841db8ca" name="tngx:RetroactiveApplicationOfRecapitalizationShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,706,861</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d44b778b-445b-41b3-a68d-4bb042fd14f6" contextRef="C_42c26e7c-eca8-426f-9a02-4c53841db8ca" name="tngx:RetroactiveApplicationOfRecapitalization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_789f3fec-d46d-42f2-aa56-fd88cb563076" contextRef="C_f8e74028-ee7b-40aa-bbb2-cc9236784ca2" name="tngx:RetroactiveApplicationOfRecapitalization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,753</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_19a66ade-aa60-4570-ad90-28280a5be4ca" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="tngx:RetroactiveApplicationOfRecapitalization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,761</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Issuance of Series B-1 redeemable convertible<br />&#160;&#160;&#160;preferred stock, net of issuance costs of less<br />&#160;&#160;&#160;than $</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_90acff59-cfc5-4936-aa87-f95c06a695f3" contextRef="C_939c93ab-b292-4ae8-9554-f6d1ea202292" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#160;million</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fc8318c3-aca0-4891-803a-f3a584b94b3f" contextRef="C_939c93ab-b292-4ae8-9554-f6d1ea202292" name="tngx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">27,152,255</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d6f9ceec-4cf5-40c6-a554-b89479698ed5" contextRef="C_939c93ab-b292-4ae8-9554-f6d1ea202292" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">51,083</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Retroactive application of recapitalization</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_53d71478-6fe6-42e7-9cf2-ef01a360ed02" contextRef="C_939c93ab-b292-4ae8-9554-f6d1ea202292" name="tngx:TemporaryStockRetroactiveApplicationOfRecapitalizationShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">27,152,255</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3137c6f9-7453-4489-8ba0-8370bd731117" contextRef="C_939c93ab-b292-4ae8-9554-f6d1ea202292" name="tngx:TemporaryStockRetroactiveApplicationOfRecapitalization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">51,083</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_62f6e394-6776-4ec5-9d24-518f0461c717" contextRef="C_42c26e7c-eca8-426f-9a02-4c53841db8ca" name="tngx:RetroactiveApplicationOfRecapitalizationSharesOne" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">9,224,122</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_433481f0-6a29-4ec2-8398-4a7c0fbbb2eb" contextRef="C_42c26e7c-eca8-426f-9a02-4c53841db8ca" name="tngx:RetroactiveApplicationOfRecapitalizationOne" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_54f59faa-b996-481b-a15d-bda12305b2b4" contextRef="C_f8e74028-ee7b-40aa-bbb2-cc9236784ca2" name="tngx:RetroactiveApplicationOfRecapitalizationOne" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">51,075</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_09c09368-8f15-42b3-8757-d7b5e52a4b48" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="tngx:RetroactiveApplicationOfRecapitalizationOne" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">51,083</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Vesting of restricted common<br />&#160;&#160;&#160;stock awards</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_98d4a42c-6367-4eef-9201-4d7ccc7696e7" contextRef="C_f8e74028-ee7b-40aa-bbb2-cc9236784ca2" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aa68538b-557c-4b09-a67e-681245d71c67" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ef2faa70-2fd5-4ae5-ba34-0e78f93708c9" contextRef="C_42c26e7c-eca8-426f-9a02-4c53841db8ca" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">27,813</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5b7178ba-914c-4bdb-8d86-bcc42a353106" contextRef="C_f8e74028-ee7b-40aa-bbb2-cc9236784ca2" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_db9ed9de-c470-414f-aee6-79877cc698f0" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Repurchases of restricted common<br />&#160;&#160;&#160;stock awards</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7e0a3a38-4dfb-496a-9404-86f64ac4f1fb" contextRef="C_42c26e7c-eca8-426f-9a02-4c53841db8ca" name="us-gaap:StockRepurchasedDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">39,095</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Stock based compensation expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_87dba0f1-932a-407c-8a85-a1f6e6c5ae95" contextRef="C_f8e74028-ee7b-40aa-bbb2-cc9236784ca2" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,764</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_db18fcae-16d9-41d7-803e-e6430c7a81b0" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,764</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Other comprehensive income</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_069f48ed-51e7-4fd9-8d0d-d091e87e641b" contextRef="C_088edbda-4c95-4fa9-9856-74af91d7facd" name="us-gaap:OtherComprehensiveIncomeLossTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9cddd0c7-b962-41ac-85c9-d006504dc6c4" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:OtherComprehensiveIncomeLossTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ee15d893-c644-476b-beed-f9f12220db1d" contextRef="C_e1cb9353-41dd-47bf-b30c-2b16642be52c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">51,972</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8393a688-70c7-4d47-948a-be0a89b1c149" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">51,972</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab521929-728c-489f-bdf4-7fcbe79b3bbf" contextRef="C_fdf14edc-6cd9-4108-8f54-a48f0e34f4c2" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">40,372,133</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_81ae7846-f311-48da-9730-3b36b69a5753" contextRef="C_fdf14edc-6cd9-4108-8f54-a48f0e34f4c2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c5f2f1cb-0401-4c1b-8069-c064ec812425" contextRef="C_cb1f4de9-e84a-4dfa-b4b7-550c176b4251" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">141,644</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4a5223f4-2ec6-4b4d-bb0b-dac2bd1a5bba" contextRef="C_68e2d926-73f9-4065-8798-88999cfc5071" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0788c9ca-9bac-457a-905a-db4c97196c10" contextRef="C_1018e487-acae-48dc-9a83-1bc597615eb9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">103,101</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d56f29ce-00fd-457e-b620-2f0e9afd2632" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,600</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Issuance of Series B redeemable<br />&#160;&#160;&#160;convertible preferred stock, net<br />&#160;&#160;&#160;of issuance costs of $</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_137e8aba-d828-4610-8c18-ec4d15f66f95" contextRef="C_bc1dd469-9b82-45a6-89fd-03f80ff198f8" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#160;million</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_21d9ee4d-b77c-488e-aeb3-08229019b761" contextRef="C_bc1dd469-9b82-45a6-89fd-03f80ff198f8" name="tngx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">22,686,025</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b39edfbf-d903-4f87-a95f-1e1a55b81aa3" contextRef="C_bc1dd469-9b82-45a6-89fd-03f80ff198f8" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,990</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Retroactive application of recapitalization</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e25c9582-d714-4862-a833-a04c223dbbf7" contextRef="C_bc1dd469-9b82-45a6-89fd-03f80ff198f8" name="tngx:TemporaryStockRetroactiveApplicationOfRecapitalizationShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">22,686,025</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_814e84bd-5dc9-4195-ab6f-a527b8e84add" contextRef="C_bc1dd469-9b82-45a6-89fd-03f80ff198f8" name="tngx:TemporaryStockRetroactiveApplicationOfRecapitalization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,990</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_feeccf46-eaf0-400c-9b66-bbab00abaa49" contextRef="C_355ebba5-ee81-4e5b-b3ac-c79944317418" name="tngx:RetroactiveApplicationOfRecapitalizationShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,706,861</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_50f29c5c-b153-45f3-a70c-a7452354ff69" contextRef="C_355ebba5-ee81-4e5b-b3ac-c79944317418" name="tngx:RetroactiveApplicationOfRecapitalization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ee140c1f-0d43-4218-8233-9fb82743507d" contextRef="C_44358ddc-7505-46e1-8119-f33db1fa516a" name="tngx:RetroactiveApplicationOfRecapitalization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,982</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_33f3a454-f082-4764-9e4b-79d78ced5132" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="tngx:RetroactiveApplicationOfRecapitalization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,990</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Shares issued in Business Combination and PIPE<br />&#160;&#160;&#160;Financing, net of issuance costs of $</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6f91935a-af05-44e5-991d-ef61843371b2" contextRef="C_355ebba5-ee81-4e5b-b3ac-c79944317418" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#160;million</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_84ca698d-f15d-4d47-8c0a-b891250c535b" contextRef="C_355ebba5-ee81-4e5b-b3ac-c79944317418" name="tngx:StockIssuedDuringPeriodSharesAcquisitionsAndPrivateInvestments" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">38,880,436</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4401150a-6c6a-499f-adb8-0f4b3764d386" contextRef="C_355ebba5-ee81-4e5b-b3ac-c79944317418" name="tngx:StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">39</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_675b6e67-44e4-4d60-988f-b290a3737bfb" contextRef="C_44358ddc-7505-46e1-8119-f33db1fa516a" name="tngx:StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">326,238</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_167f0d10-f69c-4a41-90e6-f9596437a08f" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="tngx:StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">326,277</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cfe2b58c-be6d-4486-b83f-a0036ebedd71" contextRef="C_355ebba5-ee81-4e5b-b3ac-c79944317418" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">638,754</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_91fd5f33-b9ce-4cc6-943f-8971aa521e40" contextRef="C_355ebba5-ee81-4e5b-b3ac-c79944317418" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_39171d90-90cf-447a-8d62-8f43c796955b" contextRef="C_44358ddc-7505-46e1-8119-f33db1fa516a" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,057</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c05168e1-5d47-4b00-8fef-c65d57be7604" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,058</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Vesting of restricted common<br />&#160;&#160;&#160;stock awards</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3cba5d27-e6e1-44e2-a87a-b39c84f124a2" contextRef="C_44358ddc-7505-46e1-8119-f33db1fa516a" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_91ea28eb-17bb-45d5-95b7-5176e99d36ec" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Stock based compensation expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_94b1a056-eed4-45e2-8cfc-d253cd5946c5" contextRef="C_44358ddc-7505-46e1-8119-f33db1fa516a" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,833</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a62b5b51-c3ab-4b3b-9e74-b3b9a35a997a" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,833</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Other comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ceef4420-910a-429b-8cca-e4bd7081e625" contextRef="C_c17d0f8f-c6ae-43cd-9b51-09d002c47c3f" name="us-gaap:OtherComprehensiveIncomeLossTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">782</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_739f82db-2c8e-4612-9873-283fe9638082" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:OtherComprehensiveIncomeLossTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">782</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fae5f4ce-1ee7-4aec-8658-d83c98e2b6b6" contextRef="C_39540783-7152-4a82-98d0-fe1bcc069278" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">58,235</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_36d5e686-0166-4edd-ac55-f27dd101355c" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">58,235</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2943fc5a-450c-4748-80b6-c663d80c5b56" contextRef="C_5a4c4d12-3d56-4c37-9a9a-c58a9b3e58b1" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">87,598,184</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c188b8d6-6141-4070-bd52-df9bad2a5eab" contextRef="C_5a4c4d12-3d56-4c37-9a9a-c58a9b3e58b1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">88</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8be18e0a-4418-46d4-8c6a-da7cb1cd9a97" contextRef="C_f993a7f8-4d25-4be9-b713-6bb38ecf342b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">506,760</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8fc90f3e-c9eb-4e3f-96c7-f67a15e6a92d" contextRef="C_7055bdf6-8d9f-4ea6-913c-d9194c0435b5" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">765</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3593e539-48b6-4a73-ab3f-2832318f4ae0" contextRef="C_08368de2-8657-4cb0-a2d6-6c41c8497c13" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">161,336</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0dc40263-3cea-45ca-a2d8-6050998fe6ee" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">344,747</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying notes are an integral part of the consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="fin118907_21"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">TANGO THERAPEUTICS, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_of_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CONSOLIDATED STATEM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ENTS OF CASH FLOWS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:65.315%;"></td>
    <td style="width:1.66%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:13.536%;"></td>
    <td style="width:0.865%;"></td>
    <td style="width:1.66%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:13.536%;"></td>
    <td style="width:0.865%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br />December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cash flows from operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_29934e4b-65d5-46c7-b790-42ea5b8f5283" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">58,235</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_258cc906-1da0-4375-9c0e-071edc2a5754" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">51,972</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adjustments to reconcile net loss to net cash (used in) provided by<br />&#160;&#160;&#160;operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_711116fe-1317-4642-b95d-e9ba3ef55bd7" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">897</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5cb92fad-0849-4052-96bb-c2aa73d99ff2" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">718</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Noncash operating lease expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ad03d357-9eb8-4424-bed9-66e1ec5916d6" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,069</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_950479c2-acc8-4e36-9c0e-c57ecc304829" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">907</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c75d5d0c-d55f-4419-bce8-3c5fbde269bc" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,833</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7b68097a-1e40-4a47-a7e0-d5ab111a74af" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,764</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_43e3ee88-7671-46d4-bfa3-77f2f0470a9f" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">254</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a85eae59-cd62-4cff-9afa-5b8629328930" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts receivable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8aaa2e91-deb9-47db-b108-21616495bddb" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_14023ccc-9a1c-4f69-8cd3-f65d0cc40343" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,159</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7389081e-5ede-471f-8a79-c596489612b4" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">81</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other long-term assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a2c0ccf9-1ad6-4cf0-a46f-39d52db3ffd2" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">139</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_05183bed-2b3d-4b36-b4d6-079ba1b7cc6d" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts payable</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d4281038-0a66-454b-ae48-91721fd0205f" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,232</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f4ae22ca-1436-4d9a-b8c2-9bc038657ff5" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,171</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f7623431-3471-4a81-83d1-5efb79cacf68" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="tngx:IncreaseDecreaseInAccruedExpensesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,829</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2dc33cf3-6734-4a70-a2dc-4974f63e059c" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="tngx:IncreaseDecreaseInAccruedExpensesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,196</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e6bfb091-64db-4a27-aee4-4d4c27f9760a" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="tngx:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,066</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d4e09062-081f-4b19-bc7f-665e6590a03f" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="tngx:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">655</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5a3726b3-4fe3-4ae5-9d60-ca34dc1f77eb" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">12,042</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_32e9f5e9-9ff1-484c-ad33-0bdab2d82c37" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">119,081</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash (used in) provided by operating activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a674aae7-e26a-433c-bccb-fc52bcf0f254" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">59,527</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dea93068-35f1-4707-bd48-6c80d24e930a" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70,074</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cash flows from investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Purchase of property and equipment</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b903ad3b-233d-4b60-9348-e13ad2d6d8eb" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,837</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c2723199-1b00-465a-8926-25f4fa76a30f" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,106</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sales and maturities of marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1630f679-0899-433b-a518-9434d31e7fb1" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">190,764</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_64407ffa-5742-4f28-8dc8-8e2b8ab61c26" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63,220</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Purchases of marketable securities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b06ba735-bbe9-49a4-a8f1-73edc008cdee" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">372,361</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d9773f11-ef77-4c19-a222-c7e9ba76f165" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">207,540</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_52284c34-6116-4830-89f7-f3e3021302d7" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d596570b-08f1-4136-a989-0f03ff7d3026" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">183,434</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_110f7d73-4e99-412b-b58a-042b3a72562c" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">145,466</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cash flows from financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from issuance of preferred stock, net of issuance costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c6ed33d5-66b4-4da0-8ee7-cf9a5db2f15f" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,990</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_76b19e1b-41ea-47f9-a595-03a94cb285dc" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">80,844</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from issuance of common stock upon exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b602bef7-e4e9-4d19-9717-a78bc7d617f1" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,058</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7f073485-9f2b-413e-b902-a6faea4a074d" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Business Combination and PIPE Financing, gross proceeds</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0de99c2f-fc19-467f-8f21-505a596684b1" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="tngx:ProceedsFromBusinessCombinationAndPipeFinancingGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">342,113</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payment of Business Combination and PIPE Financing transaction costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8f1f4434-5d4a-4d03-8e34-0617baa51973" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="tngx:PaymentOfBusinessCombinationAndPipeFinancingTransactionCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,836</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a0dc0327-86d0-4ef4-8fdc-621dfd0caec6" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">357,325</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c68101e8-e9be-47f1-b4c3-009b3cbfbc36" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">80,884</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net change in cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f1d3b3b1-d8be-4ce8-b68c-33e2cbe7da3f" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">114,364</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0486f9a9-a7ac-452e-8a8b-be860fa13dd1" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,492</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash, beginning of period</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fa9e4f81-1cc0-405f-9688-699506e155d0" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,660</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_49b99ecf-bd85-4c82-9f13-cc5d926ab8de" contextRef="C_4a669c96-a649-4a8a-b346-1cb396dbfc42" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,168</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash, end of period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9d2d5f01-dc3c-4afd-946c-197846c2b2bb" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">145,024</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d5cb6717-19a2-48f7-9a92-9a318f883ca6" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,660</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Supplemental cash flow information:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash paid for leases</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f2f3715a-6d31-4017-922b-b9ca426f3682" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="tngx:CashPaidForLeases" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,835</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cb463ef7-846c-4dd6-832a-1b4d71b3f297" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="tngx:CashPaidForLeases" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,782</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Supplemental disclosure of noncash investing and financing activity:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Conversion of Preferred Shares to Common Shares</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_11308887-b89a-4b79-89b4-2ecd58b06064" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">166,534</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revaluation of right-of-use asset and lease liability upon lease modification</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e9b32e14-362c-4b05-9d79-794c067f4959" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="tngx:RevaluationOfRightOfUseAssetAndLeaseLiabilityUponLeaseModification" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,315</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Purchases of property and equipment included in accounts payable and<br />&#160;&#160;&#160;accrued expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f86c92c-d942-4a85-81d4-7a188451bca8" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">154</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0f9945af-c03f-4992-a19d-b89c233679ef" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying notes are an integral part of the consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="fin118907_22"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">TANGO THERAPEUTICS, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_consolidated_financial_stmts"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">NOTES TO CONSOLIDA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">TED FINANCIAL STATEMENTS</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c85936f9-644b-4e16-be9c-975b8d143431" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true" continuedAt="F_c85936f9-644b-4e16-be9c-975b8d143431_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. Nature of the Business and Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tango Therapeutics, Inc. (&#x201c;Tango&#x201d; or the &#x201c;Company&#x201d;) is a precision oncology company committed to the discovery and development of novel drugs in defined patient populations with high unmet medical need.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tango Therapeutics, Inc. (together with its consolidated subsidiaries, &#x201c;Tango&#x201d; or the &#x201c;Company&#x201d;) formerly known as BCTG Acquisition Corp. (&#x201c;BCTG&#x201d;), was incorporated in Delaware on May 21, 2020. BCTG was a Special Purpose Acquisition Company (&#x201c;SPAC&#x201d;) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Merger with BCTG Acquisition Corporation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On April 13, 2021, the Company, BCTG Merger Sub Inc., a Delaware corporation, and Tango Therapeutics, Inc. (now known as Tango Therapeutics Sub, Inc. or &#x201c;Old Tango&#x201d;) signed a definitive merger agreement (the &#34;Merger Agreement&#34;) memorializing the terms of BCTG&#x2019;s acquisition of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b940f57b-147f-4539-92ca-6519fefa8fd7" contextRef="C_568bffaa-6246-4bbc-8efb-5c5ca93b43f9" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">100</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of Old Tango's issued and outstanding equity securities in exchange for $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_095887f4-061e-4b16-ace6-f92dc800f672" contextRef="C_c5112e96-b096-400a-8231-13c5db592e8e" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">550.0</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million worth of consideration in the form of BCTG common stock (the &#x201c;Business Combination&#x201d;). The Business Combination was approved on August 9, 2021 by shareholders of BCTG, resulting in BCTG acquiring 100% of Old Tango's issued and outstanding equity securities on August 10, 2021. The Business Combination was accounted for as a &#x201c;reverse recapitalization&#x201d; in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). As a result of the Business Combination, BCTG was renamed Tango Therapeutics, Inc. The Company's common stock is </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">trading on The Nasdaq Global Market under the ticker symbol TNGX</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tango received gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bde133bf-4517-420c-8d83-7157db7821f4" contextRef="C_8312ce29-e29e-402c-b364-5d664fa10451" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">167.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon the closing of the Business Combination. Tango continues to operate under the Old Tango management team. Simultaneous with the closing of the Business Combination, an aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_371cec27-30b8-4af4-a4bd-daf72f93f3e9" contextRef="C_ea92a304-c585-4deb-947b-651b75dbc182" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">18,610,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock (the &#x201c;PIPE Financing&#x201d;) were issued, resulting in gross proceeds of an additional $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f6282f6-a5f1-4590-b758-451ef97d9a58" contextRef="C_ea92a304-c585-4deb-947b-651b75dbc182" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">186.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon the closing of the PIPE Financing. Total transaction costs and redemptions</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> approximated $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a745bd1a-daea-4b66-9bc6-4c26f8c63d2b" contextRef="C_d451c16b-ca67-4909-afea-ed3cd220991d" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">26.9</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, resulting in total net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4721bd98-9140-4625-b007-c4e025a94557" contextRef="C_c0c8b2a4-7004-44a5-89e9-321b90380e0e" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">326.3</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">BCTG Acquisition Corporation IPO</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registration statement for BCTG&#x2019;s initial public offering (&#x201c;IPO&#x201d;) was declared effective on September 2, 2020. On September 8, 2020, the Company consummated its Initial Public Offering of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3683f488-a1d6-4bcf-ad4e-84289cc0f50e" contextRef="C_33f11eaf-355a-47f4-a2b2-89b65a3ddda0" name="us-gaap:StockIssuedDuringPeriodSharesOther" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">16,675,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock (the &#x201c;Public Shares&#x201d;), including the </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b5649cb3-b05b-42d7-a609-9dc4e52ed888" contextRef="C_e188203d-bb78-4e16-8893-867ab9986a87" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,175,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Public Shares as a result of the underwriters&#x2019; full exercise of their over-allotment option, at an offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cefa750f-4d95-4cef-be96-5b65e5762ba5" contextRef="C_48837b32-a7ba-4536-82fb-eeef4e91837e" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">10.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per Public Share, generating gross proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9dd4f655-720f-4f58-982e-a3c63f4a0c15" contextRef="C_42915faf-8358-4b14-8b2d-d0e8b545540d" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">166.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and incurring offering costs of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_93d39f8a-bef4-4ca0-880e-b522d8cfc11c" contextRef="C_0c877e59-744f-49bd-b36b-26c23781fc80" name="tngx:OfferingCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, inclusive of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e5fc9803-8890-4621-bb41-9beb6ff0afce" contextRef="C_c46a5787-04cc-4ee6-8232-98fef420c001" name="us-gaap:AmortizationOfDeferredSalesCommissions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in deferred underwriting commissions. Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (&#x201c;Private Placement&#x201d;) of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_06127e6f-75ce-4c37-8cbf-f8a31e9a4420" contextRef="C_fc96726e-aa67-4543-82fb-ba75a0a854df" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">533,500</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock (the &#x201c;Private Placement shares&#x201d;), at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d74b479a-5b28-48d2-8888-777947e514fb" contextRef="C_2a1ab7b1-38dd-41eb-9f72-c6425108c827" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">10.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per Private Placement Share to the Sponsor, generating gross proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_33d7235e-707e-4e2f-a01a-515e85ec92ff" contextRef="C_fc96726e-aa67-4543-82fb-ba75a0a854df" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. Upon the closing of the Initial Public Offering and the Private Placement, the net proceeds of the Initial Public Offering and certain of the proceeds of the Private Placement was placed in a trust account (&#x201c;Trust Account&#x201d;) in the United States maintained by Continental Stock Transfer &amp; Trust Company, as trustee, and remained invested only in U.S. government treasury bills, notes and bonds with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act and which invest solely in U.S. Treasuries, until the completion of the Business Combination as described below</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_c85936f9-644b-4e16-be9c-975b8d143431_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying consolidated financial statements have been prepared in conformity with U.S. GAAP. The accompanying consolidated financial statements reflect the operations of Tango and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated. The functional and reporting currency of the Company and its subsidiaries is the U.S. dollar.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div><ix:nonNumeric id="F_cd183504-c409-427d-bab5-9f490c93540f" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2. Summary of Significant Accounting Policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_db596b93-1010-4504-8b92-f45ed83d1a51" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:UseOfEstimates" escape="true" continuedAt="F_db596b93-1010-4504-8b92-f45ed83d1a51_1"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_db596b93-1010-4504-8b92-f45ed83d1a51_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of consolidated financial statements requires that the Company make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. Significant estimates and assumptions made in the consolidated financial statements include, but are not limited to, the revenue recognized from collaboration agreements, the valuation of stock-based awards and the accrual for research and development expenses. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7609ea95-c6f0-4cea-a50d-dcd27c8d23e4" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true" continuedAt="F_7609ea95-c6f0-4cea-a50d-dcd27c8d23e4_1"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Segment Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_7609ea95-c6f0-4cea-a50d-dcd27c8d23e4_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating segments are defined as components of an enterprise for which separate financial information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company operates in </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ebb4d28b-386a-450f-87c4-9cfb97cb8b09" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> operating segment, the business of discovering and developing precision oncology therapies.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f8af7adc-ab61-41bb-ab4e-4db20cd956c3" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true" continuedAt="F_f8af7adc-ab61-41bb-ab4e-4db20cd956c3_1"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_f8af7adc-ab61-41bb-ab4e-4db20cd956c3_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All highly liquid marketable securities purchased with an original maturity date of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f3b8ae00-27e8-4b18-a670-5cd9743dd1e9" contextRef="C_758f7c30-6f5d-40eb-bfbc-5d756f87d621" name="tngx:CashAndCashEquivalentMaturityPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90 days</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or less at the date of purchase are considered to be cash equivalents. Cash equivalents consisted of money market funds and U.S. Treasury bills as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_659fdc7a-ba78-4b77-9f73-187aeda98f29" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:InvestmentPolicyTextBlock" escape="true" continuedAt="F_659fdc7a-ba78-4b77-9f73-187aeda98f29_1"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investments in Marketable Securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Marketable debt securities consist of investments with original maturities greater than </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6975358a-c672-4591-b93a-f9457fdda32c" contextRef="C_5a10696c-6f1a-45a5-9a37-ea3703aed7cc" name="tngx:MarketableDebtSecuritiesMaturitiesDuration" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90 days</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company classifies its investments with maturities beyond one year as short-term, based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. The Company considers its investment portfolio of marketable securities to be available-for-sale. Accordingly, these investments are recorded at fair value, which is based on quoted market prices. Unrealized gains are reported as a component of accumulated other comprehensive income in stockholders&#x2019; equity (deficit). Amortization and accretion of premiums and discounts are recorded in interest income. Realized gains and losses are included as a component of other income, net in the consolidated statements of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_659fdc7a-ba78-4b77-9f73-187aeda98f29_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company evaluates its investments with unrealized losses for impairment. When assessing investments for unrealized declines in value, the Company considers whether the decline in value is related to a credit loss or non-credit loss. For credit losses, the Company reduces the investment to fair value through an allowance for credit losses recorded to the balance sheet and corresponding charge to the statement of operations. The allowance for credit losses and corresponding impairment charge is adjusted each period for changes in fair value. For non-credit losses, the Company reduces the investment to fair value through a charge to the statement of comprehensive loss, reported as a component of accumulated other comprehensive income (loss) in stockholders&#x2019; equity. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7d142be8-86c6-4349-befe-845d5f205c92" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> such credit losses were recorded during the periods presented.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_66d8cccd-ee54-4e4a-8dab-e295c14bee5a" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true" continuedAt="F_66d8cccd-ee54-4e4a-8dab-e295c14bee5a_1"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accounting standard for fair value measurements defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and requires certain disclosures about fair value measurements. Under this standard, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1 &#x2014; Fair values are determined utilizing prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access. </span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2 &#x2014; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves, and foreign currency spot rates. </span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3 &#x2014; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. </span></div></div></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_66d8cccd-ee54-4e4a-8dab-e295c14bee5a_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of the Company&#x2019;s cash equivalents and marketable securities are determined according to the fair value hierarchy described below (see Note 5)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The carrying values of the Company&#x2019;s accounts receivable, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c8856d64-e8dc-4c3a-85cf-d8ffcc9bbd79" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ConcentrationRiskCreditRisk" escape="true" continuedAt="F_c8856d64-e8dc-4c3a-85cf-d8ffcc9bbd79_1"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk and Significant Suppliers</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash, cash equivalents and marketable debt securities. The Company&#x2019;s cash, cash equivalent and marketable securities balances are held by major financial institutions that management believes to be creditworthy. The Company uses multiple financial institutions to limit the amount of credit exposure to any one financial institution. Substantially all the Company&#x2019;s cash, cash equivalent and marketable debt securities were invested in money market funds, U.S. Treasury bills, and U.S. government agency bonds at December 31, 2021 and 2020. At times, the Company&#x2019;s cash deposits may exceed the amount of federal insurance provided on such deposits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant credit risk beyond the normal credit risk associated with commercial banking relationships.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_c8856d64-e8dc-4c3a-85cf-d8ffcc9bbd79_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company relies, and expects to continue to rely, on a small number of vendors to perform research activities and clinical trial activities that continue to progress its product candidates for its development programs. These programs could be adversely affected by a significant interruption in the related processes of these vendors.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_af80fe8a-cf76-4051-97a2-d465ec3827a6" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash accounts with any type of restriction are considered restricted cash and are classified on the balance sheet based on the length of the restrictive obligation. As of both December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company recorded restricted cash of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4368990a-2677-47d0-bfe2-5fdf0c78b439" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_23b60ae0-bc48-4e5d-86f9-a97786091c0d" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.3</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, all of which was related to security deposits associated with the Company&#x2019;s facility leases in Boston, Massachusetts and Cambridge, Massachusetts. The security deposit associated with the Company's facility lease in Boston, Massachusetts is recorded as non-current in its balance sheet as of December 31, 2021 and December 31, 2020 because the deposit is required for the duration of the lease which is greater than a year. The security deposit associated with the Company's facility lease in Cambridge, Massachusetts is recorded as current in its balance sheet as of December 31, 2021 because the deposit is required for the duration of the amended lease which is less than a year from the balance sheet date. The security deposit associated with the Company's facility lease in Cambridge, Massachusetts was recorded as non-current in its balance sheet as of December 31, 2020 because the deposit was required for the duration of the original lease which, prior to the 2021 lease amendment, was for greater than a year from the December 31, 2020 balance sheet date.</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6da94655-e134-469b-b9a3-da08efc57453" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The reconciliation of cash and cash equivalents and restricted cash to amounts presented in the consolidated statements of cash flows are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.312%;"></td>
          <td style="width:1.6%;"></td>
          <td style="width:1.282%;"></td>
          <td style="width:13.33%;"></td>
          <td style="width:0.636%;"></td>
          <td style="width:1.6%;"></td>
          <td style="width:1.282%;"></td>
          <td style="width:13.32%;"></td>
          <td style="width:0.636%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b28766b9-3d89-4967-8a62-9f9cbca36bce" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">142,745</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_985d0d72-45eb-4770-b95b-2fb815b97de7" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,381</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c09a1042-5693-4383-ae58-bcf7ca837abe" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:RestrictedCashCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">567</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash, net of current portion</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d7cc3dfe-6b26-49c5-8f10-83ce6d923f46" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,712</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a6cf3ca0-f5ba-4557-804a-6d5336776f72" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,279</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b9ded5a5-6e29-4ac5-bc2c-f3fef6a3d87b" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">145,024</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a3adc122-7d95-4824-b6e7-1865d95d6ba0" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,660</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p>
         <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude></ix:nonNumeric></div></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_95b0f37b-e76b-480b-9588-99ea51ca6fc2" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true" continuedAt="F_95b0f37b-e76b-480b-9588-99ea51ca6fc2_1"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful lives of each asset. Estimated useful lives are periodically assessed to determine if changes are appropriate. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fbb20133-b717-45e6-bafc-f8597944c387" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="tngx:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" escape="true" continuedAt="F_fbb20133-b717-45e6-bafc-f8597944c387_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated useful lives of the Company&#x2019;s property and equipment are as follows: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:continuation id="F_fbb20133-b717-45e6-bafc-f8597944c387_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:43.72%;"></td>
          <td style="width:1.835%;"></td>
          <td style="width:54.444%;"></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Asset</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Estimated useful life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3c8f1896-8689-433f-859f-f76ba4e7e7b8" contextRef="C_c887ec60-971a-4690-a982-03a761ebe233" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3 years</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer software</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9c55108f-bba5-4c8c-a46f-f57c62e5804e" contextRef="C_22555df1-4efe-4a08-bb1c-08f931ec7211" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5 years</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d5719339-0f75-42fc-bee4-45a52c9fe39c" contextRef="C_23d38092-0393-490f-b401-5d223a840f61" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7 years</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_09e47c29-61d8-476d-97c8-37735bea6058" contextRef="C_ddf3c437-2a6f-4dfd-a511-55b637ea608a" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7 years</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e48e2d8f-55a5-4843-aa17-8fc2637de639" contextRef="C_fcb0c4a1-8080-44f5-9e53-5ea3f5e568e5" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shorter of remaining lease term or 10 years</span></ix:nonNumeric></span></p></td>
         </tr>
        </table></ix:continuation></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company reviews long-lived assets, such as property and equipment, for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. If indicators of impairment are present, the assets are tested for recoverability by comparing the carrying amount of the assets to the related estimated future undiscounted cash flows that the assets are expected to generate. If the expected cash flows are less than the carrying value of the asset group, then the asset group is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows. To date, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3d67304f-e72c-4cfb-9943-5b63f342fba2" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> such impairment losses have been recorded.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_95b0f37b-e76b-480b-9588-99ea51ca6fc2_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Costs for assets not yet placed into service are capitalized as construction-in-progress and depreciated or amortized in accordance with the above useful lives once placed into service. Upon retirement or sale, the related cost and accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in the consolidated statements of operations. Repairs and maintenance costs are expensed as incurred.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_99bce0f7-2c66-4a08-90b4-f5d60fc09ea5" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true" continuedAt="F_99bce0f7-2c66-4a08-90b4-f5d60fc09ea5_1"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances and the existence of an identified asset(s), if any, and its control over the use of the identified asset(s), if applicable. Upon lease commencement, operating lease liabilities and their corresponding right-of-use assets are recorded on the balance sheet based at the present value of lease payments over the expected lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense is recognized over the expected term on a straight-line basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease payments are discounted at the lease commencement date using the interest rate implicit in the lease contract. As this rate is typically not readily determinable, the Company determines an incremental borrowing rate that is used to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Certain prospective adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_99bce0f7-2c66-4a08-90b4-f5d60fc09ea5_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company elected to account for lease and non-lease components as a single lease component, however non-lease components that are variable, such as common area maintenance and utilities, are generally paid separately from rent based on actual costs incurred and therefore are not included in the right-of-use asset and operating lease liability and are reflected as an expense in the period incurred. The Company&#x2019;s lease terms often include renewal options. The amounts determined for the Company&#x2019;s right-of-use assets and lease liabilities generally do not assume that any renewal options or any early-termination provisions, if any, are exercised, unless it is reasonably certain that the Company will exercise such options.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5db006f7-2c60-4b33-a816-708c8ebe6c16" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true" continuedAt="F_5db006f7-2c60-4b33-a816-708c8ebe6c16_1"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At contract inception, the Company assesses whether the collaboration arrangements are within the scope of ASC Topic 808, Collaborative Arrangements, or ASC 808, to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed based on the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the arrangement are within the scope of ASC 808 and which elements are within the scope of ASC 606 (as described below). For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, either by analogy to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">authoritative accounting literature or by applying a reasonable and rational policy election. To date, the Company has not entered into any arrangements within the scope of ASC 808.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s revenues are generated through its license and collaboration agreements with Gilead. Refer to Note 4, &#x201c;Collaboration Agreements.&#x201d; elsewhere in these notes to the Company's consolidated financial statements.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers. ASC 606 provides a five-step framework whereby revenue is recognized when control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the  contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) performance obligations are satisfied. The Company only applies this framework to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation. Goods and services that are determined not to be distinct are combined with other promised goods and services until a distinct bundle is identified. The Company then allocates the transaction price (that is, the amount of consideration the Company expects to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The Company&#x2019;s estimate of the transaction price for each contract includes all variable consideration to which the Company expects to be entitled, subject to the constraint on variable consideration. Variable consideration is not constrained if the potential reversal of cumulative revenue recognized at the contract level is not significant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under active agreements, the Company must use its judgment to determine: (a) the number of performance obligations based on the determination under step (ii) above; (b) the transaction price under step (iii) above; (c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above; and (d) the contract term and pattern of satisfaction of the performance obligations under step (v) above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to the identified performance obligations on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. In certain instances, the timing of satisfying these obligations can be difficult to estimate. Accordingly, the Company&#x2019;s estimates may change in the future and those changes could be material. Such changes to estimates would result in a change in amounts of revenue recognized. If these estimates and judgments change over the course of these agreements, it may affect the timing and amount of revenue that the Company recognizes and records in future periods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the collaboration agreements are recorded as accounts receivable in the Company&#x2019;s consolidated balance sheet. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&#x2019;s consolidated balance sheets. Amounts expected to be recognized as revenue within the one year following the balance sheet date are classified as current deferred revenue. Amounts not expected to be recognized as revenue within the one year following the balance sheet date are classified as deferred revenue, net of current portion. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as contract assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Exclusive License Rights</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> &#x2014; If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, which generally include research and development services, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a license is distinct from the other promises, the Company considers relevant facts and circumstances of each arrangement, including the research and development capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from the license for its intended purpose without the receipt of the remaining promises, whether the value of the license is dependent on the unsatisfied promises, whether there are other vendors that could provide the remaining promises and whether it is separately identifiable from the remaining promises. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation and whether the license is the predominant promise within the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. If the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">license is the predominant promise, and it is determined that the license represents functional intellectual property (&#x201c;IP&#x201d;), revenue is recognized at the point in time when control of the license is transferred. If it is determined that the license does not represent functional IP, revenue is recognized over time using an appropriate method of measuring progress.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Services</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> &#x2014; The obligations under the Company&#x2019;s collaboration agreements may include research and development services to be performed by the Company to benefit the collaboration partner. For performance obligations that include research and development services, the Company generally recognizes revenue allocated to such performance obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for purposes of recognizing revenue, which is generally an input measure such as costs incurred. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods of which revenue should be recognized, are subject to estimates by management and may change over the course of the contract. Reimbursements from the partner that are the result of a collaborative relationship with the partner, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense. No collaborative arrangements existed that would result in such reimbursements for the periods presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Customer Options</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> &#x2014; The Company&#x2019;s arrangements may provide a collaborator with the right to acquire additional goods or services in the future. Under these agreements, fees may be due to the Company (i) upon the exercise of the customer option or (ii) in equal installment payments over an agreed upon period. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the additional goods and services underlying the customer options are evaluated in order to determine if these additional goods or services are distinct from those included as a performance obligation at the outset of the arrangement. If the additional services are not determined to be distinct, the variable consideration pertaining to the customer option is added to the initial transaction price at the time in which the option exercise becomes probable, so long as a potential for reversal of cumulative revenue recognized at the contract level is not significant. Any such adjustments to the transaction price are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If the additional services are distinct, the Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company allocates the transaction price to material rights based on the relative stand-alone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Milestone Payments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> &#x2014; At the inception of an arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant reversal of cumulative revenue recognized would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#x2019;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_5db006f7-2c60-4b33-a816-708c8ebe6c16_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Royalties</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> &#x2014; For arrangements that include sales-based royalties, including milestone payments based on a level of sales, where the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from licensing agreements.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e1ef43ed-27a7-4774-933d-95736f984eee" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true" continuedAt="F_e1ef43ed-27a7-4774-933d-95736f984eee_1"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses include costs directly attributable to the conduct of research programs, including the cost of salaries, employee benefits, stock-based compensation expense, materials, supplies, depreciation on and maintenance of research equipment, the cost of services provided by outside contractors to conduct research and development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">activities and the allocable portions of facility costs, such as rent, utilities, and general support services. All costs incurred to fulfill the Company&#x2019;s obligations under the collaboration with Gilead are classified as research and development expenses. All costs associated with research and development are expensed as incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_e1ef43ed-27a7-4774-933d-95736f984eee_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management estimates the Company&#x2019;s accrued research and development expenses as of each balance sheet date in the Company&#x2019;s financial statements based on facts and circumstances known to the Company at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Nonrefundable advance payments for goods and services are deferred and recognized as expense in the period that the related goods are consumed or services are performed.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_becdf442-0105-4a66-ba70-e8de42b6d52b" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="tngx:PatentCostsPolicyTextBlock" escape="true" continuedAt="F_becdf442-0105-4a66-ba70-e8de42b6d52b_1"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patent Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_becdf442-0105-4a66-ba70-e8de42b6d52b_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_87d4b924-e847-43b9-890c-fc10e8b83461" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true" continuedAt="F_87d4b924-e847-43b9-890c-fc10e8b83461_1"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company measures the cost of employee services received in exchange for stock-based awards based on the grant-date fair value of the awards. The Company calculates the fair value of restricted stock awards based on the grant date fair value of the underlying common stock. The Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period of the awards for service-based awards, which is generally the vesting period. The Company recognizes stock-based compensation for performance-based awards when the underlying performance conditions are considered probable of occurrence and recognizes the cumulative effect of current and prior period changes in the period of change.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to the </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">consummation of the Business Combination transaction, as there was not a public market for the common stock of the Company prior to becoming publicly traded, the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fair value of common stock underlying stock-based awards was based on a valuation provided by the board of directors as derived from a recommendation by an unrelated third-party valuation firm. The Company determined the estimated per share fair value of its common stock at various dates considering contemporaneous and retrospective valuations that incorporated objective and subjective factors, including actual and forecasted financial results, market conditions and performance of comparable publicly traded companies, developments and milestones of the Company, the rights and preferences of common and redeemable convertible preferred stock, advice from the third-party valuation specialists, and transactions involving the Company&#x2019;s stock. The estimated per share fair value of the Company&#x2019;s common stock was determined in accordance with the guidance outlined in the American Institute of Certified Public Accountants Practice Aid, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Valuation of Privately-Held Company Equity Securities Issued as Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The fair value of each restricted common stock award was estimated on the date of grant based on the fair value of the Company&#x2019;s common stock on that same date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Subsequent to becoming a publicly traded Company upon the consummation of the Business Combination transaction, the fair value of common stock underlying stock-based awards is based on an estimate at each grant date using the market price of our common stock and each of the assumptions discussed below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Term</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">:    The expected term of the stock options is estimated using the &#x201c;simplified method,&#x201d; as prescribed in SEC&#x2019;s Staff Accounting Bulletin (SAB) No. 107, as the Company has limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting period and the contractual term of the option.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Volatility</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">:    Since there is limited historical data for the Company&#x2019;s common stock and limited company-specific historical volatility, the Company has determined the share price volatility for options granted based on an analysis of the volatility used by a peer group of publicly traded companies. In evaluating similarity, the Company considers factors such as industry, stage of life cycle and size.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risk-free Interest Rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">:    The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected life of the option.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Dividend Rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">:    The expected dividend is assumed to be </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_43b55140-5091-4ca4-aca4-7290aad81823" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="tngx:ExpectedDividendAssumed" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as the Company has never paid dividends and has no current plans to do so.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The assumptions used in estimating the fair value of stock-based awards represent management&#x2019;s estimate and involve inherent uncertainties and the application of management&#x2019;s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_87d4b924-e847-43b9-890c-fc10e8b83461_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation is classified in the accompanying consolidated statements of operations and comprehensive loss based on the function to which the related services are provided. Forfeitures are accounted for as they occur. Any consideration paid by employees on exercising stock options and the corresponding portion previously credited to additional paid-in capital are credited to share capital.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f7939279-63d1-4b10-bd89-90c7d084c06e" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="tngx:DeferredFinancingCostsPolicyTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Deferred Financing Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded in shareholders&#x2019; equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d48f72c0-7c91-4a0e-a7b2-2c1e5839b9ca" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true" continuedAt="F_d48f72c0-7c91-4a0e-a7b2-2c1e5839b9ca_1"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period corresponding to the enactment date. A valuation allowance is established when it is more likely than not that all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a more likely than not likelihood of being realized upon ultimate settlement with the tax authority. The recognition and measurement of tax benefits requires significant judgments that are subject to change as new information becomes available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_d48f72c0-7c91-4a0e-a7b2-2c1e5839b9ca_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Penalties and interest expense related to income taxes are included as components of income tax expense and interest expense, respectively, as necessary.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7f6c1276-15b6-45ee-b017-1c8453ea020b" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comprehensive Gain (Loss)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity (deficit) that result from transactions and economic events other than those with stockholders. The Company&#x2019;s only element of other comprehensive loss for the years ended December 31, 2021 and 2020</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was unrealized gains (losses) on investments in marketable securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d920d7b2-e22f-43ab-8392-0fbd335b19a2" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share attributable to common stockholders is computed by dividing net loss by the weighted-average number of shares of common shares outstanding during each reporting period. The weighted-average number of shares of common stock outstanding used in the basic net loss per share calculation does not include unvested restricted stock awards as these instruments are considered contingently issuable shares until they vest. Diluted net loss per share attributable to common stockholders includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. The Company&#x2019;s unvested restricted stock entitles the holder to participate in dividends and earnings of the Company, and, if the Company were to recognize net income, it would apply the two-class method to calculate earnings per share. The two-class method is not applicable during periods with a net loss, as the holders of the unvested restricted stock have no obligation to fund losses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The two-class method of computing net loss per share would be applicable in a reporting period that resulted in a net income position, as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_82355b4a-1e95-4b41-ad2c-f9ac3d0f6180" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" escape="true" continuedAt="F_82355b4a-1e95-4b41-ad2c-f9ac3d0f6180_1"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_82355b4a-1e95-4b41-ad2c-f9ac3d0f6180_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a7f59441-4834-46f4-85e1-457c88f7e808" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:SubsequentEventsPolicyPolicyTextBlock" escape="true" continuedAt="F_a7f59441-4834-46f4-85e1-457c88f7e808_1"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Subsequent Events</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_a7f59441-4834-46f4-85e1-457c88f7e808_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1b8711b3-3739-4ef6-a845-aa4f2cb3befa" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Emerging Growth Company Status</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is an &#x201c;emerging growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act (&#x201c;JOBS Act&#x201d;), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards and as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of an initial public offering or such earlier time that it is no longer an emerging growth company. However, the Company has not yet delayed the adoption of any new accounting standards.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a15e44e2-36b5-4af0-a283-530a34a886cd" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Adopted Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2016, the FASB issued ASU 2016-13</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">, Financial Instruments &#x2014; Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren&#x2019;t measured at fair value through net income. For available-for-sale debt securities, entities are required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities are no longer permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. For public entities, the guidance was effective for annual reporting periods beginning after December 15, 2019 and for interim periods within those fiscal years. Early adoption was permitted. The Company </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_180eabe9-140b-4a93-be62-2378d90e4750" contextRef="C_d651794e-8630-4ab5-a33f-7df95e076d4e" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">early </span></ix:nonNumeric></span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4c9ad851-5e44-471c-9c5f-54e9600b893f" contextRef="C_d651794e-8630-4ab5-a33f-7df95e076d4e" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adopted </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">this standard as of</span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cd78e2d3-66fb-4eba-a398-9c7f877e1d7d" contextRef="C_d651794e-8630-4ab5-a33f-7df95e076d4e" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> January 1, 2020</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on a prospective basis. The adoption did</span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f82bed08-49e3-4854-9f84-f398266729a9" contextRef="C_d651794e-8630-4ab5-a33f-7df95e076d4e" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> no</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t have a material impact on the Company&#x2019;s consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2018, the FASB issued ASU 2018-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The amendments become effective for the Company&#x2019;s fiscal year beginning January 1, 2020. Early adoption of the amendments in full or only the provisions that eliminate or modify the disclosure requirements for fair value measurements is permitted. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_59585859-15d0-4fc0-8b8f-ce69e2eb7fa9" contextRef="C_165d6390-156d-4d13-94be-fad709b50c15" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adoption </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of this standard on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_51e30a61-8e20-44cd-9233-1ef2b5644919" contextRef="C_165d6390-156d-4d13-94be-fad709b50c15" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2020</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> did </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5f4661e2-43f5-450e-a9c5-67c5322a73a5" contextRef="C_165d6390-156d-4d13-94be-fad709b50c15" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2018, the FASB issued ASU 2018-15, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The new standard requires a customer in a cloud computing arrangement to determine which implementation costs to capitalize as assets or expense as incurred. Capitalized implementation costs related to a hosting arrangement that is a service contract will be amortized over the term of the hosting arrangement, beginning when the module or component of the hosting arrangement is ready for its intended use. The new standard became effective for the Company&#x2019;s fiscal year beginning January 1, 2020. Early adoption was permitted. The </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cb48d8f8-25b1-444d-9a30-abfc4194aa41" contextRef="C_79ee2c85-0407-439c-899d-6ad699fae605" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">early </span></ix:nonNumeric></span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a128f944-c9d8-4e27-9c45-9357f0729c22" contextRef="C_79ee2c85-0407-439c-899d-6ad699fae605" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adoption </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of this standard on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_954014c0-b06e-468a-ae71-1d4bda094803" contextRef="C_79ee2c85-0407-439c-899d-6ad699fae605" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2020</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> did </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_640b41ff-1781-4a6b-97f1-1a9a75d24f26" contextRef="C_79ee2c85-0407-439c-899d-6ad699fae605" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2019, the FASB issued ASU 2019-12, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Simplifying the Accounting for Income Taxes,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (&#x201c;ASC 740&#x201d;). The ASU enhances and simplifies various aspects of the income tax accounting guidance in ASC 740, including requirements related to hybrid tax regimes, the tax basis step-up in goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intra-period tax allocation exception to the incremental approach, ownership changes in investments, changes from a subsidiary to an equity method investment, interim-period accounting for enacted changes in tax law, and the year-to-date loss limitation in interim-period tax accounting. This guidance became effective for the Company's fiscal year beginning </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fca83597-bd95-4bb3-bd3d-6064ae10a682" contextRef="C_709432d5-f52b-4cb9-a494-7b1bae2706a5" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_95736867-c622-4fa9-bc10-2ab3c067c5fa" contextRef="C_709432d5-f52b-4cb9-a494-7b1bae2706a5" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adoption </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of this guidance did </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7322a915-a96b-4971-b6cd-6fabe97b840c" contextRef="C_709432d5-f52b-4cb9-a494-7b1bae2706a5" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t have a material impact on the Company&#x2019;s consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2020, the FASB issued ASU 2020-06, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Debt &#x2014; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 &#x2014; 40)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The amendments in this update affect entities that issue convertible instruments and/or contracts indexed to and potentially settled in an entity&#x2019;s own equity. The new ASU eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, the new guidance modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company elected to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_00f14349-4449-4ab8-836c-2fcd4cd272fa" contextRef="C_ee85dddd-830e-4471-966a-17bed0f1923f" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">early </span></ix:nonNumeric></span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ad1a9dc3-6fb5-4672-a037-ac8315911ab9" contextRef="C_ee85dddd-830e-4471-966a-17bed0f1923f" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adopt </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">this guidance on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_471afcdb-f6a9-438e-b366-a7d5a7abe203" contextRef="C_ee85dddd-830e-4471-966a-17bed0f1923f" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Adoption of the ASU 2020-06 guidance as of January 1, 2021 had </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fd5cfc02-d238-47b9-a179-d3a3e094f71b" contextRef="C_ee85dddd-830e-4471-966a-17bed0f1923f" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">impact on its consolidated financial statements for the year ended December 31, 2020. The Company issued the second tranche of its redeemable convertible Series B preferred stock in March 2021 at an original issue price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a230475a-0b1a-4824-8628-26c6469b950d" contextRef="C_934e45d0-2851-4e4a-848b-28c197e06283" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">1.32</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, which would have resulted in the recognition of a beneficial conversion feature of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b72c6569-39ae-4998-9f9e-6b42ddecb760" contextRef="C_bee96a77-f86f-42a4-a0c1-11fced7670fe" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">28.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million prior to the adoption of ASU 2020-06. However, the consummation of the Business Combination and the application of a retroactive adjustment to historical redeemable convertible preferred stock in all periods presented under the reverse recapitalization accounting treatment have resulted in the adoption of this guidance not resulting in a material impact on the Company&#x2019;s financial statements for the year ended December 31, 2021.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_26e27cd8-ae1d-4b3a-a0bb-96a3ea88411a" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="tngx:RecentlyIssuedAccountingPronouncementsPolicyTextBlock" escape="true"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Issued Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that recently issued standards that are not yet effective will not have a material impact on the Company&#x2019;s consolidated financial statements. </span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c70f0afe-74c7-4893-bfbe-aed13e8d8491" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:BusinessCombinationDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3. Business Combination</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_206ae606-8bbf-4051-86a4-0d1dbd639207" contextRef="C_dbf730ab-1e1d-4b66-831b-495fa57b10da" name="us-gaap:BusinessAcquisitionDateOfAcquisitionAgreement1" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">August 10, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (the &#34;Closing Date&#34;), BCTG, a Delaware corporation and now predecessor of the Company, consummated the Business Combination, pursuant to the Merger Agreement, by and among BCTG, BCTG Merger Sub Inc., a Delaware corporation (&#34;BCTG Merger Sub&#34;), and Old Tango. Prior to consummation of the Business Combination, Old Tango changed its name from &#x201c;Tango Therapeutics, Inc.&#x201d; to &#x201c;Tango Therapeutics Sub, Inc.&#x201d; and in connection with the Business Combination, BCTG changed its name to &#x201c;Tango Therapeutics, Inc.&#x201d; (the former name of Old Tango). Pursuant to the Merger Agreement, on the Closing Date, BCTG Merger Sub merged with and into Old Tango, or the Merger, with Old Tango surviving the Merger as a wholly-owned subsidiary of BCTG, and BCTG changed its name to &#x201c;Tango Therapeutics, Inc.&#x201d;, or New Tango.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the terms and conditions of the Merger Agreement, the aggregate consideration paid to Old Tango equity holders upon the closing of the Merger was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c5a5c030-8a64-4919-934c-b23d956c2855" contextRef="C_dbf730ab-1e1d-4b66-831b-495fa57b10da" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">55,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of New Tango common stock. Subsequent to the closing of the Business Combination, New Tango entered into subscription agreements with certain investors (&#34;PIPE Investors&#34;) pursuant to which the PIPE Investors purchased </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6a53cd3f-1a78-4a40-9781-dffab9abf911" contextRef="C_ea92a304-c585-4deb-947b-651b75dbc182" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">18,610,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of New Tango common stock at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9ce492f4-9357-492a-9476-bb8881e1fe7e" contextRef="C_8de344bc-88b0-4716-8a86-20e32b63eab2" name="tngx:PricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">10.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, for aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_12caa095-3664-4407-adc7-7a1709e439a1" contextRef="C_ea92a304-c585-4deb-947b-651b75dbc182" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">186.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, under the PIPE Financing.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6b88051f-6663-4901-b4da-30028e1468bc" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the elements of the net proceeds from the Business Combination and PIPE Financing transaction as of December 31, 2021 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:75.102%;"></td>
        <td style="width:4.662%;"></td>
        <td style="width:1.282%;"></td>
        <td style="width:18.09%;"></td>
        <td style="width:0.865%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Recapitalization</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash - BCTG's Trust Account and cash (net of redemptions)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5d730546-1b97-4998-a9f4-a9aae5f30fa5" contextRef="C_aefe6aea-0fcf-40c7-a8cb-fa9395426cc3" name="us-gaap:CashAcquiredFromAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">156,013</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash - PIPE Financing</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9f121583-1c10-43d6-9415-43ece685a7c1" contextRef="C_fc96726e-aa67-4543-82fb-ba75a0a854df" name="us-gaap:CashAcquiredFromAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">186,100</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less transaction costs and advisory fees paid</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_79686c8d-18fa-4239-afca-0638efa67c7f" contextRef="C_df7e4b79-2a16-44a2-844e-a0a5c357c1b4" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,836</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash proceeds from the Business Combination and PIPE Financing</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b85b5f84-20df-4ccc-a1eb-14c376fc088f" contextRef="C_4a921be2-dfdf-4ce8-8e66-04b6835527ad" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">326,277</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Add: non-cash net assets assumed from BCTG</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_352c5c3e-bf24-403d-a10a-dd887d029d35" contextRef="C_0d31393e-af6d-4a5d-92ee-02bb00706dea" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net contributions from Business Combination and PIPE Financing</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4a0d1a3b-27e0-4d0f-83d0-3001fd44dc97" contextRef="C_4a921be2-dfdf-4ce8-8e66-04b6835527ad" name="us-gaap:BusinessCombinationConsiderationTransferred1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">326,280</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8f48ef59-f463-4b6b-9192-7e40d40dad7d" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the number of shares of common stock outstanding immediately following the consummation of the Business Combination and PIPE Financing transaction:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.237%;"></td>
        <td style="width:3.886%;"></td>
        <td style="width:0.646%;"></td>
        <td style="width:15.366%;"></td>
        <td style="width:0.865%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">BCTG common shares outstanding prior to the Business Combination</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_28612aa6-04ff-4b46-8607-34c0f7998121" contextRef="C_ecff8a34-7794-4031-8fce-96f60d31dc7c" name="tngx:CommonStockOutstandingPriorToBusinessCombination" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">21,377,250</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less redemption of BCTG shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2fecf504-e4c7-44a4-8771-e46f4b17b03e" contextRef="C_ecff8a34-7794-4031-8fce-96f60d31dc7c" name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,106,814</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common shares of BCTG outstanding as of the Business Combination</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_63e687f6-1589-4b5a-88c4-6c1f92530e38" contextRef="C_ecff8a34-7794-4031-8fce-96f60d31dc7c" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">20,270,436</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares issued pursuant to the PIPE Financing</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_34405a3b-89b5-4fc8-b448-debc72e5afc2" contextRef="C_c73c0fe0-50a5-469f-988c-1cd417a6095d" name="us-gaap:SharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">18,610,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Business Combination and PIPE Financing shares</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6d588992-84e9-43f1-8429-f1484f6f4ee3" contextRef="C_9e7c0cdf-ecd0-49cb-bcb4-d8123eab2f15" name="us-gaap:SharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">38,880,436</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Old Tango common shares (after preferred shares were converted 1-for-</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2f2d1597-f849-442b-9ad3-36742fc66f6f" contextRef="C_637f6044-163f-4ffe-baaa-808b1b634223" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" unitRef="U_pure" decimals="INF" format="ixt:numdotdecimal">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;for common shares)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_124f5f26-8fd4-4fb6-8f1f-e0e6636dcc82" contextRef="C_afd5c297-0100-4e5c-a1d4-238c915c6ebd" name="us-gaap:PreferredStockConvertibleSharesIssuable" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">48,593,803</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total shares of Common Stock immediately after Business Combination consummation</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c458b3a5-8ad7-40f6-9bdd-54ced095b19e" contextRef="C_278d8753-1cb2-473c-a8e0-50755d56d579" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">87,474,239</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The merger consideration of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_37aaf2ee-f3b9-4ec5-b080-829e1875cc24" contextRef="C_dbf730ab-1e1d-4b66-831b-495fa57b10da" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">55,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0 shares of New Tango common stock issued to Old Tango equity holders consists of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_94351134-3bac-405c-9808-a23dea1e9b06" contextRef="C_afd5c297-0100-4e5c-a1d4-238c915c6ebd" name="us-gaap:PreferredStockConvertibleSharesIssuable" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">48,593,803</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares issued in exchange for Old Tango common and preferred shares outstanding, included in the table above, as well as </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7d9960c5-69b4-43d9-bde8-0f6e96f1665a" contextRef="C_9157c232-bd25-4b99-8aaa-53493f84a8b0" name="tngx:StockIssuedDuringPeriodSharesInExchangeForUnvestedRestrictedStockAwardsAndUnexercisedStockOptions" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,406,197</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares issued in exchange for the Old Tango unvested restricted stock awards and unexercised stock options outstanding immediately prior to the effective time of the Business Combination.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Retrospective Application of Recapitalization</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As discussed above, the Business Combination with BCTG, which was consummated on August 10, 2021, is accounted for as a reverse recapitalization of equity structure. Under the reverse recapitalization model, the Business Combination was treated as Old Tango issuing equity for the net assets of BCTG, with </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d5869b32-e96d-4d10-858f-8a8e31180cbf" contextRef="C_ecff8a34-7794-4031-8fce-96f60d31dc7c" name="us-gaap:Goodwill" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_417022ae-cc14-4dcd-ae37-b90d7ca16af0" contextRef="C_ecff8a34-7794-4031-8fce-96f60d31dc7c" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> goodwill or intangible assets recorded. Under this method of accounting, BCTG was treated as the &#x201c;acquired&#x201d; company for financial reporting purposes. This determination was primarily based on the fact that subsequent to the Business Combination, Old Tango&#x2019;s stockholders possess a majority of the voting power of the combined company, the Company comprises all of the ongoing operations of Old Tango, the Company comprises a majority of the governing body of Old Tango, and the Company&#x2019;s senior management comprises all of the senior management of Old Tango.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These consolidated financial statements contain recasted stockholders' equity balances resulting from the retroactive application of reverse recapitalization accounting in accordance with U.S. GAAP.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Retroactive Application of Recapitalization to the Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#x2019; Equity (Deficit)</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7c08b689-5c1a-449b-8953-33c14bcc998a" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="tngx:SummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the terms of the Merger Agreement, upon the closing of the Business Combination on August 10, 2021 (the &#x201c;Effective Time&#x201d;), each share of Old Tango&#x2019;s redeemable convertible preferred stock (the &#x201c;Preferred Stock&#x201d;) issued and outstanding immediately prior to the Effective Time was converted into a share of the Company&#x2019;s common stock using the exchange ratio of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fafa8017-3b7d-4e93-9589-43fcdb1bc517" contextRef="C_278d8753-1cb2-473c-a8e0-50755d56d579" name="tngx:MergerRecapitalizationExchangeRatio" unitRef="U_pure" scale="0" decimals="2" format="ixt:numdotdecimal">0.34</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:9.468%;"></td>
        <td style="width:1.003%;"></td>
        <td style="width:16.066%;"></td>
        <td style="width:1.003%;"></td>
        <td style="width:0.646%;"></td>
        <td style="width:15.002%;"></td>
        <td style="width:0.646%;"></td>
        <td style="width:1.003%;"></td>
        <td style="width:0.646%;"></td>
        <td style="width:12.767%;"></td>
        <td style="width:0.646%;"></td>
        <td style="width:1.003%;"></td>
        <td style="width:0.646%;"></td>
        <td style="width:11.515%;"></td>
        <td style="width:0.646%;"></td>
        <td style="width:1.003%;"></td>
        <td style="width:0.646%;"></td>
        <td style="width:11.783%;"></td>
        <td style="width:0.646%;"></td>
        <td style="width:1.003%;"></td>
        <td style="width:0.646%;"></td>
        <td style="width:10.919%;"></td>
        <td style="width:0.646%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Date</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Redeemable Convertible Preferred Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Preferred to Common Exchange Ratio</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Common Stock Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">8/10/2021 Merger Recapitalization Exchange Ratio</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Recapitalization Common Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12/31/2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Series A</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bf56ec4f-96d1-4942-a8a8-e300c528a420" contextRef="C_28c70236-1fd3-49b1-a137-9ccf19f5d150" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">55,700,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_54fb9fc0-4acd-40bc-803a-b2047041f2e9" contextRef="C_28c70236-1fd3-49b1-a137-9ccf19f5d150" name="us-gaap:PreferredStockConvertibleConversionRatio" unitRef="U_pure" scale="0" decimals="2" format="ixt:numdotdecimal">1.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_59cea69e-137e-4a5a-b37f-a6d61d8685cb" contextRef="C_28c70236-1fd3-49b1-a137-9ccf19f5d150" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">55,700,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a7894194-fb92-460a-91cf-b9ee66922549" contextRef="C_86fa47f4-0478-4603-9095-4af7a4e6165d" name="tngx:MergerRecapitalizationExchangeRatio" unitRef="U_pure" scale="0" decimals="2" format="ixt:numdotdecimal">0.34</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bccb352e-b6eb-413c-ba66-a4697f7aad15" contextRef="C_28c70236-1fd3-49b1-a137-9ccf19f5d150" name="tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">18,922,317</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4/7/2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Series B (tranche 1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4f389613-2817-4c51-8c4b-7a8d1b8bb924" contextRef="C_d3c3e34d-cd50-4fb1-a2a9-829d2a4cfdc4" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">22,686,025</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7b606af7-3dd5-4221-8f57-f2a924779de4" contextRef="C_d3c3e34d-cd50-4fb1-a2a9-829d2a4cfdc4" name="us-gaap:PreferredStockConvertibleConversionRatio" unitRef="U_pure" scale="0" decimals="2" format="ixt:numdotdecimal">1.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3e8b4605-7580-4cad-bfcc-77b9eb271ab7" contextRef="C_d3c3e34d-cd50-4fb1-a2a9-829d2a4cfdc4" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">22,686,025</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b983b8f8-31e9-4280-9e5f-d727dab34b44" contextRef="C_c96d2de7-cf25-4b3d-9e34-1a5c2b302481" name="tngx:MergerRecapitalizationExchangeRatio" unitRef="U_pure" scale="0" decimals="2" format="ixt:numdotdecimal">0.34</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b39ab471-34ee-4b5e-bb14-2827fb4a671f" contextRef="C_d3c3e34d-cd50-4fb1-a2a9-829d2a4cfdc4" name="tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,706,861</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8/17/2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Series B-1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_958fc6fb-244b-4afd-98fc-c56d33a5f9cb" contextRef="C_1efa7be9-29eb-4c8a-a7b7-04a5517b4c9c" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">27,152,255</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_15afca3d-eaad-44eb-ad81-f1ff8bdbdef6" contextRef="C_1efa7be9-29eb-4c8a-a7b7-04a5517b4c9c" name="us-gaap:PreferredStockConvertibleConversionRatio" unitRef="U_pure" scale="0" decimals="2" format="ixt:numdotdecimal">1.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_18547699-337d-4d73-a1b6-051bc454a108" contextRef="C_1efa7be9-29eb-4c8a-a7b7-04a5517b4c9c" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">27,152,255</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_09138e1e-215a-4169-8b6f-2c9a39ece7e2" contextRef="C_4cfd2b0e-b7d6-48f4-ace9-bcb7b07f4adc" name="tngx:MergerRecapitalizationExchangeRatio" unitRef="U_pure" scale="0" decimals="2" format="ixt:numdotdecimal">0.34</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_277dcc74-619d-4183-a679-6d12fa33806f" contextRef="C_1efa7be9-29eb-4c8a-a7b7-04a5517b4c9c" name="tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">9,224,122</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3/18/2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Series B (tranche 2)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9ca7cabc-dc64-45c9-8bb1-5372498fe983" contextRef="C_eb62df54-f0e0-4a6d-9c99-33f08d82c127" name="us-gaap:TemporaryEquitySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">22,686,025</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b0711d9c-0e8f-4db4-9b58-93657e16cc28" contextRef="C_eb62df54-f0e0-4a6d-9c99-33f08d82c127" name="us-gaap:PreferredStockConvertibleConversionRatio" unitRef="U_pure" scale="0" decimals="2" format="ixt:numdotdecimal">1.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_961c9d02-9c5f-4003-a4f4-7cde2e0db906" contextRef="C_eb62df54-f0e0-4a6d-9c99-33f08d82c127" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">22,686,025</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b55e122e-906d-458b-9e93-0b0f8f6f8431" contextRef="C_9943303c-4c93-4a64-a1b1-6e1c309ffbd6" name="tngx:MergerRecapitalizationExchangeRatio" unitRef="U_pure" scale="0" decimals="2" format="ixt:numdotdecimal">0.34</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aa6625a1-676b-443d-a9fd-6747b445c031" contextRef="C_eb62df54-f0e0-4a6d-9c99-33f08d82c127" name="tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,706,861</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All common shares, as well as previously issued share options and restricted stock awards (&#x201c;RSAs&#x201d;), presented in the accompanying recasted consolidated statements of redeemable convertible preferred stock and stockholders' equity (deficit) and/or in the related notes are presented on an as-converted basis, converted at the ratio of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e69657ab-1181-47e6-8a20-9b6c29bbf771" contextRef="C_278d8753-1cb2-473c-a8e0-50755d56d579" name="tngx:MergerRecapitalizationExchangeRatio" unitRef="U_pure" scale="0" decimals="2" format="ixt:numdotdecimal">0.34</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Retroactive Application of Recapitalization to the Consolidated Statements of Operations and Comprehensive Loss</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In accordance with the retroactive application of recapitalization to the accompanying consolidated statements of redeemable convertible preferred stock and stockholders' equity (deficit), the basic and diluted weighted-average shares of common stock outstanding for the years ended December 31, 2021 and 2020 have been retroactively converted using the exchange ratio of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0d5eeb87-721a-427e-afc1-30f239cb65ce" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="tngx:MergerRecapitalizationExchangeRatio" unitRef="U_pure" scale="0" decimals="2" format="ixt:numdotdecimal"><ix:nonFraction id="F_67783860-36f6-4e32-b474-2e366acd6835" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="tngx:MergerRecapitalizationExchangeRatio" unitRef="U_pure" scale="0" decimals="2" format="ixt:numdotdecimal">0.34</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ca13be4e-b747-41bd-b410-9b649e94d6e1" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the weighted-average common shares, basic and diluted, for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2020:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:8.153%;"></td>
        <td style="width:0.945%;"></td>
        <td style="width:20.491%;"></td>
        <td style="width:1.293%;"></td>
        <td style="width:0.567%;"></td>
        <td style="width:9.704%;"></td>
        <td style="width:0.567%;"></td>
        <td style="width:0.716%;"></td>
        <td style="width:0.577%;"></td>
        <td style="width:10.022%;"></td>
        <td style="width:0.567%;"></td>
        <td style="width:0.945%;"></td>
        <td style="width:0.577%;"></td>
        <td style="width:10.668%;"></td>
        <td style="width:0.567%;"></td>
        <td style="width:0.945%;"></td>
        <td style="width:9.356%;"></td>
        <td style="width:0.945%;"></td>
        <td style="width:8.381%;"></td>
        <td style="width:0.945%;"></td>
        <td style="width:0.567%;"></td>
        <td style="width:11.941%;"></td>
        <td style="width:0.567%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Date</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As previously recorded</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">8/10/2021 Merger Exchange Ratio</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Recapitalized Common Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Days Outstanding in 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">% of weighting</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted average common shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12/31/2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Weighted-average shares, <br />basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_36b0bb38-a089-4064-98d7-1a090528326c" contextRef="C_bbbc1247-505e-469d-9e7c-232824266da5" name="tngx:WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">11,461,011</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0cbc5fe6-f759-4981-bd7e-a3c39c73b1fa" contextRef="C_278d8753-1cb2-473c-a8e0-50755d56d579" name="tngx:MergerRecapitalizationExchangeRatio" unitRef="U_pure" scale="0" decimals="2" format="ixt:numdotdecimal">0.34</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bb8683bb-ba7a-4d9b-99c2-4b61c482c2c0" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="tngx:WeightedAverageRecapitalizedCommonShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,893,305</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aace0a91-c528-4a01-b83f-0baac36038f0" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="tngx:ConversionWeightagePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_22e4287a-81fb-4ebf-b64b-4e3235ff75a7" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="tngx:WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,893,305</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12/31/2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Series A shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b48bc1cc-456c-4bb7-ac2f-4773cd4ff826" contextRef="C_02f13488-10b7-4401-9968-07685eb9a45e" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">55,700,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_30653cd8-8a6d-43c0-b645-ccb7c7a56050" contextRef="C_9c964121-e164-4d55-976f-d2ed2a2c4cf3" name="tngx:MergerRecapitalizationExchangeRatio" unitRef="U_pure" scale="0" decimals="2" format="ixt:numdotdecimal">0.34</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c105b53e-6b48-4e86-a9cd-4a35a3d237dc" contextRef="C_215089d0-d271-4311-98aa-2b60bca282f8" name="tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">18,922,317</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c008dea8-2235-4406-b739-09545a97e242" contextRef="C_54d3a1d3-953e-4a0b-ad72-8cc7769a4e4c" name="tngx:NumberOfDaysOutstanding" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">365</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b106d99a-8a93-4b9a-b94b-e3a0879b04d9" contextRef="C_54d3a1d3-953e-4a0b-ad72-8cc7769a4e4c" name="tngx:ConversionWeightagePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b7edcc1a-141d-4369-9e56-468ad403b284" contextRef="C_54d3a1d3-953e-4a0b-ad72-8cc7769a4e4c" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">18,922,317</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4/7/2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Series B shares</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_24351bfa-0dac-4703-8b9f-e8b3fd32da16" contextRef="C_9ce5d825-ac92-4a7e-80e6-cb453f08db17" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">22,686,025</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_78d5671c-2dc1-42f4-b207-5ac24c21ed21" contextRef="C_bec60272-dcf8-4c0e-bcea-ea6c80078013" name="tngx:MergerRecapitalizationExchangeRatio" unitRef="U_pure" scale="0" decimals="2" format="ixt:numdotdecimal">0.34</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c8b9133e-c7d9-4cb3-934a-fdbb706d8149" contextRef="C_f0761b4f-fae1-40c4-a58b-8ac4939b226c" name="tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,706,443</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d3657253-8591-4fbd-abdb-ba68217923e6" contextRef="C_4d340cce-d3f4-48f6-8dc7-031a8c6e1628" name="tngx:NumberOfDaysOutstanding" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">268</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_efab343e-7de7-4a97-9e06-73a5da896b4d" contextRef="C_4d340cce-d3f4-48f6-8dc7-031a8c6e1628" name="tngx:ConversionWeightagePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">73</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2d145607-27d2-4a0d-a5f9-22a9baf260c7" contextRef="C_4d340cce-d3f4-48f6-8dc7-031a8c6e1628" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,664,025</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8/17/2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Series B-1 shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_03688942-d6bd-4811-b09a-55a74cca03eb" contextRef="C_102b7845-9bed-440d-ab31-e9a0c961e54f" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">27,152,255</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6e4c8c27-26c8-4bdb-8143-d896d424fa82" contextRef="C_8b25831a-e551-4e81-9130-6ba7264df810" name="tngx:MergerRecapitalizationExchangeRatio" unitRef="U_pure" scale="0" decimals="2" format="ixt:numdotdecimal">0.34</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_362d9dd8-25fe-4990-9156-9f8dd23db5b8" contextRef="C_12c81343-6906-4a1c-8cc1-2e51478b9b44" name="tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">9,223,621</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_489983f5-5796-4407-b741-04f9f6d9d2ed" contextRef="C_a1ba7f84-139b-48f6-aaf0-8e1842c93c6e" name="tngx:NumberOfDaysOutstanding" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">136</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d769b50c-d5b2-4cfe-b869-93a3243d9e4e" contextRef="C_a1ba7f84-139b-48f6-aaf0-8e1842c93c6e" name="tngx:ConversionWeightagePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">37</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7d106fb2-c781-4756-a754-41b885495ca6" contextRef="C_a1ba7f84-139b-48f6-aaf0-8e1842c93c6e" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,452,558</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td colspan="19" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Weighted average number of common shares outstanding &#x2013; basic and diluted for the year ended December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_db11dded-8361-4b1a-b33e-9c6cd9e5074a" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">31,932,204</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Retroactive Application of Recapitalization to the Consolidated Balance Sheets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To conform to the retroactive application of recapitalization to the accompanying consolidated statements of redeemable convertible preferred stock and stockholders' equity (deficit), historical proceeds from the issuance of preferred stock, less the par value of the historical preferred shares that were converted into common shares using the </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6ae278b7-4df9-4903-b06d-b16a726eea8c" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="tngx:MergerRecapitalizationExchangeRatio" unitRef="U_pure" scale="0" decimals="2" format="ixt:numdotdecimal"><ix:nonFraction id="F_966b9a87-40d8-4258-ac61-aae33defa722" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="tngx:MergerRecapitalizationExchangeRatio" unitRef="U_pure" scale="0" decimals="2" format="ixt:numdotdecimal">0.34</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> ratio at the Effective Time, have been reclassified to additional paid in capital for the years ended December 31, 2021 and 2020, respectively.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eef2ecbe-38f1-4f4c-ba87-c652471f8a2e" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4. Collaboration Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2018 Gilead Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2018, the Company entered into a Research Collaboration and License Agreement (the &#x201c;2018 Gilead Agreement&#x201d;) with Gilead Sciences, Inc. (&#x201c;Gilead&#x201d;). Pursuant to the 2018 Gilead Agreement, the Company performed target discovery and validation activities in accordance with an agreed-upon a multi-year research plan. During the initial </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2bf8c9ee-4d2f-41c0-9330-304bd29c7087" contextRef="C_b5f7538f-2233-432c-8332-5f9eee3f4625" name="tngx:ResearchTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> research term, Gilead had the option to obtain exclusive, worldwide licenses to develop and commercialize up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_51dad5c5-cee4-479c-ba80-c67f14efa43d" contextRef="C_b5f7538f-2233-432c-8332-5f9eee3f4625" name="tngx:NumberOfLicensedProduct" unitRef="U_Program" decimals="INF" format="ixt-sec:numwordsen">five</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> validated programs (&#x201c;Gilead Program License&#x201d;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2018, Gilead paid the Company a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f27b6607-8e9b-404a-941b-09bbe2f47c21" contextRef="C_f0aee49e-cda1-49dc-bfc8-ca8549516a0d" name="tngx:NonrefundableUpfrontPaymentsReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million non-refundable upfront payment upon the execution of the 2018 Gilead Agreement. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company was eligible to receive milestone payments of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_91ba0a90-b4e0-4ace-a66e-2f62c4e78855" contextRef="C_53e4d63e-21a6-43e4-9dcd-522040ca6553" name="tngx:MilestonePaymentsReceivable" unitRef="U_USD" scale="9" decimals="-8" format="ixt:numdotdecimal">1.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> billion across all programs and royalties on future sales of commercialized products, if any. For up to two programs licensed by Gilead, the Company had the option to co-develop and co-promote certain programs licensed by Gilead in the U.S. and was eligible to receive royalties on ex-U.S. sales</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company assessed this arrangement in accordance with ASC 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and concluded that the contract counterparty, Gilead, was a customer. The Company identified a single performance obligation under the arrangement consisting of the combination of participating on the joint steering committee and the research and development services provided during the research term. The identified promises were determined to not be individually distinct due to the specialized nature of the early-stage research services to be provided by the Company and the interdependent relationship between the promises. The Company determined that the option for Gilead to extend the term of the arrangement was not priced at a discount, and therefore did not provide Gilead with a material right. This option will be excluded from the transaction price until exercised. At the inception of the 2018 Gilead Agreement, the Company also determined that the Gilead program license options provided to Gilead did not include a material right.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The total transaction price, subject to variable consideration constraints, was allocated to the combined single performance obligation. The Company determined that the single combined performance obligation is satisfied over time as the customer is simultaneously receiving and consuming the benefit of the Company&#x2019;s performance. The future milestone payments represent variable consideration that is fully constrained at inception of the arrangement as the achievement of the milestone events are highly uncertain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Amended Gilead Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2020, Gilead made an equity investment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_be2eb3eb-0672-4217-9bc6-cc3a56bcfad7" contextRef="C_1788c8d9-b2a8-41ee-b8fb-f1e5436c41eb" name="us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million into the Company as a participant in the Company&#x2019;s Series B-1 preferred stock offering. At the time of the original investment, as well as of the December 31, 2021 balance sheet date, Gilead maintains an ownership of less than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4983ff61-83fb-418f-b28f-7b58ea228ead" contextRef="C_a752877b-c28d-4699-ba2c-e36a1efb2376" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company's common stock and is thus not considered to be a related party to the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2020, the Company and Gilead also entered into an Amended Research Collaboration and License Agreement (the &#x201c;Gilead Agreement&#x201d;), which superseded and replaced the 2018 Gilead agreement. The Gilead Agreement represents a continuation of the initial target discovery and validation research and development efforts begun under the 2018 Gilead Agreement. Under the Gilead Agreement:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company received upfront, non-refundable consideration of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5ddffacb-bf10-426c-89aa-c0e9b56f1218" contextRef="C_ff6e5760-462e-48b4-9885-3a1afb5a7028" name="us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">125.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million from Gilead upon execution of the Gilead Agreement in 2020; </span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The term of the 2018 Gilead Agreement ended on the date the Gilead Agreement was executed. The Gilead Agreement has a research term of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ed706d5e-3798-463e-a304-790a6be0ba6c" contextRef="C_7e5ec8fe-aded-4985-ba52-0a77d0cc933c" name="tngx:ResearchTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seven years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">; </span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gilead expanded its option to license up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1526fb82-6538-4208-9982-8cc7dc325eff" contextRef="C_7e5ec8fe-aded-4985-ba52-0a77d0cc933c" name="tngx:NumberOfLicensedProduct" unitRef="U_Program" decimals="INF" format="ixt:numdotdecimal">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> programs for which Gilead may obtain exclusive, worldwide licenses to develop and commercialize therapies, subject to applicable license fees; </span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to exercising its option to license a program, Gilead may &#x201c;extend&#x201d; such program, in which case Gilead will pay research extension fees and the Company will continue to collaborate with Gilead to discover and develop programs, potentially through early clinical development; </span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gilead has the option to &#x201c;reserve&#x201d; a target during which Gilead may: (i) license the target, (ii) &#x201c;extend&#x201d; the target, or (iii) decline the target, during the designated reserve target period. If, during the reserve target period Tango elects to work on the reserved target, Tango will retain full rights to the target program and Gilead receives a right of first negotiation in connection with any future partnering or licensing of such target by Tango, if any; and </span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For up to five programs licensed by Gilead, the Company has the option to co-develop and co-promote the lead product in the U.S., subject to certain exceptions, and is eligible to receive tiered royalties in the first decile on ex-U.S. sales. </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company is eligible to receive up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1d89d071-84ac-4e22-9bb7-4bd9084bdd64" contextRef="C_ff6e5760-462e-48b4-9885-3a1afb5a7028" name="tngx:MilestonePaymentsReceivable" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">410.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million per program in license, research extension, and clinical, regulatory, and commercial milestones</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Gilead Agreement was accounted for as a modification of the 2018 Gilead Agreement under ASC 606 as both the scope and price of the contract were changed under the Gilead Agreement. The additional goods and services to be provided under the Gilead Agreement are not distinct from the combined performance obligation identified under the 2018 Gilead Agreement which was only partially satisfied at the date of contract modification. As such, the Company identified a single combined performance obligation under the Gilead Agreement consisting of the research services and continued participation on the joint steering committee during the research term. As a result, the Company&#x2019;s progress towards completing its research services to Gilead over the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_87eee455-78ac-4648-9de6-a005c014a83a" contextRef="C_7e5ec8fe-aded-4985-ba52-0a77d0cc933c" name="tngx:ResearchTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seven-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> term of the Amended Gilead Agreement was lower than its progress under the three-year term of the 2018 Gilead Agreement and a cumulative catch-up adjustment was recorded during the third quarter of 2020 resulting in a charge of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_425c1843-e530-4a01-afee-cb0a0a96fcf1" contextRef="C_f2607f6a-532b-425d-bef1-6f23ecb3ca7b" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">11.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million against revenue previously recognized through the date of the Gilead Agreement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020 and in September 2021, Gilead elected to extend two programs for a research extension fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_03c2c1c1-5a67-4a99-a2e0-dc7d54ef601d" contextRef="C_e9180ff9-f174-4296-94c6-215c9a213af5" name="tngx:ResearchExtensionFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_d289aea2-7441-4ae9-b488-d6852e839383" contextRef="C_23df1860-e6dc-439c-b62d-1e850c67c5c6" name="tngx:ResearchExtensionFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">12.0</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million each. The Company determined that the additional goods and services relating to the continued research services were not distinct from the early-stage research services already promised to Gilead under the on-going research plan. Consideration pertaining to each of the research extensions is paid to the Company in equal quarterly installment payments over an agreed upon payment schedule. Although future research installment payments are not payable in the event of scientific failure, the Company determined that the variable consideration of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6942ab59-2cd3-403c-aa12-30b4284207f4" contextRef="C_16173712-f7d9-4b40-a745-785b1fd272f9" name="tngx:ResearchExtensionFeeVariableConsideration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">12.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">for each of the extensions should</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">be constrained as the potential for a significant reversal of cumulative revenue recognized at the contract level is remote, and therefore the research extension consideration was added to the transaction price under the Gilead Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2021, Gilead licensed a program for an $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f134a5e-eff7-434c-a2e7-1498f52338ec" contextRef="C_fe7f16a9-c541-41d8-939f-8739b8cdc7e4" name="tngx:SponsoredALicenceProgramfeeAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million license fee. The $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7cda1dca-bb1e-4455-a25b-3dbfad427b5f" contextRef="C_2a0dabb0-2512-43fe-b76a-9eb289d5c030" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million license fee was received and recognized as revenue in the second quarter of 2021 since Tango has no continued involvement in the advancement of the program, Gilead can benefit from the license on its own and the license is separately identifiable from the research services.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Gilead Revenue Recognized</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The total transaction price allocated to the combined performance obligation under the Gilead Agreement was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_26185bd4-2e53-4998-ad36-a5ffa083c7a1" contextRef="C_511b1fab-19fa-4719-9e1a-7d2d78a9c251" name="us-gaap:RevenueRemainingPerformanceObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">199.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The total transaction price was comprised of the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b9d37a94-9802-4469-bfd8-5e25cefbb43a" contextRef="C_89ff1d64-5c59-4fe4-b302-72f7ae4dcbe5" name="tngx:NonrefundableUpfrontPaymentsReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upfront payment pursuant to the 2018 Gilead Agreement, the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5ee05e3a-f5b8-4e2c-ade0-a30075125dd5" contextRef="C_16173712-f7d9-4b40-a745-785b1fd272f9" name="tngx:NonrefundableUpfrontPaymentsReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">125.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upfront payment pursuant to the Gilead Agreement, the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b179ec0b-273c-4aa9-88c0-757b49f7c6d4" contextRef="C_e9180ff9-f174-4296-94c6-215c9a213af5" name="tngx:ResearchExtensionFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">12.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million payment pursuant to the research extension fee in December 2020, and the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b0287f0d-2988-4acf-8172-13220bd3646c" contextRef="C_23df1860-e6dc-439c-b62d-1e850c67c5c6" name="tngx:ResearchExtensionFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">12.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million payment pursuant to the research extension fee in September 2021. During the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021, the Company recognized </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6947e454-f864-496a-b27e-155af57c4837" contextRef="C_ee792758-9f05-4175-9451-5b418924373a" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">26.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of collaboration revenue associated with the Gilead Agreements based on performance completed during the period. During the year ended December 31, 2020, the Company recognized </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_03b44042-9157-4629-b5f9-002f8b6e211c" contextRef="C_27037302-4c51-4ed7-bedc-d4aef3c65de1" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of collaboration revenue associated with the Gilead Agreements based on performance completed during the period which was partially offset by a reduction in revenue resulting from a cumulative catch-up adjustment that was recorded during the third quarter in connection with the Amended Gilead Agreement. During the year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company recognized license revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_de52f843-dd3b-463e-bf26-33fdd8a6370b" contextRef="C_7736b799-fc9e-41cb-ac3c-ebefeef52eb3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, associated with the payment received in the second quarter of 2021 pursuant to the April 2021 program license. During the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2020, the Company recognized license revenue </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fb374ce8-f8fa-402a-a036-7cece09ecb1d" contextRef="C_eafdff08-f1e7-45e0-b53f-598f4991a9f3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">associated with the payments received in 2019 pursuant to the program license and Gilead side letter agreement. The consideration allocated to the Gilead License was recognized upon delivery of the underlying license in 2019 as Gilead could benefit from the license on its own and the Gilead License was separately identifiable from the Gilead side letter agreement research services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company reevaluates the transaction price and the total estimated costs expected to be incurred to satisfy the performance obligations at the end of each reporting period and as uncertain events, such as changes to the expected timing and cost of certain research and development activities that the Company is responsible for, are resolved or other changes in circumstances occur.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> As of December 31, 2021 and 2020</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company had short-term deferred revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_22c89913-bb51-480f-9a81-028a8ead370d" contextRef="C_511b1fab-19fa-4719-9e1a-7d2d78a9c251" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">26.0</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_40a3d5f4-06fe-4fed-bcaf-65c28dd86a5e" contextRef="C_cf39d22f-09b3-4d53-87d3-8d7dc1f67897" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">32.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and long-term deferred revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_017116b3-e3e8-415a-86d5-e184ba780e67" contextRef="C_511b1fab-19fa-4719-9e1a-7d2d78a9c251" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">114.7</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f2cbb6fe-3d72-44d0-81e7-e28bc0058520" contextRef="C_cf39d22f-09b3-4d53-87d3-8d7dc1f67897" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">120.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, res</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">pectively, related to the Gilead collaboration. The remaining long-term revenue is expected to be recognized proportionally to the completed obligations over an expected remaining contractual term of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9e226477-5820-4ffa-b090-6184cee6ce55" contextRef="C_407a2f79-30e9-41df-8dfa-8788fa29b7cb" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.6</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amounts due to the Company that have not yet been received are recorded as accounts receivable and amounts received that have not yet been recognized as revenue are recorded as deferred revenue on the Company&#x2019;s consolidated balance sheets. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9d8a29e9-e82b-4a5e-b61f-778b339de60b" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ProceedsFromFeesReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">14.0</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of the total research extension fees of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dd021af2-bd9e-4b3c-ae96-aefe8dc566d4" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="tngx:ReceivableResearchExtensionFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">24.0</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million had been received, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_43bddbac-e397-4d47-8239-77953b5a30b7" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="tngx:AccountsReceivableCurrentResearchExtensionFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million had been recorded as accounts receivable and the remaining $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_09fa9dd0-320d-47dc-a9e6-7354889b7c0d" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="tngx:Contractassetresearchextensionfee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.0</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was determined to be conditional upon the satisfaction of additional research obligations, and thus a contract asset. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The contract asset balance is presented net of the deferred revenue contract liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Costs incurred pursuant to the Gilead Agreements are recorded as research and development expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6016809a-f078-4e9e-abdf-b2bd66857a12" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" escape="true" continuedAt="F_6016809a-f078-4e9e-abdf-b2bd66857a12_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5. Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_58a07f75-5377-41ef-8d53-96f5f4be7833" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.325%;"></td>
        <td style="width:1.163%;"></td>
        <td style="width:1.263%;"></td>
        <td style="width:9.884%;"></td>
        <td style="width:0.616%;"></td>
        <td style="width:1.163%;"></td>
        <td style="width:1.263%;"></td>
        <td style="width:9.943%;"></td>
        <td style="width:0.616%;"></td>
        <td style="width:1.163%;"></td>
        <td style="width:1.263%;"></td>
        <td style="width:9.735%;"></td>
        <td style="width:0.616%;"></td>
        <td style="width:1.163%;"></td>
        <td style="width:1.263%;"></td>
        <td style="width:9.943%;"></td>
        <td style="width:0.616%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Market Value Measurements<br />as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7fa0b138-4641-4718-83be-7b9e30fba07f" contextRef="C_c15c2969-e6e9-437c-89f0-0a388a5877e2" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,244</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a762df4b-f3ed-4d4a-a408-0c28875d2805;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_50941480-7cbb-4d2d-acd2-82a05d5e66ef" contextRef="C_068a6be4-9f16-496f-98c5-0d1f32f3787e" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,244</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury bills</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d5f33a62-ad8c-4e17-b3c6-58449ff6fa3a" contextRef="C_298c6bea-143e-4985-beea-3b429f7512a4" name="us-gaap:USGovernmentSecuritiesAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,433</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7aed663f-33c9-4a86-b405-e03e3ed8f388" contextRef="C_068a6be4-9f16-496f-98c5-0d1f32f3787e" name="us-gaap:USGovernmentSecuritiesAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,433</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Marketable debt securities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury bills</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fcd7719b-4d90-46b3-b3f9-e55f6e0b0092" contextRef="C_f6a066c6-0c2f-4fc7-b6b0-b827d92388ad" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">287,123</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3c8eee5a-6008-4232-a776-7a2fcb0b787b" contextRef="C_541297f2-8d87-4855-8f1c-53e1e755ed5a" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">287,123</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government agency bonds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1f968655-26b8-43a1-b89a-2eb3fc35baa6" contextRef="C_7d2bf4c6-5a88-4f48-9b87-0040ef400364" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,387</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8ae047a4-f0f4-4a60-a859-e287b6bce81e" contextRef="C_77f3de9c-11d0-45e7-b744-00f10cdd56b9" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,387</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_489a5919-b4ec-4e1a-92e1-b7b2f31491e5" contextRef="C_c15c2969-e6e9-437c-89f0-0a388a5877e2" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,244</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_65fb2b09-ada2-44f0-87bd-20b3f246c592" contextRef="C_298c6bea-143e-4985-beea-3b429f7512a4" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">380,943</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1a00d671-aa7f-4b14-8a4e-00790f3d5327" contextRef="C_068a6be4-9f16-496f-98c5-0d1f32f3787e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">443,187</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.518%;"></td>
        <td style="width:1.193%;"></td>
        <td style="width:1.273%;"></td>
        <td style="width:9.526%;"></td>
        <td style="width:0.636%;"></td>
        <td style="width:1.193%;"></td>
        <td style="width:1.273%;"></td>
        <td style="width:9.546%;"></td>
        <td style="width:0.636%;"></td>
        <td style="width:1.193%;"></td>
        <td style="width:1.273%;"></td>
        <td style="width:9.456%;"></td>
        <td style="width:0.636%;"></td>
        <td style="width:1.193%;"></td>
        <td style="width:1.273%;"></td>
        <td style="width:9.546%;"></td>
        <td style="width:0.636%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Market Value Measurements<br />as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b4c86d23-ce77-4c41-928b-4f0d0d5ce706" contextRef="C_a908a175-5b6c-474d-a2f6-5ae2b7895667" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,698</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0b637d1f-640c-496c-91b4-be2bae95b9b9;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3be42864-8852-4424-a1fc-49a50849c90a" contextRef="C_274ae3eb-6528-4797-924a-99295d4ce141" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,698</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury bills</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3e9adffe-05c9-49c3-be48-3ac87cb53ed4" contextRef="C_3461b9bd-5e6d-4357-91f1-01033ae50263" name="us-gaap:USGovernmentSecuritiesAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,175</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1f15c3bb-7e33-48cb-b944-f11daf67706d" contextRef="C_274ae3eb-6528-4797-924a-99295d4ce141" name="us-gaap:USGovernmentSecuritiesAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,175</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Marketable debt securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury bills</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1f0a7138-e397-4d22-a346-3ea6d8678a2e" contextRef="C_50f18cbc-9bd3-450e-8121-9d1f8276ed3c" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">131,939</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e5864452-a828-4444-a88f-eeae82ba735a" contextRef="C_c89c0bd3-61fe-4fe1-aaf8-04c333eb7930" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">131,939</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government agency bonds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8a5b092b-6db4-43c5-87a1-78e408fa1464" contextRef="C_b1561790-aba2-4710-8ff9-2107c95bfddb" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6694cd62-8d36-4e2d-806e-1e485d94d6a9" contextRef="C_28f5ff88-be03-44d4-a0e8-fd39586ab708" name="us-gaap:InvestmentsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3b13b35f-1e6b-438f-a760-c03a03f6dee7" contextRef="C_a908a175-5b6c-474d-a2f6-5ae2b7895667" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,698</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4ac6b563-c792-4484-9822-3655bda61417" contextRef="C_3461b9bd-5e6d-4357-91f1-01033ae50263" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">169,114</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6614c887-0b1d-4fb2-8e54-db85eb4acded" contextRef="C_274ae3eb-6528-4797-924a-99295d4ce141" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">181,812</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_6016809a-f078-4e9e-abdf-b2bd66857a12_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_40883a4f-816d-488c-a120-8b3f62f9e51c" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7f00175c-fa11-4af8-b562-4e8b810ae48f" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7bf213e2-d3a3-4d3b-9306-4405a4100af1" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_34752e3c-2e9e-4f44-b6fd-fda362010f62" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> transfers between fair value levels during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f41d5099-9526-4498-b949-3300ae8dedf5" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal"><ix:nonFraction id="F_2ee338b9-c6bf-4189-8fb3-e62f9e40006c" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal"><ix:nonFraction id="F_0bc77dc7-5149-40fd-90a8-90e9e5fbfc89" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal"><ix:nonFraction id="F_e29565d5-3353-4ce0-a300-370835d0257b" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_00e7c4ec-3fef-4f34-866f-649673519cde" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true" continuedAt="F_00e7c4ec-3fef-4f34-866f-649673519cde_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6. Marketable Securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company values its marketable securities using independent pricing services which normally derive security prices from recently reported trades for identical or similar securities, making adjustments based on significant observable transactions. At each balance sheet date, observable market inputs may include trade information, broker or dealer quotes, bids, offers or a combination of these data sources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_40147b34-1987-4f5d-a0dc-8da33b0c0534" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the Company&#x2019;s marketable debt securities, classified as available-for-sale:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:41.286%;"></td>
        <td style="width:1.382%;"></td>
        <td style="width:1.272%;"></td>
        <td style="width:11.333%;"></td>
        <td style="width:0.636%;"></td>
        <td style="width:1.382%;"></td>
        <td style="width:1.272%;"></td>
        <td style="width:11.333%;"></td>
        <td style="width:0.636%;"></td>
        <td style="width:1.382%;"></td>
        <td style="width:1.272%;"></td>
        <td style="width:11.333%;"></td>
        <td style="width:0.855%;"></td>
        <td style="width:1.382%;"></td>
        <td style="width:1.272%;"></td>
        <td style="width:11.333%;"></td>
        <td style="width:0.636%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value Measurements<br />as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized<br />Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br />Unrealized<br />Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br />Unrealized<br />Loss</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair<br />Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Marketable debt securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury bills</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1ac5e498-b89f-42d5-b6c8-97bc6871609c" contextRef="C_f6d997d2-d3a1-431e-a764-711fd76bb4c5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">287,699</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_741f0ef8-4d86-4ef9-8ef5-a0469c718a18" contextRef="C_f6d997d2-d3a1-431e-a764-711fd76bb4c5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f3ebf75-7f0e-44d3-bda1-7391c47ca0ba" contextRef="C_f6d997d2-d3a1-431e-a764-711fd76bb4c5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">577</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_525de4b1-6361-46f4-9a03-9c1b0b05120e" contextRef="C_f6d997d2-d3a1-431e-a764-711fd76bb4c5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">287,123</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government agency bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_571e912b-dd31-465e-bbb0-2042cc8e0ad2" contextRef="C_2065fc3b-bae5-4c9b-8a8a-012ebcce2f51" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,576</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_388c1bac-a8b7-40dd-be44-a79f3345d1f7" contextRef="C_2065fc3b-bae5-4c9b-8a8a-012ebcce2f51" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">189</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_22104bce-4971-4365-982e-17071bf90f0e" contextRef="C_2065fc3b-bae5-4c9b-8a8a-012ebcce2f51" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,387</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_789c2ac8-4cae-4a6f-b8fc-4f201b0b38b7" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">343,275</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d5a23b42-be6c-4e7c-9da2-8e085d0c46dd" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1dacb90a-e873-4c87-990a-85986a570461" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">766</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_19abf988-4243-488a-8ee6-f9f53e99394f" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">342,510</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:41.397%;"></td>
        <td style="width:1.392%;"></td>
        <td style="width:1.272%;"></td>
        <td style="width:11.351%;"></td>
        <td style="width:0.636%;"></td>
        <td style="width:1.392%;"></td>
        <td style="width:1.272%;"></td>
        <td style="width:11.351%;"></td>
        <td style="width:0.636%;"></td>
        <td style="width:1.392%;"></td>
        <td style="width:1.272%;"></td>
        <td style="width:11.351%;"></td>
        <td style="width:0.636%;"></td>
        <td style="width:1.392%;"></td>
        <td style="width:1.272%;"></td>
        <td style="width:11.351%;"></td>
        <td style="width:0.636%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value Measurements<br />as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized<br />Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br />Unrealized<br />Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br />Unrealized<br />Loss</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Marketable debt securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury bills</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f1c4b91e-8194-41de-8e9c-0612d39e272b" contextRef="C_7b2e605f-e833-48d9-925e-ef6e94396041" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">131,927</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b926604b-47fa-4f7a-b709-a5acd49256b0" contextRef="C_7b2e605f-e833-48d9-925e-ef6e94396041" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2fadbd78-6098-4b9b-9a40-1a073d67d39c" contextRef="C_7b2e605f-e833-48d9-925e-ef6e94396041" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">131,939</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government agency bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d0033d8d-398b-46eb-bde8-de804069f76e" contextRef="C_443492d4-1dcb-460f-9785-b7dc5f094e40" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,995</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ff3b4b11-e345-46fa-9473-69b7de6d053a" contextRef="C_443492d4-1dcb-460f-9785-b7dc5f094e40" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c9cc05fe-a260-4f3f-bc4d-89d820d346a6" contextRef="C_443492d4-1dcb-460f-9785-b7dc5f094e40" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_efde379e-15dd-40d0-a89c-40eca236eb06" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">161,922</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_334a2a0e-0ee1-44a1-9a89-bc643eea7858" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_786a1fce-2205-4e91-8887-7bdeb2c30e27" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">161,939</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_00e7c4ec-3fef-4f34-866f-649673519cde_1"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company holds investment grade marketable securities, with less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1dc8f64f-ae7b-4fb7-b8aa-8372fe77e911" contextRef="C_767a7086-7e98-4669-a6a3-ba4e0f1c5fc1" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of marketable debt securities considered to be in an unrealized loss position as of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7a44167a-8aa9-43c1-a467-d6e44b038ed0" contextRef="C_cca1c772-6eb6-4c26-835c-7b92064cf842" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">none</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> considered to be in an unrealized loss position as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2020. Although the marketable debt securities are held at an unrealized loss position at December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company does not intend to sell the marketable securities prior to the value of the securities being recovered. Further, the Company has concluded that it is more likely than not that the marketable securities cost basis values will be recovered prior to sale of the securities and that there are no conditions or events that might require the Company to sell the securities before recovery of the cost basis occurs. As a result, the Company did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_91431bd5-0193-403e-bc4a-3a462a1d667e" contextRef="C_4941cdcd-9899-46a1-b43b-5fcbeb247365" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_30585799-ecdb-4a5b-ac64-83c04278c2c3" contextRef="C_adf61d0e-b654-4419-b270-224361ec9e78" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t record any impairments to marketable securities or reserves for credit losses related to its marketable debt securities during the periods then ended. Marketable securities include $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3021dfb0-68b9-4d4d-ad3c-125d703abf14" contextRef="C_13789a54-6583-461f-ace8-50d596a0d9e6" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ed50fb45-dee6-4085-a31f-d7b8a84e9930" contextRef="C_cca1c772-6eb6-4c26-835c-7b92064cf842" name="us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in accrued interest at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and December 31, 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c368f663-2504-4667-8364-bb089ab27bc0" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7. Supplemental Balance Sheet Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_38736709-ec07-419c-a22f-30e125f435b4" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020 consists of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.267%;"></td>
        <td style="width:1.558%;"></td>
        <td style="width:1.525%;"></td>
        <td style="width:13.268%;"></td>
        <td style="width:1.016%;"></td>
        <td style="width:1.558%;"></td>
        <td style="width:1.525%;"></td>
        <td style="width:13.268%;"></td>
        <td style="width:1.016%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bd23512a-e93d-4e01-96d6-1d37e1dfdeae" contextRef="C_3a91db9e-6734-413e-8e17-66bb5d8bf9ac" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,587</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1e314af0-55f2-4bd3-88eb-99747a8d103f" contextRef="C_292501bc-d852-43e2-83eb-a3fe171ce656" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,580</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b1fb9eb1-3fc8-4c65-a122-9381745bd5fc" contextRef="C_31658d1c-3873-4646-a06e-c5e4358d9429" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">198</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7b05af27-89af-4f99-8ecb-0e63e2501afa" contextRef="C_282b9328-036d-4123-bd3c-893d0d979dbc" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">172</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer software</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_943e230c-9b65-4872-bce2-6e5bfcaf6220" contextRef="C_e935a51c-44f5-45c0-8969-0acd3c8dce51" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">125</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c416a4ec-699b-4319-9d4d-61c77b861b30" contextRef="C_8b242d70-f5a0-401d-9c7c-8f5525429c2b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">125</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4e7764a7-850f-4846-a4a3-ff1fb55c8f45" contextRef="C_8a373566-cfe9-4a8d-b52b-3ba1ff5a8bdc" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">467</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1b9b6fdc-6b97-4291-84e3-00e0330519f0" contextRef="C_9229ee0f-56b0-498f-a9f5-422119379b39" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">384</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b78c211c-4f90-4f0f-8699-3c822920b69e" contextRef="C_af91c863-9582-40c7-8c3d-51a5ac90d570" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">246</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1c5cdde5-73ae-43f6-9a71-7c32132af269" contextRef="C_b1745945-8454-47c6-9623-cbfd040e27d1" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">246</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction in progress</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_307b1605-d508-489a-b8fb-3ba69503bfd2" contextRef="C_f25b4a33-16a9-486a-8c10-2233f7ee8a8a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">738</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_951d6af3-a973-46b9-9f17-f5ebae843137" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,361</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7302655d-1f06-4be5-8f80-8e613dc8ed83" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,507</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Accumulated depreciation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0ed5c54d-0bf4-4616-ac7d-ce9c3068df9c" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,529</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_632e349c-4fb8-4c1b-9c97-a46c0a184364" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,684</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c852d4c1-47e7-4e03-ba86-8a208d810a01" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,832</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0e9e3463-5c1a-4514-ad6e-ee6f1f12e102" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,823</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation expense was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4ba0b50f-2f23-4489-bfed-2101eee3e0d6" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_53f1e10b-aa87-4f30-831f-30c7720cc8be" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for the years ended December 31, 2021 and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accrued Expenses and Other Current Liabilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_36a57877-65e9-4a67-828f-a74358c257d1" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="tngx:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other current liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020 include the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.54%;"></td>
        <td style="width:1.568%;"></td>
        <td style="width:1.535%;"></td>
        <td style="width:13.408%;"></td>
        <td style="width:0.718%;"></td>
        <td style="width:1.568%;"></td>
        <td style="width:1.535%;"></td>
        <td style="width:13.408%;"></td>
        <td style="width:0.718%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payroll and employee-related costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3b930ce5-b0ba-445d-a95e-a64f0bb269a0" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,688</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c9d49251-fd37-458a-845e-872c951f8a9f" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,652</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development costs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1b130c08-94fe-41da-8c67-d1066a88f619" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="tngx:AccruedResearchAndDevelopmentCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,533</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_89257bd4-2188-40eb-8bc6-55943165df56" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="tngx:AccruedResearchAndDevelopmentCostsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,695</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c5f88c6d-1dab-4960-bb50-9fd842ddc1e9" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">666</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c85dc1e7-567e-4c6d-b27b-076ce99ca6af" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">793</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_903fe0bd-2cce-4cde-8592-9240198bc0d3" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="tngx:AccruedExpensesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,887</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_92f83b91-9f17-47e6-92ef-7a154992bbdc" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="tngx:AccruedExpensesAndOtherCurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,140</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div><ix:nonNumeric id="F_ac6240d7-36c5-4cf4-9910-0f11d29716e2" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8. Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2017, the Company entered into a lease of office and laboratory space at 100 Binney Street in Cambridge, Massachusetts for the Company&#x2019;s corporate headquarters. The lease commenced in March 2018 and rent commenced in June 2018. This lease had an original term of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f4ec1fab-2c83-406c-bc22-39784328f83d" contextRef="C_f01892b3-15ca-4460-8be5-0c673db5d09c" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">eight years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> with an </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e2c0065f-e016-40a4-99fc-148aa5612190" contextRef="C_4a8a40a2-67af-41ac-a7da-247f61928fb4" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_651aa0e8-a146-429b-b499-66da6cd5f106" contextRef="C_4a8a40a2-67af-41ac-a7da-247f61928fb4" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">option to extend</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_9ce82792-73b0-4614-be7e-852d5e09b293;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional</span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_086f3570-1f34-4156-b124-f1c8a8434a53" contextRef="C_75a3203a-e21d-4b7a-bf56-5007b4cfa6c3" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> three-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> period.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon commencement of the lease, the Company recorded an operating lease liability in the amount of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_88efa716-1882-46d5-8ce9-cd8d35b0af00" contextRef="C_42860419-a9e3-4801-beb1-962b31b7feab" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and related operating lease right-of-use asset in the amount of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a883da04-cd62-4b2a-a8f4-aa7250936e25" contextRef="C_42860419-a9e3-4801-beb1-962b31b7feab" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. Upfront payments totaling $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bc519695-199d-47c1-aa82-d541faf2256a" contextRef="C_1c301094-2824-489c-bf63-ea4093ace32f" name="tngx:UpfrontPaymentsForRentAndTenantImprovements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for rent and tenant improvements were included as a reduction in the calculation of the lease liability amount upon the commencement of the lease. There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_507ea5ed-e817-4c6d-997a-91cd364dbb62" contextRef="C_02d11875-4147-4360-a8aa-e87bfd6290ea" name="us-gaap:PaymentsForTenantImprovements" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_3c5f4874-aa9e-4c99-ba8e-b76f4c804eea" contextRef="C_7aee73e0-1a70-49bf-b3fe-767d20ffc569" name="us-gaap:PaymentsForTenantImprovements" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> tenant obligation payments made for leasehold improvements for the periods ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The fixed annual rent payable under the lease was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_58765829-2e83-4cc3-aa65-3ec05e585aaf" contextRef="C_42860419-a9e3-4801-beb1-962b31b7feab" name="tngx:AnnualRentPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, increasing by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3456c49d-9f42-495e-bc1f-bc690b683863" contextRef="C_1c301094-2824-489c-bf63-ea4093ace32f" name="tngx:PercentageOfIncreaseInAnnualRentPayable" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% annually from the rent commencement date. The minimum rent payments to be paid over the original term of the lease totaled $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_89254cf9-f419-4dd4-85f7-2023e9844ebb" contextRef="C_1c301094-2824-489c-bf63-ea4093ace32f" name="tngx:MinimumRentPaymentsToBePaidOverOriginalTerm" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The additional rental payments associated with the renewal option are not included in the calculation of the operating lease right-of-use asset and associated operating lease liability as the renewal is not considered probable of occurring. The lease agreement required the Company to provide a letter of credit for $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8c9a8a11-421b-4f40-845b-6240474dd1f0" contextRef="C_1c301094-2824-489c-bf63-ea4093ace32f" name="tngx:LetterOfCreditToProvideForAmountThatCollateralizedWithCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million that is collateralized with cash that is recorded as restricted cash in the accompanying balance sheet.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2019, the Company entered into a new lease for office and laboratory space at 201 Brookline Avenue in Boston, Massachusetts. As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the space was undergoing construction and the lease is expected to commence for accounting purposes in the first half of 2022. The Company is not deemed to be the accounting owner of the construction project due to the nature of the work being performed and the Company&#x2019;s lack of control over the project. In conjunction with executing the lease, the Company provided the landlord a letter of credit for $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_218845b8-fbe4-427d-bb02-fcc4a4a4f1ac" contextRef="C_d6f8304a-f49a-468d-abae-98d9b92542a1" name="us-gaap:ProceedsFromLinesOfCredit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The letter of credit is collateralized with cash that is recorded as restricted cash in the accompanying balance sheet as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> In January 2022, the Company provided an additional letter of credit in the amount of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7d896240-5e0d-4c0f-87b7-add0ab289262" contextRef="C_cba5ebca-4842-4066-b09c-3a3e8776378b" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.7</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the remaining security deposit balance on the lease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon commencement of the 201 Brookline Avenue lease, the Company will determine the appropriate classification of the lease, the amount of the associated lease liability and the amount of the right-of-use asset that will be recognized on the balance sheet. The lease has a non-cancelable term of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4b08bec9-6143-44db-be7d-bf4ab1449878" contextRef="C_06dcd5da-541e-4c79-b858-c0104fee1630" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ten years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> with an </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5162f810-3db1-40fb-8c5f-fa09c61224be" contextRef="C_4fb87c77-49f5-455c-a642-6e57e4c31b2f" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_70ffd28e-bbff-497d-a664-02bf9b83c57e" contextRef="C_d6f8304a-f49a-468d-abae-98d9b92542a1" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">option to extend</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for up to two five-year periods.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The fixed annual rent payable under the lease is $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_96be534f-0cd4-4d85-9a06-b96b831ff4d5" contextRef="C_06dcd5da-541e-4c79-b858-c0104fee1630" name="tngx:AnnualRentPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, increasing by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d02e1845-2a45-4fd9-a848-b19dd3970f7d" contextRef="C_d6f8304a-f49a-468d-abae-98d9b92542a1" name="tngx:PercentageOfIncreaseInAnnualRentPayable" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% annually from the rent commencement date. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is entitled to a tenant improvements allowance of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_59047520-687c-4868-8faa-8912b6efd2c7" contextRef="C_06dcd5da-541e-4c79-b858-c0104fee1630" name="us-gaap:TenantImprovements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">12.7</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e8405208-a919-4345-b8d0-c55cd4c2efe7" contextRef="C_46942445-32c3-4ade-9ca0-aa6a6b83839a" name="tngx:LeaseTerminationAgreementMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">November 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company entered into a lease termination agreement for the leased office and laboratory space at 100 Binney Street in Cambridge, Massachusetts. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0d0aa3d9-550c-41cd-91c4-07acca00252d" contextRef="C_02d11875-4147-4360-a8aa-e87bfd6290ea" name="us-gaap:LesseeOperatingLeaseOptionToTerminate"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The lease termination agreement is a modification of the original lease agreement that provides for, among other things, the acceleration of the expiration of the original term of the lease from </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_55314f2b-faba-43ea-a44f-c0efdcd0287f" contextRef="C_50520bd5-264f-47a4-b3f4-8fbfc12d12ed" name="us-gaap:LeaseExpirationDate1" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June 30, 2026</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to an earlier lease termination date, for which the earlier date shall be no later than </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a614fdd0-e419-466a-9996-f64fcc44fb23" contextRef="C_9325e76a-6e44-41b8-9985-b303b44f8869" name="us-gaap:LeaseExpirationDate1" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">October 15, 2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The execution of the lease termination agreement resulted in reductions to the associated lease liability and right-of-use asset balances of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e539b622-0343-475c-a55d-8c5e6961f5da" contextRef="C_b961f57f-cd1e-4000-be3a-575c1acb8245" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.3</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e3af9591-aa25-401f-96d1-9a86c8c15f38" contextRef="C_b961f57f-cd1e-4000-be3a-575c1acb8245" name="tngx:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.2</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, in the fourth quarter of 2021. The $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d91a7cbe-3f65-48fa-8c75-c7db3c6c7d2c" contextRef="C_babc5d15-ca37-4230-bde3-b6ec0c32b755" name="tngx:LetterOfCreditToProvideForAmountThatCollateralizedWithCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million letter of credit associated with the lease and recorded as restricted cash on the balance sheet as of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 will be returned to the Company on the last day of the modified lease term.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s rent payments for the lease at 100 Binney Street are classified as operating lease costs in the chart below. The lease is a net lease and therefore the non-lease components, such as common area maintenance, are paid separately from rent based on actual costs incurred; therefore, the non-lease components are not included in the right-of-use asset and liability and are reflected as an expense in the period incurred. The non-lease components are classified as variable costs in the chart below. As of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, assets under the operating lease totaled $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_42d3031c-f66c-4628-b2b9-b257ef14801a" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0f08b93d-1da9-43bf-88de-86bf9e19d3b7" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, res</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">pectively. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_91af77cd-1719-4df5-a985-1f6205c7089c" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:LeaseCostTableTextBlock" escape="true" continuedAt="F_91af77cd-1719-4df5-a985-1f6205c7089c_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The elements of lease cost were as follows: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:continuation id="F_91af77cd-1719-4df5-a985-1f6205c7089c_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.656%;"></td>
        <td style="width:1.581%;"></td>
        <td style="width:1.272%;"></td>
        <td style="width:12.435%;"></td>
        <td style="width:2.137%;"></td>
        <td style="width:1.581%;"></td>
        <td style="width:1.272%;"></td>
        <td style="width:11.928%;"></td>
        <td style="width:2.137%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_68a1d63a-2cc2-4e5b-9c5c-d2070f889a50" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,889</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_242003bc-e832-4ea0-b3c2-2d30359f4fdf" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,889</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term lease cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_38afe6e3-e2fd-4fd7-be23-1fdcc4ce78e4" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">133</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_741dd134-15ce-4579-b177-947378b735fe" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">93</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0907d66d-fb35-475a-b43d-62bb37d37d55" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">673</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_050e69d9-e1d3-4013-b835-4f737de8274e" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">643</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating lease costs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_00314b0d-3c4e-4f2c-bc9e-ecffac8f6bbd" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,695</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0327c104-6fc1-4d66-bb3f-60e45b5ed9fc" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,625</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Other information</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating cash flows used for operating leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8e4a35fd-8124-425c-8e7e-6a3e67c0bb8f" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,835</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1d37abfc-43fe-495d-bc6c-779917f3e7b8" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,782</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted average remaining lease term in years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f1dd46af-9ae0-4ce9-888e-81cfa972a2c5" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_12cc2453-8d82-42f4-8b4d-b6318c8b328a" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted average discount rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e916dbc7-1405-407c-9234-e27910751d6b" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">12</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_199b49c6-add6-4fb7-9d5a-9a2a77cf340c" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">12</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></ix:continuation></div><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b884b2d7-3b13-4ec3-ae7f-e85640aa7ae0" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Future minimum lease payments under leases that have commenced as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:78.205%;"></td>
        <td style="width:1.865%;"></td>
        <td style="width:1.828%;"></td>
        <td style="width:16.884%;"></td>
        <td style="width:1.218%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Maturity of Lease<br />Liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_84ec807a-762e-4ba9-b23f-bc2e02ce9a59" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,572</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2475fca3-10a9-47cd-9798-8e8ae1243fb5" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,572</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: imputed interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_25b4b562-7b78-43d9-b01d-9063b9fb6103" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3ae637bc-1017-4ebc-8d08-97d948b0bf9b" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,503</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_67f9acb2-5816-4880-8450-0c6fd0315de1" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9. Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research Collaboration Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 2017, the Company entered into a Research Collaboration Agreement (the &#x201c;HitGen Agreement&#x201d;) with HitGen Ltd (&#x201c;HitGen&#x201d;). Under the terms of the HitGen Agreement, HitGen would use its DNA-encoded library technology to screen up to three targets and deliver to the Company the structures of certain compounds that bind to the targets. The Company would provide certain materials containing each target for purposes of the screen. The Company could have been obligated to make certain milestone payments. The Company and HitGen mutually agreed to terminate the HitGen</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Agreement </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in March 2021. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f05165a8-f0af-4d8a-83d2-8bce6d6d0ad6" contextRef="C_91ba7dc3-6470-42de-a194-06f0b8e6a25d" name="tngx:NumberOfMilestonesAchieved" unitRef="U_Milestone" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> milestones were achieved or owed upon the termination of the agreement and the Company did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dec98646-540f-41be-b114-081b8cc2403a" contextRef="C_539c3823-b618-476a-9106-5362f015288f" name="tngx:PaymentsUponTerminationOfAgreement" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t make any payments upon termination of the HitGen Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2020, the Company entered into a License Agreement (the &#x201c;Medivir Agreement&#x201d;) with Medivir AB (&#x201c;Medivir&#x201d;), pursuant to which the Company obtained an exclusive license to all patents, know-how and other intellectual property associated with a preclinical-stage research program. Pursuant to the Medivir Agreement, the Company made an upfront payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0f8d3129-b7b0-42eb-b7cb-220225e2dceb" contextRef="C_b17588f4-eb89-4f86-9706-bd7d2b333a9e" name="tngx:UpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the terms of the Medivir Agreement, the Company is obligated to pay Medivir in connection with development, regulatory and commercial activities. The Company has agreed to make certain milestone payments of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_17c7ef8a-ba7e-4d4b-a085-f8317cc7de64" contextRef="C_b17588f4-eb89-4f86-9706-bd7d2b333a9e" name="tngx:MilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the aggregate for the first licensed product that achieves specified clinical milestones, plus $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dd37528d-22cb-4010-80dc-eadecf09eb2b" contextRef="C_ab502c57-9eb1-4c1e-b776-cac4cbc580eb" name="us-gaap:ContractualObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the first licensed product that achieves specified regulatory approval and sales milestones, in each case, in either of the first two specified genetic contexts and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2d14ff42-8850-46cd-b163-7e1ccb219b47" contextRef="C_edcd82c0-9d7d-49ac-abb2-37406bcefb72" name="us-gaap:ContractualObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the aggregate if that first licensed product achieves specified clinical milestones, plus $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b6d19092-9efc-4dc9-8ce3-449b818fafb8" contextRef="C_4e0ebfbb-6d60-400e-82c5-2271bdc193d9" name="us-gaap:ContractualObligation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million if that first licensed product achieves specified regulatory and sales milestones for a third genetic context or the second licensed product achieves such specified development, regulatory and sales milestones in either of the first two specified genetic contexts. The Company has the right to reduce these milestone payments by a specified amount in the event the licensed product is not covered by Medivir&#x2019;s patents or if payments are due to a third party for a license under such third party&#x2019;s intellectual property rights. The Company is also obligated to pay Medivir a low single-digit royalty on net sales of any product covered by a licensed patent. The Medivir Agreement expires on the date of expiration of all royalty obligations. Either party may terminate the Medivir Agreement earlier upon an uncured material breach of the other party.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upfront fees paid pursuant to the Medivir License Agreement were recorded to research and development expense. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ace40862-cc80-4ff4-ac00-3f008ad6c366" contextRef="C_ca4a9ca6-a360-4a08-9af0-9f6ec20dc073" name="tngx:MilestonePaymentsAchieved" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> milestones have been achieved to date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other Funding Commitments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company had ongoing non-clinical studies for its various pipeline programs. The Company enters into contracts in the normal course of business with contract research organizations in preparation for clinical trials, professional consultants for expert advice and other vendors for clinical supply manufacturing or other services. These contracts are generally cancellable, with notice, at the Company's option and do not have significant cancellation penalties.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Guarantees</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company enters into certain agreements with other parties in the ordinary course of business that contain indemnification provisions. These typically include agreements with directors and officers, business partners, contractors, landlords, contract research organizations and clinical sites. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party under the terms of the contract, including as a result of the Company&#x2019;s activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these obligations is minimal.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Litigation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company, from time to time, may be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal proceedings as of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and no material legal proceedings are currently pending or threatened. Because of uncertainties related to claims, proceedings and litigation, assessments of potential liabilities are based on the Company's best estimates based on information available at the time of the assessment. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation, court decisions or settlement of claims (and offers of settlement), the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in a material adverse effect on the operating results of the Company. Costs associated with involvement in legal proceedings are expensed as incurred. The outcome of any such proceedings, regardless of the merits, is inherently uncertain. If the Company were to be unable to prevail in any such proceedings, the consolidated financial position, results of operations, and future cash flows of the Company may be materially impacted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a504e159-ade8-4fd8-bd1b-58bc09da99a8" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="tngx:RedeemableConvertiblePreferredStockDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10. Redeemable Convertible Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2017, Old Tango executed a stock purchase agreement to sell </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_154cd096-4c55-4951-bb28-2bb997308445" contextRef="C_1f668a19-d708-4382-b6de-856bbfb1c08d" name="us-gaap:TemporaryEquityShareSubscriptions" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">55,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of redeemable convertible series A preferred stock (&#x201c;Series A&#x201d;). This agreement was subsequently amended in July 2017 to increase the authorized capital to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1d6c7d2c-775e-4609-a460-ec6fcd683cf5" contextRef="C_27a26b8d-6763-4206-ad2e-220eddc0e107" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">55,700,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series A.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the initial closing of the Series A stock purchase agreement, Old Tango issued an aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_82d3a4c6-c8e2-4c3e-97c2-5c79cbfd2e8c" contextRef="C_36f9a5bb-51f4-4c4c-a4a4-483900a01305" name="tngx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">18,700,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series A convertible preferred stock for $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8e33a9b1-2918-4f7b-826a-8e7be165a8c0" contextRef="C_1f668a19-d708-4382-b6de-856bbfb1c08d" name="tngx:RedeemableConvertiblePreferredStockIssuePricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">1.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, resulting in net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d040f9a8-2f80-4f81-9cb9-4c982c0259e2" contextRef="C_36f9a5bb-51f4-4c4c-a4a4-483900a01305" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">14.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million after deducting $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cd9906da-c91d-4c84-9e20-7f0cbc135a11" contextRef="C_96e2833b-b37d-4d45-9d0e-e469973ab162" name="us-gaap:RepaymentsOfConvertibleDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to the settlement of the convertible notes and accrued interest that were previously outstanding. During the year-ended December 31, 2018, Old Tango issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_843bf854-a0a9-4cac-bf89-de2b9ff4ad91" contextRef="C_4dbe3a85-64de-49a0-bef8-5deb3b1b9ca7" name="tngx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">26,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional shares of Series A preferred stock at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_07102adb-6b49-4931-bd4d-7f8f43811f4d" contextRef="C_2097a9ea-7fc6-47b9-9264-c5cfd08007fd" name="tngx:RedeemableConvertiblePreferredStockIssuePricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">1.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share resulting in total proceeds from this issuance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_23ae0992-d372-4c29-996d-5693b74af2a5" contextRef="C_4dbe3a85-64de-49a0-bef8-5deb3b1b9ca7" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">26.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. In January 2019, Old Tango issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e5f68440-7b4f-4ece-a493-acb5386012bb" contextRef="C_ce1e3322-9b6b-477f-bd0a-0c49d4aedd8b" name="tngx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">11,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional shares of Series A preferred stock at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5425488b-0bdf-4eb8-9ec7-60e7b002fc35" contextRef="C_2a0457d3-f3a5-4a7b-982f-ab2cbc2377f5" name="tngx:RedeemableConvertiblePreferredStockIssuePricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">1.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share resulting in total proceeds from this issuance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bf47174c-3e12-41fc-9fcd-fb74e81bafcd" contextRef="C_ce1e3322-9b6b-477f-bd0a-0c49d4aedd8b" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The aggregate issuance costs associated with the issuance of all three issuances of Series A preferred stock was less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_de83262d-5597-4aad-9641-d92402834ccc" contextRef="C_ce1e3322-9b6b-477f-bd0a-0c49d4aedd8b" name="tngx:TemporaryStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2020, Old Tango executed a stock purchase agreement to sell shares of redeemable convertible series B preferred stock (&#x201c;Series B&#x201d;). The Series B stock purchase agreement allows for the issuance of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c85ed3a5-12ea-4ac0-a3c8-96f8e2d9f199" contextRef="C_84b473ca-21a7-4595-869a-d3b15476e2cd" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">45,372,051</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares. In April 2020, Old Tango issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c82371b1-66bd-4f19-925f-255ba25bc20d" contextRef="C_cf54194b-5ca8-4902-bc7c-8ad279e05960" name="tngx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">22,686,025</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series B at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_502fdb40-9bfd-45f9-9727-c28fdefec61d" contextRef="C_84b473ca-21a7-4595-869a-d3b15476e2cd" name="tngx:TemporaryEquityIssuePricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">1.32</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. Proceeds from this issuance totaled $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0ae1679d-ec41-4f22-8d1f-99dd8060e8e0" contextRef="C_cf54194b-5ca8-4902-bc7c-8ad279e05960" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">29.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, net of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e6845c3d-7c66-4d3c-bef0-e4e7dd8e5117" contextRef="C_cf54194b-5ca8-4902-bc7c-8ad279e05960" name="tngx:TemporaryStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in issuance costs. In March 2021, Old Tango sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_75e24edd-a9de-4e27-b269-c16fbe497c55" contextRef="C_2d621dea-8b02-473e-8bc5-76032a18426e" name="tngx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">22,686,025</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional shares of Series B stock at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7824e604-180f-4a3e-af7e-7f8b093789b1" contextRef="C_8d0e1ab2-5dfb-47e6-a9e8-b49f9f14bd25" name="tngx:TemporaryEquityIssuePricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">1.32</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share upon the achievement of specified development milestones in connection with the second tranche of the Series B stock purchase agreement. Proceeds from this issuance totaled $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_92469fb7-92a6-4d51-923e-ab193d6f50b9" contextRef="C_2d621dea-8b02-473e-8bc5-76032a18426e" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. Total issuance costs associated with the March 2021 issuance of Series B preferred stock was less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_986ea157-420f-4067-bd39-77451e8067b8" contextRef="C_2d621dea-8b02-473e-8bc5-76032a18426e" name="tngx:TemporaryStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2020, Old Tango executed a stock purchase agreement to sell shares of redeemable convertible series B-1 preferred stock (&#x201c;Series B-1&#x201d;). The Series B-1 stock purchase agreement allowed for the issuance of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a59435ee-9319-4c34-abb4-8b7c530f7755" contextRef="C_1a15ceae-2bb5-42b0-a18d-a0d58154057d" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">27,152,255</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares. All </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_107ef6ad-771a-4466-b8b2-e8d71e359253" contextRef="C_43fb107b-c6af-4569-9ee5-f77bf1f34285" name="tngx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">27,152,255</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series B-1 were issued at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9dbdd99e-6fc7-4cbc-95ed-fc6a39764a26" contextRef="C_1a15ceae-2bb5-42b0-a18d-a0d58154057d" name="tngx:TemporaryEquityIssuePricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">1.89</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share in August 2020. Proceeds from this issuance was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_84c0b945-b6cd-45fc-8eec-a64b82d3d528" contextRef="C_43fb107b-c6af-4569-9ee5-f77bf1f34285" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">51.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, net of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_381295ac-ff8c-4741-87ad-3b52d869fb83" contextRef="C_43fb107b-c6af-4569-9ee5-f77bf1f34285" name="tngx:TemporaryStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in issuance costs</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Conversion of Redeemable Convertible Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the terms of the Merger Agreement, upon the Effective Time, each share of Old Tango&#x2019;s Preferred Stock issued and outstanding immediately prior to the Effective Time was converted into a share of Old Tango&#x2019;s common stock and subsequently converted into shares of New Tango common stock using an exchange ratio of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5663b10c-b454-4fea-b813-f2464496ae46" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:PreferredStockConvertibleConversionRatio" unitRef="U_pure" scale="0" decimals="2" format="ixt:numdotdecimal">0.34</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. A retroactive adjustment has been applied to all periods presented to reflect the Business Combination and reverse recapitalization, therefore, resulting in no outstanding Preferred Stock as of December 31, 2021 and 2020. Refer to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Note 3 for additional discussion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Undesignated Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s Certificate of Incorporation, as amended and restated, authorizes the Company to issue shares of preferred stock with a par value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8d7af768-483b-49d4-b26b-3b12e53060db" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. The number of shares of preferred stock authorized to be issued is </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_65674825-72c7-4abf-981f-ec2afcd7eab9" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The shares of preferred stock are currently undesignated.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_75946027-8b48-4114-aad2-9f084e60463a" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">11. Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s Certificate of Incorporation, as amended and restated, authorizes the Company to issue shares of common stock with a par value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_055f4bc7-3827-4955-8242-ad2ed988e6e7" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4c516627-6966-4e7f-8670-337ea3ed2c9f" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:CommonStockVotingRights"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The holder of each share of common stock is entitled to one vote in respect of each share of stock held.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the funds and assets available for distribution to the stockholders of the Company will be distributed among the holders of shares of common stock, pro rata based on the number of shares of common stock held by each such holder. The holders of Common Stock are also entitled to receive dividends whenever funds and assets are legally available and when declared by the Board of Directors. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_680c4d32-42e1-4755-91eb-ce1ebe1e5102" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:DividendsPayableCurrentAndNoncurrent" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> dividends have been declared as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company increased the number of shares of common stock authorized to be issued to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dd418f94-7a4e-4da1-80fd-4acb17d0d341" contextRef="C_97c1afc9-4f65-4a11-89cf-32bdc6c820ab" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares in August 2021, at the time in which the Certificate of Incorporation was amended and restated.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> As of December 31, 2021 and 2020, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c4921bb1-8f82-4ab9-af12-7b2e8112040c" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_a155432b-5892-46ee-a0dc-0386e030d4e6" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">87,598,184</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2cbefa3a-ab6a-42fa-a853-09aa51f075cf" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_099f296a-bbc3-4037-be34-e48588d7db76" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">40,372,133</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock issued and outstanding,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> respectively, as adjusted to reflect the Business Combination and reverse recapitalization through the application of a retroactive adjustment</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div><ix:nonNumeric id="F_5e093ca4-047a-4f73-9aeb-58721df2e54b" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">12. Equity Incentive Plans</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the terms of the Business Combination, upon the Closing Date, each option to purchase Old Tango&#x2019;s common stock became an option to purchase shares of common stock of the surviving entity and was subsequently adjusted using an exchange ratio of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_66eb0723-54ff-4acf-8fca-a84b6856b484" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="tngx:MergerRecapitalizationExchangeRatio" unitRef="U_pure" scale="0" decimals="2" format="ixt:numdotdecimal">0.34</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. A retroactive adjustment has been applied to all periods presented to reflect the Business Combination and reverse recapitalization as discussed further in Note 3.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Founder and Advisor Awards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During 2017, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5ae546f9-da76-4ac4-be99-a7e01aedc484" contextRef="C_ae71f40f-3665-48a2-9117-946f426ce1db" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,690,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of restricted common stock outside of the Company&#x2019;s 2017 Stock Option and Grant Plan to nonemployee founders and advisors (the &#x201c;Founders and Advisors&#x201d;). The shares are issued under the terms of the respective restricted common stock agreements and are subject to repurchase by the Company at the original purchase price per share upon the termination of the grantee&#x2019;s service relationship with the Company. As the restrictions are released and the awards vest, the value is recorded as common stock and excess of par value is recorded as additional paid in capital on the accompanying balance sheet. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021, all founder and advisor restricted stock awards (&#x201c;RSAs&#x201d;) had vested.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2017 Stock Option and Grant Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2017, the Company&#x2019;s stockholders approved the 2017 Stock Option and Grant Plan (the &#x201c;2017 Plan&#x201d;), under which stock options and RSAs were granted to eligible employees, officers, directors, consultants, or other key persons who provide services to the Company. Such issuances under the 2017 Plan were subject to vesting, forfeiture and other restrictions as deemed appropriate by the board of directors (&#x201c;Board of Directors&#x201d;) at the time of issuance.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon effectiveness of the 2021 Stock Option and Incentive Plan (the &#34;2021 Plan&#34;) in August 2021, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the remaining shares available under the 2017 Plan ceased to be available for issuance and no future issuances will be made under the 2017 Plan. The shares of common stock underlying outstanding awards under the 2017 Plan that are forfeited, cancelled, reacquired by the Company prior to vesting, expire or are otherwise terminated (other than by exercise) will be added to the shares of common stock available for issuance under the 2021 Plan.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2021 Stock Option and Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon the closing of the Business Combination in August 2021, the Company's stockholders approved the 2021 Plan under which stock options, RSAs, unrestricted stock awards, restricted stock units, or any combination of the forgoing may be granted to eligible employees, officers, directors, consultants, or other key persons who provide services to the Company. Such issuances are subject to vesting, forfeiture and other restrictions as deemed appropriate by the Board of Directors at the time of issuance.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon approval, the maximum number of shares of stock reserved and available for issuance under the 2021 Plan was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f58f8c08-2a29-4b96-be61-ca4a1a68db2b" contextRef="C_d122636a-689d-4ab0-b872-bae54aeb140c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">9,498,725</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares. The number of shares available for future grant will automatically increase on the first day of each fiscal year by an amount equal to the least of: (i) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fa765f0a-fe10-4d8d-ae6c-9af2c4d46e0b" contextRef="C_19df7953-ecc1-48a3-9c5b-5d80830b8fdb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt-sec:numwordsen">five</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> percent of the number of shares of Stock issued and outstanding on the immediately preceding December 31 or (ii) such lesser number of shares as determined by the 2021 Plan Administrator, as appointed by the Board of Directors. Awards that are returned to the Company's equity plan as a result of forfeiture, cancellation, are reacquired by the Company prior to vesting, expiration, or any other form of termination (other than by exercise) are automatically made available for issuance under the 2021 Plan. As of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cbe217d6-becb-46f2-bd52-aad50e058f3a" contextRef="C_d122636a-689d-4ab0-b872-bae54aeb140c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,271,873</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares available for future grant under the 2021 Plan and on January 1, 2022, the number of shares available for future grant under the 2021 Plan increased by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3d4223fc-0a8b-44bb-abff-118aaf0418e4" contextRef="C_34a6b51f-9398-4a33-b000-f084738ed301" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,377,321</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2021 Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2021 Employee Stock Purchase Plan (the &#x201c;2021 ESPP&#x201d;) was adopted and approved by the Company&#x2019;s board of directors and by the Company&#x2019;s stockholders and became effective upon the closing of the Business Combination in August 2021. An aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0a16a20c-cecf-4976-8390-ddb93dd1225e" contextRef="C_b6540ba0-6a70-4698-835b-62e3f28a76b7" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">949,873</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares were reserved for issuance. The 2021 ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2022 and each January 1 thereafter, by the least of (i) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ed1afbc9-5c6b-4f0a-8481-40e3e689b63a" contextRef="C_c520f9bc-41be-4b8e-a264-4f675e8eec11" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the outstanding number of shares of the Company&#x2019;s common stock on the immediately preceding December 31, (ii) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_33a42449-ad7c-450b-bd04-e951223a26c5" contextRef="C_b6540ba0-6a70-4698-835b-62e3f28a76b7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">949,873</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares or (iii) such number of shares as determined by the administrator. The 2021 ESPP was increased by</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_245949e9-85f1-415f-93a8-6d6daffe904e" contextRef="C_e025e6fe-ae40-47de-b624-610d8a25ba64" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">875,464</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares on January 1, 2022.</span><span style="background-color:rgba(255,255,0,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br /></span><span style="background-color:rgba(255,255,0,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Stock Awards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6bbfeb3a-3778-48ac-9f51-277050347338" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the RSA activity of the Company&#x2019;s plans as of and for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.186%;"></td>
        <td style="width:1.878%;"></td>
        <td style="width:0.972%;"></td>
        <td style="width:11.601%;"></td>
        <td style="width:1.028%;"></td>
        <td style="width:1.558%;"></td>
        <td style="width:1.525%;"></td>
        <td style="width:13.534%;"></td>
        <td style="width:0.718%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br />shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted Average<br />Grant-Date<br />Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Unvested restricted common stock outstanding as of December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d5bfce56-1195-476a-90dd-0c9372203edd" contextRef="C_5b4da818-3aaf-49ee-92af-9ab384f7fb73" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,084,125</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_43bb8a79-7500-4d03-8a83-469d947400ca" contextRef="C_5b4da818-3aaf-49ee-92af-9ab384f7fb73" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">1.07</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_91efeb8b-d265-45c9-b4ba-9867cdc1bcb2" contextRef="C_12217c4f-04a9-422a-9151-5c1ab378d58e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">788,227</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca285c29-6e07-4edf-8fcc-c61d95abd20a" contextRef="C_12217c4f-04a9-422a-9151-5c1ab378d58e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">1.06</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_764d4d8e-07e4-4dda-820c-0d0173fa9bde" contextRef="C_12217c4f-04a9-422a-9151-5c1ab378d58e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">39,087</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fa13c02a-c3d3-439f-bb1e-1a722865f670" contextRef="C_12217c4f-04a9-422a-9151-5c1ab378d58e" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">0.23</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Unvested restricted common stock outstanding as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8407376d-5cac-4c08-b6bf-23a467809e4f" contextRef="C_cab846a0-8d37-4a4b-ae82-af6adf0f78e9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">256,811</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_31386810-8a17-4114-943d-80f7040aa893" contextRef="C_cab846a0-8d37-4a4b-ae82-af6adf0f78e9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">1.22</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6a208750-8f5e-4fc9-a3b1-387126c329ed" contextRef="C_5dd62d57-3336-4d82-b4cc-8df9199613af" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">256,598</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_923c6cd1-1bed-4632-815b-d074a42319d2" contextRef="C_5dd62d57-3336-4d82-b4cc-8df9199613af" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">1.22</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_46ed3c46-b457-4c67-82fd-6ef929daec86" contextRef="C_5dd62d57-3336-4d82-b4cc-8df9199613af" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">213</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_51794608-0174-49a3-8344-ec73d1f7b9d3" contextRef="C_5dd62d57-3336-4d82-b4cc-8df9199613af" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">1.35</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Unvested restricted common stock outstanding as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">RSAs represent an unsecured promise to grant at no cost a set number of shares of common stock upon vesting. RSA recipients are not entitled to cash dividends and have no voting rights during the vesting period. The RSAs are issued under the terms of the respective RSA agreements and are subject to repurchase upon the holder&#x2019;s termination of their service relationship with the Company. The award restrictions are released as the awards vest. Upon vesting, the value is recorded as common stock and excess of par value as is recorded as additional paid in capital on the accompanying balance sheets. The common stock is subject to the Company&#x2019;s right to repurchase at the original purchase price per share.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, all RSAs had vested. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The aggregate fair value of RSAs that vested during the years ended December 31, 2021 and 2020</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f9e64f8e-d27a-4901-88f4-1169b49b55ab" contextRef="C_a1adf0bb-c238-43d9-ba7a-df912e357f96" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6a22e0fc-cb64-46aa-a71f-58dfcfbc13d7" contextRef="C_04267f13-0c83-44a3-836a-4da5571814a2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Options</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d37deea0-d63a-4029-87cf-de06913d2a85" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the stock option activity of the Company&#x2019;s plans as of and for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.488%;"></td>
        <td style="width:1.193%;"></td>
        <td style="width:0.636%;"></td>
        <td style="width:9.931%;"></td>
        <td style="width:0.865%;"></td>
        <td style="width:1.193%;"></td>
        <td style="width:1.272%;"></td>
        <td style="width:9.524%;"></td>
        <td style="width:0.636%;"></td>
        <td style="width:1.193%;"></td>
        <td style="width:0.646%;"></td>
        <td style="width:10.081%;"></td>
        <td style="width:0.636%;"></td>
        <td style="width:1.193%;"></td>
        <td style="width:1.272%;"></td>
        <td style="width:9.603%;"></td>
        <td style="width:0.636%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br />shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br />Average<br />Exercise<br />Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br />Average<br />Contractual<br />Term</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br />Intrinsic<br />Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Options outstanding as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cf026018-c93a-45d7-a0f9-fb3390f145dd" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,094,544</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_31e96357-e07d-44d3-82cd-b4a6b60d6dab" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">1.88</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_75b330dc-efde-4877-9fac-4076418291b1" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.58</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3a6d5c60-85c0-4817-9b69-6bb259ad79a5" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,635,627</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7bff2bc0-fcf8-4e9f-aae6-24656cdbff3c" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,200,841</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8da9f47a-6816-44fe-ad67-507e8eb39257" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">7.53</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b1440ffa-e46c-4fc8-a86d-559c80fa6a3f" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">638,754</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_29a461b1-5cc9-48c4-b6c7-528b21e33d98" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">1.66</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cancelled</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d4291fd7-06ca-4422-81e7-55054bc60b7c" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">283,638</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dad2c886-8af2-4b59-be63-94dd67e07218" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">3.34</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Options outstanding as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_00c7f178-e7e2-4153-9b55-dfe804b3e092" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">9,372,993</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4990f315-1da3-4f9d-ac0e-2150c3f76f27" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">5.59</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_50cf44a4-7d3e-40fa-92b3-f209762ca5f8" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.55</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3aeabfa6-c259-43c0-af96-85e127b388c0" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">51,415,394</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options exercisable as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6a329763-d5ce-4ccf-92cc-ab5ddf11f4a4" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,117,654</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_06c997f9-a386-4b70-adea-c802cbb426be" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">2.56</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0591494c-5990-4efa-9c61-19d942604176" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.52</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a48f8b66-5daf-42bb-b69d-8677ce0f2106" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,759,485</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The aggregate intrinsic value of options is calculated as the difference between the exercise price of the options and the fair value of the Company&#x2019;s common stock for those options that had exercise prices lower than the fair value of the Company&#x2019;s common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The total intrinsic value of options exercised totaled $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2b0bb40b-d7b1-4aea-ba28-0c77d27985d9" contextRef="C_b3962309-cf85-4622-8558-52f8101a1c1a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.8</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a86b7d6f-d2c0-4e08-a715-940ccf5c2948" contextRef="C_369296b3-0383-4744-8c6b-7b140def6872" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020, respectively. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average grant date fair value per share of stock options granted was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_15423e32-9bff-4bec-aa94-1f3913e235e3" contextRef="C_b3962309-cf85-4622-8558-52f8101a1c1a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">5.40</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_38d4b8cb-8332-4b80-af13-98766f4b38d7" contextRef="C_f301ea89-3456-4254-8f42-f5814959d712" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">1.44</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for the years ending </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, total unrecognized compensation expense related to stock options was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1c338873-7b98-490a-8a6f-fa70917de56e" contextRef="C_4c74beb2-4bb1-4873-8bda-4048130ed6a9" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">29.3</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">which the Company expects to recognize over a remaining weighted-average period of</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_66d7e5a4-1857-41ff-abf8-fc9f666b65af" contextRef="C_b3962309-cf85-4622-8558-52f8101a1c1a" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.0</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Substantially all options outstanding as of December 31, 2021 are expected to vest.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Option Valuation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1f990f55-e76b-4eb3-b239-c008fafd8b98" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted average assumptions used to estimate the grant date fair value of the stock options using the Black-Scholes option pricing model were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.997%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:14.881%;"></td>
        <td style="width:1.62%;"></td>
        <td style="width:14.881%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected option life (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7cdb8f99-5430-4dfd-a2af-004800c69ee1" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.2</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b3fcbf18-1c66-451f-8982-de05458cf349" contextRef="C_10e2e047-49ac-448b-9f30-e2610064f1ce" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.0</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#x2013;</span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_78db9301-2ef9-4210-bc9d-da1ad0fdd31a" contextRef="C_b638cb65-3908-4aeb-bd7c-94437b4d77af" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> 6.1</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5729a3e0-e0ab-409b-bbda-d89129afc4dd" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">72</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_11836e2d-1d8d-40e2-a4a4-03ca9ea9ea10" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">67</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% &#x2013; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3de1a3f1-df7b-4c28-8f1c-f981b8ce33bd" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">72</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1b03b14c-11d6-477c-bb3f-02962754cf2c" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9094527f-a5a5-4d11-a116-85ae659b9fcb" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% &#x2013; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_01bab1c9-22dd-4716-94a3-7f56faac70ee" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014; %</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014; %</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company measures stock-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ed698ebb-ff3c-488f-9a7a-a25ad95e94e3" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true" continuedAt="F_ed698ebb-ff3c-488f-9a7a-a25ad95e94e3_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recorded stock-based compensation expense in the following expense categories in its accompanying statements of operations: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:continuation id="F_ed698ebb-ff3c-488f-9a7a-a25ad95e94e3_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.603%;"></td>
        <td style="width:1.569%;"></td>
        <td style="width:1.524%;"></td>
        <td style="width:13.388%;"></td>
        <td style="width:0.718%;"></td>
        <td style="width:1.569%;"></td>
        <td style="width:1.524%;"></td>
        <td style="width:13.388%;"></td>
        <td style="width:0.718%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_17ed7c60-2167-487d-9927-07047f53a78a" contextRef="C_5bbc6677-f9f3-4cc3-b8fc-b7c1ac21c7d4" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,616</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_76071ff5-6bc7-46f5-ae55-3874e229f29d" contextRef="C_a3730188-5277-496a-8a25-6d10f45c0e37" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,003</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8c9134e5-4088-4821-8961-448c32fcbf96" contextRef="C_c654669a-ad97-4deb-8c23-e8cf0a2ed78f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,217</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e68e4616-bddc-42f8-bbaa-3b7670f1d8c4" contextRef="C_a34864eb-c999-4a01-906e-ed6300c59215" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">761</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f9dbab9-0c59-4f05-aa9d-a96d41bc38c8" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,833</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_96e4f117-c2ae-403b-b600-6937175b66fd" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,764</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dd113ab0-ebe9-4f85-92b9-7aed50be7f83" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">13. Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company recorded a total tax provision of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d64eb59e-28dd-4aa9-b134-a9a7442f1db3" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. During the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company recorded </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_53656c61-8f4c-49bd-a3e8-21bd90f4b073" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> tax provision or benefits due to the losses incurred and the need for a full valuation allowance against its deferred tax assets. All of the Company&#x2019;s operating losses since inception have been generated in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_766b0c96-2ad6-4522-b412-ac66011e9d90" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.503%;"></td>
        <td style="width:1.513%;"></td>
        <td style="width:0.696%;"></td>
        <td style="width:11.709%;"></td>
        <td style="width:3.524%;"></td>
        <td style="width:1.513%;"></td>
        <td style="width:0.696%;"></td>
        <td style="width:12.338%;"></td>
        <td style="width:2.507%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income taxes at U.S. federal statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_60dcf1cf-2e3a-4144-9f2e-ee755e42e40b" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_23308eb9-88cf-4a64-b3dd-fdc4fd12dae6" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State income taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5c9e590d-0283-40d3-b3ad-70fd81891271" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">6.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d1ada027-46a5-482c-afe3-4c771fa015eb" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">5.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal and state research and development tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4267f9ec-3796-4e69-983f-cd4f111d7548" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="tngx:EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">5.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c55cfb88-16a8-43f7-b6d0-a97a7d91e7d8" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="tngx:EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">4.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_37d7cea4-2d96-4cc0-9c56-55185fca2769" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5e4531ad-65b7-4a09-9dc8-5dac380cd2c0" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Nondeductible/nontaxable permanent items</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_652cc06e-7582-4510-958c-93d2d40db2a6" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_590cb1f9-84bf-45e6-b7ad-b987381d857c" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8905ac12-d107-4a02-a8bc-438ac97758af" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">1.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9fb1f9ee-c775-451f-8c33-8e96385d3288" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">32.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d2d992e6-04ae-425d-912a-98e075ff9400" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">28.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effective tax rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_05307467-6cae-4e9f-9895-fe8e05313a77" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e3a2f50c-f87f-4da5-8688-3ad0bd6e5d3e" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The tax effects of temporary differences that give rise to significant components of the deferred tax assets and liabilities are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.094%;"></td>
        <td style="width:1.546%;"></td>
        <td style="width:1.524%;"></td>
        <td style="width:13.366%;"></td>
        <td style="width:1.016%;"></td>
        <td style="width:1.546%;"></td>
        <td style="width:1.524%;"></td>
        <td style="width:13.366%;"></td>
        <td style="width:1.016%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br />December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7b5a30f3-2755-4066-9f4f-ce371afce969" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,403</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0477d62f-b82e-4de1-9eb5-936423cff3ce" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,085</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development credit carryforwards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d037756d-8e72-4726-8fbe-2a7f4237f961" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,084</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9b338914-19f5-4ce8-b7ba-f76859dcffb9" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,213</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b0e762db-fd83-4491-9698-550f3a5a5f0f" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="tngx:DeferredTaxAssetsOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">411</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_af8c18f5-98a3-4eba-a205-a2542baf19f1" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="tngx:DeferredTaxAssetsOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,154</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_52522cb9-00bc-4685-9141-51a1ead8ba1b" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34,625</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_25515a85-7252-4be4-a7bb-75b8462cf64c" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,891</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accruals and reserves</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_297dc627-9dac-452c-b7fc-41187319eb54" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">958</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_66fd5365-b3bf-4648-ad9b-a7503e78f358" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">648</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Capitalized research costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_06e31553-d107-45a0-910f-6473b4d261ec" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,193</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2cc36d75-73ee-46db-925f-f92e7d3479f2" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,506</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f8d5197-7050-46d6-aeb9-03171a01933c" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,008</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3e31ccf8-f778-4283-80ce-76ed6c9d63d8" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">88</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_59c5f819-198b-45ad-bf51-5797443506dc" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50,682</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1776594c-3f7e-4dbc-89d8-6762bde57811" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,585</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_57d999d4-5032-4e9d-8de3-006a37db2738" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49,568</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4f49acc1-6781-4d7a-9311-9c8ae6407ccc" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,945</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ee48b4e8-1ad5-4043-8d89-b444a0d0b0d2" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,114</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f32a86c0-6252-4788-8e1c-522e9cebbc31" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,640</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_de4b57f8-5374-451e-bf14-9c8cc7974da0" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="tngx:DeferredTaxLiabilitiesDepreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">771</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d083dd15-a3cd-4422-9186-c442c3b5128d" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="tngx:DeferredTaxLiabilitiesDepreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">597</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right-of-use asset</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f63eec34-738d-4917-b2f4-5492f06c073a" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">343</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d6f596b8-784f-4b9f-ba07-648cdd08e17a" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,043</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total gross deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e740bb65-0396-4347-922b-7ca356b209a9" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,114</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9e5a7cc1-129f-4e6d-b267-67f1b2cfde66" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,640</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred taxes</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company had U.S. federal and state net operating loss (&#x201c;NOL&#x201d;) carryforwards of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0aa3f758-5d2a-4f1a-9a38-3ac93fc8f6b7" contextRef="C_2ac7ee07-3d73-4617-8ee2-9f9c91ec3957" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">19.3</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8ee59b47-5975-418c-8dda-692f744b7e0d" contextRef="C_90016151-b8de-4c70-b40c-6a6565310359" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">17.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, which may be available to offset future taxable income. The federal NOLs include $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_68f74862-75b3-45ab-892c-e4b4354fc43e" contextRef="C_2ac7ee07-3d73-4617-8ee2-9f9c91ec3957" name="tngx:OperatingLossCarryForwardWithExpirationOfUsage" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million which expire at various dates beginning in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f0b20abf-60aa-43c7-bdf7-f0b3e3b6d64b" contextRef="C_5c11f77a-567b-409b-b802-3c267191840f" name="tngx:OperatingLossCarryforwardsExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2036</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d0e9a4e0-36ec-4bda-9446-eaefaa0450a0" contextRef="C_2ac7ee07-3d73-4617-8ee2-9f9c91ec3957" name="tngx:OperatingLossCarryForwardWithExpirationOfUsageIndefinite" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">16.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million which carry forward indefinitely. The state NOLs expire at various dates beginning in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7c89b087-c025-4e7c-bc2b-e7afaf880037" contextRef="C_764718f8-db6b-4222-a924-e17f308b9e1f" name="tngx:OperatingLossCarryforwardsExpirationStartingYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2036</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company also had U.S. federal and state research and development tax credit carryforwards of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_39649ccb-4678-4fb1-af85-f119e0ae3a90" contextRef="C_aa1ca7f9-0b3a-4f12-96b6-45a3b58f76db" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.9</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4e4c954e-9702-4ea4-ac00-69bdc866d561" contextRef="C_46657909-6cf1-47fc-8643-1f04c29704bd" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, which may be available to offset future tax liabilities and begin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_43d4c431-d4fe-4406-8915-e09acc0941b5" contextRef="C_34cc5401-52f8-4cad-9b24-31c1f9fae295" name="tngx:TaxCreditCarryforwardExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2034</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d64a87b1-a314-4d76-973e-b10437a0295f" contextRef="C_0494c044-9ff9-41c2-8ddb-c0be1c1a2795" name="tngx:TaxCreditCarryforwardExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2030</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Utilization of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In general, an ownership change results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_523cc609-eb9b-48bd-9576-10fdcc40959a" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="tngx:PercentageOfIncreaseInOwnershipPercentageOverAThreeYearPeriod" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% over a three-year period. The Company has performed an analysis of ownership changes through December 31, 2021 and determined that on February 6, 2017 and August 17, 2020, ownership changes had occurred. Based on this analysis, the Company&#x2019;s ability to use its pre-change tax attributes to offset federal and state taxable income are subject to annual limitations and a portion of the attributes generated prior to February 6, 2017 will expire unutilized, which could potentially result in an increased future tax liability. The Company has adjusted its deferred tax assets and valuation allowance balance for the affected tax attribute carryforwards to reflect the expiration of the attributes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ASC 740 requires a valuation allowance to reduce the deferred tax assets reported, if based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company&#x2019;s history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and has concluded that it is more likely than not that the Company will not realize the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the net deferred tax assets as of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Management reevaluates the positive and negative evidence at each reporting period. The Company recorded an increase to the valuation allowance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_12a83e09-beca-467c-b386-4753a5de3204" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">18.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021 related primarily to the increase in deferred revenue and research and development tax credit carryforwards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_54ee779e-6bfc-4531-b34d-babf598e699b" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d6c406e2-c071-4c93-8c4d-e2b6dbeabe89" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t recorded any amounts for unrecognized tax benefits. The Company&#x2019;s policy is to record interest and penalties related to income taxes as part of its income tax provision. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ea136242-84fe-4cee-9f9f-d14edfceb40c" contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_74bf1f41-c440-4251-af10-fd3341b251ba" contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> accrued interest or penalties related to uncertain tax positions in the consolidated statements of operations and comprehensive loss.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company files income tax returns in the U.S. federal and Massachusetts jurisdictions, as prescribed by tax laws. The Company will file a final California income tax return for the short-period through the Closing Date of the Business Combination. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The statute of limitations for federal and state tax authorities is generally closed for years prior to December 31, 2018, although carryforward attributes that were generated prior to 2018 may still be subject to change upon examination if they are utilized to offset taxable income in subsequent tax years. There are currently no federal or state income tax audits in progress.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_d5190e4b-1806-4851-8ca8-6a142ad48b9b" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">14. Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_51df3310-9f73-46e7-817b-db541c59da8d" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.243%;"></td>
        <td style="width:1.525%;"></td>
        <td style="width:1.514%;"></td>
        <td style="width:13.823%;"></td>
        <td style="width:1.017%;"></td>
        <td style="width:1.525%;"></td>
        <td style="width:1.514%;"></td>
        <td style="width:13.823%;"></td>
        <td style="width:1.017%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands, except share and per<br />share data)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1937a6a6-025a-4ae6-9f77-7e1d09b4ed59" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">58,235</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fa9972ce-cc4b-442c-b765-dcf374c005c9" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">51,972</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average common stock outstanding &#x2013; basic and diluted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_877d8ae5-bfa1-4e03-9782-5e0e05412817" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">62,108,032</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0061e2ba-098a-4a12-bdf1-9aacb993ad61" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">31,932,204</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per common share &#x2013; basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d198f292-1581-4b96-8443-1786f7098595" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">0.94</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bec40dcc-ef49-4d02-b457-600b1ca3f855" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">1.63</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s potential dilutive securities, which include common stock options and unvested restricted common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ab95bfbb-edfa-4fca-8ee4-60438d38e681" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_ab95bfbb-edfa-4fca-8ee4-60438d38e681_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:continuation id="F_ab95bfbb-edfa-4fca-8ee4-60438d38e681_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.094%;"></td>
        <td style="width:1.569%;"></td>
        <td style="width:0.718%;"></td>
        <td style="width:14.448%;"></td>
        <td style="width:0.718%;"></td>
        <td style="width:1.569%;"></td>
        <td style="width:0.718%;"></td>
        <td style="width:14.448%;"></td>
        <td style="width:0.718%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options to purchase common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ee6faa3d-2d37-428b-9bff-cd51e396a4c7" contextRef="C_0bd03243-27c2-444e-894b-d4ebc2dc9598" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">9,372,993</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7e10d5b3-c16f-44d0-ae66-3c53b6477fc5" contextRef="C_acbb8224-ebbe-4c79-b11c-d87062900529" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,094,544</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested restricted common stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_980e2564-bf20-440e-82ca-2df68f1f95ad" contextRef="C_19209eb4-ef67-4899-926b-0331243cd6b1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">256,811</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d3517e9b-5e9c-4818-9e91-5faec1b705b6" contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">9,372,993</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d98a3a94-9407-455e-b35c-86509ec6f270" contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">4,353,375</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>tngx-ex4_2.htm
<DESCRIPTION>EX-4.2
<TEXT>
<html>
 <head>
  <title>EX-4.2</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 4.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">DESCRIPTION OF REGISTRANT&#x2019;S SECURITIES<br>REGISTERED PURSUANT TO SECTION 12 OF THE<br>SECURITIES EXCHANGE ACT OF 1934</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following summary of certain provisions of Tango Therapeutics, Inc.&#x2019;s (&#x201c;Tango&#x201d;, &#x201c;we&#x201d;, &#x201c;our&#x201d;) securities does not purport to be complete and is subject to the Second Amended and Restated Certificate of Incorporation (the &#x201c;Certificate of Incorporation&#x201d; or &#x201c;Charter&#x201d;), the Amended and Restated Bylaws (the &#x201c;Bylaws&#x201d;) and the provisions of applicable law. The Certificate of Incorporation and the Bylaws are incorporated by reference to our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Authorized and Outstanding Stock</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Charter authorizes the issuance of 210,000,000 shares, consisting of 200,000,000 shares of common stock, $0.001 par value per share, and 10,000,000 shares of preferred stock, $0.001 par value, all of which shares of preferred stock are undesignated.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Common Stock</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Charter provides the following with respect to the rights, powers, preferences and privileges of the common stock.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Voting Power. </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Except as otherwise required by law or as otherwise provided in any certificate of designation for any series of preferred stock, the holders of common stock possess all voting power for the election of Tango&#x2019;s directors and all other matters requiring stockholder action. Holders of common stock are entitled to one vote per share on matters to be voted on by stockholders.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Dividends. </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Holders of common stock will be entitled to receive such dividends, if any, as may be declared from time to time by our board of directors in its discretion out of funds legally available therefor. In no event will any stock dividends or stock splits or combinations of stock be declared or made on common stock unless the shares of common stock at the time outstanding are treated equally and identically.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidation, Dissolution and Winding Up. </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the event of Tango&#x2019;s voluntary or involuntary liquidation, dissolution, distribution of assets or  winding-up, the holders of the common stock will be entitled to receive an equal amount per share of all of Tango&#x2019;s assets of whatever kind available for distribution to stockholders, after the rights of the holders of the preferred stock have been satisfied.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preemptive or Other Rights. </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Listing of Securities</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our common stock is listed on the Nasdaq Capital Market under the symbol &#x201c;TNGX&#x201d;.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Transfer Agent</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The transfer agent for our common stock is Computershare Trust Company, N.A.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preferred stock</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our board of directors will have the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115585734.3</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. No shares of convertible preferred stock are outstanding, and we have no present plan to issue any shares of convertible preferred stock</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Registration Rights</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain of our stockholders (&#x201c;Holders&#x201d;) hold registration rights pursuant to an amended and restated registration and stockholder rights agreement</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(the &#x201c;Amended and Restated Registration and Stockholder Rights Agreement&#x201d;). Stockholders holding a majority-in-interest of such registrable securities are entitled to make a written demand for registration under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), of all or part of their registrable securities.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In particular, the Amended and Restated Registration and Stockholder Rights Agreement provides for the following registration rights:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Shelf registration/demand registration rights</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. At any time and from time to time when an effective shelf registration statement is on file with the SEC, a Holder may request to sell all or any portion of such Holder&#x2019;s registrable securities by means of an underwritten takedown off of the shelf registration statement, except that we are only obligated to effect such underwritten shelf takedown if such offering will include registrable securities proposed to be sold by the requesting Holder, either individually or together with other requesting Holders, with a total offering price reasonably expected to exceed, in the aggregate, $20.0 million. Additionally, we are not required to effect more than one underwritten shelf takedown in any six-month period.</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Piggyback registration rights</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Subject to exceptions for certain offerings and registration statements, if at any time, we propose to file a registration statement under the Securities Act, in connection with an offering of our equity securities or securities or other obligations exercisable or exchangeable for, or convertible into, our equity securities, either for our own account or for the account of other stockholders, the Holders are entitled to include their registrable securities in such registration statement.</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Indemnification</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Amended and Restated Registration and Stockholder Rights Agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify Holders of registrable securities in the event of material misstatements or omissions in the registration statement attributable to us, and Holders of registrable securities are obligated to indemnify us for material misstatements or omissions attributable to them.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Expiration of Registration Rights</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registration rights granted under the Amended and Restated Registration and Stockholder Rights Agreement will terminate on the earlier of (i) the 10th anniversary of the date of the agreement and (ii) with respect to any Holder, on the date that such Holder no longer holds any Registrable Securities.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Anti-Takeover Effects of our Certificate of Incorporation and Bylaws and Delaware Law</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Charter and Bylaws</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our Charter and Bylaws include a number of provisions that may have the effect of delaying, deferring or preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue non-negotiated takeover attempts. These provisions include the items described below:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate, including the right to approve an acquisition or other change of control;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115585734.3</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">provide that the authorized number of directors may be changed only by resolution of our board of directors;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">provide that, subject to the rights of any series of preferred stock to elect directors, directors may be removed only with cause by the holders of at least two thirds (2/3) of all of our then-outstanding shares of the capital stock entitled to vote generally at an election of directors;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">provide that, subject to the rights of any series of preferred stock to fill director vacancies, all director vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&#x2019;s notice;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">provide that special meetings of our stockholders may be called by our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">provide that our board of directors will be divided into three classes of directors, with the classes to be as nearly equal as possible, and with the directors serving three-year terms, therefore making it more difficult for stockholders to change the composition of our board of directors;</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">provide that any amendment of our Charter must first be approved by a majority of our board of directors, and if required by law or our certificate of incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment of the provisions relating to stockholder action, board composition, limitation of liability and certificate of incorporation must be approved by not less than two-thirds of the outstanding shares entitled to vote on the amendment, and not less than two-thirds of the outstanding shares of each class entitled to vote thereon as a class. Our Bylaws may be amended by the affirmative vote of a majority of the directors then in office, subject to any limitations set forth in the bylaws; and may also be amended by the affirmative vote of a majority of the outstanding shares entitled to vote on the amendment; and</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</font><div style="display:inline;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not provide for cumulative voting rights, therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Delaware Anti-Takeover Law</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tango has opted out of Section 203 of the Delaware General Corporation Law (the &#x201c;DGCL&#x201d;). Section 203 of the DGCL prohibits a Delaware corporation from engaging in a &#x201c;business combination&#x201d; with an &#x201c;interested stockholder&#x201d; (i.e. a stockholder owning 15% or more of company&#x2019;s voting stock) for three years following the time that the &#x201c;interested stockholder&#x201d; becomes such, subject to certain exceptions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Exclusive Jurisdiction of Certain Actions</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Bylaws require, to the fullest extent permitted by law, unless we consent in writing to the selection of an alternative forum, that derivative actions brought in the name of Tango, actions against any current or former directors, officers and employees for breach of fiduciary duty, actions asserting a claim arising pursuant to any provision of the DGCL or the Certificate of Incorporation or the Bylaws, actions to interpret, apply, enforce or determine the validity of the Certificate of Incorporation or the Bylaws and actions asserting a claim governed by the internal affairs doctrine may be brought only in the Court of Chancery in the State of Delaware (the &#x201c;Delaware Forum Provision&#x201d;).  The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act and the Securities Exchange Act of 1934. Any person or entity purchasing or otherwise acquiring any</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115585734.3</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">interest in shares of capital stock of Tango shall be deemed to have notice of and consented to this choice of forum provision.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115585734.3</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>3
<FILENAME>tngx-ex10_14.htm
<DESCRIPTION>EX-10.14
<TEXT>
<html>
 <head>
  <title>EX-10.14</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">201 BROOKLINE AVENUE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:24.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">BOSTON, MASSACHUSETTS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:24.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">AMENDED AND RESTATED LEASE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:24.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">FROM</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:24.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ARE-MA REGION NO. 87 TENANT, LLC</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:24.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">TANGO THERAPEUTICS, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:1.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Table of Contents</font></p>
  <p style="margin-left:1.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:1.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;margin-right:1.065%;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Page</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:96.652%;"></td>
    <td style="width:3.348%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;" id="mptableofcontents"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article I	BASIC LEASE PROVISIONS AND ENUMERATIONS OF EXHIBITS</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">1.1	Introduction</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">1.2	Basic Data</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">1.3	Measurement</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">1.4	Enumeration of Exhibits</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article II	PREMISES</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">10</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2.1	Demise and Lease of Premises; Condition of Premises</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">10</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2.2	Appurtenant Rights and Reservations</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">10</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2.3	Landlord&#x2019;s Right to Modify the Project</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">14</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2.4	Tenant&#x2019;s Right of First Offer.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">15</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article III	LEASE TERM AND EXTENSION OPTIONS</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">18</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3.1	Term</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">18</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3.2	Intentionally Omitted.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">18</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3.3	Tenant&#x2019;s Remedies in the Event of Delay in the Commencement Date.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">19</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3.4	Extension Option.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">19</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article IV	ANNUAL FIXED RENT; ADDITIONAL RENT</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">22</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">4.1	Payment of Rent</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">22</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">4.2	Management Fee Rent</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">22</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">4.3	Late Payment</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">23</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">4.4	Tenant&#x2019;s Payments</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">23</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">4.5	Additional Allowance.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">23</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article V	TAXES</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">24</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">5.1	Definitions</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">24</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">5.2	Tenant&#x2019;s Payment of Taxes</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">25</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article VI	OPERATING EXPENSES</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">26</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">6.1	Definitions</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">26</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">6.2	Operating Expense Exclusions Defined</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">28</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">6.3	Payment of Tenant&#x2019;s Expense Share.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">30</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">6.4	Tenant&#x2019;s Audit Rights.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">31</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article VII	BUILDING SERVICES</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">32</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.582%;"></td>
    <td style="width:10.846%;"></td>
    <td style="width:44.572%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">i</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">-</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115992888.1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:1.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Table of Contents</font></p>
  <p style="margin-left:1.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(continued)</font></p>
  <p style="margin-left:1.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;margin-right:1.065%;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Page</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:96.652%;"></td>
    <td style="width:3.348%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.1	Building Services</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">32</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.2	Heating, Ventilation and Air Conditioning</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">33</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.3	Electricity</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">33</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.4	Water</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">34</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.5	Gas</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">34</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.6	Elevators</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">35</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.7	Common Areas</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">35</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.8	Access and Security</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">35</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.9	Tenant&#x2019;s Telecommunications Provider</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">35</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.10	No Damage</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">36</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.11	Tenant&#x2019;s Remedy in the Event of Service Interruption</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">36</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.12	Sustainability Initiative; Consumption Data.  See Exhibit 7.12.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">37</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article VIII	TENANT&#x2019;S REPAIRS</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">37</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">8.1	Structural Repairs</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">37</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">8.2	Other Repairs to be Made by Landlord</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">37</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">8.3	Tenant&#x2019;s Repairs and Maintenance</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">38</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article IX	ALTERATIONS</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">38</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9.1	Landlord&#x2019;s Approval</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">38</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9.2	Conformity of Work</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">39</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9.3	Performance of Work, Governmental Permits and Insurance</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">40</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9.4	Liens</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">40</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9.5	Nature of Alterations</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">41</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9.6	Increases in Taxes</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">41</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9.7	Alterations Permitted Without Landlord&#x2019;s Consent.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">42</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article X	PARKING</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">42</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">10.1	Parking Privileges</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">42</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">10.2	Parking Charges</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">42</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">10.3	Parking Facilities Operation</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">43</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">10.4	Limitations</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">43</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article XI	CERTAIN TENANT COVENANTS</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">44</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.582%;"></td>
    <td style="width:10.846%;"></td>
    <td style="width:44.572%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ii</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">-</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115992888.1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:1.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Table of Contents</font></p>
  <p style="margin-left:1.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(continued)</font></p>
  <p style="margin-left:1.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;margin-right:1.065%;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Page</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:96.652%;"></td>
    <td style="width:3.348%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.1	Rent.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">44</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.2	Use.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">44</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.3	Signage and Items Visible Outside of the Premises</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">45</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.4	Rules and Regulations</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">45</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.5	Licenses and Permits</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">45</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.6	Floor Load</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">46</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.7	Taxes on Personal Property</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">46</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.8	Payment of Legal Fees</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">46</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.9	Compliance with Law</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">46</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.10	Reserved</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">47</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.11	Transportation Access Plan Agreement</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">47</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.12	OFAC</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">47</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.13	Permits and Approvals</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">48</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.14	Premises Cleaning; Pest Control</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">49</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.15	Hazardous Materials</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">49</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.16	Landlord&#x2019;s Representations, Covenants and Indemnity.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">54</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article XII	ASSIGNMENT AND SUBLETTING</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">55</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12.1	Restrictions on Transfer</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">55</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12.2	Tenant&#x2019;s Notice</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">55</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12.3	Landlord&#x2019;s Termination Right</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">55</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12.4	Consent of Landlord</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">56</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12.5	Permitted Transfers</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">57</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12.6	Profit on Subleasing or Assignment</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">58</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12.7	Additional Conditions</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">58</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article XIII	INDEMNITY AND INSURANCE</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">60</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">13.1	Tenant&#x2019;s Insurance</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">60</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">13.2	Indemnification</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">61</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">13.3	Property of Tenant</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">62</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">13.4	Limitation of Landlord&#x2019;s Liability for Damage or Injury</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">62</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">13.5	Waiver of Subrogation; Mutual Release</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">62</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.582%;"></td>
    <td style="width:10.846%;"></td>
    <td style="width:44.572%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">iii</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">-</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115992888.1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:1.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Table of Contents</font></p>
  <p style="margin-left:1.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(continued)</font></p>
  <p style="margin-left:1.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;margin-right:1.065%;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Page</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:96.652%;"></td>
    <td style="width:3.348%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">13.6	Tenant&#x2019;s Acts--Effect on Insurance</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">63</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">13.7	Landlord&#x2019;s Insurance.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">63</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article XIV	FIRE, CASUALTY AND TAKING</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">64</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">14.1	Damage</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">64</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">14.2	Termination Rights.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">65</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">14.3	Rent Abatement</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">66</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">14.4	Taking for Temporary Use</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">66</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">14.5	Disposition of Awards</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">66</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article XV	DEFAULT</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">67</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">15.1	Tenant&#x2019;s Default</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">67</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">15.2	Termination; Re-Entry</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">68</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">15.3	Continued Liability; Re-Letting</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">69</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">15.4	Liquidated Damages</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">69</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">15.5	Waiver of Redemption</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">70</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">15.6	Landlord&#x2019;s Default</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">71</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">15.7	Tenant&#x2019;s Self-Help Right</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">71</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article XVI	MISCELLANEOUS PROVISIONS</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">72</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.1	Waiver</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">72</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.2	Cumulative Remedies</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">72</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.3	Quiet Enjoyment</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">72</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.4	Surrender</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">73</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.5	Brokerage</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">75</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.6	Invalidity of Particular Provisions</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">75</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.7	Provisions Binding, etc.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">75</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.8	Recording; Confidentiality</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">76</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.9	Notices and Time for Action</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">76</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.10	When Lease Becomes Binding and Authority</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">77</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.11	Paragraph Headings</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">77</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.12	Rights of Mortgagee</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">77</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.13	Rights of Ground Lessor</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">78</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.582%;"></td>
    <td style="width:10.846%;"></td>
    <td style="width:44.572%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">iv</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">-</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115992888.1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:1.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Table of Contents</font></p>
  <p style="margin-left:1.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.065%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(continued)</font></p>
  <p style="margin-left:1.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;margin-right:1.065%;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Page</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:96.652%;"></td>
    <td style="width:3.348%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.14	Notice to Mortgagee and Ground Lessor</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">78</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.15	Assignment of Rents</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">79</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.16	Estoppel Certificate and Financial Statements</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">80</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.17	Self-Help</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">80</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.18	Holding Over</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">80</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.19	Entry by Landlord</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">81</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.20	Counterparts</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">82</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.21	Entire Agreement</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">82</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.22	Limitations on Liability</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">82</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.23	No Partnership</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">83</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.24	Security Deposit</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">83</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.25	Governing Law</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">86</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.26	Waiver of Trial by Jury</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">87</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.27	Signage</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">87</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.28	Landlord&#x2019;s Future Redevelopment/Changes</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">87</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.29	Rooftop Equipment</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">89</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.30	Force Majeure</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">92</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:36.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.31	Landlord&#x2019;s REIT Requirements</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">92</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.582%;"></td>
    <td style="width:10.846%;"></td>
    <td style="width:44.572%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">-</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">v</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">-</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115992888.1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">THIS AMENDED AND RESTATED LEASE AGREEMENT AMENDS, RESTATES AND SUPERSEDES IN ITS ENTIRETY THAT CERTAIN LEASE AGREEMENT DATED AS OF SEPTEMBER 26, 2019 (THE &#x201c;ORIGINAL LEASE&#x201d;), BY AND BETWEEN TENANT (AS DEFINED BELOW) AND LANDMARK CENTER PARK DRIVE LLC, A DELAWARE LIMITED LIABILITY COMPANY, THE PREDECESSOR-IN-INTEREST TO LANDLORD (AS DEFINED BELOW).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">201 BROOKLINE AVENUE</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">THIS INSTRUMENT IS AN INDENTURE OF LEASE </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">in which Landlord and Tenant are the parties hereinafter named, and which relates to space in the building to be constructed and known as 201 Brookline Avenue, Boston, Massachusetts.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The parties to this instrument hereby agree with each other as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article I<br>BASIC LEASE PROVISIONS AND ENUMERATIONS OF EXHIBITS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">1.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Introduction</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The following sets forth the basic data and identifying Exhibits elsewhere hereinafter referred to in this Lease, and, where appropriate, constitute definitions of the terms hereinafter listed.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">1.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Basic Data</font></p>
  <table style="margin-left:0.4965277777777778in;border-spacing:0;table-layout:fixed;width:92.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:43.781%;"></td>
    <td style="width:56.219%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Effective Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">November </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">4_</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, 2021</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Landlord:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ARE-MA REGION NO. 87 TENANT, LLC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, a Delaware limited liability company</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Present Mailing Address of Landlord:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">c/o Alexandria Real Estate Equities, Inc.<br>26 North Euclid Avenue<br>Pasadena, CA 91101<br>Attention:  Corporate Secretary</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Landlord&#x2019;s Construction Representative:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Mr.  Michael Carli and Ms. Shay Sims</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Tenant:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">TANGO THERAPEUTICS, INC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.,<br>a Delaware corporation</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Present Mailing Address of Tenant:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">100 Binney Street, Cambridge, MA 02142</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Construction Representative:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Dr.  Dimitris Papoutsakis</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <table style="margin-left:0.4965277777777778in;border-spacing:0;table-layout:fixed;width:92.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:43.781%;"></td>
    <td style="width:56.219%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Term or Lease Term:  (sometimes called the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Original Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The period beginning on the Commencement Date and expiring on the date that is one hundred twenty (120) full calendar months after the Rent Commencement Date (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Expiration Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), unless extended or sooner terminated as hereinafter provided.</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Extension Option:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Two (2) periods of five (5) years as provided in and on the terms set forth in Section 3.4 hereof</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Rent Year:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">A period of twelve (12) consecutive calendar months beginning on the Rent Commencement Date or an anniversary of the Rent Commencement Date, except that if the Rent Commencement Date does not fall on the first day of a calendar month, then the first Rent Year shall begin on the Rent Commencement Date and end on the last day of the month containing the first anniversary of the Rent Commencement Date, and each succeeding Rent Year shall begin on the day following the last day of the prior Rent Year.</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Estimated Commencement Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">March 15, 2022</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Commencement Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The date on which Landlord achieves Premises Substantial Completion, as defined in Section I of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Occupancy Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The date which is the earlier of (i) Outside Occupancy Date, as hereinafter defined, or (ii) the date on which Tenant first commences to use the Premises, or any portion thereof, for any Permitted Use.  For the purposes of the definition of the Occupancy Date, neither the performance of Tenant&#x2019;s Work nor the installation of any of Tenant&#x2019;s furniture, fixtures or equipment shall be deemed to be &#x201c;use of the Premises for any Permitted Use&#x201d;.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <table style="margin-left:0.4965277777777778in;border-spacing:0;table-layout:fixed;width:92.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:43.781%;"></td>
    <td style="width:56.219%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Outside Occupancy Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The date seven (7) months after the Commencement Date, except that the Outside Occupancy Date shall be extended by the number of days, if any, that Tenant&#x2019;s Work is actually delayed by any Landlord Delay.  Subject to Section I.E of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#160;(Effect of Tenant Delay) and the second sentence of Section I.D(2) of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#160;(Exceptions from Requirement that All of Landlord&#x2019;s Work Must Be Complete as of Substantial Completion), Landlord&#x2019;s failure to achieve Substantial Completion of Landlord&#x2019;s Work on or before the date seven (7) months after the Commencement Date shall be deemed to be a Landlord Delay.</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Landlord Delay:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">A delay in Tenant&#x2019;s Work solely caused by any default by Landlord in its obligations under this Lease.  Landlord shall not be charged with any period of Landlord Delay prior to the time that Landlord receives written notice of such Landlord Delay from Tenant.</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Rent Commencement Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The date that is four (4) months after the Occupancy Date.</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Premises:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">A portion of the Building consisting of (a) the entire eighth (8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-5.628pt;white-space:pre-wrap;font-weight:normal;font-size:8.040000000000001pt;font-family:Times New Roman;position:relative;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) floor (known as Suite 801) containing approximately 41,905 rentable square feet, (b) a portion of the ninth (9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-5.628pt;white-space:pre-wrap;font-weight:normal;font-size:8.040000000000001pt;font-family:Times New Roman;position:relative;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) floor of the Building (known as Suite 901) containing approximately 22,513 rentable square feet, (c) those portions of the first floor of the Building, known as Room S103, containing approximately 86 rentable square feet of chemical storage space and , and Room S104, containing approximately 86 rentable square feet of chemical storage space (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Chemical Storage Rooms</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) (d) a portion of the penthouse floor of the Building, known as Room S1510, containing approximately 215 rentable square feet of mechanical space, all as shown on the floor plans annexed hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 1.2-1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Sheets 1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#160;and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">and incorporated herein by reference, and as further defined and limited in Section 2.1 hereof</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <table style="margin-left:0.4965277777777778in;border-spacing:0;table-layout:fixed;width:92.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:43.781%;"></td>
    <td style="width:56.219%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Rentable Floor Area of the Premises:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Approximately 64,805 square feet.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:0.4965277777777778in;border-spacing:0;table-layout:fixed;width:92.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38.787%;"></td>
    <td style="width:34.703%;"></td>
    <td style="width:26.51%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Annual Fixed Rent:</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a) During the Original Term:</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Period of Time</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Annual Fixed Rent</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Monthly Fixed Rent</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Commencement Date Through the day immediately preceding the Rent Commencement Date</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">$0</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">$0</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Rent Year 1</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">$5,119,595.00</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">$426,632.92</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Rent Year 2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">$5,273,182.85</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">$439,431.90</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Rent Year 3</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">$5,431,378.34</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">$452,614.86</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Rent Year 4</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">$5,594,319.69</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">$466,193,31</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Rent Year 5</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">$5,762,149.27</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">$480,179.11</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Rent Year 6</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">$5,935,013.76</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">$494,584.48</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Rent Year 7</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">$6,113,064.17</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">$509,422.01</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Rent Year 8</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">$6,296,456.09</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">$524,704.67</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Rent Year 9</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">$6,485,349.77</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">$540,445.81</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Rent Year 10</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">$6,679,910.27</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:0.500pt solid;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">$556,659.19</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:0.4965277777777778in;border-spacing:0;table-layout:fixed;width:92.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:43.781%;"></td>
    <td style="width:56.219%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:12.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b) During any Extended Term (if any and if exercised), as determined pursuant to Section 3.4.</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Additional Rent:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">All charges and other sums payable by Tenant as set forth in this Lease, other than Annual Fixed Rent.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <table style="margin-left:0.4965277777777778in;border-spacing:0;table-layout:fixed;width:92.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:43.781%;"></td>
    <td style="width:56.219%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Share:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Share</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">:  Subject to Section 1.3, a fraction, the numerator of which is the number of rentable square feet of the Premises and the denominator of which is the number of rentable square feet in the Building (i.e., 12.73%).</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Expense Share</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">:  See Section 6.1.</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Building:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The fourteen-(14)-story building and other improvements on the Land to be constructed in accordance with </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#160;hereto and to be known as 201 Brookline Avenue in Boston, Massachusetts, as the same may, subject to the provisions of Section 2.2 of the Lease and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#160;hereto, be altered, expanded, reduced or otherwise changed by Landlord from time to time.</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Land:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The parcel of land described in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 1.2-2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">attached hereto.</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Landlord has advised Tenant that the Land has neither been subjected to a condominium nor subdivided, but in the future Landlord may elect to subject the parcel to a condominium or subdivide the parcel.  If the Land is either subjected to a condominium or subdivided, Landlord will notify Tenant of the new definition of the &#x201c;Land&#x201d;, which will be either the condominium unit which includes the Building or the subdivided portion(s) of the Land on which the Building is located.  Prior to creating any condominium or completing any subdivision, the portion of the Land which is reasonably related to the Building, as determined by Landlord in its reasonable discretion, shall be known as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">201 Building Land</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">5</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <table style="margin-left:0.4965277777777778in;border-spacing:0;table-layout:fixed;width:92.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:43.781%;"></td>
    <td style="width:56.219%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Office Area:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The portions of the Building devoted from time to time for general office use, as the same may be altered, expanded, reduced or otherwise changed by Landlord from time to time.  The Office Area shall not include any areas which are to be leased for laboratory, retail, restaurant or entertainment purposes, nor shall it include the parking facilities located within the Project.</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Laboratory Area:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The portions of the Building devoted from time to time for research and development and laboratory use, as the same may be altered, expanded, reduced or otherwise changed by Landlord from time to time.  The Laboratory Area shall not include any areas which are to be leased for general office, retail, restaurant or entertainment purposes, nor shall it include the parking facilities located within the Project.</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Retail/Restaurant Area:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The portions of the Building devoted from time to time for retail, restaurant or entertainment purposes, as the same may be altered, expanded, reduced or otherwise changed by Landlord from time to time.  The Retail/Restaurant Area shall not include any areas which are to be leased for general office, research and development and laboratory use, nor shall it include the parking facilities located within the Project.</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Project:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Building and the Land, together with the building commonly known as 401 Park Drive (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">401 Building</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) and other buildings, land and garages, together with all common areas and other improvements thereon, commonly known as &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">The Landmark Center</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;.  Tenant acknowledges that the Project is a mixed use project consisting of retail areas, office and laboratory buildings and other commercial uses and may be altered, expanded, reduced or otherwise changed from time to time and that Landlord reserves the right to modify the Project, to change the uses thereof, and to designate areas of the Project as common areas or as areas for the exclusive use of one or more occupants or one or more uses.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <table style="margin-left:0.4965277777777778in;border-spacing:0;table-layout:fixed;width:92.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:43.781%;"></td>
    <td style="width:56.219%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Permitted Use:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Subject in all events to applicable Legal Requirements, as hereinafter defined, Tenant shall have the right to use each portion of the Premises for the following purposes only:</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Premises</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">:  General office purposes, research and development and laboratory purposes (which at Tenant&#x2019;s election may include a vivarium), consistent with a first-class office and laboratory building in Boston and Cambridge.  In addition, Tenant may use the lab portion of the Premises for the keeping of laboratory animals - such as, but without limitation, mice, rats, rabbits, and guinea pigs.</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Chemical Storage Rooms</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">:  The storage of Hazardous Materials for Tenant&#x2019;s use in, or produced from, the Premises.</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Maximum Amount of Landlord&#x2019;s Allowance:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Up to [***] (i.e., [***] per rentable square foot of the Premises), payable as set forth in Exhibit 2.1.</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Maximum Additional Allowance:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Up to $[***] (i.e., [***] per rentable square foot of the Premises), payable as set forth in Exhibit 2.1.</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Landlord&#x2019;s Fit Plan Allowance:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Up to [***] (i.e., [***] per rentable square foot of the Premises).</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Brokers:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">CBRE Inc.  (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Broker</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) and Newmark Knight Frank (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Landlord&#x2019;s Broker</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;)</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Security Deposit Amount:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***] in the form of cash or an irrevocable letter of credit, and subject to reduction as set forth in Section 16.24 hereof.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <table style="margin-left:0.4965277777777778in;border-spacing:0;table-layout:fixed;width:92.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:43.781%;"></td>
    <td style="width:56.219%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Normal Business Hours:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Normal Business Hours</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; are Monday through Friday of each week, from 8:00 </font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">a.m.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">to 6:00 </font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">p.m.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">on business days and 9:00 </font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">a.m.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">to 2:00 </font><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">p.m.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">on Saturdays, excluding New Year&#x2019;s Day, Martin Luther King Day, Presidents&#x2019; Day, Memorial Day, Independence Day, Labor Day, Thanksgiving Day, Christmas Day and any other day on which the New York Stock Exchange is closed in observance of a holiday (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Holidays</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  Landlord may designate additional Holidays that are commonly recognized by other office buildings in the area where the Building is located.</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Tenant Party</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Tenant, any affiliate of Tenant, any subtenant or any other occupant of the Premises, and each of their respective direct or indirect partners, officers, shareholders, directors, members, trustees, beneficiaries, servants, employees, principals, contractors, licensees, agents, invitees or representatives.</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Landlord Party</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Landlord, any affiliate of Landlord, Landlord&#x2019;s managing agent for the Building and/or the Project, each mortgagee (if any), each ground lessor (if any), and each of their respective direct or indirect partners, officers, shareholders, directors, members, trustees, beneficiaries, servants, employees, principals, contractors, licensees, agents or representatives.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">1.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Measurement</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The parties acknowledge that the Rentable Floor Area of:  (i) the Premises will be approximately 64,805 rentable square feet, and (ii) the Building will be 512,749 rentable square feet, each as determined in accordance with the Base Building Plans and Specifications (as hereinafter defined) and the measurement spreadsheet attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 1.3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (collectively referred to herein as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Measurement Standard</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  By not later than thirty (30) days following the Occupancy Date, Landlord shall cause Landlord&#x2019;s architect to deliver a certificate to Tenant certifying the actual Rentable Floor Area of the Premises and the Building (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Landlord&#x2019;s Architect&#x2019;s Rentable Floor Area Certificate</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  Landlord&#x2019;s Architect&#x2019;s Rentable Floor Area Certificate shall certify that the measurements the rentable area of the Premises and the Building as set forth in the Landlord&#x2019;s Architect&#x2019;s Rentable Floor Area Certificate have been determined in accordance with the Measurement Standard.  In the event that the actual Rentable Floor Area of the Premises set forth in Landlord&#x2019;s Architect&#x2019;s Rentable Floor Area Certificate is greater than 64,805 rentable square feet, there shall be no increase in Fixed Rent, the Maximum Amount of</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">8</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Landlord&#x2019;s Allowance, the Maximum Additional Allowance, the Security Deposit Amount, or any other number or amount in this Lease which is based on the Rentable Floor Area of the Premises, except that Tenant&#x2019;s Share shall be revised to equal a fraction, the numerator of which is the actual Rentable Floor Area of the Premises as certified by Landlord&#x2019;s Architect in Landlord&#x2019;s Architect&#x2019;s Rentable Floor Area Certificate, and the denominator of which is the actual Rentable Floor Area of the Building as certified by Landlord&#x2019;s Architect in Landlord&#x2019;s Architect&#x2019;s Rentable Floor Area Certificate.  In the event that the actual Rentable Floor Area of the Premises set forth in Landlord&#x2019;s Architect&#x2019;s Rentable Floor Area Certificate is less than 64,805 rentable square feet, there shall be a proportionate reduction in Fixed Rent, the Maximum Amount of Landlord&#x2019;s Allowance, the Maximum Additional Allowance, the Security Deposit Amount, and all other numbers or amounts in this Lease which are based on the Rentable Floor Area of the Premises. Landlord and Tenant shall enter into an agreement setting forth such reduced amounts within thirty (30) days of delivery of Landlord&#x2019;s Architect&#x2019;s Rentable Floor Area Certificate.  In addition, in the event that either Landlord or Tenant has overpaid any amounts to the other party as a result of the reduction in the Rentable Floor Area of the Premises, the party who received the overpayment shall refund the amount of the overpayment to the other party within thirty (30) days following delivery of Landlord&#x2019;s Architect&#x2019;s Rentable Floor Area Certificate.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">1.4	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Enumeration of Exhibits</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The following Exhibits attached hereto are a part of this Lease, are incorporated herein by reference, and are to be treated as a part of this Lease for all purposes. Undertakings contained in such Exhibits are agreements on the part of Landlord and Tenant, as the case may be, to perform the obligations stated therein to be performed by Landlord and Tenant, as and where stipulated therein.</font></p>
  <p style="margin-left:13.333%;text-indent:-23.81%;padding-left:16.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Exhibit 1.2-1	Plans of Premises (Sheets 1 and 2)</font></p>
  <p style="margin-left:13.333%;text-indent:-23.81%;padding-left:16.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Exhibit 1.2-2	Legal Description of the Land</font></p>
  <p style="margin-left:13.333%;text-indent:-23.81%;padding-left:16.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Exhibit 1.3	Measurement Spreadsheet</font></p>
  <p style="margin-left:13.333%;text-indent:-23.81%;padding-left:16.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Exhibit 2.1	Work Letter</font></p>
  <p style="margin-left:13.333%;text-indent:-23.81%;padding-left:16.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Exhibit 2.1-1	Base Building Plans and Specifications</font></p>
  <p style="margin-left:13.333%;text-indent:-23.81%;padding-left:16.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Exhibit 2.1-2	Landlord Work Matrix</font></p>
  <p style="margin-left:13.333%;text-indent:-23.81%;padding-left:16.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Exhibit 2.1-3	Tenant Plan and Working Drawings Requirements</font></p>
  <p style="margin-left:13.333%;text-indent:-23.81%;padding-left:16.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Exhibit 2.2(d)	Roof Decks</font></p>
  <p style="margin-left:13.333%;text-indent:-23.81%;padding-left:16.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Exhibit 3.1	Form of Declaration Affixing the Commencement Date of Lease</font></p>
  <p style="margin-left:13.333%;text-indent:-23.81%;padding-left:16.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Exhibit 7.12	&#x201c;Green&#x201d; Lease Rider</font></p>
  <p style="margin-left:13.333%;text-indent:-23.81%;padding-left:16.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Exhibit 7.12-1	Landlord&#x2019;s Energy and Sustainability Construction Guidelines &amp; Requirements</font></p>
  <p style="margin-left:13.333%;text-indent:-23.81%;padding-left:16.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Exhibit 9.5-1	List of Required Removables</font></p>
  <p style="margin-left:13.333%;text-indent:-23.81%;padding-left:16.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Exhibit 9.5-2	List of Installations which Must Remain</font></p>
  <p style="margin-left:13.333%;text-indent:-23.81%;padding-left:16.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Exhibit 11.4	Rules and Regulations</font></p>
  <p style="margin-left:13.333%;text-indent:-23.81%;padding-left:16.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Exhibit 11.4-1	Construction Rules and Regulations</font></p>
  <p style="margin-left:13.333%;text-indent:-23.81%;padding-left:16.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Schedule 1	Insurance Requirements for Tenant&#x2019;s Alterations</font></p>
  <p style="margin-left:13.333%;text-indent:-23.81%;padding-left:16.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Exhibit 11.4-2	Loading Dock Rules and Regulations</font></p>
  <p style="margin-left:13.333%;text-indent:-23.81%;padding-left:16.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Exhibit 11.11-1	Intentionally Omitted</font></p>
  <p style="margin-left:13.333%;text-indent:-23.81%;padding-left:16.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Exhibit 11.11-2	Intentionally Omitted</font></p>
  <p style="margin-left:13.333%;text-indent:-23.81%;padding-left:16.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Exhibit 11.15(a)	Tenant&#x2019;s Hazardous Materials</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="margin-left:13.333%;text-indent:-23.81%;padding-left:16.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Exhibit 11.15(f)	Form of Environmental Questionnaire</font></p>
  <p style="margin-left:13.333%;text-indent:-23.81%;padding-left:16.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Exhibit 11.16	Environmental Assessment Reports</font></p>
  <p style="margin-left:13.333%;text-indent:-23.81%;padding-left:16.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Exhibit 16.13	Form of Recognition Agreement</font></p>
  <p style="margin-left:13.333%;text-indent:-23.81%;padding-left:16.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Exhibit 16.14	List of Mortgagees</font></p>
  <p style="margin-left:13.333%;text-indent:-23.81%;padding-left:16.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Exhibit 16.24	Form of Letter of Credit</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article II<br>PREMISES</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Demise and Lease of Premises; Condition of Premises</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Landlord hereby demises and leases to Tenant, and Tenant hereby hires and accepts from Landlord, the Premises for the Lease Term, excluding exterior faces of exterior walls, the common stairways and stairwells, elevators and elevator walls, mechanical rooms, electric and telephone closets, janitor closets, and pipes, ducts, shafts, conduits, wires and appurtenant fixtures serving exclusively or in common with other parts of the Building, and if the Premises includes less than the entire rentable area of any floor, excluding the common corridors, elevator lobbies and restrooms located on such floor.  Without limiting the foregoing, the Premises extend to the middle of any interior demising walls. The condition of the Premises upon Landlord&#x2019;s delivery along with any work to be performed by either Landlord or Tenant shall be as set forth on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> attached hereto and made a part hereof.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Appurtenant Rights and Reservations</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	Subject to Landlord&#x2019;s right to change or alter any of the following in Landlord&#x2019;s discretion as herein provided so long as such changes or alterations do not materially and adversely affect Tenant&#x2019;s use or occupancy of, or access to, the Premises, Tenant shall have, as appurtenant to the Premises, the non-exclusive right to use in common with others, but not in a manner or extent that would materially interfere with the normal operation and use of the Building as a multi-tenant office and laboratory building and subject to reasonable rules of general applicability to tenants of the Building from time to time made by Landlord in accordance with Section 11.4 of which Tenant is given notice:  (a) the common lobbies, corridors, stairways, and elevators of the Building, and the pipes, ducts, shafts, conduits, wires and appurtenant meters and equipment serving the Premises in common with others, (b) the loading areas, loading docks, and freight elevators serving the Building and the common walkways and driveways necessary for access to the Building, (c) if the Premises include less than the entire rentable floor area of any floor, the common restrooms, corridors and elevator lobby of such floor, (d) the showers located on the first (1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) floor, (e) the bicycle storage area located on the first (1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) floor, and (f) the plazas and other common areas of the Project as Landlord makes the same available from time to time (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Common Areas</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;); and no other appurtenant rights and easements, except as otherwise expressly set forth in the Lease.  From and after the Occupancy Date, Tenant shall have reasonable access to the use of at least two (2) loading docks and two (2) freight elevators. Tenant shall have access to such loading docks during Normal Business Hours at no separate cost or fee to Tenant; provided, however, that Tenant acknowledges and agrees that the costs and expenses of operating and maintaining the loading docks may be included in Operating Expenses. Such access shall be subject to Landlord&#x2019;s priority of use during the performance of Landlord&#x2019;s Work and to Landlord&#x2019;s reasonable requirements.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">10</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	Acid Neutralization System.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)	Landlord shall provide Tenant with non-exclusive access to the acid neutralization system existing as of the date of this Lease (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Acid Neutralization System</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) pursuant to the terms and conditions of this Lease.  Tenant acknowledges and agrees that the Acid Neutralization System shall be shared with other tenants of the Building.  Tenant&#x2019;s obligation to pay its share of ongoing operation costs of the Acid Neutralization System shall be allocated among Tenant and other user tenants on a pro rata basis, with Tenant&#x2019;s share based on the ratio of the rentable square footage of the Premises to the sum of the rentable square footages of the Premises and the premises of all other user tenants, provided, however, that, at any time and from time to time, Landlord may equitably adjust such allocation based on use by Tenant and other tenant users of the Acid Neutralization System.  Landlord&#x2019;s sole obligations for providing the Acid Neutralization System, or any acid neutralization system facilities, to Tenant shall be (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Acid Neutralization Obligations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) to (i) to obtain and maintain the permit required from the Massachusetts Water Resources Authority for discharge through the Acid Neutralization System (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Discharge Permit</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), provided that Tenant reasonably cooperates with Landlord and provides all information and documents reasonably necessary in connection with the Discharge Permit, and (ii) contract with a third party to maintain the Acid Neutralization System as operating as per the manufacturer&#x2019;s standard maintenance guidelines. Notwithstanding anything herein to the contrary, if the Acid Neutralization System must be replaced and the cost thereof is not included in such third party maintenance contract, then, Landlord shall replace the Acid Neutralization System, it being acknowledged, however, that Tenant shall be responsible for its share of all costs incurred in connection therewith as an Operating Expense allocated to the Laboratory Area Expense Pool, as provided in Article VI below (subject to amortization set forth therein relating to Permitted Capital Expenditures).</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(ii)	Tenant shall be solely responsible for the use of the Acid Neutralization System by Tenant, its employees, any contractors, sublessees, invitees or any party other than Landlord or Landlord&#x2019;s contractors, and Tenant shall be jointly and severally responsible for the use of the Acid Neutralization System with the other user tenants. Tenant shall use, and cause other parties under its control or for which it is responsible to use, the Acid Neutralization System in accordance with this Lease and in accordance with all applicable Legal Requirements, the Discharge Permit and any permits and approvals from Governmental Authorities for or applicable to Tenant&#x2019;s use of the Acid Neutralization System.  Neither Landlord nor Tenant shall take any action or make any omission that would result in a violation of the Discharge Permit or any other permit or Legal Requirements applicable to the Acid Neutralization System.  Tenant&#x2019;s compliance with applicable permits and Legal Requirements shall include but not be limited to posting signs at all sinks located in the Premises containing applicable notices regarding the use of sink drains for the disposal of chemicals and other Hazardous Materials. Tenant shall maintain a chemical management plan prohibiting the improper discharge or disposal of chemicals. Tenant shall train all laboratory personnel in the Premises on the proper disposal of chemicals and other Hazardous Materials. Landlord reserves the right, at any time and from time to time, to require reasonable limitations and restrictions on discharges by Tenant to the Acid Neutralization System as Landlord may reasonably determine to be necessary for the operation of the Acid Neutralization System.  Landlord and its contractors and consultants shall be permitted to perform periodic sampling of all substances regulated under permits applicable to the Acid Neutralization System, including without limitation the Discharge Permit, or as otherwise deemed</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">appropriate by Landlord in its sole discretion.  Landlord and its contractors and consultants shall be permitted to perform periodic inspections of the Acid Neutralization System and the discharge points and connections thereto located in the Premises. If requested by Landlord based on conditions pertaining to the Acid Neutralization System, Tenant shall promptly provide updates to its list of Tenant&#x2019;s Hazardous Materials List (as defined in Section 11.15(a) below) to Landlord.  Tenant shall promptly notify Landlord of any changes in the flow volume or properties that could impact the operation of the Acid Neutralization System or compliance with applicable permits or Legal Requirements, including without limitation a discharge known or reasonably believed to be non-compliant, changes in Tenant&#x2019;s operations in the Premises and addition of new equipment by Tenant such as cage washers, glass washers or autoclaves.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iii)	The scope of the Surrender Plan (as defined in Section 16.4(b) of this Lease) shall include all actions for the proper cleaning, decommissioning and cessation of Tenant&#x2019;s use of the Acid Neutralization System, and all requirements under this Lease for the surrender of the Premises shall also apply to Tenant&#x2019;s cessation of use of the Acid Neutralization System, in each case whether at Lease expiration, termination or prior thereto (but Tenant shall not be required to complete the decommissioning of the Acid Neutralization System if other tenants or occupants will continue to use the same after the expiration or earlier termination of this Lease, nor shall Tenant be responsible for or bear any costs of decommissioning arising from the use of the Acid Neutralization System by any party other than Tenant; it being agreed that if multiple tenants use the Acid Neutralization System, then Landlord shall be responsible for completing the decommissioning thereof, and Tenant shall pay to Landlord within thirty (30) days after invoice therefor Tenant&#x2019;s share of the reasonable, actual costs of decommissioning based on the ratio of the rentable square footage of the Premises to the rentable square footage of the Premises and the premises of all other user tenants).  The obligations of Tenant under this Lease with respect to the Acid Neutralization System shall be joint and several with such other tenants as aforesaid, except in the event that Tenant can provide evidence to Landlord&#x2019;s reasonable satisfaction that neither Tenant nor any Tenant Party caused, contributed to or exacerbated the matter for which Tenant would otherwise be responsible but for this exception.  Without in any way limiting the Acid Neutralization Obligations, Landlord shall have no obligation to provide Tenant with operational emergency or back-up acid neutralization facilities or to supervise, oversee or confirm that the third party maintaining the Acid Neutralization System is maintaining such system as per the manufacturer&#x2019;s standard guidelines or otherwise.  During any period of replacement, repair or maintenance of the Acid Neutralization System when such system is not operational, including any delays thereto due to the inability to obtain parts or replacement equipment, Landlord shall have no obligation to provide Tenant with an alternative back-up system or facilities. Tenant expressly acknowledges and agrees that Landlord does not guaranty that such Acid Neutralization System will be operational at all times or that such system will be available to the Premises when needed.  Without in any way limiting the Acid Neutralization Obligations, in no event shall Landlord be liable to Tenant or any other party for any damages of any type, whether actual or consequential, suffered by Tenant or any such other person in the event that the Acid Neutralization System or back-up system, if any, or any replacement thereof fails or does not operate in a manner that meets Tenant&#x2019;s requirements. For the avoidance of doubt, the foregoing shall not abrogate Landlord&#x2019;s responsibilities under this Lease.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Emergency Generator</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Landlord&#x2019;s sole obligation for either providing an emergency generator or providing emergency back-up power to Tenant shall be:  (i) to provide an</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">emergency generator with not less than the capacity of the emergency generator serving the Building as of the Occupancy Date, and (ii) to contract with a third party to maintain the life safety back-up generator as per the manufacturer&#x2019;s standard maintenance guidelines. Except as otherwise provide in the immediately preceding sentence, Landlord shall have no obligation to provide Tenant with operational emergency or life safety back-up generators or back-up power or to supervise, oversee or confirm that the third party maintaining the life safety back-up generator is maintaining the generator as per the manufacturer&#x2019;s standard guidelines or otherwise.  During any period of replacement, repair or maintenance of the life safety back-up generator when the life safety back-up generator is not operational, including any delays thereto due to the inability to obtain parts or replacement equipment, Landlord shall have no obligation to provide Tenant with an alternative life safety back-up or emergency generator or generators or alternative sources of back-up power.  Tenant expressly acknowledges and agrees that Landlord does not guaranty that such life safety back-up or emergency generators will be operational at all times or that life safety back-up or emergency power will be available to the Premises when needed.  In no event shall Landlord be liable to Tenant or any other person for any damages of any type, whether actual or consequential, suffered by Tenant or any such other person in the event that any life safety backup or emergency generator or life safety back-up power or any replacement thereof fails or does not provide sufficient power.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Roo f Decks. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Landlord shall construct and maintain rooftop decks (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Roof Decks</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) on the penthouse level of the Office Area (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Penthouse Roof Deck</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) and above the fourth floor (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Fourth Floor Roof Deck</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) for nonexclusive use by tenants and occupants of the Building and others entitled thereto.  Subject to Force Majeure (as hereinafter defined), construction of the Roof Decks shall be completed on or prior to the Occupancy Date (except for any items which, due to construction limitations caused by the weather or season, cannot be completed by the Occupancy Date, in which event Landlord shall complete such items as soon as possible after the Occupancy Date).  Subject to Force Majeure and closures for repair and maintenance, and subject to Landlord&#x2019;s rights to modify one or both of the Roof Decks in accordance with Section 2.2 (but subject to Section 16.28(a) and (c) below), Tenant shall have the right, during such times as Landlord makes the Roof Decks available for use by the tenants and occupants of the Building and others entitled thereto:  (i) to use the Roof Decks on a nonexclusive basis in common with other tenants, at no additional charge (other than inclusion in Operating Expenses), and (ii) to reserve the Roof Decks for its exclusive use from time to time on a first- come, first-served basis. Tenant shall reimburse Landlord upon invoice therefor, for all of Landlord&#x2019;s reasonable third party out-of-pocket costs and the provision of Building personnel (including additional security, janitorial or other services reasonably needed to facilitate Tenant&#x2019;s exclusive use of the Roof Decks) incurred in connection with any exclusive use of the Roof Decks by Tenant.  Tenant&#x2019;s use of the Roof Decks shall be subject to availability and such rules and regulations as Landlord may establish from time to time in accordance with Section 11.4.  Notwithstanding the foregoing, Landlord reserves the right to use or designate the portion(s) of the Roof Decks which are not shown as &#x201c;Minimum Exterior Roof Deck&#x201d; on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 2.2(d)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> attached hereto, and other portions of the rooftop area, for other uses or for the exclusive use by other tenants; provided, however, that in no event shall Landlord permanently designate the portion(s) of the Roof Decks shown as &#x201c;Minimum Exterior Roof Deck&#x201d; on said plan for other uses or for the exclusive use by other tenants.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Landlord&#x2019;s Right to Modify the Project</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">13</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">The Property</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Landlord reserves for its benefit the right from time to time, subject to Section 16.28(a) and (c) below, so long as the following does not cause any unreasonable interference with Tenant&#x2019;s use or, have a material adverse effect on, Tenant&#x2019;s occupancy of or access to the Premises:  (i) to enter the Premises to install, use, maintain, repair, replace and relocate for service to the Premises and other parts of the Building, pipes, ducts, conduits, wires and appurtenant fixtures, wherever located in the Premises, the Building, or the Land, (ii) to alter or relocate or perform, or cause to be performed, construction in any other common facility, provided that substitutions are substantially equivalent or better and (iii) to reduce, increase, enclose or otherwise change but not eliminate at any time and from time to time the size, number, location, lay-out and nature of the Common Areas and facilities and other premises in the Building or the Land.  Installations, replacements and relocations referred to in clause (i) above shall be located so far as practicable in the central core area of the Building, above ceiling surfaces, below floor surfaces or within perimeter walls of the Premises. Except in the case of emergencies or for normal cleaning and maintenance operations, Landlord agrees to give Tenant reasonable advance notice of any of the foregoing activities which require work in the Premises.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">The Project</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Landlord reserves and excepts for its benefit all rights of ownership and use in all respects outside the Premises, including without limitation, the Building and all other structures and improvements and plazas and Common Areas in the Project, except that at all times during the Lease Term, Tenant shall have (i) a reasonable means of access from a public street to the Premises, and (ii) subject to Section 16.28(a) and (c), Landlord shall not eliminate or materially adversely affect Tenant&#x2019;s right to use the showers, Roof Decks, bicycle storage area, freight elevators or loading docks. Subject to Section 16.28(a) and (c), it is understood that in its sole discretion, Landlord shall have the right to change and rearrange the plazas and other Common Areas, to change, relocate and eliminate facilities therein, to erect new buildings thereon, to permit the use of or lease all or part thereof for exhibitions and displays and to sell, lease or dedicate all or part thereof to public use; and further that Landlord shall have the right to make changes in, additions to and eliminations from the Building and other structures and improvements in the Project the Premises excepted; provided however that (A) Tenant, its employees, agents, clients, customers, and invitees shall at all times have reasonable access to the Building and Premises and (B) the exercise of Landlord&#x2019;s rights under this Section shall not have a material adverse effect on Tenant&#x2019;s occupancy of the Premises. Landlord is not under any obligation to permit individuals without proper building identification to enter the Building after 6:00 p.m.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2.4	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Right of First Offer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Definitions. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">For the purposes of this Section 2.4:</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ROFO Premises</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall be defined as:  (x) the entire seventh (7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) floor of the Building, or any portion thereof, when it becomes Available for Lease to Tenant (as hereinafter defined), and (y) the balance (i.e., other than the portion of the ninth (9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) floor initially leased to Tenant) of the ninth (9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) floor of the Building, or any portion thereof, when it becomes available for lease to Tenant.  The parties agree that the entire seventh (7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) floor contains approximately 41,585 rentable square feet and that the balance of the ninth (9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) floor contains approximately 19,495 rentable square feet.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">14</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(ii)	Any ROFO Premises shall be deemed to be &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Available for Lease to Tenant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;:  (1) after the expiration of the term or prior termination of the initial lease (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Initial Lease</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) of such ROFO Premises to a third party (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Initial Tenant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), as such lease may be extended or renewed, (2) when all Prior Rights, as hereinafter defined, to lease such ROFO Premises, have either lapsed unexercised or by have been waived in writing by the holder of such Prior Rights, and (3) when Landlord intends to offer such ROFO Premises for lease (provided that, in any event, Landlord shall give an Offer (as hereinafter defined) with respect to such ROFO Premises to Tenant not later than one hundred twenty (120) days after Landlord determines, in its good faith judgment, that such ROFO Premises will be Available for Lease to Tenant).</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iii)	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ROFO Conditions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall be deemed to be satisfied if:</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(1)	as of both the date that Landlord would be required to give Tenant an Offer, as hereinafter defined, and as of the commencement of the term of the Lease with respect to such ROFO Premises:  (x) this Lease is in full force and effect, (y) there exists no uncured Event of Default by Tenant, and (z) Tango Therapeutics, Inc., itself, together with any Permitted Transferee, as defined in Section 12.4, are occupying at least sixty percent (60%) of the rentable area of the Premises then demised to Tenant, and</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(2)	as of the date on which such ROFO Premises are expected to be delivered to Tenant, there remain at least eighteen (18) months left in the Term (it being understood and agreed that Tenant shall have the right to elect to unconditionally exercise its option to extend the Term pursuant to Section 3.4, if any such right remains in force, if necessary to meet this ROFO Condition (provided that the determination of the Extension Term Fixed Rent shall occur as if Tenant provided its Extension Notice eighteen (18) months prior to the expiration of the then-current term).</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iv)	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Prior Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall be defined as any extension or renewal option under the Initial Lease of such ROFO Premises.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Procedures. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Subject to satisfaction of all of the ROFO Conditions (any of which ROFO Conditions Landlord may waive, by written notice to Tenant, in Landlord&#x2019;s sole discretion), Tenant shall have a one-time right of first offer to lease any ROFO Premises whenever such ROFO Premises become Available for Lease to Tenant.  When Landlord determines that a ROFO Premises is Available for Lease to Tenant, Landlord shall give Tenant a written notice (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Offer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) offering to lease such ROFO Premises to Tenant.  Each Offer shall set forth:  (i) the location and size of the ROFO Premises, (ii) the Fixed Rent which would be payable by Tenant (which Fixed Rent shall be equal to the Prevailing Market Rent of such ROFO Premises, as defined in Section 3.4, and determined in accordance with this Section 2.4, (iii) the estimated Commencement Date with respect to such ROFO Premises (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Estimated ROFO Commencement Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), (iv) the term of the Lease and the estimated expiration date with respect to the ROFO Premises, and (v) any other terms applicable to such Offer.  Tenant may accept such Offer by giving written notice (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Acceptance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) to Landlord on or before the date ten (10) business days after Landlord gives such Offer to Tenant.  If Tenant fails timely give an Acceptance of such Offer to Landlord, then Tenant shall have no further right to lease the offered ROFO Premises pursuant to this Section 2.4.  Any Acceptance by Tenant must be unconditional, except that Tenant may, in its Acceptance, object to Landlord&#x2019;s designation of the Prevailing Market Rent of such ROFO</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">15</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Premises. If the Acceptance does not include an objection to Landlord&#x2019;s designation of the Prevailing Market Rent of such ROFO Premises, then Tenant shall conclusively be deemed to have accept such designation.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Terms Applicable to Demise of ROFO Premises. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The demise of any ROFO Premises shall be upon the terms set forth in the Offer, and otherwise upon all of the same terms and conditions of the Lease, except:</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Commencement Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">:  The Commencement Date with respect to any ROFO Premises shall be the later of:  (1) the Estimated ROFO Commencement Date for such ROFO Premises, as set forth in the Offer, or (2) the day after the Initial Tenant of such ROFO Premises vacates and delivers such ROFO Premises to Landlord, free and clear of all occupants and tenants.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(ii)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Occupancy Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">:  Unless otherwise set forth in such Offer, the Occupancy Date with respect to such ROFO Premises shall be the Commencement Date with respect to such ROFO Premises; provided, that, if the Commencement Date with respect to such ROFO Premises has not occurred on or before the date ninety (90) days after the Estimated ROFO Commencement Date with respect to such ROFO Premises, then Tenant shall have the right to cancel its demise of such ROFO Premises by giving Landlord a written thirty (30) day cancellation notice delivered after such ninetieth (90</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) day, but before the date that such Commencement Date occurs. If such Commencement Date occurs on or before the thirtieth (30th) day after Landlord receives such cancellation notice, Tenant&#x2019;s cancellation notice shall be deemed to be void and of no force or effect.  If such Commencement Date does not occur on or before such thirtieth (30th) day, then Tenant&#x2019;s exercise of its right to lease such ROFO Premises shall be void and without force or effect, and neither party shall have any further obligation to the other party with respect to such ROFO Premises, except that Tenant shall again have a one-time right to lease such ROFO Premises if such ROFO Premises again become Available for Lease to Tenant after the expiration or prior termination of the lease of the next tenant to lease such ROFO Premises.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iii)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Rent Commencement Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">:  Unless otherwise set forth in such Offer, the Rent Commencement Date with respect to such ROFO Premises shall be the Commencement Date with respect to such ROFO Premises.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iv)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Expiration Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">:  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Expiration Date with respect to any ROFO Premises shall be based upon the term of the Lease with respect to such ROFO Premises as set forth in the Offer.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(v)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Annual Fixed Rent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">:  The Annual Fixed Rent shall be the amount set forth in such Offer, unless Tenant has objected to Landlord&#x2019;s designation of such Annual Fixed Rent in its Acceptance of such Offer.  In such event, if the parties have not agreed upon such Annual Fixed Rent in writing on or before the date thirty (30) days after Tenant gives its Acceptance (which thirty (30) day period shall be deemed to be the Negotiation Period for the purposes of Section 3.4(d)), then such Annual Fixed Rent shall be equal to the Prevailing Market Rent for such ROFO Premises as of the Commencement Date with respect to such ROFO, as determined by Broker Determination in accordance with Section 3.4(d).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(vi)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Condition of ROFO Premises</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">:  Unless otherwise set forth in such Offer, Tenant shall take each ROFO Premises &#x201c;as-is&#x201d;, in the condition in which such ROFO Premises are in as of the date of Tenant&#x2019;s Acceptance with respect to such ROFO Premises, subject to reasonable wear and tear, free from any personal property of the existing tenant or anyone claiming under the existing tenant, and the rights and/or obligations of the existing tenant within such ROFO Premises to remove any alterations, without any obligation on the part of Landlord to prepare or construct such ROFO Premises for Tenant&#x2019;s occupancy, and without any obligation on the part of Landlord to give Tenant any allowance with respect to such ROFO Premises. Notwithstanding the foregoing, at Tenant&#x2019;s request and prior to the date Tenant is required to deliver the Acceptance with respect to the applicable ROFO Premises, Landlord will advise Tenant whether the existing tenant in such ROFO Premises has any right or obligation to remove any of the existing alterations in such ROFO Premises. In addition, if and to the extent that the existing tenant in the applicable ROFO Premises used such ROFO Premises for a laboratory use, on or prior to the Commencement Date with respect to such ROFO Premises:</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(1)	Landlord shall deliver to Tenant a copy of the existing tenant&#x2019;s approved Surrender Plan (as hereinafter defined) and a copy of the Industrial Hygienist Certification (as hereinafter defined) for such ROFO Premises; and</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(2)	Landlord shall be deemed to have represented to Tenant that, to the Best of Landlord&#x2019;s Knowledge (as that term is defined in this paragraph), except to the extent (if any) set forth in the Industrial Hygienist Certification for such ROFO Premises (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ROFO Disclosed Materials</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), there exist, as of the Commencement Date with respect to such ROFO Premises, no Hazardous Materials in such ROFO Premises which are in violation of applicable Environmental Laws or that require reporting, investigation, remediation or other response under Charter 21E or other Environmental Laws. For purposes of this Section 2.4(c)(vi), &#x201c;to the Best of Landlord&#x2019;s Knowledge&#x201d; shall mean the best of the knowledge of Landlord&#x2019;s then-current asset manager.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Without limiting the foregoing, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> of the Lease shall have no applicability to any ROFO Premises.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(vii)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Tenant&#x2019;s Extension Options. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 3.4 of this Lease shall be applicable to the ROFO Premises.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Confirmatory Lease Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  If Tenant timely gives its Acceptance of an Offer, then Landlord shall submit to Tenant, and Tenant shall execute and deliver to Landlord within forty-five (45) days of receipt thereof, a reasonable form of lease amendment consistent with the provisions of this Section 2.4.  Landlord and Tenant shall reasonably diligently negotiate such lease amendment in good faith.  If the determination of the Annual Fixed Rent payable with respect to a ROFO Premises is to be determined in accordance with a Broker Determination, then, after such Annual Fixed Rent is determined or mutually agreed to, the parties shall execute an agreement confirming such Annual Fixed Rent.  Notwithstanding anything to the contrary, the failure by either party (or both parties) to execute such lease amendment shall not be deemed to nullify, cancel, modify or otherwise affect Tenant&#x2019;s binding acceptance (as evidenced by the Acceptance) of the Offer.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">17</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(e)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Termination of Rights. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">In no event shall Tenant have any rights under this Section 2.4 if less than eighteen (18) months remain in the Lease Term (unless Tenant exercises its option to extend the Term as described in Section 2.4(a)(iii)(2) above), and all rights of Tenant under this Section 2.4 shall terminate upon the expiration or earlier termination of the Term of this Lease.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(f)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Rights Personal to Tenant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Tenant may not assign, mortgage, pledge, encumber or otherwise transfer its interest or rights under this Section 2.4 other than to a Permitted Transferee, as defined in Section 12.4, and any such purported transfer or attempt to transfer shall be void and without effect, shall terminate Tenant&#x2019;s rights under this Section 2.4, and shall constitute an Event of Default under this Lease.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(g)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Time is of the Essence</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Time is of the essence with respect to all aspects of this Section 2.4.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article III<br>LEASE TERM AND EXTENSION OPTIONS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Term</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Lease Term hereof shall commence on the Commencement Date and expire on the Expiration Date, unless earlier terminated or extended as provided herein.  Once the Commencement Date is determined, Landlord and Tenant shall endeavor to execute an agreement, substantially in the form attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 3.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, confirming the Commencement Date, Rent Commencement Date and Expiration Date; provided, however, the failure to execute said agreement will not limit or detract from the occurrence of such dates. If Tenant shall fail to execute such agreement, the Commencement Date, Rent Commencement Date and Expiration Date shall be as reasonably determined by Landlord in accordance with the terms of this Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Intentionally Omitted</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Remedies in the Event of Delay in the Commencement Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The provisions of this Section 3.3 sets forth Tenant&#x2019;s sole remedy, both in law and in equity, in the event of any delay the performance of Landlord&#x2019;s Work and the Commencement Date.  If the Commencement Date has not occurred on or before the Outside Rent Credit Date, as hereinafter defined, Tenant shall be entitled to a rent abatement following the Rent Commencement Date equal to [***] for every day in the period beginning on the Outside Rent Credit Date and ending on the Commencement Date.  The &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Outside Rent Credit Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall be March 15, 2022, except that the Outside Rent Credit Date shall be extended by any period of time that Landlord is delayed in the performance of Landlord&#x2019;s Work by reason of Force Majeure.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3.4	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Extension Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Definitions. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">For the purposes of this Section 3.4:</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Extension Option Conditions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall be deemed to be satisfied if as of both the date that Tenant gives its Extension Notice, and as of the commencement of the Extended</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">18</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Term:  (1) this Lease is in full force and effect, (2) there exists no uncured Event of Default by Tenant, and (3) Tango Therapeutics, Inc., itself, together with any Permitted Transferee, as defined in Section 12.4, are occupying at least sixty percent (60%) of the rentable area of the Premises then demised to Tenant.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(ii)	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Market Area</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall be defined as the Fenway/Longwood Medical Area in Boston, Massachusetts.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iii)	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Prevailing Market Rent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall be defined as the fair market rental value of the Premises then demised to Tenant as of the commencement of the date in question as determined in accordance with the process described below, for renewals and new leases of Class A laboratory space in buildings comparable to the Building in the Market Area.  All relevant factors shall be taken into account, including, without limitation:  (1) tenant improvement funds and free rent, (2) provision for annual increases in rent during said Extended Term if so determined, (3) the as-is condition of the Premises, and (4) the Tenant&#x2019;s obligation to pay its share of Taxes and Operating Expenses, and utility costs, as set forth in this Lease.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Tenant&#x2019;s Extension Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Subject to satisfaction of all of the Extension Option Conditions (any of which Extension Option Conditions Landlord may waive, by written notice to Tenant, in Landlord&#x2019;s sole discretion), Tenant shall have the right (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Extension Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) to extend the Term hereof upon all the same terms, conditions, covenants and agreements herein contained (except for the Annual Fixed Rent which shall be adjusted during the option period as hereinbelow set forth and except that there shall be no further option to extend) for two (2) periods of five (5) years each as hereinafter set forth.  Each option period is sometimes herein referred to as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Extended Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.&#x201d;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Exercise and Negotiation Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  If Tenant desires to exercise an option to extend the Term, then Tenant shall give notice (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Extension Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) to Landlord, not earlier than twenty-four (24) months nor later than eighteen (18) months prior to the expiration of the then Term of this Lease (as it may have been previously extended) exercising such option to extend.  Promptly after Landlord&#x2019;s receipt of the Extension Notice, Landlord shall provide Landlord&#x2019;s quotation to Tenant of a proposed Annual Fixed Rent for the applicable Extended Term (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Landlord&#x2019;s Rent Quotation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  If at the expiration of thirty (30) days after the date when Landlord provides such quotation to Tenant (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Negotiation Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), Landlord and Tenant have not reached agreement on a determination of an Annual Fixed Rent for such Extended Term and executed a written instrument extending the Term of this Lease pursuant to such agreement, then Tenant shall have the right, for thirty (30) days following the expiration of the Negotiation Period, to make a request to Landlord for a broker determination (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Broker Determination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) of the Prevailing Market Rent for such Extended Term, which Broker Determination shall be made in the manner set forth below.  If Tenant timely shall have requested the Broker Determination, then the Annual Fixed Rent for such Extended Term shall be the Prevailing Market Rent as determined by the Broker Determination.  If Tenant does not timely request the Broker Determination, then the Annual Fixed Rent during the applicable Extended Term shall be equal to Landlord&#x2019;s Rent Quotation.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Terms Applicable During Extended Terms. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Upon the giving of the Extension Notice by Tenant to Landlord exercising Tenant&#x2019;s applicable option to extend the Lease Term in</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">19</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">accordance with the provisions of Section 3.4(b) above, then this Lease and the Lease Term hereof shall automatically be deemed extended, for the applicable Extended Term for the entire Premises, without the necessity for the execution of any additional documents, except that Landlord and Tenant agree to enter into an instrument in writing setting forth the Annual Fixed Rent for the applicable Extended Term as determined in the relevant manner set forth in this Section 3.4; and in such event all references herein to the Lease Term or the Term of this Lease shall be construed as referring to the Lease Term, as so extended, unless the context clearly otherwise requires, and except that there shall be no further option to extend the Lease Term.  Notwithstanding anything contained herein to the contrary, in no event shall Tenant have the right to exercise more than one extension option at a time and, further, Tenant shall not have the right to exercise its second extension option unless it has duly exercised its first extension option.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(e)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Determination of Prevailing Market Rent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Where in the Lease provision is made for a Broker Determination of Prevailing Market Rent, the following procedures and requirements shall apply:</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(1)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Tenant&#x2019;s Request</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Tenant shall send a notice (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Request</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) to Landlord on or before the date thirty (30) days after the applicable Negotiation Period, requesting a Broker Determination of the Prevailing Market Rent, which notice to be effective must (i) make explicit reference to the Lease and to the specific section of the Lease pursuant to which said request is being made, (ii) include the name of a broker selected by Tenant to act for Tenant, which broker shall be affiliated with a major Boston commercial real estate brokerage firm selected by Tenant and which broker shall have at least ten (10) years&#x2019; experience dealing in properties of a nature and type generally similar to the Building located in the Fenway, Longwood Medical Area of Boston, and (iii) explicitly state that Landlord is required to notify Tenant within thirty (30) days of an additional broker selected by Landlord.</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(2)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Landlord&#x2019;s Response</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Within thirty (30) days after Landlord&#x2019;s receipt of Tenant&#x2019;s notice requesting the Broker Determination and stating the name of the broker selected by Tenant, Landlord shall give written notice (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Landlord&#x2019;s Response</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) to Tenant of Landlord&#x2019;s selection of a broker having at least the affiliation and experience referred to above.  If the parties have not agreed upon the Annual Fixed Rent payable by Tenant on or before the end of the Negotiation Period and Tenant fails timely to send a Tenant&#x2019;s Request, then Landlord may give a Landlord&#x2019;s Response without having received a Tenant&#x2019;s Request.</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(3)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Selection of Third Broker</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  If the two brokers so selected do not on or before the date ten (10) days after the selection of the second broker mutually agree in writing upon the Prevailing Market Rent, then the two brokers shall select a third such broker also having at least the affiliation and experience referred to above.</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(4)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Rental Value Determination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Within thirty (30) days after the selection of the third broker, the three (3) brokers so selected, by majority opinion, shall make a determination of the annual fair market rental value of the Premises for the Extended Term.  The brokers shall advise Landlord and Tenant in writing by the expiration of said thirty (30) day period of the Prevailing Market Rent.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">20</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(5)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Resolution of Broker Deadlock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  If the Brokers are unable to agree at least by majority on a determination of annual fair market rental value, then the brokers shall send a notice to Landlord and Tenant by the end of the thirty (30) day period for making said determination setting forth their individual determinations of annual fair market rental value, and the highest such determination and the lowest such determination shall be disregarded and the remaining determination shall be deemed to be the determination of annual fair market rental value and shall be referred to as the Prevailing Market Rent.</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(6)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Costs. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Each party shall pay the costs and expenses of the broker selected by it and each shall pay one half (1/2) of the costs and expenses of the third broker.</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(7)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Failure to Select Broker or Failure of Broker to Serve</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If Tenant shall have requested a Broker Determination and Landlord shall not have designated a broker within the time period provided therefor above and such failure shall continue for more than ten (10) days after notice thereof, then Tenant&#x2019;s broker shall alone make the determination of the Prevailing Market Rent in writing to Landlord and Tenant within thirty (30) days after the expiration of Landlord&#x2019;s right to designate a broker hereunder.  If Tenant shall have failed timely to give a Tenant&#x2019;s Request, and Landlord gives a Landlord Response, then Tenant shall have ten (10) days after it receives such Landlord Response to designate its broker.  If Tenant fails to do so, then Landlord&#x2019;s broker shall alone make the determination of the Prevailing Market Rent in writing to Landlord and Tenant within thirty (30) days after Landlord gives such Landlord Response.  If Tenant and Landlord have both designated brokers but the two brokers so designated do not, within a period of fifteen (15) days after the appointment of the second broker, agree upon and designate the third broker willing so to act, Tenant, Landlord or either broker previously designated may request the Boston Bar Association (or such organization as may succeed to the Boston Bar Association) to designate the third broker willing so to act and a broker so appointed shall, for all purposes, have the same standing and powers as though he/she had been seasonably appointed by the brokers first appointed.  In case of the inability or refusal to serve of any person designated as a broker, or in case any broker for any reason ceases to be such, a broker to fill such vacancy shall be appointed by Tenant, Landlord, the brokers first appointed or the Boston Bar Association, as the case may be, whichever made the original appointment, or if the person who made the original appointment fails to fill such vacancy, upon application of any broker who continues to act or by Landlord or Tenant such vacancy may be filled by the said Boston Bar Association, and any broker so appointed to fill such vacancy shall have the same standing and powers as though originally appointed.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article IV<br>ANNUAL FIXED RENT; ADDITIONAL RENT</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">4.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Payment of Rent</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Tenant agrees to pay to Landlord, commencing on the Rent Commencement Date, and continuing and monthly in advance throughout the remainder of the Lease Term, on the first day of each and every calendar month during the Original Term, a sum equal to one-twelfth (1/12</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) of the Annual Fixed Rent specified in Section 1.2 hereof and on the first day of each and every calendar month during each Extended Term (if exercised), a sum equal to one-twelfth of the Annual Fixed Rent as determined in Section 3.4 for the applicable Extended Term.  Annual Fixed</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">21</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Rent for any partial month shall be paid by Tenant to Landlord at such rate on a pro rata basis, and, if the Rent Commencement Date shall be other than the first day of a calendar month, the first payment of Annual Fixed Rent which Tenant shall make to Landlord shall be a payment equal to a proportionate part of such monthly Annual Fixed Rent for the partial month from the Rent Commencement Date to the first day of the succeeding calendar month.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Annual Fixed Rent, Additional Rent, and all other charges for which provision is herein made shall be paid by remittance to or for the order of Landlord to the address for rent payment provided by Landlord to Tenant prior to the Rent Commencement Date or by via federally insured wire transfer (including ACH) pursuant to the wire instructions provided to Tenant by Landlord.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Additional Rent payable by Tenant on a monthly basis, as elsewhere provided in this Lease, likewise shall be prorated, and the first payment on account thereof shall be determined in similar fashion and shall, unless otherwise expressly stated in this Lease, commence on the Commencement Date and other provisions of this Lease calling for monthly payments shall be read as incorporating this undertaking by Tenant.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Annual Fixed Rent, Additional Rent and all other charges for which provision is made in this Lease shall be paid by Tenant to Landlord in lawful money of the United States in immediately available funds and without notice or demand and with setoff, deduction or abatement, except as otherwise expressly set forth in this Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">4.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Management Fee Rent</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Commencing as of the Rent Commencement Date, and continuing thereafter throughout the remainder of the Lease Term, as it may be extended, Tenant shall pay Management Fee Rent, as hereinafter defined, to Landlord.  Management Fee Rent shall be considered to be Additional Rent and shall be payable by Tenant at the same time and under the same terms and conditions as Annual Fixed Rent, Tenant&#x2019;s Tax Share, and Tenant&#x2019;s Expense Share are payable by Tenant to Landlord.  &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Management Fee Rent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall be defined as three and one-half percent (3.5%) of the sum of Annual Fixed Rent, Tenant&#x2019;s Tax Share, and Tenant&#x2019;s Expense Share which is payable by Tenant to Landlord, from time to time.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">4.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Late Payment</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If Landlord shall not have received any payment or installment of Annual Fixed Rent or Additional Rent (the &#x201c;Outstanding Amount&#x201d;) on or before the date on which the same first becomes payable under this Lease (the &#x201c;Due Date&#x201d;), the amount of such payment or installment shall incur a late charge equal to the sum of:  (a) five percent (5%) of the Outstanding Amount for administration and bookkeeping costs associated with the late payment (&#x201c;Late Fee&#x201d;) and (b) interest on the Outstanding Amount from the Due Date through and including the date such payment or installment is received by Landlord, at an annual rate of interest (the &#x201c;Lease Interest Rate&#x201d;) of twelve (12%) percent per annum.  Landlord agrees to waive the Late Fee with respect to the first late payment in any twelve-(12)-month period.  Such interest and any Late Fees payable by Tenant shall be deemed Additional Rent and shall be paid by Tenant to Landlord upon demand.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">4.4	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Payments</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">22</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Each and every payment and expenditure, other than Annual Fixed Rent, shall be deemed to be Additional Rent hereunder, whether or not the provisions requiring payment of such amounts specifically so state, and shall be payable, unless otherwise provided in this Lease, within thirty (30) days after written demand by Landlord, and in the case of the non-payment of any such amount, Landlord shall have, in addition to all of its other rights and remedies, all the rights and remedies available to Landlord hereunder or by law in the case of non-payment of Annual Fixed Rent.  Unless expressly otherwise provided in this Lease, the performance and observance by Tenant of all the terms, covenants and conditions of this Lease to be performed and observed by Tenant shall be at Tenant&#x2019;s sole cost and expense.  If Tenant has not objected to any statement of Additional Rent which is rendered by Landlord to Tenant within one hundred eighty (180) days after Landlord has rendered the same to Tenant, then the same shall be deemed to be a final account between Landlord and Tenant not subject to any further dispute.  In the event that Tenant shall seek Landlord&#x2019;s consent or approval under this Lease, then Tenant shall reimburse Landlord, upon demand, as Additional Rent, for all reasonable costs and expenses, including legal and architectural costs and expenses, incurred by Landlord in processing such request, whether or not such consent or approval shall be given.  Notwithstanding the foregoing:  (i) the amount of legal fees which Tenant is required to reimburse Landlord with respect to any Transfer, as hereinafter defined, shall not exceed the Transfer Legal Fee Cap, as hereinafter defined, with respect to such Transfer, and (ii) with respect any request by Tenant to review and approve Tenant&#x2019;s plans and specifications with respect to any Alteration, Tenant shall only be required to reimburse Landlord for third party consultants engaged by Landlord to review such plans and specifications as Landlord, in good faith determines is necessary (e.g., reviews by structural engineers, MEP engineers, etc.).  The &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Transfer Legal Fees Cap</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall be defined as $2,500.00, except that (a) the Transfer Legal Fees Cap shall be defined as $5,000.00 for any request by Tenant for Landlord&#x2019;s approval of any sub-sublease of any tier, and (b) the applicable Transfer Legal Fees Cap shall increase by $500 every fifth (5th) anniversary of the Occupancy Date.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">4.5	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Additional Allowance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">In addition to the Maximum Amount of Landlord&#x2019;s Allowance, Landlord shall, subject to the terms of Exhibit 2.1, make available to Tenant the Maximum Additional Allowance.  Commencing on the Rent Commencement Date and continuing thereafter on the first day of each month during the Lease Term, Tenant shall pay the amount necessary to fully amortize the portion of the Maximum Additional Allowance actually funded by Landlord, if any, in equal monthly payments with interest at a rate of 8% per annum over the Lease Term, which interest shall begin to accrue on the date that Landlord first disburses such Maximum Additional Allowance or any portion(s) thereof (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">TI Rent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  Any TI Rent remaining unpaid as of the expiration or earlier termination of this Lease shall be paid to Landlord in a lump sum at the expiration or earlier termination of this Lease.  Tenant may, at Tenant&#x2019;s option, prepay the then-outstanding TI Rent (including applicable interest remaining unpaid) in full at any time without penalty.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article V<br>TAXES</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">5.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Definitions</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">23</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Tax Year</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the twelve-(12)-month period beginning July 1 each year during the Lease Term or if the appropriate governmental fiscal period shall begin on any date other than July 1, such other date.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Landlord&#x2019;s Tax Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; with respect to any Tax Year means the aggregate &#x201c;Real Estate Taxes&#x201d; (hereinafter defined) with respect to that Tax Year, reduced by any net abatement receipts with respect to that Tax Year.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Real Estate Taxes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means all taxes and special assessments of every kind and nature, payments in lieu of taxes or otherwise pursuant to M.G.L. c. 121A and any Section 6A contract to which the Project is subject, excise taxes and user fees and other like fees assessed by any Governmental Authority (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Taxes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) on, or allocable to (i) the Building or (ii) the Land, open areas, public areas and amenities, plazas, Common Areas and other non-leasable areas of the Building or Land which Landlord shall be obligated to pay because of or in connection with the ownership or operation of the Building and reasonable expenses of and fees for any formal or informal proceedings for negotiation or abatement of taxes (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Abatement Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  Without limiting the foregoing, Taxes shall include payments in lieu of taxes or otherwise pursuant to M.G.L. c. 121A and any Section 6A contract to which the Land is subject.  Notwithstanding the foregoing, if:  (x) Landlord subjects the Project to a condominium, then Real Estate Taxes shall mean all Taxes assessed against the unit(s) of the condominium that contain the Building, and (y) Landlord subdivides the Land, then the Real Estate Taxes shall mean all Real Estate Taxes assessed against the subdivided portion of the Land that contains the Building.  For so long as the Building and Land are not separately assessed from the 401 Building and the land on which the 401 Building is located, Real Estate Taxes shall be determined as follows:  (1) Real Estate Taxes shall include any Taxes attributable to any improvements on the 201 Building Land, based upon reasonable evidence provided by the tax assessor for the City of Boston, (2) Real Estate Taxes shall not include any Taxes attributable to the 401 Building, and (3) Real Estate Taxes shall include an allocation of taxes attributable to the Land based on Landlord&#x2019;s reasonable determination of the portion of the Land that is reasonably related to the Building.  Landlord&#x2019;s allocation, if made in good faith, shall be final.  The amount of special taxes or special assessments to be included in Taxes shall be limited to the amount of the installment (plus any interest other than penalty interest payable thereon) of such special tax or special assessment required to be paid during the year in respect of which such taxes are being determined.  There shall be excluded from such Taxes all income, estate, succession, inheritance and transfer taxes; provided, however, that if at any time during the Lease Term the present system of ad valorem taxation of real property shall be changed so that in lieu of, or in addition to, the whole or any part of the ad valorem tax on real property, there shall be assessed on Landlord a capital levy or other tax on the gross rents received with respect to the Building or Land, or a Federal, State, County, Municipal, or other local franchise, excise or similar tax, assessment, levy or charge (distinct from any now in effect in the jurisdiction in which the Building is located) measured by or based, in whole or in part, upon any such gross rents, then any and all of such taxes, assessments, levies or charges, to the extent so measured or based, shall be deemed to be included within the term Taxes but only to the extent that the same would be payable if the Building and Land, were the only property of Landlord.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	If during the Lease Term the Tax Year is changed by applicable law to less than a full 12-month period, the Taxes Allocable to the Premises shall be proportionately reduced.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">24</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">5.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Payment of Taxes</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Commencing as of the Rent Commencement Date and continuing thereafter throughout the remainder of the Term of the Lease, Tenant shall pay to Landlord, as Additional Rent, Tenant&#x2019;s Share of Real Estate Taxes (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Tax Share</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  Landlord may make a good faith estimate of the Taxes to be due by Tenant for any Tax Period or part thereof during the Term, and Tenant shall pay to Landlord, on the Rent Commencement Date and on the first (1st) day of each calendar month thereafter, an amount equal to Tenant&#x2019;s Tax Share for such Tax Period or part thereof divided by the number of months therein.  Landlord may not more than two (2) times per Tax Year (including the adjustment at the end of each Tax Year) estimate and re-estimate Tenant&#x2019;s Tax Share and deliver a copy of the estimate or re-estimate to Tenant.  Thereafter, the monthly installments of Tenant&#x2019;s Tax Share shall be appropriately adjusted in accordance with the estimations so that, by the end of the Tax Period in question, Tenant shall have paid all of Tenant&#x2019;s Tax Share as estimated by Landlord.  Any amounts paid based on such an estimate shall be subject to adjustment as herein provided when actual Taxes are available for each Tax Period.  If the total of such monthly remittances is greater than Tenant&#x2019;s Tax Share actually due for such Tax Period, then, Landlord shall credit the difference against the next installment of Additional Rent on account of Taxes due hereunder, except that if such difference is determined after the end of the Term, Landlord shall refund such difference to Tenant within thirty (30) days after such determination to the extent that such difference exceeds any amounts then due from Tenant to Landlord.  If the total of such remittances is less than Tenant&#x2019;s Tax Share actually due for such Tax Period, Tenant shall pay the difference to Landlord, as Additional Rent hereunder, within thirty (30) days of Tenant&#x2019;s receipt of an invoice therefor, which invoice shall include a copy of the applicable tax bill.  Landlord&#x2019;s estimate for the next Tax Period shall be based upon actual Taxes for the prior Tax Period plus a reasonable adjustment based upon estimated future Taxes. Landlord shall provide Tenant with a copy of each Tax bill received by Landlord within thirty (30) days after Landlord&#x2019;s receipt of such Tax bill; provided however, that in no event shall Landlord&#x2019;s failure to timely deliver any Tax bill de deemed to be a default by Landlord in its obligations hereunder or be considered to be a waiver of Landlord&#x2019;s right to receive payment from Tenant of Tenant&#x2019;s Tax Share imposed pursuant to such Tax bill.  The provisions of this Section 5.2 shall survive the expiration or earlier termination of this Lease.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article VI<br>OPERATING EXPENSES</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">6.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Definitions</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">For the purposes of this Article VI:</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Expense Pools&#x201d; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">shall be defined as the amount of Operating Expenses, as hereinafter defined, which are allocated by Landlord, in accordance with this Section 6.1(a) either to a Portion of the Building Expense Pool (as hereinafter defined), the entirety of the Building (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Building Expense Pool</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), or the entirety of the Project (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Project Expense Pool</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  An Operating Expense shall be allocated by Landlord to an Expense Pool only if the rentable areas of the premises within such Expense Pool have the benefit from the service or facility on which such Operating Expense is based.  With respect to an Operating Expense which benefits more than one Portion of the Building Expense Pool, allocation of such Operating Expense shall be made among</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">25</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">the Portions of the Building Expense Pools based upon the relative rentable areas within such Portions of the Building Expense Pool, unless Landlord has a reasonable basis for a different allocation.  For example, premises janitorial services shall be allocated entirely to the Office Area Expense Pool, and insurance premiums relating to the Building shall be included in the Building Expense Pool.  The &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Portion of the Building Expense Pools</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall be defined as the Expense Pools for each of the Laboratory Area, Office Area, and Retail/Restaurant Area.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Expense Share</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall be defined as the sum of the shares of each Expense Pool which is allocable to Tenant.  The Project Expense Pool, the Building Expense Pool, and the Laboratory Expense Pool shall all be allocated to Tenant on the basis of the relative square footage of the Premises to the aggregate square footage of the rentable areas within the applicable Expense Pool, unless Landlord has a reasonable basis for a different allocation.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Operating Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the cost of maintenance, repair, replacement, management and operation of the Building and the Building&#x2019;s share of the cost of maintenance, repair, replacement, management and operation other areas of the Project as more specifically provided below.  Notwithstanding any provision of this Lease to the contrary, Operating Expenses shall not include Operating Expense Exclusions, as set forth in Section 6.2, Operating Expenses shall include, without limitation:</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)	compensation, wages and all fringe benefits, workmen&#x2019;s compensation insurance premiums and payroll taxes paid to, for or with respect to all persons for their services below the level of general manager in the operating, maintaining, managing, insuring or cleaning of the Building;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(ii)	payments under service contracts with independent contractors for operating, maintaining or cleaning of the Project;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iii)	steam, water, sewer, gas, oil, electricity and telephone charges (excluding such utility charges separately chargeable to tenants for additional or separate services and electricity charges paid by Tenant) and costs of maintaining letters of credit or other security as may be required by utility companies as a condition of providing such services;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iv)	cost of maintenance, cleaning and repairs and replacements (other than repairs reimbursed from contractors under warranties or guarantees);</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(v)	cost of snow and ice removal and care of landscaping;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(vi)	cost of building and cleaning supplies and equipment;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(vii)	premiums for insurance carried with respect to the Building (including, without limitation, liability insurance, insurance against loss in case of fire or casualty and of monthly installments of Annual Fixed Rent and any Additional Rent which may be due under this Lease and other leases of space in the Building for not more than twelve (12) months in the case of both Annual Fixed Rent and Additional Rent and, if there be any first mortgage on the Building, including such insurance as may be required by the holder of such first mortgage);</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">26</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(viii)	Operating Expenses related to the operation of the open areas, public areas and amenities, plazas, Common Areas, facilities and other non-leasable areas of the Project and other mixed use common area maintenance costs incurred by Landlord and allocated to the Project and any shuttle buses and other like amenities, for use of tenants of the Project either alone or in common with tenants of other buildings in the Project;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(ix)	depreciation for capital improvements made by Landlord during the Lease Term (x) to reduce Operating Expenses if Landlord reasonably shall have determined on the basis of independent, third party engineering estimates that the annual reduction in Operating Expenses shall exceed depreciation therefor or (y) to comply with Legal Requirements not in effect as of the Effective Date (the capital expenditures described in subsections (x) and (y) being hereinafter referred to as &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Permitted Capital Expenditures</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) plus, in the case of both (x) and (y), an interest factor, reasonably determined by Landlord, as being the interest rate then charged for long term mortgages by institutional lenders on like properties within the general locality in which the Building is located, and depreciation in the case of both (x) and (y) shall be determined by dividing the original cost of such capital expenditure by the number of years of useful life of the capital item acquired, which useful life shall be determined reasonably by Landlord in accordance with generally accepted accounting principles and practices consistently applied in effect at the time of acquisition of the capital item; provided, however, if Landlord reasonably concludes on the basis of engineering estimates that a particular capital expenditure will effect savings in other Operating Expenses, including, without limitation, energy related costs, and that such projected savings will, on an annual basis (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Projected Annual Savings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), exceed the annual depreciation therefor, then and in such event the amount of depreciation for such capital expenditure shall be increased to an amount equal to the Projected Annual Savings; and in such circumstance, the increased depreciation (in the amount of the Projected Annual Savings) shall be made for such period of time as it would take to fully amortize the cost of the item in question, together with interest thereon at the interest rate as aforesaid in equal monthly payments, each in the amount of 1/12th of the Projected Annual Savings, with such payment to be applied first to interest and the balance to principal;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(x)	any reasonable costs or expenses incurred by Landlord in implementing the provisions of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 7.12</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(xi)	all other reasonable and necessary expenses paid in connection with the operating, cleaning and maintenance of the Building or said Common Areas and facilities and properly chargeable against income.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">6.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Operating Expense Exclusions Defined</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Operating Expense Exclusions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall mean:</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	Real Estate Taxes and Abatement Expenses;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	principal and interest on indebtedness, debt amortization (except to the extent that the same are included as the result of Permitted Capital Expenditures), and fixed and percentage ground rent paid by Landlord in connection with any mortgages, deeds of trust or other financing encumbrances, or ground leases of the Building;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">27</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	capital improvements, capital repairs, capital alterations or other capital items to the Building and/or the Project other than Permitted Capital Expenditures;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	legal, auditing, consulting and professional fees and other costs paid or incurred in connection with financings, refinancings or sales of any interest in Landlord or of Landlord&#x2019;s interest in the Building or in connection with any ground lease;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(e)	legal fees, space planner&#x2019;s fees, architect&#x2019;s fees, leasing and brokerage commissions, advertising and promotional expenditures and any other marketing expense incurred in connection with the leasing of space in the Building (including new leases, lease amendments, lease terminations and lease renewals);</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(f)	the cost of any items to the extent to which such cost is reimbursed to Landlord by tenants of the Building (other than pursuant to this Article VI), or other third parties, or is covered by a warranty to the extent of reimbursement for such coverage;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(g)	expenditures for any leasehold improvement which is made in connection with the preparation of any portion of the Building for occupancy by any tenant or which is not made generally to or for the benefit of the Building;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(h)	the cost of performing work or furnishing service to or for any tenant other than Tenant, at Landlord&#x2019;s expense, to the extent such work or service is in excess of any work or service Landlord is obligated to provide to Tenant or generally to other tenants in the Building at Landlord&#x2019;s expense;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)	the cost of repairs or replacements incurred by reason of fire or other casualty, or condemnation (other than costs not in excess of any commercially reasonable deductible on any insurance maintained by Landlord which provides a recovery for such repair or replacement);</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(j)	expenses related solely and exclusively to the operation of the Parking Facilities;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(k)	fees, costs and expenses incurred by Landlord in connection with or relating to claims against or disputes with tenants of the Building;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(l)	interest, fines or penalties for late payments by Landlord, if any;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(m)	interest, fines or penalties for violations of Legal Requirements by Landlord, if any, except if such interest, fines or penalties are incurred as a result of a violation of a Legal Requirement by Tenant, Tenant shall be responsible for the full amount of such expense;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(n)	costs and expenses incurred for the administration of the entity which constitutes Landlord, as the same are distinguished from the costs of operation, management, maintenance and repair of the Project, including, without limitation, entity accounting and legal matters;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(o)	the wages and benefits of any employee who does not devote substantially all of his or her employed time to the Building unless such wages and benefits are prorated on a</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">28</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">reasonable basis to reflect time spent on the operation and management of the Project vis-a-vis time spent on matters unrelated to the operation and management of the Project;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(p)	except as may be otherwise expressly provided in this Lease with respect to specific items, the cost of any services or materials provided by any party related to Landlord, to the extent such cost exceeds, the reasonable cost for such services or materials absent such relationship in self-managed buildings similar to the Building in the vicinity of the Building;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(q)	depreciation for the Building and the Project;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(r)	management or administrative fees;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(s)	any costs or expenses incurred in connection with the enforcement of Landlord&#x2019;s Warranty (as hereinafter defined);</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(t)	legal fees or other expenses incurred in connection with negotiating and enforcing leases, letters, deal memos, letters of intent, subleases and/or assignments with tenants or occupants in the Building, including costs incurred in connection with consents and approvals under leases in the Building;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(u)	the cost of remediating Hazardous Materials from the Building or the Project other than Included Hazardous Materials, as hereinafter defined; &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Included Hazardous Materials</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall be defined as all Hazardous Materials, other than:  (A) any material or substance located on the Land on the Effective Date which, as of the Effective Date, is not considered under then existing Legal Requirements, to be Hazardous Material, but which is subsequently determined to be a Hazardous Material by reason of a Legal Requirement which first becomes effective after the Effective Date of this Lease, and (B) any material or substance that is introduced to the Building or the Land after the Effective Date which, when introduced to the Building or the Land, is not then (i.e., at the time of introduction to the Building or the Land) considered, as a matter of any Legal Requirement, to be a Hazardous Material, but which is subsequently determined to be a Hazardous Material by reason of Legal Requirements which first becomes effective after the date of introduction of such material or substance to the Building or Land;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(v)	the cost of installing any specialty service, such as an observatory, broadcasting facilities, child or daycare, restaurant, fitness facility, theatre or cafe in the Building;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(w)	advertising, lobbying, marketing and promotional expenditures, and costs of acquisition and maintenance of signs in or on the Building exclusively identifying the owner of the Building or exclusively identifying other tenants;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(x)	lease payments for rental equipment (other than equipment for which depreciation is properly charged as an expense) that would constitute a capital expenditure if the equipment were purchased to the extent that such lease payments exceed the amount which would have been included in Operating Expenses if such equipment had been purchased rather than leased;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(y)	penalties or fees or damages incurred by Landlord due to the violation by Landlord or any tenant of the terms and conditions of any lease of space in the Building;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">29</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(z)	cost of acquiring sculptures, paintings and other works of art or charitable or political contributions;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(aa)	all other items for which another party compensates or pays so that Landlord shall not recover any item of cost more than once;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(bb)	all costs and expenses paid by Landlord pursuant to the TAPA prior to the issuance of a certificate of occupancy for the Building, but Landlord may include in Operating Expenses any ongoing costs and expenses to be paid by Landlord to comply with the TAPA after issuance of a certificate of occupancy for the Building; and</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(cc)	rent for any office space occupied by Project management personnel to the extent the size or rental rate for such office space exceeds the size or fair market rental value of office space occupied by management personnel of comparable buildings.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">6.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Payment of Tenant&#x2019;s Expense Share</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	Commencing as of the Rent Commencement Date and continuing thereafter throughout the remainder of the Term of the Lease, Tenant shall pay to Landlord, as Additional Rent, Tenant&#x2019;s Expense Share.  Landlord may not more than two (2) times per calendar year (including the adjustment at the end of each calendar year) make a good faith estimate of Tenant&#x2019;s Expense Share for any fiscal year or part thereof during the Term, and Tenant shall pay to Landlord, on the Rent Commencement Date and on the first (1st) day of each calendar month thereafter, an amount equal to Tenant&#x2019;s Expense Share for such fiscal year and/or part thereof divided by the number of months therein.  Landlord may estimate and re-estimate Tenant&#x2019;s Expense Share and deliver a copy of the estimate or re-estimate to Tenant.  Thereafter, the monthly installments of Tenant&#x2019;s Expense Share shall be appropriately adjusted in accordance with the estimations so that, by the end of the fiscal year in question, Tenant shall have paid all of Tenant&#x2019;s Expense Share as estimated by Landlord.  Any amounts paid based on such an estimate shall be subject to adjustment as herein provided when actual Operating Expenses are available for each fiscal year.  As of the Effective Date, the fiscal year for the payment of Operating Expenses is January 1 - December 31.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	Within one hundred fifty (150) days after the end of the first calendar year or fraction thereof ending December 31 and of each succeeding calendar year during the Lease Term or fraction thereof at the end of the Lease Term, Landlord shall render Tenant a statement (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Year End Statement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) in reasonable detail and according to usual accounting practices, showing for the preceding calendar year or fraction thereof, as the case may be, the Operating Expenses for the Building and the Tenant&#x2019;s Expense Share.  Said statement to be rendered to Tenant also shall show for the preceding year or fraction thereof, as the case may be, the amounts already paid by Tenant on account of Tenant&#x2019;s Expense Share and the amount of Tenant&#x2019;s Expense Share remaining due from, or overpaid by, Tenant for the year or other period covered by the statement.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	If such Year End Statement shows a balance remaining due to Landlord, Tenant shall pay same to Landlord on or before the thirtieth (30th) day following receipt by Tenant of said Year End Statement.  Any balance shown as due to Tenant shall be credited against Annual Fixed Rent next due, or refunded to Tenant if within sixty (60) days after the end of the Lease</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">30</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Term.  Landlord&#x2019;s failure to render any Year End Statement on a timely basis with respect to any calendar year shall not prejudice Landlord&#x2019;s right to thereafter render a Year End Statement with respect to such calendar year or any subsequent calendar year, nor shall the rendering of a Year End Statement prejudice Landlord&#x2019;s right to thereafter render a corrected Year End Statement for that calendar year; provided Landlord shall have waived reimbursement as to any item, cost or expense not billed to Tenant within two (2) years after the end of the calendar year to which such item, cost or expense relates.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">6.4	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Audit Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Subject to the provisions of this Section 6.4, Tenant shall have the right, at Tenant&#x2019;s cost and expense, to examine all documentation and calculations prepared in the determination of the Tenant&#x2019;s Expense Share and any utility payments hereunder:</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)	Tenant shall have the right to make such examination no more than once in respect of any period in which Landlord has given Tenant a statement of the actual amount of Operating Expenses (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Operating Expense Statement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  Tenant shall have no right to examine all documentation and calculations pursuant to this Section 6.4 unless Tenant has paid the amount shown on the Operating Expense Statement.  Tenant shall exercise such right by giving Landlord written notice (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Documentation Request</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) no more than one hundred eighty (180) days after Landlord gives Tenant an Operating Expense Statement in respect of such period (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Documentation Request Due Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) (or if Landlord subsequently charges Tenant for any amount respecting any period covered by a prior Operating Expense Statement, Tenant shall have one hundred eighty (180) days after notice of such subsequent charge to exercise Tenant&#x2019;s rights under this Section 6.4 as to such charge).</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(ii)	Such documentation and calculations shall be made available to Tenant at the offices in the Greater Boston area where Landlord keeps such records during normal business hours within a reasonable time not to exceed sixty (60) days after Landlord receives a Documentation Request.  Landlord shall notify Tenant (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Documentation Availability Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) when such documents and calculations are available for examination.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iii)	Such examination (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Examination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) may be made only by a nationally or regionally recognized independent certified public accounting firm (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Major CPA Firm </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">), or by another certified public accounting firm reasonably approved by Landlord, in either case licensed to do business in the jurisdiction where the Project is located.  Without limiting Landlord&#x2019;s approval rights, Landlord may withhold its approval of any examiner of Tenant who is representing, or in the case of an examiner other than a Major CPA Firm) has within the last two (2) years prior to Tenant&#x2019;s request represented, any other tenant in the Project.  In no event shall Tenant use any examiner who is being paid by Tenant on a contingent fee basis.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iv)	As a condition to performing any such Examination, Tenant and its examiners shall be required to execute and deliver to Landlord an agreement, in form reasonably acceptable to Landlord, agreeing to keep confidential any information which it discovers about Landlord or the Project in connection with such examination.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">31</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(v)	Provided that the Landlord provides reasonable access to the documentation, the Examination shall be commenced within forty-five (45) days after Landlord delivers the Documentation Availability Notice and shall be concluded within one hundred twenty (120) days of its commencement.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(vi)	If, after the Examination with respect to any calendar year, it is finally determined that:  (a) Tenant has made an overpayment on account of the Tenant&#x2019;s Expense Share, Landlord shall credit such overpayment against the next installment(s) of Fixed Rent thereafter payable by Tenant, except that if such overpayment is determined after the termination or expiration of the Term, Landlord shall promptly refund to Tenant the amount of such overpayment less any amounts then due from Tenant to Landlord; or (b) Tenant has made an underpayment on account of the Tenant&#x2019;s Expense Share Tenant shall, within thirty (30) days of such determination, pay such underpayment to Landlord; and (c) if the amount of the Tenant&#x2019;s Expense Share was overstated by more than five percent (5%), Landlord shall pay Tenant&#x2019;s reasonable out-of-pocket cost for such audit.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(vii)	Time is of the essence of the provisions of this Section 6.4.  Should Tenant fail to give Landlord the Documentation Request by the Documentation Request Due Date (subject to the provisions of Section 6.4(i)), then in any such case Tenant shall have no further right to question said Operating Expenses, and the amounts shown on Operating Expense Statement shall be final as between the parties</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article VII<br>BUILDING SERVICES</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Building Services</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Throughout the Term, Landlord shall provide the Building services to Tenant set forth in this Article VII, subject to reimbursement as part of Operating Expenses (except as otherwise provided herein).  In addition, Landlord agrees to furnish, at Tenant&#x2019;s expense, such additional special services as may be mutually agreed upon by Landlord and Tenant, upon reasonable and equitable rates from time to time established by Landlord.  Tenant agrees to pay to Landlord, as Additional Rent, the cost of any such additional Building services requested by Tenant and agreed to be provided by Landlord within thirty (30) days after delivery of an invoice therefor.  Except as otherwise expressly provided in this Article VII, Landlord shall not be required to furnish any other services to the Premises.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Heating, Ventilation and Air Conditioning</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The parties hereby acknowledge that Base Building portion of the HVAC System (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Base Building HVAC System</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) to be installed by Landlord as part of Landlord&#x2019;s Work, will provide:  (i) chilled water (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Chilled Water</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) to be utilized by the portion of the HVAC System to be installed by Tenant as part of Tenant&#x2019;s Work (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Premises HVAC Equipment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), (ii) condenser water (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Condenser Water</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) which may, if applicable, be utilized by Tenant to serve supplemental air conditioning units and related equipment (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Supplemental HVAC Equipment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) to cool areas in the Premises used by for the operation of telecommunications and other specialized equipment which may be installed by Tenant in accordance with the provisions of this Lease, and (iii) hot</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">32</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">water for heating (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Hot Water</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  Landlord shall not be responsible based upon any failure or defect in either the Premises HVAC Equipment and/or any Supplemental HVAC Equipment or Tenant&#x2019;s use of the Premises which exceeds the electrical, human occupancy or environmental factors for which the Premises HVAC Equipment or Supplemental HVAC Equipment is designed.  Tenant shall install (as part of Tenant&#x2019;s Work) one or more submeters to measure Tenant&#x2019;s use of Chilled Water and, if applicable, Condenser Water and Hot Water in the Premises, and Tenant shall pay the actual utility cost of Tenant&#x2019;s use of the Chilled Water and, if applicable, Condenser Water and Hot Water, as measured by said submeter(s).  From and after the Occupancy Date or such later date as Chilled Water and, if applicable, Condenser Water and Hot Water, is provided to the Premises, Tenant shall pay to Landlord, as Additional Rent, on demand from time to time, but not more frequently than monthly, for Chilled Water and, if applicable, Condenser Water and Hot Water, based on such submeter(s) (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s HVAC Charge</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  At Landlord&#x2019;s election, on a monthly basis at the time and in the fashion herein provided for the payment of Annual Fixed Rent, Tenant shall pay Landlord, as Additional Rent, an amount equal to 1/12</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> of the annual amount of Tenant&#x2019;s HVAC Charge, as reasonably estimated by Landlord.  Following the end of each full or partial calendar year during the Lease Term, Landlord shall deliver to Tenant a statement setting forth the amount of Tenant&#x2019;s HVAC Charge based on Tenant&#x2019;s actual usage of Chilled Water and, if applicable, Condenser Water and Hot Water, for the partial or full calendar year in question and the sum of Tenant&#x2019;s HVAC Charge estimates that have been paid by Tenant.  If the amount of Tenant&#x2019;s HVAC Charge exceeds the sum of the Tenant&#x2019;s HVAC Charge estimates paid by Tenant for such period, Tenant shall pay Landlord the difference within thirty (30) days after receipt of such statement.  If the sum of the Tenant&#x2019;s HVAC Charge estimates paid by Tenant for such period exceeds Tenant&#x2019;s HVAC Charge for such period, Landlord shall credit the difference toward the Tenant&#x2019;s HVAC Charge estimate payment(s) next due and, at the end of the Lease Term, refund any excess amount of Tenant&#x2019;s HVAC Charge estimates paid by Tenant, less the amount of any moneys owed to Landlord by Tenant.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Electricity</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Landlord shall provide electricity to the Premises through the base building electrical system to be installed by Landlord as part of Landlord&#x2019;s Work.  Tenant&#x2019;s electrical use in the Premises shall be sub-metered and from and after the Occupancy Date, Tenant shall pay to Landlord, as Additional Rent, on demand from time to time, but not more frequently than monthly, for its consumption of electricity based on such submeter(s) (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Electricity Charge</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  At Landlord&#x2019;s election, on a monthly basis at the time and in the fashion herein provided for the payment of Annual Fixed Rent, Tenant shall pay Landlord, as Additional Rent, an amount equal to 1/12</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> of the annual cost, as reasonably estimated by Landlord, of the cost of Tenant&#x2019;s consumption of electricity.  Following the end of each full or partial calendar year during the Lease Term, Landlord shall deliver to Tenant a statement setting forth the amount of Tenant&#x2019;s Electricity Charge based on Tenant&#x2019;s actual usage of electricity service for the partial or full calendar year in question and the sum of the Electricity Charge estimates that have been paid by Tenant.  If the amount of Tenant&#x2019;s Electricity Charge exceeds the sum of the Electricity Charge estimates paid by Tenant for such period, Tenant shall pay Landlord the difference within thirty (30) days after receipt of such statement.  If the sum of the Electricity Charge estimates paid by Tenant for such period exceeds Tenant&#x2019;s Electricity Charge for such period, Landlord shall credit the difference toward the Electricity Charge estimate payment(s) next due and, at the end of the Lease Term, refund any excess amount of Electricity Charge estimates paid by Tenant, less the amount of any</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">33</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">moneys owed to Landlord by Tenant.  Tenant shall maintain in good order and repair (and replace, if necessary) all meters serving the Premises. Tenant shall not install or use within the Premises any equipment, appliance or machine which shall require amounts of electrical energy exceeding the standard capacity provided for the Premises pursuant to Exhibit 2.1, unless the installation and use of such additional equipment, appliance, or machine has been approved by Landlord, which approval shall not be unreasonably withheld, conditioned or delayed.  If Tenant fails to pay any charges for electricity on a timely basis, and such failure remains uncured for thirty (30) days after notice thereof to Tenant, then Landlord may pay such charges directly to the utility company, and Tenant shall reimburse Landlord as Additional Rent for all amounts reasonably expended by Landlord in connection therewith within thirty (30) days after receipt of an invoice therefor, except as expressly set forth in this Lease.  Landlord shall not be liable in any way to Tenant for any failure, defect or interruption of, or change in the supply, character and/or quantity of electricity service furnished to the Premises by any utility provider.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.4	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Water</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Landlord shall provide (i) cold water to each floor of the Building on which the Premises are located for Base Building equipment only, the cost of which shall be included in Operating Expenses, and (ii) hot and cold water to the core restrooms on each floor of the Building on which the Premises are located, the cost of which shall be included in Operating Expenses. Tenant shall pay the cost of heating water and of redistributing water within the Premises and/or additional water capacity, and for all maintenance, repairs and replacements of all installations, improvements, and equipment relating thereto.  Tenant shall install (as part of Tenant&#x2019;s Work) one or more submeters to measure Tenant&#x2019;s use such water.  From and after the Occupancy Date or such later date as water is provided to the Premises, Tenant shall pay to Landlord, as Additional Rent, on demand from time to time, but not more frequently than monthly, for such water, based on such submeter(s).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.5	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Gas</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Landlord shall provide gas service to the Base Building equipment only, the cost of which shall be included in Operating Expenses. Tenant shall install (as part of Tenant&#x2019;s Work) one or more submeters to measure Tenant&#x2019;s use such gas. From and after the Occupancy Date or such later date as gas is provided to the Premises, Tenant shall pay to Landlord, as Additional Rent, on demand from time to time, but not more frequently than monthly, for such gas, based on such submeter(s).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.6	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Elevators</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Landlord shall provide passenger elevator service to the floors on which the Premises is located and two (2) freight elevator service on a non-exclusive basis with other tenants of the Building.  Subject to Force Majeure, Landlord shall provide sufficient passenger elevator service to each floor of the Premises on a twenty-four hours (24) a day, seven (7) days a week, three hundred sixty-five (365) days a year basis subject always to restrictions based on emergency conditions and with at least three (3) elevators in the Building in operation at all times during Normal Business Hours on business days and at least one (1) elevator in operation twenty-four (24) hours per day.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">34</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.7	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Common Areas</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Landlord shall provide in the Common Areas of the Building:  electricity for normal lighting purposes, customary heating, air conditioning, cleaning and trash removal services on business days and routine repair and maintenance in such manner as Landlord deems reasonable in order to maintain the first-class character of the Building.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.8	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Access and Security</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">So long as Tenant, and any person accessing the Premises pursuant to Tenant &#x2018;s access rights hereunder (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Accessees</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) shall comply with Landlord&#x2019;s reasonable security program for the Project, Landlord shall provide Tenant with, and Tenant&#x2019;s Accessees shall have, access to the Building and Premises twenty-four (24) hours per day, seven (7) days per week, during the Term of this Lease, except in an emergency or due to casualty or Force Majeure.  Outside of normal business hours, Landlord may restrict access to the Building in accordance with the Building security system.  Tenant shall be responsible for all security for and within the Premises and provide such security for and within the Premises as Tenant deems appropriate, at Tenant&#x2019;s sole cost and expense.  All security systems installed by Tenant shall be subject to Landlord&#x2019;s approval, which shall not be unreasonably withheld, conditioned or delayed, and shall be compatible with the base Building systems. Throughout the Term Landlord shall provide the following for the Building and site:  (i) manned security in the Building lobby during Normal Business Hours; (ii) turnstile access control from the lobby(ies) of the Building and elevator access control; and (iii) video/camera/closed circuit television monitoring in and around the Building.  Notwithstanding the foregoing, to the maximum extent permitted by Legal Requirements, in no event shall Landlord have any liability or obligation to Tenant arising from any claims for loss, injury or damage to persons or property in connection therewith.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.9	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Telecommunications Provider</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Tenant shall have the right to select its own telecommunications provider (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Telecom Provider</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) for the Premises for telecommunications services, excluding a DAS or similar system, which may be installed in the Building only by Landlord.  Subject to Tenant&#x2019;s Telecom Provider entering into reasonable access agreement with Landlord consistent with this Section 7.10, Landlord shall permit Tenant&#x2019;s Telecom Provider to install cabling to Tenant&#x2019;s floors, and to have access to the Office Portion of the Building and the Premises to install telecommunications equipment, using a portion of available Building shafts, conduits, and related telecommunications rooms (on floors on which the Premises is located and in Building shafts proportionate to the portion of the Building leased by Tenant).  All such installations and replacements from time to time shall be made by Tenant or the applicable service provider in accordance with Article IX.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.10	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">No Damage</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	Subject to Section 7.11, Landlord shall not be liable to Tenant for any compensation or reduction of rent by reason of inconvenience or annoyance or for loss of business arising from the necessity of Landlord or its agents entering the Premises for any purposes authorized in this Lease, or for repairing or replacing the Premises or any portion of the Building</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">35</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">or Project however the necessity may occur, which entry, repair and replacement shall be performed in accordance with the provisions of this Lease.  If Landlord is prevented or delayed from making any repairs, alterations or improvements, or furnishing any services or performing any other covenant or duty to be performed on Landlord&#x2019;s part, by reason of any cause reasonably beyond Landlord&#x2019;s control, including, without limitation, by reason of Force Majeure or for any cause due to any act or neglect of Tenant or Tenant&#x2019;s servants, agents, employees, licensees or any person claiming by, through or under Tenant, Landlord shall not be liable to Tenant therefor, nor, except as expressly otherwise provided in this Lease, shall Tenant be entitled to any abatement or reduction of rent by reason thereof, or right to terminate this Lease, nor shall the same give rise to a claim in Tenant&#x2019;s favor that such failure constitutes actual or constructive, total or partial, eviction from the Premises.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	Landlord reserves the right to stop any service or utility system, when necessary by reason of accident or emergency, or until necessary repairs have been completed; provided, however, that in each instance of stoppage, Landlord shall exercise reasonable diligence to eliminate the cause thereof.  Except in case of emergency repairs, Landlord will give Tenant reasonable advance notice of any contemplated stoppage and will use reasonable efforts to avoid unnecessary inconvenience to Tenant by reason thereof.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.11	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Remedy in the Event of Service Interruption</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The provisions of this Section 7.11 set forth Tenant&#x2019;s sole right and remedy, both in law and in equity, in the event of any Service Interruption, as hereinafter defined.  In the event that:  (i) there shall be an interruption, curtailment or suspension of any service or failure to perform any obligation required to be provided or performed by Landlord pursuant to Article VII (and no reasonably equivalent alternative service or supply is provided by Landlord) that shall materially interfere with Tenant&#x2019;s use and enjoyment of the Premises, or any portion thereof (any such event, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Service Interruption</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), and (ii) such Service Interruption shall continue for five (5) consecutive business days following receipt by Landlord of written notice (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Service Interruption Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) from Tenant describing such Service Interruption (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Abatement Service Interruption Cure Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), and (iii) such Service Interruption shall not have been caused by an act or omission of Tenant or Tenant&#x2019;s agents, employees, or contractors (an event that satisfies the foregoing conditions (i)-(iii) being referred to hereinafter as a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Material Service Interruption</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) then, Tenant, subject to the next following sentence, shall be entitled to an equitable abatement of Annual Fixed Rent, Tenant&#x2019;s Tax Share, and Tenant&#x2019;s Expense Share based on the nature and duration of the Material Service Interruption and the area of the Premises affected, for any and all days following the Abatement Service Interruption Cure Period that both (x) the Material Service Interruption is continuing and (y) Tenant does not use such affected areas of the Premises for a bona fide business purpose.  Any efforts by Tenant to respond or react to any Material Service Interruption, including, without limitation, any activities by Tenant to remove its personal property from the affected areas of the Premises, shall not constitute a use that precludes abatement pursuant to this Section 7.11.  The Abatement Service Interruption Cure Period shall be extended by reason of any delays in Landlord&#x2019;s ability to cure the Service Interruption in question caused by Force Majeure, provided however, that in no event shall the Abatement Service Interruption Cure Period with respect to any Service Interruption be longer than ten (10) consecutive business days after Landlord receives the applicable Service Interruption Notice.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">36</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The provisions of this Section 7.11 shall not apply in the event of a Service Interruption caused by Casualty or Taking (see Article XIV hereof).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.12	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Sustainability Initiative; Consumption Data.  See Exhibit 7.12</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article VIII<br>TENANT&#x2019;S REPAIRS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">8.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Structural Repairs</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Except for damage caused by fire or casualty and by eminent domain which shall be repaired by Landlord subject to the terms and conditions of Article XIV, Landlord shall, throughout the Lease Term, keep and maintain, or cause to be kept and maintained, in good order, and in first-class condition and repair the Building and Common Areas including, without limitation, the following portions of the Building:  the structural portions of the roof, the roof membrane, the exterior and load bearing walls, the foundation, the structural columns and floor slabs and other structural elements of the Building.  Tenant shall, subject to the terms and conditions of Section 13.5 and of Article XIV, pay to Landlord, as Additional Rent, the cost of any and all such repairs which may be required as a result of repairs, alterations, or installations made by Tenant or any subtenant, assignee, licensee or concessionaire of Tenant or any agent, servant, employee or contractor of any of them or to the extent of any loss, destruction or damage caused by the misuse, default, negligence or willful misconduct of Tenant or any Tenant Parties.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">8.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Other Repairs to be Made by Landlord</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Except for damage caused by fire or casualty and by eminent domain which shall be repaired by Landlord subject to the terms and conditions of Article XIV, and except as otherwise provided in this Lease, Landlord agrees to keep and maintain, or cause to be kept and maintained, in good order, and in first-class condition and repair the Base Building systems, Common Areas and facilities of the Building, except that Landlord shall in no event be responsible to Tenant for (x) the condition of glass in the Premises (other than for glass in exterior walls for which Landlord shall be responsible unless, subject to the provisions of Section 13.5 and Article XIV, the damage thereto is attributable to Tenant&#x2019;s or any Tenant Party&#x2019;s misuse, default, negligence or willful misconduct, in which event the responsibility therefor shall be Tenant&#x2019;s), (y) any condition in the Premises or the Building caused by any negligence or willful misconduct of Tenant or any agent, employee, contractor, assignee, subtenant, licensee, concessionaire or invitee of Tenant or (z) any specialized HVAC equipment installed by Tenant, which shall be Tenant&#x2019;s responsibility.  Without limitation, Landlord shall not be responsible to make any improvements or repairs to the Building or the Premises other than as expressly provided in Section 8.1 or in this Section 8.2, unless expressly otherwise provided in this Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">8.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Repairs and Maintenance</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	Subject to Landlord&#x2019;s obligations in Sections 8.1 and 8.2 above, Tenant covenants and agrees that, from and after the date that possession of the Premises is delivered to Tenant and until the end of the Lease Term, Tenant will keep neat and clean and maintain in good order, condition and repair the Premises and every part thereof, including, without limitation, those portions of the heating, ventilating, air conditioning excluding the Base Building HVAC System,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">37</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">plumbing and other Building systems equipment to the extent solely servicing the Premises, excepting only:  (i) those repairs for which Landlord is responsible under the terms of Article VII and Article VIII of this Lease, (ii) damage by fire or casualty and as a consequence of the exercise of the power of eminent domain, and (iii) and normal wear and tear.  Tenant shall not permit or commit any waste, and Tenant shall, subject to the provisions of Section 13.5 and Article XIV, be responsible for the cost of repairs which may be made necessary by reason of damages to Common Areas in the Building or the Project by the misuse, default, negligence or willful misconduct of Tenant and any Tenant Parties. Tenant shall maintain all its equipment, furniture and furnishings in good order and repair.  With respect to the HVAC system and other systems within the Premises, Tenant specifically agrees to maintain at all times a service contract satisfactory to Landlord with respect thereto, furnishing evidence thereof (including renewals) to Landlord.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Landlord Self-Help Right</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  If repairs are required to be made by Tenant pursuant to the terms hereof, and Tenant fails to make such repairs within thirty (30) days after written notice from Landlord (or such longer period of time as Tenant may reasonably require, so long as Tenant commences to perform such repair within such thirty (30) day period and thereafter diligently prosecutes such cure to completion, Landlord may (but shall not be required to do so) make or cause such repairs to be made and shall not be responsible to Tenant for any loss or damage that may accrue to Tenant&#x2019;s stock or business by reason thereof.  Notwithstanding the foregoing, in an emergency, Landlord may exercise its right to make such repairs under the immediately preceding sentence without any prior notice to Tenant.  If Landlord makes or causes such repairs to be made, Tenant agrees that Tenant will forthwith on demand, pay to Landlord as Additional Rent the reasonable cost thereof together with interest thereon at the rate specified in Section 16.17, and if Tenant shall default in such payment, Landlord shall have the remedies provided for non-payment of rent or other charges payable hereunder.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article IX<br>ALTERATIONS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Landlord&#x2019;s Approval</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	Tenant covenants and agrees not to make Alterations to the Premises (collectively &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Alterations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), whether before or during the Lease Term, except in accordance with plans and specifications therefor first approved by Landlord in writing, which approval shall not be unreasonably withheld, conditioned or delayed.  However, Landlord&#x2019;s determination of matters relating to aesthetic issues relating to Alterations which are visible outside the Premises shall be in Landlord&#x2019;s sole discretion.  Without limiting such standard, Landlord shall not be deemed unreasonable:</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	for withholding approval of any Alterations which (i) in Landlord&#x2019;s opinion might affect any structural or exterior element of the Building, any area or element outside of the Premises or any facility or base building mechanical system serving any area of the Building outside of the Premises, or (ii) involve or affect the exterior design, size, height or other exterior dimensions of the Building, or (iii) enlarge the Rentable Floor Area of the Premises, or (iv) are inconsistent, in Landlord&#x2019;s reasonable judgment, with alterations satisfying Landlord&#x2019;s standards for new alterations in the Building, or (v) will require unusual expense to readapt the Premises to normal office and laboratory use on Lease termination or increase the cost of construction or of</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">38</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">insurance or taxes on the Building or of the services called for by Article VII unless Tenant first gives assurance acceptable to Landlord for payment of such increased cost and that such readaptation will be made prior to such termination without expense to Landlord; and</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	subject to Tenant&#x2019;s rights and obligations and the limitations set forth in Section 9.5 below, for making its approval conditional on Tenant&#x2019;s agreement to restore the Premises to its condition prior to such alteration, addition, or improvement at the expiration or earlier termination of the Lease Term.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	Landlord&#x2019;s review and approval of any such plans and specifications or under </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and consent to perform work described therein shall not be deemed an agreement by Landlord that such plans, specifications and work conform with applicable all applicable laws, ordinances, rules, regulations, statutes, by-laws, court decisions, and orders and requirements of all public authorities (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Legal Requirements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) and requirements of insurers of the Building and the other requirements of the Lease with respect to Tenant&#x2019;s insurance obligations (herein called &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Insurance Requirements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) nor deemed a waiver of Tenant&#x2019;s obligations under this Lease with respect to applicable Legal Requirements and Insurance Requirements nor impose any liability or obligation upon Landlord with respect to the completeness, design sufficiency or compliance of such plans, specifications and work with applicable Legal Requirements and Insurance Requirements. Further, Tenant acknowledges that Tenant is acting for its own benefit and account, and that Tenant shall not be acting as Landlord&#x2019;s agent in performing any work in the Premises, accordingly, no contractor, subcontractor or supplier shall have a right to lien Landlord&#x2019;s interest in the Project in connection with any such work.  Within thirty (30) days after receipt of an invoice from Landlord, Tenant shall pay to Landlord, as a fee for Landlord&#x2019;s review of any plans or work, as Additional Rent, an amount equal to the sum of (i) $150.00 per hour, plus (ii) reasonable, actual third party expenses incurred by Landlord to review Tenant&#x2019;s plans and Tenant&#x2019;s work.  Such fee shall be payable in connection with Landlord&#x2019;s review of plans or work relating to any assignment or subletting.  The parties expressly agree that, notwithstanding the foregoing, the fees payable with respect to the initial improvements shall be as set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Conformity of Work</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Tenant covenants and agrees that any alterations, additions, improvements or installations made by it to or upon the Premises shall be done in a good and workmanlike manner and in compliance with all applicable Legal Requirements and Insurance Requirements now or hereafter in force, that materials of first and otherwise good quality shall be employed therein, that the structure of the Building shall not be endangered or impaired thereby and that the Premises shall not be diminished in value thereby.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Performance of Work, Governmental Permits and Insurance</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">All of Tenant&#x2019;s Alterations and installation of furnishings shall be coordinated with any work being performed by or for Landlord and in such manner as to maintain harmonious labor relations and not to damage the Building or Project or interfere with Building construction or operation and, except for installation of furnishings, shall be performed by contractors or workers first approved by Landlord.  Except for work by Landlord&#x2019;s general contractor, Tenant shall procure all necessary governmental permits before making any repairs, alterations, other</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">39</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">improvements or installations. Tenant agrees to save harmless and indemnify Landlord from any and all injury, loss, claims or damage to any person or property occasioned by or arising out of the doing of any such work whether the same be performed prior to or during the Term of this Lease except (subject to Section 13.5) to the extent caused by the negligence or willful misconduct of Landlord or any Landlord Parties. At Landlord&#x2019;s election, for any future Alterations the cost of which is expected to exceed $500,000.00, Tenant shall cause its contractor to obtain and maintain:  (i) a payment and performance bond in such amount and with such companies as Landlord shall reasonably approve, and (ii) a lien bond, in recordable form, covering all work performed on the Premises. Tenant shall not be required to cause its contractor to obtain such bonds with respect to the initial improvements to be performed pursuant to Exhibit 2.1.  In addition, Tenant shall cause each contractor to carry insurance in accordance with Schedule 1 of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 11.4-1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> hereof and to deliver to Landlord certificates of all such insurance.  Tenant shall also prepare and submit to Landlord a set of as-built plans, in both print and electronic forms, showing such work performed by Tenant to the Premises promptly after any such alterations, improvements or installations are substantially complete and promptly after any wiring or cabling for Tenant&#x2019;s computer, telephone and other communications systems is installed by Tenant or Tenant&#x2019;s contractor.  Without limiting any of Tenant&#x2019;s obligations hereunder, Tenant shall be responsible, as Additional Rent, for the costs of any Alterations in or to the Building that are required in order to comply with Legal Requirements as a result of any work performed by Tenant.  Landlord shall, in accordance with Section 11.4, have the right to provide rules and regulations relative to the performance of any alterations, additions, improvements and installations by Tenant hereunder and Tenant shall abide by all such reasonable rules and regulations of which Tenant has prior notice and shall cause all of its contractors to so abide including, without limitation, payment for the costs of using Building services. Tenant acknowledges and agrees that Landlord shall be the owner of any additions, alterations and improvements in the Premises or the Building to the extent paid for by Landlord.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9.4	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Liens</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Tenant covenants and agrees to pay promptly when due the entire cost of any work done on the Premises by Tenant, its agents, employees or contractors, and not to cause or permit any liens for labor or materials performed or furnished in connection therewith to attach to the Premises or the Building or the Project and to discharge any such liens which may so attach within ten (10) days after notice thereof.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9.5	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Nature of Alterations</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">All work, construction, repairs, Alterations or installations made to or upon the Premises (including, but not limited to, the construction performed by Landlord under Exhibit 2.1), shall become part of the Premises and shall become the property of Landlord and remain upon and be surrendered with the Premises as a part thereof upon the expiration or earlier termination of the Lease Term, except as follows:</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	All trade fixtures and personal property whether by law deemed to be a part of the realty or not, installed at any time or times by Tenant or any person claiming under Tenant shall remain the property of Tenant or persons claiming under Tenant and may be removed by Tenant or any person claiming under Tenant at any time or times during the Lease Term or any occupancy by Tenant thereafter and shall be removed by Tenant at the expiration or earlier</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">40</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">termination of the Lease Term if so requested by Landlord.  Tenant shall repair any damage to the Premises occasioned by the removal by Tenant or any person claiming under Tenant of any such property from the Premises.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	At the expiration or earlier termination of the Lease Term, Tenant shall remove any Alterations made with Landlord&#x2019;s consent during the Lease Term for which such removal was made a condition of such consent under Section 9.1(b), provided, however, that Landlord shall only require Tenant to remove Alterations which are non-customary to general office or laboratory use or which have uniquely specialized requirements. Notwithstanding the foregoing, Tenant shall remove at the end of the Term the equipment listed on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 9.5-1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, attached hereto and incorporated herein (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Required Removables</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  Upon such removal Tenant shall restore the Premises to their condition prior to such Alterations and repair any damage occasioned by such removal and restoration.  Notwithstanding anything to the contrary herein contained, Tenant shall not, without obtaining Landlord&#x2019;s prior written agreement (which agreement Landlord may withhold in its sole discretion), remove any of the items listed on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 9.5-2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Installations which Must Remain</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	If Tenant shall make any Alterations to the Premises for which Landlord&#x2019;s approval is required under Section 9.1 without obtaining such approval, then at Landlord&#x2019;s request at any time during the Lease Term, and at any event at the expiration or earlier termination of the Lease Term, Tenant shall remove such Alterations and restore the Premises to their condition prior to same and repair any damage occasioned by such removal and restoration.  Nothing herein shall be deemed to be a consent to Tenant to make any such Alterations, the provisions of Section 9.1 being applicable to any such work.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9.6	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Increases in Taxes</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Tenant shall pay, as Additional Rent, one hundred percent (100%) of any increase in real estate taxes on the Building which shall result from Alterations to the Premises made by Tenant after the Rent Commencement Date if the taxing authority specifically determines such increase results from such Alterations made by Tenant.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9.7	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Alterations Permitted Without Landlord&#x2019;s Consent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Notwithstanding anything to the contrary herein contained, Tenant shall have the right without obtaining the prior consent of Landlord, but upon prior notice to Landlord as provided below, to make Alterations to the Premises where:  (i) the same are within the interior of the Premises, and do not affect the exterior of the Building and do not affect any of the Building&#x2019;s systems or the ceiling of the Premises; (ii) the same do not affect the roof or any structural element of the Building, or the fire protection systems of the Building; (iii) the cost of any individual Alteration shall not exceed $100,000.00 in cost; (iv) Tenant shall comply with the provisions of this Lease, and if such work increases the cost of insurance or taxes, Tenant shall pay for any such increase in cost; and (v) Tenant gives Landlord at least five (5) business days&#x2019; prior notice describing such work in reasonable detail, accompanied by copies of plans and specifications therefor (to the extent plans and specifications are typically prepared in accordance with such work).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">41</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article X<br>PARKING</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">10.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Parking Privileges</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Number</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Commencing as of the Occupancy Date, and continuing thereafter throughout the Term of this Lease, Tenant shall be entitled to monthly parking privileges (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Parking Privileges</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) for .7 automobiles per 1,000 Rentable Floor Area of the Premises (i.e., forty-six (46) passenger automobiles) for the parking by Tenant&#x2019;s employees and business invitees of motor vehicles in unreserved stalls in the Parking Facilities, as hereinafter defined.  In the event that the Rentable Floor Area of the Premises decreases at any time during the Lease Term, the number of parking privileges provided to Tenant shall be reduced proportionately.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Parking Facilities. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Parking Facilities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall be in the structured parking facilities in the Project (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">On-Site Garage</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), except that, at Landlord&#x2019;s election (which may be exercised, from time to time during the Lease Term), up to fifty (50%) percent of the Parking Privileges will allow the Tenant employee holding such Parking Privileges to park at one of the following locations (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Alternative Parking Facilities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;):</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)	Trilogy; or</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(ii)	Van Ness.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">10.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Parking Charges</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Tenant shall pay to Landlord, the owner of the applicable Alternative Parking Facility, or, if directed by Landlord or such owner (if applicable), to the operator of the Parking Facility in question (each, sometimes referred to as a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Parking Facilities Manager</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) fees for such parking privileges (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Parking Fees</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) at the monthly rates from time to time charged by the applicable Parking Facility Manager, which rates shall not be in excess of market rates. Tenant acknowledges that said monthly charges to be paid under this Section are for the use by Tenant of the parking privileges referred to herein, and not for any other service.  Tenant&#x2019;s failure to make payment when due to the applicable Parking Facilities Manager shall be considered to be a failure in the payment of rent hereunder for which Landlord shall have all its rights and remedies under this Lease and at law and in equity.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">10.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Parking Facilities Operation</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Unless otherwise determined by the applicable Parking Facilities Manager, each of the Parking Facilities are to be operated on a self-parking basis, and Tenant shall be obligated to park and remove its own automobiles, and Tenant&#x2019;s parking shall be on an unreserved basis, Tenant having the right to park in any available stalls; provided, however, that Tenant&#x2019;s right to park in the On-Site Garage shall be limited to any available stalls on levels P3 - P6 of the On-Site Garage.  Tenant&#x2019;s access and use privileges with respect to each of the Parking Facilities shall be in accordance with regulations of uniform applicability to the users of such Parking Facility, from time to time established by the applicable Parking Facilities Manager.  Overnight parking is not permitted in any of the Parking Facilities. Tenant shall receive one (1) identification sticker or pass and one (1) magnetic card so-called, or other suitable device providing access to the applicable</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">42</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Parking Facility, for each parking privilege paid for by Tenant.  Tenant shall supply Parking Facilities Manager with an identification roster listing, for each identification sticker or pass, the name of the employee and the make, color and registration number of the vehicle to which it has been assigned, and shall provide a revised roster to Parking Facilities Manager monthly indicating changes thereto.  Any automobile found parked in any of the Parking Facilities during normal business hours without appropriate identification will be subject to being towed at said automobile owner&#x2019;s expense.  The parking privileges granted herein are non-transferable (other than to a permitted assignee or subtenant pursuant to the applicable provisions of Article XII hereof).  Each of the Parking Facilities Managers may institute at no additional cost to Tenant beyond the Parking Fees a so-called valet parking program for the Parking Facility which it operates, and in such event Tenant shall cooperate in all respects with such program.  The Parking Facility Manager of the On-Site Garage shall have the right to alter the On-Site Garage, which it operates as it sees fit and in such case to change in the On-Site Garage, including the reduction in area of the same so long as Tenant&#x2019;s Parking Privileges are not diminished or materially adversely affected, but subject to Landlord&#x2019;s rights pursuant to this Article X.  Other than a loss of Parking Privileges by reason of a Casualty, a Taking, or a temporary closure due to Force Majeure, it shall be deemed a material default of Landlord if there is a total loss of Tenant&#x2019;s Parking Privileges.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">10.4	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Limitations</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Tenant agrees that it and all persons claiming by, through and under it, shall at all times abide by all reasonable rules and regulations promulgated by Parking Facilities Manager with respect to the use of the Parking Facilities in accordance with Section 10.4.  Except to the extent of its negligence or willful misconduct, Parking Facilities Manager does not assume any responsibility whatsoever for loss or damage due to fire or theft or otherwise to any automobile or to any personal property therein, however caused, and Tenant agrees, upon request from Parking Facilities Manager, from time to time, to notify its officers, employees and agents then using any of the parking privileges provided for herein, of such limitation of liability.  Tenant further acknowledges and agrees that a license only is hereby granted, and no bailment is intended or shall be created.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article XI<br>CERTAIN TENANT COVENANTS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Tenant covenants and agrees to the following during the Lease Term and for such further time as Tenant occupies any part of the Premises:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Rent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">To pay when due all Annual Fixed Rent and Additional Rent and all charges for utility services rendered to the Premises therefor except as otherwise provided in Article VII and, as further Additional Rent, all charges for additional and special services rendered pursuant to Article VII.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Use</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Permitted Use</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  To use and occupy the Premises for the Permitted Use only, and not to injure or deface the Premises or the Building or the Project and not to permit in the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">43</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Premises any auction sale or, except in compliance with the provisions of Section 11.17 hereof, flammable fluids or chemicals, or nuisance, or the emission from the Premises of any objectionable noise or odor, nor to permit in the Premises anything which would in any way result in the leakage of fluid or the growth of mold, and not to use or devote the Premises or any part thereof for any purpose other than the Permitted Use, nor any use thereof which is inconsistent with the maintenance of the Building as an office and laboratory building of the first-class in the quality of its maintenance, use and occupancy, or which is improper, offensive taking into account the Permitted Use of the Premises (as determined in Landlord&#x2019;s reasonable discretion based upon written complaints received from other occupants of the Building or Project), contrary to Legal Requirements or liable to invalidate or increase the premiums for any insurance on the Building or its contents or liable to render necessary any alteration or addition to the Building.  Tenant shall use all service and utility areas (whether or not a part of the Premises) only for the particular purpose for which they are designed.  Tenant shall keep the Premises equipped with appropriate safety appliances to the extent required by applicable Legal Requirements or Insurance Requirements.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Vivarium</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Tenant shall be responsible, at its sole expense, for the operation of a vivarium (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Vivarium</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) located within the Premises in accordance with all Legal Requirements, with the standards for the operation of vivariums promulgated by the American Association for Laboratory Care, or its successor, and with best industry practices. Without limiting the general application of the foregoing, Tenant shall separately dispose of all waste products from the operation of Tenant&#x2019;s Vivarium, including, without limitation, dead animals, strictly in accordance with Legal Requirements. Landlord shall have the right, from time to time by written notice to Tenant, to promulgate reasonable rules and regulations with respect to the operation of Tenant&#x2019;s Vivarium so as to minimize any adverse effects that such operation may have on other occupants of the Building, including without limitation, regulations as to noise mitigation.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Transportation of Animals. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">No animals, animal waste, food or supplies relating to the animals maintained from time to time in the animal storage areas of the Premises shall be transported within the Building except as provided in this Section 11.2.  All deliveries of animals or animal food or supplies to Tenant at the Building shall be made prior to 11:00 a.m.  No transportation of animals, animal waste, food or supplies within the Building shall occur between the hours of 6:00 p.m.  and 7:00 a.m.  At all times that animals are transported within the Common Areas, they shall be transported in an appropriate cage or other container so that no animals are visible and such container is labeled or marked in a manner which does not indicate that it contains an animal.  At no time shall any animals, animal waste, food or supplies relating to the animals be brought into, transported through, or delivered to the lobby of the Building or be transported within the Building in elevators other than the freight elevators.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Vacancy by Tenant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Notwithstanding anything to the contrary contained in the Lease, if Tenant shall abandon or vacate the entire Premises, other than by reason of a Casualty, a Taking, the performance of Alterations in the Premises or a temporary closure due to Force Majeure, for a period of not less than one hundred eighty (180) days, then Landlord shall have the right to terminate this Lease upon written notice to Tenant.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Signage and Items Visible Outside of the Premises</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">44</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Not to obstruct in any manner any portion of the Building not hereby leased or any portion thereof or of the Project used by Tenant in common with others; not without prior consent of Landlord to permit the painting or placing of any signs, curtains, blinds, shades, awnings, aerials or flagpoles, or the like, visible from outside the Premises. Notwithstanding the foregoing, Tenant shall be entitled to install:  (i) a listing of Tenant&#x2019;s name on any tenant directory in the main lobby of the Building, (ii) Tenant&#x2019;s name on building standard way-finding signage in the elevator lobbies on the eighth (8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) and ninth (9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) floors, and (iii) Tenant identification signage (which shall be subject to Landlord&#x2019;s prior written approval, which approval shall not be unreasonably withheld) at the entrances to the Premises on the eighth (8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) and ninth (9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) floors. Such signage shall be at Tenant&#x2019;s sole expense, except that:  (i) Tenant may apply Landlord&#x2019;s Allowance to such costs, and (ii) the initial listing way-finding signage and listing on any building directory in the main lobby of the Building shall be at Landlord&#x2019;s expense.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.4	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Rules and Regulations</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">To comply with the Rules and Regulations attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 11.4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, the Construction Rules and Regulations attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 11.4-1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, the Loading Dock Rules and Regulations attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 11.4-2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, and all other reasonable rules and regulations hereafter made by Landlord, of which Tenant has been given notice, for the care and use of the Building and the Project and their facilities and approaches, but Landlord shall not be liable to Tenant for the failure of other occupants of the Building to conform to such rules and regulations. In the event of any conflict between any rule or regulation promulgated by Landlord and the provisions of this Lease, the provisions of this Lease shall control.  Landlord shall enforce such Rules and Regulations in a non-discriminatory manner unless differing circumstances justify differing treatment.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.5	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Licenses and Permits</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">To keep the Premises equipped with all safety appliances required by law or ordinance or any other regulation of any public authority because of any use made by Tenant other than normal office use and those safety appliances included in the Base Building Plans and Specifications, and to procure all licenses and permits so required because of any use made by Tenant other than Land Use Permits (as hereinafter defined), and, if requested by Landlord, to do any work so required because of such use, it being understood that the foregoing provisions shall not be construed to broaden in any way Tenant&#x2019;s Permitted Use.  &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Land Use Permits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall be defined as any zoning approvals, the building permit for Landlord&#x2019;s Work, a certificate of occupancy for Landlord&#x2019;s Work and any other governmental land use approvals or permits required to allow the Building to be used for office and laboratory uses.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.6	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Floor Load</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Not to place a load upon any floor in the Premises exceeding the live load (including partitions) per square foot of floor area for which the Building is designed; and not to move any safe, vault or other heavy equipment in, about or out of the Premises except in such manner and at such time as Landlord shall in each instance authorize.  Tenant&#x2019;s business machines and mechanical equipment shall be placed and maintained by Tenant at Tenant&#x2019;s expense in settings</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">45</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">sufficient to absorb and prevent vibration or noise that may be transmitted to the Building structure or to any other space in the Building.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.7	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Taxes on Personal Property</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">To pay promptly when due all taxes which may be imposed upon personal property (including, without limitation, fixtures and equipment) in the Premises to whomever assessed.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.8	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Payment of Legal Fees</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">In the event of litigation or other legal proceeding between Landlord and Tenant relating to the provisions of this Lease or Tenant&#x2019;s occupancy of the Premises, the losing party shall, upon demand, reimburse the prevailing party for its reasonable costs of prosecuting and/or defending such proceeding (including, without limitation, reasonable attorneys&#x2019; fees).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.9	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Compliance with Law</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Tenant shall, and shall cause all Tenant Parties to, comply with all applicable laws, ordinances, rules, regulations, statutes, by-laws, court decisions, and orders and requirements of all public authorities (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Legal Requirements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) now or hereafter in force which shall impose a duty on Landlord or Tenant relating to the operation of Tenant&#x2019;s business and/or the use, condition, configuration and occupancy of the Premises, including without limitation, all applicable standards and regulations of the Federal Occupational Safety and Health Administration (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">OSHA Requirements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), which obligation shall include ensuring that all contractors (including subcontractors) that Tenant utilizes to perform work in the Premises comply with OSHA Requirements. Tenant shall promptly pay all fines, penalties and damages that may arise out of or be imposed because of its failure to comply with the provisions of this Section 11.9.  Notwithstanding the foregoing, Tenant shall not be required to make any alterations or additions to the structure, roof, exterior and load bearing walls, foundation, structural floor slabs and other structural elements of the Building, the Base Building (as hereinafter defined), or to add, install or upgrade any Building systems, unless the same are required by Legal Requirements as a result of or in connection with:</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)	Tenant&#x2019;s use or occupancy of the Premises, provided, however, that Tenant shall not be required to make such Alterations if the same are required for general office use or for laboratory uses which are applicable to all laboratory tenants in the Building, or</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(ii)	Alterations performed or requested by Tenant (excluding Landlord&#x2019;s Work), or</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iii)	arising from the negligence or willful misconduct of Tenant, its agents, contractors or employees.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Base Building</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall include the structural portions of the Building, the public restrooms, Common Areas and the Building mechanical, electrical and plumbing systems and equipment located in the internal core of the Building on the floor or floors on which the Premises are located.  Notwithstanding the foregoing, Landlord shall be responsible during the Term for maintaining the Common Areas and all paths of travel in Common Areas in compliance with all Legal</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">46</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Requirements, including, without limitation, the ADA and the rules and regulations promulgated thereunder and any Legal Requirements related to life safety or building codes.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.10	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Reserved</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.11	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Transportation Access Plan Agreement</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Tenant acknowledges that the Project is subject to a Transportation Access Plan Agreement dated May 5, 2017, with The City of Boston Transportation Department, as amended and restated in its entirety by that certain Transportation Access Plan Agreement Amendment dated December 4, 2019 (collectively, as the same may be amended from time to time, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">TAPA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), and Tenant hereby acknowledges that Landlord is required to comply with the TAPA for the Project.  Tenant is encouraged (but not required) to join the MASCO Transportation Management Association.  In addition, Tenant shall (i) promote and encourage employees of Tenant and other occupants of the Premises to rideshare or carpool, (ii) promote and encourage employees to use public transportation and other alternative modes of transportation to commute to the Premises, and (iii) provide transit directions and transit schedules on its website to encourage the use of public transportation for trips to the Premises and to make transit maps and schedules available on-site; provided that if at any time the TAPA no longer obligates Landlord to include any of the foregoing provisions in this Lease, then Tenant shall have no further obligation to comply with the same.  Tenant shall reasonably cooperate with Landlord (at no cost to Tenant) in programs and other activities initiated by Landlord to comply with Landlord&#x2019;s obligations under the TAPA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">including without limitation, participating in Landlord surveys of employee commuting modes (provided however, the Tenant shall not be obligated to provide Landlord with any personally identifying information about its employees).  Tenant acknowledges receipt of a copy of the TAPA prior to the execution of this Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.12	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">OFAC</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">As an inducement to Landlord to enter into this Lease, Tenant hereby represents and warrants that:  (i) Tenant is not, nor to Tenant&#x2019;s knowledge is it owned or controlled directly or indirectly by, any person, group, entity or nation named on any list issued by the Office of Foreign Assets Control of the United States Department of the Treasury (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">OFAC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) pursuant to Executive Order 13224 or any similar list or any law, order, rule or regulation or any Executive Order of the President of the United States as a terrorist, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Specially Designated National and Blocked Person</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; or other banned or blocked person (any such person, group, entity or nation being hereinafter referred to as a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Prohibited Person</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;); (ii) Tenant is not (nor to Tenant&#x2019;s knowledge is it owned, controlled, directly or indirectly, by any person, group, entity or nation which is) acting directly or indirectly for or on behalf of any Prohibited Person; and (iii) from and after the effective date of the above-referenced Executive Order, Tenant (and any person, group, or entity which Tenant controls, directly or indirectly) has not conducted nor will conduct business nor has engaged nor will engage in any transaction or dealing with any Prohibited Person in violation of the U.S. Patriot Act or any OFAC rule or regulation, including without limitation any assignment of this Lease or any subletting of all or any portion of the Premises or the making or receiving of any contribution of funds, goods or services to or for the benefit of a Prohibited Person in violation of the U.S. Patriot Act or any OFAC rule or regulation.  In connection with the foregoing, it is expressly understood and agreed that (x) any breach by Tenant of the foregoing representations</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">47</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">and warranties shall be deemed an Event of Default by Tenant under Section 15.1(d) of this Lease and shall be covered by the indemnity provisions of Section 13.1 below, and (y) the representations and warranties contained in this subsection shall be continuing in nature and shall survive the expiration or earlier termination of this Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.13	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Permits and Approvals</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Tenant shall maintain in full force and effect all certifications or permissions required by any authority having jurisdiction to authorize, franchise or regulate Tenant&#x2019;s use of the Premises and/or Tenant&#x2019;s Rooftop Equipment (as hereinafter defined), and in any event shall not undertake any operations or use of Tenant&#x2019;s Rooftop Equipment unless all applicable permits and approvals are in place.  Tenant shall be solely responsible for procuring and complying at all times with any and all necessary permits and approvals directly or indirectly relating or incident to:  the conduct of its activities on the Premises; its scientific experimentation, transportation, storage, handling, use and disposal of any chemical or radioactive or bacteriological or pathological substances or organisms or other hazardous wastes or environmentally dangerous substances or materials or medical waste or animals or laboratory specimens. Within ten (10) business days of a request by Landlord, which request shall be made not more than once during each period of twelve (12) consecutive months during the Lease Term, unless otherwise requested by any mortgagee of Landlord or unless Landlord reasonably suspects that Tenant has violated the provisions of this Section 11.13, Tenant shall furnish Landlord with copies of all such permits and approvals that Tenant possesses or has obtained together with a certificate certifying that such permits are all of the permits that Tenant possesses or has obtained with respect to the Premises. Tenant shall promptly give written notice to Landlord of any warnings or violations relative to the above received from any federal, State or Municipal agency or by any court of law and shall promptly cure the conditions causing any such violations. Tenant shall not be deemed to be in default of its obligations under the preceding sentence to promptly cure any condition causing any such violation in the event that, in lieu of such cure, Tenant shall contest the validity of such violation by appellate or other proceedings permitted under applicable law, provided that:  (i) any such contest is made reasonably and in good faith, (ii) Tenant makes provisions, including, without limitation, posting bond(s) or giving other security, reasonably acceptable to Landlord to protect Landlord, the Building and the Project from any liability, costs, damages or expenses arising in connection with such alleged violation and failure to cure (provided that Landlord may waive such requirement at the time of any such contest if Tenant demonstrates adequate creditworthiness as determined in Landlord&#x2019;s reasonable discretion), (iii) Tenant shall agree to indemnify, defend (with counsel reasonably acceptable to Landlord) and hold Landlord harmless from and against any and all liability, costs, damages, or expenses arising in connection with such condition and/or violation, (iv) Tenant shall promptly cure any violation in the event that its appeal of such violation is overruled or rejected, and (v) Tenant&#x2019;s decision to delay such cure shall not, in Landlord&#x2019;s good faith determination, be likely to result in any actual or threatened bodily injury, property damage, or any civil or criminal liability to Landlord, any tenant or occupant of the Project.  Nothing contained in this Section 11.13 shall be construed to expand the uses permitted hereunder beyond the Permitted Uses.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.14	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Premises Cleaning; Pest Control</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">48</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Tenant shall be responsible, at its sole cost and expense for:  (i) janitorial services within the laboratory portions of the Premises, (ii) removing trash from the entire Premises to the common dumpster designated by Landlord, and (iii) providing biohazard disposal services for the Premises, including the laboratory areas thereof.  Such services shall be performed by licensed (where required by Legal Requirements), insured and qualified contractors approved in advance, in writing, by Landlord (which approval shall not be unreasonably withheld, delayed or conditioned) and on a sufficient basis to ensure that the Premises are at all times kept neat and clean.  Landlord shall provide a dumpster and/or compactor at the Building loading dock for Tenant&#x2019;s disposal of non-hazardous and non-controlled substances. Tenant, at Tenant&#x2019;s sole cost and expense, shall cause the Premises to be exterminated on a monthly basis to Landlord&#x2019;s reasonable satisfaction and shall cause all portions of the Premises used for the storage, preparation, service or consumption of food or beverages to be cleaned daily in a manner reasonably satisfactory to Landlord, and to be treated against infestation by insects, rodents and other vermin and pests whenever there is evidence of any infestation.  Tenant shall not permit any person to enter the Premises for the purpose of providing such extermination services, unless such persons have been approved by Landlord.  If requested by Landlord, Tenant shall, at Tenant&#x2019;s sole cost and expense, store any refuse generated in the Premises by the consumption of food or beverages in a cold box or similar facility.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.15	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Hazardous Materials</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Prohibition</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Tenant shall not, without the prior written consent of Landlord, bring or permit to be brought or kept in or on the Premises or elsewhere in the Building or the Property (i) any inflammable, combustible or explosive fluid, material, chemical or substance (except for standard office supplies stored in proper containers); and (ii) any Hazardous Material (hereinafter defined), other than the types and quantities of Hazardous Materials which are listed on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 11.15(a)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> attached hereto (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Hazardous Materials</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), provided that the same shall at all times be brought upon, kept or used in so-called &#x2018;control areas&#x2019;, in accordance with all applicable Environmental Laws (hereinafter defined) and prudent environmental practice and (with respect to medical waste and so-called &#x201c;biohazard&#x201d; materials) good scientific and medical practice.  The control areas shall consist of:</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)	Intentionally omitted;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(ii)	one or two (at Tenant&#x2019;s election) control areas to be located in the Premises on the eighth (8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) floor of the Building and designed and installed by Tenant as part of Tenant&#x2019;s Work, in which Tenant may store an amount of Hazardous Materials equal to all the Hazardous Materials permitted by applicable Legal Requirements to be stored in control areas on the eighth (8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) floor of the Building; and</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iii)	one control area to be located in the Premises on the ninth (9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) floor of the Building and designed and installed by Tenant as part of Tenant&#x2019;s Work, in which Tenant may store an amount of Hazardous Materials equal to 50% of all the Hazardous Materials permitted by applicable Legal Requirements to be stored in control areas on the ninth (9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) floor of the Building.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">49</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">In no event shall the types and quantities of Hazardous Materials that Tenant is permitted to keep or store in any control area contained within the Premises be reduced as a result of Landlord granting rights to other tenants in the Building to keep or store Hazardous Materials in so-called &#x201c;controlled areas&#x201d; or by any other act or omission of Landlord (other than any action taken by Landlord based upon a default by Tenant in its obligations under the Lease and any action by Landlord in exercising a right which Landlord has to terminate the Lease, as set forth herein.  Tenant shall be responsible for assuring that all laboratory uses are adequately and properly vented.  On or before each anniversary of the Occupancy Date, and on any earlier date during the twelve- (12)-month period on which Tenant intends to add a new Hazardous Material or materially increase the quantity of any Hazardous Material to the list of Tenant&#x2019;s Hazardous Materials, Tenant shall submit to Landlord an updated list of Tenant&#x2019;s Hazardous Materials for Landlord&#x2019;s review and approval, which approval shall not be unreasonably withheld, conditioned or delayed.  Landlord shall have the right, from time to time, to inspect the Premises for compliance with the terms of this Section 11.15.  Notwithstanding the foregoing, with respect to any of Tenant&#x2019;s Hazardous Materials which Tenant does not properly handle, store or dispose of in compliance with all applicable Environmental Laws (hereinafter defined), prudent environmental practice and (with respect to medical waste and so-called &#x201c;biohazard materials&#x201d;) good scientific and medical practice, Tenant shall, upon written notice from Landlord, no longer have the right to bring such material into the Building or the Property until Tenant has demonstrated, to Landlord&#x2019;s reasonable satisfaction, that Tenant has implemented programs to thereafter properly handle, store or dispose of such material.  In order to induce Landlord to waive its otherwise applicable requirement that Tenant maintain insurance in favor of Landlord against liability arising from the presence of radioactive materials in the Premises, and without limiting the foregoing, Tenant hereby represents and warrants to Landlord that at no time during the Term will Tenant bring upon, or permit to be brought upon, the Premises any radioactive materials whatsoever.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Environmental Laws. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">For purposes hereof, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Environmental Laws</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall mean all laws, statutes, ordinances, rules and regulations of any local, state or federal governmental authority (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Governmental Authorities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) having jurisdiction concerning environmental, health and safety matters, including but not limited to any discharge by any of the Tenant Parties into the air, surface water, sewers, soil or groundwater of any Hazardous Material (hereinafter defined) whether within or outside the Premises, including, without limitation (a) the Federal Water Pollution Control Act, 33 U.S.C.  Section 1251 et seq., (b) the Federal Resource Conservation and Recovery Act, 42 U.S.C.  Section 6901 et seq., (c) the Comprehensive Environmental Response, Compensation and Liability Act, 42 U.S.C.  Section 9601 et seq., (d) the Toxic Substances Control Act of 1976, 15 U.S.C.  Section 2601 et seq., and (e) Chapter 21E of the General Laws of Massachusetts. Tenant, at its sole cost and expense, shall comply with (i) Environmental Laws, and (ii) any rules, requirements and safety procedures of the Massachusetts Department of Environmental Protection, the City of Boston and any insurer of the Building or the Premises in each case with respect to Tenant&#x2019;s use, storage and disposal of any Hazardous Materials.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Hazardous Material De fined</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  As used herein, the term &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Hazardous Material</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means asbestos, oil or any hazardous, radioactive or toxic substance, material or waste or petroleum derivative which is or becomes regulated by any Environmental Law, including without limitation live organisms, viruses and fungi, medical waste and any so-called &#x201c;biohazard&#x201d; materials. The term &#x201c;Hazardous Material&#x201d; includes, without limitation, oil and/or any material or</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">50</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">substance which is (i) designated as a &#x201c;hazardous substance,&#x201d; &#x201c;hazardous material,&#x201d; &#x201c;oil,&#x201d; &#x201c;hazardous waste&#x201d; or toxic substance under any Environmental Law or other chemical or biological materials used in the operation of the Premises.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Chemical Safety Program</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Tenant shall establish and maintain a chemical safety program administered by a licensed, qualified individual in accordance with the requirements of any applicable Governmental Authority.  Tenant shall be solely responsible for all costs incurred in connection with such chemical safety program, and Tenant shall provide Landlord with such documentation as Landlord may reasonably require evidencing Tenant&#x2019;s compliance with the requirements of (a) any applicable Governmental Authority with respect to such chemical safety program and (b) this Section.  Tenant shall obtain and maintain during the Term any permit required by any such applicable Governmental Authority.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(e)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Testing</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  If any Mortgagee or Governmental Authority requires testing to determine whether there has been any release of Hazardous Materials and such testing is required as a result of the acts or omissions of any of the Tenant Parties, then Tenant shall reimburse Landlord within thirty (30) days after written demand, as Additional Rent, for the reasonable costs thereof, together with interest at the Lease Interest Rate until paid in full.  Tenant shall execute certifications as may be reasonably requested by Landlord from time to time concerning Tenant&#x2019;s best knowledge and belief concerning the presence of Hazardous Materials in or on the Premises, the Building or the Property as a result of the activities of Tenant or any Tenant Parties. In addition to the foregoing, if Landlord reasonably believes that any Hazardous Materials have been released on the Premises by Tenant or any Tenant Parties in violation of this Lease or any Legal Requirement, Landlord shall have the right to conduct appropriate tests of the Premises or any portion thereof to demonstrate that Hazardous Materials are present or that contamination has occurred due to the acts or omissions of any of the Tenant Parties. Tenant shall pay all reasonable costs of such tests if such tests reveal that Tenant or any Tenant Party has caused Hazardous Materials to exist at the Premises in violation of this Lease or any Legal Requirement.  Further, Landlord shall have the right to cause a third party consultant retained by Landlord, at Landlord&#x2019;s expense (provided, however, that such costs shall be included in Operating Expenses), to review, but not more than once in any calendar year, Tenant&#x2019;s lab operations, procedures and permits to ascertain whether or not Tenant is complying with law and adhering to best industry practices. Tenant agrees to cooperate in good faith with any such review and to provide to such consultant any information requested by such consultant and reasonably required in order for such consultant to perform such review, but nothing contained herein shall require Tenant to provide proprietary or confidential information to such consultant.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(f)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Environmental Questionnaires. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Tenant shall, prior to commencing to use the Premises, or any portion thereof, for the Permitted Use, complete an Environmental Questionnaire, as hereinafter defined, and submit such completed Environmental Questionnaire for Landlord&#x2019;s approval, which approval shall not be unreasonably withheld, conditioned, or delayed.  In addition, Landlord shall have the right, from time to time, to require Tenant to complete and submit to Landlord an updated Environmental Questionnaire.  Landlord may request that Tenant update its answers to Environmental Questionnaires no more often than one time every twelve (12) months, unless Landlord has a reasonable basis for believing that Tenant is then in violation of any of the provisions of this Lease relating to Hazardous Materials. If Landlord reasonably disapproves any of Tenant&#x2019;s answers to any question in an Environmental Questionnaire, then Tenant shall, within</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">51</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">five (5) business days of Landlord advises Tenant of its disapproval to such answer, submit to Landlord a revised answer addressing Landlord&#x2019;s disapproval.  An &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Environmental Questionnaire</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall be in the form attached hereto as Exhibit 11.15(f), except that Landlord may, from time to time, make reasonable revisions to such form.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(g)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Indemnity; Remediation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Tenant hereby covenants and agrees to indemnify, defend and hold the Landlord Parties harmless from and against any and all Claims against any of the Landlord Parties arising out of contamination of any part of the Property or other adjacent property, which contamination arises as a result of:  (i) the presence of Hazardous Material in the Premises, the presence of which is caused by any act or omission of any of the Tenant Parties, or (ii) from a breach by Tenant of its obligations under Sections 11.13 through 11.15.  This indemnification of the Landlord Parties by Tenant includes, without limitation, reasonable costs incurred in connection with any investigation of site conditions or any cleanup, remedial, removal or restoration work or any other response actions required by any federal, state or local governmental agency or political subdivision because of Hazardous Material present in the soil, soil vapor or ground water on or under or any indoor air in the Building based upon the circumstances identified in the first sentence of this Section.</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(1)	The indemnification and hold harmless obligations of Tenant under this Section shall survive the expiration or any earlier termination of this Lease.  Without limiting the foregoing, if the presence of any Hazardous Material in the Building or otherwise in the Property is caused by any of the Tenant Parties and results in any contamination of any part of the Property or any adjacent property, Tenant shall promptly take all actions at Tenant&#x2019;s sole cost and expense as are necessary to return the Property and/or the Building or any adjacent property to their condition as of the date of this Lease, provided that Tenant shall first obtain Landlord&#x2019;s written approval of such actions, which approval shall not be unreasonably withheld, conditioned or delayed so long as such actions, in Landlord&#x2019;s reasonable discretion, would not potentially have any adverse effect on the Property, and, in any event, Landlord shall not withhold its approval of any proposed actions which are required by applicable Environmental Laws. The provisions of this Section shall survive the expiration or earlier termination of the Lease.</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(2)	Without limiting the obligations set forth above, if any Hazardous Material is in, on, under, at or about the Building or the Property as a result of the acts or omissions of any of the Tenant Parties and results in any contamination of any part of the Property or any adjacent property that is in violation of any applicable Environmental Law or that requires the performance of any response action pursuant to any Environmental Law, Tenant shall promptly take all actions at Tenant&#x2019;s sole cost and expense as are necessary to reduce such Hazardous Material to amounts below any applicable Reportable Quantity, any applicable Reportable Concentration and any other applicable standard set forth in any Environmental Law such that no further response actions are required; provided that Tenant shall first obtain Landlord&#x2019;s written approval of such actions, which approval shall not be unreasonably withheld, conditioned or delayed so long as such actions would not be reasonably expected to have an adverse effect on the market value or utility of the Property for the Permitted Uses, and in any event, Landlord shall not withhold its approval of any proposed actions which are required by applicable Environmental Laws (such approved actions, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Remediation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">52</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(3)	In the event that Tenant fails to complete Tenant&#x2019;s Remediation prior to the end of the Term, then:</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)	until the completion of Tenant&#x2019;s Remediation (as evidenced by the certification of Tenant&#x2019;s Licensed Site Professional (as such term is defined by applicable Environmental Laws), who shall be reasonably acceptable to Landlord) (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Remediation Completion Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), Tenant shall pay to Landlord, with respect to the portion of the Premises which reasonably cannot be occupied by a new tenant until completion of Tenant&#x2019;s Remediation, Annual Fixed Rent and Additional Rent in accordance with the rates set forth in Section 16.18 below; and</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(ii)	Tenant shall maintain responsibility for Tenant&#x2019;s Remediation and Tenant shall complete Tenant&#x2019;s Remediation as soon as reasonably practicable in accordance with Environmental Laws. If Tenant does not diligently pursue completion of Tenant&#x2019;s Remediation, Landlord shall have the right to either (A) assume control for overseeing Tenant&#x2019;s Remediation, in which event Tenant shall pay all reasonable costs and expenses of Tenant&#x2019;s Remediation (it being understood and agreed that all costs and expenses of Tenant&#x2019;s Remediation incurred pursuant to contracts entered into by Tenant shall be deemed reasonable) within thirty (30) days of demand therefor (which demand shall be made no more often than monthly), and Landlord shall be substituted as the party identified on any governmental filings as the party responsible for the performance of such Tenant&#x2019;s Remediation or (B) require Tenant to maintain responsibility for Tenant&#x2019;s Remediation, in which event Tenant shall complete Tenant&#x2019;s Remediation as soon as reasonably practicable in accordance with Environmental Laws, it being understood that Tenant&#x2019;s Remediation shall not contain any requirement that Tenant remediate any contamination to levels or standards more stringent than those associated with the Property&#x2019;s current office, research and development, laboratory, and vivarium uses.</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(4)	The provisions of this Section shall survive the expiration or earlier termination of this Lease.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(h)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Disclosures. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Prior to bringing any Hazardous Material into any part of the Property, Tenant shall deliver to Landlord the following information with respect thereto:  (a) a description of handling, storage, use and disposal procedures; (b) all plans or disclosures and/or emergency response plans which Tenant has prepared, including without limitation Tenant&#x2019;s Spill Response Plan, and all plans which Tenant is required to supply to any governmental agency or authority pursuant to any Environmental Laws; (c) copies of all Required Permits relating thereto; and (d) other information reasonably requested by Landlord.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Removal</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Tenant shall be responsible, at its sole cost and expense, for Hazardous Material and other biohazard disposal services for the Premises. Such services shall be performed by contractors reasonably acceptable to Landlord and on a sufficient basis to ensure that the Premises are at all times kept neat, clean and free of Hazardous Materials and biohazards except in appropriate, specially marked containers reasonably approved by Landlord.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.16	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Landlord&#x2019;s Representations, Covenants and Indemnity</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">53</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	Landlord hereby represents and warrants to Tenant that, to the Best of Landlord&#x2019;s Knowledge (as that term is defined in clause (c) below), except to the extent (if any) as may be disclosed in the environmental assessment reports listed on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 11.16</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> attached hereto, which have been made available by Landlord to Tenant (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Disclosed Materials</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), there exist, as of the Effective Date of this Lease, no Hazardous Materials on the Land which are in violation of applicable Environmental Laws or that require reporting, investigation, remediation or other response under Chapter 21E or other Environmental Laws. Landlord covenants that neither Landlord nor any of the Landlord Parties shall bring any Hazardous Materials in or on to the Building or the Land or discharge any Hazardous Materials in or on to the Building or the Land which are, in either case, in violation of applicable Environmental Laws. Landlord hereby indemnifies and shall defend and hold Tenant, its officers, directors, employees, and agents harmless from any claims arising as result of any breach by Landlord of its representations, warranties, or covenants under this Section 11.16(a).</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Landlord Remediation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  If Hazardous Materials are discovered in, on or under the Land which are not in compliance with applicable Environmental Laws or that require reporting, investigation, remediation or other response under Chapter 21E or other Environmental Laws, and which are not the responsibility of Tenant pursuant to this Article XI, then Landlord shall remove or remediate the same, when, if, and in the manner required by applicable Environmental Laws.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">To the Best of Landlord&#x2019;s Knowledge</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The phrase &#x201c;to the Best of Landlord&#x2019;s Knowledge&#x201d; under shall mean the best of the knowledge of Abe Menzin, Landlord&#x2019;s Development Manager.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Land</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  For purposes of this Section 11.16, the defined term &#x201c;Land&#x201d; includes only the real property described in Exhibit 1.2-2, and expressly excludes any improvements located thereon.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article XII<br>ASSIGNMENT AND SUBLETTING</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Restrictions on Transfer</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Except as otherwise expressly provided herein, Tenant covenants and agrees that it shall not directly or indirectly assign, mortgage, pledge, hypothecate or otherwise transfer this Lease and/or Tenant&#x2019;s interest in this Lease or sublet (which term, without limitation, shall include granting of concessions, licenses or the like) the whole or any part of the Premises (any such assignment, mortgage, pledge, hypothecation, transfer, and sublease being referred to herein sometimes as a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Transfer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;.  Any Transfer not expressly permitted in or consented to by Landlord under this Article XII shall, at Landlord&#x2019;s election, be void; shall be of no force and effect; and shall confer no rights on or in favor of third parties. In addition, Landlord shall be entitled to seek specific performance of or other equitable relief with respect to the provisions hereof.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Notice</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Notwithstanding the provisions of Section 12.1 above, in the event Tenant desires to assign this Lease or to sublet the whole or any portion of the Premises, Tenant shall give Landlord notice</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">54</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Proposed Transfer Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) of any proposed sublease or assignment, and said notice shall specify the provisions of the proposed assignment or subletting, including (a) the name and address of the proposed assignee or subtenant, (b) in the case of a proposed assignment or subletting pursuant to Section 12.4 below, such information as to the proposed assignee&#x2019;s or proposed subtenant&#x2019;s net worth and financial capability and standing as may reasonably be required for Landlord to make the determination referred to in said Section 12.4 (provided, however, that Landlord shall hold such information confidential having the right to release same to its officers, accountants, attorneys and mortgage lenders on a confidential basis), (c) all of the terms and provisions upon which the proposed assignment or subletting is to be made, (d) in the case of a proposed subletting identifies the portion of the Premises to be sublet (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Affected Portion</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), (e) in the case of a proposed assignment or subletting pursuant to Section 12.4 below, all other information necessary to make the determination referred to in said Section 12.4 and (f) in the case of a proposed assignment or subletting pursuant to Section 12.5 below, such information as may be reasonably required by Landlord to determine that such proposed assignment or subletting complies with the requirements of said Section 12.5.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Landlord&#x2019;s Termination Right</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Landlord shall have the right at its sole option, to be exercised within thirty (30) days after receipt of Tenant&#x2019;s Proposed Transfer Notice (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Acceptance Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), to terminate this Lease (i) as to the Affected Portion for the term of the proposed sublease, and (ii) with respect to the entire Premises in the case of a proposed assignment, as of a date specified in a notice to Tenant, which date shall not be earlier than sixty (60) days nor later than one hundred and twenty (120) days after Landlord&#x2019;s notice to Tenant; provided, however, that upon the termination date as set forth in Landlord&#x2019;s notice, all obligations relating to the period after such termination date (but not those relating to the period before such termination date) through the end of the term of the proposed sublease or assignment shall cease and promptly upon being billed therefor by Landlord, Tenant shall make final payment of all Annual Fixed Rent and Additional Rent due from Tenant through the termination date.  For avoidance of doubt, if a proposed sublease, for example, is for a proposed term from Rent Year 7 through the end of Rent Year 8, Tenant shall recommence its lease of the Affected Portion as of Rent Year 9 on the terms and conditions and for the remaining term set forth in this Lease.  In the event that Landlord shall not exercise its termination rights as aforesaid, or shall fail to give any or timely notice pursuant to this Section the provisions of Sections 12.4, 12.6 and 12.7 shall be applicable.  This Section 12.3 shall not be applicable to an assignment or sublease pursuant to Section 12.5.  Notwithstanding the foregoing to the contrary, Landlord&#x2019;s recapture rights under this Section 12.3 shall not apply to any Initial Subleases (as hereinafter defined).  An &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Initial Sublease</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall be defined as a sublease for any portion of the Premises located on the eighth (8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) floor of the Building, the term of which (i) commences prior to the date three (3) years after the Rent Commencement Date, and (ii) expires no later than five (5) years after the commencement date of the applicable Initial Sublease (including all extension and renewal options).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12.4	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Consent of Landlord</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Notwithstanding the provisions of Section 12.1 above, but subject to the provisions of this Section 12.4 and the provisions of Sections 12.6 and 12.7 below, in the event that Landlord shall not have exercised the termination right as set forth in Section 12.3, or shall have failed to give</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">55</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">any or timely notice under Section 12.3, then for a period of ninety (90) days (i) after the receipt of Landlord&#x2019;s notice stating that Landlord does not elect the termination right, or (ii) after the expiration of the Acceptance Period, in the event Landlord shall not give any or timely notice under Section 12.3 as the case may be, Tenant shall have the right to assign this Lease or sublet the whole or any portion of the Premises in accordance with the Proposed Transfer Notice provided that, in each instance, Tenant first obtains the express prior written consent of Landlord, which consent shall not be unreasonably withheld, conditioned or delayed.  Without limiting the foregoing standard, Landlord shall not be deemed to be unreasonably withholding its consent to such a proposed assignment or subleasing if:</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	the proposed assignee or subtenant is a tenant in the Building or elsewhere in the Project if Landlord has, or reasonably expects to have at the time of the proposed commencement and during the term of the proposed sublease, comparable space available in the Building, or is (or within the previous sixty (60) days has been) in active negotiation with Landlord or an affiliate of Landlord for premises in the Building or elsewhere in the Project or is not of a character consistent with the operation of a first class office building (by way of example Landlord shall not be deemed to be unreasonably withholding its consent to an assignment or subleasing to any governmental or quasi-governmental agency), or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	the proposed assignee or subtenant (i) is not of good character and reputation or (ii) will use the Premises for, and does not have reasonable experience in, the operation and management of research and development and laboratory purposes, including vivariums, in first-class office and laboratory buildings, or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	the proposed assignee or subtenant does not possess adequate financial capability to perform Tenant obligations as and when due or required, or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	the assignee or subtenant proposes to use the Premises (or part thereof) for a purpose other than the purpose for which the Premises may be used as stated in Section 1.2 hereof, or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(e)	the character of the business to be conducted or the proposed use of the Premises by the proposed subtenant or assignee shall (i) be likely to materially increase Operating Expenses for the Building beyond that which Landlord now incurs for use by Tenant; (ii) be likely to materially increase the burden on elevators or other Building systems or equipment over the burden prior to such proposed subletting or assignment; or (iii) violate or be likely to violate any provisions or restrictions contained herein relating to the use or occupancy of the Premises, or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(f)	there shall be existing an Event of Default (defined in Section 15.1), or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(g)	any part of the rent payable under the proposed assignment or sublease shall be based in whole or in part on the income or profits derived from the Premises or if any proposed assignment or sublease shall potentially have any adverse effect on the real estate investment trust qualification requirements applicable to Landlord and its affiliates, or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(h)	the holder of any mortgage on property which includes the Premises has a contractual right to approve the assignment or sublease and does not approve of the proposed assignment or sublease, or</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">56</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)	due to the identity or business of a proposed assignee or subtenant, such approval would cause Landlord to be in violation of any covenant or restriction contained in another lease or other agreement affecting space in the Building or elsewhere in the Project.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If Landlord shall consent to the proposed assignment or subletting, as the case may be, then, in such event, Tenant may thereafter sublease or assign pursuant to Tenant&#x2019;s notice, as given hereunder; provided, however, that if such assignment or sublease shall not be executed and delivered to Landlord within one hundred eighty (180) days after the date of Landlord&#x2019;s consent, the consent shall be deemed null and void and the provisions of Section 12.2 shall be applicable.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12.5	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Permitted Transfers</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	Notwithstanding the foregoing provisions of Sections 12.1, 12.3 and 12.4 above, but subject to the provisions of Sections 12.6 and 12.7 below, Tenant shall have the right, without obtaining Landlord&#x2019;s consent, to assign this Lease or to sublet the Premises (in whole or in part) to any Permitted Transferee, as hereinafter defined (any such assignment and sublease being referred to herein as a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Permitted Transfer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  Except in cases of statutory merger, in which case the surviving entity in the merger shall be liable as Tenant under this Lease, Tenant shall continue to remain fully liable under this Lease, on a joint and several basis with the Permitted Transferee.  &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Permitted Transferee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall be defined as:  (i) any Successor Entity, (ii) any Tenant Affiliate, and (iii) any TRV Fund Entity, each as hereinafter defined.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	A &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Successor Entity</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall be defined as any entity which (i) which purchases all or substantially all of the assets of Tenant, (ii) which purchases all or substantially all of the stock of (or other membership interests in) Tenant or (iii) which merges or combines with Tenant, provided that the entity to which this Lease is so assigned or which so sublets the Premises, together with any Guarantor of Tenant&#x2019;s obligations under the Lease, has a credit worthiness (e.g., assets on a pro forma basis using generally accepted accounting principles consistently applied and using the most recent financial statements) which is the same or better than the creditworthiness of Tenant and the Guarantor as of the date of such Permitted Transfer.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	A &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Tenant Affiliate</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall be defined as:  (i) any entity which controls or is controlled by Tenant or Tenant&#x2019;s parent corporation, or (ii) which is under common control with Tenant.  If any parent or subsidiary of Tenant to which this Lease is assigned or the Premises sublet (in whole or in part) shall cease to be such a parent or subsidiary, then such parent or subsidiary shall no longer be considered as a Tenant Affiliate and such cessation shall be considered an assignment or subletting requiring Landlord&#x2019;s consent.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	A &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">TRV Fund Entity</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall be an entity that is a portfolio company of a fund that is managed by Third Rock Ventures, LLC (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">TRV Fund</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), provided that (i) such TRV Fund has the right to appoint a representative to the board of directors of such portfolio company, (ii) such TRV Fund owns more than thirty-five percent (35%) of the outstanding preferred stock of such portfolio company, and (iii) further provided that in the case of an assignment only, such entity, together with any Guarantor of Tenant&#x2019;s obligations under the Lease satisfies the terms of Section 12.4(c) above.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12.6	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Profit on Subleasing or Assignment</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">57</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">In the case of any assignment or subleasing as to which Landlord may consent (other than a Permitted Transfer) such consent shall be upon the express and further condition, covenant and agreement, and Tenant hereby covenants and agrees that, in addition to the Annual Fixed Rent, Additional Rent and other charges to be paid pursuant to this Lease, fifty percent (50%) of the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Assignment/Sublease Profits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; (hereinafter defined), if any, shall be paid to Landlord.  The &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Assignment/Sublease Profits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall be the excess, if any, of (a) the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Assignment/Sublease Net Revenues</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; as hereinafter defined over (b) the Annual Fixed Rent and Additional Rent and other charges provided in this Lease (provided, however, that for the purpose of calculating the Assignment/Sublease Profits in the case of a sublease, appropriate proportions in the applicable Annual Fixed Rent, Additional Rent and other charges under this Lease shall be made based on the percentage of the Premises subleased and on the terms of the sublease).  The &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Assignment/Sublease Net Revenues</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall be the fixed rent, Additional Rent and all other charges and sums payable either initially or over the term of the sublease or assignment </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">plus</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> all other profits and increases to be derived by Tenant for such subletting or assignment, less the reasonable costs of Tenant incurred in such subleasing or assignment (the definition of which shall be limited to brokerage commissions, legal fees, free rent, architect and engineer fees and alteration allowances, in each case actually paid), as set forth in a statement certified by an appropriate officer of Tenant and delivered to Landlord within thirty (30) days of the full execution of the sublease or assignment document, amortized over the term of the sublease or assignment.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">All payments of the Assignment/Sublease Profits due Landlord shall be made within ten (10) days of receipt of same by Tenant.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12.7	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Additional Conditions</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	It shall be a condition of the validity of any assignment or subletting consented to under Section 12.4 above, or any Permitted Transfer, that both Tenant and the assignee or sublessee enter into a separate written instrument directly with Landlord in a form and containing terms and provisions reasonably required by Landlord, including, without limitation, the agreement of the assignee or sublessee to be bound directly to Landlord for all the obligations of Tenant under this Lease (including any amendments or extensions thereof), including, without limitation, the obligation (a) to pay the rent and other amounts provided for under this Lease (but in the case of a partial subletting pursuant to Section 12.5, such subtenant shall agree on a pro rata basis to be so bound) and (b) to comply with the provisions of Article XII hereof and (c) to indemnify the Landlord Parties as provided in Section 13.1 hereof.  Such assignment or subletting shall not relieve Tenant named herein of any of the obligations of Tenant hereunder and Tenant shall remain fully and primarily liable therefor and the liability of Tenant and such assignee (or subtenant, as the case may be) shall be joint and several.  Further, and notwithstanding the foregoing, the provisions hereof shall not constitute a recognition of the sublease or the subtenant thereunder, as the case may be, and at Landlord&#x2019;s option, upon the termination or expiration of the Lease (whether such termination is based upon a cause beyond Tenant&#x2019;s control, a default of Tenant, the agreement of Tenant and Landlord or any other reason), the sublease shall be terminated.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	As Additional Rent, Tenant shall pay to Landlord as a fee for Landlord&#x2019;s review of any proposed assignment or sublease requested by Tenant and the preparation of any associated documentation in connection therewith, within thirty (30) days after receipt of an</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">58</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">invoice from Landlord, an amount equal to the sum of (i) $1,000.00 and/or (ii) reasonable out of pocket legal fees or other expenses incurred by Landlord in connection with such request, subject to the terms of Section 4.4.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	If this Lease be assigned, or if the Premises or any part thereof be sublet or occupied by anyone other than Tenant, Landlord may upon prior notice to Tenant, at any time during the continuance of an Event of Default, collect rent and other charges from the assignee, sublessee or occupant and apply the net amount collected to the rent and other charges herein reserved, but no such assignment, subletting, occupancy or collection shall be deemed a waiver of this covenant, or a waiver of the provisions of Article XII hereof, or the acceptance of the assignee, sublessee or occupant as a tenant or a release of Tenant from the further performance by Tenant of covenants on the part of Tenant herein contained, Tenant herein named to remain primarily liable under this Lease.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	The consent by Landlord to an assignment or subletting under Section 12.4 above, or the consummation of an assignment or subletting of right under Section 12.5 above, shall in no way be construed to relieve Tenant from obtaining the express consent in writing of Landlord to any further assignment or subletting.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(e)	Without limiting Tenant&#x2019;s obligations under Article IX, Tenant shall be responsible (except in the event Landlord exercises its right under Section 12.3), at Tenant&#x2019;s sole cost and expense, for performing all work necessary to comply with Legal Requirements and Insurance Requirements in connection with any assignment or subletting hereunder including, without limitation, any work in connection with such assignment or subletting and the cost to make the Affected Portion a self-contained rental unit (including installing any required common corridors).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article XIII<br>INDEMNITY AND INSURANCE</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">13.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Insurance</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Liability Insurance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Tenant shall procure, pay for and keep in force throughout the Term (and for so long thereafter as Tenant remains in occupancy of the Premises) commercial general liability insurance insuring Tenant on an occurrence basis against all claims and demands for personal injury liability (including, without limitation, bodily injury, sickness, disease, and death) or damage to property which may be claimed to have occurred from and after the time any of the Tenant Parties shall first enter the Premises, of not less than One Million Dollars ($1,000,000.00) per occurrence and Two Million Dollars ($2,000,000.00) in the aggregate annually on a per location basis, and from time to time thereafter shall be not less than such higher amounts, if procurable, as may be reasonably required by Landlord.  Tenant shall also carry umbrella liability coverage in an amount of no less than Five Million Dollars ($5,000,000.00) per occurrence and in the aggregate on a per location basis. Such policies shall also include contractual liability coverage covering Tenant&#x2019;s liability assumed under this Lease, including without limitation Tenant&#x2019;s indemnification obligations and claims arising from Tenant&#x2019;s use of the Generator.  Such insurance policy(ies) shall include coverage for hostile fire, and terrorism, and the policy(ies) shall name Landlord, Landlord&#x2019;s managing agent and persons claiming by, through</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">59</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">or under them, as well as Landlord&#x2019;s Lender/mortgagee where warranted, if any, as additional insureds on a primary and non-contributory basis.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Property Insurance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Tenant shall procure and maintain throughout the Term a property insurance policy on a special cause of loss form or its equivalent including coverage for flood, earthquake and terrorism in an amount equal to one hundred percent (100%) of the replacement cost insuring (i) all items or components of Alterations (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Tenant-Insured Improvements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; and Tenant&#x2019;s Work), and (ii) all of Tenant&#x2019;s furniture, machinery and equipment, fixtures, contents (including animals and related research materials) and personal property of Tenant, which may be in or upon the Premises or the Building, including without limitation Tenant&#x2019;s Rooftop Equipment (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Property</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  The insurance required to be maintained by Tenant pursuant to this Section 14.1(2) (referred to herein as &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Tenant Property Insurance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) shall insure the interests of both Landlord and Tenant as their respective interests may appear from time to time.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Business Interruption Insurance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Tenant shall procure and maintain a policy of business interruption insurance throughout the Term sufficient to cover at least twelve (12) months of Rent due hereunder and Tenant&#x2019;s business-related losses during such twelve-(12)- month period or such greater time period as Tenant may desire; however, in no event shall Tenant look to Landlord for Tenant business interruption losses whether insured or not, including any expenses relating to research costs and related losses, if any.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Builders Risk Insurance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  During periods when Tenant&#x2019;s Work and/or any Alterations are being performed, Tenant shall maintain, or cause to be maintained, so-called all risk or special cause of loss property insurance or its equivalent and/or builders risk insurance on 100% replacement cost coverage basis, including hard and soft costs coverages. Such insurance shall protect and insure Landlord, Landlord&#x2019;s agents, Tenant and Tenant&#x2019;s contractors, as their interests may appear, against loss or damage by fire, water damage, vandalism and malicious mischief, and such other risks as are customarily covered by so-called all risk or special cause of loss property / builders risk coverage or its equivalent.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(e)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Worker s Compensation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Tenant shall procure and maintain worker&#x2019;s compensation insurance to meet statutory requirements and include coverage for employer&#x2019;s liability insurance.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(f)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Automobile Liability Insurance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Tenant shall procure and maintain auto liability coverage for all Tenant-owned, hired, and non-owned vehicles, with a combined single of not less than One Million Dollars ($1,000,000.00) each accident for bodily injury and property damage.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(g)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Intentionally Ommited</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(1)	Tenant shall procure and maintain at its sole expense such additional insurance as may be necessary to comply with any Legal Requirements.</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(2)	Tenant shall cause all contractors and subcontractors to maintain during the performance of any Alterations the insurance described in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 11.4-1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">attached hereto.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">60</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(3)	The insurance required pursuant to Sections 13.1(a), (b), (c), (d), (e), (f), and (g), etc.  (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Insurance Policies</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) shall be effected with insurers approved by Landlord, with a rating of not less than &#x201c;A-X&#x201d; by the then current </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Best&#x2019;s Insurance Reports</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, and authorized to do business in the Commonwealth of Massachusetts under valid and enforceable policies. Tenant&#x2019;s Insurance Policies shall each provide that it shall not be canceled or materially reduced without at least thirty (30) days&#x2019; prior written notice to Tenant and Landlord; provided, however, to the extent Tenant&#x2019;s insurer will not provide such notice to Landlord, Tenant shall be obligated to provide Landlord with thirty (30) days prior written notice of any cancellation or material reduction.  Tenant&#x2019;s Insurance Policies may include deductibles in an amount no greater than the greater of (x) $25,000.00 or (y) commercially reasonable amounts. Tenant&#x2019;s insurance policies may be maintained on blanket policies and/or programs, provided that by doing so, the insurance provided is not diminished or reduced and such coverage will meet the location specific insurance requirements herein.  On or before the date on which any of the Tenant Parties shall first enter the Premises and thereafter not less than fifteen (15) days prior to the expiration date of each expiring policy, Tenant shall deliver to Landlord certificates of insurance as evidence of all insurance coverage required of Tenant herein issued by the respective insurers together with evidence satisfactory to Landlord of the payment of all premiums for such policies. In the event of any claim, and upon Landlord&#x2019;s request, Tenant shall deliver to Landlord complete copies of Tenant&#x2019;s Insurance Policies. Upon request of Landlord, Tenant shall deliver to any Mortgagee copies of the foregoing documents to the extent required to be delivered to Landlord.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">13.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Indemnification</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Subject to Section 13.5, except to the extent caused by the negligence or willful misconduct of any of the Landlord Parties, Tenant shall defend, indemnify and save the Landlord Parties harmless from and against any and all Claims asserted by or on behalf of any person, firm, corporation or public authority arising from:</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	Tenant&#x2019;s breach of any covenant or obligation under this Lease;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	Any injury to or death of any person, or loss of or damage to property, sustained or occurring in or upon the Premises;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	Any injury to or death of any person, or loss of or damage to property arising out of the use or occupancy of the Premises by or the negligence or willful misconduct of any of the Tenant Parties; and</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	On account of or based upon any work or thing whatsoever done (other than by Landlord or any of the Landlord Parties) in the Premises during the Term and during the period of time, if any, prior to the Term Commencement Date that any of the Tenant Parties may have been given access to the Premises.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">13.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Property of Tenant</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Tenant covenants and agrees that, to the maximum extent permitted by Legal Requirements, all of Tenant&#x2019;s Property (and related operations/business interruption and related research exposure) at the Premises shall be at the sole risk and hazard of Tenant, and that if the whole or any part thereof shall be damaged, destroyed, stolen or removed from any cause or reason</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">61</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">whatsoever, no part of said damage or loss shall be charged to, or borne by, Landlord, except, subject to Section 13.5 hereof, to the extent such damage or loss is due to the negligence or willful misconduct of any of the Landlord Parties.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">13.4	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Limitation of Landlord&#x2019;s Liability for Damage or Injury</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Landlord shall not be liable for any injury or damage to persons, animals or property including, business interruption, research, and/or related sturdies, resulting from fire, explosion, falling plaster, steam, gas, air contaminants or emissions, electricity, electrical or electronic emanations or disturbance, water, rain or snow or leaks from any part of the Building or from the pipes, appliances, equipment or plumbing works or from the roof, street or sub-surface or from any other place or caused by dampness, vandalism, malicious mischief or by any other cause of whatever nature, except, subject to Section 13.5, to the extent caused by or due to the negligence or willful misconduct of any of the Landlord Parties. Notwithstanding the foregoing, in no event shall any of the Landlord Parties be liable for any loss which is covered by insurance policies actually carried or required to be so carried by this Lease; nor shall any of the Landlord Parties be liable for any such damage caused by other tenants or persons in the Building or caused by operations in construction of any private, public, or quasi-public work; nor shall any of the Landlord Parties be liable for any latent defect in the Premises or in the Building, subject to Landlord&#x2019;s Warranty.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">13.5	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Waiver of Subrogation; Mutual Release</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Landlord and Tenant each hereby waives on behalf of itself and its property insurers (none of which shall ever be assigned any such claim or be entitled thereto due to subrogation or otherwise) any and all rights of recovery, claim, action, or cause of action against the other and its agents, officers, servants, partners, shareholders, or employees (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Related Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) for any loss or damage that may occur to or within the Premises or the Building or the Project (for so long as the building commonly known as 401 Park Drive is owned by Landlord or an affiliate of Landlord) or any improvements thereto, or any business and/or personal property of such party therein, including any related business interruption, which is insured against under any Property (as defined in Sections 13.1) policy or any self-insurance maintained (or required to be maintained) by the waiving party from time to time, even if not required hereunder, or which would be insured against under the terms of any such policies policy required to be carried or maintained by the waiving party hereunder, whether or not such insurance coverage is actually being maintained (including deductibles and/or self-insurance), including, in every instance, such loss or damage that may be caused by the negligence of the other party hereto and/or its Related Parties. Landlord and Tenant each agrees to cause appropriate clauses to be included in its Property Insurance policies (including self-insurance where applicable) necessary to implement the foregoing provisions.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">13.6	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Acts--Effect on Insurance</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Tenant shall not do or permit any Tenant Party to do any act or thing upon the Premises or elsewhere in the Building which will invalidate or be in conflict with any insurance policies covering the Building and the fixtures and property therein; and shall not do, or permit to be done, any act or thing upon the Premises which shall subject Landlord to any liability or responsibility</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">62</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">for injury to any person or persons or to property by reason of any business or operation being carried on upon said Premises or for any other reason.  Notwithstanding anything to the contrary contained herein, Tenant shall not be liable for any increases in the rate of insurance unless such increases arise from Tenant&#x2019;s manner of use of the Premises (as opposed to Tenant&#x2019;s use of the Premises for the Permitted Uses).  If by reason of the failure of Tenant to comply with the provisions hereof the insurance rate applicable to any policy of insurance shall at any time thereafter be higher than it otherwise would be, Tenant shall reimburse Landlord upon demand for that part of any insurance premiums which shall have been charged because of such failure by Tenant, together with interest at the Lease Interest Rate until paid in full, within ten (10) days after receipt of an invoice therefor.  In addition, Tenant shall reimburse Landlord for any increase in insurance premium arising as a result of Tenant&#x2019;s use and/or storage of any Hazardous Materials in the Premises in violation of the terms of this Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">13.7	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Landlord&#x2019;s Insurance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Required insurance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Landlord shall carry at all times during the Term of this Lease (a) commercial general liability insurance with respect to the Building, the Land and the Common Areas in an amount not less than Five Million Dollars ($5,000,000) combined single limit per occurrence, (b) with respect to the Building, excluding Tenant-Insured Improvements and alterations made by other tenants or occupants, insurance against loss or damage caused by any peril covered under fire, extended coverage and all risk insurance with coverage against vandalism, malicious mischief and such other insurable hazards and contingencies as are from time to time normally insured against by owners of similar first-class office/research/laboratory buildings in the Longwood/Fenway area or which are required by any Mortgagee, in an amount equal to one hundred percent (100%) of the full replacement cost thereof above foundation walls, and (c) rent interruption insurance covering at least twelve (12) months. Any and all such insurance (i) may be maintained under a blanket policy affecting other properties of Landlord and/or its affiliated business organizations, and (ii) may be written with commercially reasonable deductibles as determined by Landlord.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Optional insurance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Landlord may maintain such additional insurance with respect to the Building and the Project as is consistent with the insurance maintained by Landlord or affiliates of Landlord for similar first-class office/research/laboratory buildings in the Longwood/Fenway area, including, without limitation, earthquake insurance, terrorism insurance, flood insurance, liability insurance and/or rent insurance, as Landlord may in its sole discretion elect.  Landlord may also maintain such other insurance as may from time to time be required by the holder of any mortgage on the Building or the Project.  The cost of all such additional insurance shall also be part of the Operating Expenses for the Building.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">No obligation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Landlord shall not be obligated to insure, and shall not assume any liability of risk of loss for, Tenant&#x2019;s Property, including any such property or work of Tenant&#x2019;s subtenants or occupants except (subject to Section 13.5) to the extent caused by Landlord&#x2019;s negligence or willful misconduct.  Landlord will also have no obligation to carry insurance against, nor be responsible for, any loss suffered by Tenant, subtenants or other occupants due to interruption of Tenant&#x2019;s or any subtenant&#x2019;s or occupant&#x2019;s business</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">63</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article XIV<br>FIRE, CASUALTY AND TAKING</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">14.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Damage</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If the Premises are damaged in whole or part because of fire or other casualty (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Casualty</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), or if the Premises are subject to a taking in connection with the exercise of any power of eminent domain, condemnation, or purchase under threat or in lieu thereof (any of the foregoing, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Taking</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), then unless this Lease is terminated in accordance with Section 14.2 below, Landlord shall restore the Building and/or the Premises to substantially the same condition as existed immediately following completion of Landlord&#x2019;s Work, or in the event of a partial Taking which affects the Building and the Premises, restore the remainder of the Building and the Premises not so Taken to substantially the same condition as is reasonably feasible.  If, in Landlord&#x2019;s reasonable judgment, any element of the Tenant-Insured Improvements can more effectively be restored as an integral part of Landlord&#x2019;s restoration of the Building or the Premises, such restoration shall also be made by Landlord, but at Tenant&#x2019;s sole cost and expense.  Subject to rights of the holders of any mortgages, the lessors under any ground leases, Tenant Delays, Legal Requirements then in existence and to delays for adjustment of insurance proceeds or Taking awards, as the case may be, and instances of Force Majeure, Landlord shall substantially complete such restoration within fifteen (15) months after the Casualty or Taking with respect to substantial reconstruction of at least fifty percent (50%) of the Building, or, within two hundred seventy (270) days after the Casualty or Taking in the case of restoration of less than fifty percent (50%) of the Building.  Upon substantial completion of such restoration by Landlord, Tenant shall use diligent efforts to complete restoration of the Premises to substantially the same condition as existed immediately prior to such Casualty or Taking, as the case may be, as soon as reasonably possible.  Tenant agrees to cooperate with Landlord in such manner as Landlord may reasonably request to assist Landlord in collecting insurance proceeds due in connection with any Casualty which affects the Premises or the Building.  In no event shall Landlord be required to expend more than the Net (hereinafter defined) insurance proceeds Landlord receives for damage to the Premises and/or the Building or the Net Taking award attributable to the Premises and/or the Building.  &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Net</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the insurance proceeds or Taking award actually paid to Landlord (and not paid over to the holder of any mortgagee) less all costs and expenses, including reasonable adjusters and attorney&#x2019;s fees, of obtaining the same.  In the Operating Year in which a Casualty occurs, there shall be included in Operating Expenses Landlord&#x2019;s deductible under its property insurance policy.  Except as Landlord may elect pursuant to this Section 14.1, under no circumstances shall Landlord be required to repair any damage to, or make any repairs to or replacements of, any Tenant-Insured Improvements.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">14.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Termination Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Landlord&#x2019;s Termination Rights. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Landlord may terminate this Lease upon thirty (30) days&#x2019; prior written notice to Tenant if:</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)	any material portion of the Building or any material means of access thereto is taken;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">64</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(ii)	more than thirty-five percent (35%) of the Building is damaged by Casualty; or</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iii)	if an uninsured Casualty occurs and the cost of the restoration of such uninsured Casualty is expected to exceed ten percent (10%) of the replacement cost of the Building; or</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iv)	if the estimated time to complete restoration exceeds fifteen (15) months from the date of the Casualty, such termination notice, to be effective, must be received by Tenant on or before the date what is sixty (60) days after the Casualty or the Taking, as applicable.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Termination Right</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  If Landlord is so required but fails to complete restoration of the Premises within the time frames and subject to the conditions set forth in Section 14.1 above, then Tenant may terminate this Lease upon thirty (30) days&#x2019; written notice to Landlord; provided, however, that if Landlord completes such restoration within thirty (30) days after receipt of any such termination notice, such termination notice shall be null and void and this Lease shall continue in full force and effect.  The remedies set forth in this Section 14.2(b) and in Section 14.2(c) below are Tenant&#x2019;s sole and exclusive rights and remedies based upon Landlord&#x2019;s failure to complete the restoration of the Premises as set forth herein.  Notwithstanding anything to the contrary contained herein, Tenant shall not have the right to terminate this Lease pursuant to this Section 14 if the Casualty was caused by the intentional misconduct of any Tenant Party.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Either Party May Terminate</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  In the case of any Casualty or Taking affecting the Premises and occurring during the last twelve (12) months of the Term, then (i) if such Casualty or Taking results in more than ten percent (10%) of the floor area of the laboratory area of the Premises or more than twenty-five percent (25%) of the floor area of the Premises being unsuitable for the Permitted Uses, or (ii) the damage to the Premises costs more than $250,000.00 to restore, then either Landlord or Tenant shall have the option to terminate this Lease upon thirty (30) days&#x2019; written notice to the other which notice, to be effective, shall be given on or before the date which is sixty (60) days after the such Casualty or Taking.  In addition, if Landlord&#x2019;s Mortgagee does not release sufficient insurance proceeds to cover the cost of Landlord&#x2019;s restoration obligations, then Landlord shall (i) notify Tenant thereof, and (ii) have the right to terminate this Lease on or before the date that is thirty (30) days after Landlord first learns of such insufficient insurance proceeds. If Landlord does not terminate this Lease pursuant to the previous sentence and such notice by Landlord does not include an agreement by Landlord to pay for the difference between the cost of such restoration and such released insurance proceeds, then Tenant may terminate this Lease by written notice to Landlord on or before the date that is thirty (30) days after such notice.  Notwithstanding anything to the contrary contained in this Section 14, in no event may Tenant elect to terminate this Lease hereunder if the Casualty that would otherwise give rise to such right results from the gross negligence or willful misconduct of Tenant, its agents, contractors, or employees.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Automatic Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  In the case of a Taking of the entire Premises, then this Lease shall automatically terminate as of the date of possession by the Taking authority.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">14.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Rent Abatement</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">65</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">In the event of a Casualty affecting the Premises, there shall be an equitable adjustment of Fixed Rent, Operating Expenses and Taxes based upon the degree to which Tenant &#x2018;s ability to conduct its business in the Premises is impaired by reason of such Casualty from and after the date of a Casualty, and continuing until the earlier to occur of:</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	the date Tenant begins to conduct its business in the portion of the Premises impaired by reason of such Casualty; and</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	the date which is one hundred twenty (120) days following the later of:</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)	substantial completion of any repair and restoration work to be performed by Landlord within the Premises, and</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(ii)	substantial completion of any repair and restoration work to be performed by Landlord with respect to the Common Areas to the extent that damage to the Common Areas caused by such Casualty materially adversely affects Tenant&#x2019;s use of, or access to, the Premises.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">14.4	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Taking for Temporary Use</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If the Premises are Taken for temporary use, this Lease and Tenant&#x2019;s obligations, including without limitation the payment of Rent, shall continue.  For purposes hereof, a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Taking for temporary use</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall mean a Taking of ninety (90) days or less.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">14.5	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Disposition of Awards</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Except for any separate award for Tenant&#x2019;s movable trade fixtures, relocation expenses, and unamortized leasehold improvements paid for by Tenant (provided that the same may not reduce Landlord&#x2019;s award), all Taking awards to Landlord or Tenant shall be Landlord&#x2019;s property without Tenant&#x2019;s participation, and Tenant hereby assigns to Landlord Tenant&#x2019;s interest, if any, in such award.  Tenant may pursue its own claim against the Taking authority.  Notwithstanding the foregoing, Tenant shall be entitled to receive any award or payment from the condemning authority with respect to any Taking for temporary use, which award shall be received, held and applied by Tenant as a trust fund for payment of the Rent falling due.  Time is of the essence with respect to Landlord&#x2019;s and Tenant&#x2019;s obligations under this Article XIV.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article XV<br>DEFAULT</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">15.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Default</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">This Lease and the term of this Lease are subject to the limitation that Tenant shall be in default if, at any time during the Lease Term, any one or more of the following events (herein called an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Event of Default</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">default of Tenant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; or similar reference) shall occur and not be cured prior to the expiration of the grace period (if any) herein provided, as follows:</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	Tenant shall fail to pay any installment of the Annual Fixed Rent, or any Additional Rent or any other monetary amount due under this Lease on or before the date on which</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">66</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">the same becomes due and payable, and such failure continues for five (5) days after written notice from Landlord thereof; or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	Tenant shall, in accordance with Section 16.24, fail to (i) pay the Balance of the Cash Security Deposit, or (ii) deliver the Balance of the Letter of Credit, on or before the date on which the same becomes due, and, in either case, such failure continues for five (5) business days after written notice from Landlord thereof; or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	Landlord having rightfully given the notice specified in (a) above to Tenant twice in any twelve (12) month period, Tenant shall fail thereafter to pay the Annual Fixed Rent, Additional Rent or any other monetary amount due under this Lease on or before the date on which the same becomes due and payable; or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	Tenant shall assign its interest in this Lease or sublet any portion of the Premises in violation of the requirements of Article XII of this Lease; or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(e)	Tenant shall fail to perform or observe some term or condition of this Lease which, because of its character, would immediately jeopardize Landlord&#x2019;s interest (such as, but without limitation, failure to maintain general liability insurance, or the employment of labor and contractors within the Premises which interfere with Landlord&#x2019;s Work, in violation of Sections 9.3 or 11.15 or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> or a failure to observe the requirements of Section 11.2), and such failure continues for three (3) business days after notice from Landlord to Tenant thereof; or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(f)	Tenant shall fail to perform or observe any other requirement, term, covenant or condition of this Lease (not hereinabove in this Section 15.1 specifically referred to) on the part of Tenant to be performed or observed and such failure shall continue for thirty (30) days after notice thereof from Landlord to Tenant, or if said default shall reasonably require longer than thirty (30) days to cure, if Tenant shall fail to commence to cure said default within thirty (30) days after notice thereof and/or fail to continuously prosecute the curing of the same to completion with due diligence; or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(g)	The estate hereby created shall be taken on execution or by other process of law; or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(h)	Tenant shall make an assignment or trust mortgage arrangement, so-called, for the benefit of its creditors; or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)	Tenant shall judicially be declared bankrupt or insolvent according to law; or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(j)	a receiver, guardian, conservator, trustee in involuntary bankruptcy or other similar officer is appointed to take charge of all or any substantial part of Tenant&#x2019;s property by a court of competent jurisdiction; or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(k)	any petition shall be filed against Tenant in any court, whether or not pursuant to any statute of the United States or of any State, in any bankruptcy, reorganization, composition, extension, arrangement or insolvency proceeding, and such proceedings shall not be dismissed within sixty (60) days after the institution of the same; or</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">67</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(l)	Tenant shall file any petition in any court, whether or not pursuant to any statute of the United States or any State, in any bankruptcy, reorganization, composition, extension, arrangement or insolvency proceeding; or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(m)	Any default by Tenant which is expressly defined in this Lease as an &#x201c;Event of Default&#x201d;.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">15.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Termination; Re-Entry</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Upon the happening of any one or more of the aforementioned Events of Default (notwithstanding any license of a former breach of covenant or waiver of the benefit hereof or consent in a former instance), Landlord or Landlord&#x2019;s agents or servants may give to Tenant a notice (hereinafter called &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">notice of termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) terminating this Lease on a date specified in such notice of termination (which shall be not less than five (5) days after the date of the mailing of such notice of termination), and this Lease and the Lease Term, as well as any and all of the right, title and interest of Tenant hereunder, shall wholly cease and expire on the date set forth in such notice of termination (Tenant hereby waiving any rights of redemption) in the same manner and with the same force and effect as if such date were the date originally specified herein for the expiration of the Lease Term, and Tenant shall then quit and surrender the Premises to Landlord.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">In addition or as an alternative to the giving of such notice of termination, Landlord or Landlord&#x2019;s agents or servants may, by any suitable proceeding at law, immediately or at any time thereafter re-enter the Premises and remove therefrom Tenant, its agents, employees, servants, licensees, and any subtenants and other persons, and all or any of its or their property therefrom, and repossess and enjoy the Premises, together with all additions, alterations and improvements thereto; but, in any event under this Section 15.2, Tenant shall remain liable as hereinafter provided.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The words &#x201c;re-enter&#x201d; and &#x201c;re-entry&#x201d; as used throughout this Article XV are not restricted to their technical legal meanings.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">15.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Continued Liability; Re-Letting</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If this Lease is terminated for an Event of Default or if Landlord shall re-enter the Premises as aforesaid, or in the event of the termination of this Lease, or of re- entry, by or under any proceeding or action or any provision of law by reason of an Event of Default hereunder on the part of Tenant, Tenant covenants and agrees forthwith to pay and be liable for, on the days originally fixed herein for the payment thereof, amounts equal to the several installments of Annual Fixed Rent, all Additional Rent and other charges reserved as they would, under the terms of this Lease, become due if this Lease had not been terminated or if Landlord had not entered or re-entered, as aforesaid, and whether the Premises be relet or remain vacant, in whole or in part, or for a period less than the remainder of the Lease Term, or for the whole thereof, but, in the event the Premises be relet by Landlord, Tenant shall be entitled to a credit in the net amount of rent and other charges received by Landlord in reletting, after deduction of all reasonable expenses incurred in reletting the Premises (including, without limitation, remodeling costs, brokerage fees and the like), and in collecting the rent in connection therewith, in the following manner:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">68</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Amounts received by Landlord after reletting shall first be applied against such Landlord&#x2019;s expenses, until the same are recovered, and until such recovery, Tenant shall pay, as of each day when a payment would fall due under this Lease, the amount which Tenant is obligated to pay under the terms of this Lease (Tenant&#x2019;s liability prior to any such reletting and such recovery not in any way to be diminished as a result of the fact that such reletting might be for a rent higher than the rent provided for in this Lease); when and if such expenses have been completely recovered, the amounts received from reletting by Landlord as have not previously been applied shall be credited against Tenant&#x2019;s obligations as of each day when a payment would fall due under this Lease, and only the net amount thereof shall be payable by Tenant.  Further, Tenant shall not be entitled to any credit of any kind for any period after the date when the term of this Lease is scheduled to expire according to its terms.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Landlord agrees to use reasonable efforts to relet the Premises after Tenant vacates the same (or Landlord re-enters the Premises as aforesaid) in the event this Lease is terminated based upon an Event of Default by Tenant hereunder.  The marketing of the Premises in a manner similar to the manner in which Landlord markets other premises within Landlord&#x2019;s control within the Laboratory Area shall be deemed to have satisfied Landlord&#x2019;s obligation to use &#x201c;reasonable efforts&#x201d; hereunder.  In no event shall Landlord be required to (i) solicit or entertain negotiations with any other prospective tenant for the Premises until Landlord obtains full and complete possession of the Premises (including, without limitation, the final and unappealable legal right to relet the Premises free of any claim of Tenant), (ii) relet the Premises before leasing other vacant space in the Office Area, or (iii) lease the Premises for a rental less than the current fair market rent then prevailing for similar office space in the Office Area.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">15.4	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Liquidated Damages</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Landlord may elect, as an alternative, to have Tenant pay liquidated damages, which election may be made by notice given to Tenant at any time after the termination of this Lease under Section 15.2, above, and whether or not Landlord shall have collected any damages as hereinbefore provided in this Article XV, and in lieu of all other such damages beyond the date of such notice.  Upon such notice, Tenant shall promptly pay to Landlord, as liquidated damages, in addition to any damages collected or due from Tenant from any period prior to such notice and all expenses which Landlord may have incurred with respect to the collection of such damages, such a sum as at the time of such notice represents the amount of the excess, if any, of (a) the discounted present value, at a discount rate of 6%, of the Annual Fixed Rent, Additional Rent and other charges which would have been payable by Tenant under this Lease for the remainder of the Lease Term if the Lease terms had been fully complied with by Tenant, over and above (b) the discounted present value, at a discount rate of 6%, of the Annual Fixed Rent, Additional Rent and other charges that would be received by Landlord if the Premises were re-leased at the time of such notice for the remainder of the Lease Term at the fair market value (including provisions regarding periodic increases in Annual Fixed Rent if such are applicable) prevailing at the time of such notice as reasonably determined by Landlord.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">For the purposes of this Article, if Landlord elects to require Tenant to pay liquidated damages in accordance with this Section 15.4, the total rent shall be computed by assuming the Tenant&#x2019;s Tax Share under Section 5.2 and Tenant&#x2019;s Expense Share under Section 6.3 to be the same as were payable for the twelve (12) calendar months (or if less than twelve (12) calendar</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">69</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">months have been elapsed since the date hereof, the partial year) immediately preceding such termination of re-entry.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Nothing contained in this Lease shall limit or prejudice the right of Landlord to prove for and obtain in proceedings for bankruptcy or insolvency by reason of the termination of this Lease, an amount equal to the maximum allowed by any statute or rule of law in effect at the time when, and governing the proceeds in which, the damages are to be proved, whether or not the amount be greater, equal to, or less than the amount of the loss or damages referred to above.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">In lieu of any other damages or indemnity and in lieu of the recovery by Landlord of all sums payable under all the foregoing provisions of this Section 15.4, Landlord may elect to collect from Tenant, by notice to Tenant, at the time this Lease is terminated under any of the provisions contained in this ARTICLE XV or otherwise terminated by breach of any obligation of Tenant and before such full recovery, and Tenant shall thereupon pay, as liquidated damages, an amount equal to the sum of the Annual Fixed Rent and all Additional Rent payable for the twelve (12) months ended next prior to the such termination plus the amount of Annual Fixed Rent and Additional Rent of any kind accrued and unpaid at the time of such election plus any and all expenses which Landlord may have incurred for and with respect to the collection of any of such rent.  Notwithstanding any provision of this Lease to the contrary, except for Tenant&#x2019;s obligations under Section 11.17 (Hazardous Materials) and Section 16.18 (Holdover), in no event shall Landlord or Tenant be liable under this Lease for any consequential, indirect or special damages or lost profits.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">15.5	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Waiver of Redemption</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Tenant, for itself and any and all persons claiming through or under Tenant, including its creditors, upon the termination of this Lease and of the term of this Lease in accordance with the terms hereof, or in the event of entry of judgment for the recovery of the possession of the Premises in any action or proceeding, or if Landlord shall enter the Premises by process of law or otherwise, hereby waives any right of redemption provided or permitted by any statute, law or decision now or hereafter in force, and does hereby waive, surrender and give up all rights or privileges which it or they may or might have under and by reason of any present or future law or decision, to redeem the Premises or for a continuation of this Lease for the term of this Lease hereby demised after having been dispossessed or ejected therefrom by process of law, or otherwise.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">15.6	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Landlord&#x2019;s Default</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Landlord shall in no event be in default in the performance of any of Landlord&#x2019;s obligations hereunder unless and until Landlord shall have failed to perform such obligations within thirty (30) days, or such additional time as is reasonably required to correct any such default, after notice by Tenant to Landlord properly specifying wherein Landlord has failed to perform any such obligation.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Tenant shall not assert any right to deduct the cost of repairs or any monetary claim against Landlord from rent thereafter due and payable, but shall look solely to Landlord for satisfaction of such claim, except as set forth in Section 16.17.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">15.7	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Self-Help Right</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">70</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If Landlord shall at any time fail to perform any Tenant Self-Help Obligation, as hereinafter defined, and should such failure continue beyond the applicable grace period set forth in this Section, Tenant may, but shall not be obligated so to do, after ten (10) days&#x2019; written notice (except that, in the case of emergency or imminent threat to the safety of occupants in the Premises or material property damage within the Premises, upon such shorter notice as may be reasonably practicable under the circumstances), to and demand upon Landlord explicitly setting forth the basis for Tenant&#x2019;s claim of default and specifying that Tenant intends to invoke Tenant&#x2019;s rights under this Section 15.7 (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Tenant&#x2019;s Self Help Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), and without waiving, or releasing Landlord from, any obligations of Landlord in this Lease contained, perform such Tenant Self-Help Obligation in such manner and to such extent as may be reasonably necessary.  For the purposes hereof, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Tenant Self-Help Obligations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall be defined as any service, maintenance or repair obligation that Landlord is obligated to provide or perform pursuant to the provisions of this Lease, except for any service, maintenance or repair which (a) requires work outside of the Premises (except for components of systems which may be located outside of the Premises but which exclusively serve the Premises, provided that Tenant&#x2019;s exercise of its rights under this Section 15.7 will in no way affect Landlord&#x2019;s operation of the Building or other tenants or occupants of the Building), or (b) might affect other tenants or occupants of the Building or the Project.  All sums reasonably so incurred and paid by Tenant and all reasonable and necessary costs and expenses of Tenant incidental to Tenant&#x2019;s proper exercise of self help rights pursuant to this Section 15.7, together with interest thereon at the Lease Interest Rate from the date of the making of such expenditures by Tenant, shall be payable to the Tenant within thirty (30) days of Tenant&#x2019;s furnishing Landlord an invoice therefor, accompanied by reasonable substantiation, and Landlord covenants to pay any such sum or sums with interest as aforesaid if not timely paid.  If Landlord fails to reimburse Tenant for the sums paid by Tenant within thirty (30) days of Tenant&#x2019;s invoice (together with supporting documentation), and Landlord has not, within thirty (30) days of its receipt of such invoice, given written notice to Tenant objecting to such demand and stating that Landlord has filed suit in a court of competent jurisdiction to determine whether or not Tenant had validly exercised its self-help right hereunder (or if Landlord has timely disputed Tenant&#x2019;s invoice, has filed suit and has thereafter failed to pay Tenant the amount of any final, unappealable award against Landlord within thirty (30) days after the issuance thereof) then Tenant shall have the right to offset the amount of such sums demanded by Tenant (together with any attorneys&#x2019; fees and costs to which Tenant may be entitled pursuant to Section 11.8 if there has been a final, unappealable award against Landlord) against fifty (50%) percent of the Annual Fixed Rent payable under this Lease until offset in full.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Article XVI<br>MISCELLANEOUS PROVISIONS</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.1	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Waiver</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Failure on the part of Landlord or Tenant to complain of any action or non-action on the part of the other, no matter how long the same may continue, shall never be a waiver by Tenant or Landlord, respectively, of any of its rights hereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Further, no waiver at any time of any of the provisions hereof by Landlord or Tenant shall be construed as a waiver of any of the other provisions hereof, and a waiver at any time of any of the provisions hereof shall not be construed as a waiver at any subsequent time of the same</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">71</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">provisions. The consent or approval of Landlord or Tenant to or of any action by the other requiring such consent or approval shall not be construed to waive or render unnecessary Landlord&#x2019;s or Tenant&#x2019;s consent or approval to or of any subsequent similar act by the other.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">No payment by Tenant, or acceptance by Landlord, of a lesser amount than shall be due from Tenant to Landlord shall be treated otherwise than as a payment on account.  The acceptance by Landlord of a check for a lesser amount with an endorsement or statement thereon, or upon any letter accompanying such check, that such lesser amount is payment in full, shall be given no effect, and Landlord may accept such check without prejudice to any other rights or remedies which Landlord may have against Tenant.  Further, the acceptance by Landlord of Annual Fixed Rent, Additional Rent or any other charges paid by Tenant under this Lease shall not be or be deemed to be a waiver by Landlord of any default by Tenant, whether or not Landlord knows of such default, except for such defaults as to which such payment relates.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.2	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Cumulative Remedies</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Except as expressly provided in this Lease, the specific remedies to which Landlord and Tenant may resort under the terms of this Lease are cumulative and are not intended to be exclusive of any other remedies or means of redress which they may be lawfully entitled to seek in case of any breach or threatened breach of any provisions of this Lease.  In addition to the other remedies provided in this Lease, Landlord shall be entitled to the restraint by injunction of the violation or attempted or threatened violation of any of the covenants, conditions or provisions of this Lease or to seek specific performance of any such covenants, conditions or provisions, provided, however, that the foregoing shall not be construed as a confession of judgment by Tenant.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.3	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Quiet Enjoyment</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	This Lease is subject and subordinate to all matters of record as of the Effective Date.  Landlord agrees that, upon Tenant&#x2019;s paying the Annual Fixed Rent, Additional Rent and other charges herein reserved, and performing and observing the covenants, conditions and agreements hereof upon the part of Tenant to be performed and observed, Tenant shall and may peaceably hold and enjoy the Premises during the term of this Lease (exclusive of any period during which Tenant is holding over after the expiration or termination of this Lease without the consent of Landlord), without interruption or disturbance from Landlord or persons claiming through or under Landlord, subject, however, to the terms of this Lease.  This covenant shall be construed as running with the land to and against subsequent owners and successors in interest, and is not, nor shall it operate or be construed as, a personal covenant of Landlord, except to the extent of Landlord&#x2019;s interest in the Premises, and this covenant and any and all other covenants of Landlord contained in this Lease shall be binding upon Landlord and upon such subsequent owners or successors in interest of Landlord&#x2019;s interest under this Lease, including ground or master lessees, to the extent of their respective interests, as and when they shall acquire same and then only for so long as they shall retain such interest.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	Landlord shall have the right to subdivide the Project, and to enter into, and subject the Project to the terms and conditions of, a reciprocal easement agreement (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">REA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), provided that such subdivision and REA shall not materially adversely affect Tenant&#x2019;s rights or increase Tenant&#x2019;s obligations hereunder.  In connection with such subdivision, and REA, Tenant</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">72</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">shall, within ten (10) business days of Landlord&#x2019;s written request, execute such commercially reasonable documents (which may be in recordable form) evidencing such subordination, consistent with the foregoing.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	Landlord shall have the right to establish a condominium (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Condominium</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) and to subject the Project and this Lease to such Condominium, provided that such Condominium shall not materially adversely affect Tenant&#x2019;s rights or increase Tenant&#x2019;s obligations hereunder.  In connection with the subordination of the Project and the Lease to such Condominium, Tenant shall, within ten (10) business days of Landlord&#x2019;s written request, execute such commercially reasonable documents (which may be in recordable form) evidencing such subordination, consistent with the foregoing.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.4	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Surrender</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	Upon the expiration or earlier termination of the Term, Tenant shall (i) peaceably quit and surrender to Landlord the Premises (including without limitation all fixed lab benches, fume hoods, electric, plumbing, heating and sprinkling systems, fixtures and outlets, vaults, paneling, molding, shelving, radiator enclosures, cork, rubber, linoleum and composition floors, ventilating, silencing, air conditioning and cooling equipment therein and all other furniture, fixtures, and equipment that was either provided by Landlord or paid for in whole or in part by any allowance provided to Tenant by Landlord under this Lease) broom clean, in good order, repair and condition excepting only ordinary wear and tear and damage by fire or other insured Casualty; (ii) remove all of Tenant&#x2019;s Property, all autoclaves and cage washers and, to the extent specified by Landlord, Alterations made by Tenant; and (iii) repair any damages to the Premises or the Building caused by the installation or removal of Tenant&#x2019;s Property and/or such Alterations. Tenant&#x2019;s obligations under this Section 16.4(a) shall survive the expiration or earlier termination of this Lease.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Surrender Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Prior to the expiration of this Lease (or within thirty (30) days after any earlier termination), Tenant shall clean and otherwise decommission all interior surfaces (including floors, walls, ceilings, and counters), piping, supply lines, waste lines, acid neutralization systems and plumbing in and/or exclusively serving the Premises, and all exhaust or other ductwork in and/or exclusively serving the Premises, in each case which has carried or released or been contacted by any Hazardous Materials used in the operation of the Premises, and shall otherwise clean the Premises so as to permit the Surrender Plan (defined below) to be issued.  At least thirty (30) days prior to the expiration of the Term (or, if applicable, within five (5) business days after any earlier termination of this Lease), Tenant shall deliver to Landlord a reasonably detailed narrative description of the actions proposed (or required by any Legal Requirements) to be taken by Tenant in order to render the Premises (including any Alterations permitted or required by Landlord to remain therein) free of Hazardous Materials and otherwise released for unrestricted use and occupancy including without limitation causing the Premises to be decommissioned in accordance with the regulations of the U.S. Nuclear Regulatory Commission and/or the Massachusetts Department of Public health (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">MDPH</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) for the control of radiation, and cause the Premises to be released for unrestricted use by the Radiation Control Program of the MDPH (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Surrender Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  The Surrender Plan (i) shall be accompanied by a current list of (A) all Required Permits held by or on behalf of any Tenant Party with respect to Hazardous Materials in, on, under, at or about the Premises, and (B) Tenant&#x2019;s Hazardous Materials,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">73</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">and (ii) shall be subject to the review and approval of Landlord&#x2019;s environmental consultant.  In connection with review and approval of the Surrender Plan, upon request of Landlord, Tenant shall deliver to Landlord or its consultant such additional non-proprietary information concerning the use of and operations within the Premises as Landlord shall request.  On or before the expiration of the Term (or within thirty (30) days after any earlier termination of this Lease, during which period Tenant&#x2019;s use and occupancy of the Premises shall be governed by Section 16.18 below), Tenant shall (i) perform or cause to be performed all actions described in the approved Surrender Plan, and (ii) deliver to Landlord a certification from a third party certified industrial hygienist reasonably acceptable to Landlord certifying that the Premises do not contain any Hazardous Materials (an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Industrial Hygienist Certification</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) and evidence that the approved Surrender Plan shall have been satisfactorily completed by a contractor acceptable to Landlord, and Landlord shall have the right, subject to reimbursement at Tenant&#x2019;s expense as set forth below, to cause Landlord&#x2019;s environmental consultant to inspect the Premises and perform such additional procedures as may be deemed reasonably necessary to confirm that the Premises are, as of the expiration of the Term (or, if applicable, the date which is thirty (30) days after any earlier termination of this Lease), free of Hazardous Materials and otherwise available for unrestricted use and occupancy as aforesaid.  Landlord shall have the unrestricted right to deliver the Surrender Plan and any report by Landlord&#x2019;s environmental consultant with respect to the surrender of the Premises to third parties. Such third parties and the Landlord Parties shall be entitled to rely on the Surrender Report.  If Tenant shall fail to prepare or submit a Surrender Plan approved by Landlord, or if Tenant shall fail to complete the approved Surrender Plan, or if such Surrender Plan, whether or not approved by Landlord, shall fail to adequately address the use of Hazardous Materials by any of the Tenant Parties in, on, at, under or about the Premises, Landlord shall have the right to take any such actions as Landlord may deem reasonable or appropriate to assure that the Premises and the Property are surrendered in the condition required hereunder, the cost of which actions shall be reimbursed by Tenant as Additional Rent upon demand.  Tenant&#x2019;s obligations under this Section 16.4(b) shall survive the expiration or earlier termination of the Term.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	No act or thing done by Landlord during the Term shall be deemed an acceptance of a surrender of the Premises, and no agreement to accept such surrender shall be valid, unless in writing signed by Landlord.  Unless otherwise agreed by the parties in writing, no employee of Landlord or of Landlord&#x2019;s agents shall have any power to accept the keys of the Premises prior to the expiration or earlier termination of this Lease.  The delivery of keys to any employee of Landlord or of Landlord&#x2019;s agents shall not operate as a termination of this Lease or a surrender of the Premises.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	Subject to Section 9.5(c), Tenant shall, at its sole cost and expense, remove from the Premises, prior to the end of the Term, any item installed by or for Tenant and which, pursuant to Legal Requirements, must be removed therefrom before the Premises may be used by a subsequent tenant.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.5	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Brokerage</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Tenant warrants and represents that Tenant has not dealt with any broker in connection with the consummation of this Lease other than the brokers, person or firm designated in Section 1.2 hereof; and in the event any claim is made against Landlord relative to Tenant&#x2019;s dealings with brokers other than the brokers designated in Section 1.2 hereof, Tenant shall defend the claim</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">74</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">against Landlord with counsel of Landlord&#x2019;s selection and save harmless and indemnify Landlord on account of loss, cost or damage which may arise by reason of such claim.  Landlord warrants and represents that Landlord has not dealt with any broker in connection with the consummation of this Lease other than the brokers, person or firm designated in Section 1.2 hereof; and in the event any claim is made against Tenant relative to Landlord&#x2019;s dealings with brokers other than the brokers designated in Section 1.2 hereof, Landlord shall defend the claim against Tenant and save harmless and indemnify Tenant on account of actual loss, cost or damage which may arise by reason of such claim.  Landlord agrees that it shall be solely responsible for the payment of brokerage commissions to the brokers, person or firm designated in Section 1.2 hereof.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.6	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Invalidity of Particular Provisions</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If any term or provision of this Lease, or the application thereof to any person or circumstance shall, to any extent, be invalid or unenforceable, the remainder of this Lease, or the application of such term or provision to persons or circumstances other than those as to which it is held invalid or unenforceable, shall not be affected thereby, and each term and provision of this Lease shall be valid and be enforced to the fullest extent permitted by law.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.7	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Provisions Binding, etc.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The obligations of this Lease shall run with the land, and except as herein otherwise provided, the terms hereof shall be binding upon and shall inure to the benefit of the successors and assigns, respectively, of Landlord and Tenant and, if Tenant shall be an individual, upon and to his/her heirs, executors, administrators, successors and assigns. Each term and each provision of this Lease to be performed by Tenant shall be construed to be both a covenant and a condition.  The reference contained to successors and assigns of Tenant is not intended to constitute a consent to assignment by Tenant, but has reference only to those instances in which Landlord may have later given consent to a particular assignment as required by the provisions of Article XII hereof.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.8	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Recording; Confidentiality</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Each of Landlord and Tenant agree not to record the within Lease, but each party hereto agrees, on the request of the other, to execute a so-called Notice of Lease or short form lease in form recordable and complying with applicable law and reasonably satisfactory to Landlord&#x2019;s and Tenant&#x2019;s attorneys. In no event shall such document set forth the rent or other charges payable by Tenant under this Lease; and any such document shall expressly state that it is executed pursuant to the provisions contained in this Lease, and is not intended to vary the terms and conditions of this Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Tenant agrees that this Lease and the terms contained herein will be treated as strictly confidential and except as required by law (or except with the written consent of Landlord) Tenant shall not disclose the same to any third party except for Tenant&#x2019;s partners, lenders, accountants and attorneys who have been advised of the confidentiality provisions contained herein and agree to be bound by the same.  In the event Tenant is required by law to provide this Lease or disclose any of its terms, Tenant shall give Landlord prompt notice of such requirement prior to making disclosure so that Landlord may seek an appropriate protective order.  If failing the entry of a protective order Tenant is compelled to make disclosure, Tenant shall only disclose portions of the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">75</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Lease which Tenant is required to disclose and will exercise reasonable efforts to obtain assurance that confidential treatment will be accorded to the information so disclosed.  Notwithstanding anything to the contrary in this Lease, the provisions of this Section shall not prohibit any disclosures required by securities laws.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.9	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Notices and Time for Action</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Whenever, by the terms of this Lease, notice shall or may be given either to Landlord or to Tenant, such notices shall be in writing and shall be sent by hand, registered or certified mail, or overnight or other commercial courier, postage or delivery charges, as the case may be, prepaid as follows:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If intended for Landlord, addressed to Landlord at the address set forth on the first page of this lease, and copies in like fashion to:</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Samuels &amp; Associates, 136 Brookline Avenue, Boston, MA 02215, Attn:  Legal Department (or to such other address or addresses as may from time to time hereafter be designated by Landlord by like notice).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If intended for Tenant, addressed to Tenant at the address set forth in Article I of this Lease except that from and after the Commencement Date the address of Tenant shall be the Premises (or to such other address or addresses as may from time to time hereafter be designated by Tenant by like notice).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Except as otherwise provided herein, all such notices shall be effective when received; provided, that (i) if receipt is refused, notice shall be effective upon the first occasion that such receipt is refused, (ii) if the notice is unable to be delivered due to a change of address of which no notice was given, notice shall be effective upon the date such delivery was attempted, (iii) if the notice address is a post office box number, notice shall be effective the day after such notice is sent as provided hereinabove or (iv) if the notice is to a foreign address, notice shall be effective two (2) days after such notice is sent as provided hereinabove.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Any notice given by an attorney on behalf of Landlord or by Landlord&#x2019;s managing agent shall be considered as given by Landlord and shall be fully effective.  The notice provisions of this Section are subject to the additional requirements of Section 16.14.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Time is of the essence with respect to any and all notices and periods for giving of notice or taking any action thereto under this Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.10	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">When Lease Becomes Binding and Authority</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Employees or agents of Landlord have no authority to make or agree to make a lease or any other agreement or undertaking in connection herewith.  The submission of this document for examination and negotiation does not constitute an offer to lease, or a reservation of, or option for, the Premises, and this document shall become effective and binding only upon the execution and delivery hereof by both Landlord and Tenant.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">76</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">All negotiations, considerations, representations and understandings between Landlord and Tenant are incorporated herein and may be modified or altered only by written agreement between Landlord and Tenant, and no act or omission of any employee or agent of Landlord shall alter, change or modify any of the provisions hereof.  Landlord and Tenant hereby represents and warrants to the other that all necessary action has been taken to enter this Lease and that the person signing this Lease on behalf of Landlord and Tenant has been duly authorized to do so.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.11	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Paragraph Headings</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The paragraph headings throughout this instrument are for convenience and reference only, and the words contained therein shall in no way be held to explain, modify, amplify or aid in the interpretation, construction or meaning of the provisions of this Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.12	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Rights of Mortgagee</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">This Lease shall be subject and subordinate to any mortgage now or hereafter on the Building (or any part thereof) or on the fee interest (or any part thereof) held by Ground Lessor (as defined in Section 16.13 below), and to all renewals, modifications, consolidations, replacements and extensions thereof and all substitutions therefor, provided that the holder of such mortgage enters into subordination, non-disturbance and recognition agreement with Tenant, in the standard form used by such holder, with such commercially reasonable changes as Tenant may request (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">SNDA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), which may include an acknowledgment of Tenant&#x2019;s offset rights set forth in Exhibit 2.1.  In the event that any mortgagee or its respective successor in title shall succeed to the interest of Landlord or Ground Lessor, as applicable, then this Lease shall nevertheless continue in full force and effect and Tenant shall and does hereby agree to attorn to such mortgagee or successor and to recognize such mortgagee or successor as its landlord or ground lessor, as applicable.  If any holder of a mortgage which includes the Premises, executed and recorded prior to the Date of this Lease, shall so elect, this Lease, and the rights of Tenant hereunder, shall be superior in right to the rights of such holder, with the same force and effect as if this Lease had been executed, delivered and recorded, or a statutory Notice hereof recorded, prior to the execution, delivery and recording of any such mortgage.  The election of any such holder shall become effective upon either notice from such holder to Tenant in the same fashion as notices from Landlord to Tenant are to be given hereunder or by the recording in the appropriate registry or recorder&#x2019;s office of an instrument in which such holder subordinates its rights under such mortgage to this Lease.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If in connection with obtaining financing a bank, insurance company, pension trust or other institutional lender shall request reasonable modifications in this Lease as a condition to such financing, Tenant will not unreasonably withhold, delay or condition its consent thereto, provided that such modifications do not increase the monetary obligations of Tenant hereunder or materially adversely affect the leasehold interest hereby created or Tenant&#x2019;s rights hereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.13	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Rights of Ground Lessor</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Landlord and Tenant hereby acknowledge that the Building is subject to that certain Second Amended and Restated Construction, Development and Lease Agreement dated May 29, 2020, by and between ARE-MA Region NO. 87 Owner Limited Partnership (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Ground Lessor</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), as landlord, and Landlord, as tenant (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Existing Ground Lease</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), notice of which is recorded in</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">77</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">the Suffolk County Registry of Deeds in Book 63127, Page 306 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Notice of Ground Lease</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  On or about the date hereof, Landlord, Ground Lessor and Tenant shall enter into a Recognition Agreement in the form attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 16.13</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  If (a) Landlord enters into a new ground lease or extends the term of the Existing Ground Lease, or (b) Landlord&#x2019;s interest in property (whether land only or land and buildings) which includes the Premises is acquired by another party and simultaneously leased back to Landlord herein, the holder of the ground lessor&#x2019;s interest in such ground lease shall enter into a recognition agreement with Tenant simultaneously with (x) the amendment to the Existing Ground Lease or the new ground lease, as the case may be, or (y) the sale and leaseback, wherein the ground lessor will agree to recognize the right of Tenant to use and occupy the Premises upon the payment of Annual Fixed Rent, Additional Rent and other charges payable by Tenant under this Lease and the performance by Tenant of Tenant&#x2019;s obligations hereunder, and wherein Tenant shall agree to attorn to such ground lessor as its Landlord and to perform and observe all of the tenant obligations hereunder, in the event such ground lessor succeeds to the interest of Landlord hereunder under such ground lease.  Notwithstanding any provision of this Lease to the contrary, Landlord hereby represents and warrants to Tenant that the Permitted Use of the Premises as contemplated in this Lease is, and at all times during the Term, shall be, permitted and that the Permitted Use does not violate any of the terms, provisions or conditions of the Existing Ground Lease or the limitations on the permitted uses set forth in the 121A Designation (as defined in the Existing Ground Lease) affecting the Land.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.14	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Notice to Mortgagee and Ground Lessor</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">After receiving notice from any person, firm or other entity that it holds a mortgage which includes the Premises as part of the mortgaged premises, or that it is the ground lessor under a lease with Landlord as ground lessee, which includes the Premises as a part of the leased premises, no notice from Tenant to Landlord shall be effective unless and until a copy of the same is given to such holder or ground lessor at the address as specified in said notice (as it may from time to time be changed), and the curing of any of Landlord&#x2019;s defaults by such holder or ground lessor within a reasonable time after such notice (including a commercially reasonable amount of time to be mutually agreed upon between Tenant and such holder in an SNDA to obtain possession of the premises if the curing of such default requires the mortgagee or ground lessor to do so) shall be treated as performance by Landlord.  For the purposes of this Section 16.14, the term &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">mortgage</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; includes a mortgage on a leasehold interest of Landlord (but not one on Tenant&#x2019;s leasehold interest).  If any mortgage is listed on </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 16.14</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> then the same shall constitute notice from the holder of such mortgage for the purposes of this Section 16.14.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.15	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Assignment of Rents</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">With reference to any assignment by Landlord of Landlord&#x2019;s interest in this Lease, or the rents payable hereunder, conditional in nature or otherwise, which assignment is made to the holder of a mortgage or ground lease on property which includes the Premises, Tenant agrees:</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	That the execution thereof by Landlord, and the acceptance thereof by the holder of such mortgage, or the ground lessor, shall never be treated as an assumption by such holder or ground lessor of any of the obligations of Landlord hereunder, unless such holder, or ground lessor, shall, acquire possession of the Building; and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">78</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	That, except as aforesaid, such holder or ground lessor shall be treated as having assumed Landlord&#x2019;s obligations hereunder only upon foreclosure of such holder&#x2019;s mortgage and the taking of possession of the Premises, or, in the case of a ground lessor, the assumption of Landlord&#x2019;s position hereunder by such ground lessor.  In no event shall the acquisition of title to the Office Area and the land on which the same is located by a purchaser which, simultaneously therewith, leases the entire Office Area or such land back to the seller thereof be treated as an assumption, by operation of law or otherwise, of Landlord&#x2019;s obligations hereunder, but Tenant shall look solely to such seller-lessee, and its successors from time to time in title, for performance of Landlord&#x2019;s obligations hereunder.  In any such event, this Lease shall be subject and subordinate to the lease to such purchaser provided that such purchaser-lessor agrees to recognize the right of Tenant to use and occupy the Premises upon the payment of rent and all other charges payable by Tenant under this Lease and the performance by Tenant of Tenant&#x2019;s obligations under this Lease.  For all purposes, such seller-lessee, and its successors in title, shall be the landlord hereunder unless and until Landlord&#x2019;s position shall have been assumed by such purchaser-lessor.  Tenant acknowledges that it has been informed by Landlord that Landlord has entered into certain agreements with its lenders (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Lenders</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) which require it to include in this Lease (and requires Tenant to include in any sublease which may be permitted hereunder) the following provisions:  (i) no rent payable under this Lease or under any such sublease may be based in whole or in part on the income or profits derived from the Premises or any subleased premises except for percentage rent based on gross (not net) receipts or sales; (ii) if Lenders succeed to Landlord&#x2019;s interests under this Lease and are advised by Lenders&#x2019; counsel that all or any portion of the rent payable under this Lease is or may be deemed to be unrelated business income within the meaning of the Internal Revenue Code of the 1986, as amended, or the regulations issued thereunder, Lenders may elect to amend unilaterally the calculation of rents under this Lease so that none of the rents payable to Lenders under this Lease will constitute unrelated business income, provided that such amendment will not increase Tenant&#x2019;s payment obligations or other liability under this Lease or reduce Landlord&#x2019;s obligations under this Lease; and (iii) if Lenders request, Tenant will be obligated to execute any document Lenders may deem necessary to effect the amendment of this Lease in accordance with the foregoing subsection (ii).  Further, no Annual Fixed Rent or Additional Rent may be paid by Tenant more than thirty (30) days in advance except with Lenders&#x2019; prior written consent, and any such payment without such consent shall not be binding on Lenders.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.16	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Estoppel Certificate and Financial Statements</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Recognizing that Landlord may find it necessary to establish to third parties, such as accountants, banks, potential or existing mortgagees, potential purchasers or the like, the then current status of performance hereunder, Tenant, within ten (10) business days after the request of Landlord made from time to time, will furnish to Landlord, or any existing or potential holder of any mortgage encumbering the Premises, the Office Area or the Project, or any potential purchaser of the Premises, the Office Area, or the Project (each an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Interested Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) an estoppel certificate stating the status of any matter pertaining to this Lease reasonably requested, including, without limitation, acknowledgments that (or the extent to which) each party is in compliance with its obligations under the terms of this Lease.  In addition, Tenant shall deliver to Landlord, or any Interested Party designated by Landlord, financial statements of Tenant, and any guarantor of Tenant&#x2019;s obligations under this Lease, as reasonably requested by Landlord including, but not</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">79</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">limited to, financial statements for the prior year.  Any such status statement or financial statement delivered by Tenant pursuant to this Section 16.16 may be relied upon by any Interested Party.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.17	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Self-Help</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If Tenant shall at any time fail to make any payment or perform any act which Tenant is obligated to make or perform under this Lease within ten (10) days after written notice from Landlord (or such longer period of time as Tenant may reasonably require, so long as Tenant commences to cure such failure within such ten-(10)-day period and thereafter diligently prosecutes such cure to completion), Landlord may (but shall not be required to do so) make or cause such payment to made or act to be performed and shall not be responsible to Tenant for any loss or damage that may accrue to Tenant&#x2019;s stock or business by reason thereof.  Notwithstanding the foregoing, in an emergency, Landlord may exercise its rights under the immediately preceding sentence without any prior notice to Tenant.  No act taken or payment made by Landlord pursuant to this Section 16.17 shall be deemed to waive, or release, Tenant from, any obligations of Tenant in this Lease contained.  Landlord may exercise its rights under this Section 16.17 in such manner and to such extent as may be reasonably necessary, and, in exercising any such rights, pay any costs and expenses, employ counsel and incur and pay reasonable attorneys &#x2018; fees. All sums so paid by Landlord and all reasonable and necessary costs and expenses of Landlord incidental thereto, together with interest thereon at the annual rate equal to the Lease Interest Rate, as defined in Section 4.3, from the date of the making of such expenditures by Landlord, shall be deemed to be Additional Rent and, except as otherwise in this Lease expressly provided, shall be payable to Landlord on demand, and if not promptly paid shall be added to any rent then due or thereafter becoming due under this Lease, and Tenant covenants to pay any such sum or sums with interest as aforesaid, and Landlord shall have (in addition to any other right or remedy of Landlord) the same rights and remedies in the event of the non-payment thereof by Tenant as in the case of default by Tenant in the payment of Annual Fixed Rent.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.18	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Holding Over</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	Any holding over by Tenant after the expiration of the Term of this Lease shall be treated as a tenancy at sufferance and shall be on the terms and conditions as set forth in this Lease, as far as applicable except that Tenant shall pay as a daily use and occupancy charge in an amount equal to the greater of (x) the Hold Over Percentage (as hereinafter defined) of the Annual Fixed Rent and Additional Rent calculated (on a daily basis) at the rate payable as of the last day of the Term under the terms of this Lease or (y) the fair market rental value of the Premises. In addition, if such holdover continues for more than thirty (30) days, Tenant shall save Landlord, its agents and employees harmless and will exonerate, defend and indemnify Landlord, its agents and employees from and against any and all damages which Landlord may suffer on account of Tenant&#x2019;s hold-over in the Premises after the expiration or prior termination of the term of this Lease.  Nothing in the foregoing nor any other term or provision of this Lease shall be deemed to permit Tenant to retain possession of the Premises or hold over in the Premises after the expiration or earlier termination of the Lease Term.  All property which remains in the Office Area or the Premises after the expiration or termination of this Lease shall be conclusively deemed to be abandoned and may either be retained by Landlord as its property or sold or otherwise disposed of in such manner as Landlord may see fit.  If any part thereof shall be sold, then Landlord may receive the proceeds of such sale and apply the same, at its option against the expenses of the sale,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">80</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">the cost of moving and storage, any arrears of rent or other charges payable hereunder by Tenant to Landlord and any damages to which Landlord may be entitled under this Lease and at law and in equity.  The &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Hold Over Percentage</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall be (i) 150% for the first thirty (30) days of such holdover, (ii) 175% for the second thirty (30) days of such holdover, and (iii) 200% for any period of holdover after the first sixty (60) days.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	Subject to the provisions of this Section 16.18(b), the failure of Tenant or any Tenant Party to perform all of its obligations under Section 16.4 above, shall be deemed to be a holdover by Tenant after the expiration of the Term of this Lease.  Notwithstanding the foregoing, in the event that (i) Tenant completes the Surrender Plan approved by Landlord, and delivers to Landlord the Industrial Hygienist Certification, but after the end of the Term it is discovered that there exist Hazardous Materials that have been introduced to the Building or the Land by any of the Tenant Parties, and (ii) the Premises are otherwise surrendered in accordance with the terms and conditions of this Lease on or prior to the expiration or earlier termination of the Term, then</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)	the provisions of Section 16.18(a) shall not be applicable to the period of time after the expiration or earlier of termination of this Lease which is required for Landlord to finish decommissioning the Premises and obtain an Industrial Hygienist Certification, but (y) Tenant shall be responsible for the costs and expenses incurred by Landlord to fully decommission the Premises and the Property in accordance with Section 16.4 above.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.19	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Entry by Landlord</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Landlord, and its duly authorized representatives, shall, upon reasonable prior notice (except in the case of emergency or for normal cleaning and maintenance operations), have the right to enter the Premises at all reasonable times (except at any time in the case of emergency) for the purposes of inspecting the condition of same and making such repairs, Alterations thereto as may be necessary if Tenant fails to do so as required hereunder (but Landlord shall have no duty whatsoever to make any such inspections, repairs, Alterations except as otherwise provided in Sections 4.1, 8.1 and 8.2 and </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">); provided, however, that (except in the case of emergency) Landlord shall provide prior notice to Tenant before entering any laboratory portions of the Premises, Landlord shall comply with all reasonable safety requirements and guidelines for access to such laboratory portions of the Premises and Tenant shall have the right to accompany Landlord during any such entry into the laboratory portions of the Premises, and to show the Premises to prospective tenants during the twelve (12) months preceding expiration of the term of this Lease as it may have been extended and at any reasonable time during the Lease Term to show the Premises to prospective purchasers and mortgagees.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.20	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Counterparts</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">This Lease may be executed in several counterparts, each of which shall be deemed an original, and such counterparts shall constitute but one and the same instrument.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.21	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Entire Agreement</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">This Lease constitutes the entire agreement between the parties hereto, Landlord&#x2019;s managing agent and their respective affiliates with respect to the subject matter hereof and thereof and supersedes all prior dealings between them with respect to such subject matter, and there are</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">81</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">no verbal or collateral understandings, agreements, representations or warranties not expressly set forth in this Lease.  No subsequent alteration, amendment, change or addition to this Lease shall be binding upon Landlord or Tenant, unless reduced to writing and signed by the party or parties to be charged therewith.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.22	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Limitations on Liability</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	Landlord Liability.  Tenant shall neither assert nor seek to enforce any claim for breach of this Lease against any of Landlord&#x2019;s assets other than Landlord&#x2019;s interest in the Building and Land and any sale, insurance or condemnation proceeds thereof (provided that Tenant&#x2019;s right to reach insurance and condemnation proceeds shall be subordinate to Landlord&#x2019;s right to use such proceeds for purposes of restoring the Building and the Project), and Tenant agrees to look solely to such interest for the satisfaction of any liability of Landlord under this Lease, it being specifically agreed that neither Landlord, nor any successor holder of Landlord&#x2019;s interest hereunder, nor any beneficiary of any Trust of which any person from time to time holding Landlord&#x2019;s interest is Trustee, nor any such Trustee, nor any member, manager, partner, director or stockholder nor Landlord&#x2019;s managing agent shall ever be personally liable for any such liability.  This paragraph shall not limit any right that Tenant might otherwise have to obtain injunctive relief against Landlord or Landlord&#x2019;s successors-in-interest, or to take any other action which shall not involve the personal liability of Landlord, or of any successor holder of Landlord&#x2019;s interest hereunder, or of any beneficiary of any trust of which any person from time to time holding Landlord&#x2019;s interest is Trustee, or of any such Trustee, or of any manager, member, partner, director or stockholder of Landlord or of Landlord&#x2019;s managing agent, to respond in monetary damages from Landlord&#x2019;s assets other than Landlord&#x2019;s interest in said Building or Land, as aforesaid, but in no event shall Tenant have the right to terminate or cancel this Lease (except as expressly set forth herein) or to withhold rent or to set-off any claim or damages against rent as a result of any default by Landlord or breach by Landlord of its covenants or any warranties or promises hereunder, except in the case of a wrongful eviction of Tenant from the Premises (constructive or actual) by Landlord continuing after notice to Landlord thereof and a reasonable opportunity for Landlord to cure the same.  In no event shall Landlord ever be liable for any indirect or consequential damages or loss of profits or the like.  In the event that Landlord shall be determined to have wrongfully withheld any consent or approval under this Lease, the sole recourse and remedy of Tenant in respect thereof shall be to specifically enforce Landlord&#x2019;s obligation to grant such consent or approval, and in no event shall Landlord be responsible for any damages of whatever nature in respect of its failure to give such consent or approval nor shall the same otherwise affect the obligations of Tenant under this Lease or act as any termination of this Lease.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	Tenant Liability.  Landlord shall neither assert nor seek to enforce any claim against Tenant or any of the Tenant Parties for breach of this Lease or otherwise, other than against the assets and property of Tenant, the Cash Security Deposit and/or the Letter of Credit, and Landlord agrees to look solely to such assets and property and the Cash Security Deposit and/or the Letter of Credit for the satisfaction of any liability of Tenant or any Tenant Parties under this Lease.  This Section 16.22 shall not limit any right that Landlord might otherwise have to obtain injunctive relief against Tenant.  Landlord and Tenant specifically agree that in no event shall any officer, director, trustee, employee or representative of Tenant or any of the other Tenant Parties ever be personally liable for any obligation under this Lease.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">82</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.23	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">No Partnership</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The relationship of the parties hereto is that of landlord and tenant and no partnership, joint venture or participation is hereby created.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.24	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Security Deposit</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Tenant shall deliver to Landlord either (at Tenant&#x2019;s election):  (i) cash in the Security Deposit Amount, as set forth in Section 1.2 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Cash Security Deposit</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), which shall be held by Landlord in accordance with Section 16.24(a) below, or (ii) an irrevocable, unconditional, and negotiable letter of credit (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Letter of Credit</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) in said Security Deposit Amount satisfying the requirements of this Section 16.24.  Landlord shall hold either the Cash Security Deposit or the Letter of Credit, as the case may be, as security for the performance by Tenant of all obligations on the part of Tenant to be performed under this Lease in accordance with this Section 16.24, throughout the Term of this Lease (including the Extended Term(s), if applicable), subject to reduction in accordance with the provisions of this Section 16.24.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Cash Security Deposit</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  If Tenant elects to deliver a Cash Security Deposit to Landlord:  (i) Tenant shall, at the time of execution and delivery of this Lease to Landlord, pay to Landlord fifty percent (50%) of the Security Deposit Amount, and (ii) Tenant shall pay the remaining fifty percent (50%) of the Security Deposit Amount (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Balance of the Cash Security Deposit</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) to Landlord on or before the date thirty (30) days after Landlord gives Landlord&#x2019;s Estimated Delivery Date Notice, as defined in Section 1D(1) of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, to Tenant.  Landlord shall hold the Cash Security Deposit, throughout the Term of this Lease (including any extension thereof), as security for the performance by Tenant of all obligations on the part of Tenant to be performed.  Landlord shall have the right from time to time without prejudice to any other remedy Landlord may have on account thereof, to apply such deposit, or any part thereof, to Landlord&#x2019;s damages arising from any default on the part of Tenant that remains uncured after the expiration of all applicable notice and cure periods. If Landlord so applies all or any portion of such deposit, Tenant shall within seven (7) days after notice from Landlord deliver cash to Landlord in an amount sufficient to restore such deposit to the full amount stated in Section 1.2 (as the same may have been reduced pursuant to Section 16.24).  Tenant not then being in default and having performed all of its obligations under this Lease, including the payment of all Annual Fixed Rent, Landlord shall return the deposit, or so much thereof as shall not have theretofore been applied in accordance with the terms of this Section 16.24, to Tenant on or before the latest to occur of:  (i) the end of the Term, (ii) the delivery by Tenant to Landlord of the Premises free and clear of all parties claiming under Tenant and in compliance with Section 16.4 of the Lease, and (iii) the satisfaction of all of Tenant&#x2019;s obligations under Section 16.4 of the Lease.  While Landlord holds such deposit, Landlord shall have no obligation to pay interest on the same and shall have the right to commingle the same with Landlord&#x2019;s other funds. If Landlord conveys Landlord&#x2019;s interest under this Lease, the deposit, or any part thereof not previously applied, shall be turned over by Landlord to Landlord&#x2019;s grantee for proper application of the deposit in accordance with the terms of this Section 16.24, and the return thereof in accordance herewith, and Landlord shall have no further liability therefor.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Neither the holder of a mortgage nor the landlord in a ground lease on property which includes the Premises shall ever be responsible to Tenant for the return or application of any such</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">83</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">deposit, whether or not it succeeds to the position of Landlord hereunder, unless such deposit shall have been received by such holder or ground lessor.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Letter of Credit</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  If Tenant elects to deliver a Letter of Credit to Landlord:  (i) Tenant shall, at the time of execution and delivery of this Lease to Landlord, deliver to Landlord a Letter of Credit satisfying the requirements of this Section 16.24 in the amount of fifty percent (50%) of the Security Deposit Amount (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Initial Letter of Credit</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), and (ii) Tenant shall, on or before the date thirty (30) days after Landlord gives Landlord&#x2019;s Estimated Delivery Date Notice, as defined in Section 1D(1) of </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 2.1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, to Tenant, deliver to either additional Letter of Credit satisfying the requirements of this Section 16.24 in the amount of fifty percent (50%) of the Security Deposit Amount, or an amendment to the Initial Letter of Credit, in form reasonably acceptable to Landlord, increasing the amount of the Initial Letter of Credit to the full Security Deposit Amount (in either case, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Balance of the Letter of Credit</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  Any Letter of Credit provided by Tenant to Landlord shall (i) be issued by and drawn on a bank reasonably approved by Landlord and at a minimum having a long term issuer credit rating from Standard and Poor&#x2019;s Professional Rating Service of A or a comparable rating from Moody&#x2019;s Professional Rating Service, (ii) be substantially in the form attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exhibit 16.24</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, (iii) permit one or more draws thereunder to be made accompanied only by certification by Landlord or Landlord&#x2019;s managing agent that pursuant to the terms of this Lease, Landlord is entitled to draw upon such Letter of Credit, (iv) permit transfers at any time without charge to Landlord, (v) permit presentment in Boston, Massachusetts and (vi) provide that any notices to Landlord be sent to the notice address provided for Landlord in this Lease.  If the credit rating for the issuer of such Letter of Credit falls below the standard set forth in (i) above or if the financial condition of such issuer changes in any other material adverse way or if any trustee, receiver or liquidator shall be appointed for the issuer, Landlord shall have the right to require that Tenant provide a substitute letter of credit that complies in all respects with the requirements of this Section, and Tenant&#x2019;s failure to provide the same within thirty (30) days following Landlord&#x2019;s written demand therefor shall entitle Landlord to immediately draw upon the Letter of Credit.  Any such Letter of Credit shall be for a term of two (2) years (or for one (1) year if the issuer thereof regularly and customarily only issues letters of credit for a maximum term of one (1) year) and shall in either case provide for automatic renewals through the date which is sixty (60) days subsequent to the scheduled expiration of this Lease (as the same may be extended).  Any failure or refusal of the issuer to honor the Letter of Credit shall be at Tenant&#x2019;s sole risk and shall not relieve Tenant of its obligations hereunder with regard to the security deposit.  Upon the occurrence of any Event of Default, Landlord shall have the right from time to time without prejudice to any other remedy Landlord may have on account thereof, to draw on all or any portion of such deposit held as a Letter of Credit and to apply the proceeds of such Letter of Credit or any cash held as such deposit, or any part thereof, to Landlord&#x2019;s damages arising from such Event of Default on the part of Tenant under the terms of this Lease.  If Landlord so applies all or any portion of such deposit, Tenant shall within seven (7) days after notice from Landlord deposit cash with Landlord in an amount sufficient to restore such deposit to the full amount stated in this Section 16.24.  While Landlord holds any cash deposit Landlord shall have no obligation to pay interest on the same and shall have the right to commingle the same with Landlord&#x2019;s other funds. Neither the holder of a mortgage nor Landlord in a ground lease on property which includes the Premises shall ever be responsible to Tenant for the return or application of any such deposit, whether or not it succeeds to the position of Landlord hereunder, unless such deposit shall have been received by such holder or ground Landlord.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">84</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Transfer of Letter of Credit</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  In the event that Landlord transfers its interest in the Premises, Tenant shall upon notice from and at no cost to Landlord, deliver to Landlord an amendment to the Letter of Credit or a replacement Letter of Credit naming Landlord&#x2019;s successor as the beneficiary thereof.  If Tenant fails to deliver such amendment or replacement within ten (10) business days after written notice from Landlord, Landlord shall have the right to draw down the entire amount of the Letter of Credit and hold the proceeds thereof in accordance with this Section 26.14.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Cash Proceeds of Letter of Credit</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Landlord shall hold the Cash Security Deposit, the Letter of Credit, the balance of proceeds remaining after a draw on Cash Security Deposit and/or the Letter of Credit, as the case may be (each sometimes hereinafter referred to collectively as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Security Deposit</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) as security for Tenant&#x2019;s performance of all its Lease obligations. After an Event of Default, Landlord may apply the Security Deposit, or any part thereof, to Landlord&#x2019;s damages without prejudice to any other Landlord remedy.  Landlord has no obligation to pay interest on the Security Deposit and may co-mingle the Security Deposit with Landlord&#x2019;s funds. If Landlord conveys its interest under this Lease, the Security Deposit, or any part not applied previously, may be turned over to the grantee in which case Tenant shall look solely to the grantee for the proper application and return of the Security Deposit.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(e)	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Return of Security Deposit or Letter of Credit</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Should Tenant comply with all of such terms, covenants and conditions and promptly pay all sums payable by Tenant to Landlord hereunder, the Security Deposit shall (less any portion thereof which may have been utilized by Landlord to cure any default or applied to any actual damage suffered by Landlord) be returned to Tenant within forty-five (45) days after the latest to occur of:  (i) the end of the Term, (ii) the delivery by Tenant to Landlord of the Premises free and clear of all parties claiming under Tenant and in compliance with Section 16.4 of the Lease, and (iii) the satisfaction of all of Tenant&#x2019;s obligations under Section 16.4.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(f)	Reduction of the Cash Security Deposit and/or Letter of Credit.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)	On the conditions (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Reduction Conditions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) that as of the applicable Effective Reduction Date, as hereinafter defined:  (x) Tenant is then in full compliance with its obligations under the Lease, and (y) there has been no Event of Default during the twelve- (12)-month period immediately preceding such Effective Reduction Date, as it may be delayed, as hereinafter set forth (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Prior Default Condition</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), then the amount of the Cash Security Deposit/Letter of Credit may be reduced in accordance with the below-listed schedule:</font></p>
  <table style="margin-left:0.9965277777777778in;border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:40.938%;"></td>
    <td style="width:59.062%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Effective Reduction Date</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">New Reduced Security Deposit Amount</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">First (1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-5.628pt;white-space:pre-wrap;font-weight:normal;font-size:8.040000000000001pt;font-family:Times New Roman;position:relative;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) anniversary of the Rent Commencement Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Third (3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-5.628pt;white-space:pre-wrap;font-weight:normal;font-size:8.040000000000001pt;font-family:Times New Roman;position:relative;">rd</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) anniversary of the Rent Commencement Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Fifth (5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-5.628pt;white-space:pre-wrap;font-weight:normal;font-size:8.040000000000001pt;font-family:Times New Roman;position:relative;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) anniversary of the Rent Commencement Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:center;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">85</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(ii)	The reduction in the Security Deposit shall be accomplished as follows:  (a) for a Cash Security Deposit, Tenant shall request such reduction in a written notice to Landlord (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Reduction Notice</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), and if the Reduction Conditions have been met, Landlord shall, within ten (10) business days after Landlord&#x2019;s receipt of such Reduction Notice, refund to Tenant a portion of the Cash Security Deposit which Landlord is then holding so that Landlord will be holding the reduced amount, as set forth above, and (b) for a Security Deposit in the form of a Letter of Credit, Tenant shall give a Reduction Notice to Landlord, and if the Reduction Conditions have been met, Landlord shall, within five (5) business days of its receipt of such Reduction Notice, so notify Tenant, whereupon Tenant shall deliver to Landlord either:  (i) a substitute letter of credit (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Substitute Letter of Credit</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) in the applicable reduced amount, in form satisfying the requirements of this Section 16.24, or (ii) an amendment to the existing Letter of Credit, in form and substance reasonably acceptable to Landlord, reducing the amount of the existing Letter of Credit to the applicable reduced amount.  If Tenant delivers to Landlord a Substitute Letter of Credit satisfying the foregoing requirements, as aforesaid, then Landlord shall exchange the existing Letter of Credit which Landlord is then holding for such Substitute Letter of Credit within five (5) business days after Landlord receives such Substitute Letter of Credit to Landlord.  If Landlord declines to reduce the Security Deposit based upon the fact that any of the Reduction Conditions have not been satisfied, but Tenant subsequently satisfies the Reduction Conditions, then Tenant may submit a new Reduction Notice to Landlord for the reduction in the Security Deposit in accordance with the provisions of this Section 16.24.  In such event, the Prior Default Condition shall be determined based on the twelve-(12)-month period immediately preceding the delayed Effective Reduction Date.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iii)	In no event shall the amount of the Cash Security Deposit or Letter of Credit held by Landlord ever be less than [***]</font><font style="background-color:rgba(0,0,0,0);color:rgba(133,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.25	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Governing Law</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">This Lease shall be governed exclusively by the provisions hereof and by the law of The Commonwealth of Massachusetts, as the same may from time to time exist.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.26	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Waiver of Trial by Jury</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">To induce Landlord to enter into this Lease, Tenant hereby waives any right to trial by jury in any action, proceeding or counterclaim brought by either Landlord or Tenant on any matters whatsoever arising out of or any way connected with this Lease, the relationship of Landlord and Tenant, Tenant&#x2019;s use or occupancy of the premises and/or any claim of injury or damage, including but not limited to, any summary process eviction action.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.27	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Signage</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Landlord shall provide building standard signage in the standard graphics for the Building listing Tenant on all internal non-electronic directory(ies) for the Premises. The initial listing of Tenant&#x2019;s name shall be at Landlord&#x2019;s expense.  Any changes or additions to such directory(ies) shall be at Tenant&#x2019;s cost and expense.  Tenant may install signage identifying Tenant, which may</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">86</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">include Tenant&#x2019;s corporate logo and colors, on the entrance door to the Premises and/or within the Premises, which signage shall be subject to Landlord&#x2019;s approval.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.28	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Landlord&#x2019;s Future Redevelopment/Changes</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Tenant acknowledges that Landlord intends to undertake a redevelopment of the Project that may include, among other changes, the replacement of the existing garage with a subsurface parking facility and the replacement of some of the existing retail and/or common areas of the Project with new construction (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Redevelopment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  Notwithstanding any provision of the Lease to the contrary, Landlord and Tenant agree as follows:</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	In connection with the Redevelopment:</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(1)	Landlord shall provide Tenant with reasonable advance notice prior to the commencement of the Redevelopment work.</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(2)	In carrying out any Redevelopment work, Landlord shall use commercially reasonable efforts to minimize any adverse effect upon, or interference with, the use and enjoyment by Tenant of the Premises.</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(3)	Landlord shall provide Tenant with reasonable advance notice of any work in connection with the Redevelopment planned in the immediate vicinity of the Premises or that will affect pedestrian access to the Premises or vehicular access to and from the Parking Facilities.</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(4)	At all times during the Redevelopment, Tenant shall have a reasonable means of access from a public street to the Premises and between the parking facilities in the Project to the Premises.</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(5)	At all times during the Redevelopment, Landlord shall provide parking within the Project, or in an offsite facility reasonably proximate to the Project, for not less than Tenant&#x2019;s parking allocation.</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(6)	In connection with any installation, replacement or relocation of Project services, pipes, ducts, conduits, wires and/or appurtenant fixtures, Landlord shall not unreasonably interfere with Tenant&#x2019;s use of the Premises, and any such installations, replacements and relocations in or about the Premises shall be located so far as practicable above ceiling surfaces, below floor surfaces or within perimeter walls of the Premises.</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(7)	Throughout the Redevelopment, Landlord shall make available to Tenant a construction representative who is available on a 24-7 basis.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	Tenant acknowledges that the Project, and its mix of uses, may be altered, expanded, with facilities reduced or otherwise changed from time to time, and that Landlord reserves the right to modify the Project, to change the uses thereof, and to designate areas of the Project as Common Areas or common facilities, or as areas/facilities for the exclusive use of one or more occupants or one or more uses, all as more particularly set forth below.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">87</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	Landlord reserves for its benefit all rights of ownership and use in all respects outside the Premises, including without limitation, all structures and improvements and plazas and Common Areas and facilities in the Project.  Without limitation of the foregoing, it is understood that in its sole discretion Landlord shall have the right to change and rearrange the Common Areas and facilities, to add to, change, relocate and eliminate such areas and facilities, to erect new buildings and structures thereon, to permit the use of or lease all or part thereof for exhibitions and displays, to sell, lease or dedicate all or part thereof to public use, and to configure the public and private roadways in the vicinity of the Project, subject to the issuance of necessary governmental approvals, which reconfigurations shall not be deemed to be eminent domain takings subject to the provisions of Article XIV of the Lease.  Tenant&#x2019;s rights under the Lease to use the Common Areas and facilities of the Project, and, if applicable, other areas outside the Premises, shall be subject to Landlord&#x2019;s right to change or alter the same as set forth herein.  Notwithstanding any provision hereof to the contrary, Landlord&#x2019;s rights to change and rearrange the Common Areas and facilities of the Project pursuant to this Section 16.28(c) are subject to the following:</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(1)	Landlord shall not have the right to reduce or eliminate the showers or bicycle storage area or, except as expressly set forth in Section 2.2, the Roof Decks, to be provided by Landlord pursuant to Section 2.2, nor to eliminate the freight elevators or loading docks to be used by Tenant as set forth herein, but Landlord shall have the right to relocate the showers, bicycle storage area, freight elevators or loading docks to be used by Tenant within the Building;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(2)	Landlord shall not have the right to reduce or suspend Tenant&#x2019;s Parking Privileges except as expressly set forth in Article X;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(3)	no such change or rearrangement shall materially adversely affect any of the utility services required to be provided by Landlord under the Lease or materially adversely affect any of the other services required to be provided by Landlord under this Lease; and</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(4)	no such change shall materially adversely interfere with Tenant&#x2019;s access to and use of the Premises for the Permitted Use.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	Landlord reserves the right to add to, change or eliminate any services offered to the occupants of the Project from time to time; provided, however, that Landlord shall not change or eliminate any such services required to be provided by Landlord to Tenant pursuant to the Lease.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(e)	Landlord shall not be liable to Tenant for any compensation or reduction of rent by reason of inconvenience or annoyance or for loss of business arising from the exercise of Landlord&#x2019;s rights hereunder.  If Landlord is prevented or delayed from making any repairs, alterations or improvements, or furnishing any services or performing any other covenant or duty to be performed on Landlord&#x2019;s part under the Lease, by reason of any cause reasonably beyond Landlord&#x2019;s control in connection with the exercise of its rights hereunder, Landlord shall not be liable to Tenant therefor, nor, subject to Tenant&#x2019;s rights pursuant to Section 7.11, shall Tenant be entitled to any abatement or reduction of rent by reason thereof.  Tenant shall not have the right to terminate the Lease due to the exercise of Landlord&#x2019;s rights hereunder, nor shall the same give rise</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">88</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">to a claim in Tenant&#x2019;s favor that such failure constitutes actual or constructive, total or partial, eviction from the Premises. Without limitation of the foregoing, in no event shall Tenant seek injunctive or any similar relief, to stop, delay or modify the Redevelopment.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.29	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Rooftop Equipment</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Subject to the terms of this Section 16.29, Tenant shall have the right to install, operate, maintain, repair and replace on the roof of the Office Area a satellite dish or antenna, and air conditioning equipment required for its operations in the Premises, together with access to use of available Office Area shafts, conduits and risers to connect to such equipment (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Rooftop Equipment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  There shall be no additional charges or fees payable by Tenant in connection therewith.  Tenant shall not install any Rooftop Equipment until Landlord shall have approved the size, location, weight and manner of attachment thereof, such approval not to be unreasonably withheld, conditioned or delayed.  Tenant&#x2019;s rights under this Section 16.29 shall be subject to all of the terms and conditions of this Lease, as well as the following additional conditions:</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(1)	Tenant shall be solely and exclusively responsible for all costs, expenses and charges, of every kind, of installing, operating, maintaining, repairing, replacing, and removing the Rooftop Equipment and, except to the extent resulting from the negligence or willful misconduct of Landlord, Landlord shall have no liability or obligation in connection therewith.  Tenant shall enter into a service contract with a contractor reasonably approved by Landlord for the installation, operation, maintenance, repair, replacement and removal of the Rooftop Equipment, which contract shall be subject to Landlord&#x2019;s reasonable approval.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(2)	If, in the reasonable judgment of Landlord, any electrical, electromagnetic, radio frequency or other material interference shall result from the operation of any of the Rooftop Equipment, Tenant shall upon Landlord&#x2019;s request shut down Tenant&#x2019;s equipment upon twenty-four (24) hours prior notice to Tenant, which notice may be electronic if given to Dr.  Dimitris Papoutsakis at dpapoutsakis@tangotx.com or such other person as designed by Tenant in writing from time to time; provided, however, if an emergency situation exists, which Landlord reasonably determines in its good faith discretion to be attributable to the Rooftop Equipment, Landlord shall immediately notify Tenant verbally, who shall act immediately to remedy the emergency situation.  Should Tenant fail to so remedy said emergency situation, Landlord may then act to shut down Tenant&#x2019;s equipment.  Tenant agrees to cease operations of the Rooftop Equipment (except for intermittent testing on a schedule approved by Landlord) until the interference has been corrected to the reasonable satisfaction of Landlord.  If such interference is caused by telecommunications equipment and has not been corrected to the reasonable satisfaction of Landlord within thirty (30) days, Landlord may require that Tenant immediately remove from the Roof the specific item of telecommunications equipment causing such interference.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(3)	Tenant shall, at its sole cost and expense, and at its sole risk, install, operate and maintain the Rooftop Equipment in a good and workmanlike manner, and in</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">89</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">compliance with all electric, communication, and safety codes, ordinances, standards, regulations and requirements, now in effect or hereafter promulgated, of the Federal Government, including, without limitation, the Federal Communications Commission (the &#x201c;FCC&#x201d;), the Federal Aviation Administration (&#x201c;FAA&#x201d;) or any successor agency of either the FCC or FAA having jurisdiction over radio or telecommunications, and of the state, city and county in which the Office Area is located.  Tenant shall reasonably cooperate generally with Landlord and other carriers to permit the Office Area&#x2019;s rooftop to be and remain in compliance with all FCC and OSHA rules and regulations relating to radio frequency emission levels and maximum permissible exposure.  Except to the extent resulting from Landlord&#x2019;s negligence or willful misconduct, neither Landlord nor its agents shall be liable to Tenant for any stoppages or shortages of electrical power furnished to the Rooftop Equipment or the roof area because of any act, omission or requirement of the public utility serving the Office Area, or the act or omission of any other tenant, invitee or licensee or their respective agents, employees or contractors, or for any other cause beyond the reasonable control of Landlord, and Tenant shall not be entitled to any rental abatement for any such stoppage or shortage of electrical power.  Neither Landlord nor its agents shall have any responsibility or liability for the conduct or safety of any of Tenant&#x2019;s representatives, repair, maintenance and engineering personnel while in or on any part of the Office Area or the roof area.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(4)	Tenant shall be responsible for connecting the Rooftop Equipment to the Office Area&#x2019;s utility systems and for the costs and expenses of all electricity consumed in connection with the Rooftop Equipment.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(5)	Tenant shall not make any changes, alterations, or other improvements on or to the roof of the Office Area without Landlord&#x2019;s prior written consent in each instance, which consent, Landlord may withhold at its discretion; provided, however, in connection with the installation, operation, maintenance, repair or replacement of the Rooftop Equipment, Landlord&#x2019;s consent shall not be unreasonably withheld, conditioned or delayed.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(6)	Tenant shall have no right of access to the roof of the Office Area unless Tenant has given Landlord reasonable advance notice and unless Tenant&#x2019;s representatives are accompanied by a representative of Landlord.  Landlord will make a representative available to Tenant (i) during Normal Business Hours upon reasonable advance notice and (ii) during emergencies, as soon as practicable (taking into account the circumstances) after receipt of a request from Tenant.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(7)	At the expiration or prior termination of this Lease, Tenant shall remove the Rooftop Equipment from the roof of the Office Area, and Tenant shall be responsible for the cost of repairing any damage to the roof of the Office Area caused by the installation or removal of the Rooftop Equipment or the exercise of Tenant&#x2019;s rights under this Section 16.29.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">90</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(8)	Tenant shall have no right to transfer or assign its rights under this Section 16.29, other than to a permitted assignee or sublessee of all or substantially all of the Premises.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(9)	To the maximum extent permitted by law, the Rooftop Equipment and all other related installations shall be at the sole risk of Tenant, and except to the extent caused by negligent acts or willful misconduct by Landlord or its agents, employees or contractors, Landlord shall have no liability to Tenant in the event that the Rooftop Equipment or any related installations are damaged for any reason.</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(10)	Tenant shall comply with all Legal Requirement and Insurance Requirements in connection with Tenant&#x2019;s exercise of its rights pursuant to this Section 16.29.</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Landlord shall have the right not more than two (2) times during the Original Term and one (1) time during each Extension Term, if any, upon thirty (30) days&#x2019; notice to Tenant, to require Tenant to relocate the Rooftop Equipment to another area on the roof of the Office Area equally suitable for Tenant&#x2019;s use.  In such event, Tenant shall on or before the thirtieth (30</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) day after Landlord gives such notice, relocate the Rooftop Equipment and Landlord shall reimburse Tenant for all reasonable costs and expenses incurred by Tenant in connection with said relocation and any resulting relocation of utility lines.</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">In addition to the indemnification provisions set forth in this Lease (which indemnification provisions shall be applicable to the use by Tenant of the Rooftop Equipment), except to the extent resulting from the negligence or willful misconduct of Landlord or its agents, employees or contractors, Tenant shall, to the maximum extent permitted by law, indemnify, defend, and hold Landlord harmless from any and all claims, losses, demands, actions or causes of actions suffered by any person, firm, corporation, or other entity to the extent that the same arises out of or results from Tenant&#x2019;s use of the Rooftop Equipment and the rights granted to Tenant and the performance of Tenant&#x2019;s obligations under this Section 16.29.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.30	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Force Majeure</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Other than for Tenant&#x2019;s obligations under this Lease that can be performed by the payment of money (e.g., payment of Rent and maintenance of insurance), whenever a period of time is herein prescribed for action to be taken by either party hereto, such party shall not be liable or responsible for, and there shall be excluded from the computation of any such period of time, any delays due to strikes, riots, acts of God, shortages of labor or materials, war, acts of terrorism, governmental laws, regulations, or restrictions, or any other causes which are beyond the control of such party (collectively &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Force Majeure</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  In no event shall financial inability of a party be deemed to be Force Majeure.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.31	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Landlord&#x2019;s REIT Requirements</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Tenant and Landlord intend that all amounts payable by Tenant to Landlord shall qualify as &#x201c;rents from real property,&#x201d; and will otherwise not constitute &#x201c;unrelated business taxable income&#x201d; or &#x201c;impermissible tenant services income,&#x201d; all within the meaning of Sections 512(b)(3)</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">91</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">and 856(d) of the Internal Revenue Code of 1986, as amended (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Code</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) and the U.S. Department of Treasury Regulations promulgated thereunder (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Regulations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  In the event that Landlord determines that there is any risk that any amount payable under this Lease may not qualify as &#x201c;rents from real property&#x201d; or will otherwise constitute unrelated business taxable income or impermissible tenant services income within the meaning of Sections 512(b)(3) or 856(d) of the Code and the Regulations promulgated thereunder, Tenant agrees (a) to cooperate with Landlord by entering into such amendment or amendments as Landlord deems necessary to qualify all amounts payable under the Lease as &#x201c;rents from real property&#x201d; and (b) to permit (and, upon request, to acknowledge in writing) an assignment of the obligation to provide certain services under this Lease, and, upon request, to enter into direct agreements with the parties furnishing such services (which shall include but not be limited to a taxable REIT subsidiary of Landlord).  Notwithstanding the foregoing, Tenant shall not be required to take any action pursuant to the preceding sentence (including acknowledging in writing an assignment of services pursuant thereto) if such action would result in (A) Tenant&#x2019;s incurring more than de minimus additional liability under this Lease or (B) more than a de minimus negative change in the quality or level of Project operations or services rendered to Tenant under this Lease.  For the avoidance of doubt, (i) if Tenant does not acknowledge in writing an assignment as described in clause (b) above (it being agreed that Tenant shall not unreasonably withhold, condition or delay such acknowledgment so long as the criteria in clauses (A) and (B) are satisfied), then Landlord shall not be released from liability under this Lease with respect to the services so assigned; and (ii) nothing in this Section shall limit or otherwise affect Landlord&#x2019;s ability to assign its entire interest in this Lease to any party as part of a conveyance of Landlord&#x2019;s ownership interest in the Project.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">92</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">EXECUTED as a sealed instrument in two or more counterparts by persons or officers hereunto duly authorized on the Date set forth in Section 1.2 above.</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">LANDLORD</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">:</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ARE-MA REGION NO. 87 TENANT, LLC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">,<br>a Delaware limited liability company</font></p>
  <p style="margin-left:20.0%;text-indent:-9.091%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By:	ARE-MA REGION NO. 87, LLC,<br>a Delaware limited liability company,<br>managing member</font></p>
  <p style="margin-left:26.667%;text-indent:-10.0%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By:	ARE-MA REGION NO. 87 MM, LLC,<br>a Delaware limited liability company,<br>managing member</font></p>
  <p style="margin-left:33.333%;text-indent:-11.111%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By	ALEXANDRIA REAL ESTATE EQUITIES, L.P.,<br>a Delaware limited partnership,<br>managing member</font></p>
  <p style="margin-left:40.0%;text-indent:-12.5%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:30.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By:	ARE-QRS CORP.,<br>a Maryland corporation,<br>general partner</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:24.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By:  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;"> /s/ Allison Grochola	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"><br>Its:   </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">SVP &#x2013; Real Estate Legal Affairs	</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">TENANT</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">:</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:30.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">TANGO THERAPEUTICS, INC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.,<br>a Delaware corporation</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By:   </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">/s/ Barbara Weber	</font></p>
  <p style="margin-left:26.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Barbara Weber<br>Chief Executive Officer</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[x] I hereby certify that the signature, name, and title above are my signature, name and title</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">93</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Arial;">Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">EXHIBITS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>tngx-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:24.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-</font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">260258</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) of Tango Therapeutics, Inc. of our report dated March 28, 2022 relating to the financial statements, which appears in this Form 10-K.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ PricewaterhouseCoopers LLP<br>Boston, Massachusetts<br>March 28, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>tngx-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13a-14(a) / RULE 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">I, Barbara Weber, M.D., certify that:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">I have reviewed this Annual Report on Form 10-K of Tango Therapeutics, Inc.;</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:5.731%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="margin-left:5.731%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:5.731%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:5.731%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="margin-left:5.731%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="margin-left:5.731%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Dated:  March 28, 2022			 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">/s/ Barbara Weber, M.D.</font></p>
  <p style="margin-left:13.6%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">					Barbara Weber, M.D.</font></p>
  <p style="margin-left:13.6%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">					Chief Executive Officer</font></p>
  <p style="margin-left:13.6%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">					(Principal Executive Officer)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>tngx-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13a-14(a) / RULE 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">I, Daniella Beckman, certify that:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">I have reviewed this Annual Report on Form 10-K of Tango Therapeutics, Inc.;</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:5.731%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="margin-left:5.731%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:5.731%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:5.731%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="margin-left:5.731%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="margin-left:5.731%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.5356267702001714%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Dated:  March 28, 2022			 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">/s/ Daniella Beckman</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:13.6%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">					Daniella Beckman</font></p>
  <p style="margin-left:13.6%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">					Chief Financial Officer</font></p>
  <p style="margin-left:13.6%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">					(Principal Financial Officer)</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>tngx-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.587%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">In connection with the Annual Report on Form 10-K of Tango Therapeutics, Inc. (the &#x201c;Company&#x201d;) for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission (the &#x201c;Report&#x201d;), I, Barbara Weber, M.D., Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Dated:   March 28, 2022			</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">/s/ Barbara Weber, M.D.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">                                                             Barbara Weber, M.D.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">					                Chief Executive Officer</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">					                (Principal Executive Officer)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>tngx-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Exhibit 32.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.587%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">In connection with the Annual Report on Form 10-K of Tango Therapeutics, Inc. (the &#x201c;Company&#x201d;) for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission (the &#x201c;Report&#x201d;), I, Daniella Beckman, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that:</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Dated:   March 28, 2022			</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">/s/ Daniella Beckman</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">                                                             Daniella Beckman</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">				                         Chief Financial Officer</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">					                (Principal Financial Officer)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img158215518_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img158215518_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &_!2L# 2(  A$! Q$!_\0
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M33%:8XPJS*H)X_X"/^^S]:GM/A%+-=VQ\0>*M0UBQMR&2SE#*N1TZNV!CC
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MYN:_3] .&\&Z]<^&/&VI7ESD:%?ZI-93OGB*;<61CZ=2/IN]*I#_ ))9>?\
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MK?\ 8NE?] RS_P"_"_X4?V+I7_0,L_\ OPO^%/W0*G_"7>&O^AATG_P-C_\
MBJ/^$N\-?]##I/\ X&Q__%5;_L72O^@99_\ ?A?\*/[%TK_H&6?_ 'X7_"CW
M0*G_  EWAK_H8=)_\#8__BJ/^$N\-?\ 0PZ3_P"!L?\ \55O^Q=*_P"@99_]
M^%_PH_L72O\ H&6?_?A?\*/= J?\)=X:_P"AATG_ ,#8_P#XJC_A+O#7_0PZ
M3_X&Q_\ Q56_[%TK_H&6?_?A?\*/[%TK_H&6?_?A?\*/= J?\)=X:_Z&'2?_
M  -C_P#BJ/\ A+O#7_0PZ3_X&Q__ !56_P"Q=*_Z!EG_ -^%_P */[%TK_H&
M6?\ WX7_  H]T"I_PEWAK_H8=)_\#8__ (JC_A+O#7_0PZ3_ .!L?_Q56_[%
MTK_H&6?_ 'X7_"C^Q=*_Z!EG_P!^%_PH]T"I_P )=X:_Z&'2?_ V/_XJC_A+
MO#7_ $,.D_\ @;'_ /%5;_L72O\ H&6?_?A?\*/[%TK_ *!EG_WX7_"CW0*G
M_"7>&O\ H8=)_P# V/\ ^*H_X2[PU_T,.D_^!L?_ ,55O^Q=*_Z!EG_WX7_"
MC^Q=*_Z!EG_WX7_"CW0*G_"7>&O^AATG_P #8_\ XJC_ (2[PU_T,.D_^!L?
M_P 55O\ L72O^@99_P#?A?\ "C^Q=*_Z!EG_ -^%_P */= J?\)=X:_Z&'2?
M_ V/_P"*H_X2[PU_T,.D_P#@;'_\55O^Q=*_Z!EG_P!^%_PH_L72O^@99_\
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M_0,L_P#OPO\ A1_8NE?] RS_ ._"_P"%'N@5/^$N\-?]##I/_@;'_P#%4?\
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MO^$M\-_]##I/_@;'_C2_\);X;_Z&'2?_  -C_P :L_V-I7_0-L_^_"_X4O\
M8NE?] RS_P"_"_X4>Z!6_P"$M\-?]##I/_@;'_\ %4?\)=X:_P"AATG_ ,#8
M_P#XJK7]BZ5_T#+/_OPO^%+_ &+I7_0,L_\ OPO^%'N@5?\ A+O#7_0PZ3_X
M&Q__ !5'_"7>&O\ H8=)_P# V/\ ^*JW_8NE?] RS_[\+_A1_8NE?] RS_[\
M+_A1[H%3_A+O#7_0PZ3_ .!L?_Q5'_"7>&O^AATG_P #8_\ XJK?]BZ5_P!
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M#)_A0- T;_H$V'_@,G^% %'_ (37PI_T,^B_^!\7_P 51_PFOA3_ *&?1?\
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M%_\ %4?\)MX3_P"AGT7_ ,#XO_BJO_V!HW_0(L/_  &3_"C^P-&_Z!%A_P"
MR?X4 4/^$V\)_P#0SZ+_ .!\7_Q5+_PFWA/_ *&?1?\ P/B_^*J]_8&C?] B
MP_\  9/\*/[ T;_H$6'_ (#)_A0!1_X3;PG_ -#/HO\ X'Q?_%4?\)MX3_Z&
M?1?_  /B_P#BJO?V!HW_ $"+#_P&3_"C^P-&_P"@18?^ R?X4 4?^$W\)_\
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M (#)_A1_8&C?] BP_P# 9/\ "@"E_P )OX3_ .AHT7_P81?_ !5'_";^$_\
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ML?\ C2_\);X:_P"AATG_ ,#8_P#XJK/]BZ5_T#+/_OPO^%+_ &+I7_0,L_\
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M>&O^AATG_P #8_\ XJC_ (2[PU_T,.D_^!L?_P 55O\ L72O^@99_P#?A?\
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M7^(8I)_#6JQ1(TDCV<RHB#)8E"  .YKS;3['6++X"OIL>EWO]I3EX!;&!A(
M\Q!)7&0-I)S1&TJ?+YH"3P[X(N/$W@31?MFJR06ES<27]_:QH<7F]PP#,&&!
MA1V/)SV%-\ O:V7Q/UW2?#DLC>'8H S1^87C6<; 2I)SV89[X[@"KGQ'FU_2
MO"NG>'?#6G7TRO (9YK2W:39$JA0N5'!/\A[U;^&S:?I5JNBV7AWQ!9R%#+/
M?:C8^2LSC'4[CCKPO8>^2;;;@V^O0#T*BBBN484444 %-?[AIU-?[AH B%%
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MJ?\ ?G_Z]+Y%[_S^I_WY_P#KT 7*452\B]_Y_4_[\_\ UZ7R+[_G]3_OQ_\
M7H N4M4_(OO^?U/^_'_UZ/(OO^?U/^_'_P!>@"Y15/R+[_G]3_OQ_P#7H\B^
M_P"?U/\ OQ_]>@"Y15/R+[_G]3_OQ_\ 7H\B^_Y_4_[\?_7H N453\B^_P"?
MU/\ OQ_]>CR+[_G]3_OQ_P#7H N453\B^_Y_4_[\?_7H\B^_Y_4_[\?_ %Z
M+3_<-15"\%[M.;U/^_'_ ->HO)O/^?Q/^_/_ ->@"Y2BJ?DWO_/XG_?G_P"O
M2^3>_P#/XG_?G_Z] %P4M4_(O?\ G\3_ +\__7I?(O?^?U/^_/\ ]>@"X*45
M2\B]_P"?U/\ OS_]>E\B^_Y_4_[\?_7H NBBJ?D7W_/ZG_?C_P"O1Y%]_P _
MJ?\ ?C_Z] %RBJ?D7W_/ZG_?C_Z]'D7W_/ZG_?C_ .O0!<HJGY%]_P _J?\
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M?^?Q/^_/_P!>CR;W_G\3_OS_ /7H N"BJGDWO_/XG_?G_P"O1Y%[_P _B?\
M?G_Z] %NEJGY%[_S^)_WY_\ KTOD7O\ S^)_WY_^O0!;HJIY%[_S^I_WY_\
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M*44 **6D%+0 HI12"E% "BB@44 %%%% !1110 4444 12?>'TIM.D^\/I3:
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M(_ YKO:*/:/KN!X]ITEWK/AC7[O4(V670]"GTGY^\X5O-;_OE8_S->C>#O\
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MF[F_N'\Q1N;^X?S% #J*;N;^X?S%&YO[A_,4 .HINYO[A_,4;F_N'\Q0 /\
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M%=_ZH?[U5QTJ:Y),8RI'S5".E "K_K4_WA5ZJ*_ZU/\ >%7J "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J _>/UJ>H#]X_6@ I
M:2EH 44"@5S/B'7]2MM9L=#T2VM9=1NXWF\R[<B**-<#)"\L<GH*:3;L@.GI
M:Y?2M3\3PZY%INO:=:213QL\=]IPD,2%<?+(&SM)SP<\_P L?6M8\>:-+8*Y
M\-NM]>I9Q;8I\JS!B"WS=/E[52IMNUP/0:45Q>HZUXHT#2(;C5!H\L\U_!;I
M]E27:(W;#$[FSN].U7->\27D.JP:#X?@ANM8E DE,V3#:Q9Y>3!!Y[#.3^63
MD8'44M<]XE\40>%],C>X!N=0F1A;VT$9S.ZC+$#G:HSDDG@>M-T[Q3 / UEX
MCUF2*W66W267RU.-S=E').3P!S2Y':X'1T5S/@KQ-<^*;+4KJXL_LGV>_>VC
MA92'"!$(WY/WOF.:Z*XN(;2WDN+F:.&&-=SR2,%51ZDG@"DXM.S DHK/BUW2
M)[IK:+5;&2X5=[1)<(7"XSG&<XQS4EGJVFZC'+)8ZA:721'$C03*X3ZD'BBS
M N455_M.P_L[^T?MUM]AV[_M/FKY>WUW9QBL*Z\96=OXWLO#_P!JL@LT!=W:
M<;A(2NR,#/5@V0.IXQ346]@.GHHHJ0&O]PU%4K_<-14 +2BDI10 HI:04M "
MBE%(*44 ***!10 4444 %%%% !1110!%)]X?2FTZ3[P^E-H 6EI*6@!:6DI:
M %I:2EH 6BBB@ HHHH **** "BBB@"!OO'ZTE*WWC]:2@!:*** "EI*6@ HH
MHH 6BBB@ I:2EH **** %HHHH *6DI: "BBB@!:*** "EI*6@ HHHH ****
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MG2FL)KR2Z".5A=I&.(A]T;2<*<==O!KH*B22>@!1112 *@/WC]:GJ _>/UH
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M%%=AU!1110 4444 %%%% !1110 4444 %36MU/974=S:RO%/$VY'0X*FH:*
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M--:VDLZ*X)4LJ%AG&.,BN/UWQYJ6C^'/"^JQV,-PVI1I-=Q*K9"^4)'\OGC
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MZB@"*\M(-0L;BRND\RWN(VBE3)&Y6&",CD<'M5,>']+":6HM>-* %F/,;]T
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MGH]MI%SIZFPM6#PP12/$$8 @'Y"#W/YYJKIW@#PUI.H0WUE821W,)RCF[F<
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M 'U_.E\V/^^OYT /I:9YL?\ ?7\Z7S8_[Z_G0 ^EIGFQ_P!]?SI?-C_OK^=
M#Z*;YL?]]?SH\V/^^OYT .HIOFQ_WU_.CS8_[Z_G0 ZBF^;'_?7\Z/-C_OK^
M= #J*;YL?]]?SH\V/^^OYT 1-]X_6DI&DCW'YUZ^M)YD?]]?SH ?13?,C_OK
M^='F1_WU_.@!U+3/,C_OK^=+YL?]]?SH =13?-C_ +Z_G1YL?]]?SH ?13?-
MC_OK^='FQ_WU_.@!U+3/-C_OK^=+YL?]]?SH =13?-C_ +Z_G1YL?]]?SH ?
M13?-C_OK^='FQ_WU_.@!U+3/-C_OK^=+YL?]]?SH =13?-C_ +Z_G1YL?]]?
MSH ?13/-C_OK^=+YL?\ ?7\Z '4M,\V/^^OYT>;'_?7\Z 'T4WS8_P"^OYT>
M;'_?7\Z '44WS8_[Z_G1YL?]]?SH =13?-C_ +Z_G1YL?]]?SH =13?-C_OK
M^='FQ_WU_.@!U%-\V/\ OK^='FQ_WU_.@!U%-\V/^^OYT>;'_?7\Z '44WS8
M_P"^OYT>;'_?7\Z '44WS8_[Z_G1YL?]]?SH =13?-C_ +Z_G1YL?]]?SH =
M13?-C_OK^='FQ_WU_.@!U%-\V/\ OK^='FQ_WU_.@!U12?>_"I001D'(J*3[
MP^E #*6DI: "@5D>(_$-KX9TL7]W#<31F58@ENH9RS' P"1_.L<_$.RMG0ZG
MHVN:7;NP3[3>V@6)2>F6#''XU2A)JZ0'844@(8 @@@\@BEJ0%%% HH *6LS4
M];MM)NM.MYTE9[^X^SQ&, @-@G+9(XX[9K3IV ****0"T444 %+24M !115'
M1=7M=>TF#4[(N;:?<8RZ[20&(SC\*+=0+]%%%  *6@44 %%%8Y\1VQOM:LX[
M6[FGTB%)I4BC#&7>C,JQC.6;Y2,'')%-)O8#8HJ*VG^TVD,_E2Q>:BOY<J[7
M3(SAAV([BJ5GK5M>ZWJ6DQI*)]/6%I68#:WF E=ISG^$YR!19@:5%%9\.L6D
M^N76D1ES=6L22R_+\H#YQSW/%*P&A1110 45REWX_P!/MY;OR=.U6]M;-REQ
M>6MMOAC8?>&203CO@'%:$_BK38KK1(4,DZZR6^RRQ %,!0V6R00,'T-5R2[
M;=%9NNZW;>'].%]=I*\1ECBQ$ 6R[!1U(XR:TJ5M+@%%<E<?$+383<R1:?JM
MU8VKE)[^WMMT"$<-SD$@=R :TM4\5:;I=G8SCSKQM0Q]C@M$\R2<8W94<<8(
M.20.:?)+L!MT5B:7XJT[4[*^N#YUF; G[9#>)Y<D'&[+#D8QSD$BLV#X@Z;*
M]J\VG:M:65VZQP7US;;(9"WW><Y /8D"CDEV ZVBN>U/Q=:Z?JCZ9!8:CJ5Y
M&@DFBL8 _E*>FXD@#/89S6AHFN67B#35OK!W,98HR2*5>-QU5@>A%#BTK@:-
M%%%2!!=?ZH?[U5QTJQ=_ZH?[U5QTH 5?]:G^\*O517_6I_O"KU !1110 444
M4 %%%% !16#XVN)K3P1K-Q;320S1VCLDD;%64XZ@CD&KGAZ62?PUI4LKM)(]
MG"SNYR6)0$DGN:KETN!I45Y?!KVL6WP:@U**[G:Z:XD2:\?,SPQ?:'5GYR3M
M7CV'TJ[9:3)/'#?>%/'-WJ-TCJTD5[?B>&5,C<&4 E#C.,#_ .M?L[;L#T.B
MO/\ Q%;W.K_$ZPTC^U]4LK1M+:=EL;MH<N)",G''2F(MUX7\?Z)I5IKNHZE!
MJ*S"YM;ZX\YH@J[E<$C*C^=+V>FX'H=%>?>)M9\0_P#"3:+'% ]AHXUB&U:0
MR8DNR03T'2/Y2.>O%>@U,HV28!1114@%%%% !1110 5 ?O'ZU/4!^\?K0 5F
M>)/^16U?_KRF_P#0#6G5;4K/^T-*N[+S/+^T0/%OQG;N4C.._6FMP/.["V\>
MW7P]LX+*30OLLNF1K$H243F,QC R25W[?;&:K:M?6]S\/_ =UHULS1IK%HL$
M$TF"S)YB[2V./F4C./?%=#:^$/%-KID.FIXUV6D,*P*(],17"*-H ;<2#@=:
MO3^"+7^QO#^EV5PUO;Z/?0WB[DWF786)!Y&"Q8G/Z5OSQO\ ,1SWB?5]>UAH
M/"FI:7::+'JW[L7DEV9U8 @E$VH!O/8,1G-:5W;I'\4_#MG(-UM:Z7*;4.<X
MD!"D_7:!70^)_#MMXGT273IW,3DAX9U&6AD'W7'3I]1QFJVJ>%VUC3-/6ZU&
M1-6L,-!J4$81E?&&.TDC##J.E2IQLNFX&CK5GI-Y91C6!#]FBF21&FDV!9 ?
ME.<CG)_6N.\9:[8)XYT'3;Z65;.Q)U&X\N%Y?G *Q A%)ZY-:S>$-0U.ZM7\
M1:^VI6MM()DM(K58(W<="^"2V/3@5IZ/X>_LS6M9U6:Z^TW.I2JV?+V^5&@P
MB#DYQSSQGTI1<8];@<S\,]6M3+K.@6TCM;V=RT]EYD;1DV\A) VL ?E;(Z#J
M*;K>@:?I/CGPW=VT3&ZOM3GEGFD;<[$QL0N3T49P!V%=-=^'/.\86'B*WN_(
ME@@>VN(O+W"XC/*C.1C!Y[U-J^@_VKJ^C7_VGRO[-G>;9LW>9N0KC.1CKGO3
MYUS774"AK(_M'QKH.F\F.T674IAGC*CRX_\ QYV/_ :C\0:W!H2G1M!L8IM<
MO=SPVD"!0I;K-)C@+GDD]:U[71Q;^(=0U=Y_,DNHHH8TV8\I$R<9SSEF)Z"N
M5M/ GB'3]4U#4+/Q=%'<7\IDFD?2D=B.RY+_ '1V XI1<>KV MV^KZ!\-/#V
MDZ+K&I^5(L)"MY,CAR#EB-JG RW>J%T\_B;XAVT%IK>H6VCS:#'>;;29HC+N
ME;:1W4D$$G@\ 5W&FP7EMI\,-_>"\NE!\RX$0B#G/]T$@<8'X52&AX\8OX@^
MT_>T];+R-GI(7W;L^^,8_&A25V^HS@;.QU6]T+Q/)/XFUC_B27-S;V9CN=C'
MRUWAI"!E_O <G&!6K8:W?:AJGP^FDN95%]8W,ETBL525Q%&<LHX/))'IFMZT
M\+?9=-\0V?VS=_;%S//O\K'D^:@7&,_-C&<\9]JHR>!Y4TGP_#9:N]MJ.B(4
M@O! &5@RA7#1D]" .]5SQ>_]:"*NH&XO_&NOZ9)?7D=I_8\<BI#.R;&WMDK@
M\$XP2.HXJQ\+K);7P#IL@GN)#/&)"LLI=4[80'[HXZ"K&D>#Y['7-0U:^UB2
M_N+^U6WES (\8)Y7!( Q@8QVSDYJ]X4T&Y\-Z,FES:B+V&$[;<^0(RB?W3R=
MQ]^*4I+ELGV S_B9_P D^U3_ +9?^C4KYZKZ%^)G_)/M4_[9?^C4KYZKMP7\
M-^IZ.$^!^H4445V'4%%%% !1110 4444 %2VUS/9W,=S;2M%-&VY'4X(-144
M >Y>#?&4'B.V%O<%8M2C7YTZ"0?WE_J.U=77B7@/PM>ZOJ46H"22UM+9PWGH
M<,S#^%?ZFO;:\C$PC"=HGEUX1C*T0HHHKG,2.3[P^E-ITGWA]*;0 4M)2T +
M2TE+0 M+24M "T444 %%%% !1110 4444 0M]X_6DI6^\?K24 +1110 4444
M %%%% "T444 %+24M !1110 M%%% !2TE+0 4444 +1110 4M)2T %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!-!.8S@\J
M?TJPY!((.015..-I&VK^=6R@C 4>E "4M)2T <5\4/\ D6+7_L(VW_H=;_BB
M.WF\)ZNEV%,'V.4ON[ *3G\*@\6^'7\3Z,MA'>_8W6=)EE\KS,%3D?+D?SK)
MN?!NN:O%]DUSQ;+=:>Q!EM[>Q2W,H!SM+ DX]JUBU97>PCFGUZ_&C>#M',FK
M1Q7&G"XNI--B9[EU50%5<#('JWTK1TAM7O[C6-$M9/$4>GSV!DM;S4XI(I;>
MX!QM$A + Y#=<\'WSU&M>%TU%]/NM/NVTV_T[*VT\<8<!",%&4\,N ..U&A^
M&Y].U2ZU;4M3?4=2N(UA\WRA$D<8.0JH"<<\GFJ<XVT YN/7[SQ!HWA/3X+B
M:"^O9LWS1R%'1+?_ %P)'(W, /QK/EUJ?6]=UIKN7Q5'#9WDEG:QZ+#)Y:^7
MP69E!W,3G@]!CBNOT;P=;Z1XJU/6TN#)]LSY4!3 @+'=)@YYW, >@Q[U%<^$
MK^#4KZ[T'7FTM+]O,N86M5F4R8P73)&UCWZ\TU.%] .:%]JE_:>"Y-8@GCO8
M]8:)FGA,32@*^URI QD8_'-:6DV5_P",FU74KG7=3LECO);6S@LIS&D2QG 9
M@/ODGDYXK4C\$6]M::#;6UW(JZ5=?:F:1=[7#$-NR<C!);.>?2F2>#]0M;R_
MDT+Q!)IMM?R&:>W-JLH61OO-&21M)_'FDYQZ:?\ #@<O-K.MZUX=\*HNJ36E
M]/JCV5S<VYV^8%WJ6QT.0,X/&:Z"VCO?#/CG3=,75+V^T_58)CY=[,97BDB
M.58\X(;I67XG\.0:79^#M$TZXFM@FI82X!!D#[6;>>Q.[D_E73Z5X8N8-;_M
MG6-6;4[](3! 1 (8X4)R<*"?F..3FG)QMY:@>>VPUJ'X2Q>+7\2:L^I0CS(T
M:X)BVB7;M93]_(YR>><=!73S0WWAKQGX:C_MK4KU=3,T5Y'<S;XV94R&1<83
MYO3M6C_P@_\ Q;?_ (1#^T?^6>S[5Y'_ $TWYV;OPZUIZQX>_M77=$U/[5Y7
M]ERR2>7Y>[S=R[<9R,8^AH=2+?W_ /  \]AUNY\03ZC?7-QXMB87,D5HNDV\
MC01(AP"=HP[9'.?IQ5^:_P#$.M+X&@NKJ^TF]O6NDO5C!A=@B')*$8!(4D9'
M&X$5O2^#=0MI[]=#\12:;9W\C2RV_P!E678[?>,;$C9G\<=JN0>#K:SN?#;6
MEPT<&AB8+&R[C-YB%22V1@Y)/0Y]J'.'3^M ,FQLKFT\9:CX8;6-4GL+C3$N
MT>6Z8S0MYA0A9/O '&:D^$UFMMX T^<3W$AN%9BDDI94P[#" _='L.]= -#Q
MXP?7_M'WK!;+R-GI(7W;L^^,8_&H/"7AZX\,:0-+?4?MEK$3]FS (VC4DG!(
M)W')Z\5$IIQMZ 8]V+SQ-XZU#1SJ=[8Z=IEM$Y2RF\F2:23)R6'.T 8P.],U
M%+_0O"XM-<\4RVZ?;MD-W!&9+JX@ZK%P,B0_W@#T^M:VK>&+FXUO^VM'U4Z9
M?O"()R8!-',@.1E21R.QS6=)\/\ _0;=X=8F36(;UK\Z@\*OOE88;,>0-N,
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MWW"SCF$F?,7&-Q(ZUZE6/XFT'_A(](%A]I^SXGBFW[-_W'#8QD=<8K7.<'!
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M06*YBN[HR%SL8@CN%ZY7[OW>.*] G@ANH'@N(HYH9%*O'(H96![$'@BH<4K
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MWC]:2E;[Q^M)0 M%%% !2TE+0 4444 +1110 4M)2T %%%% "T444 %+24M
M!1110 M%%% !2TE+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSI=H]_SI110 FT>_YT;1[_G2TM #=H]_SHVCW_.G44 )L'O^=&P>_P"=.HH
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MB^%[70KJTN$EO+^WN4Q<*!\R*B=0_P#M 8%3>*]&DO/B'IUG;NOV;6(E.HQ
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M?[_Z"E^TR_W_ -!4-+0!+]IE_O\ Z"C[3+_?_05%10!-]IE_O_H*/M,O]_\
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M8^H!'XUT=+3B[.X'!:9J4'BWQC;:NA_XE^D:<LH[@3SKN/XJ@_ FN9OU%_\
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M]QORH\J3^XWY5HT4 9WE2?W&_*CRI/[C?E6C10!G>5)_<;\J/*D_N-^5:-%
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MH *!10* %HHHH 444"B@ I:2EH **** %HHHH *6DI: "@44"@!:*** %%%
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ME+0 4"B@4 +1110 HHH%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNBF;*-E #_MC?W11]L;^Z*9LHV4 /^V-_=%'VQO[HIFRC90 IN"3G;1]H/\
M=I-E&R@!?M!_NT?:#_=I-E&R@!?M)_NT?:3_ ':391LH 7[2?[M'VD_W:391
MLH =]J/]VC[4?[M-V4;* '?:C_=H^U-_=INRC90 [[4W]VC[4W]VF[*-E #O
MM;?W11]K;^Z*;LHV4 .^UM_=%+]K;^Z*9LHV4 /^UM_=%'VMO[HIFRC90 _[
M8W]T4?;&_NBF;*-E #_MC?W11]L;^Z*9LHV4 /\ MC?W11]L;^Z*9LHV4 /^
MV-_=%'VQO[HIFRC90 _[8W]T4?;&_NBF;*-E #_MC?W11]L;^Z*9LHV4 /\
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M( ]>:[JS\,Z+8:3-I=OI\(LI\^=$V7\S/4L6R6/N34&D^#= T.]^V:?IXCN
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MTV[($R@3!R""I!!SW!S5JHEKZ"-)(TCC6.-51% "JHP !V KR'3O^17\+_\
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MH ;BC%.Q1B@!N*,4[%&* &XHQ3L48H ;BC%.Q1B@!N*,4[%&* &XHQ3L48H
M;BC%.Q1B@!N*,4[%&* &XHQ3L48H ;BC%.Q1B@!N*,4[%&* &XHQ3L48H ;B
MC%.Q1B@!N*,4[%&* &XHQ3L48H ;BC%.Q1B@!N*,4[%&* &XHQ3L48H ;BC%
M.Q1B@!N*,4[%&* &XHQ3L48H ;BC%.Q1B@!N*,4[%&* &XHQ3L48H ;BC%.Q
M1B@!N*,4[%&* &XHQ3L48H ;BC%.Q1B@!N*,4[%&* &XHQ3L48H ;BC%.Q1B
M@!,48I<48H 3%%+10 E&*6B@ HHHH **XKQA<^*8M7T\:+"9;2%A<RE(7/'*
M%&(<"0?.&V8'W,YXI/&/A^8Z+JNMC7M:M[NWL7E$5G>O%!O2,G(0= 2,]?QJ
MU#:[W [:BO/]*BM?#&C:7K]_K7B&^FNX8D2TDNGN!++(H.U8^YZXYXK?TKQ=
M:ZEJ_P#94VGZCIU\8C+'%?0A/,0<$J58@X^M#@^@'0T5Q2_$S2Y+2XNX=*UF
M:UMG=+F:.U!2#:<$L=WX\9P#SBM?5/%VFZ;#8,B7-]-J"[[2WLX]\DJX!W $
M@!<$<DCK1R2[ ;U%<WI?C;2]4N-0@,5W9OIT(FNQ>1"/R0<\'GJ N?3!&":K
M0?$/3)6MI);#5+6QNI!'!?W%MM@D)^[SG(![$@4<DNP'6T45RMYX\T^VN[N&
MWT_5+^.R8I=7%G;[XH6'4$DC)'? .*E1;V ZJBL2T\5:;?:I8V5LTDGV^T:[
MMYP!Y;J" 5ZYW#.<8_'/%5[+QMI%_:ZY<Q&81Z,[I<EE W; 22G/(.TXSCI3
MY)=@.CHKE)_'UA!>6=D--U6:\O+%+Z&WA@5W*,2,'#8!&"3G@>M7M-\7:7J.
ME7NH,TMG'8.R7<=VFQX&49(8<_IG-#A)= -VBN6LO'=A=75G%/IVJV,5ZXCM
M;B\MMD4S'[J@Y)!/;(&>U2ZAXTL;+5)]/BL=2OY+50UT]E;^8EOGD;SD<XYP
M,FCDE>U@.DHKDOAQ?S:GX2%U/=2W)>ZN-LLCER5\QMO)[8QBIYM7LK+Q5JQ>
M?4WEM-,6YE@W@VX0%CE%S]\X.<\=*;@TVNP'345Q:?$[1S:VM[+8ZM!IUU@1
MWLMKB+<1G9D$G/!' (R#@FM32?%UIJFKMI3V&HV%YY/GQQWL C\V/."5P3T/
M8X/M0Z<EN@.@HKB8_BAI$MA_:"Z=J_V!)#'/=?9AY<#!MOSG=]#\N>HS@\5H
M67C?3[S5K2P-EJ5N+W=]CN;BWV17&!GY3G/3D9 R*'3DN@'345FZ3K5MK+:@
MMNDJFQO'LY?, &74 DK@GCYAUQ]*Q'^(FD1Z-I&J-;WYAU5V2W180S[ESP5#
M'DD8&,]124)/2P'6T5@Z/XLL]7U&XTY[2^T^^@B$S6]]$$8QDXWC!((SQUK/
M_P"%BZ3M-R++4SI8D\LZH+;-MUQG=G.W/&[&/>CDEV ZZBD5@RAE(((R".]<
MM=^/=/M[F[CAT_5+VWLW*75W:6V^&%A]X$Y!..^T'%)1;V ZJBL:+Q/IT^KZ
M?I\1D?\ M"U:ZM;A0/*D48R <YW8(.,=.]17'B[3+2XUB.?SDCTB.-[J;:"@
M+C*JN#DMC'&.XI\K[ ;U%<O;>.+274K2RN]*U?3C>-LMY;VV"1R-C(4$,2"?
M0@4E]X[L;.ZO8H]-U6\AL6*7=U:VX>*%@,L"2P)P.N <4^278#J:*YR35+"X
M\5Z(([O4"UW9RS0)$X%M(F%.YU/);!&..YJG-\1=*C$\\=CJEQIUNYCEU&&V
MW6ZD'!.<Y(!ZD BCDD]@.OHKF]5\;:;I>H65CY%[>3WUN;BV%G$)/-7T'/7'
M/I@')%6]!\26GB W<<,%U:W5FXCN+6ZCV21DC(R 2,$="#2Y)6O8#9HK#\1^
M*[#PP;(7T=R_VR0Q1""/>=P&<8SGGH,9Y-1:7XPLM2NKJS>TOK&^MHO/:UO(
M@DC1_P!Y<$@CMUHY)6O8#H:*Y/2?B!IFK6+ZBMEJ5KIJ0M,U]<PA80%ZKD,2
M6SQ@ Y(.,TZS\>Z?<W5G#<:?JEA'>L$M;B\MMD4S'H 0203VR!FG[.78#JJ*
MYS4O&=EI^JRZ;#8:EJ-S @>X6P@\P0 ]-Q)')'.!D^U57^(NBKX?36UCO)+)
M[[[$I2(%F;)&X+G.WCZ^U')+L!UM%<U+XTM[>UMGFTC5X[NZD=(+ VX,\FT
ME@ V N#U)%.L?&=A>1:GYEG?V=SIL)GGM+J$)+LP2".2"#@]Z7)+L!T=%<6G
MQ.T<VMK>RV.K0:==8$=[+:XBW$9V9!)SP1P",@X)K4TGQ=::IJ[:4]AJ-A>>
M3Y\<=[ (_-CS@E<$]#V.#[4W3DMT!T%%%%0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYEJJ*OPJ\'J% !ETTD?7:36OJ9(^,.A<]=-G_G7;44>T_7\0/)K957]GN](
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M+7M[O4;N"30&,5SJ!.^=1N!9<@?)G@8 ''O7L-%3&HDK6&>9:JBK\*O!ZA0
M9=-)'UVDUKZF2/C#H7/739_YUVU%+VGZ_B 4445F 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img158215518_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img158215518_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '+!&<# 2(  A$! Q$!_\0
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M\R3_ )Z/^9H\R3_GH_YFG;:-M #?,D_YZ/\ F:/,D_YZ/^9IVVC;0 WS)/\
MGH_YFCS)/^>C_F:=MHVT -\R3_GH_P"9H\R3_GH_YFG;:-M #?,D_P">C_F:
M/,D_YZ/^9IVVC;0 WS)/^>C_ )FCS)/^>C_F:=MHVT -\R3_ )Z/^9H\R3_G
MH_YFG;:-M #?,D_YZ/\ F:/,D_YZ/^9IVVC;0 WS)/\ GH_YFCS)/^>C_F:=
MMHVT -\R3_GH_P"9H\R3_GH_YFG;:-M #?,D_P">C_F:/,D_YZ/^9IVVC;0
MWS)/^>C_ )FCS)/^>C_F:=MHVT -\R3_ )Z/^9H\R3_GH_YFG;:-M #?,D_Y
MZ/\ F:/,D_YZ/^9IVVC;0 WS)/\ GH_YFCS)/^>C_F:=MHVT -\R3_GH_P"9
MH\R3_GH_YFG;:-M #?,D_P">C_F:/,D_YZ/^9IVVC;0 WS)/^>C_ )FCS)/^
M>C_F:=MHVT -\R3_ )Z/^9H\R3_GH_YFG;:-M #?,D_YZ/\ F:/,D_YZ/^9I
MVVC;0 WS)/\ GH_YFCS)/^>C_F:=MHVT -\R3_GH_P"9H\R3_GH_YFG;:-M
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MQ_\ Q5'_  EWAG_H8M(_\#8__BJ^3J*/JB[A<^L?^$N\,_\ 0Q:1_P"!L?\
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MIU% #<48IU% #<48IU% #<48IU% #<48IU% #<48IU% #<48IU% #<48IU%
M#<48IU% #<48IU% #<5\D>,1_P 5OK__ &$;C_T8U?7-?(WC'_D=]?\ ^PE<
M?^C&KLP?Q,3,3%&*6BN\DZ?P!X;L_%7BJ+2[Z6>.!XG<M P#9 R.H(_2JWC#
MPQ<>$_$,VGR$O ?WEM-_STC/0_7L?<5T7P9_Y*);_P#7O+_Z#5[0G3XB>"F\
M-W++_;VDH9=-E;K+$.L9/Y#_ +Y/8UA*;C-]M!G->*/#-GHGAWPUJ%M+.\VJ
M6S33"1@54C;]W &!\QZYKE<5ZUXATG^T[/X9Z3<JT8FC\F56^5E&8PP]CC/X
MU5\3?$35O#WBNYTG1$MK32-/E,"V0MEV2!>&W9&3DYY!'&/K1";:LM7K^8'E
M^*,5[UH^D:=IGQA$EE;"&TU#1#>&W485-QP0!V'RYQ[US/@CQ?J_BCXE:-;Z
MC.IM(Y+AX;=(U18@8) %& #@#@9H]M=-I;*X6/*\48KV;P)XKN?%GB>^T2^B
MMG\/M:R&'3Q;HJ1HI 4# SG'O5?P1XGO_&EYK&A:NELVDOITLD5K' J+;[2H
M79@9& >^>@INK)7NM@/(<48KT;P!_P )%_85ZOAC1(A>M,-^LS.@$*8'R*'&
M/0\$]>G3'1>++/4;SX6:A<>)+O3=0U:PNX_*N+5E9XU8J"CE0 #R>/I[4.K:
M5@L>?^+O#=GH-AX>GM99W;4M.CNYA*P(5V )"X P.>^:Y?%>@_$G_D#^"O\
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M &XHQ3J* *4P_?M^'\J%%+-_KV_#^5"T / IX%(*<* % I<4HI: $Q1BG44
M-Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1B
MG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44 -Q1BG44
M-Q1BG44 -Q7BWQ_'_(O?]O/_ +2KVNO%OV@/^9=_[>?_ &E6^&_BH3/%,48I
M:*]0D3%;?A7PQ=^*]8%A;.D2*AEGN)/NPQCJQ_08]_QK%KT?X=8_X0KQZ$_U
MW]GKCUV[9=W]*BI)QC=#*'V'X;)>?87U/7W(.PWR1Q"#/]X+@OM_S[UB>+?"
MMSX2UG[#/*MQ%)&);>X0865#T..WTK"KHM-&JG6]%.IZ7?ZI%\OV2SG+A9D
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MW>/9?NVFS_MF@_F:]!HH \^\SXA+\QCR/3$-']I^.XOO6.__ +9*?Y&O0:*
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MU_6O#;:'!I'AW2)(U$GF37]\J&YD/]T%<[5]@?ZYZC_A96C?\+-MO$OV:_\
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M_21AVA!?]1Q7.1> =1OF$NK:L6;J0"9#^9QBMJS\":':@&2&2Y;UED/\A@4
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MO^%2>!_^@)_Y-S__ !='_"I/ _\ T!/_ ";G_P#BZ[6BCVL^[ XK_A4G@?\
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M^3<__P 71_PJ3P/_ - 3_P FY_\ XNNUHH]K/NP.*_X5)X'_ .@)_P"3<_\
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M#7,F5A0]SZGV% &7XO\ %+:?_P 2S3B6OY<!F7DQ@] /]HU-X2\+KH\'VN[
M?4)1R3SY8/8>_J:H^"] D9VUW4@7N9B6AW]0#U<^Y[>U=M0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5P'B?0;C
M1;T:_HN8]AW2QH.%]3C^Z>X_R._I" P((!!X(- &3X=U^#7[#SD 2=,":+^Z
M?;V-:]>;ZM9W'@OQ FJ6"DV$S8:,=!GJA_F/_K5Z!8WL&HV45W;/OBD&5/\
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M[ZN+\=Z*\D4>M68*W%MCS"O4J#PWU!_3Z5N^&]977-'CN>!,OR3*.S#^AZT
M:]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPZE;B&21=RJ)4?C./X2<<UG5+33LRHR4E=.Z"BBBD,**** "BBB@#T;X+_\
M(XW?_8/?_P!&1U[I7A?P7_Y'&[_[![_^C(Z]TKV,%_"/F\S_ -X?H@H(!&",
M@T45UGGGG%L3X0\<M ?EL+O@>@5CQ^1X^E>CUR?C_2Q>:']K1<RVC;LCKL/!
M'\C^%:?A74O[4\/6LS-NE0>5(>^Y>,_B,'\: -FBBB@ HHHH **** "BBB@
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MKL)_H<?F: .RHK,\/:E_:VA6MV3F1DVR?[XX/^/XUIT %%%% !1110 4444
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M444 %(S*BEF("@9)/84M8OBV]^P^&;V0'#.GE+]6X_D2: .6\+J=?\9WNLR
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M_D3^/?%\GBG6"(9)#I\!(@5CC<>[$>_\JZKX:>$)($B\17T14N";-3V'0O\
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !4%U_JQ_O5/4%U_JQ_O4
M0+10M% #6K0K/:M"@ HHHH **** .0^(ET8= C@4\SS 'Z $_P \5N>';06/
MAZP@ P1"K-_O-R?U)KDOB&QN=2TJP4\MDX_WB /Y&N_50BA5& !@"@!:***
M"BBB@#R+XX?\P'_MX_\ :=>15Z[\</\ F _]O'_M.O(J\7%_QG_70^GR[_=H
M_/\ -CHD\V5(]RIN8+N<X SW)]*[_5O"'AW1+B2RU"37;=E3C4F@5K5GVY&
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M&JZ_>7MLLZP2./+%Q,TK[0 !N9B23QZG'3M697-*W,[;';3YN1<VYZ-\%_\
MD<;O_L'O_P"C(Z]TKPOX+_\ (XW?_8/?_P!&1U[I7K8+^$?.YG_O#]$%%%%=
M9YX5QGQ'M!+HUM= ?-#-M_X"PY_4"NSK#\8V_P!H\*WRXY51(/\ @+ _R!H
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M;LXSSCK0!9:TC1F0W"B11R"N!^=1/!MMHYMV=Y(QCIBKXD4DB6:&6#MN^_\
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M"@#T"BBB@ HHHH *S-7_ .6/_ OZ5IUG:I'))Y6Q&;&<[1GTH RJ*E^S3_\
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MR!K(S.(^&0^34SZF(?\ H==_7#_#2/&GWTG]Z55_(?\ UZ[B@ HHHH ****
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M<9\-(\65_)_>D5?R!_QH [JBBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *@NO]6/]ZIZ@NO]6/\ >H @6BA:* &M6A6>U:%
M!1110 4444 >?>.O]"\2Z1J'3&.?]Q\_^S5Z#7%?$BW+Z3:7 &?*F*GV##_Z
MPKJ=)N1>:/9W .?,A1C]<<_K0!<HHHH **** /*?C1_S!/\ MO\ ^TZ\IKU;
MXT?\P3_MO_[3KRFO1H?PT?,9C_O,OE^2"K%C+#!J%M-<1>;!'*K21_WU!!(_
M$57JSIUTEEJ5M=2V\=Q'%(KO#( 5D /((/K6KV.2.Z/2-176->UAM1\,>*X9
M8VP\-D+HPR1@?P^6>"/KU[UA'3)?$WB#7(]5M6LM;6W,T,$ "))(@Y!!SDL,
M'(..IIEW8>#+^]:^@\03:?%*WF-9M8LS1DG)52ORX[#T]Z+WQ;]K\?6&KV$,
MQCMC'#$K#,LJ#@Y]6;)'XBL$GT/0G*+=YO=]'>_G;H9]AH-K)X:_M2\DF62>
M]2UM43 #=W8Y!R,<#'?UK?E\*>%D\4MX;%YJOVUF*)-^[\I&(RH(QD\8Z8YJ
MMXWO+2V\466E6@$=AI;] .CN^]^GX#\*BGUW37^*8UE;G.G_ &E9/.V-]T*!
MG&,_I3]YJ_\ 7D3:E!\K2T:3_&YH6L&F6?PVU2VO%O&DAU#RYC$Z@&49"E<C
M[N,9SSUHUV+PY]C\-R:S-J'FOI,"+'9A!L49^9BV<Y)/ _NFJ2:KH][H6O:=
M/J/V5Y]0-W;NT#NL@YP.!D$^_K61XGU&TU!=%%K+YGV;2X;>7Y2-LBELCD<]
M1R.*2BVPG4BH:6>B_,V8_ L*>(]9M9[F=]/TM$D=H(]TTH=0451TR<]?;\HK
MWPQI@TAM7M8M7@M;2>-;RWO459#&Q W1M@ GM@C_ .OJ/XPTP^)M>5+^Y@L=
M4A@6._M@ZO"\:  XX;&<@XZ_0UEZSJ]DOAR>Q7Q#J.MWEQ(I\R229(HD4@XV
M.<,21W''MCD3G=7\ARC047RVZ]?/3S['2:S9V&H_$O2K2"?4K6ZDA7S)X9E0
MJ@B)780,@\8-<AIVA:5!X<77-=GNQ#/,8;:"TVAW(ZL2V0!VKH&U_06\<Z/X
M@&J?NEB"7$+6[AH<1%>3C#<G'&:Q;'4=)U7PE!H>J7S:?-9SM+;W'DM(C*W5
M2%YSFB/,DOE^HZCIRDWI>[MKITM^OS,G7]/TVREMI=*OOM-I<Q"0([*983W1
MPO&:V;>"2Z^%\5O$-TLOB (@]28<"L?7O[$C:TMM%WRB&+$]VX9?/<GJ$/W0
M/\^IOV6N6UCX*M[:.0'4(-:6]6$J<%%C !SC'WAC&<U;NTCGBXJ<KVM;I^AM
MOX)T:#4DT>7^W'NSA&O8K<&V60CTQDJ">3FC2[+3-+\)^*;'4X[XS6\T$=WY
M#H 2)&"&/(Z>N>W2K-QXDTF^U<:JWB[5[:U<B232D\X-D#E%93M )^GX5B:=
MJVEWUGXFM;^^>Q_M*2&2"259)R CLV&/))P0,FL_>:U\CI?LHR]RW7MVT_IZ
MFIK:: - \,/K,FH%C8*J)9[!@9Y9BWUX ]#67<>$M/L/%-Y8WNI,EA! )XV&
MWSIP0"J(">6YQ^'O5'Q+J=GJ&F:!#:S>9):6(BF&TC:^>G(Y_"NK'BS1/^$C
MU"XCOS;O/810VVH"W9_(=1\PVD9YXY [4_>BM//\R6Z527O6TM^1B:IX7TX>
M%KC6M.BU:U^S2HCQ:BBCS%8X!4@#N12_$W_D9;;_ *\8?ZU<U'Q!I[^$-7TQ
M_$-SJM].\4B2S1.J$!QE4SG& ,\X'(Q6-XZU:QUG7(+BPG\Z);2.,ML9<,,Y
M'(%.',Y:^?Z"K>S5-J-M;?J<S1116QYYZ#\'_P#D;;K_ *\7_P#1D=>UUXI\
M'_\ D;;K_KQ?_P!&1U[77!B/C/I,L_W=>K/$/$?_ "7"'_K_ +/_ -!CKV^O
M$/$?_)<(?^O^S_\ 08Z]OJ\1\,/0]BO\,/0*Q_%-Q]F\+ZA)G&8BG_?7R_UK
M8KD_B'<B'PXL.?FGF5<>PR?Z"N4YQ_P_M_)\,+)C_73._P"6%_\ 9:ZFLKPU
M;FU\-Z?$1@^2&(]"WS?UK5H **** "BBB@ HHHH **X/X6:E=7OA.[N=1O9I
MVCO''FW$I8JH1#U8\#DFNMDUW2(;>*XDU6Q2"7)CE:X0*^.#@YP:N=-QDXER
M@XR<2_152:YCGTJ:XMIDD0Q,R21/D'@\@BN3\!:]$G@JUN=:U9!(\L@$MY<C
M+8;U8\T*#<6Q*#:N=O145O<07<*S6TT<T3?=>-@RGZ$5Q;+-IGP^UV2#Q*^K
M2J9'2[CF):$[5^0,&;&.O4?>Z41A<(QN=S17,>&]>LH?"VD'5-6MTNIK9&)N
MK@!W)[_,<FMV^VSZ5<[+L6ZO V+D-Q&"I^?.1TZYS2<6G9@XM.S+5%<5=ZR/
M"OP]$T6NV^JWBJWV>ZFE#?:#YG./F);:#C@G[M=#X?U:#5]'M9X[R"YG\F,S
M^4ZMM<J"00.ASGBFZ;2OT&X-*_0U**SVU[1TN?LS:M8K/G'E&X0-GZ9S5NYN
M8+.W>XNIXX(4^])*X55[<D\"ILR;,EHJDNKZ8]VMHNHVC7+ %81.I<@\@@9S
M5VAIH5K!1112 **** "BBB@"E-_KV_#^5*M)-_KV_#^5*M $BT\4Q:>* 'BE
MI!2T +1110 5Y]>_Z!\5+>7HL^W_ ,>39_,5Z#7G_CT&SU_2=1 ^[CG_ '&#
M?^S4 >@44@(8 @Y!Y!%+0 4444 %>4_&C_F"?]M__:=>K5Y3\:/^8)_VW_\
M:=;4/XB.+,?]VE\OS1Y31117H'S!>T7[%_;=C_:.?L7GIYW^[GG/MZ^U>EZC
M=>-[6^>ZTV&WOM!#YAALTC>-X>RX W9QCI^%>:Z+)I\6L6KZK 9K#?B9%8@[
M3QGCGCK^%=5!X?CL=3-YH_C/2[6S+[U?[44E5,YP8^Y'H>M95$KZG=AI247;
MOT=G_P %&4VE0:\->U&RB_L][("<:=C=\F</AN,;>3C;W J&S\-_:-%M-0FN
M_)-Y?+:01>7NWCC<^<C@9QTZUO1^);.?XI&_M4+6%XXM905QYJ,H0L1[G#8]
MJB\0W%M8^*]&T6"519Z,\432' !D+!I'/ISU^AI*4M@=.G9RWUMZZ[_=?[A/
M^$$L3K,NB)XCB;5@6$<'V5MC8!(!?. 2O)'..G-*NFZ6GPQF>:^,5R-0RW^B
MDGS5B;$.<].IW=!GI4EOJ%DOQA-\;N 6GVMV\\R#R\;3SNSC%5R;;4/!>J6D
M>H645Q%JKW@CFF"&2,1D?)_>)/04KRTN^Q:5-<W*E]I=?+S-CQ1HFEZEJVE"
M]UU+*XGLH(XH1;-+GC +$$!02<5S-MX.G.J:I;7]Y%9VVE\W5T06 !^[M7J2
MW85;\5WMK<^)](F@N898H[6V5W20,%(Z@D="*Z7_ (22V'B'Q196NJVEK)>O
M'+9WK[9(2RJ,JQ.1@],XXY]J2<HQ5BI1I5*C<N_WZ/S[^AR$_ABP%E%J5IK7
MVG2Q,(;F<6K*]N3T)0GD?C75ZEIB?\+(ECT;5A:71M#YB+9@K"JPIA1DX.X>
MF,5E^(M6N4\*RV6H>(;6^O+F9<6^GK"8@BD'+LJ YR. #_6M8W.GQ_$5]:&K
M:<UG>6;!"MRN4*PJN'!^Z2>@H;D]7YCC&FG9+K&_EOYO^F<=8>&K5]%BU;5]
M673K:XD:.W @,SR[>&.T$8 /&?\ ZV:.OZ*VAWZ0?:([F&:)9X)X^!)&W0X[
M=#Q6_MM/$WA+2+--3L;*^TPR1O'>2B)9$<Y#*QX)&,$?7\<+7[/3-/O(K;3+
MPWFR%?M$P(*&7N$X'R].>:TBVWJ<M2$5"\5VUO\ ?H;\D,ES\*],@A0O+)JY
M1%'<E2 *C;P58)J TAO$< UD_+]F^SMY?F8R$\S.,]NGZ\5-9ZO:6'@C1&,T
M4D]IK2W+VZN/,V*"<[<YQ[UTDNL3S:VU_'XPTN+17<S8$</VE%Z[0AC+;L\9
M.?7DUFW)7MYG3&%*:3EJ[+\O5&%9:5I\/PXU-;V[-M=+>A)_]&W-'(F0(\@\
M@]<]!FI-=TG2[RS\-SZEKB:?OTF"*-!;M*QQDEC@C:OS#GZ^E5H+JVUGPIK]
MN-1MXKJ;4?MBB\E6)I5Y.>P+'T'Z5D^+;F"Y70/(GCE\K2((Y/+<-L<%LJ<=
M",CBFDW+<F<H*GLFK+\_4E7P7/'KVIV%W>PP6VFIYMQ=E2P"$ KA>I)!''U_
M&/4?#-K%H#:SI6K#4+6*80S!K<PLA(X."3D=/SKK)+S1KGQCX@N4NM*>],-O
M_9\UZX:WR$4/S]W=P /?/O46MZL9O >I65_K>FWE_P"?&ZQ6C*%1-PX7 &[&
M"3C..,T*<KKY#="DHR^=OEMU_1G/_$G_ )*!J?\ VR_]%)7*5TWQ NK>]\<:
MC<6L\4\+^5MDB<,K8C4'!''4&N9K6G\"./$.]:;7=_F%>@_!_P#Y&VZ_Z\7_
M /1D=>?5Z#\'_P#D;;K_ *\7_P#1D=36^!FF"_WB'J>UUXAXC_Y+A#_U_P!G
M_P"@QU[?7B'B/_DN$/\ U_V?_H,=<^%^*7H?98;XGZ'M]%%%<ISF5XEN/LWA
MK49,X/DLH/NWR_UK(^'L'E>&S)CF:=FS[# _H:?\0+@0^&6BSS/,B8^GS?\
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MV/S#^9_*NJ(# @C(/!!KSWPFQT/QA?:-*<)*2$SW*\K^:DT >AT444 %%%%
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M.[!4 E!.ZN3UZV\1:TUK''X9U"TLK.+RK:W2UD;8.Y+$9)/K6/\ \(OX@_Z
M6I_^ DG^%9J":U9TRK2B[1B[+;[DNWEY&IK9/_" ^%1DX+WAQ_VT6NMT^^@M
M-=T6.>2%'NO#$=O"UQGR_,+$J&Z<'&.HZXKS[_A%_$'_ $ M3_\  23_  H_
MX1?Q!_T M3_\!)/\*MQBU:_<QA4J1ES*+Z?@=S*NJ:5H>L3:CI&AZ(DEJ]NA
MBA)DN"W&U,2?CG!QQP>:\QK5_P"$7\0?] +4_P#P$D_PH_X1?Q!_T M3_P#
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M?TCY8]VZ5%'"$]<C^Z?TKK="UNWUW3UN(3M<<2QD\HW^'H: -2BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN5\7
M>*/[)B^PV1W:A*,<<^6#W^OH* ,WQCK<U_=KX=TS+R2,%F*GJ?[OT[G_ /77
M3Z!HD.A:8EM'AI#\TLF/O-_AZ5D^#O#+:5$U_?#-]..C<F,'M]3WKJZ "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUI^*?$T6@VFR+:][*/W:'HH_O'V_G69X-\.RH[:UJBLUY,2T8?JH/5C[G^5
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MHH **** "BBB@ HHHH I3?Z]OP_E2K23?Z]OP_E2K0!(M/%,6GB@!XI:04M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH I3?Z]OP_E2K23?Z]OP_E2K0!(M/%,6GB@!XI:04M "T4
M44 %%%% !1110 4444 %%%% !1110 V2..:-HY45T88*L,@_A7):MX L+LF7
M3W-G-U"CE"?IU'X?E77T4 >=+?\ B_PR-EU ;RU7^(CS!C_>'(_&MC3?B#I=
MWA+M)+.0]V^9/S'/Z5UM9.H^&=(U3+7%F@D/_+2/Y&_,=?QH O6M]:7R;[6Y
MBF7&<QN#BK%<)<_#A$?S-.U*2)A]T2KG_P >&/Y5"++QSI/$-P;N,?[8D_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4
MIO\ 7M^'\J5:2;_7M^'\J5: )%IXIBT\4 /%+2"EH 6BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "HY((93F2)'_WE!J2B@"HVEZ>_W["U
M;ZPJ?Z5X_P#"NV@NO%%REQ#',@LV8+(@8 [TYYKVNO&?A)_R-=U_UXO_ .AQ
MUPXK^/2]7^AZV!_W7$>B_4]>73[)/N6ENOTC _I4ZJJ+M50H] ,4M%=QY(44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %077^K'^]4]077^K'^]0!
M M%"T4 -:M"L]JT* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ^8/V<?\ DH>H?]@J3_T;%7T_7S!^SC_R4/4/^P5)_P"C
M8J^GZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@"E-_KV_#^5*M)-_KV_#^5*M $BT\4Q:>* 'BEI!2T +1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5XS\)/^1KNO\ KQ?_ -#C
MKV:O&?A)_P C7=?]>+_^AQUPXK^/2]7^AZV!_P!UQ'HOU/9J***[CR0HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *@NO]6/]ZIZ@NO\ 5C_>H @6
MBA:* &M6A6>U:% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 445YE\7_&'BGP196.J:*EG)82.8;@3PEC&_53D,." 1[$#UH \M
M_9Q_Y*'J'_8*D_\ 1L5?3]?$7@SQAJW@K6I-0T:.![J>$VQ6:,N"K,K< $<Y
M45]F:"=4;0;)]:\K^TFB#7 A7:JN>2H&3TZ?A0!HT444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *@NO]6/]ZIZ@NO\
M5C_>H @6BA:* &M6A6>U:% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5D^)M M?%'AN_T6\XBNXBF[&=C=58>X8 _A6M10!\N?
M!_X>W5U\2+DZM;[8O#\I,RGD-."0@'J,@MG_ &1ZU]1U##:6]O-<30PI')<.
M))F48,C!0H)]3M51^%34 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% %*;_7M^'\J5:2;_7M^'\J5: )%IXIBT\4 /%+2"EH
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M -@IOYS4XIJ*E?K^I%>4:E6I2E%64+WMK=13WW_0]$HHHKJ/ "BBB@ HHHH
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MW./XCV[UHT4^5;6)]K.[ES.[T^04444S,**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *AN?]6/
M]ZIJAN?]6/K0!76BE6B@ 85=JF15R@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH J2_ZYJ44LH_>M0!0 X4\4T4X4 .%
M+24M "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0W'^K'UJ
M:HI_N#ZT 0***<!10 $4XSOZ"@TPT *;A_1:3[3)Z+^5---H ?\ :I/1?RI/
MM<G]U?R-,IIH E^UR_W4_(T?:Y?[J?D:BHH E^UR_P!U/R-'VN7^ZGY&HJ*
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M]U/R-+]LE_NI^1J+%)0!+]LE_NI^5+]LE_NI^50XHH <9W9B2%I?/<=EIE%
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M:Y?[J?D:/M<O]U/R-144 2_:Y?[J?D:/M<O]U/R-144 2_:Y?[J?D:/M<O\
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,,%.% #@**444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img158215518_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img158215518_2.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2..4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (W*^D'0X0DE-! 0      %H< 5H  QLE1QP"   "K@ < E  "')R,CDS
M-S0Y' (% #E-:6-R;W-O9G0@5V]R9" M(%1A;F=O("T@06UE;F1M96YT($YO
M+B Q('1O($9O<FT@4RTQ+F1O8W@X0DE-!"4      !":XE'0J?SP#J-"FTJA
M"EAM.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           ! 0   ET          0                         !
M          )=   ! 0                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   ! 0    !29VAT;&]N9P   ET    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   0$
M    4F=H=&QO;F<   )=     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    $.$))300,     !CY     0   *    !$   !X
M?X   !C= !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT
M<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(
M          $  /;6  $     TRU(4" @
M                                   18W!R=    5     S9&5S8P
M 80   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@    49UA9
M6@   BP    48EA96@   D     49&UN9    E0   !P9&UD9    L0   "(
M=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P
M   D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P
M!#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K
M87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ
M           2<U)'0B!)14,V,3DV-BTR+C$
M                                         %A96B        #S40 !
M     1;,6%E:(                     !865H@        ;Z(  #CU   #
MD%A96B        !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C
M         !9)14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@
M:'1T<#HO+W=W=RYI96,N8V@
M                        9&5S8P         N245#(#8Q.38V+3(N,2!$
M969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#
M(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M                         &1E<V,         +%)E9F5R96YC92!6:65W
M:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E
M<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                          !V:65W       3I/X %%\N !#/%  #[<P
M!!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,          0
M                      */     G-I9R      0U)4(&-U<G8        $
M      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H
M &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4
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M0SI#?4/ 1 -$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T? 2 5(2TB1
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M4WU]F7>VNUBT.YK\(Q 'YH (YLS!$TG@9@KI^U]ZNUYVW;WBZ/#KL^VM7!Q
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MYHB*FO;[+N5N<0NH Q DP*QJ8S@ 029-.<( 7I;/VR]KKEL\"XWRU%W8PM8
MYT-!)YK<40"2X&! Q$D2ZM8_=H\9/\:OB(_KDR%_B/6#]B[/_P#Z?_C;KE_^
M9JI_SS[9_P#5KQ_Y'I^[5XR/XUO$5_7+D#_$VH_8EQZ+.[_^:K_GGVO_ .NV
MW_FM/PI^[2XQ-U3]U7Q#<O/F3(/_ $DZ_P"N>LPV%<NBT32C9[ZB%F?[<^TC
M3'[<M^VU>/\ _HKC^[3XQ/XU7$/_ %R9 Y?_ /3Z?L.Y]%E<J)_GKVD_ZW>/
M_([\:Y_NT>,?^-9Q%_UQ9 _Q/J/V-<-S?U_:L?\ GKVB_P"M[2[WI^[4XQOX
MU_$3_7-/O\4ZC]A7+/ R-^ ^BG_/?M%_UW:/_D=ZI^[1XQ?XU?$+_7+D#_I)
M]6_8ERW#[!TSUT4_Y[]I/^N6W_F=^)/W:/&+_&KXA?ZY<@_XGU/[#N6[_P#U
MGU3_ #W[2?\ 7+;_ ,S_ ,2?NU.,;^-?Q$_US3[[O_\ =.J?L.X]!GV/R4?Y
M[]H_^N[1_P#([U7']VEQB?QJ^(;S?PR9"_Q-Y=7_ &)<-WW5/^>_:3_KEL?_
M /,_U"Y?NT>,7^-7Q"_URY!_Q/I^P[EN'_C/KP/<G^>_:3_KEM_YG_B3]VIQ
MC?QK^(G^N:??]92FJ?L.X]!GV/R4?Y[]H_\ KNT?_([U4/W:7&)_&KXAOZY,
MA?XF][5_V)<-WW5/^>_:3_KEM_YG?B4?W:/&+_&KXA?ZY<@_XGU'[$N6X?8/
MJG^>_:3_ *Y;?^9_XEM;P>_)9>)[AMRJRD^0<CY!SMCDHC<=,81D*:G92][/
M156DE#"<D)/Z@$C9*[JWIW0.915%%]D029#<G;'LQ8VEB18M:TF@<(\12),$
M"8)F3)KZSV8_Q3V]LK:MA:;3O3K]<S(=9N)%#T9GG0TEK@'&!E$AWVZX&SUC
M'B3QH RMB:3,Y+$9"WIO-'%FI:7;!W1OUD269JO7!Q49=V;DQA%*:Z*D7I(J
M+S^6WRYV]QM76-J*UC<16.!G=-*Y4G]>;&VU<-O7*QOMU>'V=H :4<UTRYKQ
M6#.ZA!IC!5=RWCV[E&*-HO;+T!;;6=XDF]+^IA<?]+U+LK0O)G9BM5=CE3Q@
M6(]C*Y1UN)1ZI9*7>R-%U6/:'@U,5BHWZD;\Z$@:+K?K]1])6D+;@++M0[ ;
M5/(CX:+"\"QR,7A4.-QIS)V>!2N3R LGE$F(FE+T[)#7JEU$.TQZANR)P':R
MVE"RNU#IO6=];9F8=SI)Q.!PEV&@G0821NG(B@D QUUD#K%=]!Q%"(@D"KC_
M )'X#:1-Q'O&@*V(NW8)5-,X@3<.F @9@:6X2<1X8[DTSD<@0"BS0V9%M"<C
M+J)$/EB2)MN7U9VT'%P=4 !XJ0!SG-()&4\T]4D5!A8^3$?$:D&8RX9]>9KD
M*05*2O@^D;().YFC]G-I^^QMD,?'0$)C@R.7VF1I+#^%</%9/%24SF?4@?B?
M->&AK+!5)$DO161LE4O_ +.*IF/?G/M0^8&)LS$%HQAS2 ()<UYJX$2 8!&)
M.3%1.>I!H3&N*@![Q3(TS6ZX<+[_  CC7&UPR'JE,1ET5R.?D1 $I4;),B-Y
M@LXR$=N"U(C:J:IW*"\K)U(A#YFIA51:MEV\]M>ZVE^!Y.!68($'*!$B9:*C
M(\ NYL+:PV3>GVG.(?=7W0X7.8YK2T#$T@&""T&DD27"2*X]KX.RKZQ6-,3H
M(]CS9_6HX93#;_6+@5YGJ/9P?MC;MS*"+(HX>*(<1;I#AHMJB.U+HG)!.N"S
MV=M@02]I.@/ AU1+@9 - 0,45T7KW>WC67X[1%P#;P7.O)<TPYMY_9KMERPB
M,,.B\@NQ.Q#X!S2WIN<$K1NQ*-Q,G!L.TE/N+K>W#[79)2\\SRUS.#'2!BU+
M-%,QMBS:K!28):D[6#NWE32H1S::J/99\F;Q45@-H#B^8 P6P ,H,9:K&[VX
M;;6MA;VMV<XM)YV,8\)V>;E+'F3CDFW!)JXEQ?SB3D?#7#2+QE+:IH1) SQJ
MV(/,![<=%J0[2+.Y),9#+"=J+VW)$A5'A5]F<I#]F<E2EJX6IVJ/*FE/2N&P
MS<[0.-O0 Y"@Q&#$D@#2@.9PY2M'VB]LF[=N-WN-A=N39=7M.-QQ7F\AMT;9
MA]\<)QWB68B]QK#9FH%D'>$,H1DN2S@V<"1+>=5OR#5G3%2!-+1QY.(U-&SX
MF[+R<@^1K0\C*,"@V+OX\',*40H@L76)%='0O/LTZU?>B+P(O0XT-'<X%QG=
MS305AOPGIW+VXNUVL-A65KLOWC]DO<7ESFC$PAS0T0T$!H(< YIYS<)FKACR
M;<'<[E$E$BG1J+/Q!>+9^\9YDZB%+I(^<RC-8288-8A'W<P5Z+-LV%N1N8Y)
M4(.^R>I= HE2O=EUK;V=O!-B/>) ]]+CGAQP9%1!,".N:02NC=/;W9=WN-O=
MQL^]B#L\7)K;\UO_ -.Z.L_]9_H0+TR].?\ ZIL"<!+ Z<)J%/"%*)82RVXD
M)4/&+$M>9H%A7+*.MG<E)"LCC& %N3DAYE(%0V,9,V:OAX.I@(=TNNR$JII[
M(WJAGLM;N))O %70:3#H!!(.5,Z"9B<AKVGMS<+.Y7&Z6%VM'6ONEP;>VD@7
M9K[D2?\ 2M(EA>7!I+R Z[M#"6F2;S+\&0DC.9=(&1B/,8_)1KMBTCE^,FZ$
M"JXQH[QL@YM=CTRCS%8;0R=H6[$[/1$?.WJT%&A51945G/LH076C;<5$B0X0
M#0M)$2,SAD\W(T)6&P_Q'?9;%NNR/<L5I=;<$/EH:_\ UGO8=&$RZ + Q @
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MD+3;:VTQ5U02<3APU:).8H>"V#QMQ.\1V&XZL.Q'GO,&+HIUYP36,P#)DPB
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M"'3#'68>]K+,NP,Y5I82YU""YG-Q/-HS"6N7:YV1-!(KGB@$NB3A(, F:2)
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M0[3.QK>\#:<[0<UA.SC<F2PO+6C#:'" UL6C0VT:YSWCFO :6NQLV==>5(B
M"X!SIK )F"21B!;,$ 0209EM[">"+@[<$9-*6F* $K#6>$'%^9(\1A)'BAGF
M$Y'*)SG5W%E.XX91@ZO$4:9,H4\;AI*#D24EH]-A):HJ($!Q72JU;'VB]I[1
MEFQUI:,<;\;,%XL>4:\;/+BU_-=9 NPX@6,P&Z&RP S*V#LZ[ R&B(Q'"7$
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MS<C_  'L9(0ER#2T7C\K[;3/$&&0NFJV2$1T[*"QT54,*2>0#"B;EJZZNC"
M*NJ'9-#Z:S+FR8R&0PY# >5,P3V]1X:=Y.9F%EOAZFW$9*LVQJ]DV[F)C"0U
MW.L6#U$X$=$1R:-[T5X:);$3,VOO<'XI1H[8$B>78]&S:1*&B:*HP\BPR_(R
MRE"L@K;MNX$60$0TFM09<#\SZ  0))EQDD1 "UI.*G#NDP-3F1!C14DG*>(@
MSDBX1ZAE@@2$'K(<Q$G.(I"-QS$QUSBYPH*95PZ6(# ,<CM*L1CI#)U,)(9
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MHQQE,WP69XQP5X&4S\;(IAA$I%9 YI+4F)LG:T(%0RQNQ)!MJ D8CA$\P'$
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MBUH:<)(.$&&N(!#8$$2'@Q%*FLA4??77EHOMXMR3>*ESCB<Z "9)S$" 1&H
M@B+<8\?,*=CU>7\<SEBR;3V_!I(6(OX/8B,>J2+XXF3$F2G[B4>(MA@;"9-#
M(+4A(6C,J6$2T6**/*A0A3.9VS7LF"*"00'$G.D1,T%!O%#FJ65HVTM+*SY8
M223(RH!$:QG6N1U5U1/B]#FSAD3=B,J?B(QFF088E$\9-8R+CT9ESC-4IQ'
MPC@$YG!*6FD=OA 129X,-42OC$(+JS$=&7"8-KF[86LM* O:"W.2*3!@@9B
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MWKT7-2TP!.Q9U)D1/%N4R !=?/*FR#QK52(M&A)':5U5"EI*UZCK%P( @R7
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MRS_XKOMGU3W6Z_RUW_VS/PJ'8(?W&&?!K?\ 6U/*6G\1_P!IWJGNMU_EKO\
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M)&9!.K)UW4Z=L)#8>P8T2R"*I+K6PJ .W<S1R45>UW9!:C;6]"&@OX:_+&9
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M!,I%LJ.HIV6@GLI1&;]HAL 6$QA@\T& [$<K.),D$P'#-L.J8-@,P<L@9@4
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M#=]\^,GK)ZS0>1'D.2[J*V[DU9S???WN8X$5 UI-=]-T3-:NFW.LSF=QTIJ
M)H)SE?6Y@3B(JD.+L,<6XU%'OX>T;2R7V6?TE8\/_P!G\WQI*>2/F%P(TD;\
M<,5-JI4!B19=^R437FMI72SOEE>+$0")#)T(-"2)/-I(R,5SA>7VG9<F\D5T
MINSK0 &M!2IF)7TE6KU+JU;O6JE6S>M4W;5RC??941439%^6W1=T3;9=E1-U
MYZ^:Y+D*9T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31%9TZ^M*2?S
M01_1$T18(@7TRW]K_NU:67R]OU2U^;L^BV,$_2K/\FK_ *Z(JYHB:(FB)HBZ
M[OTNK[G]I-$7F5QQ&;Q/(>%(&MRJH4(83K*1%O9N+1N?9V@\&ABN_+?8*QED
M\?[<_HJS:%4YB.?J/9BQ8^VO#R!B#&M&E"9?USS>T#>LEF,9 $Z&-XB!6)&=
M-U,]/E ^2WY")&\W1''%#BOL."PEN55IX3YW4_+G3Q\Z=<MT3Z"-(\BKY51W
MNB^7WMT8,]YUK$$ #.HFL=M5ZRYOF- ),@G/+,Y946C.(,70+(4=R:9E4_DL
M/OXUB7CHY8A\?-);8)@$D\1B%75W3[(,.ZB7[;F0Y4&H/V44S=E>UDV04N:W
MMC9.93XC'S",W9P0*"N0!(B9IOVEXS)SX1!.0D[J@'?NT5,AF \F9"#A345%
MB2%N4R2Q$XH+=RJ(BY/)RW;L<CB-H]%2YL<?,CT-2F.CBA0>P[*$]:>\U425
M44M;[961C( 5)! SJ230ZS!D4)^(3K\OE$Y;A)RKV:".&^<GF.#[(<3@LUF<
MU=,(]7$Q%B2,1C.XVD363 'CIFU;DQ\@$O"#2EDK_K U:53Z$&0[H1W<M8V;
M2!U!RF<\B<NS=,9SFI%OK.>L=H/&" =9GNQOPW9$)8JSMBN;#G-=CLN:!VY1
M*+NR/0!=V@>1-?(B(^!O'.^^VR=^_/;8O8QR(%08F<Z4.>1C@(X@+-;<]@,P
M3GO R @SQW>%?MCX<##N*<34)NM;MZT-R=$Y?C,XPL\NTBT<&.\I0HZ^\G^S
MC*/Y-'#$3_\ SIYSJUX/VCL;,V#;8'G-<!.^2&]Q#@>R-%Y#:0Y.U-(F3'B.
MVI%:T7IE,</XOG;FP1F$"B4B+M+*T#SI (QN2,3W_/(B2=40T%O\MT=#R+)>
M2[5<UUXYMHX1#J#*LBHRC+TE:),]\_EU4"L'U*L@0N[<>8HRK(*V6U*+!,NN
MR.28Q=IYJB#9@^=^JD%?O?E54F0F,U%-*=]HJJKMJP>TGGMI02V >W>3 %32
M3 R">?'AX:1!X 3I5XQF/PD@&0;)4;=XSR$3KOV1(]\^[:A\U<M&U+ATN.IT
MW:L6<C6VT:.2'81-C%9OV4T=E2T*%#5ZUJ"S5IQ").4B,Y$TWC@AC\N[*>V)
MKO6?-T3O7;6,F/*BA-2B:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(M8Y
MG_"$2_DCOT=MJ-1U'S:IT/6/)RR^ ]9;^T4ZN[Y?Z1]51OS?U'Z*_=55E)O/
M64_TOS)HBPI,_J2K[:G]I-6/PM_N\U4?$[^WR5P8E^M2_P#SR^_0VNJ#+M=Y
ME7.?8WR"ROJ5":(FB)HB:(FB)HBX>#3PG3W7N[O?VV[_ #;>3S\]_)HBU)XU
MJ+W[G":U6.AT&QS%[TBJ5>M!LLL0IU(.L]WSOV-9(;KOLB)55OR7;?V&,%_N
MF5'NSK$,=,3.[/=*F8SR]8RXKYM_DK(<D5X5Z7;*BNIL!R7$#)=-MD4>Y8'P
M'?W;(8+CEY^\B^5=?2[K\8$30R1D3(BNE*9G/)>HNN0TR\OUGXB0OFN;7? N
M+-[_ ,.X2\BT;+Y?(B_8Y;[=VWEWUVRW'NU@5FL@3J#I34%=@,)[1K%<\M\@
M:Z#=GMG1FZ!$>([-^6"320# 63C&3B4+.>*49F4E@9":RI#P [1#S)EA'GQV
MV(\/'R*5'T0;07=E!94D5&"]N7[JYMFQL@D-8TF3$@-:0" "1 )% 9@2))&G
MR8DU,5H!6FIF>V,HE;!7N+WAZ:P2H"$QA<:G%;Y#8T&+&,8:%D-E_+1F8@[:
M3^,4;GX\"QK/M)[&!Y.)1_'XL2*%"JQ8LL5%1B&BM:9N5K,C$1UD]&(URQ16
M9R/.D4Y*!%)B,B(&?;.LB#-05H;FB:C\C9@ROD8/8?LPL]R).9B(;$[;:R39
MLI#(RQ5LU(MV+H@SJ?=3=-U(*P(%.6Z[<E375NC!860!SB3%!O,#LR&M*$TV
MK-G)Y9:=\C([R>K?&?T/\ K% / <+=RFA:1%\5E,XZM./<#M(^KE>]/G%6+-
MP13_ .[7SKMSKR[G'J&4:$Q74NW4T@F5Q]I95,9T,[AI,UR'',FD?4UAIJ4:
MXCQ:V-]-"[?'<,LEEO+\NI)O'Q/7>Y.]7G6.2]ZZ^4V__P EME\3ZB(-36E*
MKS?Z_6>:RMJB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(K.G7UI23
M^:"/Z(FB+!$"^F6_M?\ =JTLOE[?JEK\W9]%L8)^E6?Y-7_71%7-$31$T1-$
M7"A.A0F^R;(JKM]_R=ZHG+[G+1%Y<<:S"H=FK$9RI*NIRG'V0HS4XK5%L=KQ
M4W$C(L;RW^?WS$_)2*+OS2..^2=%=>I]FG\^U8,Q#OM"!6<Y;&6Y;=T(:XU%
M8&$YP/IIE3-?*C\EOQZ1"YNB>1J6URH)-86Q$U//!KX!)!''3VPX:K5R3F$>
M#^7->3S9=N[W5RM:1/9$9NXQ.^:P#!.4^EN>7;QWZT(F 8@CJU7F,"ELAC+"
M6C@KRAJSG,:\39-;JL-;ZO0"R2/2_JN[[=&GT9C$<(=I#^[J:;<T76[;V(M"
MTD26DEI,B*.:2#$S!/WI"Z+VP?'*@,T\::9\5D&$\0&3<=!@86+$P[/Q6D;>
M310PZB\;,R6*D.W([(?]GI 6"$'H5B]-1>.DB@U-MU9.E[S\@4MA?=A:2"#!
M!$&8<(/Q DMU(.^DS#8P.87TB)@$9R>KP !B14P"JQ*>)W,$O%GP90T(L!)$
M*L""@<3%XT-;JP:NNM*U^<6G7=NNIVCVG414NNR+OW*BQN754S)KND"D90*3
MG2%FL;O.51E%8D@F!.6<00!7/)2/#7CTCE//&+(4.;UWU)3$.X*+2BJEJ/AW
M3(Q(7/-$^H@C-RFR]ZIYM9;6UL["EJ8M\J4F@)F!)K&<QK1+=PXSF<M)DBD:
MT.4$"LE?:9@MM<,<3^%1;.M.LQRO)&27RJG+L$3C\MCMRX7S*IO+D6Z.Z\TI
M>)W4JFO ^T&,7=K;3>V*G,.'B0#.FN=5Y#:#K,VE!)SD'(4!II.0F1EF:CV7
M6NE.Y47S[*G+[/?KQCG88I,KG*"7$7O^5\W25.?^?O+Z=I!G]'Z@(K)EL-CL
MZ"/HQ*Q#8V#()9\.TO)>;W&]]JX5XQ(CGK);1(*5&O;5@B+.#B+4L)*M&A40
M\:%6FZ2UYS:2/RWC([U--3QZJ;HSK'>,C*Q/CT[)(3+KN&L@F7<D<7!U\_BJ
M>&%;U%YK$A]QHV+@9-6U:,&=4Z@#MTR[0<V!^TABI03(?EBUN:(,N[G$N C>
M!$ ZGJ/94P)56B@@^!K4_K='%;):HI31$T1-$31$T1-$31$T1-$31$T1-$31
M$T1-$31%K',_X0B7\D=^CMM1J.H^;5.AZQY.67P'K+?VBG5W?+_2/JJ-^;^H
M_17[JJLI-YZRG^E^9-$6&)I]37?Y;C^SJ[LF=7T"J/CM/ZCYE5S$OUJ7_P">
M7WZ&UUC&7:[S*N<^QOD%E?4J$T1-$31$T1-$31$U5_PGL\PBQYE"$,,EX\G.
M.B]V[9&SJ*R&)/G3;;P[9K(ACT14Y;;;;.6B._#HJU?_  J*J*FZ:RV=H;)[
M;0&"QP/9J*[Q([47@7*(1;RUC*>8;RBPH82-O8+8XR&)L(M*!I8,I:TV2PQ'
MVWT/N.>QI3&B?+M4&4!DU^J%37TJ[7D6MDU[2(< X&HD. )$9D'.-(-!KV[G
M>#E4$$@U!@F==W$<8.H^4G.^!)]P^S@E#9F,<VK-+IRH4\EM%&2(?UE4;$1[
MKN2M-DW&+S%[[HFVRKV["\2 .H#/4B"?(9 C(SS5WK.U&XU .0I C<==:3 ,
MF1.%-;G*</'\EEQ-W^!]$U&$]$_:'HF-N_P/HMB>&WALG/$E.Q\8C+)TU MW
MEB]+)56W^A@4>BIUKYY3=.OD_ENSAVR\_P#\LV1=:UMOW?'2F>>HG,5/49WG
M';VN [J9:P,^&0CA)W2/INE+G$N(XGB?"9\HVB>/#S^(P$Z0OM29%H#Q8T<B
M6TT*2%PT:$$8CB8=/%13A#84*/RP"I7UM2ZX[@Y]E>K:Q ?>@UQ:"1SG@$M;
M!+:DTS @DD@1'DK[>@;0 G6O9%:P1G(CJK)7T>1XT$D8,88CA-@:!DV=AV,*
MBG;9\-?L7=K9LX:N6U*-'=FZFVVRKMWHNR)KY>]CV.(>"UP,$.$&<S,YS((.
MN<E:>_CO&=?UY*XUKH1=EJI15[D6I$5?)W;[]_+55"Y:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB*SIU]:4D_F@C^B)HBP1 OIEO[7_=JTLOE[?JEK
M\W9]%L2&]9;^Q5_>U+LSUGS4-R'4/)5_4*4T1-$31$T1:L\5F''^8<5N6L8M
MLDR/!C+?(6-'+[YC9JEPBP[97P[EQO2C)A,HT5D$$*$M]Q;"1W"B(M32E5VK
MA>WW:\APB*M=/1.1SH03-#-2 "3"D.(@@D$0!W'Z3V2O#S,>)X+Q8XG)PN3M
M'8H@S)7[%=EY;6Q)L=SL0O52(Y^W1=F95GMV>0'HJT%T1%W*BBJIKZ-8VP!E
MI!;0@MK(,$94R,@B )D&C9[EWO<C.*S7.DB.%:S CS^:G/7"7F# )LBSDD;>
M%HXWO;CY<'9N7@=XW1$V<NT3=0W?SZ_RW7EVKMKLV%Z H#&7F)U=GK$C?G3N
M65MC)K'AO@$TW'SR(6LZ4K[&K?S*BI]_?;;S_P"6L[+>RC.-\^?Z&:V6-'9.
M0G/>>'ZT60,?XIR)E0RV!P.)F9"\OW? HK9DJ#Z.6^[HGMU)GY?J]%WVV\JJ
ML/ON 0)\\P!G-)SH)KDJVEZ-GD0,ZDR)ZS4>$$B97T7<&_!Y%^$J*DLCY"+C
M+^0'H._<DI]S<\ &B0'ZJ<BF3A[NO>S7M$BG[[U-$][7!OMI:;4M?>;/.I -
M0:TBNLB3G2H,RN+?KSS))!I,TBI, ;XID1VKT+Q%/<S<,LF*\2F7<%F'^ LM
M@0 FU+8SVB2R1@V$QPD8="S60L=HS5[4*ECPPLK+$!J]KQX7V6&+T]I@!8G7
M)VFZZ[9#;A=+T&WF[O>0QYAENXL(.!QGG-8UQAF7[PN!!Q#REK;6GQ.;(SR,
MM&*DCC4Y9 5&2].9%Q?\-<4QL*S :S/"F^.I$E* #S8G45J/.4VJ=#08IDCL
MR7+,/ENT@;$>I46O(D.2K7DK/8^U;>\F[6-UM#:- +F%I! T<7&&87P0QQ<&
MO(< 782&WQL DS%3F,AK ).HD"HWU6.,>_)!^%K)$R 0,+.RPB4REQ8:18?-
MX+.X):DCEXZ5@U:A2<JC0X6]?E+RV%8#4?H5=(ZW1%UM7[V?VK<[#EGV=W+0
M)<67NQ=A$29:QY>7"H :T@X3!(J;B#K/?.D9P 8WG+2D+>KIT>RI^XJ+^;7&
MHT;@%"UWXDF%-G&3[(#>UTI%A1XF9(S=LVUZYUB%-WCL^';5)S;K-(.[D\$*
M*J4KV3*W:;<JM9K$C'A/PO!8?[J"-Q!R(KIJI&OZ[.T>D56?K-ZS?MVKUFXE
MVU?LK59N4;+X2WS79._?9%1:51$1=_+K$H4YHB:(FB)HB:(FB)HB:(FB)HB:
M(FB)HB:(FB)HBUCF?\(1+^2._1VVHU'4?-JG0]8\G++X#UEO[13J[OE_I'U5
M&_-_4?HK]U564F\]93_2_,FB+"DT^H:_MJ_W=6/PM_N\U4?$[^WR5P8E^M2_
M_/+[]#:ZH,NUWF5<Y]C?(+*^I4)HB:(FB)HB:(FB)HB:(M!^*#A>*3DGZKN)
M;C$?E5B.MBY $(U*UC>3P#!=V(<V\;-KU0F0 OFZQ26HQ*5":G3L<2%DQ=70
M'=G9&UK2Y$-?& R29,@DGS!U C*BLPAC\4:B@X" 9!,1,TGN7E+/(WC#-=LC
MB?+L5J$2UDJW7D$FS%J/DPR^UY];$7EIZ@=8<NDAJ'D"@W9/EB5*[KKV3;>R
MOMD8J#NRW3$\*C0@#JZME?0W,P8D:$D&( $&)C1>?TN^1&XV)$+[N*3>0 &E
MV[X6TPOWF]]M83;R==:$7B>951_Y$5-MN6VR]7FS@&W)SI3*=]3%-^_2%T+.
M_.S)RW" ? =4:TWD*H0GY$KBT(0M/9A+3\DL6;J+U%+K5@SO(BIMUE6;0<\1
M%5%Y=?VY(J*O?JSK_?8)Y<[\A%(H3 I09S,1G!2UOTSSISSRX4FDS)SXA>@F
M-@43C-=K#'#? VTOEC%.KWHS%$;L0("]O]5SR4LFB,XWSV4BOT5/EJ=B8F+E
M539=&\WNSN-F"XP!0 TJ=9F"TQE%*[X7-M[_ ,H-9J012L  $BAZQQR-3ZW<
M/?"G'\8QF4.LA4"LBY'R:RL,LDEB0EM?C]\-LZ5KCT((?*^1G! R/'"(-?\
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M6Y]^VI=0!?7CWF,9< '1!(8)HZ0"0XD.+2O3^P>P+CM_;?N%[M\-A=\3H B
M"TP" 0!6!!&7-!%!LS@/,<\E^0 \-EI=Q*F)CM!6CDBU9.W\9.6QA;P!\*XZ
M@B,GS-.L4HJ[54H[7HJJ*N_X#_\ 3)_Z@_\ $W;W^)=Q]FO:;:][V]L[:PM&
MN:\$D  '%.989YPR>)!)(&'ZU[<>QNQ+ALSW^YW<7.VNA9#IYMZ;(,08@0W#
MB;D"(Z)VGX'YG)IGPZQ2]-RSLY.(R8FL(F)%_?N.R5\Y$I<7#+<<N72^&J<U
M-&C6_4J]Z5;\N2+_ %/OUD+*U>UL82UKF!H@%K@08PBAQ G3N@KY/[772ZW3
M;UYLMGF+E^[=99Q!L 3.AQ34F:N%:E91XC8Q.YGA;(4=QJ\9-YV[!7[L::D+
M_5!D@(M5I?)$SKI53J8:96VM^+EB*)4HL25=%*$6MJE*X[I:-LWA]JV8TB<M
M:D9&N^@@$Y^1MA:N:661AQ @SE)$Y2:BD#.37=:,*R(PQ+ HC#<ISUA*L@AQ
M+>U)7$;&.+@^T_WWNCAR-FE*=E _WF%H8^CQ$6S8DRO3*.JE74O-[LA:$@5=
M)(!FLU)J=:QEE7,KMW#8.U;Z 6V!(,$.@M!!#3$0#%3SLL\@K^ YYQD=OVV5
MJ0VFCR[1\SME&CMC:7;R]9OHK-.]41*7R;;<T3EK"+[8FE03H8RW[NJO7"S7
MKV=VK=1B?=R1!/-DZ99 Y\-"!*RPV(,7MM+K5U8NT(J]"Y:NI=HW]=W(JJG+
M;?9*MU\VMH.:?F'>/UU;UQGV%NPP6N;P(RIPGCY*=2NU;IWN5VD3SJGW]U7;
M_+[R:C&W?Y^G_*QM9:DT$G<1Z#ZKA1>MWE2JFJU>_P#+:7=?.BKMOOR3;955
M-O(G/:001(5G-<W,03E.2F=T6C=*-T]ALB>7[&WO]W?R[]2J@@Y=N?Y+LT4I
MHB:(FB)HB:(FB)HB:(FB)HBUCF?\(1+^2._1VVHU'4?-JG0]8\G++X#UEO[1
M3J[OE_I'U5&_-_4?HK]U564F\]93_2_,FB+"DS^I*OMJ?VDU8_"W^[S51\3O
M[?)7!B7ZU+_\\OOT-KJ@R[7>95SGV-\@LKZE0FB)HB:(FB)HB:(FB)HB:(L,
M90P3B7-0JL1DV"QJ5-TK2ZVO$AC6\Z;.%^IW+9RM*_-Z41-E14Y*B>95R65X
MO%B>:X@3D#S8TH?45G1/U7]?KP6J!+Y''B%:U6,33,,3M<O!M6N2I>086*$Y
M(V:BWI:H8Q;;;)MV?MY.ELJ:ZW[?VD<[:LR:9T@"L_K*,U+7O&1(&X$TZM#-
M,HW56,9;P0X^A===;['^><\AVHF^2?W+V8V#< Y5IUKPXE]%99/QM!I\K1JO
M13L^H4J.ME5%14IRLV[?G81[P&DF/A+CP,D@"N<S.D&@BT>\C? D$D4IE%!.
M58S6V7#6@-M%P5F$\/C[#,"*Q@=(8^\J?XWOM'#$DV9OAXSJ<0ETD=VG"LG*
M..FJH,I5K5M4NZ4ZY=[M;2V)-K>'6CAH:1O(@89XD&1/.*Q61Q-D-W5Z^WA&
MD[@MK^==/^]0J_<7T[;_ &%7;R(NM195Y\\<L$FUMU@KB2QQ%24ZD_#/D$I)
M"T&#V_#')/CB:QN_$,C,HLR7D\DK4'78?C&ZKSJ9NDI3>I4J[.R[2ZWBY;;V
M)>W"[V6W+D+I[R?D>UTM,Y0X&)(HYK #)4-;^_N]H#5KJ'@[>*:@4F2#NDC4
M3)&+89"3-IW(<N8X@  Y89G& R?R9O'9L+8$VJNVPLA$GBU%^U&3)YT4'LNB
MBUIT41%JIU_+?VE_]#WMAM#VTVAM38NTFG8#[Y[Z+X02YLWV3( '.($34$8:
MDBGZ(]F_;YK]F^X'8YO5X'-H>:0!/-=2ZCG" YX;+A#IA<WW$U@2,<0G#WD&
M"R,Y)L?X_P ;37$>6)VQATONA!(9ZL??P]X]+(&I'/F]^1LG':*L5=*-1VMS
MH\ZM?TL]C?8FW]G?9.X[#LG##<KK9"QQ6C)MRT$VCF,)EK@)<&N(S(HT&/-C
MV>V]>]C;7LK>PN3+Q?;XR^W,&_W,$F1B:TAPJ&M ;! $21$S[#!YC%I%'6\O
M#'1!:,NAZEVAX>];/!5X:C;K2/+!%O\ .UUGMR15^5Y+6J+2JIJ;6R?9.=RX
M<PV)J'-+7 YRX4W;B"(,C7Y/:7.WL+?W:UL',O#CA#2*R3';E(<#!%8(JO-W
M*&2BV0I"\>7'3BV"L.%M!Q:5KX.W8[D==7VWZ^]Y)OMMMMRUYN]6]K:S0B30
M:$'=,YBM8WU*^M[&V!=KA9 VT%Q +S2HXG4"3 )U T!.-Z+EVS=MWK5RNW>M
M_-;5RCDO>O)=T[N:^\GG3O378^TW<.W?(B,CF3.?7W;:RN#XY:Q%:"A,R(@5
MX<=05DD=F+)HKH=7EY>Y3:V2BV\J;DM_-S<M'R\UV3=-E1=N2KK>_:%IG)&>
MX:R?'O'!<:V]G]B6E/=0,1YQ:()'70@Q,:PK^M<3>1J!UQM>M!;KVJS\R*=0
MOV+EM._?J_6E:;)LO/DNR[+W;I3]J0"VDG([A(XQ$5C6I!%%R'>Q^SWVHY)[
ML(D89YI-1607:BLP"(B9FW1'$!E$<[H<73MLG:[[C(HQ&TVZ^[_P+-@[[_+S
M\J;;;ZJS:=K(B3OXQ.F[@>\#+=MO9.XV]G^[L8H<)!@Y:28G.)(&1A;I8JR\
M(R6ROVJ6]0TZQH2X0%W[BW$\'6J_/+:_NB/&'2Y\MM]]ME5-=F[7H6U,C /?
MVSO]<X^<[8V+;;,M '$EI, C,'*"(B=,0 %0,XG-VMQ<5-$31$T1-$31$T1-
M$31%9TZ^M*2?S01_1$T18(@7TRW]K_NU:67R]OU2U^;L^BV)#>LM_8J_O:EV
M9ZSYJ&Y#J'DJ_J%*:(FB)HB:(FB+@M:4HG35$5=^Y%5.7W%7N5._44<-X**6
M<-+3NU58=6[+FU=W5;5ZWX2UMW[(J]R=VV_W/?F7-(+3!WR1Y(K;2'Q2Y7TU
MB\?JJ1.578X[IHGE7ZD3ENOD5-O-JO+7@9.<)W/=EV2@IE2%JWET=F['L6<2
MV*Y2C8X6VG,"9OQ5G%8QNW$0>0Y(C8&7%'+KQE5+SV)0<J;,H3149J@CY82J
M)KI7:\72T(;:W0O)F";XYHRD"<, D@-HX5J*BN.U%)G"1 TC45$@TSS),9&5
MLK#@LH!CW#64S*]-B5Q\E^T4K C0E5BQU9I\ZJV$4^!1.5]5<IS7KG/N7?1<
M6GX6X=]2?/(:]IKDK@0/U/A3PRCMOG_W?S7[GLO>_I?]/7>755*T4D_"[V=G
M/(.9P).HE!,IP+JV;\,=CTN[N0)I"AE+6!2F(DNT&"1V3HRZ8XC5T;E):FEH
MBJE3FDF,U?:;9>QO;7V1=[&^U&S[/:5P+N;;6A(<&.PXV.$D_$,3<)&$0T4:
M[%O[-O=ZN5]L+:QO!NIQ >\M!EH<0V<P,+0"29,$3!(I@6" ^(0,1=DL.\(
MV".R#:]2.F&=,LL$>#[+E47J]R)Q)J4+,Z:=D5:4(]IHG*I%77S;V _]/G^$
M7^&MZ_;&QKJYNUH(QAA>1.6"T>.3$#0AU! +?A7TS:>T=CWZ[6-GM3VMM+XU
MD 7.Y7%S1(K\>*\,(DU^%L4.A4GCNOB3X+KDP/96AL9R5B?(<VD>29R4PNDB
M?%\72>4.FSDX0MQHY\^&H.M3-N^JI'_144B%BCMS4M2=:^TO-C?7,:QQL[1E
MFRS:+6 VT8T$-J,G<XB@/]!BFCM/]B^U]EL^QV9;NN6T+G<V7,>_$-;>_=@,
M!!;1KN=$P*D -@-6Y9[B&@9?$]N?XUE8R3MY'1?' "(IU;=^!?\ @[O6E>65
M^HGH95^?Q[Y.LTNT;-2?15-DXE]-I= X%I#@8((@9$TJ)!(WUX"0/.7'V=O;
MML'9]_L76'NYYY/ T@D&03,D - ! #3EH/=NWG%VN[<JKO7W%[PMVY7<5;];
MA>]5WWW3;FFZ>1.[947S.*V>-<XXD1EI$1H*087UN[LM+L:Z98>%8F09I'#/
M,+I5:4Y55)OMLN]6V^_+DF^W-=^:>7[.K<A;:R.O%Z'*G@LELQ]Z$2!6E8KG
M2E8W;NJ5,LWSIG=HO,'EYDYHYTN&;AQ9O^9.;%>_DJ[^_P MM^4EMXZ)TF)X
MS J.P1W0M2TN%S?_ /IR<\XH<YDP9&=.)U5QE)S+C;&R*+R0J2865VJ:WW;F
M_:VY[(YWYN^2\NOJOE3;ESAUM:D"2:;YCLT^AH.)UK'8NS1)%V:#$$PT%PW3
MF1NK%<\EPC<TE$.=TNH\9?,*D5?"6+=WPS&YMW=9;?4;O;FJ<E7S^35[&^AF
M0@TB(%>JD[LQKUFU]V%<;]90;N,I&8.44DTZ^O=*]$L.Y-]4B.W'#E+5@X.N
MHU)-[6_@:D54\ ];)OOU-WMY$V16KFE$3;9>Y=K?E6P<QK6#.0G*NE<JZB/D
M>W=D_LR]FR83@-6DP:U&'4Y9$]+A)S?K:7$31$T1-$31$T1-$31$T1-$31%K
M',_X0B7\D=^CMM1J.H^;5.AZQY.67P'K+?VBG5W?+_2/JJ-^;^H_17[JJLI-
MYZRG^E^9-$6%II]1?_[5_M)JQ^%O]WFJCXG?V^2KV)?K4O\ \\OOT-KJ@R[7
M>95SGV-\@LKZE0FB)HB:(FB)HB:(FB)HB:(FB)HBZ$7PF]NXFU2;*FRISY?=
M3?9?L;;\DVT1:Y\.+RH/ JL5O;*V#&#2[C%#EM54BW[L=CEAK7C@Y<5$V5)5
MC5U$CE?D0L1?"_7,G::RVL%V)HYKA(K-<B)RD'.IA8V# (.<Q-*TG(<9C7?,
MRMD]8E<@$05T_3$KM[>#VV\VZ^_MYMDIVV[N7-4Y:*5A8]@?#,CEM^=2'&4%
M/S)W2PM5R,W%PI@O19&T> 8]6>%6KF^SZC8J79&"TINJ:R-MK5H#6VCV@$D!
MKBVIUD5.>O&(E;]EM2]6-F+*SMW!H,@!Q%3.K2"9)X1Q-5D9R$#.1E\->%LJ
MA5]K4RO#KC)O4/N-:[?5G#>[8W5JK=;.Z=65554Y+NGRNL1M'-'*@G$.=,U!
M!SG.GCPS&NV\WAML+06[@X0Z<3IH9%34 FA.4;PO*S*4!@G#A)I?5C*>&H5C
M@R%?ELB8PJ>MEQK'77A&Q.\<$.'&[F)U(S:.:B X>G92C-D6FD;3V6K:%]M;
M[=3=F!KKTT ,M(A^"O,<14P3F#4D4,8C]2]G[2UVU8<MM6P#K>Z@>Y7Z"U^3
MA#A0$5)@F))(:'-:X^!&3?D[?#K'6A*SC''>0LAFFSJ^W8J7I&0V..VS7?Z)
M]H(Z/G^H+MR3Q?[47?DB<M;5T]C[X\?O1U&,HX94WP2=YK'KP,NP3/'Z9U@'
M?,QYOSCY.7Q;2)Y?6'@L58_&^%^=;32.$I,23O3=P3+F^J/>7/G'A7.I57==
MM>FL/8C9( Y428T$"L4.9I $R5E%G9==1NTJ0(U-=^DFDJSP?R:SC>%WZ+SP
MMC.16]U^8&(&EJQ<7EMRCIH!Y=DY>=.:IWW_ ,G79^XR/^#NBNHIW@V-D+3,
M"NF@H1J=^O#>"5N'B;Y/D9MN&;/.F"AU]C<O;/CN,3+EJZM^=TUBLC[1H=[[
MHNRS!.6^W?MKD7KV"LM(.>1GJ.=2--34S-!!L0S=KO-,Q,$FO [Z2O<7ATXN
M\!<5 9P5PQ.QY]VPL-[YR+NZ' R71WK?E)1][L]:#T1/WRV45WJI1439?$W_
M &)>+D>6;(B3KVR<A0TDTI4Z8[8&SM9@4&_/KD5BD0 ==:[:Q65F888LF0#K
MJKVQ0E&]VWX>Q78=5?/#=RVYHC)%3=%3FE2(NV_=S[*_6H(LA&E:;O+3+*15
M<K;&SAM*SY%PD4D'<*@@@R'" 1&4#4+T-Q'EP?D494V=TVATB86.@0'TU[V+
MMM4_?(:N^U]A?5-]UY-?+MONOH;"]6=X!PQ)R$Z$2*Y]1 \5\GVSL2UV=:.,
M$W<DP3F(/PDF)BD14DPXK.MRA*T3GMMOY-TV7O\ -YO/K:7!) S79HI31$T1
M-$31$T1-$5H3KZT)-_-3[]#JT18&@7TRW]K_ +M6EE\O;]4M?F[/HMBPWTFW
M]FK\U6B*NZ(FB)HB:(FB)HB:(FB)HBLB;Q 9/H=+(,92[;#S"-GXR5K:U)8=
M4#I$-=B'];=S_P"Y?]7>5<U79.7OIJ6DM((T/?P4C7]9\.J>J58.&)N1ET3J
M82NXWL9)@KZF$Y08V;=+?J\N$M6GAR[9EO\ ,1$O8NA\SC6Z?/47D I?7)53
M3:\V;+*T%L#+",37 0,)(@9D@M^$S!BLY1CL'M>;1O)F0Z(.<QGN(<*B)$
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M*M8J8KJ:F-1$?3/[U8,NUYN=V]P'NHNN0RKE'6 !UC@ OB%7E_K[/O<U[O\
MUU]FM>7L[,Q$CKKVS0:037?,K>MIL[.),4XY&I[@(''3)>M,FX1ADIR%8Q?&
ML$.87BBUD,<$QIQ*B3\@>2+-D!:8ZG<O\9!T8ELG\4\C$<@QB+MIQ=]2P<'6
M#WWM$22*R M(@ I.-:6KL,D0Z&DMD$-.HH*P9'&(U7&M;Y:V<:D#6" #'#K(
M%,R!H%SE_P CRQ;&"UJ*7<RR ;(9)>,/XT2D,8M"(O&0$=PIPS9H,.)Y05>
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MD<Q6-ES[2)1<>^=;/3A_LGJ";K2@P6KLF@TFK5!I/#>;>\74?3/4',=<:[J
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MO2Y:LR+Q$C[PIB0.24CR<U 9#35VL*V*R#IMMKE9V9_<L>]SF3B:Z &BS;:
M"=8>X;B0' Q75_?.(IA%=0,Y+9H*9 D[R087?(8/Q--W1%I&961OM+9(1<AQ
M)Q(V"UB+%!0"]FCB96GH]5DC0\&60B(D/2DKV Z5-JQ*H+*1^UE;[- ;RC1
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MW]1^BOW5592;SUE/]+\R:(L*3/ZDJ^VI_:35C\+?[O-5'Q._M\E<&)?K4O\
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M)OSYJJ>]OW?'OY-81=;2TJ9,TI.O:)XZ5[^^R_7!\AM9I0".Z<\M1I)R4M<
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M/6NB52BKI:JVRM'SA;,9U&^-Z8QO\.^F?>.(D*BG.*?!D>J%VGTM)N+YM'U
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MV5E8P;A;=A"[SJ7P\T(@DO(#YM'.UH2C2.O54NB(TT-A:5.$<V<56\V!)!K
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M@L$9Q*RC@=<(EY>3,R4C)_#CGX<2L@1F3*BRG9$?077WZVAL8<30X3AT)$
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M%7WMO-J477X.W0GRZ[JOG54^\B+OYM]U7[F^H) $E%SI6W3NB+2GGW7GW?\
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M,;\B-,R867;QQ2WT5G*ENR!"8N,+GLG[/Y)H<W$^6@XLP7%N-T@.,-$D"8I
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M^J(Z$%^UNQ_&,M'<PN3R2 X&,0) H"TM!$SIB!.5 [<5.-HJ9&5-:R)S)K'
M&=!58^L\?<R+0?(>014$&LX<7K'T8,/D2]N^:;%B_!7CSBU:@Y_$&Z[HQZB0
MF@_MP9(TK0NS#B/%11*^-BY6W%KK069?43C$&H#G,D$2!4"6SBBI-9(VC1-)
M@9TS+9RD4K,SN%,UM3AWB<L9AR')(8UQ]+  =E>R=XNS!X,E;86:]2+)#+%\
MG0DY,0N/@V+]^=O=H0\9'9'.5+1MJ^JEGBB79I'M:EK8&S'.(.0(H8D$Q1Q&
M??4B0F)M8D]D2!0D]0@[@,RL*QGC:F,F6$CXUA]O)'<KL0,;9*%\@M8FWKE4
MYP%),_VFCH:VC$C<,A#&+PLV/(D]GA>DN\CM(@.5#ERYB-[MIL^P#L/O.9?
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:$T1-$31$T1-$31$T1-$31$T1-$31$T1?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img158215518_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img158215518_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )J KH# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W3=1OJ8JO
M]T?E3"%]!^5 #-U+OJQL3^ZOY4;$_NK^5 %;=1OJSL3^ZOY4;$_NK^5 %;?1
MOJSL3^XOY4;$_N+^5 %;?1OJSL3^XOY4;$_N+^5 %;?1OJSL3^XOY4;$_N+^
M5 %;?1OJSL3^XOY4;$_N+^5 %;?1OJSL3^XOY4;$_N+^5 %;?1OJSL3^XOY4
M;$_N+^5 %;?1OJSL3^XOY4;$_N+^5 %;?1OJSL3^XOY4;$_N+^5 %;?1OJSL
M3^XOY4;$_N+^5 %;?1OJSL3^XOY4;$_N+^5 %;?1OJSL3^XOY4;$_N+^5 %;
M?1OJSL3^XOY4;$_N+^5 %;?1OJSL3^XOY4;$_N+^5 %;?1OJSL3^XOY4;$_N
M+^5 %;?1OJSL3^XOY4;$_N+^5 %;?1OJSL3^XOY4;$_N+^5 %;?1OJSL3^XO
MY4;$_N+^5 %;?1OJSL3^XOY4;$_N+^5 %;?1OJSL3^XOY4;$_N+^5 %;?1OJ
MSL3^XOY4;$_N+^5 %;?1OJSL3^XOY4;$_N+^5 %;?1OJSL3^XOY4;$_N+^5
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MYN#Z!1113("F2RK#&7;.!CI3ZKWW_'F_U'\Q0!8HHHH **** "BBB@ HHHH
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M2_<A_M_G^ O_  J[3?\ G_NOR7_"C_A5VF_\_P#=?DO^%)_PM'3_ /GPN?\
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MFJZ9!?1HR),NX*W4<XJY6GLX/H<SQF(3LY'"?\*NTW_G_NOR7_"C_A5VF_\
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MEOP_G4E1S_ZEOP_G0!66I*C6I* %:H'J=J@>@"_1110 4444 %%%% !1110
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M/"O^$3U[_H%7/_?!H_X1/7O^@5<_]\&O=:*/J\>X?VK5_E7XGA7_  B>O?\
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MWH^KR[A_:M+L_P #QFBO:X?!7AUX48Z:N2H)_>O_ /%4_P#X0?PY_P! U?\
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M5Y=P_M6EV?X'B-%>T3^"_#T9BVZ:OS2!3F1SQS[U-_P@_AS_ *!J_P#?U_\
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M6?K/_/K8?]^W_P#BZ/\ A9^L_P#/K8?]^W_^+H_X5AK/_/U8?]_'_P#B*/\
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M[H_X2W7O^@I<_P#?='UB/8/[*J_S+\3W+RX_[B_E1Y<?]Q?RKPW_ (2W7O\
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M_P +1TS_ )\;O_QW_&C_ (6CIG_/C=_^._XT?N0_V_S_  &_\*ML/^@A<_\
M?*U#=_#2PMK*><7]P3'&S@;1S@9JQ_PM'3/^?&[_ /'?\:@O/B7IUS93P+97
M0,D;("=O&1CUI_N0_P!O\_P'1_#"P>)'^WW(W '[JT__ (5;8?\ 00N?^^5I
M(_B=IJ1(GV&Z.U0/X?\ &G_\+1TS_GQN_P#QW_&E^Y#_ &_S_ ;_ ,*ML/\
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M]DWO(_U#_P#H)I_5X]P_M6K_ "K\3Q,>%M=(R-*NL?\ 7,TO_"*Z[_T"KO\
M[]&O<;<C[-%R/N#^529'J*7U>/</[5J_RK\3PK_A%==_Z!5W_P!^C1_PBNN_
M] J[_P"_1KW7(]11D>HH^KQ[A_:M7^5?B>%?\(KKO_0*N_\ OT:/^$5UW_H%
M7?\ WZ->ZY'J*6CZO'N']JU?Y5^)X3_PBNN_] J[_P"_1J:S\+ZXE[ S:7=
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M.9P%EW1@^8!T#>N*8^D:;+=?:I-/M6N./WK0J6XZ<XSQB@"Y7%_$S_D78O\
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M ,51]7EW#^U:79_A_F>)9HS7MO\ P@WAO_H&C_O])_\ %4?\(-X;_P"@:/\
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MDJ.?_4M^'\Z *RU)4:U)0 K5 ]3M4#T 7Z*** "BBB@ HHHH **** "BBB@
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M;_\ A-?#O_023_OV_P#A1_PFOAW_ *"2?]^W_P *\0HH^L2[!_95+^9GM_\
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MUR/\Q0!8HHHH **** "BBB@ JO??\>;_ %'\Q5BJ]]_QYO\ 4?S% %BBBB@
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MC_A5ME_T$9_^^!4O_"T=+_Y\;S\E_P :/^%HZ7_SXWGY+_C1^Y"^/\_P(O\
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MDKH/("BBB@ HHHH **** ((?]=/_ +P_E4]00_ZZ?_>'\JGH **** "BBB@
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MD_Y4?9IO^>3_ )4>WGV#^S,/_,_O7^1[#_PL'PY_S^2?]^7_ ,*/^%@^'/\
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MI^/\S0!9HHHH **** "BBB@ JN?^0B/^N1_F*L57/_(1'_7(_P Q0!8HHHH
M**** "BBB@ JO??\>;_4?S%6*KWW_'F_U'\Q0!8HHHH **** "BBB@ HHHH
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M=35.[GAMKB"2>6.) &&Z1@H[=S2DKJS+IS<)J2W1Y!_P@?B7_H&G_O\ Q_\
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M+?A_.I*CG_U+?A_.@"LM25&M24 *U0/4[5 ] %^BBB@ HHHH **** "BBB@
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M* "J]]_QYO\ 4?S%6*KWW_'F_P!1_,4 6**** "BBB@ HHHH **** "HY_\
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M'%5(\^U]3@/^%CZ__>M_^_57='\>ZU>ZU96LS0&.:=(VQ'@X+ &G?\*MO_\
MH(6WY-_A5O2_AS>V&JVEV]] RP3)(5 .2 0<?I7.E5OJ>O.>!Y7RVOZ,]&HH
MHKJ/#"BBB@ JIJG_ "";W_K@_P#Z":MU4U3_ )!-[_UP?_T$T(">W_X]HO\
M<'\JDJ.W_P"/:+_<'\JDH **** "BBB@ HHHH @A_P!=/_O#^53U!#_KI_\
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M"EN3C' K4KC/B4K/X>B"@D^<.E3)VBVC6A!3J1B]FR[_ ,)_X;_Y_F_[\/\
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MR[@6&0.O-3/J5C%>I927ENMTXRL+2 .?H.M %JL?7]'M]=B@L;IY5B+%\Q$
MY&/4&MBL+Q/K0\/VL-^T!G 8IL#[>OO@TI6MJ73YG-<F_0R/^%8Z)_S\W_\
MW\3_ .)K0T;P3IFAZ@M[;373RJ" )'4CD8[**Y\?%2,G_D$'_P "/_L:] @E
M$]O'*!@.H;'ID9K."IM^Z=5>6*@K56[,DHHHK4X@HHHH *J:I_R";W_K@_\
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MHY_]2WX?SJ2HY_\ 4M^'\Z *RU)4:U)0 K5 ]3M4#T 7Z*** "BBB@ HHHH
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MU!#_ *Z?_>'\JGH **** "BBB@ HHHH KW76#_KJ/Y&K%5[KK!_UU'\C5B@
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M):]<K/LM#TS3IS-9V,,$I7;N1<''I^E:%*G#DC8TQ==5ZG.D%%%%6<P4444
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M_F* +%%%% !1110 4444 %5[[_CS?ZC^8JQ5>^_X\W^H_F* +%%%% !1110
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MTM%<QHWC%-6U&WMSI\UO!>+(]E.[J?."'#94<K^-=/0 4444 %%%% !1110
M5'/_ *EOP_G4E1S_ .I;\/YT 5EJ2HUJ2@!6J!ZG:H'H OT444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7)ZGX-DO]4O)5U
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M $-'VJ'^_P#H: )J*A^U0_W_ -#1]JA_O_H: )J*A^U0_P!_]#1]JA_O_H:
M)J*A^U0_W_T-'VJ'^_\ H: )J*A^U0_W_P!#1]JA_O\ Z&@":BH?M4/]_P#0
MT?:H?[_Z&@":BH?M4/\ ?_0T?:H?[_Z&@":BH?M4/]_]#1]JA_O_ *&@":BH
M?M4/]_\ 0T?:H?[_ .AH FHJ'[5#_?\ T-'VJ'^_^AH FHJ'[5#_ '_T-'VJ
M'^_^AH FHJ'[5#_?_0T?:H?[_P"AH FHJ'[5#_?_ $-'VJ'^_P#H: )J*A^U
M0_W_ -#1]JA_O_H: )J*A^U0_P!_]#1]JA_O_H: )J*A^U0_W_T-'VJ'^_\
MH: )J*A^U0_W_P!#1]JA_O\ Z&@":BH?M4/]_P#0T?:H?[_Z&@":BH?M4/\
M?_0T?:H?[_Z&@":BH?M4/]_]#1]JA_O_ *&@":BH?M4/]_\ 0T?:H?[_ .AH
M FHJ'[5#_?\ T-'VJ'^_^AH FHJ'[5#_ '_T-'VJ'^_^AH FHJ'[5#_?_0T?
M:H?[_P"AH FHJ+[3#_?_ $-'VB+^]^AH EJ.;_5-^%'GQ_WOT-))(C(0#D_2
M@"%14F*:HI^* *>RC94^VEVT 5]E&RK&VC;0!7V4;*L;:-E %?91LJQLI-E
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M(YKE21'$C-G![*,FBTNX>TI?R?B_Z_I>=\M;:,7<=U<PZU)-"K!VEVOLC8$
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MHHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH
M,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48H
MHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,5SGC-UBTBWD=L*MY$23V&
M:Z.B@#G-0UG3]9TN\L--O4ENYH'$<:Y!;@DCIZ9K)M#IUW'IEN=3U6>X62,B
MT0)F%E[M\HP!]>E=S10!YY;)9VVDW%AJ6H:C#<B1TDLH0I,N6/* KSG(YS78
MW5J[>&YK6W$GF&S:.,2$;L[,#..]:5% '!6HTZZLM/LY-1U66X#1K]B0)F)U
M]05& ,=<]*WO#T\0N]7M"X%P+Z60QGKM.,'Z5OT4 <MJNI&W\02PFYM], A4
MBY>W\QY\]@?0>G-9>@L7OM*+$[CJ%V3N7:<^63R.WTKO:* ,Z36].B@DG>YQ
M''<&V8[&XD'&WI^O2GZP/^))?_\ 7M)_Z":K^(R?[(QV,\(/N/,6M:@#D?LT
MMGHFD:Y9(6GM[.);B-?^6T.T9'U'45G:?J!M=.T:+SK:Q5K5F^VRP[V^^?W:
M^GK7?T4 >="0OIFK3-(\H7489'D:/82O'SE<< ]:[F\C74]&GC@D4K=6[*CC
MH0R\']:N44 <G'K,,.BP6-Q?MI-_;JL;AXMY.T8^4$$$'KQ6;,^HW=C9WVH3
M7?V:&_8B<1*DBQ%0%?:%(QG/;O7?44 <!J0L9[#5KFUOKZ^=;01M/+M,6"X.
MT$ 9;_Z]='J4:IXA\/JJ@!7F  '0>4:W** ,CQ!K<>A6 F(#S2-LB1C@$^I/
M8"N<,5GJFC:I';7ZZCK%Q#YDC(".%8':H/0=O>NZHH Y>YU*WU^\TB"Q)D:.
MX6YGX(\D*IX;C@Y.*MZM_P C3X?_ -ZX_P#1=;M% ''>(-,U&&TUF^:XM9(Y
MHR/FC;>D8Z*IS@?EUKHM%$XT:T^T-&S^4N#&I VX&.I/.*OT4 %%%% !1110
#!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img158215518_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img158215518_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,Z!BX# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"&4_.
M/I30:)O]8/I2 T .MNK_ (5/5>VZO^%6* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEG8]%'O1*G*+LT%/$TJD7*,M$:-8ND^+-$UR^DL].O?/N(T+LGE.N%! )RP
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MAWN K8_W=I_G4QIRELC2KB:5%VG*QZA16)X;\4Z=XHLVFLF99$P)89,!T/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>XGMVC(CZ$%CU&..!FJII<MS+%3G[9QL[6TLKM_,O?!<G&MC/'[C_P!J5A>
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MI7AB]U._T&"XUBU-M>LS;X]I7C<<<'D<8ZUG6UC%HZL$W&I4A).]VRC\0O\
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MQY;\8T6.RT5$4*JM* !T PM8,NB>-M/\,6VJP:Q=/8?9TE6*WO9 8HRH(RO
MP >@SC'I74_%G3;_ %*WTH6-E<W11Y=X@B9]N0N,X'%=GX>A>+PMI4$\3(ZV
M4*21NN""$ ((/\J%4Y:<298;VN)J)W6BM]QY1\.M%TG7]6-UJ-_+/?P-YOV6
M1>'QT8L22P'''%;7QF_X]M'_ -^7^2UD>(/"NK^%_%T>H^';*YF@+>="((FD
M\OU1L#I_0UK_ !'@U'Q#HNAW-II-^TA\QI81;N7B)"\,,9'(/UJ[WJ1E?0Q4
M7'#5*3C:2_'4Y[6XI-!/@W6T7!-G$QQ_$4(;GZJX%6]'9?$OC;Q)JQ8M#':7
M!C;V*^6O_CN:W?%NA7=_\--#2&SGDO;2*#,*1DR >6%8;<9X.,_2CX=^'[RQ
M\+:R]W:36]S=AHUCEC*OM"'!P1GDL?RHYUR7Z[ J,O;J%O=T?SM_F9GP:_Y"
M&J_]<H_YFO2/%'_(I:S_ ->,_P#Z+:N"^$^E:CIM]J37VGW5JKQ(%,\+(&.3
MTR.:[_Q'%)/X8U:&%&DEDLYE1$&2Q*$  =S655_O3LP<6L)9^9P/P9_X]M8_
MWXOY-77>--(L]<T5+*]U2/3X_.$@D<KAL C')'K7-_";3;_3;?51?65S:EWB
MV">)DW8#9QD<UT'CGPRWB?0O(@95NX'\V$MT8XP5)[9_F!1-KVM[BH1?U)+E
MN[/3YF)#\+_#LGATB&=KFY>,M'?++\I.." "5V_G]:R/@[J,_P!JU#36=FM_
M+$RJ>BMG!Q]<C\JS;6[\?Z;HS^'XM)NC"08UD-LS%%.<A7'RXY//..U=M\//
M"$WAJPFN+X*+ZZQN0'/EJ.@SZ\\_A5S=H-2=[[&%&*G6A*E#ELM3MLT9I**Y
M3V!<T9I** %S1FDHH 7-&:2B@!<T9I** %S1FDHH 7-&:2B@!<T9I** %S1F
MDHH 7-&:2B@!<T9I** %S1FDHH 7-&:2B@!<T9I** %S1FDHH 7-&:2B@!<T
M4E% "T4E&: %HHS10 4444 %%%% !1110 4444 5;G_6C_=I@IUS_K1_NTU:
M )+3J_X59JM:=7_"K- !1110 4444 %(30324 %%(329H 7-&?>FYI,T /S[
MT9IFZC- #LTN:9FC- #\T9IF:7- #LT9IN:,T .S1FFYHS0 [-&:;FC- #LT
M9IN:,T .S1FFYHS0 [-&:;FC- #LT9IN:,T .S1FFYHS0 [-&:;FC- #LT9I
MN:,T .S1FFYHS0 [-&:;FC- #LT9IN:,T .S1FFYHS0 [-&:;FC- #LT9IN:
M,T .S1FFYHS0 [-&:;FC- #LT9IN:,T .S1FFYHS0 [-&:;FC- #LT9IN:,T
M .S1FFYHS0 [-&:;FC- #LT9IN:,T .S1FFYHS0 [-&:;FC- #LT9IN:,T .
MS1FFYHS0 [-&:;FC- #LT9IN:,T .S1FFYHS0 [-&:;FC- #LT9IN:,T .S1
MFFYHS0 [-&:;FC- #LT9IN:,T /S13<T9H =FEIN:,T .I*3-&: '44VC- "
MYHI,TF: '49IN:,T +FC--S1F@!V:,TW-&: '9HS3<T9H =FC--S1F@!V:,T
MW-&: '9J*[5I;.>-!EFC90,]213\T9H!ZGG/PV\+:SX?U.]FU.S\B.2$*A\U
M&R=V?X2:](S3<T9JIS<W=F-"C&C#DCL.S1FFYHS4FP[-&:;FC- #LT9IN:,T
M .S1FFYHS0 [-&:;FC- #LT9IN:,T .S1FFYHS0 [-&:;FC- #LT9IN:,T .
MS1FFYHS0 [-&:;FC- #LT9IN:,T .S1FFYHS0 [-&:;FC- #LT9IN:,T .S1
MFFYHS0 [-&:;FC- #LT9IN:,T .S1FFYHS0 [-&:;FC- #LT9IN:,T .S1FF
MYHS0 [-&:;FC- #LT9IN:,T .S1FFYHS0 [-&:;FC- #LT9IN:,T .S1FFYH
MS0 [-&:;FC- #LT9IN:,T .S1FFYHS0 [-&:;FDS0 _-&?>FYHS0 [-+FF9I
M<T .HIH-+0 [-+3:4&@!:*** "BBB@ HHHH J7/^N'^[35IUS_KA_NTU: )+
M3J_X59JM:=7_  JS0 4444 %(:6FT %-)I332:  FFDTA-,R2<#F@!VZD+4T
MJ_\ <;\J:5D_N-^5 #]U&ZH]LG]QORI=LG]QORH ?NI=U1[7_N-^5+M?^XWY
M4 /W4NZH]K_W&_*EVO\ W&_*@"3-&:9A_P"ZWY4;7_NM^5 #\T9IFU_[K?E1
MM?\ NM^5 #\T9IFU_P"ZWY4;7_NM^5 #\T9IFU_[K?E1M?\ NM^5 #\T9IFU
M_P"ZWY4;7_NM^5 #\T9IFU_[K?E1M?\ NM^5 #\T9IFU_P"ZWY4;7_NM^5 #
M\T9IFU_[K?E1M?\ NM^5 #\T9IFU_P"ZWY4;7_NM^5 #\T9IFU_[K?E1M?\
MNM^5 #\T9IFU_P"ZWY4;7_NM^5 #\T9IFU_[K?E1M?\ NM^5 #\T9IFU_P"Z
MWY4;7_NM^5 #\T9IFU_[K?E1M?\ NM^5 #\T9IFU_P"ZWY4;7_NM^5 #\T9I
MFU_[K?E1M?\ NM^5 #\T9IFU_P"ZWY4;7_NM^5 #\T9IFU_[K?E1M?\ NM^5
M #\T9IFU_P"ZWY4;7_NM^5 #\T9IFU_[K?E1M?\ NM^5 #\T9IFU_P"ZWY4;
M7_NM^5 #\T9IFU_[K?E1M?\ NM^5 #\T9IFU_P"ZWY4;7_NM^5 #\T9IFU_[
MK?E1M?\ NM^5 #\T9IFU_P"ZWY4;7_NM^5 #\T9IFU_[K?E1M?\ NM^5 #\T
M9IFU_P"ZWY4;7_NM^5 #\T9IFU_[K?E1M?\ NM^5 #\T9IFU_P"ZWY4;7_NM
M^5 #\T9IFU_[K?E1M?\ NM^5 #\T9IFU_P"ZWY4;7_NM^5 #\T9IFU_[K?E1
MM?\ NM^5 #\T9IFU_P"ZWY4;7_NM^5 #\T9IFU_[K?E1M?\ NM^5 #\T9IFU
M_P"ZWY4;7_NM^5 #\T9IFU_[K?E1M?\ NM^5 #\T9IFU_P"ZWY4N'_NM^5 #
M\T9IF&_NG\J7#?W3^5 #\TN:9AO[I_*EP?0T .S2YI@-&: 'YI,TW- R>G-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AI&^X?I2
MTU_N-]* (,TN:CS2YH ?FGQ'YS]*AS4D!_>'Z4 6**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** *TI_>M2 TV8_OV_#^5"F@"4&G@U$#4@
MH ?2BFBE'6@!U%%% !1110!4N?\ 7#_=IJTZY_UP_P!VFK0!):=7_"K-5K3J
M_P"%6: "@]**#TH ;2'K2TTT ,)J-C3VJ)J (V-%L?\ 24_'^5,>EM3_ *6G
MX_RH TZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H-%!H 2F2?ZMOH:
M?3)/]6WT- %0&ES3 :7- "YJ6V.93]*AJ6U_UI_W: +=%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% %"X/^D-^'\J%--N3_I+_ (?RH4T
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MDUOL3457L;ZVU*P@O;23S+>= \;[2-RGH<'D58IDM-.S"BBB@04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% &;<_\?+_ (?RI$HNO^/I_P /Y4BF@"=:E%1)4HH D%.IHIU #ATHH'2B
M@ HHHH J7/\ KA_NTU:=<_ZX?[M-6@"2TZO^%6:K6G5_PJS0 4'I10>E #>U
M,/2G]J8>E $35$]2M4+T 0/2VG_'['^/\J1Z+/\ X_8_Q_D: ->BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;(GV>5MIR>X4BJYXJ:;?0Q^K598:4(0E=26EKM:/?3]#0^+/_($T7_L,0?\
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M$71/^O./^5=!6T/A1YN*_CS]7^844451@%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!F77_ !]O^'\J
M1*6Z_P"/M_P_E2)0!,E2K42U*M $HIW:FBG=J '#I10.E% !1110!4N?]</]
MVFK3KG_7#_=IJT 26G5_PJS5:TZO^%6: "@]**#TH ;VIAZ4_M3#TH B:H7J
M9JA>@"!^E%G_ ,?L?X_R-#]*+/\ X_8_Q_D: ->BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *#10: $J.7_ %3_ .Z:DJ.7_5/_ +IH SQ3J:*=0 AJ
M:S_UQ_W?ZU":FL_]<?\ =_K0!>HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN/\ N_UJYY4?]Q?RH"(IRJJ#["@!U%%% !1110 4444 %%%% !1110 4444
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MZGQYQA=7(& 2#C/Y8K1\&_\ (I6'^ZW_ *&U &[1110 4444 %%%% !1110
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M@(5:,1K(21A7.W)&<CD#J>>:ZSQ5IWBN'6[36O#5T+A8D,<^ESRE8I!S\PY
MW<^W0>XK#O\ 1?%_CG4M+37=(M-&TZQN1</MN%FED([*5) _'Z\XK2+32O\
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M=VH <.E% Z44 %%%% %2Y_UP_P!VFK3KG_7#_=IJT 26G5_PJS5:TZO^%6:
M"@]**#TH ;VIAZ4_M3#TH B:H7J9JA>@"!^E%G_Q^Q_C_(T/THL_^/V/\?Y&
M@#7HHHH **** "BBB@ HHHH **** "BBB@ HHK,M-=M;S6KK2HXYA/;+N=F
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_-E KIE8.H92"I&00>"*B491^)6(<7'="T445(@HHHH **** "BBB@#,NO\
MC[?\/Y4B4MU_Q]O^'\J1* )EJ5:B6I5H E%.[4T4[M0 X=**!THH **** *E
MS_KA_NTU:=<_ZX?[M-6@"2TZO^%6:K6G5_PJS0 4'I10>E #>U,/2G]J8>E
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MC^(T 6Z*K"=QZ&G"X]5H GHJ,3H>N13@ZGHPH =1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4&B@T )4<O\
MJG_W34E1R_ZI_P#=- &>*=313J $-36?^N/^[_6H34UG_KC_ +O]: +U%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1132ZKU(H =141G4=,FFF<]@!0!/154RN?XORII)/4DT 6BZCJPIIF0
M=\U6HH L&=>P---QZ+^M0T4 2^>WH*3SG]1^51T4 /\ -?\ O4GF/_>--HH
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MI!HVEVMV;NWTVSAN3DF:.!5<YZ_,!GFKU%%V%V4I=&TN>]6]FTVSDNU(83O
MID!'0[B,Y&!BK,]O!=1&*XACFC/5)%# _@:DHHNPNS.M] T:TF$UMI%A#*IR
M'CMD5@?J!6C110VWN#;>X4444A!1110 4444 %%%% &9=?\ 'V_X?RI$I;K_
M (^W_#^5(E $RU*M1+4JT 2BG=J:*=VH <.E% Z44 %%%% %2Y_UP_W::M.N
M?]</]VFK0!):=7_"K-5K3J_X59H *#THH/2@!O:F'I3^U,/2@")JA>IFJ%Z
M('Z46?\ Q^Q_C_(T/THL_P#C]C_'^1H UZ*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHIK.J]30 ZBH6G_ +H_.HVD=NI_
M*@"R65>I J,SJ.@)JO10!*9V/3 IA=CU8TVB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 4,1T)%/$SCOGZ
MU'10!.)QW'Y5()$;HPJI10!=HJH'9>A-2+.?XAF@">BF+*C=\?6GT %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %!HH- "5'+_JG_ -TU
M)4<O^J?_ '30!GBG4T4Z@!#4UG_KC_N_UJ$U-9_ZX_[O]: +U%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !113&E5>^3[4 /H)QUJ
MNT['H,5&23U)- %AID'?/TJ,SD] !45% #B[-U8TVBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
M@$CH<444 2"9QWS]:>LX_B&*@HH MJZMT(IU4J>LKKW_ #H M45"LX/WABI0
MP8<'- "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% &9=?\?;_A_*D2ENO^/M_P /Y4B4 3+4JU$M2K0!**=VIHIW:@!PZ44#
MI10 4444 5+G_7#_ '::M.N?]</]VFK0!):=7_"K-5K3J_X59H *#THH/2@!
MO:F'I3^U,/2@")JA>IFJ%Z ('Z46?_'['^/\C0_2BS_X_8_Q_D: ->BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD)"C).*B:?^Z/Q- $
MQ('6HFG4=.:@9BQY.:2@![2NW?'TIE%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4=*** )4G(X;D5.K!AD&J=*"0<@X- %RBH4G[-^=3=: "BBB@
M HHHH **** "BBB@ HHHH *#10: $J.7_5/_ +IJ2HY?]4_^Z: ,\4ZFBG4
M(:FL_P#7'_=_K4)J:S_UQ_W?ZT 7J*** "BBB@ HHHH **** "BBB@ HHHH
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M4 %%%% !1110 4444 %%%% !1110 4444 9EU_Q]O^'\J1*6Z_X^W_#^5(E
M$RU*M1+4JT 2BG=J:*=VH <.E% Z44 %%%% %2Y_UP_W::M.N?\ 7#_=IJT
M26G5_P *LU6M.K_A5F@ H/2B@]* &]J8>E/[4P]* (FJ%ZF:H7H @?I19_\
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MHH **** "BBB@":.;^%OSJ>J52Q2[?E;I_*@"Q1110 4444 %%%% !0:*#0
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M@=3Z@C(I9(8I86ADC1XF&UD905(]"/2K>CZ8+J\MK"VB6.,D*%1<!%'7 '3
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M?X5ZS6?J^D6^L6A@G&&',<@'*'_/:O.S+!?6J?N_$MO\CT\KQ_U2K[WPO?\
MS/):*T]5T&^TESY\1:'/$R#*G_#\:S*^/J4YTY<LU9GVM.K"K'G@[H***L6=
MA=:A-Y5K \K_ .R.!]3T%3&+D[15V5*2BN:3LB*&&2XF2&)"\CG:JCJ37K.C
MZ>NEZ7!:C!91ER.['DUF>'?#,>D*+B<K)>$=1T0>@]_>NAKZO*L \.G4J?$_
MP1\AF^8QQ,E2I_"OQ84445[!XAPGCVW(O+2YQ\K1F/\ (Y_K7FWB72+C6;6S
MBMWB5H;M)V\PD J <XP#SS7N'B#2O[6TF2!<><OSQ'_:';\>17E;HT<C1NI5
MU)#*>H([5\IFD)X?%^VCUU7ZGV&4U(8G!^QETT?YHX]_"$HU+7+F.6+;>P.E
MNA)^1G W%N..1VSQ6JNDW \'_P!D;X_M'V,P;LG9NVXSG&<?A6S17GSQ=6=N
M9[6_ ]*&#I0ORK>_XZG+W?AR^N?#.F:-YL"I$T8NVW-\R+U"\<^O..E17W@B
MTA^S7.A11VM[!.L@:25RK =0<Y_E76T4XXVM'9Z7;MT=^_<F6 H2^)7=DK]5
M;:W8FLH&NKV"!1EI'5<?4U[)7">"M':2X.IS+B./*Q9_B;N?P_STKNZ^@R2@
MZ=%U)?:_)'S>>XB-2LJ<?L_FPHJAJNKVND6WFW#_ #'[D:_>8^U<'J7B[4KY
MBL4GV6+LL1Y_%NOY8KKQ>8T<-I+5]D<>#RVOBO>BK1[L]+HKQF2>69MTDKNW
MJS$FIK?4KVT8&WNYH_97./RKSEGT;ZPT]?\ @'IOAV5M*FOI_P $]@HKB-'\
M;OO6'5%!4\>>@P1]0/Z?E7:QR)+&LD;!T895E.017KX;%TL3&]-_+J>-BL'6
MPLN6HOGT'4445TG*%%%% !1110 4 X.1110!9CEW<'K_ #J2J56(I-PP>O\
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M:W_#&C7.AVUQ;3R1R(TF]&0GTP<@].@J]I.E0Z5:F*-FDE<[Y96^](W<FK]
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !145Q=06D1DN
M)DB0=W;%8<_C31X6PKS3>\<?^.*QJXBE2_B22-Z6&K5OX<6SH:*YR+QMI$C
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M/>N<U'P7I]XQDMV:TD/9!E/^^?\  U\[C<FDY.>'Z]/\CZ; 9W%15/$=.O\
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M* &331V\+S2L%C12S,>P%>5:WK$VL7S3.2L2\11_W1_C79>-[MH-&2!3@SR
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M_2@#2L-9T[4V9+.Z61UY*$%6Q]" :OUSWB&)(=3T:]BPMP;Q(21U9&ZY]O\
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M'@AE#*00>01WKU_25*Z/8JW46\8/_?(KRK2=/-[?6UC"@56(7"C 51U_(5[
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M 8OZU14WNM&?"YC@_JE9P6SU7H%%%%=IPA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %2P-A\>M14JG:P/H: +E%%% !1110 4444 9EU_Q]O\
MA_*D2ENO^/M_P_E2)0!,M2K42U*M $HIW:FBG=J '#I10.E% !1110!4N?\
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MBBB@!\1Q(*M534X8'WJY0 4&B@T )4<O^J?_ '34E1R_ZI_]TT 9XIU-%.H
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M=6? 0E@M[^TF1XY(I58HXP1D8_\ 9:Z^DVC<6P-Q&,T +1110 4444 %%%%
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MIOB?4+, 9BLX V.[;1D_GFKFF_\ )1=:_P"O>+^2UTJVT"7#W"01K/( 'D"
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M7;A;SQ9+::Q=3V]C&<((QD 8&#^/K@UK:-HDMEJD5UHVJ17&FG'FQO)DX/;
M&,]^U%]J>DZEK4^F:U8I;F$E8[AY,$\\<X& 0<\G%8DT5II/B2R&@WKW!=P'
M16W#J/ER.H//TH [%_$&SQ1'HOV7.]<^=YG3Y2WW<>WK3;GQ#]G\20:1]EW>
M: ?-\S&,Y[8]O6L+4+B*Q^)$%Q<N(XM@R[< 90KGZ9J&>]M[[XB6DMM*LD:E
M4WKR"0#TH CU&_&F_$.>Z,3S%0H6-.K$Q  ?K70Z3XLCU#43875G)97)SM5S
MG)].@P:P[F\M['XE2SW3!8AM&\]%)B !I^H7,&J>/=.-@RRB/;YDD?(."2>1
MUXH VIO$TTFI7%EINF/>O;9$K>:$ (X.,CFG67B5K[3+JYATVX-Q;X_<<G?S
MV('U[5BW&D1W>NW4V@ZTL5X6+2Q$D<D\X8=1G/'-7_"FM:A>WMW87[),UN.)
MDQU!QC(X/UH SO!FKWT^H31S0SW(N&S)<DDB/"D@'C'/3J*M6WCF6\^2VT6:
M:7/*1R%L#UX6JW@"Z@A2ZMY)D2:21=D;'#-P>@IWPZ \O4#CG,8S_P!]4 ;-
MSXDE&IMIUCIKWEU&FZ51*$5/49(YZTW3_% U"RO7BL9?M=J,FV!R6^A _I6<
MVIZCK'B*\TZ/4%T^VMMV2JC<P4X)R?S^E5O I7^U]3VR&08X8G)8;CS0 SPE
MK5_+J=PLUO/<BX=?,G).(0 <9XQ_*M&X\<*)YA9:;-=6\/WYE8@ >O0\?7%9
M7A.>-;;6+0S(ES.-D*,<%FPPXJKX=G,6G7,1UZ/3@')>&2V5]PP!D$\GTQ0!
MW^E:G;ZO8)=VY.TG!5NJGN#5VN=\(6-M96$WV345O89),Y$>S:<<\$GVKHJ
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MSSPVMO)<7$J10QJ6=W. H'4DT 2=*\^\5_%G1]!:2UT\#4;U>"$;$2'W;O\
M0?F*X#Q]\4+G7GETW1WDMM,!*O(#A[@>_<+[=^_I7F]=M+"]9B;.JUSXB^)M
M>=A-J+V\!Z06I\M0/PY/XDURQ)8DDDD\DFDHKLC%1T2)"BBBJ 4$J002".01
M74Z%\1?$V@,!!J+W$ _Y879,J?09.0/H17*T5,HJ2LT!]#>%/BSH^O,EKJ(&
MFWS< 2-F*0^S=C['\S7H5?&]>C^ OBA=Z!)'IVL227.EG"JY^9[?Z=ROMV[>
MAXZN%ZP*3/H&BHK>XAN[:.YMI4EAE4.DB'(8'H0:EKB&%%%% !1110 4444
M%%%% "J,L![U<JK$,R"K5 !0:*#0 E1R_P"J?_=-25'+_JG_ -TT 9XIU-%.
MH 0U-9_ZX_[O]:A-36?^N/\ N_UH O4444 %%%% %><?,#[5%5B<94'T-5Z
M"BBB@ HHHH **** "BBB@ JKJ&G6NJ6IM[N(2(>1ZJ?4'L:M44 <X'UCP_\
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M ,*U:*7)'L:_6J_\[^]F5_PC.@?] /3?_ 2/_"C_ (1G0/\ H!Z;_P" D?\
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M"Y?/I45685VIGN>: )**** "BBB@ HHHH S+K_C[?\/Y4B4MU_Q]O^'\J1*
M)EJ5:B6I5H E%.[4T4[M0 X=**!THH **** *ES_ *X?[M-6G7/^N'^[35H
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MNR(''T(S4E>,4%%%% !1110 4Y%W.!3:L0IA=QZF@"6BBB@ H-%!H 2HY?\
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MVX6 [H0(QB,^J\<?A7DQS!1@H\NRM^&OXV9[,\M<JCGS;N_SO=?A='/>+/\
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M444 %%%% !1110 4444 %%%% !1110 4444 .1=[@5;J*%-JY/4U+0 4444
M%%%% !1110!F77_'V_X?RI$I;K_C[?\ #^5(E $RU*M1+4JT 2BG=J:*=VH
M<.E% Z44 %%%% %2Y_UP_P!VFK3KG_7#_=IJT 26G5_PJS5:TZO^%6: "@]*
M*#TH ;VIAZ4_M3#TH B:H7J9JA>@"!^E%G_Q^Q_C_(T/THL_^/V/\?Y&@#7H
MHHH **** "BBB@ J"=,'<._6IZ0@$$'I0!3HISJ4;!IM !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MENRPHHHI %%% &3@4 .C3>V.W>K=,C38N._>GT %%%% !0:*#0 E1R_ZI_\
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MU\G]:^O-(M38Z+8VC#!@MXXB/]U0/Z5R8S9#1<HHHK@*"BBB@ HHHH ****
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M !1110!4N?\ 7#_=IJTZY_UP_P!VFK0!):=7_"K-5K3J_P"%6: "@]**#TH
M;VIAZ4_M3#TH B:H7J9JA>@"!^E%G_Q^Q_C_ "-#]*+/_C]C_'^1H UZ***
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MDB,59&&"I'4$=C3:](D**** "BBB@ HHHH ***?%%)-*D42,\CD*JJ,EB>@
MH FT[3[G5=1M["SB,EQ.X1%'<G^GO7U/X7T"W\,^'[72X,$QKF5P/]8Y^\WY
M_IBN4^&GP_'AFU_M/444ZK.N O7R$/\ #_O'N?P]<^AUYN(K<[Y5L4D%%%%<
MPPJ6*+=\S=/YTL<.?F;\JGH **** "BBB@ HHHH *#10: $J.7_5/_NFI*CE
M_P!4_P#NF@#/%.IHIU "&IK/_7'_ '?ZU":FL_\ 7'_=_K0!>HHHH **** "
MBBB@ HHHH *0@,,'I2T4 59(RA]1ZTRKI (P>E5Y(BO*\B@"*BBB@ HHHH *
MY/XDZ2VL>!-1BC!,L*BX0#N4.3_X[FNLI&574JRAE88((R"*J,N5I@?'%%=!
MXT\//X8\4WFG$'R-WF6['^*)N5_+D'W!KGZ]A--71 445>L+7S&\UQ\HZ#U-
M8XBO"A3=2?0[,#@JF-KQH4MW^"[EBQM?)3>X^=OT%1:A<_\ +!#_ +Q_I5F[
MN!;Q9'WSPHK&)))).2:\;+Z$\55>*K?+^NR/K<\QE/+L,LLPN]O>?E_F^OEZ
MB5I:?<Y'DN>1]W_"LVE!*L"#@CH:]?%X:.)I.$OEZGRV69A4P&(5:&W5=U_6
MWF:U];>='O4?.OZBLBMNUN!<1!OXAPPJEJ%ML;S4'RMU'H:\G+,3*E-X6MOT
M_P O\CZ?B++J>)HK,\+JFO>]._RV?_ 91HHHKWSX@W?!FDG6_&&F6.TLC3J\
MF/[B_,WZ U]5UX_\$O#C1Q7?B&XCQY@^SVQ([9R[#\0!^!KV"O-Q4^:=NQ2"
MBBBN884444 %%%% !1110 4444 %%%% ' ^/8F&I6LV/E:':/J"3_45Y=XMM
M;BYFT7R())1'?QO)L0MM7N3CH*]P\7:6=0T@R1KF:W/F*!U(_B']?PKS2OD\
MQ4L-C74MOJONL?8Y:XXK JE?5:/[[H\V_L#4(UUN%K:9H+2!X;%!&?F$C[LK
MZG'!QZUTU_;3O\/S;+!(T_V%$\H(2V[:.,=<UT=%<E3'3J.+:V=_Z]=SLIX"
M%-22>Z:_KTV^1QNK6]_/X.T;1X+:<272013MY9/DJ%7);TYQUQWJ"[T;6-'U
M/2]4^V/J8@<6[1PV@1DB((/"YR!_A7<T41QTHKE25M;^=_/IIV"> A)\SD[J
MUO*WEL]>Y)!$9[B.)1EG<*!]3BO9J\X\':8U[JRW+#]S;?-GU;L/Z_A7H]>W
MD=%QI2J/[7Z'@Y_64ZL::^ROS"BBBO</ "BBB@ HHHH **** "BBB@ HHHH
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M_7-6JXJN(E/1:(:0444](V?IT]:YQC0"3@=:GCB"\MR:>B!!QU]:=0 4444
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MR:M445]%&*C%1BK)'S,I2G)RD[MA1115$A1110 4444 %%%% !1110 4444
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M)10!49&0X(IM72 1@BH7@[K^5 $%%*5*G!&*2@ HHHH **** "BBB@ HHHH
M*S/$=E/J7AG5+&V.)[BUDCCYQEBI 'X]*TZ*:=G<#SJT\8:2GA"QT@Z:U[JJ
M0Q6S:-)"0Q=< [@5("@C.3QTK,>.#1/%>NC7==U711=W'VFWEMF AG0CIN*-
MEEZ8X^E>L45HJB6R$>.3VJ1>%;6[CCU!8[WQ+#,KW\@:289QYF B[=V,XY^M
M;%U9SZAK?Q-M+9"\\MI:+&@ZLWD-@#W/2O2Z*?MO+^M/\@L>0^(_$VF:A\-;
M'3+2226\A%JMQ&(F!@VE0=^1A>>/<FMNZEG@\>^+);6U6ZG31D,<#+N$AP<*
M1WSZ=Z]#HI>T5K)?UH!X9K%];7_@&51XCU*^O1;INTVVMQ#!;8(+*Z*@VJH!
M R<<#&:[?12K?%*5U((.@PX(]-XKO**;JW5K!8*\=M;::?X.120Q/+]FU,SR
M*BY;8LQW$#O@<U[%140GRC/-M<\2:9K_ (I\)C2YFN8HK_,DRQL$4E3A<D#Y
MN"<>U;?@T#^V_%I[_P!J'_T!:ZZBFYJUD@/']/CDM=!T#6/(DELM-UBZ:Y6)
M-Q1&=E#X'93Z5V,?B/3?$.KF'1[)-0$=G*9-25,"$GI&I*\ENX![=^W7T4Y5
M%+5H#R*"_M;KX8:!:PRAI[/4;2*XCP0T;>8>"#6_9ZK9^$?%GB!-<<VL6H3K
M<VUTR,8Y5VX*;AW![5WU%#J)W5A'D%_')<Z!KVL>1+#9ZEK-L]LDJ%2Z*ZC?
MM/(#>]=CXR _MOPD<<_VH.?^ -7744.I=[ >17EU9Z;>:K+9ZSJ7AO5UN)'_
M +,*F>&X;J'1"N#O]NF?2O3- N+Z[T"PN-3A$-[) K31@8PQ'IV^G:M&BE.?
M,MAA11168!1110 4444 %%%% !1110 4444 %%%% !1110 444=: "E ). ,
MFI$A)Y;@5.JA1@"@")(>[?E4W2BB@ HHHH **** "BBB@ HHHH **** "@T4
M&@!*CE_U3_[IJ2HY?]4_^Z: ,\4ZFBG4 (:FL_\ 7'_=_K4)J:S_ -<?]W^M
M %ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ J)X0>5X-2T4 4V4J<$4E
M7" 1@C-1/!W4_@: (**4J5.",4E '!^,_A?IGB=I+VT86.IMRTBK\DI_VU]?
M<<^N:\.U_P ):WX:F*:G8R1QYPLZC=&_T8<?@>?:OJVFR1I+&T<B*Z,,%6&0
M1]*Z*>(E#1ZH5CXYHKZ6U7X7>$]58N=.^R2'^*T;R_\ QW[OZ5S%U\"M/=C]
MDUNZB7L)85D_D5KJCBJ;WT%8\0HKV5?@.H/S>(R1[66/_:E:ME\$-!A(:\O[
MZY(_A4K&I_0G]:;Q-/N%CP8 LP5022< #O7>^%?A3K6O21SWZ-IU@<$O*/WC
MC_97^IQ^->WZ-X0T#0,'3=+@AD'_ "U(WR?]]-D_K6W6$\6WI%#L9'A[PUI?
MABP%IIEL(P<>9(>7D([L>_\ *M>BBN1MMW8PHHHI %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 45(L3-[#WJ9(E3W/K0!"D+-R>!4ZHJ#@4ZB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** ,RZ_X^W_#^5(E+=?\?;_A_*D2@"9:
ME6HEJ5: )13NU-%.[4 .'2B@=** "BBB@"I<_P"N'^[35IUS_KA_NTU: )+3
MJ_X59JM:=7_"K- !0>E%!Z4 -[4P]*?VIAZ4 1-4+U,U0O0! _2BS_X_8_Q_
MD:'Z46?_ !^Q_C_(T :]%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 (0&&",U$T'=3^!J:B@"FRE3@C%)5T@$8(J)H%/3B@"O13VB=>V1[4
MR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***<J,W04 -H )Z5
M.L']X_E4JJ%' Q0! L!/WN!4RHJ=!3J* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ H-%!H 2HY?]4_^Z:DJ.7_ %3_ .Z: ,\4ZFBG4 (:FL_]<?\
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MBBB@ HHHH **** "BBB@ HHHH **4 GH":>(7/;'UH CHJ<0#N?RJ01HO04
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MH 3T!I1&Y_A-6Z* *PA<^@IPMSW:IZ* (A @ZY-/$:#HHIU% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M&B@T )4<O^J?_=-25'+_ *I_]TT 9XIU-%.H 0U-9_ZX_P"[_6H34UG_ *X_
M[O\ 6@"]1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 THIZJ*:84/;%244 1&!>Q---N>S
M?I4]% %?R&]12>2_H/SJS10!5\I_[M)Y;_W35NB@"IL?^Z?RHV-_=/Y5;HH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[?\ #^5(E+=?\?;_ (?RI$H F6I5J):E6@"44[M313NU #ATHH'2B@ HHHH
MJ7/^N'^[35IUS_KA_NTU: )+3J_X59JM:=7_  JS0 4'I10>E #>U,/2G]J8
M>E $35"]3-4+T 0/THL_^/V/\?Y&A^E%G_Q^Q_C_ "- &O1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>W_4M_\ D]_]KKQVBCV%/L'L8=CV+_A>W_4M_P#D]_\ :Z/^%[?]2W_Y/?\
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MA?\ 81M__1BU]6UA@_A9ZO$O\6GZ/\PHHHKL/F@HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:^!/B9=>)+A;"^TF8SC@W-JA:,>[C^'\S6KHR4>8T=*2CS'I%%%%8F04444
M%>:_&_\ Y$NS_P"PBG_HN2O2J\U^-_\ R)=G_P!A%/\ T7)65?\ AL]#*O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMO=.KJDH&Z/&>,CKU]*Z:BBAMR=V-MMW84444A!1110 4444 %%%% !1110
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MFVC>4!"[L<XSVS3Z**]8_/0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,/4&O$-4T^72M3N+*7[T3X!_O#L?Q&#7NE<-\1-'\VVBU:)?FBQ'-CNI/!_
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MB7B7_H7M6_\  *3_ .)H_P"$2\2_]"]JW_@%)_\ $U]644?6GV#ZR^Q\I_\
M")>)?^A>U;_P"D_^)H_X1+Q+_P!"]JW_ (!2?_$U]64&CZT^P?67V/E/_A$O
M$G_0O:M_X!2?X4'PGXD R?#^J@?]>4G^%?5=1R_ZI_\ =-'UI]@^LOL?*W_"
M+>(?^@%J?_@))_A1_P (MXA_Z .J?^ <G^%?3(IU'UI]@^LOL?,G_"+>(?\
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M!2?_ !-'_")>)?\ H7M6_P# *3_XFOJRBCZT^P?67V/E/_A$O$O_ $+VK?\
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M ;VIAZ4_M3#TH B:H7J9JA>@"!^E%G_Q^Q_C_(T/THL_^/V/\?Y&@#7HHHH
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MS.1USO/\J(5*DK>[IZBQ&"PE)22KWDKZ<KW72YZ)17BNB?\ )P5Y_P!=9_\
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MONC+@'')[5'_ ,+!T/\ Z>?^_7_UZT8+NQ\6Z)=)#YGD/NA8NN"&P#G\,@T
M2^'(TB\-::L?W3;HQ^I&3^I-:$UO#<ILGACE3.=KJ&&?7FN,TK79?"]N-*UN
MUF5821#<1KN1US3-4U:?Q?Y>EZ-#,MLSAI[IU*J #G']?7(H [E5"J%4  #
M [5QGAS_ )'S7OQ_]"%=A!"MO;QPH25C0("QR< 8YKC_  Y_R/FO?C_Z$* .
MTHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "@T4&@!*CE_U3_P"Z:DJ.7_5/_NF@#/%.IHIU "&IK/\
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M+U\B:F'AB<+1A&K!.-[WE;=GL=>6_''_ )%O3?\ K\_]D:NP\%_\))_8;?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !0:*#0 E1R_P"J?_=-25'+_JG_ -TT 9XIU(*6@!#4UG_KC_N_UJ(U-9_Z
MX_[O]: +M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &9=
M?\?;_A_*D2ENO^/M_P /Y4BT 3)4JU&E2K0!(*=VIHIW:@!PZ44#I10 4444
M 5+G_7#_ '::M.N?]:/]VFB@"6UZO^%6*KVW5_PJQ0 4'I10>E #>U,/2GTP
MT 1D5"]3M43T 5FI;3_C\3\?Y&E846H_TM/Q_E0!J4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !0:*#0 E1R_ZI_P#=-25'+_JF^AH H"G4 4M #34U
MI_KC_N_UJ/%2VO\ K3_NT 7**** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *#110 E,D_U;?0T^FR?<;Z&@"D!2
MXI0*7% #,5+;#]Z?I3<5);C$A^E %FBBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M* (\R?WV_.C,G]]OSJ2B@"/,G]]OSHS)_?;\ZDHH CS)_?;\Z,R?WV_.I**
M(\R?WV_.C,G]]OSJ2B@"/,G]]OSHS)_?;\ZDHH CS)_?;\Z,R?WV_.I** (\
MR?WV_.C,G]]OSJ2B@"/,G]]OSHS)_?;\ZDHH CS)_?;\Z,R?WV_.I** (\R?
MWV_.C,G]]OSJ2B@"/,G]]OSHS)_?;\ZDHH CS)_?;\Z,R?WV_.I** (\R?WV
M_.C,G]]OSJ2B@"/,G]]OSHS)_?;\ZDHH CS)_?;\Z,R?WV_.I** (\R?WV_.
MC,G]]OSJ2B@"/,G]]OSHS)_?;\ZDHH CS)_?;\Z,R?WV_.I** (\R?WV_.C,
MG]]OSJ2B@"/,G]]OSHS)_?;\ZDHH CS)_?;\Z,R?WV_.I** (\R?WV_.C,G]
M]OSJ2B@"/,G]]OSHS)_?;\ZDHH CS)_?;\Z,R?WV_.I** (\R?WV_.C,G]]O
MSJ2B@"/,G]]OSHS)_?;\ZDHH CS)_?;\Z,R?WV_.I** (\R?WV_.C,G]]OSJ
M2B@"/,G]]OSHS)_?;\ZDHH CS)_?;\Z,R?WV_.I** (\R?WV_.EW2?WV_.GT
MM #-TG]]O^^J4-)_?;\Z?2B@!NZ3^^W_ 'U3MTG]]O\ OJG4M #=TG]]O^^J
M7?)_?;_OJG44 -W2?WV_[ZII:3^^W_?524=Z (BTG]]O^^J:6D_OM_WU4II#
M0!$6D_OM^=-W2?WV_.I324 1;I/[[?G1F3^^WYU)10!'F3^^WYT9D_OM^=24
M4 1YD_OM^=&9/[[?G4E% $>9/[[?G1F3^^WYU)10!'F3^^WYT9D_OM^=244
M1YD_OM^=&9/[[?G4E% $>9/[[?G1F3^^WYU)10!'F3^^WYT9D_OM^=244 1Y
MD_OM^=&9/[[?G4E% $>9/[[?G1F3^^WYU)10!'F3^^WYT9D_OM^=244 1YD_
MOM^=&9/[[?G4E% $>9/[[?G1F3^^WYU)10!'F3^^WYT9D_OM^=244 1YD_OM
M^=&9/[[?G4E% $>9/[[?G1F3^^WYU)10!'F3^^WYT9D_OM^=244 1YD_OM^=
M&9/[[?G4E% $>9/[[?G1F3^^WYU)10!'F3^^WYT9D_OM^=244 1YD_OM^=&9
M/[[?G4E% $>9/[[?G1F3^^WYU)10!'F3^^WYT9D_OM^=244 1YD_OM^=&9/[
M[?G4E% $>9/[[?G1F3^^WYU)10!'F3^^WYT9D_OM^=244 1YD_OM^=&9/[[?
MG4E% $>9/[[?G1F3^^WYU)10!'F3^^WYT9D_OM^=244 1YD_OM^=&9/[[?G4
ME% $>9/[[?G1F3^^WYU)10!'F3^^WYT9D_OM^=244 1YD_OM^=&9/[[?G4E%
M $>9/[[?G1F3^^WYU)10!'F3^^WYT9D_OM^=244 1YD_OM^=&9/[[?G4E% $
M>9/[[?G1F3^^WYU)10!'F3^^WYTF9/[[?F:EI* (\R?WV_,TF9/[[?\ ?52T
ME $>9/[[?]]49D_OM_WU4E+0 P-)_?;\Z<&D_OM^=.%**  -)_?;_OJGAI/[
M[?\ ?5 IXH  \G_/1O\ OJGAY/\ GH__ 'T:!3A0 N^3_GH__?1I0\G_ #T?
M_OJBE% "[Y/^>C?G2AY/[[?G12T *'?^^WYT\,_]YOSIHIPH 7DG))-.%(*>
$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img158215518_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img158215518_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (T![P# 2(  A$! Q$!_\0
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M_45/10!#Y3>HI?+;U%2T4 1%2N,T9I93]VF9H 2,_O15BJL1_?+5J@ HHHH
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MHHHH **** "BBB@ HHHH *AN#C;^-35!<_P_C0!&#2YI@-+F@!V::31FFDT
M6HO]6*DJ*'_5+4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %4P:N51!H D!I<TP&ES0
MI-(I^=?J*0FD0_O%^HH N"EI*6@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (9_P"'\:8#
M3KC^'\:C!H (O]<OX_RJW5.'_7K^/\JN4 %%%% !1110 4444 %>._%EC+XM
MTNWE)$'V=3_WU(P;] *]BKA?B3X1G\06,-[8)OO;4$>7WD0\X'N#T]<FM:,D
MIZG'CJ<IT&HZG<(BQQK&BA44 *HZ "J=M_90OIQ:_8A=[CYWE;?,SWW8YS]:
M\LM_BGK.G6(T^\TD27\:B-9)"R'(XRR8R3^(K2^'/AK4I-8G\3ZS'(DTNXPB
M089F;[SX[#' ^M-TG%-R9,<9&K.,::OW\ANN^%;:X\075WXJ\4PI:-EH88Y0
MDB@G@!6S@ >F<UE?#R_:Q\=RZ597\ESIDOF*A;(#!02K8/0\5C:>]II/B2^'
MC#2;N^N7)VJ"23)GKU&X'UYK1\)G[/\ %6!IK'^S5FWF*V88V*T9*C\L?C70
MT^5IZZ'FQFG5C**L^;7>_P PDLKK4_BQJ.GVMX]H;F:1)98_O",#<P'UQBF^
M(M*D\ >*]/?2K^Y82A9#YC#)^;!#8P"#]*TM'_Y+A=?]=9O_ $ T?%O_ )&3
M2/\ KE_[/23?.H]+#E!>QG4ZJ6GWEWXA:M?ZAXHL/"ME<O;Q3&,3,IQN9VXS
MCJ ,'%3GX7W>EW]K=>'M;EMW3F5ISDD^P48(//!_6H/B'I%_I_B:P\56-NUQ
M%"8S,JC.UD;(SCL1@9]OI4TOQ3N=1N;:W\/Z)/<2M_K4F7G/HNT]/<_E4+FY
M5R;=3HE[+VL_;WO?3?;R*_Q-\0W,>I66@+>FUMW1'NYXU8=3CH.< #.!G.>]
M<MJ$NB>'_LU]X3\1W<MXK@2QR1NN[@Y/*@8[;3GK73_$;0M0_M+3O$B6*W*Q
MI&+NW \Q593GD8Y4YQT[>]1Q^,/"]W/!!8>!8[F9^'06D65/^S@'/XXJH:15
MD8UTW6ESNSZ7O?Y6*GQ+U/\ M71O"NI( C3Q2R$#D*V(\C\#FNQ\)^"+?3)[
M?7+F\NKG4Y8MTAD<; SCG QD]2.37*_%N*.&Q\.I%:K:H$FQ J@"//EG;A>.
M/:O5;#_D'VW_ %R7^0K.<FJ:MYG51IJ6*FYZM<OWV$U&\73],N[UEW+;PO*1
MZA5)_I7D7ACP_-\19;_4];U*YQ&X1$B(P"1GC.0 .. *]=U&S74-,N[)FVK<
M0O$3Z!E(_K7D7ACQ!-\.I[_3-;TZYVR.'1X@.2!CC. 0>.<TJ5^5\NY6,Y?:
MP]K\&OI?S.R\,:%JW@ZSU"34-46[L(XGDC@&XE=O.03TR!R!WKS>TOM*\47]
MW>^+M=N;8Y_<0PQLP&<],*P ''&,FO1/#?B#5O&4>H07>DBTTR6)XTN,L#\W
M '/WC@\D8%<+HTMIX)U&\L?%/A];M&8>7,;=)#QG[I;@@_7M6D+WE??R.:OR
M\M/D^#7>]OG^AK_#SQ!);>+)M!BU"2_TR4/]FDDR""HW9 ;D< Y'KS3/A=_R
M.VL_]<I/_1@KI?!FIZ7K5\T]GX0CT\1 F.\6",#TP& !R0>@S7-?"[_D=M9_
MZY2?^C!1)Z2TZ#@K2I:W5W;?]0^''_)2=;_ZY3_^CDKGHKJQUGQ#>GQI?ZA;
MN'VJ(0"(SD@J00< >P]:Z#X=;A\1]<V@%O)GP"< GSD[T[5/$]D^J7$'C3PD
MJD8$<L"?O/\ OLD;ATP015?;=ET1BDG1C=VU>][?.QN^ -'FT^\N);'Q';ZA
MI# A8%8LP]"1_ ?YUWY 92K $$8(/>O&? NG377CL:EHMG=6>CQYR9CG*E<;
M<]R3SCG'X9KV>N>LK2/2P,KTM%;7^K7Z'DO@>5?"_CS6]%GD*6Y5V4D=D^93
MC_<)-<OH&L3Q>.[379@RQ75\ZNYZ?-@,/P#@_E70_%FQET_7[35K=BGVJ!H7
M8>H&T_FK8_"H]6\.FV^$6EWBH1/%*+IV']V0X_EY?Y5TIIKF?VM#S9QG&3IK
M_EW=_E8NRJ?$_P 9PA!:VTTC/<#R^?\ T8<53^'5LE[XI\06DA81SVLT;%>H
M#. <>_-;/PDL9)(-3URXRTUS+Y8<]\?,Q_$D?E69\+O^1VUG_KE)_P"C!4MV
M4DNB1I"-YTYR^TVS"TCPG87_ ,0;O0)9;D6D+RJKJR[R%Z9.,?I5[Q=93#XF
M6-A83M#,%MX89CU0X #?4=:=)J!\)?%2_P!0U"UN&B>24H(UY</]TC. >HJ?
M6KA;OXNZ/<JI596M9 &Z@$ \U5WS7Z6,>6"IN/7G_ K^-O#)\&2Z?J>G:I>O
M<RN0\DKC=O&#D$8X]CFO8=+N7O=(LKJ0 /- DC =,E03_.O/?C+_ ,@S2_\
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M.TCG!Z5ZA7F'@/1-2U+Q3=>+-1MS:I*7,,; @L6XR ?X0.,]Z]/K&M;FT.[
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M\+_;/LG]L0^;NVYVMLS_ +^-OZTE%O9%2J0C;F:5SHZ*\A^%W_([:Q_UR?\
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M:0<KO32YB_$:[EG\<V-@]M+>6UJD82T1VW2ECDC/)R>!GD\51\0P7>K0V_\
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MK8@MYLNRP0X^\RE>W &">YKT>L*MN;1W/0P2DJ7O1MKZ?@+1245D=8M%)10
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M - +3/\ P$C_ ,*T4X026_4YG0K5ISFM$]-5T.<^%>L?VAX5^QNV9;%_+_X
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M*N[)./<_2I=,^)&M:Y;+:Z5H:3ZL,L_S8A5..>2#U/0G\:G^&G'@"^]YIO\
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MN:;FC- #JS%Z5I9K-6@!XIV::#2T (:$_P!:G^\*#2)_K4_WA0!H4N:;FC-
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M10 W8G]Q?RHV)_<7\J=10 W8G]Q?RHV)_<7\J=10 W8G]Q?RHV)_<7\J=10
MW8G]Q?RHV)_<7\J=10 W8G]Q?RHV)_<7\J=10 W8G]Q?RHV)_<7\J=10 W8G
M]Q?RHV)_<7\J=10 W8G]Q?RHV)_<7\J=10 W8G]Q?RHV)_<7\J=10 W8G]Q?
MRHV)_<7\J=10 W8G]Q?RHV)_<7\J=10 W8G]Q?RHV)_<7\J=10 W8G]Q?RHV
M)_<7\J=10 W8G]Q?RHV)_<7\J=10 W8G]Q?RHV)_<7\J=10 W8G]Q?RHV)_<
M7\J=10 W8G]Q?RHV)_<7\J=10 W8G]Q?RHV)_<7\J=10 W8G]Q?RHV)_<7\J
M=10 W8G]Q?RHV)_<7\J=10 W8G]Q?RHV)_<7\J=10 W8G]Q?RHV)_<7\J=10
M W8G]Q?RHV)_<7\J=10 W8G]Q?RHV)_<7\J=10 W8G]Q?RHV)_<7\J=10 W8
MG]Q?RHV)_<7\J=10 W8G]Q?RHV)_<7\J=10 W8G]Q?RHV)_<7\J=10 W8G]Q
M?RHV)_<7\J=10 W8G]U?RHV)_=7\J=10 W8G]U?RHV+_ '1^5.HH 38O]T?E
M1M7^Z/RI:* *EV "F!ZU".E3WG6/\?Z5 .E #H/^/E?Q_E5^J$'_ !\+^/\
M*K] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M* "BBB@ HHHH **** $JK>=4_&K55;SJGXT 5Q3NM(*6@ [4PT^FF@"[;?\
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MGQ_P(UU6V@!FVEVT_;2XH CVT!:DVUGZWK6G^'=*EU'4IO*MX\#@%F=B<!5
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M4 1%::5J4BFD4 1$4L;F.0,*4BFD4 :JL&4$4M5K-\Q[?2K- !1110 4444
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MDB"2>6KX#. >&!'0^E ':T5\WZ+KGQU\0Z-#J^E7!N+&?<8Y1'9+NVL5/RL
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M"Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% "5FKTK2K-7I0 \4M(*6@!#0G^M3_>%!H3_6I_O"
M@#0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BFF
M6)>>OI3W;:I;TK+D<R.6- "R2/*<L:0"@"G@4 (!3@*4"G@4 - IV*4"G 4
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MB@ HHHH **** "BBB@ HHHH **** "BBB@"M=]4_&HATJ6[ZI^-1#I0 L/\
MKU_'^57:I0_Z]?Q_E5V@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@"E>OT4?C54"IKGF4U&* % IX%(!3P* % IP% %. H  *7%*!3L4
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M ()U/Q7%9ZF+#3IDAEC:*/S69B@&T;\$?..I'>N>_P"&CO!__0-US_OQ#_\
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M[^O+?A9XN\%>*+J;^Q_#EAHFM11$O%%;QJS1DC.UU4%AG&00.W%>I4 %%%%
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M_P )YX:;6/[?^PXN'A\K['YOW0#G.]?7TKTVY\$)X"^ NOZ8TZSW<L#SW,J
M[2YVC"YYP  /?D\9KRKP5X1^(6J^#9]5\+:[/;V4<SK]B@OY87=P 20HPN3D
M=30!+XCT;7?@CXFTN73]?:ZBF'F[$!B$@4C<KQY(P<]<^O0BMW]I"3S=9\/R
M8(WV;M@]1EA6/\+M#TSQUXR!\6:W?7.J6QWI9766-P$Y(,C,3P<Y3 XSSUK;
M_:5_Y#^A?]>LG_H0H ZS]GW494T+6?#=T<7.E7IRO]U6R"!]&1_SKQ;XEW\O
MB'QMKVMJ<VD=Z+.-NQ"J5&/PCS_P+WKT'6-7'PP^,GB&8,4M]1TIY(/0R^7E
M2?K(C#_@5<5JFBM8_ _1=28?/?ZO-*2>N A1?P_=L?QH ]?U+X9?\+&^'G@7
M_B;_ -G_ &#2HO\ EV\W?OBB_P!M<8V>_6O'=0^&WV#XJ6_@G^UM_G-&OVS[
M-C&Y-WW-W;I]ZOJ+P)_R3SPU_P!@JU_]%+7C7B#_ ).HT_\ ZZ0?^B: .F\-
M?#3_ (5/8>(?$/\ ;OVXKIDN$^R^3M*C>#G>W]W'XUY#X)^'.E>*=%^WZGXQ
ML-$E>X:&&WN%0M* %^89D4]21C':OICX@6!U;P-JFG#4;73C=1B+[3=/MC4%
MAD$^XR/QKQ^Q_9_TN?P7+J!\1BYU'RGDBFLW1[0E<\9QEAD8)R,<\<4 >J_#
M?P,/ 'AV?2QJ7]H":Z:Y$H@\K&41<8W-G[F<Y[UV%>-_L[Z]?:EX5U#3;N5I
M8M.F1;=G.2J,#\GT!4X^M>R4 %%%% !1110 4444 %%%% !1110 4444 5KO
MJGXU$.E2W?5/QJ(=* %A_P!>OX_RJ[5*'_7K^/\ *KM !1110 4444 %%%%
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M/XA0!HCH**13E12T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD-TX["DT+X<Z-X>\&:CX7LY;QK/4%E6>61U,O[Q-A((4#@ 8X_.@#AOV;O\
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M %%%% "5FKTK2K-7I0 \4M(*6@!#0G^M3_>%!H3_ %J?[PH T**** "BBB@
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M3R":>))4BV2KSO&Y@"&[CUSZTWXJ^"?&'CR;PY>6^A&*5+4I>Q?:H?W#EAD
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M-!,@>.1&RK*1D$'N* '&FFGFF&@",BF'K4AJ,]: +\?W!3JCAYB%24 %%%%
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MJUYJK+^[@C\E#ZNW)_(#_P >J*KM!LZ<)!SKQ7F>P4AI:0UYA]6---IYIAH
M8:8:D-1F@!C5:MS\E535BU.5- %BBBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *UWU3\:B'2I;O
MJGXU$.E "P_Z]?Q_E5VJ4/\ KU_'^57: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "JURG1JLTV1=R$4 4A3Q4>-IP:>* )!3A3!3Q0
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M]>_=/YD(#[9:GCPS\;;[#7/B_3+53U5% *_]\Q?UKV.*&."%(88TCB0!51%
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M1110 E5KOJGXU9JM=]4_&@" 4ZFBG4 !IAIYIAH NVW_ ![K^/\ .I:BMO\
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MHHH **** "BBB@ HHHH **** "BBB@ I&&Y2*6B@#/(VL0:<*DN$PV[UJ,4
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M9#.HW2N/XW/4_P!/H!7S]H&KRZ%KEIJ46287RRC^)3PP_$$U]*6UQ%=VL5S
MX>&5 Z,.A4C(-<V*;T70]7*8P]Z7VOT)33:<:0UR'M#33#3S3: &&F&GFF&@
M!AJ:U/#"H34EL?F- %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** *UWU3\:B'2I;OJGXU$.E "
MP_Z]?Q_E5VJ4/^O7\?Y5=H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/4DH"37S?7T=X:_Y%71_^O&'_P! %=V5_'(\G/\ ^'#U-6BDI:]H^8"BBB@
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M==.DL;6QLWU&_O@6@@C<("H&=S,?NCWJGIWC"YN?$L.A7VBR6-V\;R/NF#J
M!D%2!A@>>>,8K)^TPZ/XO\/ZE?LL5E<:.MHDTAPL<H.[D]L@XI9]3L]8^*=C
M'I]TDOE6$L;31-N4,<G (ZD<'\:E4U;;IN2H*VW3<T1XSOKY[F30_#TVI6-L
MY1KG[0L6\CKL4@EJW]$UFUU[2HM0M"WER9!5QAD8<%2/45R7@;7M+T?PH--U
M.[@L;S3GD2XAF8*V=[-D \MP>U7OAQ#*GAZZNG1DCO;Z6YA5A@^6V ./P)I5
M())Z6M^(IP23TV.OHHHKG,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB@ HHHH *",C%%% %)UV.1VI0:EN%Z&H10 \4\4P4X4 >%_$/_D>M2_[9?\
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MW$?3/PLO_M_P\TW+9>#? WMM8X_\=*UV!%>5? J^\S0]5L"PS#<+,![.N/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2^N[31]-BTQX9I1=ZA+YEU+DG#950 ^>F3Z?CM6]O!<ZGX >>&.1IM.E,A=
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MN.]UZO2WH6J*CMX([6WC@B#".-0JAF+' ]SR:DKK/.?D%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% "56N^J?C5FJUWU3\: (!3J:
M*=0 &F&GFF&@"[;?\>Z_C_.I:BMO^/=?Q_G4M !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG<Y+'U)J.G1QO-(L<:,\CD*JJ,DD] !7IOA#P%96E[;S>)981=2*9(=.=AG
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M8A5 R23@ 4 #R)%&TDC*B*"69C@ >IKQ/QIXJM=9\0)-:VD,MO;#RP\JD^<
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M_P JNT %%9?F/_>-*)9!_%0!IT5G"YE'>I%O&'WAF@"[14"72-UXJ8$$9!H
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MN:<DZ=YK7Y7 ]U)P3^(KR2BLYTH3W0[GU3H/C+0/$JJ-.U"-IR,FWD.R4?\
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MTE%%8RE*6K9DY.6["BBBI$%%%% !1110 4444 %%%% !1110 4444 %)2T4
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MQI,4]A\U)B@!N*3%/Q1B@!F*,4_%&* &8HQ3L48H ;BC%.Q1B@!N*,4[%&*
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MF:]>6MZS/.LA)D;_ ): \AOQSFLVOF,34E4J-R/O,%0A1H1C#5;W[^99T_\
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MV04445UGG!1110 4444 %%%% !1110 4444 %%%% !24M% "44M)0 E%+10
ME<5XR^']KXA5[RRV6VI ?>QA)O9L=_?\\]NVHQ51DXNZ,ZM*%6/+-71\NWUA
M=Z9>26E[ \$\9PR..?\ ZX]ZK5]'>)O"FG>)[/RKM-DZ#]U<(/G0_P!1[?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC5FJMWU3\: (13J:*=0 &F&GFF&@"[;?\>Z_C_.I:BMO^/=?Q_G4M !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 E9@Z5IUE*: )!2TP4N: %-$?\ KD_WA32:(S^^C_WA0!J4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% "55O.J?C5HU5O?X/Q_I
M0!7%/I@IPH 6HR<4\TQJ +]M_P >Z_C_ #J6H;;_ (]U_'^=34 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 E9 -:]8P- $H-&:9FC- #B:6(_OH_]X4S-+$?W\?\ O#^=
M &O1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M #T3_OH5G;:-M &CYL?_ #T3_OH4>;'_ ,]$_P"^A6=MHVT :/FQ_P#/1/\
MOH4>;'_ST3_OH5G;:-M &CYL?_/1/^^A1YL?_/1/^^A6=MHVT :/FQ_\]$_[
MZ%'FQ_\ /1/^^A6=MHVT :/FQ_\ /1/^^A1YL?\ ST3_ +Z%9VVC;0!H^;'_
M ,]$_P"^A1YL?_/1/^^A6=MHVT :/FQ_\]$_[Z%'FQ_\]$_[Z%9VVC;0!H^;
M'_ST3_OH4>;'_P ]$_[Z%9VVC;0!H^;'_P ]$_[Z%'FQ_P#/1/\ OH5G;:-M
M &CYL?\ ST3_ +Z%'FQ_\]$_[Z%9VVC;0!H^;'_ST3_OH4>;'_ST3_OH5G;:
M-M &CYL?_/1/^^A1YL?_ #T3_OH5G;:-M &CYL?_ #T3_OH4>;'_ ,]$_P"^
MA6=MHVT :/FQ_P#/1/\ OH4>;'_ST3_OH5G;:-M &CYL?_/1/^^A1YL?_/1/
M^^A6=MHVT :/FQ_\]$_[Z%'FQ_\ /1/^^A6=MHVT :/FQ_\ /1/^^A1YL?\
MST3_ +Z%9VVC;0!H^;'_ ,]$_P"^A1YL?_/1/^^A6=MHVT :/FQ_\]$_[Z%'
MFQ_\]$_[Z%9VVC;0!H^;'_ST3_OH4>;'_P ]$_[Z%9VVC;0!H^;'_P ]$_[Z
M%'FQ_P#/1/\ OH5G;:-M &CYL?\ ST3_ +Z%'FQ_\]$_[Z%9VVC;0!H^;'_S
MT3_OH4>;'_ST3_OH5G;:-M &CYL?_/1/^^A1YL?_ #T3_OH5G;:-M &CYL?_
M #T3_OH4>;'_ ,]$_P"^A6=MHVT :/FQ_P#/1/\ OH4>;'_ST3_OH5G;:-M
M&CYL?_/1/^^A1YL?_/1/^^A6=MHVT :/FQ_\]$_[Z%'FQ_\ /1/^^A6=MHVT
M :/FQ_\ /1/^^A1YL?\ ST3_ +Z%9VVC;0!H^;'_ ,]$_P"^A1YL?_/1/^^A
M6=MHVT :/FQ_\]%_.CS8_P#GHOYUG[:7;0!H>;'_ 'U_.CS$_OK^=4 M."T
M7=Z?WE_.JMV0Q3!!Z]*3%1R\;: &BG4T4[I0 4PT^F&@"[;.H@4%AW[^]2^8
MG]]?SJE"/D/UIQ% %OS$_OK^='FQ_P!]?SJB5I"M %[S8_\ GHOYT>;'_P ]
M%_.L_;1MH T/-C_YZ)_WT*/-C_YZ)_WT*SMM&V@#1\V/_GHG_?0H\V/_ )Z)
M_P!]"L[;1MH T?-C_P">B?\ ?0H\V/\ YZ)_WT*SMM&V@#1\V/\ YZ)_WT*/
M-C_YZ)_WT*SMM&V@#1\V/_GHG_?0H\V/_GHG_?0K.VT;: -'S8_^>B?]]"CS
M8_\ GHG_ 'T*SMM&V@#1\V/_ )Z)_P!]"CS8_P#GHG_?0K.VT;: -'S8_P#G
MHG_?0H\V/_GHG_?0K.VT;: -'S8_^>B?]]"CS8_^>B?]]"L[;1MH T?-C_YZ
M)_WT*/-C_P">B?\ ?0K.VT;: -'S8_\ GHG_ 'T*/-C_ .>B?]]"L[;1MH T
M?-C_ .>B?]]"CS8_^>B?]]"L[;1MH T?-C_YZ)_WT*/-C_YZ)_WT*SMM&V@#
M1\V/_GHG_?0H\V/_ )Z)_P!]"L[;1MH T?-C_P">B?\ ?0H\V/\ YZ)_WT*S
MMM&V@#1\V/\ YZ)_WT*/-C_YZ)_WT*SMM&V@#1\V/_GHG_?0H\V/_GHG_?0K
M.VT;: -'S8_^>B?]]"CS8_\ GHG_ 'T*SMM&V@#1\V/_ )Z)_P!]"CS8_P#G
MHG_?0K.VT;: -'S8_P#GHG_?0H\V/_GHG_?0K.VT;: -'S8_^>B?]]"CS8_^
M>B?]]"L[;1MH T?-C_YZ)_WT*/-C_P">B?\ ?0K.VT;: -'S8_\ GHG_ 'T*
M/-C_ .>B?]]"L[;1MH T?-C_ .>B?]]"CS8_^>B?]]"L[;1MH T?-C_YZ)_W
MT*/-C_YZ)_WT*SMM&V@#1\V/_GHG_?0H\V/_ )Z)_P!]"L[;1MH T?-C_P">
MB?\ ?0H\V/\ YZ)_WT*SMM&V@#1\V/\ YZ)_WT*/-C_YZ)_WT*SMM&V@#1\V
M/_GHG_?0H\V/_GHG_?0K.VT;: -'S8_^>B?]]"CS8_\ GHG_ 'T*SMM&V@#1
M\V/_ )Z)_P!]"CS8_P#GHG_?0K.VT;: -'S8_P#GHG_?0H\V/_GHG_?0K.VT
M;: -'S8_^>B?]]"CS8_^>B?]]"L[;1MH T?-C_YZ)_WT*/-C_P">B?G6=MHV
MT :/FQ_\]%_.CS8_[Z_G6?MI=M &AYB?WU_.CS$_OK^=40M. H N;U_O#\ZJ
M@48IP% !BBG8HQ0 PBA1AU/O3\4TB@"QO3^\OYT>8G]]?SJKBFE: +GF1_WU
M_.D\V/\ OK^=4BM-VT 7_-C_ .>B_G1YL?\ ST3\ZS]M)MH T?-C_P">B?\
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MZ)_WT*SMM&V@#1\V/_GHG_?0H\V/_GHG_?0K.VT;: -'S8_^>B?]]"CS8_\
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MM%3D5#%_KEJR10!$12;:E(I,4 1;:3;4NVC;0!%MHVU)MHVT 1[:-M2;:-M
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M&V@"/;1MJ3;1MH CVT;:DVT;: (]M&VI-M&V@"/;1MJ3;1MH CVT;:DVT;:
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M;: (]M&VI-M&V@"/;1MJ3;1MH CVT;:DVT;: (]M&VI-M&V@"/;1MJ3;1MH
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M,<8Y/\.#UK0Q6;5G8AJSL,Q1BGXHQ2$,Q1BGXHQ0 S%&*?BC% #,48I^*,4
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M@8HQ7&^$/'?]O7KZ;J%LMKJ !*A<A7QU&#R"/3ZTGB_QU+H>HQZ7IEJMU?L
M6# D+GHN!R2>OXBCZU2]G[2^@?4*_MO8VUW^7>YV>*,5PWA?Q]<ZEK/]CZU9
M+:7C9";59/F SM96R0<5/XF\:7>GZY%H>BV*W>H-C<),[02,@8!';DG(P*%B
MJ3ASWTV^8/ 5U5]DUK:_E;O<[+%&*X?1_&^I#Q&FA^(M-CM+F4A4:(G&3T[G
M(/3(-=WBM*56-17B8U\/.@TI]=5U3&8HQ6#K%UXGAUJVBTG3K6XTYE3SY9&
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M,2SM:O"&/?Y&9O\ V6L81?NTNC2?W(Z:DX^]7ZQ;C][5OP9K_"'_ )!NI_\
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M(#&@/)8'J0">A_"KGQ!UW3]?\%PW.G3&6)-12-B5*D'RG/0\]ZW[3_DDC?\
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MK6<3V^DV$,H.1)';(K _4"M"BA-H+M'G7Q;TV_U+3M-6PLKFZ9)7+"")G*C
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M_D*M447=K#N]@HHHI""BBB@ HHHH **** "BBB@!#5:ZZI^-635>ZZI^- $
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M4$5+VTM[E5Y431JX'TR*L44N5=@YY::[%&71-)FABAETNRDBBSY:/;H53/7
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M=%_SU3_OH4 /HIGG1?\ /5/^^A1YT7_/5/\ OH4 /HIGG1?\]4_[Z%'G1?\
M/5/^^A0 ^BF>=%_SU3_OH4>=%_SU3_OH4 /HIGG1?\]4_P"^A1YT7_/5/^^A
M0 ^BF>=%_P ]4_[Z%'G1?\]4_P"^A0 ^BF>=%_SU3_OH4>=%_P ]4_[Z% #Z
M*9YT7_/5/^^A1YT7_/5/^^A0 ^BF>=%_SU3_ +Z%'G1?\]4_[Z% #Z*9YT7_
M #U3_OH4>=%_SU3_ +Z% #Z*9YT7_/5/^^A1YT7_ #U3_OH4 /HIGG1?\]4_
M[Z%'G1?\]4_[Z% #Z*9YT7_/5/\ OH4>=%_SU3_OH4 /HIGG1?\ /5/^^A1Y
MT7_/5/\ OH4 /HIGG1?\]4_[Z%'G1?\ /5/^^A0 ^BF>=%_SU3_OH4>=%_SU
M3_OH4 /HIGG1?\]4_P"^A1YT7_/5/^^A0 ^BF>=%_P ]4_[Z%'G1?\]4_P"^
MA0 ^BF>=%_SU3_OH4>=%_P ]4_[Z% #Z*9YT7_/5/^^A1YT7_/5/^^A0 ^BF
M>=%_SU3_ +Z%'G1?\]4_[Z% #Z*9YT7_ #U3_OH4>=%_SU3_ +Z% #Z*9YT7
M_/5/^^A1YT7_ #U3_OH4 /HIGG1?\]4_[Z%'G1?\]4_[Z% #Z*9YT7_/5/\
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M_?5 $M%1>='_ ,]%_P"^J/.C_P">B_\ ?5 $M%1>='_ST7_OJCSH_P#GHO\
MWU0!+147G1_\]%_[ZH\Z/_GHO_?5 $M%1>='_P ]%_[ZH\Z/_GHO_?5 $M%1
M>='_ ,]%_P"^J/.C_P">B_\ ?5 $M%1>='_ST7_OJCSH_P#GHO\ WU0!+147
MG1_\]%_[ZH\Z/_GHO_?5 $M%1>='_P ]%_[ZH\Z/_GHO_?5 $M%1>='_ ,]%
M_P"^J/.C_P">B_\ ?5 $M%1>='_ST7_OJCSH_P#GHO\ WU0!+147G1_\]%_[
MZH\Z/_GHO_?5 $M%1>='_P ]%_[ZH\Z/_GHO_?5 $M%1>='_ ,]%_P"^J/.C
M_P">B_\ ?5 $M%1>='_ST7_OJCSH_P#GHO\ WU0!+147G1_\]%_[ZH\Z/_GH
MO_?5 $M%1>='_P ]%_[ZH\Z/_GHO_?5 $M%1>='_ ,]%_P"^J/.C_P">B_\
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MZH EHJ+SH_\ GHO_ 'U1YT?_ #T7_OJ@"6BHO.C_ .>B_P#?5'G1_P#/1?\
MOJ@"6BHO.C_YZ+_WU1YT?_/1?^^J ):*B\Z/_GHO_?5'G1_\]%_[ZH EHJ+S
MH_\ GHO_ 'U1YT?_ #T7_OJ@"6BHO.C_ .>B_P#?5'G1_P#/1?\ OJ@"6BHO
M.C_YZ+_WU1YT?_/1?^^J ):*B\Z/_GHO_?5'G1_\]%_[ZH EHJ+SH_\ GHO_
M 'U1YT?_ #T7_OJ@"6BHO.C_ .>B_P#?5'G1_P#/1?\ OJ@"6BHO.C_YZ+_W
MU1YT?_/1?^^J ):*B\Z/_GHO_?5'G1_\]%_[ZH EHJ+SH_\ GHO_ 'U1YT?_
M #T7_OJ@"6BHO.C_ .>B_P#?5'G1_P#/1?\ OJ@"6BHO.C_YZ+_WU1YT?_/1
M?^^J ):*B\Z/_GHO_?5'G1_\]%_[ZH EHJ+SH_\ GHO_ 'U1YT?_ #T7_OJ@
M"6BHO.C_ .>B_P#?5'G1_P#/1?\ OJ@"6BHO.C_YZ+_WU1YT?_/1?^^J ):*
MB\Z/_GHO_?5'G1_\]%_[ZH EHJ+SH_\ GHO_ 'U1YT?_ #T7_OJ@"6BHO.C_
M .>B_P#?5'G1_P#/1?\ OJ@"6BHO.C_YZ+_WU1YT?_/1?^^J ):*B\Z/_GHO
M_?5'G1_\]%_[ZH EHJ+SH_\ GHO_ 'U1YT?_ #T7_OJ@"6BHO.C_ .>B_P#?
M5'G1_P#/1?\ OJ@"6BHO.C_YZ+_WU1YT?_/1?^^J ):*B\Z/_GHO_?5'G1_\
M]%_[ZH EHJ+SH_\ GHO_ 'U1YT?_ #T7_OJ@"6BHO.C_ .>B_P#?5'G1_P#/
M1?\ OJ@"6BHO.C_YZ+_WU1YT?_/1?^^J ):*B\Z/_GHOYTOG1_WU_.@"3-+4
M?FI_?7\Z/,3^^OYT ,N/X?QJ,4^8AMN"#]*:* &M49HHH 8:8:** &XHHHH
M3%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*
M** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #
M%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&**
M* #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** "E
MHHH 44\=*** 'BGK110 _O2BBB@ I*** &'K3#110 PTS%%% "$4F*** #%&
M*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&***
M#%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*
M** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #
M%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&**
M* #%+BBB@!<48HHH ,4N.*** $Q1BBB@ Q28HHH 3%&*** #%&*** #%&***
M #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&
M*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&***
M#%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*
M** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** % I1110
-\4\444 2+4E%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img158215518_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img158215518_6.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1584&AO=&]S:&]P(#,N,  X0DE-! 0
M    %3R^5#8X0DE-! 0      &(< 5H  QLE1QP!6@ #&R5'' (   *N !P"
M4  (<G(R.3,W-#D< @4 .4UI8W)O<V]F="!7;W)D("T@5&%N9V\@+2!!;65N
M9&UE;G0@3F\N(#$@=&\@1F]R;2!3+3$N9&]C>#A"24T$)0      $"7&DZ^>
M9-W>FT@!\PIN8D X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 5X            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-! T       0   !X.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      ,U    !@              V0   DT
M         0                         !              )-    V0
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG    V0
M  !29VAT;&]N9P   DT    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    '
M.$))300,      JE     0   *     [   !X   ;J    J) !@  ?_8_^T
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M05%A<2(3!3*!D12AL4(CP5+1\#,D8N$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                      #_X4 9
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X]
M(N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M
M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!8
M35 @0V]R92 U+C,M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z
M,C<@(" @(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W
M=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS
M.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(^"B @(" @(" @
M(#QX;7 Z0W)E871O<E1O;VP^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I-;V1I9GE$871E
M/C(P,C$M,#DM,CA4,#<Z-#8Z,S@K,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@
M(" @(" @(" \>&UP.D-R96%T941A=&4^,C R,2TP.2TR.%0P-SHR,3HQ.2LP
M-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$
M871E/C(P,C$M,#DM,CA4,#<Z-#8Z,S@K,#4Z,S \+WAM<#I-971A9&%T841A
M=&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT
M=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R
M;V1U8V5R/D%C<F]B870@1&ES=&EL;&5R(#$P+C$N,38@*%=I;F1O=W,I/"]P
M9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN
M<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @
M(" @(" \9&,Z=&ET;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @
M(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/DUI8W)O<V]F
M="!7;W)D("T@5&%N9V\@+2!!;65N9&UE;G0@3F\N(#$@=&\@1F]R;2!3+3$N
M9&]C>#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @
M(#PO9&,Z=&ET;&4^"B @(" @(" @(#QD8SIC<F5A=&]R/@H@(" @(" @(" @
M(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3YR<C(Y,S<T.3PO
M<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z
M8W)E871O<CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF
M;W)M870^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-
M33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @
M(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z<W12968]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E
M9B,B/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C8R1$%!
M-C X,#(R,$5#,3%"-#,V1$9%0S@S.4,X14)$/"]X;7!-33I);G-T86YC94E$
M/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C%&.3 Y-3=$
M,#$R,$5#,3%"-#,V1$9%0S@S.4,X14)$/"]X;7!-33I$;V-U;65N=$E$/@H@
M(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z,48Y
M,#DU-T0P,3(P14,Q,4(T,S9$1D5#.#,Y0SA%0D0\+WAM<$U-.D]R:6=I;F%L
M1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @
M(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C%&.3 Y-3=$,#$R,$5#,3%"-#,V
M1$9%0S@S.4,X14)$/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 Y+3(X5# W.C0T.C4R*S U.C,P/"]S
M=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!
M9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F
M='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^
M+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z-C%$04$V,#@P,C(P14,Q,4(T,S9$1D5#.#,Y0SA%0D0\+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,C$M,#DM,CA4,#<Z-#8Z,S@K,#4Z,S \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC
M871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V
M=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC
M;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P
M('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C8R1$%!-C X,#(R,$5#,3%"-#,V
M1$9%0S@S.4,X14)$/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3 Y+3(X5# W.C0V.C,X*S U.C,P/"]S
M=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!
M9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F
M='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^
M+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y
M/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N
M:6ED.C8Q1$%!-C X,#(R,$5#,3%"-#,V1$9%0S@S.4,X14)$/"]S=%)E9CII
M;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N
M9&ED.C%&.3 Y-3=$,#$R,$5#,3%"-#,V1$9%0S@S.4,X14)$/"]S=%)E9CID
M;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N
M=$E$/GAM<"YD:60Z,48Y,#DU-T0P,3(P14,Q,4(T,S9$1D5#.#,Y0SA%0D0\
M+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$
M97)I=F5D1G)O;3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS
M.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP
M+R(^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO
M<#I#;VQO<DUO9&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D
M9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ W@): P$1  (1
M 0,1 ?_$ !\  0 ! P4! 0             ' 08( @0%"0H#"__$ '<0  $#
M @,"!PD)"0@(#1$)  $" P0%!@ '$1(A"!,4,5%2T0D6%R)!89*4H14R5%9Q
M@9&BTB,U5W26L;.TTR0F,S9"=<'P&"4G-&)SM>$9*41%4W)V=X*%I;+Q-S@Y
M1EAD96=H>)6CI*:VPL-#1U5C9H.$AK?_Q  = 0$  04! 0$
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M#T#6K5&MSF*9)B)-A<WYWF1<=5/##?Z??R*<1HM0"8$3; 04I4%D/+05!:7
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M3+ZK"YK2 ;-U/'*&@Z1/:.*\NRMF;U-I5SC6XA]!E4-H9*E6DXOAQSES7AY
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MKE9?N"WC"89J4N\J+84*+.$]I$MFOQ9%=;5%:92)SL="68AVIR4+] H5Z=(
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M:N7,NF3GWE LU>+6[JBH3 T4\^&^+0"_(C-N2=F.&LC7G%A,Z'AIXCE/VIG
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M5K6JE6KE:AW'=5 J=U+N9JY'(#]-=%5H%V2Z1/JE!095.E-PXZ9U$@R(DYM
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M7:J*:;W@I2=K:UWI!T4E: "5D+(;"U[))).H"BO80$K^XZ".,\YT]VHOU09
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M*@D%&J0HE("1IM$J!UT._$@ S<-[<WA /BI53';4E22 H*U*]4C4J(4-O5*
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MMB4,=O51"DME6UN"?>[:]M6@4VH;SL\^N@0@#30ZP9X"W:WS'P"D$Q]RJ_\
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M>.B%$_0-X(H%ME@.O54C7<ZV/EV^4@@CS:[B-/.3NQ=:*9XNT-K<1&OO5+C
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M#&*;:!:UKH ,/%1M61)X%LR(/%;*]+NZ]+T?[2V1A,":E6GM ?PSJA8:C 2
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M[H&]6I3&U*B0LJPG;VW&[+VM4P%(M>QK9S5<Q?) @$M<P<@1D!O.EEM;=/\
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M PDAU-K^C,R[_JR ^VI:6B18KYVU-SJ."V;4QK>E=49N^=K!KW4S3-<-+LA
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M(7?+8MBVMEO:M(LFS*4Q1+:H++K-+I<8JXB(B3)?FOH;*B5;*Y,EYT DZ%9
MT&[&,X<4\,P86B(%$ "!87F\6GN7SMI[2Q6VL2=H8^HZIBZSG/Q#C;.XD1,0
M3$$7D_G>&[4:C=KJ4@D C30CIT/E]NHU!OAQF3^75/#D%X V.)[^W2(C54
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MZ8TONY4;2WCV=2+\TXX GBT.<)XF_JVX<;775V^E3"MW*VT6%]]D56@ "/\
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M1H!>+1:57BTCFU _K^?%?JYB[*)=!/6183PTZK^"@DG7\N*; \_]?FQ)(,0
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M](_581N^V/2OMN^KJQ[F JY+MW(OH=:Z;D/R:(X4GY]KYM/+C77^BQ'6*/\
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MP$IT3M;D ;5&#:S[P]'H:+C6I8S;@6CA)DZ1*Y<QKJ;S5Z1SFTSZ7:H<^):
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M;E;"/M;+HCLBB+^.GBN-S 3I1KIW\U3I(^F\,WS_ /3]OFW^_<<_Q_$CG2^
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M1LH2-P20II2".8Z(XLZ)W@$@#Q=V*+F9^KE><'*(:3';:X,_$CO6G=N
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M^2?1_P ?KLLJV*VW&S&S8CQVT,LL-V"PRRTD(:898IE=0A#+:0$H2AH):;0
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M4]2U7[4K<BNRG;8M&J1[WH4RO3GPS*CTV*Q)J<.,),U#<4/R$)UVE;1SO9V
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MZ&[1(V$&WG[90?'"# $=9CX\("W/Z1G!N_$5H#!LS'5!Q]332-9DG4<SK/H
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MZZ#&[=J8IF PE.O4S96X<@AHDYLKH %A![9(O<S/&@HNQ..Q%%OWNG+B9(;
M>>8/6!S(BP 7Z*V3]@S,M,J\N+ D2XU2DV58]LVI)FL-J88FOT*CQ:<Y,:;<
M4XM"'W(Y=0VM9*$J *BH:XT#B:@KUZ]6\5*CWB;&'.D QU+.:5/HFL8V0P-
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M>5=:[YZY<MM7W5+:]WX](:FTN/28$Z(ERD-2VHSD=3SB%LE8F.)>T\792D)
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M/#R3H^OP^:>#_,+\+]:_)ZD?ML,P]@>'DG1]?A\T\'^87X7ZU^3U(_;89A[
M\/).CZ_#YIX/\POPOUK\GJ1^VPS#V!X>2='U^'S3P?YA?A?K7Y/4C]MAF'L#
MP\DZ/K\/FG@_S"_"_6OR>I'[;#,/8'AY)T?7X?-/!_F%^%^M?D]2/VV&8>P/
M#R3H^OP^:>#_ #"_"_6OR>I'[;#,/8'AY)T?7X?-/!_F%^%^M?D]2/VV&8>P
M/#R3H^OP^:>#_,+\+]:_)ZD?ML,P]@>'DG1]?A\T\'^87X7ZU^3U(_;89A[
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D:[\2BER(R8\6-'40I3$=EDJ',2TVE!(W#<2G4;AN\@P1?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img158215518_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img158215518_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )L BD# 2(  A$! Q$!_\0
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MH-3;5_NC\J-J^@_*@",&EIA^\?K2YH (C\Y^E357@/[P_2K% !1110 4444
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M2;NRL-2FZDYQ7(FM/\['SYXLAU][FWU#Q!N6>[5C'&_!10>FW^$<].OK7O\
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MIE_IMOJHOK&YM2[Q;!/$R;L!LXR.:]'HH=1M-=PCA5&4)7^%6/)?$6CZG/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH H/_K7_P!XTO%(_P#K
M7_WC10 ^V($IR<<5:WI_>7\ZI)RY^E.(H M^8G]]?SH\R/\ OK^=4BM-*T 7
MO-C_ +Z_G1YL?_/1?SJAMI-M &AYL?\ ST7\Z/-C_P">B_G6?MI-M &CYL?_
M #T3_OH4>;'_ ,]$_P"^A6=MHVT :/FQ_P#/1/\ OH4>;'_ST3_OH5G;:-M
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M #T3_OH5G;:-M &CYL?_ #T3_OH4>;'_ ,]$_P"^A6=MHVT :/FQ_P#/1/\
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M6+2?A5/X2NIE\^^BD-U-$,@2N,9'KMPH]]O;- 'B?A'X>7GQ<O-7UYKJRT:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% %*;_ %[?A_*FTZ;_ %[?A_*F
MT 26W^N/^[5NJEM_KC_NU;H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]1PYG)IO8****YC4**** "BBB@ HHHH **** *4W^O;\/Y4VG3?Z]OP_E3:
M)+;_ %Q_W:MU4MO]<?\ =JW0 4444 %%%% !2, RD'H>*6FOG8=O7'% 'ANM
M?"J\\#F76?"/C(Z1&#N:&_G"1M[;NC?0J:G^&?Q@UCQ#XHA\-:Q:6MQ,XDQ?
M6K;1\BELD#((.,9&*SI/AUI":K'<?$OQTMUJ$A&VR%UCKT&3\V/H%KU_PWI/
MAG1X[BR\/VUC";9_*G6#!=6QG#G[V?K0!OT444 %%%% !1110 4444 %>%S_
M /)V-M_U[_\ MJU>Z5X7/_R=C;?]>_\ [:M0![I1110 445B:]XP\/\ AB2&
M/6M4ALGG!:,29^8#KT'N* -NBL30?%^@>)WG31=3AO6@"F41Y^4'.,Y'L:VZ
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\PTKPAK4'QMU+Q#
M/9[-*EC81S^:AWDHJXV@[AT/4=J]/HJX3<;VZDN*=CR'X;_#C4_#/CS5=1OK
M01V4:R16,GF(V\,_#8!)'RCN!UJ_\&_"6N>%+35TUJQ^RM<21&(>:C[@ V?N
MDXZCK7I]%7.O*2:?6WX$JFE:W0\P^,GA+7/%=II":+8_:FMY)3*/-1-H(7'W
MB,]#TI_Q3\,>(/%^H:'INGV9;2HY?,NY_.10I)"YP3N.U=QX!^]7IE%$:THV
MMTO^(W33OYG"R?!WP,\3JFBE&((#B[F)4^O+U@^ ?"_BG0_"/B7P_J=AMCFC
MD-BXGC82.R%2.&RN<*><=3TKUBBE[:=K-W]0]G&]T<+\)O#VJ>&?!SV&KVOV
M:Y-V\@3S%?Y2% .5)'8UW5%%1.3G)R?4J*LK#719(VC<!D8$,#W!KQ/X<_"_
M6M!^(#:CJED(K"T$IM93,C^8Q^53@$D?*2>0.@KVZBJA5E!.*ZBE!2:;Z'CO
MQ?\ A[K7B76['4]"L1<N8##< 3)'C:V5/S$9SN/3TKU'0=-71O#^G::HP+6W
M2(^Y"@$_GFM&BB564H*#V0*"3<NYY?\ $;PCKFO>-O#>H:98^?:V;H9Y/-1=
MF) QX9@3P.U>H444I3<DD^@**3;[A1114%!1110 4444 %%%% !1110!2F_U
M[?A_*FTZ;_7M^'\J;0!);?ZX_P"[5NJEM_KC_NU;H **** "BBB@ JIJEQ+:
M:3>7,";YH8'D1/[S!20/SJW6#JWC3PUHEZ;+5-;LK2Y"AC%-(%;!Z'% 'S?;
M:%I^H_#I/&5S=27GB"?6HXYV>7/E@OT(]2,')_"O1K6*'2/VE7@TFZDECU*S
MDEU*+?N$;X8C/IRJ<'IN]ZYWQ%X+^&&K:E->Z;XZM-+$S[Y+=&62/=U^49!'
MTYKL?ACI'@#P[J31:-XCM]7UR[4J96D!<J/F(11T'&3U/'6@#UFBBB@ HKFO
M&OC33/!6A2ZA?2*TVTBWMMV'G?L![>I[4>!/%1\9>$[;6S:"U\YG7R@^_&UB
M.N!Z4 =+17EWB3XP"P\276A>'_#UWKEU9Y^U- 2%CQ]X# )..A/'-=+X#\>Z
M=X\TF6[LHY+>>W?R[BVE.6C)Z<]P><'V- '645Y'JWQM$>L7UGX>\-WFM6^G
MD_:KJ)B$4 \D84\<'DXSBNZ\&>,--\;: FJZ=O5=QCEADQNB<=5/Y@Y]#0!T
M5>%S_P#)V-M_U[_^VK5[I7A<_P#R=C;?]>__ +:M0![I117@?BKXI?$30/%S
MZ.ND6:K<7#)IZR0$M.F\JA&&[\4 >^5YA\<O#NEZAX#O=:N;<O?Z?&HMI=[#
M9ND0-P#@\>M=QX:NM4N_#>GW&M6XM]2DB#7,07 1_3&3_.N:^,I_XM/KW^Y%
M_P"C4H S_@CX=TO3O 5CK%K;&.^U&+_2I-['?M=PO!.!QZ5Z97#_  ?_ .24
M:!_UR?\ ]&/7<4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X
MAXM^(/BC2/'.H6=G??Z#:RJ?(\B,_)A21DKGOZU[?7AEWI2ZU\8?$%@>6EMI
ME3_>,( _4@USXARLE%]3V,FC2=2I*M%-*+>JOU1Z!X]\4SZ3X1M[O1YPMY?R
M1):/M#<-\V<'(Z#'XUA_#CQ)XD\5:%KXN-122_B0)9RO$BK&[*^"=J\C(!Y!
MZ5R?AJ_E\7ZIX3T1LXTF"9Y"V<;ESL_(+&/Q-;WP*_X\M;_ZZ0_R:LXU'.HG
M?1_Y';6PE/#8*I%Q3G%IWMK9RLOO2_$S_%FM?$CP=%:R:AXALY1<LRI]G@C;
M&W&<YB'K7<>'[3QOIE]+=^*-<L+K3(X'9DA0!@1SGB->  >]<O\ '7_CRT3_
M *Z3?R6NE^+&M?V3X(N(4;$U^PME_P!T\L?^^01^-->[*3;>ENI$OW]&A&,(
MIU')-J*Z-;=M#@;'XF>)QJ]IJM[<XT"XOVA,7DQC:@P2-VW/"N.<\XKVC6;F
M2UT'4+JW?;+%:R21M@'#!20>>*^?[SQ/X=G^&5KX<CM;T:A XF$S1IL,A)W<
M[LXPQ'3L*]1\-ZW_ &[\(;B9VW3P6,UM,?\ :1" ?Q7:?QI4:F\6[Z7*S/")
M*%6-/E2ER[;KHSE_#5[\3?%6COJ6G^(;)8ED:/9-#&K$@ \8B([^M='\.O&6
MK:UJ.I:)KJ(;^Q)S(BA<X;:P('&0<<BN+\ :9XZO?#,C>'=:LK.P,[J8YE&[
M?@9(/EL>F.]=_P""? \GA%=0U&\NOM^J70)=DSC'WL GDDGDGZ44N=N+5_.X
M\P^KPC5A+DO?W5%6:UZZ([>N8D^(?A2(7?F:O&AM)!%,K1."&R1@#;EONGIF
MLS1/'6NZIK-M977@C4;""5B'N92^V/@G)S&!VQU[UQ_P]T+3-9\<^)WU*SAN
MA!*X1)D#*"TC9.#QGBM956VE#J<%++XPC4EB;KE2>C3W=O,]9T;7M+\0VANM
M*O([F)3M8J""I]"" 1^(J+0O$ND>)89IM(N_M,<+!7/ENF">?X@*\Y^$42VO
MBGQ5:PY6".4*J9X #N!^E2? UE&C:OD@8G0GGH-II0JN7+?K?\"L3E].DJSB
MW[G+;_M[N=[I_BC2M>L[^31[SSVM%(D/E,NQL''W@,]#7%>#/%VN:M\/?$>J
M7M]YM[9QS&"3RD785BW#@* >>>15#X0L&TWQ4RG(+*01WX>JGP[_ .23^+_^
MN4__ *(J%4E+E?=,Z98.E1]K32ORRA9NU]=SN_AKK>HZ_P"$4OM3N//N3.Z%
M]BKP,8X4 5U]<#\'?^1!C_Z^9?YBN^K>DVX)L\K,(QABJD8JR384445H<844
M44 %%%% !1110!2F_P!>WX?RIM.F_P!>WX?RIM $EM_KC_NU;JI;?ZX_[M6Z
M "BBB@ HHHH *XWQ%\+_  MXKU=M4U>QEFNV18RRSN@P.G -=E10!YQ_PHOP
M%_T"Y_\ P*D_QK2T'X4^$O#.LP:MI5A+%>0!@CM<.P&Y2IX)QT)KJ-3UC3M&
MMFN=3OK>T@'\<\@4?AGK7':5\7?#>O\ B^U\.Z.;B[EG\S-R$V1+M4MQGD_=
M]* .^H/2BB@#Q[XE?#C25TGQ3XMO);B\U!K<O;K*_P"[MN@^4=SUZ^O2MCX'
M,5^$VGL.2))S_P"/M6]\3()KKX;Z]!;Q233/:L$CC4LS'(X ')K(^"]G<V'P
MQT^WO+::WF66;='-&489<XX/- '&_L]@7%_XLOY1FXDN(PQ/7DN3^M9_@"9M
M,^)/Q'AM#B)(+J10G0,LAV_EDBGV,?B3X0>,]=:V\-WFLZ1J;[X'M@3@@DKD
M@'!&X@@CT(KH_A%X-U2W.O\ B+Q':M;7FMLP%NPPRQL2S$CMDG@'GB@"K^SE
M!&W@[5YF"L\U]M?(R2 BX!_,_G5/]GYS#JGBZQ0GR([A"GH,,X_D!67X?N?%
MWP?FUG0T\+7>K6]U*9+*YMU9DW8P"=H/;;E>#Q7<_!;P;J'A;P]>7>L1&'4-
M3F$K1-]Y$&<!O<DL?Q% &7K_ ,6O%NE>(-0T^T\#7-W;VUP\4=PJ2D2J#@-P
MN.?:N.\(Z]?^)?VBM/U/4]+?3;J2)U:V<,"H%NP!^8 \CFOI,#WKPR?_ ).Q
MM_\ KW_]M6H ]2\7>,])\%VEO=:NTXBGD,:>3'O.0,\UX+X]\?:'XB^(7AC6
MK!K@V>G.AG+Q;6XDW' SSQ7;?M%?\BUH_P#U^-_Z :^=37LX'+Z5>ESRO<SE
M-IGU=I7QD\)ZUJ,=A9O>F>179=]O@852Q[^BFN=^(?CW1?$W@/4](T\W)NKE
M4$8DBVKPZL<G/' ->.?#O_D>++_KE<?^B)*U.PKQ\Z7U*K&%+9J^I]1P[E-#
M,85)5K^[;8]2^'_C[1/#?@72M(OS<BZM8V601Q;ER78\'/H:]9L+R+4-/M[V
M#=Y4\:R)N&#@C(R*^5*^G/"O_(HZ/_UY1?\ H KAPF(G5;YB^(,GP^7PA*C?
MWF]_^&->BBD) &2<"NT^8%HJE_;&F?\ 01M/^_Z_XU<!W#(P0?2@!:*** "B
MBB@ HHHH **** "BBB@ HHHH *Y&R\#BS^(%WXJ.H;S.I46WDXVY &=V[GIZ
M=ZZZBIE%2M?H:TZTZ2DH.W,K/T..\+_#^W\,^)-3UB.\\[[7N$<7D[?)5GW$
M9R<] .@Z4_P)X'_X0J&]C_M'[9]J9&SY'E[=H/\ M'/6NNHI*G%6LMC6IC:]
M124Y7YK7VZ;'(^._ _\ PFL-E'_:/V/[*SMGR/,W;@/]H8Z4GBWP/_PENKZ7
M<SZEY5I8MN-L(-WF98%OFW#&0 .AKKZ*'3B[W6X4\;7IJ*C+X;VT6E]QLD:2
MQM'(H9'!5@>X-<3X:^'K^'-.UK3X]7,]KJ4;(JM;X,)(9<YW'=P1Z9P*[BBF
MX)N[,Z>(J4X.$'H[7^6QSO@OPM_PB&AMIOVS[7F9I?,\KR^H QC)]/6NBHHI
MQBHJR)JU9U9NI-W;"N2\*^"?^$8UK5]1_M#[3_:+[_+\G9Y?S,W7<<_>]NE=
M;12<4VF^@X5IPA*$7I+?Y')>%?!/_",:UJ^H_P!H?:?[1??Y?D[/+^9FZ[CG
M[WMTK!?X011ZE=2V'B&^LK"Z/[ZUA&-RYSMW!@".3C(->ET5+HP:M8Z(YCB8
MS<U+5V3T73;IT./\(>!$\)6VJP1W_P!H2^(VYAV^4 & 'WCN^][=*B\._#_^
MP/">L:'_ &GY_P#:*2+YWV?;Y>Y-GW=QSCKU%=K10J4%:RV)ECL1)R<I?%9O
M1=-C \'>&?\ A$M 72_M?VK;(TGF>7LZ]L9/\ZWZ**M)15D<]6I*K-SF[MA1
M113("BBB@ HHHH **** *4W^O;\/Y4VG3?Z]OP_E3: )+;_7'_=JW52V_P!<
M?]VK= !1110 4444 %>#?&#XG>)/#OB@^'](N(;& P1N;GR]TAW9SR<X ]AF
MO>:S=7T#2-?MOL^JZ=;7D7831AB/H>H_"@#YGOO T.K>#M4\5WWCB'6K^WA\
MWR8)#(0<@88N=P'/3:*]D^$/AG1;+P-HVKV^F6R:C<6^Z6ZV9D))(/S'D?05
MSOB+]GC1[OS)O#]_/ITI_P"6,V98C[9^\/S-.^'NF?$GPAXDT_P]JRI<^&]L
MBB:,"1(L(Q7#<,H+ #YACF@#V:BBB@ HHHH **** "BBB@ KPN?_ ).QMO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\TKZ++?]ZC\_R/@9['A]>P_L[_\ (WZK_P!>'_M1:\>KV']G?_D;]5_Z\/\
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M??<%?PJWJOU"OISPK_R*.C_]>47_ * *^8Z^G/"O_(HZ/_UY1?\ H KR<O\
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M_P#::U[)7S6._P!YF:Q^$****Y"@HHHH **** "BBB@ HHHH **** "BBB@
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M!P2:^/Z^IO@5_P DRM_^OF;_ -"KKS/#4J=%2A&SN3!MO4]*HHHKPC4****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"E-_KV_
M#^5-ITW^O;\/Y4V@"2V_UQ_W:MU4MO\ 7'_=JW0 4444 %%%% !7%747C8_$
MJ"2WEC'A/R?WL9\O=YFQO;?][;WKM:\P\<:#\2]0\2-/X6UZ"RTPQ(%B>0 [
M_P"(XV'^= '-&T^/N3B]M<?]NO\ \36]X-M_B['XIM&\574#Z, _GJGD9)V'
M;]T9^]BL/_A$_C=_T-EK_P!_A_\ &ZW?!_A_XHZ?XHM+CQ+X@@N]*4/YT*2
MEB4.WC8/XL'KVH ]5HHHH ***#Q0 454N]3L+ *;V]M[;=]WSI53/TR:LQR)
M-&LD;JZ,,AE.0?QH =16?<:[I%I.T%SJMC!,GWHY;A%8?4$YJ6SU33]0W_8K
MZVNMF-WD2J^W/3.#Q0!;KPN?_D[&V_Z]_P#VU:O=*\+G_P"3L;;_ *]__;5J
M +W[17_(M:/_ -?C?^@&OG4U]%?M%?\ (M:/_P!?C?\ H!KYU-?3Y5_NZ]68
MSW.I^'?_ "/%E_URN/\ T1)6IV%9?P[_ .1XLO\ KE<?^B)*U.PKYKBC_>(>
MGZGWW!7\*MZK]0KZ<\*_\BCH_P#UY1?^@"OF.OISPK_R*.C_ /7E%_Z *\G+
M_BD:<8_PJ7J_R1KFOG_]H[_D(>'O^N4_\TKZ -?/_P"T=_R$/#W_ %RG_FE?
M19;_ +U'Y_D? SV/#Z[_ .&?_'GXM_[!!_\ 1J5P%=_\,_\ CS\6_P#8(/\
MZ-2O;S3_ '.IZ&F _P!ZI_XE^8VK.G_\A*T_Z[I_Z$*K59T__D)6G_7=/_0A
M7YE'XD?M5?\ A2]&?50H- H-?1GXF?*GQP_Y*C??]<8?_0!7G5>B_'#_ )*C
M??\ 7&'_ - %>=5]C@_]WAZ(PEN?1O[.W_(IZM_U_?\ M-:]CKQS]G;_ )%/
M5O\ K^_]IK7L=?-8[_>9FL=@HHHKD*"OCSXF_P#)2_$'_7V?Y"OL.OCSXF_\
ME+\0?]?9_D*];)_XS]/U(GL<E7U-\"O^296__7S-_P"A5\LU]3? K_DF5O\
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MTP'^]4_\2_,;5G3_ /D)6G_7=/\ T(56JSI__(2M/^NZ?^A"OS*/Q(_:J_\
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M6YF7<D>QW;&<9;:#M'H3C.#Z&NABECGA2:&1)(I%#(Z,"K*>001U%>-IY?\
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M/@ #7-< '3]\G_Q-;'A?X/:1X4\0VVLVFJZK/- '"QW$JLAW*5.0%'K7HM%
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M_#?C*22[T:4_N+LDOL7.-Z,>2H[J>1V]_H&"6.>!)HG62.10R.IR&!Y!!]*
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MBBB@"E-_KV_#^5-ITW^O;\/Y4V@"2V_UQ_W:MU4MO]<?]VK= !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7G/Q:^'9\:Z1%=Z<=FM6(+
M6YSCS5ZE">QSR#V/UKT:B@#PKPA\6;"YTRY\*?$>(V]S$AMY9;B(E9E'!60
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MOPN\/>+_ !#--I.K1Z7XDA"S3"$@YR?E=D!!!X^\/QKA_BCJVI^%OC@FK:9
M);V2Q5;960MEG1H\@=R#T'K7?_"[X;7.@S2^)O$<TEQXBO5+/N?/DANH)[L>
M_8=!0!:\#?"L^'-<?Q!K>L3:SK)3RXYI,XB7&.,DDG''L,UZ1110 9Q2;AZU
M#>DBQG(D,9$;$..J\'FOF7X:_%74_"UVL7B"2YNM"OYG(N9 6:-\_,RD]1D_
M,OOGZ@&EX"M=";XD>)O#WC>P@N=4O;EA!-=+D,VYB0I/W2P(((]/I1KV@ZS\
M$O$J:]H4DMUX<NI D\$AR,?\\Y/UVM_D]_\ $?X;6GQ L(-;T2YBCU=(PT%P
MC?)<IU4%AW]&_P C@;SQ/\1M0\+W?@?5_"-U>W\ZB!;QXF^[D?,2!M8C PV1
MZG- '17?PDTWQ,;/Q;X&UF316O$$ZJ@.P;NNW:04.<@CD?2NT^'_ ,.;;P1'
M=7,MY)J&K7IS<WD@P3SG Y)QGDDG)K4\ >'I_"O@?2]&N9%>XMXR92O0,S%B
M![ G'X5TE !1110 4&BB@#E;7P#I%GXYN/%\;7/]IW"E7!D'EX*A>!CT4=Z7
M5_ .D:UXNT_Q-=-<B_L HA"2 )\K$C(QSR3WKJ:* .6O_ 6D:CXVL_%DYN/[
M2M%5(PKCR\#=C(Q_M'O4%S\-M N_',?B^1)_[3C=7 #CRRRKM!*XZX []J["
MB@#ED\!:0GCQO& :Y_M-EVD>8/+QLV=,>GO74T44 %%%% !1110 4444 %%%
M% %*;_7M^'\J;3IO]>WX?RIM $EM_K3_ +M6ZJVW^M/^[5J@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH SKK0M,O-9M-6N+**6^LU9()F&3&&ZX
M_P \<^M:-%% !1110!7OK.+4+&>SG!,,\;12!6*DJP(.".G!KC%^%.@?\( O
MA*</-;QN\D5RP'FQR,20P/J,@>X%=W10!X#X(O\ Q1\,_&T/@C5K6?4-+O)#
M]CDA4MM!/WT_V?[R]NOU]^IIC1G5RBEESM8CD9ZXIU !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!2F_U[?A_*FT^;_7M^'\J;0!
M);_ZT_2K55H!^\/TJS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!4F_US?A3:?*/WS4W% $L(_>'Z5/50TTT 7:*SS32* -*
MBLO%(10!JT5E8HQ0!JT5E8HQ0!JT5E8HQ0!JT5E8HQ0!JT5E8HQ0!JT5E8HQ
M0!JT5E8HQ0!JT5E8HQ0!JT5E8HQ0!JT5E8HQ0!JT5E8HQ0!JT5E8HQ0!JT5E
M8HQ0!JT5E8HQ0!JT5E8HQ0!JT5E8HQ0!JT5E8HQ0!JT5E8HQ0!JT5E8HQ0!J
MT5E8HQ0!JT5E8HQ0!JT5E8HQ0!JT5E8HQ0!JT5E8HQ0!JT5E8HQ0!JT5E8HQ
M0!JT5E8HQ0!JT5E8HQ0!JT5E8I<4 :E%9F*4"@#2HK/ IXH DD'[TTF*!3J
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img158215518_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img158215518_8.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1E@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &42^9&@X0DE-! 0      &(< 5H  QLE1QP!6@ #&R5'' (   *N !P"
M4  (<G(R.3,W-#D< @4 .4UI8W)O<V]F="!7;W)D("T@5&%N9V\@+2!!;65N
M9&UE;G0@3F\N(#$@=&\@1F]R;2!3+3$N9&]C>#A"24T$)0      $"7&DZ^>
M9-W>FT@!\PIN8D X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 5X            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-! T       0   !X.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      ,U    !@             !!    @4
M         0                         !              (%   !!
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !!
M  !29VAT;&]N9P   @4    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   00     4F=H=&QO;F<   (%
M     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%
M6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-
M3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M
M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N
M=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y
M<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T
M<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U
M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    %
M.$))300,      ZM     0   *    !0   !X   E@    Z1 !@  ?_8_^T
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M\]W_ ))+U[_]-9_GN_\ )*3+]E?IEC7MDD;NQ(VRW_S)3=F;GE_HL#B221P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                  #_X4 9:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[
MOR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A
M('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @
M0V]R92 U+C,M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@
M(" @(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW
M,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM
M<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(^"B @(" @(" @(#QX
M;7 Z0W)E871O<E1O;VP^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\
M+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P
M,C$M,#DM,CA4,#@Z,#DZ,3,K,#4Z,S \+WAM<#I-;V1I9GE$871E/@H@(" @
M(" @(" \>&UP.D-R96%T941A=&4^,C R,2TP.2TR.%0P-SHR,3HQ.2LP-3HS
M,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$871E
M/C(P,C$M,#DM,CA4,#@Z,#DZ,3,K,#4Z,S \+WAM<#I-971A9&%T841A=&4^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z
M+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U
M8V5R/D%C<F]B870@1&ES=&EL;&5R(#$P+C$N,38@*%=I;F1O=W,I/"]P9&8Z
M4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @(" @
M(" \9&,Z=&ET;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @
M(" @(" \<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/DUI8W)O<V]F="!7
M;W)D("T@5&%N9V\@+2!!;65N9&UE;G0@3F\N(#$@=&\@1F]R;2!3+3$N9&]C
M>#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO
M9&,Z=&ET;&4^"B @(" @(" @(#QD8SIC<F5A=&]R/@H@(" @(" @(" @(" \
M<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3YR<C(Y,S<T.3PO<F1F
M.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z8W)E
M871O<CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M
M870^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @
M>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP
M92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT
M=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B
M/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.D9!-#8R1#%&
M,#4R,$5#,3%"-#,V1$9%0S@S.4,X14)$/"]X;7!-33I);G-T86YC94E$/@H@
M(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C$U,#%!.$1!,#(R
M,$5#,3%"-#,V1$9%0S@S.4,X14)$/"]X;7!-33I$;V-U;65N=$E$/@H@(" @
M(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z,34P,4$X
M1$$P,C(P14,Q,4(T,S9$1D5#.#,Y0SA%0D0\+WAM<$U-.D]R:6=I;F%L1&]C
M=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C$U,#%!.$1!,#(R,$5#,3%"-#,V1$9%
M0S@S.4,X14)$/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z=VAE;CXR,#(Q+3 Y+3(X5# X.C U.C$Y*S U.C,P/"]S=$5V
M=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A
M<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO
M<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM
M<"YI:60Z1CDT-C)$,48P-3(P14,Q,4(T,S9$1D5#.#,Y0SA%0D0\+W-T179T
M.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P
M,C$M,#DM,CA4,#@Z,#DZ,3,K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I
M;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP
M87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T
M:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV
M97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O
M(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D9!-#8R1#%&,#4R,$5#,3%"-#,V1$9%
M0S@S.4,X14)$/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z=VAE;CXR,#(Q+3 Y+3(X5# X.C Y.C$S*S U.C,P/"]S=$5V
M=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A
M<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO
M<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@
M(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED
M.D8Y-#8R1#%&,#4R,$5#,3%"-#,V1$9%0S@S.4,X14)$/"]S=%)E9CII;G-T
M86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED
M.C$U,#%!.$1!,#(R,$5#,3%"-#,V1$9%0S@S.4,X14)$/"]S=%)E9CID;V-U
M;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$
M/GAM<"YD:60Z,34P,4$X1$$P,C(P14,Q,4(T,S9$1D5#.#,Y0SA%0D0\+W-T
M4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I
M=F5D1G)O;3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!H
M;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^
M"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#
M;VQO<DUO9&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI2
M1$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!"@(0 P$1  (1 0,1
M ?_$ !X  0  !P$! 0             ! @,%!@<(! D*_\0 :!    4" @0%
M#0L(! @+!P4  0(#! 4&$0 '"!(3(10Q45:1%A<8(D%289*4E:'1U D555=B
M<8&6TM7D(S)3HK'3UO!"5+;!)"4S-C=ULK4F-#4X149R=':%X4."AI.DQ/$*
M9:6FQ?_$ !L! 0$! 0$! 0$            ! @,$!08'_\0 4Q$  0("!08)
M"P$$" 4#! ,  0 1 B$#,5&1T002%4%AH0434E-Q@9+2\ 84%R(C8I.BL<'A
M5#)"LO$',S1R@I33XB0U-D-S=+/"%D1D@R6$P__:  P# 0 "$0,1 #\ _3UI
M6Z1><>7N=%1TO2-8.8>$9,X%5!@$5!/$0,ZCV;EP%Y.)>'NH*Z@B&L/YIMVX
M1Q_ ?+ORHX9X%X<IJ&@I8C!$W%P@. ##"0 -; UBW8OF9;EE/0TF;1Q,  *G
MK#N009DFNO:N<>S$TC;!;,AZ(6^ J4MQ[P_Y Y/H\ =S\%!_23Y42(I:7->L
M4<4A/6Q%=6LF2\D7"&4" N^=;FC.ETBQNDD="=F'I&#OZY,AOY(*E+?1_B'B
MQKTC^47.TMS?9-)Y3RX;CW4[,#2+^,E]YAI7[@Q?2/Y0\]271=U-)Y3RX;CW
M4[,#2*^,E]YAI7^'\/2/Y0\]271=U-)Y3RX;CW4[,#2*^,E]YAI7^'\/2/Y0
M\]271=U-)Y3RX;CW4[,#2*^,E]YAI7^'\/2/Y0\]271=U-)Y3RX;CW4[,#2*
M^,E]YAI7^'\/2/Y0\]271=U-)Y3RX;CW4[,#2*^,E]YAI7^'\/2/Y0\]271=
MU-)Y3RX;CW4[,#2*^,E]YAI7^'\/2/Y0\]271=U-)Y3RX;CW4[,#2*^,E]YA
MI7^'\/2/Y0\]271=U-)Y3RX;CW4[,#2*^,E]YAI7^'\/2/Y0\]271=U-)Y3R
MX;CW4[,#2*^,E]YAI7^'\/2/Y0\]271=U-)Y3RX;CW4[,#2*^,E]YAI7^'\/
M2/Y0\]271=U-)Y3RX;CW4[,#2*^,E]YAI7^'\/2/Y0\]271=U-)Y3RX;CW4[
M,#2*^,E]YAI7^'\/2/Y0\]271=U-)Y3RX;CW4[,#2*^,E]YAI7^'\/2/Y0\]
M271=U-)Y3RX;CW4[,#2*^,E]YAI7^'\/2/Y0\]271=U-)Y3RX;CW4[,#2*^,
ME]YAI7^'\/2/Y0\]271=U-)Y3RX;CW4[,#2*^,E]YAI7^'\/2/Y0\]271=U-
M)Y3RX;CW4[,#2*^,E]YAI7^'\/2/Y0\]271=U-)Y3RX;CW4[,#2*^,E]YAI7
M^'\/2/Y0\]271=U-)Y3RX;CW4[,#2*^,E]YAI7^'\/2/Y0\]271=U-)Y3RX;
MCW4[,#2*^,E]YAI7^'\/2/Y0\]271=U-)Y3RX;CW4[,#2*^,E]YAI7^'\/2/
MY0\]271=U-)Y3RX;CW4'3!TB@X\RGP?/ TI]P8>D;RB-5-2GJB[J:2RHU10G
M_">ZG9@Z10\693X?_(:4^X,#_2-Y1"NFI1TB+NH>$LJ%<4(Z83W4[,#2*^,E
M]YAI7^'\/2/Y0\]271=U-)Y3RX;CW4[,#2*^,E]YAI7^'\/2/Y0\]271=U-)
MY3RX;CW4[,#2*^,E]YAI7^'\/2/Y0\]271=U-)Y3RX;CW4[,#2*^,E]YAI7^
M'\/2/Y0\]271=U-)Y3RX;CW4[,'2*#CS*?!_Y#2O\/X>D?RAYZDNB[J:2RDU
M1PGJ/=4.S!TBAXLRGH_^0TI]P8>D?RAYZDNB[JNDLJ%<0'^$]U1[,#2*^,E]
MYAI7^'\/2/Y0\]271=U32>4\N&X]U.S TBOC)?>8:5_A_#TC^4//4ET7=32>
M4\N&X]U.S TBOC)?>8:5_A_#TC^4//4ET7=32>4\N&X]U.S TBOC)?>8:5_A
M_#TC^4//4ET7=32>4\N&X]U.S TBOC)?>8:5_A_#TC^4//4ET7=32>4\N&X]
MU.S TBOC)?>8:5_A_#TC^4//4ET7=32>4\N&X]U.S TBOC)?>8:5_A_#TC^4
M//4ET7=32>4\N&X]U0[,'2)^,I[YBI3[@P](_E#SU)=%W5=(Y5RAV3W5'LP-
M(KXR7WF&E?X?P](_E#SU)=%W5-)Y3RX;CW4[,#2*^,E]YAI7^'\/2/Y0\]27
M1=U-)Y3RX;CW4[,#2*^,E]YAI7^'\/2/Y0\]271=U-)Y3RX;CW4[,#2*^,E]
MYAI7^'\/2/Y0\]271=U-)Y3RX;CW4[,#2*^,E]YAI7^'\/2/Y0\]271=U-)Y
M3RX;CW5#LP=(GXRGOF*E/N#%](OE%SM+V8NZKI'*N4.R>ZG9@Z1/QE/?,5*?
M<&)Z1_*'GJ2Z+NII'*N4.R>ZH]F!I%?&2^\PTK_#^'I'\H>>I+HNZII/*>7#
M<>ZG9@:17QDOO,-*_P /X>D?RAYZDNB[J:3RGEPW'NIV8&D5\9+[S#2O\/X>
MD?RAYZDNB[J:3RGEPW'NIV8&D5\9+[S#2O\ #^'I'\H>>I+HNZFD\IY<-Q[J
M=F!I%?&2^\PTK_#^'I'\H>>I+HNZFD\IY<-Q[J=F!I%?&2^\PTK_  _AZ1_*
M'GJ2Z+NII/*>7#<>ZG9@:17QDOO,-*_P_AZ1_*'GJ2Z+NII/*>7#<>ZG9@:1
M7QDOO,-*_P /X>D?RAYZDNB[J:3RGEPW'NIV8&D5\9+[S#2O\/X>D?RAYZDN
MB[J:3RGEPW'NIV8&D5\9+[S#2O\ #^'I'\H>>I+HNZFD\IY<-Q[JAV8.D3\9
M3WS%2GW!AZ1_*'GJ2Z+NJZ2RKE#LGNJ/9@:17QE/O,-*_P /X>D?RAYZDNB[
MJFDLIY<-Q[J=F!I%?&2^\PTK_#^'I'\H>>I+HNZFD\IY<-Q[J=F!I%?&2^\P
MTK_#^'I'\H>>I+HNZFD\IY<-Q[JAV8.D3\93WS%2GW!AZ1_*'GJ2Z+NJZ2RK
ME#LGNJ/9@Z10\693X?\ R&E?X?P](_E#SU)=%W5-)92*XX1U'NIV8&D5\9+[
MS#2O\/X>D?RAYZDNB[J:3RGEPW'NKI?1,TALXLP\XHNG*PK-S,PSF,EE561X
MFGV@F5:L'+E!0%V<.W7$$U4P.*8' NZX\=P_=_T?^6?"G"W"])DN511TCT)B
M ,)<@"(L^;/-,+U2U+VY%E-)E-(8:2($ %V#.XD'D=MNH5K16G/<=(JK-X;F
M5-6L/_["TM?DM8>/N[N+?C\K_2OQH\HY4@9PX)##U(9SJD /Y$+AET4$-*7$
M_5F;1".@:WV-?R( B!>[O$1O>X[O!;N\7=^;N#_-J6F-%DX,/K/4VVJ8V[&U
MV+R4D4!A9K"\R)5R-?1-CM4-4?Y W]P#^T<<!%2$#UH:A6(7ZYCZ!<\Z'D'Y
ML$U1_D#?9Q7I.5#\O>3.AY!^;!-4?Y WV<'I.5#\O>3.AY!^;!-4?Y WV<'I
M.5#\O>3.AY!^;!-4?Y WV<'I.5#\O>3.AY!^;!-4?Y WV<'I.5#\O>3.AY!^
M;!-4?Y WV<'I.5#\O>3.AY!^;!-4?Y WV<'I.5#\O>3.AY!^;!-4?Y WV<'I
M.5#\O>3.AY!^;!-4?Y WV<'I.5#\O>3.AY!^;!-4?Y WV<'I.5#\O>3.AY!^
M;!-4?Y WV<'I.5#\O>3.AY!^;!-4?Y WV<'I.5#\O>3.AY!^;!-4?Y WV<'I
M.5#\O>3.AY!^;!-4?Y WV<'I.5#\O>3.AY!^;!-4?Y WV<'I.5#\O>3.AY!^
M;!-4?Y WV<'I.5#\O>3.AY!^;!-4?Y WV<'I.5#\O>3.AY!^;!-4?Y WV<'I
M.5#\O>3.AY!^;!-4?Y WV<'I.5#\O>3.AY!^;!-7P^@WJP>DJSH7L:'O)G0\
M@_-@FKX0Z#=WB[G=Q?:DL"";&#_5,Z#DGYL%"WA#H-ZL&I79P]C![G3.@Y)^
M;!!"W=#T_P!X!C.=&^;G0YW) !BN!?<F=#R#\V"6Y1M\]_[@'%!I"3#G#.%<
M+ &XETSH>0?FP2WA#T^K%/&P_M$#I 'UB3.AY!^;!+>$/3ZL9SHR'$<!%OJM
M?G)G0\@_-@EO"'I]6*32!GBA#U. 'Z/6FF=#R#\V"6MQB ?0;U8T13"N3AP\
M(J%9KJ#B>U,Z'D'YL$MX0Z#?/R<F_!J9V< MG-FS82)8$EMM29T/(/S8);PA
MZ?5AFTI#@@C9#X"F?#R(A?\ 9TL'*'I]6#4WB$8JYT/(/S8)8.4/3ZL3VMHN
M&*9T/(/S8)8.4/3ZL/:VBX8IG0\@_-@HZH_R!O5B/2<J&X=Y,^#DGYL$U1_D
M#?9P>DY4/R]Y,Z'D'YL$U1Y?0;U89T?*A^7O)G0\@_-@FJ/+Z#>K%:E< D!Z
MG GT3<]2&. ?NGYL%"WA#H-ZL5J1R!%"3"'( F!:1J&TL%GC(.0;REO"'0;U
M8C4S/)K<T->ZUGP<D_-@EO"'0;U8>UM%P[RF? *X6ZXL%'5MQB ?0;U8 4QJ
M8ZI0@SLK5SH>0?FP35'E]!O5@U+,N&%982Z9IG0<D_-@H6\(>GU8@-(0XBA(
MM !%^<F=#R#\V"@ 7QF&.*,M#'#$;(0"=Q3.AY!^;!3:OA]!O5CKF4UHE7ZI
M4SX>;BO*:OA#H-ZL9'&F'.!!AY0 ,-[LKG0<D_-@H6\(>GU8AXP%B80;" #O
MB3.AY!^;!1U?#Z#>K#VEL-P[R9T')/S8)JC_ "!OLX/2<J'Y>\F=#R#\V":H
M_P @;[.#TG*A^7O)G0\@_-@H6\(>GU8OM;1<,4SX!7"1VL$MX0]/JQ/:.SPO
M8P>[.4SX#5"_7%@EO"'+Q&XN7BQ3QL(>(B$6D "\E7.AY!^;!+>$/3ZL1Z1@
M<Z%C,%H6(M!SIIG0\@_-@EO"'I]6*U-LG5ZHGO3.AY!^;!1U?"'0;U8N;2G6
M'%8S2XZ5,^'FXMZA;NW"W+8WJQ#Q@+9T+] ^A+JYT/(/S8)8.4/3ZL&I6=PU
MK!KW3.AY!^;!+!RAZ?5B#C"'!A(M !'\29T/(/S8);PAT&]6-"&E(=QV<)*9
M\/(B-_W91U1_D#>K&7I.7">H?<A7.AY!^;!-4?Y WV<'I.5#\O>3.AY!^;!=
MD:"EB:0$"(B'_)-0!8;A_P!"ON4/[L?TW^BFD,/E*88AG$Y+2EX1(#,I!J<2
M,ZPU=1=?0X.8TQ(.;ZI#$G87F ;JR-3+QZ<O_.)J_P#[G3'^X&^,_P!+'_4M
M)TP_P0+APG_70_W?L%R*/$7_ +)O]G'\XC_LU%_>A^@7"'^J'0/JJF.*PF")
M@B8(F")@B8(F")@B8(F")@B8(F")@B8(F")@B8(F"*0VX0'C[ENY<;@'<W\8
M[O"&-"'U8J3D$;ZWN^J*0-81$0X@$ $0X@W@ !<.+C ..^^V,PQ1L:6$%Y"U
MPYF),17T-<36L8H#8;B-N[<0XP ;\?S[]P<@8"EB%-011PF(4AC#L6 !A +@
M, Y'U 0-<TK1X\24P@ F$0O?=?<.\0N-AW7XK" = 84I%'E0I!!$88C6 2*J
MS6>L./JJ[S#,[@2U[-?4@@7C'B,&[BXPW6 >Z([]U^X/'NMZ(X('-/"P+:[)
ML"^VO>5"6U2<R&IW.\L-I0+'W@81'B[@[A[E@Y?7CC%$:89I:>N8U;>N?T91
MV<V3U=/AT$H6N&^X#Q!QCN'<&^VX!OW Z QH4,-#04CPDB&%Y!R_3,B<W&H]
M+,XDU&35BSH?4)-7O4HB AOL @ ?.(#:W@^C>/S8YQT]%345'F!HX6+$3#.#
M7?JN"KNT@&$VKV.,6/VB(7&]P$ "VX0$>(1W_*U0$?H&X6XNV44=+&(*6CC!
M(H<U@7.<3#)@93%5@EK<\MDIM<S6N\J[TXA"XAR"%]W=N []U^+<%K\5MU^?
M%TV<(\X9QH(J,AY@Q$%I3<L9%C*2F<;#JMJ=K-5EE4IF-MVX0 /"-P'T"'<X
M^/YN(.@H::"" ",538FOI=_#:D)(:5<]>!-]B@(#OWD\/$%K<?<W>'$-'3F6
M?TS/W)V*9QL_B[J6$O;7 ;!?N\0[K_-OX^+&3!2T8,9BS@-5KRU=+H"[CZ/@
M/JFN/= !#^1\/* XP*8NQA OE8JPM-YQ4^X1*.^X@-NCN].-,\)CVRLF:WO3
M8-373;Z*;&55*8;%'^>[C,0<$6L+R$4I@ +6$/S;6'NA8>3EOX/!COE$1HZ2
MBS=4,I5F1;I&I"W35>P.XJ COL(<=MP#<=X!N'YPL.\+\G& ARC$=#3&.)\V
MFHS 2S5U]4R-LAJ1F%1U5;1;JU-]E$UQ'<%PN(<=[B ;[!RE"][<5AOQ8[Q0
M4T=$.*,Q#J!-?1,8'I5&HD2>>"A80 >X  !K#N&UP#6W@%@ VZ_='M;B..%!
M#20"DSP7S(R*Y'-)!;^?T"D3.&$GE7*1Z>CK= N&X-XC81"UP[EKVW[M_%?N
M6X\6DXV@IJ*A#D4D'&;"6)O>S95)$ =PW'CM\]Q_-OR@(WXMX]VX8U0",T=*
M(JL\"<AFF1Z U>QTZ*M=V.Y0$ WB%@ -U[W[;D^?BW=SNV'=C-/'!"T%&'HP
MP)A'J@/,/5UFO5:(X_G(W'5M40U0L("'=#?8=][6  &XCRAW/HMCM",FHGCH
MF<D!@9[7&UQ]&DKG$VEJG?Z],K7U241&UP !WA?NV&XCQ!W;6"_<[8-P@-L<
M8Z2F@RFGHF+&<)8SD&8[:I:Q6X=4UDU.:ME<]DP1X> 7 H!;P6M83 4!UOH
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MC9LC),$0*":K^(7:$$IP!1J<'(#<P"..%O)S):#R9X.X2 ]?*"<^)PS.&!U
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M6"4.ZRTKA]+R#96)E7!Y!DHS.T2<L@;,E@524,J!U1URG @?F"-RX[<">5'
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M4=#D^7T$<0BHC1TL,(,B'AB  >3C6TG!(<L_T:.G$ I(,\QT)$69(N7'JL"
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M29.3QE&W&PU%AT#4Q\,U:V8'J!JF[;*B/YU%1#6N(]P;[PL(\6[B 1'B#C$
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M=;?W1ONWWW6W]WY]Q4F4TL5'1:J*($G6T.X 62V"I!%46Z*P7/1/\/JFHAN
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MLX;][LQ=Y-'4E@^9.P=SW^!XOR_\+AZ+.&_>[,7>31U)8/F3L'<]_@>+\O\
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M^%P]%G#?O=F+O)HZDL'S)V#N>_P/%^7_ (7$]%?#5A[![R:.I+!\R=@[GO\
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M\!N(#C$8)A(%?BR_J3Q@M:*97P*ZJJJDE5IA44,>Y*OJ$"W..L8"D)))D3*
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MRS_,4N*9@M.[!.M73P?])5?]-85);_>IOV#\V&C:'5E.5OMRBE(WE.+%IO\
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M$4IT4E2F*HDFH4P !BG(4Y3 '$!@, @(!W $! ,$4VH01UA(43;^VU0OVP
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M3;22KMVVA()1:4D'J1E9#@P*DUBE,"#I$X!80'%SXI>H1JFVS9U VV@*+8=
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M8'UJYWMK%7A]D.I-P&_JLJX/#PR("W_\5C4/!N7 _P!MC+BK-HC_ /Y[%J"
MPFUPU9-FH]"=2KCG;5WEL1]UXWHW+?U=)\.B_P!-=6-AN*=2KCG;5WEL1]UX
M:-RW]72?#HO]-&-AN*=2KCG;5WEL1]UX:-RW]72?#HO]-&-AN*=2KCG;5WEL
M1]UX:-RW]72?#HO]-&-AN*#2KCG;5H^ 7L1;_=0_LPT;EPJRRD?_ ,=%UU48
M-6U (K".@%0ZE7'.RK ^9Y#W_P!TABG@[+_UD?PX*M=<)^BT<ZV,](.)4>I5
MQSMJ[RV(^Z\31N6_JZ3X=%_IK+&PW%.I5QSMJ[RV(^Z\-&Y;^KI/AT7^FC&P
MW%.I5QSMJ[RV(^Z\-&Y;^KI/AT7^FC&PW%!I9P "/5;5XV"]BO8D3#;N% (D
MPB(]P *81'B*([A:-RW]92=<%$W7[,?4=*AA+&1$CJ*LDHA%PCB(9S.9$O$N
M9Z0"*A$Y"=@&RDQ*&2<N/>^,34C"<-< U;G7!-LH9;534%(BQ2F,$T=E_P"N
MB=JLVA:_-\6+EQ<6L[6EK%56W;UZ\:K>K<N<ME8A+,+.Y*B5:C> QAB515E+
M12DN^.) !K%@^CVQG2YC' !!( OK  &,)B@9H[+_ -?%L]6B+]/JRZRIQ1+3
MU6#;[M5VM76HY&E*09L'U49K/(%K)*D1C7<Q45/-&[U0Q2K)E9N',6FDL(D$
MI@(D<2)@<IS !;AAH[+S,9?$9V40!^6HZI34XJ(Z[+,-@64)4V==-)=&LJH5
M;N$TE6ZR<E$*)KHJIE.DJD=.(.0Q50,4URG.3B*FHH14B@M'Y?+_ (Z*;?NT
M7<W2UNS*BCBM&["NUMK-JGZE7'.VKO+8C[KQ=&Y;^KI/AT7^FN[&PW%.I5QS
MMJ[RV(^Z\-&Y;^KI/AT7^FC&PW%.I5QSMJ[RV(^Z\-&Y;^KI/AT7^FC&PW%.
MI5QSMJ[RV(^Z\-&Y;^KI/AT7^FC&PW%7J,CS1R:J9I.1DSB<-1206:++$*'&
M <%;-2AW0L<IAY=^['6"AC$HR2TG,B;@P+O9*O4JSS):9=RY%I(EUZ]BN9N,
M>/C'CX^/NV[N.K-*R2ZBH= 4,%4P1,$3!$.) )VPEU;@8UM76,4H[R@ @(:X
M&U=43W):]PW8W"2!;8'G596V+LN44ST5F=K3EJG;4U<E\Z\T<]M&'-O,VD\N
MJBSCRR;163^9U/5<^I]6K(GJDJ;-*DWY9&D*6AX$JIY9P2(J3WNDY!VW::KV
M09(0[,7!7#Y1KL!J@237/77,REM8ZQL627;4!4P\3Z^M?1(H@)"" :H"0O:B
M(")1U0N4PA8-<!N!P_HF 2]S'**1(\-JW+K#4.OZE38BTF")@B8(F"*\4?\
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M&CZ1;SRU5-Z8I]&IW"(MUZC2A(TDZN@9-LB**TN5 )!5,46;1+4.X,4$VZ)
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M!;\72V3\U2W4BT,X@%G?7FB>VI0X4]YNU>'_ ,*3GL X:6R?FJ6ZEQ*QG16
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MZDER\"<.:$.T=C,"_5.5T0R*Q"AVU%%1:J* 2 _9!\?0:K4=];^/Y3UKZD(
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M.+H^;@[,."+6U9$(6K\K[$+_ )Q38\7)1E2>O?RV"_$&/FY9!",JR!@ #3S
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MK*#,7-2/HNH,PW-!TQ*5*A1M*II+3]2!&I;08V)374334>+!?4*)@ 0*([@
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M&(X7#AW%0K%=BHLE/6=7C6;%JD]#5NJJJ<F9LJB0RAS$1+"LQ(D4PW*F0YG
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M8HZ@D$HZJXBN41 3%5,8P" &, D584$S6U@$UBB6PV$-4;7 0$+#N  N("(
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M:-^";$G<1)XJ?V<3B\DY$5_X1A:-^"EX.E^A)T)_9Q<S)>0=W=1A:-^"FV)
M_P#8D\5/[.)Q>2<B*_\ ",+1OP39$_0D\5/[&'%Y)R(K_P (PM&_!-D3]"3Q
M4_L8<7DG(BO_  C"T;\$V1/T)/%3^QAQ>2<B*_\ ",+1OP39$_0D\5/[&'%Y
M)R(K_P (PM&_!-D3]"3Q4_L8<7DG(BO_  C"T;\$V1/T)/%3^QAQ>2<B*_\
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M3 !VKE;5X<?=<XP7D]32Z=:Q,\;6 &,"=0Q^S QA(!H<#G IA$0*80<!>W$
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M^T3(8M$0 9RTY,*CUOU[EDPQ$O)Y6ZNI;-   +!_=\XC8   N/<* %#B*
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MZ81@JYU$WK*UUXQ!OPH4F9&@E$R;O;(ILQ.(!LBJ+@(D$BQQ*5-0"F+?7*<
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MU]0I3B!M4RHD4"QAN(%, 7U;[@L(C@B@HFBL-Q*0YB%LDH8@#<IR]J3:"41
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2')C<L )R%PL1R07+S'_R7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img158215518_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img158215518_9.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1D.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &/*^8X8X0DE-! 0      &(< 5H  QLE1QP!6@ #&R5'' (   *N !P"
M4  (<G(R.3,W-#D< @4 .4UI8W)O<V]F="!7;W)D("T@5&%N9V\@+2!!;65N
M9&UE;G0@3F\N(#$@=&\@1F]R;2!3+3$N9&]C>#A"24T$)0      $"7&DZ^>
M9-W>FT@!\PIN8D X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 5T            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T#\@      "@  ________   X
M0DE-! T       0   !X.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      ,U    !@              W    98
M         0                         !              &6    W
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG    W
M  !29VAT;&]N9P   98    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    %
M.$))300,      Y;     0   *    !7   !X   HR    X_ !@  ?_8_^T
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ME/\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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ME9>DI:;$X?#_Q  = 0$  04! 0$              0(#!0<(!@0)_\0 41$
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MNU_@+O::3-,H*>87V8=E@7\BC6XBXN?D,(J$%<6Z803Y\U('K:@@!+ <H\%
M"F$GM"8"E,;DI0["  (G4,/2(I^\Q#F+WZ #0&/=1<)XCVLY_P#%57M&)+=;
M<"O,686L4E#/V]BM;_*LPZI[65L$<@]%19[.2;^Q*BBX1:*%1:J&$#D2;I&
MH%D],IN,]SN)LW9@RLKE3#LID^Z8,"V8_P -X/FAC\&8?QA9T'E%BYQE)0Y&
M%F>M7()KW6R-&[Y-%F02%3<))',,??S]GE.0)3=D55W69,V_7F A,P2>)(.J
M[A+DVQ%EF3PI5RV#,>'$8=BC%S<M5C&K$:DJ:?5=MFMF0:I*RC:";D,D*914
M+(*[;=['N$I^]'+NW;+V<$LUUJ%VVX.S)79-2@QE'>Q<O>\C9ZJ<VP]7B9&1
M1=H@TQM#N"JKK)*&%V/2D <E .>>?ODS1ZNCVA 1ZC<B'''F/'E]'GSWY\^/
M( .70#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0&
MAO(?J'Z/=H"DN4,O8UPE5E[QE:YP%"J+9RU9*6&R/DHV*1=O5P;-&IG"IBE$
MZZ_ \\=Q'S#L.OHNMQO6D+3V%SL(K>W:;4,,+B=-R3;K1+-T4WC;M+2"QAG$
MU"FW+*;Y?4,7Y>QGFZJI7;$]U@;_ %%PZ>1J-CK3]*3BU'S%?H>M2.$#&(*[
M4P@ FX'I$0 1 >VEYN5ZN%H["]V45A;I3<$4#A:GA-.6#FLL'-(F"."U4U5;
M*?:Y>-45:#R#CRX#C7SE9:?FW>1MOV\V9A4LN9*BZE-R,>A,^KN6[Y=&/@W4
M@2,0F)MVT;*MXB,5D%"-A>OE$$>LP%*?N(Z N<0FH=6.829)1@,=(LTGS!Z9
MV@1L\9JM >INFZISE(JB9G^RO2$$2@@ JB($ 3 !R)R\2J8I$I2.4.9KZ\4B
M;UL<QF/?]F%*541%K[(_L@ %'L/M]AT!XZZ9&I%%JMGO%ELD4QK=0A7$]8I
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MD4HTO+SU&@S:*IV:SUK"L31KP3 DS5220)IU\\[6QU;^WNXTG,NG\6 *%1,
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M5!KD289C(1M-<3L:G8Y!@<@B9VTBSKE>*HG22%4#)D$52)F A3"FIH"JI>#
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M*19X%QNFV:6F.LVW5:>';PDBO=&S-U!54)L32'V5M1 '5C$ (D9$$Q.GU=]
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MU.%W#I>RQ-)K4;8%G3M0ZKIRM,LXQ&147<JG.JX6.Y,HLH<YU#&,81$"H8
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M/3+^A]'?^O\ 5V9@- _"MN+^G&96Y?,/P _/K0IZ/]_^GS-^A4- - - - -
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MS)<"@ %  Y^8IYCW$>_<?>'/P$ 'XAJ(?WOXF2Z=W>IF&-3_ +^PX_E+*_\
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M*T=T$Z3O0>CK>^V]G972QCC=]BL8[37CFVYV2AQEFJ[2_G5HUJ- - - - -
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M$0 B9>0.<1$>!* AU ')0*0!'D Y#0'RTYM@J195*39+)-RF4<JI/&YP;$(
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M==BP[)3,]ZTNK_M0O+A@@@UM'71M0))-I1*LL^MSQ)3=63F\: : : : : :
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MI">B[<#WT!AVFA93;Y1K;@N-R+3,G4^Z(;7K!F+<3B>\7AU'OL:WK*\-$VN
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MQU9I\)'U^$9J.%?3.%48Z,0;-BK.%A](X6]&*JY_:5.<>^@+&:X4I?%=S84
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M    &L4?G8Y3<E)3<EL4\"X70@: : : : : : : : : : : : : : : : :
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MQGU85E6DS)#H]L97.H5BWQJ"S=E;(&(L+%LN0/66[69CF\@DBL0! /2(IJD
MXE$P&.!^D.DNK)S>>P3.8P\&X]X!QW^;T^UR   =0& >._UZ YM - - - -
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MJ$FT1*LQ544 3=)AT!T]L>QM3 >7JK;X_)D5.8PQ%@V"P1A2B1T.V:24/&)
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M)XE6?;/=\)7K LDQV7;9X5"IY$4CE)F3CR9FW6OD["S&,.= 8QTX>+L4>O\
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MELM-)E[@';\6'C#R9VF2K/*/0*ND@#9C&6"&<N7!A5,4#B5,INDA/:$P=M:
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M,=*/\.O1_P#TWH+QNI=5X.<;'QV8\H^I,FK/TU/:K*^KH)H^F6/+N!.LKT%
M5%#G$3'.?D1,81$>^L7Y'YTVB7M(JX.-*N6M/KK*ID7E,(<]9B]QX*(<<#J'
M/+:NS,I.34@: : : : : : : : : : : : : : : : : L4\02[5:)VX9,QX
M^W&8QVW9!RE3+%!XQMN2<CPV-T7,NS(T5?M8V8>R+*3;)JM'"<;)RT*1:2@$
MY=*5;@"J2/2'///$BS\)!:]R^8Y9O,9"P(A7*-4KVRB:-BO>HTW12]DC[C?'
MUGC)24BF<I*GBH^J$>&CF4_,.!FGR:P(*-VB*16Y ESYE['B-*IW: :8]LVU
MZ_9XJM+L6-LH,8FKV;',1'WB8AK>R6/57:%RL$08&L>DC\IRIU"(D<L$E$XY
MUZWT@40Z_;FL<.?OI'X1F%AQM8MV%Q)AS/&&FN2YC%"L=6,XY!J&2G+:)K+'
M(3=I$4ZRUBQ624<05<^6EF;=I8EDGK-JO%L6[ARDT7,BS[/,F?=M7VX^!-RG
MST$Y$!'H+R(   (\!R(  F  ^  8P 'O'ST!Y&]4&I9+J-CH=WB"SE3ML8YA
MK#$'>2+$LE%NP '+-1Y%NV4@BDN4.A3U5V@<R8F3ZN@QBB!:W3?#NV:X^IUD
MQ_3<(P\)3+8Q:QTU72V2]/HTS9D\)(,QC$I.TO#5]TT>ID=-7]?/%OT%RE42
M<E$- 5XQ#@C$N"*\ZK&**5&U**D)%27EC(+R,G*SDLH4B9I.?L$X]DY^?D"H
MIIMDGDS)OG"+5,C5)0C<A4P L]KA"E\5W-H  <?J#-L!^//V@SMN]* ]^>W!
MAY+\T1'D0$>^I>6]>;*(L5NC2[DR102@4  H<!T'[?\ UM6X,'Q\D5F#U=?O
MO^4/XX;1_P F-KIRR_9A;?RY>#*NAOZ]Z"^?77ZZ$JEBCOAC<24?(T-C;G_\
M1H,//S#L(\<"' \"'< $.<;QY?\ [9WOZU/ZF='E_P ^Z_5LF#\-:\2N/=IM
MLGH>$93SAQN&C:^JR?2PPB9"6QCCBMMWA7HLGY51;R<NR,=L")5!0,J*0G,!
M$A^90N*<DVTF^I)OMIU[I'!7LXHF]6&GOIY53>&VF*6%&\:38-#G.F7TI")J
MB4HJ$(83% _ =92"8I1,4AN2E.)2^D* 'Z2\\!26SL@("(@ ^7G]&@-= - -
M - - 6U;R_W)6Y?^(C+']19W65T%\<Z+^?W7ZZ MVWYJU^3C^BS"$VA?M,;@
M_P#:3$W_ (VWZWGZ5_T7H[\G;_5V!O/U0/UZ7"]?6V*+T;"4/M"X:,!>H1G<
MC\@'<PB,C%  @3@1/P(\])0'X\:Y]M$XHX4ZR<26Y4G+J[3T_K1IQ^DB\5F_
M<MACG^<2^S J5#Y(G(_Q(]K=4)>Y=J@,;A>-3K9K.[8LS-GT?A<RT:6)4D$D
MS(/@065<M ; BZ$@F5(<0U[:QL++^[UZCB@AUE86C3E.).&=9J<VLD]^,C5-
MWNUFM VL;LX)J!N:43;HW26+23DI3GK;S+J;E,4P\AP42AT]ND0X @"42]PX
M*(]A*/ \B/<?+P222ISVU/ /%\7OSR.WJ2!H!H!H!H!H#C-Y*_@_^4=6X?AQ
M=?B@8D\^ COEST <\C/;F #CSY^P_(_ES[_A].LQ;.5A W@KO/L/T8Z4M+U=
M.C[>"Z-:";X)W5G?VFYXA]NL#N$R/+N["R]'CHT3$R57;,'$M%SSLLVYBG@I
MRA#,$4D7#0AE/64UB*% W!1Y#7S72XVE]?Y-)I;9R:SPP:E1//8?GO<KC:7R
M/6@4U[]X.*<XG.>KA3"4Y3JJ,R"MEVX*%W'8.K%V@WEED3(MVD5+R5K:QS64
M?R[9@U6D7:A(LI&/0NLJ8R MTTDP#MT (:B]76.ZVBLXTE-324\)R6/V(IOM
MTBNMHH8OWITJO''?U83+P]?*?"- - - - - - - - - - - - - - - - -
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M#$G[R3E)8.<\6I.M2WIZ^PWVVAM-9-PII)2JGME1;L]KP+^_NFF'/X(]UO\
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M!P/D &'ZNP?#O\- J)3=7MVO+\#J]  *AA,!@,<"AR;];(;H H@GU\]9#"4
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M 8. -V'J^/("/ >XO/2'?MH#C]6((\B)^> #D!*!NW^L4H''GW@)A*(]^GD
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MDZ93^C2ZBD,/2 BF7D \A#@1DID]KW3EXRJ=[CZ1_)^C0D  AYB(_7Q_< :
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MC&,FS?-"G(S>-GS1)VW=-B*&%4C9PDJ15$JIA/Z,Y>HYA 1U!4?>T T T T
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M:!2B98PJ "10$Q^D '0'FJ[F/&=ND5(FK7ZF6&318)2RS"'LL3(/21*A1/\
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I8.1[?'CO\??H#LZ : : : : : : : : : : : : : : : : : : _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img158215518_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img158215518_10.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &.!/<# 2(  A$! Q$!_\0
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MY+^JT>2_JM3T4 0>2_JM'DOZK4]% $'DOZK1Y+^JU/10!!Y+^JT>2_JM3T4
M0>2_JM'DOZK4]% $'DOZK1Y+^JU/10!!Y+^JT>2_JM3T4 0>2_JM'DOZK4]%
M $'DOZK1Y+^JU/10!!Y+^JT>2_JM3T4 0>2_JM'DOZK4]% $'DOZK1Y+^JU/
M10!!Y+^JT>2_JM3T4 0>2_JM'DOZK4]% $'DOZK1Y+^JU/10!!Y+^JT>2_JM
M3T4 0>2_JM'DOZK4]% $'DOZK1Y+^JU/10!!Y+^JT>2_JM3T4 0>2_JM'DOZ
MK4]% $'DOZK1Y+^JU/10!!Y+^JT>2_JM3T4 0>2_JM'DOZK4]% $'DOZK1Y+
M^JU/10!!Y+^JT>2_JM3T4 0>2_JM'DOZK4]% $'DOZK1Y+^JU/10!!Y+^JT>
M2_JM3T4 0>2_JM'DOZK4]% $'DOZK1Y+^JU/10!!Y+^JT>2_JM3T4 0>2_JM
M'DOZK4]% $'DOZK1Y+^JU/10!!Y+^JT>2_JM3T4 0>2_JM'DOZK4]% $'DOZ
MK1Y+^JU/10!!Y+^JT>2_JM3T4 0>2_JM'DOZK4]% $'DOZK1Y+^JU/10!!Y+
M^JT>2_JM3T4 0>2_JM'DOZK4]% $'DOZK2>2_JM6** *_D/ZK1Y#^JU8HH K
M&%P,DK1Y$GJOYU/)_JS3J *WD2>J_G2^0_JM6** *_D/ZK1Y+^JU8HH @\E_
M5:/)?U6IZ* (/)?U6CR7]5J>B@"#R7]5H\E_5:GHH @\E_5:/)?U6IZ* (/)
M?U6CR7]5J>B@"#R7]5H\E_5:GHH @\E_5:/)?U6IZ* (/)?U6CR7]5J>B@"#
MR7]5H\E_5:GHH @\E_5:/)?U6IZ* (/)?U6CR7]5J>B@"#R7]5H\E_5:GHH
M@\E_5:/)?U6IZ* (/)?U6CR7]5J>B@"#R7]5H\E_5:GHH @\E_5:/)?U6IZ*
M (/)?U6CR7]5J>B@"#R7]5H\E_5:GHH @\E_5:/)?U6IZ* (/)?U6CR7]14]
M% $/E/ZBE$;>HJ6B@"+H<&BFN?WAHH ;&?WRU9JI$?WR_C_*K= !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "
M%@" 3R3@4M12_P"L@_WS_P"@FI: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH 9-_JFI]1S_P"I:I* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH K2']ZU%-E_P!<W^>U% "0_P"O7\?Y5<JG#_Q\
M+^/\JN4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMD\08%UBD*,&R3EL%#QCO^"^)?&MYI7CC1-!LH+>2&ZDC6\DD5B8_,8A0N"
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M@\GKC\O3JY/2O =EHVLZ;J=C=3PRVE@MA,BA0MU&HPI<8^\,=1764 8WB_\
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M 4444 %%%% !1110 4444 12_P"L@_WS_P"@FI:BE_UD'^^?_034M !1110
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MSM(5R\F>OS9#9_V3SCIZ+\,M6O-8\')-?79O9(;F>W2\(Q]H1'*J_P"('Z4
M=C7):!X1O/#]EXC2UU)/M6JWT]Y!-Y.1;LX&,@GYL$9[9KK:* .&U;P3K%]<
MZ3K%IXA6U\0V=H;2>\-HKQW"M][,>1M.>1@UO>$_#=OX2\-VNC6TKS+"&+RN
M,-([$LS'TR2:VZ* ///B_P#\@+0?^P]9_P VKT.O//B__P @+0?^P]9_S:O0
MZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B/B]
M_P DLUS_ *YQ_P#HQ:\GMW>/0&^'(<[[O5;:55S_ ,NTD0F;\ 5'YU[MXIT"
M'Q3X<O-%N)I(8KH*K21@%EPP;C/TK%3X=:;'XNLO$?VB8W%I9"T6/ VMA"@<
M]\[3^E=V'Q$*=+EEO=M>NEB&KLY/X:Z3INI?!E)+[3[6Y>$79B:>%7*<MT)'
M'0?E5WX16>D6/PPL==GLK1+F%+AY+OR5\P*'?/S8ST&.M==X;\(6WAGPD?#U
MO<S30D2CS9 -WSYSTXXS5&W\ 6]K\.6\&PZE=);NK*UR%7S"K/N(].<D?2E4
MKQGSJ^CE?Y:C2/#?[>TQ+>+QN-1A/B7^W#=O:;CO^S'Y=GY#\C7<^.+R*?XM
M^'+R#1/[>AFT@R)9A5;S58R$-ALCC.?PKT5_ OA]_#1T3^S[81&U^S><(4\S
M&W;NW8^]WSZUG:-\.;;2-8T34O[4NKB72+-K.(2*H#H2V,X] ^/P%;/%TI/F
M[72]&M-A<K,;X=^'-3M_&>M^(9]#7P_I]Y$D4.G!U))&,N0O Z'T^\:K>/-0
MC\'?%'1O$TF%M[G3KBUF/8LBEE!^I*C\*]9KE?'7@:R\=Z7;V5[<36X@F\U)
M(0"W0@CGL<_I7/"NI5N:ILU9^EK#MIH>+Z)/<?#Y(-<NI6#>(M"N9F+?\_&2
MZ?H4_,UUT_A/3M,_9_:6XTZU?45TSSOM#PJ9%9SOX8C(QNKM/%_P[TSQ?H^F
MZ;<2RVT5@P,30@$[0NW;SV( _*MK7M"@USPU=Z(\C007$/DEHP,HOMGZ5K/%
MJ3C+K>[^6WX"Y3)^'NDZ;9^#=%O+;3[6&ZGT^'S9HX55Y,J"=S 9///-=95#
M1=-CT;1+'2XY&D2T@2!7;JP4 9./I5^N*I+FFY%(****@93F_P!>WX?RHHF_
MU[?A_*B@ A_X^%_'^57*IP_\?"_C_*KE !5>^O[33+.2[OKJ&VMHQEY9G"JO
MU)JQ7F6K:[K/B*_U+38=#T.;3["\:-IM4D9EMFB7?YDT>/NL/N$'W- %Z3XT
M^!8YS&-6D=0<&6.TE9!^.VNNT;7])\0V?VO2-0M[V#."T+YVGT(Z@^QJGX2U
M&/7?"6G:E]BBMA<Q;C"@^0<D?+QRIQD>Q%:-II&G6%U/<V=C;6\UP )GAB"&
M3&<;L=<9/YT 7**\Z^)^H>)-#LGUG3M8>UM((PL5M!:"4R39))F9@0L6T=>,
M5GZ_XC\2:CJNH6^E:Q'IZ:1H::G(8(DE6YF8%MN6!_=X';UH ]5HKR&Z\7^(
M_$C[](U/^RDL_#D>L.J0))YTSC<$.X'"8!Z<\TEQXO\ $7B=HO[*U/\ LD6W
MAQ-8E\N%9/.F;HAW X3@].>: /7ZX*3_ )+Y#_V+;?\ I14L/Q,T>R\+Z#J>
MMO-!-JEHLX6&WDE&[ W?=!P,GC-86@>)M+\5?&T7FE2RR0Q^'VB8R0O$=WG@
M]& /0CF@#U6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"*7_60?[Y
M_P#034M12_ZR#_?/_H)J6@ HKC/%_B_3;:SN["T\6Z=I.HPNBSR2()Y(5;TC
M'5OY=ZR+7X<2:G;Q:E'\1/$UPTRB2.X@O L; \@A0,8H ]*HK"\-:7KFDQSV
M^K:[_:\/R_9Y9+<1RJ.<AR#ANV#@'K5'Q)X_TSPQ?-:W5GJ-QY4(GN9;6WWQ
MVT9. SG([]ADT =717(:]\1M'T&Z6![>^O2+47D[V</F+;P$X$CG(P/IDXHU
MSXCZ-HEQ'%Y%]?9M!?2O90^8L%N>DCG(P/IDXH Z^BN0USXCZ-HDT48@OK_=
M:"_D:QA\P0VQZ2OR,+^9KJ;6YAO;2&ZMY!)!,BR1N.C*1D'\J .(@_Y+W=_]
MBXG_ *4&N]K@H/\ DO=W_P!BXG_I0:[V@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9--%;023SR)'%&I9W
M<X"@<DD]A7!?#OQ'X>U34_$%OI>IQW$[W[S+'YC$M%M0!@&ZC.>1[>U'Q5U2
M&X\.S>$[,2W.N:P@BMK6 _,!D$N_]U.#DGW]\>;?![X8Z_I?CI]7U$QVT&E2
M20.J2AC+(4QM&/X<.#G_ " #Z)HHHH :Z)+&T<BJR,"&5AD$'L168/#.@@@C
M0]-!'(Q:1_X5?NKF.SM)KF8D10HTCD#. !D_RKD!\4_"S, +N?)./^/=O\*3
MK*GO*U_,Z*.$KUTW2@Y6[*YVM%(#E01T(I:9SE#5M$TO7K3[)JUA;WL ;<$G
MC# 'U&>AJ";PQH5QHJ:-+I%DVFIC;:F%?+4CN!V/O65XK\7W.B:IIFC:5I?]
MIZOJ(D:&%IQ"BJ@RS,Q!_ 5AK\5/M>CZ<=/T:2;7+Z\DL1ILDZH(Y8QF3<^,
M;0,'..<T =]I^G66E64=EI]K#:VT0PD4*!57\!6>/"F@#3UL!I5L+1;C[4L6
MSY1+G._ZYJMX/\4KXJTRXFDLVLKVSN7M+NU9P_E2IU 8=1R.:F/C+PT+J&U_
MM[3?/F)$:"Y3+$'!'7U!'X4 97C?P);^)M#U."P6VM-2U PB:[="2ZQL" V.
MO P*U+7P9X<LX+R*#1+&(7J;+KRX0OFKW!QV]JDM?%WAV]M)[NVUNPEMK=Q'
M-*MPNU&)P 3GC)Z>M4-3\=:-!HFLWNEWUGJ5SI<#RRV\-P"1M['&<>F: -9/
M#^D1W-C<II\"SV$7DVL@7!B3&-H/ICM6E6+HWB2RU2RTPR3V\-_?VB72V?F@
MR!64'@=2!ZXK:H QO%__ ")6O?\ 8.N/_1;5G_#;_DFOAW_KPB_]!%:'B_\
MY$K7O^P=<?\ HMJS_AM_R37P[_UX1?\ H(H ZFBBB@ HHHH CN/]0U25'<?Z
MAJDH **** "LKQ%<ZQ9Z)//H-A%?ZBI7RK>60(K?,,Y)(Q@9/X5JT4 >*SOX
MV&MOJ4_PX\.KJ=U&8C,U]&LDBD8('SY/'&1SBO2/ Z:A%X6MH=1T>TTB2+*1
MVEI('C6,?=(()Z]>M>,>)+BVT/XCRZAXCT_59=1763+#<(C/$VGF-E5(\'&[
M)&?Y]:]4^%5G>V/@.UBO(+BW0RRO:V]R29(H"Y,:MGN!0!VM%%% !1110!YY
M\7_^0%H/_8>L_P";5Z'7GGQ?_P"0%H/_ &'K/^;5Z'0!P_Q+^( \!:1;RQ6J
MW-[=N4@1R0@V@%F;'/<<>]9WPN^*#^.WN[*^LH[:_MD$N822DB9QG!Y!!([G
MK3/&+>!OB+*GAN7Q!!'JD$I^SO$V2K]"H)^5LXZ YXK4^'_PWTSP&ES)!=O>
MWMP LD[J%PHYVJH)P,\GDUW6H1PUIIJ9.M_([BBBBN$H**** "BBB@ HHHH
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MV>F6BE;>TA6&,$Y.U1@9]ZXZ3_DO</\ V+;?^E%=[7!2?\E\A_[%MO\ THH
M[VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M% !1110 4444 %%%% !1110 4444 %%%% "8HVYI:* $Q1MI:* $Q1CWI:*
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M?C6-H&@_\(]\;1:_VKJ>I;_#[2>;J-QYKK^_ V@X''&<>YH ]5HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** *<W^O;\/Y443?Z]OP_E10 0_\ 'POX_P JN53A_P"/A?Q_E5R@
M H(SUHHH X:]NOAHNMW4%W%H!U&T4RW!:V1C$ 0"6;;@'+#J<\UVT*1)"BPJ
MBQ #:$ "X]L5\VZG#)HFL7>BI>>$Y8]E[:O>7%ZBN1<.K%IEZETVX'7]*^A=
M!ABMO#NF007(N88K6)$G!R)5" !OQZT :%%)D#O2Y% !11D#O1D"@ K@I/\
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M;2@?7N?>O1*^?YOB+K1N=2O+GQ=;6,S6MX8M-,*_Z'+#,@CC(/+NZ[A^)]*
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MFTOPKI;:AJEQY<>=L<:C+ROV5%[DT 7K_4+32[&:^O[B.WM85W22R-A5%>=
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M474+V29G#DE#Y8X'K]W]:ZB\^'O]K6<@UG7;^]NG'RN2%CC/^S&./SK"\#>
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MRBBBN,H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1Y_G7'^"/AAX3T[XE:C);:D]Y)I,B26ULTJ$HQ');')V'CM@]>:]KH ****
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M\J> !TH \1\=^$]7T2UT.ZOO%^I:M"=:M4^SW**%!+'YN.XQ^M>W5YY\7_\
MD!:#_P!AZS_FU>AT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;K/&EU<+&>0"0,D9P3BN7L]3L-5^.L<VG7UM>1+X=96>WE610?M ."5)YY%
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M-/MD@A'4+U8^I/4GW-7J**Q225D>5*<IR<I.[84444R0HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:2@!IJ)JE-1-0!
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MN3X?9DEAMA"%3SQ\N 3DYR<^] 'JM%%% !1110 4444 %%%% !1110 4444
M%%8WBCQ'9>%- N-6OI8TCB&$61BOF.>BC )R?H:Y+1_C1X6U#P^NI7ETEK<E
MS&+",M-,3V 4*"<^PQ[T >C53U/5M/T:S:[U.]@M+=>LD\@4?KU/M7$_VSX[
M\5\:+I4?AS3V_P"7W5%WW##U6$< _P"]5S3/ACH\-XNHZY-<^(-3'/VG4G\Q
M5/\ L1_=4>V#0!4;XA:CX@8P^"/#\^HKG']I7N;>T7W!/S/] !5+5/AKJ'B;
M3+B3QKXFO+M@A=+73U$5O P'!"]7([%J],_=PQ_PHBCZ "N:U_Q#9O836NFZ
M@[7^,QBU4R'([' (Q0!Q/P8\!:;H*WFLAKN34&9[<?:(A&$CW9& "<E@%).>
M.E>N,RHI9F"J.I)P!7EFA:WJ5O;23S:WI]G:99=]],J@,3DD+QD\]^.:6;Q7
MX-DFVW^OWNOW /\ J+2&1TS[*@Q^M:PH5:GP1;^0FTCN+GQ5IL,I@MWDOKC_
M )Y6B>8?S' _.H?-\2ZE_JH;?2H3_%*?-EQ]!P/QK!MO&&I-$(O#OP^U3R_X
M3=!+-/KSDU-N^)>H](] T>,_WF>XD'Y86M/JLU\;2]6OR5W^ N8VHO"EG)()
M=2GN-2F'>X?*CZ*.*URUGIUO\S06T"^I"*/Z5QW_  A'B&__ .0OX[U1P>L>
MGQ):CZ9&34D/PJ\)K();RTN-2F'_ "TO[J24G\"<?I1[.A'XJE_1?YV"[[%'
MQ[X\\+P>&+^!-9M;B\V9B@MIMS,_8$KT&>OMFJV@?$-KK0;.'P]X7UO5-L84
MRLHCB#=QYC'G!R*N>,?A=H^MZ(EMIEA!:30;C#' 5@C9B,;G(0DX]/K6UX&\
M)Q>$-!%C&\W[QO->)YA*L;D8.T[5X. >E=3E@XX:\4W*^S?^7]>8O>N9?F?$
MK5?N6^B:'$?^>CM=2C\L+4<_@#6-0MY3JWC/5KR8H=L4#"TA+8X#! 3C-=]1
M7-];G'X$H^B_5W?XCY>YX'X'^&EWI_C^5Y]1T?4/L##[3#(#(7#KR0"#A@>Y
M[U[TB*B!$4*H&  , 5%%96L,[SQ6T*3/G=(L8#-GU/>IZ>,QE3%34Y]%8(Q4
M=@HHHKD*"BBB@ HHHH **** (I?]9!_OG_T$U+44O^L@_P!\_P#H)J6@ KS3
M1OC-X<^SSV_B/4K:QU2WN)898XHY'C(5R%*L <Y&/QS7I=>#R7FLZEX>U;QL
MGB;3[$V<T^S1FLXB@$;$".0GYB[8^O(_  ]RM;F&]M(;NW<203QK)&X'WE(R
M#^1J:J>DW)O=&L;HP^09[>.3RO[FY0=OX9Q7%?$;7_$VC3Z7_9:06VFR7]M%
M/=EPTDA=\&-4QP,#ECZ\4 >@T5Y?XOU_Q%+XB\06VC:M_9T/A_2EOB@@23[3
M(0S;6+#A=JXX[FJ&H>+_ !'K[W,^CZF-+BT[P_#JS1K LGGRNI?8Q8'"8&..
M>: /7Z*\@OO&'B+Q"TTVD:F-*CT_P]%J[HL"R>?,ZE]C;@<)@8XYYKJ?^%FZ
M%I_A[0]0UNXDM9=4LTN52.WDD'*@M]T'')[T 00?\E[N_P#L7$_]*#7>UY9X
M7\2:7XI^-5[?Z1.\UNN@+$6>)HSN$^2,, >A%>IT %%%% !1110 4444 %%%
M% !5/5-6L-$T^2_U.[BM;6,9>65L >WN?85S'B#X@066H-HF@6C:UKW>V@;$
M=O\ [4TG1 /3K]*Y6R\-:CXEU=;[6+N/6=1B;ARO_$OL#Z1(?]8_^T?_ *]
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M?T,'0_!^C:  UI:A[C&#<3?/(?Q/3Z#%;U%%<:BEHC.I5G5ES5'=^9'/"MQ
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MC4DD@#U)Y-7:* ///B__ ,@+0?\ L/6?\VKT.O//B_\ \@+0?^P]9_S:O0Z
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M+$] !FM>DFGL7.G.&DTUZA1113("BC-1_:(3_P MH_\ OH4!8DHHHH ****
M(I?]9!_OG_T$U+44O^L@_P!\_P#H)J6@ KP!/#&M>,M8N/$]EX8\(QDW4BB.
M]DF\S<CE<RHIV[LC/(YKW^OFZWTSPG'/?#Q)X5\7:CJGVR8RWMO#+LG&\[6
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MM=8Z3>'IO$[&.XL'UV.#R6595,ZQ9W;2,Y SS0!S7_"H?#'_ #UU?_P93?\
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M-+^)7B;6K>6?3OA[=3Q13/ [#4H5PZ'##D#H:75OB1XGT/2Y]2U+X>75O9P
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M]LZ7_P!!*S_[_K_C0!=HJE_;.E_]!*S_ ._Z_P"-']LZ7_T$K/\ [_K_ (T
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MV-=)XHZBBB@ HHHH **** "BBB@"G-_KV_#^5%$W^O;\/Y44 $/_ !\+^/\
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MJ;WN9!^X@7<%^;D$DYX4?7M7;5S?CWP_=>*?!.I:+9211W%TJ!&F)"C#JW.
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MRAL[<!CTQTKU&O,9_ASK$FI3V"WMB/#=QK0UB0%6^T!LAC$!]W:6'7.:].H
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M57:T4 <5_P *B\!?]"W;?]]R?_%4?\*B\!?]"W;?]]R?_%5VM% '%?\ "HO
M7_0MVW_?<G_Q5'_"HO 7_0MVW_?<G_Q5=K10!Q7_  J+P%_T+=M_WW)_\57&
M?%7X=>$M!^'>HZCI>B06UW$T(256<E<RJ#U/H2*]HJCK&C:?K^F2Z=JELMS9
MRE2\3$@'!!'0@]0* .6C^%/@M;?%OHJ6SR*,R0RN&_4D4\?"GP8\:+<:,MPR
M# >65RQ_(@5V8 50!T P*6IY(\W-;4V^LUO9>QYGR[VOI]QQ1^$?@,]?#EL?
M^!R?_%4?\*B\!?\ 0MVW_?<G_P 57:T51B<5_P *B\!?]"W;?]]R?_%4?\*B
M\!?]"W;?]]R?_%5VM% '%?\ "HO 7_0MVW_?<G_Q5'_"HO 7_0MVW_?<G_Q5
M=K10!YIXH^%G@FQ\):S=VWA^WCN(+&>2-P[Y5E0D'[WJ*S/#/PO\/ZO\-]'N
M[6U2RU2YLHI'NTW,68J"=P)Q@^V*]8N[2"_LI[.YC$EO/&T4J'HRL,$?D:98
M6%KI>GV]A91"&UMXQ'%&"2%4# '-3**DN5[&M&M.C452F[26QY,OP7O"N6UF
M -Z"%B/YU?TKX-VL%[OU:]6]M0,&W6,H'X_B.>GTKU.BL(X2C%W2/5J\0YC4
M@X2J:/R7^1Q(^$?@(_\ ,MVW_?<G_P 576:=IUII.G06%A L%K NR*-2<*/3
MFK5%=)XH4444 %%%% !1110 4444 4YO]>WX?RHHF_U[?A_*B@ A_P"/A?Q_
ME5RJ</\ Q\+^/\JN4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5POB#Q_J&F>,_\ A&=)\,S:O=_8Q>$I=I#A"Q4_>'8X[]Z[JO(=>UNU\,_'
M<ZKJ,5U]C;0Q )(;=Y?G,A./E![ T =KX6\<67B*UU W%O)I5YIDGEWUK=L
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MU*SFN@H<P1SJSA3R#M!SBD&MZ2VI'31J=F;\=;83KYO_ 'SG->06^A1Z??\
MPKGTZP6VNI+:47$R0X;<8!S(<<_,3U]ZP8]-#>![7PU%H5VGCU-2$CW)M&#J
M_FEC,9\8V;>,Y_QH ]]N];TFPNXK2\U.SM[F7_5PS3JCO] 3DU8^VVIN)+?[
M3#YT2[Y(]XW(OJ1U ]Z\7O(],TKQ#XQ@\7>'+K5[S4;I)-/"6CR&YBP J1R
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M'!Z<#M7;?"BT-A/XQM4@:"V37I_(CV[5"8&-H]..U 'HU%%% !1110 4444
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M&QE<\X-=30 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24M)0
MTU$U2FHFH @>K]4'J_0 4444 %%%% !1110 4444 %%%% !1110 54EU2PAU
M*'39;N%+V=&DBMV<!W5>I [XJUD9(SR*\MUR33OB5<2)86=]9MIAD>S\3@+'
M%'+&>0ISEESP>W!/:@";Q!\3-5LM<N[71](M+RWL;N.RDCEN"MQ<S, 2L* '
M[H.23QP?2O0=*U.UUG38;^SFCE@ESAHW##()##(X.""./2O(-#\,7WBCQ)>7
MUU/>^'?%=G&(-0NK2%7@O8V&%EC8C"LRCJ/RKUO0]%LO#VBVNDZ?&4M;9-B
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M[PKI(TW34D$6]I7>5R[R.W5F8]2:UZ** ,;6?#-CKFI:1?W;3";2IS<6XC8
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M:J VGZAYZRQ-NY42$#Y"1_GO0!9\>>-K^SAOM&\*V+:IJT=K))<M;S*#9+@
M,1R2^6R%Z\5R.A:7++9VEWX;>?Q+X3UG;;ZKIE]-NEMI#C=)ENA!Y/YCL1V'
MBKP5??V[%XL\(20VNOIA;B)SB&]CXRLF.^._M]".JTCP]IFC7%[=V5C#;7-^
MXENC%G:[@8R/U[#J30!R?@#P)<^!]:U6WCCLY])E"M:7;+BZ4$\Q.<<J.W^<
M>@T44 %%%% !1110 4444 %%%% !1110 4444 4YO]>WX?RHHF_U[?A_*B@
MA_X^%_'^57*IP_\ 'POX_P JN4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 12_ZR#_?/_H)J6HI?]9!_OG_T
M$U+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4E+24 --1-4IJ)J ('J_5!ZOT %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"*7_60?[Y_]!-2U%+_K(/\
M?/\ Z":EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *2EI* &FHFJ4U$U $#U?J@]7Z
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH IS?Z]OP_E11-_KV_#^5% !#_KU_'^57*J1?ZY:MT %%%% !1110 4444
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M^>C?F:-\G_/1OS- &C16=OD_YZ-^9HWR?\]&_,T :-%9V^3_ )Z-^9HWR?\
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JJE]KD]$_*E^UR>B_E0!<HJH+F0]E_*G"X<]EH )!^]:BC.YB3WHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img158215518_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img158215518_11.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %/!"$# 2(  A$! Q$!_\0
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MV,_\]/\ QVK5% %7[&?^>G_CM'V,_P#/3_QVK5% %7[&?^>G_CM'V,_\]/\
MQVK5% %7[&?^>G_CM'V,_P#/3_QVK5% %7[&?^>G_CM'V,_\]/\ QVK5% %7
M[&?^>G_CM'V,_P#/3_QVK5% %7[&?^>G_CM'V,_\]/\ QVK5% %7[&?^>G_C
MM'V,_P#/3_QVK5% %7[&?^>G_CM'V,_\]/\ QVK5% %7[&?^>G_CM'V,_P#/
M3_QVK5% %7[&?^>G_CM'V,_\]/\ QVK5% %7[&?^>G_CM'V,_P#/3_QVK5%
M%7[&?^>G_CM'V,_\]/\ QVK5% %7[&?^>G_CM'V,_P#/3_QVK5% %7[&?^>G
M_CM'V,_\]/\ QVK5% %7[&?^>G_CM'V,_P#/3_QVK5% %7[&?^>G_CM'V,_\
M]/\ QVK5% %7[&?^>G_CM'V,_P#/3_QVK5% %7[&?^>G_CM'V,_\]/\ QVK5
M% %7[&?^>G_CM'V,_P#/3_QVK5% %7[&?^>G_CM'V,_\]/\ QVK5% %7[&?^
M>G_CM'V,_P#/3_QVK5% %7[&?^>G_CM'V,_\]/\ QVK5% %7[&?^>G_CM'V,
M_P#/3_QVK5% %7[&?^>G_CM'V,_\]/\ QVK5% %7[&?^>G_CM'V,_P#/3_QV
MK5% %7[&?^>G_CM'V,_\]/\ QVK5% %7[&?^>G_CM'V,_P#/3_QVK5% %7[&
M?^>G_CM'V,_\]/\ QVK5% %7[&?^>G_CM'V,_P#/3_QVK5% %7[&?^>G_CM'
MV,_\]/\ QVK5% %7[&?^>G_CM'V,_P#/3_QVK5% %7[&?^>G_CM'V,_\]/\
MQVK5% %7[&?^>G_CM'V,_P#/3_QVK5% %7[&?^>G_CM'V,_\]/\ QVK5% %7
M[&?^>G_CM'V,_P#/3_QVK5% %7[&?^>G_CM'V,_\]/\ QVK5% %7[&?^>G_C
MM'V,_P#/3_QVK5% %7[&?^>G_CM'V,_\]/\ QVK5% %7[&?^>G_CM'V,_P#/
M3_QVK5% %7[&?^>G_CM'V,_\]/\ QVK5% %7[&?^>G_CM'V,_P#/3_QVK5%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6
M:[?OW_WC_.M*LES_ *1)_OG^= $VZBH\T4 7+'_CSC_'^9JQ5:P_X\H_Q_F:
MLT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$9& !DD $Y;ITK3^PW?_  EOBR;[+/Y4]A&D+^6=LC",@A3W.?2E%*,==_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "L9S_I,O\ OG^=;-8K_P#'U+_OG^= $E%)10!>L/\ CRC_ !_F
M:LU7L?\ CSC_ !_F:L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^>C_ /?1HWR?\]'_ .^C0!HT5G;Y/^>C_P#?1HWR?\]'_P"^C0!HT5G;Y/\
MGH__ 'T:-\G_ #T?_OHT :-%9V^3_GH__?1HWR?\]'_[Z- &C16=OD_YZ/\
M]]&C?)_ST?\ [Z- &C16=OD_YZ/_ -]&C?)_ST?_ +Z- &C16=OD_P">C_\
M?1HWR?\ /1_^^C0!HT5G;Y/^>C_]]&C?)_ST?_OHT :-%9V^3_GH_P#WT:-\
MG_/1_P#OHT :-%9V^3_GH_\ WT:-\G_/1_\ OHT :-%9V^3_ )Z/_P!]&C?)
M_P ]'_[Z- &C16=OD_YZ/_WT:-\G_/1_^^C0!HT5G;Y/^>C_ /?1HWR?\]'_
M .^C0!HT5G;Y/^>C_P#?1HWR?\]'_P"^C0!HT5G;Y/\ GH__ 'T:-\G_ #T?
M_OHT :-%9V^3_GH__?1HWR?\]'_[Z- &C16=OD_YZ/\ ]]&C?)_ST?\ [Z-
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M&V@"';1MJ;;1MH AVT;:FVT;: (=M&VIMM&V@"';1MJ;;1MH AVT;:FVT;:
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MPNT2(KX],C-2XH2-8HUC10J* J@=@*=6!WKS&XHQ3J*!C<48IU% #<48IU%
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M(I]^.*KZ5X7C;Q1X?TSQ#IMI<1+I^H3PV-PJW"6B-<1&.+)!!*(P7(X&, D
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M** "BBB@ HHHH *HM_K7_P!XU>JBW^M?_>- #J*** )[?_4+^/\ .I:BM_\
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M';.5*6^XY*QX (7))P2<9XP*U:* "BBB@ HHHH **** "BBB@ HHHH ****
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MXTLD0-:[5!B(PT+ @@QD <8!& 00:V** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBD(R"/6@#A[[_ )+3I/\
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MGY@=W3WQ6K-X(T.?Q$-;>VD^U"59R@E81-*HVK(8\[2P' .*U=7_ .0+?_\
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M!QQ7H7Q/NG_X10:3 ?\ 2=7N([&,#J0[?,?P7-=)HMM'9::EI",10'RD'LO
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MIM$O;F:!!BUB8X!?/?(/ ]* .OGT#2;EKQIK"%S>H([DLO\ K5'0'VKGM/\
MASI%OKVJZG>VUK>_:[B.:W26 '[/L0* ">O2NH.HV:6<5V]S$EO*%,<CL%#!
MN1U]:K)XCT201%-6LF$SF./$R_,PZ@<]: $F\-Z-<1W*2Z;;NMU*L\P*_?D7
MHQ]QBM2J!UO2ENDM3J-J+B1RB1&5=Q8=1CUK.T'Q=8:Y;7$W_'KY-_+8!9V
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M'"%C7A0!U))))R?RKB-$GD76-+N[&4OXGGO-474D\PF38JOL#KG@ B/;Q]*
M/>0ZL2%8$@X.#TH5U<95@P]0<U\ZV5RUKH$TOA^YD-S-X4>;5&AD+.+CS -S
M\G$F#)[X%=MX*8VNM>)8/!XM;BQ2SLY((VF/D?:"AW_,,X)&"<=Z -SQW_R-
M?@;_ +"K_P#HEJ[JO)]<G\53>,O!8U^PTNVA&IMY;6=P\C%O*;J&48&*]8H
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M;^;Y,2[4\V9Y6Q[LY+'\35BBB@ JBW^M?_>-7JHM_K7_ -XT .HHHH GM_\
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M5U5 !1110 45QJ_%/P>WB9] _M9%O$8QEF4B+>.J[^F?TKE/&7QXTSPUKO\
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M5&HZ<MT-.ZN%%%%9#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "J+?ZU_]XU>JBW^M?\ WC0 ZBBB@">W_P!0OX_SJ6HK?_4+^/\ .I:
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MZ#+2S.%4?B: +%<9XF^*'ACPIJ9T[4;QC=A-YBA0N5XR <=">P]ZKOXYU'Q
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M/N&D;8BQLQ;=MQ@9SGM65J'BC0O#NFP2:AJ,40= 8DWEY)<C(VJ,LU<1XT\
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M:+BSB@.UG)R4R3RF?;D5V^L_!_P7K=_!>3:4+=H0%\NT/E1N!T#*/Z8-9?\
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MG@$XY)Z>]:L4B31)*ARCJ&4^H/2@#QM_"7CX2,J:_P"("N;3!-\G1O\ 7_\
M?/;^M5-)T;Q?K+22VGB?Q!);17-[;R.+Q05,?^I'([GK_2O5];\7Z!X<N(8-
M6U.&UEE&Y4;)./4X!P/<\4IU#0- 6TA66UM1J4_[A8P!Y\C\Y&.N>N: /+I/
M"?Q#%E(Z:[KYN!8P.B_;DP;@MB5/H%Y'\S4S>#_&IN@L_B#7S9B_979KU"1:
MB/(?IUW<?TKV6L'5?&'AS2-232]2U2WANI0/W3Y. W W'&%S[XH \@T31?&N
ML>'5U/3M>UMS+82/&4NT4-<K)M5.F<;1G^M:5YX$\837-PW]KZU,%GMDB>2Z
MC8M$1^^)R.JGI_6O1HO$GA31=3B\-P7MG:7(8*EK&NU59N0.!M!/7&:Z6E8I
M2DG=,\(O/ OBAM.A?5=4U<VEO'>2RJ]Q&RQ;,^20,?Q#KC]*JZ#X1\7R:"+_
M $?5=7B2ZM[6:+R;E$$C,?WN1C^$=,_K7L=QXI\.2:RWARXU&V>^E_=M:MSN
MR/NGC&2.V<U5M?&'A2SUB/PO:7L$5[$X@2SCB8!#CA1@8'%%E>X_:3Y>6[L>
M<3_#36KK47DN3>W(?4)$:>:9&=K81Y5R>Y+8'T[5DZWX/U[3O#BZCK$UZXMM
M/#,)I4=89S(%\M0/X=O/]:^A:R-2O=$N;Y/#^H/;S3W,1E%I*N[<B]21TP/>
MH]C3UTW.I9CBURVJ/W=O(\H'P\\0Q2R1V%YJ<-B;Z)8Q%/& ULR9>3&/O!N/
MZ54_X5OXGGMH&NS>3S?9KAW$TL9"RJW[I!C'##J>?PKUO2/&'AS6=0?3=,U2
MWGN8@?W29Y X.TD88#VS6]3=.#CRM:$0QV(A5]M&;YNY\Z:OX$OM&LS>7XG@
M!GM((/G4HS2\2;@.?E/ Z5H)\*]=:YC6>.58?-F1C!(JMM5?D;))X8\8ZBO8
M+_4?#][?RZ/?R6LT]I&MY)!*,B)0>'.>!@T_0_%6A^)/._LC48;LPD>8$R",
M]#@X.#Z]*S^K4KIVV.M9UCN24/:?%O\ UT/%3\,/$ZVQD6W(F6WCE"JZ@F0M
MAHP<]5'.>E5]:\$ZO8ZU!;2[V6^O/LMG)<2AGD^7.21T'45]#RR)#$\KD!$4
MLQ/8#K7+6/BWP=XHD::WO;2[.F@W)EDC($&.-X+ 8^HJ7A*35K&T>(<?&HJC
ME=I6V/.CX(\8)ID$2/J0!LIC) +I=BS!L(@&<;2,U1MOAMXKMKV.1;=H@DL8
M,D,ZA@IZE3GM_G->TZ'XFT;Q)%++H]_%=K$P639D%2>F00#@]CWJ_=W=O86D
MMW=S)#;Q*7DDD.%4#N33EAJ<FGV,Z6=XNE&<8M>]OI^1\\7O@W7EU]-.DB+7
MUVL\T"RR@O(D9ZD],D8_^M70WW@;Q9)!<PQS:E-$8+;RHI;H%6=O]:I&>B]O
MZUZ)'XK\'WUH_B-;^R>.PS$;MEP\.[^'D;AN].];6D:SIVO6"WVEW4=S;,2H
M=.Q'4$'D'V-$<-3C>W4*N>8RKR<S7N;:?F>*Z9\.?%%MJ*.\,UNF9$,MM.JN
M,+P<YZ$\?X5C0^#?$+ZN^F^0#JD5JEY)$)1N 9L<'INS[U[]KOB'2_#=DMYJ
M]TMM;LX0.5+?,>@X!K%@\9>"Y+6?Q-%?VNQ2+62\\I@Y/41]-Q]<"I^ITK)&
MW^L>.YY3NKM6V. U7P'XKN7N+=)KZY@^U(L/VFZ#(8MF6=AGJ'XK.M?AYXNM
MUF=;>>'?;2D""X4%G'W5;GH?\XKW33M1L]6L(KZPN([BUE&Y)8SD,*H:_P"*
MM%\,)"^LWRVJSDK&61FW$=>@-6\-3<N:QA3SK%TZ#H)Z/RU/'_!_@_4QXW,#
M- LFDR0RW*ECT89 '')%>\"N+/COP+IZ)K(U"VA&I9Q<K ^9MG')"YXSWKJ=
M+U2SUK38-1T^83VDZ[HY " P_&JI48TE:)SX[,*^.FIUGJE8N51;_6O_ +QJ
M]5%O]:_^\:U.$=1110!/;_ZA?Q_G4M16_P#J%_'^=2T %%%% !1110 4444
M%%%% 'B/Q&2$>)?$R7T6Z^N=/LTT/<FYC()#N$1QPP;!..WM7M-N'%M$)?\
M6!!N^N.:>45B"5!*]"1TIU !1110 5P?Q/T^QU#3+"SDL;6:_P!2NX]/@N)8
ME=H%<DNRDC@[5;'OBN\I&16(+*#@Y&1TH K:=I]MI6G6]A91+%;6\8CC1>BJ
M!@5:HHH **** //=7TN*U^,?AJ_$L\DUU#=AA)(65%6-<*B]%')/N37+V=WJ
MT_QKT;4-6TK4K>XN%NXHXI%7RXX  $VX;GNS'CEN]>TE%+!BH+#H<<BD**6#
M%1N'0XY% #J*** "O&OBE?>%9/$+:+<O9VNJ7D,?VO4[K<WV2!6W 1CG$A[8
MQZDU[+4;V\,C;GAC9O4J": /-]<TRWM_BMX)U&*XN)WN?M2@RREE5%@& J]!
MG))[DFO3*:40E254E>AQTIU !1110!YM\6-6\/:7'I_]IVUI<ZI,)(K$7A)@
MA# !Y''(P!CL3G@5YWXKM-/@TO2K:VU&&>UC\.F.WO+B RB^82?ZN'(_=R9!
MPPYP1QQ7T4\,4I!DC1R.FY0:/*C 5?+7"\J,=/I0!6TIR^D6;M"\+- A,4AR
MR':.">Y%7*** "N;\;RZ/#H*MKD2M:&= LDD)EBADYV22*.J ]<\5TE(RA@0
MP!!Z@T >"06>FW7@31K75=2;3].@UBZ:.]^Q"6VN3\VV3:WRQH=QV@@BO4?A
MQ<W-UX$TZ2ZM(K5\.JI##Y2L@<A7"?P[AAL>]=28T9-A12O3:1Q3NE !1110
M!B^++[5-/\.7<VBV4EYJ)4)!&@!().-V"1G;UQWQ7CN@ZAH>A^#/%(\1Z9?S
MVMKK?FI'>$!KB?:N$?#$%L@LP.1@]Z]\J-H(F!#1(03D@J.3ZT <1\*%L3X8
MNI[*^L[DW-[)/,EDI$%N[8/E("!P!C\Z[NFI&D0Q&BH/11BG4 %%%% !1110
M 4444 %%%% !7#_%52WA.W\Q2UB-1M3?#&1]G\P;]W^STS[5W%(RAE*L 0>"
M#WH X7X8B'[)K[6 4:0VKS&P\L8C\O"Y*=MN[=C'%=W3418U"HH51P !@"G4
M <%\4[#3[[1K.VFT^UN-1OKJ/3[.:>(.8#*?F=<^B@GZ@5V&DZ7::)I-KIEC
M$(K6VC$<:#L!_7O5MHT<J656*G(R,X/K3J (KB(SVTL(E>(R(5$D9PR9&,CW
M%>3^'WOO#6D>.X]#M;O4+V+5S% #F:0LT<8,C9Y;&2Q]<5Z[35C1"Q5%!8Y;
M QD^] 'FGP=?RK;Q'9"WU%/*U1V,M['M=RRKG=S]_()([;A70_$:\T'3_",M
MUXC@-Q912HRVP;'G2 Y1#V(SU!XP.:ZI8T3=M55W')P,9/K22PQ3+MEC21<Y
MPR@B@#QVQT?3]0^$/B%X-5B9&>YO9;;29\6\+&/(@XZJ."0, GVKTSPE_P B
M9H?_ %X0?^BUK52WACC:-(8U1NJJH /X4]5"J%4  #  [4 ><?%;4/#MA'IP
MU:VM+K4IO,BL([V3%O&6&&ED!XPHQS@GL*\\\566GV^G:3:)J5G<P6_AQDAO
M;I/,2\/F?<M_[DN0<-R<$<<5]#2VT$Y!FACD(Z%U!Q^='V:#:B^3'M3E1M&%
M^GI0!!I4AETBRD,4D1:"-C'*<NF5'#'U'>O+/BHVBG4PRI&-=@:VD\MXF\ZZ
MC$F52V?HK9SDJ/K7K],:*-W5V12R_=)&2/I0!XEXACLK?XESZI%/;7VL/J5I
M#_9-WIX,@3:HWQ2$YP!EMR\9'->X=J88HS()"B[P,!L<@?6GT >)KJFH7/QD
MT34M6TO5;5G>[MX(I(=L<< 3"L#GD\EV/8$>E6/ <WA;4OB$EQX?FLK.WLH9
M[>&%9-US?LS O+)WVC!VY))Z\"O86BC=@S(I(R 2,XSUID=I;0N'BMXD8=U0
M T ,U&YDL]-N;F&WDN98HF=((_O2, 2%'N>E>#V'VO4+KQO!JRZM97NH:/%-
M=W$ULV(&!<E0JDG9C"J!R0IKZ!IOEIO+[%W,,$XY(H \J^$HE?Q#XCFMEL%T
MIDM0@TT,+;S@GS;,@9.,;N.M=;\1XH9_ &K07-U+:V\D:I+/% 9BBEAD[01D
M8Z^U=1'&D2[8T5%]%&!2D @@C(- 'SS<J8_#-U8Z=_9D^AVVNV@EU.*S\JWN
M(BA)\U4X94;:"1P>,UZC\+ITF\+SK%:VL,,5_/'')9JRP7 #?ZR-23M4Y/ .
M.#BNR$,2Q>4L:"/IL"C'Y4Y45%"HH51P !@"@#S7XMI(UQX8\V2SBTT7K_:9
M+^(R6R-Y9V&1<C(SG&3C.*Y34Y]"U#X7Z;%J%I::9J'V*Y6PDN(7DMRH?#>5
MN/RNX *9R1GBO=9(TE0I(BLIZAAD&D:&)U"O&C*IR 5! H S/"\K3>%=)D>"
M:!FLXB8IVW.GRCACW-<?\1/#^D:]KV@:5/IUK)>ZG.1-=-&#*EM"-[A6ZC)(
M7/\ M&O1J:8T9U<HI9<X8CD4 >'>+K>U@\4:_;M"BZR+C2UT(;?G$:D9$7^R
M#NW8_&O<^U,:*-G5V12Z_=8CD?2GT >:W'AS1=5^+\:QZ5:1G2X!J-S,D0#S
M7$C$1[F[@!6;ZXI= \-Z)=_%'5M1L]+M+:/10MO&88@IDN)%WR.Q'4A2 /J:
M]'$:!RX50YX+8Y-"QHA8JJJ6.6(&,GWH =1110 4444 %%%% !1110 4444
M>*OINHG7#H/]FWGVX^)1J7VOR&\K[/@'=YG3C&,9S7M5&**  ]*XKP_:2ZEX
M\UW6;RW=%LBMC8!T*@+C<[KGU) S[5VM% !7$?%70[?5O VH2FQ-U>6T1:U
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MTZ3%?ZCJ>I7%M;YN1&HV9ZX7@#&/?K6E8_%:6Z\0)9/I2?9/M1LGDCF9I$D
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4?_>-7JHM_K7_ -XT .HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img158215518_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img158215518_12.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $4 <(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4E<@@^A!Y!^HI<KM>Q2J0<N5-7+U%%%(L**** "BBB@ HHHH **** "BBB@
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M7D#"[G)SYDQ(W.0Q+ 9 SC(.%  ,;X?3OXE-SXGUB)8]<#&T:S*,IT]%P?+
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(#'E,@9&?<UUE<'%_P EUG_[ "_^CJ[R@ HHHH **** "BBB@ HHHH ****
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M-3-XL\/K(T9UJP#K&96'GKP@ZGKTH FN?#^CWDMO+=:79S26P A>2%6,8'0
MD<"GR:'I<R7:2Z?:R)>$-<*\0(E(X!;/4U _B;0X[*.]?5K);:1#(DIF7:RC
MJ0>^*HOXSL!XCL-*B*RPWEG)>)>+(#$$3&>?QH VK#3;+2K5;73[2"U@4Y$<
M*!%SZX%6JBM[B&[MTGMY4EA<95T.0P]C4M '!Q?\EUG_ .P O_HZN\K@XO\
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M <9 ( .?U+^S/ <%]<:,L4<]R(%BT=)%C@$CR+$LH0#* EUW$<';TW=:>O\
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MR ,$],C.1JZCX/T_4[O4;J6>ZCGO5MLO$Z@PM;NSQ.G!PP9L\Y!P..N:G_"
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M&/"FHI+'<IOU'4;9]RVUOG!56'\;\@>@R:[G3=.M-(TZWL+&%8;:W0)'&O0
M4 6@,"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@!,#THP*6B@!,"@D*,D@#U-+5/5-+LM
M:TZ;3]0@6>TF $D;$@, <]N>HH Y?X=$&#Q$0<C^W+O_ -#KM*X7X76=OI^E
MZW9VD8BMX-9NHXT!)"J&P!S7=4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !112,P52Q( '))H 6O&OCMXB,WAR70=)N7DNHV6;4$A&1%#V$C=%RQ7
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img158215518_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img158215518_13.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (V Y\# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*JD_.WU-6JIL?WC?4T .M_\ 7'_=JU52V_UQ_P!VK= !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!7NNJ?C3$IUUU3\:8E $RU(*C6I!0 M+24M
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M_J:NU1;_ %K_ .\: 'VW^N/^[5NJEM_KC_NU;H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** *UUU3\:8M/NNJ?C3%H F6I!4:U(* %I:2EH ****
M "BBB@ HHHH **** "J57:I4 %9?B7_D5=7_ .O*;_T UJ53U>TDO]%O[.(J
M)+BWDB0N< %E(&?;FG'=$5%>#2/'?#5R- N-#UJ5?W$WGP28.,@=/U8?E5)8
M7:XT/4)1^^OKYYF8]_WBC^8/YUV]Q\/]0G\$V>D>?:"]M[EI=^]MFTYR,[<Y
MY';M5K4?!%[/9^&;>VFME&E\SEV8;B2A.W"^JMUQVKL]K&][_P!:GB_5:O+:
MVB2?STO^1'XNU)D\1Q6MSKLUG9K'D6VFL_VEV/<X7 'U/3MS47@/5[_4;#7[
M:\NI[A+4#RFN.9 "'!#'K_"/UJ_>>%M9MO%]QKNBW=D&N8]DB7:L=O !Q@<_
M=![>G2E\+^$]3T*;6?M-S;3I?J-LBE@VX;N2,8 ^8]":RO'DL=2A6]OS-.UW
M]UM.OZ:'+^'+B>T^$NM3VTTD,R7?RR1L58<1="*N:CXAU2'P9X;M;:\E2[U(
ME7N68L^ P'4\_P 0YZ\5IZ=X*U*T\!ZEH4D]H;JZG\Q'5VV ?)U.W/\ ">WI
M3-8\,11^$-(LKW5K*QU"Q),,TLH6-FSD@$X/H>G:JYH.7S_0R5*M&G9:>[^O
M^1F^*[75_#<^D+!XAU.>WFFVN)9SNW9&>1R5/H<X_&KFO7.JS_$VUTJRU.YM
MHIX &".=JC#%B%/&<#K65XPBUB2[T'^UKRTN+AY@(8;-3MQE<N<\DDX[8XXK
ML+CPU>3?$.T\0++ +2&(HR%CYA.QEX&,=6'>BZ23?9C493G*,$[7C]W4Q])N
M-1T?XDG0VU2[O;.6(N/M4F]E^7<.?P[8ZUFZYJTKZGJOG>(KWSH]WV2UTAG*
MQXS_ *P[0#VS@^M=4_AJ];XAQ^(!+!]D6+84W'S,["O3&.I]:R;3P5KVF-J=
MG8:C9+I^H$B221&:95.1P.F<$CK^5)2C>_DBI4ZO*XI.UW]W3JBJFNZG=?"*
M[OY+R47D4BQK<(Q5\>:@ZCO@XJIJ UJW\#67B(^(-1^U8C_=++B/;T&1W;N2
M<YK:MO!NJ1?#Z\\/R2V?VF68/&ZNVS&Y&Y.W(/RGMZ5=U'PM?7?@"WT&.6W%
MU$L8+LS;/E.3SC/Z4<T4]._X"=&K*.M[\OXG*^/O,O\ 1_#FJ2W$PDNH8]\2
MOB-25#%@.S?-C/H!7IFF6']F62VWVNZNMI)\VZDWN<^IQ7,Z[X/N]5\)Z3IT
M-Q!'>6"1C<V=C%4VGG&>OM73:6-26Q4:JULUWD[C; [,=L9YJ)R3@DCIH4W&
MM*4ENEK^9PNKS:K>?$]=)M=6NK2WEA&X1R'"@+D[5Z G'7'>I]*O-1T+XA#P
M]-J5S?V=S$7C:Y?>Z':6^]_P$CTYZ5GZQ!>7'Q=1+"Y6WNA &C=UW+D1G@CT
M/3\:Z'1_"^I?\)/)XAUVZMI;L)LABM0=B#&.K<]"?SZU;:4=>QSP4Y5&XWNI
M;]+=4<7'XI769-0O-1\37VF2 G[%;6P<)CMNVCGL.<5I3>)]1U'X62WQN98K
MV"Y6!IXF*,V"ISD>S#-:T7A+7]%FOX?#^H6<=E>,6Q<!@\)/=2HZBKFJ>$[^
M[\$_V,NHM=7C.KO<7<C$$@Y(SR0/04W*%U8F-+$<LKWO9_-].OZ(J6%C?6_@
MJZUJXUG49[N;2WE56N#Y<>8]RE1_> QSFL*35]2'PFBO1J-W]J-WM,_G-OQN
M/&[.<5WO]DS_ /"%_P!C;X_M']G?9=V3LW^7MSG&<9]JX?Q#HMSX?^%J:?=O
M$\J788F(DKR2>X%*$DW\RZU.4(W6W*_OT'ZM%K>D>%K+Q&GB&^DNB(WDA=\P
MD,!@!?;/).<U#XRN9]3U;PA=6Q$-Q=)')&<9V.S(1^1-7QX8\1:WX>TW3IM4
MM!I)CBDW!&\_;M!"D=#CMR*UM:\(W%YK/AZXL9(([72V0,DC$,55E.!@$'A>
M^*:E%-7\R94JDX-13L^7[[ZLR+J34O#/CK2+1-8OKVWOB!+'=2;AR=IQV'J,
M51U'Q,FH>+-2MM2U^\TBQM&:&%;3<&=U."25![@GFNJU[PU>ZIXKT?58)8%@
MLF4R*[$,<-G@ $?J*KW'A?6=.\17FK>'KNS3[:"9H;L-M#'G(*CUY_'O24H]
M=[%3I54VHWY;_A;U77S,71?$U_J'@KQ#')>R2SV"?N;M24=E;.#GKGY3[\UI
M>!K.^O=(M=<O]9U"9OGV0/<D1$ E<OW)R"<UH0^&=27PGJ&GW6J27M_>(P\R
M>1C&A/0+G) _"K>@:#-IW@V/1+R1#)Y<L;O"21AV8\9 [-4RE&SMW+I4JG/%
MSN[+\;Z?@>=ZEK5S]EO;G_A)=0N-223<B:<S_98UR.&) ]^1QTZUH^,;Z?4O
MA?HMY<L&GDN$+MC&2$D&?TJW#X'\1PZ!=:"FHZ<-/E<R!MC>8QX(!XP 2!GJ
M?Y5<U/P;JE_X$TW0UELUNK68.[%VV%0''!VYS\P[>M:<T+K7J<ZI5G&2:>J_
M&_JSM++_ (\+;_KDO\A4]16\9AMHHF(+(@4XZ<"I:Y&>PMAR??7ZBK=5$^^O
MU%6Z!A6;KVGWFJZ)<V-AJ3Z;<3 *MU&FYHQD9QR.2,C.>,UI5E>(YM:M]#GF
MT"WMKC44P8X;C.UQGD<$<XZ<TX[JP'EOAZRT_1?BU8:-X5GD$=M:M'K'F2,%
MF=0P)VL>6R0<+P.W -#:3%XZUWQS>:L\KOI)>WT\"1E$!7?\P ..J _B:T)#
MK/CCQ?X6OE\/:AI)TH^=?7%Y"80Q.TE$SRRY4@?[W('.8KB#6O!^M^+X8-"U
M#4H==W36<UG"9%21MV1)C[H!?]*Z[N^^MOU$=?\ #36;G7? >GW=[(TMRH:*
M21CDOM8@$^^,9]:Y3XN7,%UXA\,://9W5[ 96N;BUM%+RRH,#:H!!Y ?OZUH
M6'PLM;[P%H^BZY/<Q3VK/.XM9%&'<DE22I!P"!QZ5:G;6/A[%I&GZ/I%QJWA
MR)62<Q)YMXCEF;("D CD?P]CDC(K-<JFW'S Q;'5O#.C^ /$VH^#K*XTZ]A0
M17,%RS^;#)DHI(9FP1EB,'J.>F*PY-.3P;IG@KQ1I\LJZAJ$B?VA(9F/VI90
M'(8$XX_G@]0#6QI_A#5?$=MXSU2YLY=-.M+MLK6Y&V3Y3D%Q_#DJHY]2>F":
MB66N^*;7PEX<GT'4;$:/(K7UU<P[(ML6%7RVS\Y(]/KR,D:II-Z^OW 4/%GF
M?\+"U+=]K_X2+[;9_P!D;-^/(P=^W'R[?7WS_M5Z!I!_X2;X@7VM'YK#1@VG
MV6>AG/\ KI!^&$]Q6KXUUJ71/#<LEH"VH73K:62#JTTG"X^G)_"O*_&^B6/A
MU=+TO5#.VGPZ/-]G>/?MDU DG=QW)(//;K41?.DMNG]?UW ]UHK)\,?;_P#A
M%M*_M3S/MWV6/S_,^_NVC.[W]?>M:N9JSL,****0!1110 4444 %%%% !111
M0 4444 %46_UK_[QJ]5%O]:_^\: 'VW^N/\ NU;JI;?ZX_[M6Z "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@"M==4_&F+3[KJGXTQ: )EJ05&M2"
M@!:6DI: "BBB@ HHHH **** "BBB@ JE5VJ5 !1110 4444 %%%% !5/4M)L
M-8MOL^H6R7$0.0&['U!'(JY7GEEK'B76/%NLZ1:ZG%;PV\C[)7MU<Q*&P !@
M9)R.I[5<(MZI[&-:I&%HR5[Z'3:=X.\/Z5=K=6>FHDZ?==G9RON-Q.*W:X/P
MWXMOUCU^#6G2XETG<QE10N_:6!& ,=5XX[UCCQ=KDVC2:V/$&F0N')72BJ%B
M@./7=GV[CFK=.<GJSGCBJ,(KDC:]]%9;'JE%>>^)_&.H1^'-#U32I/(:\8^8
MA16R1U7D'OGGBIO$#^+-!\/'4CK8N)4E0RQK:1JJ(>" <$GG'/%2J3TUW-'B
MXJ]DVDK].NO<[RBN&U_Q1>W5QX?LM!N/)GU(+*[A%?;&?J#T^;/^[4>L^*+R
M;Q6^AV>K6NDP6T>Z:\N A+-@' #8'<<?6A4I,)8NFK_)>MSO:*X[P9XFNM4O
M]0TJ_N(+J>T.Y+JWQLE3.,\<>G3U]JT_&.L76A>&Y[VSC#S!E4%AD)D_>(_S
MUI.#4N4TCB(.FZO1?H73H6FG6QK!MO\ 3U7:)=[=,8Z9QT]JKWGB6SLO$=IH
M<L4YNKI Z.JC8 2PY.<_PGM7%:7XJUF6^L&MM;M=668@7%I)%';/'ZA2<;CZ
M8].E.\8?:S\4-&%B8UN3;*(VD&54EI!DCOCK6BIN]I/H<KQ4>3FIJVJOMK?T
MT/3**X73M:UO3O'L?A[4[Z._AGB+I*(%B*_*6Z#_ '2.]4F\6:CK6L:A'::]
M8:+:6C;(OM(0M.<D9.[H..W3(J?9,V^N02V=[VMIT^=OQ/1ZI:II-CK5G]DU
M"#SH"P;9O9>1TY!!KF- \6W^K^$;V[2WBEU.T)0KO5(W/9LD@ 8R3SVKF[CQ
MGK.ES6$C>(+349)6'VBSC@3;%TX\Q?O>F0?SHC2E?3=$U,72Y$VKI_U_6YZ6
M;FPTI;2R::.'=MAMXBV6; P .Y^M4[SQ+9V7B.TT.6*<W5T@='51L )8<G.?
MX3VKAO%EIJ#?$K2D34MDDP4V\GD*?LXR1C'\7.3SZTOB:/4(_B-H$4$\<M^+
M.-//D3"L^9 7*CIW.*I4T[7>Z,YXJ:NE&UFD>HT5PNG:UK>G>/8_#VIWT=_#
M/$7240+$5^4MT'^Z1WKNJRE%Q.NE551-I6L[!1114FH4444 %%%% #D^^OU%
M6ZJ)]]?J*MT %%%<A\4?^2;:U_US3_T8M5%<S2 Z^BN*\'ZBFB^%-3LKU\?\
M(]--"Y)Y,2_.A_%" /I7,?#K1UU'4_&-EKD7G_;5LKFYB8D?-*CRE>.>"V/P
MJ_9[MO8#URBO+%\ >%C\3)-+_LB/[$-'6X$7F/CS#,R[LYST %:'BW2+74)-
M$\!:>OV>SD5[F=48_NX8P=HZYP7(_P"^:.2-TDP/0Z*Y+PEJTVK> C]K_P"/
MZSCEL[M2<D2Q@J<^Y&#^-<%X.TGX;S>"["XUN;2TU$QL9]]]LE!W-CY0X(.,
M=!0J>]^@'M5%<=\,I[NX\'(UQ)-+ +B5;.2?.]X WR$YY/?\,5=\2>*9]"U?
M2--MM*DU"XU/SA&L<H0@QA3W&,?,23D8 /6I<'S<J Z2BN4M/&-P3K-MJ6D&
MRU'3+7[68!<"1)8]I(*N /3!XX]ZFO\ Q9]B\!P>)_L6_P V"WF^S>;C'FE!
MC=CMO].<=J.25[ =+17FFN?\A[X@_P#8 7_T7)7;^&O^15T?_KRA_P#0!1*%
ME<#4HHHJ "BBB@ HHHH **** "BBB@ JBW^M?_>-7JHM_K7_ -XT /MO]<?]
MVK=5+;_7'_=JW0 4444 022.LA /%,\Y_P"]^E$W^M-,H ?YS_WOTH\Y_P"]
M^E,HH ?YS_WOTH\Y_P"]^E,HH ?YS_WOTH\Y_P"]^E,HH ?YS_WOTH\Y_P"]
M^E,HH ?YS_WOTH\Y_P"]^E,HH ?YS_WOTH\Y_P"]^E,HH ?YS_WOTH\Y_P"]
M^E,HH ?YS_WOTH\Y_P"]^E,HH ?YS_WOTH\Y_P"]^E,HH ?YS_WOTH\Y_P"]
M^E,HH ?YS_WOTH\Y_P"]^E,HH ?YS_WOTH\Y_P"]^E,HH ?YS_WOTH\Y_P"]
M^E,HH ?YS_WOTH\Y_P"]^E,HH MQDM&">M.ID/\ JA3Z "BBB@ HHHH K775
M/QIBT^ZZI^-,6@"9:D%1K4@H 6EI*6@ HHHH @:\M48J]S"K X(,@!%)]OL_
M^?N#_OX*++_4-_UUD_\ 0VJQ0!7^WV?_ #]P?]_!1]OL_P#G[@_[^"K%% %?
M[?9_\_<'_?P4?;[/_G[@_P"_@JQ10!7^WV?_ #]P?]_!457:I4 %%%% !111
M0 4444 %<;X;T+4M/\::[J%U;>7:W3,89-ZG=E\] <CCUKLJ*I2:37<SG24Y
M1D^AP>C^%;XZOXJ&H0>3::FTBPR!U;(9V(. <C@@\XK*M_"^OV.FMI,?A[29
MI1)^[U218G(7.>58$G\1P.U>HT5?MI&#P5.R5WU_'Y' ^+/"VI7>BZ+9:?!'
M</:.3*8Q'"O.,D+P!SG@5VU]9Q:A87%G.,Q3QM&WT(Q5BFF2-9%C9U#OG:I/
M+8ZX%2YMI+L:QHP@V^]OPT//? O@_4]*UF6]U>/:+>+R;7]XK9!)R1@G'&>O
M]ZI];\+7L'BU]<LM*M-6@N$VS6EP4&UL 9!?CL.?K7>T57M9.7,9+!TU35-=
M'<Y7PCHM_8RW=[J-M8VDDQQ%;6MO$OE)G."Z@$]NYZ5K>(;74KS1Y8M*N4@N
MNH\R-75QW4A@1S].U:E%0Y-RYC:-&,:?LTW^IY5>>#M6UEK6(^';/295<&>]
MBN%(<=R(U/'K_A71:MH.I7'Q$T?5(8#)96T"I+,9%R""_;.3]X=!WKLZ*MU9
M&,<'375[I].GR.-NM"U*3XH66L);9L(X2KR[UX.QQTSGJ1VK(;PGJ6C:QJ,E
MIH-AK-I=L7B-P8PT!Y/\?;GMUP*])HI*JT.6$@[N[O>_WG!2^#]5E\"W&GL]
MHNHS2+*R00I"A Z(=B@'ZGO6)J/ACQ)?Z/IUM%X?M+7[$0&6.>/?.V.7)S@=
M.YSDUZQ135:2)G@J<E:[VL<5XKT;5KCQ'H^MZ98K=-:C]Y TJQMP<XR3CN?6
MFWVBZQ?>.]#UEK$)!#:H+DB52(W^<E>N3C<.0*[>BDJC2L7+"Q;;N]6G\T<;
M=:%J4GQ0LM82VS81PE7EWKP=CCIG/4CM79445,I.5K]#6G24+VZNX4445)H%
M%%% !1110 Y/OK]15NJB??7ZBK= !7+?$>TN;[X?ZM;6EO+<3R1J$BB0NS?.
MIX Y-=313B[-,#SKQ5HFHS^,1;6EI*^FZ_'#'J$J*2L?DON)8]!NC^49ZUK>
M'K*Y@^(GC*YEMIH[:X^P^1*T9"2;82&VGH<'@XZ5U]%7[1VM_7]: <LMI<_\
M+5DO/L\OV4Z(D0GV'9O\]CMW=,XYQ6-I_AJ?Q)XGUS7=1EU;3OWPL[(03/;,
MT"#ENQ*LW(KT*BDJC6P'GNEZ+=^%_%NK6%O'?W>EZK9&X6XDW2E+A00RN_JP
MYYZ\"K7P_P##-C%X(TH:EH=NE\J-YGVFT42@[VQG<,YQBNXHINHV@,C7=!&N
M6D-NNJ:GIHB;<'TZX\EFXQ@G!X]JP)=#N-.\6>#HHY-1U""SCOA+>73&5P75
M2N]\8]0,]ACM7;45*FUH!P][I-[>>-?$6RWE6*ZT-;>*9D(C9R7&-W3/(XKG
M-3O-7O?AG;>'(O#.KK>VT=M!<E[8[ (G090C[^2H/RYP,DXQ7K=%6JEK: >>
MZQIU]+K7CF2.RN'2YT18H&6)B)7\N0;5./F.2.!ZUV'AZ*2'PUI44J-'(EG"
MKHXP5(0 @CL:TJ*F4[JP!1114 %%%% !1110 4444 %%%% !5%O]:_\ O&KU
M46_UK_[QH ?;?ZX_[M6ZJ6W^N/\ NU;H **** *LW^M-,I\W^M-,H **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@"U#_ *H4^F0_ZH4^@ HHHH **** *UUU3\:8M/NNJ?C3%H F6I!4
M:U(* %I:2EH **** *]E_J&_ZZR?^AM5BJ]E_J&_ZZR?^AM5B@ HHHH ****
M "J57:I4 %%%% !1110 4444 %%%% !1110 5Y5"_B!OBK>+&VGF_2+!$AD\
MD1[5/R]\X(]LYKU6O/;V&^T?XFSZN-*OKNUN( BM;1%_FVJO/IRM:TGOZ''C
M(W4'V:-C1O$M[J/C/5='FB@6WM%)C9%(<X8#DDX[^E0:=XLO[O7/$-E)%;"+
M3DD:$JK9;:2!NYY_#%9:Q:CX;^(.IZB=(O;VTO4(1[2/?@G:>?3D$<U#X;L=
M5.M^)[N]TRXMFN[>1D5HS@EB3M!QACSVJ^6-K^2,%5J74=;W=_36P^S\:^*+
M_P .7&L06&FB&U8B5GWC?TSM7/8$9)-23^./$']@1:_%IEBFFEQ&RR.QD<YP
M2,8 &X$=S4?A_3+^'X7:M9RV-S'<R-+LA:)@[95<87&34<^EZ@?@];6(L+HW
M8D), A;S!^^8_=QGIS56A?;J9J5?EOS/X;_,Z37/&,>EZ#87T%L9KC450VT!
M./O 'GZ9'YU0G\5:[H%W9_\ "26-DMG=-M$MHS9B/^UDG./:JFN^'M2O?"OA
MJYL[<O>:9#$S6SC:Q^5,C![@J./K46O)JGCJ73["/1;W3X(I/,N)KM-@7C!"
M_P![O]?:IC&-OON:5*M:[M>^EE;1]S2USQ7K%GXQAT+3;6TF,T2E#*&!#'/)
M(/08STIFM^+=7T2;3M-G72UU&Y4O).Y=;>,9('4Y[<FF7EA>-\7;"]6TG-HL
M!#3B,^6#Y;C!;&.I'YU/XVL[JXNK1I="CU73 ")/)5OM,9_V2&''3MVY[4)1
MNE;H.3J\LY)O1V7IH7/#OB#5K[4Y['4[&(JB[H[ZR#-;R=. QR,X/K745YGX
M/T.[MO&!O+"RU&PTA8R'2^&UI"00!CZX/X=:],K.JDI:'3A)SE3O/N%%%%9G
M2%%%% !1110 4444 %%%% #D^^OU%6ZJ)]]?J*MT %0W=S'9VDUS*<1Q(7;Z
M 9J:LO7M.N-5L%LHI$2*25?/+$@F,') XZ\#TH Y[0S<:9JEG=7;'&M1L\@)
MX67)9?\ QTXK7.I:O>W-[_9D-IY-I(8OW^[=*X ) P0 .<9.:AU#P?8-:%M+
MMXK6^1E>&7<V P.>>M/&F:S:->"QEM!'>,96\QFS#(PPQ7 Y&>1G% #QJ6KW
MM]-:V4%K ]M&AG-SE_G9<[1M/;UJI=^)KFWN(+.;[%877D^9.;EBZJ<X"KM/
M.<9Z]*LQ:3JFF74DVGW$%QY\4:S?;&;)=%V[\C.<CJ/UID.B:GI]S#>6MW%<
MW)@\JX^U,P$AW;@01DC&<?2@#.761K%WH[-Y1E@OVC=H22C?(2&7/8TLGC1S
M'-=0S:>L4;-MMI&;SI%!QG.< GL,&M5M*U.XFT^>\NH))(+IIG51M55*D!5X
MR?J:CM]+UO3K62PT^YM!:EV,4TNXR1*3G&W&&QD]: 'VNJZAJ6K30V8M4LXE
MAD+RJQ=E=0V!@XSU_2JMYKVJ:?";JY_LU%$@#67F9FVEL=0<$XYZ5JVFFSP:
MAJ5Q),"+I(E1U^\"J;22,8'//%<^WA34CI)L532U?()N0&,LO.>3CC/?K0!,
MFH7FEZEXAO;IX9(8/++(BL"24&P D\#GGWYIUIXK<WUI%<7.G3I<ML(M2VZ)
MB.,Y.".V>*MW>@W-W=:LCO"+34$0[@Q\R-U4 <8P1D9ZU8MX->>:W6[N+-((
M_P#6F$%FGXZ$,,*/7% &'K&HZGJ?A*[OA%;+82J=B?-YH7=@,3TZCICI7:UR
M=SH&L_V'+HEM/9?8^1')(6$FW=D*0!CVS^E=90 4444 %%%% !1110 4444
M%%%% !5%O]:_^\:O51;_ %K_ .\: 'VW^N/^[5NJEM_KC_NU;H **** *LW^
MM-,I\W^M-,H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@"U#_JA3Z9#_JA3Z "BBB@ HHHH K775/QI
MBT^ZZI^-,6@"9:D%1K4@H 6EI*6@ HHHH KV7^H;_KK)_P"AM5BJ]E_J&_ZZ
MR?\ H;58H **** "BBB@ JE5VJ5 !1110 4444 %%%% !1110 4444 %%%%
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MB\YCI,4A5\X+;VPQ]\?SH [.BN(M[&TO/"=SK-TS#4MLLAN/,(:-U)VJ/0<
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M/JI]:R_^%1Z!_P _>I?]_(__ (BNSO-2L-."&^O;:U#YVF>54W8ZXR>:J_\
M"3:!_P!!S3?_  +C_P :J-2JE:+=AQJ5$M&7K2V2RLH+6,L4AC6-2W4@# S^
M535GG7M'6W6X.K6 @9BBR&Y3:6'4 YQGD5?#*R!PP*D9!!XQ633ZF;3ZBT5G
M?V_HWG>3_:UAYN<;/M*;L_3-:(.1D=*&FMP::W"BJEKJFGWTSPVE]:W$L?WT
MBF5RO;D \4ZYU*QLY8HKJ]MX))3B-)954OVX!/-%G>P6>Q9HHHI""BBB@"U#
M_JA3Z9#_ *H4^@ HHHH **** *UUU3\:8M/NNJ?C3%H F6I!4:U(* %I:2EH
M **** *]E_J&_P"NLG_H;58JO9?ZAO\ KK)_Z&U6* "BBB@ HHHH *I5=HH
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M]^E #Z*9YR?WOTH\Y/[WZ4 /HIGG)_>_2CSD_O?I0 ^BF><G][]*/.3^]^E
M#Z*9YR?WOTH\Y/[WZ4 /HIGG)_>_2CSD_O?I0 ^BF><G][]*/.3^]^E #Z*9
MYR?WOTH\Y/[WZ4 /HIGG)_>_2CSD_O?I0 ^BF><G][]*/.3^]^E #Z*9YR?W
MOTH\Y/[WZ4 /HIGG)_>_2CSD_O?I0 ^BF><G][]*/.3^]^E #Z*9YR?WOTIP
M(89'2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *HM_K7_WC5ZJ+?ZU_]XT /MO]<?\ =JW52V_UQ_W:MT %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %6H?]4*JU:A_U0H
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MEZ#=C^(=_6N,\"ZO8:-X?UJUO[F."X5SB)CAF.W;A1U)R.@JOHG_ "1[7?\
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M=0FZE+RP2)P<.>2#G/L:7LWM?49WM%>;:5I^O'X<#6+'5=3O-:NK)2J2W)9
M"RYV*> ^P'!ZY-6/"VHV9\10VT>M:[!.\3B33-;5F>4C!W(S< CG(&<^@Q3=
M/>SV ]!HKF_'4EY:^%Y=0L9IHYK"6.Z(B<KYB(P+JV.H*YX/!Q7/S>(;IOB5
M!<I>O_82E-/90Y$9E>)I0Q'3/W1FE&FY*Z [F^OOL)M1]ENKC[1.L'^CQ[_+
MR"=[^B#')]Q55_$-DDVL1#S6?28UDN0%]4+@+D\G:/IS7$PZCJ4NCZ!JC7UT
MO]K>(UD"><V%MV\P+'C/W<*#CIS4<.DI;:W\0)!>7TA@ME $MRS!]]L3\P/W
ML=!GH.!5*FNO]:B/1M.OHM3TNTU"%76*ZA29 X 8*RAAG&><&K->5"SU'1/A
MOI7B*+7-1-W##:,(#+_HYC8HHC\L#& K#GKD=:]5J)QML,****@ HHHH M0_
MZH4^F0_ZH4^@ HHHH **** *UUU3\:8M/NNJ?C3%H F6I!4:U(* %I:2EH *
M*** *]E_J&_ZZR?^AM5BJ]E_J&_ZZR?^AM5B@ HHHH **** "J\_WQ]*L57G
M^^/I0!%1110!7N["SU!%2]M(+E%.56:,. ?49%/N;6WO(&@NH(IX6ZQRH&4_
M@:EHHN+E1%!;06UNMO!!'% HPL<:!5 ^@XJ"WTC3;2<SVVGVD,QZR1PJK?F!
MFKASCCK4.ZZ_YXP_]_3_ /$T[L.5=ALUA97%S%<SVD$L\7^KE>,,R=^"1D42
MV%E/=1W4UI!)<1?ZN5XP73Z$C(IVZZ_YXP_]_3_\31NNO^>,/_?T_P#Q-%V'
M*NQ-52[TK3K]P]Y86MRP& 9H5<C\Q4NZZ_YXP_\ ?T__ !-&ZZ_YXP_]_3_\
M32O8&D]&-:QM'L_L;6L#6N,>28P4QG/W>G6FOIEA)9+9R6-LUJGW8&B4H/HN
M,5)NNO\ GC#_ -_3_P#$T;KK_GC#_P!_3_\ $T[L.5=B.?3+"ZBBBN+&VFCA
M_P!4DD2L$[?*"./PI;O3K&_"B\L[>YV<KYT2OM^F13]UU_SQA_[^G_XFC==?
M\\8?^_I_^)HNQ<L>Q'%IEA!<_:8K&VCN-NSS4B4-MQC&<9Q@"DATO3[>&:&"
MPM8HIP1*B0JJR9&#N '/XU+NNO\ GC#_ -_3_P#$T;KK_GC#_P!_3_\ $T78
M<L>P6UI;64 @M+>*"($D1Q(%4?@*=/;PW4+0W$,<L3?>210RGZ@TW==?\\8?
M^_I_^)HW77_/&'_OZ?\ XFE<=E:PRTTZQT\,+*RM[8-][R8E3/UP*9<Z3IM[
M,)KK3[2>4='EA5F'XD5-NNO^>,/_ ']/_P 31NNO^>,/_?T__$T[O<7+&UK:
M!/:6US;&VN+>*6W( ,4B!E..1P>.PJ&72=-F@A@ET^UDAA_U4;PJ5C_W1CC\
M*FW77_/&'_OZ?_B:-UU_SQA_[^G_ .)HNQN*>Z)JKQV%G#>27D5I EU(,/,L
M8#L.."V,GH/RIVZZ_P">,/\ W]/_ ,31NNO^>,/_ ']/_P 32!I/<A;2M.:[
M^UMI]J;G.?.,*[\_[V,T)I.FQ6<EG'I]HEK(=SPK"H1CQR5Q@]!^0J;==?\
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MRW'N.<CZ]!=>(?*\6V7A^VM?/FE@>YN)/,VBWB!P#C!R2W&.*7)) ;=%%%0
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M2KI8IM3M1"&$HA'!#YRHP/0]S].?T[Q9=Z5-/KBZ))J.JZ\LE\D)G6+[/8Q
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M#25U.\O+&^L)IHQ=RF22&2/'(<\X(/2N>@@U>+X71^*&\1ZLVI10B9 ;@F+
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M"HUJ04 +2TE+0 4444 5[+_4-_UUD_\ 0VJQ5>R_U#?]=9/_ $-JL4 %%%%
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MK33*?-_K33* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH M0_ZH4^F0_P"J%/H **** "BBB@"M==4_
M&F+3[KJGXTQ: )EJ05&M2"@!:6DI: "BBB@"O9?ZAO\ KK)_Z&U6*KV7^H;_
M *ZR?^AM5B@ HHHH **** "J\_WQ]*L57G^^/I0!%6)XG\-V_B;31;3.8I8V
MWPS*,E&^G<5MT4TVG=$SA&<7&2T9YW-X2\:WMJ-/N_$5NUCC:2,EV7W^4$_B
MU:7B'P;<W_A&QT6PNE9[:99#+=NWS *P/(![MT]*[*BK]K+0YUA*=FG=WTWZ
M'(^,?"U]XAT6PL[26W22W8%S*S 'Y<<8!J;Q)X7N-2U.SUC2[M+74[4;5,@R
MCKSP<?4_@:ZBBDJDE8N6'IR;;ZV_#8Y"R\+ZG>^(X=;\0W5K)+;+BWM[0,(U
MZ\DMSWS_ %XQ26WA&[7Q=K6ISS0BTU"V>!0C'S%W;>2,8_A/?TKL**/:2%]6
MIZ>M_F><0^!_$<.@76@IJ.G#3Y7,@;8WF,>" >, $@9ZG^57-3\&ZI?^!--T
M-9;-;JUF#NQ=MA4!QP=N<_,.WK7=T57M9$K!TDFM=K;]#D?&/A:^\0Z+86=I
M+;I);L"YE9@#\N., U#XMTE9O$&G:E8:O8V.L0@*D5U(%$JY...O=ATYS7:5
MF:MX?TK7 @U*R2<IPK$E6'X@@THU&K7"KAU)-QW=OP.!FAU _%72/[0N8;F\
M\O=(MLI$<*@/\HSSZGGUKIM(\+W=CXPU?5KA[=[6]1E5%8EN2#R",= >]:ND
M^&-&T.5I=.L$AD88+[F9L>F6)(K6IRJ7T1-'"\NL][W_  L<-:>%?$7A_P"U
M6N@:E9_8+AMRB[5M\)/=< @G'KZ=*O6/@6SM?"=SHDLS2/=?/+/CG?P00/08
M'UY]:ZNBDZDF:1PM-=/+[SA(O#7B\:=;:1_;5K!8P$ 7%N76<H.B]A^M3:CX
M2U6+Q/!K>BWEL94A6)EOBS9PNW.0"22/IS7:T4>UD+ZK3M;7IU[''>&/"VJ:
M+XCU#4;VZMKE+Q,LZ95MY(8_+C&,Y[^E3^!O#5YX9TZZM[V6"1Y90ZF%B0!@
M#G(%=512=1N]RH8:$&FNE_QW.+D\+:SI6O7NI>'+NS5+[+3078;:&Y.1M'J2
M1]>]/;PIJLOA'4=/NM6:\U"\*G?/(QBCPP.%ZD#KT'IZ5V-%/VDA?5:>OG?K
MWW."U?P1J5_X.TG2(I[07%FQ,C.[;#UZ';GOZ5I^-?#5[XDAL$LY8$-O*7?S
MF(R..F :ZJBCVDKI@\+3:<>]E]VQRNO>%[RYUVWU[1;N*WU&)=C+,"8Y!TYQ
MR.#C\NF*;I7A>_?Q)_PD&O75O->(FR"*V!\N,<CJ>3U/YUUE%+VDK6']7I\W
M-YW\K]SE?"7AJ\T'4=9N+J6!TO95>,1,20 7/.0/[P]:I^'?!^H:1X5UC2[B
M:U:>]1UC:-F*C<FT9RH/7V-=M10ZDM1+#4TDETO^.YP1\!WDW@.+0IKJ!+N&
MX,ZNA)0GG@\ ]&/:H;_P?XGU233)[R]TPOI[*(XH]ZIM&,G.W.3M';%>AT57
MM9$O!TFK:]%OVV"BBBLCJ"K4/^J%5:M0_P"J% #Z*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *HM_K7_WC5ZJ+?ZU_
M]XT /MO]<?\ =JW52V_UQ_W:MT %%%% %6;_ %IIE/F_UIIE !1110 4444
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M0'RITWHW"\$=Z:IK7Y$/$R2CMJG>VNQZ78/IFJ6,5[9QPRV\H)1_*VYP<="
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MV,4B5@#ER.@Y]OTH=.2*CBJ<DVNFNW0W/L=K_P ^T/\ WP*/L=K_ ,^T/_?
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MZI^-,6@"9:D%1K4@H 6EI*6@ HHHH KV7^H;_KK)_P"AM5BJ]E_J&_ZZR?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M HHHH *M0_ZH55JU#_JA0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH JS?ZTTRGS?ZTTR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** +4/^J%/ID/\ JA3Z "BBB@ HHHH
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M EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ JBW^M?_>-7JHM_K7_WC0 ^V_UQ_P!VK=5+;_7'_=JW0 4444 59O\
M6FF4^;_6FF4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!:A_U0I],A_P!4*?0 4444 %%%% %:ZZI^
M-,6GW75/QIBT 3+4@J-:D% "TM)2T %%%% %>R_U#?\ 763_ -#:K%5[+_4-
M_P!=9/\ T-JL4 %%%% !1110 5#<?P_C4U0W'\/XT 04444 8GC#_D3]5_Z]
MVKAO"OA/5M3\-6EY:^*KVQADW[;>(/M3#L#C#@<D9Z=Z]*U*PBU33;BQG9UB
MG0HQ0@, ?3(-1:-I,&AZ3!IMJ\CPP[MK2D%CEBQS@ =3Z5K&IRPLMSDJ895*
MRE+:W?K?R///A^C1Z3XJC9R[*,%CU8A7YJAI=I]N^%<UN+ZVM':_+#[1,(UD
MPH^7)XSW_"O1-)\)V&CPZC%;RW++?Y\WS&4D=?NX _O'KFHK3P7I%MX?ET1A
M-<6DDAES,PW*V ,@@#&,5HZL;M^AS1PE3DC%]$U][/.I'?2=2TN;6]!;3?L[
M@)=:=MC#XQRW#*_'H1G)K=\1Z?:/\5]'C>T@:&XA#2H8P5D;,F2P[G@=?05T
M%OX TN*XMY+B[U&]CMR##!=7&^-,=,# X]JNZYX4L==O+>\FGN[:ZMQB.:UD
M",!G/4@T.K&X1PE10::ZI_=OT.4N;6#5/BNNFW\2-8VEL/LUN1A/N _=Z=2>
M/]D=A3K2&/1OBXECIBB&TN("T\,?W0=C$<=N0/S]ZZ?4_!^F:HMJTK7,=S:H
MJ1W<,NV7 Z9;')_"I=$\+:=H4\US 9Y[N;B2YN9-\C#TS4^T5OE8T6&GSWLO
MBO?K;L<5X>GEM=?\=7%O_KHO/>/_ '@SD?K3O".@Z3J?@>]OKZ".>ZE,IDGD
M.70@<8/;U_&NSTOPS9:3JFHZA!).\M^Y>59&4J"6+<  <<GKFLV;X>Z/)+,8
M9[^U@G.9;:WGVQ/]5P>*;J1?EL3'"U(I-I/?3U>YP;:E?O\ "38TLA0:A]GS
MG_EELW8^F[BM7QOH&CZ?X)T^ZM+>**<&-1(@^:4,I)R>_KDUV.MV.D:7X1>S
METR>?38P%,-JNYUYSNY(Z'G.:\UU1-#OM(M;'0I]4O[]Y L=O=;F^S)W   4
M<XZ9K2$N9W6FIS5Z?LHN,K-\J7G\CHO$D9T:X\,>)XE.V)(X+C;W4K_@7'Y5
M9\+X\0^/]6U[AK>U'D6Y'0_PY'X G_@53>-]0L;'PFNA7(:6_E@C$,:(3D@@
M;@<8XP?>MKP3HSZ)X7MK>9"EQ)F:93U#-V_  #\*S<K4[]=OD=$:=\1RK96;
M]=O^"9]OXRU:35$M9O"E]!;F78]TQ?:BY^^?W?3'/6N*D1-2TC7-0T[21<6I
M=FEU'495:4'@_( !M/(]>O6O92 001D'J#7)?\*YT4-.J37Z6TS;FM4N,19[
M'&,G';)-*%2*Z6+KX>K-)7YM^R_3_@G)7]U<1_!?3!&[8EN#%(0?X-\AQ],J
MM6/&^@:/I_@G3[JTMXHIP8U$B#YI0RDG)[^N3747VCZ7X?\ !<NG7%O?ZAIZ
M$DHH5Y$R<Y&-N #S^->?:HFAWVD6MCH4^J7]^\@6.WNMS?9D[@  *.<=,UI!
MW=UW.6O#DCRRLWRI>>G8V/%]NMYJG@ZU<D)/''$Q'HQ0'^=6-?TZSTCXB^'!
MIUO':B1D#B%=H/S8Z#VXKK+CPG:7\VC75W+.MQIBIL$3 *S+@\Y!)&5]JGU+
MPU9:IK5CJL\LZSV1!C5& 4X.>003^HJ%42LO4Z)863YI6U;B_NL<A;6\.N_%
M74H=719DM(O]'@EY7 VX^4]>"3^-)I2IH_Q,U33-/D%OI[VY>10?DB.P'=[8
M)_6NLUCPGIVLWL=\[W%K>QC N;23RWQ]<&I=$\,Z=H*S&V622:?_ %L\[;W?
MZFE[16^5BEAI\_3>]^OH>4_V3?V&EWJ/I-EK%@SLS:C:NLDBXY)#C)7UP16S
MKLECJ'PJL[FUCE?[-*(D>YVM+&,X(W #C[O3' %=1)\/=*S.MO=ZE:6\YS+;
M6]QMB;Z@@\5JS>&-+F\._P!A^24L@  $.&!!SNSZYJG5BVGYF4,%42E'HU;^
MM/S.)\86=K:?#+33;6T,)E:!Y/+0+O;RSR<=3[TFMJ+_ ,5>$],O!NL&M8W,
M9.%9CD<_]\J/Q]ZZ:3P)I\VA_P!DRWVI2V_FK(K23*S+M7:%&5P%P>F*O:KX
M5TW6+&UMKH2AK50(9XWVR)@ =<>P[4E4BOQ+EAJDKNW1:>CV*MKH6@Z5XJ%S
M:7:VE[-'M^P1RHB2+CKY>,]L\>GUKI:P=(\(Z?I&H/J FN[N]<;?M%W+YC@>
MQP*WJQF[O>YVT8N*=U;7H%%%%2:A5B#[A^M5ZL0?</UH EHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JBW^M?_>-7
MJHM_K7_WC0 ^V_UQ_P!VK=5+;_7'_=JW0 4444 59O\ 6FF4^;_6FF4 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5><G# @'C Z^U=?151DX[&=2E&HDI+;4YS0/":Z/J-SJ=W?2:AJ-P-K3N@7
MXX R<=!WZ#M6?%X#FL[R].G:[<6EE>,3-;I$I.#G@.3QU(SC-=G13]I*]R/J
MU*R5MO4Y;0O!-OI&BW^E7%S]KM[QB6_=["HQCU//?-9Y^'UR]BFER>(KE](1
M]PM?(4-USC?G^F/:NYHH]I*][B>%I64;;>IS-WX.BGU_2=2@N1!%IL:QI;B+
M=N"DX^;/'7T-26_A467BN?6;.[$4-TFVXM#%E7/<@YXYYZ>OK7144<\BOJ].
M][=;_,XE_A_+"EW:Z;KL]GIMVQ,MH(0XP>H#9XXX^GK6M=^$;&?PF/#\+O#
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M%S'I^F-=QVS%))/-"?,.JJ".2*9<^)42QL+FUM6N/MDGEHA<(0WH>O?BL?\
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M44 %%%% !1110 4444 %%%% %:ZZI^-,6GW75/QIBT 3+4@J-:D% "TM)2T
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M_O&@!]M_KC_NU;JI;?ZX_P"[5N@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH K775/QIBT^ZZI^-,6@"9:D%1K4@H 6EI*6@ HHHH **** "BBB@
M HHHH *AN/X?QJ:H;C^'\: (**** "BBB@ HHHH **** "L#Q4LKPZ8L#A)C
M?Q[&(R <-C(K?IDD,4VSS8T?8P=-R@[6'0CT/O0!D1:;J%UJ4=YJ<T"F"-DA
MCM2V 6&"Q)[XK/BT'5X=(ETJ.6PC@964S*K>8X.>&XQWQGGBNJHH Q;;2+F+
M4M.N7:+;;6?V=P&));CD<=*)M#-U<ZQY[J(;Y(E3;RRE0>2/KBMJB@#"AL=;
M<VL%S=VZ6\#*6>W+B24#H#V />K6GZ6T%OJ$-R49+JYEDPA/W'['WK3HH YQ
M-*UV&Q73(KVV2U7Y5N!N$RIGH!TSCCK4EQI%_#K/]H6+6LQ,*Q$798E<=P0*
MWZ* .?M-#O([?6([FXBDDOUXD4$8)4@Y'H">.>E/M=*OQ<:1+<M;#["DD;>6
MS'<"JJI&1UXYK=HH YV/2=8L;673["YMELV9O+D?<)8E;D@8X.,G!I^KP&X?
M2M(#-*WF++*[')V1CDGW)Q^-;],$48F,PC3S2NTOCDCTSZ4 /HHHH **** "
MBBB@ HHHH **** "K$'W#]:KU8@^X?K0!+7+ZU#//XOTN.VNFM93;RXE5 ^/
MP/%=15>2QMI;Z*]>/-Q$I5'W'@'KQTH YV2UO;;Q;HGVO47O-RW&W=$J;/D&
M?NCG/'Y5F6=C+>:-HAC2VO1' Y:PFEV%AN^^/ITYXKMI;.WFN[>ZDCS-;[A$
MV3\NX8/'0].]4W\/:6]O;P&UPEN"(BLC*R@]1N!S^M '+-:V%Y:::C6DBF+5
M?LTD-PP<Q@JS&,$=5Z5>L=,LM4AU6YU%<317$L2N7.;=%^[MQTP.?>MUM"TQ
MK!++[*! DGF*%=@0_P#>W YSSUS3+CP[I5U,TLMKEV #XD8!\=-P!PWXT <B
M=2OOL7VX.WVO^Q/]9_%_K<;OKCG-:UWIUEI!T>YTX[)I;J*)G5B3.C?>W>O'
M-='_ &?:?://\A-_D_9_]GR\YV[>F/PJK:>']+LITG@M0LB9V%G9@F?[H)('
MX4 <G+8VM[X)N]7N<MJ+AV>8N=RL'(V?3&!CWJ[/>'P]<W$Z+\M]8K)$ .#.
MH"X_'<II+_0KJ^6YA;18DN9G.;M+C$/)^_Y><[L>W6M6]TV>_P!5T^![0+8V
M+B47#."9"%X4#J.>N?2@".UOO[!MK72O[+U.X:-%#S00;XRQY8[L^I-86IQV
MMSIVI7]OIT\X#.PU&><(RL./D'7 / &!7?UDOX9T>1I"UF")"2R>8VS)ZG;G
M /T% &186T.N:M<KJ@,X@MK?R4=C@;DRS #OGO67I5G!=G1K64M) ;F\!^8_
M.!@C)[]!6YJ>ELUVBC15O+>.%8X7BN3%(H'!5R6&X=/6K6AZ%'86-H;F-/M4
M+22+L8[8RYY ]>,"@# O%_L^;4].M7>WL7N[5'",<1(X^<CTS@5=U"PMM)U6
MSATZ5;$74,Z388A0!&2'.3Q@XYKHI-+LI6NS);J_VL*)PQ)#A1@<=L>U0VN@
MZ99L[16HRZ>6QD=G.W^[\Q.![4 <Q8V<>GWUA%?:<L0GS +JUGWQW.Y?XU/)
M!'.:;86EO!H.C2Q1*DDNJKO8#[VV20#\A73VGA_2[*=)X+;$D?W"TC,$^@)(
M'X4Z/0M-B.8[?;^^%P )&P'&<$#.!U/'2@#GK*QT[4-'O-5U65Q<B:0R7 8A
M[?:V J]<8 '&.]=?"RO#&RL64J"&/4C'6L^;P_I=Q=-<2V@,CL'8!V"L1W*@
MX)^HK3H **** "BBB@ JBW^M?_>-7JHM_K7_ -XT /MO]<?]VK=5+;_7'_=J
MW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5KKJGXTQ:?==4_&F
M)0!,M2"HUJ04 +2TE+0 4444 %%%% !1110 4444 %0W'\/XU-4-Q_#^- $%
M%%% !1110 4444 %%%% !1110 4444 4KK6-,L7D2[U&SMVC4,ZRSJA53P"<
MG@&K%M=6]Y;K<6L\4\+\K)$X96^A'%<6-,LM0^+E[)>6T4_D:7$8UE4,%)=A
MG![XX_$U8\#11VM_XHM8$$=O%JK>7$O"IE%)P.P]JT<$E<#L:*P-=\-W&MW2
M2+K^J:=%''A8K&41Y?)^9CCYAT&/:H]#T#6M.OA-J/BBXU.W1"D<#VZQXSW9
M@<L?K4V5KW O>(-0O].L(VTRP:]O)IDAC3!V)N_C<@9"#')K*M=:UVP\26.D
M:]#I\BZ@DAM[BR#J%=%W,K*Q/;H<UM:WK-GH&ERZA>N1$F %499V/15'<DUB
M:%I6HZEK*^)M>00SB,QV-B#G[+&W4L>[D=?3I]*C;ENT!2/BGQ#?65_K6DV-
M@^D6<DBK',S^?<K&2'92/E7H< @YQ77Z??0ZGIMM?6YS#<1+*A]F&17#^$;B
M*R^$MU#<3 /8I>17!8\JX=S@^_(_.NB\#V\MKX'T6*;.\6B$@]1D9 _(TZB2
MO;HQ&_11160PHHHH **** "BBB@ HHHH **** "K$'W#]:KU8@^X?K0!+6??
M:O%97,=JMO<7-PZ%Q% @)"@XR<D #/O6A7.ZW+>C5HHMVHQZ?Y.[=81;F:3)
MX)P2!C% $[^*+&/3A>-%<@?:/LS1>7\Z2>A&?Y9ZTX^)+5(KII[:[MY;:+SF
MAEC =DSC*\X//'6N9 N++3U>6TN]_P#;B3)',"9)%*C')X)X_.K.O>;J:WVH
MBUN+>WM[!X@9X]C.S$' !YP .M &_:^(K:YN+>)K>ZMQ<C,$D\859>,\'/IZ
MXJ*'Q39RV\MR;>[2UBSOG>,;<@XV\').<=N]4A+/K']CV\=A<PBVECGFEFCV
MJH53PI_BSGM42Z7=S>"8H4@<7,-PT_DLNTOB5CCGU'(_"@#7C\0PM+Y4UE>V
M\K1M)&DT0!E"C)"\XSCL<5(VN6HTZSO5662.[=$B5 -Q9N@/...<_2L^62;6
M]8TQXK&[@AM':662YA,?\. HSUY/:JVF:7<Q^(!:RP.MAI[RS6SE3M;S,8 /
M^SEOI0!H2^*;2)))A:7KVD3E'N4B!C!!P>^<9[XJQ8WLT^O:G;M(&MX4@:(
M#C<&).>^<"N5U!=4OM*O$N8]8>_;</(CCVVX /&"/O<>Y)-=#HL$T>L:A))#
M(B/;VH5G0@$A6R.?3O0!<OM8BLKI+5;>XN;ED\SRK= Q"YQN.2 !GCK563Q1
M8QVT,PBNG,LQM_*6/YUD'\)&>O\ C4-QYNE^)IM0:UN;BVN;=8]T$9D,;*>A
M YP1WK#G2XM=0M=2FLY@;G4VE2W"_O-@3&<>O4XH V]0\2[-*OWM[>XAO;9
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M@59H **** "BBB@ HHHH *HM_K7_ -XU>JBW^M?_ 'C0!);?ZX_[M6JJV_\
MK3]*M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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?110 ;11M%%% !M%&VBB@!=HIP6BB@!X6I%%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img158215518_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img158215518_14.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ( !!8# 2(  A$! Q$!_\0
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MI4]% $'V?_;_ $H^S_[?Z5/10!!]G_V_TH^S_P"W^E3T4 0?9_\ ;_2C[/\
M[?Z5/10!!]G_ -O]*/L_^W^E3T4 0?9_]O\ 2C[/_M_I4]% $'V?_;_2C[/_
M +?Z5/10!!]G_P!O]*/L_P#M_I4]% $'V?\ V_TH^S_[?Z5/10!!]G_V_P!*
M/L_^W^E3T4 0?9_]O]*/L_\ M_I4]% $'V?_ &_TH^S_ .W^E3T4 0?9_P#;
M_2C[/_M_I4]% $'V?_;_ $H^S_[?Z5/10!!]G_V_TH^S_P"W^E3T4 0?9_\
M;_2C[/\ [?Z5/10!!]G_ -O]*/L_^W^E3T4 0?9_]O\ 2C[/_M_I4]% $'V?
M_;_2C[/_ +?Z5/10!!]G_P!O]*/L_P#M_I4]% $'V?\ V_TH^S_[?Z5/10!!
M]G_V_P!*/L_^W^E3T4 0?9_]O]*/L_\ M_I4]% $'V?_ &_TH^S_ .W^E3T4
M 0?9_P#;_2C[/_M_I4]% $'V?_;_ $H^S_[?Z5/10!!]G_V_TH^S_P"W^E3T
M4 0?9_\ ;_2C[/\ [?Z5/10!!]G_ -O]*/L_^W^E3T4 0?9_]O\ 2C[/_M_I
M4]% $'V?_;_2C[/_ +?Z5/10!!]G_P!O]*/L_P#M_I4]% $'V?\ V_TH^S_[
M?Z5/10!!]G_V_P!*/L_^W^E3T4 0?9_]O]*/L_\ M_I4]% $'V?_ &_TH^S_
M .W^E3T4 0?9_P#;_2C[/_M_I4]% $'V?_;_ $H^S_[?Z5/10!!]G_V_TH^S
M_P"W^E3T4 0?9_\ ;_2C[/\ [?Z5/10!!]G_ -O]*/L_^W^E3T4 0?9_]O\
M2C[/_M_I4]% $'V?_;_2C[/_ +?Z5/10!!]G_P!O]*/L_P#M_I4]% $'V?\
MV_TH^S_[?Z5/10!!]G_V_P!*7[/_ +?Z5-10!#Y!_O\ Z4>0?[_Z5-10!%Y/
M^U^E+Y7^U^E244 0@T4P&B@"=/\ 5K]!3J;'_JU^@IU !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M';OV ZCK78UE./+*QE./*[!1114$A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 4%Z44B]** +T?^J3_ '13J;'_ *I/]T4Z
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[:"<G@<^U=))9VLMU%=26T+W$((BE9 70'@X/49]JGINJ[)(;J.R2,6W\/\
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M W%+BEHH H+THI5Z44 6X/\ 4K^/\ZDJ.#_4K^/\ZDH **** "BBB@ HHHH
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M,O)U@MM2LYYF7>(XIU9BOK@'.*5F5S1[EVBBBD4%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17E7Q'\&:=9
MZ??>(8YKHW<LRED9E\OYC@X&W/ZU!JG@S3M"^'=[JMK-=//=6D =964J-TL3
M' "@]1ZULJ<6D[[G%/%5(RDG#97WZ?<>N45XYI>N2R?#C6-!OP4NK6V66 /U
M>%BI&/ID?@P]*T+K5K^T\ >%M*TN9H+O4RL*S*<%1D#@]CEEY^M#HN]A+'1:
MO;I?YWM8]3HKRC5?A]I&BPQO;>*!8ZRH#H]W=)$K'H2,#<O.><GTYZUI>-+M
M[F#POITVII/I]_/LO+J A$F *#J"0 <L<9QD>U+V:;5F5]9E%-SC9JW6^^AZ
M+17F6BWJ^&/&FO:+I[M)IL-JUS% SEA%(JAB 3]2#WZ9Z5@_8F_X0+_A,_M$
MW]N?;/,^U>8V[;NV;<9QC\.G'3BFJ7G_ $R7C++2.JO?7MOZGM=%>6>+KJWN
M]?\ #USXB=E\/7-KYACC=L>;M))(7YN-R<CL?K6S\+C<MHEZ?-9].^U,+(.V
M65!U'L.G'U]:3IVCS%PQ7-5]G;^O3L=U11161UA1110 4444 %%%% !1110
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M2KQE)1CKL_O-^BBBH-@HHHH **** "BBB@ HHHH **** "BBB@"@O2BA>E%
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M;[JW_!/'M=DU?Q<J0W'@6Z35A$(4O&DD2-,')(! 7'WL98]1R:Z#5]&U+3O
MFE::^DVVKQ6[*+R!5=G S]Z(J5.1DC(]?3->@U3TW5;'6+>2?3[A9XHY6A9U
M!QN4X(&>OU'%/VKTLM$"P:]YRE=M6V7],X+PKX6%QK.IZBFE3:3ILEJUI:P3
M@B7Y@ SL"<^O4]_:LC^S]>_X1'_A"_[%O/M7VS_CZ\O_ $?R\[]WF=.O^<\5
MZG#JUC<:K<Z9#<*]Y;(LDT0!^0-G;D],\=.OYUGZKXQ\/Z)>_8]0U%(K@*&=
M COY8/0N5!"CZXIJI)O87U*'+9.V]_GN<QJNG7WA_P ::5K*:?=ZG8068M0+
M:/?)$0I&0OOZ\#D_CH?#_2[ZU;6=1N[1[*+4+HRP6CC#1KECRO;[P';[OIBN
MRCDCFB26)U>-U#*ZG(8'H0>XIU0ZC:L:1PT8U.=/SMZZ!15#6=:T_P /Z:^H
M:I<>1:H0K2;&;!)P.%!/6K-I=P7]E!>6L@DMYXUDC<=&4C(/Y5%G:YTDU%9>
MC>(])\0?:O[+NQ<?99/*F(1E"MZ<@9^HR*U*&FM& 4444@"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** //_BBCP0Z)
MJAC:2VL[P-,J\\'!'_H)'XU!XN\671MH]1\.>*-+BM4A#/;LR--(Q/&$*D@X
M(X.,=Z]#G@BN87AGB26)QATD4,K#T(/6N>A^'WA6"Y%PFCQ%P=V'D=U_[Y)*
M_ABMHSC9<RV.*M0JN4G3=N:W=-6]#F=2U72]4\"Z%_PE@NW-\Y(O+=%7R7#8
MR>P!4] IX!XR!6:^JWOA+4M.&G^+TU^WN9Q'+:EQ(548  .YMOWCTQR!P1T]
M2OM,LM2L6LKRUBFMF&/+9>!QCCT([$<CM67IG@GPYI%XMW9:7&DZC"N[O)M]
MQN)P>.HYIJI&VI$\+5<DXM=-=;Z?G\S@]?T(^(_BU/IS7+P0/;HT[(?F9 JG
M:.V2<=>!UYQBMKP!J,^D:C>^#M2;$]H[-:L?^6B'D@?F&'L3Z5V*Z'IRZVVL
MBWQJ#)Y9FWMRO QC..P[5'=^'=*O=7M]5GM U];X\N99&4C!R,@$ _CFDZB:
MY7M;\2HX64)NI'>[^Y]#E?&$^D>*_#.I2VNKS*=*#-)$N41I.RNK#YN5('N:
MT-(\464OAK1HM2G%A=:E"8H%AC91D'9E2!A>Q'ID5?OO!7AS4M0-_=Z7%)<D
MAF8,RACZE00#^(YJ]J6A:7J]@ME?644MNF-B8V[,=-I&"O3'&..*7-&R12I5
ME-STNU;KK_EIZG&>#]FA^.?$&C)<"YMA&+J2\F(,FX;<AW[_ 'VZ]P?4UG2S
MWGQ0U\6T'F0>&[.3=(^,&4_XGM_=!R>>#WUEX7T73M,N=.M+%(K:Z4K.JNVZ
M0$$8+9W=">_&367_ ,*V\)?] G_R9E_^*JE4C=OJ9O#5>10TY;MM7?W7ML<O
MJVC65]\75LM2C*V-Q:KLB#F-9=JX"Y&. 5S@=U%,\/36<G@[Q#IVK:A<QZ';
MW8ABN(P794W< $*W!PO;^+WKT#4_#&C:Q:6]K?V*316X BRS!D &,!@0<>V>
M<"I[71=,LM+_ +,@L85LL8,)7<K?[V<[OQH]JK)#6$DIN2MK?\>C\D>;WVG:
M;X:UOPM=>%97WWSK'(!,6^T1$KRP/3/.>@R.@Q3K^&2UU3Q8-$UJR6VFC9]1
MAN8G$L).[=LX ;))QS_$!Z$]SI/@[0-#O/M>GZ<D5Q@J)&=W*@]<;B<?A1J?
M@_0-8U 7]_IL<MS@ ON9=V.FX @-Z<YXXZ4>U5R?JD^72RUV5[+2VGKZ'!Z7
M8:(_PZT2V\27T]G!/<O+"L><.=Q W':<#!SVX/6M#3+.'PY\5$TG16=+"XM/
M,N;?S"ZQL V#R2<\*?\ @7I7=W^CZ?J>G?V?>6D4MK@ 1D8"XX&W'W<>U5]&
M\-:/X?\ ,_LNQ2 R??;<S,?;+$G'M2=5-/S*6$DI1M;2VO73I\S5HHHK$[PH
MHHH **** "BBB@ HHHH **** "BBB@"@O2BA>E% %N#_ %*_C_.I*C@_U*_C
M_.I* "BBB@ HHHH **** "BBB@ HHHH **** ./>_N$^+[6C74HLE\/^>83(
M?+#_ &C&_;TSCC/7%4=!M;_QS8MKU]K&IV5G<2N+&TL+@P".)6*@N5Y9C@GD
MX_I/(BR_&MHW&5;PT5(]0;FJ/A;Q!8^"=)_X1KQ'*;&:PD=()Y(V\NYB+%E9
M6 QG!P1UXK>VGN[Z".F\,V^N6#W]AJTQN[:"0?8;V1@9)HR,D.!W4\9(&:WZ
MXV'Q/JVIZ/K^IV6G2K90Q%=*;[.QFN'VG+>6>2N[&..1FJDOB"^TRQNX9+K5
M1JSB!8(=5AML 22K'YB^0,'!;D%L\#CGF'!MC.]K$UOQ;HGAV>*'5+MX9)5+
M(%MY),C..J*<5%I5S>VOB2]T6[O9+Y%MH[N&>9$60!F9&1MBJI&4R#C/)SVJ
M76]+UN_GB?2_$3Z7&JD.BV<<V\YZY?I244G9@-T7QEH7B&\>TTN\DFG2,RLK
M6TL>%! SEE ZD<5J:A?VVEZ?<7UY*(K>!#)(Y[ 5EZ+I.NV%X\NJ>)I-4@,9
M586LHH=K9'S97GH",>]5_%^AZIKL5A'I]S9QQ03B>:&[1F28KR@(4@D \XSS
M@46CS6OH!A^"=5UG4_&>MOJCRQ1R6T$]O9,QQ;HQ;:,=-Q4 D^I]JZ_7M:MO
M#NB76K7:2O!;*&=80"QR0. 2!W]:XGP^GB(?%+5_MDVELPM;?[5Y,,@!3YMN
MS+'!SUSFMGXH_P#)-M:_ZYI_Z,6KE%.HEWL(GM?'6GW.I6=I)8ZG:QWS;;2Z
MN;?9%.<9 4YR,CID#-<M8:UJ5G\7+Y;B^N9-+GNC8""24F.&0Q+(A52< DJP
MX]:Z'QRJH_A-% "KKUL !V&R2N:O;&6]/CV2U!^V65_!>VQ'4211JXQ]0"/Q
MJH*-K]_\P)?B?KFHPZOIEEIE[/:I;/%-=M!*R;O,D"(AP?0.<&O4*\<UF0ZK
MX.F\2NC(=7UJW>(-U6"-MD8_1C_P*O8ZFHK12 ****Q&%%%% !1110 4444
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MK@9KM]879X?OU!)Q:R#).3]PU#C9I#*7A7Q5I_B_2FU#3TGCC20Q,DZA74@
M] 2,$$'K59O&VF_\)3>^'8H+N>_M+<W#^4BE6PH;8OS9+<CC'7O7'> KB/PX
M]G)<,4LM5T2.[W$<"6!=K@?\ *G\*C\)6TL?Q$TN]N5*W>IZ5/?S@]C)+D#\
M%VC\*U=.*;[".DE^),,-W;VDOA;Q,EQ<!C#$UF@:3: 6P/,YQD9K:/BBWA\,
MW6NWUC?V$%LK,\-U$$E..F%R1R< <UF:_P#\E)\'?]<[_P#]%I6=\1]7M$OM
M"T.[D=;:XNA=7GEQ/(?)B.0"J@DAFP.G:I45)I);@=?H6M6OB'1X=2LUE6*7
M<-DJ[71E)!5ADX((-<__ ,+#@DO+ZWM/#OB"]%E<R6LLMK:HZ>8AP0#O^A_$
M5E^!M<L?^$SU_2+*61K*[?\ M&T\R)XB&; E4*X!^]@C ]:H^%-3\0V5YXIC
MTGPY'J4!\07;-,U^L&ULKE=I4YX .??VI^S2;T [SP_XDL?$<$[VBSQ2V\GE
M3V]S&8Y86]&7M6O7*^$=#U.RO]9UK6!!%?ZM+&S6]NVY(DC4JHSW/)S755E-
M)/084445(!1110 4444 %%%% !1110 4444 %%%% !117C]GJ-WX:\<^(-?+
MLVC/JGV/4(Q_RR!52DOX$D'V-7"'-<#V"BN-$L:_%R:8NOECP\C%\\8\]CG-
M0_\ "?7TFFR:W;^&;B70$);[7]H42M&#@R"+&2O?J#BCV;Z =Q145M<Q7EI#
M=0.'AF19(V'\2D9!_(UR/_";:E<F]N=+\-37^FV=P]N\T=RHF=D.&V18R?89
M!-)1;V [.BN=U?Q/-::E:Z5I>ER:CJ<\/VDP-((5BBSC<[$''/&,9X-<[XH\
M1'6? 'BFSNK*2PU*QA"W-L[A\!L%65A]Y2._'2FJ;=@.^O+87EE/;&6:$2QL
MGF0N4=,C&58=".QKG)O"$^JK)_;NJ"[?[&]G"UO;^3Y8<@M(<LV7)1.>!QTY
MI+GQ-<6EQ8Z-I.EMJ>HM:+/(GGB%(8^@+.0>2>@ S3[;QK:#2-6N]4MI=/N-
M(.+VU8AV0D97:1PP8$8/%-*:V N:7HMY!JC:GJFH1WMY]G%M&8K?R45,[B=N
MYLLQQDY X& *VZXZ'QEJL=Q8IJ?AF2QAU$^7:2FZ5\R%2RI( OR%L>^._2N3
MM=6N?^$+\9S:_H@NK%-2F:6+[>06?S4'E!@N0%XPPZXQ@4_9REN(]=HK&M->
M\_Q7J&A36WDR6T,=Q#)YF?/C;()Q@8PPQU-<Y=>)K/68-(N[G1_-MSXA6TL9
M/M++\RAP)\ <C(8;3D>]2H-C.\HKS73=<UZU\5^-;E]%686R0N8?MV=FV'*J
MOR<[AEN.A..>M=-=^+HH_#^D:G9VWVJ35988K:#S-F6DY.3@XVC)/';M3=-I
M@=)169XBN+RT\.W\]A")KE(6**9?+QZG=@X(&3[XQ7G_ (-U.+POX,T^X&A;
MM4U=D2!(;C?)?-@G>Y(^0#)SG.*4875P/4Z*YK2O%%S-KHT76=(;3+^2$S08
MG$T<RC[V& 'S#TQ5?P?XNU+Q9;07PT#[)ILRMBX:\#G<IP0$V@D9!&>.AXHY
M)+4#K:*\Z^+6FMK%KH6GQDB2>^98R#C#^4^W]<5>N_$DU_\ "Z"_M^-0U*%+
M.)>_VB0^6?R;<?\ @-/V=TGW [>BO+_A[X6TC6? ?]GZI:"[@M=1G\L.Q'(.
MW/!':HO"W@'PO?ZMXEANM(CDCM-1,,"F1QL38IQP?4FFZ<5>[V\O^"(]5HKR
MSQHEYK_B'4KC3G;=X6M4N(=K<-<EA(1[_NT(QZFMCQWJ4.L?!^^U&W.8;FUB
ME7GIET./J.E'L]O,9W=%>/:MIGPTLO"T]U8W=A%JB6VZ![._+3";;\N%5S_%
M[5Z=X<DOI?#6F2:F"+YK6,SAA@[]HSGW]?>E*%E<#3HHHK, HHHH **** "B
MBB@"@O2BA>E% %N#_4K^/\ZDJ.#_ %*_C_.I* "BBB@ HHHH *\RTM]1\)>&
MK[PI_P ([J%Y.C3)936T&Z"=)"2I=^BD;L'=V'>O3:*J,K: >?ZSHFI:?\)K
M3P[;I-<7<B06DK0*7*!F'F'C^$#<,^E=C?7":+HLDT%G/.EK%B.VMHR[M@85
M5 R?0>W6K]%-RON!YB/ >IZMHL^OWDS0>+YY5O+=PV!;;?N0?[N.#[]<XY[G
MPYJESK&AV]W>V%Q8W9&V>">-D*N.N,CE3U!K5HHE-R6H'FWB?3[>X\3W<NL>
M'-3DPB?8-2T1)#*1CE9"K<,#T)&,51OO#FMW6@^%]1UVSN]3ETZ2<75K'*1<
MF&3 4[D(+.H5<@'GGWKU>BJ55JPK'FNA:-;S:]<WVF^'+ZQLX+*2-+C47N//
MDD8<JB.YPN.I(Z]*RAX7N?\ A&O!VH7NCWUU%8020WMC"7BN%5^C* 5;((Y'
M<&O7Z*/;.X6/-="\.VVH:MJ4MCH-YIEBU@]K'=:C)/Y[N_#;4D<X0#'49S4V
MDZWK^D>&++P_!X;O6UNU1+57D@/V,A<#S#*"!MV\^N:]$JG9:K9:C/>0VDWF
M26<ODSC:1L? ..1SP1TH]HWNKC.,NX;VV\<:_OT^\ECU+2TB@N(;=FBWHCY#
M,,[3V /4D5 ^D7\?PO\ #]S!93_VMHZP74=MY9$C%>'CV]<E2PQ]*]&JG9:K
M9:C/>0VDWF26<ODSC:1L? ..1SP1TH]H^P'G^H:'J*_!G4HFM)Y=7U'_ $RX
M@2,M(99)%8KM'.0,#'^S6Y?BXLOBE8W[6-Y-:3Z6UD)H(3(L<AF5OG(^Z,#J
M:["L^37--BCU)VNTVZ:A>\V@MY0"[N<#D[1G YI<[?3^F!P5YI-PWQ(;043.
ME7UQ'K<W.0#&"K*1Z-((S7IM8'AW0M/LGEU>VO+R_EU!$<7-Y*781?>5%R!M
M7G.,9]:WZ4Y7T \OB\/ZM<^ [^*"SD6^@UN2^AMYE*&8++N &?4=#WK2U&]O
MO&%_H=I;:'J=E%::A%?7<]];F)4$9R$7/WR3QD<5WU%/VG6P'+>"[2YM9?$I
MN+>6$3:W/+%YB%=Z%4PRYZ@X/(]*/B+:7-]X&OK>TMY;B=I("L<2%V.)D)P!
MSP 3^%=312Y_>Y@/.O$&AZA+XX-E;6DKZ1KAMY;Z94.R,P$E@3T&\!![UJ^%
M;*ZM_&?C">>VFBAN+B!H9'C*K(!&02I/!Q[5V%%-U&U8#E+2TN5^*.I7;6\H
MMGTR%%F*'8S!V) ;H3[5CZ3X8G\1:YK7B#4IM8TV2:Y-O:I#.]LQMXP I(&#
MACD\UZ'12]HUL!YSI^BWOAK7/$>D6\%_=:9J5DUW!<2!I<3[2KJS]V;KSR<"
MM/P+X9L(?!FD_;]$MDOEA'F>?:*)0V3UR,YKLZ*;J-H!  H    X %+1168!
M1110 4444 %%%% !1110 4444 %%%% !1110 5PLO@?7%\47^O67BF*"XNSM
M7S-,64Q1CHBEGX'K@#/6NZHJHR<=@.:N_"]YJOAY+#5M9>>_AN%N;>_AMUA:
M*13E2$R1QR/?-&E^&+NWUAM9U75SJ6HK 8+=_LXBCA0\G" G)) R<_E72T4<
M[M8#G_#GA>/1$OIKJX^WZC?RF2[NGCV^8.@4+DX4#C&31X8\,MX76\M;>^,N
MF2S&6VM6CP;;/WE#9Y7/08&*Z"BAS;O<#G];\.7&H:M:ZOIFJOIVHV\30;_)
M$J21L02K(2.X!X(JBG@*VGTG5K;5+V6\O-4D66XNU01%70#844<+MQ[UUU%-
M3DE8#D[?PCJ4^IV%UKGB&34HM/?S;>!;5809,8#N03N('TI6\#6T^E:U875V
M[C4=1?4(Y8UV/;N=NW:<G)!7KQG/2NKHHYY <I:^$]1EUBRO]=U]]3%AEK:%
M;58%#D8WO@G<<?05%-X+OX)M031O$,FG6&H2-+/;?95E*LWWS&Q(V9^AQVKJ
MKN\M;"W:XO+F&W@7[TDSA%'U)XK"M/$OV_QK_95I+:W&G'2UO4GA;>6<RLF
MP."N!Z=>]-2F]0()?!?D7>A7&D:@;(Z3"UNJR0B82Q-C(/(PQQU]^E7M)\-Q
M:=9:Q:3S?:8M3O+BY<%-NU9>J=3G []_2KRZWI3Z@=/74[(WH.#;"X7S ?\
M=SFLZWUNYF\=7NALD0MH+&.X5P#O+,Q!!.<8X]*+S: @\*^$$\,Z!<:;]M:Z
MEG9B]R\>UB-H11C)^ZH Z_E5-O LJ>&]"TVUU?R;O1I1+#=&V#*Q (Y3=_M?
MWJZ1=;TI]0.GKJ=D;T'!MA<+Y@/^[G-8\GC"SC\>1^'&N;)5-H969IQO\_>J
MK%C/4J2<=3Q0G-N_S Y_Q7;V7BGQ;HNB0R22WUC+NU(I$RJMOA7*L2,8<JF
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MD$D5PO);;&RED.3ZXJM)H$LGA'Q;<:?X<N[);N%(;2*9II;J=5Y)969L<DX
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M8 Z$X0_CGO7H&K:+IVNV@M=3M$N(@P=0Q(*L.A4C!!]P:IZ1X1T+0;U[S3+
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD7%U;4S*@_M2_P %D'_'U)W9QZ^PJ,:OJGEY_M6_SL!_X^I/^>6?7UYJNO\
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M]5_]J4P?ZAO^N0_]$FN/VL[?$_O.[ZIA[O\ =K[D3V^O:TYO=VLZD=DSJO\
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M.?+8Y^UR=?)0^OJ2:DEU_65>0#6-1 &['^ER?\]$'KZ$UE/_ ,>X_P"N3?\
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M"2#QGMD UQSS#"1^&-_D6J51[L^>[?5]9GFMXH]4U*1Y)$4*MU(2V7D&.O?
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M?7U _*FW.I:BES;*NI7P#!]P^U2<XB!]?7FH)^MG_O)_Z+DIEY_Q^6G^Z_\
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M2MWQO_R.6M?]=/\ VA6$_P!Z3ZR?R2O)G\3]3]$PG\&G_A7Y(<O_ !\#_?\
M_:U1Q?ZM?]Q?_09*D7_CX'^__P"UJCB_U:_[B_\ H,E0;]&(?]6?]P_^B14K
M?ZZ3_??_ -#2HC_JS_N'_P!$BI6_UTG^^_\ Z&E /="1?ZQ/J/\ T:U1Q_ZM
M/]U/_1;5)%_K$^H_]&M4<?\ JT_W4_\ 1;4!W%?[K?1__1:T]_\ 62?[S?\
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MJLN_WNGZGI9I_N53T+,?W8OJO_M2F#_4-_UR'_HDT^/[L7U7_P!J4P?ZAO\
MKD/_ $2:XNAZ#W96M>NH?]=Y/YQU?'^N'_78?^C35"UZZA_UWD_G'5\?ZX?]
M=A_Z--=N8?[S+Y?DCS\L_P!TAZO\V1Q?ZM/]Q/\ T&2FM_J'_P"N?_M(4Z+_
M %:?[B?^@R4UO]0__7/_ -I"N+H>A]IE>?\ Y#4?TE_]"2KL?^N3_>'_ *.-
M4I_^0U'])?\ T)*NQ_ZY/]X?^CC7;B_AI?X?_;I'GX+>M_C_ /;8E2X_Y!LO
M_7 ?^BI*6W_X\8_^N1_]$K27'_(-E_ZX#_T5)2V__'C'_P!<C_Z)6E_S!?\
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M/+8P.%8X)R0#5>36+#7-#BO--N5G@-Y NX J01,F000"#]:<=P-ZOFOXE_\
M(V:M_P!=I?\ T4*^E*^:_B7_ ,C9JW_7:7_T4*Z<!_OE/Y_^DLZ(?[M7]%_Z
M5$P1_P @Z]_Z[/\ SCJ2[_Y#$/U3_P!*#48_Y!U[_P!=G_G'4EW_ ,AB'ZI_
MZ4&O1A_O<O6?_I-,WJ?[E'TA_P"E5"S/UL_]Y/\ T7)3+S_C\M/]U_\ T0*?
M/UL_]Y/_ $7)3+S_ (_+3_=?_P!$"O#PWPTO\-3\I'T6*^.M_CI_G T&_P!=
M)_OO_P"AI5$?\A=O^N _]'-5YO\ 72?[[_\ H:51'_(7;_K@/_1S5AE_Q3_P
MO\T=&9?PZ?\ B7Y,JV__ !YZ5_OQ_P#H#U3OO^/BX_[:_P#HE:N6_P#QYZ5_
MOQ_^@/5.^_X^+C_MK_Z)6OJ,#_O$O^W_ /TMGR.8_P"[Q_[<_P#3:-73_P#4
MW/\ UVE_]&)574?^0LO^]'_Z.>K6G_ZFY_Z[2_\ HQ*JZC_R%E_WH_\ T<]<
M6$_Y&U7T?Z'?C?\ D24?5?J+HO\ '_USB_\ 13TP?\A:3_>F_P#12T_1?X_^
MN<7_ **>F#_D+2?[TW_HI:NK_O6*_P '_MIE1_W3!_X__;A^M_\ '\?]P_\
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MHT?_ )!]M_OC_P!"EHTW_5S?]?+_ /HU:-'_ .0?;?[X_P#0I:\W'_\ +_\
MQQ_*1ZF6[8?_  2_.!9'^H7_ *YG_P!$U5M?O:A_UU?^4=6A_J%_ZYG_ -$U
M5M?O:A_UU?\ E'7!0_W:MZ+\T>GB/][H>LO_ $EDFG=)?^OIO_1PJOJ/^HM/
M]]?Y2U8T[I+_ -?3?^CA5?4?]1:?[Z_REKTJ7_(W^;_(\FM_R(WZ+\T1Q?\
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MD_ZZM_Z.%,7_ )"<_P#N1_S>L9?[YB/3_P!NB:P_W##>O_MLC/G_ .038?\
M7%O_ $2:N7W_ " #_P!<?_98JIS_ /()L/\ KBW_ *)-7+[_ ) !_P"N/_LL
M5>A7_P"7'_7U_P#I;/.P^]?_ *\K_P!(1-IO^KF_Z^7_ /1JT:/_ ,@^V_WQ
M_P"A2T:;_JYO^OE__1JT:/\ \@^V_P!\?^A2UYN/_P"7_P#CC^4CU,MVP_\
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M?DCS\L_W2'J_S9'%_JT_W$_]!DIK?ZA_^N?_ +2%.B_U:?[B?^@R4UO]0_\
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M4_\ 2@U&/^0=>_\ 79_YQU)=_P#(8A^J?^E!KT8?[W+UG_Z33-ZG^Y1](?\
MI50LS];/_>3_ -%R4R\_X_+3_=?_ -$"GS];/_>3_P!%R4R\_P"/RT_W7_\
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ME1'_ %9_W#_Z)%2M_KI/]]__ $-* >Z$B_UB?4?^C6J./_5I_NI_Z+:I(O\
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M .VQ*OAWPO=^))XK=89A9NL8GF7 VH5=203P2,]LUZUHOP^T#11 R6[7$\(
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M?[\?_H#U3OO^/BX_[:_^B5JY;_\ 'GI7^_'_ .@/5.^_X^+C_MK_ .B5KZC
M_P"\2_[?_P#2V?(YC_N\?^W/_3:-73_]3<_]=I?_ $8E5=1_Y"R_[T?_ *.>
MK6G_ .IN?^NTO_HQ*JZC_P A9?\ >C_]'/7%A/\ D;5?1_H=^-_Y$E'U7ZBZ
M+_'_ -<XO_13TP?\A:3_ 'IO_12T_1?X_P#KG%_Z*>F#_D+2?[TW_HI:NK_O
M6*_P?^VF5'_=,'_C_P#;A^M_\?Q_W#_Z.6KE_P#ZRT_Z^8O_ $8]4];_ ./X
M_P"X?_1RU<O_ /66G_7S%_Z,>N?[&$])?DCI^UC?6/YLK:K_ *J#_=_]H&G7
M7_(O'_KW/_H$=-U7_50?[O\ [0-.N_\ D7C_ ->Y_P#0(ZBC_NN%_P ?_MS-
M:_\ ON,_Z]_^VHGT_P#U<G_75O\ T<*8O_(3G_W(_P";UT>B^"/$EW9M/'I<
MHC:5BID94+ R!@0&()!'.:ZWPE\-+F'6[NX\16,$EH]NJQ()LD.&)S\OL?6L
M9_[W7;V:T_\  HLAXJE# 4%>[3U2W^&2_4\?G_Y!-A_UQ;_T2:TFM+G4-*6U
MLX);BX>$[(HE+,V%C)P!STKZ!@\ ^%;?RMFB6Q$7W!)EP.,=&)[5LV^EZ?:,
MC6UC;0L@PICB52HQCC ]*WK8E24.5?#)R^^39YE/%1@ZFGQ04?NBE?\  \0T
MGX;^*&MY&>Q2'=.S@2S*"5+JP.!GL*[;P/\ #7^P86.M&SO7*;1$(]ZH=[$,
M"W?#>E>B45S5)NI*4G]IIOU5_P#,CZY5]G&FG9137R=G^B*%MHFE69)MM-M(
MB<<I"HZ# [>E7@ H    X %+16:26QSRG*3O)W"BBBF2%%%% !1110 4444
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M***[#Y@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "JM^E]):[=/G@AN-P^>>(R+MSR,!E.<>]6J* /'IO NO
M;-3!TF&Z@FO&G>"66$/<NPG&_>H&44R1L _S J<=J]!TNVN[35K2"[N%F>/3
M$0L%.2P*AB3GG)YZ"N@K-/\ R,R?]>;?^ABG$"36?^0%J'_7M)_Z":^<5_X]
MX_\ KG_[1-?1VL_\@+4/^O:3_P!!-?.*_P#'O'_US_\ :)KAQ>Z/JN'?X=3U
M7ZCI/]7+]&_]!CJOJ?W5_P"OH?\ HX58D_U<OT;_ -!CJOJ?W5_Z^A_Z.%5E
MW^]T_4]+-/\ <JGH68_NQ?5?_:E,'^H;_KD/_1)I\?W8OJO_ +4I@_U#?]<A
M_P"B37%T/0>[*UKUU#_KO)_..KX_UP_Z[#_T::IZ?#+<37\4,3RR&>0A$4L3
M_J^PKN?#O@/4-4U%DU&"ZL;=<R"1H_O$2Y"\^H.<UWXZ+EBI)>7Y(\G!8BE1
MP495';?\V<=%_JT_W$_]!DKJ/#W@/4_$-F\X9;2!HT,<DJ$B0-'C*XZX(KTK
M2OA_H&E2%UMFN3M"_P"E$2 8S@@8QGDUTL,,5O"D,,:1Q(-JHBX"CT %13PO
M\YY^+SY.ZPZU[O\ R.2\.?#W3M#O1J$[F[OU+^7*05"*P *[<X/3J:[#&.E%
M%=BV2['SM6K*K-SF]6%%%%!F%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %(P)4A3AL<$C.*6B@#S37/!GB34?$"W8
MN+:6=[%K9[[:L:*"LHPL9#.K9=?F5^@.?2M'1=$O]&\.^7-;VVGI+JL,PLH<
M.L:%XEVJPP!DJ6X'\5=U6?K/_'C'_P!?5O\ ^CDIQT8,T*^:_B7_ ,C9JW_7
M:7_T4*^E*^:_B7_R-FK?]=I?_10KIP'^^4_G_P"DLZ(?[M7]%_Z5$P1_R#KW
M_KL_\XZDN_\ D,0_5/\ TH-1C_D'7O\ UV?^<=27?_(8A^J?^E!KT8?[W+UG
M_P"DTS>I_N4?2'_I50LS];/_ 'D_]%R4R\_X_+3_ '7_ /1 I\_6S_WD_P#1
M<E,O/^/RT_W7_P#1 KP\-\-+_#4_*1]%BOCK?XZ?YP-!O]=)_OO_ .AI5$?\
MA=O^N _]'-5YO]=)_OO_ .AI5$?\A=O^N _]'-6&7_%/_"_S1T9E_#I_XE^3
M*MO_ ,>>E?[\?_H#U3OO^/BX_P"VO_HE:N6__'GI7^_'_P"@/5.^_P"/BX_[
M:_\ HE:^HP/^\2_[?_\ 2V?(YC_N\?\ MS_TVC5T_P#U-S_UVE_]&)574?\
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M^\/:;JFG>&'CN+>6RA;4;=DMKI_-D5<PA\,&.,R!VZG@]!FO0:SM;_Y!R_\
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M];3QC<>)[6:&VF@D$&U$M9WDM\XFR2Q"J,9B)#*2>-I&#GT6#_4K^/\ .I*
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M "+5Y_V$)OY+6>'5ZAUYU)QP;L]VCMZ***]$^*"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ I&)"DJ,D#@9ZTM% 'F&M:MXN/B0-:VE]:R&S;99K^]CW^7,<[@-A^819
MR=V2 .":T]!O+Z3PT!='4;F%M5A6VGO(RLOE!XCEPP4XW[P..P[5WE9^L_\
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MG'<&:%?-?Q+_ .1LU;_KM+_Z*%?2E?-?Q+_Y&S5O^NTO_HH5TX#_ 'RG\_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5RNJZ_J27VE"S@:VM9-4%G<_:H2'E!!P8
M^VTX^][5U5(RJV-R@X.1D=#0!XZWQ$UW^S)93J=E'R)6N# -L$GE2O\ 9",_
M>W1JN3\WS=,XKTBTN7N?$$1D@DB?^SPS!AQDLI('TZ5KF"$J5,4>"V\C:.6]
M?K5$_P#(S)_UYM_Z&*<>H$FL_P#("U#_ *]I/_037D7@#PM8>)H[O[<\ZBWC
MAVB)@N=R,#G@^E>NZS_R M0_Z]I/_037+?##1XK'PU%J22NTE_%&70XPNS<!
MBN>I#FJ1N>O@\0Z&"JN+LVTE_7I<["RM(K"QM[.'=Y4$:QIN.3@# S4]%%;G
MDMMN["BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %8?B'5+^UL[Z'3K=TNH[-YX[
MN:+= I'8X.2V.0.GO6Y00",$9%# \HOO'6OVUP#!/%)*-.246?D LX-JTIN,
MCG D 7 X[=:Z#2-:N=3\-1O<3_V@!JJ017T4:JDT:SIB0@<<]...*[4(@((5
M<@8!QV]*H:PJII\2J JBZM\ #'_+9*<=Q&C7S?\ $6"6Y\9:I#!$\LKSRA4C
M4LS'R1T ZU](5XU%#+)\<8Y$BD:..^EWNJDA<VYQD]JUPL_9XB$^W-_Z2SJI
M*^'K+R7_ *7$Z#X4:#=Z=HFI#5=/,+3WIEB$R#+(47!_2O1:**5:JZLW-]3E
MBK*P4445D,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH H+THH7I10!4U"\
MOX[9[6PMY$F:W>1+UT5X8F!Z,-P8GT &/>N6EU_Q)'IVAWD<R3&ZT*:Y:$6_
MSR7*PJX)/ID\* ._MCOX/]2OX_SJ2@#A-$UF[U+PN9+BXEU&/^TXHH+WRE3S
M(Q)$=Q P.&++D#^&N[K.UO\ Y!R_]?$'_HY*T:;V XWPQ_R/WB__ *Z6_P#Z
M :[*N-\,?\C]XO\ ^NEO_P"@&NRK*E\/S?YG9C_XJ_PQ_P#24%%%%:'&%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5S&I^)KA+W3$T^W4VTNI"QNI+F.2-E.#_
M *M2!NZ?>SCCC/;IZCE@AGV>;$DGEL'3<H.UAT(]#[T >>ZMXXURPMK\-#IM
MO<07\T*F0L\8CCMA.%)RN7;IGH,]#CGJ[2\6\\01.$='-@'964C&YE.,D8/X
M5H3Z7I]TCI<6-M,CR"5UDA5@S@ !CD<D #GKQ4!_Y&9/^O-O_0Q3B!)K/_("
MU#_KVD_]!-9'P^_Y$+1_^N/_ +,:U]9_Y 6H?]>TG_H)K(^'W_(A:/\ ]<?_
M &8UD_XB]/\ ([(_[G+_ !+\F=+1116AQA1110 4444 %%%% !1110 4444
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MCK<$>BRP:@MQ=W&D>?+IXM?F>0V[N),XR1O4 [2 O0@EACTZ#_4+^/\ .GX
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M / -O_CE)]GU?_H(VGX6;?\ QRBWF!HT5G?9]7_Z"-K_ . A_P#CE'V?5_\
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M /@(?_BZ/LVK?]!*W_\  0__ !=%O,#1HK.^RZK_ -!.'_P%_P#LJ/LNJ_\
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MC16=OUG_ )][#_O^_P#\11OUG_GWL/\ O^__ ,118#1HK.WZS_S[V'_?]_\
MXBC?K/\ S[V'_?\ ?_XBBP&C16=OUG_GWL/^_P"__P 11OUG_GWL/^_[_P#Q
M%%@-&BL[?K/_ #[V _[;O_\ $4;M:_YXV'_?U_\ XFBP&C16=NUK_GC8?]_7
M_P#B:-VM?\\;#_OZ_P#\318#1HK.W:U_SQL/^_K_ /Q-&[6O^>-A_P!_7_\
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M /&J/.U?_GQL?_ Q_P#XU18"_15#SM7_ .?&Q_\  Q__ (U1YVK_ //C8_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 4%Z44+THH MP?ZE?Q_G4E1P?ZE?QJ2@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH H+12J.** +</\ JEI]0++L4#;G'O2&
MYQ_!^M %BBJWVL_\\_UI/MA_YY_^/4 6J*J_;#_SS_\ 'J/MA_YY_P#CU %J
MBJOVP_\ //\ \>H^V'_GG_X]0!:HJK]L/_//_P >H^V'_GG_ ./4 6J*J_;#
M_P \_P#QZC[8?^>?_CU %JBJOVP_\\__ !ZC[8?^>?\ X]0!:HJK]L/_ #S_
M /'J/MA_YY_^/4 6J*J_;#_SS_\ 'J/MA_YY_P#CU %JBJOVP_\ //\ \>H^
MV'_GG_X]0!:HJK]L/_//_P >H^V'_GG_ ./4 6J*J_;#_P \_P#QZC[8?^>?
M_CU %JBJOVP_\\__ !ZC[8?^>?\ X]0!:HJK]L/_ #S_ /'J/MA_YY_^/4 6
MJ*J_;#_SS_\ 'J/MA_YY_P#CU %JBJOVP_\ //\ \>H^V'_GG_X]0!:HJK]L
M/_//_P >H^V'_GG_ ./4 6J*J_;#_P \_P#QZC[8?^>?_CU %JBJOVP_\\__
M !ZC[8?^>?\ X]0!:HJK]L/_ #S_ /'J/MA_YY_^/4 6J*J_;#_SS_\ 'J/M
MA_YY_P#CU %JBJOVP_\ //\ \>H^V'_GG_X]0!:HJK]L/_//_P >H^V'_GG_
M ./4 6J*J_;#_P \_P#QZC[8?^>?_CU %JBJOVP_\\__ !ZC[8?^>?\ X]0!
M:HJK]L/_ #S_ /'J/MA_YY_^/4 6J*J_;#_SS_\ 'J/MA_YY_P#CU %JBJOV
MP_\ //\ \>H^V'_GG_X]0!:HJK]L/_//_P >H^V'_GG_ ./4 6J*J_;#_P \
M_P#QZC[8?^>?_CU %JBJOVP_\\__ !ZC[8?^>?\ X]0!:HJK]L/_ #S_ /'J
M/MA_YY_^/4 6J*J_;#_SS_\ 'J/MA_YY_P#CU %JBJOVP_\ //\ \>H^V'_G
MG_X]0!:HJK]L/_//_P >H^V'_GG_ ./4 6J*J_;#_P \_P#QZC[8?^>?_CU
M%JBJOVP_\\__ !ZC[8?^>?\ X]0!:HJK]L/_ #S_ /'J/MA_YY_^/4 6J*J_
M;#_SS_\ 'J/MA_YY_P#CU %JBJOVP_\ //\ \>H^V'_GG_X]0!:HJK]L/_//
M_P >H^V'_GG_ ./4 6J*J_;#_P \_P#QZC[8?^>?_CU %JBJOVP_\\__ !ZC
M[8?^>?\ X]0!:HJK]L/_ #S_ /'J/MA_YY_^/4 6J*J_;#_SS_\ 'J/MA_YY
M_P#CU %JBJOVP_\ //\ \>H^V'_GG_X]0!:HJK]L/_//_P >H^V'_GG_ ./4
M 6J*J_;#_P \_P#QZC[8?^>?_CU %JBJOVP_\\__ !ZC[8?^>?\ X]0!:HJK
M]L/_ #S_ /'J/MA_YY_^/4 6J*J_;#_SS_\ 'J/MA_YY_P#CU %JBJOVP_\
M//\ \>H^V'_GG_X]0!:HJK]L/_//_P >H^V'_GG_ ./4 6J*J_;#_P \_P#Q
MZC[8?^>?_CU %JBJOVP_\\__ !ZC[8?^>?\ X]0!:HJK]L/_ #S_ /'J/MA_
MYY_^/4 6J*J_;#_SS_\ 'J/MA_YY_P#CU %JBJOVP_\ //\ \>H^V'_GG_X]
M0!:HJK]L/_//_P >H^V'_GG_ ./4 6J*J_;#_P \_P#QZC[8?^>?_CU %JBJ
MOVP_\\__ !ZC[8?^>?\ X]0!:HJK]L/_ #S_ /'J/MA_YY_^/4 6J*J_;#_S
MS_\ 'J/MA_YY_P#CU %JBJOVP_\ //\ \>H^UG_GG^M %JBJXNL_P?K3A<9_
,@_6@"%113P** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img158215518_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img158215518_15.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &6 N0# 2(  A$! Q$!_\0
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M#P 3U/O6=;^//$/BZU\'Z;H]W!I=]K%O-/>7?D"41B(E2%5N.64]>F15^_\
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MC!511U))X IX((!!R#T(KC]'GU2+Q=JGAC6-0&K6IT^*[BFF@2-PKN\;1L$
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MY< %U!92I( SS@XKKZ* ,3PWX=&@Q7<DU[+?ZA?3>?=W<JA3(^T*,*.%4
M4>%_#W_"-V%U:_:OM'GWL]WN\O9M\QRVW&3G&<9[^E;=% ',Z)X,M--\#?\
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M9I9+02Q74<8^4M'N!# Y((;OCFGP> HX$L'.I2RW<6L?VO=W,L8+7,GENFW
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *CG_P!2WX?SJ2HY_P#4M^'\Z *HZ44#I10 Z+_7K^/\JN53B_UZ
M_C_*KE !1110!R_Q$TB;7/ 6JV%M:I<W#QJT4;R!%W*P8$D\8&,\\<5Y]I>L
M^)/MME%/X*\'QCS45Y8;RW#*,C)50Q.1V KM/BWY/_"L-:\^Y>W3RTY0'+G>
MN$X[,?E_&O,M$C\%&^TXQ_"KQ'!/YL>V9DE9(VR,,26Y /.<4 ?05<GXB^(W
MAWPQJ?\ 9^H3W!G5!+-Y%NT@@0G :0@?**ZRO*?BKX@T.33M:T&?4IM)U&.V
M$_S0@+J*[3MB#=6!/!Q@C\Z .N\0_$#0/#?V07<\TSW<1GB2TA:5C$.3(0.B
M^]&J_$#P]I.DZ=J,ES)<1:D,V:6L32R3#&20HYX'7/2O.$UJ#1?'&FZUXAB3
M2K6]\)+%#&X(2.0$$Q#/?';KR!67X8<>%Y_AKJFOM]EL!87D8GF&%B9RS+D]
MLJPQ0!ZS<_$3PW;>&K/7OMCS6EZ_EVR0Q,\LK]"@3KD8.:UO#_B'3?$^E+J6
MES-) 6:-@ZE61QU5E/((KPK1Y%TR+P;XAO<V^B'7[^832*0B)* (V/H"5:NN
M\%66IZUX9\;7&@7WV(ZGK,\FG79R%QE<N..AP10!J_'/_DDVJ?\ 72#_ -&K
M73^!O^1!\/?]@Z#_ - %>'_$7PE\0=*\$WEYKWC!-1TY&C$EL"V7)< =5'0X
M/X5[AX&_Y$'P]_V#H/\ T 4 ;]%%% !1110 4444 %%%% !1110 5YOJGQ2U
M#3/$":.W@C5Y+B=Y5M=KK_I"Q]64>F.?QKTBO.?%=Q!'\9O BO-&K>7>C#,
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M/_DXCQ+_ -@U/_0;>O4:\NT/_DXCQ+_V#4_]!MZ]1K6KNO1"04445D,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKG/%/C;2_!XA;4XKYDE5G
MWV]LTBH%QDL1TZ]ZYF\^,FCR:<1HUE?W6K3[4L+*6V:,W#-G!&>JC&2?\: -
MOQMXR;P^EOI>DP"^\1:A\EE9CMZR/Z(/UQ]2'^"O!J>&;:>[O9S?:]?GS+^^
M?J[?W5]$'8?Y$'@GP=-HSW&N:Y.+WQ+J'S75QU6)>T4?HH_7'TKLJ "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ J.?_ %+?A_.I*CG_ -2WX?SH JCI
M10.E% #HO]>OX_RJY5.+_7K^/\JN4 %%%% &+XM6W;PM?B[U:72(-@+7T3[6
MAPPP0?K@?C7E7A;QUXN?7H--TB9O&.D>8$DU![)K8Q+G!)<_*V!D\Y)Q7K'B
M>^T73O#US=>(1$=+7:)A+$9%.6 &5 .><=JT[=84MXUMT5(=HV*B[0![#M0!
M)1110 4444 %%%% 'G/QS_Y)-JG_ %T@_P#1JUT_@;_D0?#W_8.@_P#0!7,?
M'/\ Y)-JG_72#_T:M=/X&_Y$'P]_V#H/_0!0!OT444 %%%% !1110 5SWC7Q
M/%X2\,7&I%/-N3B*T@')FF;A% [\\GV!KH:\STW_ (N#\1Y-7;Y_#_AR1H+(
M?PW%W_')[A>@_ T =%X \,2>&O#W^G/YNKWTAN]0F/)>9N2,^@Z?GZUU50M=
MVR,5>XB5AU!< BI$=9%#(P93T*G(- #JR)?$NF0S-$\L@=6*D>6>HK7K%U J
M/$ND@D=)?_0: ->&9+B!)HR2CJ&7(QP:R[W_ )&33/\ <E_E5Z[U"TL(]US,
MD8[#N?H*\[OM1O9]5:X,LJR!CY>"05'8#TXH [N_U9;>46MM&;B\;[L2_P /
MNQ[5S \'7[W"EY(51N68$G;[8KJ=(L([*QB(BVSR(&E9CEBV.<GZUH4 -CC$
M421KT10HS[4ZBB@ HHHH **** $9@JEF(  R2>U8S^);)]5TVRLI;>\6\DDC
M:2&=6$11"_(&<YQCM5;QV)3X-OO+W;?D\W;G/E;UW_\ CN?PS67>'1O^$W\*
MC33:^81/Q;[?]7Y+;<X[=<?C6L()J[\_P1I"*:N_/\CH;37K5M%M=1U&>SL!
M.N<-=HZ ^@<'#?A5YK^S6S^V-=P"UQN\\R#9CUW=*\VTFW271O#$MMJ5G;ZG
M'92>5!?1%X94W_-SV;IT.<4ZTGM+B71DO+.VMM/BU:YCN1#(7M7GV91AGHI8
MG Z @U;HJ^A;I(]%AU.PN;1KN"]MI;9<[IDE5D&.N6!Q38-6TVZMI;FWU"TF
MMX03)+',K*@ R22#@<5POB&31#JBI:VZ+:KJ-J=5F7_4,,-L!YQP<;N!U&:7
MQ3]B_M6[_LKR\_V'>?;?L^-NS9^[W8[YS25),2IIG<1:QID]P]O%J-I).@):
M-)U+*!W(SD5C0>,K2]M+B:Q^RS/#>BV*&\C3*;]HD!/8\D#OVK,N]/L[2Q\&
MRV]M%%(+R!-Z* 2K1/N!/?..?6LN80+X?U%(Q&)%\2$$+C('V@8_"G&G$<81
M._FUO2;:3RY]3LHGWE-KW"J=PZC!/7D<59%S ;C[.)HS/L\SRMPW;<XW8ZXS
MQFN*LM-L[BT\9SSVT4DK7<\>YU!.T1*0!Z<L33/#UU%!K>AO<SI'YGAN$!I&
MQN(92>3U/>I=-6T)=-6T.S?4K"."6>2]MDBA<QR2-*H5&'52<\'VJAJ'B?2[
M+0[G58KRVNH80?\ 4SJ=[=E!SC)]*XBVU*SN"WE6EM>2W6NW3V<EU,4@3"CY
MVQG=P>!@]:K73&5O&BN;!F&G1EQ8@^4'&[UZL >3Q5JBKZ_UJ4J2OJ>AV.MQ
MZA>VT5M]GEMY[0W FCN48Y#!2H4<D<G+= 1CK5JWU;3;NY>VMM0M)KA/O11S
M*S+]0#FN%UHRFX<Z85,A\,S;/*Q_ST3=C'?K^-2:C_8_]A>&_P"QOLWVW[5;
M?9OL^WS/]O..<8SNS^-3[).PO9H[,ZWI*RQQ'5+(22$A$-PF6()! &>>01]1
M5^O,DT^T;X:^(;AK:(S&XNG\PJ-V5D..>O&*]&LF+V-NS$EC$I))Y)Q45(*.
MQ,XI;'FNA_\ )Q'B7_L&I_Z#;UZC7EVA_P#)Q'B7_L&I_P"@V]>HTZNZ]$9(
M****R&%%%% !1110 4444 %%%% !1110 4444 %%%% !17AGC;XI>+M"\1ZI
M;Z3+H]YIMDX\V40L?L^XX".Q8!G]ESW]#C6T37O'/Q(TB!+"2#1],.4N=8C0
M^9<$,01 AY4=LGG^5 &?\9?&\T6L0>$$=DLKF,-=&UE4S3DG AZ_NP>Y/8],
M=:_P2LKL^)=1DOH/[1-G;I;0ZF9C(EKCK;H3P<9Y*\<>AKT:Q^&/A6RT"ZTA
MM.6Y2[7%S<7!WSS-UW%^H.>1C&*Z+2-(L="TN#3=-MTM[2!=J1K_ #/J3W-
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M/_DXCQ+_ -@U/_0;>O4:UJ[KT0D%%%%9#"BBB@ HHHH **** "BBB@ HHHH
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M44 %%%% 'EWP'_Y$>]_["4G_ *+BKU&O+O@/_P B/>_]A*3_ -%Q5ZC6M?\
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M/_",?8E^S98[/.^3.#G=G[U>K6]O%:VT5O"NR*)0B+G. !@#FLJ5&I&]Y?\
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M%%% !4<_^I;\/YU)4<_^I;\/YT 51THH'2B@!T7^O7\?Y5<JG%_KU_'^57*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%?P[X9LM)DF69K92OF*NT-\Q(XYQUK8H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "HY_\ 4M^'\ZDJ.?\ U+?A_.@"
MJ.E% Z44 .B_UZ_C_*KE4XO]>OX_RJY0 4444 %%%% !1110 4R26.+'F.J9
MZ;CBGU!<6=M=A1<0I*%Z;AG% &==^)M/L[L6[NSG^)DY"UIQW,$I CFC8GH
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M.EW-OI][(\-E?.RD2.,XRH.5!P<$]:=HGB9X?AM8Z_JA>XF:W#.(U^:1R<
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MV&I1--"LK,JYZQ@EU!Z;A@\=:=X?\46GB)+66T:+RKBR6["%_P!XN6*D%<=
M01G/4&LZ/PE=+8V,#30 P:M<WSD9Y27SL <?>'FKGZ&J^E>"[Q?L:ZG<*B6^
ME16!-C<2(Q,;DAMP (!7&1ZT 3WWBS5HM6UFVL=(M9[?2MGFR2WOE,^Z,2<
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+1110!(!1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img158215518_16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img158215518_16.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1I84&AO=&]S:&]P(#,N,  X0DE-! 0
M    &CR^9Q8X0DE-! 0      %H< 5H  QLE1QP"   "K@ < E  "')R,CDS
M-S0Y' (% #E-:6-R;W-O9G0@5V]R9" M(%1A;F=O("T@06UE;F1M96YT($YO
M+B Q('1O($9O<FT@4RTQ+F1O8W@X0DE-!"4      !":XE'0J?SP#J-"FTJA
M"EAM.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M           !!    1L          0                         !
M          $;   !!                      !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   !!     !29VAT;&]N9P   1L    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   00
M    4F=H=&QO;F<   $;     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    $.$))300,      _#     0   *    "3   !X  !
M$Z    ^G !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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M>P/ (W"8<(/S:DI__]#U5,2.)U\$Z!=AXUUK+K:P^RL$,<>0"YEL?]N4U/\
M^MI*6MR:,:JMUSMC70T&"=8W?F_R6JG=U3I[[*B;@:V?I'0UY,D?H>&_F^][
ME?\ 2KL8S> Z!I/:1L,?V7*(PL0/#VTL#@[<"&@>Z-NY+13*FVNYI=6[<T.<
MV=1JT['C7^4$2$S&-8"&@ $EQCQ)W.*DDI: E"=))31ZGTK&SZ7->T"Z/9:-
M' ]I</=L5?HF9DN]7 S!MR<70$\O9V?Q_P"=K56'U<C#
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                     /_A0!9H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53
M>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T
M82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V
M,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI21$8@
M>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS
M>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O(CX*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y04V-R:7!T
M-2YD;&P@5F5R<VEO;B U+C(N,CPO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @
M(" \>&UP.DUO9&EF>41A=&4^,C R,2TP.2TR.%0P.#HR-3HR-"LP-3HS,#PO
M>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(Q
M+3 Y+3(X5# W.C(Q.C$Y*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @
M(" @/'AM<#I-971A9&%T841A=&4^,C R,2TP.2TR.%0P.#HR-3HR-"LP-3HS
M,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^
M"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @
M(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^
M"B @(" @(" @(#QP9&8Z4')O9'5C97(^06-R;V)A="!$:7-T:6QL97(@,3 N
M,2XQ-B H5VEN9&]W<RD\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B
M"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE
M;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @(" @
M/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M
M9&5F875L="(^36EC<F]S;V9T(%=O<F0@+2!486YG;R M($%M96YD;65N="!.
M;RX@,2!T;R!&;W)M(%,M,2YD;V-X/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @(" @/&1C.F-R
M96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \
M<F1F.FQI/G)R,CDS-S0Y/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E
M<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@(" @(" @(" \9&,Z9F]R;6%T
M/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @
M(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @
M(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+W-4>7!E+U)E<V]U<F-E4F5F(R(^"B @(" @(" @(#QX;7!-33I);G-T86YC
M94E$/GAM<"YI:60Z.4(Y1$0Q.#8P-S(P14,Q,4(T,S9$1D5#.#,Y0SA%0D0\
M+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$
M/GAM<"YD:60Z138U-$8Y,S0P-C(P14,Q,4(T,S9$1D5#.#,Y0SA%0D0\+WAM
M<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M
M96YT240^>&UP+F1I9#I%-C4T1CDS-# V,C!%0S$Q0C0S-D1&14,X,SE#.$5"
M1#PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ
M2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z138U
M-$8Y,S0P-C(P14,Q,4(T,S9$1D5#.#,Y0SA%0D0\+W-T179T.FEN<W1A;F-E
M240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,#DM,CA4
M,#@Z,C4Z,3@K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I
M;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA
M8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @
M/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HY03E$1#$X-C W,C!%0S$Q0C0S
M-D1&14,X,SE#.$5"1#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @
M(" @(" @/'-T179T.G=H96X^,C R,2TP.2TR.%0P.#HR-3HR-"LP-3HS,#PO
M<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E
M06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O
M9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D
M/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV97)T960\
M+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M
M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O
M(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N
M9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE
M=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z.4(Y
M1$0Q.#8P-S(P14,Q,4(T,S9$1D5#.#,Y0SA%0D0\+W-T179T.FEN<W1A;F-E
M240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,#DM,CA4
M,#@Z,C4Z,C0K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I
M;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @
M(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O
M;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=%)E
M9CII;G-T86YC94E$/GAM<"YI:60Z.4$Y1$0Q.#8P-S(P14,Q,4(T,S9$1D5#
M.#,Y0SA%0D0\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS=%)E
M9CID;V-U;65N=$E$/GAM<"YD:60Z138U-$8Y,S0P-C(P14,Q,4(T,S9$1D5#
M.#,Y0SA%0D0\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E
M9CIO<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#I%-C4T1CDS-# V,C!%0S$Q
M0C0S-D1&14,X,SE#.$5"1#PO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@
M(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" \+W)D9CI$97-C
M<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*
M(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N
M8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @(" @(" @/'!H;W1O<VAO<#I#;VQO
M<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D93X*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_
MVP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0'_P  1" $* 2$# 1$  A$! Q$!_\0 '@ !   & P$               (#
M!@<("0$$!0K_Q  _$  !! (! P,# 08$!0,#!0 ! @,$!081  <2(0@3,2)!
M410)%3)A<8$6(Z&Q)%*1P? 70E-78M$E)C=SX?_$ !H! 0$  P$!
M       ! @,$!0;_Q  U$0 " 0($ P<"!@(# 0$      1$"(0,Q0? 246$$
M<8&1H<'1L>$%$R(R4O%"D@8S8A2B_]H # ,!  (1 Q$ /P#[^. . . . 0>
MHDJ(^VBH=OG7P-^#_P#GQR2ICW7S/H#'+K+UBM>F?4;TY8E%BU3E1UDZJ7F
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M ',55Q2^K14DK+W]R?RE' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' )9(_*AM1&OYC[[^R?_ #SXX!2DN[9=G,1:ZQC2'&+1
M,&P9CRV7EQG/;+JHDI+:UF,^I(VA#R4+[?.OOP"IPM7:#X^3W$JT=IWL'Q\=
MH!/V_GP#JQ9T.<EQV*^W(2T^67%-K"PE]&PXR3\)"!HD'1\D^. 34+9='N)4
MAQ "@E2=+! 60KM4/I5]20% Z[5 I'D<>X+ Y"AWI/EAR>E09&*9?:L)RO'
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M-J[:^OMUS-U&#C5TNI4-PIA)S"2T\3T6[&*XXAE,UHO*;6X&PZ@N%I*B"Z$
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M):\_+*(R/  =.AK:"3_,E>R?^O\ ^!XY3G2BR)O ' ' ' ' ' ' ' ' ' '
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M1W+E=37$"RL,9O6H%Y#CNK#]=,>BJ>;9DLK;0M(<9)=8>;4XP^@+6VXX&U)
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M-("5N'9) 2@[_(*G#_,I3[H"?^4>!XX.8G\ < < < < < < < < < < < <
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M.SE641'FS?"VH@.'SW#1T4D $ ((V"4$E25$A*R?.SK8WUGS,W:Y$;FBE!)
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M<^H(2D^%*.T@"]#9*D))&OGQ_0D?W^/GQOYT/C@$? ' ' ' ' ' ' ' ' '
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M9.W1?18SON.] J"E ;V0.[X!^- _.OO]AK@XCL\ < < < < < < < < < <
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MGJ''7$179J6Y,:%^GG.1.YU+UE.0\E# ;UW[&33._:;W\]H)\:T3YT!H: ^
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MUM2?9*2E2A$Y\#)UM7<A*M$>-:/\B1X_(.M@_<:/WX*1\ < < < < < < <
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M3#:FK/I/+Z;Y,E=7$Y?KGN]HT-@"%$N*!'V/VU\$ ?Z<VF)/X X X X X X
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M2Z0I2M6[$*[4I*E !A>R0D*/P=[&QK[C@%2)^!X(\?!^?_/]?SH\ YX X X
MX X X X X X X X X X!UY">Y(':E6SVZ4/X@HA*D;_]H6@J!/P-#9' -%WJ
M,R7)L6]9,1='.F64MW)\<#,=<1UT18JH\5M4=<EZ.&6XK!6I0*0\HJ[?94I0
M5VSOWZ[AGK=CP\+\MUU-3PW6KG+)N?1VRU*M_:4V[CUUT_C&#(9EMU2G#.$_
M3<D2?:=4W^@!/8EA2E NJ[%+!*0CQLV]^6F?27OZY<-,4\=*YV<VS:AKN23E
M/,V@^G=E+'1CIPVV^W*1_A2M/OM-*8;*RT"H)0H)*OG164@DI/!H;EM]?30O
M7P0< < < < < < < < < < < < < < < < L+U\ZGY-TEPU.68ATZMNIUD<E
MQ^EEX_2KLH\R'76TQ4>=?N&GQ_([.5&J6@'EQ&*MQ+Y6A3K[3 4ZD-[WW%"]
M*>LN6=5LLSZMR#I5?]/J3 >H$?'\3O+]BUCG/JAZI,QV\APKJBI'(;*)(5"4
MU7_O-CO 4']+4E(&6+8TA(WOY^P3KR?ITD #M_A\ ;UL^> 1\ < < < < <
M< < < < < < < DNI4K7;O0"NY(T.\?3]'<2.SN.B5#9T" #ODO*]=Q[KQ&G
M7?7?-&BSUTR;")ZEX(3)<F>RQB<YB"VB+ *TDL!#*9?NAQ?<L):2X=*4HGN
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M:UUA(JKL0K1B%.BRGJV9^F6O]+/:8=<7#DEM0<#$A+;I1]79K@%:)(*4D?!
MX!%P!P!P!P!P!P!P!P!P!P!P!P!P#KO_  GR0=* /V'P23KSOM"NW7W.N-[W
M[DFZ7.9W[Y>+1I\_:4*]K*NF[JT1WFS D.-H=$@+0(\QQUU:WM^R.Y';VH20
MO:?CR!S577#X7J_;ER\_CKP>R8>)2\1MJI9QD\YNN40Y>:Y-F$G2B6]E/7S
M[27%9M9+M_!:+7N%"2TT\A* AU0*B&4@*3]BI.O@<RHIX5T:4>IAB8^(FJ5E
M3W)/+.;I^O6Q]+4-/8A"=%/:VA)23O6AI(*ON0 ?^O,S1+;EZW?.=>AW. .
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MUIE=7\\Y-\K0'<3H!1!)&]D$D; T  GP"!K?GQXYM.$G\ < < < < < < <
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MM)U1993(>Z_U;3"PXI+[F$8BAE0:[?=*7%+""&RM(<(4>PJ2%:V.)POXU?[
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M-]_A96#IG6%M+SK#8]E)E-Y7CF3NH-=@7^+I4%-<ZVP;01'I*Y9:363FK?\
M7<EO/6%"\)?WI>8[_'E)B_28_P"O._Q'I!0]0(F15F2XG=X3?=3\BQC)NEL6
M%G*QG?2>TM*F"&+20\JKH<9:ZC0,CBR*O'!=K9+=$_;L3(3[[YZ6]]^2\KE#
MGK[+PSY&T*,DI:'<' H@$AW1<\I!TLI4ILJ'PKVB&P00D:UP4[' ' ' ' '
M' ' ' ' ' )$A*EM%*?XB1HZ4>W9T5!*%)42 3K2@ 2%$@))X!I;RKTU>MK(
M^J'4E51=Y#0X=?\ 4G.+6JLK'+WUTZ<6N.L-5DN,JA-4G7=-Y;1(&$M3H*\:
M3BG2?]R1B:6'9WZ'0^D/;USWY%X\0Z-^HS"'T-YAC&9]7Y;2;%NHET/6!>#X
M[49 C+YEF;PPKK/;>[8P^TIEQ44M983LXR"N;0NFN(R60B>0ON]_3?(]G#>A
M7JCA8WU,IL[R.PL;/++6DS[&;'%>IEB[%K+^'<OJLL8F?OJ%3SJ:#/K9$%QR
MIH'I>+H142$IFA^:&'A(W?Y_HN#UHI/6=)ZLQH_2&PI(_2&SK*5F=/?D43=W
MCUA--ICN2OL1+/\ 3/2TU;%W SNL2TW($Z7B:Z=2F#9(;<"^[>>?ISR,:+'H
MQZ[YJU5\O(LQKZR3&I+6%(PS.L+8,#)/_1>3CF9#)I.0V*K5V ,SBXS*Z=Q,
M8:=JV;N/D]QF=?(@S*F0&][L+STWYSZ'>R;)/6O<Y1:T>!WN62X</JIG. 8O
M,K:G!X4-]-;B^6YY3WO4.ZO(;M6YC&,9+F.+=&\[BX67;*X<Z-9'8X?+%ID+
M%>AM%C>XYWT+R8)3>O%O"^KZ<YL*167/R:'_  *W ?Q8H*TW\1S-)&$3VEJ8
MA54C%?U47!*[J!"3.BY&E$K))YJGO8B"+7//7VC3E.1:G(\!_:"Y796]2Y86
ML#"EXPVW4(EY1@$&]<GJI%-1S9S\3E5[T3+8]PM]5Y*KI;N)36E1EU#3'M+<
M6+Z];;]#*#TQT?J3H;S-:_K@Y93\<9:QUK"+*=;XC);2W%IX4>P@0:['43;I
M;3<UN2[*O<JN1-LWE@-54=L&0Z!F3P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P
M!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P"$(0G6DI&N[6D@:[SW*UH>.Y7E
27Y/D[/ (N . . . . . ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img158215518_17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img158215518_17.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1?.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %[*^8&8X0DE-! 0      %H< 5H  QLE1QP"   "K@ < E  "')R,CDS
M-S0Y' (% #E-:6-R;W-O9G0@5V]R9" M(%1A;F=O("T@06UE;F1M96YT($YO
M+B Q('1O($9O<FT@4RTQ+F1O8W@X0DE-!"4      !":XE'0J?SP#J-"FTJA
M"EAM.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
M  !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R
M8F]O;       0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O
M=6) ;^            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M            0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M                4G-L=%5N=$8C4'AL0%>            *=F5C=&]R1&%T
M86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT
M1B-2;'0               !4;W @56YT1B-2;'0               !38VP@
M56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .
M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M             #^    X0DE-! T       0   !X.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         "
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      ,U    !@
M            Y@   CX          0                         !
M          (^    Y@                     !
M     !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG    Y@    !29VAT;&]N9P   CX    &<VQI8V5S5FQ,<P
M  %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M   '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I
M9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP
M90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   .8
M    4F=H=&QO;F<   (^     W5R;%1%6%0    !        ;G5L;%1%6%0
M   !        37-G951%6%0    !       &86QT5&%G5$585     $
M  YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
M  EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U
M;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E
M $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M        #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N
M9P      .$))300H       ,     C_P        .$))3001       ! 0 X
M0DE-!!0       0    %.$))300,      TZ     0   *    !    !X
M>     T> !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L
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MWVEWML/INV;T0+4ZB2RW=6S=EKF].N<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUB1"4G>2E\'1V#,XMN'Q&24G-V)R)C9'4V>RM__$ !T! 0 !!0$! 0
M       ! @,$!08'" G_Q  \$0 " 0($! ,&!@$$ @$%     0(#$00%(3$2
M05'P!F%Q!Q,B@9&A%#*QP='A\14C0E((%C,7)&)CLO_:  P# 0 "$0,1 #\
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M[B,?UZ*R9!A:*(Y;OW]J&P5D?@+:&R%493;MG63.!]U3L,A[I$'?"XCP?^\
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MJ@9FG+MW\OZ<NG[_ +CGV^NN[6ORZ/HO 479=FJ*QILQ>U7$V<F33_VD<_N
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M - - - - - - - - - - - - - - - - - - - - . ^@>./U?3\- 0X /
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MZ : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
MAP CR(!SV[\!SV[A^P>X?3Y: C^_[?.@&@&@&@&@&@&@&@&@&@&@&@&@&@&@
M&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@(<!V#@. \!P';OSV^G?O
M^.@(Z : : : : : : : : : : : : : : : : : : : : : : : : : : :
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M^D)A/F(_/CYB/@//?QS_ %_LU7!MK7Z]>^^8.>J@- - - - - - - - - -
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M(MP+ZBROI)MQ,=4 ,&]]5IOJ7XT T T T T T T T T T T T T T T T T
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M&<H1BHR=[I-=>A4I*6RDK6W5M?+5\K&1>M62- - - - - - - - - - - -
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MZ0Y$3"8"@/S'IX/U 4O@PF$H=A$.0T"6ME%MM_\ %:MW^KTOZ_9\D5.1*(J
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M%*FXP@[<<5>75-M6O8SJ4PGNE6,"RVZE-(P]NEMBZ,31X'Z":QF,'S ![=^
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M:;3NFWYJ_-=_K<J\[>1,$I1\E ?Q -39+9) <!] _9J01$ 'R #SYYT!
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M.<\$36+Z\^364*@FSA)N1<*I2CLIP.H9N@1/E 2KE*4@B0 OI;OO[F?@^!_
M?W\#_8/X#H08M9SV?;9]R,U6['G#$59R#-U1NJUA)*7"0;.$XM9RD[<0;]>-
M>QX2\&X>((.EX*=*]B%'"*:PLS*D*.@.$;LRVO0V;FVXV-PO3([,S5HFV:71
MHU707;>A##74)%I#D<?824XUKIC0+>?0B4YM.'$8TKPK,11T!WNZ, #&]7$
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MP1  #P !SYX#CG4@"4H^2@/X@ ZBR6R2^0 %* " %  'R  ' _B&I   #L
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MGWV'Q^(6"AK4HQQ%54H1<7&RII\*=^'1:_0^Y\%XC]E>"_\ '_+HYWX8P_\
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M4XB7[-E&,<!"F J:(I@4VG;':-GH@' @ =N!#@. _9SV_;VT!UYC&$Q>Y>D
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M8GMQI=@8GFK3!V^8DXV5+8XF_)3:GO3*,,V.F=JC2*G#O8<5!$R,+;(BV1Y
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MP8B9BE$?D!N.>?D/;P/'(> $.=2-;635[?+Z?4E@'' &(!A$O FZA >/F/D
M#D>X@ =OD =M-+W6]DGSZ^7*[_DB\[-6Z;-+162VL^77Y'5N*]7W"QEW$-%.
M%U.DYEEX]JLJ)N0-R951(QQ,4>/B$1'P'/8 U;]U2;;=.#;=VW%-MWOO;JB_
M'$8B+BXUZT+14;1JR2X5=J-D[-)O^M6=DDB@F7I(BF)"AX H 4H!Y*/;C@!^
M7_/57#'1<*LK6T6GIZ%'O&TW[Q^B;LE\OWOL==*0D%/L5H^6B6,I'N"=#ED_
M:I.6RI>>0*HDL0Q#E >X 8HA^SM3*%.I%TYP4HN]XR6CM^ORY&1A,?C,'4C7
MP>+KX>K'6%6E4G":>UXM;/['3Q&/:3745$X*I5Z*2<G*HY280[%LFJH4#%*=
M4B2)0.<I3"!3&#D $>![ZHIX;#T4_=T:4$^D(K[VO]_T1E8O.\YS"4)X[-,=
MBYTU*,)5\35J.*DTVHWD[7:3TYK0[Q&OP@=0C&1X@8P !19MQ H@'( '*0B
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M<)EXY[=/Y\L=\DX_T3 '!@\B CW[Z RDT T T T T T T T T T T T T T
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M!L=,HU[&=)$)^GD:(K+J.=6MK#C$$/!M7$D@U9'?2/K(NP<@"8%T\0;><'8
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MT5Y622222L=X4@%$3!SR;CGG[N ^GW:K,5))M]3GH2- - - - - - - - -
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M^K@/ Z#OO^SHV.]+&\C)S40SHNX!>1KZC-*79I[>\L"X8GD$CKL@5)^37/\
ME*29S)A\(\%$>^@OW9G=?PM*9_)GN-'OY#;QE< _5U5KD>/ CXY = /X6E,_
MDRW'?T><K?X:T _A:4S^3+<=_1YRM_AK0#^%I3/Y,MQW]'G*W^&M 3&&[/'K
MVPU>MNZIF>MN[A/-JU"O;;A7)-<AE)EVV>/&S9S,2E>:QC0%D&#LQ3.'B7)D
MA#@0[Z R=25!4!$/'80[ 4>DW/')>LQ@$.!Y$P%Y_P T.- 3= - - - - -
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M&@ ^!X\_+0%*[=I,6:[UP!P2;(*+J@F0RI^A(AE#]!" 8YS=)1Z2E 3&'@H
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M 2_2 1$1$>1^G =Q\C^(Z Z-.K5U([Y0D'#E/)N"NI$X1;$#2#@G2*:[\P(
M+Q5,2@9-1QZAR& #%$! !T!.0KT,TD'DLSC&#23D2E3D9!LR;(OGQ$R"FD5T
M[32*X<>B7@$17.IZ1>2DX*/  &C%E')"U8MT&:)7"RIDFK=)NCZ[UPLNY7!)
M,I2"JL[46>.A !,NJN==0QE%!,(%:#GI*)2D$1('''X 7M^/<!,;L4 'J\:
MK"CU% WU !T!1NV#5^BJW=HIN&RY#)KMUTR+(+IG#@4U4E2F3.00[&(<IBF
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MS<Y)M9!:%8ND?33:$;-''2*@'#0?+Z?W8M(;V0=IF8&;8V[/#25FZC6Z]5<
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M&X<</>C @U,FO7?S7T5&F*E5==70Z+*F1"02,0@&(F(I#R0H&$#++0#0#0'
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M#0#0#0#0#0#0#0#0#0#0'$Y>H #L @(" B'/ AY[?> B'/RYT!)%N @ =9@
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MU0UEAX*:B7B2["S1,?-0YA.""[N*EF:;YD\3;K="Q2*M%2*\&(!R"!B'*50
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M"'ST!/T T!Q$O;@!$._/UX\^/G\_K^&@)1T . _%QSSV$H&+W^1@'@1 ![@
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M4I0,;@@\DY,8>GD1'0%00A4R@0@<%+V*'(B !SR !R(\%#P4H=BE "E "@
M!3^F1118QPZA3,0" (B)0 I"*%'HYZ1,4YC& P@)@YXYXX#0'-N(BD7D1$>1
M[B/(CW\B(]Q'ZB(B(_,= 3] - - - - - - - - - - - - - - - - - -
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MQT@(B!2]@^ O!//P]QY %X,8 $ $"F2X'@.>5 (0XB;CJ$3%.8.1$1 !["'
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<*SZ0=.'CHZKA=50PD]7H!H!H!H!H!H!H!H#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img158215518_18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img158215518_18.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %[!'4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!_#T)HLPYD;-%)2XI#"BC%&* "BC%&* "BC%&* "BC%&* "BC%&* "BC%&*
M"BC%&* "BC%&* "BC%&* "BC%&* "BC%&* "BC%&* "BC%&* "BC%&* "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMW#YCVSB2([B-K=<\?2C4M)LM6BCBO8?-2-Q(HW$88=^*Y[4=0\0W^H:G::
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M@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQDC:0= Q8$"NCHH X&];Q)H_@J6?2],FGUK4+MI947!:!78Y/)P2JX ]ZM>
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM;^ZJNGS3W%C%+<Q>5,PRR>AINHWT6FV3W$H8A1G"C)- %S=0&S7/Q>)HY=
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M?MGVTK;W@\\@Y8^4N>O/'3\*N^$_!OAK6X]:N]3T.QN[DZM=*998@6P'XYH
M]*5E=0RD,I&00<@BEKB/ \0TC7_$?ARWD=]/L98I+978L8A(FXID]@>E=O0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\ND^(],@LKF[DN1'+8%W7>V2-V[FO0** ,+PQX;7P];7)ENI+V_O)?.NKJ0
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M/9(?O2A#M_ UUDL8EADC8X#J5R/>O%;K2-2L;TZ?;ZOI7V0%DWNXW!2><^]
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M>H?]?LO\Z .HHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAS\I]ZGTGP=H>C7"W%G9@3+PKL<E?IFM[;2XH !2T44 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#(\5/ GA356N86F@%K(7C4\L-IX%>5^&]3^+47A_3TL?#VB2V0B7R'G
M?#F/MG#@9Q[5ZIXI&?"NJ RS1 VS@O"NYUXZJ.YKYM@OWTNWA@C\9>,+6W5@
MB)]D=%&3P!\] 'U+;F5K:(SJJS%!O5>@;'.*DJO8DG3[8EG<F)<LXPQXZGWJ
MQ0 4444 %%%% $4]O!=0F&XACEC/5)%# _@:\R^&L4<'Q#\?10QK'&MY&%1!
M@ 8/05Z'K%_<:;ILEU:Z=/J$JD 6\! =LGMD@<5YK\*;J6]\;^.;F>TEM)9+
MJ-F@E(+1G!X..* /6:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUD>!94FTZ^DC8,C7DA!'<9K9?1--DD,CV43.QR21UK&\#1K%I]]'&H5%O90
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MD8?[3GD9]JZWP_\ #?PMX<<36FF1RW?4W5U^]E)]<MT_#%=1%%'!$D42*D:
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M.-[V-$%%%%0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 0S*9+>1 <%E(SZ<5X^BW]AI5WH!\-_:KB5V"W:C(.3U)KV&0 Q.'. 5
M.3Z5XU=ZS?Z1K!A\):C<:F?,.^WD0E5YYYH ]3\-V,VFZ#:6MP<RH@#>U:]4
MM+FNI].@EO8A%<,H+H.QJ[0 4444 %%%% !7,^"O^//4/^OV7^==-7,^"O\
MCSU#_K]E_G0!TU%%% !1110 4444 %%%% !1110 4444 %%%% !132:,GTH
M4TQG6-"[L%4=2:\^\<?%2T\(ZFE@+5KB;&Y]IZ"K6D7UWX_LHKP$VFF'K&#\
MS_6@#4O-;N=2N&L=%3=V>X/W5^E7M)T&WTP&1R9[IN7E?DY]JT;.RM["W6"V
MC$:*.@JQB@!N:=28I: "BBB@ I/PI:9DT /HIH)HW4 .HHII;!H =BBLO4]<
MMM)(^T+*01G*(2!3M,UBWU>-I+82!5[NI&: -*BD'2EH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (I2HA<O\
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MFARF2P,7G#8GF'FMCP/KD.N>&[>1"/,C78Z#L:KD?+<#IEZ4M(.E+4 %%%%
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M>U>/Z-XP\5Z7I-II[>"](F\A!&)#=HI8#H2.>:]HUM;!]$O5U0J+ PL+@L<
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MGZ,*>'4]&!^AKDC\-/#F?DBNHQZ)<,!3?^%;:./N7FJH?479K;FJ_P J^_\
MX!YWL<"]JLO_  '_ .V.QKE[Z&V@\1V%B^I7:&Z25MGGXR1@C^M4V^'-J/\
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MI,\]1^= $E%1Y'J/SI<_[0_.@!]%,!'J/SHW#U'YT .S0<4W(]1^=''J/SH
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M3T H Z&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6/\ PDWV7[7>_8_)#9\P_>KNNW HVCKCGUH Y.]\(VT-A<2I>WFY(V8?O3U
MJKH/A:&_T:WN9[Z\,CKDD2FNQN8?M%K-!G'F(4S]15?2K,:9IT-F9 Q08!)Z
MT <EJGA8P:A91VUW>F)R?,/FFM4^"[3:?],O,X_YZFNEVY/(%+B@#@]%\+FZ
M:Z%W=WH"2$)^\(XI^N^%1::?YEG=WIFW 8$I/%=QM]A2E<]1F@#E;?P;;/;Q
ML]Y>!BH+?O3UK.MO"Q?Q#=6[W5Z+5$!0^8>M=W^%)@>G- '(:EX2M[;3+B>.
M^O!(B$@^::CT?PI!>:3;W$U]>&1UR3YIKJ[ZW^V6,MONV^8NW-1Z=;)I]A#:
M&56,8QR>M '(W?A8QZW:P17=[]G=<N?,-:DG@RU$;%;V\R 2/WIKIL#TI<4
M<-HWA3[5;RM=WEZ'#D+F4]*36O"OV6")K2[O2S. V)2>*[H  <"D*Y/(H YE
M?!=H54F]O,D#/[TUDZ?X6:76[V">[O?LZ >6?--=[C%)M .<#- '&:UX5@LM
M'N+B&^O!(BY!,IJ73?",%SIMO-)>WA9T#']Z:Z6_MHK^SEM'<?.,$ \T^TB2
MVMX[9&!\M0,9YH XJ;PL5\116RW=[]E9,L?,/6M*X\&VR6TC)>7F]5)7]Z>M
M=5@=<?C28H X?0?"HN].\R\N[U9=Y&#(1Q4>M>%FM9K06EW>%7D DQ(>!7>
M8Z#%!7)Z9H YK_A"[3'_ !^WG_?TUE:5X5-Q?7\=S=WHCC<"(F4]*[O%(!CG
M% '#^(/#D>EZ-->VU[=B6(@KF4D=:[6U8M:0L3R8U)_*JNIV46K:?-9.XVOC
M=M/(JW%Y<4:0AU^50H&?2@"6BDS2T %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!D^)M&'B'PSJ.DEP
MGVN!HPQZ D<&N'T#POXCN]>\/2ZY9VUI;>'K8PQ/%+O-R^T*&Q_",#I7IU%
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M(Z^V*UO^%8^"/^A8T[_OU7644 >2?$;P%X4TOP_9SV6@6,$KZG:Q,R1X)1I
M&'T(XKK_ /A6/@C_ *%C3O\ OU6S+_8WB 2VDAM;X6DZF2,D/Y4JG(SZ$'FG
MV6N:3J5S-;6.I6ES/"<21Q3*S+]0#0!A_P#"L?!'_0L:=_WZK$D^$7A]O&L-
M^FBZ:-&6P:%[7R^LQ<$/CI]WBO1Z* .3_P"%8^"/^A8T[_OU1_PK'P1_T+&G
M?]^JZRB@#SO0/A)X<LEU$:IH>FW)EOI9;?\ =Y\N$GY$Y]!6Q_PK'P1_T+&G
M?]^JZRB@#S3QE\(-"U3PS<6GA_1]-L=2=D,=QLV[0&!/(]1D5M6WPN\&1VL*
M3>&M-:54 =O*ZG')KL:* .3_ .%8^"/^A8T[_OU7-ZC\'M&G\<Z1J%II.FQ:
M+;Q2+=VFPCS6*L%..AP2/RKU"B@#D_\ A6/@C_H6-._[]4?\*Q\$?]"QIW_?
MJNLK-OO$&C:9=1VM]JEG;7$GW(Y9E5C^!- 'CWPT\&>&M6\3>-X+_1;.XAL]
M2\NW1TR(DR_"^@X'Y5Z/_P *Q\$?]"QIW_?JKY_X1GPH\]XS:?IC:A+OED9E
MC\]^>3ZGD_G6W'(DL:R1NKHP#*RG((/<&@#A->^%'A:\\/ZA;:9H&FV]_+;N
MEO-Y>/+<@[6S[&F>'?A-X8L?#UC:ZMH.FW5_%$%GF\O.]O7FO0** .3_ .%8
M^"/^A8T[_OU6/JOPD\.7.LZ//8Z'IL-G;RNUY%Y>/.4J0![X/->B44 <G_PK
M'P1_T+&G?]^J/^%8^"/^A8T[_OU7644 >=:7\(_#MOKVLW-[HFFRV-P\1LH?
M+SY("X?Z9/-;/_"L?!'_ $+&G?\ ?JNLHH XZY^%W@R2UF2'PUIJRLC!&\KH
M<<&L[PS\)?#5AX;L+76-"TZ[U&*/;//Y>=[9/.37H5% ')_\*Q\$?]"QIW_?
MJN4\>>"O#6@Z=I-[I6BV=I=#5[1!+%'AL%^17J<\\-K \]Q*D4,8W/)(P55'
MJ2>E9JRZ#XIL5D26RU*UAE60,K!U213D'V(ZT :U%9]AKFDZK/-#I^I6MU+"
M<2)#*K%?J!6A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 8?BNZEM=&8PL4=W5-P[ FJ%BK:5XGAL8Y&>&X
M@\PACT(K<U?3DU33WM78KG!##L1TJAIFBS0:@;Z]N/.G"[$XZ"@#>HHHH **
M** "FM3J1O6@#&\3-<#0;A+16::3Y!MZ\UD>%76UO9+*XCEBO!&&*NV=P]:Z
M'4[)[ZS,,<IB?(97'8BJ&FZ+/!J3:C>S^=<E!&,= !0!O#I2T@Z"EH ****
M"BBCM0!R-ZVH1^-[ 27'^BR9VQ#Z=ZS[AY]0AU;4?/=);23$0!X&#757>EBZ
MU>SOM^#;YX]<UF7GAF:6>X6WN?+MKI@TJ4 ;6E7+7FFP3L,,R#-7:AMH5MX4
MB0?*@ %34 %%%% "'I3*DI,"@#D4;48?'<:7-SN@DB8I&.@ K)=KF'6+J_OX
M)Q:_:L1N&X"]N*[&?2A+KL.HE\>5&4V^N:R[CPY=3R20M>EK)Y?,*'J/:@#H
MXG62-70Y5AD&I144:+'$L:C 48%2#I0 M%%% !4<H9D;8<-C@U)44P9HG5#M
M8J0#Z&@#A;Z*?3M1M4LKF2>\1GDN6SD!<=#2*;B'3K/6?M#FXEN,2#/!4]JT
M=*\,:CITTC/>B59F)E)'+ ]JEC\+3":*%[HFQAD,J)WSZ4 =1&VZ-6]1FG4B
MX"@#H*6@ HHHH *ANXY);62.)]CLI ;TJ:J]]#+<6,T,,GER.I4-Z4 <A;PO
M:Z_;6UA<23O'&QNWSE2?\:H:7+/;7L-WJL$\8FF*K(6XSG@5MZ#X;O\ 1_W3
M7@DB;/F''S,3[TY/#-T[PPW5\9;2"3S$4]2<\4 =.M.IJTZ@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#F/B+=7%E\.M?N+5V29+-RK+U'&,_E7G&F6=OHWBKX:2:5:QPO=V
M,B7)B&#(NP$EO7!)/->T75K!>VDUK<QK)!,A21&'#*1@BN8\/_#S1_#NIQ7\
M$EW/+;Q&&U%Q,7%NAZJ@[4 =;1110 4444 %%%% !1110 4444 %4-:TZ75=
M(N+&&]FLGF7;Y\/WT'?'O5^B@#PKPK"V@>%OB;;Z>\FZTN98XW9LOPN,D^O7
MFET*SMM+NOA7=:?;QPW-Y RW+1C!E5HBS;O7GFO5-*\'Z9I,FM-&))5UB9IK
ME)#D$L,$#VJCH/PYT7P_J<-];O=S-;(T=I'<3%TME;J$!Z4 ==1110 4444
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M=10 @&#2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP16U!XRN+8D9*G)^8COCTK5U/QS;VNDZ=J&G:?=:E%?IYD30@*BKC.79N%H
MZNBO)]7^,+2^ [W6M"TR0W5K<?9IUF(*P-V8D'##TQ6LWQ+EL7T*PO-!OGU/
M5+<R1P1E225'Y#/7VH ]"HKS1?C! ]GJ$R>&]4:73&/]H1X7%N!U).>>_2M2
M^^)FFQ+I,>FV=SJ5[JD'VF"VAPI$?=F)X'?\J .WHK@;GXK:5;^$#X@6SN7$
M=V+.>UX\R*3."#ZU+:_$;S];DT>;0+^VO7M6NK2.7;_I"CL.>#]: .YHKS_X
M9>-M7\8QZE+J.G?9XX;ADC=<;5 .-GJ2.YKT"@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
8% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>img158215518_19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img158215518_19.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )!!?D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH CFD,<>X#)R!^M25#=?Z@_[R_SJ:@ HHHH **** "B
MBB@ HHHH *S[;4Q<ZQ>Z>(BIM51B^?O;@?\ "M"N>TS_ )'+7/\ KG!_(T =
M#1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 '>BCO10 4444
M%%%% !1110 4444 %%%% !144[%%4J<98"I: "BBB@ HHHH **** "BD/ -9
M?AS49M6T*WO;@()9"X(08'#D#]!0!JT444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !111WH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M</[/R[^1?B=E_P +BU?_ *!]K^9H_P"%Q:O_ - ^U_,UQO\ 84O_ $$-,_\
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M#_\ ;'8?\*L\3?\ /.V_[_"C_A5GB;_GG;?]_A7'_:;G_GYG_P"_AH^TW/\
MS\S_ /?PT7I]G]__   ]EC?^?D?_  '_ .V.P_X59XF_YYVW_?X4?\*L\3?\
M\[;_ +_"N/\ M-S_ ,_,_P#W\-'VFY_Y^9_^_AHO3[/[_P#@![+&_P#/R/\
MX#_]L=A_PJSQ-_SSMO\ O\*/^%6>)O\ GG;?]_A7'_:;G_GYG_[^&C[3<_\
M/S/_ -_#1>GV?W_\ /98W_GY'_P'_P"V.P_X59XF_P">=M_W^%'_  JSQ-_S
MSMO^_P *X_[3<_\ /S/_ -_#1]IN?^?F?_OX:+T^S^__ ( >RQO_ #\C_P"
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M'_/C<_\ ?HT?V9J'_/C<_P#?HT?V-@?Z8?ZX9U_.O_ 5_D9/_",Z9_T&)_\
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M2 Q07%T\T?G".! 2L?=CDC'\Z ,?4?#-_+IUA!!]FFDB#^;YTC(-[?\ +0$
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M%%% !1110 4444 %%%% !1WHH[T %%%% !1110 4444 %%%% !1110 4444
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MCA3.R-0JY]!73AZ4J;?,>+G.8T,7&"I7TOT)****Z3P@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH .]%'>B@
M HHHH **** "JVH6:ZAI\]HS%1*A7<.WO5FL?4=6NX=3CT_3[-+F<PF>3S)=
M@" XXX.6SVX^M %23P_J6HQPQZGJP*0NKJ+2+R^5'!))/UJ*+PO>Z>%.G:F
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M%VDIC[I'S9'.<\>E '0W2 A&(Y#C%6*@N6 "+W+BIZ "BBB@ HHHH ****
M]*^?;/XA:_I44EC:RP""">54#1 G&\]Z^@CTKYC&BWUQ+<311QE'N)2"95'\
M9[$US8ER45RGMY%3H5*TE62:MU]4=%_PM+Q/_P ]K;_OR*/^%I>)_P#GM;?]
M^17/_P#"/ZE_SRB_[_)_C1_PC^I?\\HO^_R?XUQ^TJ]V?4?5,O\ Y8_@=!_P
MM+Q/_P ]K;_OR*/^%I>)_P#GM;?]^17/_P#"/ZE_SRB_[_)_C1_PC^I?\\HO
M^_R?XT>TJ]V'U3+_ .6/X'0?\+2\3_\ /:V_[\BC_A:7B?\ Y[6W_?D5S_\
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M]Y"<%?7" #_@1KH_$D4DO@[PM8HA^U2WED$4\%=N&8_@ : /0:*** "BBB@
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M$B"' 6/=G@^]=N M[=7\S@S*_P!6EROM^9G_ -L77_/.T_\  =/\*/[8NO\
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M*** "BBB@ HHHH **** "BBB@ HHHH *.]%'>@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** ,?Q#X7TCQ3:PV^L6K3QPOYD
M865XRK8QG*D&JNA^!O#GARZ-UIFG".X(QYLDKRL!Z N21^%=%10!BW'A+1+J
MPO[&>Q#VU_+YURA=OG?(.>O'0=*MC1=/74K?41;@75O ;>)PQ^6/^[C.*OT4
M <G=?#/PA=W[7DNCH)&;>RI*Z1L?= P4_E6WJ.@Z5JNF#3;VQAFLP %B*X"X
MZ;<=/PK1HH Y_0O!'AWPW<-<:9IRQSL,>;)(\K@>@+DD#Z5T%%% !1110 44
M44 %%%% !1110 4444 %%%% %+2]+@TBV:VM2X@,C.J,<B/)R0OMFKM%% !1
M110 4444 %49M)M[C5[?4I2[RVZ,L2$C:A/5L>N.*O44 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %8?BRQGU#1TAMHS)(+B)\#_ &6!
MS^E;E% 'G5OI=Q;7?VO4]'FNEFNI)I(UC$F&>)1G'UR,^U2IIGB98[&6&SAS
MI\2>4);DJP.<LH 4AOE^3)(KT"B@#ST:/JDM]@V4BVQO#? GJ')VX(_W3FH-
M&T35X;9UT^.>.9K00R_;$6 *=PR$9%R>,\D&MG7M?UBQUV:&SBW6=O#%)(PB
M5@-[,#N)8$#CL#1->^)HY=32WN+>[>W,0CC2V"L0^"3R^#@9X[T 8=GH>LPB
MQ^T6;":-$6"%566,;7).]V&Y>.>,?C6YX0T^YL]2NY)+26(/$HD:5 F'#'Y5
MQ]Y<'J<GW/:"Y\;BTGTJP:XM_MLTH2Y6X(C8<D8"Y/.?0D5H>&]>O=0U.YLK
MU&#QQ"4YMVBV$L1M^;[PX^\.#0!OW;*(MNX9RO&?>K%5[M5\K=M&<KSCWJQ0
M 4444 %%%% !1110 4444 %>0^+X)IO'>H&*&1P((<[5)QP:]>KR'Q?/-#X[
MU 1321@P0Y",1G@UW9=?ZPK>9Y^9V^K2OY?F97V*[_Y]9_\ OV:/L5W_ ,^L
M_P#W[-'VZ\_Y^[C_ +^&C[=>?\_=Q_W\-?1^_P"1\M[GF(;.Z _X]9O^_9KV
MK3 1I=J"""(ER#]*X'P!<3S:Y.LTTDBB G#N2.H]:](KP\TJMR5-K;]3Z#**
M*C!U4]]/N"BBBO*/9"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM+'&29"-I4=AF@#JKG[B_P"^/YU-4%R&PA!XWC(Q4] !1110 4444 %%%%
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MA^_L8;I-."K*H8*7;(_6LZN-5)7G!K[O\S:C@'6=J<T_O_R.5^'_ /R,+_\
M7$UZA69I_A[2]+N#/9VHBE(V[@Q/'XFM.O"QE>->KSQV/H<#AY8>ER2WN%%%
M%<IV!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4=Z*.] !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %9%UXCL[6_FL_*NIIH0ID$,)<+N&1DCVK7K TG_D:_$7^];_ /HH4 2?
M\)-;_P#/CJ7_ ("M1_PDUO\ \^.I?^ K5L\T9- &-_PDUO\ \^.I?^ K4?\
M"36__/CJ7_@*U;.3FEH Q?\ A)K?_GQU+_P%:C_A)K?_ )\=2_\  5JV<\4=
M: ,;_A)K?_GQU+_P%:C_ (2:W_Y\=2_\!6K9)'K3&E1>K4 9!\46PZV.I?\
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M(%['UKMR^WMU?S.#,K_5I6\OS,W[1IO_ $#Y?_ C_P"M1]HTW'_(/E_\"/\
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M^L=/_GV_O#_B'^)_Y_1^YF]@^A_*C!]#^58/_"3ZY_T$I?R'^%'_  D^N?\
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M^)/]HV5O:ZXJVNIN,E2I16'][GIF@#U*@4R.59!D$9]*>: "BBB@ HHS1WH
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M/MWJV"#R.E<#XANUT>WM8[1"LLORJQS^['J36EI?B:-4M[>YE#NXQY@'?T-
M'6"BFHXD0,#P>E.H 7%,E'[I_P#=/\J?3)?]2_\ NG^5 &7X4_Y%/2O^O9/Y
M5L5C^%/^13TK_KV3^5;% !1110 4444 %%%% !1110 4444 %%%% !6#XN>Y
MCT5&M))4E%S%S$2"1O&1QV-;U4-7U2'1[-;F='=&E2+" $@LP /TYH X.*\6
M:[,NMZC>6MI/=R2#-T\.T&)2J @CIGIZU976=?V:?/'I^I7,=G$C3NI10^?O
M;PS E@F#@ \UO-XMAEN9;>TTRZNY8[AX-J;!DJH8L-S#CFKB>)+&1M/"^9B]
M7<I*X"9X ;T)/'UH Y$:AJ4U[]GCGN_*-\;I9 S8,>=HCSZ9.<5!H5]JT5M*
M^G3/JMP]H"\<5PSF*0L.6\U\!@,\ CI77-XLL4.WR)]WVTV>W SN SNZ_=JM
MIWC.UU&.9K6PG:1(Q*(T>-BPSCG#87_@6* .?L;N\8:/<7EW<B=8@HL9Y766
M4[SEAL;:YQV.<8K?\-S*VMZDEM>S7=HR(P+R,_E/DAE.[HQ]!@8 XJ2+QE8W
M$]G%';2L]QCC<@,>3CIN^;H?NYXK5TW5;?4Y;U((Y$-K/Y+EUV[CM#9'M\PH
M M77^H/^\O\ .IJK7:9CW9;JO&>.M6: "BBB@ HHHH **** "BBB@ KQWQIC
M_A/+_P#ZX0_R->Q5Y+XKNVMO'6HA8H7S!#_K$#=C7=EU_K"MYGGYHD\-*_E^
M9SW'M5G3L?VI9]/]>G\ZF_M23_GVM/\ OR*L6&IR-J5JOV:U&9E&1",]:^AD
MY<KT_$^8A&',M?P/9****^0/MPHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ [T4=Z* "BBB@ HHHH *R'\3Z4EY);-/)OCSEO(?82!DJ'QM+>P.:UZYF+1
M-2%S%:2?9/[-ANC<K*&8ROR3L*XP.3UR?I0!K3:WIUO#!++=*D<\9DC8@X*@
M9R?3CUJ.'Q#ILVFS7_G/';PG$AFA>-E]/E8 \_2L4>$KI[?4;:6ZC\HH8M/X
M)\M"V_Y_?=QQVJ:ZT;6]=6!=3N;>PCCD$I2Q/F,Q P 6D7!&>?N^WO0!HZCX
MFTO2YH8KJ2;=+'YH,5O)(H3.-S%5(49/?%3VVM6%WJ,MA#*S3QC)!C8*P_V6
M(PW4=":YF?P9?W$2K)J3LT%LT$3^85\T;PP$@4 $8X.*V;33M1.O+>W45G%%
M%$8T:!V+."!\I4C P<\@\^@H UKE@ BGJ7':IZAN?N+_ +X_G4U !1110 44
M44 %%%%  >E?/]E\/-:U6&2_MY;(0SSRL@>;#8WGJ,5] 'I7RO)/,MU=*LTH
M N9< .0!\YKFQ32BKH]W((U95Y>RDD[=5?JO-'8?\*L\0?\ /;3_ /O_ /\
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M/T*RM)]OFPPJC;3D9 [5H5#:?\>4'_7-?Y5-7JK1'YW4DY3;84444R HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "CO11WH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4)(XW=Q5UYY=/\,M%+;QR2VL67&#@D] I[GZ5Q?BVSCT_P 8IJ=C 0LQ5S.
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M<E:W&\316NGQW5W;R*CL%C'!:3W S0!=O]*@U%8HI9",9(7/4?2H1I&E21)
MMN)/*8.N2<[@>#SZ5?B<7MO'+M>%F'!XW >E2K"J.7QER,%CUH J66H3:?.\
M5]+$2SGR]G V]ASW]:Z%) ZJRC(;N*YK6GBM[)KF2#SV# *JCG\ZR/#?Q%T[
M4]1.F;6@NE;:8G/;L0: ._ILO^ID_P!T_P J<K!ER.]-D_U+_P"Z?Y4 9?A3
M_D4]*_Z]D_E6Q6/X4_Y%/2O^O9/Y5L4 %%%% !1110 4444 %%%% !1110 4
M444 %9^LZ7'J]B+:20QKYB/D#T.:T*P?%UI/>Z,D5O&\D@N8G 4<_*X.: *<
M?A66P,<EAJJQ3(Y)>:+?G,:H?XASQG\::W@'398P)KJ^:545(W2Z>,#;R"54
MA6.[YN16!%I@CNOM6N://<13W<D[Q_96FPS1+C@ ]#D9]JLI9>*=EA/#8QG^
MSHDV"XN663/5U "D,=GRY)'- &TG@^$7GVI[YV<G+#: I;=NSC/7M1I_AJYL
MT!BU.'SX81#"\=L  N0?G&3NSCVK"&F:E->[/L4ZVK7IO@Q!'S$[=I'T.:KZ
M%I&J6]M(-'@,=R]H(YC<VYM0K[AG#!?G.,_-@T =''X0CCG#B\CW3,KW/[D9
M<JVX;#GY!GMS6[8V*6EU?S++O-U,)6']TA%7'_CM<,FF70T;289-,FCUF#:8
M756D7 <\&4@%/4YQGWK5\&6$]E=W?F6[J7C7SY7M_*)E!.0/[XY^]S]: .HN
MV;9C9\N5^;/O5FH+HCR<9&<KQ^-3T %%%% !1110 4444 %%%% !7CGC6XL8
M/'E^+R[,!,$.T",MG@^E>QUX)\3XI9/B!=&.-W MHL[5)]:3Q$\/^\I[HZL%
M@*./K+#U_A?;3;43[?HO_03;_OPU7]#?3+_7;*VMM1+3-*"JF%@#CGK7"?9;
MC_GWF_[X-=#X$@G3QQI3-#(H$IR2A Z&B.=XN346UKY'K5^#<JI4I5(\UTF_
MB['T/1113/GPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY(P2JJ<]?ZUQGBCP7/K^JFZMWA10R,N]SEC_ !'VQ0!<CO;^;QC-;V,7E6\
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 =Z*.]% !1110
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MD CC'3J>M:4T491P4'W37-^'_$6G^(-?D^SK(MU!;?.IZ*">A[9KIY.4D/\
MLG^5 #/"7_(HZ3_UZI_*MFL;PE_R*.D_]>J?RK9H **** "BBB@ HHHH ***
M* "BBB@ HHHH *HZMJL&CVBW-PDC(TJ18C&2"S  _3FKU9VM:6NL6 M6E\H"
M5)-V,_=.<4 9DOC&'[1+!9Z7?WLL=P]N5A$8R54,6&YQQSCU]JO)XBL)'T]4
M9R+Y=T;;<!?3=Z9/'UK'3PI>Z>8Y=.U>WBG60L7N;8R YC5#P'7GC.?>G?\
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M'V22[^9YV4*?M9-]O+N:=%%%>&?0!1110 4444 %%%% !1110 4444 %%%%
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MR99?,5!P#YC=.*]++*G)4;LWITU/+S:FZE**32UZNW0Q<#THP/2NJ^Q^#/\
MH(7WY?\ UJ/L?@S_ *"%]^7_ -:O9^LK^67W'@_5'_-'[T<H0,'BO8/"7_(L
M6/\ N?UKGM,\)>'=8A>6SN[QT0[6)('/Y5V6G6$6F6$5G"S-'&, L<FO+S'%
M0J04%>Z?4]?*\)4I3=25K-=&6J***\@]L**** "BBB@ HHHH **** "BBB@
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M)_Z]4_E6S6-X2_Y%'2?^O5/Y5LT %%%% !1110 4444 %%%% !1110 4444
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M(='TJ417^I6UO(?X)) #^56[*_M-1@\^RN8KB+.-T;!A19VN!8HHHI %%%%
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MB@#=!N[L?05T$M[*FO068EM!$\+.8V<^<2#U4=-OK0!H5S^E?\C5XB_WK?\
M]%"N@K TG_D:_$7^];_^BA0!NC%</\1O%H\+^&+F\1L7$A\BU&>LA'7\!S7:
MR-LC8^U?-OQSNM0U3Q)#IUM&[6FFP"23!P/,?O[G  H G^&UI_:FL10B_>-H
M&$TFY ?.)Y.">_J:].OX=1L-5EG3(M'^4;!U)&!FO#_A/).GBZS@6&621&W
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M!79E<C'/6K-5KN10FPD[B5[>]6: "BBB@ HHHH **** "BBB@ KD]$*S^/\
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MQ9O;R*@E1FP?-C8D!N/=>GTH T[K_4'ZK_.IZK7:93?O88*\9XZU9H ****
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M3U.\MO$'B"*"RAENA F9"#C9SSU["N-\=Z[9P37.C1V;Q16@W1%P=K,>K T
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M% !T&!@<<4G..3S2GI30",DGDT ,=AYD:^;M;D[,_>J3M5*;3(9]2@OF9Q+
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M/Y&GD ^2 2S_ $/;/>O8K*SBM+>.**-4CC4*BJ.% H GAC\M,=SU-/Q1UHH
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M-*&8<[;:2M;374]9HHHIGG!1110 4444 %%%% !1110 4444 %%%% !1110
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MBB@ HHHH **** "BBB@ KG]*_P"1J\1?[UO_ .BA705S^E?\C5XB_P!^W_\
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M02<D#JQSR?8<4 :EVA*;M[8ROR]NM6:K7;'R]NPXROS=NM6: "BBB@ HHHH
M**** "BB@\#- 'COB>6VNO$M\]SIMK-(DGE[V#9('3H:VOA@L*ZAK@@MXX$S
M%\D><=#ZUCZO!;76LWMPFHVX625B P;(_2MSX;1+#JFN*DR3#,1W)G'0^M>M
MB\/0A04H1M+36QY&#QV+JUW2J5&X*]E>Z\M#T2BBBO)/7"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW_/+2?\ ON3_  H V?:HYW$<1;^597_%3?\ /+2?^^Y/\*;*GB:1"OEZ2/\
M@<G^% &Q&?D4FGBL4#Q, !Y>D\?[<G^%.SXF_P">6D_]]R?X4 ; HZ5C9\3?
M\\M)_P"^Y/\ "C_BIO\ GEI/_?R3_"@#9-&/:L?/B;_GEI/_ '\D_P *,^)O
M^>6D_P#?<G^% %^:PM;C/FP(3ZXJA)X=LG.5\Q/H:,^)O^>6D_\ ?<G^%&?$
MW_/+2?\ OY)_A0 D>@K!\RW3Y'/W:M1Z<F 6D9JJM_PDQ7'E:3_WW)_A0H\3
M*H'E:3Q_TTD_PH TTM(4'"Y^M3  # &*Q\^)O^>6D_\ ?<G^%&?$W_/+2?\
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MMID=YY=SIRR/=3R' ?M'DXXSG)^E=<;:W^T"X,,7G 8$FT;@/3-.,<*F1RB
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M7K7EPMQ#$ENN/)=7RS>N1VJU1WH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@""Z \DG'\2
M_P ZGJ&Z!,!P">0>/K1]I3T?_O@T 345 +N(YQO.#C[AI?M*>C_]\&@":BH?
MM*>C_P#?!H^TIZ/_ -\&@":BH#=1J,D.!_N&E^TIZ/\ ]\&@":BH?M*>C_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8%#2+Y+IM!Z?> KH: "BBB@!JH%9B.K')IU4]5U6QT33I=0U*Y2VM8AEY'/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7,3:[;:G>WV
MBZEH6I0V*1MYMY=0A;9U'7#;L\_2NGJIJFF6FLZ9<:=?1F6UN$*2('*[AZ9!
M!H Y'3T'BCQ'IVIV=D+31=+#"VG=-KW+$;?E'41@=SU-=S7*:5\./#&B7\%[
M864\4\!S&3>3,!QC[I8C]*ZN@ JAK&I-I.FR7BV-W?%,?N+1 \C9/8$BK]%
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M!6C:K!K=]JU[HMKH%O-"L2:=;3+(&8'F1BH"Y[<5W5% !1110 4444 %%%%
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M'-.+>2ZG;>X1L["&&!P>.15Z_P#$]Y'XAU6PM(H&M]-TUKJ9W!)\T@E%X/3
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MKW3D8 4C.U1U[&LG1K?Q=X)LKG0K'0$U6U\^1[*[CN%0(KG($@//!/:O2Z*
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M5(;>UB03$#KYC+P?8"NQHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4>H7,D]S8P),CR-EF21<I^O%:MYX%:SU:]D\/6UC96%_ILEK<6\:B-?,YV.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKL"'2HM]Q. 1D*?X0.I-4K'6-<T_3/&FGF_UA$L[..>U.I3![B)F/)W+V]J
M/;E4*H50 H& !VI:\SLH]3\.:UX?O)/$E[J,>L K=07,@:-3Y>[?&/X0*Y+7
M=6U.*T;Q%I6M>*;DK<@K=2;8;!E+XPL9^\N.!UH ]YK'C\3Z9)-91;Y4DO99
M(8%DA92S)G=U' XZ]ZY2&WO]>^(VHP2ZUJ%M8V4-K<+;6TNQ7=E.0?\ 9]0.
MM<O%]OU^+PM')J]Q;W$FJW\?VO=F14!8;5)Z'' ]* /:ZJF_A74UL")/.:(R
M@[#MV@X^]TS[5RO@UKW3M?UKP[<:G<ZG;V0BD@N+IP\JAP<HS=^F:K^*=1O;
M;Q1=PPW4T<2Z!<3!$<@!PPPWU'K0!WE%>1Z/%KFC3>#-5G\2ZC?OK#)#=V]P
MX,.UH]P*KC@CCGO526X\0Z+XC;4/$-[XCM@+H[;FW*S:>8BV IC'W>,#)H ]
MGHKQ_P 2ZEXBU[QGJFGV,6N_8]-$:Q#2+J. EF7=N?=RP]!TXJQ<2>*M5;P?
MIFHZC>Z1>W3W*7C0.H>2-5R#QE0Q'?L: /6*CGF6WMY)GW;(U+':,G ]!WKR
MN$>*ET'Q+H6EZG>7UQIU_''%/)*OVEH&4,RASQN]":D\+ZG<6MAKVG37WB&.
M\CLGG2VUD!I8\ Y9)1]X9Q]* /0X=<L)Y[*W68K/>0F>&)U*L4'4D'IU[U/8
M7\.I6YG@$@0.R'S(RAR#@\'M7E&GZ=+JGCCP3?W&JZCYTFC&9]L_#%0N0?9L
M\^M7;+5]4MM T_7Y+ZYEAM=7FANT:0D-"TA49'^SQCTH ]4ID<4<*[8HU1<D
MX48&37F.N>*=4MM+\4>(M.FDDBBF33[%0V8P=P#R 'C.3U]JB\))XPL/$MGY
MEMK[Z=<9%X=5NX9E4XX:/:<KSV'% 'I>H:C;:9;B>Z<JK.L:A0268G   ZFJ
MFM>)-*\/O9)J5R(3>S""#Y2=S?AT'O63K+M<?$+P_9.?W,<,UR!V+@8'Y9S7
M%>,9;_Q'XJU>"QT&YU6"QLS9Q2P2HH@G;YBWS$<C '% 'INM^(M+\.Q6\NJ7
M(MX[B40QL02"QZ ^E2:SK>GZ!I4NIZG<K!:1 ;I#SUZ8]:\RUJX7QGX-\)1W
M0Q-<7@MKA2>4E52IS[@C-5]6U"3Q-X)AL+H9ETRRGEO4/:6+*)G\?FH ]1OO
M$6F:;X>.NW5QY>GB,2^9M/W3TXZ]Z==Z[866@G6I)':Q$0F,D:%SL/? YKS3
M6]0N;RQ\(>'K/2IM55;2*^OK6%U!,:J H.X@<L?TK;^&VJR)X?U'1-<@-G-I
M,C*\-RP)6W;+(6/0C&1GIQ0!UE[XFTFPT6#5IKM39W&P0M&"QE+?="@<DGTK
M55MZ!@",C.",&O$O!YM(O&]G)>K<KX=FEE/AH3_ZI9"?FP/4\[,]NE>U3F46
M\A@"&;:=@<\9[9]J '22)$F^1U11W8X%.KS%&@?7+<^/Y+M+OS1]DC;Y=/W9
M^7:5X+?[YKT+5+NXL=.FN;6QDOID&5MXF"L_L">* (-<U_3?#MD+K4IS&C-L
M154LSMZ*HY)JIHOB?0O$'GW5E*/.M5Q,)XC')$O7D, 0*IOK]JNC+K?B317T
MV6UE(@BN-DLI8\#9MSR>F!S7+ZO8ZK=^'O%7BF[LS83W>GF"WM/^6BQ#G=)C
M^(^G:@#K-+\?^'=8U--/M+QS-(2(3)"R)-CKL8C#?A6U9:I:W\]W! Y,MI)Y
M4R,I!4XR.#V/8UP_B=+5/!_A0V@4.MY9_93&!GMG'X=:U9B;3XK6HB.!>Z:_
MG+ZE&^4_J10!U]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML'+.<=-QZ#KQ7144 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
>4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>img158215518_20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img158215518_20.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %6 EX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8%<D%D?[I/' /;.*AUCQUHFF2:A9IJ%L^J6<;.UK(Y7&$W_,<' QSFN+\<^
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MO_LJSR$NX!;RB(RN%!!^<J30!ZM17FTOQ,NXOB!;:']CL9+"XO39!XIV>9&
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MGC+;TSRI4CMZU1T'4M5NOB:W@V;Q)-+IVDW$MTDPG?S[OH1;N_\ $$W'(SR
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M4-M&67)&-P R5ZCTJPOC;0Y++3+J.YD>/4UE:TQ"^9/+4LW&,CA3UZUS>D^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO$$DUY=1G6TMTF";?W8A(*[<COMYS4>I_#?3=4EUB66\NTDU/[,2T94&%H
MC+QUXR<YKLZ* .#;X7V<]CK4%WK.I7,^K/!+-=2%/,5XL;67"X[#C&,<5HZ%
MX>OK3QAJFKW\K3 VEO8V\KE=\RH"SR,%  )9CQ[5U=% !1110 4444 %%%%
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M6/[<TL7ALY[)Q+)$]O/MWHR,5(.TD=1V-:=8?A?_ (\[_P#["=W_ .CFK<H
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MA=@Q4E0X((X.0P_6N;\(02VWQ)\;137<UVXCT_,TP0,?W<G9%4?I0!WE%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!C>(];?
M0=/^V"TGN(UY<Q(&V#@<Y8>O;-:&GW$MU9I--;RP.V<QRJ P^H!/\Z\W^.'C
M&\\+^&+:VL[1)&U*1HVFD!*QA<-C [GM]#76^ O$=SXL\&:?K-W9_99YU.Y
M#M.#C<N?X3C(H Z2BBB@ HHHH **** "BBB@ HHHH Q]>\3Z/X;CA;5;^.U,
M^X1;U8YVC)/ / R.?<#N*YW2K;6/$MHNKZ?X]E>%V8*MOIT:1H0<%2C@MP?4
MYKK[G3;.\N[:ZN+=))K;=Y+M_#N&&^H.!^0]*\W7QHVC^(;_ $6P;P[800WY
M0Q75S*9Y&8AF?@$9);@9]C0!Z78QW<5G&E]/%<7*C#RQ1&-6]]N3C\ZL444
M%%%% &'X7_X\[_\ ["=W_P"CFK<K#\+_ /'G?_\ 83N__1S5N4 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M '<U:FFBMX))II%CBC4L[N<!0.I)KB]+AE\<:O#KU[&R:#:/NTNU<8^T./\
MEY<'M_<![<]Z ,/5]'U+6])N]=UC1KBZOKR/R[&P'EE=/AW _-O8?O&_B(SC
MIQW]*T^3S;&)OL<MF ,""4*"@' 'RDC\C61XIU673K>&..-&$^X$MVQC_&M#
M1=0DU/3([J1%1F)!"].#0!H4444 %%%% !1110 4444 %%%% !7D5U)';^+]
M233;GQ=*CZANG^PZ5'+;+*=NY=Y7.!QFO7&8(I9C@ 9)KQ:?2X+KQ-J&K[]
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MHGU8D^U:&E>%M&\/RM?/FXOW'[S4+Z3S)F_X$WW1[# J_P#9M3N/]?>) O\
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MG\0/&D.JZBNHW82P+7*VX@##RY,#8"0,#WH ]$HHHH **** "BBD# ]"#^-
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M4$;6!?:"0"17KM>2:I/I-QXZNI%\-6CS07B)*]SK26XDD7;B0VYX;J,$CG%
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M<Z3^V-+_ .@E9_\ ?]?\:B_X2'1?^@QI_P#X$I_C0/#VB@@C2;'(_P"G=?\
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MXJ6%D(C=>&_%, FE6&+S=*9=\C?=49/+'L*>WQ.M$FCA;POXL660$HATE]S
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M(#;<YQD$9]J(OBI83W5Q:P^&_%,EQ;E1/$FE,6BW#*[AG(R.1FNS%A:#46U
M6\8O&B$+3[?F,8)(7/IDD_C5"[N]!\/WDMW=S6=E<WY!DD=@K3;!@$GN%&!G
MM0!S-O\ %;3KJS-W;^'?%$UL-V9H]+9D&TD-R#C@@@^F#1<?%?3;6S%Y<>'?
M%$-J=N)I-+94.X@+\Q..20!ZY%:OANUT?0K(>%!JD%W<[IIC"Q =EE=I"-N3
MV?\ +FMVYTRQO; 6%S:Q2V@V8A=<J-I!7CV(!'TH Y*3XFVL3Q))X7\6(TK;
M(PVD."[8+8'/)PI/T!IA^*=@+Y;(^&_%(NVC,JP?V4^\H" 6VYSC) S[UV\D
M$4TD+R1JSPOOC)'*-M*Y'OAF'XFHS86C:BNH&WC-XD1A6?;\P0D$KGTR ?PH
M X]/B=:22R1)X7\6-)'C>@TER5SR,C/&:9;?%.PO5D:U\-^*9UCD:)S%I3L%
M=3AE.#P0>".U=LEO#'/+,D:K++CS' Y; P,_2F6=A::>DJVEO' LLK32!%QN
MD8Y9C[DT <3+\6=,@T[^T9O#_B>.QV"3[2^EL(]AZ-NSC!R.:?/\4["V>!)_
M#?BF)[A_+A5]*=3(V"=JY/)P"<#TKKYM)T^YTG^RIK.&2P,8B^SLN4V#HN/3
M@4M[:V$BPW-[%"19,9XY) ,0D*06![<$\T <_I/CZRU77+?2&TC6["ZN(WDB
M_M"Q,"N$ +8)/.,C\ZZNN1OKG0+W5M*\6'7;9+735GM@=P*NTH3@G/! 7.,<
M@UUD<B31)+$ZO&ZAE93D,#T(- #J*** "BBB@ HHHH **** &31+/#)$^=KJ
M5./0C%4M.T33]+TZVL;:V3R;:-8XRZ@MA1@9/<UH44 %%%% !17.^*=9O-.F
MT>QL&BCN=3NS;B:6/>L8$;N3MR,GY,=>]1Z-XRL+GPQI.J:M=6MC-?0>9L>3
M )'#;<]L_P Z +7A?_CSO_\ L)W?_HYJW*XOPYXL\/P6E\)=9LD)U&Z8;I@,
M@RL0?IBM;_A-O"_E>;_PD&G>7C._[0NW'KG.,4 ;U%81\:>&0H8Z]I^#C!\]
M<'/2@^-?#"LJMKVGAF^Z#.H+?3GF@#=HK"_X33PP'"?V]I^\C(7SUR1ZXS2C
MQGX9)(&NV!(ZCSUR* -RBL)?&OAB3.S7M/;!*G;.IP1U'7K2+XV\+M'YB^(-
M.:/&=XN%*X^N: -ZBL)O&OAA &?7M/4$@ M<*!D].]#>-/#"%0VO:>I8X4&=
M1D^@YYH W:*P_P#A,_#.X+_;MAN(SCSUSBD'C7PPSL@U[3RZXW*)UR,],C/%
M &[16$OC3PPY8)KVGL5.UMLZG!]#SP:3_A-?"XC,AU_3M@&2WVA< ?7- &G?
M:99ZDJK=Q>8J]!N('Z'VJ>"".VA6&($(O0$D_J:Q6\;>%TC\QM?TY4X^8W"@
M<].<TX^,_#*D Z[8 DX&9UY-*RO<ISDX\K>G8W*J)I6GQSB=+*W68'.\1@-G
MZUF_\)IX8#A#KVG[R,A?/7)'KC- \:>&"Y0:]IY<#)7SUR!ZXS19,%*4=F;M
M%88\9^&6) UVP.#@XG7@TU?&WA=X_,77].:/KO%PI'YYIDFEJ.F0:G$(KAYP
M@ZK%,T>?KM(STJ>W@6V@6)7D<#^*5R[?F>:QCXV\+B+S3X@TX1XSO-PNW'KG
M.,4K>-?#"E0VO:>I8X7,ZC)]!SS2LKW+=23CR-Z=C=K#CTZ\7Q*^IM:V(#Q"
M N&/F;0Q.?N]>1Q[4A\:^& ZH=>T\.V=JF=<G'7 S1_PFOACS/+_ +>T_?C=
MM\]<X]<9Z4.-QTZKIII=58W:*PE\:>&'+!=>T]BIPP$ZG!]#SP:%\:^&'7<F
MOZ<R\C*W"D<=>],S-VBH;2[MK^TBN[.>.>WE7='+$P97'J".HJ:@ HHHH **
M** "BBB@ KSGPIH.JV7B6S^TVLL<=A_:/FSM@)+Y\ZO'M/\ %\H)/I7HU% !
M1110 444UW2-&>1E1%&69C@ >] #J*@MKZTO=WV6Z@GV_>\J0-CZXJ>@ KS#
MQ!X/NY]6\8KI6G^6FHZ5%L<  3S^8[.,GN01U]17I]% ',>$+2ZBGUR^N+>6
MWCO[X3013#:X011IDCMDJ:Z>BB@ HIH=2I8,"!U.>E0V]]:79(MKJ"8CDB.0
M-CMV^E %BBBD#JP)# @<$@T +7$?$4ZK>6MMHFFV<_D:B'BOM0B@,IMX,?,J
M@<[FZ#TZUVRL&4,I!!Y!'>EH \TT[P]J-OXLMXUM)_LL6K&_2Y<846_V01*N
M>N[=QM]L]*]+I"RA@I8!CT&>32T %%%(S*BEF( '4DT +1110 5%=.8[65Q
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M$#'YU:HH S-&T.UT*.]2T:5A>7DM[)YC XDD;<P& .,]*KZ=X6L-+\(_\(U
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML%R,MCTJEIWB*QU%F5&,3*0 )2!NSZ<UI301W$+Q2J&1U*D>QJM8Z39:;O\
MLL.S?C=DD]/K0 S6;^33M/\ -AC62>26.")6^[O=PH)]@3D^PK#U37-6T.>*
MUN7M;E[AHC%,D)0 &9(W4KN/:0$'/U'KT>H6$&I63VMQNV,00R'#*P(*L#V(
M(!'TK*G\,1WI\R^O;BXG!CVR$*NQ4D5\  8Y*C)ZG':@"F?'FGB6>$6EVT\7
MEXA38SN'E$0^4-E3N(X;!P:?>^-['3[![JYM;F/RC(L\;F-3$4QN&2P#'!!
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M<^8I _UF0OS=?E]SE\WA"*ZE>\NKZ:75-T;07NU0\&SH$&, $EMP_BW$'C&
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M0V4;&Y64]0< _4"LJX\%V]S$2]_="Y=)A+< @-(\FS+' X \M0 .,<4 3_\
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MC!T5U.589!JIIFI0ZK:O<0+(J)<3VY#@ [HI6B8\$\;D)'MCITJV %  & .
M*P/!O_(#N?\ L*ZE_P"ELU '04444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4],TV'2K5[>!I&1[B
M>X)<@G=+*TK#@#C<Y ]L=>M%% %RBBB@ HHHH **** "BBB@ HHHH **** "
6BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>30
<FILENAME>tngx-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-28T06:45:11.8675+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="tngx-20211231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="tngx-20211231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="tngx-20211231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="tngx-20211231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="tngx-20211231.xsd#StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="tngx-20211231.xsd#StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="tngx-20211231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:href="tngx-20211231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="tngx-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombination1" xlink:href="tngx-20211231.xsd#DisclosureBusinessCombination1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreements" xlink:href="tngx-20211231.xsd#Role_DisclosureCollaborationAgreements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="tngx-20211231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecurities" xlink:href="tngx-20211231.xsd#Role_DisclosureMarketableSecurities" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformation" xlink:href="tngx-20211231.xsd#Role_DisclosureSupplementalBalanceSheetInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeases" xlink:href="tngx-20211231.xsd#Role_DisclosureLeases" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="tngx-20211231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStock1" xlink:href="tngx-20211231.xsd#DisclosureRedeemableConvertiblePreferredStock1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommonStock" xlink:href="tngx-20211231.xsd#Role_DisclosureCommonStock" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlans" xlink:href="tngx-20211231.xsd#Role_DisclosureEquityIncentivePlans" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="tngx-20211231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:href="tngx-20211231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="tngx-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="tngx-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationTables" xlink:href="tngx-20211231.xsd#DisclosureBusinessCombinationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="tngx-20211231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesTables" xlink:href="tngx-20211231.xsd#Role_DisclosureMarketableSecuritiesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationTables" xlink:href="tngx-20211231.xsd#Role_DisclosureSupplementalBalanceSheetInformationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesTables" xlink:href="tngx-20211231.xsd#Role_DisclosureLeasesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables" xlink:href="tngx-20211231.xsd#Role_DisclosureEquityIncentivePlansTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="tngx-20211231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:href="tngx-20211231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:href="tngx-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails" xlink:href="tngx-20211231.xsd#DisclosureBusinessCombinationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfNetProceedsFromBusinessCombinationAndPipeFinancingTransactionsDetails" xlink:href="tngx-20211231.xsd#DisclosureBusinessCombinationSummaryOfNetProceedsFromBusinessCombinationAndPipeFinancingTransactionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionDetails" xlink:href="tngx-20211231.xsd#DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionsParentheticalD" xlink:href="tngx-20211231.xsd#DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionsParentheticalD" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationDetails" xlink:href="tngx-20211231.xsd#DisclosureBusinessCombinationSummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfWeightedaverageCommonSharesBasicAndDilutedDetails" xlink:href="tngx-20211231.xsd#DisclosureBusinessCombinationSummaryOfWeightedaverageCommonSharesBasicAndDilutedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails1" xlink:href="tngx-20211231.xsd#DisclosureCollaborationAgreementsAdditionalInformationDetails1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentNetDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentDetails" xlink:href="tngx-20211231.xsd#DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfElementsOfLeaseCostDetail" xlink:href="tngx-20211231.xsd#Role_DisclosureLeasesSummaryOfElementsOfLeaseCostDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail" xlink:href="tngx-20211231.xsd#DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureCommonStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureEquityIncentivePlansAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockAwardsActivityDetails" xlink:href="tngx-20211231.xsd#DisclosureEquityIncentivePlansSummaryOfRestrictedStockAwardsActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfStockOptionActivityDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureEquityIncentivePlansScheduleOfStockOptionActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfWeightedAverageAssumptionsUsedToEstimateGrantDateFairValueOfStockOptionsDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureEquityIncentivePlansScheduleOfWeightedAverageAssumptionsUsedToEstimateGrantDateFairValueOfStockOptionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfStockbasedCompensationExpenseDetails" xlink:href="tngx-20211231.xsd#DisclosureEquityIncentivePlansScheduleOfStockbasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="tngx-20211231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails" xlink:href="tngx-20211231.xsd#DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureNetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="tngx_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesBOnePreferredStocksMember" xlink:label="tngx_SeriesBOnePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="tngx_AccruedExpensesAndOtherCurrentLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tngx_SeriesBOnePreferredStocksMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_TaxesPayableCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesBOnePreferredStocksMember" xlink:label="tngx_SeriesBOnePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tngx_SeriesBOnePreferredStocksMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_CollaborationRevenueMember" xlink:label="tngx_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_LicenseRevenueMember" xlink:label="tngx_LicenseRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_9"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tngx_CollaborationRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tngx_LicenseRevenueMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization" xlink:label="tngx_StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SharesOutstandingBeforeRetroactiveApplicationOfRecapitalization" xlink:label="tngx_SharesOutstandingBeforeRetroactiveApplicationOfRecapitalization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesBOnePreferredStocksMember" xlink:label="tngx_SeriesBOnePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TemporaryEquityBeforeRetroactiveApplicationOfRecapitalization" xlink:label="tngx_TemporaryEquityBeforeRetroactiveApplicationOfRecapitalization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TemporaryEquitySharesOutstandingBeforeRetroactiveApplicationOfRecapitalization" xlink:label="tngx_TemporaryEquitySharesOutstandingBeforeRetroactiveApplicationOfRecapitalization"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalization" xlink:label="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalization"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares" xlink:label="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TemporaryEquityRetroactiveApplicationOfRecapitalization" xlink:label="tngx_TemporaryEquityRetroactiveApplicationOfRecapitalization"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TemporaryEquityRetroactiveApplicationOfRecapitalizationShares" xlink:label="tngx_TemporaryEquityRetroactiveApplicationOfRecapitalizationShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_RetroactiveApplicationOfRecapitalization" xlink:label="tngx_RetroactiveApplicationOfRecapitalization"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_RetroactiveApplicationOfRecapitalizationShares" xlink:label="tngx_RetroactiveApplicationOfRecapitalizationShares"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_RetroactiveApplicationOfRecapitalizationOne" xlink:label="tngx_RetroactiveApplicationOfRecapitalizationOne"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_RetroactiveApplicationOfRecapitalizationSharesOne" xlink:label="tngx_RetroactiveApplicationOfRecapitalizationSharesOne"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TemporaryStockRetroactiveApplicationOfRecapitalization" xlink:label="tngx_TemporaryStockRetroactiveApplicationOfRecapitalization"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TemporaryStockRetroactiveApplicationOfRecapitalizationShares" xlink:label="tngx_TemporaryStockRetroactiveApplicationOfRecapitalizationShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments" xlink:label="tngx_StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_StockIssuedDuringPeriodSharesAcquisitionsAndPrivateInvestments" xlink:label="tngx_StockIssuedDuringPeriodSharesAcquisitionsAndPrivateInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_30"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_31"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_32"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_33"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_SharesOutstandingBeforeRetroactiveApplicationOfRecapitalization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tngx_SeriesBOnePreferredStocksMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_TemporaryEquityBeforeRetroactiveApplicationOfRecapitalization" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_TemporaryEquitySharesOutstandingBeforeRetroactiveApplicationOfRecapitalization" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalization" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_TemporaryEquityRetroactiveApplicationOfRecapitalization" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_TemporaryEquityRetroactiveApplicationOfRecapitalizationShares" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_RetroactiveApplicationOfRecapitalization" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_RetroactiveApplicationOfRecapitalizationShares" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_RetroactiveApplicationOfRecapitalizationOne" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_RetroactiveApplicationOfRecapitalizationSharesOne" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_TemporaryStockRetroactiveApplicationOfRecapitalization" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_TemporaryStockRetroactiveApplicationOfRecapitalizationShares" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_StockIssuedDuringPeriodSharesAcquisitionsAndPrivateInvestments" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossTax" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_30" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_31" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_32" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_33" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesBOnePreferredStocksMember" xlink:label="tngx_SeriesBOnePreferredStocksMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tngx_SeriesBOnePreferredStocksMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_CashPaidForLeases" xlink:label="tngx_CashPaidForLeases"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_RevaluationOfRightOfUseAssetAndLeaseLiabilityUponLeaseModification" xlink:label="tngx_RevaluationOfRightOfUseAssetAndLeaseLiabilityUponLeaseModification"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ProceedsFromBusinessCombinationAndPipeFinancingGross" xlink:label="tngx_ProceedsFromBusinessCombinationAndPipeFinancingGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_PaymentOfBusinessCombinationAndPipeFinancingTransactionCosts" xlink:label="tngx_PaymentOfBusinessCombinationAndPipeFinancingTransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_IncreaseDecreaseInAccruedExpensesAndOtherLiabilities" xlink:label="tngx_IncreaseDecreaseInAccruedExpensesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="tngx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="tngx_CashPaidForLeases" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="tngx_RevaluationOfRightOfUseAssetAndLeaseLiabilityUponLeaseModification" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="tngx_ProceedsFromBusinessCombinationAndPipeFinancingGross" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="tngx_PaymentOfBusinessCombinationAndPipeFinancingTransactionCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="tngx_IncreaseDecreaseInAccruedExpensesAndOtherLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="tngx_IncreaseDecreaseInOperatingLeaseLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombination1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_CollaborationAgreementsAbstract" xlink:label="tngx_CollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_CollaborationAgreementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecurities" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStock1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_RedeemableConvertiblePreferredStockDisclosureTextBlock" xlink:label="tngx_RedeemableConvertiblePreferredStockDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="tngx_RedeemableConvertiblePreferredStockDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommonStock" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlans" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_PatentCostsPolicyTextBlock" xlink:label="tngx_PatentCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_DeferredFinancingCostsPolicyTextBlock" xlink:label="tngx_DeferredFinancingCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:label="tngx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tngx_PatentCostsPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tngx_DeferredFinancingCostsPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tngx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:label="tngx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tngx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationTableTextBlock" xlink:label="tngx_SummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="tngx_SummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentTableTextBlock" xlink:label="tngx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="tngx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_BctgAcquisitionCorpMember" xlink:label="tngx_BctgAcquisitionCorpMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MergerAgreementMember" xlink:label="tngx_MergerAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_PublicSharesMember" xlink:label="tngx_PublicSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_OfferingCost" xlink:label="tngx_OfferingCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDeferredSalesCommissions" xlink:label="us-gaap_AmortizationOfDeferredSalesCommissions"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tngx_BctgAcquisitionCorpMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tngx_MergerAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tngx_PublicSharesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_OfferingCost" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfDeferredSalesCommissions" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SignificantAccountingPoliciesLineItems" xlink:label="tngx_SignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SignificantAccountingPoliciesTable" xlink:label="tngx_SignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_CashAndCashEquivalentMaturityPeriod" xlink:label="tngx_CashAndCashEquivalentMaturityPeriod"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MarketableDebtSecuritiesMaturitiesDuration" xlink:label="tngx_MarketableDebtSecuritiesMaturitiesDuration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201813Member" xlink:label="us-gaap_AccountingStandardsUpdate201813Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201815Member" xlink:label="us-gaap_AccountingStandardsUpdate201815Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ExpectedDividendAssumed" xlink:label="tngx_ExpectedDividendAssumed"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tngx_SignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_SignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_VestingAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="tngx_CashAndCashEquivalentMaturityPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="tngx_MarketableDebtSecuritiesMaturitiesDuration" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201813Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201815Member" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_SignificantAccountingPoliciesTable" xlink:to="tngx_SignificantAccountingPoliciesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCash" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="tngx_ExpectedDividendAssumed" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsAbstract" xlink:label="us-gaap_ScheduleOfInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SignificantAccountingPoliciesLineItems" xlink:label="tngx_SignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SignificantAccountingPoliciesTable" xlink:label="tngx_SignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_LaboratoryEquipmentMember" xlink:label="tngx_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tngx_SignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_SignificantAccountingPoliciesTable" xlink:to="tngx_SignificantAccountingPoliciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tngx_LaboratoryEquipmentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MergerAgreementMember" xlink:label="tngx_MergerAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TangoTherapeuticsIncMember" xlink:label="tngx_TangoTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_BctgAcquisitionCorpMember" xlink:label="tngx_BctgAcquisitionCorpMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_PricePerShare" xlink:label="tngx_PricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_StockIssuedDuringPeriodSharesInExchangeForUnvestedRestrictedStockAwardsAndUnexercisedStockOptions" xlink:label="tngx_StockIssuedDuringPeriodSharesInExchangeForUnvestedRestrictedStockAwardsAndUnexercisedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MergerRecapitalizationExchangeRatio" xlink:label="tngx_MergerRecapitalizationExchangeRatio"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tngx_MergerAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tngx_TangoTherapeuticsIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tngx_BctgAcquisitionCorpMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="tngx_PricePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="tngx_StockIssuedDuringPeriodSharesInExchangeForUnvestedRestrictedStockAwardsAndUnexercisedStockOptions" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="tngx_MergerRecapitalizationExchangeRatio" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfNetProceedsFromBusinessCombinationAndPipeFinancingTransactionsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_BctgTrustAccountMember" xlink:label="tngx_BctgTrustAccountMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_BctgBusinessCombinationAndPipeFinancingMember" xlink:label="tngx_BctgBusinessCombinationAndPipeFinancingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_BctgAcquisitionCorpMember" xlink:label="tngx_BctgAcquisitionCorpMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tngx_BctgTrustAccountMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tngx_BctgBusinessCombinationAndPipeFinancingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tngx_BctgAcquisitionCorpMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_CommonStockOutstandingPriorToBusinessCombination" xlink:label="tngx_CommonStockOutstandingPriorToBusinessCombination"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_BctgAcquisitionCorpMember" xlink:label="tngx_BctgAcquisitionCorpMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_BctgBusinessCombinationAndPipeFinancingMember" xlink:label="tngx_BctgBusinessCombinationAndPipeFinancingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TangoTherapeuticsIncMember" xlink:label="tngx_TangoTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:to="tngx_CommonStockOutstandingPriorToBusinessCombination" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tngx_BctgAcquisitionCorpMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tngx_BctgBusinessCombinationAndPipeFinancingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tngx_TangoTherapeuticsIncMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:to="us-gaap_SharesIssued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionsParentheticalD" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TangoTherapeuticsIncMember" xlink:label="tngx_TangoTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tngx_TangoTherapeuticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="tngx_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesBTrancheOneRedeemableConvertiblePreferredStockMember" xlink:label="tngx_SeriesBTrancheOneRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesBOneRedeemableConvertiblePreferredStockMember" xlink:label="tngx_SeriesBOneRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesBTrancheTwoRedeemableConvertiblePreferredStockMember" xlink:label="tngx_SeriesBTrancheTwoRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MergerRecapitalizationExchangeRatio" xlink:label="tngx_MergerRecapitalizationExchangeRatio"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares" xlink:label="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tngx_SeriesARedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tngx_SeriesBTrancheOneRedeemableConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tngx_SeriesBOneRedeemableConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tngx_SeriesBTrancheTwoRedeemableConvertiblePreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tngx_MergerRecapitalizationExchangeRatio" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfWeightedaverageCommonSharesBasicAndDilutedDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesACommonSharesMember" xlink:label="tngx_SeriesACommonSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments" xlink:label="tngx_WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesBCommonSharesMember" xlink:label="tngx_SeriesBCommonSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesB1CommonSharesMember" xlink:label="tngx_SeriesB1CommonSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MergerRecapitalizationExchangeRatio" xlink:label="tngx_MergerRecapitalizationExchangeRatio"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares" xlink:label="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_WeightedAverageRecapitalizedCommonShares" xlink:label="tngx_WeightedAverageRecapitalizedCommonShares"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_NumberOfDaysOutstanding" xlink:label="tngx_NumberOfDaysOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ConversionWeightagePercentage" xlink:label="tngx_ConversionWeightagePercentage"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tngx_SeriesACommonSharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tngx_WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RestatementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tngx_SeriesBCommonSharesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tngx_SeriesB1CommonSharesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tngx_MergerRecapitalizationExchangeRatio" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tngx_WeightedAverageRecapitalizedCommonShares" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tngx_NumberOfDaysOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tngx_ConversionWeightagePercentage" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesBOnePreferredStockMember" xlink:label="tngx_SeriesBOnePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TwoThousandAndEighteenGileadAgreementMember" xlink:label="tngx_TwoThousandAndEighteenGileadAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_CollaborationAgreementsAbstract" xlink:label="tngx_CollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ResearchTerm" xlink:label="tngx_ResearchTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_CollaborationRevenueMember" xlink:label="tngx_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_NumberOfLicensedProduct" xlink:label="tngx_NumberOfLicensedProduct"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_GileadLetterAgreementMember" xlink:label="tngx_GileadLetterAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_LicenseRevenueMember" xlink:label="tngx_LicenseRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_DelayInOptionToLicenseOrResearchExtensionProgramPeriod" xlink:label="tngx_DelayInOptionToLicenseOrResearchExtensionProgramPeriod"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_AmendedGileadAgreementMember" xlink:label="tngx_AmendedGileadAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_NonrefundableUpfrontPaymentsReceived" xlink:label="tngx_NonrefundableUpfrontPaymentsReceived"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_GileadAgreementMember" xlink:label="tngx_GileadAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_GileadAgreementBasedPerformanceMember" xlink:label="tngx_GileadAgreementBasedPerformanceMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MilestonePaymentsReceivable" xlink:label="tngx_MilestonePaymentsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_CollaborativeAgreementsUpfrontPaymentReceived" xlink:label="tngx_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_PaymentAsConsiderationForThePerformanceOfAdditionalResearchService" xlink:label="tngx_PaymentAsConsiderationForThePerformanceOfAdditionalResearchService"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ResearchExtensionFee" xlink:label="tngx_ResearchExtensionFee"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ResearchExtensionFeeVariableConsideration" xlink:label="tngx_ResearchExtensionFeeVariableConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SponsoredALicenceProgramfeeAmount" xlink:label="tngx_SponsoredALicenceProgramfeeAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromFeesReceived" xlink:label="us-gaap_ProceedsFromFeesReceived"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_AccountsReceivableCurrentResearchExtensionFee" xlink:label="tngx_AccountsReceivableCurrentResearchExtensionFee"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_Contractassetresearchextensionfee" xlink:label="tngx_Contractassetresearchextensionfee"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ReceivableResearchExtensionFee" xlink:label="tngx_ReceivableResearchExtensionFee"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tngx_SeriesBOnePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tngx_TwoThousandAndEighteenGileadAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_CollaborationAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tngx_ResearchTerm" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tngx_CollaborationRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tngx_NumberOfLicensedProduct" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tngx_GileadLetterAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tngx_LicenseRevenueMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tngx_DelayInOptionToLicenseOrResearchExtensionProgramPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tngx_AmendedGileadAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tngx_NonrefundableUpfrontPaymentsReceived" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tngx_GileadAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tngx_GileadAgreementBasedPerformanceMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tngx_MilestonePaymentsReceivable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tngx_CollaborativeAgreementsUpfrontPaymentReceived" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tngx_PaymentAsConsiderationForThePerformanceOfAdditionalResearchService" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tngx_ResearchExtensionFee" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tngx_ResearchExtensionFeeVariableConsideration" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tngx_SponsoredALicenceProgramfeeAmount" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromFeesReceived" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tngx_AccountsReceivableCurrentResearchExtensionFee" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tngx_Contractassetresearchextensionfee" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tngx_ReceivableResearchExtensionFee" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_CollaborationAgreementsAbstract" xlink:label="tngx_CollaborationAgreementsAbstract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_CollaborationAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MarketableDebtSecuritiesMember" xlink:label="tngx_MarketableDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSecuritiesAtCarryingValue" xlink:label="us-gaap_USGovernmentSecuritiesAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="tngx_MarketableDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_USGovernmentSecuritiesAtCarryingValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MarketableDebtSecuritiesMember" xlink:label="tngx_MarketableDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="tngx_MarketableDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MarketableDebtSecuritiesMember" xlink:label="tngx_MarketableDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="tngx_MarketableDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ComputerSoftwareMember" xlink:label="tngx_ComputerSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tngx_ComputerSoftwareMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="tngx_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="tngx_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="tngx_AccruedResearchAndDevelopmentCostsCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="tngx_AccruedExpensesAndOtherCurrentLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TheTwoHundredAndOneBrooklineAvenueLeaseMember" xlink:label="tngx_TheTwoHundredAndOneBrooklineAvenueLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_HundredBinneyStreetInCambridgeMember" xlink:label="tngx_HundredBinneyStreetInCambridgeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_UpfrontPaymentsForRentAndTenantImprovements" xlink:label="tngx_UpfrontPaymentsForRentAndTenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForTenantImprovements" xlink:label="us-gaap_PaymentsForTenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_AnnualRentPayable" xlink:label="tngx_AnnualRentPayable"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_PercentageOfIncreaseInAnnualRentPayable" xlink:label="tngx_PercentageOfIncreaseInAnnualRentPayable"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MinimumRentPaymentsToBePaidOverNoncancelableTerm" xlink:label="tngx_MinimumRentPaymentsToBePaidOverNoncancelableTerm"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MinimumRentPaymentsToBePaidOverOriginalTerm" xlink:label="tngx_MinimumRentPaymentsToBePaidOverOriginalTerm"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_LetterOfCreditToProvideForAmountThatCollateralizedWithCash" xlink:label="tngx_LetterOfCreditToProvideForAmountThatCollateralizedWithCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_LeaseTerminationAgreementMonthAndYear" xlink:label="tngx_LeaseTerminationAgreementMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="tngx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_LetterOfCreditMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tngx_TheTwoHundredAndOneBrooklineAvenueLeaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tngx_HundredBinneyStreetInCambridgeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="tngx_UpfrontPaymentsForRentAndTenantImprovements" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForTenantImprovements" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="tngx_AnnualRentPayable" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="tngx_PercentageOfIncreaseInAnnualRentPayable" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="tngx_MinimumRentPaymentsToBePaidOverNoncancelableTerm" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="tngx_MinimumRentPaymentsToBePaidOverOriginalTerm" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="tngx_LetterOfCreditToProvideForAmountThatCollateralizedWithCash" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_TenantImprovements" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="tngx_LeaseTerminationAgreementMonthAndYear" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="tngx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfElementsOfLeaseCostDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_OtherInformationAbstract" xlink:label="tngx_OtherInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_OtherInformationAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="tngx_OtherInformationAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_OtherInformationAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_OtherInformationAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_AgreementDomain" xlink:label="tngx_AgreementDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_HitgenAgreementMember" xlink:label="tngx_HitgenAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_CommitmentsAndContingenciesDetailsLineItems" xlink:label="tngx_CommitmentsAndContingenciesDetailsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_NumberOfMilestonesAchieved" xlink:label="tngx_NumberOfMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_CommitmentsAndContingenciesDetailsTable" xlink:label="tngx_CommitmentsAndContingenciesDetailsTable"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_AgreementAxis" xlink:label="tngx_AgreementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SpecifiedRegulatoryApprovalAndSalesMilestonesMember" xlink:label="tngx_SpecifiedRegulatoryApprovalAndSalesMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MedivirAgreementMember" xlink:label="tngx_MedivirAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SpecifiedClinicalMilestonesMember" xlink:label="tngx_SpecifiedClinicalMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SpecifiedRegulatoryAndSalesMilestonesForGeneticContextMember" xlink:label="tngx_SpecifiedRegulatoryAndSalesMilestonesForGeneticContextMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_UpfrontPayment" xlink:label="tngx_UpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_PaymentsUponTerminationOfAgreement" xlink:label="tngx_PaymentsUponTerminationOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MilestonePayments" xlink:label="tngx_MilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_FirstLicensedProductAchievesSpecifiedClinicalMilestones" xlink:label="tngx_FirstLicensedProductAchievesSpecifiedClinicalMilestones"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_FirstLicensedProductThatAchievesSpecifiedRegulatoryApprovalAndSalesMilestones" xlink:label="tngx_FirstLicensedProductThatAchievesSpecifiedRegulatoryApprovalAndSalesMilestones"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SpecifiedRegulatoryAndSalesMilestones" xlink:label="tngx_SpecifiedRegulatoryAndSalesMilestones"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MilestonePaymentsAchieved" xlink:label="tngx_MilestonePaymentsAchieved"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_AgreementDomain" xlink:to="tngx_HitgenAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_CommitmentsAndContingenciesDetailsLineItems" xlink:to="tngx_NumberOfMilestonesAchieved" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="tngx_CommitmentsAndContingenciesDetailsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_CommitmentsAndContingenciesDetailsTable" xlink:to="tngx_AgreementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_AgreementAxis" xlink:to="tngx_AgreementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="tngx_SpecifiedRegulatoryApprovalAndSalesMilestonesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_AgreementDomain" xlink:to="tngx_MedivirAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="tngx_SpecifiedClinicalMilestonesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_CommitmentsAndContingenciesDetailsLineItems" xlink:to="us-gaap_ContractualObligation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_CommitmentsAndContingenciesDetailsTable" xlink:to="us-gaap_OtherCommitmentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="tngx_SpecifiedRegulatoryAndSalesMilestonesForGeneticContextMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_CommitmentsAndContingenciesDetailsTable" xlink:to="tngx_CommitmentsAndContingenciesDetailsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_CommitmentsAndContingenciesDetailsLineItems" xlink:to="tngx_UpfrontPayment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_CommitmentsAndContingenciesDetailsLineItems" xlink:to="tngx_PaymentsUponTerminationOfAgreement" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_CommitmentsAndContingenciesDetailsLineItems" xlink:to="tngx_MilestonePayments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_CommitmentsAndContingenciesDetailsLineItems" xlink:to="tngx_FirstLicensedProductAchievesSpecifiedClinicalMilestones" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_CommitmentsAndContingenciesDetailsLineItems" xlink:to="tngx_FirstLicensedProductThatAchievesSpecifiedRegulatoryApprovalAndSalesMilestones" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_CommitmentsAndContingenciesDetailsLineItems" xlink:to="tngx_SpecifiedRegulatoryAndSalesMilestones" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_CommitmentsAndContingenciesDetailsLineItems" xlink:to="tngx_MilestonePaymentsAchieved" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityShareSubscriptions" xlink:label="us-gaap_TemporaryEquityShareSubscriptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="tngx_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="tngx_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesBOneRedeemableConvertiblePreferredStockMember" xlink:label="tngx_SeriesBOneRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_RedeemableConvertiblePreferredStockIssuePricePerShare" xlink:label="tngx_RedeemableConvertiblePreferredStockIssuePricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TemporaryStockIssuanceCosts" xlink:label="tngx_TemporaryStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TemporaryEquityIssuePricePerShare" xlink:label="tngx_TemporaryEquityIssuePricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityShareSubscriptions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tngx_SeriesARedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tngx_SeriesBRedeemableConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tngx_SeriesBOneRedeemableConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tngx_RedeemableConvertiblePreferredStockIssuePricePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tngx_TemporaryStockIssuanceCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tngx_TemporaryEquityIssuePricePerShare" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_CommonStockVotingRights" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_DividendsPayableCurrentAndNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MergerRecapitalizationExchangeRatio" xlink:label="tngx_MergerRecapitalizationExchangeRatio"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_FoundersAndAdvisorsMember" xlink:label="tngx_FoundersAndAdvisorsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_StockOptionsMember" xlink:label="tngx_StockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TwoThousandAndTwentyOnePlanMember" xlink:label="tngx_TwoThousandAndTwentyOnePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_RestrictedCommonStockAwardMember" xlink:label="tngx_RestrictedCommonStockAwardMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:label="tngx_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfStockIssuedAndOutstandingOnImmediatelyPrecedingPercentage" xlink:label="tngx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfStockIssuedAndOutstandingOnImmediatelyPrecedingPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MinimumPercentageOfEstimatedFairValueOfSharesOnGrantDateAsExercisePrice" xlink:label="tngx_MinimumPercentageOfEstimatedFairValueOfSharesOnGrantDateAsExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ThresholdPercentageOfShareholderGrantExercisePriceForCalculationOfPercentOfEstimatedFairValue" xlink:label="tngx_ThresholdPercentageOfShareholderGrantExercisePriceForCalculationOfPercentOfEstimatedFairValue"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MinimumPercentageOfEstimatedFairValueToBeMaintainedForExercisePriceOfTenPercentShareholderThreshold" xlink:label="tngx_MinimumPercentageOfEstimatedFairValueToBeMaintainedForExercisePriceOfTenPercentShareholderThreshold"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tngx_MergerRecapitalizationExchangeRatio" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="tngx_FoundersAndAdvisorsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tngx_StockOptionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tngx_TwoThousandAndTwentyOnePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tngx_RestrictedCommonStockAwardMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="tngx_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tngx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfStockIssuedAndOutstandingOnImmediatelyPrecedingPercentage" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tngx_MinimumPercentageOfEstimatedFairValueOfSharesOnGrantDateAsExercisePrice" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tngx_ThresholdPercentageOfShareholderGrantExercisePriceForCalculationOfPercentOfEstimatedFairValue" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tngx_MinimumPercentageOfEstimatedFairValueToBeMaintainedForExercisePriceOfTenPercentShareholderThreshold" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockAwardsActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_RestrictedCommonStockAwardMember" xlink:label="tngx_RestrictedCommonStockAwardMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tngx_RestrictedCommonStockAwardMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfWeightedAverageAssumptionsUsedToEstimateGrantDateFairValueOfStockOptionsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfStockbasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ResearchAndDevelopmentMember" xlink:label="tngx_ResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_IncomeTaxesLineItems" xlink:label="tngx_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_IncomeTaxesTable" xlink:label="tngx_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_OperatingLossCarryforwardLimitationsOnUse" xlink:label="tngx_OperatingLossCarryforwardLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_OperatingLossCarryForwardWithExpirationOfUsage" xlink:label="tngx_OperatingLossCarryForwardWithExpirationOfUsage"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_OperatingLossCarryForwardWithExpirationOfUsageIndefinite" xlink:label="tngx_OperatingLossCarryForwardWithExpirationOfUsageIndefinite"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_OperatingLossCarryforwardsIndefinite" xlink:label="tngx_OperatingLossCarryforwardsIndefinite"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_OperatingLossCarryforwardsExpirationYear" xlink:label="tngx_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_OperatingLossCarryforwardsExpirationStartingYear" xlink:label="tngx_OperatingLossCarryforwardsExpirationStartingYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TaxCreditCarryforwardExpirationYear" xlink:label="tngx_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_IncreaseOfGrossDeferredTaxAssets" xlink:label="tngx_IncreaseOfGrossDeferredTaxAssets"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_PercentageOfIncreaseInOwnershipPercentageOverAThreeYearPeriod" xlink:label="tngx_PercentageOfIncreaseInOwnershipPercentageOverAThreeYearPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="tngx_ResearchAndDevelopmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="tngx_IncomeTaxesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="tngx_OperatingLossCarryforwardLimitationsOnUse" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_IncomeTaxesTable" xlink:to="tngx_IncomeTaxesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="tngx_OperatingLossCarryForwardWithExpirationOfUsage" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="tngx_OperatingLossCarryForwardWithExpirationOfUsageIndefinite" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="tngx_OperatingLossCarryforwardsIndefinite" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="tngx_OperatingLossCarryforwardsExpirationYear" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="tngx_OperatingLossCarryforwardsExpirationStartingYear" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="tngx_TaxCreditCarryforwardExpirationYear" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="tngx_IncreaseOfGrossDeferredTaxAssets" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="tngx_PercentageOfIncreaseInOwnershipPercentageOverAThreeYearPeriod" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment" xlink:label="tngx_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="tngx_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_DeferredTaxLiabilitiesDepreciation" xlink:label="tngx_DeferredTaxLiabilitiesDepreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="tngx_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="tngx_DeferredTaxLiabilitiesDepreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="tngx_DeferredTaxAssetsOperatingLeaseLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>31
<FILENAME>tngx-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-28T06:45:06.6027+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.tangotx.com/20211231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:tngx="http://www.tangotx.com/20211231" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tngx-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tngx-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tngx-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tngx-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails2" id="DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails2">
        <link:definition>100020 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities Assets (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail2" id="DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail2">
        <link:definition>100030 - Disclosure - Leases - Summary of Future Minimum Lease Payments Under Operating Leases (Detail) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100040 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100050 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" id="StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100060 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>100070 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100080 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation" id="Role_DisclosureNatureOfBusinessAndBasisOfPresentation">
        <link:definition>100090 - Disclosure - Nature of the Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombination1" id="DisclosureBusinessCombination1">
        <link:definition>100110 - Disclosure - Business Combination</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreements" id="Role_DisclosureCollaborationAgreements">
        <link:definition>100120 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100130 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecurities" id="Role_DisclosureMarketableSecurities">
        <link:definition>100140 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformation" id="Role_DisclosureSupplementalBalanceSheetInformation">
        <link:definition>100150 - Disclosure - Supplemental Balance Sheet Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100160 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100170 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStock1" id="DisclosureRedeemableConvertiblePreferredStock1">
        <link:definition>100180 - Disclosure - Redeemable Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommonStock" id="Role_DisclosureCommonStock">
        <link:definition>100190 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlans" id="Role_DisclosureEquityIncentivePlans">
        <link:definition>100200 - Disclosure - Equity Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100210 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100220 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100230 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100240 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationTables" id="DisclosureBusinessCombinationTables">
        <link:definition>100250 - Disclosure - Business Combination (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100260 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesTables" id="Role_DisclosureMarketableSecuritiesTables">
        <link:definition>100270 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationTables" id="Role_DisclosureSupplementalBalanceSheetInformationTables">
        <link:definition>100280 - Disclosure - Supplemental Balance Sheet Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100290 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables" id="Role_DisclosureEquityIncentivePlansTables">
        <link:definition>100300 - Disclosure - Equity Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100310 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100320 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" id="Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>100330 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100340 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails">
        <link:definition>100350 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails">
        <link:definition>100360 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails" id="DisclosureBusinessCombinationAdditionalInformationDetails">
        <link:definition>100370 - Disclosure - Business Combination - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfNetProceedsFromBusinessCombinationAndPipeFinancingTransactionsDetails" id="DisclosureBusinessCombinationSummaryOfNetProceedsFromBusinessCombinationAndPipeFinancingTransactionsDetails">
        <link:definition>100380 - Disclosure - Business Combination - Summary of Net Proceeds from Business Combination and PIPE Financing Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionDetails" id="DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionDetails">
        <link:definition>100390 - Disclosure - Business Combination - Summary of Common Stock Outstanding After Consummation of Business Combination and PIPE Financing Transaction (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionsParentheticalD" id="DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionsParentheticalD">
        <link:definition>100400 - Disclosure - Business Combination - Summary of Common Stock Outstanding After Consummation of Business Combination and PIPE Financing Transactions (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationDetails" id="DisclosureBusinessCombinationSummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationDetails">
        <link:definition>100410 - Disclosure - Business Combination - Summary of Redeemable Convertible Preferred Stock Issued and Outstanding After Consummation of Business Combination (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfWeightedaverageCommonSharesBasicAndDilutedDetails" id="DisclosureBusinessCombinationSummaryOfWeightedaverageCommonSharesBasicAndDilutedDetails">
        <link:definition>100420 - Disclosure - Business Combination - Summary of Weighted-Average Common Shares, Basic and Diluted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" id="Role_DisclosureCollaborationAgreementsAdditionalInformationDetails">
        <link:definition>100430 - Disclosure - Collaboration Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails1" id="DisclosureCollaborationAgreementsAdditionalInformationDetails1">
        <link:definition>100440 - Disclosure - Collaboration Agreements - Additional Information (Details1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100450 - Disclosure - Fair Value Measurements - Summary Financial Assets Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100460 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails" id="Role_DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails">
        <link:definition>100470 - Disclosure - Marketable Securities - Summary of Debt Securities, Available For Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" id="Role_DisclosureMarketableSecuritiesAdditionalInformationDetails">
        <link:definition>100480 - Disclosure - Marketable Securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentNetDetails" id="Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentNetDetails">
        <link:definition>100490 - Disclosure - Supplemental Balance Sheet Information - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetails" id="Role_DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetails">
        <link:definition>100500 - Disclosure - Supplemental Balance Sheet Information - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentDetails" id="DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentDetails">
        <link:definition>100510 - Disclosure - Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Current Liabilities Current (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" id="Role_DisclosureLeasesAdditionalInformationDetails">
        <link:definition>100520 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfElementsOfLeaseCostDetail" id="Role_DisclosureLeasesSummaryOfElementsOfLeaseCostDetail">
        <link:definition>100530 - Disclosure - Leases - Summary of Elements of Lease Cost (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail" id="DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail">
        <link:definition>100540 - Disclosure - Leases - Summary of Future Minimum Lease Payments Under Operating Leases (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100550 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" id="Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>100560 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails" id="Role_DisclosureCommonStockAdditionalInformationDetails">
        <link:definition>100570 - Disclosure - Common Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails" id="Role_DisclosureEquityIncentivePlansAdditionalInformationDetails">
        <link:definition>100580 - Disclosure - Equity Incentive Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockAwardsActivityDetails" id="DisclosureEquityIncentivePlansSummaryOfRestrictedStockAwardsActivityDetails">
        <link:definition>100590 - Disclosure - Equity Incentive Plans - Summary of Restricted Stock Awards Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfStockOptionActivityDetails" id="Role_DisclosureEquityIncentivePlansScheduleOfStockOptionActivityDetails">
        <link:definition>100600 - Disclosure - Equity Incentive Plans - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfWeightedAverageAssumptionsUsedToEstimateGrantDateFairValueOfStockOptionsDetails" id="Role_DisclosureEquityIncentivePlansScheduleOfWeightedAverageAssumptionsUsedToEstimateGrantDateFairValueOfStockOptionsDetails">
        <link:definition>100610 - Disclosure - Equity Incentive Plans - Schedule of Weighted Average Assumptions Used to Estimate Grant Date Fair Value of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfStockbasedCompensationExpenseDetails" id="DisclosureEquityIncentivePlansScheduleOfStockbasedCompensationExpenseDetails">
        <link:definition>100620 - Disclosure - Equity Incentive Plans - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100630 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails" id="Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails">
        <link:definition>100640 - Disclosure - Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails" id="DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails">
        <link:definition>100650 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails" id="Role_DisclosureNetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails">
        <link:definition>100660 - Disclosure - Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
        <link:definition>100670 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="tngx_CollaborationAgreementsAbstract" name="CollaborationAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_OtherInformationAbstract" name="OtherInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_AgreementAxis" name="AgreementAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_AccountsReceivableCurrentResearchExtensionFee" name="AccountsReceivableCurrentResearchExtensionFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tngx_AccruedExpensesAndOtherCurrentLiabilities" name="AccruedExpensesAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tngx_AccruedResearchAndDevelopmentCostsCurrent" name="AccruedResearchAndDevelopmentCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tngx_AnnualRentPayable" name="AnnualRentPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tngx_CashAndCashEquivalentMaturityPeriod" name="CashAndCashEquivalentMaturityPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_CashPaidForLeases" name="CashPaidForLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tngx_CollaborativeAgreementsUpfrontPaymentReceived" name="CollaborativeAgreementsUpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tngx_CommonStockOutstandingPriorToBusinessCombination" name="CommonStockOutstandingPriorToBusinessCombination" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tngx_Contractassetresearchextensionfee" name="Contractassetresearchextensionfee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tngx_ConversionWeightagePercentage" name="ConversionWeightagePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_DeferredTaxAssetsOperatingLeaseLiability" name="DeferredTaxAssetsOperatingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tngx_DeferredTaxLiabilitiesDepreciation" name="DeferredTaxLiabilitiesDepreciation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tngx_DelayInOptionToLicenseOrResearchExtensionProgramPeriod" name="DelayInOptionToLicenseOrResearchExtensionProgramPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment" name="EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_ExpectedDividendAssumed" name="ExpectedDividendAssumed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tngx_FirstLicensedProductAchievesSpecifiedClinicalMilestones" name="FirstLicensedProductAchievesSpecifiedClinicalMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tngx_FirstLicensedProductThatAchievesSpecifiedRegulatoryApprovalAndSalesMilestones" name="FirstLicensedProductThatAchievesSpecifiedRegulatoryApprovalAndSalesMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tngx_IncreaseDecreaseInAccruedExpensesAndOtherLiabilities" name="IncreaseDecreaseInAccruedExpensesAndOtherLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tngx_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tngx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tngx_IncreaseOfGrossDeferredTaxAssets" name="IncreaseOfGrossDeferredTaxAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tngx_LeaseTerminationAgreementMonthAndYear" name="LeaseTerminationAgreementMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_LetterOfCreditToProvideForAmountThatCollateralizedWithCash" name="LetterOfCreditToProvideForAmountThatCollateralizedWithCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tngx_MarketableDebtSecuritiesMaturitiesDuration" name="MarketableDebtSecuritiesMaturitiesDuration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_MergerRecapitalizationExchangeRatio" name="MergerRecapitalizationExchangeRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tngx_MilestonePayments" name="MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tngx_MilestonePaymentsAchieved" name="MilestonePaymentsAchieved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tngx_MilestonePaymentsReceivable" name="MilestonePaymentsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tngx_MinimumPercentageOfEstimatedFairValueOfSharesOnGrantDateAsExercisePrice" name="MinimumPercentageOfEstimatedFairValueOfSharesOnGrantDateAsExercisePrice" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_MinimumPercentageOfEstimatedFairValueToBeMaintainedForExercisePriceOfTenPercentShareholderThreshold" name="MinimumPercentageOfEstimatedFairValueToBeMaintainedForExercisePriceOfTenPercentShareholderThreshold" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_MinimumRentPaymentsToBePaidOverNoncancelableTerm" name="MinimumRentPaymentsToBePaidOverNoncancelableTerm" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tngx_MinimumRentPaymentsToBePaidOverOriginalTerm" name="MinimumRentPaymentsToBePaidOverOriginalTerm" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tngx_NonrefundableUpfrontPaymentsReceived" name="NonrefundableUpfrontPaymentsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tngx_NumberOfDaysOutstanding" name="NumberOfDaysOutstanding" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_NumberOfLicensedProduct" name="NumberOfLicensedProduct" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_NumberOfMilestonesAchieved" name="NumberOfMilestonesAchieved" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_OfferingCost" name="OfferingCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tngx_OperatingLossCarryforwardLimitationsOnUse" name="OperatingLossCarryforwardLimitationsOnUse" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tngx_OperatingLossCarryforwardsExpirationStartingYear" name="OperatingLossCarryforwardsExpirationStartingYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_OperatingLossCarryforwardsIndefinite" name="OperatingLossCarryforwardsIndefinite" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tngx_OperatingLossCarryForwardWithExpirationOfUsage" name="OperatingLossCarryForwardWithExpirationOfUsage" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tngx_OperatingLossCarryForwardWithExpirationOfUsageIndefinite" name="OperatingLossCarryForwardWithExpirationOfUsageIndefinite" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tngx_PaymentAsConsiderationForThePerformanceOfAdditionalResearchService" name="PaymentAsConsiderationForThePerformanceOfAdditionalResearchService" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tngx_PaymentOfBusinessCombinationAndPipeFinancingTransactionCosts" name="PaymentOfBusinessCombinationAndPipeFinancingTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tngx_PaymentsUponTerminationOfAgreement" name="PaymentsUponTerminationOfAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tngx_PercentageOfIncreaseInAnnualRentPayable" name="PercentageOfIncreaseInAnnualRentPayable" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_PercentageOfIncreaseInOwnershipPercentageOverAThreeYearPeriod" name="PercentageOfIncreaseInOwnershipPercentageOverAThreeYearPeriod" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tngx_PricePerShare" name="PricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tngx_ProceedsFromBusinessCombinationAndPipeFinancingGross" name="ProceedsFromBusinessCombinationAndPipeFinancingGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tngx_ReceivableResearchExtensionFee" name="ReceivableResearchExtensionFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tngx_RedeemableConvertiblePreferredStockIssuePricePerShare" name="RedeemableConvertiblePreferredStockIssuePricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tngx_ResearchExtensionFee" name="ResearchExtensionFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tngx_ResearchExtensionFeeVariableConsideration" name="ResearchExtensionFeeVariableConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tngx_ResearchTerm" name="ResearchTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_RetroactiveApplicationOfRecapitalization" name="RetroactiveApplicationOfRecapitalization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tngx_RetroactiveApplicationOfRecapitalizationOne" name="RetroactiveApplicationOfRecapitalizationOne" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tngx_RetroactiveApplicationOfRecapitalizationShares" name="RetroactiveApplicationOfRecapitalizationShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_RetroactiveApplicationOfRecapitalizationSharesOne" name="RetroactiveApplicationOfRecapitalizationSharesOne" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_RevaluationOfRightOfUseAssetAndLeaseLiabilityUponLeaseModification" name="RevaluationOfRightOfUseAssetAndLeaseLiabilityUponLeaseModification" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tngx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfStockIssuedAndOutstandingOnImmediatelyPrecedingPercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfStockIssuedAndOutstandingOnImmediatelyPrecedingPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_SharesOutstandingBeforeRetroactiveApplicationOfRecapitalization" name="SharesOutstandingBeforeRetroactiveApplicationOfRecapitalization" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tngx_SpecifiedRegulatoryAndSalesMilestones" name="SpecifiedRegulatoryAndSalesMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tngx_SponsoredALicenceProgramfeeAmount" name="SponsoredALicenceProgramfeeAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tngx_StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization" name="StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalization" name="StockHoldersEquityRetroactiveApplicationOfRecapitalization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares" name="StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tngx_StockIssuedDuringPeriodSharesAcquisitionsAndPrivateInvestments" name="StockIssuedDuringPeriodSharesAcquisitionsAndPrivateInvestments" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_StockIssuedDuringPeriodSharesInExchangeForUnvestedRestrictedStockAwardsAndUnexercisedStockOptions" name="StockIssuedDuringPeriodSharesInExchangeForUnvestedRestrictedStockAwardsAndUnexercisedStockOptions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments" name="StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tngx_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_TemporaryEquityBeforeRetroactiveApplicationOfRecapitalization" name="TemporaryEquityBeforeRetroactiveApplicationOfRecapitalization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tngx_TemporaryEquityIssuePricePerShare" name="TemporaryEquityIssuePricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tngx_TemporaryEquityRetroactiveApplicationOfRecapitalization" name="TemporaryEquityRetroactiveApplicationOfRecapitalization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tngx_TemporaryEquityRetroactiveApplicationOfRecapitalizationShares" name="TemporaryEquityRetroactiveApplicationOfRecapitalizationShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tngx_TemporaryEquitySharesOutstandingBeforeRetroactiveApplicationOfRecapitalization" name="TemporaryEquitySharesOutstandingBeforeRetroactiveApplicationOfRecapitalization" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_TemporaryStockIssuanceCosts" name="TemporaryStockIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tngx_TemporaryStockRetroactiveApplicationOfRecapitalization" name="TemporaryStockRetroactiveApplicationOfRecapitalization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="tngx_TemporaryStockRetroactiveApplicationOfRecapitalizationShares" name="TemporaryStockRetroactiveApplicationOfRecapitalizationShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_ThresholdPercentageOfShareholderGrantExercisePriceForCalculationOfPercentOfEstimatedFairValue" name="ThresholdPercentageOfShareholderGrantExercisePriceForCalculationOfPercentOfEstimatedFairValue" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_UpfrontPayment" name="UpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tngx_UpfrontPaymentsForRentAndTenantImprovements" name="UpfrontPaymentsForRentAndTenantImprovements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="tngx_WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments" name="WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_WeightedAverageRecapitalizedCommonShares" name="WeightedAverageRecapitalizedCommonShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_AgreementDomain" name="AgreementDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_CommitmentsAndContingenciesDetailsLineItems" name="CommitmentsAndContingenciesDetailsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_SignificantAccountingPoliciesLineItems" name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_AmendedGileadAgreementMember" name="AmendedGileadAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_BctgAcquisitionCorpMember" name="BctgAcquisitionCorpMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_BctgBusinessCombinationAndPipeFinancingMember" name="BctgBusinessCombinationAndPipeFinancingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_BctgTrustAccountMember" name="BctgTrustAccountMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_CollaborationRevenueMember" name="CollaborationRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_ComputerSoftwareMember" name="ComputerSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_FoundersAndAdvisorsMember" name="FoundersAndAdvisorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_GileadAgreementBasedPerformanceMember" name="GileadAgreementBasedPerformanceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_GileadAgreementMember" name="GileadAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_GileadLetterAgreementMember" name="GileadLetterAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_HitgenAgreementMember" name="HitgenAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_HundredBinneyStreetInCambridgeMember" name="HundredBinneyStreetInCambridgeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_LicenseRevenueMember" name="LicenseRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_MarketableDebtSecuritiesMember" name="MarketableDebtSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_MedivirAgreementMember" name="MedivirAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_MergerAgreementMember" name="MergerAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_PublicSharesMember" name="PublicSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_ResearchAndDevelopmentMember" name="ResearchAndDevelopmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_RestrictedCommonStockAwardMember" name="RestrictedCommonStockAwardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_SeriesACommonSharesMember" name="SeriesACommonSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_SeriesARedeemableConvertiblePreferredStockMember" name="SeriesARedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_SeriesB1CommonSharesMember" name="SeriesB1CommonSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_SeriesBCommonSharesMember" name="SeriesBCommonSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_SeriesBOnePreferredStockMember" name="SeriesBOnePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_SeriesBOnePreferredStocksMember" name="SeriesBOnePreferredStocksMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_SeriesBOneRedeemableConvertiblePreferredStockMember" name="SeriesBOneRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_SeriesBRedeemableConvertiblePreferredStockMember" name="SeriesBRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_SeriesBTrancheOneRedeemableConvertiblePreferredStockMember" name="SeriesBTrancheOneRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_SeriesBTrancheTwoRedeemableConvertiblePreferredStockMember" name="SeriesBTrancheTwoRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_SpecifiedClinicalMilestonesMember" name="SpecifiedClinicalMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_SpecifiedRegulatoryAndSalesMilestonesForGeneticContextMember" name="SpecifiedRegulatoryAndSalesMilestonesForGeneticContextMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_SpecifiedRegulatoryApprovalAndSalesMilestonesMember" name="SpecifiedRegulatoryApprovalAndSalesMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_StockOptionsMember" name="StockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_TangoTherapeuticsIncMember" name="TangoTherapeuticsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_TheTwoHundredAndOneBrooklineAvenueLeaseMember" name="TheTwoHundredAndOneBrooklineAvenueLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_TwoThousandAndEighteenGileadAgreementMember" name="TwoThousandAndEighteenGileadAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" name="TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_TwoThousandAndTwentyOnePlanMember" name="TwoThousandAndTwentyOnePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_PatentCostsPolicyTextBlock" name="PatentCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" name="RecentlyIssuedAccountingPronouncementsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_CommitmentsAndContingenciesDetailsTable" name="CommitmentsAndContingenciesDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_SignificantAccountingPoliciesTable" name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="tngx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentTableTextBlock" name="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" name="ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_DeferredFinancingCostsPolicyTextBlock" name="DeferredFinancingCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_RedeemableConvertiblePreferredStockDisclosureTextBlock" name="RedeemableConvertiblePreferredStockDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="tngx_SummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationTableTextBlock" name="SummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>32
<FILENAME>tngx-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-28T06:45:12.3061+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="tngx-20211231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails2" xlink:href="tngx-20211231.xsd#DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail2" xlink:href="tngx-20211231.xsd#DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="tngx-20211231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="tngx-20211231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:href="tngx-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentNetDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentDetails" xlink:href="tngx-20211231.xsd#DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfElementsOfLeaseCostDetail" xlink:href="tngx-20211231.xsd#Role_DisclosureLeasesSummaryOfElementsOfLeaseCostDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail" xlink:href="tngx-20211231.xsd#DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails" xlink:href="tngx-20211231.xsd#DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="tngx_AccruedExpensesAndOtherCurrentLiabilities" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_TaxesPayableCurrent" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="tngx_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeExpenseNet" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="tngx_ProceedsFromBusinessCombinationAndPipeFinancingGross" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="2" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="tngx_PaymentOfBusinessCombinationAndPipeFinancingTransactionCosts" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" order="3" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="4" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="5" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="6" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="7" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="8" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tngx_IncreaseDecreaseInAccruedExpensesAndOtherLiabilities" order="9" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tngx_IncreaseDecreaseInOperatingLeaseLiabilities" order="10" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="11" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ProceedsFromBusinessCombinationAndPipeFinancingGross" xlink:label="tngx_ProceedsFromBusinessCombinationAndPipeFinancingGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_PaymentOfBusinessCombinationAndPipeFinancingTransactionCosts" xlink:label="tngx_PaymentOfBusinessCombinationAndPipeFinancingTransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_IncreaseDecreaseInAccruedExpensesAndOtherLiabilities" xlink:label="tngx_IncreaseDecreaseInAccruedExpensesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="tngx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_USGovernmentSecuritiesAtCarryingValue" order="2" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSecuritiesAtCarryingValue" xlink:label="us-gaap_USGovernmentSecuritiesAtCarryingValue"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentNetDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="tngx_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="tngx_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="tngx_AccruedResearchAndDevelopmentCostsCurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="tngx_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="tngx_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="tngx_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfElementsOfLeaseCostDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="2" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="tngx_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="5" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment" xlink:label="tngx_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="tngx_DeferredTaxLiabilitiesDepreciation" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="tngx_DeferredTaxAssetsOperatingLeaseLiability" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_DeferredTaxLiabilitiesDepreciation" xlink:label="tngx_DeferredTaxLiabilitiesDepreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="tngx_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>33
<FILENAME>tngx-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-28T06:45:12.0771+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="tngx-20211231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="tngx-20211231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="tngx-20211231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="tngx-20211231.xsd#StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="tngx-20211231.xsd#StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables" xlink:href="tngx-20211231.xsd#Role_DisclosureEquityIncentivePlansTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails" xlink:href="tngx-20211231.xsd#DisclosureBusinessCombinationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfNetProceedsFromBusinessCombinationAndPipeFinancingTransactionsDetails" xlink:href="tngx-20211231.xsd#DisclosureBusinessCombinationSummaryOfNetProceedsFromBusinessCombinationAndPipeFinancingTransactionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionDetails" xlink:href="tngx-20211231.xsd#DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionsParentheticalD" xlink:href="tngx-20211231.xsd#DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionsParentheticalD" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationDetails" xlink:href="tngx-20211231.xsd#DisclosureBusinessCombinationSummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfWeightedaverageCommonSharesBasicAndDilutedDetails" xlink:href="tngx-20211231.xsd#DisclosureBusinessCombinationSummaryOfWeightedaverageCommonSharesBasicAndDilutedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails1" xlink:href="tngx-20211231.xsd#DisclosureCollaborationAgreementsAdditionalInformationDetails1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentNetDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureEquityIncentivePlansAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockAwardsActivityDetails" xlink:href="tngx-20211231.xsd#DisclosureEquityIncentivePlansSummaryOfRestrictedStockAwardsActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfStockOptionActivityDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureEquityIncentivePlansScheduleOfStockOptionActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfWeightedAverageAssumptionsUsedToEstimateGrantDateFairValueOfStockOptionsDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureEquityIncentivePlansScheduleOfWeightedAverageAssumptionsUsedToEstimateGrantDateFairValueOfStockOptionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfStockbasedCompensationExpenseDetails" xlink:href="tngx-20211231.xsd#DisclosureEquityIncentivePlansScheduleOfStockbasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="tngx-20211231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="tngx-20211231.xsd#Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="tngx_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesBOnePreferredStocksMember" xlink:label="tngx_SeriesBOnePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="tngx_AccruedExpensesAndOtherCurrentLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tngx_SeriesBOnePreferredStocksMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_TaxesPayableCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesBOnePreferredStocksMember" xlink:label="tngx_SeriesBOnePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tngx_SeriesBOnePreferredStocksMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_CollaborationRevenueMember" xlink:label="tngx_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_LicenseRevenueMember" xlink:label="tngx_LicenseRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tngx_CollaborationRevenueMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tngx_LicenseRevenueMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization" xlink:label="tngx_StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SharesOutstandingBeforeRetroactiveApplicationOfRecapitalization" xlink:label="tngx_SharesOutstandingBeforeRetroactiveApplicationOfRecapitalization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TemporaryEquityBeforeRetroactiveApplicationOfRecapitalization" xlink:label="tngx_TemporaryEquityBeforeRetroactiveApplicationOfRecapitalization"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesBOnePreferredStocksMember" xlink:label="tngx_SeriesBOnePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TemporaryEquitySharesOutstandingBeforeRetroactiveApplicationOfRecapitalization" xlink:label="tngx_TemporaryEquitySharesOutstandingBeforeRetroactiveApplicationOfRecapitalization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalization" xlink:label="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalization"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares" xlink:label="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TemporaryEquityRetroactiveApplicationOfRecapitalization" xlink:label="tngx_TemporaryEquityRetroactiveApplicationOfRecapitalization"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TemporaryEquityRetroactiveApplicationOfRecapitalizationShares" xlink:label="tngx_TemporaryEquityRetroactiveApplicationOfRecapitalizationShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_RetroactiveApplicationOfRecapitalization" xlink:label="tngx_RetroactiveApplicationOfRecapitalization"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_RetroactiveApplicationOfRecapitalizationShares" xlink:label="tngx_RetroactiveApplicationOfRecapitalizationShares"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_RetroactiveApplicationOfRecapitalizationOne" xlink:label="tngx_RetroactiveApplicationOfRecapitalizationOne"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_RetroactiveApplicationOfRecapitalizationSharesOne" xlink:label="tngx_RetroactiveApplicationOfRecapitalizationSharesOne"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TemporaryStockRetroactiveApplicationOfRecapitalization" xlink:label="tngx_TemporaryStockRetroactiveApplicationOfRecapitalization"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TemporaryStockRetroactiveApplicationOfRecapitalizationShares" xlink:label="tngx_TemporaryStockRetroactiveApplicationOfRecapitalizationShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments" xlink:label="tngx_StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_StockIssuedDuringPeriodSharesAcquisitionsAndPrivateInvestments" xlink:label="tngx_StockIssuedDuringPeriodSharesAcquisitionsAndPrivateInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_SharesOutstandingBeforeRetroactiveApplicationOfRecapitalization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_TemporaryEquityBeforeRetroactiveApplicationOfRecapitalization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tngx_SeriesBOnePreferredStocksMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_TemporaryEquitySharesOutstandingBeforeRetroactiveApplicationOfRecapitalization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_TemporaryEquityRetroactiveApplicationOfRecapitalization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_TemporaryEquityRetroactiveApplicationOfRecapitalizationShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_RetroactiveApplicationOfRecapitalization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_RetroactiveApplicationOfRecapitalizationShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_RetroactiveApplicationOfRecapitalizationOne" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_RetroactiveApplicationOfRecapitalizationSharesOne" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_TemporaryStockRetroactiveApplicationOfRecapitalization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_TemporaryStockRetroactiveApplicationOfRecapitalizationShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_StockIssuedDuringPeriodSharesAcquisitionsAndPrivateInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesBOnePreferredStocksMember" xlink:label="tngx_SeriesBOnePreferredStocksMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tngx_SeriesBOnePreferredStocksMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_BctgAcquisitionCorpMember" xlink:label="tngx_BctgAcquisitionCorpMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_PublicSharesMember" xlink:label="tngx_PublicSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MergerAgreementMember" xlink:label="tngx_MergerAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_OfferingCost" xlink:label="tngx_OfferingCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDeferredSalesCommissions" xlink:label="us-gaap_AmortizationOfDeferredSalesCommissions"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tngx_BctgAcquisitionCorpMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tngx_PublicSharesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tngx_MergerAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tngx_OfferingCost" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfDeferredSalesCommissions" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SignificantAccountingPoliciesLineItems" xlink:label="tngx_SignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SignificantAccountingPoliciesTable" xlink:label="tngx_SignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_CashAndCashEquivalentMaturityPeriod" xlink:label="tngx_CashAndCashEquivalentMaturityPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201813Member" xlink:label="us-gaap_AccountingStandardsUpdate201813Member"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MarketableDebtSecuritiesMaturitiesDuration" xlink:label="tngx_MarketableDebtSecuritiesMaturitiesDuration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201815Member" xlink:label="us-gaap_AccountingStandardsUpdate201815Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ExpectedDividendAssumed" xlink:label="tngx_ExpectedDividendAssumed"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="tngx_SignificantAccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tngx_SignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="tngx_CashAndCashEquivalentMaturityPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tngx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201813Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="tngx_MarketableDebtSecuritiesMaturitiesDuration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tngx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201815Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tngx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="tngx_ExpectedDividendAssumed" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredOfferingCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SignificantAccountingPoliciesLineItems" xlink:label="tngx_SignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SignificantAccountingPoliciesTable" xlink:label="tngx_SignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_LaboratoryEquipmentMember" xlink:label="tngx_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="tngx_SignificantAccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tngx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tngx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tngx_LaboratoryEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MergerAgreementMember" xlink:label="tngx_MergerAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TangoTherapeuticsIncMember" xlink:label="tngx_TangoTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_BctgAcquisitionCorpMember" xlink:label="tngx_BctgAcquisitionCorpMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_PricePerShare" xlink:label="tngx_PricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_StockIssuedDuringPeriodSharesInExchangeForUnvestedRestrictedStockAwardsAndUnexercisedStockOptions" xlink:label="tngx_StockIssuedDuringPeriodSharesInExchangeForUnvestedRestrictedStockAwardsAndUnexercisedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MergerRecapitalizationExchangeRatio" xlink:label="tngx_MergerRecapitalizationExchangeRatio"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tngx_MergerAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tngx_TangoTherapeuticsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tngx_BctgAcquisitionCorpMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="tngx_PricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="tngx_StockIssuedDuringPeriodSharesInExchangeForUnvestedRestrictedStockAwardsAndUnexercisedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="tngx_MergerRecapitalizationExchangeRatio" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfNetProceedsFromBusinessCombinationAndPipeFinancingTransactionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_BctgTrustAccountMember" xlink:label="tngx_BctgTrustAccountMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_BctgBusinessCombinationAndPipeFinancingMember" xlink:label="tngx_BctgBusinessCombinationAndPipeFinancingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_BctgAcquisitionCorpMember" xlink:label="tngx_BctgAcquisitionCorpMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tngx_BctgTrustAccountMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tngx_BctgBusinessCombinationAndPipeFinancingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tngx_BctgAcquisitionCorpMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_CommonStockOutstandingPriorToBusinessCombination" xlink:label="tngx_CommonStockOutstandingPriorToBusinessCombination"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_BctgAcquisitionCorpMember" xlink:label="tngx_BctgAcquisitionCorpMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_BctgBusinessCombinationAndPipeFinancingMember" xlink:label="tngx_BctgBusinessCombinationAndPipeFinancingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TangoTherapeuticsIncMember" xlink:label="tngx_TangoTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:to="tngx_CommonStockOutstandingPriorToBusinessCombination" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tngx_BctgAcquisitionCorpMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tngx_BctgBusinessCombinationAndPipeFinancingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tngx_TangoTherapeuticsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:to="us-gaap_SharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionsParentheticalD">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TangoTherapeuticsIncMember" xlink:label="tngx_TangoTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="tngx_TangoTherapeuticsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="tngx_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesBTrancheOneRedeemableConvertiblePreferredStockMember" xlink:label="tngx_SeriesBTrancheOneRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesBOneRedeemableConvertiblePreferredStockMember" xlink:label="tngx_SeriesBOneRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesBTrancheTwoRedeemableConvertiblePreferredStockMember" xlink:label="tngx_SeriesBTrancheTwoRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MergerRecapitalizationExchangeRatio" xlink:label="tngx_MergerRecapitalizationExchangeRatio"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares" xlink:label="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tngx_SeriesARedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tngx_SeriesBTrancheOneRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tngx_SeriesBOneRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tngx_SeriesBTrancheTwoRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tngx_MergerRecapitalizationExchangeRatio" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfWeightedaverageCommonSharesBasicAndDilutedDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments" xlink:label="tngx_WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesACommonSharesMember" xlink:label="tngx_SeriesACommonSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesBCommonSharesMember" xlink:label="tngx_SeriesBCommonSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MergerRecapitalizationExchangeRatio" xlink:label="tngx_MergerRecapitalizationExchangeRatio"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesB1CommonSharesMember" xlink:label="tngx_SeriesB1CommonSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares" xlink:label="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_WeightedAverageRecapitalizedCommonShares" xlink:label="tngx_WeightedAverageRecapitalizedCommonShares"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_NumberOfDaysOutstanding" xlink:label="tngx_NumberOfDaysOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ConversionWeightagePercentage" xlink:label="tngx_ConversionWeightagePercentage"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tngx_WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tngx_SeriesACommonSharesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RestatementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tngx_SeriesBCommonSharesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tngx_MergerRecapitalizationExchangeRatio" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tngx_SeriesB1CommonSharesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tngx_WeightedAverageRecapitalizedCommonShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tngx_NumberOfDaysOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tngx_ConversionWeightagePercentage" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_CollaborationRevenueMember" xlink:label="tngx_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesBOnePreferredStockMember" xlink:label="tngx_SeriesBOnePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TwoThousandAndEighteenGileadAgreementMember" xlink:label="tngx_TwoThousandAndEighteenGileadAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ResearchTerm" xlink:label="tngx_ResearchTerm"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_LicenseRevenueMember" xlink:label="tngx_LicenseRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_GileadLetterAgreementMember" xlink:label="tngx_GileadLetterAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_NumberOfLicensedProduct" xlink:label="tngx_NumberOfLicensedProduct"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_DelayInOptionToLicenseOrResearchExtensionProgramPeriod" xlink:label="tngx_DelayInOptionToLicenseOrResearchExtensionProgramPeriod"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_AmendedGileadAgreementMember" xlink:label="tngx_AmendedGileadAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_NonrefundableUpfrontPaymentsReceived" xlink:label="tngx_NonrefundableUpfrontPaymentsReceived"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_GileadAgreementMember" xlink:label="tngx_GileadAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MilestonePaymentsReceivable" xlink:label="tngx_MilestonePaymentsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_GileadAgreementBasedPerformanceMember" xlink:label="tngx_GileadAgreementBasedPerformanceMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_CollaborativeAgreementsUpfrontPaymentReceived" xlink:label="tngx_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_PaymentAsConsiderationForThePerformanceOfAdditionalResearchService" xlink:label="tngx_PaymentAsConsiderationForThePerformanceOfAdditionalResearchService"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ResearchExtensionFee" xlink:label="tngx_ResearchExtensionFee"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ResearchExtensionFeeVariableConsideration" xlink:label="tngx_ResearchExtensionFeeVariableConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SponsoredALicenceProgramfeeAmount" xlink:label="tngx_SponsoredALicenceProgramfeeAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromFeesReceived" xlink:label="us-gaap_ProceedsFromFeesReceived"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_AccountsReceivableCurrentResearchExtensionFee" xlink:label="tngx_AccountsReceivableCurrentResearchExtensionFee"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_Contractassetresearchextensionfee" xlink:label="tngx_Contractassetresearchextensionfee"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ReceivableResearchExtensionFee" xlink:label="tngx_ReceivableResearchExtensionFee"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tngx_CollaborationRevenueMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tngx_SeriesBOnePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tngx_TwoThousandAndEighteenGileadAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tngx_ResearchTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tngx_LicenseRevenueMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tngx_GileadLetterAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tngx_NumberOfLicensedProduct" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tngx_DelayInOptionToLicenseOrResearchExtensionProgramPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tngx_AmendedGileadAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tngx_NonrefundableUpfrontPaymentsReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tngx_GileadAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tngx_MilestonePaymentsReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="tngx_GileadAgreementBasedPerformanceMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tngx_CollaborativeAgreementsUpfrontPaymentReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tngx_PaymentAsConsiderationForThePerformanceOfAdditionalResearchService" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tngx_ResearchExtensionFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tngx_ResearchExtensionFeeVariableConsideration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tngx_SponsoredALicenceProgramfeeAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromFeesReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tngx_AccountsReceivableCurrentResearchExtensionFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tngx_Contractassetresearchextensionfee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="tngx_ReceivableResearchExtensionFee" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails1">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MarketableDebtSecuritiesMember" xlink:label="tngx_MarketableDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSecuritiesAtCarryingValue" xlink:label="us-gaap_USGovernmentSecuritiesAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="tngx_MarketableDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_USGovernmentSecuritiesAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MarketableDebtSecuritiesMember" xlink:label="tngx_MarketableDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="tngx_MarketableDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MarketableDebtSecuritiesMember" xlink:label="tngx_MarketableDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="tngx_MarketableDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ComputerSoftwareMember" xlink:label="tngx_ComputerSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tngx_ComputerSoftwareMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TheTwoHundredAndOneBrooklineAvenueLeaseMember" xlink:label="tngx_TheTwoHundredAndOneBrooklineAvenueLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_HundredBinneyStreetInCambridgeMember" xlink:label="tngx_HundredBinneyStreetInCambridgeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_UpfrontPaymentsForRentAndTenantImprovements" xlink:label="tngx_UpfrontPaymentsForRentAndTenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForTenantImprovements" xlink:label="us-gaap_PaymentsForTenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_AnnualRentPayable" xlink:label="tngx_AnnualRentPayable"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_PercentageOfIncreaseInAnnualRentPayable" xlink:label="tngx_PercentageOfIncreaseInAnnualRentPayable"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MinimumRentPaymentsToBePaidOverNoncancelableTerm" xlink:label="tngx_MinimumRentPaymentsToBePaidOverNoncancelableTerm"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MinimumRentPaymentsToBePaidOverOriginalTerm" xlink:label="tngx_MinimumRentPaymentsToBePaidOverOriginalTerm"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_LetterOfCreditToProvideForAmountThatCollateralizedWithCash" xlink:label="tngx_LetterOfCreditToProvideForAmountThatCollateralizedWithCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_LeaseTerminationAgreementMonthAndYear" xlink:label="tngx_LeaseTerminationAgreementMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="tngx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_LetterOfCreditMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tngx_TheTwoHundredAndOneBrooklineAvenueLeaseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="tngx_HundredBinneyStreetInCambridgeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="tngx_UpfrontPaymentsForRentAndTenantImprovements" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForTenantImprovements" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="tngx_AnnualRentPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="tngx_PercentageOfIncreaseInAnnualRentPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="tngx_MinimumRentPaymentsToBePaidOverNoncancelableTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="tngx_MinimumRentPaymentsToBePaidOverOriginalTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="tngx_LetterOfCreditToProvideForAmountThatCollateralizedWithCash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_TenantImprovements" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="tngx_LeaseTerminationAgreementMonthAndYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="tngx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_CommitmentsAndContingenciesDetailsLineItems" xlink:label="tngx_CommitmentsAndContingenciesDetailsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_CommitmentsAndContingenciesDetailsTable" xlink:label="tngx_CommitmentsAndContingenciesDetailsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SpecifiedRegulatoryApprovalAndSalesMilestonesMember" xlink:label="tngx_SpecifiedRegulatoryApprovalAndSalesMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_AgreementAxis" xlink:label="tngx_AgreementAxis"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_AgreementDomain" xlink:label="tngx_AgreementDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_AgreementDomain" xlink:label="tngx_AgreementDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_HitgenAgreementMember" xlink:label="tngx_HitgenAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_NumberOfMilestonesAchieved" xlink:label="tngx_NumberOfMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SpecifiedClinicalMilestonesMember" xlink:label="tngx_SpecifiedClinicalMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MedivirAgreementMember" xlink:label="tngx_MedivirAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SpecifiedRegulatoryAndSalesMilestonesForGeneticContextMember" xlink:label="tngx_SpecifiedRegulatoryAndSalesMilestonesForGeneticContextMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_UpfrontPayment" xlink:label="tngx_UpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_PaymentsUponTerminationOfAgreement" xlink:label="tngx_PaymentsUponTerminationOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MilestonePayments" xlink:label="tngx_MilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_FirstLicensedProductAchievesSpecifiedClinicalMilestones" xlink:label="tngx_FirstLicensedProductAchievesSpecifiedClinicalMilestones"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_FirstLicensedProductThatAchievesSpecifiedRegulatoryApprovalAndSalesMilestones" xlink:label="tngx_FirstLicensedProductThatAchievesSpecifiedRegulatoryApprovalAndSalesMilestones"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SpecifiedRegulatoryAndSalesMilestones" xlink:label="tngx_SpecifiedRegulatoryAndSalesMilestones"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MilestonePaymentsAchieved" xlink:label="tngx_MilestonePaymentsAchieved"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tngx_CommitmentsAndContingenciesDetailsLineItems" xlink:to="tngx_CommitmentsAndContingenciesDetailsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="tngx_SpecifiedRegulatoryApprovalAndSalesMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tngx_CommitmentsAndContingenciesDetailsTable" xlink:to="tngx_AgreementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="tngx_AgreementAxis" xlink:to="tngx_AgreementDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="tngx_AgreementAxis" xlink:to="tngx_AgreementDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_AgreementDomain" xlink:to="tngx_HitgenAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_CommitmentsAndContingenciesDetailsLineItems" xlink:to="tngx_NumberOfMilestonesAchieved" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="tngx_SpecifiedClinicalMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tngx_CommitmentsAndContingenciesDetailsTable" xlink:to="us-gaap_OtherCommitmentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_CommitmentsAndContingenciesDetailsLineItems" xlink:to="us-gaap_ContractualObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_AgreementDomain" xlink:to="tngx_MedivirAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="tngx_SpecifiedRegulatoryAndSalesMilestonesForGeneticContextMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_CommitmentsAndContingenciesDetailsLineItems" xlink:to="tngx_UpfrontPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_CommitmentsAndContingenciesDetailsLineItems" xlink:to="tngx_PaymentsUponTerminationOfAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_CommitmentsAndContingenciesDetailsLineItems" xlink:to="tngx_MilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_CommitmentsAndContingenciesDetailsLineItems" xlink:to="tngx_FirstLicensedProductAchievesSpecifiedClinicalMilestones" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_CommitmentsAndContingenciesDetailsLineItems" xlink:to="tngx_FirstLicensedProductThatAchievesSpecifiedRegulatoryApprovalAndSalesMilestones" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_CommitmentsAndContingenciesDetailsLineItems" xlink:to="tngx_SpecifiedRegulatoryAndSalesMilestones" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_CommitmentsAndContingenciesDetailsLineItems" xlink:to="tngx_MilestonePaymentsAchieved" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="tngx_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityShareSubscriptions" xlink:label="us-gaap_TemporaryEquityShareSubscriptions"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="tngx_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesBOneRedeemableConvertiblePreferredStockMember" xlink:label="tngx_SeriesBOneRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_RedeemableConvertiblePreferredStockIssuePricePerShare" xlink:label="tngx_RedeemableConvertiblePreferredStockIssuePricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TemporaryStockIssuanceCosts" xlink:label="tngx_TemporaryStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TemporaryEquityIssuePricePerShare" xlink:label="tngx_TemporaryEquityIssuePricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tngx_SeriesARedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityShareSubscriptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tngx_SeriesBRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tngx_SeriesBOneRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tngx_RedeemableConvertiblePreferredStockIssuePricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tngx_TemporaryStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="tngx_TemporaryEquityIssuePricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_StockOptionsMember" xlink:label="tngx_StockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MergerRecapitalizationExchangeRatio" xlink:label="tngx_MergerRecapitalizationExchangeRatio"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_FoundersAndAdvisorsMember" xlink:label="tngx_FoundersAndAdvisorsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_RestrictedCommonStockAwardMember" xlink:label="tngx_RestrictedCommonStockAwardMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TwoThousandAndTwentyOnePlanMember" xlink:label="tngx_TwoThousandAndTwentyOnePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:label="tngx_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfStockIssuedAndOutstandingOnImmediatelyPrecedingPercentage" xlink:label="tngx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfStockIssuedAndOutstandingOnImmediatelyPrecedingPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MinimumPercentageOfEstimatedFairValueOfSharesOnGrantDateAsExercisePrice" xlink:label="tngx_MinimumPercentageOfEstimatedFairValueOfSharesOnGrantDateAsExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ThresholdPercentageOfShareholderGrantExercisePriceForCalculationOfPercentOfEstimatedFairValue" xlink:label="tngx_ThresholdPercentageOfShareholderGrantExercisePriceForCalculationOfPercentOfEstimatedFairValue"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MinimumPercentageOfEstimatedFairValueToBeMaintainedForExercisePriceOfTenPercentShareholderThreshold" xlink:label="tngx_MinimumPercentageOfEstimatedFairValueToBeMaintainedForExercisePriceOfTenPercentShareholderThreshold"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tngx_StockOptionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tngx_MergerRecapitalizationExchangeRatio" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="tngx_FoundersAndAdvisorsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tngx_RestrictedCommonStockAwardMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tngx_TwoThousandAndTwentyOnePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="tngx_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tngx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfStockIssuedAndOutstandingOnImmediatelyPrecedingPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tngx_MinimumPercentageOfEstimatedFairValueOfSharesOnGrantDateAsExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tngx_ThresholdPercentageOfShareholderGrantExercisePriceForCalculationOfPercentOfEstimatedFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="tngx_MinimumPercentageOfEstimatedFairValueToBeMaintainedForExercisePriceOfTenPercentShareholderThreshold" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockAwardsActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_RestrictedCommonStockAwardMember" xlink:label="tngx_RestrictedCommonStockAwardMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="tngx_RestrictedCommonStockAwardMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfWeightedAverageAssumptionsUsedToEstimateGrantDateFairValueOfStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_IncomeTaxesLineItems" xlink:label="tngx_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_IncomeTaxesTable" xlink:label="tngx_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ResearchAndDevelopmentMember" xlink:label="tngx_ResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_OperatingLossCarryforwardLimitationsOnUse" xlink:label="tngx_OperatingLossCarryforwardLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_OperatingLossCarryForwardWithExpirationOfUsage" xlink:label="tngx_OperatingLossCarryForwardWithExpirationOfUsage"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_OperatingLossCarryForwardWithExpirationOfUsageIndefinite" xlink:label="tngx_OperatingLossCarryForwardWithExpirationOfUsageIndefinite"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_OperatingLossCarryforwardsIndefinite" xlink:label="tngx_OperatingLossCarryforwardsIndefinite"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_OperatingLossCarryforwardsExpirationYear" xlink:label="tngx_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_OperatingLossCarryforwardsExpirationStartingYear" xlink:label="tngx_OperatingLossCarryforwardsExpirationStartingYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TaxCreditCarryforwardExpirationYear" xlink:label="tngx_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_IncreaseOfGrossDeferredTaxAssets" xlink:label="tngx_IncreaseOfGrossDeferredTaxAssets"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_PercentageOfIncreaseInOwnershipPercentageOverAThreeYearPeriod" xlink:label="tngx_PercentageOfIncreaseInOwnershipPercentageOverAThreeYearPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="tngx_IncomeTaxesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tngx_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="tngx_ResearchAndDevelopmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tngx_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="tngx_OperatingLossCarryforwardLimitationsOnUse" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="tngx_OperatingLossCarryForwardWithExpirationOfUsage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="tngx_OperatingLossCarryForwardWithExpirationOfUsageIndefinite" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="tngx_OperatingLossCarryforwardsIndefinite" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="tngx_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="tngx_OperatingLossCarryforwardsExpirationStartingYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="tngx_TaxCreditCarryforwardExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="tngx_IncreaseOfGrossDeferredTaxAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="tngx_PercentageOfIncreaseInOwnershipPercentageOverAThreeYearPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>34
<FILENAME>tngx-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-28T06:45:11.3919+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ThresholdPercentageOfShareholderGrantExercisePriceForCalculationOfPercentOfEstimatedFairValue" xlink:label="tngx_ThresholdPercentageOfShareholderGrantExercisePriceForCalculationOfPercentOfEstimatedFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_DelayInOptionToLicenseOrResearchExtensionProgramPeriod" xlink:label="tngx_DelayInOptionToLicenseOrResearchExtensionProgramPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MergerRecapitalizationExchangeRatio" xlink:label="tngx_MergerRecapitalizationExchangeRatio"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ResearchExtensionFee" xlink:label="tngx_ResearchExtensionFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_CommonStockOutstandingPriorToBusinessCombination" xlink:label="tngx_CommonStockOutstandingPriorToBusinessCombination"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesBOnePreferredStocksMember" xlink:label="tngx_SeriesBOnePreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SharesOutstandingBeforeRetroactiveApplicationOfRecapitalization" xlink:label="tngx_SharesOutstandingBeforeRetroactiveApplicationOfRecapitalization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesB1CommonSharesMember" xlink:label="tngx_SeriesB1CommonSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ConversionWeightagePercentage" xlink:label="tngx_ConversionWeightagePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesBTrancheTwoRedeemableConvertiblePreferredStockMember" xlink:label="tngx_SeriesBTrancheTwoRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ExpectedDividendAssumed" xlink:label="tngx_ExpectedDividendAssumed"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MinimumPercentageOfEstimatedFairValueOfSharesOnGrantDateAsExercisePrice" xlink:label="tngx_MinimumPercentageOfEstimatedFairValueOfSharesOnGrantDateAsExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_WeightedAverageRecapitalizedCommonShares" xlink:label="tngx_WeightedAverageRecapitalizedCommonShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SpecifiedRegulatoryAndSalesMilestones" xlink:label="tngx_SpecifiedRegulatoryAndSalesMilestones"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ReceivableResearchExtensionFee" xlink:label="tngx_ReceivableResearchExtensionFee"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_BctgBusinessCombinationAndPipeFinancingMember" xlink:label="tngx_BctgBusinessCombinationAndPipeFinancingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TaxCreditCarryforwardExpirationYear" xlink:label="tngx_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDeferredSalesCommissions" xlink:label="us-gaap_AmortizationOfDeferredSalesCommissions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInvestmentsAbstract" xlink:label="us-gaap_ScheduleOfInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:label="tngx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments" xlink:label="tngx_WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TemporaryStockRetroactiveApplicationOfRecapitalizationShares" xlink:label="tngx_TemporaryStockRetroactiveApplicationOfRecapitalizationShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_OfferingCost" xlink:label="tngx_OfferingCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TemporaryEquityBeforeRetroactiveApplicationOfRecapitalization" xlink:label="tngx_TemporaryEquityBeforeRetroactiveApplicationOfRecapitalization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfStockIssuedAndOutstandingOnImmediatelyPrecedingPercentage" xlink:label="tngx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfStockIssuedAndOutstandingOnImmediatelyPrecedingPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_AnnualRentPayable" xlink:label="tngx_AnnualRentPayable"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesBOnePreferredStockMember" xlink:label="tngx_SeriesBOnePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MilestonePayments" xlink:label="tngx_MilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SignificantAccountingPoliciesLineItems" xlink:label="tngx_SignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_PricePerShare" xlink:label="tngx_PricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_CommitmentsAndContingenciesDetailsTable" xlink:label="tngx_CommitmentsAndContingenciesDetailsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_OtherInformationAbstract" xlink:label="tngx_OtherInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:label="us-gaap_AccountingStandardsUpdate201912Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="tngx_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_PaymentsUponTerminationOfAgreement" xlink:label="tngx_PaymentsUponTerminationOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201813Member" xlink:label="us-gaap_AccountingStandardsUpdate201813Member"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:label="tngx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TemporaryEquityRetroactiveApplicationOfRecapitalizationShares" xlink:label="tngx_TemporaryEquityRetroactiveApplicationOfRecapitalizationShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_BctgAcquisitionCorpMember" xlink:label="tngx_BctgAcquisitionCorpMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_HundredBinneyStreetInCambridgeMember" xlink:label="tngx_HundredBinneyStreetInCambridgeMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization" xlink:label="tngx_StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_LetterOfCreditToProvideForAmountThatCollateralizedWithCash" xlink:label="tngx_LetterOfCreditToProvideForAmountThatCollateralizedWithCash"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationTableTextBlock" xlink:label="tngx_SummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_UpfrontPaymentsForRentAndTenantImprovements" xlink:label="tngx_UpfrontPaymentsForRentAndTenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TemporaryEquityRetroactiveApplicationOfRecapitalization" xlink:label="tngx_TemporaryEquityRetroactiveApplicationOfRecapitalization"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_OperatingLossCarryforwardsExpirationYear" xlink:label="tngx_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentTableTextBlock" xlink:label="tngx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments" xlink:label="tngx_StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_OperatingLossCarryForwardWithExpirationOfUsage" xlink:label="tngx_OperatingLossCarryForwardWithExpirationOfUsage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TemporaryStockRetroactiveApplicationOfRecapitalization" xlink:label="tngx_TemporaryStockRetroactiveApplicationOfRecapitalization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TemporaryEquitySharesOutstandingBeforeRetroactiveApplicationOfRecapitalization" xlink:label="tngx_TemporaryEquitySharesOutstandingBeforeRetroactiveApplicationOfRecapitalization"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_AmendedGileadAgreementMember" xlink:label="tngx_AmendedGileadAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MinimumPercentageOfEstimatedFairValueToBeMaintainedForExercisePriceOfTenPercentShareholderThreshold" xlink:label="tngx_MinimumPercentageOfEstimatedFairValueToBeMaintainedForExercisePriceOfTenPercentShareholderThreshold"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ResearchTerm" xlink:label="tngx_ResearchTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_RevaluationOfRightOfUseAssetAndLeaseLiabilityUponLeaseModification" xlink:label="tngx_RevaluationOfRightOfUseAssetAndLeaseLiabilityUponLeaseModification"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_RedeemableConvertiblePreferredStockIssuePricePerShare" xlink:label="tngx_RedeemableConvertiblePreferredStockIssuePricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_AgreementDomain" xlink:label="tngx_AgreementDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_IncreaseDecreaseInAccruedExpensesAndOtherLiabilities" xlink:label="tngx_IncreaseDecreaseInAccruedExpensesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalization" xlink:label="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MinimumRentPaymentsToBePaidOverOriginalTerm" xlink:label="tngx_MinimumRentPaymentsToBePaidOverOriginalTerm"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_StockIssuedDuringPeriodSharesAcquisitionsAndPrivateInvestments" xlink:label="tngx_StockIssuedDuringPeriodSharesAcquisitionsAndPrivateInvestments"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesBOneRedeemableConvertiblePreferredStockMember" xlink:label="tngx_SeriesBOneRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_LicenseRevenueMember" xlink:label="tngx_LicenseRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TwoThousandAndTwentyOnePlanMember" xlink:label="tngx_TwoThousandAndTwentyOnePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_BctgTrustAccountMember" xlink:label="tngx_BctgTrustAccountMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_AccountsReceivableCurrentResearchExtensionFee" xlink:label="tngx_AccountsReceivableCurrentResearchExtensionFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MedivirAgreementMember" xlink:label="tngx_MedivirAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_RestrictedCommonStockAwardMember" xlink:label="tngx_RestrictedCommonStockAwardMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_FoundersAndAdvisorsMember" xlink:label="tngx_FoundersAndAdvisorsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSecuritiesAtCarryingValue" xlink:label="us-gaap_USGovernmentSecuritiesAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_NumberOfDaysOutstanding" xlink:label="tngx_NumberOfDaysOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_CollaborativeAgreementsUpfrontPaymentReceived" xlink:label="tngx_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_CashPaidForLeases" xlink:label="tngx_CashPaidForLeases"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_FirstLicensedProductAchievesSpecifiedClinicalMilestones" xlink:label="tngx_FirstLicensedProductAchievesSpecifiedClinicalMilestones"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_LeaseTerminationAgreementMonthAndYear" xlink:label="tngx_LeaseTerminationAgreementMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TangoTherapeuticsIncMember" xlink:label="tngx_TangoTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_GileadAgreementMember" xlink:label="tngx_GileadAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_PaymentAsConsiderationForThePerformanceOfAdditionalResearchService" xlink:label="tngx_PaymentAsConsiderationForThePerformanceOfAdditionalResearchService"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_GileadLetterAgreementMember" xlink:label="tngx_GileadLetterAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_PaymentOfBusinessCombinationAndPipeFinancingTransactionCosts" xlink:label="tngx_PaymentOfBusinessCombinationAndPipeFinancingTransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MarketableDebtSecuritiesMaturitiesDuration" xlink:label="tngx_MarketableDebtSecuritiesMaturitiesDuration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MarketableDebtSecuritiesMember" xlink:label="tngx_MarketableDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="tngx_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_OperatingLossCarryForwardWithExpirationOfUsageIndefinite" xlink:label="tngx_OperatingLossCarryForwardWithExpirationOfUsageIndefinite"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:label="tngx_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_CommitmentsAndContingenciesDetailsLineItems" xlink:label="tngx_CommitmentsAndContingenciesDetailsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_PercentageOfIncreaseInAnnualRentPayable" xlink:label="tngx_PercentageOfIncreaseInAnnualRentPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="tngx_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForTenantImprovements" xlink:label="us-gaap_PaymentsForTenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_NonrefundableUpfrontPaymentsReceived" xlink:label="tngx_NonrefundableUpfrontPaymentsReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_LaboratoryEquipmentMember" xlink:label="tngx_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesBCommonSharesMember" xlink:label="tngx_SeriesBCommonSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_OperatingLossCarryforwardsIndefinite" xlink:label="tngx_OperatingLossCarryforwardsIndefinite"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_OperatingLossCarryforwardsExpirationStartingYear" xlink:label="tngx_OperatingLossCarryforwardsExpirationStartingYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SpecifiedRegulatoryAndSalesMilestonesForGeneticContextMember" xlink:label="tngx_SpecifiedRegulatoryAndSalesMilestonesForGeneticContextMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_IncomeTaxesLineItems" xlink:label="tngx_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_NumberOfMilestonesAchieved" xlink:label="tngx_NumberOfMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_GileadAgreementBasedPerformanceMember" xlink:label="tngx_GileadAgreementBasedPerformanceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityShareSubscriptions" xlink:label="us-gaap_TemporaryEquityShareSubscriptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:label="tngx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TemporaryEquityIssuePricePerShare" xlink:label="tngx_TemporaryEquityIssuePricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MergerAgreementMember" xlink:label="tngx_MergerAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="tngx_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_RetroactiveApplicationOfRecapitalization" xlink:label="tngx_RetroactiveApplicationOfRecapitalization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SpecifiedRegulatoryApprovalAndSalesMilestonesMember" xlink:label="tngx_SpecifiedRegulatoryApprovalAndSalesMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_CollaborationAgreementsAbstract" xlink:label="tngx_CollaborationAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TemporaryStockIssuanceCosts" xlink:label="tngx_TemporaryStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SignificantAccountingPoliciesTable" xlink:label="tngx_SignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesBTrancheOneRedeemableConvertiblePreferredStockMember" xlink:label="tngx_SeriesBTrancheOneRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_StockOptionsMember" xlink:label="tngx_StockOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_DeferredTaxLiabilitiesDepreciation" xlink:label="tngx_DeferredTaxLiabilitiesDepreciation"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_AgreementAxis" xlink:label="tngx_AgreementAxis"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ResearchExtensionFeeVariableConsideration" xlink:label="tngx_ResearchExtensionFeeVariableConsideration"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ProceedsFromBusinessCombinationAndPipeFinancingGross" xlink:label="tngx_ProceedsFromBusinessCombinationAndPipeFinancingGross"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="tngx_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_OperatingLossCarryforwardLimitationsOnUse" xlink:label="tngx_OperatingLossCarryforwardLimitationsOnUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SponsoredALicenceProgramfeeAmount" xlink:label="tngx_SponsoredALicenceProgramfeeAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TwoThousandAndEighteenGileadAgreementMember" xlink:label="tngx_TwoThousandAndEighteenGileadAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ComputerSoftwareMember" xlink:label="tngx_ComputerSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_UpfrontPayment" xlink:label="tngx_UpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_CollaborationRevenueMember" xlink:label="tngx_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_PercentageOfIncreaseInOwnershipPercentageOverAThreeYearPeriod" xlink:label="tngx_PercentageOfIncreaseInOwnershipPercentageOverAThreeYearPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares" xlink:label="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_CashAndCashEquivalentMaturityPeriod" xlink:label="tngx_CashAndCashEquivalentMaturityPeriod"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_ResearchAndDevelopmentMember" xlink:label="tngx_ResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_RetroactiveApplicationOfRecapitalizationOne" xlink:label="tngx_RetroactiveApplicationOfRecapitalizationOne"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SpecifiedClinicalMilestonesMember" xlink:label="tngx_SpecifiedClinicalMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MilestonePaymentsReceivable" xlink:label="tngx_MilestonePaymentsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_HitgenAgreementMember" xlink:label="tngx_HitgenAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_StockIssuedDuringPeriodSharesInExchangeForUnvestedRestrictedStockAwardsAndUnexercisedStockOptions" xlink:label="tngx_StockIssuedDuringPeriodSharesInExchangeForUnvestedRestrictedStockAwardsAndUnexercisedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment" xlink:label="tngx_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_RedeemableConvertiblePreferredStockDisclosureTextBlock" xlink:label="tngx_RedeemableConvertiblePreferredStockDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_Contractassetresearchextensionfee" xlink:label="tngx_Contractassetresearchextensionfee"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_TheTwoHundredAndOneBrooklineAvenueLeaseMember" xlink:label="tngx_TheTwoHundredAndOneBrooklineAvenueLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_RetroactiveApplicationOfRecapitalizationSharesOne" xlink:label="tngx_RetroactiveApplicationOfRecapitalizationSharesOne"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MilestonePaymentsAchieved" xlink:label="tngx_MilestonePaymentsAchieved"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="tngx_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201815Member" xlink:label="us-gaap_AccountingStandardsUpdate201815Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_IncomeTaxesTable" xlink:label="tngx_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_NumberOfLicensedProduct" xlink:label="tngx_NumberOfLicensedProduct"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_PublicSharesMember" xlink:label="tngx_PublicSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_RetroactiveApplicationOfRecapitalizationShares" xlink:label="tngx_RetroactiveApplicationOfRecapitalizationShares"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_SeriesACommonSharesMember" xlink:label="tngx_SeriesACommonSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_MinimumRentPaymentsToBePaidOverNoncancelableTerm" xlink:label="tngx_MinimumRentPaymentsToBePaidOverNoncancelableTerm"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_FirstLicensedProductThatAchievesSpecifiedRegulatoryApprovalAndSalesMilestones" xlink:label="tngx_FirstLicensedProductThatAchievesSpecifiedRegulatoryApprovalAndSalesMilestones"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_DeferredFinancingCostsPolicyTextBlock" xlink:label="tngx_DeferredFinancingCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_PatentCostsPolicyTextBlock" xlink:label="tngx_PatentCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="tngx-20211231.xsd#tngx_IncreaseOfGrossDeferredTaxAssets" xlink:label="tngx_IncreaseOfGrossDeferredTaxAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromFeesReceived" xlink:label="us-gaap_ProceedsFromFeesReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesAbstract" xlink:label="us-gaap_MarketableSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ThresholdPercentageOfShareholderGrantExercisePriceForCalculationOfPercentOfEstimatedFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Threshold percentage of shareholder grant exercise price for calculation of percent of estimated fair value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ThresholdPercentageOfShareholderGrantExercisePriceForCalculationOfPercentOfEstimatedFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Threshold Percentage Of Shareholder Grant Exercise Price For Calculation Of Percent Of Estimated Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ThresholdPercentageOfShareholderGrantExercisePriceForCalculationOfPercentOfEstimatedFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Threshold percentage of shareholder grant exercise price for calculation of percent of estimated fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Level1 To Level2 Transfers Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value liabilities transfer from Level 1 to Level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting rights description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle accounting standards update early adoption [true or false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Early Adoption [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_DelayInOptionToLicenseOrResearchExtensionProgramPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Delay in option to license or research extension program period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_DelayInOptionToLicenseOrResearchExtensionProgramPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Delay in Option to License or Research Extension Program Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_DelayInOptionToLicenseOrResearchExtensionProgramPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Delay in option to license or research extension program period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MergerRecapitalizationExchangeRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Merger Exchange Ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MergerRecapitalizationExchangeRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Merger recapitalization exchange ratio.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MergerRecapitalizationExchangeRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Merger Recapitalization Exchange Ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ResearchExtensionFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research Extension Fee .</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ResearchExtensionFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Extension Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ResearchExtensionFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research extension fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments, Fair Value Disclosure, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable debt securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reduction of operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction of operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_CommonStockOutstandingPriorToBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares outstanding prior to business combination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_CommonStockOutstandingPriorToBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock outstanding prior to business combination.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_CommonStockOutstandingPriorToBusinessCombination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Outstanding Prior To Business Combination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments in Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesBOnePreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable Convertible Preferred Stock Series B-1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesBOnePreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B One Preferred Stocks [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesBOnePreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock Series B-1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested restricted common stock outstanding, Weighted average grant-date fair value, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for future grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SharesOutstandingBeforeRetroactiveApplicationOfRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning before retroactive application of recapitalization (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SharesOutstandingBeforeRetroactiveApplicationOfRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance at the beginning before retroactive application of recapitalization (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SharesOutstandingBeforeRetroactiveApplicationOfRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares outstanding before retroactive application of recapitalization.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SharesOutstandingBeforeRetroactiveApplicationOfRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding Before Retroactive Application Of Recapitalization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Common Stock Outstanding After Consummation of Business Combination and PIPE Financing Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions by Acquisition, Equity Interest Issued or Issuable [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesB1CommonSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B-1 Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesB1CommonSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B-1 common shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesB1CommonSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B-1 Common Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; 200,000,000 and 56,393,261 shares authorized at December 31, 2021 and December 31, 2020, respectively;87,598,184 and 40,372,133 shares issued and outstanding as of December 31, 2021 and 2020, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Awards Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Sharebased Compensation Restricted Stock And Restricted Stock Units Activity Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ConversionWeightagePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">% of weighting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ConversionWeightagePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion weightage percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ConversionWeightagePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Weightage Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Income (Expense), Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Goodwill, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Goodwill, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesBTrancheTwoRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B (Tranche 2) Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesBTrancheTwoRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B tranche two redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesBTrancheTwoRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Tranche Two Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Assets Measured at Fair Value on a Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Outstanding common shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Old Tango common shares (after preferred shares were converted 1-for-1 for common shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Convertible, Shares Issuable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ExpectedDividendAssumed_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Expected dividend assumed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ExpectedDividendAssumed_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expected Dividend Assumed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ExpectedDividendAssumed_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend assumed</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MinimumPercentageOfEstimatedFairValueOfSharesOnGrantDateAsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum percentage of estimated fair value of shares on grant date as exercise price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MinimumPercentageOfEstimatedFairValueOfSharesOnGrantDateAsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Percentage Of Estimated Fair Value Of Shares On Grant Date As Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MinimumPercentageOfEstimatedFairValueOfSharesOnGrantDateAsExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum percentage of estimated fair value of shares on date of grant as exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_WeightedAverageRecapitalizedCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average common shares, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_WeightedAverageRecapitalizedCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares, basic and diluted, Recapitalized Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_WeightedAverageRecapitalizedCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average recapitalized common shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average number of common stock outstanding - basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average number of common shares outstanding - basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SpecifiedRegulatoryAndSalesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Specified regulatory and sales milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SpecifiedRegulatoryAndSalesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Specified Regulatory And Sales Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SpecifiedRegulatoryAndSalesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Specified regulatory and sales milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, estimated useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Estimated Useful Lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ReceivableResearchExtensionFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivable research extension fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ReceivableResearchExtensionFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivable Research Extension Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ReceivableResearchExtensionFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Receivable research extension fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_BctgBusinessCombinationAndPipeFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BCTG Business Combination and PIPE Financing [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_BctgBusinessCombinationAndPipeFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">BCTG business combination and PIPE financing.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_BctgBusinessCombinationAndPipeFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">BCTG Business Combination and PIPE Financing [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Contractual Term Options exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock Series B [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Receivable, after Allowance for Credit Loss, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards, expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Revenue Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract with customer liability, revenue recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDeferredSalesCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDeferredSalesCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Deferred Sales Commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Contractual obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contractual Obligation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Obligation to make payments upon termination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Weighted Average Assumptions Used to Estimate Grant Date Fair Value of Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Investments [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total gross deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total gross deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Redeemable convertible preferred stock par or stated value per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Par Or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury Bills [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle accounting standards update adopted [true or false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Recently Issued Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for recently issued accounting pronouncements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recently Issued Accounting Pronouncements Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 9)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average common shares, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average number of share outstanding basic and diluted adjustments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted Adjustments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred to Common exchange ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Convertible, Conversion Ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized (loss) gain on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Unrealized Gain (Loss), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvements allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle accounting standards update immaterial effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryStockRetroactiveApplicationOfRecapitalizationShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Retroactive application of recapitalization (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryStockRetroactiveApplicationOfRecapitalizationShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary stock retroactive application of recapitalization shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryStockRetroactiveApplicationOfRecapitalizationShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Stock Retroactive Application Of Recapitalization Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Noncash Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Income Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_OfferingCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_OfferingCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Offering Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_OfferingCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Offering cost.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryEquityBeforeRetroactiveApplicationOfRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning before retroactive application of recapitalization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryEquityBeforeRetroactiveApplicationOfRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance at the beginning before retroactive application of recapitalization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryEquityBeforeRetroactiveApplicationOfRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity before retroactive application of recapitalization.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryEquityBeforeRetroactiveApplicationOfRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Before Retroactive Application Of Recapitalization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment included in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of shares issued as a proportion of outstanding capital stock on preceding December 31</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfStockIssuedAndOutstandingOnImmediatelyPrecedingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of shares issued as a proportion of outstanding capital stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfStockIssuedAndOutstandingOnImmediatelyPrecedingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Of Stock Issued And Outstanding On Immediately Preceding Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfStockIssuedAndOutstandingOnImmediatelyPrecedingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares of stock issued and outstanding on immediately preceding percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll and employee-related costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common stock issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_AnnualRentPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual rent payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_AnnualRentPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual Rent Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_AnnualRentPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual rent payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesBOnePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series B-1 Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesBOnePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B One Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesBOnePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B One&#160;Preferred Stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesBOnePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B One Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unvested restricted common stock outstanding, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_PricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price per share (in Dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_PricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Price per share.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_PricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total gross deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_CommitmentsAndContingenciesDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and Contingencies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_CommitmentsAndContingenciesDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Details [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_CommitmentsAndContingenciesDetailsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies Details [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Available to Common Stockholders, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to common stockholders &#8211; basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_OtherInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_OtherInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_OtherInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2019-12 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2019-12 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development costs current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Costs Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_AccruedResearchAndDevelopmentCostsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_PaymentsUponTerminationOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments upon termination of agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_PaymentsUponTerminationOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments upon Termination of Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_PaymentsUponTerminationOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments upon termination of agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201813Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2018-13 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201813Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2018-13 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of estimated useful lives of the Company's property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Estimated Useful Lives Of Property And Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of estimated useful lives of the Company's property and equipment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Deferred Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryEquityRetroactiveApplicationOfRecapitalizationShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel">Retroactive application of recapitalization (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryEquityRetroactiveApplicationOfRecapitalizationShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity retroactive application of recapitalization shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryEquityRetroactiveApplicationOfRecapitalizationShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Retroactive Application Of Recapitalization Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental cash flow information:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_BctgAcquisitionCorpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">BCTG acquisition corp.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_BctgAcquisitionCorpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bctg Acquisition Corp [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_BctgAcquisitionCorpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BCTG Acquisition Corp [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Add: non-cash net assets assumed from BCTG</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_HundredBinneyStreetInCambridgeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">100 Binney Street in Cambridge [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_HundredBinneyStreetInCambridgeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hundred Binney Street in Cambridge [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_HundredBinneyStreetInCambridgeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hundred Binney Street in Cambridge.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning before retroactive application of recapitalization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance at the beginning before retroactive application of recapitalization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock holders equity before retroactive application of recapitalization.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Holders Equity Before Retroactive Application Of Recapitalization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_LetterOfCreditToProvideForAmountThatCollateralizedWithCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Letter of credit to provide for amount that collateralized with cash.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_LetterOfCreditToProvideForAmountThatCollateralizedWithCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letter Of Credit To Provide For Amount That Collateralized With Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_LetterOfCreditToProvideForAmountThatCollateralizedWithCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit to provide for amount that collateralized with cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Redeemable Convertible Preferred Stock Issued and Outstanding After Consummation of Business Combination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of redeemable convertible preferred stock issued and outstanding after consummation of business combination.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Redeemable Convertible Preferred Stock Issued and Outstanding After Consummation of Business Combination [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue remaining performance obligations expected remaining contractual term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_UpfrontPaymentsForRentAndTenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payments for rent and tenant improvements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_UpfrontPaymentsForRentAndTenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payments For Rent And Tenant Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_UpfrontPaymentsForRentAndTenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payments for rent and tenant improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryEquityRetroactiveApplicationOfRecapitalization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel">Retroactive application of recapitalization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryEquityRetroactiveApplicationOfRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retroactive application of recapitalization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryEquityRetroactiveApplicationOfRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity retroactive application of recapitalization.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryEquityRetroactiveApplicationOfRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Retroactive Application Of Recapitalization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards, expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Existence Of Option To Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, option to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Accrued Expenses and Other Current Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of accrued expenses and other current liabilities current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Expenses And Other Current Liabilities Current Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Ownership Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity method investment, ownership percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued in Business Combination and PIPE Financing, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value acquisitions and private investments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Acquisitions And Private Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_OperatingLossCarryForwardWithExpirationOfUsage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carry forward with expiration of usage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_OperatingLossCarryForwardWithExpirationOfUsage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carry Forward with Expiration of Usage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_OperatingLossCarryForwardWithExpirationOfUsage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carry forward with expiration of usage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level2 To Level1 Transfers Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value assets transfer from Level 2 to Level 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Agencies Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Agency Bonds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Private Placement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PIPE Financing [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional letter of credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Face Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryStockRetroactiveApplicationOfRecapitalization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Retroactive application of recapitalization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryStockRetroactiveApplicationOfRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary stock retroactive application of recapitalization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryStockRetroactiveApplicationOfRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Stock Retroactive Application Of Recapitalization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of shares (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the ending (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryEquitySharesOutstandingBeforeRetroactiveApplicationOfRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning before retroactive application of recapitalization (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryEquitySharesOutstandingBeforeRetroactiveApplicationOfRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance at the beginning before retroactive application of recapitalization (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryEquitySharesOutstandingBeforeRetroactiveApplicationOfRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity shares outstanding before retroactive application of recapitalization.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryEquitySharesOutstandingBeforeRetroactiveApplicationOfRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Outstanding Before Retroactive Application Of Recapitalization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_AmendedGileadAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended Gilead Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_AmendedGileadAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended gilead agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_AmendedGileadAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended Gilead Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss before income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MinimumPercentageOfEstimatedFairValueToBeMaintainedForExercisePriceOfTenPercentShareholderThreshold_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum percentage of estimated fair value to be maintained for exercise price of ten percent shareholder threshold.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MinimumPercentageOfEstimatedFairValueToBeMaintainedForExercisePriceOfTenPercentShareholderThreshold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Percentage Of Estimated Fair Value To Be Maintained For Exercise Price Of Ten Percent Shareholder Threshold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MinimumPercentageOfEstimatedFairValueToBeMaintainedForExercisePriceOfTenPercentShareholderThreshold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum percentage of estimated fair value to be maintained for exercise price of ten percent shareholder threshold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ResearchTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ResearchTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ResearchTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net contributions from Business Combination and PIPE Financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Consideration Transferred, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds At Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents, Money market funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-13 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-13 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_RevaluationOfRightOfUseAssetAndLeaseLiabilityUponLeaseModification_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revaluation of right-of-use asset and lease liability upon lease modification</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_RevaluationOfRightOfUseAssetAndLeaseLiabilityUponLeaseModification_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revaluation of Right-of-use Asset and Lease Liability Upon Lease Modification</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_RevaluationOfRightOfUseAssetAndLeaseLiabilityUponLeaseModification_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revaluation of right-of-use asset and lease liability upon lease modification.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_RedeemableConvertiblePreferredStockIssuePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity issue price per share.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_RedeemableConvertiblePreferredStockIssuePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock Issue Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_RedeemableConvertiblePreferredStockIssuePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock issue price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options to purchase common stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of redeemable convertible preferred stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">'Weighted Average Contractual Term, Options outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based compensation expense, weighted average period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale and Maturity of Marketable Securities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale And Maturity Of Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales and maturities of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax provision or benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of noncash investing and financing activity:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_AgreementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_AgreementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_AgreementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_IncreaseDecreaseInAccruedExpensesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in accrued expenses and other liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_IncreaseDecreaseInAccruedExpensesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Expenses And Other Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_IncreaseDecreaseInAccruedExpensesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share attributable to common stockholders - basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic and Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per common share &#8211; basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retroactive application of recapitalization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retroactive application of recapitalization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock holders equity retroactive application of recapitalization.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Holders Equity Retroactive Application Of Recapitalization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unvested restricted common stock outstanding, Number of Shares Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unvested restricted common stock outstanding, Number of Shares Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested restricted common stock outstanding, Number of shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Net Proceeds from Business Combination and PIPE Financing Transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MinimumRentPaymentsToBePaidOverOriginalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum rent payments to be paid over original term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MinimumRentPaymentsToBePaidOverOriginalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum rent payments to be paid over original term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_StockIssuedDuringPeriodSharesAcquisitionsAndPrivateInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued in Business Combination and PIPE Financing, net of issuance costs (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_StockIssuedDuringPeriodSharesAcquisitionsAndPrivateInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares acquisitions and private investments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_StockIssuedDuringPeriodSharesAcquisitionsAndPrivateInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Acquisitions And Private Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesBOneRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B one redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesBOneRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B One Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesBOneRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B-1 Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchases of restricted common stock awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Accumulated depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Consideration Received On Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash proceeds from the Business Combination and PIPE Financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Businesses, Net of Cash Acquired, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Payable Current And Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends declared</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Outstanding [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_LicenseRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_LicenseRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">'Weighted Average Exercise Price, Options outstanding Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Options outstanding Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Minimum Lease Payments Under Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TwoThousandAndTwentyOnePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TwoThousandAndTwentyOnePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty one plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TwoThousandAndTwentyOnePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from line of credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Lines of Credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Lines of Credit, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Date of Acquisition Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2020-06 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Emerging Growth Company Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk and Significant Suppliers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of redeemable convertible preferred stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_BctgTrustAccountMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BCTG's Trust Account [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_BctgTrustAccountMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">BCTG trust account.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_BctgTrustAccountMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">BCTG Trust Account [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive (loss) income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total intrinsic value of options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares, Options outstanding Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares, Options outstanding Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_AccountsReceivableCurrentResearchExtensionFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounts Receivable Current Research Extension Fee .</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_AccountsReceivableCurrentResearchExtensionFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Current Research Extension Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_AccountsReceivableCurrentResearchExtensionFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable current, research extension fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MedivirAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Medivir agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MedivirAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Medivir Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MedivirAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Medivir Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Options outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2021 and 2020, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2021 and 2020, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Attributable To Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the ending</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, existence of option to terminate [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Terminate [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenues, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Collaboration revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in number of shares available for grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Unrealized Loss Position, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Unrealized Loss Position</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt securities considered to be an unrealized loss position</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Elements of Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_RestrictedCommonStockAwardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Common Stock Award [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_RestrictedCommonStockAwardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Common Stock Award [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_RestrictedCommonStockAwardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted common stock award.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other comprehensive (loss) income:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_FoundersAndAdvisorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Founders and advisors.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_FoundersAndAdvisorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Founders And Advisors [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_FoundersAndAdvisorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Founders and Advisors [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentSecuritiesAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Securities At Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentSecuritiesAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents, U.S. Treasury bills</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">As Previously Recorded [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Previously Reported [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions by Acquisition, Equity Interest Issued or Issuable [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock Series A [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Balance Sheet Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Redeemable convertible preferred stock issued during period shares new issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock issued during period shares new issues.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of redeemable convertible preferred stock, net of issuance costs, (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected option life (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_NumberOfDaysOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Days Outstanding in 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_NumberOfDaysOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of days outstanding.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_NumberOfDaysOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Days Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Proceeds From Other Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the ending</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized Tax Benefits, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized Tax Benefits, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_CollaborativeAgreementsUpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative agreements upfront payment received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_CollaborativeAgreementsUpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Agreements Upfront Payment Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_CollaborativeAgreementsUpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative agreements upfront payment received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows used for operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Gain (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_CashPaidForLeases_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash paid for leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_CashPaidForLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid for leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_CashPaidForLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid For Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_CashPaidForLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_FirstLicensedProductAchievesSpecifiedClinicalMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First licensed product achieves specified clinical milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_FirstLicensedProductAchievesSpecifiedClinicalMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Licensed Product Achieves Specified Clinical Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_FirstLicensedProductAchievesSpecifiedClinicalMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First licensed product achieves specified clinical milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_LeaseTerminationAgreementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease termination agreement month and year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_LeaseTerminationAgreementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease termination agreement month and year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_LeaseTerminationAgreementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Termination Agreement Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leases Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TangoTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tango Therapeutics, Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TangoTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tango Therapeutics, Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TangoTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tango Therapeutics, Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-term Debt, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Award Tranche Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_GileadAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gilead Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_GileadAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gilead Agreement .</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_GileadAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gilead Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock voting description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Voting Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_PaymentAsConsiderationForThePerformanceOfAdditionalResearchService_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment as consideration for the performance of additional research service.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_PaymentAsConsiderationForThePerformanceOfAdditionalResearchService_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment As Consideration For The Performance Of Additional Research Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_PaymentAsConsiderationForThePerformanceOfAdditionalResearchService_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment as consideration for the performance of additional research service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment estimated useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASC 606 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_GileadLetterAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gilead Letter Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_GileadLetterAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gilead Letter Agreement .</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_GileadLetterAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gilead Letter Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_PaymentOfBusinessCombinationAndPipeFinancingTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of Business Combination and PIPE Financing transaction costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_PaymentOfBusinessCombinationAndPipeFinancingTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of business combination and pipe financing transaction costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_PaymentOfBusinessCombinationAndPipeFinancingTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of Business Combination And PIPE Financing Transaction Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Taxes Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Taxes Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MarketableDebtSecuritiesMaturitiesDuration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable debt securities maturities duration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MarketableDebtSecuritiesMaturitiesDuration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Debt Securities Maturities Duration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MarketableDebtSecuritiesMaturitiesDuration_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Marketable debt securities maturities duration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Redeemable Convertible Preferred Stock Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, non-cancelable term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increases recorded to income tax provision</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Valuation allowance, increase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Other Reconciling Items Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Acquired from Acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MarketableDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable Debt Securities .</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MarketableDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MarketableDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MarketableDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">U.S. Government Agency Bonds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in operating lease liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock Option Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_OperatingLossCarryForwardWithExpirationOfUsageIndefinite_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carry forward with expiration of usage indefinite</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_OperatingLossCarryForwardWithExpirationOfUsageIndefinite_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carry Forward with Expiration of Usage Indefinite</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_OperatingLossCarryForwardWithExpirationOfUsageIndefinite_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carry forward with expiration of usage indefinite.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand and Twenty One Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty one employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_CommitmentsAndContingenciesDetailsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and Contingencies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_CommitmentsAndContingenciesDetailsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Details [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_CommitmentsAndContingenciesDetailsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies (Details) [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business combination, consideration transferred, equity securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_PercentageOfIncreaseInAnnualRentPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of increase in annual rent payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_PercentageOfIncreaseInAnnualRentPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Increase In Annual Rent Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_PercentageOfIncreaseInAnnualRentPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of increase in annual rent payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of preferred stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from the sale of preferred shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Preferred Stock And Preference Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares Options exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested restricted common stock outstanding, Weighted average grant-date fair value, Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Leases [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest or penalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_AccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued expenses and other current liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_AccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Expenses And Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_AccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_AccruedExpensesAndOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable Trade</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForTenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant obligation payments for leasehold improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForTenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Tenant Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_NonrefundableUpfrontPaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-refundable upfront payments received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_NonrefundableUpfrontPaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonrefundable Upfront Payments Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_NonrefundableUpfrontPaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable upfront payment received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesBCommonSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesBCommonSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B common shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesBCommonSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Common Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_OperatingLossCarryforwardsIndefinite_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards indefinite.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_OperatingLossCarryforwardsIndefinite_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Indefinite</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_OperatingLossCarryforwardsIndefinite_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards, indefinite</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting rights percentage upon first anniversary of issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Convertible Conversion Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock price per shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_OperatingLossCarryforwardsExpirationStartingYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss carryforwards expiration starting year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_OperatingLossCarryforwardsExpirationStartingYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Starting Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_OperatingLossCarryforwardsExpirationStartingYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Loss carryforwards expiration starting year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unvested restricted common stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Awards [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less redemption of BCTG shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Number of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options, granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Marketable Securities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction price allocated to performance obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SpecifiedRegulatoryAndSalesMilestonesForGeneticContextMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Specified Regulatory And Sales Milestones For Genetic Context [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SpecifiedRegulatoryAndSalesMilestonesForGeneticContextMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Specified Regulatory And Sales Milestones For Genetic Context [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SpecifiedRegulatoryAndSalesMilestonesForGeneticContextMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Specified regulatory and sales milestones for genetic context.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Option To Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases, option to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_NumberOfMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of milestones achieved.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_NumberOfMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Milestones Achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_NumberOfMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of milestones achieved upon termination of agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities Available For Sale [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock-based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchases of restricted common stock awards, (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Weighted-Average Common Shares, Basic and Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted common stock awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Percentage Of Voting Interests Acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition, percentage of voting interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_GileadAgreementBasedPerformanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gilead Agreement Based Performance [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_GileadAgreementBasedPerformanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gilead Agreement Based Performance [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Options exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityShareSubscriptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Share Subscriptions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityShareSubscriptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock allocated to investors</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate fair value of awards vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted common stock awards issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reduction of operating lease right-of-use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction of operating lease right-of-use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Right of use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in operating lease right of use asset.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryEquityIssuePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Redeemable convertible preferred stock issue price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryEquityIssuePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity issue price per share.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryEquityIssuePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Issue Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryEquityIssuePricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock issue price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of the Business and Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Valuation allowance as of end of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Valuation allowance as of beginning of year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock upon exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Merger agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Merger Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MergerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Merger Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value per share of stock options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_RetroactiveApplicationOfRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retroactive application of recapitalization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_RetroactiveApplicationOfRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Retroactive application of recapitalization.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_RetroactiveApplicationOfRecapitalization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retroactive Application Of Recapitalization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SpecifiedRegulatoryApprovalAndSalesMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Specified Regulatory Approval And Sales Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SpecifiedRegulatoryApprovalAndSalesMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Specified Regulatory Approval And Sales Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SpecifiedRegulatoryApprovalAndSalesMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Specified regulatory approval and sales milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized, cumulative catch-up adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Modification Of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Revenue recognized, cumulative catch-up adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_CollaborationAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration Agreements .</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_CollaborationAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Acquiree [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition, Acquiree</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Redeemable convertible preferred stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary stock issuance costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TemporaryStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesBTrancheOneRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B (Tranche 1) Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesBTrancheOneRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B tranche one redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesBTrancheOneRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Tranche One Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Than Temporary Impairment Loss Debt Securities Available For Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairments to marketable securities or reserves for credit losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Debt Securities, Available-for-sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share conversion ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_StockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_StockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_DeferredTaxLiabilitiesDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities depreciation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_DeferredTaxLiabilitiesDepreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_DeferredTaxLiabilitiesDepreciation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_AgreementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_AgreementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_AgreementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ResearchExtensionFeeVariableConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research extension fee variable consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ResearchExtensionFeeVariableConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Extension Fee Variable Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ResearchExtensionFeeVariableConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research extension fees, variable consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ProceedsFromBusinessCombinationAndPipeFinancingGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combination and PIPE Financing, gross proceeds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ProceedsFromBusinessCombinationAndPipeFinancingGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from business combination and pipe financing gross.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ProceedsFromBusinessCombinationAndPipeFinancingGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Business Combination And PIPE Financing Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_DeferredTaxAssetsOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets operating lease liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average amortization period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals and reserves</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_OperatingLossCarryforwardLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating loss carryforward limitations on use</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_OperatingLossCarryforwardLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforward limitations on use.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_OperatingLossCarryforwardLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforward Limitations On Use</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_OperatingLossCarryforwardLimitationsOnUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards, expire</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle accounting standards update adoption date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SponsoredALicenceProgramfeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sponsored a license program, fee amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SponsoredALicenceProgramfeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sponsored A Licence Programfee Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SponsoredALicenceProgramfeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License fee amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum of number of shares reserved and available for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TwoThousandAndEighteenGileadAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">2018 Gilead Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TwoThousandAndEighteenGileadAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand And Eighteen Gilead Agreement .</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TwoThousandAndEighteenGileadAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Eighteen Gilead Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TwoThousandAndEighteenGileadAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Two Thousand And Eighteen Gilead Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term in years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ComputerSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer Software [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ComputerSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Software [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ComputerSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Software [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities, Accrued interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_UpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other long-term assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License fee amount received, recognized as revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued pursuant to the PIPE Financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Shares, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Shares, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Incentive Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Value Excluding Additional Paid In Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary equity, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_PercentageOfIncreaseInOwnershipPercentageOverAThreeYearPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of increase in ownership percentage over a three year period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_PercentageOfIncreaseInOwnershipPercentageOverAThreeYearPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Increase In Ownership Percentage Over A Three Year Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_PercentageOfIncreaseInOwnershipPercentageOverAThreeYearPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of increase in ownership percentage over a three year period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retroactive application of recapitalization (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recapitalization Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock holders equity retroactive application of recapitalization shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Holders Equity Retroactive Application Of Recapitalization Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unvested restricted common stock outstanding, Weighted average grant-date fair value Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unvested restricted common stock outstanding, Weighted average grant-date fair value Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested restricted common stock outstanding, Weighted average grant-date fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credit carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of redeemable convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Redeemable Convertible Preferred Stock Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the ending (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_CashAndCashEquivalentMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalent maturity period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_CashAndCashEquivalentMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalent Maturity Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_CashAndCashEquivalentMaturityPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalent maturity period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_ResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_RetroactiveApplicationOfRecapitalizationOne_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retroactive application of recapitalization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_RetroactiveApplicationOfRecapitalizationOne_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retroactive Application Of Recapitalization One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_RetroactiveApplicationOfRecapitalizationOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Retroactive application of recapitalization one.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letter of Credit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Equity Interests Issued or Issuable [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-term Debt, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional extension period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SpecifiedClinicalMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Specified Clinical Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SpecifiedClinicalMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Specified Clinical Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SpecifiedClinicalMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Specified clinical milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments receivable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_HitgenAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">HitGen agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_HitgenAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hitgen Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_HitgenAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">HitGen Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_StockIssuedDuringPeriodSharesInExchangeForUnvestedRestrictedStockAwardsAndUnexercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued in exchange for Unvested restricted stock awards and unexercised stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_StockIssuedDuringPeriodSharesInExchangeForUnvestedRestrictedStockAwardsAndUnexercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares in exchange for unvested restricted stock awards and unexercised stock options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_StockIssuedDuringPeriodSharesInExchangeForUnvestedRestrictedStockAwardsAndUnexercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares in Exchange for Unvested Restricted Stock Awards and Unexercised Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation tax credits research and development.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Credits Research And Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and state research and development tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Level2 To Level1 Transfers Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value liabilities transfer from Level 2 to Level 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_RedeemableConvertiblePreferredStockDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_RedeemableConvertiblePreferredStockDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable convertible preferred stock disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_RedeemableConvertiblePreferredStockDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_RedeemableConvertiblePreferredStockDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unvested restricted common stock outstanding, Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_Contractassetresearchextensionfee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ContractAssetResearchExtensionFee .</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_Contractassetresearchextensionfee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractassetresearchextensionfee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_Contractassetresearchextensionfee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract asset, research extension fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TheTwoHundredAndOneBrooklineAvenueLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">201 Brookline Avenue Lease [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TheTwoHundredAndOneBrooklineAvenueLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The Two Hundred And One Brookline Avenue Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_TheTwoHundredAndOneBrooklineAvenueLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">The Two Hundred And One Brookline Avenue Lease [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset Amortization Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash operating lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Convertible Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayments of convertible notes and accrued interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes at U.S. federal statutory rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_RetroactiveApplicationOfRecapitalizationSharesOne_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retroactive application of recapitalization (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_RetroactiveApplicationOfRecapitalizationSharesOne_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retroactive Application Of Recapitalization Shares One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_RetroactiveApplicationOfRecapitalizationSharesOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Retroactive application of recapitalization shares one.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gross proceeds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Or Sale Of Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MilestonePaymentsAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments achieved.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MilestonePaymentsAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MilestonePaymentsAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Software Intangible Asset [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Software [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesARedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201815Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2018-15 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201815Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2018-15 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based compensation expense, exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_NumberOfLicensedProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number Of Licensed Product.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_NumberOfLicensedProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Licensed Product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_NumberOfLicensedProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of licensed product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease terminate option description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to terminate, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Terminate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_PublicSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Share [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_PublicSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_PublicSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less transaction costs and advisory fees paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs and redemptions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Transaction Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_RetroactiveApplicationOfRecapitalizationShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retroactive application of recapitalization (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_RetroactiveApplicationOfRecapitalizationShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Retroactive application of recapitalization shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_RetroactiveApplicationOfRecapitalizationShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retroactive Application Of Recapitalization Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesACommonSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesACommonSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A common shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_SeriesACommonSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Common Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MinimumRentPaymentsToBePaidOverNoncancelableTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum rent payments to be paid over noncancelable term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MinimumRentPaymentsToBePaidOverNoncancelableTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Rent Payments To Be Paid Over Noncancelable Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_MinimumRentPaymentsToBePaidOverNoncancelableTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum rent payments to be paid over the non-cancelable term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_FirstLicensedProductThatAchievesSpecifiedRegulatoryApprovalAndSalesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First licensed product that achieves specified regulatory approval and sales milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_FirstLicensedProductThatAchievesSpecifiedRegulatoryApprovalAndSalesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Licensed Product That Achieves Specified Regulatory Approval And Sales Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_FirstLicensedProductThatAchievesSpecifiedRegulatoryApprovalAndSalesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First licensed product that achieves specified regulatory approval and sales milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unit price (in Dollars per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of stock, price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#8217; Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_DeferredFinancingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Financing Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_DeferredFinancingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Financing Costs [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_DeferredFinancingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred financing costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_PatentCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for patent costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_PatentCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patent Costs Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_PatentCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right-of-use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_IncreaseOfGrossDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase of gross deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_IncreaseOfGrossDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase of Gross Deferred Tax Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="tngx_IncreaseOfGrossDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase of gross deferred tax assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other income (expense):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of Preferred Shares to Common Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Amount Converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other (expense) income, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total fair value of options vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of units issued in transaction (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromFeesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Fees Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromFeesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from fees received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nondeductible/nontaxable permanent items</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level1 To Level2 Transfers Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value assets transfer from Level 1 to Level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value Options exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation related unvested shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_ThresholdPercentageOfShareholderGrantExercisePriceForCalculationOfPercentOfEstimatedFairValue" xlink:to="tngx_ThresholdPercentageOfShareholderGrantExercisePriceForCalculationOfPercentOfEstimatedFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_DelayInOptionToLicenseOrResearchExtensionProgramPeriod" xlink:to="tngx_DelayInOptionToLicenseOrResearchExtensionProgramPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_MergerRecapitalizationExchangeRatio" xlink:to="tngx_MergerRecapitalizationExchangeRatio_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_ResearchExtensionFee" xlink:to="tngx_ResearchExtensionFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_CommonStockOutstandingPriorToBusinessCombination" xlink:to="tngx_CommonStockOutstandingPriorToBusinessCombination_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_SeriesBOnePreferredStocksMember" xlink:to="tngx_SeriesBOnePreferredStocksMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_SharesOutstandingBeforeRetroactiveApplicationOfRecapitalization" xlink:to="tngx_SharesOutstandingBeforeRetroactiveApplicationOfRecapitalization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_SeriesB1CommonSharesMember" xlink:to="tngx_SeriesB1CommonSharesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_ConversionWeightagePercentage" xlink:to="tngx_ConversionWeightagePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_SeriesBTrancheTwoRedeemableConvertiblePreferredStockMember" xlink:to="tngx_SeriesBTrancheTwoRedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_ExpectedDividendAssumed" xlink:to="tngx_ExpectedDividendAssumed_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_MinimumPercentageOfEstimatedFairValueOfSharesOnGrantDateAsExercisePrice" xlink:to="tngx_MinimumPercentageOfEstimatedFairValueOfSharesOnGrantDateAsExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_WeightedAverageRecapitalizedCommonShares" xlink:to="tngx_WeightedAverageRecapitalizedCommonShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_SpecifiedRegulatoryAndSalesMilestones" xlink:to="tngx_SpecifiedRegulatoryAndSalesMilestones_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_ReceivableResearchExtensionFee" xlink:to="tngx_ReceivableResearchExtensionFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_BctgBusinessCombinationAndPipeFinancingMember" xlink:to="tngx_BctgBusinessCombinationAndPipeFinancingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_TaxCreditCarryforwardExpirationYear" xlink:to="tngx_TaxCreditCarryforwardExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDeferredSalesCommissions" xlink:to="us-gaap_AmortizationOfDeferredSalesCommissions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfInvestmentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:to="tngx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments" xlink:to="tngx_WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionRatio" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TenantImprovements" xlink:to="us-gaap_TenantImprovements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_TemporaryStockRetroactiveApplicationOfRecapitalizationShares" xlink:to="tngx_TemporaryStockRetroactiveApplicationOfRecapitalizationShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_OfferingCost" xlink:to="tngx_OfferingCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_TemporaryEquityBeforeRetroactiveApplicationOfRecapitalization" xlink:to="tngx_TemporaryEquityBeforeRetroactiveApplicationOfRecapitalization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfStockIssuedAndOutstandingOnImmediatelyPrecedingPercentage" xlink:to="tngx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfStockIssuedAndOutstandingOnImmediatelyPrecedingPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_AnnualRentPayable" xlink:to="tngx_AnnualRentPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_SeriesBOnePreferredStockMember" xlink:to="tngx_SeriesBOnePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_MilestonePayments" xlink:to="tngx_MilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_SignificantAccountingPoliciesLineItems" xlink:to="tngx_SignificantAccountingPoliciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_PricePerShare" xlink:to="tngx_PricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_CommitmentsAndContingenciesDetailsTable" xlink:to="tngx_CommitmentsAndContingenciesDetailsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_OtherInformationAbstract" xlink:to="tngx_OtherInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201912Member" xlink:to="us-gaap_AccountingStandardsUpdate201912Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="tngx_AccruedResearchAndDevelopmentCostsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_PaymentsUponTerminationOfAgreement" xlink:to="tngx_PaymentsUponTerminationOfAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201813Member" xlink:to="us-gaap_AccountingStandardsUpdate201813Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:to="tngx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_TemporaryEquityRetroactiveApplicationOfRecapitalizationShares" xlink:to="tngx_TemporaryEquityRetroactiveApplicationOfRecapitalizationShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_BctgAcquisitionCorpMember" xlink:to="tngx_BctgAcquisitionCorpMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_HundredBinneyStreetInCambridgeMember" xlink:to="tngx_HundredBinneyStreetInCambridgeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization" xlink:to="tngx_StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_LetterOfCreditToProvideForAmountThatCollateralizedWithCash" xlink:to="tngx_LetterOfCreditToProvideForAmountThatCollateralizedWithCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_SummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationTableTextBlock" xlink:to="tngx_SummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_UpfrontPaymentsForRentAndTenantImprovements" xlink:to="tngx_UpfrontPaymentsForRentAndTenantImprovements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_TemporaryEquityRetroactiveApplicationOfRecapitalization" xlink:to="tngx_TemporaryEquityRetroactiveApplicationOfRecapitalization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_OperatingLossCarryforwardsExpirationYear" xlink:to="tngx_OperatingLossCarryforwardsExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentTableTextBlock" xlink:to="tngx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments" xlink:to="tngx_StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_OperatingLossCarryForwardWithExpirationOfUsage" xlink:to="tngx_OperatingLossCarryForwardWithExpirationOfUsage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_TemporaryStockRetroactiveApplicationOfRecapitalization" xlink:to="tngx_TemporaryStockRetroactiveApplicationOfRecapitalization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_TemporaryEquitySharesOutstandingBeforeRetroactiveApplicationOfRecapitalization" xlink:to="tngx_TemporaryEquitySharesOutstandingBeforeRetroactiveApplicationOfRecapitalization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_AmendedGileadAgreementMember" xlink:to="tngx_AmendedGileadAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_MinimumPercentageOfEstimatedFairValueToBeMaintainedForExercisePriceOfTenPercentShareholderThreshold" xlink:to="tngx_MinimumPercentageOfEstimatedFairValueToBeMaintainedForExercisePriceOfTenPercentShareholderThreshold_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_ResearchTerm" xlink:to="tngx_ResearchTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201613Member" xlink:to="us-gaap_AccountingStandardsUpdate201613Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_RevaluationOfRightOfUseAssetAndLeaseLiabilityUponLeaseModification" xlink:to="tngx_RevaluationOfRightOfUseAssetAndLeaseLiabilityUponLeaseModification_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_RedeemableConvertiblePreferredStockIssuePricePerShare" xlink:to="tngx_RedeemableConvertiblePreferredStockIssuePricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_AgreementDomain" xlink:to="tngx_AgreementDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_IncreaseDecreaseInAccruedExpensesAndOtherLiabilities" xlink:to="tngx_IncreaseDecreaseInAccruedExpensesAndOtherLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalization" xlink:to="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_MinimumRentPaymentsToBePaidOverOriginalTerm" xlink:to="tngx_MinimumRentPaymentsToBePaidOverOriginalTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_StockIssuedDuringPeriodSharesAcquisitionsAndPrivateInvestments" xlink:to="tngx_StockIssuedDuringPeriodSharesAcquisitionsAndPrivateInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_SeriesBOneRedeemableConvertiblePreferredStockMember" xlink:to="tngx_SeriesBOneRedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:to="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_LicenseRevenueMember" xlink:to="tngx_LicenseRevenueMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_TwoThousandAndTwentyOnePlanMember" xlink:to="tngx_TwoThousandAndTwentyOnePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:to="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202006Member" xlink:to="us-gaap_AccountingStandardsUpdate202006Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_BctgTrustAccountMember" xlink:to="tngx_BctgTrustAccountMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_AccountsReceivableCurrentResearchExtensionFee" xlink:to="tngx_AccountsReceivableCurrentResearchExtensionFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_MedivirAgreementMember" xlink:to="tngx_MedivirAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ClassOfStockDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_RestrictedCommonStockAwardMember" xlink:to="tngx_RestrictedCommonStockAwardMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_FoundersAndAdvisorsMember" xlink:to="tngx_FoundersAndAdvisorsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentSecuritiesAtCarryingValue" xlink:to="us-gaap_USGovernmentSecuritiesAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_NumberOfDaysOutstanding" xlink:to="tngx_NumberOfDaysOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_CollaborativeAgreementsUpfrontPaymentReceived" xlink:to="tngx_CollaborativeAgreementsUpfrontPaymentReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_CashPaidForLeases" xlink:to="tngx_CashPaidForLeases_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_FirstLicensedProductAchievesSpecifiedClinicalMilestones" xlink:to="tngx_FirstLicensedProductAchievesSpecifiedClinicalMilestones_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_LeaseTerminationAgreementMonthAndYear" xlink:to="tngx_LeaseTerminationAgreementMonthAndYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_TangoTherapeuticsIncMember" xlink:to="tngx_TangoTherapeuticsIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_GileadAgreementMember" xlink:to="tngx_GileadAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_PaymentAsConsiderationForThePerformanceOfAdditionalResearchService" xlink:to="tngx_PaymentAsConsiderationForThePerformanceOfAdditionalResearchService_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201409Member" xlink:to="us-gaap_AccountingStandardsUpdate201409Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_GileadLetterAgreementMember" xlink:to="tngx_GileadLetterAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_PaymentOfBusinessCombinationAndPipeFinancingTransactionCosts" xlink:to="tngx_PaymentOfBusinessCombinationAndPipeFinancingTransactionCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_MarketableDebtSecuritiesMaturitiesDuration" xlink:to="tngx_MarketableDebtSecuritiesMaturitiesDuration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_MarketableDebtSecuritiesMember" xlink:to="tngx_MarketableDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="tngx_IncreaseDecreaseInOperatingLeaseLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_OperatingLossCarryForwardWithExpirationOfUsageIndefinite" xlink:to="tngx_OperatingLossCarryForwardWithExpirationOfUsageIndefinite_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember" xlink:to="tngx_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_CommitmentsAndContingenciesDetailsLineItems" xlink:to="tngx_CommitmentsAndContingenciesDetailsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_PercentageOfIncreaseInAnnualRentPayable" xlink:to="tngx_PercentageOfIncreaseInAnnualRentPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="tngx_AccruedExpensesAndOtherCurrentLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForTenantImprovements" xlink:to="us-gaap_PaymentsForTenantImprovements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_NonrefundableUpfrontPaymentsReceived" xlink:to="tngx_NonrefundableUpfrontPaymentsReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_LaboratoryEquipmentMember" xlink:to="tngx_LaboratoryEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_SeriesBCommonSharesMember" xlink:to="tngx_SeriesBCommonSharesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_OperatingLossCarryforwardsIndefinite" xlink:to="tngx_OperatingLossCarryforwardsIndefinite_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_OperatingLossCarryforwardsExpirationStartingYear" xlink:to="tngx_OperatingLossCarryforwardsExpirationStartingYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" xlink:to="us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_SpecifiedRegulatoryAndSalesMilestonesForGeneticContextMember" xlink:to="tngx_SpecifiedRegulatoryAndSalesMilestonesForGeneticContextMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_IncomeTaxesLineItems" xlink:to="tngx_IncomeTaxesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_NumberOfMilestonesAchieved" xlink:to="tngx_NumberOfMilestonesAchieved_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_GileadAgreementBasedPerformanceMember" xlink:to="tngx_GileadAgreementBasedPerformanceMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityShareSubscriptions" xlink:to="us-gaap_TemporaryEquityShareSubscriptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="tngx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_TemporaryEquityIssuePricePerShare" xlink:to="tngx_TemporaryEquityIssuePricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_MergerAgreementMember" xlink:to="tngx_MergerAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_SeriesBRedeemableConvertiblePreferredStockMember" xlink:to="tngx_SeriesBRedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_RetroactiveApplicationOfRecapitalization" xlink:to="tngx_RetroactiveApplicationOfRecapitalization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_SpecifiedRegulatoryApprovalAndSalesMilestonesMember" xlink:to="tngx_SpecifiedRegulatoryApprovalAndSalesMilestonesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_CollaborationAgreementsAbstract" xlink:to="tngx_CollaborationAgreementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_TemporaryStockIssuanceCosts" xlink:to="tngx_TemporaryStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_SignificantAccountingPoliciesTable" xlink:to="tngx_SignificantAccountingPoliciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_SeriesBTrancheOneRedeemableConvertiblePreferredStockMember" xlink:to="tngx_SeriesBTrancheOneRedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_StockOptionsMember" xlink:to="tngx_StockOptionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_DeferredTaxLiabilitiesDepreciation" xlink:to="tngx_DeferredTaxLiabilitiesDepreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_AgreementAxis" xlink:to="tngx_AgreementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_ResearchExtensionFeeVariableConsideration" xlink:to="tngx_ResearchExtensionFeeVariableConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_ProceedsFromBusinessCombinationAndPipeFinancingGross" xlink:to="tngx_ProceedsFromBusinessCombinationAndPipeFinancingGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="tngx_DeferredTaxAssetsOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_OperatingLossCarryforwardLimitationsOnUse" xlink:to="tngx_OperatingLossCarryforwardLimitationsOnUse_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_SponsoredALicenceProgramfeeAmount" xlink:to="tngx_SponsoredALicenceProgramfeeAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_TwoThousandAndEighteenGileadAgreementMember" xlink:to="tngx_TwoThousandAndEighteenGileadAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_ComputerSoftwareMember" xlink:to="tngx_ComputerSoftwareMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_UpfrontPayment" xlink:to="tngx_UpfrontPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_CollaborationRevenueMember" xlink:to="tngx_CollaborationRevenueMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:to="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_PercentageOfIncreaseInOwnershipPercentageOverAThreeYearPeriod" xlink:to="tngx_PercentageOfIncreaseInOwnershipPercentageOverAThreeYearPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares" xlink:to="tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_CashAndCashEquivalentMaturityPeriod" xlink:to="tngx_CashAndCashEquivalentMaturityPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_ResearchAndDevelopmentMember" xlink:to="tngx_ResearchAndDevelopmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_RetroactiveApplicationOfRecapitalizationOne" xlink:to="tngx_RetroactiveApplicationOfRecapitalizationOne_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_SpecifiedClinicalMilestonesMember" xlink:to="tngx_SpecifiedClinicalMilestonesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_MilestonePaymentsReceivable" xlink:to="tngx_MilestonePaymentsReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_HitgenAgreementMember" xlink:to="tngx_HitgenAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_StockIssuedDuringPeriodSharesInExchangeForUnvestedRestrictedStockAwardsAndUnexercisedStockOptions" xlink:to="tngx_StockIssuedDuringPeriodSharesInExchangeForUnvestedRestrictedStockAwardsAndUnexercisedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment" xlink:to="tngx_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_RedeemableConvertiblePreferredStockDisclosureTextBlock" xlink:to="tngx_RedeemableConvertiblePreferredStockDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_Contractassetresearchextensionfee" xlink:to="tngx_Contractassetresearchextensionfee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_TheTwoHundredAndOneBrooklineAvenueLeaseMember" xlink:to="tngx_TheTwoHundredAndOneBrooklineAvenueLeaseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_RetroactiveApplicationOfRecapitalizationSharesOne" xlink:to="tngx_RetroactiveApplicationOfRecapitalizationSharesOne_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_MilestonePaymentsAchieved" xlink:to="tngx_MilestonePaymentsAchieved_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_SeriesARedeemableConvertiblePreferredStockMember" xlink:to="tngx_SeriesARedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201815Member" xlink:to="us-gaap_AccountingStandardsUpdate201815Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_IncomeTaxesTable" xlink:to="tngx_IncomeTaxesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_NumberOfLicensedProduct" xlink:to="tngx_NumberOfLicensedProduct_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToTerminate" xlink:to="us-gaap_LesseeOperatingLeaseOptionToTerminate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_PublicSharesMember" xlink:to="tngx_PublicSharesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_RetroactiveApplicationOfRecapitalizationShares" xlink:to="tngx_RetroactiveApplicationOfRecapitalizationShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_SeriesACommonSharesMember" xlink:to="tngx_SeriesACommonSharesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_MinimumRentPaymentsToBePaidOverNoncancelableTerm" xlink:to="tngx_MinimumRentPaymentsToBePaidOverNoncancelableTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_FirstLicensedProductThatAchievesSpecifiedRegulatoryApprovalAndSalesMilestones" xlink:to="tngx_FirstLicensedProductThatAchievesSpecifiedRegulatoryApprovalAndSalesMilestones_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_DeferredFinancingCostsPolicyTextBlock" xlink:to="tngx_DeferredFinancingCostsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_PatentCostsPolicyTextBlock" xlink:to="tngx_PatentCostsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tngx_IncreaseOfGrossDeferredTaxAssets" xlink:to="tngx_IncreaseOfGrossDeferredTaxAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromFeesReceived" xlink:to="us-gaap_ProceedsFromFeesReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139210450056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 21, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TANGO THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001819133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TNGX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,707,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-1195036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">100 Binney St.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">320-4900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139210506776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 142,745<span></span>
</td>
<td class="nump">$ 28,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">342,510<span></span>
</td>
<td class="nump">161,939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash, current</a></td>
<td class="nump">567<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,516<span></span>
</td>
<td class="nump">1,312<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">492,338<span></span>
</td>
<td class="nump">193,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,832<span></span>
</td>
<td class="nump">3,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,254<span></span>
</td>
<td class="nump">7,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, net of current portion</a></td>
<td class="nump">1,712<span></span>
</td>
<td class="nump">2,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">500,155<span></span>
</td>
<td class="nump">207,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,226<span></span>
</td>
<td class="nump">1,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">9,887<span></span>
</td>
<td class="nump">6,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,503<span></span>
</td>
<td class="nump">959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">26,022<span></span>
</td>
<td class="nump">31,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income tax payable</a></td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">40,690<span></span>
</td>
<td class="nump">40,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">114,718<span></span>
</td>
<td class="nump">120,805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">155,408<span></span>
</td>
<td class="nump">168,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2021 and 2020, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200,000,000 and 56,393,261 shares authorized at December 31, 2021 and December 31, 2020, respectively;87,598,184 and 40,372,133 shares issued and outstanding as of December 31, 2021 and 2020, respectively</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">506,760<span></span>
</td>
<td class="nump">141,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="num">(765)<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(161,336)<span></span>
</td>
<td class="num">(103,101)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">344,747<span></span>
</td>
<td class="nump">38,600<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 500,155<span></span>
</td>
<td class="nump">$ 207,252<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139210729624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Aug. 10, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary Equity, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary Equity, Shares Authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary Equity, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,393,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">87,598,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,372,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">87,598,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,474,239<span></span>
</td>
<td class="nump">40,372,133<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139210176680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 37,042<span></span>
</td>
<td class="nump">$ 7,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">77,636<span></span>
</td>
<td class="nump">49,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">17,596<span></span>
</td>
<td class="nump">9,865<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">95,232<span></span>
</td>
<td class="nump">59,856<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(58,190)<span></span>
</td>
<td class="num">(52,200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income</a></td>
<td class="nump">495<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(248)<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(57,943)<span></span>
</td>
<td class="num">(51,972)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(292)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (58,235)<span></span>
</td>
<td class="num">$ (51,972)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share &#8211; basic and diluted</a></td>
<td class="num">$ (0.94)<span></span>
</td>
<td class="num">$ (1.63)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of common stock outstanding - basic and diluted</a></td>
<td class="nump">62,108,032<span></span>
</td>
<td class="nump">31,932,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (58,235)<span></span>
</td>
<td class="num">$ (51,972)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized (loss) gain on marketable securities</a></td>
<td class="num">(782)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(59,017)<span></span>
</td>
<td class="num">(51,965)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=tngx_CollaborationRevenueMember', window );">Collaboration Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">26,042<span></span>
</td>
<td class="nump">6,972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=tngx_LicenseRevenueMember', window );">License Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="nump">$ 684<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tngx_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tngx_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tngx_LicenseRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tngx_LicenseRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139207123976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss) [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Redeemable Convertible Preferred Stock Series A [Member]</div></th>
<th class="th"><div>Redeemable Convertible Preferred Stock Series B [Member]</div></th>
<th class="th"><div>Redeemable Convertible Preferred Stock Series B-1 [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization', window );">Balance at the beginning before retroactive application of recapitalization at Dec. 31, 2019</a></td>
<td class="num">$ (47,795)<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 3,319<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="num">$ (51,129)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_SharesOutstandingBeforeRetroactiveApplicationOfRecapitalization', window );">Balance at the beginning before retroactive application of recapitalization (in Shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,530,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_TemporaryEquityBeforeRetroactiveApplicationOfRecapitalization', window );">Balance at the beginning before retroactive application of recapitalization at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_TemporaryEquitySharesOutstandingBeforeRetroactiveApplicationOfRecapitalization', window );">Balance at the beginning before retroactive application of recapitalization (in Shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalization', window );">Retroactive application of recapitalization at Dec. 31, 2019</a></td>
<td class="nump">55,700<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">55,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares', window );">Retroactive application of recapitalization (in Shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,922,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_TemporaryEquityRetroactiveApplicationOfRecapitalization', window );">Retroactive application of recapitalization at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (55,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_TemporaryEquityRetroactiveApplicationOfRecapitalizationShares', window );">Retroactive application of recapitalization (in Shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Dec. 31, 2019</a></td>
<td class="nump">7,905<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">59,000<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="num">(51,129)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the beginning (in Shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,452,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,761<span></span>
</td>
<td class="nump">$ 51,083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of redeemable convertible preferred stock, net of issuance costs, (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,686,025<span></span>
</td>
<td class="nump">27,152,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_RetroactiveApplicationOfRecapitalization', window );">Retroactive application of recapitalization</a></td>
<td class="nump">29,761<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">29,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_RetroactiveApplicationOfRecapitalizationShares', window );">Retroactive application of recapitalization (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,706,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_RetroactiveApplicationOfRecapitalizationOne', window );">Retroactive application of recapitalization</a></td>
<td class="nump">51,083<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">51,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_RetroactiveApplicationOfRecapitalizationSharesOne', window );">Retroactive application of recapitalization (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,224,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_TemporaryStockRetroactiveApplicationOfRecapitalization', window );">Retroactive application of recapitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (29,761)<span></span>
</td>
<td class="num">$ (51,083)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_TemporaryStockRetroactiveApplicationOfRecapitalizationShares', window );">Retroactive application of recapitalization (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,686,025)<span></span>
</td>
<td class="num">(27,152,255)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Vesting of restricted common stock awards</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of restricted common stock awards, (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,095)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock based compensation expense</a></td>
<td class="nump">1,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Other comprehensive loss</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(51,972)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51,972)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the ending at Dec. 31, 2020</a></td>
<td class="nump">38,600<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">141,644<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="num">(103,101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the ending (in Shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,372,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at the ending at Dec. 31, 2020</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance at the ending (in Shares) at Dec. 31, 2020</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of redeemable convertible preferred stock, net of issuance costs, (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,686,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_RetroactiveApplicationOfRecapitalization', window );">Retroactive application of recapitalization</a></td>
<td class="nump">$ 29,990<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">29,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_RetroactiveApplicationOfRecapitalizationShares', window );">Retroactive application of recapitalization (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,706,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_TemporaryStockRetroactiveApplicationOfRecapitalization', window );">Retroactive application of recapitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (29,990)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_TemporaryStockRetroactiveApplicationOfRecapitalizationShares', window );">Retroactive application of recapitalization (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,686,025)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Vesting of restricted common stock awards</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments', window );">Shares issued in Business Combination and PIPE Financing, net of issuance costs</a></td>
<td class="nump">326,277<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">326,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_StockIssuedDuringPeriodSharesAcquisitionsAndPrivateInvestments', window );">Shares issued in Business Combination and PIPE Financing, net of issuance costs (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,880,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 1,058<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, (in Shares)</a></td>
<td class="nump">638,754<span></span>
</td>
<td class="nump">638,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock based compensation expense</a></td>
<td class="nump">$ 7,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Other comprehensive loss</a></td>
<td class="num">(782)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(782)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(58,235)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58,235)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the ending at Dec. 31, 2021</a></td>
<td class="nump">344,747<span></span>
</td>
<td class="nump">$ 88<span></span>
</td>
<td class="nump">$ 506,760<span></span>
</td>
<td class="num">$ (765)<span></span>
</td>
<td class="num">$ (161,336)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the ending (in Shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,598,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at the ending at Dec. 31, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance at the ending (in Shares) at Dec. 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_RetroactiveApplicationOfRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Retroactive application of recapitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_RetroactiveApplicationOfRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_RetroactiveApplicationOfRecapitalizationOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Retroactive application of recapitalization one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_RetroactiveApplicationOfRecapitalizationOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_RetroactiveApplicationOfRecapitalizationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Retroactive application of recapitalization shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_RetroactiveApplicationOfRecapitalizationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_RetroactiveApplicationOfRecapitalizationSharesOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Retroactive application of recapitalization shares one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_RetroactiveApplicationOfRecapitalizationSharesOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_SharesOutstandingBeforeRetroactiveApplicationOfRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares outstanding before retroactive application of recapitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_SharesOutstandingBeforeRetroactiveApplicationOfRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock holders equity before retroactive application of recapitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock holders equity retroactive application of recapitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock holders equity retroactive application of recapitalization shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_StockIssuedDuringPeriodSharesAcquisitionsAndPrivateInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares acquisitions and private investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_StockIssuedDuringPeriodSharesAcquisitionsAndPrivateInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value acquisitions and private investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_TemporaryEquityBeforeRetroactiveApplicationOfRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity before retroactive application of recapitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_TemporaryEquityBeforeRetroactiveApplicationOfRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_TemporaryEquityRetroactiveApplicationOfRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity retroactive application of recapitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_TemporaryEquityRetroactiveApplicationOfRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_TemporaryEquityRetroactiveApplicationOfRecapitalizationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity retroactive application of recapitalization shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_TemporaryEquityRetroactiveApplicationOfRecapitalizationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_TemporaryEquitySharesOutstandingBeforeRetroactiveApplicationOfRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity shares outstanding before retroactive application of recapitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_TemporaryEquitySharesOutstandingBeforeRetroactiveApplicationOfRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_TemporaryStockRetroactiveApplicationOfRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary stock retroactive application of recapitalization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_TemporaryStockRetroactiveApplicationOfRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_TemporaryStockRetroactiveApplicationOfRecapitalizationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary stock retroactive application of recapitalization shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_TemporaryStockRetroactiveApplicationOfRecapitalizationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139214226456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts', window );">Issuance of redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="nump">$ 15.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Redeemable Convertible Preferred Stock Series B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts', window );">Issuance of redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tngx_SeriesBOnePreferredStocksMember', window );">Redeemable Convertible Preferred Stock Series B-1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts', window );">Issuance of redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from issuance costs from a share-lending arrangement entered into, in contemplation of a convertible debt offering or other financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 20A<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=SL6757427-112606<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tngx_SeriesBOnePreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tngx_SeriesBOnePreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139210345272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (58,235)<span></span>
</td>
<td class="num">$ (51,972)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">897<span></span>
</td>
<td class="nump">718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Noncash operating lease expense</a></td>
<td class="nump">1,069<span></span>
</td>
<td class="nump">907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">7,833<span></span>
</td>
<td class="nump">1,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="nump">254<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(3,159)<span></span>
</td>
<td class="num">(81)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="num">(139)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">1,232<span></span>
</td>
<td class="nump">1,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_IncreaseDecreaseInAccruedExpensesAndOtherLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">3,829<span></span>
</td>
<td class="nump">1,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(1,066)<span></span>
</td>
<td class="num">(655)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(12,042)<span></span>
</td>
<td class="nump">119,081<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used in) provided by operating activities</a></td>
<td class="num">(59,527)<span></span>
</td>
<td class="nump">70,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(1,837)<span></span>
</td>
<td class="num">(1,106)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales and maturities of marketable securities</a></td>
<td class="nump">190,764<span></span>
</td>
<td class="nump">63,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(372,361)<span></span>
</td>
<td class="num">(207,540)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(183,434)<span></span>
</td>
<td class="num">(145,466)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred stock, net of issuance costs</a></td>
<td class="nump">29,990<span></span>
</td>
<td class="nump">80,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock upon exercise of stock options</a></td>
<td class="nump">1,058<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_ProceedsFromBusinessCombinationAndPipeFinancingGross', window );">Business Combination and PIPE Financing, gross proceeds</a></td>
<td class="nump">342,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_PaymentOfBusinessCombinationAndPipeFinancingTransactionCosts', window );">Payment of Business Combination and PIPE Financing transaction costs</a></td>
<td class="num">(15,836)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">357,325<span></span>
</td>
<td class="nump">80,884<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="nump">114,364<span></span>
</td>
<td class="nump">5,492<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">30,660<span></span>
</td>
<td class="nump">25,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">145,024<span></span>
</td>
<td class="nump">30,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_CashPaidForLeases', window );">Cash paid for leases</a></td>
<td class="nump">1,835<span></span>
</td>
<td class="nump">1,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of Preferred Shares to Common Shares</a></td>
<td class="nump">166,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_RevaluationOfRightOfUseAssetAndLeaseLiabilityUponLeaseModification', window );">Revaluation of right-of-use asset and lease liability upon lease modification</a></td>
<td class="nump">5,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable and accrued expenses</a></td>
<td class="nump">$ 154<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_CashPaidForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_CashPaidForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_IncreaseDecreaseInAccruedExpensesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in accrued expenses and other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_IncreaseDecreaseInAccruedExpensesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_PaymentOfBusinessCombinationAndPipeFinancingTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of business combination and pipe financing transaction costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_PaymentOfBusinessCombinationAndPipeFinancingTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_ProceedsFromBusinessCombinationAndPipeFinancingGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from business combination and pipe financing gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_ProceedsFromBusinessCombinationAndPipeFinancingGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_RevaluationOfRightOfUseAssetAndLeaseLiabilityUponLeaseModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revaluation of right-of-use asset and lease liability upon lease modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_RevaluationOfRightOfUseAssetAndLeaseLiabilityUponLeaseModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139213838712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of the Business and Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. Nature of the Business and Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tango Therapeutics, Inc. (&#8220;Tango&#8221; or the &#8220;Company&#8221;) is a precision oncology company committed to the discovery and development of novel drugs in defined patient populations with high unmet medical need.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tango Therapeutics, Inc. (together with its consolidated subsidiaries, &#8220;Tango&#8221; or the &#8220;Company&#8221;) formerly known as BCTG Acquisition Corp. (&#8220;BCTG&#8221;), was incorporated in Delaware on May 21, 2020. BCTG was a Special Purpose Acquisition Company (&#8220;SPAC&#8221;) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Merger with BCTG Acquisition Corporation</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On April 13, 2021, the Company, BCTG Merger Sub Inc., a Delaware corporation, and Tango Therapeutics, Inc. (now known as Tango Therapeutics Sub, Inc. or &#8220;Old Tango&#8221;) signed a definitive merger agreement (the "Merger Agreement") memorializing the terms of BCTG&#8217;s acquisition of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of Old Tango's issued and outstanding equity securities in exchange for $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">550.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million worth of consideration in the form of BCTG common stock (the &#8220;Business Combination&#8221;). The Business Combination was approved on August 9, 2021 by shareholders of BCTG, resulting in BCTG acquiring 100% of Old Tango's issued and outstanding equity securities on August 10, 2021. The Business Combination was accounted for as a &#8220;reverse recapitalization&#8221; in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). As a result of the Business Combination, BCTG was renamed Tango Therapeutics, Inc. The Company's common stock is </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">trading on The Nasdaq Global Market under the ticker symbol TNGX</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tango received gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">167.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon the closing of the Business Combination. Tango continues to operate under the Old Tango management team. Simultaneous with the closing of the Business Combination, an aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,610,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock (the &#8220;PIPE Financing&#8221;) were issued, resulting in gross proceeds of an additional $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">186.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon the closing of the PIPE Financing. Total transaction costs and redemptions</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> approximated $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26.9</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, resulting in total net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">326.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">BCTG Acquisition Corporation IPO</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registration statement for BCTG&#8217;s initial public offering (&#8220;IPO&#8221;) was declared effective on September 2, 2020. On September 8, 2020, the Company consummated its Initial Public Offering of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,675,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock (the &#8220;Public Shares&#8221;), including the </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,175,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Public Shares as a result of the underwriters&#8217; full exercise of their over-allotment option, at an offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per Public Share, generating gross proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">166.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and incurring offering costs of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, inclusive of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in deferred underwriting commissions. Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (&#8220;Private Placement&#8221;) of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">533,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock (the &#8220;Private Placement shares&#8221;), at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per Private Placement Share to the Sponsor, generating gross proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. Upon the closing of the Initial Public Offering and the Private Placement, the net proceeds of the Initial Public Offering and certain of the proceeds of the Private Placement was placed in a trust account (&#8220;Trust Account&#8221;) in the United States maintained by Continental Stock Transfer &amp; Trust Company, as trustee, and remained invested only in U.S. government treasury bills, notes and bonds with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act and which invest solely in U.S. Treasuries, until the completion of the Business Combination as described below</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying consolidated financial statements have been prepared in conformity with U.S. GAAP. The accompanying consolidated financial statements reflect the operations of Tango and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated. The functional and reporting currency of the Company and its subsidiaries is the U.S. dollar.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139292642184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2. Summary of Significant Accounting Policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of consolidated financial statements requires that the Company make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. Significant estimates and assumptions made in the consolidated financial statements include, but are not limited to, the revenue recognized from collaboration agreements, the valuation of stock-based awards and the accrual for research and development expenses. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Segment Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating segments are defined as components of an enterprise for which separate financial information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company operates in </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> operating segment, the business of discovering and developing precision oncology therapies.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All highly liquid marketable securities purchased with an original maturity date of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90 days</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or less at the date of purchase are considered to be cash equivalents. Cash equivalents consisted of money market funds and U.S. Treasury bills as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investments in Marketable Securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Marketable debt securities consist of investments with original maturities greater than </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90 days</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company classifies its investments with maturities beyond one year as short-term, based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. The Company considers its investment portfolio of marketable securities to be available-for-sale. Accordingly, these investments are recorded at fair value, which is based on quoted market prices. Unrealized gains are reported as a component of accumulated other comprehensive income in stockholders&#8217; equity (deficit). Amortization and accretion of premiums and discounts are recorded in interest income. Realized gains and losses are included as a component of other income, net in the consolidated statements of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company evaluates its investments with unrealized losses for impairment. When assessing investments for unrealized declines in value, the Company considers whether the decline in value is related to a credit loss or non-credit loss. For credit losses, the Company reduces the investment to fair value through an allowance for credit losses recorded to the balance sheet and corresponding charge to the statement of operations. The allowance for credit losses and corresponding impairment charge is adjusted each period for changes in fair value. For non-credit losses, the Company reduces the investment to fair value through a charge to the statement of comprehensive loss, reported as a component of accumulated other comprehensive income (loss) in stockholders&#8217; equity. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> such credit losses were recorded during the periods presented.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accounting standard for fair value measurements defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and requires certain disclosures about fair value measurements. Under this standard, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1 &#8212; Fair values are determined utilizing prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access. </span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2 &#8212; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves, and foreign currency spot rates. </span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3 &#8212; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. </span></div></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of the Company&#8217;s cash equivalents and marketable securities are determined according to the fair value hierarchy described below (see Note 5)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The carrying values of the Company&#8217;s accounts receivable, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk and Significant Suppliers</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash, cash equivalents and marketable debt securities. The Company&#8217;s cash, cash equivalent and marketable securities balances are held by major financial institutions that management believes to be creditworthy. The Company uses multiple financial institutions to limit the amount of credit exposure to any one financial institution. Substantially all the Company&#8217;s cash, cash equivalent and marketable debt securities were invested in money market funds, U.S. Treasury bills, and U.S. government agency bonds at December 31, 2021 and 2020. At times, the Company&#8217;s cash deposits may exceed the amount of federal insurance provided on such deposits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant credit risk beyond the normal credit risk associated with commercial banking relationships.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company relies, and expects to continue to rely, on a small number of vendors to perform research activities and clinical trial activities that continue to progress its product candidates for its development programs. These programs could be adversely affected by a significant interruption in the related processes of these vendors.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash accounts with any type of restriction are considered restricted cash and are classified on the balance sheet based on the length of the restrictive obligation. As of both December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company recorded restricted cash of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, all of which was related to security deposits associated with the Company&#8217;s facility leases in Boston, Massachusetts and Cambridge, Massachusetts. The security deposit associated with the Company's facility lease in Boston, Massachusetts is recorded as non-current in its balance sheet as of December 31, 2021 and December 31, 2020 because the deposit is required for the duration of the lease which is greater than a year. The security deposit associated with the Company's facility lease in Cambridge, Massachusetts is recorded as current in its balance sheet as of December 31, 2021 because the deposit is required for the duration of the amended lease which is less than a year from the balance sheet date. The security deposit associated with the Company's facility lease in Cambridge, Massachusetts was recorded as non-current in its balance sheet as of December 31, 2020 because the deposit was required for the duration of the original lease which, prior to the 2021 lease amendment, was for greater than a year from the December 31, 2020 balance sheet date.</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The reconciliation of cash and cash equivalents and restricted cash to amounts presented in the consolidated statements of cash flows are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.312%;"/>
          <td style="width:1.6%;"/>
          <td style="width:1.282%;"/>
          <td style="width:13.33%;"/>
          <td style="width:0.636%;"/>
          <td style="width:1.6%;"/>
          <td style="width:1.282%;"/>
          <td style="width:13.32%;"/>
          <td style="width:0.636%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">142,745</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28,381</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">567</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash, net of current portion</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,712</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,279</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">145,024</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,660</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful lives of each asset. Estimated useful lives are periodically assessed to determine if changes are appropriate. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated useful lives of the Company&#8217;s property and equipment are as follows: </span></span><span style=""/></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:43.72%;"/>
          <td style="width:1.835%;"/>
          <td style="width:54.444%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Asset</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Estimated useful life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer software</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shorter of remaining lease term or 10 years</span></span></p></td>
         </tr>
        </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company reviews long-lived assets, such as property and equipment, for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. If indicators of impairment are present, the assets are tested for recoverability by comparing the carrying amount of the assets to the related estimated future undiscounted cash flows that the assets are expected to generate. If the expected cash flows are less than the carrying value of the asset group, then the asset group is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows. To date, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> such impairment losses have been recorded.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Costs for assets not yet placed into service are capitalized as construction-in-progress and depreciated or amortized in accordance with the above useful lives once placed into service. Upon retirement or sale, the related cost and accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in the consolidated statements of operations. Repairs and maintenance costs are expensed as incurred.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances and the existence of an identified asset(s), if any, and its control over the use of the identified asset(s), if applicable. Upon lease commencement, operating lease liabilities and their corresponding right-of-use assets are recorded on the balance sheet based at the present value of lease payments over the expected lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense is recognized over the expected term on a straight-line basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease payments are discounted at the lease commencement date using the interest rate implicit in the lease contract. As this rate is typically not readily determinable, the Company determines an incremental borrowing rate that is used to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Certain prospective adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company elected to account for lease and non-lease components as a single lease component, however non-lease components that are variable, such as common area maintenance and utilities, are generally paid separately from rent based on actual costs incurred and therefore are not included in the right-of-use asset and operating lease liability and are reflected as an expense in the period incurred. The Company&#8217;s lease terms often include renewal options. The amounts determined for the Company&#8217;s right-of-use assets and lease liabilities generally do not assume that any renewal options or any early-termination provisions, if any, are exercised, unless it is reasonably certain that the Company will exercise such options.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At contract inception, the Company assesses whether the collaboration arrangements are within the scope of ASC Topic 808, Collaborative Arrangements, or ASC 808, to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed based on the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the arrangement are within the scope of ASC 808 and which elements are within the scope of ASC 606 (as described below). For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, either by analogy to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">authoritative accounting literature or by applying a reasonable and rational policy election. To date, the Company has not entered into any arrangements within the scope of ASC 808.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s revenues are generated through its license and collaboration agreements with Gilead. Refer to Note 4, &#8220;Collaboration Agreements.&#8221; elsewhere in these notes to the Company's consolidated financial statements.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers. ASC 606 provides a five-step framework whereby revenue is recognized when control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the  contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) performance obligations are satisfied. The Company only applies this framework to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation. Goods and services that are determined not to be distinct are combined with other promised goods and services until a distinct bundle is identified. The Company then allocates the transaction price (that is, the amount of consideration the Company expects to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The Company&#8217;s estimate of the transaction price for each contract includes all variable consideration to which the Company expects to be entitled, subject to the constraint on variable consideration. Variable consideration is not constrained if the potential reversal of cumulative revenue recognized at the contract level is not significant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under active agreements, the Company must use its judgment to determine: (a) the number of performance obligations based on the determination under step (ii) above; (b) the transaction price under step (iii) above; (c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above; and (d) the contract term and pattern of satisfaction of the performance obligations under step (v) above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to the identified performance obligations on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. In certain instances, the timing of satisfying these obligations can be difficult to estimate. Accordingly, the Company&#8217;s estimates may change in the future and those changes could be material. Such changes to estimates would result in a change in amounts of revenue recognized. If these estimates and judgments change over the course of these agreements, it may affect the timing and amount of revenue that the Company recognizes and records in future periods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the collaboration agreements are recorded as accounts receivable in the Company&#8217;s consolidated balance sheet. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&#8217;s consolidated balance sheets. Amounts expected to be recognized as revenue within the one year following the balance sheet date are classified as current deferred revenue. Amounts not expected to be recognized as revenue within the one year following the balance sheet date are classified as deferred revenue, net of current portion. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as contract assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Exclusive License Rights</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> &#8212; If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, which generally include research and development services, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a license is distinct from the other promises, the Company considers relevant facts and circumstances of each arrangement, including the research and development capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from the license for its intended purpose without the receipt of the remaining promises, whether the value of the license is dependent on the unsatisfied promises, whether there are other vendors that could provide the remaining promises and whether it is separately identifiable from the remaining promises. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation and whether the license is the predominant promise within the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. If the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">license is the predominant promise, and it is determined that the license represents functional intellectual property (&#8220;IP&#8221;), revenue is recognized at the point in time when control of the license is transferred. If it is determined that the license does not represent functional IP, revenue is recognized over time using an appropriate method of measuring progress.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Services</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> &#8212; The obligations under the Company&#8217;s collaboration agreements may include research and development services to be performed by the Company to benefit the collaboration partner. For performance obligations that include research and development services, the Company generally recognizes revenue allocated to such performance obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for purposes of recognizing revenue, which is generally an input measure such as costs incurred. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods of which revenue should be recognized, are subject to estimates by management and may change over the course of the contract. Reimbursements from the partner that are the result of a collaborative relationship with the partner, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense. No collaborative arrangements existed that would result in such reimbursements for the periods presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Customer Options</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> &#8212; The Company&#8217;s arrangements may provide a collaborator with the right to acquire additional goods or services in the future. Under these agreements, fees may be due to the Company (i) upon the exercise of the customer option or (ii) in equal installment payments over an agreed upon period. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the additional goods and services underlying the customer options are evaluated in order to determine if these additional goods or services are distinct from those included as a performance obligation at the outset of the arrangement. If the additional services are not determined to be distinct, the variable consideration pertaining to the customer option is added to the initial transaction price at the time in which the option exercise becomes probable, so long as a potential for reversal of cumulative revenue recognized at the contract level is not significant. Any such adjustments to the transaction price are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If the additional services are distinct, the Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company allocates the transaction price to material rights based on the relative stand-alone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Milestone Payments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> &#8212; At the inception of an arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant reversal of cumulative revenue recognized would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#8217;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Royalties</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> &#8212; For arrangements that include sales-based royalties, including milestone payments based on a level of sales, where the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from licensing agreements.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses include costs directly attributable to the conduct of research programs, including the cost of salaries, employee benefits, stock-based compensation expense, materials, supplies, depreciation on and maintenance of research equipment, the cost of services provided by outside contractors to conduct research and development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">activities and the allocable portions of facility costs, such as rent, utilities, and general support services. All costs incurred to fulfill the Company&#8217;s obligations under the collaboration with Gilead are classified as research and development expenses. All costs associated with research and development are expensed as incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management estimates the Company&#8217;s accrued research and development expenses as of each balance sheet date in the Company&#8217;s financial statements based on facts and circumstances known to the Company at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Nonrefundable advance payments for goods and services are deferred and recognized as expense in the period that the related goods are consumed or services are performed.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patent Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company measures the cost of employee services received in exchange for stock-based awards based on the grant-date fair value of the awards. The Company calculates the fair value of restricted stock awards based on the grant date fair value of the underlying common stock. The Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period of the awards for service-based awards, which is generally the vesting period. The Company recognizes stock-based compensation for performance-based awards when the underlying performance conditions are considered probable of occurrence and recognizes the cumulative effect of current and prior period changes in the period of change.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to the </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">consummation of the Business Combination transaction, as there was not a public market for the common stock of the Company prior to becoming publicly traded, the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fair value of common stock underlying stock-based awards was based on a valuation provided by the board of directors as derived from a recommendation by an unrelated third-party valuation firm. The Company determined the estimated per share fair value of its common stock at various dates considering contemporaneous and retrospective valuations that incorporated objective and subjective factors, including actual and forecasted financial results, market conditions and performance of comparable publicly traded companies, developments and milestones of the Company, the rights and preferences of common and redeemable convertible preferred stock, advice from the third-party valuation specialists, and transactions involving the Company&#8217;s stock. The estimated per share fair value of the Company&#8217;s common stock was determined in accordance with the guidance outlined in the American Institute of Certified Public Accountants Practice Aid, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Valuation of Privately-Held Company Equity Securities Issued as Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The fair value of each restricted common stock award was estimated on the date of grant based on the fair value of the Company&#8217;s common stock on that same date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Subsequent to becoming a publicly traded Company upon the consummation of the Business Combination transaction, the fair value of common stock underlying stock-based awards is based on an estimate at each grant date using the market price of our common stock and each of the assumptions discussed below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Term</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">:    The expected term of the stock options is estimated using the &#8220;simplified method,&#8221; as prescribed in SEC&#8217;s Staff Accounting Bulletin (SAB) No. 107, as the Company has limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting period and the contractual term of the option.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Volatility</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">:    Since there is limited historical data for the Company&#8217;s common stock and limited company-specific historical volatility, the Company has determined the share price volatility for options granted based on an analysis of the volatility used by a peer group of publicly traded companies. In evaluating similarity, the Company considers factors such as industry, stage of life cycle and size.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risk-free Interest Rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">:    The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected life of the option.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Dividend Rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">:    The expected dividend is assumed to be </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as the Company has never paid dividends and has no current plans to do so.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The assumptions used in estimating the fair value of stock-based awards represent management&#8217;s estimate and involve inherent uncertainties and the application of management&#8217;s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation is classified in the accompanying consolidated statements of operations and comprehensive loss based on the function to which the related services are provided. Forfeitures are accounted for as they occur. Any consideration paid by employees on exercising stock options and the corresponding portion previously credited to additional paid-in capital are credited to share capital.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Deferred Financing Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded in shareholders&#8217; equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period corresponding to the enactment date. A valuation allowance is established when it is more likely than not that all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a more likely than not likelihood of being realized upon ultimate settlement with the tax authority. The recognition and measurement of tax benefits requires significant judgments that are subject to change as new information becomes available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Penalties and interest expense related to income taxes are included as components of income tax expense and interest expense, respectively, as necessary.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comprehensive Gain (Loss)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity (deficit) that result from transactions and economic events other than those with stockholders. The Company&#8217;s only element of other comprehensive loss for the years ended December 31, 2021 and 2020</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was unrealized gains (losses) on investments in marketable securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share attributable to common stockholders is computed by dividing net loss by the weighted-average number of shares of common shares outstanding during each reporting period. The weighted-average number of shares of common stock outstanding used in the basic net loss per share calculation does not include unvested restricted stock awards as these instruments are considered contingently issuable shares until they vest. Diluted net loss per share attributable to common stockholders includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. The Company&#8217;s unvested restricted stock entitles the holder to participate in dividends and earnings of the Company, and, if the Company were to recognize net income, it would apply the two-class method to calculate earnings per share. The two-class method is not applicable during periods with a net loss, as the holders of the unvested restricted stock have no obligation to fund losses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The two-class method of computing net loss per share would be applicable in a reporting period that resulted in a net income position, as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Subsequent Events</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Emerging Growth Company Status</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act (&#8220;JOBS Act&#8221;), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards and as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of an initial public offering or such earlier time that it is no longer an emerging growth company. However, the Company has not yet delayed the adoption of any new accounting standards.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Adopted Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2016, the FASB issued ASU 2016-13</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">, Financial Instruments &#8212; Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren&#8217;t measured at fair value through net income. For available-for-sale debt securities, entities are required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities are no longer permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. For public entities, the guidance was effective for annual reporting periods beginning after December 15, 2019 and for interim periods within those fiscal years. Early adoption was permitted. The Company </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">early </span></span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adopted </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">this standard as of</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> January 1, 2020</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on a prospective basis. The adoption did</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> no</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t have a material impact on the Company&#8217;s consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2018, the FASB issued ASU 2018-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The amendments become effective for the Company&#8217;s fiscal year beginning January 1, 2020. Early adoption of the amendments in full or only the provisions that eliminate or modify the disclosure requirements for fair value measurements is permitted. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adoption </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of this standard on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2020</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> did </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2018, the FASB issued ASU 2018-15, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The new standard requires a customer in a cloud computing arrangement to determine which implementation costs to capitalize as assets or expense as incurred. Capitalized implementation costs related to a hosting arrangement that is a service contract will be amortized over the term of the hosting arrangement, beginning when the module or component of the hosting arrangement is ready for its intended use. The new standard became effective for the Company&#8217;s fiscal year beginning January 1, 2020. Early adoption was permitted. The </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">early </span></span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adoption </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of this standard on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2020</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> did </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2019, the FASB issued ASU 2019-12, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Simplifying the Accounting for Income Taxes,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (&#8220;ASC 740&#8221;). The ASU enhances and simplifies various aspects of the income tax accounting guidance in ASC 740, including requirements related to hybrid tax regimes, the tax basis step-up in goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intra-period tax allocation exception to the incremental approach, ownership changes in investments, changes from a subsidiary to an equity method investment, interim-period accounting for enacted changes in tax law, and the year-to-date loss limitation in interim-period tax accounting. This guidance became effective for the Company's fiscal year beginning </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adoption </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of this guidance did </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t have a material impact on the Company&#8217;s consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2020, the FASB issued ASU 2020-06, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Debt &#8212; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8212; 40)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The amendments in this update affect entities that issue convertible instruments and/or contracts indexed to and potentially settled in an entity&#8217;s own equity. The new ASU eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, the new guidance modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company elected to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">early </span></span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adopt </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">this guidance on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Adoption of the ASU 2020-06 guidance as of January 1, 2021 had </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">impact on its consolidated financial statements for the year ended December 31, 2020. The Company issued the second tranche of its redeemable convertible Series B preferred stock in March 2021 at an original issue price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.32</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, which would have resulted in the recognition of a beneficial conversion feature of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million prior to the adoption of ASU 2020-06. However, the consummation of the Business Combination and the application of a retroactive adjustment to historical redeemable convertible preferred stock in all periods presented under the reverse recapitalization accounting treatment have resulted in the adoption of this guidance not resulting in a material impact on the Company&#8217;s financial statements for the year ended December 31, 2021.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Issued Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that recently issued standards that are not yet effective will not have a material impact on the Company&#8217;s consolidated financial statements. </span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139213952024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combination</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3. Business Combination</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">August 10, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (the "Closing Date"), BCTG, a Delaware corporation and now predecessor of the Company, consummated the Business Combination, pursuant to the Merger Agreement, by and among BCTG, BCTG Merger Sub Inc., a Delaware corporation ("BCTG Merger Sub"), and Old Tango. Prior to consummation of the Business Combination, Old Tango changed its name from &#8220;Tango Therapeutics, Inc.&#8221; to &#8220;Tango Therapeutics Sub, Inc.&#8221; and in connection with the Business Combination, BCTG changed its name to &#8220;Tango Therapeutics, Inc.&#8221; (the former name of Old Tango). Pursuant to the Merger Agreement, on the Closing Date, BCTG Merger Sub merged with and into Old Tango, or the Merger, with Old Tango surviving the Merger as a wholly-owned subsidiary of BCTG, and BCTG changed its name to &#8220;Tango Therapeutics, Inc.&#8221;, or New Tango.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the terms and conditions of the Merger Agreement, the aggregate consideration paid to Old Tango equity holders upon the closing of the Merger was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of New Tango common stock. Subsequent to the closing of the Business Combination, New Tango entered into subscription agreements with certain investors ("PIPE Investors") pursuant to which the PIPE Investors purchased </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,610,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of New Tango common stock at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, for aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">186.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, under the PIPE Financing.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the elements of the net proceeds from the Business Combination and PIPE Financing transaction as of December 31, 2021 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:75.102%;"/>
        <td style="width:4.662%;"/>
        <td style="width:1.282%;"/>
        <td style="width:18.09%;"/>
        <td style="width:0.865%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Recapitalization</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash - BCTG's Trust Account and cash (net of redemptions)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">156,013</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash - PIPE Financing</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">186,100</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less transaction costs and advisory fees paid</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,836</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash proceeds from the Business Combination and PIPE Financing</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">326,277</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Add: non-cash net assets assumed from BCTG</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net contributions from Business Combination and PIPE Financing</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">326,280</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the number of shares of common stock outstanding immediately following the consummation of the Business Combination and PIPE Financing transaction:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.237%;"/>
        <td style="width:3.886%;"/>
        <td style="width:0.646%;"/>
        <td style="width:15.366%;"/>
        <td style="width:0.865%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">BCTG common shares outstanding prior to the Business Combination</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,377,250</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less redemption of BCTG shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,106,814</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common shares of BCTG outstanding as of the Business Combination</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,270,436</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares issued pursuant to the PIPE Financing</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,610,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Business Combination and PIPE Financing shares</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38,880,436</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Old Tango common shares (after preferred shares were converted 1-for-</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;for common shares)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48,593,803</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total shares of Common Stock immediately after Business Combination consummation</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87,474,239</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The merger consideration of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0 shares of New Tango common stock issued to Old Tango equity holders consists of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48,593,803</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares issued in exchange for Old Tango common and preferred shares outstanding, included in the table above, as well as </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,406,197</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares issued in exchange for the Old Tango unvested restricted stock awards and unexercised stock options outstanding immediately prior to the effective time of the Business Combination.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Retrospective Application of Recapitalization</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As discussed above, the Business Combination with BCTG, which was consummated on August 10, 2021, is accounted for as a reverse recapitalization of equity structure. Under the reverse recapitalization model, the Business Combination was treated as Old Tango issuing equity for the net assets of BCTG, with </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> goodwill or intangible assets recorded. Under this method of accounting, BCTG was treated as the &#8220;acquired&#8221; company for financial reporting purposes. This determination was primarily based on the fact that subsequent to the Business Combination, Old Tango&#8217;s stockholders possess a majority of the voting power of the combined company, the Company comprises all of the ongoing operations of Old Tango, the Company comprises a majority of the governing body of Old Tango, and the Company&#8217;s senior management comprises all of the senior management of Old Tango.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These consolidated financial statements contain recasted stockholders' equity balances resulting from the retroactive application of reverse recapitalization accounting in accordance with U.S. GAAP.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Retroactive Application of Recapitalization to the Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the terms of the Merger Agreement, upon the closing of the Business Combination on August 10, 2021 (the &#8220;Effective Time&#8221;), each share of Old Tango&#8217;s redeemable convertible preferred stock (the &#8220;Preferred Stock&#8221;) issued and outstanding immediately prior to the Effective Time was converted into a share of the Company&#8217;s common stock using the exchange ratio of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.34</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:9.468%;"/>
        <td style="width:1.003%;"/>
        <td style="width:16.066%;"/>
        <td style="width:1.003%;"/>
        <td style="width:0.646%;"/>
        <td style="width:15.002%;"/>
        <td style="width:0.646%;"/>
        <td style="width:1.003%;"/>
        <td style="width:0.646%;"/>
        <td style="width:12.767%;"/>
        <td style="width:0.646%;"/>
        <td style="width:1.003%;"/>
        <td style="width:0.646%;"/>
        <td style="width:11.515%;"/>
        <td style="width:0.646%;"/>
        <td style="width:1.003%;"/>
        <td style="width:0.646%;"/>
        <td style="width:11.783%;"/>
        <td style="width:0.646%;"/>
        <td style="width:1.003%;"/>
        <td style="width:0.646%;"/>
        <td style="width:10.919%;"/>
        <td style="width:0.646%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Date</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Redeemable Convertible Preferred Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Preferred to Common Exchange Ratio</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Common Stock Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">8/10/2021 Merger Recapitalization Exchange Ratio</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Recapitalization Common Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12/31/2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Series A</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">55,700,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1.00</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">55,700,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.34</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">18,922,317</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4/7/2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Series B (tranche 1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">22,686,025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">22,686,025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.34</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7,706,861</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8/17/2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Series B-1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">27,152,255</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1.00</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">27,152,255</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.34</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9,224,122</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3/18/2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Series B (tranche 2)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">22,686,025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">22,686,025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.34</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7,706,861</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All common shares, as well as previously issued share options and restricted stock awards (&#8220;RSAs&#8221;), presented in the accompanying recasted consolidated statements of redeemable convertible preferred stock and stockholders' equity (deficit) and/or in the related notes are presented on an as-converted basis, converted at the ratio of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.34</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Retroactive Application of Recapitalization to the Consolidated Statements of Operations and Comprehensive Loss</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In accordance with the retroactive application of recapitalization to the accompanying consolidated statements of redeemable convertible preferred stock and stockholders' equity (deficit), the basic and diluted weighted-average shares of common stock outstanding for the years ended December 31, 2021 and 2020 have been retroactively converted using the exchange ratio of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.34</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the weighted-average common shares, basic and diluted, for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2020:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:8.153%;"/>
        <td style="width:0.945%;"/>
        <td style="width:20.491%;"/>
        <td style="width:1.293%;"/>
        <td style="width:0.567%;"/>
        <td style="width:9.704%;"/>
        <td style="width:0.567%;"/>
        <td style="width:0.716%;"/>
        <td style="width:0.577%;"/>
        <td style="width:10.022%;"/>
        <td style="width:0.567%;"/>
        <td style="width:0.945%;"/>
        <td style="width:0.577%;"/>
        <td style="width:10.668%;"/>
        <td style="width:0.567%;"/>
        <td style="width:0.945%;"/>
        <td style="width:9.356%;"/>
        <td style="width:0.945%;"/>
        <td style="width:8.381%;"/>
        <td style="width:0.945%;"/>
        <td style="width:0.567%;"/>
        <td style="width:11.941%;"/>
        <td style="width:0.567%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Date</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As previously recorded</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">8/10/2021 Merger Exchange Ratio</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Recapitalized Common Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Days Outstanding in 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">% of weighting</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted average common shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12/31/2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Weighted-average shares, <br/>basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">11,461,011</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.34</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,893,305</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,893,305</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12/31/2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Series A shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">55,700,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.34</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">18,922,317</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">365</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">18,922,317</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4/7/2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Series B shares</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">22,686,025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.34</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7,706,443</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">268</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">73</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,664,025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8/17/2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Series B-1 shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">27,152,255</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.34</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9,223,621</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">136</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">37</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,452,558</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td colspan="19" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Weighted average number of common shares outstanding &#8211; basic and diluted for the year ended December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">31,932,204</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Retroactive Application of Recapitalization to the Consolidated Balance Sheets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To conform to the retroactive application of recapitalization to the accompanying consolidated statements of redeemable convertible preferred stock and stockholders' equity (deficit), historical proceeds from the issuance of preferred stock, less the par value of the historical preferred shares that were converted into common shares using the </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.34</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> ratio at the Effective Time, have been reclassified to additional paid in capital for the years ended December 31, 2021 and 2020, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139213959912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_CollaborationAgreementsAbstract', window );"><strong>Collaboration Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration Agreements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4. Collaboration Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2018 Gilead Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2018, the Company entered into a Research Collaboration and License Agreement (the &#8220;2018 Gilead Agreement&#8221;) with Gilead Sciences, Inc. (&#8220;Gilead&#8221;). Pursuant to the 2018 Gilead Agreement, the Company performed target discovery and validation activities in accordance with an agreed-upon a multi-year research plan. During the initial </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> research term, Gilead had the option to obtain exclusive, worldwide licenses to develop and commercialize up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> validated programs (&#8220;Gilead Program License&#8221;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2018, Gilead paid the Company a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million non-refundable upfront payment upon the execution of the 2018 Gilead Agreement. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company was eligible to receive milestone payments of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> billion across all programs and royalties on future sales of commercialized products, if any. For up to two programs licensed by Gilead, the Company had the option to co-develop and co-promote certain programs licensed by Gilead in the U.S. and was eligible to receive royalties on ex-U.S. sales</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company assessed this arrangement in accordance with ASC 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and concluded that the contract counterparty, Gilead, was a customer. The Company identified a single performance obligation under the arrangement consisting of the combination of participating on the joint steering committee and the research and development services provided during the research term. The identified promises were determined to not be individually distinct due to the specialized nature of the early-stage research services to be provided by the Company and the interdependent relationship between the promises. The Company determined that the option for Gilead to extend the term of the arrangement was not priced at a discount, and therefore did not provide Gilead with a material right. This option will be excluded from the transaction price until exercised. At the inception of the 2018 Gilead Agreement, the Company also determined that the Gilead program license options provided to Gilead did not include a material right.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The total transaction price, subject to variable consideration constraints, was allocated to the combined single performance obligation. The Company determined that the single combined performance obligation is satisfied over time as the customer is simultaneously receiving and consuming the benefit of the Company&#8217;s performance. The future milestone payments represent variable consideration that is fully constrained at inception of the arrangement as the achievement of the milestone events are highly uncertain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Amended Gilead Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2020, Gilead made an equity investment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million into the Company as a participant in the Company&#8217;s Series B-1 preferred stock offering. At the time of the original investment, as well as of the December 31, 2021 balance sheet date, Gilead maintains an ownership of less than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company's common stock and is thus not considered to be a related party to the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2020, the Company and Gilead also entered into an Amended Research Collaboration and License Agreement (the &#8220;Gilead Agreement&#8221;), which superseded and replaced the 2018 Gilead agreement. The Gilead Agreement represents a continuation of the initial target discovery and validation research and development efforts begun under the 2018 Gilead Agreement. Under the Gilead Agreement:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company received upfront, non-refundable consideration of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million from Gilead upon execution of the Gilead Agreement in 2020; </span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The term of the 2018 Gilead Agreement ended on the date the Gilead Agreement was executed. The Gilead Agreement has a research term of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seven years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">; </span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gilead expanded its option to license up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> programs for which Gilead may obtain exclusive, worldwide licenses to develop and commercialize therapies, subject to applicable license fees; </span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to exercising its option to license a program, Gilead may &#8220;extend&#8221; such program, in which case Gilead will pay research extension fees and the Company will continue to collaborate with Gilead to discover and develop programs, potentially through early clinical development; </span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gilead has the option to &#8220;reserve&#8221; a target during which Gilead may: (i) license the target, (ii) &#8220;extend&#8221; the target, or (iii) decline the target, during the designated reserve target period. If, during the reserve target period Tango elects to work on the reserved target, Tango will retain full rights to the target program and Gilead receives a right of first negotiation in connection with any future partnering or licensing of such target by Tango, if any; and </span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For up to five programs licensed by Gilead, the Company has the option to co-develop and co-promote the lead product in the U.S., subject to certain exceptions, and is eligible to receive tiered royalties in the first decile on ex-U.S. sales. </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company is eligible to receive up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">410.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million per program in license, research extension, and clinical, regulatory, and commercial milestones</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Gilead Agreement was accounted for as a modification of the 2018 Gilead Agreement under ASC 606 as both the scope and price of the contract were changed under the Gilead Agreement. The additional goods and services to be provided under the Gilead Agreement are not distinct from the combined performance obligation identified under the 2018 Gilead Agreement which was only partially satisfied at the date of contract modification. As such, the Company identified a single combined performance obligation under the Gilead Agreement consisting of the research services and continued participation on the joint steering committee during the research term. As a result, the Company&#8217;s progress towards completing its research services to Gilead over the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seven-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> term of the Amended Gilead Agreement was lower than its progress under the three-year term of the 2018 Gilead Agreement and a cumulative catch-up adjustment was recorded during the third quarter of 2020 resulting in a charge of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million against revenue previously recognized through the date of the Gilead Agreement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020 and in September 2021, Gilead elected to extend two programs for a research extension fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million each. The Company determined that the additional goods and services relating to the continued research services were not distinct from the early-stage research services already promised to Gilead under the on-going research plan. Consideration pertaining to each of the research extensions is paid to the Company in equal quarterly installment payments over an agreed upon payment schedule. Although future research installment payments are not payable in the event of scientific failure, the Company determined that the variable consideration of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">for each of the extensions should</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">be constrained as the potential for a significant reversal of cumulative revenue recognized at the contract level is remote, and therefore the research extension consideration was added to the transaction price under the Gilead Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2021, Gilead licensed a program for an $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million license fee. The $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million license fee was received and recognized as revenue in the second quarter of 2021 since Tango has no continued involvement in the advancement of the program, Gilead can benefit from the license on its own and the license is separately identifiable from the research services.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Gilead Revenue Recognized</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The total transaction price allocated to the combined performance obligation under the Gilead Agreement was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">199.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The total transaction price was comprised of the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upfront payment pursuant to the 2018 Gilead Agreement, the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upfront payment pursuant to the Gilead Agreement, the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million payment pursuant to the research extension fee in December 2020, and the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million payment pursuant to the research extension fee in September 2021. During the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021, the Company recognized </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of collaboration revenue associated with the Gilead Agreements based on performance completed during the period. During the year ended December 31, 2020, the Company recognized </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of collaboration revenue associated with the Gilead Agreements based on performance completed during the period which was partially offset by a reduction in revenue resulting from a cumulative catch-up adjustment that was recorded during the third quarter in connection with the Amended Gilead Agreement. During the year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company recognized license revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, associated with the payment received in the second quarter of 2021 pursuant to the April 2021 program license. During the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2020, the Company recognized license revenue </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">associated with the payments received in 2019 pursuant to the program license and Gilead side letter agreement. The consideration allocated to the Gilead License was recognized upon delivery of the underlying license in 2019 as Gilead could benefit from the license on its own and the Gilead License was separately identifiable from the Gilead side letter agreement research services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company reevaluates the transaction price and the total estimated costs expected to be incurred to satisfy the performance obligations at the end of each reporting period and as uncertain events, such as changes to the expected timing and cost of certain research and development activities that the Company is responsible for, are resolved or other changes in circumstances occur.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> As of December 31, 2021 and 2020</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company had short-term deferred revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and long-term deferred revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114.7</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, res</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">pectively, related to the Gilead collaboration. The remaining long-term revenue is expected to be recognized proportionally to the completed obligations over an expected remaining contractual term of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.6</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amounts due to the Company that have not yet been received are recorded as accounts receivable and amounts received that have not yet been recognized as revenue are recorded as deferred revenue on the Company&#8217;s consolidated balance sheets. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of the total research extension fees of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million had been received, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million had been recorded as accounts receivable and the remaining $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was determined to be conditional upon the satisfaction of additional research obligations, and thus a contract asset. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The contract asset balance is presented net of the deferred revenue contract liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Costs incurred pursuant to the Gilead Agreements are recorded as research and development expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_CollaborationAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_CollaborationAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139213960472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5. Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.325%;"/>
        <td style="width:1.163%;"/>
        <td style="width:1.263%;"/>
        <td style="width:9.884%;"/>
        <td style="width:0.616%;"/>
        <td style="width:1.163%;"/>
        <td style="width:1.263%;"/>
        <td style="width:9.943%;"/>
        <td style="width:0.616%;"/>
        <td style="width:1.163%;"/>
        <td style="width:1.263%;"/>
        <td style="width:9.735%;"/>
        <td style="width:0.616%;"/>
        <td style="width:1.163%;"/>
        <td style="width:1.263%;"/>
        <td style="width:9.943%;"/>
        <td style="width:0.616%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Market Value Measurements<br/>as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62,244</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a762df4b-f3ed-4d4a-a408-0c28875d2805;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62,244</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury bills</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38,433</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38,433</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Marketable debt securities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury bills</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">287,123</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">287,123</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government agency bonds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55,387</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55,387</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62,244</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">380,943</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">443,187</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.518%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.273%;"/>
        <td style="width:9.526%;"/>
        <td style="width:0.636%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.273%;"/>
        <td style="width:9.546%;"/>
        <td style="width:0.636%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.273%;"/>
        <td style="width:9.456%;"/>
        <td style="width:0.636%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.273%;"/>
        <td style="width:9.546%;"/>
        <td style="width:0.636%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Market Value Measurements<br/>as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,698</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0b637d1f-640c-496c-91b4-be2bae95b9b9;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,698</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury bills</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,175</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,175</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Marketable debt securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury bills</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">131,939</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">131,939</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government agency bonds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,698</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">169,114</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">181,812</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> transfers between fair value levels during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139214039656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6. Marketable Securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company values its marketable securities using independent pricing services which normally derive security prices from recently reported trades for identical or similar securities, making adjustments based on significant observable transactions. At each balance sheet date, observable market inputs may include trade information, broker or dealer quotes, bids, offers or a combination of these data sources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the Company&#8217;s marketable debt securities, classified as available-for-sale:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:41.286%;"/>
        <td style="width:1.382%;"/>
        <td style="width:1.272%;"/>
        <td style="width:11.333%;"/>
        <td style="width:0.636%;"/>
        <td style="width:1.382%;"/>
        <td style="width:1.272%;"/>
        <td style="width:11.333%;"/>
        <td style="width:0.636%;"/>
        <td style="width:1.382%;"/>
        <td style="width:1.272%;"/>
        <td style="width:11.333%;"/>
        <td style="width:0.855%;"/>
        <td style="width:1.382%;"/>
        <td style="width:1.272%;"/>
        <td style="width:11.333%;"/>
        <td style="width:0.636%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value Measurements<br/>as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Loss</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Marketable debt securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury bills</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">287,699</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">577</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">287,123</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government agency bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55,576</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">189</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55,387</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">343,275</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">766</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">342,510</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:41.397%;"/>
        <td style="width:1.392%;"/>
        <td style="width:1.272%;"/>
        <td style="width:11.351%;"/>
        <td style="width:0.636%;"/>
        <td style="width:1.392%;"/>
        <td style="width:1.272%;"/>
        <td style="width:11.351%;"/>
        <td style="width:0.636%;"/>
        <td style="width:1.392%;"/>
        <td style="width:1.272%;"/>
        <td style="width:11.351%;"/>
        <td style="width:0.636%;"/>
        <td style="width:1.392%;"/>
        <td style="width:1.272%;"/>
        <td style="width:11.351%;"/>
        <td style="width:0.636%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value Measurements<br/>as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Loss</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Marketable debt securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury bills</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">131,927</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">131,939</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government agency bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,995</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">161,922</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">161,939</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company holds investment grade marketable securities, with less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of marketable debt securities considered to be in an unrealized loss position as of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">none</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> considered to be in an unrealized loss position as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2020. Although the marketable debt securities are held at an unrealized loss position at December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company does not intend to sell the marketable securities prior to the value of the securities being recovered. Further, the Company has concluded that it is more likely than not that the marketable securities cost basis values will be recovered prior to sale of the securities and that there are no conditions or events that might require the Company to sell the securities before recovery of the cost basis occurs. As a result, the Company did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t record any impairments to marketable securities or reserves for credit losses related to its marketable debt securities during the periods then ended. Marketable securities include $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in accrued interest at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and December 31, 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139210418856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Supplemental Balance Sheet Information</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7. Supplemental Balance Sheet Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020 consists of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.267%;"/>
        <td style="width:1.558%;"/>
        <td style="width:1.525%;"/>
        <td style="width:13.268%;"/>
        <td style="width:1.016%;"/>
        <td style="width:1.558%;"/>
        <td style="width:1.525%;"/>
        <td style="width:13.268%;"/>
        <td style="width:1.016%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,587</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,580</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">198</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">172</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer software</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">467</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">384</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">246</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">246</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction in progress</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">738</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,361</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,507</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Accumulated depreciation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,529</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,684</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,832</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,823</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation expense was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for the years ended December 31, 2021 and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accrued Expenses and Other Current Liabilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other current liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020 include the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.54%;"/>
        <td style="width:1.568%;"/>
        <td style="width:1.535%;"/>
        <td style="width:13.408%;"/>
        <td style="width:0.718%;"/>
        <td style="width:1.568%;"/>
        <td style="width:1.535%;"/>
        <td style="width:13.408%;"/>
        <td style="width:0.718%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payroll and employee-related costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,688</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,652</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development costs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,533</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,695</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">666</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">793</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,887</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,140</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139214921032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8. Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2017, the Company entered into a lease of office and laboratory space at 100 Binney Street in Cambridge, Massachusetts for the Company&#8217;s corporate headquarters. The lease commenced in March 2018 and rent commenced in June 2018. This lease had an original term of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">eight years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> with an </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">option to extend</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_9ce82792-73b0-4614-be7e-852d5e09b293;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> three-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> period.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon commencement of the lease, the Company recorded an operating lease liability in the amount of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and related operating lease right-of-use asset in the amount of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. Upfront payments totaling $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for rent and tenant improvements were included as a reduction in the calculation of the lease liability amount upon the commencement of the lease. There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> tenant obligation payments made for leasehold improvements for the periods ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The fixed annual rent payable under the lease was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, increasing by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% annually from the rent commencement date. The minimum rent payments to be paid over the original term of the lease totaled $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The additional rental payments associated with the renewal option are not included in the calculation of the operating lease right-of-use asset and associated operating lease liability as the renewal is not considered probable of occurring. The lease agreement required the Company to provide a letter of credit for $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million that is collateralized with cash that is recorded as restricted cash in the accompanying balance sheet.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2019, the Company entered into a new lease for office and laboratory space at 201 Brookline Avenue in Boston, Massachusetts. As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the space was undergoing construction and the lease is expected to commence for accounting purposes in the first half of 2022. The Company is not deemed to be the accounting owner of the construction project due to the nature of the work being performed and the Company&#8217;s lack of control over the project. In conjunction with executing the lease, the Company provided the landlord a letter of credit for $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The letter of credit is collateralized with cash that is recorded as restricted cash in the accompanying balance sheet as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> In January 2022, the Company provided an additional letter of credit in the amount of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.7</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the remaining security deposit balance on the lease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon commencement of the 201 Brookline Avenue lease, the Company will determine the appropriate classification of the lease, the amount of the associated lease liability and the amount of the right-of-use asset that will be recognized on the balance sheet. The lease has a non-cancelable term of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ten years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> with an </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">option to extend</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for up to two five-year periods.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The fixed annual rent payable under the lease is $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, increasing by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% annually from the rent commencement date. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is entitled to a tenant improvements allowance of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.7</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">November 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company entered into a lease termination agreement for the leased office and laboratory space at 100 Binney Street in Cambridge, Massachusetts. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The lease termination agreement is a modification of the original lease agreement that provides for, among other things, the acceleration of the expiration of the original term of the lease from </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June 30, 2026</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to an earlier lease termination date, for which the earlier date shall be no later than </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">October 15, 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The execution of the lease termination agreement resulted in reductions to the associated lease liability and right-of-use asset balances of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.2</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, in the fourth quarter of 2021. The $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.6</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million letter of credit associated with the lease and recorded as restricted cash on the balance sheet as of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 will be returned to the Company on the last day of the modified lease term.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s rent payments for the lease at 100 Binney Street are classified as operating lease costs in the chart below. The lease is a net lease and therefore the non-lease components, such as common area maintenance, are paid separately from rent based on actual costs incurred; therefore, the non-lease components are not included in the right-of-use asset and liability and are reflected as an expense in the period incurred. The non-lease components are classified as variable costs in the chart below. As of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, assets under the operating lease totaled $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, res</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">pectively. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The elements of lease cost were as follows: </span></span><span style=""/></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.656%;"/>
        <td style="width:1.581%;"/>
        <td style="width:1.272%;"/>
        <td style="width:12.435%;"/>
        <td style="width:2.137%;"/>
        <td style="width:1.581%;"/>
        <td style="width:1.272%;"/>
        <td style="width:11.928%;"/>
        <td style="width:2.137%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,889</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,889</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term lease cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">673</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">643</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating lease costs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,695</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,625</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Other information</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating cash flows used for operating leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,835</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,782</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted average remaining lease term in years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted average discount rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></div><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Future minimum lease payments under leases that have commenced as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:78.205%;"/>
        <td style="width:1.865%;"/>
        <td style="width:1.828%;"/>
        <td style="width:16.884%;"/>
        <td style="width:1.218%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Maturity of Lease<br/>Liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,572</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,572</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: imputed interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,503</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139213984792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9. Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research Collaboration Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 2017, the Company entered into a Research Collaboration Agreement (the &#8220;HitGen Agreement&#8221;) with HitGen Ltd (&#8220;HitGen&#8221;). Under the terms of the HitGen Agreement, HitGen would use its DNA-encoded library technology to screen up to three targets and deliver to the Company the structures of certain compounds that bind to the targets. The Company would provide certain materials containing each target for purposes of the screen. The Company could have been obligated to make certain milestone payments. The Company and HitGen mutually agreed to terminate the HitGen</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Agreement </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in March 2021. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> milestones were achieved or owed upon the termination of the agreement and the Company did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t make any payments upon termination of the HitGen Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2020, the Company entered into a License Agreement (the &#8220;Medivir Agreement&#8221;) with Medivir AB (&#8220;Medivir&#8221;), pursuant to which the Company obtained an exclusive license to all patents, know-how and other intellectual property associated with a preclinical-stage research program. Pursuant to the Medivir Agreement, the Company made an upfront payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the terms of the Medivir Agreement, the Company is obligated to pay Medivir in connection with development, regulatory and commercial activities. The Company has agreed to make certain milestone payments of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the aggregate for the first licensed product that achieves specified clinical milestones, plus $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the first licensed product that achieves specified regulatory approval and sales milestones, in each case, in either of the first two specified genetic contexts and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the aggregate if that first licensed product achieves specified clinical milestones, plus $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million if that first licensed product achieves specified regulatory and sales milestones for a third genetic context or the second licensed product achieves such specified development, regulatory and sales milestones in either of the first two specified genetic contexts. The Company has the right to reduce these milestone payments by a specified amount in the event the licensed product is not covered by Medivir&#8217;s patents or if payments are due to a third party for a license under such third party&#8217;s intellectual property rights. The Company is also obligated to pay Medivir a low single-digit royalty on net sales of any product covered by a licensed patent. The Medivir Agreement expires on the date of expiration of all royalty obligations. Either party may terminate the Medivir Agreement earlier upon an uncured material breach of the other party.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upfront fees paid pursuant to the Medivir License Agreement were recorded to research and development expense. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> milestones have been achieved to date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other Funding Commitments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company had ongoing non-clinical studies for its various pipeline programs. The Company enters into contracts in the normal course of business with contract research organizations in preparation for clinical trials, professional consultants for expert advice and other vendors for clinical supply manufacturing or other services. These contracts are generally cancellable, with notice, at the Company's option and do not have significant cancellation penalties.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Guarantees</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company enters into certain agreements with other parties in the ordinary course of business that contain indemnification provisions. These typically include agreements with directors and officers, business partners, contractors, landlords, contract research organizations and clinical sites. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party under the terms of the contract, including as a result of the Company&#8217;s activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these obligations is minimal.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Litigation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company, from time to time, may be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal proceedings as of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and no material legal proceedings are currently pending or threatened. Because of uncertainties related to claims, proceedings and litigation, assessments of potential liabilities are based on the Company's best estimates based on information available at the time of the assessment. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation, court decisions or settlement of claims (and offers of settlement), the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in a material adverse effect on the operating results of the Company. Costs associated with involvement in legal proceedings are expensed as incurred. The outcome of any such proceedings, regardless of the merits, is inherently uncertain. If the Company were to be unable to prevail in any such proceedings, the consolidated financial position, results of operations, and future cash flows of the Company may be materially impacted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139213960472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityDisclosureAbstract', window );"><strong>Temporary Equity Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_RedeemableConvertiblePreferredStockDisclosureTextBlock', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10. Redeemable Convertible Preferred Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2017, Old Tango executed a stock purchase agreement to sell </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of redeemable convertible series A preferred stock (&#8220;Series A&#8221;). This agreement was subsequently amended in July 2017 to increase the authorized capital to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55,700,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series A.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the initial closing of the Series A stock purchase agreement, Old Tango issued an aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,700,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series A convertible preferred stock for $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, resulting in net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million after deducting $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to the settlement of the convertible notes and accrued interest that were previously outstanding. During the year-ended December 31, 2018, Old Tango issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional shares of Series A preferred stock at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share resulting in total proceeds from this issuance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. In January 2019, Old Tango issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional shares of Series A preferred stock at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share resulting in total proceeds from this issuance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The aggregate issuance costs associated with the issuance of all three issuances of Series A preferred stock was less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2020, Old Tango executed a stock purchase agreement to sell shares of redeemable convertible series B preferred stock (&#8220;Series B&#8221;). The Series B stock purchase agreement allows for the issuance of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45,372,051</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares. In April 2020, Old Tango issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,686,025</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series B at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.32</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. Proceeds from this issuance totaled $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, net of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in issuance costs. In March 2021, Old Tango sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,686,025</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional shares of Series B stock at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.32</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share upon the achievement of specified development milestones in connection with the second tranche of the Series B stock purchase agreement. Proceeds from this issuance totaled $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. Total issuance costs associated with the March 2021 issuance of Series B preferred stock was less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2020, Old Tango executed a stock purchase agreement to sell shares of redeemable convertible series B-1 preferred stock (&#8220;Series B-1&#8221;). The Series B-1 stock purchase agreement allowed for the issuance of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,152,255</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares. All </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,152,255</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series B-1 were issued at a price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.89</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share in August 2020. Proceeds from this issuance was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, net of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in issuance costs</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Conversion of Redeemable Convertible Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the terms of the Merger Agreement, upon the Effective Time, each share of Old Tango&#8217;s Preferred Stock issued and outstanding immediately prior to the Effective Time was converted into a share of Old Tango&#8217;s common stock and subsequently converted into shares of New Tango common stock using an exchange ratio of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.34</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. A retroactive adjustment has been applied to all periods presented to reflect the Business Combination and reverse recapitalization, therefore, resulting in no outstanding Preferred Stock as of December 31, 2021 and 2020. Refer to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Note 3 for additional discussion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Undesignated Preferred Stock</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s Certificate of Incorporation, as amended and restated, authorizes the Company to issue shares of preferred stock with a par value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. The number of shares of preferred stock authorized to be issued is </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The shares of preferred stock are currently undesignated.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_RedeemableConvertiblePreferredStockDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable convertible preferred stock disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_RedeemableConvertiblePreferredStockDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139213831112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Class Of Stock Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">11. Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s Certificate of Incorporation, as amended and restated, authorizes the Company to issue shares of common stock with a par value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The holder of each share of common stock is entitled to one vote in respect of each share of stock held.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the funds and assets available for distribution to the stockholders of the Company will be distributed among the holders of shares of common stock, pro rata based on the number of shares of common stock held by each such holder. The holders of Common Stock are also entitled to receive dividends whenever funds and assets are legally available and when declared by the Board of Directors. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> dividends have been declared as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company increased the number of shares of common stock authorized to be issued to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">200,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares in August 2021, at the time in which the Certificate of Incorporation was amended and restated.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> As of December 31, 2021 and 2020, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87,598,184</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40,372,133</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock issued and outstanding,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> respectively, as adjusted to reflect the Business Combination and reverse recapitalization through the application of a retroactive adjustment</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139210418856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Plans</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">12. Equity Incentive Plans</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the terms of the Business Combination, upon the Closing Date, each option to purchase Old Tango&#8217;s common stock became an option to purchase shares of common stock of the surviving entity and was subsequently adjusted using an exchange ratio of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.34</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. A retroactive adjustment has been applied to all periods presented to reflect the Business Combination and reverse recapitalization as discussed further in Note 3.</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Founder and Advisor Awards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During 2017, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,690,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of restricted common stock outside of the Company&#8217;s 2017 Stock Option and Grant Plan to nonemployee founders and advisors (the &#8220;Founders and Advisors&#8221;). The shares are issued under the terms of the respective restricted common stock agreements and are subject to repurchase by the Company at the original purchase price per share upon the termination of the grantee&#8217;s service relationship with the Company. As the restrictions are released and the awards vest, the value is recorded as common stock and excess of par value is recorded as additional paid in capital on the accompanying balance sheet. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021, all founder and advisor restricted stock awards (&#8220;RSAs&#8221;) had vested.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2017 Stock Option and Grant Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2017, the Company&#8217;s stockholders approved the 2017 Stock Option and Grant Plan (the &#8220;2017 Plan&#8221;), under which stock options and RSAs were granted to eligible employees, officers, directors, consultants, or other key persons who provide services to the Company. Such issuances under the 2017 Plan were subject to vesting, forfeiture and other restrictions as deemed appropriate by the board of directors (&#8220;Board of Directors&#8221;) at the time of issuance.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon effectiveness of the 2021 Stock Option and Incentive Plan (the "2021 Plan") in August 2021, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the remaining shares available under the 2017 Plan ceased to be available for issuance and no future issuances will be made under the 2017 Plan. The shares of common stock underlying outstanding awards under the 2017 Plan that are forfeited, cancelled, reacquired by the Company prior to vesting, expire or are otherwise terminated (other than by exercise) will be added to the shares of common stock available for issuance under the 2021 Plan.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2021 Stock Option and Incentive Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon the closing of the Business Combination in August 2021, the Company's stockholders approved the 2021 Plan under which stock options, RSAs, unrestricted stock awards, restricted stock units, or any combination of the forgoing may be granted to eligible employees, officers, directors, consultants, or other key persons who provide services to the Company. Such issuances are subject to vesting, forfeiture and other restrictions as deemed appropriate by the Board of Directors at the time of issuance.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon approval, the maximum number of shares of stock reserved and available for issuance under the 2021 Plan was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,498,725</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares. The number of shares available for future grant will automatically increase on the first day of each fiscal year by an amount equal to the least of: (i) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> percent of the number of shares of Stock issued and outstanding on the immediately preceding December 31 or (ii) such lesser number of shares as determined by the 2021 Plan Administrator, as appointed by the Board of Directors. Awards that are returned to the Company's equity plan as a result of forfeiture, cancellation, are reacquired by the Company prior to vesting, expiration, or any other form of termination (other than by exercise) are automatically made available for issuance under the 2021 Plan. As of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,271,873</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares available for future grant under the 2021 Plan and on January 1, 2022, the number of shares available for future grant under the 2021 Plan increased by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,377,321</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2021 Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2021 Employee Stock Purchase Plan (the &#8220;2021 ESPP&#8221;) was adopted and approved by the Company&#8217;s board of directors and by the Company&#8217;s stockholders and became effective upon the closing of the Business Combination in August 2021. An aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">949,873</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares were reserved for issuance. The 2021 ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2022 and each January 1 thereafter, by the least of (i) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the outstanding number of shares of the Company&#8217;s common stock on the immediately preceding December 31, (ii) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">949,873</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares or (iii) such number of shares as determined by the administrator. The 2021 ESPP was increased by</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">875,464</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares on January 1, 2022.</span><span style="background-color:rgba(255,255,0,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br/></span><span style="background-color:rgba(255,255,0,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Stock Awards</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the RSA activity of the Company&#8217;s plans as of and for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.186%;"/>
        <td style="width:1.878%;"/>
        <td style="width:0.972%;"/>
        <td style="width:11.601%;"/>
        <td style="width:1.028%;"/>
        <td style="width:1.558%;"/>
        <td style="width:1.525%;"/>
        <td style="width:13.534%;"/>
        <td style="width:0.718%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br/>shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted Average<br/>Grant-Date<br/>Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Unvested restricted common stock outstanding as of December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,084,125</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.07</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">788,227</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.06</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39,087</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.23</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Unvested restricted common stock outstanding as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">256,811</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.22</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">256,598</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.22</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">213</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.35</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Unvested restricted common stock outstanding as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">RSAs represent an unsecured promise to grant at no cost a set number of shares of common stock upon vesting. RSA recipients are not entitled to cash dividends and have no voting rights during the vesting period. The RSAs are issued under the terms of the respective RSA agreements and are subject to repurchase upon the holder&#8217;s termination of their service relationship with the Company. The award restrictions are released as the awards vest. Upon vesting, the value is recorded as common stock and excess of par value as is recorded as additional paid in capital on the accompanying balance sheets. The common stock is subject to the Company&#8217;s right to repurchase at the original purchase price per share.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, all RSAs had vested. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The aggregate fair value of RSAs that vested during the years ended December 31, 2021 and 2020</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Options</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the stock option activity of the Company&#8217;s plans as of and for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.488%;"/>
        <td style="width:1.193%;"/>
        <td style="width:0.636%;"/>
        <td style="width:9.931%;"/>
        <td style="width:0.865%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.272%;"/>
        <td style="width:9.524%;"/>
        <td style="width:0.636%;"/>
        <td style="width:1.193%;"/>
        <td style="width:0.646%;"/>
        <td style="width:10.081%;"/>
        <td style="width:0.636%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.272%;"/>
        <td style="width:9.603%;"/>
        <td style="width:0.636%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br/>shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Contractual<br/>Term</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Options outstanding as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,094,544</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.88</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.58</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,635,627</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,200,841</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.53</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">638,754</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.66</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cancelled</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">283,638</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.34</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Options outstanding as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,372,993</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.59</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.55</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,415,394</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options exercisable as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,117,654</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.56</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.52</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,759,485</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The aggregate intrinsic value of options is calculated as the difference between the exercise price of the options and the fair value of the Company&#8217;s common stock for those options that had exercise prices lower than the fair value of the Company&#8217;s common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The total intrinsic value of options exercised totaled $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.8</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020, respectively. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average grant date fair value per share of stock options granted was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.40</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.44</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for the years ending </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, total unrecognized compensation expense related to stock options was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">which the Company expects to recognize over a remaining weighted-average period of</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.0</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Substantially all options outstanding as of December 31, 2021 are expected to vest.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Option Valuation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted average assumptions used to estimate the grant date fair value of the stock options using the Black-Scholes option pricing model were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.997%;"/>
        <td style="width:1.62%;"/>
        <td style="width:14.881%;"/>
        <td style="width:1.62%;"/>
        <td style="width:14.881%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected option life (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.2</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.0</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#8211;</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> 6.1</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% &#8211; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% &#8211; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212; %</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212; %</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company measures stock-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recorded stock-based compensation expense in the following expense categories in its accompanying statements of operations: </span></span><span style=""/></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.603%;"/>
        <td style="width:1.569%;"/>
        <td style="width:1.524%;"/>
        <td style="width:13.388%;"/>
        <td style="width:0.718%;"/>
        <td style="width:1.569%;"/>
        <td style="width:1.524%;"/>
        <td style="width:13.388%;"/>
        <td style="width:0.718%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,616</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,003</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,217</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">761</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,833</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,764</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139214029528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">13. Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company recorded a total tax provision of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. During the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company recorded </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> tax provision or benefits due to the losses incurred and the need for a full valuation allowance against its deferred tax assets. All of the Company&#8217;s operating losses since inception have been generated in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.503%;"/>
        <td style="width:1.513%;"/>
        <td style="width:0.696%;"/>
        <td style="width:11.709%;"/>
        <td style="width:3.524%;"/>
        <td style="width:1.513%;"/>
        <td style="width:0.696%;"/>
        <td style="width:12.338%;"/>
        <td style="width:2.507%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income taxes at U.S. federal statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State income taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.9</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal and state research and development tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Nondeductible/nontaxable permanent items</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.7</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effective tax rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The tax effects of temporary differences that give rise to significant components of the deferred tax assets and liabilities are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.094%;"/>
        <td style="width:1.546%;"/>
        <td style="width:1.524%;"/>
        <td style="width:13.366%;"/>
        <td style="width:1.016%;"/>
        <td style="width:1.546%;"/>
        <td style="width:1.524%;"/>
        <td style="width:13.366%;"/>
        <td style="width:1.016%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,403</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,085</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development credit carryforwards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,084</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,213</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">411</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,154</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34,625</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,891</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accruals and reserves</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">958</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">648</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Capitalized research costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,193</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,506</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,008</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50,682</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,585</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49,568</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,945</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,114</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,640</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">771</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">597</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right-of-use asset</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">343</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,043</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total gross deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,114</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,640</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred taxes</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company had U.S. federal and state net operating loss (&#8220;NOL&#8221;) carryforwards of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, which may be available to offset future taxable income. The federal NOLs include $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million which expire at various dates beginning in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2036</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million which carry forward indefinitely. The state NOLs expire at various dates beginning in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2036</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company also had U.S. federal and state research and development tax credit carryforwards of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.9</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, which may be available to offset future tax liabilities and begin to expire in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2034</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2030</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Utilization of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In general, an ownership change results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% over a three-year period. The Company has performed an analysis of ownership changes through December 31, 2021 and determined that on February 6, 2017 and August 17, 2020, ownership changes had occurred. Based on this analysis, the Company&#8217;s ability to use its pre-change tax attributes to offset federal and state taxable income are subject to annual limitations and a portion of the attributes generated prior to February 6, 2017 will expire unutilized, which could potentially result in an increased future tax liability. The Company has adjusted its deferred tax assets and valuation allowance balance for the affected tax attribute carryforwards to reflect the expiration of the attributes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ASC 740 requires a valuation allowance to reduce the deferred tax assets reported, if based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company&#8217;s history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and has concluded that it is more likely than not that the Company will not realize the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the net deferred tax assets as of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Management reevaluates the positive and negative evidence at each reporting period. The Company recorded an increase to the valuation allowance of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021 related primarily to the increase in deferred revenue and research and development tax credit carryforwards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t recorded any amounts for unrecognized tax benefits. The Company&#8217;s policy is to record interest and penalties related to income taxes as part of its income tax provision. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company had </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> accrued interest or penalties related to uncertain tax positions in the consolidated statements of operations and comprehensive loss.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company files income tax returns in the U.S. federal and Massachusetts jurisdictions, as prescribed by tax laws. The Company will file a final California income tax return for the short-period through the Closing Date of the Business Combination. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The statute of limitations for federal and state tax authorities is generally closed for years prior to December 31, 2018, although carryforward attributes that were generated prior to 2018 may still be subject to change upon examination if they are utilized to offset taxable income in subsequent tax years. There are currently no federal or state income tax audits in progress.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139213992184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">14. Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.243%;"/>
        <td style="width:1.525%;"/>
        <td style="width:1.514%;"/>
        <td style="width:13.823%;"/>
        <td style="width:1.017%;"/>
        <td style="width:1.525%;"/>
        <td style="width:1.514%;"/>
        <td style="width:13.823%;"/>
        <td style="width:1.017%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands, except share and per<br/>share data)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58,235</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,972</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average common stock outstanding &#8211; basic and diluted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62,108,032</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,932,204</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per common share &#8211; basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.94</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.63</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s potential dilutive securities, which include common stock options and unvested restricted common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: </span></span><span style=""/></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.094%;"/>
        <td style="width:1.569%;"/>
        <td style="width:0.718%;"/>
        <td style="width:14.448%;"/>
        <td style="width:0.718%;"/>
        <td style="width:1.569%;"/>
        <td style="width:0.718%;"/>
        <td style="width:14.448%;"/>
        <td style="width:0.718%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options to purchase common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,372,993</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,094,544</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested restricted common stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">256,811</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,372,993</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,353,375</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139214183624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of consolidated financial statements requires that the Company make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. Significant estimates and assumptions made in the consolidated financial statements include, but are not limited to, the revenue recognized from collaboration agreements, the valuation of stock-based awards and the accrual for research and development expenses. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Segment Information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating segments are defined as components of an enterprise for which separate financial information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company operates in </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> operating segment, the business of discovering and developing precision oncology therapies.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All highly liquid marketable securities purchased with an original maturity date of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90 days</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or less at the date of purchase are considered to be cash equivalents. Cash equivalents consisted of money market funds and U.S. Treasury bills as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments in Marketable Securities</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investments in Marketable Securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Marketable debt securities consist of investments with original maturities greater than </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90 days</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company classifies its investments with maturities beyond one year as short-term, based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. The Company considers its investment portfolio of marketable securities to be available-for-sale. Accordingly, these investments are recorded at fair value, which is based on quoted market prices. Unrealized gains are reported as a component of accumulated other comprehensive income in stockholders&#8217; equity (deficit). Amortization and accretion of premiums and discounts are recorded in interest income. Realized gains and losses are included as a component of other income, net in the consolidated statements of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company evaluates its investments with unrealized losses for impairment. When assessing investments for unrealized declines in value, the Company considers whether the decline in value is related to a credit loss or non-credit loss. For credit losses, the Company reduces the investment to fair value through an allowance for credit losses recorded to the balance sheet and corresponding charge to the statement of operations. The allowance for credit losses and corresponding impairment charge is adjusted each period for changes in fair value. For non-credit losses, the Company reduces the investment to fair value through a charge to the statement of comprehensive loss, reported as a component of accumulated other comprehensive income (loss) in stockholders&#8217; equity. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> such credit losses were recorded during the periods presented.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value Measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accounting standard for fair value measurements defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and requires certain disclosures about fair value measurements. Under this standard, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1 &#8212; Fair values are determined utilizing prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access. </span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2 &#8212; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves, and foreign currency spot rates. </span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3 &#8212; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. </span></div></div><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of the Company&#8217;s cash equivalents and marketable securities are determined according to the fair value hierarchy described below (see Note 5)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The carrying values of the Company&#8217;s accounts receivable, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Significant Suppliers</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk and Significant Suppliers</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash, cash equivalents and marketable debt securities. The Company&#8217;s cash, cash equivalent and marketable securities balances are held by major financial institutions that management believes to be creditworthy. The Company uses multiple financial institutions to limit the amount of credit exposure to any one financial institution. Substantially all the Company&#8217;s cash, cash equivalent and marketable debt securities were invested in money market funds, U.S. Treasury bills, and U.S. government agency bonds at December 31, 2021 and 2020. At times, the Company&#8217;s cash deposits may exceed the amount of federal insurance provided on such deposits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant credit risk beyond the normal credit risk associated with commercial banking relationships.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company relies, and expects to continue to rely, on a small number of vendors to perform research activities and clinical trial activities that continue to progress its product candidates for its development programs. These programs could be adversely affected by a significant interruption in the related processes of these vendors.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash accounts with any type of restriction are considered restricted cash and are classified on the balance sheet based on the length of the restrictive obligation. As of both December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company recorded restricted cash of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, all of which was related to security deposits associated with the Company&#8217;s facility leases in Boston, Massachusetts and Cambridge, Massachusetts. The security deposit associated with the Company's facility lease in Boston, Massachusetts is recorded as non-current in its balance sheet as of December 31, 2021 and December 31, 2020 because the deposit is required for the duration of the lease which is greater than a year. The security deposit associated with the Company's facility lease in Cambridge, Massachusetts is recorded as current in its balance sheet as of December 31, 2021 because the deposit is required for the duration of the amended lease which is less than a year from the balance sheet date. The security deposit associated with the Company's facility lease in Cambridge, Massachusetts was recorded as non-current in its balance sheet as of December 31, 2020 because the deposit was required for the duration of the original lease which, prior to the 2021 lease amendment, was for greater than a year from the December 31, 2020 balance sheet date.</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The reconciliation of cash and cash equivalents and restricted cash to amounts presented in the consolidated statements of cash flows are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.312%;"/>
          <td style="width:1.6%;"/>
          <td style="width:1.282%;"/>
          <td style="width:13.33%;"/>
          <td style="width:0.636%;"/>
          <td style="width:1.6%;"/>
          <td style="width:1.282%;"/>
          <td style="width:13.32%;"/>
          <td style="width:0.636%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">142,745</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28,381</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">567</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash, net of current portion</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,712</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,279</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">145,024</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,660</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful lives of each asset. Estimated useful lives are periodically assessed to determine if changes are appropriate. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated useful lives of the Company&#8217;s property and equipment are as follows: </span></span><span style=""/></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:43.72%;"/>
          <td style="width:1.835%;"/>
          <td style="width:54.444%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Asset</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Estimated useful life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer software</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shorter of remaining lease term or 10 years</span></span></p></td>
         </tr>
        </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company reviews long-lived assets, such as property and equipment, for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. If indicators of impairment are present, the assets are tested for recoverability by comparing the carrying amount of the assets to the related estimated future undiscounted cash flows that the assets are expected to generate. If the expected cash flows are less than the carrying value of the asset group, then the asset group is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows. To date, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> such impairment losses have been recorded.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Costs for assets not yet placed into service are capitalized as construction-in-progress and depreciated or amortized in accordance with the above useful lives once placed into service. Upon retirement or sale, the related cost and accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in the consolidated statements of operations. Repairs and maintenance costs are expensed as incurred.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Operating Leases</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances and the existence of an identified asset(s), if any, and its control over the use of the identified asset(s), if applicable. Upon lease commencement, operating lease liabilities and their corresponding right-of-use assets are recorded on the balance sheet based at the present value of lease payments over the expected lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense is recognized over the expected term on a straight-line basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lease payments are discounted at the lease commencement date using the interest rate implicit in the lease contract. As this rate is typically not readily determinable, the Company determines an incremental borrowing rate that is used to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Certain prospective adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company elected to account for lease and non-lease components as a single lease component, however non-lease components that are variable, such as common area maintenance and utilities, are generally paid separately from rent based on actual costs incurred and therefore are not included in the right-of-use asset and operating lease liability and are reflected as an expense in the period incurred. The Company&#8217;s lease terms often include renewal options. The amounts determined for the Company&#8217;s right-of-use assets and lease liabilities generally do not assume that any renewal options or any early-termination provisions, if any, are exercised, unless it is reasonably certain that the Company will exercise such options.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At contract inception, the Company assesses whether the collaboration arrangements are within the scope of ASC Topic 808, Collaborative Arrangements, or ASC 808, to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed based on the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the arrangement are within the scope of ASC 808 and which elements are within the scope of ASC 606 (as described below). For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, either by analogy to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">authoritative accounting literature or by applying a reasonable and rational policy election. To date, the Company has not entered into any arrangements within the scope of ASC 808.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s revenues are generated through its license and collaboration agreements with Gilead. Refer to Note 4, &#8220;Collaboration Agreements.&#8221; elsewhere in these notes to the Company's consolidated financial statements.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers. ASC 606 provides a five-step framework whereby revenue is recognized when control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the  contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) performance obligations are satisfied. The Company only applies this framework to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation. Goods and services that are determined not to be distinct are combined with other promised goods and services until a distinct bundle is identified. The Company then allocates the transaction price (that is, the amount of consideration the Company expects to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The Company&#8217;s estimate of the transaction price for each contract includes all variable consideration to which the Company expects to be entitled, subject to the constraint on variable consideration. Variable consideration is not constrained if the potential reversal of cumulative revenue recognized at the contract level is not significant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under active agreements, the Company must use its judgment to determine: (a) the number of performance obligations based on the determination under step (ii) above; (b) the transaction price under step (iii) above; (c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above; and (d) the contract term and pattern of satisfaction of the performance obligations under step (v) above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to the identified performance obligations on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. In certain instances, the timing of satisfying these obligations can be difficult to estimate. Accordingly, the Company&#8217;s estimates may change in the future and those changes could be material. Such changes to estimates would result in a change in amounts of revenue recognized. If these estimates and judgments change over the course of these agreements, it may affect the timing and amount of revenue that the Company recognizes and records in future periods.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the collaboration agreements are recorded as accounts receivable in the Company&#8217;s consolidated balance sheet. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&#8217;s consolidated balance sheets. Amounts expected to be recognized as revenue within the one year following the balance sheet date are classified as current deferred revenue. Amounts not expected to be recognized as revenue within the one year following the balance sheet date are classified as deferred revenue, net of current portion. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as contract assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Exclusive License Rights</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> &#8212; If the license to the Company&#8217;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, which generally include research and development services, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a license is distinct from the other promises, the Company considers relevant facts and circumstances of each arrangement, including the research and development capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from the license for its intended purpose without the receipt of the remaining promises, whether the value of the license is dependent on the unsatisfied promises, whether there are other vendors that could provide the remaining promises and whether it is separately identifiable from the remaining promises. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation and whether the license is the predominant promise within the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. If the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">license is the predominant promise, and it is determined that the license represents functional intellectual property (&#8220;IP&#8221;), revenue is recognized at the point in time when control of the license is transferred. If it is determined that the license does not represent functional IP, revenue is recognized over time using an appropriate method of measuring progress.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Services</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> &#8212; The obligations under the Company&#8217;s collaboration agreements may include research and development services to be performed by the Company to benefit the collaboration partner. For performance obligations that include research and development services, the Company generally recognizes revenue allocated to such performance obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for purposes of recognizing revenue, which is generally an input measure such as costs incurred. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods of which revenue should be recognized, are subject to estimates by management and may change over the course of the contract. Reimbursements from the partner that are the result of a collaborative relationship with the partner, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense. No collaborative arrangements existed that would result in such reimbursements for the periods presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Customer Options</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> &#8212; The Company&#8217;s arrangements may provide a collaborator with the right to acquire additional goods or services in the future. Under these agreements, fees may be due to the Company (i) upon the exercise of the customer option or (ii) in equal installment payments over an agreed upon period. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the additional goods and services underlying the customer options are evaluated in order to determine if these additional goods or services are distinct from those included as a performance obligation at the outset of the arrangement. If the additional services are not determined to be distinct, the variable consideration pertaining to the customer option is added to the initial transaction price at the time in which the option exercise becomes probable, so long as a potential for reversal of cumulative revenue recognized at the contract level is not significant. Any such adjustments to the transaction price are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If the additional services are distinct, the Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company allocates the transaction price to material rights based on the relative stand-alone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Milestone Payments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> &#8212; At the inception of an arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant reversal of cumulative revenue recognized would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#8217;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Royalties</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> &#8212; For arrangements that include sales-based royalties, including milestone payments based on a level of sales, where the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from licensing agreements.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses include costs directly attributable to the conduct of research programs, including the cost of salaries, employee benefits, stock-based compensation expense, materials, supplies, depreciation on and maintenance of research equipment, the cost of services provided by outside contractors to conduct research and development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">activities and the allocable portions of facility costs, such as rent, utilities, and general support services. All costs incurred to fulfill the Company&#8217;s obligations under the collaboration with Gilead are classified as research and development expenses. All costs associated with research and development are expensed as incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management estimates the Company&#8217;s accrued research and development expenses as of each balance sheet date in the Company&#8217;s financial statements based on facts and circumstances known to the Company at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Nonrefundable advance payments for goods and services are deferred and recognized as expense in the period that the related goods are consumed or services are performed.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patent Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company measures the cost of employee services received in exchange for stock-based awards based on the grant-date fair value of the awards. The Company calculates the fair value of restricted stock awards based on the grant date fair value of the underlying common stock. The Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period of the awards for service-based awards, which is generally the vesting period. The Company recognizes stock-based compensation for performance-based awards when the underlying performance conditions are considered probable of occurrence and recognizes the cumulative effect of current and prior period changes in the period of change.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to the </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">consummation of the Business Combination transaction, as there was not a public market for the common stock of the Company prior to becoming publicly traded, the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fair value of common stock underlying stock-based awards was based on a valuation provided by the board of directors as derived from a recommendation by an unrelated third-party valuation firm. The Company determined the estimated per share fair value of its common stock at various dates considering contemporaneous and retrospective valuations that incorporated objective and subjective factors, including actual and forecasted financial results, market conditions and performance of comparable publicly traded companies, developments and milestones of the Company, the rights and preferences of common and redeemable convertible preferred stock, advice from the third-party valuation specialists, and transactions involving the Company&#8217;s stock. The estimated per share fair value of the Company&#8217;s common stock was determined in accordance with the guidance outlined in the American Institute of Certified Public Accountants Practice Aid, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Valuation of Privately-Held Company Equity Securities Issued as Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The fair value of each restricted common stock award was estimated on the date of grant based on the fair value of the Company&#8217;s common stock on that same date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Subsequent to becoming a publicly traded Company upon the consummation of the Business Combination transaction, the fair value of common stock underlying stock-based awards is based on an estimate at each grant date using the market price of our common stock and each of the assumptions discussed below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Term</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">:    The expected term of the stock options is estimated using the &#8220;simplified method,&#8221; as prescribed in SEC&#8217;s Staff Accounting Bulletin (SAB) No. 107, as the Company has limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting period and the contractual term of the option.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Volatility</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">:    Since there is limited historical data for the Company&#8217;s common stock and limited company-specific historical volatility, the Company has determined the share price volatility for options granted based on an analysis of the volatility used by a peer group of publicly traded companies. In evaluating similarity, the Company considers factors such as industry, stage of life cycle and size.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risk-free Interest Rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">:    The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected life of the option.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Dividend Rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">:    The expected dividend is assumed to be </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as the Company has never paid dividends and has no current plans to do so.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The assumptions used in estimating the fair value of stock-based awards represent management&#8217;s estimate and involve inherent uncertainties and the application of management&#8217;s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation is classified in the accompanying consolidated statements of operations and comprehensive loss based on the function to which the related services are provided. Forfeitures are accounted for as they occur. Any consideration paid by employees on exercising stock options and the corresponding portion previously credited to additional paid-in capital are credited to share capital.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_DeferredFinancingCostsPolicyTextBlock', window );">Deferred Financing Costs</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Deferred Financing Costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded in shareholders&#8217; equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period corresponding to the enactment date. A valuation allowance is established when it is more likely than not that all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a more likely than not likelihood of being realized upon ultimate settlement with the tax authority. The recognition and measurement of tax benefits requires significant judgments that are subject to change as new information becomes available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Penalties and interest expense related to income taxes are included as components of income tax expense and interest expense, respectively, as necessary.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Gain (Loss)</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comprehensive Gain (Loss)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity (deficit) that result from transactions and economic events other than those with stockholders. The Company&#8217;s only element of other comprehensive loss for the years ended December 31, 2021 and 2020</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was unrealized gains (losses) on investments in marketable securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per share attributable to common stockholders is computed by dividing net loss by the weighted-average number of shares of common shares outstanding during each reporting period. The weighted-average number of shares of common stock outstanding used in the basic net loss per share calculation does not include unvested restricted stock awards as these instruments are considered contingently issuable shares until they vest. Diluted net loss per share attributable to common stockholders includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. The Company&#8217;s unvested restricted stock entitles the holder to participate in dividends and earnings of the Company, and, if the Company were to recognize net income, it would apply the two-class method to calculate earnings per share. The two-class method is not applicable during periods with a net loss, as the holders of the unvested restricted stock have no obligation to fund losses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The two-class method of computing net loss per share would be applicable in a reporting period that resulted in a net income position, as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Subsequent Events</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Emerging Growth Company Status</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Emerging Growth Company Status</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act (&#8220;JOBS Act&#8221;), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards and as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of an initial public offering or such earlier time that it is no longer an emerging growth company. However, the Company has not yet delayed the adoption of any new accounting standards.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Adopted Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2016, the FASB issued ASU 2016-13</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">, Financial Instruments &#8212; Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren&#8217;t measured at fair value through net income. For available-for-sale debt securities, entities are required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities are no longer permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. For public entities, the guidance was effective for annual reporting periods beginning after December 15, 2019 and for interim periods within those fiscal years. Early adoption was permitted. The Company </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">early </span></span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adopted </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">this standard as of</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> January 1, 2020</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on a prospective basis. The adoption did</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> no</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t have a material impact on the Company&#8217;s consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2018, the FASB issued ASU 2018-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The amendments become effective for the Company&#8217;s fiscal year beginning January 1, 2020. Early adoption of the amendments in full or only the provisions that eliminate or modify the disclosure requirements for fair value measurements is permitted. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adoption </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of this standard on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2020</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> did </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2018, the FASB issued ASU 2018-15, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The new standard requires a customer in a cloud computing arrangement to determine which implementation costs to capitalize as assets or expense as incurred. Capitalized implementation costs related to a hosting arrangement that is a service contract will be amortized over the term of the hosting arrangement, beginning when the module or component of the hosting arrangement is ready for its intended use. The new standard became effective for the Company&#8217;s fiscal year beginning January 1, 2020. Early adoption was permitted. The </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">early </span></span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adoption </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of this standard on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2020</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> did </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t have a material impact on the Company&#8217;s consolidated financial statements and related disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2019, the FASB issued ASU 2019-12, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Simplifying the Accounting for Income Taxes,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (&#8220;ASC 740&#8221;). The ASU enhances and simplifies various aspects of the income tax accounting guidance in ASC 740, including requirements related to hybrid tax regimes, the tax basis step-up in goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intra-period tax allocation exception to the incremental approach, ownership changes in investments, changes from a subsidiary to an equity method investment, interim-period accounting for enacted changes in tax law, and the year-to-date loss limitation in interim-period tax accounting. This guidance became effective for the Company's fiscal year beginning </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adoption </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of this guidance did </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t have a material impact on the Company&#8217;s consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2020, the FASB issued ASU 2020-06, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Debt &#8212; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity (Subtopic 815 &#8212; 40)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The amendments in this update affect entities that issue convertible instruments and/or contracts indexed to and potentially settled in an entity&#8217;s own equity. The new ASU eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, the new guidance modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company elected to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">early </span></span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adopt </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">this guidance on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 1, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Adoption of the ASU 2020-06 guidance as of January 1, 2021 had </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">impact on its consolidated financial statements for the year ended December 31, 2020. The Company issued the second tranche of its redeemable convertible Series B preferred stock in March 2021 at an original issue price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.32</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, which would have resulted in the recognition of a beneficial conversion feature of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million prior to the adoption of ASU 2020-06. However, the consummation of the Business Combination and the application of a retroactive adjustment to historical redeemable convertible preferred stock in all periods presented under the reverse recapitalization accounting treatment have resulted in the adoption of this guidance not resulting in a material impact on the Company&#8217;s financial statements for the year ended December 31, 2021.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Issued Accounting Pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that recently issued standards that are not yet effective will not have a material impact on the Company&#8217;s consolidated financial statements. </span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_DeferredFinancingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_DeferredFinancingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for patent costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recently issued accounting pronouncements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123368208&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139210937992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The reconciliation of cash and cash equivalents and restricted cash to amounts presented in the consolidated statements of cash flows are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.312%;"/>
          <td style="width:1.6%;"/>
          <td style="width:1.282%;"/>
          <td style="width:13.33%;"/>
          <td style="width:0.636%;"/>
          <td style="width:1.6%;"/>
          <td style="width:1.282%;"/>
          <td style="width:13.32%;"/>
          <td style="width:0.636%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">142,745</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28,381</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">567</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash, net of current portion</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,712</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,279</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">145,024</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,660</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
         </tr>
        </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock', window );">Summary of estimated useful lives of the Company's property and equipment</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated useful lives of the Company&#8217;s property and equipment are as follows: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:43.72%;"/>
          <td style="width:1.835%;"/>
          <td style="width:54.444%;"/>
         </tr>
         <tr style="height:8.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Asset</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Estimated useful life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer software</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shorter of remaining lease term or 10 years</span></span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of estimated useful lives of the Company's property and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139214826952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Summary of Net Proceeds from Business Combination and PIPE Financing Transactions</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the elements of the net proceeds from the Business Combination and PIPE Financing transaction as of December 31, 2021 (in thousands):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:75.102%;"/>
        <td style="width:4.662%;"/>
        <td style="width:1.282%;"/>
        <td style="width:18.09%;"/>
        <td style="width:0.865%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Recapitalization</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash - BCTG's Trust Account and cash (net of redemptions)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">156,013</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash - PIPE Financing</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">186,100</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less transaction costs and advisory fees paid</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,836</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash proceeds from the Business Combination and PIPE Financing</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">326,277</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Add: non-cash net assets assumed from BCTG</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net contributions from Business Combination and PIPE Financing</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">326,280</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock', window );">Summary of Common Stock Outstanding After Consummation of Business Combination and PIPE Financing Transaction</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the number of shares of common stock outstanding immediately following the consummation of the Business Combination and PIPE Financing transaction:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.237%;"/>
        <td style="width:3.886%;"/>
        <td style="width:0.646%;"/>
        <td style="width:15.366%;"/>
        <td style="width:0.865%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">BCTG common shares outstanding prior to the Business Combination</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,377,250</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less redemption of BCTG shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,106,814</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common shares of BCTG outstanding as of the Business Combination</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,270,436</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares issued pursuant to the PIPE Financing</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,610,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Business Combination and PIPE Financing shares</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38,880,436</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Old Tango common shares (after preferred shares were converted 1-for-</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;for common shares)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48,593,803</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total shares of Common Stock immediately after Business Combination consummation</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87,474,239</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_SummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationTableTextBlock', window );">Summary of Redeemable Convertible Preferred Stock Issued and Outstanding After Consummation of Business Combination</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the terms of the Merger Agreement, upon the closing of the Business Combination on August 10, 2021 (the &#8220;Effective Time&#8221;), each share of Old Tango&#8217;s redeemable convertible preferred stock (the &#8220;Preferred Stock&#8221;) issued and outstanding immediately prior to the Effective Time was converted into a share of the Company&#8217;s common stock using the exchange ratio of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.34</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:9.468%;"/>
        <td style="width:1.003%;"/>
        <td style="width:16.066%;"/>
        <td style="width:1.003%;"/>
        <td style="width:0.646%;"/>
        <td style="width:15.002%;"/>
        <td style="width:0.646%;"/>
        <td style="width:1.003%;"/>
        <td style="width:0.646%;"/>
        <td style="width:12.767%;"/>
        <td style="width:0.646%;"/>
        <td style="width:1.003%;"/>
        <td style="width:0.646%;"/>
        <td style="width:11.515%;"/>
        <td style="width:0.646%;"/>
        <td style="width:1.003%;"/>
        <td style="width:0.646%;"/>
        <td style="width:11.783%;"/>
        <td style="width:0.646%;"/>
        <td style="width:1.003%;"/>
        <td style="width:0.646%;"/>
        <td style="width:10.919%;"/>
        <td style="width:0.646%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Date</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Redeemable Convertible Preferred Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Preferred to Common Exchange Ratio</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Common Stock Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">8/10/2021 Merger Recapitalization Exchange Ratio</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Recapitalization Common Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12/31/2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Series A</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">55,700,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1.00</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">55,700,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.34</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">18,922,317</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4/7/2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Series B (tranche 1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">22,686,025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">22,686,025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.34</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7,706,861</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8/17/2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Series B-1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">27,152,255</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1.00</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">27,152,255</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.34</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9,224,122</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3/18/2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Series B (tranche 2)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">22,686,025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">22,686,025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.34</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7,706,861</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Summary of Weighted-Average Common Shares, Basic and Diluted</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the weighted-average common shares, basic and diluted, for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2020:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:8.153%;"/>
        <td style="width:0.945%;"/>
        <td style="width:20.491%;"/>
        <td style="width:1.293%;"/>
        <td style="width:0.567%;"/>
        <td style="width:9.704%;"/>
        <td style="width:0.567%;"/>
        <td style="width:0.716%;"/>
        <td style="width:0.577%;"/>
        <td style="width:10.022%;"/>
        <td style="width:0.567%;"/>
        <td style="width:0.945%;"/>
        <td style="width:0.577%;"/>
        <td style="width:10.668%;"/>
        <td style="width:0.567%;"/>
        <td style="width:0.945%;"/>
        <td style="width:9.356%;"/>
        <td style="width:0.945%;"/>
        <td style="width:8.381%;"/>
        <td style="width:0.945%;"/>
        <td style="width:0.567%;"/>
        <td style="width:11.941%;"/>
        <td style="width:0.567%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Date</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As previously recorded</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">8/10/2021 Merger Exchange Ratio</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Recapitalized Common Stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Days Outstanding in 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">% of weighting</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted average common shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12/31/2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Weighted-average shares, <br/>basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">11,461,011</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.34</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,893,305</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,893,305</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12/31/2019</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Series A shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">55,700,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.34</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">18,922,317</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">365</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">18,922,317</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4/7/2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Series B shares</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">22,686,025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.34</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7,706,443</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">268</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">73</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,664,025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8/17/2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Series B-1 shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">27,152,255</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">0.34</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">9,223,621</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">136</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">37</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,452,558</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td colspan="19" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Weighted average number of common shares outstanding &#8211; basic and diluted for the year ended December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">31,932,204</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_SummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of redeemable convertible preferred stock issued and outstanding after consummation of business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_SummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the equity interest issued or issuable in a business acquisition (or series of individually immaterial business acquisitions) planned, initiated, or completed during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139214919608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Financial Assets Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following tables present information about the Company&#8217;s financial assets measured at fair value on a recurring basis:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.325%;"/>
        <td style="width:1.163%;"/>
        <td style="width:1.263%;"/>
        <td style="width:9.884%;"/>
        <td style="width:0.616%;"/>
        <td style="width:1.163%;"/>
        <td style="width:1.263%;"/>
        <td style="width:9.943%;"/>
        <td style="width:0.616%;"/>
        <td style="width:1.163%;"/>
        <td style="width:1.263%;"/>
        <td style="width:9.735%;"/>
        <td style="width:0.616%;"/>
        <td style="width:1.163%;"/>
        <td style="width:1.263%;"/>
        <td style="width:9.943%;"/>
        <td style="width:0.616%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Market Value Measurements<br/>as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62,244</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a762df4b-f3ed-4d4a-a408-0c28875d2805;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62,244</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury bills</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38,433</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38,433</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Marketable debt securities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury bills</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">287,123</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">287,123</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government agency bonds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55,387</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55,387</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62,244</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">380,943</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">443,187</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.518%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.273%;"/>
        <td style="width:9.526%;"/>
        <td style="width:0.636%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.273%;"/>
        <td style="width:9.546%;"/>
        <td style="width:0.636%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.273%;"/>
        <td style="width:9.456%;"/>
        <td style="width:0.636%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.273%;"/>
        <td style="width:9.546%;"/>
        <td style="width:0.636%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Market Value Measurements<br/>as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,698</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0b637d1f-640c-496c-91b4-be2bae95b9b9;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,698</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury bills</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,175</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,175</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Marketable debt securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury bills</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">131,939</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">131,939</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government agency bonds</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,698</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">169,114</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">181,812</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139214006424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Debt Securities, Available-for-sale</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the Company&#8217;s marketable debt securities, classified as available-for-sale:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:41.286%;"/>
        <td style="width:1.382%;"/>
        <td style="width:1.272%;"/>
        <td style="width:11.333%;"/>
        <td style="width:0.636%;"/>
        <td style="width:1.382%;"/>
        <td style="width:1.272%;"/>
        <td style="width:11.333%;"/>
        <td style="width:0.636%;"/>
        <td style="width:1.382%;"/>
        <td style="width:1.272%;"/>
        <td style="width:11.333%;"/>
        <td style="width:0.855%;"/>
        <td style="width:1.382%;"/>
        <td style="width:1.272%;"/>
        <td style="width:11.333%;"/>
        <td style="width:0.636%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value Measurements<br/>as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Loss</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Marketable debt securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury bills</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">287,699</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">577</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">287,123</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government agency bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55,576</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">189</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55,387</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">343,275</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">766</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">342,510</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:41.397%;"/>
        <td style="width:1.392%;"/>
        <td style="width:1.272%;"/>
        <td style="width:11.351%;"/>
        <td style="width:0.636%;"/>
        <td style="width:1.392%;"/>
        <td style="width:1.272%;"/>
        <td style="width:11.351%;"/>
        <td style="width:0.636%;"/>
        <td style="width:1.392%;"/>
        <td style="width:1.272%;"/>
        <td style="width:11.351%;"/>
        <td style="width:0.636%;"/>
        <td style="width:1.392%;"/>
        <td style="width:1.272%;"/>
        <td style="width:11.351%;"/>
        <td style="width:0.636%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value Measurements<br/>as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Loss</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Marketable debt securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. Treasury bills</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">131,927</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">131,939</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government agency bonds</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,995</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">161,922</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">161,939</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139213905960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020 consists of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.267%;"/>
        <td style="width:1.558%;"/>
        <td style="width:1.525%;"/>
        <td style="width:13.268%;"/>
        <td style="width:1.016%;"/>
        <td style="width:1.558%;"/>
        <td style="width:1.525%;"/>
        <td style="width:13.268%;"/>
        <td style="width:1.016%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,587</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,580</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">198</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">172</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer software</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">467</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">384</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">246</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">246</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction in progress</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">738</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,361</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,507</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Accumulated depreciation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,529</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,684</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,832</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,823</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities Current</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued expenses and other current liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020 include the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.54%;"/>
        <td style="width:1.568%;"/>
        <td style="width:1.535%;"/>
        <td style="width:13.408%;"/>
        <td style="width:0.718%;"/>
        <td style="width:1.568%;"/>
        <td style="width:1.535%;"/>
        <td style="width:13.408%;"/>
        <td style="width:0.718%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payroll and employee-related costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,688</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,652</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development costs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,533</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,695</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">666</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">793</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total accrued expenses and other current liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,887</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,140</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of accrued expenses and other current liabilities current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139211261080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Elements of Lease Cost</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The elements of lease cost were as follows: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.656%;"/>
        <td style="width:1.581%;"/>
        <td style="width:1.272%;"/>
        <td style="width:12.435%;"/>
        <td style="width:2.137%;"/>
        <td style="width:1.581%;"/>
        <td style="width:1.272%;"/>
        <td style="width:11.928%;"/>
        <td style="width:2.137%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Operating leases</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,889</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,889</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term lease cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">673</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">643</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating lease costs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,695</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,625</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Other information</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating cash flows used for operating leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,835</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,782</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted average remaining lease term in years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted average discount rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Minimum Lease Payments Under Operating Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Future minimum lease payments under leases that have commenced as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:78.205%;"/>
        <td style="width:1.865%;"/>
        <td style="width:1.828%;"/>
        <td style="width:16.884%;"/>
        <td style="width:1.218%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Maturity of Lease<br/>Liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,572</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,572</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: imputed interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,503</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139213802504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Awards Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the RSA activity of the Company&#8217;s plans as of and for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.186%;"/>
        <td style="width:1.878%;"/>
        <td style="width:0.972%;"/>
        <td style="width:11.601%;"/>
        <td style="width:1.028%;"/>
        <td style="width:1.558%;"/>
        <td style="width:1.525%;"/>
        <td style="width:13.534%;"/>
        <td style="width:0.718%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br/>shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted Average<br/>Grant-Date<br/>Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Unvested restricted common stock outstanding as of December 31, 2019</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,084,125</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.07</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">788,227</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.06</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39,087</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.23</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Unvested restricted common stock outstanding as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">256,811</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.22</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">256,598</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.22</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">213</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.35</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Unvested restricted common stock outstanding as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the stock option activity of the Company&#8217;s plans as of and for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.488%;"/>
        <td style="width:1.193%;"/>
        <td style="width:0.636%;"/>
        <td style="width:9.931%;"/>
        <td style="width:0.865%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.272%;"/>
        <td style="width:9.524%;"/>
        <td style="width:0.636%;"/>
        <td style="width:1.193%;"/>
        <td style="width:0.646%;"/>
        <td style="width:10.081%;"/>
        <td style="width:0.636%;"/>
        <td style="width:1.193%;"/>
        <td style="width:1.272%;"/>
        <td style="width:9.603%;"/>
        <td style="width:0.636%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br/>shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Contractual<br/>Term</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Options outstanding as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,094,544</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.88</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.58</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,635,627</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,200,841</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.53</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">638,754</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.66</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cancelled</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">283,638</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.34</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Options outstanding as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,372,993</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.59</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.55</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,415,394</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options exercisable as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,117,654</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.56</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.52</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,759,485</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted Average Assumptions Used to Estimate Grant Date Fair Value of Stock Options</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted average assumptions used to estimate the grant date fair value of the stock options using the Black-Scholes option pricing model were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.997%;"/>
        <td style="width:1.62%;"/>
        <td style="width:14.881%;"/>
        <td style="width:1.62%;"/>
        <td style="width:14.881%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected option life (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.2</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.0</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#8211;</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> 6.1</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% &#8211; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% &#8211; </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212; %</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212; %</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recorded stock-based compensation expense in the following expense categories in its accompanying statements of operations: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.603%;"/>
        <td style="width:1.569%;"/>
        <td style="width:1.524%;"/>
        <td style="width:13.388%;"/>
        <td style="width:0.718%;"/>
        <td style="width:1.569%;"/>
        <td style="width:1.524%;"/>
        <td style="width:13.388%;"/>
        <td style="width:0.718%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,616</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,003</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,217</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">761</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,833</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,764</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139213487224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.503%;"/>
        <td style="width:1.513%;"/>
        <td style="width:0.696%;"/>
        <td style="width:11.709%;"/>
        <td style="width:3.524%;"/>
        <td style="width:1.513%;"/>
        <td style="width:0.696%;"/>
        <td style="width:12.338%;"/>
        <td style="width:2.507%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income taxes at U.S. federal statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State income taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.9</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal and state research and development tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.4</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Nondeductible/nontaxable permanent items</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.7</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effective tax rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The tax effects of temporary differences that give rise to significant components of the deferred tax assets and liabilities are as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.094%;"/>
        <td style="width:1.546%;"/>
        <td style="width:1.524%;"/>
        <td style="width:13.366%;"/>
        <td style="width:1.016%;"/>
        <td style="width:1.546%;"/>
        <td style="width:1.524%;"/>
        <td style="width:13.366%;"/>
        <td style="width:1.016%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended<br/>December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,403</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,085</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development credit carryforwards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,084</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,213</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">411</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,154</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34,625</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,891</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accruals and reserves</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">958</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">648</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Capitalized research costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,193</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,506</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,008</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50,682</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,585</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49,568</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,945</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,114</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,640</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">771</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">597</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Right-of-use asset</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">343</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,043</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total gross deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,114</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,640</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred taxes</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139214008008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.243%;"/>
        <td style="width:1.525%;"/>
        <td style="width:1.514%;"/>
        <td style="width:13.823%;"/>
        <td style="width:1.017%;"/>
        <td style="width:1.525%;"/>
        <td style="width:1.514%;"/>
        <td style="width:13.823%;"/>
        <td style="width:1.017%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands, except share and per<br/>share data)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58,235</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,972</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average common stock outstanding &#8211; basic and diluted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62,108,032</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,932,204</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per common share &#8211; basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.94</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.63</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.094%;"/>
        <td style="width:1.569%;"/>
        <td style="width:0.718%;"/>
        <td style="width:14.448%;"/>
        <td style="width:0.718%;"/>
        <td style="width:1.569%;"/>
        <td style="width:0.718%;"/>
        <td style="width:14.448%;"/>
        <td style="width:0.718%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options to purchase common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,372,993</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,094,544</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested restricted common stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">256,811</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,372,993</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,353,375</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139211864072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 11, 2021</div></th>
<th class="th"><div>Aug. 10, 2021</div></th>
<th class="th"><div>Apr. 13, 2021</div></th>
<th class="th"><div>Sep. 08, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDeferredSalesCommissions', window );">Underwriting commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Purchase of shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Unit price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=tngx_PublicSharesMember', window );">Public Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of units issued in transaction (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of units issued in transaction (in Shares)</a></td>
<td class="nump">18,610,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">533,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds</a></td>
<td class="nump">$ 186.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Unit price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tngx_BctgAcquisitionCorpMember', window );">BCTG Acquisition Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 167.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Transaction costs and redemptions</a></td>
<td class="nump">26.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds</a></td>
<td class="nump">$ 326.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tngx_MergerAgreementMember', window );">Merger Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition, percentage of voting interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Business combination, consideration transferred, equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of units issued in transaction (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_OfferingCost', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_OfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_OfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDeferredSalesCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period for the periodic realization of capitalized fees that were paid to salespeople, distributors, brokers, and agents at the time of the conclusion of the sale. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDeferredSalesCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tngx_PublicSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tngx_PublicSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=tngx_BctgAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=tngx_BctgAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=tngx_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=tngx_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139209844040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Impairments to marketable securities or reserves for credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_ExpectedDividendAssumed', window );">Expected dividend assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Gross proceeds from the sale of preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,990,000<span></span>
</td>
<td class="nump">$ 80,844,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member', window );">ASU 2016-13 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption', window );">Change in accounting principle accounting standards update early adoption [true or false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle accounting standards update adopted [true or false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle accounting standards update adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle accounting standards update immaterial effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201813Member', window );">ASU 2018-13 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle accounting standards update adopted [true or false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle accounting standards update adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle accounting standards update immaterial effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201815Member', window );">ASU 2018-15 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption', window );">Change in accounting principle accounting standards update early adoption [true or false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle accounting standards update adopted [true or false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle accounting standards update adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle accounting standards update immaterial effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member', window );">ASU 2019-12 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle accounting standards update adopted [true or false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle accounting standards update adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle accounting standards update immaterial effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">ASU 2020-06 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption', window );">Change in accounting principle accounting standards update early adoption [true or false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle accounting standards update adopted [true or false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle accounting standards update adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle accounting standards update immaterial effect</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Share-based Payment Arrangement, Tranche Two [Member] | Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share | $ / shares</a></td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Gross proceeds from the sale of preferred shares</a></td>
<td class="nump">$ 28,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_CashAndCashEquivalentMaturityPeriod', window );">Cash and cash equivalent maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_MarketableDebtSecuritiesMaturitiesDuration', window );">Marketable debt securities maturities duration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_CashAndCashEquivalentMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalent maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_CashAndCashEquivalentMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_ExpectedDividendAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividend assumed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_ExpectedDividendAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_MarketableDebtSecuritiesMaturitiesDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable debt securities maturities duration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_MarketableDebtSecuritiesMaturitiesDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 33: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was early adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123877278&amp;loc=SL120174030-210619<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120320025-210437<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL120254519-210437<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123341672&amp;loc=SL120154346-209984<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31010-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201813Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201813Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201815Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201815Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139210721112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsAbstract', window );"><strong>Schedule Of Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 142,745<span></span>
</td>
<td class="nump">$ 28,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">567<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, net of current portion</a></td>
<td class="nump">1,712<span></span>
</td>
<td class="nump">2,279<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 145,024<span></span>
</td>
<td class="nump">$ 30,660<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139210522904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tngx_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and equipment, estimated useful life</a></td>
<td class="text">Shorter of remaining lease term or 10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123364984&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tngx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tngx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139211769112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 11, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 10, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_StockIssuedDuringPeriodSharesInExchangeForUnvestedRestrictedStockAwardsAndUnexercisedStockOptions', window );">Shares issued in exchange for Unvested restricted stock awards and unexercised stock options | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,406,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_MergerRecapitalizationExchangeRatio', window );">Merger Exchange Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.34<span></span>
</td>
<td class="nump">0.34<span></span>
</td>
<td class="nump">0.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">PIPE Financing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of units issued in transaction (in Shares) | shares</a></td>
<td class="nump">18,610,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">533,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_PricePerShare', window );">Price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds | $</a></td>
<td class="nump">$ 186,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tngx_MergerAgreementMember', window );">Merger Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1', window );">Acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 10,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of units issued in transaction (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tngx_TangoTherapeuticsIncMember', window );">Tango Therapeutics, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Outstanding common shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,593,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tngx_BctgAcquisitionCorpMember', window );">BCTG Acquisition Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds | $</a></td>
<td class="nump">$ 326,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_MergerRecapitalizationExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Merger recapitalization exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_MergerRecapitalizationExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_PricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_PricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_StockIssuedDuringPeriodSharesInExchangeForUnvestedRestrictedStockAwardsAndUnexercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares in exchange for unvested restricted stock awards and unexercised stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_StockIssuedDuringPeriodSharesInExchangeForUnvestedRestrictedStockAwardsAndUnexercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the business acquisition agreement was executed, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=tngx_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=tngx_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=tngx_TangoTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=tngx_TangoTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=tngx_BctgAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=tngx_BctgAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139210428376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination - Summary of Net Proceeds from Business Combination and PIPE Financing Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 11, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">PIPE Financing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash</a></td>
<td class="nump">$ 186,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tngx_BctgTrustAccountMember', window );">BCTG's Trust Account [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash</a></td>
<td class="nump">156,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tngx_BctgBusinessCombinationAndPipeFinancingMember', window );">BCTG Business Combination and PIPE Financing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Less transaction costs and advisory fees paid</a></td>
<td class="num">(15,836)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash proceeds from the Business Combination and PIPE Financing</a></td>
<td class="nump">326,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Net contributions from Business Combination and PIPE Financing</a></td>
<td class="nump">326,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tngx_BctgAcquisitionCorpMember', window );">BCTG Acquisition Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Less transaction costs and advisory fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (26,900)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Add: non-cash net assets assumed from BCTG</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=tngx_BctgTrustAccountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=tngx_BctgTrustAccountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=tngx_BctgBusinessCombinationAndPipeFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=tngx_BctgBusinessCombinationAndPipeFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=tngx_BctgAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=tngx_BctgAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139211827976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combination - Summary of Common Stock Outstanding After Consummation of Business Combination and PIPE Financing Transaction (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 10, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems', window );"><strong>Business Acquisition, Equity Interests Issued or Issuable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding</a></td>
<td class="nump">87,598,184<span></span>
</td>
<td class="nump">87,474,239<span></span>
</td>
<td class="nump">40,372,133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">PIPE Financing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems', window );"><strong>Business Acquisition, Equity Interests Issued or Issuable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued pursuant to the PIPE Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,610,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tngx_BctgAcquisitionCorpMember', window );">BCTG Acquisition Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems', window );"><strong>Business Acquisition, Equity Interests Issued or Issuable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_CommonStockOutstandingPriorToBusinessCombination', window );">Common shares outstanding prior to business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,377,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares', window );">Less redemption of BCTG shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,106,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,270,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tngx_BctgBusinessCombinationAndPipeFinancingMember', window );">BCTG Business Combination and PIPE Financing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems', window );"><strong>Business Acquisition, Equity Interests Issued or Issuable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued pursuant to the PIPE Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,880,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tngx_TangoTherapeuticsIncMember', window );">Tango Therapeutics, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems', window );"><strong>Business Acquisition, Equity Interests Issued or Issuable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Old Tango common shares (after preferred shares were converted 1-for-1 for common shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,593,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_CommonStockOutstandingPriorToBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock outstanding prior to business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_CommonStockOutstandingPriorToBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares that would be issued, determined under the conditions specified in the contract, if the settlement were to occur at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109262807&amp;loc=d3e22047-110879<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=tngx_BctgAcquisitionCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=tngx_BctgAcquisitionCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=tngx_BctgBusinessCombinationAndPipeFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=tngx_BctgBusinessCombinationAndPipeFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=tngx_TangoTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=tngx_TangoTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139213856936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combination - Summary of Common Stock Outstanding After Consummation of Business Combination and PIPE Financing Transactions (Parenthetical) (Details)<br></strong></div></th>
<th class="th"><div>Aug. 10, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=tngx_TangoTherapeuticsIncMember', window );">Tango Therapeutics, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems', window );"><strong>Business Acquisition, Equity Interests Issued or Issuable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Share conversion ratio</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=tngx_TangoTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=tngx_TangoTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139205307704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combination - Summary of Redeemable Convertible Preferred Stock Issued and Outstanding After Consummation of Business Combination (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th"><div>Aug. 10, 2021</div></th>
<th class="th">
<div>Mar. 18, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 17, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 07, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable Convertible Preferred Stock Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable Convertible Preferred Stock Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Preferred to Common exchange ratio</a></td>
<td class="nump">0.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock Shares</a></td>
<td class="nump">87,598,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,372,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_MergerRecapitalizationExchangeRatio', window );">Merger Recapitalization Exchange Ratio</a></td>
<td class="nump">0.34<span></span>
</td>
<td class="nump">0.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tngx_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable Convertible Preferred Stock Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Preferred to Common exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_MergerRecapitalizationExchangeRatio', window );">Merger Recapitalization Exchange Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares', window );">Recapitalization Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,922,317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tngx_SeriesBTrancheOneRedeemableConvertiblePreferredStockMember', window );">Series B (Tranche 1) Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable Convertible Preferred Stock Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,686,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Preferred to Common exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,686,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_MergerRecapitalizationExchangeRatio', window );">Merger Recapitalization Exchange Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares', window );">Recapitalization Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,706,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tngx_SeriesBOneRedeemableConvertiblePreferredStockMember', window );">Series B-1 Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable Convertible Preferred Stock Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,152,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Preferred to Common exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,152,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_MergerRecapitalizationExchangeRatio', window );">Merger Recapitalization Exchange Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares', window );">Recapitalization Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,224,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tngx_SeriesBTrancheTwoRedeemableConvertiblePreferredStockMember', window );">Series B (Tranche 2) Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable Convertible Preferred Stock Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,686,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Preferred to Common exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,686,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_MergerRecapitalizationExchangeRatio', window );">Merger Recapitalization Exchange Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares', window );">Recapitalization Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,706,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_MergerRecapitalizationExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Merger recapitalization exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_MergerRecapitalizationExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock holders equity retroactive application of recapitalization shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tngx_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tngx_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tngx_SeriesBTrancheOneRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tngx_SeriesBTrancheOneRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tngx_SeriesBOneRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tngx_SeriesBOneRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tngx_SeriesBTrancheTwoRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tngx_SeriesBTrancheTwoRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139205358648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination - Summary of Weighted-Average Common Shares, Basic and Diluted (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 17, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 07, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th"><div>Aug. 10, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments', window );">Weighted average common shares, basic and diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,893,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding - basic and diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,108,032<span></span>
</td>
<td class="nump">31,932,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_MergerRecapitalizationExchangeRatio', window );">Merger Exchange Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.34<span></span>
</td>
<td class="nump">0.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_WeightedAverageRecapitalizedCommonShares', window );">Weighted-average shares, basic and diluted, Recapitalized Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,893,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,598,184<span></span>
</td>
<td class="nump">40,372,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_ConversionWeightagePercentage', window );">% of weighting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tngx_SeriesACommonSharesMember', window );">Series A Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding - basic and diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,922,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_MergerRecapitalizationExchangeRatio', window );">Merger Exchange Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares', window );">Recapitalization Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,922,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_NumberOfDaysOutstanding', window );">Days Outstanding in 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">365 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_ConversionWeightagePercentage', window );">% of weighting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tngx_SeriesBCommonSharesMember', window );">Series B Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding - basic and diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,664,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_MergerRecapitalizationExchangeRatio', window );">Merger Exchange Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares', window );">Recapitalization Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,706,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_NumberOfDaysOutstanding', window );">Days Outstanding in 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">268 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_ConversionWeightagePercentage', window );">% of weighting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tngx_SeriesB1CommonSharesMember', window );">Series B-1 Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding - basic and diluted</a></td>
<td class="nump">3,452,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_MergerRecapitalizationExchangeRatio', window );">Merger Exchange Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares', window );">Recapitalization Common Stock</a></td>
<td class="nump">9,223,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_NumberOfDaysOutstanding', window );">Days Outstanding in 2020</a></td>
<td class="text">136 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_ConversionWeightagePercentage', window );">% of weighting</a></td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Recorded [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments', window );">Weighted average common shares, basic and diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,461,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Recorded [Member] | Series A Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Recorded [Member] | Series B Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,686,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As Previously Recorded [Member] | Series B-1 Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock Shares</a></td>
<td class="nump">27,152,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_ConversionWeightagePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion weightage percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_ConversionWeightagePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_MergerRecapitalizationExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Merger recapitalization exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_MergerRecapitalizationExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_NumberOfDaysOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of days outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_NumberOfDaysOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock holders equity retroactive application of recapitalization shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average number of share outstanding basic and diluted adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_WeightedAverageRecapitalizedCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average recapitalized common shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_WeightedAverageRecapitalizedCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tngx_SeriesACommonSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tngx_SeriesACommonSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tngx_SeriesBCommonSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tngx_SeriesBCommonSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tngx_SeriesB1CommonSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tngx_SeriesB1CommonSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139206487512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($) </div>
<div>Program</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>Program</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromFeesReceived', window );">Proceeds from fees received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_AccountsReceivableCurrentResearchExtensionFee', window );">Accounts receivable current, research extension fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_Contractassetresearchextensionfee', window );">Contract asset, research extension fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_ReceivableResearchExtensionFee', window );">Receivable research extension fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tngx_TwoThousandAndEighteenGileadAgreementMember', window );">2018 Gilead Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_ResearchTerm', window );">Research term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_NumberOfLicensedProduct', window );">Number of licensed product | Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_NonrefundableUpfrontPaymentsReceived', window );">Non-refundable upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_MilestonePaymentsReceivable', window );">Milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tngx_GileadLetterAgreementMember', window );">Gilead Letter Agreement [Member] | License Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with customer liability, revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tngx_AmendedGileadAgreementMember', window );">Amended Gilead Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_ResearchTerm', window );">Research term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_NumberOfLicensedProduct', window );">Number of licensed product | Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_NonrefundableUpfrontPaymentsReceived', window );">Non-refundable upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_MilestonePaymentsReceivable', window );">Milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 410,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital', window );">Temporary equity, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract', window );">Revenue recognized, cumulative catch-up adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_ResearchExtensionFee', window );">Research extension fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_ResearchExtensionFeeVariableConsideration', window );">Research extension fees, variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with customer liability, revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_SponsoredALicenceProgramfeeAmount', window );">License fee amount</a></td>
<td class="nump">$ 11,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tngx_AmendedGileadAgreementMember', window );">Amended Gilead Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tngx_AmendedGileadAgreementMember', window );">Amended Gilead Agreement [Member] | Series B-1 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital', window );">Temporary equity, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tngx_GileadAgreementMember', window );">Gilead Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price allocated to performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Short-term deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000,000.0<span></span>
</td>
<td class="nump">32,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Long-term deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,700,000<span></span>
</td>
<td class="nump">120,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tngx_GileadAgreementMember', window );">Gilead Agreement [Member] | Collaboration Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with customer liability, revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000,000.0<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=tngx_GileadAgreementBasedPerformanceMember', window );">Gilead Agreement Based Performance [Member] | License Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License fee amount received, recognized as revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_AccountsReceivableCurrentResearchExtensionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable Current Research Extension Fee .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_AccountsReceivableCurrentResearchExtensionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_Contractassetresearchextensionfee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ContractAssetResearchExtensionFee .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_Contractassetresearchextensionfee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_MilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_MilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_NonrefundableUpfrontPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-refundable upfront payments received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_NonrefundableUpfrontPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_NumberOfLicensedProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Licensed Product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_NumberOfLicensedProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_ReceivableResearchExtensionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable research extension fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_ReceivableResearchExtensionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_ResearchExtensionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research Extension Fee .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_ResearchExtensionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_ResearchExtensionFeeVariableConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research extension fee variable consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_ResearchExtensionFeeVariableConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_ResearchTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_ResearchTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_SponsoredALicenceProgramfeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sponsored a license program, fee amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_SponsoredALicenceProgramfeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received for fees during the current period. This element excludes cash proceeds from license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of the par value of temporary equity outstanding. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tngx_TwoThousandAndEighteenGileadAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tngx_TwoThousandAndEighteenGileadAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tngx_GileadLetterAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tngx_GileadLetterAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tngx_LicenseRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tngx_LicenseRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tngx_AmendedGileadAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tngx_AmendedGileadAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tngx_SeriesBOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tngx_SeriesBOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tngx_GileadAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tngx_GileadAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tngx_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tngx_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=tngx_GileadAgreementBasedPerformanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=tngx_GileadAgreementBasedPerformanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139216640616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements - Additional Information (Details1)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue remaining performance obligations expected remaining contractual term</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139205331816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary Financial Assets Measured at Fair Value on a Recurring Basis (Details) - Fair Value Measurements Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Cash equivalents, Money market funds</a></td>
<td class="nump">$ 62,244<span></span>
</td>
<td class="nump">$ 12,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_USGovernmentSecuritiesAtCarryingValue', window );">Cash equivalents, U.S. Treasury bills</a></td>
<td class="nump">38,433<span></span>
</td>
<td class="nump">7,175<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">443,187<span></span>
</td>
<td class="nump">181,812<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=tngx_MarketableDebtSecuritiesMember', window );">Marketable Debt Securities [Member] | U.S. Treasury Bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable debt securities</a></td>
<td class="nump">287,123<span></span>
</td>
<td class="nump">131,939<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=tngx_MarketableDebtSecuritiesMember', window );">Marketable Debt Securities [Member] | U.S. Government Agency Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable debt securities</a></td>
<td class="nump">55,387<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Cash equivalents, Money market funds</a></td>
<td class="nump">62,244<span></span>
</td>
<td class="nump">12,698<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">62,244<span></span>
</td>
<td class="nump">12,698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Cash equivalents, Money market funds</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_USGovernmentSecuritiesAtCarryingValue', window );">Cash equivalents, U.S. Treasury bills</a></td>
<td class="nump">38,433<span></span>
</td>
<td class="nump">7,175<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">380,943<span></span>
</td>
<td class="nump">169,114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Marketable Debt Securities [Member] | U.S. Treasury Bills [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable debt securities</a></td>
<td class="nump">287,123<span></span>
</td>
<td class="nump">131,939<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Marketable Debt Securities [Member] | U.S. Government Agency Bonds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable debt securities</a></td>
<td class="nump">$ 55,387<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_USGovernmentSecuritiesAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt (bills, notes or bonds) that are issued by the government of the United States which are short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_USGovernmentSecuritiesAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=tngx_MarketableDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=tngx_MarketableDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139210366088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Fair value assets transfer from Level 1 to Level 2</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Fair value assets transfer from Level 2 to Level 1</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount', window );">Fair value liabilities transfer from Level 1 to Level 2</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount', window );">Fair value liabilities transfer from Level 2 to Level 1</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139207093112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Summary of Debt Securities, Available For Sale (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 343,275<span></span>
</td>
<td class="nump">$ 161,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(766)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">342,510<span></span>
</td>
<td class="nump">161,939<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Bills [Member] | Marketable Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">287,699<span></span>
</td>
<td class="nump">131,927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(577)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">287,123<span></span>
</td>
<td class="nump">131,939<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government Agency Bonds [Member] | Marketable Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">55,576<span></span>
</td>
<td class="nump">29,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(189)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Value</a></td>
<td class="nump">$ 55,387<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=tngx_MarketableDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=tngx_MarketableDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139211675496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Impairments to marketable securities or reserves for credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=tngx_MarketableDebtSecuritiesMember', window );">Marketable Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Debt securities considered to be an unrealized loss position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Impairments to marketable securities or reserves for credit losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss', window );">Marketable securities, Accrued interest</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Marketable Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Debt securities considered to be an unrealized loss position</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267853-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=SL121698322-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL120267856-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=tngx_MarketableDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=tngx_MarketableDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139209828792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 7,361<span></span>
</td>
<td class="nump">$ 5,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(2,529)<span></span>
</td>
<td class="num">(1,684)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,832<span></span>
</td>
<td class="nump">3,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">5,587<span></span>
</td>
<td class="nump">4,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tngx_ComputerSoftwareMember', window );">Computer Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">467<span></span>
</td>
<td class="nump">384<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">246<span></span>
</td>
<td class="nump">$ 246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tngx_ComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tngx_ComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139213932168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 897<span></span>
</td>
<td class="nump">$ 718<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139214098648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Current Liabilities Current (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and employee-related costs</a></td>
<td class="nump">$ 3,688<span></span>
</td>
<td class="nump">$ 2,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_AccruedResearchAndDevelopmentCostsCurrent', window );">Research and development costs</a></td>
<td class="nump">5,533<span></span>
</td>
<td class="nump">2,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">666<span></span>
</td>
<td class="nump">793<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_AccruedExpensesAndOtherCurrentLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 9,887<span></span>
</td>
<td class="nump">$ 6,140<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development costs current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139206694424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Operating leases, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">option to extend for up to two five-year periods.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,503,000<span></span>
</td>
<td class="nump">$ 1,503,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,254,000<span></span>
</td>
<td class="nump">1,254,000<span></span>
</td>
<td class="nump">$ 7,480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tngx_TheTwoHundredAndOneBrooklineAvenueLeaseMember', window );">201 Brookline Avenue Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating leases, non-cancelable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Operating leases, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_AnnualRentPayable', window );">Annual rent payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_PercentageOfIncreaseInAnnualRentPayable', window );">Percentage of increase in annual rent payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvements allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tngx_TheTwoHundredAndOneBrooklineAvenueLeaseMember', window );">201 Brookline Avenue Lease [Member] | Letter of Credit [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Additional letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tngx_HundredBinneyStreetInCambridgeMember', window );">100 Binney Street in Cambridge [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating leases, non-cancelable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Operating leases, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">option to extend for one additional three-year period.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Operating leases, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_UpfrontPaymentsForRentAndTenantImprovements', window );">Upfront payments for rent and tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForTenantImprovements', window );">Tenant obligation payments for leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_AnnualRentPayable', window );">Annual rent payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_PercentageOfIncreaseInAnnualRentPayable', window );">Percentage of increase in annual rent payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_MinimumRentPaymentsToBePaidOverOriginalTerm', window );">Minimum rent payments to be paid over original term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_LetterOfCreditToProvideForAmountThatCollateralizedWithCash', window );">Letter of credit to provide for amount that collateralized with cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_LeaseTerminationAgreementMonthAndYear', window );">Lease termination agreement month and year</a></td>
<td class="text">2021-11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToTerminate', window );">Lease terminate option description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The lease termination agreement is a modification of the original lease agreement that provides for, among other things, the acceleration of the expiration of the original term of the lease from June 30, 2026 to an earlier lease termination date, for which the earlier date shall be no later than October 15, 2022.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Reduction of operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Reduction of operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tngx_HundredBinneyStreetInCambridgeMember', window );">100 Binney Street in Cambridge [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Additional extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">Oct. 15,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tngx_HundredBinneyStreetInCambridgeMember', window );">100 Binney Street in Cambridge [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Additional extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">Jun. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tngx_HundredBinneyStreetInCambridgeMember', window );">100 Binney Street in Cambridge [Member] | Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_LetterOfCreditToProvideForAmountThatCollateralizedWithCash', window );">Letter of credit to provide for amount that collateralized with cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_AnnualRentPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual rent payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_AnnualRentPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in operating lease right of use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_LeaseTerminationAgreementMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease termination agreement month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_LeaseTerminationAgreementMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_LetterOfCreditToProvideForAmountThatCollateralizedWithCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Letter of credit to provide for amount that collateralized with cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_LetterOfCreditToProvideForAmountThatCollateralizedWithCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_MinimumRentPaymentsToBePaidOverOriginalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum rent payments to be paid over original term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_MinimumRentPaymentsToBePaidOverOriginalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_PercentageOfIncreaseInAnnualRentPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of increase in annual rent payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_PercentageOfIncreaseInAnnualRentPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_UpfrontPaymentsForRentAndTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payments for rent and tenant improvements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_UpfrontPaymentsForRentAndTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tngx_TheTwoHundredAndOneBrooklineAvenueLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tngx_TheTwoHundredAndOneBrooklineAvenueLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=tngx_HundredBinneyStreetInCambridgeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=tngx_HundredBinneyStreetInCambridgeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139210217272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Elements of Lease Cost (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,889<span></span>
</td>
<td class="nump">$ 1,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">673<span></span>
</td>
<td class="nump">643<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease costs</a></td>
<td class="nump">2,695<span></span>
</td>
<td class="nump">2,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_OtherInformationAbstract', window );"><strong>Other information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows used for operating leases</a></td>
<td class="nump">$ 1,835<span></span>
</td>
<td class="nump">$ 1,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term in years</a></td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_OtherInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_OtherInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139210731368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Future Minimum Lease Payments Under Operating Leases (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 1,572<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">1,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(69)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 1,503<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139205249256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>Milestone</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_AgreementAxis=tngx_HitgenAgreementMember', window );">HitGen Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_CommitmentsAndContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_NumberOfMilestonesAchieved', window );">Number of milestones achieved upon termination of agreement | Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_PaymentsUponTerminationOfAgreement', window );">Payments upon termination of agreement</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_AgreementAxis=tngx_MedivirAgreementMember', window );">Medivir Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_CommitmentsAndContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_UpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_MilestonePaymentsAchieved', window );">Milestone payments achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_AgreementAxis=tngx_MedivirAgreementMember', window );">Medivir Agreement [Member] | Specified Regulatory Approval And Sales Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_CommitmentsAndContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_AgreementAxis=tngx_MedivirAgreementMember', window );">Medivir Agreement [Member] | Specified Clinical Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_CommitmentsAndContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_AgreementAxis=tngx_MedivirAgreementMember', window );">Medivir Agreement [Member] | Specified Regulatory And Sales Milestones For Genetic Context [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_CommitmentsAndContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_CommitmentsAndContingenciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_CommitmentsAndContingenciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_MilestonePaymentsAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_MilestonePaymentsAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_NumberOfMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of milestones achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_NumberOfMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_PaymentsUponTerminationOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments upon termination of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_PaymentsUponTerminationOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_UpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_UpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_AgreementAxis=tngx_HitgenAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_AgreementAxis=tngx_HitgenAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_AgreementAxis=tngx_MedivirAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_AgreementAxis=tngx_MedivirAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=tngx_SpecifiedRegulatoryApprovalAndSalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=tngx_SpecifiedRegulatoryApprovalAndSalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=tngx_SpecifiedClinicalMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=tngx_SpecifiedClinicalMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=tngx_SpecifiedRegulatoryAndSalesMilestonesForGeneticContextMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=tngx_SpecifiedRegulatoryAndSalesMilestonesForGeneticContextMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139206540568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock - Additional Information (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Aug. 17, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th">
<div>Jul. 31, 2017 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable convertible preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayments of convertible notes and accrued interest | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Preferred to Common exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock par or stated value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tngx_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityShareSubscriptions', window );">Redeemable convertible preferred stock allocated to investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable convertible preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Redeemable convertible preferred stock issued during period shares new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
<td class="nump">18,700,000<span></span>
</td>
<td class="nump">26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_RedeemableConvertiblePreferredStockIssuePricePerShare', window );">Redeemable convertible preferred stock issue price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from issuance of redeemable convertible preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.0<span></span>
</td>
<td class="nump">$ 14.0<span></span>
</td>
<td class="nump">$ 26.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Preferred to Common exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_TemporaryStockIssuanceCosts', window );">Redeemable convertible preferred stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tngx_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable convertible preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,372,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Redeemable convertible preferred stock issued during period shares new issues</a></td>
<td class="nump">22,686,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,686,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from issuance of redeemable convertible preferred stock | $</a></td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_TemporaryStockIssuanceCosts', window );">Redeemable convertible preferred stock issuance costs | $</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_TemporaryEquityIssuePricePerShare', window );">Redeemable convertible preferred stock issue price per share | $ / shares</a></td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tngx_SeriesBOneRedeemableConvertiblePreferredStockMember', window );">Series B-1 Redeemable Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable convertible preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,152,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Redeemable convertible preferred stock issued during period shares new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,152,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from issuance of redeemable convertible preferred stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Preferred to Common exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_TemporaryStockIssuanceCosts', window );">Redeemable convertible preferred stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_TemporaryEquityIssuePricePerShare', window );">Redeemable convertible preferred stock issue price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_RedeemableConvertiblePreferredStockIssuePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity issue price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_RedeemableConvertiblePreferredStockIssuePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_TemporaryEquityIssuePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity issue price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_TemporaryEquityIssuePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_TemporaryStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary stock issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_TemporaryStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityShareSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been allocated to investors to buy. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityShareSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tngx_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tngx_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tngx_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tngx_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tngx_SeriesBOneRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tngx_SeriesBOneRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139210496408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Aug. 10, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Class Of Stock Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock voting description</a></td>
<td class="text">The holder of each share of common stock is entitled to one vote in respect of each share of stock held.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Dividends declared</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,393,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
<td class="nump">87,598,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,372,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding</a></td>
<td class="nump">87,598,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,474,239<span></span>
</td>
<td class="nump">40,372,133<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139207268760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Additional Information (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>shares</div>
</th>
<th class="th"><div>Aug. 10, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_MergerRecapitalizationExchangeRatio', window );">Merger Exchange Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.34<span></span>
</td>
<td class="nump">0.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tngx_StockOptionsMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share of stock options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.40<span></span>
</td>
<td class="nump">$ 1.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tngx_TwoThousandAndTwentyOnePlanMember', window );">2021 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum of number of shares reserved and available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,498,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Maximum number of shares issued as a proportion of outstanding capital stock on preceding December 31</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,271,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=tngx_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Maximum number of shares issued as a proportion of outstanding capital stock on preceding December 31</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">949,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">949,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | 2021 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in number of shares available for grant</a></td>
<td class="nump">4,377,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | 2021 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in number of shares available for grant</a></td>
<td class="nump">875,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Aggregate fair value of awards vested | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=tngx_RestrictedCommonStockAwardMember', window );">Restricted Common Stock Award [Member] | Founders and Advisors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted common stock awards issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,690,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_MergerRecapitalizationExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Merger recapitalization exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_MergerRecapitalizationExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tngx_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tngx_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tngx_TwoThousandAndTwentyOnePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tngx_TwoThousandAndTwentyOnePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=tngx_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=tngx_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tngx_RestrictedCommonStockAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tngx_RestrictedCommonStockAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=tngx_FoundersAndAdvisorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=tngx_FoundersAndAdvisorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139207040232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Summary of Restricted Stock Awards Activity (Details) - Restricted Common Stock Award [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted common stock outstanding, Number of Shares Beginning balance</a></td>
<td class="nump">256,811<span></span>
</td>
<td class="nump">1,084,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Unvested restricted common stock outstanding, Vested</a></td>
<td class="num">(256,598)<span></span>
</td>
<td class="num">(788,227)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Unvested restricted common stock outstanding, Forfeited</a></td>
<td class="num">(213)<span></span>
</td>
<td class="num">(39,087)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested restricted common stock outstanding, Number of Shares Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256,811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested restricted common stock outstanding, Weighted average grant-date fair value Beginning balance</a></td>
<td class="nump">$ 1.22<span></span>
</td>
<td class="nump">$ 1.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Unvested restricted common stock outstanding, Weighted average grant-date fair value, Vested</a></td>
<td class="nump">1.22<span></span>
</td>
<td class="nump">1.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Unvested restricted common stock outstanding, Weighted average grant-date fair value, Forfeited</a></td>
<td class="nump">$ 1.35<span></span>
</td>
<td class="nump">0.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested restricted common stock outstanding, Weighted average grant-date fair value Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.22<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=tngx_RestrictedCommonStockAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=tngx_RestrictedCommonStockAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139211981544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Schedule of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Options outstanding Beginning balance</a></td>
<td class="nump">4,094,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares Granted</a></td>
<td class="nump">6,200,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares Exercised</a></td>
<td class="num">(638,754)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares Cancelled</a></td>
<td class="num">(283,638)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Options outstanding Ending balance</a></td>
<td class="nump">9,372,993<span></span>
</td>
<td class="nump">4,094,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares Options exercisable</a></td>
<td class="nump">2,117,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options outstanding Beginning balance</a></td>
<td class="nump">$ 1.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Granted</a></td>
<td class="nump">7.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercised</a></td>
<td class="nump">1.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Cancelled</a></td>
<td class="nump">3.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">'Weighted Average Exercise Price, Options outstanding Ending balance</a></td>
<td class="nump">5.59<span></span>
</td>
<td class="nump">$ 1.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Options exercisable</a></td>
<td class="nump">$ 2.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">'Weighted Average Contractual Term, Options outstanding</a></td>
<td class="text">8 years 6 months 18 days<span></span>
</td>
<td class="text">8 years 6 months 29 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Term Options exercisable</a></td>
<td class="text">6 years 6 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Options outstanding</a></td>
<td class="nump">$ 51,415,394<span></span>
</td>
<td class="nump">$ 6,635,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value Options exercisable</a></td>
<td class="nump">$ 17,759,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139210215304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Schedule of Weighted Average Assumptions Used to Estimate Grant Date Fair Value of Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life (in years)</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">72.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139215116856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 7,833<span></span>
</td>
<td class="nump">$ 1,764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">4,616<span></span>
</td>
<td class="nump">1,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,217<span></span>
</td>
<td class="nump">$ 761<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139210433512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax provision or benefits</a></td>
<td class="nump">$ 292,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance, increase</a></td>
<td class="nump">$ 18,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_PercentageOfIncreaseInOwnershipPercentageOverAThreeYearPeriod', window );">Percentage of increase in ownership percentage over a three year period</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest or penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">19,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_OperatingLossCarryForwardWithExpirationOfUsage', window );">Operating loss carry forward with expiration of usage</a></td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_OperatingLossCarryForwardWithExpirationOfUsageIndefinite', window );">Operating loss carry forward with expiration of usage indefinite</a></td>
<td class="nump">$ 16,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards, expiration year</a></td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member] | Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforwards, expiration year</a></td>
<td class="text">2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 17,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_OperatingLossCarryforwardsExpirationStartingYear', window );">Operating Loss carryforwards expiration starting year</a></td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member] | Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforwards, expiration year</a></td>
<td class="text">2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_OperatingLossCarryForwardWithExpirationOfUsage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carry forward with expiration of usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_OperatingLossCarryForwardWithExpirationOfUsage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_OperatingLossCarryForwardWithExpirationOfUsageIndefinite">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carry forward with expiration of usage indefinite.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_OperatingLossCarryForwardWithExpirationOfUsageIndefinite</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_OperatingLossCarryforwardsExpirationStartingYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss carryforwards expiration starting year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_OperatingLossCarryforwardsExpirationStartingYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_PercentageOfIncreaseInOwnershipPercentageOverAThreeYearPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of increase in ownership percentage over a three year period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_PercentageOfIncreaseInOwnershipPercentageOverAThreeYearPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=tngx_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=tngx_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139210235464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income taxes at U.S. federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">6.10%<span></span>
</td>
<td class="nump">5.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment', window );">Federal and state research and development tax credits</a></td>
<td class="nump">5.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation expense</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Nondeductible/nontaxable permanent items</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(1.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(32.10%)<span></span>
</td>
<td class="num">(28.90%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation tax credits research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139209774968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 4,403<span></span>
</td>
<td class="nump">$ 11,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforwards</a></td>
<td class="nump">7,084<span></span>
</td>
<td class="nump">5,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_DeferredTaxAssetsOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">411<span></span>
</td>
<td class="nump">2,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">34,625<span></span>
</td>
<td class="nump">11,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">958<span></span>
</td>
<td class="nump">648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research costs</a></td>
<td class="nump">2,193<span></span>
</td>
<td class="nump">2,506<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">1,008<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">50,682<span></span>
</td>
<td class="nump">33,585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(49,568)<span></span>
</td>
<td class="num">(30,945)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">1,114<span></span>
</td>
<td class="nump">2,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tngx_DeferredTaxLiabilitiesDepreciation', window );">Depreciation</a></td>
<td class="num">(771)<span></span>
</td>
<td class="num">(597)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use asset</a></td>
<td class="num">(343)<span></span>
</td>
<td class="num">(2,043)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total gross deferred tax liabilities</a></td>
<td class="num">$ (1,114)<span></span>
</td>
<td class="num">$ (2,640)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tngx_DeferredTaxLiabilitiesDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tngx_DeferredTaxLiabilitiesDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tngx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139210476488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (58,235)<span></span>
</td>
<td class="num">$ (51,972)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of common stock outstanding - basic and diluted</a></td>
<td class="nump">62,108,032<span></span>
</td>
<td class="nump">31,932,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share &#8211; basic and diluted</a></td>
<td class="num">$ (0.94)<span></span>
</td>
<td class="num">$ (1.63)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140139210511208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">9,372,993<span></span>
</td>
<td class="nump">4,353,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options to purchase common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">9,372,993<span></span>
</td>
<td class="nump">4,094,544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256,811<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>tngx-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:tngx="http://www.tangotx.com/20211231"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="tngx-20211231.xsd" xlink:type="simple"/>
    <context id="C_eb62df54-f0e0-4a6d-9c99-33f08d82c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBTrancheTwoRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="C_ce1e3322-9b6b-477f-bd0a-0c49d4aedd8b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="C_b3962309-cf85-4622-8558-52f8101a1c1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tngx:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_acbb8224-ebbe-4c79-b11c-d87062900529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_088edbda-4c95-4fa9-9856-74af91d7facd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_c17d0f8f-c6ae-43cd-9b51-09d002c47c3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_42c26e7c-eca8-426f-9a02-4c53841db8ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_b6540ba0-6a70-4698-835b-62e3f28a76b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tngx:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_16173712-f7d9-4b40-a745-785b1fd272f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:AmendedGileadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d04e6201-772a-4ebf-bcb7-57256a6b7980">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_e935a51c-44f5-45c0-8969-0acd3c8dce51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8431d889-009a-406d-91d5-381ea4e8cc14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:HundredBinneyStreetInCambridgeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-31</instant>
        </period>
    </context>
    <context id="C_f0761b4f-fae1-40c4-a58b-8ac4939b226c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBCommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-07</instant>
        </period>
    </context>
    <context id="C_02f13488-10b7-4401-9968-07685eb9a45e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesACommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_bbbc1247-505e-469d-9e7c-232824266da5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_4e0ebfbb-6d60-400e-82c5-2271bdc193d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">tngx:SpecifiedRegulatoryAndSalesMilestonesForGeneticContextMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tngx:AgreementAxis">tngx:MedivirAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_96e2833b-b37d-4d45-9d0e-e469973ab162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="C_7736b799-fc9e-41cb-ac3c-ebefeef52eb3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tngx:LicenseRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:GileadAgreementBasedPerformanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3461b9bd-5e6d-4357-91f1-01033ae50263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_fe8c0009-60fd-45e6-bf12-78e38e33e502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_a34864eb-c999-4a01-906e-ed6300c59215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_4d340cce-d3f4-48f6-8dc7-031a8c6e1628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBCommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-06</startDate>
            <endDate>2020-04-07</endDate>
        </period>
    </context>
    <context id="C_0494c044-9ff9-41c2-8ddb-c0be1c1a2795">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">tngx:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e188203d-bb78-4e16-8893-867ab9986a87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tngx:PublicSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-08</startDate>
            <endDate>2020-09-08</endDate>
        </period>
    </context>
    <context id="C_9157c232-bd25-4b99-8aaa-53493f84a8b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
        </entity>
        <period>
            <startDate>2021-08-10</startDate>
            <endDate>2021-08-10</endDate>
        </period>
    </context>
    <context id="C_b5f7538f-2233-432c-8332-5f9eee3f4625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:TwoThousandAndEighteenGileadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="C_84b473ca-21a7-4595-869a-d3b15476e2cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="C_e025e6fe-ae40-47de-b624-610d8a25ba64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tngx:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="C_c5112e96-b096-400a-8231-13c5db592e8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tngx:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-13</startDate>
            <endDate>2021-04-13</endDate>
        </period>
    </context>
    <context id="C_13789a54-6583-461f-ace8-50d596a0d9e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_62d30997-cb59-4c36-9293-3ab9037d2139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0d31393e-af6d-4a5d-92ee-02bb00706dea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tngx:BctgAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_43fb107b-c6af-4569-9ee5-f77bf1f34285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBOneRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="C_53e4d63e-21a6-43e4-9dcd-522040ca6553">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:TwoThousandAndEighteenGileadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_1f668a19-d708-4382-b6de-856bbfb1c08d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="C_d651794e-8630-4ab5-a33f-7df95e076d4e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_afd5c297-0100-4e5c-a1d4-238c915c6ebd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tngx:TangoTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-10</instant>
        </period>
    </context>
    <context id="C_7055bdf6-8d9f-4ea6-913c-d9194c0435b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0c877e59-744f-49bd-b36b-26c23781fc80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-08</startDate>
            <endDate>2020-09-08</endDate>
        </period>
    </context>
    <context id="C_c46a5787-04cc-4ee6-8232-98fef420c001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
        </entity>
        <period>
            <startDate>2020-09-08</startDate>
            <endDate>2020-09-08</endDate>
        </period>
    </context>
    <context id="C_764718f8-db6b-4222-a924-e17f308b9e1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_36f9a5bb-51f4-4c4c-a4a4-483900a01305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="C_7d2bf4c6-5a88-4f48-9b87-0040ef400364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f301ea89-3456-4254-8f42-f5814959d712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tngx:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_b961f57f-cd1e-4000-be3a-575c1acb8245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:HundredBinneyStreetInCambridgeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ff6e5760-462e-48b4-9885-3a1afb5a7028">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:AmendedGileadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="C_f01892b3-15ca-4460-8be5-0c673db5d09c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:HundredBinneyStreetInCambridgeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-31</instant>
        </period>
    </context>
    <context id="C_cf54194b-5ca8-4902-bc7c-8ad279e05960">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="C_102b7845-9bed-440d-ab31-e9a0c961e54f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesB1CommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-17</instant>
        </period>
    </context>
    <context id="C_23d38092-0393-490f-b401-5d223a840f61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f993a7f8-4d25-4be9-b713-6bb38ecf342b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_54d3a1d3-953e-4a0b-ad72-8cc7769a4e4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesACommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_5bbc6677-f9f3-4cc3-b8fc-b7c1ac21c7d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_78eb35a2-1f74-40df-8fa7-52275c2dd513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_90016151-b8de-4c70-b40c-6a6565310359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_215089d0-d271-4311-98aa-2b60bca282f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesACommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_ddf3c437-2a6f-4dfd-a511-55b637ea608a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_31658d1c-3873-4646-a06e-c5e4358d9429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7e5ec8fe-aded-4985-ba52-0a77d0cc933c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:AmendedGileadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="C_637f6044-163f-4ffe-baaa-808b1b634223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tngx:TangoTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-10</startDate>
            <endDate>2021-08-10</endDate>
        </period>
    </context>
    <context id="C_2ac7ee07-3d73-4617-8ee2-9f9c91ec3957">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8d0e1ab2-5dfb-47e6-a9e8-b49f9f14bd25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_2097a9ea-7fc6-47b9-9264-c5cfd08007fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_22555df1-4efe-4a08-bb1c-08f931ec7211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1efa7be9-29eb-4c8a-a7b7-04a5517b4c9c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBOneRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-17</instant>
        </period>
    </context>
    <context id="C_511b1fab-19fa-4719-9e1a-7d2d78a9c251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:GileadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_46942445-32c3-4ade-9ca0-aa6a6b83839a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:HundredBinneyStreetInCambridgeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_709432d5-f52b-4cb9-a494-7b1bae2706a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201912Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_19df7953-ecc1-48a3-9c5b-5d80830b8fdb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tngx:TwoThousandAndTwentyOnePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c89c0bd3-61fe-4fe1-aaf8-04c333eb7930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_3a91db9e-6734-413e-8e17-66bb5d8bf9ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cba5ebca-4842-4066-b09c-3a3e8776378b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:TheTwoHundredAndOneBrooklineAvenueLeaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="C_b638cb65-3908-4aeb-bd7c-94437b4d77af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_44358ddc-7505-46e1-8119-f33db1fa516a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_27037302-4c51-4ed7-bedc-d4aef3c65de1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tngx:CollaborationRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:GileadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_2065fc3b-bae5-4c9b-8a8a-012ebcce2f51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_02d11875-4147-4360-a8aa-e87bfd6290ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:HundredBinneyStreetInCambridgeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f6d997d2-d3a1-431e-a764-711fd76bb4c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c96d2de7-cf25-4b3d-9e34-1a5c2b302481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBTrancheOneRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-10</instant>
        </period>
    </context>
    <context id="C_f0aee49e-cda1-49dc-bfc8-ca8549516a0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:TwoThousandAndEighteenGileadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_1788c8d9-b2a8-41ee-b8fb-f1e5436c41eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBOnePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:AmendedGileadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="C_9943303c-4c93-4a64-a1b1-6e1c309ffbd6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBTrancheTwoRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-10</instant>
        </period>
    </context>
    <context id="C_8a373566-cfe9-4a8d-b52b-3ba1ff5a8bdc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_42915faf-8358-4b14-8b2d-d0e8b545540d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d3c3e34d-cd50-4fb1-a2a9-829d2a4cfdc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBTrancheOneRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-07</instant>
        </period>
    </context>
    <context id="C_9325e76a-6e44-41b8-9985-b303b44f8869">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:HundredBinneyStreetInCambridgeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_541297f2-8d87-4855-8f1c-53e1e755ed5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c0c8b2a4-7004-44a5-89e9-321b90380e0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tngx:BctgAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-11</startDate>
            <endDate>2021-08-11</endDate>
        </period>
    </context>
    <context id="C_f8e74028-ee7b-40aa-bbb2-cc9236784ca2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_1a15ceae-2bb5-42b0-a18d-a0d58154057d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBOneRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="C_75a3203a-e21d-4b7a-bf56-5007b4cfa6c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:HundredBinneyStreetInCambridgeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-31</instant>
        </period>
    </context>
    <context id="C_cca1c772-6eb6-4c26-835c-7b92064cf842">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_2a1ab7b1-38dd-41eb-9f72-c6425108c827">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fcb0c4a1-8080-44f5-9e53-5ea3f5e568e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5b4da818-3aaf-49ee-92af-9ab384f7fb73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tngx:RestrictedCommonStockAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_dbf730ab-1e1d-4b66-831b-495fa57b10da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tngx:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-10</startDate>
            <endDate>2021-08-10</endDate>
        </period>
    </context>
    <context id="C_278d8753-1cb2-473c-a8e0-50755d56d579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
        </entity>
        <period>
            <instant>2021-08-10</instant>
        </period>
    </context>
    <context id="C_06dcd5da-541e-4c79-b858-c0104fee1630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:TheTwoHundredAndOneBrooklineAvenueLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_5a4c4d12-3d56-4c37-9a9a-c58a9b3e58b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b17588f4-eb89-4f86-9706-bd7d2b333a9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tngx:AgreementAxis">tngx:MedivirAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_34a6b51f-9398-4a33-b000-f084738ed301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tngx:TwoThousandAndTwentyOnePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="C_cab846a0-8d37-4a4b-ae82-af6adf0f78e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tngx:RestrictedCommonStockAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_c15c2969-e6e9-437c-89f0-0a388a5877e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_91ba7dc3-6470-42de-a194-06f0b8e6a25d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tngx:AgreementAxis">tngx:HitgenAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="C_4c74beb2-4bb1-4873-8bda-4048130ed6a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tngx:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f6a066c6-0c2f-4fc7-b6b0-b827d92388ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5c11f77a-567b-409b-b802-3c267191840f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ee85dddd-830e-4471-966a-17bed0f1923f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ae71f40f-3665-48a2-9117-946f426ce1db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">tngx:FoundersAndAdvisorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tngx:RestrictedCommonStockAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="C_407a2f79-30e9-41df-8dfa-8788fa29b7cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fc96726e-aa67-4543-82fb-ba75a0a854df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_4dbe3a85-64de-49a0-bef8-5deb3b1b9ca7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_7aee73e0-1a70-49bf-b3fe-767d20ffc569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:HundredBinneyStreetInCambridgeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_4a669c96-a649-4a8a-b346-1cb396dbfc42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_9229ee0f-56b0-498f-a9f5-422119379b39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_50f18cbc-9bd3-450e-8121-9d1f8276ed3c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_28c70236-1fd3-49b1-a137-9ccf19f5d150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_4cfd2b0e-b7d6-48f4-ace9-bcb7b07f4adc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBOneRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-10</instant>
        </period>
    </context>
    <context id="C_355ebba5-ee81-4e5b-b3ac-c79944317418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9c964121-e164-4d55-976f-d2ed2a2c4cf3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesACommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-10</instant>
        </period>
    </context>
    <context id="C_a752877b-c28d-4699-ba2c-e36a1efb2376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:AmendedGileadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5dd62d57-3336-4d82-b4cc-8df9199613af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tngx:RestrictedCommonStockAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_adf61d0e-b654-4419-b270-224361ec9e78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_654a4524-3c9b-448c-a88c-7c276a239270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_aa1ca7f9-0b3a-4f12-96b6-45a3b58f76db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">tngx:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cb1f4de9-e84a-4dfa-b4b7-550c176b4251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_a908a175-5b6c-474d-a2f6-5ae2b7895667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_68e2d926-73f9-4065-8798-88999cfc5071">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_10b1dfb3-7e3e-4852-85ed-49f7cb670c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_48837b32-a7ba-4536-82fb-eeef4e91837e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-08</instant>
        </period>
    </context>
    <context id="C_c654669a-ad97-4deb-8c23-e8cf0a2ed78f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_edcd82c0-9d7d-49ac-abb2-37406bcefb72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">tngx:SpecifiedClinicalMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tngx:AgreementAxis">tngx:MedivirAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_bec60272-dcf8-4c0e-bcea-ea6c80078013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBCommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-10</instant>
        </period>
    </context>
    <context id="C_f2607f6a-532b-425d-bef1-6f23ecb3ca7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:AmendedGileadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_19209eb4-ef67-4899-926b-0331243cd6b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_2d621dea-8b02-473e-8bc5-76032a18426e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_d8f1f3f0-246b-4352-862d-987a0d66c18f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tngx:LicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_5a10696c-6f1a-45a5-9a37-ea3703aed7cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_42860419-a9e3-4801-beb1-962b31b7feab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:HundredBinneyStreetInCambridgeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="C_50520bd5-264f-47a4-b3f4-8fbfc12d12ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:HundredBinneyStreetInCambridgeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_292501bc-d852-43e2-83eb-a3fe171ce656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_4fb87c77-49f5-455c-a642-6e57e4c31b2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_37b91a95-e41f-4fd5-94cf-030951f28c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tngx:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_babc5d15-ca37-4230-bde3-b6ec0c32b755">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:HundredBinneyStreetInCambridgeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_58f962d5-8219-4b47-8029-390de4ce2191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_fe7f16a9-c541-41d8-939f-8739b8cdc7e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:AmendedGileadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="C_2a0dabb0-2512-43fe-b76a-9eb289d5c030">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:AmendedGileadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_08368de2-8657-4cb0-a2d6-6c41c8497c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ecff8a34-7794-4031-8fce-96f60d31dc7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tngx:BctgAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-10</instant>
        </period>
    </context>
    <context id="C_ab502c57-9eb1-4c1e-b776-cac4cbc580eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">tngx:SpecifiedRegulatoryApprovalAndSalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="tngx:AgreementAxis">tngx:MedivirAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_86fa47f4-0478-4603-9095-4af7a4e6165d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-10</instant>
        </period>
    </context>
    <context id="C_9ce5d825-ac92-4a7e-80e6-cb453f08db17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBCommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-07</instant>
        </period>
    </context>
    <context id="C_a3730188-5277-496a-8a25-6d10f45c0e37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_568bffaa-6246-4bbc-8efb-5c5ca93b43f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tngx:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-13</instant>
        </period>
    </context>
    <context id="C_e9180ff9-f174-4296-94c6-215c9a213af5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:AmendedGileadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_a1ba7f84-139b-48f6-aaf0-8e1842c93c6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesB1CommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-16</startDate>
            <endDate>2020-08-17</endDate>
        </period>
    </context>
    <context id="C_939c93ab-b292-4ae8-9554-f6d1ea202292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesBOnePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_39540783-7152-4a82-98d0-fe1bcc069278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_274ae3eb-6528-4797-924a-99295d4ce141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_33f11eaf-355a-47f4-a2b2-89b65a3ddda0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-08</startDate>
            <endDate>2020-09-08</endDate>
        </period>
    </context>
    <context id="C_4b6a86ef-4245-48e0-8889-4c4163bca1a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
        </entity>
        <period>
            <instant>2022-03-21</instant>
        </period>
    </context>
    <context id="C_77f3de9c-11d0-45e7-b744-00f10cdd56b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_e1cb9353-41dd-47bf-b30c-2b16642be52c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_b1745945-8454-47c6-9623-cbfd040e27d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_7b2e605f-e833-48d9-925e-ef6e94396041">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_767a7086-7e98-4669-a6a3-ba4e0f1c5fc1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_934e45d0-2851-4e4a-848b-28c197e06283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_9e7c0cdf-ecd0-49cb-bcb4-d8123eab2f15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tngx:BctgBusinessCombinationAndPipeFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-10</instant>
        </period>
    </context>
    <context id="C_d122636a-689d-4ab0-b872-bae54aeb140c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tngx:TwoThousandAndTwentyOnePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_97c1afc9-4f65-4a11-89cf-32bdc6c820ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="C_46657909-6cf1-47fc-8643-1f04c29704bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">tngx:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_27a26b8d-6763-4206-ad2e-220eddc0e107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-31</instant>
        </period>
    </context>
    <context id="C_a1adf0bb-c238-43d9-ba7a-df912e357f96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_322de39d-6bc1-437f-9811-2ddb0203f034">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tngx:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_bee96a77-f86f-42a4-a0c1-11fced7670fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_4a921be2-dfdf-4ce8-8e66-04b6835527ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tngx:BctgBusinessCombinationAndPipeFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ce0aba6c-cd66-4a8d-9e8d-6cfea6fd49bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_ea92a304-c585-4deb-947b-651b75dbc182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-11</startDate>
            <endDate>2021-08-11</endDate>
        </period>
    </context>
    <context id="C_1c301094-2824-489c-bf63-ea4093ace32f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:HundredBinneyStreetInCambridgeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="C_10e2e047-49ac-448b-9f30-e2610064f1ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_23df1860-e6dc-439c-b62d-1e850c67c5c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:AmendedGileadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_068a6be4-9f16-496f-98c5-0d1f32f3787e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_04267f13-0c83-44a3-836a-4da5571814a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_aefe6aea-0fcf-40c7-a8cb-fa9395426cc3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tngx:BctgTrustAccountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_369296b3-0383-4744-8c6b-7b140def6872">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tngx:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_c887ec60-971a-4690-a982-03a761ebe233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_34cc5401-52f8-4cad-9b24-31c1f9fae295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">tngx:ResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8312ce29-e29e-402c-b364-5d664fa10451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tngx:BctgAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-10</startDate>
            <endDate>2021-08-10</endDate>
        </period>
    </context>
    <context id="C_12217c4f-04a9-422a-9151-5c1ab378d58e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">tngx:RestrictedCommonStockAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_443492d4-1dcb-460f-9785-b7dc5f094e40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_c73c0fe0-50a5-469f-988c-1cd417a6095d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-10</instant>
        </period>
    </context>
    <context id="C_c520f9bc-41be-4b8e-a264-4f675e8eec11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">tngx:TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b1561790-aba2-4710-8ff9-2107c95bfddb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_d558a274-44e2-47f9-ba78-6254302f1b82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_282b9328-036d-4123-bd3c-893d0d979dbc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_539c3823-b618-476a-9106-5362f015288f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tngx:AgreementAxis">tngx:HitgenAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_eafdff08-f1e7-45e0-b53f-598f4991a9f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tngx:LicenseRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:GileadLetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_79ee2c85-0407-439c-899d-6ad699fae605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201815Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_12c81343-6906-4a1c-8cc1-2e51478b9b44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesB1CommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-17</instant>
        </period>
    </context>
    <context id="C_2a0457d3-f3a5-4a7b-982f-ab2cbc2377f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="C_cf39d22f-09b3-4d53-87d3-8d7dc1f67897">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:GileadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_ee792758-9f05-4175-9451-5b418924373a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tngx:CollaborationRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:GileadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_df7e4b79-2a16-44a2-844e-a0a5c357c1b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tngx:BctgBusinessCombinationAndPipeFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ca4a9ca6-a360-4a08-9af0-9f6ec20dc073">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="tngx:AgreementAxis">tngx:MedivirAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_89ff1d64-5c59-4fe4-b302-72f7ae4dcbe5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">tngx:TwoThousandAndEighteenGileadAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_298c6bea-143e-4985-beea-3b429f7512a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_bc1dd469-9b82-45a6-89fd-03f80ff198f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_af91c863-9582-40c7-8c3d-51a5ac90d570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0bd03243-27c2-444e-894b-d4ebc2dc9598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8b242d70-f5a0-401d-9c7c-8f5525429c2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:ComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_8b25831a-e551-4e81-9130-6ba7264df810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tngx:SeriesB1CommonSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-10</instant>
        </period>
    </context>
    <context id="C_28f5ff88-be03-44d4-a0e8-fd39586ab708">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_d451c16b-ca67-4909-afea-ed3cd220991d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">tngx:BctgAcquisitionCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-11</instant>
        </period>
    </context>
    <context id="C_f25b4a33-16a9-486a-8c10-2233f7ee8a8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4941cdcd-9899-46a1-b43b-5fcbeb247365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">tngx:MarketableDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_50e1ee41-b3b0-4fe2-b580-591e5b4ec3aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_fdf14edc-6cd9-4108-8f54-a48f0e34f4c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_758f7c30-6f5d-40eb-bfbc-5d756f87d621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1a530332-b4e5-472d-a36a-9992e15ee630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tngx:LicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d6f8304a-f49a-468d-abae-98d9b92542a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:TheTwoHundredAndOneBrooklineAvenueLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_8de344bc-88b0-4716-8a86-20e32b63eab2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-11</instant>
        </period>
    </context>
    <context id="C_4a8a40a2-67af-41ac-a7da-247f61928fb4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">tngx:HundredBinneyStreetInCambridgeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="C_1018e487-acae-48dc-9a83-1bc597615eb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_165d6390-156d-4d13-94be-fad709b50c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819133</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201813Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <unit id="U_Program">
        <measure>tngx:Program</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Segment">
        <measure>tngx:Segment</measure>
    </unit>
    <unit id="U_Milestone">
        <measure>tngx:Milestone</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_8431d889-009a-406d-91d5-381ea4e8cc14"
      id="F_9ce82792-73b0-4614-be7e-852d5e09b293">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <dei:AmendmentFlag
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_0d45bf5a-7214-4f2c-834c-80c05c0d1717">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_0efe7b5a-fdb1-48a8-a6db-c093dd913725">0001819133</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_399dcbb6-a750-40fe-933f-1801b0071147">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      id="F_589030a1-b1fe-41c2-9818-779e165f6c4e"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      id="F_2d6d8938-d6e5-45f5-9e08-f42fea8356b9"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_3461b9bd-5e6d-4357-91f1-01033ae50263"
      id="F_0b637d1f-640c-496c-91b4-be2bae95b9b9"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      id="F_ef89b0d7-d3bc-47bb-b18c-a3ef93b3d967"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_298c6bea-143e-4985-beea-3b429f7512a4"
      id="F_a762df4b-f3ed-4d4a-a408-0c28875d2805"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_ee97281b-b16a-45ae-9ceb-0f63f2818525">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_ba7b0cb5-45aa-4540-bea3-b985518e48d7">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_fff4b08f-eda0-4a49-a1fc-eb24cbc2a230">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_9122552a-02bc-4d75-b171-b1db30791f35">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_66bc9990-a96a-470c-abbd-b2a081b8c718">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_671c08ba-7325-465c-bd59-300fae09e21b">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_a5a4800f-ed18-4847-a7df-44c897dba5b2">001-39485</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_1bb1c4ce-499b-4c90-8266-dfed10de8c3c">TANGO THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_47df2ec2-1e57-4ccb-81a1-faec27c93238">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_d0836344-2143-4371-b621-5b8ca18dc53f">85-1195036</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_b73bacbf-e265-43d7-82e5-169a6e6f4101">100 Binney St.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_7d3d55f7-bc0d-4a64-83df-a5c97e64da4f">Suite 700</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_8aae4df2-c46b-4da8-a872-840a3539eaad">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_609f8dbb-64f3-4496-a8c0-3aa1175e9558">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_8abec050-c84a-4457-8b84-8a56f45b6b65">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_00098317-f604-42ba-b30d-4268539d340b">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_dcfce07e-3eba-448d-868e-34216f0d6d65">320-4900</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_4874aff7-7b6d-4d6b-8cb1-e8da016cc682">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_cf7a0fcf-3f9b-4d00-8cd0-cc2879611e3f">TNGX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_08f3de99-c093-48ab-82a1-cbf41afa9973">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_9f2739cb-05a1-4f90-a237-ed5f75db590e">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_c452ca3d-201c-4da0-9ef0-eabc17456642">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_9fbaae15-947e-42eb-a4c9-8dd930374b1f">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_f789cdae-d3c0-41e8-a6d3-b2dd01c98b6a">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_53b98046-8a98-4266-9dbd-04ce4f47a590">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_0dcb5c0c-3d46-4a21-886e-cc4bcdc8bde7">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_65ae3668-f046-46e9-a540-b1dee5d1e5a0">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_af731a31-c150-403f-8632-b2bb7bc370ba">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_b09b8af7-649c-4994-99b9-8d25edbe7df2">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_611c3c3d-bfb3-4391-a152-02c9675be9ab">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_10b1dfb3-7e3e-4852-85ed-49f7cb670c71"
      decimals="-5"
      id="F_dfc562a5-9f04-403e-8baf-288beefb38ed"
      unitRef="U_USD">189800000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_4b6a86ef-4245-48e0-8889-4c4163bca1a6"
      decimals="INF"
      id="F_850abd0b-dda8-4c85-aa93-7968f629b8e0"
      unitRef="U_shares">87707499</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_8fbec538-8d0b-4847-bcf3-6870bd0b818d">238</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_9ce67f27-0312-41e4-a1c4-2acc59f21dd1">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_143a542d-ffc3-4459-a7f5-2aa932e0b155">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_99a21c5d-22bf-4ddf-9b1a-9d4b17cfcf4c"
      unitRef="U_USD">142745000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_4e038a5d-62ec-4e38-b92f-e6931f914364"
      unitRef="U_USD">28381000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_aa74e5c4-fa98-40ed-a75f-0b0029548dd5"
      unitRef="U_USD">342510000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_ee6627ee-f973-4ce0-a051-3a87c379d58f"
      unitRef="U_USD">161939000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_501e5a71-cc76-4e16-acdf-7ca6c9cd8269"
      unitRef="U_USD">2000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_ec5bb0fc-2ac7-4134-95d8-c942d206bc5a"
      unitRef="U_USD">2000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_0ffb221d-a52c-48f7-93d1-a7407dd0333f"
      unitRef="U_USD">567000</us-gaap:RestrictedCashCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_49e78aa5-8466-4f27-94fb-150f93f8dac9"
      unitRef="U_USD">4516000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_0f848ba7-c91a-4f84-84a2-43ca23fb56f8"
      unitRef="U_USD">1312000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_f1c3066e-21f8-4548-b162-269d054470c4"
      unitRef="U_USD">492338000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_90b7cca5-5740-4e27-bd2f-c56ff548b1ae"
      unitRef="U_USD">193632000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_933edb8d-7f7d-493e-85e7-2cf4a9907950"
      unitRef="U_USD">4832000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_1a29e774-85f5-48d0-8b35-9d8cea06ed1f"
      unitRef="U_USD">3823000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_726d5781-3e32-4727-ae21-376a9d078d6a"
      unitRef="U_USD">1254000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_879f780a-3d76-4c51-aa6b-d14bbc832c4e"
      unitRef="U_USD">7480000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_401ed779-421a-44ff-b31b-8648ef63311b"
      unitRef="U_USD">1712000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_557cce34-0a38-4658-b089-8d89470049cd"
      unitRef="U_USD">2279000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_7410bb02-de3c-4e9e-8099-966a8bac6061"
      unitRef="U_USD">19000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_721e824a-51a9-46bc-a6b9-097a50b8c32d"
      unitRef="U_USD">38000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_fa439791-cb6a-4b83-a450-686fce7feb15"
      unitRef="U_USD">500155000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_52f35b99-45c2-4cf7-b4df-a0c48e923bd6"
      unitRef="U_USD">207252000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_23c2de81-5e16-4fa2-9f7f-4d4308ba2573"
      unitRef="U_USD">3226000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_ed7c8c61-103a-4e64-b610-2c110fa00209"
      unitRef="U_USD">1841000</us-gaap:AccountsPayableCurrent>
    <tngx:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_84299689-ee72-4a48-a64e-f981ac19b5ae"
      unitRef="U_USD">9887000</tngx:AccruedExpensesAndOtherCurrentLiabilities>
    <tngx:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_55c7a836-8fac-44bb-a7fa-f7a1bacffe45"
      unitRef="U_USD">6140000</tngx:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_90cbf797-76f5-4bcb-b85d-3dc3d8adc0a3"
      unitRef="U_USD">1503000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_e604b740-66f3-4f04-ad89-3a8b43ec97fa"
      unitRef="U_USD">959000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_e2f1f2ac-bf3a-42e9-a678-eb5cff847ebf"
      unitRef="U_USD">26022000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_f88c7b60-6091-4389-89f3-03fba2f9cf2a"
      unitRef="U_USD">31977000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_09660582-bd63-465e-86a8-f980b5003bd4"
      unitRef="U_USD">52000</us-gaap:TaxesPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_5074d751-7d32-41a0-9e38-808944bfee13"
      unitRef="U_USD">40690000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_ddcf1e87-0e41-4f7a-acb6-303f73fa5073"
      unitRef="U_USD">40917000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_e5b74981-6b5d-4430-98fc-07bb818a1783"
      unitRef="U_USD">6925000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_c216d760-2f2a-4a2c-aaed-9c4cb004522c"
      unitRef="U_USD">114718000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_8e755994-7dfe-4b75-b9dc-f7218aaa9830"
      unitRef="U_USD">120805000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_6797c562-9f21-408b-9e5b-b45f46d76fae"
      unitRef="U_USD">5000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_6be0b411-a4d9-4012-aa17-444bae617be6"
      unitRef="U_USD">155408000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_cdcf267f-9b51-452a-8c13-564cb341e03a"
      unitRef="U_USD">168652000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="INF"
      id="F_6913b509-fa90-44f8-909d-d71909c7bae7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="INF"
      id="F_be3a7f24-1aa9-4bd2-88fb-1936a36c5458"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="INF"
      id="F_127afb8a-9d36-464f-9faa-9d9f177e0579"
      unitRef="U_shares">10000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="INF"
      id="F_1d06ec31-91d8-4c3f-b876-0fbdeadfc749"
      unitRef="U_shares">10000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="INF"
      id="F_86dddb98-e5db-4eb3-8e23-1ee6d6054b31"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="INF"
      id="F_bd3b4620-04fa-4caf-aa8e-a60880f9e910"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="INF"
      id="F_cee1591d-4ed4-4712-aa56-2f2b786c8ea9"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="INF"
      id="F_6bb264ef-fd30-4d5d-96b8-d2047af30d66"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_ab66cb03-ff58-4982-8364-4b9878250c6e"
      unitRef="U_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_ebcb7f52-2f15-4f64-a75d-62fe80675fb5"
      unitRef="U_USD">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="INF"
      id="F_189e8340-441b-4fd4-976f-47b68e876119"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="INF"
      id="F_f316d390-fc8a-4205-987c-f2e8c8d18dd1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="INF"
      id="F_fda5f06c-359d-4375-8bda-0d4bb6079891"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="INF"
      id="F_2d24a0e6-6bdb-4e89-ad18-cca209afe94d"
      unitRef="U_shares">56393261</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="INF"
      id="F_2a8b96c7-f7d9-4b3c-9414-8f48e9d3cb4e"
      unitRef="U_shares">87598184</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="INF"
      id="F_4b062acf-b302-434c-acf9-c60300fa9d97"
      unitRef="U_shares">87598184</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="INF"
      id="F_2416c1d1-9896-4bb9-af68-8f65c6f6d32b"
      unitRef="U_shares">40372133</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="INF"
      id="F_b5d15bbb-56b9-4725-9204-03239102c6f7"
      unitRef="U_shares">40372133</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_1792060f-df75-462c-8c22-e25a6273781e"
      unitRef="U_USD">88000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_0e4ee8a6-0763-4eba-a333-cd51b81d5620"
      unitRef="U_USD">40000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_85ef8028-ae65-4a60-bc39-228a5af99ebd"
      unitRef="U_USD">506760000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_1bd5ab86-a1d1-403b-8ef5-7f8c4a093bc6"
      unitRef="U_USD">141644000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_f5ee2969-db63-4e91-a2b4-68e60d838e38"
      unitRef="U_USD">-765000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_9f48f0c3-f03c-49ba-972a-f6f11b595721"
      unitRef="U_USD">17000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_3c0ae622-4a62-4876-802c-f127ea322c02"
      unitRef="U_USD">-161336000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_ceb2fd35-762a-4e1a-996d-230c174ca901"
      unitRef="U_USD">-103101000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_e8bbcfeb-3c87-4e52-8904-93c9e30a2d83"
      unitRef="U_USD">344747000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_9a0ff121-b7b0-47b6-a89e-3b89cde4eeb6"
      unitRef="U_USD">38600000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_ad906677-40d3-4014-919d-ee3117fb6767"
      unitRef="U_USD">500155000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_2c49d74c-9708-4987-9d7e-755600662159"
      unitRef="U_USD">207252000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="C_322de39d-6bc1-437f-9811-2ddb0203f034"
      decimals="-3"
      id="F_2ab7f0c2-0f14-4409-be73-46e2555c3ac7"
      unitRef="U_USD">26042000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_37b91a95-e41f-4fd5-94cf-030951f28c96"
      decimals="-3"
      id="F_04e0638d-c8f9-47bb-ba26-7a33a84adb1f"
      unitRef="U_USD">6972000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_1a530332-b4e5-472d-a36a-9992e15ee630"
      decimals="-3"
      id="F_54afb518-f3e6-4410-8997-dbf365024ad9"
      unitRef="U_USD">11000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_d8f1f3f0-246b-4352-862d-987a0d66c18f"
      decimals="-3"
      id="F_e85e39f5-6786-4d0a-ae73-645d7c10ff4b"
      unitRef="U_USD">684000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_686ea652-4ebd-4361-acf7-92a576da1616"
      unitRef="U_USD">37042000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_ee4fd431-8188-47c5-9589-aa727e78d388"
      unitRef="U_USD">7656000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_184c89f0-6205-4597-b1d2-b25fd082ea0c"
      unitRef="U_USD">77636000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_d56846bc-01c2-4511-9579-74b172c32f40"
      unitRef="U_USD">49991000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_dd02bcda-5574-45b2-b0be-0efa1747dd6f"
      unitRef="U_USD">17596000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_1fdf8e0a-8b15-4060-a090-ae50ffa37f44"
      unitRef="U_USD">9865000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_db668361-2c70-48b3-a827-e73c33ecbb22"
      unitRef="U_USD">95232000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_e4390524-a0d7-4d92-8eae-fcd5f31b7038"
      unitRef="U_USD">59856000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_06dc9e83-9991-4b16-bb8f-371138f1c269"
      unitRef="U_USD">-58190000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_f74c2ad2-474b-4319-a3c0-0ccf0f0f12b7"
      unitRef="U_USD">-52200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_9324c653-1f1a-4631-bb99-46d73b10d75a"
      unitRef="U_USD">495000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_9dc6ce5a-3982-47a4-ac02-f860a7cd46cb"
      unitRef="U_USD">108000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_f966c34b-15bd-44e0-9cbb-e7d9abfbec66"
      unitRef="U_USD">-248000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_1f7f1844-dab5-4669-a43f-fe003fcef03d"
      unitRef="U_USD">120000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_d7bbd4fd-c3ed-4caf-ba01-a90144ee06ab"
      unitRef="U_USD">247000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_9aeb3eed-c2a2-4de9-b586-f3d8258d0096"
      unitRef="U_USD">228000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_1e7ab17f-5f60-4288-87eb-651652081dbc"
      unitRef="U_USD">-57943000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_e1cc0fd9-fa89-4886-9a2f-88bc2d58190f"
      unitRef="U_USD">-51972000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_b8a3c093-cbd2-45ef-a658-d909718fcb5b"
      unitRef="U_USD">292000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_cf6c785c-678d-4830-b62b-528219f9b376"
      unitRef="U_USD">-58235000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_754d6f30-a06a-4448-8057-645b07fdb836"
      unitRef="U_USD">-51972000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="2"
      id="F_393522f9-9176-4ea1-bfd0-ccabb7b53b92"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.94</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="2"
      id="F_291e5ac9-f239-48a5-bb57-ab54621ea3cd"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.63</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="0"
      id="F_dfe6aacd-5426-4105-942e-78832d1b244d"
      unitRef="U_shares">62108032</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="0"
      id="F_1df196de-b4c0-40ab-80b1-fe1ca48f4b4d"
      unitRef="U_shares">31932204</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_d0f3052f-4c9d-498b-a151-eef4ec441902"
      unitRef="U_USD">-58235000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_10551165-37f4-4237-b548-2c9496afb2a9"
      unitRef="U_USD">-51972000</us-gaap:NetIncomeLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_d2402e84-397b-4a8b-babf-5f166a6896e1"
      unitRef="U_USD">-782000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_188b92a9-533d-4dfd-95af-4f7e066b90cb"
      unitRef="U_USD">7000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_20f432c1-e7f2-4b5f-afc1-bf9a0ffcf96f"
      unitRef="U_USD">-59017000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_7083c7e9-1b77-4007-853b-1de24066be86"
      unitRef="U_USD">-51965000</us-gaap:ComprehensiveIncomeNetOfTax>
    <tngx:TemporaryEquitySharesOutstandingBeforeRetroactiveApplicationOfRecapitalization
      contextRef="C_58f962d5-8219-4b47-8029-390de4ce2191"
      decimals="INF"
      id="F_dcd1398a-cb95-4375-be6f-2608df362d36"
      unitRef="U_shares">55700000</tngx:TemporaryEquitySharesOutstandingBeforeRetroactiveApplicationOfRecapitalization>
    <tngx:TemporaryEquityBeforeRetroactiveApplicationOfRecapitalization
      contextRef="C_58f962d5-8219-4b47-8029-390de4ce2191"
      decimals="-3"
      id="F_da361afe-4d2a-459d-a8e5-b96c275a8f93"
      unitRef="U_USD">55700000</tngx:TemporaryEquityBeforeRetroactiveApplicationOfRecapitalization>
    <tngx:SharesOutstandingBeforeRetroactiveApplicationOfRecapitalization
      contextRef="C_62d30997-cb59-4c36-9293-3ab9037d2139"
      decimals="INF"
      id="F_ac900e21-4726-4a7b-9ffa-60a3842533e9"
      unitRef="U_shares">4530115</tngx:SharesOutstandingBeforeRetroactiveApplicationOfRecapitalization>
    <tngx:StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization
      contextRef="C_62d30997-cb59-4c36-9293-3ab9037d2139"
      decimals="-3"
      id="F_a1bef661-e898-4612-9d89-75f43585febe"
      unitRef="U_USD">5000</tngx:StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization>
    <tngx:StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization
      contextRef="C_ce0aba6c-cd66-4a8d-9e8d-6cfea6fd49bf"
      decimals="-3"
      id="F_67b57927-a9a3-4d22-b6cb-28e6251f2e78"
      unitRef="U_USD">3319000</tngx:StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization>
    <tngx:StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization
      contextRef="C_fe8c0009-60fd-45e6-bf12-78e38e33e502"
      decimals="-3"
      id="F_aeaefe2c-2974-41e4-a210-8b2aace45478"
      unitRef="U_USD">10000</tngx:StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization>
    <tngx:StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization
      contextRef="C_50e1ee41-b3b0-4fe2-b580-591e5b4ec3aa"
      decimals="-3"
      id="F_48ac2206-7b8f-44c9-8a25-b224d82a6162"
      unitRef="U_USD">-51129000</tngx:StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization>
    <tngx:StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization
      contextRef="C_4a669c96-a649-4a8a-b346-1cb396dbfc42"
      decimals="-3"
      id="F_4cbe3a95-d80b-4621-84a0-5b93c5f20e53"
      unitRef="U_USD">-47795000</tngx:StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization>
    <tngx:TemporaryEquityRetroactiveApplicationOfRecapitalizationShares
      contextRef="C_58f962d5-8219-4b47-8029-390de4ce2191"
      decimals="INF"
      id="F_391d0d8a-28d7-4582-8b8d-b3c3e1c52fe6"
      unitRef="U_shares">55700000</tngx:TemporaryEquityRetroactiveApplicationOfRecapitalizationShares>
    <tngx:TemporaryEquityRetroactiveApplicationOfRecapitalization
      contextRef="C_58f962d5-8219-4b47-8029-390de4ce2191"
      decimals="-3"
      id="F_2faefb1c-ed4b-4968-a1d4-14e1e10f9104"
      unitRef="U_USD">55700000</tngx:TemporaryEquityRetroactiveApplicationOfRecapitalization>
    <tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares
      contextRef="C_62d30997-cb59-4c36-9293-3ab9037d2139"
      decimals="INF"
      id="F_002f5faa-ed44-4f60-837d-1b5a0cb16be8"
      unitRef="U_shares">18922317</tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares>
    <tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalization
      contextRef="C_62d30997-cb59-4c36-9293-3ab9037d2139"
      decimals="-3"
      id="F_1c5b1ebe-8d9e-4919-a2eb-ee9e681e932e"
      unitRef="U_USD">19000</tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalization>
    <tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalization
      contextRef="C_ce0aba6c-cd66-4a8d-9e8d-6cfea6fd49bf"
      decimals="-3"
      id="F_80878604-b602-4ea8-b400-79dd9c3372a3"
      unitRef="U_USD">55681000</tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalization>
    <tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalization
      contextRef="C_4a669c96-a649-4a8a-b346-1cb396dbfc42"
      decimals="-3"
      id="F_0f9075bb-3603-4f8f-bdaa-5d6de311b41b"
      unitRef="U_USD">55700000</tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalization>
    <us-gaap:SharesOutstanding
      contextRef="C_62d30997-cb59-4c36-9293-3ab9037d2139"
      decimals="INF"
      id="F_b3b126ea-600e-49c7-b5a1-ae996ea7da92"
      unitRef="U_shares">23452432</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_62d30997-cb59-4c36-9293-3ab9037d2139"
      decimals="-3"
      id="F_7e0a7387-cfed-4f4b-a1fa-f24bbc78aa95"
      unitRef="U_USD">24000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ce0aba6c-cd66-4a8d-9e8d-6cfea6fd49bf"
      decimals="-3"
      id="F_428ada76-46ae-47ab-8de3-dd83b207960e"
      unitRef="U_USD">59000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_fe8c0009-60fd-45e6-bf12-78e38e33e502"
      decimals="-3"
      id="F_64cf6f47-177e-449e-8658-983f0da22745"
      unitRef="U_USD">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_50e1ee41-b3b0-4fe2-b580-591e5b4ec3aa"
      decimals="-3"
      id="F_bb0e92cd-36f1-4cc1-9dc9-3a81b5ab2432"
      unitRef="U_USD">-51129000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4a669c96-a649-4a8a-b346-1cb396dbfc42"
      decimals="-3"
      id="F_2654a7a7-30ff-479a-8a9c-3d03b9899923"
      unitRef="U_USD">7905000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts
      contextRef="C_d04e6201-772a-4ebf-bcb7-57256a6b7980"
      decimals="-5"
      id="F_a70e356e-aaa4-4717-b45a-7eb8f40e6861"
      unitRef="U_USD">200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts>
    <tngx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_d04e6201-772a-4ebf-bcb7-57256a6b7980"
      decimals="INF"
      id="F_6998b12d-cec9-4499-9c31-921230e01a7a"
      unitRef="U_shares">22686025</tngx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_d04e6201-772a-4ebf-bcb7-57256a6b7980"
      decimals="-3"
      id="F_b31c0c9d-9bfe-470f-8129-1196a5aaf6a6"
      unitRef="U_USD">29761000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <tngx:TemporaryStockRetroactiveApplicationOfRecapitalizationShares
      contextRef="C_d04e6201-772a-4ebf-bcb7-57256a6b7980"
      decimals="INF"
      id="F_96e42a81-0ba2-4de6-a172-dc010b4084ae"
      unitRef="U_shares">22686025</tngx:TemporaryStockRetroactiveApplicationOfRecapitalizationShares>
    <tngx:TemporaryStockRetroactiveApplicationOfRecapitalization
      contextRef="C_d04e6201-772a-4ebf-bcb7-57256a6b7980"
      decimals="-3"
      id="F_678c0203-2493-42a8-a990-afa562b7b79b"
      unitRef="U_USD">29761000</tngx:TemporaryStockRetroactiveApplicationOfRecapitalization>
    <tngx:RetroactiveApplicationOfRecapitalizationShares
      contextRef="C_42c26e7c-eca8-426f-9a02-4c53841db8ca"
      decimals="INF"
      id="F_c14c99fc-129d-4db9-b8a2-7e0ee3387cbf"
      unitRef="U_shares">7706861</tngx:RetroactiveApplicationOfRecapitalizationShares>
    <tngx:RetroactiveApplicationOfRecapitalization
      contextRef="C_42c26e7c-eca8-426f-9a02-4c53841db8ca"
      decimals="-3"
      id="F_d44b778b-445b-41b3-a68d-4bb042fd14f6"
      unitRef="U_USD">8000</tngx:RetroactiveApplicationOfRecapitalization>
    <tngx:RetroactiveApplicationOfRecapitalization
      contextRef="C_f8e74028-ee7b-40aa-bbb2-cc9236784ca2"
      decimals="-3"
      id="F_789f3fec-d46d-42f2-aa56-fd88cb563076"
      unitRef="U_USD">29753000</tngx:RetroactiveApplicationOfRecapitalization>
    <tngx:RetroactiveApplicationOfRecapitalization
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_19a66ade-aa60-4570-ad90-28280a5be4ca"
      unitRef="U_USD">29761000</tngx:RetroactiveApplicationOfRecapitalization>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts
      contextRef="C_939c93ab-b292-4ae8-9554-f6d1ea202292"
      decimals="-5"
      id="F_90acff59-cfc5-4936-aa87-f95c06a695f3"
      unitRef="U_USD">200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts>
    <tngx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_939c93ab-b292-4ae8-9554-f6d1ea202292"
      decimals="INF"
      id="F_fc8318c3-aca0-4891-803a-f3a584b94b3f"
      unitRef="U_shares">27152255</tngx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_939c93ab-b292-4ae8-9554-f6d1ea202292"
      decimals="-3"
      id="F_d6f9ceec-4cf5-40c6-a554-b89479698ed5"
      unitRef="U_USD">51083000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <tngx:TemporaryStockRetroactiveApplicationOfRecapitalizationShares
      contextRef="C_939c93ab-b292-4ae8-9554-f6d1ea202292"
      decimals="INF"
      id="F_53d71478-6fe6-42e7-9cf2-ef01a360ed02"
      unitRef="U_shares">27152255</tngx:TemporaryStockRetroactiveApplicationOfRecapitalizationShares>
    <tngx:TemporaryStockRetroactiveApplicationOfRecapitalization
      contextRef="C_939c93ab-b292-4ae8-9554-f6d1ea202292"
      decimals="-3"
      id="F_3137c6f9-7453-4489-8ba0-8370bd731117"
      unitRef="U_USD">51083000</tngx:TemporaryStockRetroactiveApplicationOfRecapitalization>
    <tngx:RetroactiveApplicationOfRecapitalizationSharesOne
      contextRef="C_42c26e7c-eca8-426f-9a02-4c53841db8ca"
      decimals="0"
      id="F_62f6e394-6776-4ec5-9d24-518f0461c717"
      unitRef="U_shares">9224122</tngx:RetroactiveApplicationOfRecapitalizationSharesOne>
    <tngx:RetroactiveApplicationOfRecapitalizationOne
      contextRef="C_42c26e7c-eca8-426f-9a02-4c53841db8ca"
      decimals="-3"
      id="F_433481f0-6a29-4ec2-8398-4a7c0fbbb2eb"
      unitRef="U_USD">8000</tngx:RetroactiveApplicationOfRecapitalizationOne>
    <tngx:RetroactiveApplicationOfRecapitalizationOne
      contextRef="C_f8e74028-ee7b-40aa-bbb2-cc9236784ca2"
      decimals="-3"
      id="F_54f59faa-b996-481b-a15d-bda12305b2b4"
      unitRef="U_USD">51075000</tngx:RetroactiveApplicationOfRecapitalizationOne>
    <tngx:RetroactiveApplicationOfRecapitalizationOne
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_09c09368-8f15-42b3-8757-d7b5e52a4b48"
      unitRef="U_USD">51083000</tngx:RetroactiveApplicationOfRecapitalizationOne>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="C_f8e74028-ee7b-40aa-bbb2-cc9236784ca2"
      decimals="-3"
      id="F_98d4a42c-6367-4eef-9201-4d7ccc7696e7"
      unitRef="U_USD">12000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_aa68538b-557c-4b09-a67e-681245d71c67"
      unitRef="U_USD">12000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_42c26e7c-eca8-426f-9a02-4c53841db8ca"
      decimals="INF"
      id="F_ef2faa70-2fd5-4ae5-ba34-0e78f93708c9"
      unitRef="U_shares">27813</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_f8e74028-ee7b-40aa-bbb2-cc9236784ca2"
      decimals="-3"
      id="F_5b7178ba-914c-4bdb-8d86-bcc42a353106"
      unitRef="U_USD">40000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_db9ed9de-c470-414f-aee6-79877cc698f0"
      unitRef="U_USD">40000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="C_42c26e7c-eca8-426f-9a02-4c53841db8ca"
      decimals="INF"
      id="F_7e0a3a38-4dfb-496a-9404-86f64ac4f1fb"
      unitRef="U_shares">39095</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_f8e74028-ee7b-40aa-bbb2-cc9236784ca2"
      decimals="-3"
      id="F_87dba0f1-932a-407c-8a85-a1f6e6c5ae95"
      unitRef="U_USD">1764000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_db18fcae-16d9-41d7-803e-e6430c7a81b0"
      unitRef="U_USD">1764000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="C_088edbda-4c95-4fa9-9856-74af91d7facd"
      decimals="-3"
      id="F_069f48ed-51e7-4fd9-8d0d-d091e87e641b"
      unitRef="U_USD">7000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_9cddd0c7-b962-41ac-85c9-d006504dc6c4"
      unitRef="U_USD">7000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_e1cb9353-41dd-47bf-b30c-2b16642be52c"
      decimals="-3"
      id="F_ee15d893-c644-476b-beed-f9f12220db1d"
      unitRef="U_USD">-51972000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_8393a688-70c7-4d47-948a-be0a89b1c149"
      unitRef="U_USD">-51972000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_fdf14edc-6cd9-4108-8f54-a48f0e34f4c2"
      decimals="INF"
      id="F_ab521929-728c-489f-bdf4-7fcbe79b3bbf"
      unitRef="U_shares">40372133</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_fdf14edc-6cd9-4108-8f54-a48f0e34f4c2"
      decimals="-3"
      id="F_81ae7846-f311-48da-9730-3b36b69a5753"
      unitRef="U_USD">40000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_cb1f4de9-e84a-4dfa-b4b7-550c176b4251"
      decimals="-3"
      id="F_c5f2f1cb-0401-4c1b-8069-c064ec812425"
      unitRef="U_USD">141644000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_68e2d926-73f9-4065-8798-88999cfc5071"
      decimals="-3"
      id="F_4a5223f4-2ec6-4b4d-bb0b-dac2bd1a5bba"
      unitRef="U_USD">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1018e487-acae-48dc-9a83-1bc597615eb9"
      decimals="-3"
      id="F_0788c9ca-9bac-457a-905a-db4c97196c10"
      unitRef="U_USD">-103101000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_d56f29ce-00fd-457e-b620-2f0e9afd2632"
      unitRef="U_USD">38600000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts
      contextRef="C_bc1dd469-9b82-45a6-89fd-03f80ff198f8"
      decimals="-5"
      id="F_137e8aba-d828-4610-8c18-ec4d15f66f95"
      unitRef="U_USD">100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts>
    <tngx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_bc1dd469-9b82-45a6-89fd-03f80ff198f8"
      decimals="INF"
      id="F_21d9ee4d-b77c-488e-aeb3-08229019b761"
      unitRef="U_shares">22686025</tngx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_bc1dd469-9b82-45a6-89fd-03f80ff198f8"
      decimals="-3"
      id="F_b39edfbf-d903-4f87-a95f-1e1a55b81aa3"
      unitRef="U_USD">29990000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <tngx:TemporaryStockRetroactiveApplicationOfRecapitalizationShares
      contextRef="C_bc1dd469-9b82-45a6-89fd-03f80ff198f8"
      decimals="INF"
      id="F_e25c9582-d714-4862-a833-a04c223dbbf7"
      unitRef="U_shares">22686025</tngx:TemporaryStockRetroactiveApplicationOfRecapitalizationShares>
    <tngx:TemporaryStockRetroactiveApplicationOfRecapitalization
      contextRef="C_bc1dd469-9b82-45a6-89fd-03f80ff198f8"
      decimals="-3"
      id="F_814e84bd-5dc9-4195-ab6f-a527b8e84add"
      unitRef="U_USD">29990000</tngx:TemporaryStockRetroactiveApplicationOfRecapitalization>
    <tngx:RetroactiveApplicationOfRecapitalizationShares
      contextRef="C_355ebba5-ee81-4e5b-b3ac-c79944317418"
      decimals="INF"
      id="F_feeccf46-eaf0-400c-9b66-bbab00abaa49"
      unitRef="U_shares">7706861</tngx:RetroactiveApplicationOfRecapitalizationShares>
    <tngx:RetroactiveApplicationOfRecapitalization
      contextRef="C_355ebba5-ee81-4e5b-b3ac-c79944317418"
      decimals="-3"
      id="F_50f29c5c-b153-45f3-a70c-a7452354ff69"
      unitRef="U_USD">8000</tngx:RetroactiveApplicationOfRecapitalization>
    <tngx:RetroactiveApplicationOfRecapitalization
      contextRef="C_44358ddc-7505-46e1-8119-f33db1fa516a"
      decimals="-3"
      id="F_ee140c1f-0d43-4218-8233-9fb82743507d"
      unitRef="U_USD">29982000</tngx:RetroactiveApplicationOfRecapitalization>
    <tngx:RetroactiveApplicationOfRecapitalization
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_33f3a454-f082-4764-9e4b-79d78ced5132"
      unitRef="U_USD">29990000</tngx:RetroactiveApplicationOfRecapitalization>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts
      contextRef="C_355ebba5-ee81-4e5b-b3ac-c79944317418"
      decimals="-5"
      id="F_6f91935a-af05-44e5-991d-ef61843371b2"
      unitRef="U_USD">15800000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts>
    <tngx:StockIssuedDuringPeriodSharesAcquisitionsAndPrivateInvestments
      contextRef="C_355ebba5-ee81-4e5b-b3ac-c79944317418"
      decimals="INF"
      id="F_84ca698d-f15d-4d47-8c0a-b891250c535b"
      unitRef="U_shares">38880436</tngx:StockIssuedDuringPeriodSharesAcquisitionsAndPrivateInvestments>
    <tngx:StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments
      contextRef="C_355ebba5-ee81-4e5b-b3ac-c79944317418"
      decimals="-3"
      id="F_4401150a-6c6a-499f-adb8-0f4b3764d386"
      unitRef="U_USD">39000</tngx:StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments>
    <tngx:StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments
      contextRef="C_44358ddc-7505-46e1-8119-f33db1fa516a"
      decimals="-3"
      id="F_675b6e67-44e4-4d60-988f-b290a3737bfb"
      unitRef="U_USD">326238000</tngx:StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments>
    <tngx:StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_167f0d10-f69c-4a41-90e6-f9596437a08f"
      unitRef="U_USD">326277000</tngx:StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_355ebba5-ee81-4e5b-b3ac-c79944317418"
      decimals="INF"
      id="F_cfe2b58c-be6d-4486-b83f-a0036ebedd71"
      unitRef="U_shares">638754</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_355ebba5-ee81-4e5b-b3ac-c79944317418"
      decimals="-3"
      id="F_91fd5f33-b9ce-4cc6-943f-8971aa521e40"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_44358ddc-7505-46e1-8119-f33db1fa516a"
      decimals="-3"
      id="F_39171d90-90cf-447a-8d62-8f43c796955b"
      unitRef="U_USD">1057000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_c05168e1-5d47-4b00-8fef-c65d57be7604"
      unitRef="U_USD">1058000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="C_44358ddc-7505-46e1-8119-f33db1fa516a"
      decimals="-3"
      id="F_3cba5d27-e6e1-44e2-a87a-b39c84f124a2"
      unitRef="U_USD">6000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_91ea28eb-17bb-45d5-95b7-5176e99d36ec"
      unitRef="U_USD">6000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_44358ddc-7505-46e1-8119-f33db1fa516a"
      decimals="-3"
      id="F_94b1a056-eed4-45e2-8cfc-d253cd5946c5"
      unitRef="U_USD">7833000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_a62b5b51-c3ab-4b3b-9e74-b3b9a35a997a"
      unitRef="U_USD">7833000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="C_c17d0f8f-c6ae-43cd-9b51-09d002c47c3f"
      decimals="-3"
      id="F_ceef4420-910a-429b-8cca-e4bd7081e625"
      unitRef="U_USD">-782000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_739f82db-2c8e-4612-9873-283fe9638082"
      unitRef="U_USD">-782000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_39540783-7152-4a82-98d0-fe1bcc069278"
      decimals="-3"
      id="F_fae5f4ce-1ee7-4aec-8658-d83c98e2b6b6"
      unitRef="U_USD">-58235000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_36d5e686-0166-4edd-ac55-f27dd101355c"
      unitRef="U_USD">-58235000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_5a4c4d12-3d56-4c37-9a9a-c58a9b3e58b1"
      decimals="INF"
      id="F_2943fc5a-450c-4748-80b6-c663d80c5b56"
      unitRef="U_shares">87598184</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_5a4c4d12-3d56-4c37-9a9a-c58a9b3e58b1"
      decimals="-3"
      id="F_c188b8d6-6141-4070-bd52-df9bad2a5eab"
      unitRef="U_USD">88000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f993a7f8-4d25-4be9-b713-6bb38ecf342b"
      decimals="-3"
      id="F_8be18e0a-4418-46d4-8c6a-da7cb1cd9a97"
      unitRef="U_USD">506760000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7055bdf6-8d9f-4ea6-913c-d9194c0435b5"
      decimals="-3"
      id="F_8fc90f3e-c9eb-4e3f-96c7-f67a15e6a92d"
      unitRef="U_USD">-765000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_08368de2-8657-4cb0-a2d6-6c41c8497c13"
      decimals="-3"
      id="F_3593e539-48b6-4a73-ab3f-2832318f4ae0"
      unitRef="U_USD">-161336000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_0dc40263-3cea-45ca-a2d8-6050998fe6ee"
      unitRef="U_USD">344747000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_29934e4b-65d5-46c7-b790-42ea5b8f5283"
      unitRef="U_USD">-58235000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_258cc906-1da0-4375-9c0e-071edc2a5754"
      unitRef="U_USD">-51972000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_711116fe-1317-4642-b95d-e9ba3ef55bd7"
      unitRef="U_USD">897000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_5cb92fad-0849-4052-96bb-c2aa73d99ff2"
      unitRef="U_USD">718000</us-gaap:Depreciation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_ad03d357-9eb8-4424-bed9-66e1ec5916d6"
      unitRef="U_USD">1069000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_950479c2-acc8-4e36-9c0e-c57ecc304829"
      unitRef="U_USD">907000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_c75d5d0c-d55f-4419-bce8-3c5fbde269bc"
      unitRef="U_USD">7833000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_7b68097a-1e40-4a47-a7e0-d5ab111a74af"
      unitRef="U_USD">1764000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_43e3ee88-7671-46d4-bfa3-77f2f0470a9f"
      unitRef="U_USD">-254000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_a85eae59-cd62-4cff-9afa-5b8629328930"
      unitRef="U_USD">17000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_8aaa2e91-deb9-47db-b108-21616495bddb"
      unitRef="U_USD">2000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_14023ccc-9a1c-4f69-8cd3-f65d0cc40343"
      unitRef="U_USD">3159000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_7389081e-5ede-471f-8a79-c596489612b4"
      unitRef="U_USD">81000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_a2c0ccf9-1ad6-4cf0-a46f-39d52db3ffd2"
      unitRef="U_USD">139000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_05183bed-2b3d-4b36-b4d6-079ba1b7cc6d"
      unitRef="U_USD">38000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_d4281038-0a66-454b-ae48-91721fd0205f"
      unitRef="U_USD">1232000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_f4ae22ca-1436-4d9a-b8c2-9bc038657ff5"
      unitRef="U_USD">1171000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <tngx:IncreaseDecreaseInAccruedExpensesAndOtherLiabilities
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_f7623431-3471-4a81-83d1-5efb79cacf68"
      unitRef="U_USD">3829000</tngx:IncreaseDecreaseInAccruedExpensesAndOtherLiabilities>
    <tngx:IncreaseDecreaseInAccruedExpensesAndOtherLiabilities
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_2dc33cf3-6734-4a70-a2dc-4974f63e059c"
      unitRef="U_USD">1196000</tngx:IncreaseDecreaseInAccruedExpensesAndOtherLiabilities>
    <tngx:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_e6bfb091-64db-4a27-aee4-4d4c27f9760a"
      unitRef="U_USD">-1066000</tngx:IncreaseDecreaseInOperatingLeaseLiabilities>
    <tngx:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_d4e09062-081f-4b19-bc7f-665e6590a03f"
      unitRef="U_USD">-655000</tngx:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_5a3726b3-4fe3-4ae5-9d60-ca34dc1f77eb"
      unitRef="U_USD">-12042000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_32e9f5e9-9ff1-484c-ad33-0bdab2d82c37"
      unitRef="U_USD">119081000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_a674aae7-e26a-433c-bccb-fc52bcf0f254"
      unitRef="U_USD">-59527000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_dea93068-35f1-4707-bd48-6c80d24e930a"
      unitRef="U_USD">70074000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_b903ad3b-233d-4b60-9348-e13ad2d6d8eb"
      unitRef="U_USD">1837000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_c2723199-1b00-465a-8926-25f4fa76a30f"
      unitRef="U_USD">1106000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_1630f679-0899-433b-a518-9434d31e7fb1"
      unitRef="U_USD">190764000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_64407ffa-5742-4f28-8dc8-8e2b8ab61c26"
      unitRef="U_USD">63220000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_b06ba735-bbe9-49a4-a8f1-73edc008cdee"
      unitRef="U_USD">372361000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_d9773f11-ef77-4c19-a222-c7e9ba76f165"
      unitRef="U_USD">207540000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_52284c34-6116-4830-89f7-f3e3021302d7"
      unitRef="U_USD">40000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_d596570b-08f1-4136-a989-0f03ff7d3026"
      unitRef="U_USD">-183434000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_110f7d73-4e99-412b-b58a-042b3a72562c"
      unitRef="U_USD">-145466000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_c6ed33d5-66b4-4da0-8ee7-cf9a5db2f15f"
      unitRef="U_USD">29990000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_76b19e1b-41ea-47f9-a595-03a94cb285dc"
      unitRef="U_USD">80844000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_b602bef7-e4e9-4d19-9717-a78bc7d617f1"
      unitRef="U_USD">1058000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_7f073485-9f2b-413e-b902-a6faea4a074d"
      unitRef="U_USD">40000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <tngx:ProceedsFromBusinessCombinationAndPipeFinancingGross
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_0de99c2f-fc19-467f-8f21-505a596684b1"
      unitRef="U_USD">342113000</tngx:ProceedsFromBusinessCombinationAndPipeFinancingGross>
    <tngx:PaymentOfBusinessCombinationAndPipeFinancingTransactionCosts
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_8f1f4434-5d4a-4d03-8e34-0617baa51973"
      unitRef="U_USD">15836000</tngx:PaymentOfBusinessCombinationAndPipeFinancingTransactionCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_a0dc0327-86d0-4ef4-8fdc-621dfd0caec6"
      unitRef="U_USD">357325000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_c68101e8-e9be-47f1-b4c3-009b3cbfbc36"
      unitRef="U_USD">80884000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_f1d3b3b1-d8be-4ce8-b68c-33e2cbe7da3f"
      unitRef="U_USD">114364000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_0486f9a9-a7ac-452e-8a8b-be860fa13dd1"
      unitRef="U_USD">5492000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_fa9e4f81-1cc0-405f-9688-699506e155d0"
      unitRef="U_USD">30660000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_4a669c96-a649-4a8a-b346-1cb396dbfc42"
      decimals="-3"
      id="F_49b99ecf-bd85-4c82-9f13-cc5d926ab8de"
      unitRef="U_USD">25168000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_9d2d5f01-dc3c-4afd-946c-197846c2b2bb"
      unitRef="U_USD">145024000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_d5cb6717-19a2-48f7-9a92-9a318f883ca6"
      unitRef="U_USD">30660000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <tngx:CashPaidForLeases
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_f2f3715a-6d31-4017-922b-b9ca426f3682"
      unitRef="U_USD">-1835000</tngx:CashPaidForLeases>
    <tngx:CashPaidForLeases
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_cb463ef7-846c-4dd6-832a-1b4d71b3f297"
      unitRef="U_USD">-1782000</tngx:CashPaidForLeases>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_11308887-b89a-4b79-89b4-2ecd58b06064"
      unitRef="U_USD">166534000</us-gaap:ConversionOfStockAmountConverted1>
    <tngx:RevaluationOfRightOfUseAssetAndLeaseLiabilityUponLeaseModification
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_e9b32e14-362c-4b05-9d79-794c067f4959"
      unitRef="U_USD">5315000</tngx:RevaluationOfRightOfUseAssetAndLeaseLiabilityUponLeaseModification>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_3f86c92c-d942-4a85-81d4-7a188451bca8"
      unitRef="U_USD">154000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_0f9945af-c03f-4992-a19d-b89c233679ef"
      unitRef="U_USD">29000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_c85936f9-644b-4e16-be9c-975b8d143431">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;1. Nature of the Business and Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Tango Therapeutics, Inc. (&#x201c;Tango&#x201d; or the &#x201c;Company&#x201d;) is a precision oncology company committed to the discovery and development of novel drugs in defined patient populations with high unmet medical need.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Tango Therapeutics, Inc. (together with its consolidated subsidiaries, &#x201c;Tango&#x201d; or the &#x201c;Company&#x201d;) formerly known as BCTG Acquisition Corp. (&#x201c;BCTG&#x201d;), was incorporated in Delaware on May 21, 2020. BCTG was a Special Purpose Acquisition Company (&#x201c;SPAC&#x201d;) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Merger with BCTG Acquisition Corporation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On April 13, 2021, the Company, BCTG Merger Sub Inc., a Delaware corporation, and Tango Therapeutics, Inc. (now known as Tango Therapeutics Sub, Inc. or &#x201c;Old Tango&#x201d;) signed a definitive merger agreement (the "Merger Agreement") memorializing the terms of BCTG&#x2019;s acquisition of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of Old Tango's issued and outstanding equity securities in exchange for $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;550.0&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million worth of consideration in the form of BCTG common stock (the &#x201c;Business Combination&#x201d;). The Business Combination was approved on August 9, 2021 by shareholders of BCTG, resulting in BCTG acquiring 100% of Old Tango's issued and outstanding equity securities on August 10, 2021. The Business Combination was accounted for as a &#x201c;reverse recapitalization&#x201d; in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). As a result of the Business Combination, BCTG was renamed Tango Therapeutics, Inc. The Company's common stock is &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;trading on The Nasdaq Global Market under the ticker symbol TNGX&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Tango received gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;167.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million upon the closing of the Business Combination. Tango continues to operate under the Old Tango management team. Simultaneous with the closing of the Business Combination, an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,610,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock (the &#x201c;PIPE Financing&#x201d;) were issued, resulting in gross proceeds of an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;186.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million upon the closing of the PIPE Financing. Total transaction costs and redemptions&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; approximated $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26.9&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, resulting in total net proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;326.3&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;BCTG Acquisition Corporation IPO&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The registration statement for BCTG&#x2019;s initial public offering (&#x201c;IPO&#x201d;) was declared effective on September 2, 2020. On September 8, 2020, the Company consummated its Initial Public Offering of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,675,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock (the &#x201c;Public Shares&#x201d;), including the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,175,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; Public Shares as a result of the underwriters&#x2019; full exercise of their over-allotment option, at an offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per Public Share, generating gross proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;166.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, and incurring offering costs of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, inclusive of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in deferred underwriting commissions. Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (&#x201c;Private Placement&#x201d;) of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;533,500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock (the &#x201c;Private Placement shares&#x201d;), at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per Private Placement Share to the Sponsor, generating gross proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. Upon the closing of the Initial Public Offering and the Private Placement, the net proceeds of the Initial Public Offering and certain of the proceeds of the Private Placement was placed in a trust account (&#x201c;Trust Account&#x201d;) in the United States maintained by Continental Stock Transfer &amp;amp; Trust Company, as trustee, and remained invested only in U.S. government treasury bills, notes and bonds with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act and which invest solely in U.S. Treasuries, until the completion of the Business Combination as described below&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The accompanying consolidated financial statements have been prepared in conformity with U.S. GAAP. The accompanying consolidated financial statements reflect the operations of Tango and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated. The functional and reporting currency of the Company and its subsidiaries is the U.S. dollar.&lt;/span&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="C_568bffaa-6246-4bbc-8efb-5c5ca93b43f9"
      decimals="2"
      id="F_b940f57b-147f-4539-92ca-6519fefa8fd7"
      unitRef="U_pure">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="C_c5112e96-b096-400a-8231-13c5db592e8e"
      decimals="-5"
      id="F_095887f4-061e-4b16-ace6-f92dc800f672"
      unitRef="U_USD">550000000.0</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_8312ce29-e29e-402c-b364-5d664fa10451"
      decimals="-5"
      id="F_bde133bf-4517-420c-8d83-7157db7821f4"
      unitRef="U_USD">167100000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_ea92a304-c585-4deb-947b-651b75dbc182"
      decimals="INF"
      id="F_371cec27-30b8-4af4-a4bd-daf72f93f3e9"
      unitRef="U_shares">18610000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_ea92a304-c585-4deb-947b-651b75dbc182"
      decimals="-5"
      id="F_3f6282f6-a5f1-4590-b758-451ef97d9a58"
      unitRef="U_USD">186100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="C_d451c16b-ca67-4909-afea-ed3cd220991d"
      decimals="-5"
      id="F_a745bd1a-daea-4b66-9bc6-4c26f8c63d2b"
      unitRef="U_USD">26900000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_c0c8b2a4-7004-44a5-89e9-321b90380e0e"
      decimals="-5"
      id="F_4721bd98-9140-4625-b007-c4e025a94557"
      unitRef="U_USD">326300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="C_33f11eaf-355a-47f4-a2b2-89b65a3ddda0"
      decimals="INF"
      id="F_3683f488-a1d6-4bcf-ad4e-84289cc0f50e"
      unitRef="U_shares">16675000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_e188203d-bb78-4e16-8893-867ab9986a87"
      decimals="INF"
      id="F_b5649cb3-b05b-42d7-a609-9dc4e52ed888"
      unitRef="U_shares">2175000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_48837b32-a7ba-4536-82fb-eeef4e91837e"
      decimals="2"
      id="F_cefa750f-4d95-4cef-be96-5b65e5762ba5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_42915faf-8358-4b14-8b2d-d0e8b545540d"
      decimals="-5"
      id="F_9dd4f655-720f-4f58-982e-a3c63f4a0c15"
      unitRef="U_USD">166800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <tngx:OfferingCost
      contextRef="C_0c877e59-744f-49bd-b36b-26c23781fc80"
      decimals="-5"
      id="F_93d39f8a-bef4-4ca0-880e-b522d8cfc11c"
      unitRef="U_USD">9600000</tngx:OfferingCost>
    <us-gaap:AmortizationOfDeferredSalesCommissions
      contextRef="C_c46a5787-04cc-4ee6-8232-98fef420c001"
      decimals="-5"
      id="F_e5fc9803-8890-4621-bb41-9beb6ff0afce"
      unitRef="U_USD">5800000</us-gaap:AmortizationOfDeferredSalesCommissions>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_fc96726e-aa67-4543-82fb-ba75a0a854df"
      decimals="INF"
      id="F_06127e6f-75ce-4c37-8cbf-f8a31e9a4420"
      unitRef="U_shares">533500</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_2a1ab7b1-38dd-41eb-9f72-c6425108c827"
      decimals="2"
      id="F_d74b479a-5b28-48d2-8888-777947e514fb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_fc96726e-aa67-4543-82fb-ba75a0a854df"
      decimals="-5"
      id="F_33d7235e-707e-4e2f-a01a-515e85ec92ff"
      unitRef="U_USD">5300000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_cd183504-c409-427d-bab5-9f490c93540f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The preparation of consolidated financial statements requires that the Company make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. Significant estimates and assumptions made in the consolidated financial statements include, but are not limited to, the revenue recognized from collaboration agreements, the valuation of stock-based awards and the accrual for research and development expenses. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Segment Information&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating segments are defined as components of an enterprise for which separate financial information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company operates in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; operating segment, the business of discovering and developing precision oncology therapies.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Cash Equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;All highly liquid marketable securities purchased with an original maturity date of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;90 days&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; or less at the date of purchase are considered to be cash equivalents. Cash equivalents consisted of money market funds and U.S. Treasury bills as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Investments in Marketable Securities&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Marketable debt securities consist of investments with original maturities greater than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;90 days&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The Company classifies its investments with maturities beyond one year as short-term, based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. The Company considers its investment portfolio of marketable securities to be available-for-sale. Accordingly, these investments are recorded at fair value, which is based on quoted market prices. Unrealized gains are reported as a component of accumulated other comprehensive income in stockholders&#x2019; equity (deficit). Amortization and accretion of premiums and discounts are recorded in interest income. Realized gains and losses are included as a component of other income, net in the consolidated statements of operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company evaluates its investments with unrealized losses for impairment. When assessing investments for unrealized declines in value, the Company considers whether the decline in value is related to a credit loss or non-credit loss. For credit losses, the Company reduces the investment to fair value through an allowance for credit losses recorded to the balance sheet and corresponding charge to the statement of operations. The allowance for credit losses and corresponding impairment charge is adjusted each period for changes in fair value. For non-credit losses, the Company reduces the investment to fair value through a charge to the statement of comprehensive loss, reported as a component of accumulated other comprehensive income (loss) in stockholders&#x2019; equity. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; such credit losses were recorded during the periods presented.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The accounting standard for fair value measurements defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and requires certain disclosures about fair value measurements. Under this standard, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 1 &#x2014; Fair values are determined utilizing prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 2 &#x2014; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves, and foreign currency spot rates. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 3 &#x2014; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The fair value of the Company&#x2019;s cash equivalents and marketable securities are determined according to the fair value hierarchy described below (see Note 5)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The carrying values of the Company&#x2019;s accounts receivable, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Concentration of Credit Risk and Significant Suppliers&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash, cash equivalents and marketable debt securities. The Company&#x2019;s cash, cash equivalent and marketable securities balances are held by major financial institutions that management believes to be creditworthy. The Company uses multiple financial institutions to limit the amount of credit exposure to any one financial institution. Substantially all the Company&#x2019;s cash, cash equivalent and marketable debt securities were invested in money market funds, U.S. Treasury bills, and U.S. government agency bonds at December 31, 2021 and 2020. At times, the Company&#x2019;s cash deposits may exceed the amount of federal insurance provided on such deposits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company relies, and expects to continue to rely, on a small number of vendors to perform research activities and clinical trial activities that continue to progress its product candidates for its development programs. These programs could be adversely affected by a significant interruption in the related processes of these vendors.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash accounts with any type of restriction are considered restricted cash and are classified on the balance sheet based on the length of the restrictive obligation. As of both December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company recorded restricted cash of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, all of which was related to security deposits associated with the Company&#x2019;s facility leases in Boston, Massachusetts and Cambridge, Massachusetts. The security deposit associated with the Company's facility lease in Boston, Massachusetts is recorded as non-current in its balance sheet as of December 31, 2021 and December 31, 2020 because the deposit is required for the duration of the lease which is greater than a year. The security deposit associated with the Company's facility lease in Cambridge, Massachusetts is recorded as current in its balance sheet as of December 31, 2021 because the deposit is required for the duration of the amended lease which is less than a year from the balance sheet date. The security deposit associated with the Company's facility lease in Cambridge, Massachusetts was recorded as non-current in its balance sheet as of December 31, 2020 because the deposit was required for the duration of the original lease which, prior to the 2021 lease amendment, was for greater than a year from the December 31, 2020 balance sheet date.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The reconciliation of cash and cash equivalents and restricted cash to amounts presented in the consolidated statements of cash flows are as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.312%;"/&gt;
          &lt;td style="width:1.6%;"/&gt;
          &lt;td style="width:1.282%;"/&gt;
          &lt;td style="width:13.33%;"/&gt;
          &lt;td style="width:0.636%;"/&gt;
          &lt;td style="width:1.6%;"/&gt;
          &lt;td style="width:1.282%;"/&gt;
          &lt;td style="width:13.32%;"/&gt;
          &lt;td style="width:0.636%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;142,745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;28,381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted cash, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;145,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful lives of each asset. Estimated useful lives are periodically assessed to determine if changes are appropriate. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The estimated useful lives of the Company&#x2019;s property and equipment are as follows: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:43.72%;"/&gt;
          &lt;td style="width:1.835%;"/&gt;
          &lt;td style="width:54.444%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Estimated useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shorter of remaining lease term or 10 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company reviews long-lived assets, such as property and equipment, for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. If indicators of impairment are present, the assets are tested for recoverability by comparing the carrying amount of the assets to the related estimated future undiscounted cash flows that the assets are expected to generate. If the expected cash flows are less than the carrying value of the asset group, then the asset group is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows. To date, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; such impairment losses have been recorded.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Costs for assets not yet placed into service are capitalized as construction-in-progress and depreciated or amortized in accordance with the above useful lives once placed into service. Upon retirement or sale, the related cost and accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in the consolidated statements of operations. Repairs and maintenance costs are expensed as incurred.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Operating Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances and the existence of an identified asset(s), if any, and its control over the use of the identified asset(s), if applicable. Upon lease commencement, operating lease liabilities and their corresponding right-of-use assets are recorded on the balance sheet based at the present value of lease payments over the expected lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense is recognized over the expected term on a straight-line basis.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lease payments are discounted at the lease commencement date using the interest rate implicit in the lease contract. As this rate is typically not readily determinable, the Company determines an incremental borrowing rate that is used to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Certain prospective adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company elected to account for lease and non-lease components as a single lease component, however non-lease components that are variable, such as common area maintenance and utilities, are generally paid separately from rent based on actual costs incurred and therefore are not included in the right-of-use asset and operating lease liability and are reflected as an expense in the period incurred. The Company&#x2019;s lease terms often include renewal options. The amounts determined for the Company&#x2019;s right-of-use assets and lease liabilities generally do not assume that any renewal options or any early-termination provisions, if any, are exercised, unless it is reasonably certain that the Company will exercise such options.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;At contract inception, the Company assesses whether the collaboration arrangements are within the scope of ASC Topic 808, Collaborative Arrangements, or ASC 808, to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed based on the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the arrangement are within the scope of ASC 808 and which elements are within the scope of ASC 606 (as described below). For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, either by analogy to&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;authoritative accounting literature or by applying a reasonable and rational policy election. To date, the Company has not entered into any arrangements within the scope of ASC 808.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s revenues are generated through its license and collaboration agreements with Gilead. Refer to Note 4, &#x201c;Collaboration Agreements.&#x201d; elsewhere in these notes to the Company's consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers. ASC 606 provides a five-step framework whereby revenue is recognized when control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the  contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) performance obligations are satisfied. The Company only applies this framework to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation. Goods and services that are determined not to be distinct are combined with other promised goods and services until a distinct bundle is identified. The Company then allocates the transaction price (that is, the amount of consideration the Company expects to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The Company&#x2019;s estimate of the transaction price for each contract includes all variable consideration to which the Company expects to be entitled, subject to the constraint on variable consideration. Variable consideration is not constrained if the potential reversal of cumulative revenue recognized at the contract level is not significant.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under active agreements, the Company must use its judgment to determine: (a) the number of performance obligations based on the determination under step (ii) above; (b) the transaction price under step (iii) above; (c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above; and (d) the contract term and pattern of satisfaction of the performance obligations under step (v) above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to the identified performance obligations on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. In certain instances, the timing of satisfying these obligations can be difficult to estimate. Accordingly, the Company&#x2019;s estimates may change in the future and those changes could be material. Such changes to estimates would result in a change in amounts of revenue recognized. If these estimates and judgments change over the course of these agreements, it may affect the timing and amount of revenue that the Company recognizes and records in future periods.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the collaboration agreements are recorded as accounts receivable in the Company&#x2019;s consolidated balance sheet. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&#x2019;s consolidated balance sheets. Amounts expected to be recognized as revenue within the one year following the balance sheet date are classified as current deferred revenue. Amounts not expected to be recognized as revenue within the one year following the balance sheet date are classified as deferred revenue, net of current portion. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as contract assets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Exclusive License Rights&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &#x2014; If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, which generally include research and development services, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a license is distinct from the other promises, the Company considers relevant facts and circumstances of each arrangement, including the research and development capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from the license for its intended purpose without the receipt of the remaining promises, whether the value of the license is dependent on the unsatisfied promises, whether there are other vendors that could provide the remaining promises and whether it is separately identifiable from the remaining promises. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation and whether the license is the predominant promise within the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. If the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;license is the predominant promise, and it is determined that the license represents functional intellectual property (&#x201c;IP&#x201d;), revenue is recognized at the point in time when control of the license is transferred. If it is determined that the license does not represent functional IP, revenue is recognized over time using an appropriate method of measuring progress.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Research and Development Services&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &#x2014; The obligations under the Company&#x2019;s collaboration agreements may include research and development services to be performed by the Company to benefit the collaboration partner. For performance obligations that include research and development services, the Company generally recognizes revenue allocated to such performance obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for purposes of recognizing revenue, which is generally an input measure such as costs incurred. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods of which revenue should be recognized, are subject to estimates by management and may change over the course of the contract. Reimbursements from the partner that are the result of a collaborative relationship with the partner, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense. No collaborative arrangements existed that would result in such reimbursements for the periods presented.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Customer Options&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &#x2014; The Company&#x2019;s arrangements may provide a collaborator with the right to acquire additional goods or services in the future. Under these agreements, fees may be due to the Company (i) upon the exercise of the customer option or (ii) in equal installment payments over an agreed upon period. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the additional goods and services underlying the customer options are evaluated in order to determine if these additional goods or services are distinct from those included as a performance obligation at the outset of the arrangement. If the additional services are not determined to be distinct, the variable consideration pertaining to the customer option is added to the initial transaction price at the time in which the option exercise becomes probable, so long as a potential for reversal of cumulative revenue recognized at the contract level is not significant. Any such adjustments to the transaction price are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If the additional services are distinct, the Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company allocates the transaction price to material rights based on the relative stand-alone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Milestone Payments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &#x2014; At the inception of an arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant reversal of cumulative revenue recognized would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#x2019;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Royalties&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &#x2014; For arrangements that include sales-based royalties, including milestone payments based on a level of sales, where the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from licensing agreements.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development expenses include costs directly attributable to the conduct of research programs, including the cost of salaries, employee benefits, stock-based compensation expense, materials, supplies, depreciation on and maintenance of research equipment, the cost of services provided by outside contractors to conduct research and development&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;activities and the allocable portions of facility costs, such as rent, utilities, and general support services. All costs incurred to fulfill the Company&#x2019;s obligations under the collaboration with Gilead are classified as research and development expenses. All costs associated with research and development are expensed as incurred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Management estimates the Company&#x2019;s accrued research and development expenses as of each balance sheet date in the Company&#x2019;s financial statements based on facts and circumstances known to the Company at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Nonrefundable advance payments for goods and services are deferred and recognized as expense in the period that the related goods are consumed or services are performed.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Patent Costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company measures the cost of employee services received in exchange for stock-based awards based on the grant-date fair value of the awards. The Company calculates the fair value of restricted stock awards based on the grant date fair value of the underlying common stock. The Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period of the awards for service-based awards, which is generally the vesting period. The Company recognizes stock-based compensation for performance-based awards when the underlying performance conditions are considered probable of occurrence and recognizes the cumulative effect of current and prior period changes in the period of change.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prior to the &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;consummation of the Business Combination transaction, as there was not a public market for the common stock of the Company prior to becoming publicly traded, the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;fair value of common stock underlying stock-based awards was based on a valuation provided by the board of directors as derived from a recommendation by an unrelated third-party valuation firm. The Company determined the estimated per share fair value of its common stock at various dates considering contemporaneous and retrospective valuations that incorporated objective and subjective factors, including actual and forecasted financial results, market conditions and performance of comparable publicly traded companies, developments and milestones of the Company, the rights and preferences of common and redeemable convertible preferred stock, advice from the third-party valuation specialists, and transactions involving the Company&#x2019;s stock. The estimated per share fair value of the Company&#x2019;s common stock was determined in accordance with the guidance outlined in the American Institute of Certified Public Accountants Practice Aid, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Valuation of Privately-Held Company Equity Securities Issued as Compensation&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The fair value of each restricted common stock award was estimated on the date of grant based on the fair value of the Company&#x2019;s common stock on that same date.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Subsequent to becoming a publicly traded Company upon the consummation of the Business Combination transaction, the fair value of common stock underlying stock-based awards is based on an estimate at each grant date using the market price of our common stock and each of the assumptions discussed below.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Expected Term&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;:    The expected term of the stock options is estimated using the &#x201c;simplified method,&#x201d; as prescribed in SEC&#x2019;s Staff Accounting Bulletin (SAB) No. 107, as the Company has limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting period and the contractual term of the option.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Expected Volatility&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;:    Since there is limited historical data for the Company&#x2019;s common stock and limited company-specific historical volatility, the Company has determined the share price volatility for options granted based on an analysis of the volatility used by a peer group of publicly traded companies. In evaluating similarity, the Company considers factors such as industry, stage of life cycle and size.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Risk-free Interest Rate&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;:    The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected life of the option.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Dividend Rate&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;:    The expected dividend is assumed to be &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; as the Company has never paid dividends and has no current plans to do so.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The assumptions used in estimating the fair value of stock-based awards represent management&#x2019;s estimate and involve inherent uncertainties and the application of management&#x2019;s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-based compensation is classified in the accompanying consolidated statements of operations and comprehensive loss based on the function to which the related services are provided. Forfeitures are accounted for as they occur. Any consideration paid by employees on exercising stock options and the corresponding portion previously credited to additional paid-in capital are credited to share capital.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Deferred Financing Costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded in shareholders&#x2019; equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period corresponding to the enactment date. A valuation allowance is established when it is more likely than not that all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a more likely than not likelihood of being realized upon ultimate settlement with the tax authority. The recognition and measurement of tax benefits requires significant judgments that are subject to change as new information becomes available.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Penalties and interest expense related to income taxes are included as components of income tax expense and interest expense, respectively, as necessary.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Comprehensive Gain (Loss)&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity (deficit) that result from transactions and economic events other than those with stockholders. The Company&#x2019;s only element of other comprehensive loss for the years ended December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; was unrealized gains (losses) on investments in marketable securities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic net loss per share attributable to common stockholders is computed by dividing net loss by the weighted-average number of shares of common shares outstanding during each reporting period. The weighted-average number of shares of common stock outstanding used in the basic net loss per share calculation does not include unvested restricted stock awards as these instruments are considered contingently issuable shares until they vest. Diluted net loss per share attributable to common stockholders includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. The Company&#x2019;s unvested restricted stock entitles the holder to participate in dividends and earnings of the Company, and, if the Company were to recognize net income, it would apply the two-class method to calculate earnings per share. The two-class method is not applicable during periods with a net loss, as the holders of the unvested restricted stock have no obligation to fund losses.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The two-class method of computing net loss per share would be applicable in a reporting period that resulted in a net income position, as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Commitments and Contingencies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Subsequent Events&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act (&#x201c;JOBS Act&#x201d;), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards and as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of an initial public offering or such earlier time that it is no longer an emerging growth company. However, the Company has not yet delayed the adoption of any new accounting standards.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In June 2016, the FASB issued ASU 2016-13&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;, Financial Instruments &#x2014; Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren&#x2019;t measured at fair value through net income. For available-for-sale debt securities, entities are required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities are no longer permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. For public entities, the guidance was effective for annual reporting periods beginning after December 15, 2019 and for interim periods within those fiscal years. Early adoption was permitted. The Company &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;early &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;adopted &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;this standard as of&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; January 1, 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; on a prospective basis. The adoption did&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; no&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In August 2018, the FASB issued ASU 2018-13, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The amendments become effective for the Company&#x2019;s fiscal year beginning January 1, 2020. Early adoption of the amendments in full or only the provisions that eliminate or modify the disclosure requirements for fair value measurements is permitted. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Adoption &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;of this standard on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;January 1, 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In August 2018, the FASB issued ASU 2018-15, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The new standard requires a customer in a cloud computing arrangement to determine which implementation costs to capitalize as assets or expense as incurred. Capitalized implementation costs related to a hosting arrangement that is a service contract will be amortized over the term of the hosting arrangement, beginning when the module or component of the hosting arrangement is ready for its intended use. The new standard became effective for the Company&#x2019;s fiscal year beginning January 1, 2020. Early adoption was permitted. The &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;early &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;adoption &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;of this standard on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;January 1, 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Simplifying the Accounting for Income Taxes,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (&#x201c;ASC 740&#x201d;). The ASU enhances and simplifies various aspects of the income tax accounting guidance in ASC 740, including requirements related to hybrid tax regimes, the tax basis step-up in goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intra-period tax allocation exception to the incremental approach, ownership changes in investments, changes from a subsidiary to an equity method investment, interim-period accounting for enacted changes in tax law, and the year-to-date loss limitation in interim-period tax accounting. This guidance became effective for the Company's fiscal year beginning &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;January 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;adoption &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;of this guidance did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Debt &#x2014; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 &#x2014; 40)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The amendments in this update affect entities that issue convertible instruments and/or contracts indexed to and potentially settled in an entity&#x2019;s own equity. The new ASU eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, the new guidance modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company elected to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;early &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;adopt &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;this guidance on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;January 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Adoption of the ASU 2020-06 guidance as of January 1, 2021 had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;impact on its consolidated financial statements for the year ended December 31, 2020. The Company issued the second tranche of its redeemable convertible Series B preferred stock in March 2021 at an original issue price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.32&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share, which would have resulted in the recognition of a beneficial conversion feature of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;28.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million prior to the adoption of ASU 2020-06. However, the consummation of the Business Combination and the application of a retroactive adjustment to historical redeemable convertible preferred stock in all periods presented under the reverse recapitalization accounting treatment have resulted in the adoption of this guidance not resulting in a material impact on the Company&#x2019;s financial statements for the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that recently issued standards that are not yet effective will not have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_db596b93-1010-4504-8b92-f45ed83d1a51">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The preparation of consolidated financial statements requires that the Company make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. Significant estimates and assumptions made in the consolidated financial statements include, but are not limited to, the revenue recognized from collaboration agreements, the valuation of stock-based awards and the accrual for research and development expenses. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. As of the date of issuance of these consolidated financial statements, the Company is not aware of any specific event or circumstance that would require the Company to update estimates, judgments or revise the carrying value of any assets or liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_7609ea95-c6f0-4cea-a50d-dcd27c8d23e4">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Segment Information&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating segments are defined as components of an enterprise for which separate financial information is available for evaluation by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company operates in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; operating segment, the business of discovering and developing precision oncology therapies.&lt;/span&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="INF"
      id="F_ebb4d28b-386a-450f-87c4-9cfb97cb8b09"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_f8af7adc-ab61-41bb-ab4e-4db20cd956c3">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Cash Equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;All highly liquid marketable securities purchased with an original maturity date of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;90 days&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; or less at the date of purchase are considered to be cash equivalents. Cash equivalents consisted of money market funds and U.S. Treasury bills as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <tngx:CashAndCashEquivalentMaturityPeriod
      contextRef="C_758f7c30-6f5d-40eb-bfbc-5d756f87d621"
      id="F_f3b8ae00-27e8-4b18-a670-5cd9743dd1e9">P90D</tngx:CashAndCashEquivalentMaturityPeriod>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_659fdc7a-ba78-4b77-9f73-187aeda98f29">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Investments in Marketable Securities&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Marketable debt securities consist of investments with original maturities greater than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;90 days&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The Company classifies its investments with maturities beyond one year as short-term, based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. The Company considers its investment portfolio of marketable securities to be available-for-sale. Accordingly, these investments are recorded at fair value, which is based on quoted market prices. Unrealized gains are reported as a component of accumulated other comprehensive income in stockholders&#x2019; equity (deficit). Amortization and accretion of premiums and discounts are recorded in interest income. Realized gains and losses are included as a component of other income, net in the consolidated statements of operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company evaluates its investments with unrealized losses for impairment. When assessing investments for unrealized declines in value, the Company considers whether the decline in value is related to a credit loss or non-credit loss. For credit losses, the Company reduces the investment to fair value through an allowance for credit losses recorded to the balance sheet and corresponding charge to the statement of operations. The allowance for credit losses and corresponding impairment charge is adjusted each period for changes in fair value. For non-credit losses, the Company reduces the investment to fair value through a charge to the statement of comprehensive loss, reported as a component of accumulated other comprehensive income (loss) in stockholders&#x2019; equity. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; such credit losses were recorded during the periods presented.&lt;/span&gt;</us-gaap:InvestmentPolicyTextBlock>
    <tngx:MarketableDebtSecuritiesMaturitiesDuration
      contextRef="C_5a10696c-6f1a-45a5-9a37-ea3703aed7cc"
      id="F_6975358a-c672-4591-b93a-f9457fdda32c">P90D</tngx:MarketableDebtSecuritiesMaturitiesDuration>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="INF"
      id="F_7d142be8-86c6-4349-befe-845d5f205c92"
      unitRef="U_USD">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_66d8cccd-ee54-4e4a-8dab-e295c14bee5a">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The accounting standard for fair value measurements defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and requires certain disclosures about fair value measurements. Under this standard, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 1 &#x2014; Fair values are determined utilizing prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 2 &#x2014; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves, and foreign currency spot rates. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 3 &#x2014; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The fair value of the Company&#x2019;s cash equivalents and marketable securities are determined according to the fair value hierarchy described below (see Note 5)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The carrying values of the Company&#x2019;s accounts receivable, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.&lt;/span&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_c8856d64-e8dc-4c3a-85cf-d8ffcc9bbd79">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Concentration of Credit Risk and Significant Suppliers&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash, cash equivalents and marketable debt securities. The Company&#x2019;s cash, cash equivalent and marketable securities balances are held by major financial institutions that management believes to be creditworthy. The Company uses multiple financial institutions to limit the amount of credit exposure to any one financial institution. Substantially all the Company&#x2019;s cash, cash equivalent and marketable debt securities were invested in money market funds, U.S. Treasury bills, and U.S. government agency bonds at December 31, 2021 and 2020. At times, the Company&#x2019;s cash deposits may exceed the amount of federal insurance provided on such deposits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant credit risk beyond the normal credit risk associated with commercial banking relationships.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company relies, and expects to continue to rely, on a small number of vendors to perform research activities and clinical trial activities that continue to progress its product candidates for its development programs. These programs could be adversely affected by a significant interruption in the related processes of these vendors.&lt;/span&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_af80fe8a-cf76-4051-97a2-d465ec3827a6">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash accounts with any type of restriction are considered restricted cash and are classified on the balance sheet based on the length of the restrictive obligation. As of both December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company recorded restricted cash of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, all of which was related to security deposits associated with the Company&#x2019;s facility leases in Boston, Massachusetts and Cambridge, Massachusetts. The security deposit associated with the Company's facility lease in Boston, Massachusetts is recorded as non-current in its balance sheet as of December 31, 2021 and December 31, 2020 because the deposit is required for the duration of the lease which is greater than a year. The security deposit associated with the Company's facility lease in Cambridge, Massachusetts is recorded as current in its balance sheet as of December 31, 2021 because the deposit is required for the duration of the amended lease which is less than a year from the balance sheet date. The security deposit associated with the Company's facility lease in Cambridge, Massachusetts was recorded as non-current in its balance sheet as of December 31, 2020 because the deposit was required for the duration of the original lease which, prior to the 2021 lease amendment, was for greater than a year from the December 31, 2020 balance sheet date.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The reconciliation of cash and cash equivalents and restricted cash to amounts presented in the consolidated statements of cash flows are as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.312%;"/&gt;
          &lt;td style="width:1.6%;"/&gt;
          &lt;td style="width:1.282%;"/&gt;
          &lt;td style="width:13.33%;"/&gt;
          &lt;td style="width:0.636%;"/&gt;
          &lt;td style="width:1.6%;"/&gt;
          &lt;td style="width:1.282%;"/&gt;
          &lt;td style="width:13.32%;"/&gt;
          &lt;td style="width:0.636%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;142,745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;28,381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted cash, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;145,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCash
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-5"
      id="F_4368990a-2677-47d0-bfe2-5fdf0c78b439"
      unitRef="U_USD">2300000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-5"
      id="F_23b60ae0-bc48-4e5d-86f9-a97786091c0d"
      unitRef="U_USD">2300000</us-gaap:RestrictedCash>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_6da94655-e134-469b-b9a3-da08efc57453">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The reconciliation of cash and cash equivalents and restricted cash to amounts presented in the consolidated statements of cash flows are as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.312%;"/&gt;
          &lt;td style="width:1.6%;"/&gt;
          &lt;td style="width:1.282%;"/&gt;
          &lt;td style="width:13.33%;"/&gt;
          &lt;td style="width:0.636%;"/&gt;
          &lt;td style="width:1.6%;"/&gt;
          &lt;td style="width:1.282%;"/&gt;
          &lt;td style="width:13.32%;"/&gt;
          &lt;td style="width:0.636%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;142,745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;28,381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted cash, net of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;145,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_b28766b9-3d89-4967-8a62-9f9cbca36bce"
      unitRef="U_USD">142745000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_985d0d72-45eb-4770-b95b-2fb815b97de7"
      unitRef="U_USD">28381000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_c09a1042-5693-4383-ae58-bcf7ca837abe"
      unitRef="U_USD">567000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_d7cc3dfe-6b26-49c5-8f10-83ce6d923f46"
      unitRef="U_USD">1712000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_a6cf3ca0-f5ba-4557-804a-6d5336776f72"
      unitRef="U_USD">2279000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_b9ded5a5-6e29-4ac5-bc2c-f3fef6a3d87b"
      unitRef="U_USD">145024000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_a3adc122-7d95-4824-b6e7-1865d95d6ba0"
      unitRef="U_USD">30660000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_95b0f37b-e76b-480b-9588-99ea51ca6fc2">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful lives of each asset. Estimated useful lives are periodically assessed to determine if changes are appropriate. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The estimated useful lives of the Company&#x2019;s property and equipment are as follows: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:43.72%;"/&gt;
          &lt;td style="width:1.835%;"/&gt;
          &lt;td style="width:54.444%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Estimated useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shorter of remaining lease term or 10 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company reviews long-lived assets, such as property and equipment, for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. If indicators of impairment are present, the assets are tested for recoverability by comparing the carrying amount of the assets to the related estimated future undiscounted cash flows that the assets are expected to generate. If the expected cash flows are less than the carrying value of the asset group, then the asset group is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash flows. To date, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; such impairment losses have been recorded.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Costs for assets not yet placed into service are capitalized as construction-in-progress and depreciated or amortized in accordance with the above useful lives once placed into service. Upon retirement or sale, the related cost and accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in the consolidated statements of operations. Repairs and maintenance costs are expensed as incurred.&lt;/span&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <tngx:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_fbb20133-b717-45e6-bafc-f8597944c387">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The estimated useful lives of the Company&#x2019;s property and equipment are as follows: &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:43.72%;"/&gt;
          &lt;td style="width:1.835%;"/&gt;
          &lt;td style="width:54.444%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:8.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Estimated useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shorter of remaining lease term or 10 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</tngx:ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_c887ec60-971a-4690-a982-03a761ebe233"
      id="F_3c8f1896-8689-433f-859f-f76ba4e7e7b8">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_22555df1-4efe-4a08-bb1c-08f931ec7211"
      id="F_9c55108f-bba5-4c8c-a46f-f57c62e5804e">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_23d38092-0393-490f-b401-5d223a840f61"
      id="F_d5719339-0f75-42fc-bee4-45a52c9fe39c">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_ddf3c437-2a6f-4dfd-a511-55b637ea608a"
      id="F_09e47c29-61d8-476d-97c8-37735bea6058">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="C_fcb0c4a1-8080-44f5-9e53-5ea3f5e568e5"
      id="F_e48e2d8f-55a5-4843-aa17-8fc2637de639">Shorter of remaining lease term or 10 years</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="INF"
      id="F_3d67304f-e72c-4cfb-9943-5b63f342fba2"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_99bce0f7-2c66-4a08-90b4-f5d60fc09ea5">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Operating Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances and the existence of an identified asset(s), if any, and its control over the use of the identified asset(s), if applicable. Upon lease commencement, operating lease liabilities and their corresponding right-of-use assets are recorded on the balance sheet based at the present value of lease payments over the expected lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense is recognized over the expected term on a straight-line basis.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lease payments are discounted at the lease commencement date using the interest rate implicit in the lease contract. As this rate is typically not readily determinable, the Company determines an incremental borrowing rate that is used to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Certain prospective adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company elected to account for lease and non-lease components as a single lease component, however non-lease components that are variable, such as common area maintenance and utilities, are generally paid separately from rent based on actual costs incurred and therefore are not included in the right-of-use asset and operating lease liability and are reflected as an expense in the period incurred. The Company&#x2019;s lease terms often include renewal options. The amounts determined for the Company&#x2019;s right-of-use assets and lease liabilities generally do not assume that any renewal options or any early-termination provisions, if any, are exercised, unless it is reasonably certain that the Company will exercise such options.&lt;/span&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_5db006f7-2c60-4b33-a816-708c8ebe6c16">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;At contract inception, the Company assesses whether the collaboration arrangements are within the scope of ASC Topic 808, Collaborative Arrangements, or ASC 808, to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed based on the responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the arrangement are within the scope of ASC 808 and which elements are within the scope of ASC 606 (as described below). For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently, either by analogy to&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;authoritative accounting literature or by applying a reasonable and rational policy election. To date, the Company has not entered into any arrangements within the scope of ASC 808.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s revenues are generated through its license and collaboration agreements with Gilead. Refer to Note 4, &#x201c;Collaboration Agreements.&#x201d; elsewhere in these notes to the Company's consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers. ASC 606 provides a five-step framework whereby revenue is recognized when control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the  contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) performance obligations are satisfied. The Company only applies this framework to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation. Goods and services that are determined not to be distinct are combined with other promised goods and services until a distinct bundle is identified. The Company then allocates the transaction price (that is, the amount of consideration the Company expects to be entitled to from a customer in exchange for the promised goods or services) to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. The Company&#x2019;s estimate of the transaction price for each contract includes all variable consideration to which the Company expects to be entitled, subject to the constraint on variable consideration. Variable consideration is not constrained if the potential reversal of cumulative revenue recognized at the contract level is not significant.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under active agreements, the Company must use its judgment to determine: (a) the number of performance obligations based on the determination under step (ii) above; (b) the transaction price under step (iii) above; (c) the stand-alone selling price for each performance obligation identified in the contract for the allocation of transaction price in step (iv) above; and (d) the contract term and pattern of satisfaction of the performance obligations under step (v) above. The Company uses judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to the identified performance obligations on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. In certain instances, the timing of satisfying these obligations can be difficult to estimate. Accordingly, the Company&#x2019;s estimates may change in the future and those changes could be material. Such changes to estimates would result in a change in amounts of revenue recognized. If these estimates and judgments change over the course of these agreements, it may affect the timing and amount of revenue that the Company recognizes and records in future periods.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Amounts due to the Company for satisfying the revenue recognition criteria or that are contractually due based upon the terms of the collaboration agreements are recorded as accounts receivable in the Company&#x2019;s consolidated balance sheet. Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company&#x2019;s consolidated balance sheets. Amounts expected to be recognized as revenue within the one year following the balance sheet date are classified as current deferred revenue. Amounts not expected to be recognized as revenue within the one year following the balance sheet date are classified as deferred revenue, net of current portion. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as contract assets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Exclusive License Rights&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &#x2014; If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, which generally include research and development services, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. In assessing whether a license is distinct from the other promises, the Company considers relevant facts and circumstances of each arrangement, including the research and development capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the collaboration partner can benefit from the license for its intended purpose without the receipt of the remaining promises, whether the value of the license is dependent on the unsatisfied promises, whether there are other vendors that could provide the remaining promises and whether it is separately identifiable from the remaining promises. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation and whether the license is the predominant promise within the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. If the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;license is the predominant promise, and it is determined that the license represents functional intellectual property (&#x201c;IP&#x201d;), revenue is recognized at the point in time when control of the license is transferred. If it is determined that the license does not represent functional IP, revenue is recognized over time using an appropriate method of measuring progress.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Research and Development Services&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &#x2014; The obligations under the Company&#x2019;s collaboration agreements may include research and development services to be performed by the Company to benefit the collaboration partner. For performance obligations that include research and development services, the Company generally recognizes revenue allocated to such performance obligations based on an appropriate measure of progress. The Company utilizes judgment to determine the appropriate method of measuring progress for purposes of recognizing revenue, which is generally an input measure such as costs incurred. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. The measure of progress, and thereby periods of which revenue should be recognized, are subject to estimates by management and may change over the course of the contract. Reimbursements from the partner that are the result of a collaborative relationship with the partner, instead of a customer relationship, such as co-development activities, are recorded as a reduction to research and development expense. No collaborative arrangements existed that would result in such reimbursements for the periods presented.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Customer Options&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &#x2014; The Company&#x2019;s arrangements may provide a collaborator with the right to acquire additional goods or services in the future. Under these agreements, fees may be due to the Company (i) upon the exercise of the customer option or (ii) in equal installment payments over an agreed upon period. If an arrangement is determined to contain customer options that allow the customer to acquire additional goods or services, the additional goods and services underlying the customer options are evaluated in order to determine if these additional goods or services are distinct from those included as a performance obligation at the outset of the arrangement. If the additional services are not determined to be distinct, the variable consideration pertaining to the customer option is added to the initial transaction price at the time in which the option exercise becomes probable, so long as a potential for reversal of cumulative revenue recognized at the contract level is not significant. Any such adjustments to the transaction price are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If the additional services are distinct, the Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the inception of the arrangement. The Company allocates the transaction price to material rights based on the relative stand-alone selling price, which is determined based on the identified discount and the probability that the customer will exercise the option. Amounts allocated to a material right are not recognized as revenue until, at the earliest, the option is exercised or expires.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Milestone Payments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &#x2014; At the inception of an arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant reversal of cumulative revenue recognized would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether it is probable that a significant revenue reversal would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment. If a milestone or other variable consideration relates specifically to the Company&#x2019;s efforts to satisfy a single performance obligation or to a specific outcome from satisfying the performance obligation, the Company generally allocates the milestone amount entirely to that performance obligation once it is probable that a significant revenue reversal would not occur.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Royalties&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &#x2014; For arrangements that include sales-based royalties, including milestone payments based on a level of sales, where the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from licensing agreements.&lt;/span&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_e1ef43ed-27a7-4774-933d-95736f984eee">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development expenses include costs directly attributable to the conduct of research programs, including the cost of salaries, employee benefits, stock-based compensation expense, materials, supplies, depreciation on and maintenance of research equipment, the cost of services provided by outside contractors to conduct research and development&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;activities and the allocable portions of facility costs, such as rent, utilities, and general support services. All costs incurred to fulfill the Company&#x2019;s obligations under the collaboration with Gilead are classified as research and development expenses. All costs associated with research and development are expensed as incurred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Management estimates the Company&#x2019;s accrued research and development expenses as of each balance sheet date in the Company&#x2019;s financial statements based on facts and circumstances known to the Company at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Nonrefundable advance payments for goods and services are deferred and recognized as expense in the period that the related goods are consumed or services are performed.&lt;/span&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <tngx:PatentCostsPolicyTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_becdf442-0105-4a66-ba70-e8de42b6d52b">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Patent Costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.&lt;/span&gt;</tngx:PatentCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_87d4b924-e847-43b9-890c-fc10e8b83461">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company measures the cost of employee services received in exchange for stock-based awards based on the grant-date fair value of the awards. The Company calculates the fair value of restricted stock awards based on the grant date fair value of the underlying common stock. The Company recognizes stock-based compensation expense on a straight-line basis over the requisite service period of the awards for service-based awards, which is generally the vesting period. The Company recognizes stock-based compensation for performance-based awards when the underlying performance conditions are considered probable of occurrence and recognizes the cumulative effect of current and prior period changes in the period of change.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prior to the &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;consummation of the Business Combination transaction, as there was not a public market for the common stock of the Company prior to becoming publicly traded, the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;fair value of common stock underlying stock-based awards was based on a valuation provided by the board of directors as derived from a recommendation by an unrelated third-party valuation firm. The Company determined the estimated per share fair value of its common stock at various dates considering contemporaneous and retrospective valuations that incorporated objective and subjective factors, including actual and forecasted financial results, market conditions and performance of comparable publicly traded companies, developments and milestones of the Company, the rights and preferences of common and redeemable convertible preferred stock, advice from the third-party valuation specialists, and transactions involving the Company&#x2019;s stock. The estimated per share fair value of the Company&#x2019;s common stock was determined in accordance with the guidance outlined in the American Institute of Certified Public Accountants Practice Aid, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Valuation of Privately-Held Company Equity Securities Issued as Compensation&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The fair value of each restricted common stock award was estimated on the date of grant based on the fair value of the Company&#x2019;s common stock on that same date.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Subsequent to becoming a publicly traded Company upon the consummation of the Business Combination transaction, the fair value of common stock underlying stock-based awards is based on an estimate at each grant date using the market price of our common stock and each of the assumptions discussed below.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Expected Term&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;:    The expected term of the stock options is estimated using the &#x201c;simplified method,&#x201d; as prescribed in SEC&#x2019;s Staff Accounting Bulletin (SAB) No. 107, as the Company has limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting period and the contractual term of the option.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Expected Volatility&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;:    Since there is limited historical data for the Company&#x2019;s common stock and limited company-specific historical volatility, the Company has determined the share price volatility for options granted based on an analysis of the volatility used by a peer group of publicly traded companies. In evaluating similarity, the Company considers factors such as industry, stage of life cycle and size.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Risk-free Interest Rate&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;:    The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected life of the option.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Dividend Rate&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;:    The expected dividend is assumed to be &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; as the Company has never paid dividends and has no current plans to do so.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The assumptions used in estimating the fair value of stock-based awards represent management&#x2019;s estimate and involve inherent uncertainties and the application of management&#x2019;s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-based compensation is classified in the accompanying consolidated statements of operations and comprehensive loss based on the function to which the related services are provided. Forfeitures are accounted for as they occur. Any consideration paid by employees on exercising stock options and the corresponding portion previously credited to additional paid-in capital are credited to share capital.&lt;/span&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <tngx:ExpectedDividendAssumed
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_43b55140-5091-4ca4-aca4-7290aad81823"
      unitRef="U_USD">0</tngx:ExpectedDividendAssumed>
    <tngx:DeferredFinancingCostsPolicyTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_f7939279-63d1-4b10-bd89-90c7d084c06e">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Deferred Financing Costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded in shareholders&#x2019; equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</tngx:DeferredFinancingCostsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_d48f72c0-7c91-4a0e-a7b2-2c1e5839b9ca">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period corresponding to the enactment date. A valuation allowance is established when it is more likely than not that all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a more likely than not likelihood of being realized upon ultimate settlement with the tax authority. The recognition and measurement of tax benefits requires significant judgments that are subject to change as new information becomes available.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Penalties and interest expense related to income taxes are included as components of income tax expense and interest expense, respectively, as necessary.&lt;/span&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_7f6c1276-15b6-45ee-b017-1c8453ea020b">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Comprehensive Gain (Loss)&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity (deficit) that result from transactions and economic events other than those with stockholders. The Company&#x2019;s only element of other comprehensive loss for the years ended December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; was unrealized gains (losses) on investments in marketable securities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_d920d7b2-e22f-43ab-8392-0fbd335b19a2">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic net loss per share attributable to common stockholders is computed by dividing net loss by the weighted-average number of shares of common shares outstanding during each reporting period. The weighted-average number of shares of common stock outstanding used in the basic net loss per share calculation does not include unvested restricted stock awards as these instruments are considered contingently issuable shares until they vest. Diluted net loss per share attributable to common stockholders includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. The Company&#x2019;s unvested restricted stock entitles the holder to participate in dividends and earnings of the Company, and, if the Company were to recognize net income, it would apply the two-class method to calculate earnings per share. The two-class method is not applicable during periods with a net loss, as the holders of the unvested restricted stock have no obligation to fund losses.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The two-class method of computing net loss per share would be applicable in a reporting period that resulted in a net income position, as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_82355b4a-1e95-4b41-ad2c-f9ac3d0f6180">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Commitments and Contingencies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.&lt;/span&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_a7f59441-4834-46f4-85e1-457c88f7e808">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Subsequent Events&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company considers events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure.&lt;/span&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_1b8711b3-3739-4ef6-a845-aa4f2cb3befa">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Emerging Growth Company Status&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in the Jumpstart Our Business Startups Act (&#x201c;JOBS Act&#x201d;), and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards and as a result of this election, its consolidated financial statements may not be comparable to companies that comply with public company effective dates. The Company may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary of an initial public offering or such earlier time that it is no longer an emerging growth company. However, the Company has not yet delayed the adoption of any new accounting standards.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_a15e44e2-36b5-4af0-a283-530a34a886cd">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In June 2016, the FASB issued ASU 2016-13&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;, Financial Instruments &#x2014; Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren&#x2019;t measured at fair value through net income. For available-for-sale debt securities, entities are required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities are no longer permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. For public entities, the guidance was effective for annual reporting periods beginning after December 15, 2019 and for interim periods within those fiscal years. Early adoption was permitted. The Company &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;early &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;adopted &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;this standard as of&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; January 1, 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; on a prospective basis. The adoption did&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; no&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In August 2018, the FASB issued ASU 2018-13, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The amendments become effective for the Company&#x2019;s fiscal year beginning January 1, 2020. Early adoption of the amendments in full or only the provisions that eliminate or modify the disclosure requirements for fair value measurements is permitted. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Adoption &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;of this standard on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;January 1, 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In August 2018, the FASB issued ASU 2018-15, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The new standard requires a customer in a cloud computing arrangement to determine which implementation costs to capitalize as assets or expense as incurred. Capitalized implementation costs related to a hosting arrangement that is a service contract will be amortized over the term of the hosting arrangement, beginning when the module or component of the hosting arrangement is ready for its intended use. The new standard became effective for the Company&#x2019;s fiscal year beginning January 1, 2020. Early adoption was permitted. The &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;early &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;adoption &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;of this standard on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;January 1, 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t have a material impact on the Company&#x2019;s consolidated financial statements and related disclosures.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Simplifying the Accounting for Income Taxes,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (&#x201c;ASC 740&#x201d;). The ASU enhances and simplifies various aspects of the income tax accounting guidance in ASC 740, including requirements related to hybrid tax regimes, the tax basis step-up in goodwill obtained in a transaction that is not a business combination, separate financial statements of entities not subject to tax, the intra-period tax allocation exception to the incremental approach, ownership changes in investments, changes from a subsidiary to an equity method investment, interim-period accounting for enacted changes in tax law, and the year-to-date loss limitation in interim-period tax accounting. This guidance became effective for the Company's fiscal year beginning &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;January 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;adoption &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;of this guidance did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Debt &#x2014; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity (Subtopic 815 &#x2014; 40)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The amendments in this update affect entities that issue convertible instruments and/or contracts indexed to and potentially settled in an entity&#x2019;s own equity. The new ASU eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, the new guidance modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company elected to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;early &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;adopt &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;this guidance on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;January 1, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Adoption of the ASU 2020-06 guidance as of January 1, 2021 had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;impact on its consolidated financial statements for the year ended December 31, 2020. The Company issued the second tranche of its redeemable convertible Series B preferred stock in March 2021 at an original issue price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.32&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share, which would have resulted in the recognition of a beneficial conversion feature of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;28.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million prior to the adoption of ASU 2020-06. However, the consummation of the Business Combination and the application of a retroactive adjustment to historical redeemable convertible preferred stock in all periods presented under the reverse recapitalization accounting treatment have resulted in the adoption of this guidance not resulting in a material impact on the Company&#x2019;s financial statements for the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption
      contextRef="C_d651794e-8630-4ab5-a33f-7df95e076d4e"
      id="F_180eabe9-140b-4a93-be62-2378d90e4750">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_d651794e-8630-4ab5-a33f-7df95e076d4e"
      id="F_4c9ad851-5e44-471c-9c5f-54e9600b893f">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_d651794e-8630-4ab5-a33f-7df95e076d4e"
      id="F_cd78e2d3-66fb-4eba-a398-9c7f877e1d7d">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_d651794e-8630-4ab5-a33f-7df95e076d4e"
      id="F_f82bed08-49e3-4854-9f84-f398266729a9">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_165d6390-156d-4d13-94be-fad709b50c15"
      id="F_59585859-15d0-4fc0-8b8f-ce69e2eb7fa9">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_165d6390-156d-4d13-94be-fad709b50c15"
      id="F_51e30a61-8e20-44cd-9233-1ef2b5644919">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_165d6390-156d-4d13-94be-fad709b50c15"
      id="F_5f4661e2-43f5-450e-a9c5-67c5322a73a5">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption
      contextRef="C_79ee2c85-0407-439c-899d-6ad699fae605"
      id="F_cb48d8f8-25b1-444d-9a30-abfc4194aa41">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_79ee2c85-0407-439c-899d-6ad699fae605"
      id="F_a128f944-c9d8-4e27-9c45-9357f0729c22">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_79ee2c85-0407-439c-899d-6ad699fae605"
      id="F_954014c0-b06e-468a-ae71-1d4bda094803">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_79ee2c85-0407-439c-899d-6ad699fae605"
      id="F_640b41ff-1781-4a6b-97f1-1a9a75d24f26">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_709432d5-f52b-4cb9-a494-7b1bae2706a5"
      id="F_fca83597-bd95-4bb3-bd3d-6064ae10a682">2021-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_709432d5-f52b-4cb9-a494-7b1bae2706a5"
      id="F_95736867-c622-4fa9-bc10-2ab3c067c5fa">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_709432d5-f52b-4cb9-a494-7b1bae2706a5"
      id="F_7322a915-a96b-4971-b6cd-6fabe97b840c">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption
      contextRef="C_ee85dddd-830e-4471-966a-17bed0f1923f"
      id="F_00f14349-4449-4ab8-836c-2fcd4cd272fa">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_ee85dddd-830e-4471-966a-17bed0f1923f"
      id="F_ad1a9dc3-6fb5-4672-a037-ac8315911ab9">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_ee85dddd-830e-4471-966a-17bed0f1923f"
      id="F_471afcdb-f6a9-438e-b366-a7d5a7abe203">2021-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_ee85dddd-830e-4471-966a-17bed0f1923f"
      id="F_fd5cfc02-d238-47b9-a179-d3a3e094f71b">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_934e45d0-2851-4e4a-848b-28c197e06283"
      decimals="2"
      id="F_a230475a-0b1a-4824-8628-26c6469b950d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.32</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="C_bee96a77-f86f-42a4-a0c1-11fced7670fe"
      decimals="-5"
      id="F_b72c6569-39ae-4998-9f9e-6b42ddecb760"
      unitRef="U_USD">28400000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <tngx:RecentlyIssuedAccountingPronouncementsPolicyTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_26e27cd8-ae1d-4b3a-a0bb-96a3ea88411a">&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that recently issued standards that are not yet effective will not have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</tngx:RecentlyIssuedAccountingPronouncementsPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_c70f0afe-74c7-4893-bfbe-aed13e8d8491">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;3. Business Combination&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;August 10, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (the "Closing Date"), BCTG, a Delaware corporation and now predecessor of the Company, consummated the Business Combination, pursuant to the Merger Agreement, by and among BCTG, BCTG Merger Sub Inc., a Delaware corporation ("BCTG Merger Sub"), and Old Tango. Prior to consummation of the Business Combination, Old Tango changed its name from &#x201c;Tango Therapeutics, Inc.&#x201d; to &#x201c;Tango Therapeutics Sub, Inc.&#x201d; and in connection with the Business Combination, BCTG changed its name to &#x201c;Tango Therapeutics, Inc.&#x201d; (the former name of Old Tango). Pursuant to the Merger Agreement, on the Closing Date, BCTG Merger Sub merged with and into Old Tango, or the Merger, with Old Tango surviving the Merger as a wholly-owned subsidiary of BCTG, and BCTG changed its name to &#x201c;Tango Therapeutics, Inc.&#x201d;, or New Tango.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Pursuant to the terms and conditions of the Merger Agreement, the aggregate consideration paid to Old Tango equity holders upon the closing of the Merger was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;55,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of New Tango common stock. Subsequent to the closing of the Business Combination, New Tango entered into subscription agreements with certain investors ("PIPE Investors") pursuant to which the PIPE Investors purchased &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,610,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of New Tango common stock at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share, for aggregate gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;186.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, under the PIPE Financing.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes the elements of the net proceeds from the Business Combination and PIPE Financing transaction as of December 31, 2021 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:75.102%;"/&gt;
        &lt;td style="width:4.662%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:18.09%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Recapitalization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash - BCTG's Trust Account and cash (net of redemptions)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;156,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash - PIPE Financing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;186,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less transaction costs and advisory fees paid&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15,836&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net cash proceeds from the Business Combination and PIPE Financing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;326,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Add: non-cash net assets assumed from BCTG&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net contributions from Business Combination and PIPE Financing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;326,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes the number of shares of common stock outstanding immediately following the consummation of the Business Combination and PIPE Financing transaction:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.237%;"/&gt;
        &lt;td style="width:3.886%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:15.366%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;BCTG common shares outstanding prior to the Business Combination&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21,377,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less redemption of BCTG shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,106,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Common shares of BCTG outstanding as of the Business Combination&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20,270,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shares issued pursuant to the PIPE Financing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,610,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Business Combination and PIPE Financing shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;38,880,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Old Tango common shares (after preferred shares were converted 1-for-&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;for common shares)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;48,593,803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total shares of Common Stock immediately after Business Combination consummation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;87,474,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The merger consideration of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;55,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0 shares of New Tango common stock issued to Old Tango equity holders consists of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;48,593,803&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares issued in exchange for Old Tango common and preferred shares outstanding, included in the table above, as well as &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,406,197&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares issued in exchange for the Old Tango unvested restricted stock awards and unexercised stock options outstanding immediately prior to the effective time of the Business Combination.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Retrospective Application of Recapitalization&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As discussed above, the Business Combination with BCTG, which was consummated on August 10, 2021, is accounted for as a reverse recapitalization of equity structure. Under the reverse recapitalization model, the Business Combination was treated as Old Tango issuing equity for the net assets of BCTG, with &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; goodwill or intangible assets recorded. Under this method of accounting, BCTG was treated as the &#x201c;acquired&#x201d; company for financial reporting purposes. This determination was primarily based on the fact that subsequent to the Business Combination, Old Tango&#x2019;s stockholders possess a majority of the voting power of the combined company, the Company comprises all of the ongoing operations of Old Tango, the Company comprises a majority of the governing body of Old Tango, and the Company&#x2019;s senior management comprises all of the senior management of Old Tango.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;These consolidated financial statements contain recasted stockholders' equity balances resulting from the retroactive application of reverse recapitalization accounting in accordance with U.S. GAAP.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Retroactive Application of Recapitalization to the Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#x2019; Equity (Deficit)&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Pursuant to the terms of the Merger Agreement, upon the closing of the Business Combination on August 10, 2021 (the &#x201c;Effective Time&#x201d;), each share of Old Tango&#x2019;s redeemable convertible preferred stock (the &#x201c;Preferred Stock&#x201d;) issued and outstanding immediately prior to the Effective Time was converted into a share of the Company&#x2019;s common stock using the exchange ratio of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.34&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:9.468%;"/&gt;
        &lt;td style="width:1.003%;"/&gt;
        &lt;td style="width:16.066%;"/&gt;
        &lt;td style="width:1.003%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:15.002%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:1.003%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:12.767%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:1.003%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:11.515%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:1.003%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:11.783%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:1.003%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:10.919%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Preferred to Common Exchange Ratio&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Common Stock Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;8/10/2021 Merger Recapitalization Exchange Ratio&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Recapitalization Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;12/31/2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Series A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;55,700,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;55,700,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;0.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;18,922,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;4/7/2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Series B (tranche 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;22,686,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;22,686,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;0.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;7,706,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;8/17/2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Series B-1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;27,152,255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;27,152,255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;0.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;9,224,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;3/18/2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Series B (tranche 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;22,686,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;22,686,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;0.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;7,706,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;All common shares, as well as previously issued share options and restricted stock awards (&#x201c;RSAs&#x201d;), presented in the accompanying recasted consolidated statements of redeemable convertible preferred stock and stockholders' equity (deficit) and/or in the related notes are presented on an as-converted basis, converted at the ratio of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.34&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Retroactive Application of Recapitalization to the Consolidated Statements of Operations and Comprehensive Loss&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In accordance with the retroactive application of recapitalization to the accompanying consolidated statements of redeemable convertible preferred stock and stockholders' equity (deficit), the basic and diluted weighted-average shares of common stock outstanding for the years ended December 31, 2021 and 2020 have been retroactively converted using the exchange ratio of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.34&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes the weighted-average common shares, basic and diluted, for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2020:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:8.153%;"/&gt;
        &lt;td style="width:0.945%;"/&gt;
        &lt;td style="width:20.491%;"/&gt;
        &lt;td style="width:1.293%;"/&gt;
        &lt;td style="width:0.567%;"/&gt;
        &lt;td style="width:9.704%;"/&gt;
        &lt;td style="width:0.567%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
        &lt;td style="width:0.577%;"/&gt;
        &lt;td style="width:10.022%;"/&gt;
        &lt;td style="width:0.567%;"/&gt;
        &lt;td style="width:0.945%;"/&gt;
        &lt;td style="width:0.577%;"/&gt;
        &lt;td style="width:10.668%;"/&gt;
        &lt;td style="width:0.567%;"/&gt;
        &lt;td style="width:0.945%;"/&gt;
        &lt;td style="width:9.356%;"/&gt;
        &lt;td style="width:0.945%;"/&gt;
        &lt;td style="width:8.381%;"/&gt;
        &lt;td style="width:0.945%;"/&gt;
        &lt;td style="width:0.567%;"/&gt;
        &lt;td style="width:11.941%;"/&gt;
        &lt;td style="width:0.567%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As previously recorded&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;8/10/2021 Merger Exchange Ratio&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Recapitalized Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Days Outstanding in 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;% of weighting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted average common shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;12/31/2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Weighted-average shares, &lt;br/&gt;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;11,461,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;0.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;3,893,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;3,893,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;12/31/2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Series A shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;55,700,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;0.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;18,922,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;365&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;18,922,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;4/7/2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Series B shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;22,686,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;0.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;7,706,443&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;268&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;73&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;5,664,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;8/17/2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Series B-1 shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;27,152,255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;0.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;9,223,621&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;136&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;37&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;3,452,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td colspan="19" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Weighted average number of common shares outstanding &#x2013; basic and diluted for the year ended December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;31,932,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Retroactive Application of Recapitalization to the Consolidated Balance Sheets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;To conform to the retroactive application of recapitalization to the accompanying consolidated statements of redeemable convertible preferred stock and stockholders' equity (deficit), historical proceeds from the issuance of preferred stock, less the par value of the historical preferred shares that were converted into common shares using the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.34&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; ratio at the Effective Time, have been reclassified to additional paid in capital for the years ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionDateOfAcquisitionAgreement1
      contextRef="C_dbf730ab-1e1d-4b66-831b-495fa57b10da"
      id="F_206ae606-8bbf-4051-86a4-0d1dbd639207">2021-08-10</us-gaap:BusinessAcquisitionDateOfAcquisitionAgreement1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_dbf730ab-1e1d-4b66-831b-495fa57b10da"
      decimals="INF"
      id="F_c5a5c030-8a64-4919-934c-b23d956c2855"
      unitRef="U_shares">55000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_ea92a304-c585-4deb-947b-651b75dbc182"
      decimals="INF"
      id="F_6a53cd3f-1a78-4a40-9781-dffab9abf911"
      unitRef="U_shares">18610000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <tngx:PricePerShare
      contextRef="C_8de344bc-88b0-4716-8a86-20e32b63eab2"
      decimals="2"
      id="F_9ce492f4-9357-492a-9476-bb8881e1fe7e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">10.00</tngx:PricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_ea92a304-c585-4deb-947b-651b75dbc182"
      decimals="-5"
      id="F_12caa095-3664-4407-adc7-7a1709e439a1"
      unitRef="U_USD">186100000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_6b88051f-6663-4901-b4da-30028e1468bc">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes the elements of the net proceeds from the Business Combination and PIPE Financing transaction as of December 31, 2021 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:75.102%;"/&gt;
        &lt;td style="width:4.662%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:18.09%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Recapitalization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash - BCTG's Trust Account and cash (net of redemptions)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;156,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash - PIPE Financing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;186,100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less transaction costs and advisory fees paid&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15,836&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net cash proceeds from the Business Combination and PIPE Financing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;326,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Add: non-cash net assets assumed from BCTG&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net contributions from Business Combination and PIPE Financing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;326,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_aefe6aea-0fcf-40c7-a8cb-fa9395426cc3"
      decimals="-3"
      id="F_5d730546-1b97-4998-a9f4-a9aae5f30fa5"
      unitRef="U_USD">156013000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_fc96726e-aa67-4543-82fb-ba75a0a854df"
      decimals="-3"
      id="F_9f121583-1c10-43d6-9415-43ece685a7c1"
      unitRef="U_USD">186100000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="C_df7e4b79-2a16-44a2-844e-a0a5c357c1b4"
      decimals="-3"
      id="F_79686c8d-18fa-4239-afca-0638efa67c7f"
      unitRef="U_USD">15836000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="C_4a921be2-dfdf-4ce8-8e66-04b6835527ad"
      decimals="-3"
      id="F_b85b5f84-20df-4ccc-a1eb-14c376fc088f"
      unitRef="U_USD">326277000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="C_0d31393e-af6d-4a5d-92ee-02bb00706dea"
      decimals="-3"
      id="F_352c5c3e-bf24-403d-a10a-dd887d029d35"
      unitRef="U_USD">3000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="C_4a921be2-dfdf-4ce8-8e66-04b6835527ad"
      decimals="-3"
      id="F_4a0d1a3b-27e0-4d0f-83d0-3001fd44dc97"
      unitRef="U_USD">326280000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_8f48ef59-f463-4b6b-9192-7e40d40dad7d">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes the number of shares of common stock outstanding immediately following the consummation of the Business Combination and PIPE Financing transaction:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.237%;"/&gt;
        &lt;td style="width:3.886%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:15.366%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Number of Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;BCTG common shares outstanding prior to the Business Combination&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21,377,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less redemption of BCTG shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,106,814&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Common shares of BCTG outstanding as of the Business Combination&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20,270,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shares issued pursuant to the PIPE Financing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,610,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Business Combination and PIPE Financing shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;38,880,436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Old Tango common shares (after preferred shares were converted 1-for-&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;for common shares)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;48,593,803&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total shares of Common Stock immediately after Business Combination consummation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;87,474,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock>
    <tngx:CommonStockOutstandingPriorToBusinessCombination
      contextRef="C_ecff8a34-7794-4031-8fce-96f60d31dc7c"
      decimals="INF"
      id="F_28612aa6-04ff-4b46-8607-34c0f7998121"
      unitRef="U_shares">21377250</tngx:CommonStockOutstandingPriorToBusinessCombination>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
      contextRef="C_ecff8a34-7794-4031-8fce-96f60d31dc7c"
      decimals="INF"
      id="F_2fecf504-e4c7-44a4-8771-e46f4b17b03e"
      unitRef="U_shares">1106814</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_ecff8a34-7794-4031-8fce-96f60d31dc7c"
      decimals="INF"
      id="F_63e687f6-1589-4b5a-88c4-6c1f92530e38"
      unitRef="U_shares">20270436</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SharesIssued
      contextRef="C_c73c0fe0-50a5-469f-988c-1cd417a6095d"
      decimals="INF"
      id="F_34405a3b-89b5-4fc8-b448-debc72e5afc2"
      unitRef="U_shares">18610000</us-gaap:SharesIssued>
    <us-gaap:SharesIssued
      contextRef="C_9e7c0cdf-ecd0-49cb-bcb4-d8123eab2f15"
      decimals="INF"
      id="F_6d588992-84e9-43f1-8429-f1484f6f4ee3"
      unitRef="U_shares">38880436</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_637f6044-163f-4ffe-baaa-808b1b634223"
      decimals="INF"
      id="F_2f2d1597-f849-442b-9ad3-36742fc66f6f"
      unitRef="U_pure">1</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="C_afd5c297-0100-4e5c-a1d4-238c915c6ebd"
      decimals="0"
      id="F_124f5f26-8fd4-4fb6-8f1f-e0e6636dcc82"
      unitRef="U_shares">48593803</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_278d8753-1cb2-473c-a8e0-50755d56d579"
      decimals="INF"
      id="F_c458b3a5-8ad7-40f6-9bdd-54ced095b19e"
      unitRef="U_shares">87474239</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_dbf730ab-1e1d-4b66-831b-495fa57b10da"
      decimals="INF"
      id="F_37aaf2ee-f3b9-4ec5-b080-829e1875cc24"
      unitRef="U_shares">55000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="C_afd5c297-0100-4e5c-a1d4-238c915c6ebd"
      decimals="INF"
      id="F_94351134-3bac-405c-9808-a23dea1e9b06"
      unitRef="U_shares">48593803</us-gaap:PreferredStockConvertibleSharesIssuable>
    <tngx:StockIssuedDuringPeriodSharesInExchangeForUnvestedRestrictedStockAwardsAndUnexercisedStockOptions
      contextRef="C_9157c232-bd25-4b99-8aaa-53493f84a8b0"
      decimals="INF"
      id="F_7d9960c5-69b4-43d9-bde8-0f6e96f1665a"
      unitRef="U_shares">6406197</tngx:StockIssuedDuringPeriodSharesInExchangeForUnvestedRestrictedStockAwardsAndUnexercisedStockOptions>
    <us-gaap:Goodwill
      contextRef="C_ecff8a34-7794-4031-8fce-96f60d31dc7c"
      decimals="INF"
      id="F_d5869b32-e96d-4d10-858f-8a8e31180cbf"
      unitRef="U_USD">0</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="C_ecff8a34-7794-4031-8fce-96f60d31dc7c"
      decimals="INF"
      id="F_417022ae-cc14-4dcd-ae37-b90d7ca16af0"
      unitRef="U_USD">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <tngx:SummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationTableTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_7c08b689-5c1a-449b-8953-33c14bcc998a">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Pursuant to the terms of the Merger Agreement, upon the closing of the Business Combination on August 10, 2021 (the &#x201c;Effective Time&#x201d;), each share of Old Tango&#x2019;s redeemable convertible preferred stock (the &#x201c;Preferred Stock&#x201d;) issued and outstanding immediately prior to the Effective Time was converted into a share of the Company&#x2019;s common stock using the exchange ratio of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.34&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:9.468%;"/&gt;
        &lt;td style="width:1.003%;"/&gt;
        &lt;td style="width:16.066%;"/&gt;
        &lt;td style="width:1.003%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:15.002%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:1.003%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:12.767%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:1.003%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:11.515%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:1.003%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:11.783%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:1.003%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:10.919%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Preferred to Common Exchange Ratio&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Common Stock Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;8/10/2021 Merger Recapitalization Exchange Ratio&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Recapitalization Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;12/31/2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Series A&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;55,700,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;55,700,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;0.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;18,922,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;4/7/2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Series B (tranche 1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;22,686,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;22,686,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;0.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;7,706,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;8/17/2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Series B-1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;27,152,255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;27,152,255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;0.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;9,224,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;3/18/2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Series B (tranche 2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;22,686,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;22,686,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;0.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;7,706,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</tngx:SummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationTableTextBlock>
    <tngx:MergerRecapitalizationExchangeRatio
      contextRef="C_278d8753-1cb2-473c-a8e0-50755d56d579"
      decimals="2"
      id="F_fafa8017-3b7d-4e93-9589-43fcdb1bc517"
      unitRef="U_pure">0.34</tngx:MergerRecapitalizationExchangeRatio>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_28c70236-1fd3-49b1-a137-9ccf19f5d150"
      decimals="INF"
      id="F_bf56ec4f-96d1-4942-a8a8-e300c528a420"
      unitRef="U_shares">55700000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="C_28c70236-1fd3-49b1-a137-9ccf19f5d150"
      decimals="2"
      id="F_54fb9fc0-4acd-40bc-803a-b2047041f2e9"
      unitRef="U_pure">1.00</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_28c70236-1fd3-49b1-a137-9ccf19f5d150"
      decimals="INF"
      id="F_59cea69e-137e-4a5a-b37f-a6d61d8685cb"
      unitRef="U_shares">55700000</us-gaap:CommonStockSharesIssued>
    <tngx:MergerRecapitalizationExchangeRatio
      contextRef="C_86fa47f4-0478-4603-9095-4af7a4e6165d"
      decimals="2"
      id="F_a7894194-fb92-460a-91cf-b9ee66922549"
      unitRef="U_pure">0.34</tngx:MergerRecapitalizationExchangeRatio>
    <tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares
      contextRef="C_28c70236-1fd3-49b1-a137-9ccf19f5d150"
      decimals="INF"
      id="F_bccb352e-b6eb-413c-ba66-a4697f7aad15"
      unitRef="U_shares">18922317</tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_d3c3e34d-cd50-4fb1-a2a9-829d2a4cfdc4"
      decimals="INF"
      id="F_4f389613-2817-4c51-8c4b-7a8d1b8bb924"
      unitRef="U_shares">22686025</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="C_d3c3e34d-cd50-4fb1-a2a9-829d2a4cfdc4"
      decimals="2"
      id="F_7b606af7-3dd5-4221-8f57-f2a924779de4"
      unitRef="U_pure">1.00</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_d3c3e34d-cd50-4fb1-a2a9-829d2a4cfdc4"
      decimals="INF"
      id="F_3e8b4605-7580-4cad-bfcc-77b9eb271ab7"
      unitRef="U_shares">22686025</us-gaap:CommonStockSharesIssued>
    <tngx:MergerRecapitalizationExchangeRatio
      contextRef="C_c96d2de7-cf25-4b3d-9e34-1a5c2b302481"
      decimals="2"
      id="F_b983b8f8-31e9-4280-9e5f-d727dab34b44"
      unitRef="U_pure">0.34</tngx:MergerRecapitalizationExchangeRatio>
    <tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares
      contextRef="C_d3c3e34d-cd50-4fb1-a2a9-829d2a4cfdc4"
      decimals="INF"
      id="F_b39ab471-34ee-4b5e-bb14-2827fb4a671f"
      unitRef="U_shares">7706861</tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_1efa7be9-29eb-4c8a-a7b7-04a5517b4c9c"
      decimals="INF"
      id="F_958fc6fb-244b-4afd-98fc-c56d33a5f9cb"
      unitRef="U_shares">27152255</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="C_1efa7be9-29eb-4c8a-a7b7-04a5517b4c9c"
      decimals="2"
      id="F_15afca3d-eaad-44eb-ad81-f1ff8bdbdef6"
      unitRef="U_pure">1.00</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_1efa7be9-29eb-4c8a-a7b7-04a5517b4c9c"
      decimals="INF"
      id="F_18547699-337d-4d73-a1b6-051bc454a108"
      unitRef="U_shares">27152255</us-gaap:CommonStockSharesIssued>
    <tngx:MergerRecapitalizationExchangeRatio
      contextRef="C_4cfd2b0e-b7d6-48f4-ace9-bcb7b07f4adc"
      decimals="2"
      id="F_09138e1e-215a-4169-8b6f-2c9a39ece7e2"
      unitRef="U_pure">0.34</tngx:MergerRecapitalizationExchangeRatio>
    <tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares
      contextRef="C_1efa7be9-29eb-4c8a-a7b7-04a5517b4c9c"
      decimals="INF"
      id="F_277dcc74-619d-4183-a679-6d12fa33806f"
      unitRef="U_shares">9224122</tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="C_eb62df54-f0e0-4a6d-9c99-33f08d82c127"
      decimals="INF"
      id="F_9ca7cabc-dc64-45c9-8bb1-5372498fe983"
      unitRef="U_shares">22686025</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="C_eb62df54-f0e0-4a6d-9c99-33f08d82c127"
      decimals="2"
      id="F_b0711d9c-0e8f-4db4-9b58-93657e16cc28"
      unitRef="U_pure">1.00</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_eb62df54-f0e0-4a6d-9c99-33f08d82c127"
      decimals="INF"
      id="F_961c9d02-9c5f-4003-a4f4-7cde2e0db906"
      unitRef="U_shares">22686025</us-gaap:CommonStockSharesIssued>
    <tngx:MergerRecapitalizationExchangeRatio
      contextRef="C_9943303c-4c93-4a64-a1b1-6e1c309ffbd6"
      decimals="2"
      id="F_b55e122e-906d-458b-9e93-0b0f8f6f8431"
      unitRef="U_pure">0.34</tngx:MergerRecapitalizationExchangeRatio>
    <tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares
      contextRef="C_eb62df54-f0e0-4a6d-9c99-33f08d82c127"
      decimals="INF"
      id="F_aa6625a1-676b-443d-a9fd-6747b445c031"
      unitRef="U_shares">7706861</tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares>
    <tngx:MergerRecapitalizationExchangeRatio
      contextRef="C_278d8753-1cb2-473c-a8e0-50755d56d579"
      decimals="2"
      id="F_e69657ab-1181-47e6-8a20-9b6c29bbf771"
      unitRef="U_pure">0.34</tngx:MergerRecapitalizationExchangeRatio>
    <tngx:MergerRecapitalizationExchangeRatio
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="2"
      id="F_0d5eeb87-721a-427e-afc1-30f239cb65ce"
      unitRef="U_pure">0.34</tngx:MergerRecapitalizationExchangeRatio>
    <tngx:MergerRecapitalizationExchangeRatio
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="2"
      id="F_67783860-36f6-4e32-b474-2e366acd6835"
      unitRef="U_pure">0.34</tngx:MergerRecapitalizationExchangeRatio>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_ca13be4e-b747-41bd-b410-9b649e94d6e1">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes the weighted-average common shares, basic and diluted, for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2020:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:8.153%;"/&gt;
        &lt;td style="width:0.945%;"/&gt;
        &lt;td style="width:20.491%;"/&gt;
        &lt;td style="width:1.293%;"/&gt;
        &lt;td style="width:0.567%;"/&gt;
        &lt;td style="width:9.704%;"/&gt;
        &lt;td style="width:0.567%;"/&gt;
        &lt;td style="width:0.716%;"/&gt;
        &lt;td style="width:0.577%;"/&gt;
        &lt;td style="width:10.022%;"/&gt;
        &lt;td style="width:0.567%;"/&gt;
        &lt;td style="width:0.945%;"/&gt;
        &lt;td style="width:0.577%;"/&gt;
        &lt;td style="width:10.668%;"/&gt;
        &lt;td style="width:0.567%;"/&gt;
        &lt;td style="width:0.945%;"/&gt;
        &lt;td style="width:9.356%;"/&gt;
        &lt;td style="width:0.945%;"/&gt;
        &lt;td style="width:8.381%;"/&gt;
        &lt;td style="width:0.945%;"/&gt;
        &lt;td style="width:0.567%;"/&gt;
        &lt;td style="width:11.941%;"/&gt;
        &lt;td style="width:0.567%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As previously recorded&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;8/10/2021 Merger Exchange Ratio&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Recapitalized Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Days Outstanding in 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;% of weighting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted average common shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;12/31/2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Weighted-average shares, &lt;br/&gt;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;11,461,011&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;0.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;3,893,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;3,893,305&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;12/31/2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Series A shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;55,700,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;0.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;18,922,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;365&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;18,922,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;4/7/2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Series B shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;22,686,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;0.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;7,706,443&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;268&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;73&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;5,664,025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;8/17/2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Series B-1 shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;27,152,255&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;0.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;9,223,621&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;136&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;37&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;3,452,558&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td colspan="19" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Weighted average number of common shares outstanding &#x2013; basic and diluted for the year ended December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;31,932,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <tngx:WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments
      contextRef="C_bbbc1247-505e-469d-9e7c-232824266da5"
      decimals="0"
      id="F_36b0bb38-a089-4064-98d7-1a090528326c"
      unitRef="U_shares">11461011</tngx:WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments>
    <tngx:MergerRecapitalizationExchangeRatio
      contextRef="C_278d8753-1cb2-473c-a8e0-50755d56d579"
      decimals="2"
      id="F_0cbc5fe6-f759-4981-bd7e-a3c39c73b1fa"
      unitRef="U_pure">0.34</tngx:MergerRecapitalizationExchangeRatio>
    <tngx:WeightedAverageRecapitalizedCommonShares
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="INF"
      id="F_bb8683bb-ba7a-4d9b-99c2-4b61c482c2c0"
      unitRef="U_shares">3893305</tngx:WeightedAverageRecapitalizedCommonShares>
    <tngx:ConversionWeightagePercentage
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="2"
      id="F_aace0a91-c528-4a01-b83f-0baac36038f0"
      unitRef="U_pure">1</tngx:ConversionWeightagePercentage>
    <tngx:WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="0"
      id="F_22e4287a-81fb-4ebf-b64b-4e3235ff75a7"
      unitRef="U_shares">3893305</tngx:WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_02f13488-10b7-4401-9968-07685eb9a45e"
      decimals="INF"
      id="F_b48bc1cc-456c-4bb7-ac2f-4773cd4ff826"
      unitRef="U_shares">55700000</us-gaap:CommonStockSharesIssued>
    <tngx:MergerRecapitalizationExchangeRatio
      contextRef="C_9c964121-e164-4d55-976f-d2ed2a2c4cf3"
      decimals="2"
      id="F_30653cd8-8a6d-43c0-b645-ccb7c7a56050"
      unitRef="U_pure">0.34</tngx:MergerRecapitalizationExchangeRatio>
    <tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares
      contextRef="C_215089d0-d271-4311-98aa-2b60bca282f8"
      decimals="INF"
      id="F_c105b53e-6b48-4e86-a9cd-4a35a3d237dc"
      unitRef="U_shares">18922317</tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares>
    <tngx:NumberOfDaysOutstanding
      contextRef="C_54d3a1d3-953e-4a0b-ad72-8cc7769a4e4c"
      id="F_c008dea8-2235-4406-b739-09545a97e242">P365D</tngx:NumberOfDaysOutstanding>
    <tngx:ConversionWeightagePercentage
      contextRef="C_54d3a1d3-953e-4a0b-ad72-8cc7769a4e4c"
      decimals="2"
      id="F_b106d99a-8a93-4b9a-b94b-e3a0879b04d9"
      unitRef="U_pure">1</tngx:ConversionWeightagePercentage>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_54d3a1d3-953e-4a0b-ad72-8cc7769a4e4c"
      decimals="0"
      id="F_b7edcc1a-141d-4369-9e56-468ad403b284"
      unitRef="U_shares">18922317</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_9ce5d825-ac92-4a7e-80e6-cb453f08db17"
      decimals="INF"
      id="F_24351bfa-0dac-4703-8b9f-e8b3fd32da16"
      unitRef="U_shares">22686025</us-gaap:CommonStockSharesIssued>
    <tngx:MergerRecapitalizationExchangeRatio
      contextRef="C_bec60272-dcf8-4c0e-bcea-ea6c80078013"
      decimals="2"
      id="F_78d5671c-2dc1-42f4-b207-5ac24c21ed21"
      unitRef="U_pure">0.34</tngx:MergerRecapitalizationExchangeRatio>
    <tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares
      contextRef="C_f0761b4f-fae1-40c4-a58b-8ac4939b226c"
      decimals="INF"
      id="F_c8b9133e-c7d9-4cb3-934a-fdbb706d8149"
      unitRef="U_shares">7706443</tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares>
    <tngx:NumberOfDaysOutstanding
      contextRef="C_4d340cce-d3f4-48f6-8dc7-031a8c6e1628"
      id="F_d3657253-8591-4fbd-abdb-ba68217923e6">P268D</tngx:NumberOfDaysOutstanding>
    <tngx:ConversionWeightagePercentage
      contextRef="C_4d340cce-d3f4-48f6-8dc7-031a8c6e1628"
      decimals="2"
      id="F_efab343e-7de7-4a97-9e06-73a5da896b4d"
      unitRef="U_pure">0.73</tngx:ConversionWeightagePercentage>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_4d340cce-d3f4-48f6-8dc7-031a8c6e1628"
      decimals="0"
      id="F_2d145607-27d2-4a0d-a5f9-22a9baf260c7"
      unitRef="U_shares">5664025</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_102b7845-9bed-440d-ab31-e9a0c961e54f"
      decimals="INF"
      id="F_03688942-d6bd-4811-b09a-55a74cca03eb"
      unitRef="U_shares">27152255</us-gaap:CommonStockSharesIssued>
    <tngx:MergerRecapitalizationExchangeRatio
      contextRef="C_8b25831a-e551-4e81-9130-6ba7264df810"
      decimals="2"
      id="F_6e4c8c27-26c8-4bdb-8143-d896d424fa82"
      unitRef="U_pure">0.34</tngx:MergerRecapitalizationExchangeRatio>
    <tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares
      contextRef="C_12c81343-6906-4a1c-8cc1-2e51478b9b44"
      decimals="INF"
      id="F_362d9dd8-25fe-4990-9156-9f8dd23db5b8"
      unitRef="U_shares">9223621</tngx:StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares>
    <tngx:NumberOfDaysOutstanding
      contextRef="C_a1ba7f84-139b-48f6-aaf0-8e1842c93c6e"
      id="F_489983f5-5796-4407-b741-04f9f6d9d2ed">P136D</tngx:NumberOfDaysOutstanding>
    <tngx:ConversionWeightagePercentage
      contextRef="C_a1ba7f84-139b-48f6-aaf0-8e1842c93c6e"
      decimals="2"
      id="F_d769b50c-d5b2-4cfe-b869-93a3243d9e4e"
      unitRef="U_pure">0.37</tngx:ConversionWeightagePercentage>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_a1ba7f84-139b-48f6-aaf0-8e1842c93c6e"
      decimals="0"
      id="F_7d106fb2-c781-4756-a754-41b885495ca6"
      unitRef="U_shares">3452558</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="0"
      id="F_db11dded-8361-4b1a-b33e-9c6cd9e5074a"
      unitRef="U_shares">31932204</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <tngx:MergerRecapitalizationExchangeRatio
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="2"
      id="F_6ae278b7-4df9-4903-b06d-b16a726eea8c"
      unitRef="U_pure">0.34</tngx:MergerRecapitalizationExchangeRatio>
    <tngx:MergerRecapitalizationExchangeRatio
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="2"
      id="F_966b9a87-40d8-4258-ac61-aae33defa722"
      unitRef="U_pure">0.34</tngx:MergerRecapitalizationExchangeRatio>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_eef2ecbe-38f1-4f4c-ba87-c652471f8a2e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;4. Collaboration Agreements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;2018 Gilead Agreement&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In October 2018, the Company entered into a Research Collaboration and License Agreement (the &#x201c;2018 Gilead Agreement&#x201d;) with Gilead Sciences, Inc. (&#x201c;Gilead&#x201d;). Pursuant to the 2018 Gilead Agreement, the Company performed target discovery and validation activities in accordance with an agreed-upon a multi-year research plan. During the initial &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; research term, Gilead had the option to obtain exclusive, worldwide licenses to develop and commercialize up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;five&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; validated programs (&#x201c;Gilead Program License&#x201d;).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In 2018, Gilead paid the Company a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million non-refundable upfront payment upon the execution of the 2018 Gilead Agreement. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company was eligible to receive milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; billion across all programs and royalties on future sales of commercialized products, if any. For up to two programs licensed by Gilead, the Company had the option to co-develop and co-promote certain programs licensed by Gilead in the U.S. and was eligible to receive royalties on ex-U.S. sales&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company assessed this arrangement in accordance with ASC 606, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, and concluded that the contract counterparty, Gilead, was a customer. The Company identified a single performance obligation under the arrangement consisting of the combination of participating on the joint steering committee and the research and development services provided during the research term. The identified promises were determined to not be individually distinct due to the specialized nature of the early-stage research services to be provided by the Company and the interdependent relationship between the promises. The Company determined that the option for Gilead to extend the term of the arrangement was not priced at a discount, and therefore did not provide Gilead with a material right. This option will be excluded from the transaction price until exercised. At the inception of the 2018 Gilead Agreement, the Company also determined that the Gilead program license options provided to Gilead did not include a material right.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The total transaction price, subject to variable consideration constraints, was allocated to the combined single performance obligation. The Company determined that the single combined performance obligation is satisfied over time as the customer is simultaneously receiving and consuming the benefit of the Company&#x2019;s performance. The future milestone payments represent variable consideration that is fully constrained at inception of the arrangement as the achievement of the milestone events are highly uncertain.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Amended Gilead Agreement&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In August 2020, Gilead made an equity investment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million into the Company as a participant in the Company&#x2019;s Series B-1 preferred stock offering. At the time of the original investment, as well as of the December 31, 2021 balance sheet date, Gilead maintains an ownership of less than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Company's common stock and is thus not considered to be a related party to the Company.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In August 2020, the Company and Gilead also entered into an Amended Research Collaboration and License Agreement (the &#x201c;Gilead Agreement&#x201d;), which superseded and replaced the 2018 Gilead agreement. The Gilead Agreement represents a continuation of the initial target discovery and validation research and development efforts begun under the 2018 Gilead Agreement. Under the Gilead Agreement:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company received upfront, non-refundable consideration of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;125.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million from Gilead upon execution of the Gilead Agreement in 2020; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The term of the 2018 Gilead Agreement ended on the date the Gilead Agreement was executed. The Gilead Agreement has a research term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;seven years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Gilead expanded its option to license up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; programs for which Gilead may obtain exclusive, worldwide licenses to develop and commercialize therapies, subject to applicable license fees; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prior to exercising its option to license a program, Gilead may &#x201c;extend&#x201d; such program, in which case Gilead will pay research extension fees and the Company will continue to collaborate with Gilead to discover and develop programs, potentially through early clinical development; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Gilead has the option to &#x201c;reserve&#x201d; a target during which Gilead may: (i) license the target, (ii) &#x201c;extend&#x201d; the target, or (iii) decline the target, during the designated reserve target period. If, during the reserve target period Tango elects to work on the reserved target, Tango will retain full rights to the target program and Gilead receives a right of first negotiation in connection with any future partnering or licensing of such target by Tango, if any; and &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For up to five programs licensed by Gilead, the Company has the option to co-develop and co-promote the lead product in the U.S., subject to certain exceptions, and is eligible to receive tiered royalties in the first decile on ex-U.S. sales. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Company is eligible to receive up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;410.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million per program in license, research extension, and clinical, regulatory, and commercial milestones&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Gilead Agreement was accounted for as a modification of the 2018 Gilead Agreement under ASC 606 as both the scope and price of the contract were changed under the Gilead Agreement. The additional goods and services to be provided under the Gilead Agreement are not distinct from the combined performance obligation identified under the 2018 Gilead Agreement which was only partially satisfied at the date of contract modification. As such, the Company identified a single combined performance obligation under the Gilead Agreement consisting of the research services and continued participation on the joint steering committee during the research term. As a result, the Company&#x2019;s progress towards completing its research services to Gilead over the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;seven-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; term of the Amended Gilead Agreement was lower than its progress under the three-year term of the 2018 Gilead Agreement and a cumulative catch-up adjustment was recorded during the third quarter of 2020 resulting in a charge of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million against revenue previously recognized through the date of the Gilead Agreement&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2020 and in September 2021, Gilead elected to extend two programs for a research extension fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million each. The Company determined that the additional goods and services relating to the continued research services were not distinct from the early-stage research services already promised to Gilead under the on-going research plan. Consideration pertaining to each of the research extensions is paid to the Company in equal quarterly installment payments over an agreed upon payment schedule. Although future research installment payments are not payable in the event of scientific failure, the Company determined that the variable consideration of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;for each of the extensions should&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;not &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;be constrained as the potential for a significant reversal of cumulative revenue recognized at the contract level is remote, and therefore the research extension consideration was added to the transaction price under the Gilead Agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In April 2021, Gilead licensed a program for an $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million license fee. The $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million license fee was received and recognized as revenue in the second quarter of 2021 since Tango has no continued involvement in the advancement of the program, Gilead can benefit from the license on its own and the license is separately identifiable from the research services.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Gilead Revenue Recognized&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The total transaction price allocated to the combined performance obligation under the Gilead Agreement was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;199.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The total transaction price was comprised of the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million upfront payment pursuant to the 2018 Gilead Agreement, the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;125.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million upfront payment pursuant to the Gilead Agreement, the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million payment pursuant to the research extension fee in December 2020, and the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million payment pursuant to the research extension fee in September 2021. During the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021, the Company recognized &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; of collaboration revenue associated with the Gilead Agreements based on performance completed during the period. During the year ended December 31, 2020, the Company recognized &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;of collaboration revenue associated with the Gilead Agreements based on performance completed during the period which was partially offset by a reduction in revenue resulting from a cumulative catch-up adjustment that was recorded during the third quarter in connection with the Amended Gilead Agreement. During the year ended December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company recognized license revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, associated with the payment received in the second quarter of 2021 pursuant to the April 2021 program license. During the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2020, the Company recognized license revenue &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;associated with the payments received in 2019 pursuant to the program license and Gilead side letter agreement. The consideration allocated to the Gilead License was recognized upon delivery of the underlying license in 2019 as Gilead could benefit from the license on its own and the Gilead License was separately identifiable from the Gilead side letter agreement research services.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company reevaluates the transaction price and the total estimated costs expected to be incurred to satisfy the performance obligations at the end of each reporting period and as uncertain events, such as changes to the expected timing and cost of certain research and development activities that the Company is responsible for, are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; As of December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company had short-term deferred revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26.0&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;32.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;and long-term deferred revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;114.7&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;120.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, res&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;pectively, related to the Gilead collaboration. The remaining long-term revenue is expected to be recognized proportionally to the completed obligations over an expected remaining contractual term of approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.6&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Amounts due to the Company that have not yet been received are recorded as accounts receivable and amounts received that have not yet been recognized as revenue are recorded as deferred revenue on the Company&#x2019;s consolidated balance sheets. &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14.0&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of the total research extension fees of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;24.0&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million had been received, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million had been recorded as accounts receivable and the remaining $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.0&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million was determined to be conditional upon the satisfaction of additional research obligations, and thus a contract asset. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The contract asset balance is presented net of the deferred revenue contract liability.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Costs incurred pursuant to the Gilead Agreements are recorded as research and development expense.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <tngx:ResearchTerm
      contextRef="C_b5f7538f-2233-432c-8332-5f9eee3f4625"
      id="F_2bf8c9ee-4d2f-41c0-9330-304bd29c7087">P3Y</tngx:ResearchTerm>
    <tngx:NumberOfLicensedProduct
      contextRef="C_b5f7538f-2233-432c-8332-5f9eee3f4625"
      decimals="INF"
      id="F_51dad5c5-cee4-479c-ba80-c67f14efa43d"
      unitRef="U_Program">5</tngx:NumberOfLicensedProduct>
    <tngx:NonrefundableUpfrontPaymentsReceived
      contextRef="C_f0aee49e-cda1-49dc-bfc8-ca8549516a0d"
      decimals="-5"
      id="F_f27b6607-8e9b-404a-941b-09bbe2f47c21"
      unitRef="U_USD">50000000.0</tngx:NonrefundableUpfrontPaymentsReceived>
    <tngx:MilestonePaymentsReceivable
      contextRef="C_53e4d63e-21a6-43e4-9dcd-522040ca6553"
      decimals="-8"
      id="F_91ba0a90-b4e0-4ace-a66e-2f62c4e78855"
      unitRef="U_USD">1700000000</tngx:MilestonePaymentsReceivable>
    <us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital
      contextRef="C_1788c8d9-b2a8-41ee-b8fb-f1e5436c41eb"
      decimals="-5"
      id="F_be2eb3eb-0672-4217-9bc6-cc3a56bcfad7"
      unitRef="U_USD">20000000.0</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_a752877b-c28d-4699-ba2c-e36a1efb2376"
      decimals="INF"
      id="F_4983ff61-83fb-418f-b28f-7b58ea228ead"
      unitRef="U_pure">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital
      contextRef="C_ff6e5760-462e-48b4-9885-3a1afb5a7028"
      decimals="-5"
      id="F_5ddffacb-bf10-426c-89aa-c0e9b56f1218"
      unitRef="U_USD">125000000.0</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
    <tngx:ResearchTerm
      contextRef="C_7e5ec8fe-aded-4985-ba52-0a77d0cc933c"
      id="F_ed706d5e-3798-463e-a304-790a6be0ba6c">P7Y</tngx:ResearchTerm>
    <tngx:NumberOfLicensedProduct
      contextRef="C_7e5ec8fe-aded-4985-ba52-0a77d0cc933c"
      decimals="INF"
      id="F_1526fb82-6538-4208-9982-8cc7dc325eff"
      unitRef="U_Program">15</tngx:NumberOfLicensedProduct>
    <tngx:MilestonePaymentsReceivable
      contextRef="C_ff6e5760-462e-48b4-9885-3a1afb5a7028"
      decimals="INF"
      id="F_1d89d071-84ac-4e22-9bb7-4bd9084bdd64"
      unitRef="U_USD">410000000.0</tngx:MilestonePaymentsReceivable>
    <tngx:ResearchTerm
      contextRef="C_7e5ec8fe-aded-4985-ba52-0a77d0cc933c"
      id="F_87eee455-78ac-4648-9de6-a005c014a83a">P7Y</tngx:ResearchTerm>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract
      contextRef="C_f2607f6a-532b-425d-bef1-6f23ecb3ca7b"
      decimals="-5"
      id="F_425c1843-e530-4a01-afee-cb0a0a96fcf1"
      unitRef="U_USD">-11300000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract>
    <tngx:ResearchExtensionFee
      contextRef="C_e9180ff9-f174-4296-94c6-215c9a213af5"
      decimals="-5"
      id="F_03c2c1c1-5a67-4a99-a2e0-dc7d54ef601d"
      unitRef="U_USD">12000000.0</tngx:ResearchExtensionFee>
    <tngx:ResearchExtensionFee
      contextRef="C_23df1860-e6dc-439c-b62d-1e850c67c5c6"
      decimals="-5"
      id="F_d289aea2-7441-4ae9-b488-d6852e839383"
      unitRef="U_USD">12000000.0</tngx:ResearchExtensionFee>
    <tngx:ResearchExtensionFeeVariableConsideration
      contextRef="C_16173712-f7d9-4b40-a745-785b1fd272f9"
      decimals="-5"
      id="F_6942ab59-2cd3-403c-aa12-30b4284207f4"
      unitRef="U_USD">12000000.0</tngx:ResearchExtensionFeeVariableConsideration>
    <tngx:SponsoredALicenceProgramfeeAmount
      contextRef="C_fe7f16a9-c541-41d8-939f-8739b8cdc7e4"
      decimals="-5"
      id="F_5f134a5e-eff7-434c-a2e7-1498f52338ec"
      unitRef="U_USD">11000000.0</tngx:SponsoredALicenceProgramfeeAmount>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_2a0dabb0-2512-43fe-b76a-9eb289d5c030"
      decimals="-5"
      id="F_7cda1dca-bb1e-4455-a25b-3dbfad427b5f"
      unitRef="U_USD">11000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_511b1fab-19fa-4719-9e1a-7d2d78a9c251"
      decimals="-5"
      id="F_26185bd4-2e53-4998-ad36-a5ffa083c7a1"
      unitRef="U_USD">199000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <tngx:NonrefundableUpfrontPaymentsReceived
      contextRef="C_89ff1d64-5c59-4fe4-b302-72f7ae4dcbe5"
      decimals="-5"
      id="F_b9d37a94-9802-4469-bfd8-5e25cefbb43a"
      unitRef="U_USD">50000000.0</tngx:NonrefundableUpfrontPaymentsReceived>
    <tngx:NonrefundableUpfrontPaymentsReceived
      contextRef="C_16173712-f7d9-4b40-a745-785b1fd272f9"
      decimals="-5"
      id="F_5ee05e3a-f5b8-4e2c-ade0-a30075125dd5"
      unitRef="U_USD">125000000.0</tngx:NonrefundableUpfrontPaymentsReceived>
    <tngx:ResearchExtensionFee
      contextRef="C_e9180ff9-f174-4296-94c6-215c9a213af5"
      decimals="-5"
      id="F_b179ec0b-273c-4aa9-88c0-757b49f7c6d4"
      unitRef="U_USD">12000000.0</tngx:ResearchExtensionFee>
    <tngx:ResearchExtensionFee
      contextRef="C_23df1860-e6dc-439c-b62d-1e850c67c5c6"
      decimals="-5"
      id="F_b0287f0d-2988-4acf-8172-13220bd3646c"
      unitRef="U_USD">12000000.0</tngx:ResearchExtensionFee>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_ee792758-9f05-4175-9451-5b418924373a"
      decimals="-5"
      id="F_6947e454-f864-496a-b27e-155af57c4837"
      unitRef="U_USD">26000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_27037302-4c51-4ed7-bedc-d4aef3c65de1"
      decimals="-5"
      id="F_03b44042-9157-4629-b5f9-002f8b6e211c"
      unitRef="U_USD">7000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_7736b799-fc9e-41cb-ac3c-ebefeef52eb3"
      decimals="-5"
      id="F_de52f843-dd3b-463e-bf26-33fdd8a6370b"
      unitRef="U_USD">11000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_eafdff08-f1e7-45e0-b53f-598f4991a9f3"
      decimals="-5"
      id="F_fb374ce8-f8fa-402a-a036-7cece09ecb1d"
      unitRef="U_USD">700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_511b1fab-19fa-4719-9e1a-7d2d78a9c251"
      decimals="-5"
      id="F_22c89913-bb51-480f-9a81-028a8ead370d"
      unitRef="U_USD">26000000.0</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_cf39d22f-09b3-4d53-87d3-8d7dc1f67897"
      decimals="-5"
      id="F_40a3d5f4-06fe-4fed-bcaf-65c28dd86a5e"
      unitRef="U_USD">32000000.0</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_511b1fab-19fa-4719-9e1a-7d2d78a9c251"
      decimals="-5"
      id="F_017116b3-e3e8-415a-86d5-e184ba780e67"
      unitRef="U_USD">114700000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_cf39d22f-09b3-4d53-87d3-8d7dc1f67897"
      decimals="-5"
      id="F_f2cbb6fe-3d72-44d0-81e7-e28bc0058520"
      unitRef="U_USD">120800000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="C_407a2f79-30e9-41df-8dfa-8788fa29b7cb"
      id="F_9e226477-5820-4ffa-b090-6184cee6ce55">P5Y7M6D</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:ProceedsFromFeesReceived
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-5"
      id="F_9d8a29e9-e82b-4a5e-b61f-778b339de60b"
      unitRef="U_USD">14000000.0</us-gaap:ProceedsFromFeesReceived>
    <tngx:ReceivableResearchExtensionFee
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-5"
      id="F_dd021af2-bd9e-4b3c-ae96-aefe8dc566d4"
      unitRef="U_USD">24000000.0</tngx:ReceivableResearchExtensionFee>
    <tngx:AccountsReceivableCurrentResearchExtensionFee
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-5"
      id="F_43bddbac-e397-4d47-8239-77953b5a30b7"
      unitRef="U_USD">2000000.0</tngx:AccountsReceivableCurrentResearchExtensionFee>
    <tngx:Contractassetresearchextensionfee
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-5"
      id="F_09fa9dd0-320d-47dc-a9e6-7354889b7c0d"
      unitRef="U_USD">8000000.0</tngx:Contractassetresearchextensionfee>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_6016809a-f078-4e9e-abdf-b2bd66857a12">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;5. Fair Value Measurements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.325%;"/&gt;
        &lt;td style="width:1.163%;"/&gt;
        &lt;td style="width:1.263%;"/&gt;
        &lt;td style="width:9.884%;"/&gt;
        &lt;td style="width:0.616%;"/&gt;
        &lt;td style="width:1.163%;"/&gt;
        &lt;td style="width:1.263%;"/&gt;
        &lt;td style="width:9.943%;"/&gt;
        &lt;td style="width:0.616%;"/&gt;
        &lt;td style="width:1.163%;"/&gt;
        &lt;td style="width:1.263%;"/&gt;
        &lt;td style="width:9.735%;"/&gt;
        &lt;td style="width:0.616%;"/&gt;
        &lt;td style="width:1.163%;"/&gt;
        &lt;td style="width:1.263%;"/&gt;
        &lt;td style="width:9.943%;"/&gt;
        &lt;td style="width:0.616%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair Market Value Measurements&lt;br/&gt;as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;62,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_a762df4b-f3ed-4d4a-a408-0c28875d2805;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;62,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;38,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;38,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Marketable debt securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;287,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;287,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;55,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;55,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;62,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;380,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;443,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.518%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.273%;"/&gt;
        &lt;td style="width:9.526%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.273%;"/&gt;
        &lt;td style="width:9.546%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.273%;"/&gt;
        &lt;td style="width:9.456%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.273%;"/&gt;
        &lt;td style="width:9.546%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair Market Value Measurements&lt;br/&gt;as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_0b637d1f-640c-496c-91b4-be2bae95b9b9;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Marketable debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;131,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;131,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;169,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;181,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; transfers between fair value levels during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_58a07f75-5377-41ef-8d53-96f5f4be7833">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following tables present information about the Company&#x2019;s financial assets measured at fair value on a recurring basis:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.325%;"/&gt;
        &lt;td style="width:1.163%;"/&gt;
        &lt;td style="width:1.263%;"/&gt;
        &lt;td style="width:9.884%;"/&gt;
        &lt;td style="width:0.616%;"/&gt;
        &lt;td style="width:1.163%;"/&gt;
        &lt;td style="width:1.263%;"/&gt;
        &lt;td style="width:9.943%;"/&gt;
        &lt;td style="width:0.616%;"/&gt;
        &lt;td style="width:1.163%;"/&gt;
        &lt;td style="width:1.263%;"/&gt;
        &lt;td style="width:9.735%;"/&gt;
        &lt;td style="width:0.616%;"/&gt;
        &lt;td style="width:1.163%;"/&gt;
        &lt;td style="width:1.263%;"/&gt;
        &lt;td style="width:9.943%;"/&gt;
        &lt;td style="width:0.616%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair Market Value Measurements&lt;br/&gt;as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash equivalents:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;62,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_a762df4b-f3ed-4d4a-a408-0c28875d2805;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;62,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;38,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;38,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Marketable debt securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;287,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;287,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;55,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;55,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;62,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;380,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;443,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.518%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.273%;"/&gt;
        &lt;td style="width:9.526%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.273%;"/&gt;
        &lt;td style="width:9.546%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.273%;"/&gt;
        &lt;td style="width:9.456%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.273%;"/&gt;
        &lt;td style="width:9.546%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair Market Value Measurements&lt;br/&gt;as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_0b637d1f-640c-496c-91b4-be2bae95b9b9;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Marketable debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;131,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;131,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;169,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;181,812&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_c15c2969-e6e9-437c-89f0-0a388a5877e2"
      decimals="-3"
      id="F_7fa0b138-4641-4718-83be-7b9e30fba07f"
      unitRef="U_USD">62244000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_068a6be4-9f16-496f-98c5-0d1f32f3787e"
      decimals="-3"
      id="F_50941480-7cbb-4d2d-acd2-82a05d5e66ef"
      unitRef="U_USD">62244000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:USGovernmentSecuritiesAtCarryingValue
      contextRef="C_298c6bea-143e-4985-beea-3b429f7512a4"
      decimals="-3"
      id="F_d5f33a62-ad8c-4e17-b3c6-58449ff6fa3a"
      unitRef="U_USD">38433000</us-gaap:USGovernmentSecuritiesAtCarryingValue>
    <us-gaap:USGovernmentSecuritiesAtCarryingValue
      contextRef="C_068a6be4-9f16-496f-98c5-0d1f32f3787e"
      decimals="-3"
      id="F_7aed663f-33c9-4a86-b405-e03e3ed8f388"
      unitRef="U_USD">38433000</us-gaap:USGovernmentSecuritiesAtCarryingValue>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_f6a066c6-0c2f-4fc7-b6b0-b827d92388ad"
      decimals="-3"
      id="F_fcd7719b-4d90-46b3-b3f9-e55f6e0b0092"
      unitRef="U_USD">287123000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_541297f2-8d87-4855-8f1c-53e1e755ed5a"
      decimals="-3"
      id="F_3c8eee5a-6008-4232-a776-7a2fcb0b787b"
      unitRef="U_USD">287123000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_7d2bf4c6-5a88-4f48-9b87-0040ef400364"
      decimals="-3"
      id="F_1f968655-26b8-43a1-b89a-2eb3fc35baa6"
      unitRef="U_USD">55387000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_77f3de9c-11d0-45e7-b744-00f10cdd56b9"
      decimals="-3"
      id="F_8ae047a4-f0f4-4a60-a859-e287b6bce81e"
      unitRef="U_USD">55387000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c15c2969-e6e9-437c-89f0-0a388a5877e2"
      decimals="-3"
      id="F_489a5919-b4ec-4e1a-92e1-b7b2f31491e5"
      unitRef="U_USD">62244000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_298c6bea-143e-4985-beea-3b429f7512a4"
      decimals="-3"
      id="F_65fb2b09-ada2-44f0-87bd-20b3f246c592"
      unitRef="U_USD">380943000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_068a6be4-9f16-496f-98c5-0d1f32f3787e"
      decimals="-3"
      id="F_1a00d671-aa7f-4b14-8a4e-00790f3d5327"
      unitRef="U_USD">443187000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_a908a175-5b6c-474d-a2f6-5ae2b7895667"
      decimals="-3"
      id="F_b4c86d23-ce77-4c41-928b-4f0d0d5ce706"
      unitRef="U_USD">12698000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="C_274ae3eb-6528-4797-924a-99295d4ce141"
      decimals="-3"
      id="F_3be42864-8852-4424-a1fc-49a50849c90a"
      unitRef="U_USD">12698000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:USGovernmentSecuritiesAtCarryingValue
      contextRef="C_3461b9bd-5e6d-4357-91f1-01033ae50263"
      decimals="-3"
      id="F_3e9adffe-05c9-49c3-be48-3ac87cb53ed4"
      unitRef="U_USD">7175000</us-gaap:USGovernmentSecuritiesAtCarryingValue>
    <us-gaap:USGovernmentSecuritiesAtCarryingValue
      contextRef="C_274ae3eb-6528-4797-924a-99295d4ce141"
      decimals="-3"
      id="F_1f15c3bb-7e33-48cb-b944-f11daf67706d"
      unitRef="U_USD">7175000</us-gaap:USGovernmentSecuritiesAtCarryingValue>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_50f18cbc-9bd3-450e-8121-9d1f8276ed3c"
      decimals="-3"
      id="F_1f0a7138-e397-4d22-a346-3ea6d8678a2e"
      unitRef="U_USD">131939000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_c89c0bd3-61fe-4fe1-aaf8-04c333eb7930"
      decimals="-3"
      id="F_e5864452-a828-4444-a88f-eeae82ba735a"
      unitRef="U_USD">131939000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_b1561790-aba2-4710-8ff9-2107c95bfddb"
      decimals="-3"
      id="F_8a5b092b-6db4-43c5-87a1-78e408fa1464"
      unitRef="U_USD">30000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="C_28f5ff88-be03-44d4-a0e8-fd39586ab708"
      decimals="-3"
      id="F_6694cd62-8d36-4e2d-806e-1e485d94d6a9"
      unitRef="U_USD">30000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a908a175-5b6c-474d-a2f6-5ae2b7895667"
      decimals="-3"
      id="F_3b13b35f-1e6b-438f-a760-c03a03f6dee7"
      unitRef="U_USD">12698000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3461b9bd-5e6d-4357-91f1-01033ae50263"
      decimals="-3"
      id="F_4ac6b563-c792-4484-9822-3655bda61417"
      unitRef="U_USD">169114000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_274ae3eb-6528-4797-924a-99295d4ce141"
      decimals="-3"
      id="F_6614c887-0b1d-4fb2-8e54-db85eb4acded"
      unitRef="U_USD">181812000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_40883a4f-816d-488c-a120-8b3f62f9e51c"
      unitRef="U_USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_7f00175c-fa11-4af8-b562-4e8b810ae48f"
      unitRef="U_USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_7bf213e2-d3a3-4d3b-9306-4405a4100af1"
      unitRef="U_USD">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_34752e3c-2e9e-4f44-b6fd-fda362010f62"
      unitRef="U_USD">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_f41d5099-9526-4498-b949-3300ae8dedf5"
      unitRef="U_USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_2ee338b9-c6bf-4189-8fb3-e62f9e40006c"
      unitRef="U_USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_0bc77dc7-5149-40fd-90a8-90e9e5fbfc89"
      unitRef="U_USD">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
    <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_e29565d5-3353-4ce0-a300-370835d0257b"
      unitRef="U_USD">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_00e7c4ec-3fef-4f34-866f-649673519cde">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;6. Marketable Securities&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company values its marketable securities using independent pricing services which normally derive security prices from recently reported trades for identical or similar securities, making adjustments based on significant observable transactions. At each balance sheet date, observable market inputs may include trade information, broker or dealer quotes, bids, offers or a combination of these data sources.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes the Company&#x2019;s marketable debt securities, classified as available-for-sale:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:41.286%;"/&gt;
        &lt;td style="width:1.382%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:11.333%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
        &lt;td style="width:1.382%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:11.333%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
        &lt;td style="width:1.382%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:11.333%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
        &lt;td style="width:1.382%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:11.333%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair Value Measurements&lt;br/&gt;as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Marketable debt securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;287,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;287,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;55,576&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;55,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;343,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;342,510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:41.397%;"/&gt;
        &lt;td style="width:1.392%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:11.351%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
        &lt;td style="width:1.392%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:11.351%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
        &lt;td style="width:1.392%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:11.351%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
        &lt;td style="width:1.392%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:11.351%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair Value Measurements&lt;br/&gt;as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Marketable debt securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;131,927&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;131,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;29,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;161,922&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;161,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company holds investment grade marketable securities, with less than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of marketable debt securities considered to be in an unrealized loss position as of &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;none&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; considered to be in an unrealized loss position as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2020. Although the marketable debt securities are held at an unrealized loss position at December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company does not intend to sell the marketable securities prior to the value of the securities being recovered. Further, the Company has concluded that it is more likely than not that the marketable securities cost basis values will be recovered prior to sale of the securities and that there are no conditions or events that might require the Company to sell the securities before recovery of the cost basis occurs. As a result, the Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t record any impairments to marketable securities or reserves for credit losses related to its marketable debt securities during the periods then ended. Marketable securities include $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in accrued interest at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and December 31, 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, respectively.&lt;/span&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_40147b34-1987-4f5d-a0dc-8da33b0c0534">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes the Company&#x2019;s marketable debt securities, classified as available-for-sale:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:41.286%;"/&gt;
        &lt;td style="width:1.382%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:11.333%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
        &lt;td style="width:1.382%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:11.333%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
        &lt;td style="width:1.382%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:11.333%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
        &lt;td style="width:1.382%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:11.333%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair Value Measurements&lt;br/&gt;as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Marketable debt securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;287,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;577&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;287,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;55,576&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;55,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;343,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;342,510&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:41.397%;"/&gt;
        &lt;td style="width:1.392%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:11.351%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
        &lt;td style="width:1.392%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:11.351%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
        &lt;td style="width:1.392%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:11.351%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
        &lt;td style="width:1.392%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:11.351%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair Value Measurements&lt;br/&gt;as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Marketable debt securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. Treasury bills&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;131,927&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;131,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;29,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;161,922&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;161,939&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f6d997d2-d3a1-431e-a764-711fd76bb4c5"
      decimals="-3"
      id="F_1ac5e498-b89f-42d5-b6c8-97bc6871609c"
      unitRef="U_USD">287699000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_f6d997d2-d3a1-431e-a764-711fd76bb4c5"
      decimals="-3"
      id="F_741f0ef8-4d86-4ef9-8ef5-a0469c718a18"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_f6d997d2-d3a1-431e-a764-711fd76bb4c5"
      decimals="-3"
      id="F_3f3ebf75-7f0e-44d3-bda1-7391c47ca0ba"
      unitRef="U_USD">577000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_f6d997d2-d3a1-431e-a764-711fd76bb4c5"
      decimals="-3"
      id="F_525de4b1-6361-46f4-9a03-9c1b0b05120e"
      unitRef="U_USD">287123000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_2065fc3b-bae5-4c9b-8a8a-012ebcce2f51"
      decimals="-3"
      id="F_571e912b-dd31-465e-bbb0-2042cc8e0ad2"
      unitRef="U_USD">55576000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_2065fc3b-bae5-4c9b-8a8a-012ebcce2f51"
      decimals="-3"
      id="F_388c1bac-a8b7-40dd-be44-a79f3345d1f7"
      unitRef="U_USD">189000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_2065fc3b-bae5-4c9b-8a8a-012ebcce2f51"
      decimals="-3"
      id="F_22104bce-4971-4365-982e-17071bf90f0e"
      unitRef="U_USD">55387000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_789c2ac8-4cae-4a6f-b8fc-4f201b0b38b7"
      unitRef="U_USD">343275000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_d5a23b42-be6c-4e7c-9da2-8e085d0c46dd"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_1dacb90a-e873-4c87-990a-85986a570461"
      unitRef="U_USD">766000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_19abf988-4243-488a-8ee6-f9f53e99394f"
      unitRef="U_USD">342510000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_7b2e605f-e833-48d9-925e-ef6e94396041"
      decimals="-3"
      id="F_f1c4b91e-8194-41de-8e9c-0612d39e272b"
      unitRef="U_USD">131927000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_7b2e605f-e833-48d9-925e-ef6e94396041"
      decimals="-3"
      id="F_b926604b-47fa-4f7a-b709-a5acd49256b0"
      unitRef="U_USD">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_7b2e605f-e833-48d9-925e-ef6e94396041"
      decimals="-3"
      id="F_2fadbd78-6098-4b9b-9a40-1a073d67d39c"
      unitRef="U_USD">131939000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_443492d4-1dcb-460f-9785-b7dc5f094e40"
      decimals="-3"
      id="F_d0033d8d-398b-46eb-bde8-de804069f76e"
      unitRef="U_USD">29995000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_443492d4-1dcb-460f-9785-b7dc5f094e40"
      decimals="-3"
      id="F_ff3b4b11-e345-46fa-9473-69b7de6d053a"
      unitRef="U_USD">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_443492d4-1dcb-460f-9785-b7dc5f094e40"
      decimals="-3"
      id="F_c9cc05fe-a260-4f3f-bc4d-89d820d346a6"
      unitRef="U_USD">30000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_efde379e-15dd-40d0-a89c-40eca236eb06"
      unitRef="U_USD">161922000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_334a2a0e-0ee1-44a1-9a89-bc643eea7858"
      unitRef="U_USD">17000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_786a1fce-2205-4e91-8887-7bdeb2c30e27"
      unitRef="U_USD">161939000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_767a7086-7e98-4669-a6a3-ba4e0f1c5fc1"
      decimals="-5"
      id="F_1dc8f64f-ae7b-4fb7-b8aa-8372fe77e911"
      unitRef="U_USD">800000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="C_cca1c772-6eb6-4c26-835c-7b92064cf842"
      decimals="INF"
      id="F_7a44167a-8aa9-43c1-a467-d6e44b038ed0"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="C_4941cdcd-9899-46a1-b43b-5fcbeb247365"
      decimals="INF"
      id="F_91431bd5-0193-403e-bc4a-3a462a1d667e"
      unitRef="U_USD">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="C_adf61d0e-b654-4419-b270-224361ec9e78"
      decimals="INF"
      id="F_30585799-ecdb-4a5b-ac64-83c04278c2c3"
      unitRef="U_USD">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
      contextRef="C_13789a54-6583-461f-ace8-50d596a0d9e6"
      decimals="-5"
      id="F_3021dfb0-68b9-4d4d-ad3c-125d703abf14"
      unitRef="U_USD">200000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
      contextRef="C_cca1c772-6eb6-4c26-835c-7b92064cf842"
      decimals="-5"
      id="F_ed50fb45-dee6-4085-a31f-d7b8a84e9930"
      unitRef="U_USD">100000</us-gaap:DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_c368f663-2504-4667-8364-bb089ab27bc0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;7. Supplemental Balance Sheet Information&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, net as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020 consists of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.267%;"/&gt;
        &lt;td style="width:1.558%;"/&gt;
        &lt;td style="width:1.525%;"/&gt;
        &lt;td style="width:13.268%;"/&gt;
        &lt;td style="width:1.016%;"/&gt;
        &lt;td style="width:1.558%;"/&gt;
        &lt;td style="width:1.525%;"/&gt;
        &lt;td style="width:13.268%;"/&gt;
        &lt;td style="width:1.016%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;198&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Depreciation expense was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; for the years ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued expenses and other current liabilities as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020 include the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.54%;"/&gt;
        &lt;td style="width:1.568%;"/&gt;
        &lt;td style="width:1.535%;"/&gt;
        &lt;td style="width:13.408%;"/&gt;
        &lt;td style="width:0.718%;"/&gt;
        &lt;td style="width:1.568%;"/&gt;
        &lt;td style="width:1.535%;"/&gt;
        &lt;td style="width:13.408%;"/&gt;
        &lt;td style="width:0.718%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Payroll and employee-related costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,652&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_38736709-ec07-419c-a22f-30e125f435b4">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, net as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020 consists of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.267%;"/&gt;
        &lt;td style="width:1.558%;"/&gt;
        &lt;td style="width:1.525%;"/&gt;
        &lt;td style="width:13.268%;"/&gt;
        &lt;td style="width:1.016%;"/&gt;
        &lt;td style="width:1.558%;"/&gt;
        &lt;td style="width:1.525%;"/&gt;
        &lt;td style="width:13.268%;"/&gt;
        &lt;td style="width:1.016%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,587&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;198&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_3a91db9e-6734-413e-8e17-66bb5d8bf9ac"
      decimals="-3"
      id="F_bd23512a-e93d-4e01-96d6-1d37e1dfdeae"
      unitRef="U_USD">5587000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_292501bc-d852-43e2-83eb-a3fe171ce656"
      decimals="-3"
      id="F_1e314af0-55f2-4bd3-88eb-99747a8d103f"
      unitRef="U_USD">4580000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_31658d1c-3873-4646-a06e-c5e4358d9429"
      decimals="-3"
      id="F_b1fb9eb1-3fc8-4c65-a122-9381745bd5fc"
      unitRef="U_USD">198000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_282b9328-036d-4123-bd3c-893d0d979dbc"
      decimals="-3"
      id="F_7b05af27-89af-4f99-8ecb-0e63e2501afa"
      unitRef="U_USD">172000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e935a51c-44f5-45c0-8969-0acd3c8dce51"
      decimals="-3"
      id="F_943e230c-9b65-4872-bce2-6e5bfcaf6220"
      unitRef="U_USD">125000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_8b242d70-f5a0-401d-9c7c-8f5525429c2b"
      decimals="-3"
      id="F_c416a4ec-699b-4319-9d4d-61c77b861b30"
      unitRef="U_USD">125000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_8a373566-cfe9-4a8d-b52b-3ba1ff5a8bdc"
      decimals="-3"
      id="F_4e7764a7-850f-4846-a4a3-ff1fb55c8f45"
      unitRef="U_USD">467000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_9229ee0f-56b0-498f-a9f5-422119379b39"
      decimals="-3"
      id="F_1b9b6fdc-6b97-4291-84e3-00e0330519f0"
      unitRef="U_USD">384000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_af91c863-9582-40c7-8c3d-51a5ac90d570"
      decimals="-3"
      id="F_b78c211c-4f90-4f0f-8699-3c822920b69e"
      unitRef="U_USD">246000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_b1745945-8454-47c6-9623-cbfd040e27d1"
      decimals="-3"
      id="F_1c5cdde5-73ae-43f6-9a71-7c32132af269"
      unitRef="U_USD">246000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f25b4a33-16a9-486a-8c10-2233f7ee8a8a"
      decimals="-3"
      id="F_307b1605-d508-489a-b8fb-3ba69503bfd2"
      unitRef="U_USD">738000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_951d6af3-a973-46b9-9f17-f5ebae843137"
      unitRef="U_USD">7361000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_7302655d-1f06-4be5-8f80-8e613dc8ed83"
      unitRef="U_USD">5507000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_0ed5c54d-0bf4-4616-ac7d-ce9c3068df9c"
      unitRef="U_USD">2529000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_632e349c-4fb8-4c1b-9c97-a46c0a184364"
      unitRef="U_USD">1684000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_c852d4c1-47e7-4e03-ba86-8a208d810a01"
      unitRef="U_USD">4832000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_0e9e3463-5c1a-4514-ad6e-ee6f1f12e102"
      unitRef="U_USD">3823000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-5"
      id="F_4ba0b50f-2f23-4489-bfed-2101eee3e0d6"
      unitRef="U_USD">900000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-5"
      id="F_53f1e10b-aa87-4f30-831f-30c7720cc8be"
      unitRef="U_USD">700000</us-gaap:Depreciation>
    <tngx:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentTableTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_36a57877-65e9-4a67-828f-a74358c257d1">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued expenses and other current liabilities as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020 include the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.54%;"/&gt;
        &lt;td style="width:1.568%;"/&gt;
        &lt;td style="width:1.535%;"/&gt;
        &lt;td style="width:13.408%;"/&gt;
        &lt;td style="width:0.718%;"/&gt;
        &lt;td style="width:1.568%;"/&gt;
        &lt;td style="width:1.535%;"/&gt;
        &lt;td style="width:13.408%;"/&gt;
        &lt;td style="width:0.718%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Payroll and employee-related costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,652&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</tngx:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_3b930ce5-b0ba-445d-a95e-a64f0bb269a0"
      unitRef="U_USD">3688000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_c9d49251-fd37-458a-845e-872c951f8a9f"
      unitRef="U_USD">2652000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <tngx:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_1b130c08-94fe-41da-8c67-d1066a88f619"
      unitRef="U_USD">5533000</tngx:AccruedResearchAndDevelopmentCostsCurrent>
    <tngx:AccruedResearchAndDevelopmentCostsCurrent
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_89257bd4-2188-40eb-8bc6-55943165df56"
      unitRef="U_USD">2695000</tngx:AccruedResearchAndDevelopmentCostsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_c5f88c6d-1dab-4960-bb50-9fd842ddc1e9"
      unitRef="U_USD">666000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_c85dc1e7-567e-4c6d-b27b-076ce99ca6af"
      unitRef="U_USD">793000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <tngx:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_903fe0bd-2cce-4cde-8592-9240198bc0d3"
      unitRef="U_USD">9887000</tngx:AccruedExpensesAndOtherCurrentLiabilities>
    <tngx:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_92f83b91-9f17-47e6-92ef-7a154992bbdc"
      unitRef="U_USD">6140000</tngx:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_ac6240d7-36c5-4cf4-9910-0f11d29716e2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;8. Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Operating Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In July 2017, the Company entered into a lease of office and laboratory space at 100 Binney Street in Cambridge, Massachusetts for the Company&#x2019;s corporate headquarters. The lease commenced in March 2018 and rent commenced in June 2018. This lease had an original term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;eight years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; with an &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;option to extend&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_9ce82792-73b0-4614-be7e-852d5e09b293;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; additional&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; three-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; period.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Upon commencement of the lease, the Company recorded an operating lease liability in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and related operating lease right-of-use asset in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. Upfront payments totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for rent and tenant improvements were included as a reduction in the calculation of the lease liability amount upon the commencement of the lease. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; tenant obligation payments made for leasehold improvements for the periods ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The fixed annual rent payable under the lease was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, increasing by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% annually from the rent commencement date. The minimum rent payments to be paid over the original term of the lease totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. The additional rental payments associated with the renewal option are not included in the calculation of the operating lease right-of-use asset and associated operating lease liability as the renewal is not considered probable of occurring. The lease agreement required the Company to provide a letter of credit for $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million that is collateralized with cash that is recorded as restricted cash in the accompanying balance sheet.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In September 2019, the Company entered into a new lease for office and laboratory space at 201 Brookline Avenue in Boston, Massachusetts. As of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the space was undergoing construction and the lease is expected to commence for accounting purposes in the first half of 2022. The Company is not deemed to be the accounting owner of the construction project due to the nature of the work being performed and the Company&#x2019;s lack of control over the project. In conjunction with executing the lease, the Company provided the landlord a letter of credit for $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. The letter of credit is collateralized with cash that is recorded as restricted cash in the accompanying balance sheet as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2021.&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; In January 2022, the Company provided an additional letter of credit in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.7&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the remaining security deposit balance on the lease.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Upon commencement of the 201 Brookline Avenue lease, the Company will determine the appropriate classification of the lease, the amount of the associated lease liability and the amount of the right-of-use asset that will be recognized on the balance sheet. The lease has a non-cancelable term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; with an &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;option to extend&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; for up to two five-year periods.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; The fixed annual rent payable under the lease is $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, increasing by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% annually from the rent commencement date. &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is entitled to a tenant improvements allowance of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12.7&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;November 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company entered into a lease termination agreement for the leased office and laboratory space at 100 Binney Street in Cambridge, Massachusetts. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The lease termination agreement is a modification of the original lease agreement that provides for, among other things, the acceleration of the expiration of the original term of the lease from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;June 30, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to an earlier lease termination date, for which the earlier date shall be no later than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;October 15, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The execution of the lease termination agreement resulted in reductions to the associated lease liability and right-of-use asset balances of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.3&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.2&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, in the fourth quarter of 2021. The $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million letter of credit associated with the lease and recorded as restricted cash on the balance sheet as of &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 will be returned to the Company on the last day of the modified lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s rent payments for the lease at 100 Binney Street are classified as operating lease costs in the chart below. The lease is a net lease and therefore the non-lease components, such as common area maintenance, are paid separately from rent based on actual costs incurred; therefore, the non-lease components are not included in the right-of-use asset and liability and are reflected as an expense in the period incurred. The non-lease components are classified as variable costs in the chart below. As of December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, assets under the operating lease totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, res&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;pectively. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The elements of lease cost were as follows: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.656%;"/&gt;
        &lt;td style="width:1.581%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:12.435%;"/&gt;
        &lt;td style="width:2.137%;"/&gt;
        &lt;td style="width:1.581%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:11.928%;"/&gt;
        &lt;td style="width:2.137%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total operating lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Other information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating cash flows used for operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,782&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted average remaining lease term in years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Future minimum lease payments under leases that have commenced as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 are as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:78.205%;"/&gt;
        &lt;td style="width:1.865%;"/&gt;
        &lt;td style="width:1.828%;"/&gt;
        &lt;td style="width:16.884%;"/&gt;
        &lt;td style="width:1.218%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Maturity of Lease&lt;br/&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_f01892b3-15ca-4460-8be5-0c673db5d09c"
      id="F_f4ec1fab-2c83-406c-bc22-39784328f83d">P8Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_4a8a40a2-67af-41ac-a7da-247f61928fb4"
      id="F_e2c0065f-e016-40a4-99fc-148aa5612190">option to extend for one additional three-year period.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_4a8a40a2-67af-41ac-a7da-247f61928fb4"
      id="F_651aa0e8-a146-429b-b499-66da6cd5f106">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_75a3203a-e21d-4b7a-bf56-5007b4cfa6c3"
      id="F_086f3570-1f34-4156-b124-f1c8a8434a53">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_42860419-a9e3-4801-beb1-962b31b7feab"
      decimals="-5"
      id="F_88efa716-1882-46d5-8ce9-cd8d35b0af00"
      unitRef="U_USD">9500000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_42860419-a9e3-4801-beb1-962b31b7feab"
      decimals="-5"
      id="F_a883da04-cd62-4b2a-a8f4-aa7250936e25"
      unitRef="U_USD">9800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <tngx:UpfrontPaymentsForRentAndTenantImprovements
      contextRef="C_1c301094-2824-489c-bf63-ea4093ace32f"
      decimals="-5"
      id="F_bc519695-199d-47c1-aa82-d541faf2256a"
      unitRef="U_USD">300000</tngx:UpfrontPaymentsForRentAndTenantImprovements>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="C_02d11875-4147-4360-a8aa-e87bfd6290ea"
      decimals="INF"
      id="F_507ea5ed-e817-4c6d-997a-91cd364dbb62"
      unitRef="U_USD">0</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="C_7aee73e0-1a70-49bf-b3fe-767d20ffc569"
      decimals="INF"
      id="F_3c5f4874-aa9e-4c99-ba8e-b76f4c804eea"
      unitRef="U_USD">0</us-gaap:PaymentsForTenantImprovements>
    <tngx:AnnualRentPayable
      contextRef="C_42860419-a9e3-4801-beb1-962b31b7feab"
      decimals="-5"
      id="F_58765829-2e83-4cc3-aa65-3ec05e585aaf"
      unitRef="U_USD">1700000</tngx:AnnualRentPayable>
    <tngx:PercentageOfIncreaseInAnnualRentPayable
      contextRef="C_1c301094-2824-489c-bf63-ea4093ace32f"
      decimals="2"
      id="F_3456c49d-9f42-495e-bc1f-bc690b683863"
      unitRef="U_pure">0.03</tngx:PercentageOfIncreaseInAnnualRentPayable>
    <tngx:MinimumRentPaymentsToBePaidOverOriginalTerm
      contextRef="C_1c301094-2824-489c-bf63-ea4093ace32f"
      decimals="-5"
      id="F_89254cf9-f419-4dd4-85f7-2023e9844ebb"
      unitRef="U_USD">15600000</tngx:MinimumRentPaymentsToBePaidOverOriginalTerm>
    <tngx:LetterOfCreditToProvideForAmountThatCollateralizedWithCash
      contextRef="C_1c301094-2824-489c-bf63-ea4093ace32f"
      decimals="-5"
      id="F_8c9a8a11-421b-4f40-845b-6240474dd1f0"
      unitRef="U_USD">600000</tngx:LetterOfCreditToProvideForAmountThatCollateralizedWithCash>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="C_d6f8304a-f49a-468d-abae-98d9b92542a1"
      decimals="-5"
      id="F_218845b8-fbe4-427d-bb02-fcc4a4a4f1ac"
      unitRef="U_USD">1700000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_cba5ebca-4842-4066-b09c-3a3e8776378b"
      decimals="-5"
      id="F_7d896240-5e0d-4c0f-87b7-add0ab289262"
      unitRef="U_USD">1700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_06dcd5da-541e-4c79-b858-c0104fee1630"
      id="F_4b08bec9-6143-44db-be7d-bf4ab1449878">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_4fb87c77-49f5-455c-a642-6e57e4c31b2f"
      id="F_5162f810-3db1-40fb-8c5f-fa09c61224be">option to extend for up to two five-year periods.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_d6f8304a-f49a-468d-abae-98d9b92542a1"
      id="F_70ffd28e-bbff-497d-a664-02bf9b83c57e">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <tngx:AnnualRentPayable
      contextRef="C_06dcd5da-541e-4c79-b858-c0104fee1630"
      decimals="-5"
      id="F_96be534f-0cd4-4d85-9a06-b96b831ff4d5"
      unitRef="U_USD">5100000</tngx:AnnualRentPayable>
    <tngx:PercentageOfIncreaseInAnnualRentPayable
      contextRef="C_d6f8304a-f49a-468d-abae-98d9b92542a1"
      decimals="2"
      id="F_d02e1845-2a45-4fd9-a848-b19dd3970f7d"
      unitRef="U_pure">0.03</tngx:PercentageOfIncreaseInAnnualRentPayable>
    <us-gaap:TenantImprovements
      contextRef="C_06dcd5da-541e-4c79-b858-c0104fee1630"
      decimals="-5"
      id="F_59047520-687c-4868-8faa-8912b6efd2c7"
      unitRef="U_USD">12700000</us-gaap:TenantImprovements>
    <tngx:LeaseTerminationAgreementMonthAndYear
      contextRef="C_46942445-32c3-4ade-9ca0-aa6a6b83839a"
      id="F_e8405208-a919-4345-b8d0-c55cd4c2efe7">2021-11</tngx:LeaseTerminationAgreementMonthAndYear>
    <us-gaap:LesseeOperatingLeaseOptionToTerminate
      contextRef="C_02d11875-4147-4360-a8aa-e87bfd6290ea"
      id="F_0d0aa3d9-550c-41cd-91c4-07acca00252d">The lease termination agreement is a modification of the original lease agreement that provides for, among other things, the acceleration of the expiration of the original term of the lease from June 30, 2026 to an earlier lease termination date, for which the earlier date shall be no later than October 15, 2022.</us-gaap:LesseeOperatingLeaseOptionToTerminate>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_50520bd5-264f-47a4-b3f4-8fbfc12d12ed"
      id="F_55314f2b-faba-43ea-a44f-c0efdcd0287f">2026-06-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_9325e76a-6e44-41b8-9985-b303b44f8869"
      id="F_a614fdd0-e419-466a-9996-f64fcc44fb23">2022-10-15</us-gaap:LeaseExpirationDate1>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_b961f57f-cd1e-4000-be3a-575c1acb8245"
      decimals="-5"
      id="F_e539b622-0343-475c-a55d-8c5e6961f5da"
      unitRef="U_USD">5300000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <tngx:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="C_b961f57f-cd1e-4000-be3a-575c1acb8245"
      decimals="-5"
      id="F_e3af9591-aa25-401f-96d1-9a86c8c15f38"
      unitRef="U_USD">5200000</tngx:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <tngx:LetterOfCreditToProvideForAmountThatCollateralizedWithCash
      contextRef="C_babc5d15-ca37-4230-bde3-b6ec0c32b755"
      decimals="-5"
      id="F_d91a7cbe-3f65-48fa-8c75-c7db3c6c7d2c"
      unitRef="U_USD">600000</tngx:LetterOfCreditToProvideForAmountThatCollateralizedWithCash>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-5"
      id="F_42d3031c-f66c-4628-b2b9-b257ef14801a"
      unitRef="U_USD">1300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-5"
      id="F_0f08b93d-1da9-43bf-88de-86bf9e19d3b7"
      unitRef="U_USD">7500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_91af77cd-1719-4df5-a985-1f6205c7089c">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The elements of lease cost were as follows: &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.656%;"/&gt;
        &lt;td style="width:1.581%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:12.435%;"/&gt;
        &lt;td style="width:2.137%;"/&gt;
        &lt;td style="width:1.581%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:11.928%;"/&gt;
        &lt;td style="width:2.137%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,889&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total operating lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Other information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating cash flows used for operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,782&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted average remaining lease term in years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted average discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_68a1d63a-2cc2-4e5b-9c5c-d2070f889a50"
      unitRef="U_USD">1889000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_242003bc-e832-4ea0-b3c2-2d30359f4fdf"
      unitRef="U_USD">1889000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_38afe6e3-e2fd-4fd7-be23-1fdcc4ce78e4"
      unitRef="U_USD">133000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_741dd134-15ce-4579-b177-947378b735fe"
      unitRef="U_USD">93000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_0907d66d-fb35-475a-b43d-62bb37d37d55"
      unitRef="U_USD">673000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_050e69d9-e1d3-4013-b835-4f737de8274e"
      unitRef="U_USD">643000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_00314b0d-3c4e-4f2c-bc9e-ecffac8f6bbd"
      unitRef="U_USD">2695000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_0327c104-6fc1-4d66-bb3f-60e45b5ed9fc"
      unitRef="U_USD">2625000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_8e4a35fd-8124-425c-8e7e-6a3e67c0bb8f"
      unitRef="U_USD">1835000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_1d37abfc-43fe-495d-bc6c-779917f3e7b8"
      unitRef="U_USD">1782000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      id="F_f1dd46af-9ae0-4ce9-888e-81cfa972a2c5">P0Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      id="F_12cc2453-8d82-42f4-8b4d-b6318c8b328a">P5Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="2"
      id="F_e916dbc7-1405-407c-9234-e27910751d6b"
      unitRef="U_pure">0.12</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="2"
      id="F_199b49c6-add6-4fb7-9d5a-9a2a77cf340c"
      unitRef="U_pure">0.12</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_b884b2d7-3b13-4ec3-ae7f-e85640aa7ae0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Future minimum lease payments under leases that have commenced as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 are as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:78.205%;"/&gt;
        &lt;td style="width:1.865%;"/&gt;
        &lt;td style="width:1.828%;"/&gt;
        &lt;td style="width:16.884%;"/&gt;
        &lt;td style="width:1.218%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Maturity of Lease&lt;br/&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_84ec807a-762e-4ba9-b23f-bc2e02ce9a59"
      unitRef="U_USD">1572000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_2475fca3-10a9-47cd-9798-8e8ae1243fb5"
      unitRef="U_USD">1572000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_25b4b562-7b78-43d9-b01d-9063b9fb6103"
      unitRef="U_USD">69000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_3ae637bc-1017-4ebc-8d08-97d948b0bf9b"
      unitRef="U_USD">1503000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_67f9acb2-5816-4880-8450-0c6fd0315de1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;9. Commitments and Contingencies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Research Collaboration Agreement&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;September 2017, the Company entered into a Research Collaboration Agreement (the &#x201c;HitGen Agreement&#x201d;) with HitGen Ltd (&#x201c;HitGen&#x201d;). Under the terms of the HitGen Agreement, HitGen would use its DNA-encoded library technology to screen up to three targets and deliver to the Company the structures of certain compounds that bind to the targets. The Company would provide certain materials containing each target for purposes of the screen. The Company could have been obligated to make certain milestone payments. The Company and HitGen mutually agreed to terminate the HitGen&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Agreement &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;in March 2021. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; milestones were achieved or owed upon the termination of the agreement and the Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t make any payments upon termination of the HitGen Agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;License Agreement&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In March 2020, the Company entered into a License Agreement (the &#x201c;Medivir Agreement&#x201d;) with Medivir AB (&#x201c;Medivir&#x201d;), pursuant to which the Company obtained an exclusive license to all patents, know-how and other intellectual property associated with a preclinical-stage research program. Pursuant to the Medivir Agreement, the Company made an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under the terms of the Medivir Agreement, the Company is obligated to pay Medivir in connection with development, regulatory and commercial activities. The Company has agreed to make certain milestone payments of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in the aggregate for the first licensed product that achieves specified clinical milestones, plus $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the first licensed product that achieves specified regulatory approval and sales milestones, in each case, in either of the first two specified genetic contexts and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in the aggregate if that first licensed product achieves specified clinical milestones, plus $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million if that first licensed product achieves specified regulatory and sales milestones for a third genetic context or the second licensed product achieves such specified development, regulatory and sales milestones in either of the first two specified genetic contexts. The Company has the right to reduce these milestone payments by a specified amount in the event the licensed product is not covered by Medivir&#x2019;s patents or if payments are due to a third party for a license under such third party&#x2019;s intellectual property rights. The Company is also obligated to pay Medivir a low single-digit royalty on net sales of any product covered by a licensed patent. The Medivir Agreement expires on the date of expiration of all royalty obligations. Either party may terminate the Medivir Agreement earlier upon an uncured material breach of the other party.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Upfront fees paid pursuant to the Medivir License Agreement were recorded to research and development expense. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; milestones have been achieved to date.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Other Funding Commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the Company had ongoing non-clinical studies for its various pipeline programs. The Company enters into contracts in the normal course of business with contract research organizations in preparation for clinical trials, professional consultants for expert advice and other vendors for clinical supply manufacturing or other services. These contracts are generally cancellable, with notice, at the Company's option and do not have significant cancellation penalties.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Guarantees&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company enters into certain agreements with other parties in the ordinary course of business that contain indemnification provisions. These typically include agreements with directors and officers, business partners, contractors, landlords, contract research organizations and clinical sites. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party under the terms of the contract, including as a result of the Company&#x2019;s activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date the Company has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these obligations is minimal.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Litigation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company, from time to time, may be party to litigation arising in the ordinary course of business. The Company was not subject to any material legal proceedings as of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, and no material legal proceedings are currently pending or threatened. Because of uncertainties related to claims, proceedings and litigation, assessments of potential liabilities are based on the Company's best estimates based on information available at the time of the assessment. On a periodic basis, as additional information becomes available, or based on specific events such as the outcome of litigation, court decisions or settlement of claims (and offers of settlement), the Company may reassess the potential liability related to these matters and may revise these estimates, which could result in a material adverse effect on the operating results of the Company. Costs associated with involvement in legal proceedings are expensed as incurred. The outcome of any such proceedings, regardless of the merits, is inherently uncertain. If the Company were to be unable to prevail in any such proceedings, the consolidated financial position, results of operations, and future cash flows of the Company may be materially impacted.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <tngx:NumberOfMilestonesAchieved
      contextRef="C_91ba7dc3-6470-42de-a194-06f0b8e6a25d"
      decimals="INF"
      id="F_f05165a8-f0af-4d8a-83d2-8bce6d6d0ad6"
      unitRef="U_Milestone">0</tngx:NumberOfMilestonesAchieved>
    <tngx:PaymentsUponTerminationOfAgreement
      contextRef="C_539c3823-b618-476a-9106-5362f015288f"
      decimals="INF"
      id="F_dec98646-540f-41be-b114-081b8cc2403a"
      unitRef="U_USD">0</tngx:PaymentsUponTerminationOfAgreement>
    <tngx:UpfrontPayment
      contextRef="C_b17588f4-eb89-4f86-9706-bd7d2b333a9e"
      decimals="-5"
      id="F_0f8d3129-b7b0-42eb-b7cb-220225e2dceb"
      unitRef="U_USD">400000</tngx:UpfrontPayment>
    <tngx:MilestonePayments
      contextRef="C_b17588f4-eb89-4f86-9706-bd7d2b333a9e"
      decimals="-5"
      id="F_17c7ef8a-ba7e-4d4b-a085-f8317cc7de64"
      unitRef="U_USD">1400000</tngx:MilestonePayments>
    <us-gaap:ContractualObligation
      contextRef="C_ab502c57-9eb1-4c1e-b776-cac4cbc580eb"
      decimals="-5"
      id="F_dd37528d-22cb-4010-80dc-eadecf09eb2b"
      unitRef="U_USD">25000000.0</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="C_edcd82c0-9d7d-49ac-abb2-37406bcefb72"
      decimals="-5"
      id="F_2d14ff42-8850-46cd-b163-7e1ccb219b47"
      unitRef="U_USD">700000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="C_4e0ebfbb-6d60-400e-82c5-2271bdc193d9"
      decimals="-5"
      id="F_b6d19092-9efc-4dc9-8ce3-449b818fafb8"
      unitRef="U_USD">5000000.0</us-gaap:ContractualObligation>
    <tngx:MilestonePaymentsAchieved
      contextRef="C_ca4a9ca6-a360-4a08-9af0-9f6ec20dc073"
      decimals="INF"
      id="F_ace40862-cc80-4ff4-ac00-3f008ad6c366"
      unitRef="U_USD">0</tngx:MilestonePaymentsAchieved>
    <tngx:RedeemableConvertiblePreferredStockDisclosureTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_a504e159-ade8-4fd8-bd1b-58bc09da99a8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;10. Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In March 2017, Old Tango executed a stock purchase agreement to sell &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;55,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of redeemable convertible series A preferred stock (&#x201c;Series A&#x201d;). This agreement was subsequently amended in July 2017 to increase the authorized capital to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;55,700,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of Series A.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Pursuant to the initial closing of the Series A stock purchase agreement, Old Tango issued an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,700,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of Series A convertible preferred stock for $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share, resulting in net proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million after deducting $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million related to the settlement of the convertible notes and accrued interest that were previously outstanding. During the year-ended December 31, 2018, Old Tango issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; additional shares of Series A preferred stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share resulting in total proceeds from this issuance of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. In January 2019, Old Tango issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; additional shares of Series A preferred stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share resulting in total proceeds from this issuance of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. The aggregate issuance costs associated with the issuance of all three issuances of Series A preferred stock was less than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In April 2020, Old Tango executed a stock purchase agreement to sell shares of redeemable convertible series B preferred stock (&#x201c;Series B&#x201d;). The Series B stock purchase agreement allows for the issuance of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;45,372,051&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares. In April 2020, Old Tango issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22,686,025&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of Series B at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.32&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share. Proceeds from this issuance totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;29.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, net of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in issuance costs. In March 2021, Old Tango sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22,686,025&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; additional shares of Series B stock at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.32&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share upon the achievement of specified development milestones in connection with the second tranche of the Series B stock purchase agreement. Proceeds from this issuance totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. Total issuance costs associated with the March 2021 issuance of Series B preferred stock was less than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In August 2020, Old Tango executed a stock purchase agreement to sell shares of redeemable convertible series B-1 preferred stock (&#x201c;Series B-1&#x201d;). The Series B-1 stock purchase agreement allowed for the issuance of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,152,255&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares. All &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,152,255&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of Series B-1 were issued at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.89&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share in August 2020. Proceeds from this issuance was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;51.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, net of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in issuance costs&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Conversion of Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Pursuant to the terms of the Merger Agreement, upon the Effective Time, each share of Old Tango&#x2019;s Preferred Stock issued and outstanding immediately prior to the Effective Time was converted into a share of Old Tango&#x2019;s common stock and subsequently converted into shares of New Tango common stock using an exchange ratio of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.34&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. A retroactive adjustment has been applied to all periods presented to reflect the Business Combination and reverse recapitalization, therefore, resulting in no outstanding Preferred Stock as of December 31, 2021 and 2020. Refer to &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Note 3 for additional discussion.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Undesignated Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s Certificate of Incorporation, as amended and restated, authorizes the Company to issue shares of preferred stock with a par value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share. The number of shares of preferred stock authorized to be issued is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021. &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The shares of preferred stock are currently undesignated.&lt;/span&gt;&lt;/p&gt;</tngx:RedeemableConvertiblePreferredStockDisclosureTextBlock>
    <us-gaap:TemporaryEquityShareSubscriptions
      contextRef="C_1f668a19-d708-4382-b6de-856bbfb1c08d"
      decimals="INF"
      id="F_154cd096-4c55-4951-bb28-2bb997308445"
      unitRef="U_shares">55000000</us-gaap:TemporaryEquityShareSubscriptions>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_27a26b8d-6763-4206-ad2e-220eddc0e107"
      decimals="INF"
      id="F_1d6c7d2c-775e-4609-a460-ec6fcd683cf5"
      unitRef="U_shares">55700000</us-gaap:TemporaryEquitySharesAuthorized>
    <tngx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_36f9a5bb-51f4-4c4c-a4a4-483900a01305"
      decimals="INF"
      id="F_82d3a4c6-c8e2-4c3e-97c2-5c79cbfd2e8c"
      unitRef="U_shares">18700000</tngx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <tngx:RedeemableConvertiblePreferredStockIssuePricePerShare
      contextRef="C_1f668a19-d708-4382-b6de-856bbfb1c08d"
      decimals="2"
      id="F_8e33a9b1-2918-4f7b-826a-8e7be165a8c0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.00</tngx:RedeemableConvertiblePreferredStockIssuePricePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="C_36f9a5bb-51f4-4c4c-a4a4-483900a01305"
      decimals="-5"
      id="F_d040f9a8-2f80-4f81-9cb9-4c982c0259e2"
      unitRef="U_USD">14000000.0</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="C_96e2833b-b37d-4d45-9d0e-e469973ab162"
      decimals="-5"
      id="F_cd9906da-c91d-4c84-9e20-7f0cbc135a11"
      unitRef="U_USD">4700000</us-gaap:RepaymentsOfConvertibleDebt>
    <tngx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_4dbe3a85-64de-49a0-bef8-5deb3b1b9ca7"
      decimals="INF"
      id="F_843bf854-a0a9-4cac-bf89-de2b9ff4ad91"
      unitRef="U_shares">26000000</tngx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <tngx:RedeemableConvertiblePreferredStockIssuePricePerShare
      contextRef="C_2097a9ea-7fc6-47b9-9264-c5cfd08007fd"
      decimals="2"
      id="F_07102adb-6b49-4931-bd4d-7f8f43811f4d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.00</tngx:RedeemableConvertiblePreferredStockIssuePricePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="C_4dbe3a85-64de-49a0-bef8-5deb3b1b9ca7"
      decimals="-5"
      id="F_23ae0992-d372-4c29-996d-5693b74af2a5"
      unitRef="U_USD">26000000.0</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <tngx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_ce1e3322-9b6b-477f-bd0a-0c49d4aedd8b"
      decimals="INF"
      id="F_e5f68440-7b4f-4ece-a493-acb5386012bb"
      unitRef="U_shares">11000000</tngx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <tngx:RedeemableConvertiblePreferredStockIssuePricePerShare
      contextRef="C_2a0457d3-f3a5-4a7b-982f-ab2cbc2377f5"
      decimals="2"
      id="F_5425488b-0bdf-4eb8-9ec7-60e7b002fc35"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.00</tngx:RedeemableConvertiblePreferredStockIssuePricePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="C_ce1e3322-9b6b-477f-bd0a-0c49d4aedd8b"
      decimals="-5"
      id="F_bf47174c-3e12-41fc-9fcd-fb74e81bafcd"
      unitRef="U_USD">11000000.0</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <tngx:TemporaryStockIssuanceCosts
      contextRef="C_ce1e3322-9b6b-477f-bd0a-0c49d4aedd8b"
      decimals="-5"
      id="F_de83262d-5597-4aad-9641-d92402834ccc"
      unitRef="U_USD">100000</tngx:TemporaryStockIssuanceCosts>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_84b473ca-21a7-4595-869a-d3b15476e2cd"
      decimals="INF"
      id="F_c85ed3a5-12ea-4ac0-a3c8-96f8e2d9f199"
      unitRef="U_shares">45372051</us-gaap:TemporaryEquitySharesAuthorized>
    <tngx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_cf54194b-5ca8-4902-bc7c-8ad279e05960"
      decimals="INF"
      id="F_c82371b1-66bd-4f19-925f-255ba25bc20d"
      unitRef="U_shares">22686025</tngx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <tngx:TemporaryEquityIssuePricePerShare
      contextRef="C_84b473ca-21a7-4595-869a-d3b15476e2cd"
      decimals="2"
      id="F_502fdb40-9bfd-45f9-9727-c28fdefec61d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.32</tngx:TemporaryEquityIssuePricePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="C_cf54194b-5ca8-4902-bc7c-8ad279e05960"
      decimals="-5"
      id="F_0ae1679d-ec41-4f22-8d1f-99dd8060e8e0"
      unitRef="U_USD">29800000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <tngx:TemporaryStockIssuanceCosts
      contextRef="C_cf54194b-5ca8-4902-bc7c-8ad279e05960"
      decimals="-5"
      id="F_e6845c3d-7c66-4d3c-bef0-e4e7dd8e5117"
      unitRef="U_USD">200000</tngx:TemporaryStockIssuanceCosts>
    <tngx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_2d621dea-8b02-473e-8bc5-76032a18426e"
      decimals="INF"
      id="F_75e24edd-a9de-4e27-b269-c16fbe497c55"
      unitRef="U_shares">22686025</tngx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <tngx:TemporaryEquityIssuePricePerShare
      contextRef="C_8d0e1ab2-5dfb-47e6-a9e8-b49f9f14bd25"
      decimals="2"
      id="F_7824e604-180f-4a3e-af7e-7f8b093789b1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.32</tngx:TemporaryEquityIssuePricePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="C_2d621dea-8b02-473e-8bc5-76032a18426e"
      decimals="-5"
      id="F_92469fb7-92a6-4d51-923e-ab193d6f50b9"
      unitRef="U_USD">30000000.0</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <tngx:TemporaryStockIssuanceCosts
      contextRef="C_2d621dea-8b02-473e-8bc5-76032a18426e"
      decimals="-5"
      id="F_986ea157-420f-4067-bd39-77451e8067b8"
      unitRef="U_USD">100000</tngx:TemporaryStockIssuanceCosts>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_1a15ceae-2bb5-42b0-a18d-a0d58154057d"
      decimals="INF"
      id="F_a59435ee-9319-4c34-abb4-8b7c530f7755"
      unitRef="U_shares">27152255</us-gaap:TemporaryEquitySharesAuthorized>
    <tngx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="C_43fb107b-c6af-4569-9ee5-f77bf1f34285"
      decimals="INF"
      id="F_107ef6ad-771a-4466-b8b2-e8d71e359253"
      unitRef="U_shares">27152255</tngx:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <tngx:TemporaryEquityIssuePricePerShare
      contextRef="C_1a15ceae-2bb5-42b0-a18d-a0d58154057d"
      decimals="2"
      id="F_9dbdd99e-6fc7-4cbc-95ed-fc6a39764a26"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.89</tngx:TemporaryEquityIssuePricePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="C_43fb107b-c6af-4569-9ee5-f77bf1f34285"
      decimals="-5"
      id="F_84c0b945-b6cd-45fc-8eec-a64b82d3d528"
      unitRef="U_USD">51100000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <tngx:TemporaryStockIssuanceCosts
      contextRef="C_43fb107b-c6af-4569-9ee5-f77bf1f34285"
      decimals="-5"
      id="F_381295ac-ff8c-4741-87ad-3b52d869fb83"
      unitRef="U_USD">100000</tngx:TemporaryStockIssuanceCosts>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="2"
      id="F_5663b10c-b454-4fea-b813-f2464496ae46"
      unitRef="U_pure">0.34</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="INF"
      id="F_8d7af768-483b-49d4-b26b-3b12e53060db"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="INF"
      id="F_65674825-72c7-4abf-981f-ec2afcd7eab9"
      unitRef="U_shares">10000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_75946027-8b48-4114-aad2-9f084e60463a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;11. Common Stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s Certificate of Incorporation, as amended and restated, authorizes the Company to issue shares of common stock with a par value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The holder of each share of common stock is entitled to one vote in respect of each share of stock held.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the funds and assets available for distribution to the stockholders of the Company will be distributed among the holders of shares of common stock, pro rata based on the number of shares of common stock held by each such holder. The holders of Common Stock are also entitled to receive dividends whenever funds and assets are legally available and when declared by the Board of Directors. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; dividends have been declared as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company increased the number of shares of common stock authorized to be issued to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;200,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares in August 2021, at the time in which the Certificate of Incorporation was amended and restated.&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; As of December 31, 2021 and 2020, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;87,598,184&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;40,372,133&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock issued and outstanding,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; respectively, as adjusted to reflect the Business Combination and reverse recapitalization through the application of a retroactive adjustment&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="INF"
      id="F_055f4bc7-3827-4955-8242-ad2ed988e6e7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockVotingRights
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_4c516627-6966-4e7f-8670-337ea3ed2c9f">The holder of each share of common stock is entitled to one vote in respect of each share of stock held.</us-gaap:CommonStockVotingRights>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="INF"
      id="F_680c4d32-42e1-4755-91eb-ce1ebe1e5102"
      unitRef="U_USD">0</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_97c1afc9-4f65-4a11-89cf-32bdc6c820ab"
      decimals="INF"
      id="F_dd418f94-7a4e-4da1-80fd-4acb17d0d341"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="INF"
      id="F_c4921bb1-8f82-4ab9-af12-7b2e8112040c"
      unitRef="U_shares">87598184</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="INF"
      id="F_a155432b-5892-46ee-a0dc-0386e030d4e6"
      unitRef="U_shares">87598184</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="INF"
      id="F_2cbefa3a-ab6a-42fa-a853-09aa51f075cf"
      unitRef="U_shares">40372133</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="INF"
      id="F_099f296a-bbc3-4037-be34-e48588d7db76"
      unitRef="U_shares">40372133</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_5e093ca4-047a-4f73-9aeb-58721df2e54b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;12. Equity Incentive Plans&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Pursuant to the terms of the Business Combination, upon the Closing Date, each option to purchase Old Tango&#x2019;s common stock became an option to purchase shares of common stock of the surviving entity and was subsequently adjusted using an exchange ratio of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.34&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. A retroactive adjustment has been applied to all periods presented to reflect the Business Combination and reverse recapitalization as discussed further in Note 3.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Founder and Advisor Awards&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;During 2017, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,690,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of restricted common stock outside of the Company&#x2019;s 2017 Stock Option and Grant Plan to nonemployee founders and advisors (the &#x201c;Founders and Advisors&#x201d;). The shares are issued under the terms of the respective restricted common stock agreements and are subject to repurchase by the Company at the original purchase price per share upon the termination of the grantee&#x2019;s service relationship with the Company. As the restrictions are released and the awards vest, the value is recorded as common stock and excess of par value is recorded as additional paid in capital on the accompanying balance sheet. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021, all founder and advisor restricted stock awards (&#x201c;RSAs&#x201d;) had vested.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;2017 Stock Option and Grant Plan&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In March 2017, the Company&#x2019;s stockholders approved the 2017 Stock Option and Grant Plan (the &#x201c;2017 Plan&#x201d;), under which stock options and RSAs were granted to eligible employees, officers, directors, consultants, or other key persons who provide services to the Company. Such issuances under the 2017 Plan were subject to vesting, forfeiture and other restrictions as deemed appropriate by the board of directors (&#x201c;Board of Directors&#x201d;) at the time of issuance.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Upon effectiveness of the 2021 Stock Option and Incentive Plan (the "2021 Plan") in August 2021, &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;the remaining shares available under the 2017 Plan ceased to be available for issuance and no future issuances will be made under the 2017 Plan. The shares of common stock underlying outstanding awards under the 2017 Plan that are forfeited, cancelled, reacquired by the Company prior to vesting, expire or are otherwise terminated (other than by exercise) will be added to the shares of common stock available for issuance under the 2021 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;2021 Stock Option and Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Upon the closing of the Business Combination in August 2021, the Company's stockholders approved the 2021 Plan under which stock options, RSAs, unrestricted stock awards, restricted stock units, or any combination of the forgoing may be granted to eligible employees, officers, directors, consultants, or other key persons who provide services to the Company. Such issuances are subject to vesting, forfeiture and other restrictions as deemed appropriate by the Board of Directors at the time of issuance.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Upon approval, the maximum number of shares of stock reserved and available for issuance under the 2021 Plan was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,498,725&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares. The number of shares available for future grant will automatically increase on the first day of each fiscal year by an amount equal to the least of: (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;five&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; percent of the number of shares of Stock issued and outstanding on the immediately preceding December 31 or (ii) such lesser number of shares as determined by the 2021 Plan Administrator, as appointed by the Board of Directors. Awards that are returned to the Company's equity plan as a result of forfeiture, cancellation, are reacquired by the Company prior to vesting, expiration, or any other form of termination (other than by exercise) are automatically made available for issuance under the 2021 Plan. As of &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,271,873&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares available for future grant under the 2021 Plan and on January 1, 2022, the number of shares available for future grant under the 2021 Plan increased by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,377,321&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;2021 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The 2021 Employee Stock Purchase Plan (the &#x201c;2021 ESPP&#x201d;) was adopted and approved by the Company&#x2019;s board of directors and by the Company&#x2019;s stockholders and became effective upon the closing of the Business Combination in August 2021. An aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;949,873&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares were reserved for issuance. The 2021 ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2022 and each January 1 thereafter, by the least of (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the outstanding number of shares of the Company&#x2019;s common stock on the immediately preceding December 31, (ii) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;949,873&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares or (iii) such number of shares as determined by the administrator. The 2021 ESPP was increased by&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;875,464&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares on January 1, 2022.&lt;/span&gt;&lt;span style="background-color:rgba(255,255,0,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,0,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Restricted Stock Awards&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes the RSA activity of the Company&#x2019;s plans as of and for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.186%;"/&gt;
        &lt;td style="width:1.878%;"/&gt;
        &lt;td style="width:0.972%;"/&gt;
        &lt;td style="width:11.601%;"/&gt;
        &lt;td style="width:1.028%;"/&gt;
        &lt;td style="width:1.558%;"/&gt;
        &lt;td style="width:1.525%;"/&gt;
        &lt;td style="width:13.534%;"/&gt;
        &lt;td style="width:0.718%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Number of&lt;br/&gt;shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Unvested restricted common stock outstanding as of December 31, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,084,125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;788,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;39,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Unvested restricted common stock outstanding as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;256,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;256,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Unvested restricted common stock outstanding as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;RSAs represent an unsecured promise to grant at no cost a set number of shares of common stock upon vesting. RSA recipients are not entitled to cash dividends and have no voting rights during the vesting period. The RSAs are issued under the terms of the respective RSA agreements and are subject to repurchase upon the holder&#x2019;s termination of their service relationship with the Company. The award restrictions are released as the awards vest. Upon vesting, the value is recorded as common stock and excess of par value as is recorded as additional paid in capital on the accompanying balance sheets. The common stock is subject to the Company&#x2019;s right to repurchase at the original purchase price per share.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, all RSAs had vested. &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The aggregate fair value of RSAs that vested during the years ended December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock Options&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes the stock option activity of the Company&#x2019;s plans as of and for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.488%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
        &lt;td style="width:9.931%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:9.524%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:10.081%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:9.603%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Number of&lt;br/&gt;shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Options outstanding as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,094,544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.58&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,635,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,200,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;638,754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;283,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Options outstanding as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,372,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.55&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;51,415,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options exercisable as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,117,654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.52&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17,759,485&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The aggregate intrinsic value of options is calculated as the difference between the exercise price of the options and the fair value of the Company&#x2019;s common stock for those options that had exercise prices lower than the fair value of the Company&#x2019;s common stock.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The total intrinsic value of options exercised totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.8&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;and less than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020, respectively. &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The weighted-average grant date fair value per share of stock options granted was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.40&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.44&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; for the years ending &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, total unrecognized compensation expense related to stock options was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;29.3&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;which the Company expects to recognize over a remaining weighted-average period of&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; Substantially all options outstanding as of December 31, 2021 are expected to vest.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock Option Valuation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The weighted average assumptions used to estimate the grant date fair value of the stock options using the Black-Scholes option pricing model were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.997%;"/&gt;
        &lt;td style="width:1.62%;"/&gt;
        &lt;td style="width:14.881%;"/&gt;
        &lt;td style="width:1.62%;"/&gt;
        &lt;td style="width:14.881%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected option life (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#x2013;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; 6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;72&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;67&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;72&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014; %&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014; %&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company measures stock-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recorded stock-based compensation expense in the following expense categories in its accompanying statements of operations: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.603%;"/&gt;
        &lt;td style="width:1.569%;"/&gt;
        &lt;td style="width:1.524%;"/&gt;
        &lt;td style="width:13.388%;"/&gt;
        &lt;td style="width:0.718%;"/&gt;
        &lt;td style="width:1.569%;"/&gt;
        &lt;td style="width:1.524%;"/&gt;
        &lt;td style="width:13.388%;"/&gt;
        &lt;td style="width:0.718%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,833&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,764&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <tngx:MergerRecapitalizationExchangeRatio
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="2"
      id="F_66eb0723-54ff-4acf-8fca-a84b6856b484"
      unitRef="U_pure">0.34</tngx:MergerRecapitalizationExchangeRatio>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_ae71f40f-3665-48a2-9117-946f426ce1db"
      decimals="INF"
      id="F_5ae546f9-da76-4ac4-be99-a7e01aedc484"
      unitRef="U_shares">4690000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_d122636a-689d-4ab0-b872-bae54aeb140c"
      decimals="INF"
      id="F_f58f8c08-2a29-4b96-be61-ca4a1a68db2b"
      unitRef="U_shares">9498725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_19df7953-ecc1-48a3-9c5b-5d80830b8fdb"
      decimals="2"
      id="F_fa765f0a-fe10-4d8d-ae6c-9af2c4d46e0b"
      unitRef="U_pure">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_d122636a-689d-4ab0-b872-bae54aeb140c"
      decimals="INF"
      id="F_cbe217d6-becb-46f2-bd52-aad50e058f3a"
      unitRef="U_shares">6271873</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_34a6b51f-9398-4a33-b000-f084738ed301"
      decimals="0"
      id="F_3d4223fc-0a8b-44bb-abff-118aaf0418e4"
      unitRef="U_shares">4377321</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b6540ba0-6a70-4698-835b-62e3f28a76b7"
      decimals="INF"
      id="F_0a16a20c-cecf-4976-8390-ddb93dd1225e"
      unitRef="U_shares">949873</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_c520f9bc-41be-4b8e-a264-4f675e8eec11"
      decimals="2"
      id="F_ed1afbc9-5c6b-4f0a-8481-40e3e689b63a"
      unitRef="U_pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_b6540ba0-6a70-4698-835b-62e3f28a76b7"
      decimals="INF"
      id="F_33a42449-ad7c-450b-bd04-e951223a26c5"
      unitRef="U_shares">949873</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_e025e6fe-ae40-47de-b624-610d8a25ba64"
      decimals="0"
      id="F_245949e9-85f1-415f-93a8-6d6daffe904e"
      unitRef="U_shares">875464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_6bbfeb3a-3778-48ac-9f51-277050347338">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes the RSA activity of the Company&#x2019;s plans as of and for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.186%;"/&gt;
        &lt;td style="width:1.878%;"/&gt;
        &lt;td style="width:0.972%;"/&gt;
        &lt;td style="width:11.601%;"/&gt;
        &lt;td style="width:1.028%;"/&gt;
        &lt;td style="width:1.558%;"/&gt;
        &lt;td style="width:1.525%;"/&gt;
        &lt;td style="width:13.534%;"/&gt;
        &lt;td style="width:0.718%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Number of&lt;br/&gt;shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Unvested restricted common stock outstanding as of December 31, 2019&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,084,125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;788,227&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;39,087&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Unvested restricted common stock outstanding as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;256,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;256,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Unvested restricted common stock outstanding as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_5b4da818-3aaf-49ee-92af-9ab384f7fb73"
      decimals="INF"
      id="F_d5bfce56-1195-476a-90dd-0c9372203edd"
      unitRef="U_shares">1084125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_5b4da818-3aaf-49ee-92af-9ab384f7fb73"
      decimals="2"
      id="F_43bb8a79-7500-4d03-8a83-469d947400ca"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_12217c4f-04a9-422a-9151-5c1ab378d58e"
      decimals="INF"
      id="F_91efeb8b-d265-45c9-b4ba-9867cdc1bcb2"
      unitRef="U_shares">788227</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_12217c4f-04a9-422a-9151-5c1ab378d58e"
      decimals="2"
      id="F_ca285c29-6e07-4edf-8fcc-c61d95abd20a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_12217c4f-04a9-422a-9151-5c1ab378d58e"
      decimals="INF"
      id="F_764d4d8e-07e4-4dda-820c-0d0173fa9bde"
      unitRef="U_shares">39087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_12217c4f-04a9-422a-9151-5c1ab378d58e"
      decimals="2"
      id="F_fa13c02a-c3d3-439f-bb1e-1a722865f670"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_cab846a0-8d37-4a4b-ae82-af6adf0f78e9"
      decimals="INF"
      id="F_8407376d-5cac-4c08-b6bf-23a467809e4f"
      unitRef="U_shares">256811</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_cab846a0-8d37-4a4b-ae82-af6adf0f78e9"
      decimals="2"
      id="F_31386810-8a17-4114-943d-80f7040aa893"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_5dd62d57-3336-4d82-b4cc-8df9199613af"
      decimals="INF"
      id="F_6a208750-8f5e-4fc9-a3b1-387126c329ed"
      unitRef="U_shares">256598</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_5dd62d57-3336-4d82-b4cc-8df9199613af"
      decimals="2"
      id="F_923c6cd1-1bed-4632-815b-d074a42319d2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_5dd62d57-3336-4d82-b4cc-8df9199613af"
      decimals="INF"
      id="F_46ed3c46-b457-4c67-82fd-6ef929daec86"
      unitRef="U_shares">213</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_5dd62d57-3336-4d82-b4cc-8df9199613af"
      decimals="2"
      id="F_51794608-0174-49a3-8344-ec73d1f7b9d3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_a1adf0bb-c238-43d9-ba7a-df912e357f96"
      decimals="-5"
      id="F_f9e64f8e-d27a-4901-88f4-1169b49b55ab"
      unitRef="U_USD">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_04267f13-0c83-44a3-836a-4da5571814a2"
      decimals="-5"
      id="F_6a22e0fc-cb64-46aa-a71f-58dfcfbc13d7"
      unitRef="U_USD">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_d37deea0-d63a-4029-87cf-de06913d2a85">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes the stock option activity of the Company&#x2019;s plans as of and for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.488%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
        &lt;td style="width:9.931%;"/&gt;
        &lt;td style="width:0.865%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:9.524%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:0.646%;"/&gt;
        &lt;td style="width:10.081%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
        &lt;td style="width:1.193%;"/&gt;
        &lt;td style="width:1.272%;"/&gt;
        &lt;td style="width:9.603%;"/&gt;
        &lt;td style="width:0.636%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Number of&lt;br/&gt;shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Options outstanding as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,094,544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.58&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,635,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,200,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;638,754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;283,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Options outstanding as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,372,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.55&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;51,415,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options exercisable as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,117,654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.52&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17,759,485&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="INF"
      id="F_cf026018-c93a-45d7-a0f9-fb3390f145dd"
      unitRef="U_shares">4094544</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="2"
      id="F_31e96357-e07d-44d3-82cd-b4a6b60d6dab"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      id="F_75b330dc-efde-4877-9fac-4076418291b1">P8Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_3a6d5c60-85c0-4817-9b69-6bb259ad79a5"
      unitRef="U_USD">6635627000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="INF"
      id="F_7bff2bc0-fcf8-4e9f-aae6-24656cdbff3c"
      unitRef="U_shares">6200841</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="2"
      id="F_8da9f47a-6816-44fe-ad67-507e8eb39257"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="INF"
      id="F_b1440ffa-e46c-4fc8-a86d-559c80fa6a3f"
      unitRef="U_shares">638754</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="2"
      id="F_29a461b1-5cc9-48c4-b6c7-528b21e33d98"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="INF"
      id="F_d4291fd7-06ca-4422-81e7-55054bc60b7c"
      unitRef="U_shares">283638</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="2"
      id="F_dad2c886-8af2-4b59-be63-94dd67e07218"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="INF"
      id="F_00c7f178-e7e2-4153-9b55-dfe804b3e092"
      unitRef="U_shares">9372993</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="2"
      id="F_4990f315-1da3-4f9d-ac0e-2150c3f76f27"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_50cf44a4-7d3e-40fa-92b3-f209762ca5f8">P8Y6M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_3aeabfa6-c259-43c0-af96-85e127b388c0"
      unitRef="U_USD">51415394000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="INF"
      id="F_6a329763-d5ce-4ccf-92cc-ab5ddf11f4a4"
      unitRef="U_shares">2117654</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="2"
      id="F_06c997f9-a386-4b70-adea-c802cbb426be"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_0591494c-5990-4efa-9c61-19d942604176">P6Y6M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_a48f8b66-5daf-42bb-b69d-8677ce0f2106"
      unitRef="U_USD">17759485000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_b3962309-cf85-4622-8558-52f8101a1c1a"
      decimals="-5"
      id="F_2b0bb40b-d7b1-4aea-ba28-0c77d27985d9"
      unitRef="U_USD">4800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_369296b3-0383-4744-8c6b-7b140def6872"
      decimals="-5"
      id="F_a86b7d6f-d2c0-4e08-a715-940ccf5c2948"
      unitRef="U_USD">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_b3962309-cf85-4622-8558-52f8101a1c1a"
      decimals="2"
      id="F_15423e32-9bff-4bec-aa94-1f3913e235e3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_f301ea89-3456-4254-8f42-f5814959d712"
      decimals="2"
      id="F_38d4b8cb-8332-4b80-af13-98766f4b38d7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_4c74beb2-4bb1-4873-8bda-4048130ed6a9"
      decimals="-5"
      id="F_1c338873-7b98-490a-8a6f-fa70917de56e"
      unitRef="U_USD">29300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_b3962309-cf85-4622-8558-52f8101a1c1a"
      id="F_66d7e5a4-1857-41ff-abf8-fc9f666b65af">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_1f990f55-e76b-4eb3-b239-c008fafd8b98">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The weighted average assumptions used to estimate the grant date fair value of the stock options using the Black-Scholes option pricing model were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.997%;"/&gt;
        &lt;td style="width:1.62%;"/&gt;
        &lt;td style="width:14.881%;"/&gt;
        &lt;td style="width:1.62%;"/&gt;
        &lt;td style="width:14.881%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected option life (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#x2013;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; 6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;72&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;67&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;72&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014; %&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014; %&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_7cdb8f99-5430-4dfd-a2af-004800c69ee1">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_10e2e047-49ac-448b-9f30-e2610064f1ce"
      id="F_b3fcbf18-1c66-451f-8982-de05458cf349">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_b638cb65-3908-4aeb-bd7c-94437b4d77af"
      id="F_78db9301-2ef9-4210-bc9d-da1ad0fdd31a">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="2"
      id="F_5729a3e0-e0ab-409b-bbda-d89129afc4dd"
      unitRef="U_pure">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="2"
      id="F_11836e2d-1d8d-40e2-a4a4-03ca9ea9ea10"
      unitRef="U_pure">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="2"
      id="F_3de1a3f1-df7b-4c28-8f1c-f981b8ce33bd"
      unitRef="U_pure">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="3"
      id="F_1b03b14c-11d6-477c-bb3f-02962754cf2c"
      unitRef="U_pure">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="3"
      id="F_9094527f-a5a5-4d11-a116-85ae659b9fcb"
      unitRef="U_pure">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="3"
      id="F_01bab1c9-22dd-4716-94a3-7f56faac70ee"
      unitRef="U_pure">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_ed698ebb-ff3c-488f-9a7a-a25ad95e94e3">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recorded stock-based compensation expense in the following expense categories in its accompanying statements of operations: &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.603%;"/&gt;
        &lt;td style="width:1.569%;"/&gt;
        &lt;td style="width:1.524%;"/&gt;
        &lt;td style="width:13.388%;"/&gt;
        &lt;td style="width:0.718%;"/&gt;
        &lt;td style="width:1.569%;"/&gt;
        &lt;td style="width:1.524%;"/&gt;
        &lt;td style="width:13.388%;"/&gt;
        &lt;td style="width:0.718%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,833&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,764&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5bbc6677-f9f3-4cc3-b8fc-b7c1ac21c7d4"
      decimals="-3"
      id="F_17ed7c60-2167-487d-9927-07047f53a78a"
      unitRef="U_USD">4616000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a3730188-5277-496a-8a25-6d10f45c0e37"
      decimals="-3"
      id="F_76071ff5-6bc7-46f5-ae55-3874e229f29d"
      unitRef="U_USD">1003000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c654669a-ad97-4deb-8c23-e8cf0a2ed78f"
      decimals="-3"
      id="F_8c9134e5-4088-4821-8961-448c32fcbf96"
      unitRef="U_USD">3217000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_a34864eb-c999-4a01-906e-ed6300c59215"
      decimals="-3"
      id="F_e68e4616-bddc-42f8-bbaa-3b7670f1d8c4"
      unitRef="U_USD">761000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_3f9dbab9-0c59-4f05-aa9d-a96d41bc38c8"
      unitRef="U_USD">7833000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_96e4f117-c2ae-403b-b600-6937175b66fd"
      unitRef="U_USD">1764000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_dd113ab0-ebe9-4f85-92b9-7aed50be7f83">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;13. Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;During the year ended December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company recorded a total tax provision of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. During the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company recorded &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; tax provision or benefits due to the losses incurred and the need for a full valuation allowance against its deferred tax assets. All of the Company&#x2019;s operating losses since inception have been generated in the United States.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.503%;"/&gt;
        &lt;td style="width:1.513%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:11.709%;"/&gt;
        &lt;td style="width:3.524%;"/&gt;
        &lt;td style="width:1.513%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:12.338%;"/&gt;
        &lt;td style="width:2.507%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Income taxes at U.S. federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal and state research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Nondeductible/nontaxable permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;32.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;28.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Effective tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The tax effects of temporary differences that give rise to significant components of the deferred tax assets and liabilities are as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.094%;"/&gt;
        &lt;td style="width:1.546%;"/&gt;
        &lt;td style="width:1.524%;"/&gt;
        &lt;td style="width:13.366%;"/&gt;
        &lt;td style="width:1.016%;"/&gt;
        &lt;td style="width:1.546%;"/&gt;
        &lt;td style="width:1.524%;"/&gt;
        &lt;td style="width:13.366%;"/&gt;
        &lt;td style="width:1.016%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,085&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,084&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;34,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accruals and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Capitalized research costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,008&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;49,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,640&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total gross deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,640&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company had U.S. federal and state net operating loss (&#x201c;NOL&#x201d;) carryforwards of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19.3&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, which may be available to offset future taxable income. The federal NOLs include $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million which expire at various dates beginning in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2036&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million which carry forward indefinitely. The state NOLs expire at various dates beginning in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2036&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company also had U.S. federal and state research and development tax credit carryforwards of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.9&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, which may be available to offset future tax liabilities and begin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2034&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2030&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Utilization of the U.S. federal and state net operating loss carryforwards and research and development tax credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income or tax liabilities. In general, an ownership change results from transactions increasing the ownership of certain stockholders or public groups in the stock of a corporation by more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% over a three-year period. The Company has performed an analysis of ownership changes through December 31, 2021 and determined that on February 6, 2017 and August 17, 2020, ownership changes had occurred. Based on this analysis, the Company&#x2019;s ability to use its pre-change tax attributes to offset federal and state taxable income are subject to annual limitations and a portion of the attributes generated prior to February 6, 2017 will expire unutilized, which could potentially result in an increased future tax liability. The Company has adjusted its deferred tax assets and valuation allowance balance for the affected tax attribute carryforwards to reflect the expiration of the attributes.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ASC 740 requires a valuation allowance to reduce the deferred tax assets reported, if based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company&#x2019;s history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and has concluded that it is more likely than not that the Company will not realize the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the net deferred tax assets as of December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Management reevaluates the positive and negative evidence at each reporting period. The Company recorded an increase to the valuation allowance of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million during &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2021 related primarily to the increase in deferred revenue and research and development tax credit carryforwards.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t recorded any amounts for unrecognized tax benefits. The Company&#x2019;s policy is to record interest and penalties related to income taxes as part of its income tax provision. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; accrued interest or penalties related to uncertain tax positions in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company files income tax returns in the U.S. federal and Massachusetts jurisdictions, as prescribed by tax laws. The Company will file a final California income tax return for the short-period through the Closing Date of the Business Combination. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The statute of limitations for federal and state tax authorities is generally closed for years prior to December 31, 2018, although carryforward attributes that were generated prior to 2018 may still be subject to change upon examination if they are utilized to offset taxable income in subsequent tax years. There are currently no federal or state income tax audits in progress.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-5"
      id="F_d64eb59e-28dd-4aa9-b134-a9a7442f1db3"
      unitRef="U_USD">300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_53656c61-8f4c-49bd-a3e8-21bd90f4b073"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_766b0c96-2ad6-4522-b412-ac66011e9d90">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.503%;"/&gt;
        &lt;td style="width:1.513%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:11.709%;"/&gt;
        &lt;td style="width:3.524%;"/&gt;
        &lt;td style="width:1.513%;"/&gt;
        &lt;td style="width:0.696%;"/&gt;
        &lt;td style="width:12.338%;"/&gt;
        &lt;td style="width:2.507%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Income taxes at U.S. federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal and state research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Nondeductible/nontaxable permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;32.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;28.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Effective tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="3"
      id="F_60dcf1cf-2e3a-4144-9f2e-ee755e42e40b"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="INF"
      id="F_23308eb9-88cf-4a64-b3dd-fdc4fd12dae6"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="3"
      id="F_5c9e590d-0283-40d3-b3ad-70fd81891271"
      unitRef="U_pure">0.061</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="3"
      id="F_d1ada027-46a5-482c-afe3-4c771fa015eb"
      unitRef="U_pure">0.059</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <tngx:EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="3"
      id="F_4267f9ec-3796-4e69-983f-cd4f111d7548"
      unitRef="U_pure">0.054</tngx:EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment>
    <tngx:EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="3"
      id="F_c55cfb88-16a8-43f7-b6d0-a97a7d91e7d8"
      unitRef="U_pure">0.044</tngx:EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="3"
      id="F_37d7cea4-2d96-4cc0-9c56-55185fca2769"
      unitRef="U_pure">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="3"
      id="F_5e4531ad-65b7-4a09-9dc8-5dac380cd2c0"
      unitRef="U_pure">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="3"
      id="F_652cc06e-7582-4510-958c-93d2d40db2a6"
      unitRef="U_pure">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="3"
      id="F_590cb1f9-84bf-45e6-b7ad-b987381d857c"
      unitRef="U_pure">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="3"
      id="F_8905ac12-d107-4a02-a8bc-438ac97758af"
      unitRef="U_pure">-0.017</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="3"
      id="F_9fb1f9ee-c775-451f-8c33-8e96385d3288"
      unitRef="U_pure">-0.321</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="3"
      id="F_d2d992e6-04ae-425d-912a-98e075ff9400"
      unitRef="U_pure">-0.289</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="3"
      id="F_05307467-6cae-4e9f-9895-fe8e05313a77"
      unitRef="U_pure">-0.004</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_e3a2f50c-f87f-4da5-8688-3ad0bd6e5d3e">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The tax effects of temporary differences that give rise to significant components of the deferred tax assets and liabilities are as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.094%;"/&gt;
        &lt;td style="width:1.546%;"/&gt;
        &lt;td style="width:1.524%;"/&gt;
        &lt;td style="width:13.366%;"/&gt;
        &lt;td style="width:1.016%;"/&gt;
        &lt;td style="width:1.546%;"/&gt;
        &lt;td style="width:1.524%;"/&gt;
        &lt;td style="width:13.366%;"/&gt;
        &lt;td style="width:1.016%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,403&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,085&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,084&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;411&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;34,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,891&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accruals and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;958&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Capitalized research costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,008&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;88&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;49,568&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,640&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;597&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;343&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,043&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total gross deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,640&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_7b5a30f3-2755-4066-9f4f-ce371afce969"
      unitRef="U_USD">4403000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_0477d62f-b82e-4de1-9eb5-936423cff3ce"
      unitRef="U_USD">11085000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_d037756d-8e72-4726-8fbe-2a7f4237f961"
      unitRef="U_USD">7084000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_9b338914-19f5-4ce8-b7ba-f76859dcffb9"
      unitRef="U_USD">5213000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <tngx:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_b0e762db-fd83-4491-9698-550f3a5a5f0f"
      unitRef="U_USD">411000</tngx:DeferredTaxAssetsOperatingLeaseLiability>
    <tngx:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_af8c18f5-98a3-4eba-a205-a2542baf19f1"
      unitRef="U_USD">2154000</tngx:DeferredTaxAssetsOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_52522cb9-00bc-4685-9141-51a1ead8ba1b"
      unitRef="U_USD">34625000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_25515a85-7252-4be4-a7bb-75b8462cf64c"
      unitRef="U_USD">11891000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_297dc627-9dac-452c-b7fc-41187319eb54"
      unitRef="U_USD">958000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_66fd5365-b3bf-4648-ad9b-a7503e78f358"
      unitRef="U_USD">648000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_06e31553-d107-45a0-910f-6473b4d261ec"
      unitRef="U_USD">2193000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_2cc36d75-73ee-46db-925f-f92e7d3479f2"
      unitRef="U_USD">2506000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_5f8d5197-7050-46d6-aeb9-03171a01933c"
      unitRef="U_USD">1008000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_3e31ccf8-f778-4283-80ce-76ed6c9d63d8"
      unitRef="U_USD">88000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_59c5f819-198b-45ad-bf51-5797443506dc"
      unitRef="U_USD">50682000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_1776594c-3f7e-4dbc-89d8-6762bde57811"
      unitRef="U_USD">33585000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_57d999d4-5032-4e9d-8de3-006a37db2738"
      unitRef="U_USD">49568000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_4f49acc1-6781-4d7a-9311-9c8ae6407ccc"
      unitRef="U_USD">30945000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_ee48b4e8-1ad5-4043-8d89-b444a0d0b0d2"
      unitRef="U_USD">1114000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_f32a86c0-6252-4788-8e1c-522e9cebbc31"
      unitRef="U_USD">2640000</us-gaap:DeferredTaxAssetsNet>
    <tngx:DeferredTaxLiabilitiesDepreciation
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_de4b57f8-5374-451e-bf14-9c8cc7974da0"
      unitRef="U_USD">771000</tngx:DeferredTaxLiabilitiesDepreciation>
    <tngx:DeferredTaxLiabilitiesDepreciation
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_d083dd15-a3cd-4422-9186-c442c3b5128d"
      unitRef="U_USD">597000</tngx:DeferredTaxLiabilitiesDepreciation>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_f63eec34-738d-4917-b2f4-5492f06c073a"
      unitRef="U_USD">343000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_d6f596b8-784f-4b9f-ba07-648cdd08e17a"
      unitRef="U_USD">2043000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="-3"
      id="F_e740bb65-0396-4347-922b-7ca356b209a9"
      unitRef="U_USD">1114000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="-3"
      id="F_9e5a7cc1-129f-4e6d-b267-67f1b2cfde66"
      unitRef="U_USD">2640000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_2ac7ee07-3d73-4617-8ee2-9f9c91ec3957"
      decimals="-5"
      id="F_0aa3f758-5d2a-4f1a-9a38-3ac93fc8f6b7"
      unitRef="U_USD">19300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_90016151-b8de-4c70-b40c-6a6565310359"
      decimals="-5"
      id="F_8ee59b47-5975-418c-8dda-692f744b7e0d"
      unitRef="U_USD">17400000</us-gaap:OperatingLossCarryforwards>
    <tngx:OperatingLossCarryForwardWithExpirationOfUsage
      contextRef="C_2ac7ee07-3d73-4617-8ee2-9f9c91ec3957"
      decimals="-5"
      id="F_68f74862-75b3-45ab-892c-e4b4354fc43e"
      unitRef="U_USD">2800000</tngx:OperatingLossCarryForwardWithExpirationOfUsage>
    <tngx:OperatingLossCarryforwardsExpirationYear
      contextRef="C_5c11f77a-567b-409b-b802-3c267191840f"
      id="F_f0b20abf-60aa-43c7-bdf7-f0b3e3b6d64b">2036</tngx:OperatingLossCarryforwardsExpirationYear>
    <tngx:OperatingLossCarryForwardWithExpirationOfUsageIndefinite
      contextRef="C_2ac7ee07-3d73-4617-8ee2-9f9c91ec3957"
      decimals="-5"
      id="F_d0e9a4e0-36ec-4bda-9446-eaefaa0450a0"
      unitRef="U_USD">16500000</tngx:OperatingLossCarryForwardWithExpirationOfUsageIndefinite>
    <tngx:OperatingLossCarryforwardsExpirationStartingYear
      contextRef="C_764718f8-db6b-4222-a924-e17f308b9e1f"
      id="F_7c89b087-c025-4e7c-bc2b-e7afaf880037">2036</tngx:OperatingLossCarryforwardsExpirationStartingYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_aa1ca7f9-0b3a-4f12-96b6-45a3b58f76db"
      decimals="-5"
      id="F_39649ccb-4678-4fb1-af85-f119e0ae3a90"
      unitRef="U_USD">4900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_46657909-6cf1-47fc-8643-1f04c29704bd"
      decimals="-5"
      id="F_4e4c954e-9702-4ea4-ac00-69bdc866d561"
      unitRef="U_USD">3000000.0</us-gaap:TaxCreditCarryforwardAmount>
    <tngx:TaxCreditCarryforwardExpirationYear
      contextRef="C_34cc5401-52f8-4cad-9b24-31c1f9fae295"
      id="F_43d4c431-d4fe-4406-8915-e09acc0941b5">2034</tngx:TaxCreditCarryforwardExpirationYear>
    <tngx:TaxCreditCarryforwardExpirationYear
      contextRef="C_0494c044-9ff9-41c2-8ddb-c0be1c1a2795"
      id="F_d64a87b1-a314-4d76-973e-b10437a0295f">2030</tngx:TaxCreditCarryforwardExpirationYear>
    <tngx:PercentageOfIncreaseInOwnershipPercentageOverAThreeYearPeriod
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="2"
      id="F_523cc609-eb9b-48bd-9576-10fdcc40959a"
      unitRef="U_pure">0.50</tngx:PercentageOfIncreaseInOwnershipPercentageOverAThreeYearPeriod>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-5"
      id="F_12a83e09-beca-467c-b386-4753a5de3204"
      unitRef="U_USD">18600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="INF"
      id="F_54ee779e-6bfc-4531-b34d-babf598e699b"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="INF"
      id="F_d6c406e2-c071-4c93-8c4d-e2b6dbeabe89"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_654a4524-3c9b-448c-a88c-7c276a239270"
      decimals="INF"
      id="F_ea136242-84fe-4cee-9f9f-d14edfceb40c"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_86a57220-fb9c-48b2-8b06-e5537b12ef0b"
      decimals="INF"
      id="F_74bf1f41-c440-4251-af10-fd3341b251ba"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_d5190e4b-1806-4851-8ca8-6a142ad48b9b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;14. Net Loss Per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.243%;"/&gt;
        &lt;td style="width:1.525%;"/&gt;
        &lt;td style="width:1.514%;"/&gt;
        &lt;td style="width:13.823%;"/&gt;
        &lt;td style="width:1.017%;"/&gt;
        &lt;td style="width:1.525%;"/&gt;
        &lt;td style="width:1.514%;"/&gt;
        &lt;td style="width:13.823%;"/&gt;
        &lt;td style="width:1.017%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands, except share and per&lt;br/&gt;share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;58,235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;51,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average common stock outstanding &#x2013; basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;62,108,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,932,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net loss per common share &#x2013; basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s potential dilutive securities, which include common stock options and unvested restricted common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.094%;"/&gt;
        &lt;td style="width:1.569%;"/&gt;
        &lt;td style="width:0.718%;"/&gt;
        &lt;td style="width:14.448%;"/&gt;
        &lt;td style="width:0.718%;"/&gt;
        &lt;td style="width:1.569%;"/&gt;
        &lt;td style="width:0.718%;"/&gt;
        &lt;td style="width:14.448%;"/&gt;
        &lt;td style="width:0.718%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,372,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,094,544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unvested restricted common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;256,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,372,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,353,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_51df3310-9f73-46e7-817b-db541c59da8d">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.243%;"/&gt;
        &lt;td style="width:1.525%;"/&gt;
        &lt;td style="width:1.514%;"/&gt;
        &lt;td style="width:13.823%;"/&gt;
        &lt;td style="width:1.017%;"/&gt;
        &lt;td style="width:1.525%;"/&gt;
        &lt;td style="width:1.514%;"/&gt;
        &lt;td style="width:13.823%;"/&gt;
        &lt;td style="width:1.017%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands, except share and per&lt;br/&gt;share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;58,235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;51,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average common stock outstanding &#x2013; basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;62,108,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,932,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net loss per common share &#x2013; basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.94&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="-3"
      id="F_1937a6a6-025a-4ae6-9f77-7e1d09b4ed59"
      unitRef="U_USD">-58235000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="-3"
      id="F_fa9972ce-cc4b-442c-b765-dcf374c005c9"
      unitRef="U_USD">-51972000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="0"
      id="F_877d8ae5-bfa1-4e03-9782-5e0e05412817"
      unitRef="U_shares">62108032</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="0"
      id="F_0061e2ba-098a-4a12-bdf1-9aacb993ad61"
      unitRef="U_shares">31932204</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="2"
      id="F_d198f292-1581-4b96-8443-1786f7098595"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.94</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="2"
      id="F_bec40dcc-ef49-4d02-b457-600b1ca3f855"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.63</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      id="F_ab95bfbb-edfa-4fca-8ee4-60438d38e681">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.094%;"/&gt;
        &lt;td style="width:1.569%;"/&gt;
        &lt;td style="width:0.718%;"/&gt;
        &lt;td style="width:14.448%;"/&gt;
        &lt;td style="width:0.718%;"/&gt;
        &lt;td style="width:1.569%;"/&gt;
        &lt;td style="width:0.718%;"/&gt;
        &lt;td style="width:14.448%;"/&gt;
        &lt;td style="width:0.718%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,372,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,094,544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unvested restricted common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;256,811&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,372,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,353,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0bd03243-27c2-444e-894b-d4ebc2dc9598"
      decimals="0"
      id="F_ee6faa3d-2d37-428b-9bff-cd51e396a4c7"
      unitRef="U_shares">9372993</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_acbb8224-ebbe-4c79-b11c-d87062900529"
      decimals="0"
      id="F_7e10d5b3-c16f-44d0-ae66-3c53b6477fc5"
      unitRef="U_shares">4094544</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_19209eb4-ef67-4899-926b-0331243cd6b1"
      decimals="0"
      id="F_980e2564-bf20-440e-82ca-2df68f1f95ad"
      unitRef="U_shares">256811</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d558a274-44e2-47f9-ba78-6254302f1b82"
      decimals="0"
      id="F_d3517e9b-5e9c-4818-9e91-5faec1b705b6"
      unitRef="U_shares">9372993</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_78eb35a2-1f74-40df-8fa7-52275c2dd513"
      decimals="0"
      id="F_d98a3a94-9407-455e-b35c-86509ec6f270"
      unitRef="U_shares">4353375</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>102
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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ME.H;?_J-=@Y%IK^<E[+]#YXZVV &\D8J7G6-M8**U8=/\MP%8M  AA,-4-<
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MR,\'3]+]!"LVR*9 G*%H0MU@]^&GP#C/?@9?R$$(&"9PO*IQV:$@#:;$]Z1
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MLA;@_[\IBNKQ3?T[O>VO5X_^ U!+ P04    " #N/7Q4" EN8; "  #C!P
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MT%'W#+'"O7Y9H%[Z,6*(<RUMV2KJVWI2W?D&_>%^2!.L'#CO-.7XFS"]Y-*
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MI\<]X>)U9/P1;,57@ L;@BWY<:TD0$L+\'UI43GI!REH[X0O_P=02P,$%
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M/GDI9)A6%*/7[WC*5PW"$0AVX44U*>];$="RU5NZM&@QV:8$+GE:JIX#LK@
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M(7CS$]=*PAF)BRSG$HS(QMXC^'@=DSP6 $/L1\W<GSX9KA5A9>LG49$]=2G
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M*+=(WFEE]8]XN^8E$W_:7HAG$8S+/*Y-VA0J;%+LU5*/(")3#K@O],:XX:(
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M\8 FLKCP/&_6'7VR+37"3#5:3#\H&3IRQE]4)$R>^'CCL%22<H2S9Q6Z[)C
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M3'N6/#,3VFMHYV:A][6X3T9<;T)R8^%\'/AC$S*7! >YN@=R\'L7=1"$XR@
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M9("5PK5*<>I3N.@6G]A"6I"RGKX(%\SG$8+C'AU=ZU:3&\H>/@98X0W-#*3
MT(0".Z UA-(B5(N2+KHVK5@0_I3 M+)#M.\)^: SW%IV*B*H:U2*:MA(01_,
MQL'5_MJU8&&]'DE;;(?XI#,B<  )P6I-MU<JD$72&F(J=J-;ZP;;VYU2WGW1
MDN%=YA;%T B)@ON,(0]-U&.KPHFT(UJ07RO%#/FDL5 ?L=$B/+@2=%0P@KX
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MG#Z5"?6ULMUM+^4W]5WT4;R^T</5I4)6:%I ==";C#K"U;?D^B'85;R9SFW
M/3<N"_RP(,<">+^PF,C- QMH?ZI<_PU02P,$%     @ [CU\5$3]9$K+ P
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M>J5+F0OH*,A$+C"Q5=(Z%(E?\Z**:QN^4,]>00E!-Y JLTS3*]J_AL'GM$_
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MI"^OR?[0&;X;X=/*-86],-E1EK:CQV%OY0R+E<OSUY"RDE@7V\@2A,@-&\+
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M =XOC?'-#U+0_C?&PW\!4$L#!!0    ( .X]?%2%Q_MVQ0D  *@:   9
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;*U9;9/;MA'^*QBUTSHSLG0GV[5K
MW]W,G9W$GHD3CYVT'SK] )*0B!H$& "4?/WU?78!ONCEY"33+W<B""QVG]U]
M=@%>[9S_'&JEHOC2&!NN9W6,[<OE,I2U:F18N%99O%D[W\B(1[]9AM8K6?&B
MQBQ7%Q=_6S92V]G-%8]]\#=7KHM&6_7!B] UC?3W=\JXW?7L<M8/?-2;.M+
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MA'&2?M\@-L(8D;([IY//YP,'6R0Q2!J]LUIO?$!O%+,/6KG,LK<J%>FV@@%
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M!,E6!'<#A_[+7K$H@&0I3"W=1_@MV@^!1%@4>GAI=")$ZO5B^R@(T37RW#?
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M/&"2F4W1IM4Q59LU/$LLXZ(J,F",-"D*ND31GZ*R4+#F'E,BJ#"GCPOQI<9
M B7),[#8YGK'D)!Q;L&"12N2)[X(E6+(L\YJ$)!U7'/:R!,.[5OGHAD^#@.?
M/)>GKN)YH#XZ"@_GD[\]3"I.J=/T$!AN(/XX08S!(6.V5>Z8@(*2]A1U1L!'
M*TE&E?R.//S_0SK\O\,OAR3R%?*P8>*%C24:K;QL2U:U9A/#\!T,K<M=W6WW
MX\>#T92N\V TGP73>.RDVFP^6&M?JN,($SF;*;Q%DX@PI]A94?]5J2+&\7OT
M,E> 9X9X0Z*IVY<H.;&'WPEL_ LJI!DOL1\W#&4T[KM 49G18,YS=IX_PYR-
M*7@H53R8CCG%9I>KV$S >LSC-,I+!(N"5!!QH$ P#WN5 J'J/,>JFC!2(.EP
M^] M%'=+)SM"VCGX*L.#G)HV1#TP]4Q= _O-;O A.$)?7G=,B":A5=6.AG;9
M+6R35=-B))V@@+P@>3O0=OSI^BDK\HDTZN:ZM+8I0,<Q)A"]BO,DH=*J^R@Q
M&\I3N/-$.<=,GD"\*1 F03R-@MDT>01TCR6% 4S%_L&KEJL[9M>(@^-H>Z)L
MGQ?&Z:,@F4Z#!,]\YIF![WT+8V%\[>M](^#6BWMPU'XU2*-OKJ^[PF5KRFHP
MO"<,ORGL Z$K2X^41S3MQ.C]_8;&V7Z[*XAVC<K3-S=   %:H95:$;]BXGPT
M[\?:(*"CPSZBPI[OX V_-[@L.QK<Q]#J0^1GB*Z'HX5 "U<Y$KJ'+]L/[4VP
MH.9+9%?@O>T)T?!AQ+[UONLSW#%*/!:I_?;[D;086%*\YW;+E9XL'\>2O,^-
M]Z-#&-U+EMET'(PFHV[! P>&[..N$K%)X6CTUM0<12&W9$MC8FB/?_/?A>UP
M4>78HUDBTQ/NJLWQ%3?NI& 1#&@<;6$@8CIP/$)--!(7P^=G/W9>^<6<TF+X
MU48HOA)GGRK;1CYX.-*5SL=(,)K##\/9*(BPD7_#HG X/?O9RCQGT]DLB.,I
M>V:?3,X^^,H:#Y,YYMEGPS!._@1=XB&+QY-@%D5FO3C>:4+WQ_.9TP1/^IK$
M4>(>).,_0XW(4& 4OX!,?V5:727<\1DSM:\6:4O[(!BA--V!= P.7D _E$ID
M'$<-V1S-K/UNAZC-[9NA015R**]S>^P#:JID8\\."[N;IUROP:O$1%5F^7+-
M-S2.;21)88JP@ORQ1VWF;,7*=V>!-G.,74\ZIS*0?^R95$?9EMB[G#@\:LK5
M8P^7;OVYT4/G2_K^\9*KD+O:Y(\=-A'+_'GG3:YVWELYUWV7'N,5$^![_G[L
MH=]73K@,*OJG5,;GW?:YY+EW!&28P68S=)G7@]SC.,ZP-M%(PDILB[ZWI3MC
M?R?H8;"@#JS7"3^*JOO]Z?^"LW?D[?UX=@Z0&(G/SKPACR')43"<CX+Q:&0X
M;S9CLW \P_4DF"3C8!)/S[YSG3%*VN$PF(V(4*?A.#E[[ZIJHLU)@O9M/'+4
M.9F<O?6')<2ILP32+.$F83)Z@H(16L-D&@?S>8+)XW \)P5I=QE'P2@:!\E\
M)\Z5^29@I\3%011-@\F8[(W#\81-PG%,2D^A/]K0V?@>/M$G 8$Z3W<@]<>6
M2"L46VEK7YDYFLARU)A*4#XN1+.EUR=TV[<@+GE\Q=0[ #4MZEXR?+5>LDB2
M>B?(I XEV_YZF@'-OB%Z^D(V9QM)!/2 /T0'"#-44-:-PME>'E(/:]6@C(RZ
M9T]+BOL)3.IM74Y<<%O0N/TSNT<RNW<5W<F%U]^? 5D&&8>CH:..*$1^'&AX
M4)0^J.(#;:/Q*YUNI7)5@6-,D;%[)XO.%]=N*[,[]K[>5M]XOJ.\P)VC]5MJ
M$I,VVI*\6XFAY5*F8?<'N0=>M!L\Z9Z$0VL\'5DM*'&;W/0:Q/+R"2E-SK?:
M6&OLEKIW'/DS8F6M[X>6>:4X"HS2K=BZ,V7:C$L*=O>NZ2#V_@WJGO?L"U+3
M^Q4\_7QQDZ*^H++*:D+Y8\X)928*V]K!+KL_Z.=GEE00;]"AL\A-+/*E8#M6
M!M'$P-305H'1"_R.=G,VDLJ4@G:1:8R.:C+%'S^2[IQ]S/7GBR5*)<I 0=4*
MO<@59EO[%G]'O0D1_=H)]Z4=N\M%D75EZ+>]*^/\BS>FWMG[(."] ]]M#TDE
MZJ*6*D_CR O[@8 KCVS1 (^;"%S<CX!]"4R5CCX.<J()1OT81?R"WO/3IR9@
M6H/4P\K3Q]0N'^[IV954?3V/KIH[5NQV??\@A?XK5$"".D&64XW:K[P ]<;5
MKH8'A3VA B[^26>*Y@.0'D3.S3JRU7 #]FGTBL*\C2.O9 (\(6OSXOT;>FD=
M38AY@N$P.?M.5)!<N)>$7<=*%702@*[9=!*=W1H:P=X<S)+$3)VB53WVD<9E
M[R.94JB5^12(XM%6C?U>IKO;?6UT93^RV0VWGRK]P!6*0VPO8HFIPW Z'MA:
MTO]H9&T^N5G(II&EN5P+CO*=!N#Y4LK&_Z %NF^P7O\'4$L#!!0    ( .X]
M?%17.SMEBPH  !0<   9    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;*59
M:6_;.A;][E]!>%X'+>!XM^.T28 T><4K,%W0M&\P&,P'6J)MMI*H1U)QW%\_
MYUY*LKREG0X0Q%K(NR_G4I=K8[^YE5)>/*9)YJ[:*^_SE[V>BU8JE:YK<I7A
MS<+85'K<VF7/Y5;)F#>E26_8[T][J=19^_J2GWVTUY>F\(G.U$<K7)&FTFY>
MJ\2LK]J#=O7@DUZN/#WH75_F<JGNE?^2?[2XZ]548IVJS&F3":L65^V;P<O7
M8UK/"_[4:NT:UX(TF1OSC6[>QE?M/@FD$A5YHB#Q\Z!N59(0(8CQ5TFS7;.D
MC<WKBOH;UAVZS*53MR;YIX[]ZJH]:XM8+621^$]F_8<J]9D0O<@DCO^+=5@[
M&K5%5#AOTG(S)$AU%G[E8VF'QH99_\2&8;EAR'('1BSEG?3R^M*:M;"T&M3H
M@E7EW1!.9^24>V_Q5F.?OWZ;1295XK-\5.ZRYT&1GO>B<O?KL'MX8O=@*-Z9
MS*^<^#V+5;Q+H =1:GF&E3ROAT]2O%-15XP&'3'L#P=/T!O5^HV8WNB'^HD[
M[:+$N,(J\>^;N?,6$?&?)UB,:Q9C9C'^11,^N9N2[J7+9:2NVL@JI^R#:E\/
M1EW1)"ON"JNSI? K)39*6J'(W +&4NE<V=I@HL-+;DV:RVR#I(F,I852>.-E
M(CS,D%OSH#FGS$+\)OK=$>(J2?"@^Y-L^J?89&:? U)&96JAO1-QH2 %;X07
M')3265182^)E,3_/%&Y0:"#OHD@2\2"30H;D35 ]9!8I(9>H-,X+)JD6B@D0
M5PF:J$_B!ANA64/ O_]M-AR<OW("I<R"'C0L)7":2-*_G-FLY(."Q"H32XB-
MM:"M,Z;U)=-T=^_QD+BPUEFD$QTD+%E^Z=YWQ4+%V)P(A\6%-W9#+,B9)"=1
MK0RQ+Z!:+!27J8,-VD%!V(;LX%ZV_D7>X9QKL=_)*ZVW]1ZH)OTI69C><-#M
MBV?E3XNU:O!4K@-G>%*JVE_Z44R[ S'I7K3>E,_)=XZW4_1*&ZWX4:P>4/!S
ME&_/2D1P$[ELTAV+<7<,CB;Z=D;U-!;@BA[C@AW5(UTK\5P,P.D%?OO=<_&B
M]=Z0M@6L,T]4+T/5D8\2EP(^365&?."@U&'Y5+!!AZ]:'V!DRR1&3&K I&Y7
M,EN2ND<#[+D8#4O.PUGW NM_K[U2NX-(CL6+9Q6G9^+S*KP.+G0<#RK-C46K
M$['&4ZM WL'O<,V2J%GM.!*<7F9ZH2,)'<@6AK1Q540="7*V, )OCNCSFIR-
MFO;#\'C.D6P*A]WN1>OND&[K/?E\)TE$)*W=("?7TL8.]6+<&?='^!T,.OW9
MI/7IE-.#P_>VGV//6$PZP\&H]6'+1R$,:GTV8CR Q)W!9+R5T8)RA@(R&G>F
MPPDQGUT,6C=19 N9!'N4Q=.)B\E,3,>SUJW,-8J>_J[B;6Q&QL%^H'XQPO])
M?UK&"+3IS\1LUOK,A7)I2?=CII_T.]/94(Q&G0G4__-H (TO.I/IC$-HU.]<
MC"<4OS#M,7JP9&<P&.-WV)F.^[MN:?@8+] ?HK+:_ ;2Y^<4I70UN:"P9D!U
M9A9GA5.!.O$?A\@?=OIT=5J]9C@]+V4*&R'5$?D5B5Y&?^/JAN/V1XUI)>/=
MZK2M(MEA"#XGXL/^J_<?_L%7@U<O]N**.]G@8MO*F" >G2-+RT<="H(\)'*R
MZ8CU2B,>4KE!:1/R0>J$RPGRT2P69+Q%X0DK5'4F5,<N)WHE-B3B-I84L2(/
M=F>U ($\JIFFW/0H-58C]T1,_0,LESK+2$,DY; _FE8"3[N3/1*LJ2A5Q7(X
M05,O2C9!EF VEN3GN75_TE%(+O.4MWZBYA]SU1AU===3(_2A_]]1NT41A%ES
M6EJ:)N@_YG>X("339-857SRV?S_=TI\,U%U-JZ+TO]FGU-,5\Z^0BD27= .>
MF=<L0(:2!T53%#<6LT!(6'%?CCDC%*=2\+>95S;#XD]E];PUL>JP* !LI#=Z
M*@E? S9V3U OD>M.A=G,&F#(K70N(FZ=91-CM&2B$L2A.CU0S"4;@GV\(#)%
M$H<5%8P*ON+(194Z)$SJLVZ\6J:FR!B&[!HI4)<96:I@CS&*),N _0]2F,7;
MC15"VR7D2\A !X*1(S'GH<5:DPJ,#H K;&].?TS#KL+-VYTDM;(><!4F!=I9
MF02.<L0^+^:)CJ@,%[FK3,.+:)<D]Q!R8(?.-R(UI 0$0?<!:#,/BB"R7UFE
MSABG(PRUB4,]V-981\]I;F?CX$\F&Z?9Q\<\"F&6JR,5(80N0@GC)]5^LCWD
M>J/F:+XH35-:-SCG=3?%$C,KZFX8%#I'&%$UJ8*F*UXS C1D 8*XI8B=H^BX
MP@?P+[4X@I,(NK/20]Q3O;=Z7E#-:P3!0>KNQ0.AIV:^[6=82&4IX))F76@P
MVTX+.1QAB<J!>=:H;E49*K(J:JOR%E(E-UYQFB>;,N(H.."[,LAH/#HL=IM#
MQ\OX*_Q T\OQ,8DU.H9^YS+AWP7G,)1D.%OMK33>3T=#YS,)VP][6$EYW%1H
M//>WXAR0PJJ_"M@"HAP5A&D"[ZN3(-@J<@B94"_$?!M'2JSY+*9BCK(4$_3&
M.D]S%&=3HK\I*A645)GQ(:H=14/M94O2/(7"V:.T>4[U(2#-0U>HH)T*(VYN
MG.91@AR0J:7DFTI$4)(\@1<HS>R[1LR7+$Z)TQ7OD#Y+Q>V%&&,\=2!K2\[[
MV81\XW&0RE21%DF0A+K:_GB^/R63Z"1;(D.]0A*ER@*:-CLGJ8^^0A,;E[PR
M11IO*TS/);5<*IQ,CLSEQ+%4B;%6685^Y,\FDJF=U31C?3AQVLL(V(B.-^ 5
M B-/G$R0@'QVH%!E4-_=BNIN>5P1CC>.CP#R!!0+(&78%SNN1=$O(\K]3$3!
M#$JBP(1LX6Y_I%EL3XJVM:8ZI#BF:P#<,XS:%8R+P]$1"VY54A7#%/$<6C*1
MJDFCJL7[L]TOX:730+:VWN'H0>=4394W)=!P7/:*C%YA)/]>NJF*DAV3U7F4
M&[3R#04BYR@1A7IHEP@#%B)7Z&J,2"N[8*'>.:L!%6FY8%$P-LY^:F3VJWI*
M&I%50R)"'\<$*K(*K#!?#JH ;Y@L%1,H&O-R[J)I=4A1@N"J3]()AE4K.K=_
M"$=]NZ&VT(G:T=$J=+0MIP.X_0YI@@A&R_=@^!5QYF(=P%>'30>](K07" :L
MQ(U1KO>8<O839TI@39CX%E4 WLZT/)2E[GYNA9PY"PE3(R2V,O2B<+\C.%$6
MC]<%'BF, 6 Z!P_/;GL;M,KH$T)";=XZWC$O5^]Z#5'40"+J4:8E(5+M$,CL
M&6.]4C3^Y3DBD@#.=D L@IA-3$,Z'H5&0A8>>H<A2E?@AB )'9^7)[0$.]T6
M[>R%Y6 &SR1TV+1<[>3K#D*C$KTFB8_ )Z+!PX#SY+K=B:A$?-PDFS;2[(@-
M [IZ+-@"P3W81[@<@Q5@2%5@6"DVF@VHD!M@YJ$Z4JDR%@1T>^>E,%D<,I<R
M=HF !)ECGQ9ZC2\UZ)E+_AY%?0W5)WRTJ9_6G[QNPI>>[?+PO>R=M)AMT875
M EO[W?-)6]CP#2K<>)/S=Y^Y\=ZD?+E2$CK0 KQ?&*#-\H88U!\"K_\+4$L#
M!!0    ( .X]?%3-CF@?!@0  '4)   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(Q+GAM;*56VVX;-Q!]UU<,MD&1 !OM5;9D2P)\2=$"C6'$28.BZ /%'6D)
M<\D-R;6<O^^0*\F2$ZM%^B*1RYG#,W-F2$[7VMS;&M'!8R.5G46U<^U9DEA>
M8\/L4+>H:&6I3<,<3<TJL:U!5@6G1B9YFIXD#1,JFD_#MULSG^K.2:'PUH#M
MFH:9KY<H]7H69='VPP>QJIW_D,RG+5OA';I/[:VA6;)#J42#R@JMP.!R%EUD
M9Y>EMP\&?PA<V[TQ^$@66M_[R6_5+$H](93(G4=@]/> 5RBE!R(:7S:8T6Y+
M[[@_WJ+_$F*G6!;,XI66GT7EZEDTCJ#")>ND^Z#7O^(FGI''XUK:\ OKWK9(
M(^"==;K9.!.#1JC^GSUN\K#G,'[)(=\XY(%WOU%@><T<FT^-7H/QUH3F!R'4
MX$WDA/*BW#E#JX+\W/R&=/]=6PNW:."N9@:GB2-<OYKP#<9ECY&_@)'E\%XK
M5UMXIRJL#@$2(K1CE6]97>9'$:^1#Z'(8LC3/#N"5^RB+ )>\0+>.V:44*N]
M*.&OBX5UAHKB[R/XY0Z_#/CE_\KB40S??6>V91QG$;671?. T3PKA_ M.%PR
M*S@P54$E9.>P D5&TANU9&2#$7/.B$7GV$(B. U<-PWU 944OZ^UK-!86#,+
MG$G>2>91:+;4DAK5G@W^1&9Z08'DP&9!P"3)X+50X&K=6=K>QH"/'%NWW9(8
M$8&!E\UKEPYNN@8-<]J<#6ZV%%_!:QB-X[P8P9M^DL63TQS>#*Y1:2KRWOYS
MZ"BLWK('@ECA00! !XQUM!_)"C__-,ZS[-RWY[.TO(*3/,[2<9P6N6<_*?(X
M3\LG+CY=6]P0PC&LUY .)^6&=#8\*6CXL4:XTDW+U-?@>GI.H-JA<H+)WI>.
M';#(.R.<0$K9NA:\!J&X[*KG4;7^K+)AWTX]H/4;4S60DMP/]XUCJ"DSL$!4
M7@4/5L'2Z(;D"; M:1^./KT\6B<V..!R22<E':*=K C45XS!JN,85K_U&_K0
MZ0C5!N-@LGZNE^I"T=#N^QFV!])UEDCYXMP6(2RTJ[^3_1\L<-$'9UG3$]YJ
M]90QO]P7O>?S)-T!YQA"3RK/Q%\"%?@;I=&=<H?Q, ?(2%UB*70%J*KXAS3Y
M#Z%1Y@-JOQ6%2@QX:.,%<D:)W928IT5VS4;:4#0UHV:G""C4M[L:[2O@Y<Y_
MZNJ[@V(E?FUG>$UY.:SF25R<YO%D4D 9IY,R'I7EX-._5'7?@/DYY*.3>)QE
M@X_:D1K[4,6HH-D(OG=P)WM7(9T\JW#ATQGGE>IOQ=W7W9OBHK]*G\S[!\E[
M9E:"PI.X)-=T>#J*P/27?#]QN@T7*U4L7=-A6-.["(TWH/6EIF+:3/P&NY?6
M_!]02P,$%     @ [CU\5./0=ZA[-    [P  !D   !X;"]W;W)K<VAE971S
M+W-H965T,C(N>&ULS7W9<MQ&ENB[OP*AZ;@C1A0IDI(L>8V@:+E;'79;(=H]
M#Q/W(:N0Q4(;!51C(57]]7/6S)/82-GNN??%%@M +B=/GGWY^KYN?FUWWG?9
MQWU9M=\\V77=X<MGS]K-SN]=>U8?? 5/MG6S=QW\V=P^:P^-=SE]M"^?79Z?
M?_YL[XKJR;=?TV_OFV^_KONN+"K_OLG:?K]WS?&-+^O[;YY</-$?/A2WNPY_
M>/;MUP=WZV]\]\OA?0-_/0NCY,7>5VU15UGCM]\\N;KX\LWE2_R WOA[X>];
M\^\,M[*NZU_QCW?Y-T_.<46^])L.AW#POSM_[<L21X)U_%,&?1+FQ _MOW7T
M[VGSL)FU:_UU7?Y7D7>[;YZ\?I+E?NOZLOM0W__%RX9H@9NZ;.F_V3V_^_+E
MDVS3MUV]EX]A!?NBXO^[CP((\\'K\YD/+N6#2UHW3T2K_,YU[MNOF_H^:_!M
M& W_05NEKV%Q186G<M,U\+2 [[IO;_@TLGJ;W12W5;$M-J[JLJO-INZKKJAN
ML_=U66P*WV9/]5\G7S_K8&H<X-E&IGG#TUS.3'-QF?U85]VNS=Y6N<_3 9[!
MFL/"+W7A;RX71_S.;\ZRYQ>K[/+\\F)AO.<!$,]IO.<SXTWM^+^OUFW7 .+\
MWX4)7H0)7M $+V8F^*7U".6W;5< ,OEV"HB?-D+V\\YG<!</KG&$XO!P4U<M
M+#^'YWFV+2I7;0I79FT'/\!EZEJX2O_LBP:^[G:N@__X[+K>'UQU!+3ZU6=>
M1U]E_^CS6_[&57GF6KBY!YQ'/MV[8^:V6[A>- JLHVYP5K='0+:X&OC&=S!2
M6;AU419=@</B_-UQ!1_<^:KW/+K_"'2FE3\:7]+Z\Z+=E'7;-UZVAL<#"Y)Q
MZ5TS]%F"PF$CH]7O7>ZSHJ)5/PROHMJ4?>Y7V;J'B6$I5=W!K/L"O^CJE6R>
M]@+_W]2PA'_A8$V]A^'+TJUK.1]WVW@>E;^Z<V4?3@ZN^N;74Z0PL-I[U^2\
M<'S/;39-#ZL"(@PSM-XUFQT]S&':LC[@D &"9]E/,!,,6=W6B,TP8B'SZ4%[
MGAA 4\ &9T]\[[M=G==E?4O _=F,@,L<? T39KL"=M$ _$M:3E/X:N-I+'AX
MYYJB[N$]6$HS1B<$[=J7!6P)X0K_AKVZMJ[<NO0*Y1:(+6'6_:X &"!7HB>T
M28(/(#'NVNQD#<R(S]HUS1$?XO;]'((R.A*.Q@,@E,8/)I'V++NBT?!5Q"3\
M=P'[<[A[_KU]!*JEAP3[04Q#5*!!\+?VX#>(WQFN M;39)NBV?1[& .G(CC>
MUWV9ZRU/1@2@]@=:W^21$W+=%:V? )8N0"X>O)K<NZM-A_BIYX.4(2^ -#1\
M"WC_$5-ZX &-O"'7.> "[JFN\H+^.LNN=PZN/-Y">Z$;Q(4M<G8 95%%VJ,K
MD-N-*%C3&XPO\!O@+MS1O<]^K>K[ZFR!L+\,A/WE(EF^\03 [%W%0A(L?(JV
M?_(@V4^P?$<<J?6*S+!SD#G@8R1I *G]H:Z\4EN 4=7YYM#@(>)EX%VWS"&\
M0;K"3 .(YNY<4>(]HZ]\I$OK(R/#KO#;K [KR0$-22Y#EM$@?/&7'!_M 'B
M:*XLZPW."2=2]\U&;@R\B2C4MO@J#$>K -1-J0M/Q*<.VS,3"R#XIJQ[& ;&
MPKTCJZCOX+CA)4,9:9I&5UM7&Z1FM*?&'1!U%\[_\W#^GR\>W;5K=]E;N&X
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MXP=M2?6A8.N;,5 O<-8O F?]8ME64 /?J;IH\;]F-O^A:'^E^:P-_*8_'$J
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M0J%"N,7@'"6#D\+JD ZAE":A-,$V]PC+.'V[!>V)I5+:$QHHVB\_LVO_C&"
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M8'#XYA[$@@Z&R^O[*O5\I2$!$_ Q8!%0Q8W!!:Z)-P(7$/^4.5?1@7?N#F,
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MC [-:1G2>%8_/T2P4C?!'WE53:VIN'.*QCH  ]+5QI ;&Q,S5S )USBQ3Y8
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MP,^Q-MU9]J-ZI[+WRE.4SSZ<&9.(ZFEAC>#U,O']T_?!JLK&5S:H(A'B3+#
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MW._+M*![U[8]RQ()+Y[J^B#!'K'29G)-D @0#"(H->U(C'O, !.>^(D@KJ4
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M@:*#M[[@>LGC>D",@\?@ 3774Z.,"Z(":D.@9%4A]8%;Q_B70&)MX4HM2G[
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M7J%_@ 2&0\*1=%V]IW_N0'7V#;X S[<U2$;R!TZ S9UI>=_^#U!+ P04
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M",/)&ENFP$,/'GR!!T3RM+]NO%=(S6/Q=?V@(&HM'1158V@_;\,P0'Z4H#@
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M+4CZ@F'8!T8ZVT0D425IN]ZOWY&49:]-C'8H]L6FR+N'#WG/G4[G&R$?U!)
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M+"V7,9 (N'Y ?;YF3#Y?:(#FOP\6_P%02P,$%     @ [CU\5-1MDP2W @
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MTD7E#.Q](J79;%R >G8>_P502P,$%     @ [CU\5&0AH@@+!   K X  !D
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M) \;4*R$RO!,7V%RLHNDV)=/VG]E*?85DW:7S,_YDM0Q9T<GY US5S"\\*]
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M5P:M#V!_:0R]*O[DC^]6]A=02P,$%     @ [CU\5*9QF!FF!   CA@  !D
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MLH!R<-5US?EU3Z,%92;5#XI'#\[@*=#6RZQ]5E>9*?QR/[FN9Z=_]46'I2T
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M]$.>75G9=0FRQR,(^Q!^LKC$L&0RM"+-619*G=WH;($?]TPIT69 ")IU$5[
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M7%"LP H$S=H]#'M0;#H6*DN9)"?=WX^272\!6J<8^F*3$@]Y>"33X[W23Z9
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ML@;X?2ZEV4XL0/ENZ_\!4$L#!!0    ( .X]?%1@*D@IF0,  -$.   9
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MT.W7SW;2C):0A0=B)^>[G..3V-,C%T\R U#H.:=,SIQ,J>+&=66208[E@!?
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M6Z550[!N#]4>3'(A5AV;V@ZT^_6SG9"F%% ?^M 78COW')][C_%-=\/%@\P
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M!(0)T.\7G*OMQ&Q0?^#T_P-02P,$%     @ [CU\5"4&F=HI!   PA   !D
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M-V3202:3D-T1DR:T904NMF3PWC!*@KA'-Y0B)%T0-]Z\PYM/XMUFF:PH;XJ
M-$=!GL"YR_/!VQ=QVB,<RB11ZN9+.[YTDF]#CTQ3SOZ#!L^>U$RH?J(VD*EC
M Q?]+'((Q3AQ8RXZS,7T4=0'D"ZBQ7#3,.[';2B4CH2-X$L+P)-$C\*$#>UE
M77WRM\I<6[KQ,$EQD@8]6H=8&,9C98A<-2TR2?R#\HHV8P W@P@M,V>RM%:N
M7S^+%G'2#ZI++L2+:(SSTC-(\&9Y?V]$ T?.DGYM=$@%281'."]=B(3O;V[\
MTM\G.ARY- TRW36V8 ;,C-G]<GH^+/BS^;Q?<%U2\6(^XOFE+Y#IQF#GUIG8
MS2K3%>SN.!&'Y7X61OUJX9(*<#32NLBE+9#IOC":GZ,[U5(G@R%@YCI3#C''
MH?*OALQZPO]&Y9Z5RC34G='#-W/CMVR&YF:AQ='.G4]"FRG67A[,AP;(6L \
MWPFA7Q?U*-M]NJS_!U!+ P04    " #N/7Q4&[3#(-<"   Q!P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970V-2YX;6R-56UOVC 0_BNGK)I:J26)PVL'2 4Z
M;=(ZH;*NGTUBB-7$9K8#W;_?V0E9RH"5#\0O]SR^Y^Y\'NZD>M$I8P9>\TSH
MD9<:L[GU?1VG+*>Z)3=,X,Y*JIP:G*JUKS>*T<2!\LPG0=#U<\J%-QZZM;D:
M#V5A,B[87($N\IRJWQ.6R=W("[W]PB-?I\8N^./AAJ[9@IFGS5SAS*]9$IXS
MH;D4H-AJY-V%M].>M7<&/SG;Z<88K)*EE"]V\C49>8%UB&4L-I:!XF?+IBS+
M+!&Z\:OB].HC+; YWK-_=MI1RY)J-I79,T],.O+Z'B1L18O,/,K=%U;IZ5B^
M6&;:_<.NL@T\B MM9%Z!T8.<B_)+7ZLX- !A]P2 5 !R"&B? $05(')"2\^<
MK!DU=#Q4<@?*6B.;';C8.#2JX<)F<6$4[G+$F?%W+)1O4FN8,P6+E"H&-[#
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M.AL[ X>DL*95KJ_%[@LTAF+#EXA<V5^R:VH]AR25TH(W8%3 65$_Z7VS$!V
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ME-YI'T7)^GRO.UJ4]HA<"8T'KFUF>"<":0KP_5H(O>^8"=I;UN0/4$L#!!0
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M=@*]'?5V KT=]78"O0/U#@*] _4. KT#]0X"O0/U#@*] _4. KUC\K&20.]
MO8- [T"]@T#O0+V#0.] O8- [XQZ9P*],^J="?3.J'<FT#NCWIE [XQZ9P*]
M,^J="?3.DY]-OE/O.GX>2KWV?*WQ^M])]7@^MUPO?UE^[9S<XQ><TVU%??X+
M4$L#!!0    ( .X]?%2E?PYQ[@$  ) F   3    6T-O;G1E;G1?5'EP97-=
M+GAM;,W:RT[#,! %T%^ILD6-ZR</T6Z +;#@!TPRI5&3V+)=*'^/DP(2""I0
MD;B;1JWMN1./=%8]OWOV%"?;KNWCO%BEY,\8B]6*.AM+YZG/*TL7.IORU_#
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( .X]?%1 PTT16 8  #4;   8
M          " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " #N/7Q4JL>=KR\&   R&0  &               @(&<#@  >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ [CU\5"GAOEK3 @  -0H
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M965T-RYX;6Q02P$"% ,4    " #N/7Q4HQW9;88(   ?%@  &
M    @($C+P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @
M[CU\5!6<&M]?)P  KH4  !@              ("!WS<  'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( .X]?%1DH1@1V0H  $<A   9
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M970Q-"YX;6Q02P$"% ,4    " #N/7Q4G([DZ<$(  #2&   &0
M    @(&'A@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (
M .X]?%2%Q_MVQ0D  *@:   9              " @7^/  !X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L! A0#%     @ [CU\5(3R8916!@  3!(  !D
M             ("!>YD  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M% ,4    " #N/7Q4FLT?-AP$  !I"0  &0              @($(H   >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( .X]?%2O=?;1D@P
M (\E   9              " @5ND  !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L! A0#%     @ [CU\5%<[.V6+"@  %!P  !D              ("!
M)+$  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #N/7Q4
MS8YH'P8$  !U"0  &0              @('FNP  >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+ 0(4 Q0    ( .X]?%3CT'>H>S0   .\   9
M      " @2/   !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%
M  @ [CU\5(XJL.]P P  $ @  !D              ("!U?0  'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #N/7Q4SK;Y,ET&  !Q$@
M&0              @(%\^   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M 0(4 Q0    ( .X]?%0&&2Y,40,  "P(   9              " @1#_  !X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ [CU\5"Y;->D(
M P  V 8  !D              ("!F (! 'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"% ,4    " #N/7Q4*I?[AKL#  !K"   &0
M@('7!0$ >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( .X]
M?%3 T >-5 ,  -T'   9              " @<D) 0!X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L! A0#%     @ [CU\5'"%][!"!0  9@T  !D
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M=#,S+GAM;%!+ 0(4 Q0    ( .X]?%34;9,$MP(   ('   9
M  " @5DF 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @
M[CU\5#JA&UG\ @  1PL  !D              ("!1RD! 'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"% ,4    " #N/7Q49"&B" L$  "L#@  &0
M            @(%Z+ $ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4
M Q0    ( .X]?%2#G*'H: ,  &L+   9              " @;PP 0!X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ [CU\5"S8,X6A P
M"0T  !D              ("!6S0! 'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6Q02P$"% ,4    " #N/7Q48M4U#DT"  ##!   &0              @($S
M. $ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( .X]?%2F
M<9@9I@0  (X8   9              " @;<Z 0!X;"]W;W)K<VAE971S+W-H
M965T-# N>&UL4$L! A0#%     @ [CU\5&\4NK\H!0  8AH  !D
M     ("!E#\! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .X]?%1]XGN3>@,  /@,   9              "
M@2Y5 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ [CU\
M5(V#Y>P% P  PPD  !D              ("!WU@! 'AL+W=O<FMS:&5E=',O
M<VAE970T-RYX;6Q02P$"% ,4    " #N/7Q48"I(*9D#  #1#@  &0
M        @($;7 $ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0
M   ( .X]?%3M>"0,: (  &0%   9              " @>M? 0!X;"]W;W)K
M<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ [CU\5 [MN[FV @  R08
M !D              ("!BF(! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q0
M2P$"% ,4    " #N/7Q4$_!\I1H'  !4(0  &0              @(%W90$
M>&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( .X]?%0[K"8I
M&0,  -8)   9              " @<AL 0!X;"]W;W)K<VAE971S+W-H965T
M-3(N>&UL4$L! A0#%     @ [CU\5*@)6G9' @  9@4  !D
M ("!&' ! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " #N
M/7Q4ETV:*Z<#   N#@  &0              @(&6<@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( .X]?%3V"2\RB04  & <   9
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M970U.2YX;6Q02P$"% ,4    " #N/7Q4V47Y(50#   R#   &0
M    @(%*C0$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    (
M .X]?%2P\A_:]P(  .P(   9              " @=60 0!X;"]W;W)K<VAE
M971S+W-H965T-C$N>&UL4$L! A0#%     @ [CU\5"4&F=HI!   PA   !D
M             ("! Y0! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"
M% ,4    " #N/7Q4@L>?X6,#  #T"@  &0              @(%CF $ >&PO
M=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( .X]?%1[G;#,OP,
M ,8,   9              " @?V; 0!X;"]W;W)K<VAE971S+W-H965T-C0N
M>&UL4$L! A0#%     @ [CU\5!NTPR#7 @  ,0<  !D              ("!
M\Y\! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    " #N/7Q4
M!*=:$\\"  !Q"0  &0              @($!HP$ >&PO=V]R:W-H965T<R]S
M:&5E=#8V+GAM;%!+ 0(4 Q0    ( .X]?%29,^HV)P,   P3   -
M      "  0>F 0!X;"]S='EL97,N>&UL4$L! A0#%     @ [CU\5)>*NQS
M    $P(   L              ( !6:D! %]R96QS+RYR96QS4$L! A0#%
M  @ [CU\5$P#+U3D!   \RL   \              ( !0JH! 'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( .X]?%0>WYE>' (  #TG   :
M  "  5.O 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M .X]?%2E?PYQ[@$  ) F   3              "  :>Q 0!;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@    !* $H /10  ,:S 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>225</ContextCount>
  <ElementCount>397</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>78</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100080 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Nature of the Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Nature of the Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Business Combination</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombination1</Role>
      <ShortName>Business Combination</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Supplemental Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformation</Role>
      <ShortName>Supplemental Balance Sheet Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Redeemable Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStock1</Role>
      <ShortName>Redeemable Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Equity Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlans</Role>
      <ShortName>Equity Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Business Combination (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationTables</Role>
      <ShortName>Business Combination (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombination1</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecurities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Supplemental Balance Sheet Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationTables</Role>
      <ShortName>Supplemental Balance Sheet Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Equity Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables</Role>
      <ShortName>Equity Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlans</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Nature of the Business and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Business Combination - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails</Role>
      <ShortName>Business Combination - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Business Combination - Summary of Net Proceeds from Business Combination and PIPE Financing Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfNetProceedsFromBusinessCombinationAndPipeFinancingTransactionsDetails</Role>
      <ShortName>Business Combination - Summary of Net Proceeds from Business Combination and PIPE Financing Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Business Combination - Summary of Common Stock Outstanding After Consummation of Business Combination and PIPE Financing Transaction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionDetails</Role>
      <ShortName>Business Combination - Summary of Common Stock Outstanding After Consummation of Business Combination and PIPE Financing Transaction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Business Combination - Summary of Common Stock Outstanding After Consummation of Business Combination and PIPE Financing Transactions (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionsParentheticalD</Role>
      <ShortName>Business Combination - Summary of Common Stock Outstanding After Consummation of Business Combination and PIPE Financing Transactions (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Business Combination - Summary of Redeemable Convertible Preferred Stock Issued and Outstanding After Consummation of Business Combination (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationDetails</Role>
      <ShortName>Business Combination - Summary of Redeemable Convertible Preferred Stock Issued and Outstanding After Consummation of Business Combination (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Business Combination - Summary of Weighted-Average Common Shares, Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfWeightedaverageCommonSharesBasicAndDilutedDetails</Role>
      <ShortName>Business Combination - Summary of Weighted-Average Common Shares, Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Collaboration Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails</Role>
      <ShortName>Collaboration Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Collaboration Agreements - Additional Information (Details1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails1</Role>
      <ShortName>Collaboration Agreements - Additional Information (Details1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Fair Value Measurements - Summary Financial Assets Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Summary Financial Assets Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Marketable Securities - Summary of Debt Securities, Available For Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails</Role>
      <ShortName>Marketable Securities - Summary of Debt Securities, Available For Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Marketable Securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Marketable Securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Supplemental Balance Sheet Information - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Supplemental Balance Sheet Information - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Supplemental Balance Sheet Information - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetails</Role>
      <ShortName>Supplemental Balance Sheet Information - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Current Liabilities Current (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentDetails</Role>
      <ShortName>Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Current Liabilities Current (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Leases - Summary of Elements of Lease Cost (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfElementsOfLeaseCostDetail</Role>
      <ShortName>Leases - Summary of Elements of Lease Cost (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Leases - Summary of Future Minimum Lease Payments Under Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail</Role>
      <ShortName>Leases - Summary of Future Minimum Lease Payments Under Operating Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Common Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails</Role>
      <ShortName>Common Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Equity Incentive Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails</Role>
      <ShortName>Equity Incentive Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Equity Incentive Plans - Summary of Restricted Stock Awards Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockAwardsActivityDetails</Role>
      <ShortName>Equity Incentive Plans - Summary of Restricted Stock Awards Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Equity Incentive Plans - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfStockOptionActivityDetails</Role>
      <ShortName>Equity Incentive Plans - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Equity Incentive Plans - Schedule of Weighted Average Assumptions Used to Estimate Grant Date Fair Value of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfWeightedAverageAssumptionsUsedToEstimateGrantDateFairValueOfStockOptionsDetails</Role>
      <ShortName>Equity Incentive Plans - Schedule of Weighted Average Assumptions Used to Estimate Grant Date Fair Value of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Equity Incentive Plans - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfStockbasedCompensationExpenseDetails</Role>
      <ShortName>Equity Incentive Plans - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="tngx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="tngx-20211231.htm">tngx-20211231.htm</File>
    <File>tngx-20211231.xsd</File>
    <File>tngx-20211231_cal.xml</File>
    <File>tngx-20211231_def.xml</File>
    <File>tngx-20211231_lab.xml</File>
    <File>tngx-20211231_pre.xml</File>
    <File>tngx-ex10_14.htm</File>
    <File>tngx-ex23_1.htm</File>
    <File>tngx-ex31_1.htm</File>
    <File>tngx-ex31_2.htm</File>
    <File>tngx-ex32_1.htm</File>
    <File>tngx-ex32_2.htm</File>
    <File>tngx-ex4_2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img158215518_0.jpg</File>
    <File>img158215518_1.jpg</File>
    <File>img158215518_10.jpg</File>
    <File>img158215518_11.jpg</File>
    <File>img158215518_12.jpg</File>
    <File>img158215518_13.jpg</File>
    <File>img158215518_14.jpg</File>
    <File>img158215518_15.jpg</File>
    <File>img158215518_16.jpg</File>
    <File>img158215518_17.jpg</File>
    <File>img158215518_18.jpg</File>
    <File>img158215518_19.jpg</File>
    <File>img158215518_2.jpg</File>
    <File>img158215518_20.jpg</File>
    <File>img158215518_3.jpg</File>
    <File>img158215518_4.jpg</File>
    <File>img158215518_5.jpg</File>
    <File>img158215518_6.jpg</File>
    <File>img158215518_7.jpg</File>
    <File>img158215518_8.jpg</File>
    <File>img158215518_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="618">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>108
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tngx-20211231.htm": {
   "axisCustom": 1,
   "axisStandard": 27,
   "contextCount": 225,
   "dts": {
    "calculationLink": {
     "local": [
      "tngx-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "tngx-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "tngx-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "tngx-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tngx-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "tngx-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 636,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 6,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 10
   },
   "keyCustom": 78,
   "keyStandard": 319,
   "memberCustom": 39,
   "memberStandard": 37,
   "nsprefix": "tngx",
   "nsuri": "http://www.tangotx.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document And Entity Information",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Business Combination",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombination1",
     "shortName": "Business Combination",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Collaboration Agreements",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreements",
     "shortName": "Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Fair Value Measurements",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Marketable Securities",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Supplemental Balance Sheet Information",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformation",
     "shortName": "Supplemental Balance Sheet Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Leases",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Commitments and Contingencies",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tngx:RedeemableConvertiblePreferredStockDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Redeemable Convertible Preferred Stock",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStock1",
     "shortName": "Redeemable Convertible Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "tngx:RedeemableConvertiblePreferredStockDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Common Stock",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Equity Incentive Plans",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlans",
     "shortName": "Equity Incentive Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_654a4524-3c9b-448c-a88c-7c276a239270",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_654a4524-3c9b-448c-a88c-7c276a239270",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Income Taxes",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Net Loss Per Share",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Business Combination (Tables)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationTables",
     "shortName": "Business Combination (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Marketable Securities (Tables)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Supplemental Balance Sheet Information (Tables)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationTables",
     "shortName": "Supplemental Balance Sheet Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Leases (Tables)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Equity Incentive Plans (Tables)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables",
     "shortName": "Equity Incentive Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:TemporaryEquityParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_654a4524-3c9b-448c-a88c-7c276a239270",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_c46a5787-04cc-4ee6-8232-98fef420c001",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfDeferredSalesCommissions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
     "shortName": "Nature of the Business and Basis of Presentation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_c46a5787-04cc-4ee6-8232-98fef420c001",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfDeferredSalesCommissions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Segment",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_654a4524-3c9b-448c-a88c-7c276a239270",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_654a4524-3c9b-448c-a88c-7c276a239270",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_22555df1-4efe-4a08-bb1c-08f931ec7211",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_22555df1-4efe-4a08-bb1c-08f931ec7211",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_9157c232-bd25-4b99-8aaa-53493f84a8b0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "tngx:StockIssuedDuringPeriodSharesInExchangeForUnvestedRestrictedStockAwardsAndUnexercisedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Business Combination - Additional Information (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails",
     "shortName": "Business Combination - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_9157c232-bd25-4b99-8aaa-53493f84a8b0",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "tngx:StockIssuedDuringPeriodSharesInExchangeForUnvestedRestrictedStockAwardsAndUnexercisedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_fc96726e-aa67-4543-82fb-ba75a0a854df",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAcquiredFromAcquisition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Business Combination - Summary of Net Proceeds from Business Combination and PIPE Financing Transactions (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfNetProceedsFromBusinessCombinationAndPipeFinancingTransactionsDetails",
     "shortName": "Business Combination - Summary of Net Proceeds from Business Combination and PIPE Financing Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_fc96726e-aa67-4543-82fb-ba75a0a854df",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAcquiredFromAcquisition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_654a4524-3c9b-448c-a88c-7c276a239270",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Business Combination - Summary of Common Stock Outstanding After Consummation of Business Combination and PIPE Financing Transaction (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionDetails",
     "shortName": "Business Combination - Summary of Common Stock Outstanding After Consummation of Business Combination and PIPE Financing Transaction (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_c73c0fe0-50a5-469f-988c-1cd417a6095d",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_637f6044-163f-4ffe-baaa-808b1b634223",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Business Combination - Summary of Common Stock Outstanding After Consummation of Business Combination and PIPE Financing Transactions (Parenthetical) (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionsParentheticalD",
     "shortName": "Business Combination - Summary of Common Stock Outstanding After Consummation of Business Combination and PIPE Financing Transactions (Parenthetical) (Details)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_637f6044-163f-4ffe-baaa-808b1b634223",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:TemporaryEquitySharesIssued",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_654a4524-3c9b-448c-a88c-7c276a239270",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesIssued",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Business Combination - Summary of Redeemable Convertible Preferred Stock Issued and Outstanding After Consummation of Business Combination (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationDetails",
     "shortName": "Business Combination - Summary of Redeemable Convertible Preferred Stock Issued and Outstanding After Consummation of Business Combination (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tngx:SummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationTableTextBlock",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_28c70236-1fd3-49b1-a137-9ccf19f5d150",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_78eb35a2-1f74-40df-8fa7-52275c2dd513",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "tngx:WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Business Combination - Summary of Weighted-Average Common Shares, Basic and Diluted (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfWeightedaverageCommonSharesBasicAndDilutedDetails",
     "shortName": "Business Combination - Summary of Weighted-Average Common Shares, Basic and Diluted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_78eb35a2-1f74-40df-8fa7-52275c2dd513",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "tngx:WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromFeesReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Collaboration Agreements - Additional Information (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails",
     "shortName": "Collaboration Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromFeesReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_407a2f79-30e9-41df-8dfa-8788fa29b7cb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Collaboration Agreements - Additional Information (Details1)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails1",
     "shortName": "Collaboration Agreements - Additional Information (Details1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_407a2f79-30e9-41df-8dfa-8788fa29b7cb",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_068a6be4-9f16-496f-98c5-0d1f32f3787e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Fair Value Measurements - Summary Financial Assets Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Summary Financial Assets Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_068a6be4-9f16-496f-98c5-0d1f32f3787e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_654a4524-3c9b-448c-a88c-7c276a239270",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_654a4524-3c9b-448c-a88c-7c276a239270",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_654a4524-3c9b-448c-a88c-7c276a239270",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Marketable Securities - Summary of Debt Securities, Available For Sale (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails",
     "shortName": "Marketable Securities - Summary of Debt Securities, Available For Sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_654a4524-3c9b-448c-a88c-7c276a239270",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Marketable Securities - Additional Information (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails",
     "shortName": "Marketable Securities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_cca1c772-6eb6-4c26-835c-7b92064cf842",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_654a4524-3c9b-448c-a88c-7c276a239270",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Supplemental Balance Sheet Information - Schedule of Property and Equipment, Net (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentNetDetails",
     "shortName": "Supplemental Balance Sheet Information - Schedule of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_654a4524-3c9b-448c-a88c-7c276a239270",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Supplemental Balance Sheet Information - Additional Information (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetails",
     "shortName": "Supplemental Balance Sheet Information - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_4a669c96-a649-4a8a-b346-1cb396dbfc42",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "tngx:StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_4a669c96-a649-4a8a-b346-1cb396dbfc42",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "tngx:StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tngx:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_654a4524-3c9b-448c-a88c-7c276a239270",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Current Liabilities Current (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentDetails",
     "shortName": "Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Current Liabilities Current (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "tngx:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_654a4524-3c9b-448c-a88c-7c276a239270",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_4fb87c77-49f5-455c-a642-6e57e4c31b2f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseOptionToExtend",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Leases - Additional Information (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_4fb87c77-49f5-455c-a642-6e57e4c31b2f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseOptionToExtend",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Leases - Summary of Elements of Lease Cost (Detail)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfElementsOfLeaseCostDetail",
     "shortName": "Leases - Summary of Elements of Lease Cost (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_654a4524-3c9b-448c-a88c-7c276a239270",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Leases - Summary of Future Minimum Lease Payments Under Operating Leases (Detail)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail",
     "shortName": "Leases - Summary of Future Minimum Lease Payments Under Operating Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_654a4524-3c9b-448c-a88c-7c276a239270",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_91ba7dc3-6470-42de-a194-06f0b8e6a25d",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "tngx:NumberOfMilestonesAchieved",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Milestone",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_91ba7dc3-6470-42de-a194-06f0b8e6a25d",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "tngx:NumberOfMilestonesAchieved",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Milestone",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_654a4524-3c9b-448c-a88c-7c276a239270",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Redeemable Convertible Preferred Stock - Additional Information (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
     "shortName": "Redeemable Convertible Preferred Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "tngx:RedeemableConvertiblePreferredStockDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_96e2833b-b37d-4d45-9d0e-e469973ab162",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RepaymentsOfConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_654a4524-3c9b-448c-a88c-7c276a239270",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Common Stock - Additional Information (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
     "shortName": "Common Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:CommonStockVotingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_654a4524-3c9b-448c-a88c-7c276a239270",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "tngx:MergerRecapitalizationExchangeRatio",
      "reportCount": 1,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Equity Incentive Plans - Additional Information (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
     "shortName": "Equity Incentive Plans - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_4c74beb2-4bb1-4873-8bda-4048130ed6a9",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_cab846a0-8d37-4a4b-ae82-af6adf0f78e9",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Equity Incentive Plans - Summary of Restricted Stock Awards Activity (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockAwardsActivityDetails",
     "shortName": "Equity Incentive Plans - Summary of Restricted Stock Awards Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_5b4da818-3aaf-49ee-92af-9ab384f7fb73",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_86a57220-fb9c-48b2-8b06-e5537b12ef0b",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Equity Incentive Plans - Schedule of Stock Option Activity (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfStockOptionActivityDetails",
     "shortName": "Equity Incentive Plans - Schedule of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_355ebba5-ee81-4e5b-b3ac-c79944317418",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
     "shortName": "Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_355ebba5-ee81-4e5b-b3ac-c79944317418",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Equity Incentive Plans - Schedule of Weighted Average Assumptions Used to Estimate Grant Date Fair Value of Stock Options (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfWeightedAverageAssumptionsUsedToEstimateGrantDateFairValueOfStockOptionsDetails",
     "shortName": "Equity Incentive Plans - Schedule of Weighted Average Assumptions Used to Estimate Grant Date Fair Value of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Equity Incentive Plans - Schedule of Stock-based Compensation Expense (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfStockbasedCompensationExpenseDetails",
     "shortName": "Equity Incentive Plans - Schedule of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails",
     "shortName": "Income Taxes - Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_654a4524-3c9b-448c-a88c-7c276a239270",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities Assets (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_654a4524-3c9b-448c-a88c-7c276a239270",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
     "shortName": "Net Loss Per Share - Schedule of Earnings Per Share, Basic and Diluted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "shortName": "Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100080 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Nature of the Business and Basis of Presentation",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation",
     "shortName": "Nature of the Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "tngx-20211231.htm",
      "contextRef": "C_d558a274-44e2-47f9-ba78-6254302f1b82",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 78,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r636",
      "r637",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r636",
      "r637",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r636",
      "r637",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r636",
      "r637",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "verboseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer",
        "verboseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r636",
      "r637",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r283",
      "r296",
      "r341",
      "r343",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r546",
      "r592",
      "r594",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfWeightedAverageAssumptionsUsedToEstimateGrantDateFairValueOfStockOptionsDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r283",
      "r296",
      "r341",
      "r343",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r546",
      "r592",
      "r594",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfWeightedAverageAssumptionsUsedToEstimateGrantDateFairValueOfStockOptionsDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r186",
      "r326",
      "r329",
      "r548",
      "r591",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Or Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r186",
      "r326",
      "r329",
      "r548",
      "r591",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r283",
      "r296",
      "r331",
      "r341",
      "r343",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r546",
      "r592",
      "r594",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfWeightedAverageAssumptionsUsedToEstimateGrantDateFairValueOfStockOptionsDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r283",
      "r296",
      "r331",
      "r341",
      "r343",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r546",
      "r592",
      "r594",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfWeightedAverageAssumptionsUsedToEstimateGrantDateFairValueOfStockOptionsDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r3",
      "r115",
      "r116",
      "r117",
      "r119",
      "r120",
      "r123",
      "r124",
      "r125",
      "r126",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r134",
      "r150",
      "r229",
      "r230",
      "r386",
      "r416",
      "r454",
      "r458",
      "r459",
      "r460",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r654",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfWeightedaverageCommonSharesBasicAndDilutedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r3",
      "r115",
      "r116",
      "r117",
      "r119",
      "r120",
      "r123",
      "r124",
      "r125",
      "r126",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r134",
      "r150",
      "r229",
      "r230",
      "r386",
      "r416",
      "r454",
      "r458",
      "r459",
      "r460",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r654",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfWeightedaverageCommonSharesBasicAndDilutedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [
      "r3",
      "r115",
      "r117",
      "r119",
      "r120",
      "r123",
      "r124",
      "r125",
      "r126",
      "r128",
      "r129",
      "r131",
      "r132",
      "r150",
      "r229",
      "r230",
      "r386",
      "r416",
      "r454",
      "r458",
      "r459",
      "r460",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r654",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported [Member]",
        "terseLabel": "As Previously Recorded [Member]"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfWeightedaverageCommonSharesBasicAndDilutedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r189",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_AccountsReceivableCurrentResearchExtensionFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable Current Research Extension Fee .",
        "label": "Accounts Receivable Current Research Extension Fee",
        "terseLabel": "Accounts receivable current, research extension fee"
       }
      }
     },
     "localname": "AccountsReceivableCurrentResearchExtensionFee",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_AccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other current liabilities.",
        "label": "Accrued Expenses And Other Current Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_AccruedResearchAndDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentDetails": {
       "order": 1.0,
       "parentTag": "tngx_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development costs current.",
        "label": "Accrued Research And Development Costs Current",
        "terseLabel": "Research and development costs",
        "verboseLabel": "Research and development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_AgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement.",
        "label": "Agreement [Axis]",
        "terseLabel": "Agreement"
       }
      }
     },
     "localname": "AgreementAxis",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tngx_AgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement.",
        "label": "Agreement [Domain]",
        "terseLabel": "Agreement"
       }
      }
     },
     "localname": "AgreementDomain",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_AmendedGileadAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended gilead agreement.",
        "label": "Amended Gilead Agreement [Member]",
        "terseLabel": "Amended Gilead Agreement [Member]"
       }
      }
     },
     "localname": "AmendedGileadAgreementMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_AnnualRentPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual rent payable.",
        "label": "Annual Rent Payable",
        "terseLabel": "Annual rent payable"
       }
      }
     },
     "localname": "AnnualRentPayable",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_BctgAcquisitionCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BCTG acquisition corp.",
        "label": "Bctg Acquisition Corp [Member]",
        "terseLabel": "BCTG Acquisition Corp [Member]"
       }
      }
     },
     "localname": "BctgAcquisitionCorpMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfNetProceedsFromBusinessCombinationAndPipeFinancingTransactionsDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_BctgBusinessCombinationAndPipeFinancingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BCTG business combination and PIPE financing.",
        "label": "BCTG Business Combination and PIPE Financing [Member]",
        "terseLabel": "BCTG Business Combination and PIPE Financing [Member]"
       }
      }
     },
     "localname": "BctgBusinessCombinationAndPipeFinancingMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfNetProceedsFromBusinessCombinationAndPipeFinancingTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_BctgTrustAccountMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BCTG trust account.",
        "label": "BCTG Trust Account [Member]",
        "terseLabel": "BCTG's Trust Account [Member]"
       }
      }
     },
     "localname": "BctgTrustAccountMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfNetProceedsFromBusinessCombinationAndPipeFinancingTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_CashAndCashEquivalentMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalent maturity period.",
        "label": "Cash And Cash Equivalent Maturity Period",
        "terseLabel": "Cash and cash equivalent maturity period"
       }
      }
     },
     "localname": "CashAndCashEquivalentMaturityPeriod",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tngx_CashPaidForLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for leases.",
        "label": "Cash Paid For Leases",
        "negatedLabel": "Cash paid for leases",
        "terseLabel": "Cash paid for leases"
       }
      }
     },
     "localname": "CashPaidForLeases",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_CollaborationAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreements .",
        "label": "Collaboration Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAgreementsAbstract",
     "nsuri": "http://www.tangotx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "tngx_CollaborationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Revenue [Member]",
        "label": "Collaboration Revenue [Member]",
        "terseLabel": "Collaboration Revenue [Member]"
       }
      }
     },
     "localname": "CollaborationRevenueMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_CollaborativeAgreementsUpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative agreements upfront payment received.",
        "label": "Collaborative Agreements Upfront Payment Received",
        "terseLabel": "Collaborative agreements upfront payment received"
       }
      }
     },
     "localname": "CollaborativeAgreementsUpfrontPaymentReceived",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_CommitmentsAndContingenciesDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and Contingencies.",
        "label": "Commitments And Contingencies Details [Line Items]",
        "terseLabel": "Commitments and Contingencies (Details) [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDetailsLineItems",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tngx_CommitmentsAndContingenciesDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and Contingencies.",
        "label": "Commitments And Contingencies Details [Table]",
        "terseLabel": "Commitments And Contingencies Details [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDetailsTable",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tngx_CommonStockOutstandingPriorToBusinessCombination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock outstanding prior to business combination.",
        "label": "Common Stock Outstanding Prior To Business Combination",
        "terseLabel": "Common shares outstanding prior to business combination"
       }
      }
     },
     "localname": "CommonStockOutstandingPriorToBusinessCombination",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tngx_ComputerSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Software [Member]",
        "label": "Computer Software [Member]",
        "terseLabel": "Computer Software [Member]"
       }
      }
     },
     "localname": "ComputerSoftwareMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_Contractassetresearchextensionfee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ContractAssetResearchExtensionFee .",
        "label": "Contractassetresearchextensionfee",
        "terseLabel": "Contract asset, research extension fee"
       }
      }
     },
     "localname": "Contractassetresearchextensionfee",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_ConversionWeightagePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion weightage percentage.",
        "label": "Conversion Weightage Percentage",
        "terseLabel": "% of weighting"
       }
      }
     },
     "localname": "ConversionWeightagePercentage",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfWeightedaverageCommonSharesBasicAndDilutedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tngx_DeferredFinancingCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred financing costs.",
        "label": "Deferred Financing Costs [Policy Text Block]",
        "terseLabel": "Deferred Financing Costs"
       }
      }
     },
     "localname": "DeferredFinancingCostsPolicyTextBlock",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tngx_DeferredTaxAssetsOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets operating lease liability.",
        "label": "Deferred Tax Assets Operating Lease Liability",
        "negatedLabel": "Operating lease liability",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_DeferredTaxLiabilitiesDepreciation": {
     "auth_ref": [],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities depreciation.",
        "label": "Deferred Tax Liabilities Depreciation",
        "negatedLabel": "Depreciation"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDepreciation",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_DelayInOptionToLicenseOrResearchExtensionProgramPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Delay in option to license or research extension program period.",
        "label": "Delay in Option to License or Research Extension Program Period",
        "terseLabel": "Delay in option to license or research extension program period"
       }
      }
     },
     "localname": "DelayInOptionToLicenseOrResearchExtensionProgramPeriod",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tngx_EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation tax credits research and development.",
        "label": "Effective Income Tax Rate Reconciliation Tax Credits Research And Development",
        "terseLabel": "Federal and state research and development tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tngx_ExpectedDividendAssumed": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected dividend assumed",
        "label": "Expected Dividend Assumed",
        "terseLabel": "Expected dividend assumed"
       }
      }
     },
     "localname": "ExpectedDividendAssumed",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_FirstLicensedProductAchievesSpecifiedClinicalMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First licensed product achieves specified clinical milestones.",
        "label": "First Licensed Product Achieves Specified Clinical Milestones",
        "terseLabel": "First licensed product achieves specified clinical milestones"
       }
      }
     },
     "localname": "FirstLicensedProductAchievesSpecifiedClinicalMilestones",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_FirstLicensedProductThatAchievesSpecifiedRegulatoryApprovalAndSalesMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First licensed product that achieves specified regulatory approval and sales milestones.",
        "label": "First Licensed Product That Achieves Specified Regulatory Approval And Sales Milestones",
        "terseLabel": "First licensed product that achieves specified regulatory approval and sales milestones"
       }
      }
     },
     "localname": "FirstLicensedProductThatAchievesSpecifiedRegulatoryApprovalAndSalesMilestones",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_FoundersAndAdvisorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Founders and advisors.",
        "label": "Founders And Advisors [Member]",
        "terseLabel": "Founders and Advisors [Member]"
       }
      }
     },
     "localname": "FoundersAndAdvisorsMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_GileadAgreementBasedPerformanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gilead Agreement Based Performance [Member]",
        "terseLabel": "Gilead Agreement Based Performance [Member]"
       }
      }
     },
     "localname": "GileadAgreementBasedPerformanceMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_GileadAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gilead Agreement .",
        "label": "Gilead Agreement [Member]",
        "terseLabel": "Gilead Agreement [Member]"
       }
      }
     },
     "localname": "GileadAgreementMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_GileadLetterAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gilead Letter Agreement .",
        "label": "Gilead Letter Agreement [Member]",
        "terseLabel": "Gilead Letter Agreement [Member]"
       }
      }
     },
     "localname": "GileadLetterAgreementMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_HitgenAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HitGen agreement.",
        "label": "Hitgen Agreement [Member]",
        "terseLabel": "HitGen Agreement [Member]"
       }
      }
     },
     "localname": "HitgenAgreementMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_HundredBinneyStreetInCambridgeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hundred Binney Street in Cambridge.",
        "label": "Hundred Binney Street in Cambridge [Member]",
        "terseLabel": "100 Binney Street in Cambridge [Member]"
       }
      }
     },
     "localname": "HundredBinneyStreetInCambridgeMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tngx_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tngx_IncreaseDecreaseInAccruedExpensesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in accrued expenses and other liabilities.",
        "label": "Increase Decrease In Accrued Expenses And Other Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedExpensesAndOtherLiabilities",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in operating lease liabilities.",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in operating lease right of use asset.",
        "label": "Increase Decrease In Operating Lease Right of use asset",
        "negatedLabel": "Reduction of operating lease right-of-use asset",
        "terseLabel": "Reduction of operating lease right-of-use asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_IncreaseOfGrossDeferredTaxAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase of gross deferred tax assets.",
        "label": "Increase of Gross Deferred Tax Assets",
        "terseLabel": "Increase of gross deferred tax assets"
       }
      }
     },
     "localname": "IncreaseOfGrossDeferredTaxAssets",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory Equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_LeaseTerminationAgreementMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease termination agreement month and year.",
        "label": "Lease Termination Agreement Month And Year",
        "terseLabel": "Lease termination agreement month and year"
       }
      }
     },
     "localname": "LeaseTerminationAgreementMonthAndYear",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "tngx_LetterOfCreditToProvideForAmountThatCollateralizedWithCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Letter of credit to provide for amount that collateralized with cash.",
        "label": "Letter Of Credit To Provide For Amount That Collateralized With Cash",
        "terseLabel": "Letter of credit to provide for amount that collateralized with cash"
       }
      }
     },
     "localname": "LetterOfCreditToProvideForAmountThatCollateralizedWithCash",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_LicenseRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Revenue [Member]",
        "terseLabel": "License Revenue [Member]"
       }
      }
     },
     "localname": "LicenseRevenueMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_MarketableDebtSecuritiesMaturitiesDuration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable debt securities maturities duration.",
        "label": "Marketable Debt Securities Maturities Duration",
        "verboseLabel": "Marketable debt securities maturities duration"
       }
      }
     },
     "localname": "MarketableDebtSecuritiesMaturitiesDuration",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tngx_MarketableDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Debt Securities .",
        "label": "Marketable Debt Securities [Member]",
        "terseLabel": "Marketable Debt Securities [Member]",
        "verboseLabel": "U.S. Government Agency Bonds [Member]"
       }
      }
     },
     "localname": "MarketableDebtSecuritiesMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_MedivirAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medivir agreement.",
        "label": "Medivir Agreement [Member]",
        "terseLabel": "Medivir Agreement [Member]"
       }
      }
     },
     "localname": "MedivirAgreementMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_MergerAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger agreement.",
        "label": "Merger Agreement [Member]",
        "terseLabel": "Merger Agreement [Member]"
       }
      }
     },
     "localname": "MergerAgreementMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_MergerRecapitalizationExchangeRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger recapitalization exchange ratio.",
        "label": "Merger Recapitalization Exchange Ratio",
        "terseLabel": "Merger Exchange Ratio"
       }
      }
     },
     "localname": "MergerRecapitalizationExchangeRatio",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfWeightedaverageCommonSharesBasicAndDilutedDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "tngx_MilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments.",
        "label": "Milestone Payments",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_MilestonePaymentsAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments achieved.",
        "label": "Milestone Payments Achieved",
        "terseLabel": "Milestone payments achieved"
       }
      }
     },
     "localname": "MilestonePaymentsAchieved",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_MilestonePaymentsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments receivable.",
        "label": "Milestone Payments Receivable",
        "terseLabel": "Milestone payments receivable"
       }
      }
     },
     "localname": "MilestonePaymentsReceivable",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_MinimumPercentageOfEstimatedFairValueOfSharesOnGrantDateAsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of estimated fair value of shares on grant date as exercise price.",
        "label": "Minimum Percentage Of Estimated Fair Value Of Shares On Grant Date As Exercise Price",
        "terseLabel": "Minimum percentage of estimated fair value of shares on date of grant as exercise price"
       }
      }
     },
     "localname": "MinimumPercentageOfEstimatedFairValueOfSharesOnGrantDateAsExercisePrice",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tngx_MinimumPercentageOfEstimatedFairValueToBeMaintainedForExercisePriceOfTenPercentShareholderThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of estimated fair value to be maintained for exercise price of ten percent shareholder threshold.",
        "label": "Minimum Percentage Of Estimated Fair Value To Be Maintained For Exercise Price Of Ten Percent Shareholder Threshold",
        "terseLabel": "Minimum percentage of estimated fair value to be maintained for exercise price of ten percent shareholder threshold"
       }
      }
     },
     "localname": "MinimumPercentageOfEstimatedFairValueToBeMaintainedForExercisePriceOfTenPercentShareholderThreshold",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tngx_MinimumRentPaymentsToBePaidOverNoncancelableTerm": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rent payments to be paid over noncancelable term.",
        "label": "Minimum Rent Payments To Be Paid Over Noncancelable Term",
        "terseLabel": "Minimum rent payments to be paid over the non-cancelable term"
       }
      }
     },
     "localname": "MinimumRentPaymentsToBePaidOverNoncancelableTerm",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_MinimumRentPaymentsToBePaidOverOriginalTerm": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rent payments to be paid over original term.",
        "label": "Minimum rent payments to be paid over original term"
       }
      }
     },
     "localname": "MinimumRentPaymentsToBePaidOverOriginalTerm",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_NonrefundableUpfrontPaymentsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-refundable upfront payments received",
        "label": "Nonrefundable Upfront Payments Received",
        "terseLabel": "Non-refundable upfront payment received"
       }
      }
     },
     "localname": "NonrefundableUpfrontPaymentsReceived",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_NumberOfDaysOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days outstanding.",
        "label": "Number of Days Outstanding",
        "terseLabel": "Days Outstanding in 2020"
       }
      }
     },
     "localname": "NumberOfDaysOutstanding",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfWeightedaverageCommonSharesBasicAndDilutedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tngx_NumberOfLicensedProduct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Licensed Product.",
        "label": "Number Of Licensed Product",
        "terseLabel": "Number of licensed product"
       }
      }
     },
     "localname": "NumberOfLicensedProduct",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "tngx_NumberOfMilestonesAchieved": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of milestones achieved.",
        "label": "Number Of Milestones Achieved",
        "terseLabel": "Number of milestones achieved upon termination of agreement"
       }
      }
     },
     "localname": "NumberOfMilestonesAchieved",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "tngx_OfferingCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering cost.",
        "label": "Offering Cost",
        "terseLabel": "Offering costs"
       }
      }
     },
     "localname": "OfferingCost",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_OperatingLossCarryForwardWithExpirationOfUsage": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carry forward with expiration of usage.",
        "label": "Operating Loss Carry Forward with Expiration of Usage",
        "terseLabel": "Operating loss carry forward with expiration of usage"
       }
      }
     },
     "localname": "OperatingLossCarryForwardWithExpirationOfUsage",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_OperatingLossCarryForwardWithExpirationOfUsageIndefinite": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carry forward with expiration of usage indefinite.",
        "label": "Operating Loss Carry Forward with Expiration of Usage Indefinite",
        "terseLabel": "Operating loss carry forward with expiration of usage indefinite"
       }
      }
     },
     "localname": "OperatingLossCarryForwardWithExpirationOfUsageIndefinite",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_OperatingLossCarryforwardLimitationsOnUse": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforward limitations on use.",
        "label": "Operating Loss Carryforward Limitations On Use",
        "terseLabel": "Operating loss carryforwards, expire",
        "verboseLabel": "Operating loss carryforward limitations on use"
       }
      }
     },
     "localname": "OperatingLossCarryforwardLimitationsOnUse",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_OperatingLossCarryforwardsExpirationStartingYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss carryforwards expiration starting year.",
        "label": "Operating Loss Carryforwards Expiration Starting Year",
        "terseLabel": "Operating Loss carryforwards expiration starting year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationStartingYear",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "tngx_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Operating loss carryforwards, expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "tngx_OperatingLossCarryforwardsIndefinite": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards indefinite.",
        "label": "Operating Loss Carryforwards Indefinite",
        "terseLabel": "Operating loss carryforwards, indefinite"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsIndefinite",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_OtherInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Information",
        "label": "Other Information [Abstract]",
        "verboseLabel": "Other information"
       }
      }
     },
     "localname": "OtherInformationAbstract",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfElementsOfLeaseCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "tngx_PatentCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for patent costs.",
        "label": "Patent Costs Policy [Text Block]",
        "terseLabel": "Patent Costs"
       }
      }
     },
     "localname": "PatentCostsPolicyTextBlock",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tngx_PaymentAsConsiderationForThePerformanceOfAdditionalResearchService": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment as consideration for the performance of additional research service.",
        "label": "Payment As Consideration For The Performance Of Additional Research Service",
        "terseLabel": "Payment as consideration for the performance of additional research service"
       }
      }
     },
     "localname": "PaymentAsConsiderationForThePerformanceOfAdditionalResearchService",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_PaymentOfBusinessCombinationAndPipeFinancingTransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of business combination and pipe financing transaction costs.",
        "label": "Payment of Business Combination And PIPE Financing Transaction Costs",
        "negatedLabel": "Payment of Business Combination and PIPE Financing transaction costs"
       }
      }
     },
     "localname": "PaymentOfBusinessCombinationAndPipeFinancingTransactionCosts",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_PaymentsUponTerminationOfAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments upon termination of agreement.",
        "label": "Payments upon Termination of Agreement",
        "terseLabel": "Payments upon termination of agreement"
       }
      }
     },
     "localname": "PaymentsUponTerminationOfAgreement",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_PercentageOfIncreaseInAnnualRentPayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of increase in annual rent payable",
        "label": "Percentage Of Increase In Annual Rent Payable",
        "terseLabel": "Percentage of increase in annual rent payable"
       }
      }
     },
     "localname": "PercentageOfIncreaseInAnnualRentPayable",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tngx_PercentageOfIncreaseInOwnershipPercentageOverAThreeYearPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of increase in ownership percentage over a three year period.",
        "label": "Percentage Of Increase In Ownership Percentage Over A Three Year Period",
        "terseLabel": "Percentage of increase in ownership percentage over a three year period"
       }
      }
     },
     "localname": "PercentageOfIncreaseInOwnershipPercentageOverAThreeYearPeriod",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tngx_PricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price per share.",
        "label": "Price Per Share",
        "terseLabel": "Price per share (in Dollars per share)"
       }
      }
     },
     "localname": "PricePerShare",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "tngx_ProceedsFromBusinessCombinationAndPipeFinancingGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from business combination and pipe financing gross.",
        "label": "Proceeds From Business Combination And PIPE Financing Gross",
        "terseLabel": "Business Combination and PIPE Financing, gross proceeds"
       }
      }
     },
     "localname": "ProceedsFromBusinessCombinationAndPipeFinancingGross",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_PublicSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public shares.",
        "label": "Public Shares [Member]",
        "terseLabel": "Public Share [Member]"
       }
      }
     },
     "localname": "PublicSharesMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_ReceivableResearchExtensionFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivable research extension fee.",
        "label": "Receivable Research Extension Fee",
        "terseLabel": "Receivable research extension fee"
       }
      }
     },
     "localname": "ReceivableResearchExtensionFee",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_RecentlyIssuedAccountingPronouncementsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recently issued accounting pronouncements.",
        "label": "Recently Issued Accounting Pronouncements Policy [Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements [Policy Text Block]",
        "verboseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "RecentlyIssuedAccountingPronouncementsPolicyTextBlock",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tngx_RedeemableConvertiblePreferredStockDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable convertible preferred stock disclosure.",
        "label": "Redeemable Convertible Preferred Stock Disclosure [Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock",
        "verboseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockDisclosureTextBlock",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureRedeemableConvertiblePreferredStock1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tngx_RedeemableConvertiblePreferredStockIssuePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity issue price per share.",
        "label": "Redeemable Convertible Preferred Stock Issue Price Per Share",
        "terseLabel": "Redeemable convertible preferred stock issue price per share"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockIssuePricePerShare",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "tngx_ResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development.",
        "label": "Research And Development [Member]",
        "terseLabel": "Research and Development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_ResearchExtensionFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research Extension Fee .",
        "label": "Research Extension Fee",
        "terseLabel": "Research extension fee"
       }
      }
     },
     "localname": "ResearchExtensionFee",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_ResearchExtensionFeeVariableConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research extension fee variable consideration.",
        "label": "Research Extension Fee Variable Consideration",
        "terseLabel": "Research extension fees, variable consideration"
       }
      }
     },
     "localname": "ResearchExtensionFeeVariableConsideration",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_ResearchTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research term.",
        "label": "Research Term",
        "terseLabel": "Research term"
       }
      }
     },
     "localname": "ResearchTerm",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "tngx_RestrictedCommonStockAwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted common stock award.",
        "label": "Restricted Common Stock Award [Member]",
        "terseLabel": "Restricted Common Stock Award [Member]"
       }
      }
     },
     "localname": "RestrictedCommonStockAwardMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockAwardsActivityDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_RetroactiveApplicationOfRecapitalization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retroactive application of recapitalization.",
        "label": "Retroactive Application Of Recapitalization",
        "terseLabel": "Retroactive application of recapitalization"
       }
      }
     },
     "localname": "RetroactiveApplicationOfRecapitalization",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_RetroactiveApplicationOfRecapitalizationOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retroactive application of recapitalization one.",
        "label": "Retroactive Application Of Recapitalization One",
        "terseLabel": "Retroactive application of recapitalization"
       }
      }
     },
     "localname": "RetroactiveApplicationOfRecapitalizationOne",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_RetroactiveApplicationOfRecapitalizationShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retroactive application of recapitalization shares.",
        "label": "Retroactive Application Of Recapitalization Shares",
        "terseLabel": "Retroactive application of recapitalization (in Shares)"
       }
      }
     },
     "localname": "RetroactiveApplicationOfRecapitalizationShares",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "tngx_RetroactiveApplicationOfRecapitalizationSharesOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retroactive application of recapitalization shares one.",
        "label": "Retroactive Application Of Recapitalization Shares One",
        "terseLabel": "Retroactive application of recapitalization (in Shares)"
       }
      }
     },
     "localname": "RetroactiveApplicationOfRecapitalizationSharesOne",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "tngx_RevaluationOfRightOfUseAssetAndLeaseLiabilityUponLeaseModification": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revaluation of right-of-use asset and lease liability upon lease modification.",
        "label": "Revaluation of Right-of-use Asset and Lease Liability Upon Lease Modification",
        "terseLabel": "Revaluation of right-of-use asset and lease liability upon lease modification"
       }
      }
     },
     "localname": "RevaluationOfRightOfUseAssetAndLeaseLiabilityUponLeaseModification",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of accrued expenses and other current liabilities current.",
        "label": "Schedule Of Accrued Expenses And Other Current Liabilities Current Table [Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities",
        "verboseLabel": "Schedule of Accrued Expenses and Other Current Liabilities Current"
       }
      }
     },
     "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentTableTextBlock",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tngx_ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of estimated useful lives of the Company's property and equipment.",
        "label": "Schedule Of Estimated Useful Lives Of Property And Equipment [Table Text Block]",
        "terseLabel": "Summary of estimated useful lives of the Company's property and equipment"
       }
      }
     },
     "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyAndEquipmentTableTextBlock",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tngx_SeriesACommonSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A common shares.",
        "label": "Series A Common Shares [Member]",
        "terseLabel": "Series A Shares [Member]"
       }
      }
     },
     "localname": "SeriesACommonSharesMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfWeightedaverageCommonSharesBasicAndDilutedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_SeriesARedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A redeemable convertible preferred stock.",
        "label": "Series A Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Redeemable Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesARedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_SeriesB1CommonSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B-1 common shares.",
        "label": "Series B-1 Common Shares [Member]",
        "terseLabel": "Series B-1 Shares [Member]"
       }
      }
     },
     "localname": "SeriesB1CommonSharesMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfWeightedaverageCommonSharesBasicAndDilutedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_SeriesBCommonSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B common shares.",
        "label": "Series B Common Shares [Member]",
        "terseLabel": "Series B Shares [Member]"
       }
      }
     },
     "localname": "SeriesBCommonSharesMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfWeightedaverageCommonSharesBasicAndDilutedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_SeriesBOnePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B One\u00a0Preferred Stock.",
        "label": "Series B One Preferred Stock [Member]",
        "terseLabel": "Series B One Preferred Stock [Member]",
        "verboseLabel": "Series B-1 Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesBOnePreferredStockMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_SeriesBOnePreferredStocksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Convertible Preferred Stock Series B-1 [Member]",
        "label": "Series B One Preferred Stocks [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock Series B-1 [Member]"
       }
      }
     },
     "localname": "SeriesBOnePreferredStocksMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_SeriesBOneRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B one redeemable convertible preferred stock.",
        "label": "Series B One Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series B-1 Redeemable Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesBOneRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_SeriesBRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B redeemable convertible preferred stock.",
        "label": "Series B Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Redeemable Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesBRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_SeriesBTrancheOneRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B tranche one redeemable convertible preferred stock.",
        "label": "Series B Tranche One Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series B (Tranche 1) Redeemable Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesBTrancheOneRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_SeriesBTrancheTwoRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B tranche two redeemable convertible preferred stock.",
        "label": "Series B Tranche Two Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series B (Tranche 2) Redeemable Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesBTrancheTwoRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfStockIssuedAndOutstandingOnImmediatelyPrecedingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares of stock issued and outstanding on immediately preceding percentage.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Of Stock Issued And Outstanding On Immediately Preceding Percentage",
        "terseLabel": "Maximum number of shares issued as a proportion of outstanding capital stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOfStockIssuedAndOutstandingOnImmediatelyPrecedingPercentage",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tngx_SharesOutstandingBeforeRetroactiveApplicationOfRecapitalization": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares outstanding before retroactive application of recapitalization.",
        "label": "Shares Outstanding Before Retroactive Application Of Recapitalization",
        "periodStartLabel": "Balance at the beginning before retroactive application of recapitalization (in Shares)",
        "terseLabel": "Balance at the beginning before retroactive application of recapitalization (in Shares)"
       }
      }
     },
     "localname": "SharesOutstandingBeforeRetroactiveApplicationOfRecapitalization",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "tngx_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tngx_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant accounting policies.",
        "label": "Significant Accounting Policies [Table]",
        "terseLabel": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "tngx_SpecifiedClinicalMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specified clinical milestones.",
        "label": "Specified Clinical Milestones [Member]",
        "terseLabel": "Specified Clinical Milestones [Member]"
       }
      }
     },
     "localname": "SpecifiedClinicalMilestonesMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_SpecifiedRegulatoryAndSalesMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specified regulatory and sales milestones.",
        "label": "Specified Regulatory And Sales Milestones",
        "terseLabel": "Specified regulatory and sales milestones"
       }
      }
     },
     "localname": "SpecifiedRegulatoryAndSalesMilestones",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_SpecifiedRegulatoryAndSalesMilestonesForGeneticContextMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specified regulatory and sales milestones for genetic context.",
        "label": "Specified Regulatory And Sales Milestones For Genetic Context [Member]",
        "terseLabel": "Specified Regulatory And Sales Milestones For Genetic Context [Member]"
       }
      }
     },
     "localname": "SpecifiedRegulatoryAndSalesMilestonesForGeneticContextMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_SpecifiedRegulatoryApprovalAndSalesMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specified regulatory approval and sales milestones.",
        "label": "Specified Regulatory Approval And Sales Milestones [Member]",
        "terseLabel": "Specified Regulatory Approval And Sales Milestones [Member]"
       }
      }
     },
     "localname": "SpecifiedRegulatoryApprovalAndSalesMilestonesMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_SponsoredALicenceProgramfeeAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sponsored a license program, fee amount.",
        "label": "Sponsored A Licence Programfee Amount",
        "terseLabel": "License fee amount"
       }
      }
     },
     "localname": "SponsoredALicenceProgramfeeAmount",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock holders equity before retroactive application of recapitalization.",
        "label": "Stock Holders Equity Before Retroactive Application Of Recapitalization",
        "periodStartLabel": "Balance at the beginning before retroactive application of recapitalization",
        "terseLabel": "Balance at the beginning before retroactive application of recapitalization"
       }
      }
     },
     "localname": "StockHoldersEquityBeforeRetroactiveApplicationOfRecapitalization",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock holders equity retroactive application of recapitalization.",
        "label": "Stock Holders Equity Retroactive Application Of Recapitalization",
        "periodStartLabel": "Retroactive application of recapitalization",
        "terseLabel": "Retroactive application of recapitalization"
       }
      }
     },
     "localname": "StockHoldersEquityRetroactiveApplicationOfRecapitalization",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock holders equity retroactive application of recapitalization shares.",
        "label": "Stock Holders Equity Retroactive Application Of Recapitalization Shares",
        "periodStartLabel": "Retroactive application of recapitalization (in Shares)",
        "terseLabel": "Recapitalization Common Stock"
       }
      }
     },
     "localname": "StockHoldersEquityRetroactiveApplicationOfRecapitalizationShares",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfWeightedaverageCommonSharesBasicAndDilutedDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "tngx_StockIssuedDuringPeriodSharesAcquisitionsAndPrivateInvestments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares acquisitions and private investments.",
        "label": "Stock Issued During Period, Shares, Acquisitions And Private Investments",
        "terseLabel": "Shares issued in Business Combination and PIPE Financing, net of issuance costs (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitionsAndPrivateInvestments",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "tngx_StockIssuedDuringPeriodSharesInExchangeForUnvestedRestrictedStockAwardsAndUnexercisedStockOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares in exchange for unvested restricted stock awards and unexercised stock options.",
        "label": "Stock Issued During Period Shares in Exchange for Unvested Restricted Stock Awards and Unexercised Stock Options",
        "terseLabel": "Shares issued in exchange for Unvested restricted stock awards and unexercised stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesInExchangeForUnvestedRestrictedStockAwardsAndUnexercisedStockOptions",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tngx_StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value acquisitions and private investments.",
        "label": "Stock Issued During Period, Value, Acquisitions And Private Investments",
        "terseLabel": "Shares issued in Business Combination and PIPE Financing, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitionsAndPrivateInvestments",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_StockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options.",
        "label": "Stock Options [Member]"
       }
      }
     },
     "localname": "StockOptionsMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_SummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of redeemable convertible preferred stock issued and outstanding after consummation of business combination.",
        "label": "Summary of Redeemable Convertible Preferred Stock Issued and Outstanding After Consummation of Business Combination [Table Text Block]",
        "terseLabel": "Summary of Redeemable Convertible Preferred Stock Issued and Outstanding After Consummation of Business Combination"
       }
      }
     },
     "localname": "SummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationTableTextBlock",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "tngx_TangoTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tango Therapeutics, Inc [Member]",
        "label": "Tango Therapeutics, Inc [Member]",
        "terseLabel": "Tango Therapeutics, Inc [Member]"
       }
      }
     },
     "localname": "TangoTherapeuticsIncMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionsParentheticalD"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_TaxCreditCarryforwardExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration year.",
        "label": "Tax Credit Carryforward Expiration Year",
        "terseLabel": "Tax credit carryforwards, expiration year"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationYear",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "tngx_TemporaryEquityBeforeRetroactiveApplicationOfRecapitalization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity before retroactive application of recapitalization.",
        "label": "Temporary Equity Before Retroactive Application Of Recapitalization",
        "periodStartLabel": "Balance at the beginning before retroactive application of recapitalization",
        "terseLabel": "Balance at the beginning before retroactive application of recapitalization"
       }
      }
     },
     "localname": "TemporaryEquityBeforeRetroactiveApplicationOfRecapitalization",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_TemporaryEquityIssuePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity issue price per share.",
        "label": "Temporary Equity Issue Price Per Share",
        "terseLabel": "Redeemable convertible preferred stock issue price per share",
        "verboseLabel": "Redeemable convertible preferred stock issue price per share"
       }
      }
     },
     "localname": "TemporaryEquityIssuePricePerShare",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "tngx_TemporaryEquityRetroactiveApplicationOfRecapitalization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity retroactive application of recapitalization.",
        "label": "Temporary Equity Retroactive Application Of Recapitalization",
        "negatedPeriodStartLabel": "Retroactive application of recapitalization",
        "periodStartLabel": "Retroactive application of recapitalization"
       }
      }
     },
     "localname": "TemporaryEquityRetroactiveApplicationOfRecapitalization",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_TemporaryEquityRetroactiveApplicationOfRecapitalizationShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity retroactive application of recapitalization shares.",
        "label": "Temporary Equity Retroactive Application Of Recapitalization Shares",
        "negatedPeriodStartLabel": "Retroactive application of recapitalization (in Shares)"
       }
      }
     },
     "localname": "TemporaryEquityRetroactiveApplicationOfRecapitalizationShares",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "tngx_TemporaryEquitySharesOutstandingBeforeRetroactiveApplicationOfRecapitalization": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity shares outstanding before retroactive application of recapitalization.",
        "label": "Temporary Equity Shares Outstanding Before Retroactive Application Of Recapitalization",
        "periodStartLabel": "Balance at the beginning before retroactive application of recapitalization (in Shares)",
        "terseLabel": "Balance at the beginning before retroactive application of recapitalization (in Shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstandingBeforeRetroactiveApplicationOfRecapitalization",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "tngx_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period shares new issues.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of redeemable convertible preferred stock, net of issuance costs, (in Shares)",
        "verboseLabel": "Redeemable convertible preferred stock issued during period shares new issues"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "tngx_TemporaryStockIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary stock issuance costs.",
        "label": "Temporary Stock Issuance Costs",
        "terseLabel": "Redeemable convertible preferred stock issuance costs",
        "verboseLabel": "Redeemable convertible preferred stock Issuance Costs"
       }
      }
     },
     "localname": "TemporaryStockIssuanceCosts",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_TemporaryStockRetroactiveApplicationOfRecapitalization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary stock retroactive application of recapitalization",
        "label": "Temporary Stock Retroactive Application Of Recapitalization",
        "negatedLabel": "Retroactive application of recapitalization"
       }
      }
     },
     "localname": "TemporaryStockRetroactiveApplicationOfRecapitalization",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_TemporaryStockRetroactiveApplicationOfRecapitalizationShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary stock retroactive application of recapitalization shares.",
        "label": "Temporary Stock Retroactive Application Of Recapitalization Shares",
        "negatedLabel": "Retroactive application of recapitalization (in Shares)"
       }
      }
     },
     "localname": "TemporaryStockRetroactiveApplicationOfRecapitalizationShares",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "tngx_TheTwoHundredAndOneBrooklineAvenueLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Two Hundred And One Brookline Avenue Lease",
        "label": "The Two Hundred And One Brookline Avenue Lease [Member]",
        "verboseLabel": "201 Brookline Avenue Lease [Member]"
       }
      }
     },
     "localname": "TheTwoHundredAndOneBrooklineAvenueLeaseMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_ThresholdPercentageOfShareholderGrantExercisePriceForCalculationOfPercentOfEstimatedFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold percentage of shareholder grant exercise price for calculation of percent of estimated fair value.",
        "label": "Threshold Percentage Of Shareholder Grant Exercise Price For Calculation Of Percent Of Estimated Fair Value",
        "terseLabel": "Threshold percentage of shareholder grant exercise price for calculation of percent of estimated fair value"
       }
      }
     },
     "localname": "ThresholdPercentageOfShareholderGrantExercisePriceForCalculationOfPercentOfEstimatedFairValue",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "tngx_TwoThousandAndEighteenGileadAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand And Eighteen Gilead Agreement .",
        "label": "Two Thousand And Eighteen Gilead Agreement [Member]",
        "terseLabel": "Two Thousand And Eighteen Gilead Agreement",
        "verboseLabel": "2018 Gilead Agreement [Member]"
       }
      }
     },
     "localname": "TwoThousandAndEighteenGileadAgreementMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty one employee stock purchase plan.",
        "label": "Two Thousand and Twenty One Employee Stock Purchase Plan [Member]",
        "terseLabel": "2021 Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOneEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_TwoThousandAndTwentyOnePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty one plan.",
        "label": "Two Thousand And Twenty One Plan [Member]",
        "terseLabel": "2021 Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOnePlanMember",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "tngx_UpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment.",
        "label": "Upfront Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "UpfrontPayment",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_UpfrontPaymentsForRentAndTenantImprovements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payments for rent and tenant improvements.",
        "label": "Upfront Payments For Rent And Tenant Improvements",
        "terseLabel": "Upfront payments for rent and tenant improvements"
       }
      }
     },
     "localname": "UpfrontPaymentsForRentAndTenantImprovements",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "tngx_WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average number of share outstanding basic and diluted adjustments.",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted Adjustments",
        "terseLabel": "Weighted average common shares, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDilutedAdjustments",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfWeightedaverageCommonSharesBasicAndDilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "tngx_WeightedAverageRecapitalizedCommonShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average recapitalized common shares.",
        "label": "Weighted average common shares, basic and diluted",
        "terseLabel": "Weighted-average shares, basic and diluted, Recapitalized Common Stock"
       }
      }
     },
     "localname": "WeightedAverageRecapitalizedCommonShares",
     "nsuri": "http://www.tangotx.com/20211231",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfWeightedaverageCommonSharesBasicAndDilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update 2014-09 [Member]",
        "terseLabel": "ASC 606 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201613Member": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.",
        "label": "Accounting Standards Update 2016-13 [Member]",
        "terseLabel": "ASU 2016-13 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201613Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201813Member": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2018-13 Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement.",
        "label": "Accounting Standards Update 2018-13 [Member]",
        "terseLabel": "ASU 2018-13 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201813Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201815Member": {
     "auth_ref": [
      "r252",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2018-15 Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (a consensus of the FASB Emerging Issues Task Force).",
        "label": "Accounting Standards Update 2018-15 [Member]",
        "terseLabel": "ASU 2018-15 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201815Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201912Member": {
     "auth_ref": [
      "r413",
      "r414",
      "r415",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.",
        "label": "Accounting Standards Update 2019-12 [Member]",
        "terseLabel": "ASU 2019-12 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201912Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "auth_ref": [
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.",
        "label": "Accounting Standards Update 2020-06 [Member]",
        "terseLabel": "ASU 2020-06 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate202006Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r44",
      "r514"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r8",
      "r29",
      "r190",
      "r191"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable Net Current",
        "terseLabel": "Accounts receivable",
        "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r42",
      "r258"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Less: Accumulated depreciation",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r32",
      "r60",
      "r62",
      "r63",
      "r579",
      "r602",
      "r606"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive (loss) income",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r59",
      "r63",
      "r70",
      "r71",
      "r72",
      "r115",
      "r116",
      "r117",
      "r444",
      "r597",
      "r598",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r30",
      "r386",
      "r514"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid In Capital",
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "terseLabel": "Additional paid-in capital",
        "totalLabel": "Additional Paid in Capital, Total"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r383",
      "r384",
      "r385",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r119",
      "r120",
      "r121",
      "r122",
      "r134",
      "r193",
      "r194",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r269",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r413",
      "r414",
      "r415",
      "r416",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r473",
      "r474",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r510",
      "r550",
      "r551",
      "r552",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition",
        "terseLabel": "Vesting of restricted common stock awards"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition",
        "terseLabel": "Stock based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from issuance costs from a share-lending arrangement entered into, in contemplation of a convertible debt offering or other financing.",
        "label": "Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs",
        "terseLabel": "Issuance of redeemable convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash (used in) provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r345",
      "r375",
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDeferredSalesCommissions": {
     "auth_ref": [
      "r80",
      "r96"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period for the periodic realization of capitalized fees that were paid to salespeople, distributors, brokers, and agents at the time of the conclusion of the sale. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Deferred Sales Commissions",
        "terseLabel": "Underwriting commissions"
       }
      }
     },
     "localname": "AmortizationOfDeferredSalesCommissions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r110",
      "r169",
      "r178",
      "r184",
      "r218",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r442",
      "r445",
      "r472",
      "r512",
      "r514",
      "r558",
      "r576"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r57",
      "r110",
      "r218",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r442",
      "r445",
      "r472",
      "r512",
      "r514"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r461"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r200"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r201"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Gross Unrealized Loss",
        "terseLabel": "Gross Unrealized Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r199",
      "r236"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Amortized Cost Basis",
        "terseLabel": "Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r197",
      "r236"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Available For Sale Securities Debt Securities Current",
        "terseLabel": "Fair Value",
        "totalLabel": "Debt Securities, Available-for-sale, Current, Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r346",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockAwardsActivityDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r340",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionsParentheticalD",
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfNetProceedsFromBusinessCombinationAndPipeFinancingTransactionsDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r340",
      "r342",
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionsParentheticalD",
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfNetProceedsFromBusinessCombinationAndPipeFinancingTransactionsDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.",
        "label": "Business Acquisition, Transaction Costs",
        "negatedLabel": "Less transaction costs and advisory fees paid",
        "terseLabel": "Transaction costs and redemptions"
       }
      }
     },
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfNetProceedsFromBusinessCombinationAndPipeFinancingTransactionsDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the business acquisition agreement was executed, in YYYY-MM-DD format.",
        "label": "Business Acquisition, Date of Acquisition Agreement",
        "terseLabel": "Acquisition date"
       }
      }
     },
     "localname": "BusinessAcquisitionDateOfAcquisitionAgreement1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition, Equity Interests Issued or Issuable [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionsParentheticalD"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfNetProceedsFromBusinessCombinationAndPipeFinancingTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition Percentage Of Voting Interests Acquired",
        "terseLabel": "Business acquisition, percentage of voting interest"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r433",
      "r434",
      "r435"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Net contributions from Business Combination and PIPE Financing",
        "totalLabel": "Business Combination, Consideration Transferred, Total"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfNetProceedsFromBusinessCombinationAndPipeFinancingTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r433",
      "r434"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Business combination, consideration transferred, equity securities"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combination"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombination1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r431"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "terseLabel": "Add: non-cash net assets assumed from BCTG",
        "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfNetProceedsFromBusinessCombinationAndPipeFinancingTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r431"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill",
        "terseLabel": "Intangible assets",
        "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r100",
      "r101",
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred But Not Yet Paid",
        "terseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfNetProceedsFromBusinessCombinationAndPipeFinancingTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r39",
      "r98"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r17",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r17",
      "r99",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r92",
      "r98",
      "r103"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
        "periodEndLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance",
        "periodStartLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance",
        "totalLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r92",
      "r98",
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r92",
      "r482"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash investing and financing activity:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r0",
      "r1",
      "r115",
      "r116",
      "r118",
      "r193",
      "r194",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r269",
      "r379",
      "r380",
      "r381",
      "r413",
      "r448",
      "r450",
      "r451",
      "r473",
      "r475",
      "r476",
      "r477",
      "r480",
      "r481",
      "r493",
      "r510",
      "r550",
      "r551",
      "r595",
      "r596",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "terseLabel": "Change in accounting principle accounting standards update adopted [true or false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r0",
      "r1",
      "r115",
      "r116",
      "r126",
      "r193",
      "r194",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r269",
      "r379",
      "r380",
      "r381",
      "r413",
      "r448",
      "r450",
      "r451",
      "r452",
      "r455",
      "r473",
      "r475",
      "r476",
      "r477",
      "r480",
      "r481",
      "r493",
      "r510",
      "r550",
      "r551",
      "r595",
      "r596",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "terseLabel": "Change in accounting principle accounting standards update adoption date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption": {
     "auth_ref": [
      "r4",
      "r118",
      "r194",
      "r220",
      "r223",
      "r226",
      "r269",
      "r382",
      "r414",
      "r448",
      "r452",
      "r455",
      "r474",
      "r475",
      "r478",
      "r479",
      "r481",
      "r493",
      "r552",
      "r595",
      "r596",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was early adopted.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Early Adoption [true false]",
        "terseLabel": "Change in accounting principle accounting standards update early adoption [true or false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "auth_ref": [
      "r119",
      "r133",
      "r195",
      "r228",
      "r386",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "terseLabel": "Change in accounting principle accounting standards update immaterial effect"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Stock Disclosures [Abstract]"
       }
      }
     },
     "localname": "ClassOfStockDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r107",
      "r110",
      "r138",
      "r139",
      "r140",
      "r143",
      "r145",
      "r153",
      "r154",
      "r155",
      "r218",
      "r270",
      "r274",
      "r275",
      "r276",
      "r279",
      "r280",
      "r293",
      "r294",
      "r299",
      "r303",
      "r472",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfWeightedaverageCommonSharesBasicAndDilutedDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfWeightedaverageCommonSharesBasicAndDilutedDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r438",
      "r439",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails1",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r52",
      "r266",
      "r562",
      "r583"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r267",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r268",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments And Contingencies Policy [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r115",
      "r116",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock issued",
        "terseLabel": "Common Stock, Shares, Issued",
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "verboseLabel": "Common Stock Shares"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfWeightedaverageCommonSharesBasicAndDilutedDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r28",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r28",
      "r514"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, $0.001 par value; 200,000,000 and 56,393,261 shares authorized at December 31, 2021 and December 31, 2020, respectively;87,598,184 and 40,372,133 shares issued and outstanding as of December 31, 2021 and 2020, respectively",
        "totalLabel": "Common Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock Voting Rights",
        "terseLabel": "Common stock voting description"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r65",
      "r67",
      "r68",
      "r77",
      "r566",
      "r587"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income Policy Policy [Text Block]",
        "terseLabel": "Comprehensive Gain (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r247",
      "r249",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software Intangible Asset [Member]",
        "terseLabel": "Computer Software [Member]"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r158",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentration of Credit Risk and Significant Suppliers"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Modification Of Contract",
        "negatedLabel": "Revenue recognized, cumulative catch-up adjustment",
        "terseLabel": "Revenue recognized, cumulative catch-up adjustment"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r320",
      "r321",
      "r327"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract With Customer Liability Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r320",
      "r321",
      "r327"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract With Customer Liability Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract With Customer Liability Revenue Recognized",
        "terseLabel": "Contract with customer liability, revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Obligation to make payments upon termination",
        "totalLabel": "Contractual Obligation, Total",
        "verboseLabel": "Contractual obligation"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r100",
      "r101",
      "r102"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of Preferred Shares to Common Shares"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r282",
      "r286",
      "r287",
      "r490",
      "r491",
      "r492"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Additional letter of credit"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss": {
     "auth_ref": [
      "r203",
      "r236",
      "r237",
      "r238"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of accrued interest on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss",
        "terseLabel": "Marketable securities, Accrued interest",
        "totalLabel": "Debt Securities, Available-for-Sale, Accrued Interest, after Allowance for Credit Loss, Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities Available For Sale [Table]",
        "terseLabel": "Debt Securities Available For Sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities Available For Sale Table [Text Block]",
        "terseLabel": "Summary of Debt Securities, Available-for-sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r207",
      "r239",
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities Available For Sale Unrealized Loss Position",
        "terseLabel": "Debt securities considered to be an unrealized loss position",
        "totalLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r23",
      "r24",
      "r402",
      "r559",
      "r575"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Income Tax Liabilities",
        "negatedTotalLabel": "Total gross deferred tax liabilities",
        "totalLabel": "Deferred Tax Liabilities, Gross, Total"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r56",
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue Current",
        "terseLabel": "Short-term deferred revenue",
        "totalLabel": "Deferred Revenue, Current, Total"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue Noncurrent",
        "terseLabel": "Long-term deferred revenue",
        "totalLabel": "Deferred Revenue, Noncurrent, Total"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r410",
      "r411"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r403"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Gross",
        "terseLabel": "Total gross deferred tax assets",
        "totalLabel": "Total gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r410",
      "r411"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets Liabilities Net",
        "totalLabel": "Net deferred taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Net [Abstract]",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r410",
      "r411"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r410",
      "r411"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r408",
      "r410",
      "r411"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r410",
      "r411"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals",
        "terseLabel": "Accruals and reserves",
        "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "periodEndLabel": "Valuation allowance as of end of year",
        "periodStartLabel": "Valuation allowance as of beginning of year",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r410",
      "r411"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r96",
      "r256"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "totalLabel": "Depreciation, Total",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Equity Incentive Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r21",
      "r22",
      "r560",
      "r577"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.",
        "label": "Dividends Payable Current And Noncurrent",
        "terseLabel": "Dividends declared"
       }
      }
     },
     "localname": "DividendsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Country [Member]",
        "terseLabel": "Federal [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per common share \u2013 basic and diluted",
        "totalLabel": "Earnings Per Share, Basic and Diluted, Total",
        "verboseLabel": "Net loss per share attributable to common stockholders - basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r146",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r146",
      "r148",
      "r149",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r395"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Continuing Operations",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r111",
      "r395",
      "r420"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
        "terseLabel": "Income taxes at U.S. federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r395",
      "r420"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r395",
      "r420"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense",
        "terseLabel": "Nondeductible/nontaxable permanent items",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r395",
      "r420"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent",
        "negatedLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation Other Reconciling Items Percent",
        "terseLabel": "Other",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent, Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r395",
      "r420"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes",
        "terseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUSFederalStatutoryIncomeTaxRateToCompanySEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentDetails": {
       "order": 0.0,
       "parentTag": "tngx_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Payroll and employee-related costs",
        "totalLabel": "Employee-related Liabilities, Current, Total"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r376"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized",
        "terseLabel": "Unrecognized stock-based compensation expense",
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Weighted-average amortization period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r376"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options",
        "terseLabel": "Unrecognized compensation related unvested shares"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock options to purchase common stock [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory Equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r70",
      "r71",
      "r72",
      "r115",
      "r116",
      "r117",
      "r120",
      "r129",
      "r132",
      "r152",
      "r227",
      "r310",
      "r317",
      "r383",
      "r384",
      "r385",
      "r415",
      "r416",
      "r458",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r597",
      "r598",
      "r599",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment Ownership Percentage",
        "terseLabel": "Equity method investment, ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Abstract]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r461",
      "r462",
      "r463",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r461",
      "r462",
      "r463",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block]",
        "terseLabel": "Summary of Financial Assets Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value Assets Level1 To Level2 Transfers Amount",
        "terseLabel": "Fair value assets transfer from Level 1 to Level 2"
       }
      }
     },
     "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value Assets Level2 To Level1 Transfers Amount",
        "terseLabel": "Fair value assets transfer from Level 2 to Level 1"
       }
      }
     },
     "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r284",
      "r286",
      "r287",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r462",
      "r519",
      "r520",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r461",
      "r462",
      "r464",
      "r465",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Fair Value By Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r284",
      "r332",
      "r333",
      "r338",
      "r339",
      "r462",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r284",
      "r286",
      "r287",
      "r332",
      "r333",
      "r338",
      "r339",
      "r462",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r284",
      "r286",
      "r287",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r462",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Value Liabilities Level1 To Level2 Transfers Amount",
        "terseLabel": "Fair value liabilities transfer from Level 1 to Level 2"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel1ToLevel2TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Value Liabilities Level2 To Level1 Transfers Amount",
        "terseLabel": "Fair value liabilities transfer from Level 2 to Level 1"
       }
      }
     },
     "localname": "FairValueLiabilitiesLevel2ToLevel1TransfersAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.",
        "label": "Fair Value Measurement Inputs Disclosure [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement Policy Policy [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r284",
      "r286",
      "r287",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r519",
      "r520",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r466",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Fair Value Measurements Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r205",
      "r206",
      "r213",
      "r214",
      "r215",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r240",
      "r241",
      "r242",
      "r243",
      "r285",
      "r308",
      "r449",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r247",
      "r248",
      "r250",
      "r251",
      "r549",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite Lived Intangible Assets By Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r247",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and Administrative [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r245",
      "r246",
      "r514",
      "r557"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, Ending Balance",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "terseLabel": "Goodwill",
        "totalLabel": "Goodwill, Total"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "Initial Public Offering [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r96",
      "r255",
      "r260"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment of long-lived assets",
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r74",
      "r169",
      "r177",
      "r180",
      "r183",
      "r185",
      "r554",
      "r563",
      "r568",
      "r589"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Loss before income taxes",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r261",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r111",
      "r396",
      "r400",
      "r407",
      "r418",
      "r421",
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r112",
      "r131",
      "r132",
      "r168",
      "r394",
      "r419",
      "r423",
      "r590"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Provision for income taxes",
        "negatedLabel": "Provision for income taxes",
        "terseLabel": "Tax provision or benefits",
        "totalLabel": "Income Tax Expense (Benefit), Total"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r69",
      "r392",
      "r393",
      "r400",
      "r401",
      "r406",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase Decrease In Accounts Payable Trade",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase Decrease In Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase Decrease In Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r95",
      "r503"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "negatedLabel": "Reduction of operating lease liability",
        "terseLabel": "Reduction of operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other long-term assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r567"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest income",
        "terseLabel": "Interest income",
        "totalLabel": "Interest Income (Expense), Net, Total"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r217",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment Policy [Text Block]",
        "terseLabel": "Investments in Marketable Securities"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investment Type Categorization [Member]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r461"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments Fair Value Disclosure",
        "terseLabel": "Marketable debt securities",
        "totalLabel": "Investments, Fair Value Disclosure, Total"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r212",
      "r555",
      "r572",
      "r622",
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r506",
      "r508"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfElementsOfLeaseCostDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease Cost",
        "totalLabel": "Total operating lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfElementsOfLeaseCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfElementsOfLeaseCostDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease Cost Table [Text Block]",
        "terseLabel": "Summary of Elements of Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date",
        "terseLabel": "Lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee Leases Policy [Text Block]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee Operating Lease Existence Of Option To Extend",
        "terseLabel": "Operating leases, option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to terminate operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Terminate [true false]",
        "terseLabel": "Lessee, operating lease, existence of option to terminate [true false]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToTerminate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee Operating Lease Liability Maturity Table [Text Block]",
        "terseLabel": "Summary of Future Minimum Lease Payments Under Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r507"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r507"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due After Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r507"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r507"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r507"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r507"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r507"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r507"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest",
        "terseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee Operating Lease Option To Extend",
        "terseLabel": "Operating leases, option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToTerminate": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to terminate lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Terminate",
        "terseLabel": "Option to terminate, description",
        "verboseLabel": "Lease terminate option description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToTerminate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Additional extension period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Term Of Contract",
        "terseLabel": "Operating leases, non-cancelable term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r47",
      "r110",
      "r179",
      "r218",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r443",
      "r445",
      "r446",
      "r472",
      "r512",
      "r513"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r35",
      "r110",
      "r218",
      "r472",
      "r514",
      "r561",
      "r581"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities, Redeemable Convertible Preferred Stock and Stockholders\u2019 Deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r50",
      "r110",
      "r218",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r443",
      "r445",
      "r446",
      "r472",
      "r512",
      "r513",
      "r514"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Abstract]"
       }
      }
     },
     "localname": "MarketableSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r9",
      "r48"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities Current",
        "terseLabel": "Marketable securities",
        "totalLabel": "Marketable Securities, Current, Total"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Unrealized (loss) gain on marketable securities",
        "terseLabel": "Unrealized gain on marketable securities",
        "totalLabel": "Marketable Securities, Unrealized Gain (Loss), Total"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money Market Funds At Carrying Value",
        "terseLabel": "Cash equivalents, Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r92",
      "r94",
      "r97"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash (used in) provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r64",
      "r66",
      "r72",
      "r75",
      "r97",
      "r110",
      "r119",
      "r123",
      "r124",
      "r126",
      "r127",
      "r131",
      "r132",
      "r141",
      "r169",
      "r177",
      "r180",
      "r183",
      "r185",
      "r218",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r460",
      "r472",
      "r564",
      "r585"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r123",
      "r124",
      "r126",
      "r127",
      "r136",
      "r137",
      "r142",
      "r145",
      "r169",
      "r177",
      "r180",
      "r183",
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income Loss Available To Common Stockholders Basic",
        "terseLabel": "Net loss attributable to common stockholders \u2013 basic and diluted",
        "totalLabel": "Net Income (Loss) Available to Common Stockholders, Basic, Total"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income Loss Available To Common Stockholders Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income Expense",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense):",
        "terseLabel": "Other income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office Equipment [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r169",
      "r177",
      "r180",
      "r183",
      "r185"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r500",
      "r508"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfElementsOfLeaseCostDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfElementsOfLeaseCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r495"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "terseLabel": "Operating lease liability",
        "totalLabel": "Total operating lease liabilities",
        "verboseLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumLeasePaymentsUnderOperatingLeasesDetail",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r495"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r495"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r496",
      "r503"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease Payments",
        "terseLabel": "Operating cash flows used for operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfElementsOfLeaseCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r494"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease Right Of Use Asset Amortization Expense",
        "terseLabel": "Noncash operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r505",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfElementsOfLeaseCostDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r504",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Weighted average remaining lease term in years"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfElementsOfLeaseCostDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r408"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r6",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Nature of the Business and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r114",
      "r135",
      "r164",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Emerging Growth Company Status"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r49"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentDetails": {
       "order": 2.0,
       "parentTag": "tngx_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets",
        "totalLabel": "Other Assets, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive (loss) income:",
        "terseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r61",
      "r70",
      "r76",
      "r394",
      "r422",
      "r424",
      "r483",
      "r486",
      "r488",
      "r565",
      "r586"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other Comprehensive Income Loss Tax",
        "terseLabel": "Other comprehensive loss",
        "totalLabel": "Other Comprehensive Income (Loss), Tax, Total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "totalLabel": "Other Liabilities, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income Expense",
        "negatedLabel": "Other, net",
        "totalLabel": "Other Noncash Income (Expense), Total"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other (expense) income, net",
        "terseLabel": "Other income, net",
        "totalLabel": "Other Nonoperating Income (Expense), Total"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": {
     "auth_ref": [
      "r198"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).",
        "label": "Other Than Temporary Impairment Loss Debt Securities Available For Sale",
        "terseLabel": "Impairments to marketable securities or reserves for credit losses",
        "totalLabel": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Total"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables And Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r85",
      "r88"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments For Proceeds From Other Investing Activities",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForTenantImprovements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.",
        "label": "Payments for Tenant Improvements",
        "terseLabel": "Tenant obligation payments for leasehold improvements"
       }
      }
     },
     "localname": "PaymentsForTenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "terseLabel": "Net cash proceeds from the Business Combination and PIPE Financing",
        "totalLabel": "Payments to Acquire Businesses, Net of Cash Acquired, Total"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfNetProceedsFromBusinessCombinationAndPipeFinancingTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r196"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments To Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities",
        "totalLabel": "Payments to Acquire Marketable Securities, Total"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r346",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share conversion price of preferred stock.",
        "label": "Preferred Stock Convertible Conversion Price",
        "terseLabel": "Convertible preferred stock price per shares"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionPrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionRatio": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted.",
        "label": "Preferred Stock, Convertible, Conversion Ratio",
        "terseLabel": "Preferred to Common exchange ratio"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionRatio",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issuable upon conversion of preferred stock.",
        "label": "Preferred Stock, Convertible, Shares Issuable",
        "terseLabel": "Old Tango common shares (after preferred shares were converted 1-for-1 for common shares)",
        "verboseLabel": "Outstanding common shares"
       }
      }
     },
     "localname": "PreferredStockConvertibleSharesIssuable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r10",
      "r37",
      "r38"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "PIPE Financing [Member]",
        "verboseLabel": "Private Placement [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfNetProceedsFromBusinessCombinationAndPipeFinancingTransactionsDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromFeesReceived": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received for fees during the current period. This element excludes cash proceeds from license fees.",
        "label": "Proceeds From Fees Received",
        "terseLabel": "Proceeds from fees received"
       }
      }
     },
     "localname": "ProceedsFromFeesReceived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "Proceeds From Issuance Of Preferred Stock And Preference Stock",
        "terseLabel": "Gross proceeds from the sale of preferred shares",
        "verboseLabel": "Proceeds from issuance of preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.",
        "label": "Proceeds From Issuance Of Redeemable Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of redeemable convertible preferred stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r89",
      "r378"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options",
        "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options",
        "totalLabel": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds From Issuance Or Sale Of Equity",
        "terseLabel": "Net proceeds",
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total",
        "verboseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r90",
      "r109"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from line of credit",
        "totalLabel": "Proceeds from Lines of Credit, Total"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds From Sale And Maturity Of Marketable Securities",
        "terseLabel": "Sales and maturities of marketable securities",
        "totalLabel": "Proceeds from Sale and Maturity of Marketable Securities, Total"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r42",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Property and equipment, estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r41",
      "r257"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Property and equipment, gross",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r18",
      "r19",
      "r259",
      "r514",
      "r573",
      "r582"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r40",
      "r259",
      "r627",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r18",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r18",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Useful Life",
        "terseLabel": "Property and equipment estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfEstimatedUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Repayments Of Convertible Debt",
        "terseLabel": "Repayments of convertible notes and accrued interest"
       }
      }
     },
     "localname": "RepaymentsOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r390",
      "r547",
      "r631"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r103",
      "r556",
      "r578"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash",
        "totalLabel": "Restricted Cash, Total"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r7",
      "r17",
      "r103"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash, current",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r12",
      "r20",
      "r103",
      "r623"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash Noncurrent",
        "terseLabel": "Restricted cash, net of current portion"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfCashAndCashEquivalentsAndRestrictedCashDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock Awards [Member]",
        "verboseLabel": "Unvested restricted common stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockAwardsActivityDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r31",
      "r317",
      "r386",
      "r514",
      "r580",
      "r601",
      "r606"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r115",
      "r116",
      "r117",
      "r120",
      "r129",
      "r132",
      "r227",
      "r383",
      "r384",
      "r385",
      "r415",
      "r416",
      "r458",
      "r597",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r166",
      "r167",
      "r176",
      "r181",
      "r182",
      "r186",
      "r187",
      "r188",
      "r325",
      "r326",
      "r548"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue From Contract With Customer Excluding Assessed Tax",
        "terseLabel": "License fee amount received, recognized as revenue",
        "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r105",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition Policy [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue Remaining Performance Obligation",
        "terseLabel": "Transaction price allocated to performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Revenue remaining performance obligations expected remaining contractual term"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails1"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r73",
      "r110",
      "r166",
      "r167",
      "r176",
      "r181",
      "r182",
      "r186",
      "r187",
      "r188",
      "r218",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r472",
      "r568"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Total Revenue",
        "totalLabel": "Revenues, Total",
        "verboseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale Of Stock Consideration Received On Transaction",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfNetProceedsFromBusinessCombinationAndPipeFinancingTransactionsDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of units issued in transaction (in Shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale Of Stock Price Per Share",
        "terseLabel": "Sale of stock, price per share",
        "verboseLabel": "Unit price (in Dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule Of Available For Sale Securities [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r202",
      "r204",
      "r208",
      "r209",
      "r210",
      "r211",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule Of Available For Sale Securities [Table]",
        "terseLabel": "Schedule Of Available For Sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of the equity interest (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire an entity in a business combination.",
        "label": "Schedule of Business Acquisitions by Acquisition, Equity Interest Issued or Issuable [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionsParentheticalD"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the equity interest issued or issuable in a business acquisition (or series of individually immaterial business acquisitions) planned, initiated, or completed during the period.",
        "label": "Schedule of Business Acquisitions by Acquisition, Equity Interest Issued or Issuable [Table Text Block]",
        "terseLabel": "Summary of Common Stock Outstanding After Consummation of Business Combination and PIPE Financing Transaction"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionEquityInterestIssuedOrIssuableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfNetProceedsFromBusinessCombinationAndPipeFinancingTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Summary of Net Proceeds from Business Combination and PIPE Financing Transactions"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash and Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureCollaborationAgreementsAdditionalInformationDetails1",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate to Company's Effective Income Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r345",
      "r374",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansScheduleOfStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r345",
      "r374",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Investments [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r42",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r346",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockAwardsActivityDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfStockOptionActivityDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfWeightedAverageAssumptionsUsedToEstimateGrantDateFairValueOfStockOptionsDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r353",
      "r363",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Schedule of Weighted Average Assumptions Used to Estimate Grant Date Fair Value of Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Schedule Of Sharebased Compensation Restricted Stock And Restricted Stock Units Activity Table [Text Block]",
        "terseLabel": "Summary of Restricted Stock Awards Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r53",
      "r107",
      "r153",
      "r154",
      "r289",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r297",
      "r299",
      "r303",
      "r308",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule Of Stock By Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfWeightedaverageCommonSharesBasicAndDilutedDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Summary of Weighted-Average Common Shares, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting Policy Policy [Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock Series A [Member]"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock Series B [Member]"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights",
        "terseLabel": "Vesting rights description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period",
        "negatedLabel": "Unvested restricted common stock outstanding, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockAwardsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value",
        "terseLabel": "Unvested restricted common stock outstanding, Weighted average grant-date fair value, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockAwardsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period",
        "terseLabel": "Restricted common stock awards issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number",
        "periodEndLabel": "Unvested restricted common stock outstanding, Number of Shares Ending balance",
        "periodStartLabel": "Unvested restricted common stock outstanding, Number of Shares Beginning balance",
        "terseLabel": "Unvested restricted common stock outstanding, Number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockAwardsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested restricted common stock outstanding, Weighted average grant-date fair value Ending balance",
        "periodStartLabel": "Unvested restricted common stock outstanding, Weighted average grant-date fair value Beginning balance",
        "terseLabel": "Unvested restricted common stock outstanding, Weighted average grant-date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockAwardsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period",
        "negatedLabel": "Unvested restricted common stock outstanding, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockAwardsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r365"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value",
        "terseLabel": "Aggregate fair value of awards vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Unvested restricted common stock outstanding, Weighted average grant-date fair value, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockAwardsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfWeightedAverageAssumptionsUsedToEstimateGrantDateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfWeightedAverageAssumptionsUsedToEstimateGrantDateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfWeightedAverageAssumptionsUsedToEstimateGrantDateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfWeightedAverageAssumptionsUsedToEstimateGrantDateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfWeightedAverageAssumptionsUsedToEstimateGrantDateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfWeightedAverageAssumptionsUsedToEstimateGrantDateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfWeightedAverageAssumptionsUsedToEstimateGrantDateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockAwardsActivityDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfStockOptionActivityDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfWeightedAverageAssumptionsUsedToEstimateGrantDateFairValueOfStockOptionsDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized",
        "terseLabel": "Increase in number of shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized",
        "terseLabel": "Maximum of number of shares reserved and available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Number of shares available for future grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Number of shares Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r365"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Total intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Number of shares Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Number of shares Granted",
        "verboseLabel": "Options, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value per share of stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r377"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r355",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Number of shares, Options outstanding Ending balance",
        "periodStartLabel": "Number of shares, Options outstanding Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "'Weighted Average Exercise Price, Options outstanding Ending balance",
        "periodStartLabel": "Weighted Average Exercise Price, Options outstanding Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Maximum number of shares issued as a proportion of outstanding capital stock on preceding December 31"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r344",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureEquityIncentivePlansSummaryOfRestrictedStockAwardsActivityDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Exercised",
        "verboseLabel": "Share-based compensation expense, exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share Based Compensation Award Tranche Two [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche Two [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r346",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share Based Compensation Option And Incentive Plans Policy",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage",
        "terseLabel": "Vesting rights percentage upon first anniversary of issuance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period",
        "terseLabel": "Award term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r369",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected option life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfWeightedAverageAssumptionsUsedToEstimateGrantDateFairValueOfStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r377"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Aggregate Intrinsic Value Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted Average Contractual Term Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "'Weighted Average Contractual Term, Options outstanding",
        "verboseLabel": "Share-based compensation expense, weighted average period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1",
        "terseLabel": "Total fair value of options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Shares, Issued, Ending Balance",
        "periodStartLabel": "Shares, Issued, Beginning Balance",
        "terseLabel": "Shares issued pursuant to the PIPE Financing"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Balance at the ending (in Shares)",
        "periodStartLabel": "Balance at the beginning (in Shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares that would be issued, determined under the conditions specified in the contract, if the settlement were to occur at the reporting date.",
        "label": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Number of Shares",
        "terseLabel": "Less redemption of BCTG shares"
       }
      }
     },
     "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r501",
      "r508"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfElementsOfLeaseCostDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short Term Lease Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfElementsOfLeaseCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r104",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State And Local Jurisdiction [Member]",
        "terseLabel": "State [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r107",
      "r110",
      "r138",
      "r139",
      "r140",
      "r143",
      "r145",
      "r153",
      "r154",
      "r155",
      "r218",
      "r270",
      "r274",
      "r275",
      "r276",
      "r279",
      "r280",
      "r293",
      "r294",
      "r299",
      "r303",
      "r310",
      "r472",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfWeightedaverageCommonSharesBasicAndDilutedDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r55",
      "r70",
      "r71",
      "r72",
      "r115",
      "r116",
      "r117",
      "r120",
      "r129",
      "r132",
      "r152",
      "r227",
      "r310",
      "r317",
      "r383",
      "r384",
      "r385",
      "r415",
      "r416",
      "r458",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r597",
      "r598",
      "r599",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r152",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Purchase of shares (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r27",
      "r28",
      "r310",
      "r317",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Number of shares Exercised",
        "terseLabel": "Exercise of stock options, (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansScheduleOfStockOptionActivityDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r55",
      "r310",
      "r317"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r27",
      "r28",
      "r310",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period Shares",
        "negatedLabel": "Repurchases of restricted common stock awards, (in Shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r27",
      "r28",
      "r310",
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period Value",
        "negatedLabel": "Repurchases of restricted common stock awards"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r28",
      "r33",
      "r34",
      "r110",
      "r192",
      "r218",
      "r472",
      "r514"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Balance at the ending",
        "periodStartLabel": "Balance at the beginning",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r108",
      "r294",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r317",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Share conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionsParentheticalD"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r489",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r489",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r489",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureEquityIncentivePlansAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reporting subsequent events.",
        "label": "Subsequent Events Policy Policy [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfCommonStockOutstandingAfterConsummationOfBusinessCombinationAndPipeFinancingTransactionDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfNetProceedsFromBusinessCombinationAndPipeFinancingTransactionsDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Supplemental Balance Sheet Information"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r408"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward Amount",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income tax payable",
        "totalLabel": "Taxes Payable, Current, Total"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r270",
      "r274",
      "r275",
      "r276",
      "r279",
      "r280"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Carrying Amount Attributable To Parent",
        "periodEndLabel": "Balance at the ending",
        "periodStartLabel": "Balance at the beginning",
        "terseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2021 and 2020, respectively",
        "verboseLabel": "Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r16",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity Par Or Stated Value Per Share",
        "terseLabel": "Temporary Equity, Par or Stated Value Per Share",
        "verboseLabel": "Redeemable convertible preferred stock par or stated value per share"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquityShareSubscriptions": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been allocated to investors to buy. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Share Subscriptions",
        "terseLabel": "Redeemable convertible preferred stock allocated to investors"
       }
      }
     },
     "localname": "TemporaryEquityShareSubscriptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Redeemable convertible preferred stock shares authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureRedeemableConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Issued",
        "terseLabel": "Temporary Equity, Shares Issued",
        "verboseLabel": "Redeemable Convertible Preferred Stock Issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Outstanding",
        "periodEndLabel": "Balance at the ending (in Shares)",
        "periodStartLabel": "Balance at the beginning (in Shares)",
        "terseLabel": "Temporary Equity, Shares Outstanding",
        "verboseLabel": "Redeemable Convertible Preferred Stock Outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfRedeemableConvertiblePreferredStockIssuedAndOutstandingAfterConsummationOfBusinessCombinationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of redeemable convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital": {
     "auth_ref": [
      "r16",
      "r290"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of the par value of temporary equity outstanding. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Value Excluding Additional Paid In Capital",
        "terseLabel": "Temporary equity, par value"
       }
      }
     },
     "localname": "TemporaryEquityValueExcludingAdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TenantImprovements": {
     "auth_ref": [
      "r584"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.",
        "label": "Tenant Improvements",
        "terseLabel": "Tenant improvements allowance"
       }
      }
     },
     "localname": "TenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r205",
      "r206",
      "r213",
      "r214",
      "r215",
      "r285",
      "r308",
      "r449",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r119",
      "r120",
      "r121",
      "r122",
      "r134",
      "r193",
      "r194",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r269",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r413",
      "r414",
      "r415",
      "r416",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r473",
      "r474",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r510",
      "r550",
      "r551",
      "r552",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r113",
      "r332",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "U S Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. Government Agency Bonds [Member]"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentSecuritiesAtCarryingValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt (bills, notes or bonds) that are issued by the government of the United States which are short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "U S Government Securities At Carrying Value",
        "terseLabel": "Cash equivalents, U.S. Treasury bills"
       }
      }
     },
     "localname": "USGovernmentSecuritiesAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r113",
      "r332",
      "r339",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "U S Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury Bills [Member]"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfDebtSecuritiesAvailableForSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r391",
      "r399"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance",
        "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued",
        "terseLabel": "Accrued interest or penalties",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r156",
      "r157",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r405"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance Deferred Tax Asset Change In Amount",
        "terseLabel": "Increases recorded to income tax provision",
        "verboseLabel": "Valuation allowance, increase"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r502",
      "r508"
     ],
     "calculation": {
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfElementsOfLeaseCostDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureLeasesSummaryOfElementsOfLeaseCostDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted-average number of common stock outstanding - basic and diluted",
        "verboseLabel": "Weighted average number of common shares outstanding - basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/DisclosureBusinessCombinationSummaryOfWeightedaverageCommonSharesBasicAndDilutedDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails",
      "http://www.tangotx.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number Of Shares Outstanding [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.tangotx.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfEarningsPerShareBasicAndDilutedDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL121698322-111563"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL82887624-210437"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL120267853-210455"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL120267856-210455"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120431994&loc=SL118172731-207502"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120431994&loc=SL118172731-207502"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=SL6757427-112606"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498348-110258"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117817908&loc=SL117819236-161440"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "http://asc.fasb.org/topic&trid=2155941"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=123877278&loc=SL120174030-210619"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r632": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r633": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r634": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r635": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r636": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r637": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r638": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r639": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r640": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r641": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r642": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r643": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r644": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r645": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r646": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r647": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r648": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r649": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r650": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>109
<FILENAME>0000950170-22-004721-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-22-004721-xbrl.zip
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MCHB0B(Z8F$[P/--YP?_/'U0C0(Z/T8##@X5Q < DQ\ BQT"U JQH/G$P3C_
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MVY3/]*X?692 Y[ZI!_MRA934P; \"@BD;1XV9'[Z=$=BW#:%LE;C3@][[N;
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M[,@+&1<E! :$<A7@RDZ#CZTO&YUL,9_9V/UEE_=O&__N07WB2-R&H:!:Z>=
MY\EC/%Q4&EP85NFA:#?## 4N6U^V.LF"IU=.&ZF:LJ<;V1CR5 2G"?+?.3 )
M&W;DCE>*Q'7#?ORC@2E9W'(X:FP6(6WI)DJ IP6ZI]LPRP\;.282!R%Q.U!
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M<^V09U\KI6S5X22Y.>"8#N.^VANY$Q_87_/=<Z,A?^16N<!_<YMID8.\<KC
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MXW.]'R.TG$WYM&7$8R\DL*.(GW5M"NQMO.Y_9(_Q[I7U))^1D5F#WMK\/F$
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M$1@GYW?$,>Z3&,KX\6Q+2478@#!XWL6(COFA<14T2&>?K)UW^:(<>R1XP#I
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MY!^+]IZ1DQI+NBVEBN1G9@V5E\+2SQ]B^ME-T(0+O8-N_(3[QKJ_%T1M2&T
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M$E_C)3*2 J>P<L85X.O+N8EB]DTJR_VC-\<6%_7ZNCE27J;%GJ/GC%&G45>
MQ;0K@*4!].8W?!&SPKT!B_>%_,R2J>I7@'NFEYE7@%_T5X!QY/KT"5> O"O
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M@J)@/7@)O9[-(_&O _J$*)F\J3"F6N=)7.NGG.0F:C<,NO6/YM08C5J-,)<
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M$1)2LE5#X&S1)9')IS'NB[%K(%W5G<;)NL7$OK BWD^>PLS8?> 1EP_L4T)
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MUTC4=SLDT$UW\A(C^LF;W_I(S+-J@$C&5C1/?;]\[U3X^([5J9:LFF/J!SH
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MPOD#8O9_))'_-XC_8/<_&?6[:_X9R]^\]R?L_F<L_QGO_5=),0PQ9CI]OL:
M_ FCK-(28-!8L&ZVX-#2R0U W/Q_P5=B0+'*@ "4)5$A-T%.D>%2;J[\B[6=
MD)%4_L2&>K_Y\.7%6HF@>MCO)TJH?PG!GW$;'"?O1DVL/ 'TD:+P.WR.?/?H
M,::"@!B@"(!B!:*U_([NW8C,U$N:S]^,/-$IY\O/3:\ 3T6;KP!&$U$7A,.]
MI1 V6UMA@<_6%BWL.?#YVAC?%R_*)?&4,OTE+.C].075.\A[Q(7F7P0" 3A
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M6>/BCWS+F^L8SDS]7-2\&?Z[DE:_)QE#%F-3H$G7N?>/@BX0HG"_>F!%Q =
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MY70(B)[@9_:Q02%27:Y$=+NKGAKWC8V^'+ 96M5O@>>A^UIF:Y97D]?I-5R
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M4QV<F)_[B.SDQ6A>?@M_QT<8WOWSN991G/R$VIXGP*2 YVFQ(_F7RB#57<V
M.P=R#IDRGK+=?!C@=UV8I?1B.OUP:*_@\3S?NZ=-T.H/" D003)GQ[W.NU&L
MY8K$4^\=#TH*J'!7W^N-Z4G;O:KSP9@>#R^1E1)'=_*<Q5&0=Q9E&K K/6P1
MGB9XJP73"FSAJ=H>MXPZZUXLF\S:XUB'!W,CPV[,VVD(*:*M']6I2M5Y>^1N
M;&EWMY7-<T K%G_KPY"VF4E[/63;H#KWB?YMJY=>QG)/J/4F^R=A7863'1I
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M]$!X[/^Y&\8"OKF=TT?]E\X1*31554HQ>VP&!D27KFI>8IR=L[SMVXE1<@W
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MOR.H,V9A+*>MI@#<IJG5PO_+!2%#^TP]'%5L$/G;[Q"6V@-U$]\L(A(30EZ
M1F=,YHH"+PWP]N]<3)A/"][[2:MG4\.$)T.JX,F8 A5\0]U/(+4:5FOI@SD'
M3PA%H)N71ZZF-]EFU[UH_Y$3[8&Y@*@"QPSLL31\/"4WMP:?$CY90+;+U=RV
M0+-;S5ZU/&$R%*,+\;JQ1KTU6V6W)7-'_BSM25T9ZDKV;(A-N%KR2;(\*IP0
MT,E<EDY^?W5V035(F02<>5RBM,P[V87^H#0/WLYV7^6I"GLXON.QNCE=I.1Q
M=63=,(0$   )$@"''I#J@;(<Y^648,07Q5Q<!43+QY>%:C_9X<3 -@2UB#(A
M'5YEO9CZA[THPNF\-\NJI:Y-X^G$V]5FF)<D>TYBC\.]Y@2U^Z2893'/\08^
M'Q ]3&&QG[7" L&26(#5V6W$?!Q&1NJ,9(8J+(2CH$(T&/JQ>YYKCLDKX'GS
MS',*'NHC^/![8?7R+L30QM,M,,'(M@SS*]KUPDX+GK%@5P%M@9Z6E\:XJ!!;
M3WN['<IW?*;05E\@_G&K+__&=NT^!)^3H"VG^KB=:M.D[?KT9N#B&2X@\V"4
M*N&I4_\A'U32HK/ :^9_+K0M9BQX+F1P ;<9"[B#+U3K.R&T5S*X%&@,BY0-
MUE]):GK!I1R]2'W';6SX-2]E>AN-Z$NG$TDOG!LPTZ2J&[]8D-KK%'.7_CKK
M_MJZ?]XE?OG0<[-9HDK#/5)7;65(P#* ,'9 0YZ\-=J]RX.6^ZF_V^=C9F#'
MC)F695A*T5^H,!)%FH>,<T;X>S?Z^+J1S=U;C697^'"WT_'VZ_Y/'%L!DT0]
MLT;3@;;>'[_3PYH-P^?I)Q\(4*Z<-3 <#SVET4%HDZ8KO4"IV,,_H#4"OJ['
MN]5NNEZ5RXK[J1?Z3 G$56HB$O4\LH4+"Q#/1);SW:X.MY;*[X[7OGO7,S[\
MT\W5DY-SZYB<XL]2,CLG?(Q&7S?/+5+@:J9OG"5N5 5.+,3995B-?M2-?DPA
ML?2\VZS] &=_._I>Y8:JTT_:$BD]79T.WMWVF%R-ZY0Z@(ZD'GWA"A D"LKV
MW5.;0#GCXJ*CW/#P\M!.-NQC)/ HZ3,;-Z5\XIX9.8T^9_Y'9HZP%AU)H8!G
M*0:+SA-\V<*GR6>?GTM]_JFHN1:<^P1T#6G:F<P8N0_+*)E-^GEG<63R48#K
MBELS/HLF0>*&U.>EC;S-@ETB+\HH%+C<UZE3Y< \(WO=L?3'['?';I&SP, R
MII6/J+;&RB)D2N> 3XYLCD.YLW7A<**:!_>MIH9;U3[W4;[#TB$D*P[Y/T=9
MH"#H<?[!Z>N3%?< A+FFIK.1[I,] Q[Z ?*O!*M25W8L/!1H5@B90SASHJH(
M@XHM:6=F87]&*#BW-Y,GTZ.SW.J]F)*2]<*405IE:*>C]'^MP?X9GF@K_#VR
M<6YCJQI]O"#AGA[1CP]ZW]86]CU$R"9!U-KQMM=#[60[42 @=?D$PD(@\O58
ME'SPIW<D28( YLL)>+W<3L&VTO>[MM1DP8P&$?=]N15T/$II'@N<E,+&4.#"
MC7C7VI=^+ZT*@LW;619E99ABVE\*E7O;-LWL60AML?79$7P-FL("DH96!0[B
M;G$A)B8Y[7XWUCR1J>,Y(22<_X ^3;6 \K:RVA,1?B,HV$MKL/;H-)H&;YVW
M )G;89S08^UCTY($5*\LB$,[C\K1I#UUC'5?W8AKFR1=/0^K$.!1#&QB1J0"
M*: Y+:)^]7J]?28_$1ED%C13#CQ_:Y@VYRR^&%:1,&*@U%@ER1:6 ?YFC8)N
MFO\(SW4NGBT?2ANXZ[HY"9*38 1@9J_6.[  D1/=#%V]"?B]AP>;&@^ZP*KQ
MW6H:T:=51$5;E).&Q'W12J1>!A$6R.+ J(]@@>XQ+$"2^ D+'%_" OV-N'C7
MM.-0@JC9_;3<#M?Q!6%",L]$P%B 3@G%K4F !4:O88$[N"IJ>1N6 W66_DG!
M@Z'EP$&UC2M8(-$3"QP\AW3D[8/1>.!#-PCF7K,)YW_W]3_LRPL&QP6BC>#K
M%TH((>BWX(GZ(?1VVTYC[W=K:(N___0"C5A_J3 N;^O]T5OP5-U/=I 0;OV\
M#^@ 7,V=Y("O4!CU9*(;D-09)S$!3/Z>N<K)%=O=!!ZH[!@W#;=:9\_YI>@$
MK@;&\]W% K)HY\C%91"3LAP6R'%L[-6YAC+#9*H"L],M?HYV:XOJLGX>:6Y$
MJT3[%XL1Z\9<V;XIW?>JM^K)G9TT'KKPG]W$P*8<,N@F:H7(:8)=1_Q6&=P[
MQ^LV"$C5]F.A^25)==<&P3_*L #_R,<-'I^L3SE1 .??(6Z>-P[WEOG-Y)G&
M,DI9PT'E..CA,5O9>7$CP7;"1MB30NY0*W,-/$+[MFDDLH6S0TJ#P,>!@J"J
M#P5".8\55T2R/A /5Z3G[KP9!0R,M2@5.L=C@5RUNL</1MLIP%T!4=,5?,;[
M3#K*;L>.P0-/V^]#/4@S$9KZX,+QDLU@_K;QO<L?ED73E5>&>8[XLD4O.N>#
M:_$6M1^%.U3<4LF.MXGIT9]<I=+,PJ^2E(4S4W:#[3'?JBX,O]7[6;8^GVMF
MN"@3.%6R5)W+2765R/IO;_O?KR_S<AJ=M_F\7PEIM'7PM,PAI: ]O1/"F?,J
MS D@4ZM5JT5@4LLC52KW=_)!!5^W-%?Z/4C5L4OK2CJ4]9D>%O *0E] ;EY!
M:2\?%#1^G/ 0NF#.>]&@&,2_T%I2\&JI,-5]AS<H^JC_R(_,<^3"OGT""TP9
MHOCA]+4A]2GO/FBY/?.C6I^8O)C1E2$NH94KPI/Y1)"5_P^<YX\4>C@\B_E6
MOIMM_,2MI!.U-).Y)<Y2N'21/'GLEZKV"+6AJ I59.YM=SKVER/ )[[$0BR(
M%X\+2%0FVX@/*UT^Q." *Y*5#2<L)U5FU]OASC&LZQ?V,KP,T;N^NDBE9[D-
M)[3M<"AU=^7LU3GKENC@0_Y%=/8.JHC /XHS"___!I'H_FG]4*><?7%[;A^C
M5RI#S2NI>SV#$V\Y.4YG%'_L#\C!D&?9G:XW+]'6YM+I>K07U?K,Y(4>"^>!
MV4<S9C;ERVKK$@RC-ME2$1>6 V=J< CQO7>X7*G5-;-S!&@\M#^O;P7L-[Y3
M-$ZZ06I1"FPMT3[$](>0[\<LG5B@W'S2(T^[S",GA[.C)!J0>B7^K\T]#]AP
MS 56JDLX;]P['^]K(]U3RYE%*<13[DNQ]RS1*[\9\DD3"U O9I]6'*E,E0M]
MN-U8F_CLV!;L1YE-Z^3+VOAB*4,H@8/>UBI.P6\M/W=+FKQ=O"!AZ'8\N$5^
M>&SC>^XH O.8!:I@Y^"_4-?\^-YC"3,/]H>'$2BI;8U_#%C^1Q2Z_=MZTKWV
M/ZTG$?[YH_G? VQ/D!\LW\A./'I/[GG'@$9JI!A!@Y>RC 5HZC)Q0@V))K>G
MX+WWXP\;I43$J,/Y2"N@1+.[GX+DM/LESQXC6# %14@^F?ATV((R7>.[Y B(
M%J6A]'H]S'OR'P##?TR&>,M!EU<46ADQ;]XAF,=[PEZ=B&(V=\%]>YO$9,0W
MK_K>'+VL&>&%%+J@% -4)O =VIN"6F.<9SYL3?NPD![@.R63J+\<"H]^SK 5
M<0;%P/P)8WXRQKPU]!YIX[J,<V#Y/9GK_XJ^_Q'EBYPC4. D[G%U3&L[Y0_5
M6CS6B6Y^Q^40%BY'7,W,2Z,M0_@7>L9R[T![XJC L:L5]<[ =K4W(P12ZZS9
MA;D)E9U0*];UX>0A 5GN@:R,OI/N'X5ZM:JH+3SR46A/P,.P[4)2ID/N(=4Z
M5I0C=E)"I+,YUW^;ZJ9_UP'CD\P9F.5YR*XJRN**?J(TIW/7Q3 AVZG:E@]T
MHKXCMSQ1O#L;D/Y=P1B3.9./:LT&2_L;_KD^E\N'R SO2PJP]E^+*2M[0%PI
M!G;<!T4^$&E+>1;<:(GA\D1"RP%_?9H^N]CE2ZETE#>*;&TW9 M'<?!&Z]^B
M?S4LLV7X[F0E^*6Q:Q?;68_B6?CDS_6O6-*H%9F70NSGXNL$)D =[9.X$F'K
M-!:F4N%V<Q^=;&(<]5[NM/_,\#RSHZG\FNH;A?'LFC>7B@;J3]^=".(% @#P
MF")$9TP!H-'^]\F@O:I^LBR_ME']0/F^DL>&4D/%M4[#1%_[+ET'PY&+2,M3
M%__+X.=0.WJ0F6&.(==*#.F%DOK%<U),D@.IQU1B,2C"<CA$O(F'H$/\VW2M
MK:.IR/W@74N((@J2X1S\/^?V..+ZBW$F_A9W >7:@T>_%G:B3&359$C_,O':
MYF;=]LZ\@[O4G&]KKFUPFRRU.!=K%F_=]_7N7/-^;/MYJ5Z+\N,6Y'P23U>Q
M-J7'@NV#7IN.2Y;+7?O""RXT+N!9M-XD(R/)S]N,VV2T$=9"?^T=7/C6G&CH
M .1$<?YGJFZ1KY2'M]X^X7FC5OJ:[:8R;Y)Q'&CY9GPO<N9Z^XW !\,E+B?Z
MEY:JPB4I@UER]&_1.0J4Q))264@>9\U*W8F*O;+<5!^[?.6ZLHW6QM8S>A99
MVMO&7Z9JK?XDD0<C#I2!*9$!!BGJZ7SW.-ZP6-4]M-5%CZM1..MV9#RH/GCI
M0[V),!R3O4(R/L_*70-Y;A6K(892D"N^?*8[N95,2D42/*WE)#4<&\59*B;W
M'YVHYB3]#KFS>L*XQ\S;X(V%U^4DG 0O]NT*I5.*U>$+,CNVUJNK^S>*";Z>
M@-#^>Z5O#KY''2JPP.Q(YDVM!WDFBR1%)D$3FZ9M-Z8-S<96&I<>M;-_D;B/
MB2@'G/^8_?X9_:$0O\I+PTL#3)>3C#B-_I7?TD4+A<*O0S[\71ZWK/=V#'@B
MD)'!&(6")(I'B6T([7D*FF".,ZU++%=J4O2G[Z%DO1_XQ+/XNTEY'#,%"RU.
M,;-IJ/.HU%7+@+U#^)GG&E%'AD6_5$C0UR8*&23"? <CTOUH_?=Z*<]"L,!<
M+V:BDK62C@YECWXNG7D/"WA#1XYP2C'DG_W=7?3?<)4OM8:;EFI[X0M;X/\0
M@:IWQINC4U"LAAG44T*=<%I=Z[L>KR&U=A*G<0)I!]'G!G$18%UN6%!ZZS1F
M[TAR.6JAL8;QPGS1P>1F=4UUB-3@DXW^^L0CVV'-4?M\K3=*[1^4,@UBR;Y^
MOAFEXE/YI9>>?EA3>S:_^YA+SV!&+H9V M+1>J !PMSF?<O -@R]RY_YUFT@
MF*%DAH7L@+P@>?;MN4VD4Q3S\,G=J(!J@H9@ULR:U(VNTO$ E: U6EI8OJ^:
M^?2.^M2K,!6W&P[QJ\J3F3)&T1B:OD#>\I'2H;R"=+XYN#S;IRZN6?'XQ+"=
MV-:BU60$"/9J=LV$@<8@MC+;R83LH+/8]+5-O ]WI#9R&/PRS=-XBE?PYY?H
MMTD333C7C>OX38&4BD@^+, 6LX@.6\0"BDH6FQ9T^Y88I1OM%T3MF.C8UO'6
M:+I]Z(=!+/ =E$-"?.EQ=)@"[;3?>IKI-3@E4RW1CX_-2_Z$UKVKON>&N3,<
M*^B[%@X09X7!NIAFMHK.SZ ^#&TAW%SM0K=SND; +8DHZ=9>H^_(\GT((_#M
M[_KN/R?\M[_!.Y7?DN3HI3>:--V%48!O?AY-+5#[FRGH3GD1'Y<_6$98-E.O
M4NZQ=!Z(5LA_,@E,,10Q.5D<NELVP"#5_P-ZC-ILDVY.0& ZY>O$_.@E7LPG
MO@(-8EB;34DY:[>)[\+I8VE(I-!8@*46[\F??!2FP@[]\O5GX[!WFK]!C)T3
M%CCLQ1"B.?&AL_98(&,<LJ@(K<55;E)YOS;$*B@ :HCW6&"]-O-T+'='  N,
M.(+W<K6U9:C1!9"S'0[TL</%(RQP-*MYL3&IIW6IW3$3$Z#R:Y^L] 08A4C$
MG O1B@F[L]CMM").LO#M UZSA]O[1"EP;@PJ/U8D%EIB$=@?0#H;.XQ>LQ6V
M6!@I]))>0?%LY(>/E<^Z+^[HACX0,&*YLX^NC!2,+$.( FZQ!@S\[=:];HN/
MIFDW Y3/,@KTWTDRNP;3M9^A8HG@T.C\EY41N[LVQ"K"T69++/E@EMP#1*7^
M[TS.#*9XUYMHY-YN^3*Z8-I&04$2/QIV'F:QL@2EQ@(=ZKEN$"2F#L^-5LE2
MZ1RTGCI :H %FI/7LS-^;/%M/V_[-0X6 .N6_+5'KI5,1C7XD,"7T!_#V4_S
MY)I'^B0:,1DG515;<4B(4HI.BP'5S0ZRQWV].5!/2["3?\S>:Z^4IG>"]2(4
MM&RR:=[ZVN?ZRSS/[NDWBU6[U&\+295KAH+?[&"LCUWO''6E3GK'53G:/3G\
M,K_#; P]6YT9]5=XZ\^2<CGSR0@3U3V /*:W47KUR"CXRGXFBJW)@D5J]N4G
MH4Z\A/:?:**CBO2Q./AD\3$;C=7&(4_KUYKHWFU]J70P;H0]C#SF-RT)!OVF
M3B=NGKP#E>#_?)L3W_*O=@'Z7<U144#*[W9A*-B?E_ CK.^G\+70KE/:=,/:
M2N2Y^RGE$0U>%2[]$)A?-YH5T>K[5$HPSW@T1#[7T2:0J?K^-:SQEE9&&KH3
MS3/F'(-\E7\VZV+R5B:RW.@R6T4')+MWS8&@.J=&4JH8XNQ@4&^SIJA>#6D3
M!:\@I]/_+2A"^V?TI/EG,*5UB52!5 $0*I6KF:W]JY-62DQ EG.1$4+PL_)R
MBA_''?OM[\]*8=.5D)ICM8&LIV-=W9#O&V =G@](#]L?CG1T-H$3 [60IER4
M2A;%\%]"$RL25U3>!UWX8H%9KU7][78F\!JN7G<'76BT1+6861YDGHR>!S:C
M9\'@H5<TVF:]#K^C>^<<+-#/>2""#IS#%?)R#26X/)U;FSPN\3YA5H<LKC0N
M5DG.,+O;[/:7Q5R!4HKG*:D03PD0'H%TY/* J%Z_IW#ZNV7MY$![4>9SZ'#9
MW.9,*N0SVG(GN7KNO7N.C;%>,1NW0-BP0.K23D7%W8KK <8_0FTOJA_^, HB
M7BN;WQ;/7WVFY%5LH9&P,FAL;T<9^_[24>Q4GE/^#>FAH#7=; Z)PEQ'=&^>
MF?K=3)9RJOFD-U\>$B$-^X@(#IY &/M'%U8/*&-/JUQG;2^8,O)$/U>P;_FL
M:]&MG:_OY-(W')D.+CT._#:B(?WVZUXE:X(?6W,Z"YSACFU<&'?]=[* L'F6
M6G1U*VKNME5J3.487\..I)H5I 1IVC&^:7"X8*1@_^.!:8^IS=G9*=[\P=S9
MC&U!C>QR.NOWI<P=4W?*!PO4S[[X<M.?QT+$#^9X374F]*<[M9IAAA<=5]X3
M!#WU*Y O6C1=4/$BW.DRI,9GT4M*^LK2>'-U+<TY;\]M\85 QQ?M'VVI&*DO
M70G/_ 2U%3R9L_\##"?*#:3# O$]>YC/>U@@EZWR>27I?\I!/:1(I:$UR![E
M&*[",;?/4)+D\G1GIXX9Z\NG]P^][QRV_W#<T023G3T<D)"YQX>,A9 <DQPM
M4D.Z,GL1C''+8G5T8.0*9*4ABU+NOS++1'^),GY-<EE%ZA7O$V3=Z4]IAM8X
M)H'"M^T&*V?4#@3)^TWID!Z?IL&0=]GLO1E=J!(PX>56BD8(\"THI5.%B][Y
M/:/\\08X&<*X]>>!RX8L,;AJ^E-[ON.T7246N M9LAP/$?AC>5@/0H6N88%
M;6=<6JJWW(VJN.U!%0V*2XN/8DV"NX[538R'B+J_QE P%KSVFA,=F7.-O:T%
MGNZ&KH&3@PC]?%ZUR'O H5=-MY[:E##7*%*>]XU\M]P_Q6^+3EASU"IMTTM;
MP6^#'*QE6A4@2]9XI14X/RD?%"US2.E!P"[+#1YZ9R;%U[8.[UK6O_SHI3]5
M>[R#>8B1.@C,X)HF#E>AR,1C);2.Z6VFVD.5EB =X5=N*K<H!%'I+'T0DHJ0
MPP+PLW/#3%^G[QU[709:3L]<:OT SZ\9GS(^I>$[;R Y$F9O1U%3"\'U.#^=
M^^MT=LZJ3,8;]]QZO*%$)&LLU)YRUM:^K\[<;><HKH8P'^KU'["S%[.[&Z0R
M!!Y)\:P[-/YLP)$6%=L\DO W!4MK/J1W M( >5<B%*"*!: %6. I%N"7N?'G
ML/:CS&=:=_8+V.<!C7N7WK$6$>'2C>*[E7O':F$1BO=RT5G>]<>HTM9*J6GP
MLOH!Z_A^8-5\TMT ST,1Y$SV__I"5(SR=8HB,[XHS9'D)U#6)2P@:; >X4H(
MC2B[27!)KFQQ3X3CY$XCWVL7-R]>[L^:O(G0T]<$9XQ[4W*<^O3 8Y+?5_(E
MWZQ$H#Y!=E:P@.-,O&$%"B?T.TIT"V1'_)#[P /2 YF1WSS<.W7 I61A<?8C
M6^53;K?'S6E+9*<<X\UHTPX6YK%[[-63[#.NWW1C5+(,8+@:. 3OB4"OY4'%
MY3L/WS,JH[H,"!-%YR6B8Y.V3-RCCLWO[9O-^6;L7;#90:KNP/R,R-\==M;)
M,!R+8IX7%34?02QGOAO<GE1_9OD#"Y!A 5KKF)917E<44:%S,7O/UMHF_/E=
M84*&GLL"&5+.3C.?&5U.O].\*&PB+3.5K$G?/KS_**:=CT"ZL<AJZKFZ>P=/
MKN4BQ+H5=C0O%QCQGN$&F'.NCTT*300?V_2O@!8AVS][F^A/S"M97QI5MHG.
MOGB)_XQ_6*#'65F.O+PIV/_=9+$!UUZAR(*]J[=8,X0<Z6Y*-VU"NYMSGE3&
M>]?UZ56%9W05HV)FB/ZBG#%) 5NX.8?AU*Z0<"H6&,+_/EJXKVSH;?3T/EVL
MRIVRS?JV&_LUEDZI;N6\Z/F/DL+)E4Y]3_@6ONX_%5TIUY2*C0G8QR&D3MVI
M#^IO22MYAYI5*]H\^F[Y$15(>.7E7L^(0IRY17DF.)H?+M8U2QRW/Z[9ITCW
M6+[F=GI*I)KYR%5N^H<,Q64E"N*=Q#C^N7SM\4"A'.>9E!1A\I+>O*^FD?>N
M*R@U),@IZ\OD,JVTMT_#=B2M<A4J)-4DXQV34WDVIZO[&7@%#HZN$C&<'N^D
M?MZW?.U:^PZF+KZ[M=;#K"B(C_B:OB].K0=_JKRZ#M(X#M[:=)PYO^AJ;>?Q
M7]1$@B6N;05350>1F!NJFFN,N18H[[).:=TB627T>@ST^(+716#NQ+X^#QL2
M!K02S>MM-83NO#"9RG13! A?CS!#>DJW9K^G4[RXG>@;IG- .WB4RY]@O!PN
M.AFJ5PIZE^;5RZQ(O.ZI?F#Q)O\[Z0?W:PM8P,9E!,$^7<F#5\-BY-U'(!T!
M&D[5VYLXQS0],"OE7+1H!:4D7>R6><YJOA)<WX?5P2 45?[WV)\?'G?)KQ**
M#JRRM"H85N_W)!4CPP\E>'4,QN[N#$V>JE^A9L7[LL.6/,*2CB[!1)8[:CMN
M(?Q_C(2?$&8HO>56D13(9:K\\@!/NU?#Z<=,]+$SE&;!K\!8<'M'T,C"/.\6
M>SP.T=?-!].C1?$3]'Y6/DDK]52=V4:[NM;5G"B"$901)^ELVHW[Z)Y<YNE,
MNEGV4"PP(&TCOT?+$TVUES$E$AD(AF=2FGRF^J"?HMU8H_;Z$_^9@Y%'<XAR
MGY2$-N%B!(H_SZE38^J#?OLD;TP.;9VO >?<WO6%R7UQ?WT^IBV$>$]^H9H5
M."UN<_33NO4]9A^;9T1%Q2G<8?YF#1<J>JI[*1CZ;'@0$8::^;%)"Q:PKXL5
MSEAVL;=Q>J !OH6<1F>$P7GM-:8Y)N[!'-8F?JXV&+E%0UIZ%6\HR8Y"$1%"
M'Y9,]ZJ<Q^\FZR[,SL_VNS^/4[3QBHRX"QRO2'^K2.P\=XNPSD'F!$D8!*EJ
M_FS4ZN/-H(G45)!HJKG*#]U-Y5(0K-VEC_SRP+\MN;ZB'M-*0N4K\6CBN%7:
MU83\V=86XI;TD/!5@TON3?0?Q=RMH >L^\QYTMR3@D-R"(>?V1,9F!MOM2@^
M1U_7D0C\QO1\QY RBM>K7$3=_L M-VO!9*Z\M8N_K)QISE_\S ;0#,0"&D[U
MD<?OO=#/GC<T7Z_>F# V5?%A3U3AB>-/4*/M'\EBF7+5&1U2;6M>M,@( B]9
M#HXTCDE*!<%CE/1'UR<3S,5RCG):O_J4UHT:NO&/3,-L]Q7C\U6<;4N4*C4#
M6'DTA5X"G_'<YHMY8Y%88-M0(G?+(+F-ZN!V](1K8XNI%;XK1W"_C\C-QX_]
M9RQ]EM/!YLWUDXL]C 4QC==V3 +EGHCP$0UP>H=XH!WEO\%\<)G[,V2?I'CG
MR<\/,"R@\,T_C>ZUH&,+N&)A4[>I#[%[^82>C/@2DW<?:XVS9I=)-&-%NU^
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M!K=A@6'Q4<+DVAB&N'G.>*6;%43KVI(W7',_>/LD\,>^*UU68(^T"S>2<+O
M IBF"GQ->R9G5C8V%N:JSUF7RS,V;ZG_,@\?C32=&WHVGC0=BK()S1Z]]>4F
M.N&[4]J=A-&A2J.3_-PFD>P"BF<Z)32K:>?G6@32 XR=3 D:5T677/NS72+3
M<QT!/)'PWDMZ"7*W8?723VZ1^'K&'N\)\SU0,+QA,-]S9<4#D46R[1([:&#U
MX^: F)GU'(W01TX6!LGNA=J#4'(5^_O*/][X]PR%EG5&7TRYVAO6CQT[5@J1
MP@YSS]XIU<=_I1!/_)2W +-5O*>NR+V3=AJ+DB=Z)1A.-0S2^<!%9NKO7X4
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M%XLV) H@2V:0%4M!;9,@?9_[F.G,P]Q-"%)5$HP%9!<$L #^"A9@!,,Y][$
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M/[_;)ZV[2(BL2/@\'Q;K!AE <6SH8?2";O_S6=,TRO/]_C#F&QO03,C.R4'
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M204YM.UC^O"1M5,\8$+BHK6RF\+PW@.TD&1&P5TH3,&??5"O+,\A6GLA//>
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M>&I6P8JLDEYO2H>9D$J(EI#-N9')QX:OV:'#@CN2_]SEASU1^&JR./MM*7R
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M(7M"P.0N-*=YW4$;G\(2-\W4AFNO=[8>%>6/FF(T"3QAC4=0G" 3$REUKE3
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M$Y$II:%+KI5; _E84'[&11MZD+C/DX"?952]("#9S!JV]YU;#-=?Q@9)T1!
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M.EJ.N@%CV3_8$*TAJU5!NV:0%^H^T4O/HR5"$NTZ7IVW";.GKS'@[YX7V12
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M3]MJ.,]5U]A\K&22M@IT$4(9#VL0Q,AB/9/E_>."+H;/>.HD_ P"5ENR%GF
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M"=WT<6UB8;!]ZOS]#@AGR /<A?MLZ8F:X#<IX6/3VIK5]_QM25XT,=YAZ($
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M5P\+D&X86C>?F5_D<E:N5*Y 3W*O"!(,I8N5BCS.C-19M!=),<9+?5 NT:0
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M,#O30;KUDSH=3K:7:[8)RC1:C>/OHJ "F1>680$H#%[U>Y%#"//$_,4JXM:
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M$"/\%?_RW0J1B'HC:M$5PW/.YJL!T2D'%=R%A,&8-;7\"SS=!]88CY4=M>5
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M9.]_5]=?^KUQ_(,D+,*[46&C\IY5N]"Z9U9[B,OZYX:FT\'5!,S69^@UABC
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M0TQG.?OC\JBDZQ[![I\QHBJ#Y;Q@>?.=5+A#3=94HQ M3>NAHI6!FHH_W'4
M+$>-?/P3I*M3TC1D]?!)(Z7* A"_M?K0'\[-T3@CVP;5 +S$AMK$UC8)T9XU
MY1DNUVOM)0<042^%1(H<UDFYUCNL/_<G-'R_6U.9CH[1_7VW@.D0H\._H]G
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MI\E'"J'4.W+XRK* K ;YV.]P9R2(O6ZMV_67[S'E*<YV,6^@WZEQ7Q3AJ[C
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MCIZX/;W%D2!D<$"E0B<VO.=L\B" (JCRBD/-\O$/F.>R\FIAY\4'GA"44(<
ME]0M &,!Q2'<9PR8;HAEA.@9Z%N?.CQFCEIQ&?#<H*':MRK<E2D7$/4\4'E9
M-F"_/[Z=@32!&HK*7AO9I)$M[-?D!N4.N\1Y'0\6N3FL=^%+&3WNA7\B^&4
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M2V+^P.M5P]C>K>3K7+=NVI8JD^Y.(O0@PE;=.CW,S2"B4-=8NSN2]U28\N6
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M38?@B98:;-Q9B[N,<8L/U@XJ-+/?QY)$&X]*&#0_?C,>\J+8]@SVG4X>([?
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M@A"7*;?S@81S51_0Q,8*D2=C&O8,O36NF39C42W1NVU),[R3=9TG]M-T6[P
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M*>SB!+LX]Z#A@? 1H)FVDV(>M"X^C\#<*:>K+H!\@6X=.FMNW[5&^7XQT_\
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M@7RN#4$UHOU@,'^8VW3BC18HY:=D\G3/2OP^U^U),^M$R7*M=^Q8:A1_B=&
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MLJ@3P6O'Y8*-IO9GS ?=RWR()>^#M\\AU_!+C\!48\H-6D'5B&OWH7;5Z*:
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M(F;&H@5]HOGV]1=+*(.JC"A;V3QYW7@#]ZQ5]M^]Z,RC37TRRA\$\V_/->Y
M I1(5O:N&3SUP%@%]UC3A'$3A[0;7G";U+B\:06\/3)[%^!, NFTP;;",>BO
M4$+4A'6?#M;Z9.A\0$&6.;V,HZ&,L7#UZ')W^?9EO-K2X1ELSG.:-8U=)BU
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M1]\%;<K7[ !GM4B2OVSNMGMV=?QPA7FF48\%J6)792F7O<+Z=]/9P.B(J2K
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M+'*RKSSI:,"I7TTPFQ5*^+W &HT#&;B)D&O1%GE][/QK>?_E.::<Q.BU<NI
M?ZLY^JM?!&Q"[&E6!-6P&G?)Q-$GQ)X;EDX4L26HT;# VJ-2RL/K7*8 .GG8
MB-M8B^RI1G(02(D8[R87+G)4D%:./1@TK'3>$G4@@!M@YQL11E*NOZK*[,'C
M)7 FG()EC[%9?_)!9C$V\382/L%&&/<6N#[#I-\H(0&AZB^FAJ^7/P)%*J.4
M5K\K'X%  <GFIOP=EZ?[: '5AH,<8X$O(V7PWFB[X_5^N3-9B5HV#KAZ_7@]
M-*7*;77D7E;EKA'OOK]3TRS_R/ESK7/@],T.BK %'/W18I@=>;]\]ES]@ES%
M(/K]-6$&I5WP1#Z*WGCL-HMBAA4KK?TWG!@7 G(I89"@^+%30!W8CO?._9KW
M9!HIR9M#@(R\N2X5R[=6U/\1.-Y=M;G%7H#L52UJH1RU/ A[*CP"'V]+[F.]
M!;!Q7*7?':O.%5>87_A8RTN>EL<PE+QERDXY.FV?-<C:KTJ.)K/TP E8":G@
M"G(O7G4(WMY*Q9)[!%9ROIYS6EF?E6["D*J_?DMR[FXB]#O4J^<)S';]TO;9
M,8&OB.5'[ S1CI*]>_1Y$3HCD&__E 38=%QK].>PW5S<B<;\:4E*?]FC,Z'Y
MUUT[?W:[QH5L5K8<7V3=9^0N=E]@DLPFB4K*M[S&PPRP#Y58CP[OP-\GZ'$J
M9*E+8<3Z3<00GNG,O2'"$Z@^7G6OI5$1TF6K4TY;,92M8%U*G@L'+L0PA>N[
M."O1J !?*(ML@L?R!I[+KM7AP7'C#PZMZ:'>@2U77%>2]?)@;T^1J/F"<\%U
MHJ[+X2CO0V'.OXX)6+0ZXV9-!2P)8*I#9%.?#MA^2"?6Q"5=]7;;B9$WX;?I
M>*I"-ZOJZIN@Q7O@*26PW,PZTY*E-\^\-S8*K:V7Y&=7\ZX,H[JFBCIH#M2F
MB("?MB9I\ENX^(\/ZFM36Y* _0-;V<3*E?\*:4*2WCZ!ZD[8NLY]DE;?/11"
MM-%"<C:[(N38>E72.DWU"'1.WE#>&$\NC/Z'#%+_,NQ\ZNCRZZ$-%6D)&2K+
MBX;!WU9P5XD/^*-3:'D15[)?&+9O/EP7.J(V+]@+D@8B&:L=$#I\H?868$.W
ML%QIP=B^424?0I08A!SVNCF+:M+"AOZSZN%_1?B1JTJXV\WXXW035?S5[[SW
M)8G=2!'W5>:/Q4C.M&@*71^@<I5C60H\#Q<&NB^X""[Z_=O]-6DWO!]>+O[*
MNY.&.H8$?6PHG=!H#"IF0V]'+9/%FCQU6_Y=.B('[(&2CT/=U^/QEJ;C>)3?
MA UN'M#;]E4>-<BTY5?<B8VG'E->B/ONQUCCCLM/AI*Z_K:+":UVB&*?(PM>
M_-\-?4RD!0T>I#JLQ;_#,5SC'*-ZVS2D\^@KA)0*MP58PUBZ2SR0"E^CT\A-
MST\O8ZL90M8\CH^99:+;OV#/N8:JZB6]X]>S *Y]"8 #DYY^ 9=4#%W,A9H(
M(2.0<&&>7=J5&V_&J_XA-WI;KW:V'= XJ\A]R[W3(S"CX 9ILPFL3_$#VQPZ
M">;.RB_DE[[MBGD;??HB/$<TQCT45CK<.YYJ',B<W.U-_P^\J0N?OAW+>*E8
M_1VY@;^6FOUVD?W4_;B'&ZDD\ S$C%;(XEC "*8?24"T9<KX/0'GIZNNC&QQ
M]!#.%9V%R3IHV5-4\KW9Z/XT5&- 3]Z#V6*_Z$,X*@VI*N,$4^X9X)B71[0B
MB_"$9HP@?9;CD#T<T8> JGFMGS-6-?$YW2#ZQK'BR@Z"7P)4M68V7#:4;V:5
M*'7/=OXVUJ_0$/*R\F=],Z85:8'B=D4+A-!)E(O?747TO9ZC%K (#ZH=H9[K
M%\<[H(J*:@^+!4,;7@>"X7D3[DY/#J5]E"DA&76X7(-K9<@44<!8A+&#H<^_
M+2Y\ NF*7@PUVGG5'T!-K!? ]..N6UX%BL$*](7]7S?07DD[NM:$-)/O1N_J
MG:TX0%!^9 S7_208X:>4VQ)B6":==J15D%"=*&3 97^C-P]X.W-O$V7@?[6M
MG)@?T2UV"\D+#$,!L59/W;7 ?>_9>!=Y\&DVS86]C^\ A-*C^[D^Q[<JQ$/O
MH_!ZK'TF.A[!:RTB2MVMW&*_'J&$+@[7-$_A5%?G@7<3ZV4\[*PY+-]56.$!
M8U5%.+[U&TWP@U^1!$$>1<R*1V;5E.//PC0_>S_3@9C.Q*,W#I'Q%_6,"".>
M=BL% TL(6^["37F-(+T$R5_JYHQ?D47?HZ]SCP1>*J&$Z?9T[-#%*5=Z<?7@
MAE(QZ?=$U O\)BJQ2_<6<:L:LZZ:L\'1UG:U'?'B#2+K*@A+U0,[L<3>#D18
MUQ6E8+J*&HUY&E$TN7WDWBBPNI2]T'J?8/K]V-YO/MQCM2E\0+$"^K5]>)8/
M\:1R_#/1XN\"2@?-7* 8>P5RYWZ5\-!Q:73+HN26=G6BM[U>=6SP@V>?AB@#
MA-E%* 3O,(QD="0=P-K(EFTH[N$95\/K$F70QR1=:NUI:G*4BA7_U\6IOQ0#
MM?Y2'53_HV0-)_R76J"*WE^J@Y6 &AUK:<,[G_6_9I@I3Y$EXMLC4'F.">J'
MG>6FUC9JJ.2D$%RS][.'NKD"?A'=3=DS0@W:T0,X^V(\"-\;'8=<#T.XSNN/
M8QLR)%U2W>K[NYH5-'08:N" ^SX:D,\$((4%FBY*/P$;A[AY!1':[=@*C**(
M%EIHQ2WR'FV6H(7LU=L;H'7PD'(P^;?V"/G%;XJN ),V3E<D?T2U?IC'-\F%
M4"G^ P)UL^D=9&1>T\3$9:UL%3$*>9NC =TFJ&G99'%ANIX!<67"*Y8!]FA6
M(KEEGYJ#W%G.I?BET3M2-Q>7PD778E)>L-PBAE15=>0OH5R?]3)@X]NPH);+
M4T8MU; \@NUJWFV(D2(%I:F,-9"-G"$.7]E@[Z&=*ICZZ=K021#W".!XTF5)
MDH_/ZUJ%FEJRS)B(UMO4KW^LORA1^@]+@UALJT81:JT4E.'7X"]0!SNV&$33
M%8?0J!XH?LB1FEY@IRY!28$,Z:WBKK(;FRR9J4\IV^U+6U&!A![8<]?=3A*(
MK_=])\W^3>@6\I9:S#M5=TY<")R!BW\C<]:5J*0"F]S73"9Y3O:!WIZKGY=<
M<%7_< 1Z(NU%9JC99"-S_HS>NR@#)<O7R@&MUS.H9,E)H$_!P*FP2[N[/^Q;
MFM@B,90[L!HJTD,]KU N[X;..%_X134UW'4$ 3_:X^BVZ_GT_/;W:\(US?']
MU];_%V5?&17G]Z39"9H (1!<@P=W]Q#<(;@'IVG</1#<'1IW=_?@[M*X![=&
M&]_\9L_LSNR>V?W/A_K\GO?>.E7U5#U/W7/*+,LF-^G510JF]YFL$^*>V%AO
M_M3!*'1?EEMFM_UQ9I@:BCG5.]G]ILN-'$G&3&J^L'@8+FR$=))8:-0<>:0/
M*C_*Q0[36\]1?U^KOU9:A%O!7H$([I!B6/J03A6"5 YT*L9LL;[E<>TONVT2
M "K^F>P5_6N3O5]^; H( $8R'GS.K JKBX-E[-NRSU<4]3_WZ/*]5B3LLSPN
M%-_!KC1AJ=MB6^%9]'+5G>;@K9, ]PK,2CF=T'O1,TGA# #H27K&5HAAK=R'
M$'F!CSFE=D.>3-,L88>6Y,VJABWC;(,'>J\OLN*F+Z)X_B2?[II[-$<@C\AX
M=,*GE9^3"ZU?G,J @F0<XT(<]8U1PDP<H8C8WH%Z2E_]!NT':?#& 6JS/\ H
M7[8SL/4<>QJW%BJF_SM;&N12\S7U<D4N$:B^I[_U1+W-1IK65^ID@7)EY;OM
M[:LD+575#Y/K6&SK]B/>'+P#-++/S?-/XKI%BX6K3^_.R_]93L- N([)MNB<
MLEL%8.TTB@,\B;%W([<-,"09,O%?%HQ=./MF@PJ-%%F^#7?QVS>YVB0V;4T2
M3B(%FK4N_.CHRH0H@W\/FUJ8N'.1$"?RV4.(E.#O-BZUG;(>X15? 3D5KIQ[
M!*XAH"<Q:+ ">'U2J5&SOB2AXK1,9)")#_&(?O;@WQ/O&[9WQ_JBT"O=>:=G
M=,79Z_!A\K@SR:N\IA]4%K^OB4YO*F=UH>JI6VDZHWZ8V[?2O[AN8SZ:@%5X
M1)"Z#&3*MEX!:*N:W=[;I!^'XMW\;RGV.GUD+1[%2+.))QU%\$G?0K05@P]Q
M*E!CO\55UV-2+[#>'!ZF;T(*Y[A^<>9327W.O11*Y/S?'*@TUVWB3XIS%-4=
M"QR/P"67>Y<KW5RIQRA$K/3T3 1+#?Q-3W[^\V",5X!%/VKALYFWTI#PPIA6
MDM[NPT>-S)\B!P@ %R<-A,(-Q6V=):=7 #JP2=LFT;AP11;(85<>I[@7O#BY
MGT=<6A,M\4.:4>N!I&L;'7>]6L_HNCA9PO^D(AU#R-P\]1VBN&W,R<1ZERLJ
M[Q!2WNK:BE;/E9ZN.+QRGM0Y?:":^%%?II\K)UVU*6H^-L7GJ*!VDV./\E<
M"*JK'3%EP!U T8&1;X^7I+AN]^:K2Q""'V5Z.J8D=I=G*2S(<?NXF7,)E#L-
MRLU<1C[-,75Y9!OI^3HDK>+;^CTBT\,0;N9+)8DPII6J-JQU?_)R8:2'/DVT
MQAX#:$PFR'O?LL^IT*L.:7C44]\CMKR^G:G87 RU_<1PR=DJ-\GTA\:2"8"L
MZJ?@C@>XEJ&?K._".?)("MV6E\^_A.=3ZS@M-\7]R)'4:;D;G89VG)FH<FP
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MREQ4DKD\SX/A$D,%GQ4=1;#;6;=)26$;O8T>@>G:"M$@-L,U.1)WH@#_45(
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M7_;WTK50_Z7(^"^GWZ"C+1##7HNA3#^AE,B1"'Y)*<JH;\/BJH[-RK[$]-F
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MV0=5F>&T,NXUD8;L=(1)GS)F+@[%ET0JAQBW$<.(C\WP?S2'F@9]B^/"UY"
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M;S*@?]&2/.Y$>:F1SLES@OESIM#+2 (-YK)#_0T#<IEG,@A+G:&2,/]N6X\
M87T]#H"IT'HD)?OB C?10Z-FEX,G8_434Q[#3LD1%KN7$& 2K1N8>=K*<#C,
M,BXYL.'Y$Q[7B+WUY^T9_AL;*:\*]W2Y3-X_:==F0U5-GG_<6,)-:$Z ZO0@
MA-1O?'R/R'74#W:@'(9R'.+T1FRO_]U;QTUGQ$%J32-1SL(YQQBS0@.*K_[
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MND 4QGCCL*(\8&9AE[9KG<+/CPIQX9 9&I?LHV_8MEM9'HQX. J6;GDM.JT
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M@/WZ!P>J96RN/Q(5)HW5^+A($UK,&G9_ ^B[<GQL46_*8K=M?_HM!M54@U2
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M"Q[)%83ZD_RGQ/N/;:@ZO[_^ U!+ P04    " #N/7Q4!R#2S LT  "I.0
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MOY^X_*RZNWYB7DJC3+W31_!K-)Z3@^/$4AWABM NR:FFOJ&*'_Y1,HI_FG6
MND=^"U0$JK/M 5AYNBMMGQU_-M[??/]#II0I"X#]S5&JCWPSSG8J)Q+PKR)
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MI&^58[+@D/R#6>^1^.;*^($G9MF125L^E-UG8X$U8[C+:ORY(VSO LG?20.
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M@W1UZL!^@'FT5;,D]KZ'=V\A<W1M?ZIH:?!"X:+D?>,2;>:9P($:TJ050#(
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M@9BPC[6E#6PWB$H1ORK*)S1N./C'M^7/%Z_%?LSI$$/PE(B52?G4_Q;-P%J
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MWB?R64[.I$'1_;H,"W:%;'9NOU*O%O^B+W>9Z)[?_RQB3_UJ!;A?ZA&)03=
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MB&]?NB#R2]9N]DZS4-&NNTY*B4&+MU976BF %SGA_V,2M%J"Y)GD@8AJ'!4
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M/^[\C&W6MP\9"XUGP1@=;7@'HA5+,48X;W&^D#O,'B6@?[K.6GL>NORH6OT
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M8,#Z0EL-L-PKJM  PTW^+I?K_U7ETN_=TMM<;IZ.RE0,O$_@G\?KY55O3.L
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MU/PU]"2Q43[ZT*]]C49D*6^R%\EW,29N8ZS:OO&33(FQ<U@_V NM49309?#
M=P+MNS9%=[F@\^U?)FBLU?\56B)O&&N&ZT5 UDQZA/,SAN4?<8:PUDKHTG,T
ML\?;I1^3I8WJ32,V&_]IME&E4[> P0J)TV:8J>R^<\?"V$=;M&G56,79["1)
M')7_C.M6Y/76H\'.1M:FO97.4JR@9 ;X^R>6<P)' V.#)K(*? U?@_:=1E2-
M&D1L/![_XT35_WR6S8/_"NVBDU[)%UO&H6);)RB_?LUN/"5PHH-1&[#2O2YT
M<LWJM!P:R9X:9YU;YR0@_G>G+"+W*\9B"3,=<N8;S0&IE?6;;&O):TP(L0Q=
MZ-AJLE;O@!2+K7)1HR_I_KRFX!%?A$MG:-%ZUMTT&86,/S-Z?UO9^#_!:_"_
M#Q'<O]BE^/ZLZ"4MXY!%*<$C@Q!&TR'!C72;K'T8.Z=.NXO>&P_^HH63,5&_
M1VR4+QCMFUD>-.]W.G",KD.9-'K[#5:+@M<210TA\V,#Q,T^M(BC:SFU,6=<
M^8^!$ZWZLH#)0TL_\?4CTI#%:R:-X,6Y)FNN-%>:]F+1:@@9P16W5'CRL17;
MI8[+M<1=,@(V9@CR2I6G>J\SSWOO%B!M[6FI?RT&D0:S?WV/^TB60&B!VK7@
M^'3LRAX_,I$LV-,DA#5AR;/ZA/WAO7/?>B$)8\4C#]:3$D^,EL[QQ@CFJVUW
M9$@QG,/W"Z7,27JNP6P;Z$/&5^FJ%5XSFXTZ&IP"6CBSRU14R)6G>9%XHFO>
MA"X]8/9IE\-]IJ@"- 1'[XB2]:3VHT0AE\5NEFOIFH=-4F%>A*BF*/]HJV5E
M/#C/K?>[@^P,S\*A0?>P+55;HDO4HO=+9?/LF=,RV78L3+JOD+QP>R00_493
M*WG]U0^>6/CE#0MD]JV5ZH(RY9.AI<9(YKN;(TL";Q.IS9]+X928(FCCX[/6
MB6\!K<;OG+]O>%0F@8BQ:ZP7?Q!!WKC21XH@BX85M$!\;WZH.R@W0,_<(9Z>
M^"=1^_S>!B =I$O50TSMRB]-_7"==!7M! ZP4JOX\S'NSGCG?%TKYF[*88%:
MGO<3',<L1Q<Z&<-R%0<'=&-:.^GZ)9"U] _)_#GV^6X![0()#GIP='V,U,<V
MWH>2FR)T7_&\K0@)-Q+WKKC&BE=*:R)791/-.(EQ/A:B<,.3CT)_;??% =;G
MT*WA&Y:D?XE#E:^1>>38O5Y@\;.22%$8*_T7H\G6>]'112WJ@Y)M$\B<X9>%
MNY[.Q"T=1<:9QO8KR=II?!(/CV9?(MNJ:GV^D<9(OW3@#:]+IYCNV?'0*1B6
M>;WVT_KEI\QD55>[S%!V_-9_?,&AOR1&2^^W\$@2_KO/F?L+A@KTR*^Z0-X"
MW(8PT'\!4=]4_N600Z<_W ]MV^/<)-7?D.I__%S#_QZ.K]]!8/S[/V3<C_&?
MKW!MU\MV<59\QU,I30[<4?<QX4F0G+D@CJ"6$#D3Y.N(K8GP _:&B&-8CCGI
MRM<-L8J^&F;IZ-9BC5^7=B"#ZO@J^6LYNL#4L'FK!G.=YZS4X)?NS]QV(X]&
MZC"L0E$?X6FJLOMDW[.M3K<*I E2G4FJB9XYL!>!65O<3G%(DZ>Z0CGKN0G#
M61 ,GA;W[9\F<"+8F]N]D9?3GZ(=5,0*KU,PAEESLXICBK[W_L"D4]?5@0#W
MT(%7"3K"J2"^UV0&3&6RJA9V_"5+,B_#/.\TR5A801A&*G3?Q=[L,_X2F,('
MN!6IEBM:F.G-ZMEN 4K(S&1E?K3%P\K)-T5,OSQ(D.Y="78APQ(3OO5B7&,J
M-X=3-24J;PT!B!Q/IXN@G*V, W_I!67GJ*BSN:4CM UF):E@6]!/<N]'@IG_
M2U,&DFA>U9_SZ:1& X9^.ZSY4)A) SQT=>I-POTWPO+!#/[K,DK__%'_8678
MH;^]V R<X7\GZ/X?+#WY#XS_D<Z>O^6?IED4S*+EV?\\C?/-9NGEQ-K=Y_87
M2%.U#A 8LUP)OUZ]1P0[?AC ^_ Y+A$"-5X@\K3.O\^+_X[7DU+)!U6)#)+K
M.,DS#\J+SPBED?#[MKLC&SO?6"-EJIT/),G/ 8(T+[J!0[^[43I6]*8[,#W#
M/H;<#8^+M1.)T]1T]!J0QQ/#:'OXX9$RHY5P_'9L8>[65A1?9F1H/1Z!%>%C
MMT()_&G]KD<=7%ENJR(?<J(9+>M$B%O##PUIU)N&G:#JP\?XO /HZ'?X[;@,
MZNAH^Y>Q#O5^RT?7C+W>A 8ASBE@?2,$FOGQ"QGVTI4'@9+WI_Q^8%R%]M2/
M;W/=X$]O# U$Y2N \#]-8=."OH%?UGD<8UYS##USXF1ZG98[>E1$I?#6Y7%5
ME?P$3*I3DMJ,L#?;D$E9Z="GUCESCK;J+NDCNC.R%SIHTG8E2YS)CV#T83H[
M\/7%POOZL)>>*:J8\_KS;KF=[2]'<Z[#3W"9I_MH)G_ZE=ITT<X63;)'=(;E
M&,Y"9P>2S(&]J(\CDL4HFN?M%KG$*PV==L^-!_-*@OBL01_1,)5D,V5-K:J[
MKZ+\F&1FVTPIJ&JUJ)[6(8!TU#FYN;4YTQLAE#,M#R/,3&#/_1W3=P+B!CV.
M<=$O5,>8=(]QJ:PK-./UOVA+$OZ@'VG)F]3K7].?G.[@3F"<IU;,,Q'"C1:V
MA.O M:<OJB.Y\(U;8]T>2P?9TR!\UWNPTNJB!%_?HP9(=0NQK'NLI4#N57V9
M=2N3IDR(TX,(,'NO/*C&N;F02'.*^3!E(-#O399B23-M!F]MSI2&U'RT*):R
MMK4RY]^3(4J6?@;1PYI;*Z)V9L%(MTH$6D0/F"Y^9UF<BTH_7YV_H-)YJZXW
M-3VI_P2>321U%X]9G5[+Z.I.<X&5V>[3WXFVZ+^)>?\Z'?SO)7C_!X,RMOF7
MP%F2\!\,BO/?G)J+]?9WK"S^V[S\^UIO_VJ0??\C5N[^;5_^- S:?WB,H-,_
M)!KP&DZ?/YY- JBH^%KQAT$SZKN6]D6^E3CB+R+]J[__2A/]]A>U0O^0:$#H
M?_8\J_^G331)Z8M**1H11(4:EB]#@PRMM$=HZ:\K#Z@0ZLL"^44D_X=\_3I4
M"\"W^>\W-O^G/S\2=7E=@FQ"*("39';K>O%\N,&W7D(8X/Q_ZZ>13X0O\7\M
M]O\M"II\&XG@_8)"JJC%JP]W__@M#N[VQ+@)-UNU.K@OE]MW"]EF00GI#JT]
MBRS7(C>5WI,38_XEXQ>>:-Q4^68[  V@<,6KOM-GS%/5<APID ^C:YDZ*2J6
M*0FK0W!^G#9QE=&*VCVP$[837LL!NUEL;J_'*A=NG@CLE/';@+,U*6$XF'[8
M<A)I0E*=IXP01N CD*UO\UQFP=3F!?@HET-9=F1):HPQR>!&<IP BK)6%FD?
M]Q"T]H8YVML= GY$^FBNSQ T9HW'!MATUXQ_?OS"@T:+U,CZ4L33O :R<P\Z
M<;>LWO]-0'<+"TEE54+5L'MEXO,9N53;D+;P:QD.WO-XM(,'1\0>K*[ RHAC
M'RM^=C#)%O3BV?U2V6::8#5>-PRH4_GFA3FT*\8^?TI:X.HP]C?):;^05)ZI
ML'.6X.''L J-QUHOMYM9*9ZI K1]3VXB5OB:IL9I]2K'?2MR[QRQB(&8)[-B
M]<ME0PN3X\,37XZ+3%M6LU._*BMPJ!ZP3T51CV8WE0<=B"C8+"@E86N01>.\
M&V1PC!NZ>?,VF'='-S,TQ[$8E.!X_E@O(I78=U#(4LNV.UG!@$I)VS S994E
M?G77F-L&?8ZBK3DJI)N^$/@Z<@NPUG6WFGY[,_(-9RCU.,^B?86TCN]#89F5
M]O,>3(>Y::;!G^PC^;R^M2\&%Q5L"S>0CA5DR)/RUTT>@JO:[XX!PQ;4PPTP
M_<RBV7D]75GF^MI/L_>;0=GW")= )TCMT^@0J&6H6Y1<2!O;E0P'P>;)D\S\
M/BA(;8;*W5F$=0T'6R!-VG(C=8R.Q"UAODU/9RI-^VWJ$KEK()=G>D;W@)@,
MD&PV)%Y7EDMY/:*7(P[A7'!,]V#:""0\EV3NU"DA_#97E?.^P==E?@)/6C=8
M(%=6Y>A[R,D.UEW@O)!=?A>-U(+)J/T']2(*,5PG+4^E2Y$C;DM7K%ZVWRT=
M.,M6'0J@7-BG7U+W3IO^,GA+:[.=SN[ZP]W_&;:V_ZV ?[497T*4YAL!NK:S
M(<P_D"^WMIM7USHW#5/5M@_.5+415T"0N_52T32YV7SE'/VE)D$SB@"'V3+/
MXPBJV,JIJ5Q=FI;V/NT!STL,@#<OODP6Z/D'C]>4X*+NO;8Z:T4ITX1GCGXX
MFAMZG7G/GE4)L;^+5^S5F)J]F.\^' Q>']X09X](K6-M,1W[HK.:#W))MSG3
M 58W5E:X-#T3'WX>8=8:E<@2?GK%,<R7?G_BP]XFCWZ?0Y]ONL!/<V;GRVJ,
MRRZ8%8<JU@;9'%WBJW? CNQ8"L<7^+T3&/1^/.':D<4V\]_[J9^HR'<<*7MO
M'Q;0'*4I*:7H#^DK7XKX)>JY3+2AJ*OP2KJ^4_1 YXDV3J+VC>4BT/0?;!CP
MV<E;WE+QFOW8<:/QQG(BNP&,+%57Q2[MJC=$S@3@/=:A0KUV:FY&3<&V("2E
M2%O.W:>0G:G-F?="4+-[S99B\GS"I=5R]]6E<FOS3FV'5KC )F/B'+ 4WT?
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M E"_G"<*PK\:X+\U!$0D9!14-'2,5Y@O!.AK "("$A(B,A(*"C+R2R_HI1^
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MX+LK]SA/''L.7@*'?>CI]F\A621A"XCU3D[7"K8PM1F7;77CU$-3X!CA>68
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M[O%FL<?88B#QBO4YN,9<Q\W3VZ?9XF\%H?3E(4%M89?8-HLAQ#&Y4DC42S#
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M$=2X'F8NLD?'=NSF;5-VISOZ P Z'#^$,<U+ G4Y1<7#Q 7W;Y($JJ]5) D
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MCL:I:)W0G&X'D3^2[?U?XW7)'YX!%C%HZ_R4GOPY\TWZ8.U GV+OA2,A,N;
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MTVE[(_M@79:<O3COT60TG>L101:@QR*7>V3$JLV[%@%^W8.1-]20^PPH[7&
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M3H+[1(24"X]]_;PE"?L>N#/N=CJ(XHR$)WS.T.DRA99?]WX3N'KD,'"UH!^
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MWSR3X$X:Q:L)9V?!LJP]C>/#<B0AUD^$_&B#>):<2RF8]T.L_(UW@R1?NJ2
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M;F:=27'"14UCU7N*I@;L73ID-== G%*PZ-+]&[L!'^SOSLTP>0C?*N A^_V
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MM2]W<#2*?JP\DKPI"[\@8W];[MJ-/&8;6FU/D(1V3!_/ -0UGE=C9X#LRV_
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M5F(@1S&Y6A'/\/+OP!7-SM^TZ[_]6Y\LNQ5.(:CU#=%CL1K!OM<9';X).#[
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M=;&D1PI>,HF&EHVY6-_J <CH3Z:S&Z>:*(#FNB\_LJ&4%9)@FLL=*8#\^C*
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MXC((78CS;:3\=3'A9Q0FB"DU0HZ.$**6G^"L1KAI,PL0X;W-$IPU"52QB60
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M%_AD"K@_QKYA\8H:\KRJU]2G%V.VM>9HB8](H T%7ZV%%H0?%*MHCN@5/5_
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M40/P*N!([UH"HP>W72"*:D.[ 5.U$PHXL\ F' >IKX#AF:EI%%),!]C34Q]
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M85.<B%7@]N-C,LW^+%7Y^26 ?:&!+))Q;VR?2G7;(*6,&P]G8<26>A<)VA/
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M55]-<K*&@!Z0PW(,C3+IQ?HN%=QD&4UQS"4C=:QQUHI3O=-S84%!#6:6A-'
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M-S*(UGE.Z*?50!ZD6I&L:]GK(-L.]N(: )..%+E4+T/6_KM\3'8BQX^L(9D
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M()FQUK2O!0<Y<2]\MDXW@>?F1N-F(PV+6G-] R-DT4!.RU^:+.^Y;<!-N$R
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M)V279QW,8_O]D=NJRH?@$-S _P)02P,$%     @ [CU\5&3,G@']>   Z8H
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M=.;2GI2M"D?&#[GB+@?';0C6G>2L,*-U'XDB:'\QY4<\K'_[],J?N%L)+^R
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MV)(DV24EH2&@2,Z66K,H_0F+'F=('_Q1L=*POC &,K- JJT*6H0DNT4(O."
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M6OV]?_<VE?W+U38"8$S30@#E<?X[T^59'<LG=%?>]YUC_CO( 4([?_?43A
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MP84>>?$#9I_KKES1:+7SDOE( L^L'+LGL1<!8)MTA@V_XG#/B5GM/^S7=T
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MZO(SI/W1]BDWMY!<<:&\7X50K%AV<#HH8[I62>4.+Y.PWX0$6A%6FWAT@?-
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M7RF[UKU2J^Q]-1B(^O,;NK,:TY\18*$_^>#K=P9Y&:X&86T$FZ\I>0\MYWD
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MKDKL2>U)-:0QQO]__O%7+8*3@>-R '&@Q-]I0_?_YU;\:>Y_ U!+ P04
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MWYY-EZ_BZ5N8"#:7(9,(5D9?#[BP%(O8D5'>W?#5M4.90QBG5GG2]KREAHF
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MI=*:<],5C]U#PBT'NIB4Y)'+2H4R"0*EPRIA41EUS@I>RJ7Y3:EC:[6;1$<
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M720K8)OKDL$H_^J)5@/=F2#YS2*+QX,"]=MOH%>'"8JW=&^XD(J+!S_2'OS
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MUQ!?EY/9?T:9QT#/8?Q-=DV>8F7SQ@/TI;WZ'Q?AV4S(VPEQT='?=/V[.*1
MF@7LQ#IA /X)'O5:'KUXTQ_V_T H_XU&B@;?F$N@YZKEDR3IUTXS%W^2'%8\
MR/YN/ (*7"ZXZN/@C8IIG&EE_>DZ%<75O4YX49-<F*<M:@H*XS,G:D! ,BJ
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M/BB595LRI='RP"%C'# NG?=7]BX!ZZ4S^S38$;E3'ROZSNDK]EEOXU[%D^7
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MF>%N6\'CH&ERBA<56JFK'O@U*4;0C"1TK*#R#_YZ?7.34FAPJ4'(5C>![L"
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MO(QF"E8-BQ">HG$!ZVCEA5#[9[O@;'F]F+84.)"H;2HZO^,RW3 %-57]NO+
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M, @DU,6'OL:MF4ED;'T&AW?344D9]" HFT7")49->$52Q<(+6.T!U81J9^&
M]*D1?TSACU$# QU+ ?;[?G'\32VW=B/6U4[5=L1,O 6O*41*6HK;$NH($HJK
M8%S8)?^\-*I^_"NHJC'2*;=BQ^>Y "WKXMCK3YG-B+Y/&.U/&W[C*E$057'+
M[3I.,/<NL"()AX@U?#"FZV[YTF@O+8AX"/7X6#!+(?C@*,H$^4.+-,P6N37
MD2N10^#OGPP2(\[W[']?AHN:OZ[T]9IUZKOBS=E#A<E.4X/\<D-1UJ01@A+D
M?K$?.W]^KJGXT4SX"'CEVX55R$ R/GFD*BN0J\W;B%/\RQ?7?8XXVW!!?:_7
MN/HH'PU%L4\-(R1F,W4D4KDYND;K@!G^COW*Z72MN0W.=$-']M(Y<;/*]B.
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M[FC;NX?\#?N+R_3RTH> !D;$Q>VH1GE9ACBNHC4BJ7N/MU^2)@Y-;-8492Z
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M($3%S!&H):VG]1/LNX$:! RVT@1"79U4S>TL+MEH #4 ! "^_&,%( =H H
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MK:'CC=;;0":%>??VNBR*R";#/0[Z7#-^R6."5%!JTBM0T*2U4XV#N2'X_07
MEF_P-/30N-, 3)H6=<<E-$I'Q0SQW6WS]3%S'0UA;;GMUR:O.-<':PQY*>Y
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MLP^KF6'"&#\!94086&ZS[Y,)"CEX,9%'VR*/G1%]EN%)I=:\'ZKCRFO'OE(
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M]2*HJW5_LDEA#!39@D?-XX7D'DY/^*-*BFK&:6J^=>5#-_.;K__>7-=_IP]
M!5#O=AMM 22BA=RV/%XSC\R:0%C>=EU'A@8O(R[ )[4? +Q?@!"A[Q*Q>PC-
MHN@!GL\>9V4WA\OC_LNJT;A0R))>5].KW7C:2"X%46ALIV\ G(B>X^H>T<.+
MR^+3C?^HQA+4BPB;+A'90.[R<2N7R'F:5'$S!$#:K#SG?=OLTZZ/I#@U7CQM
M8[?>/<U&+IE/ 8" B<>(0[Y?4CZ@^<<ZEGO@:4W+W5UD/57;>E$?KN>D,0T
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M&)%Z*%NG"BH1W5?9=W 9//%#6+0[3@@ 8@ _Q JGKM*NX6Y4/135:9B;$DB
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MN6)W+!7LRI9--.:T5O)Q8!]<^6N!73M3%3*ZRXZ]SSA&SR@N"I>#F8-;#&/
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M$">M,2Z%&AL1I[U4#4%:_FY%-*\<4R+YY.IPU:I?J09$#X5^?]8/M8@ ]_1
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M^<T@LB2\3,-#9B[*1JV D<6%C>B6[US=J; #AE_8HIO?4MR^&FF/TGE*/R_
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M+#-AXU<6._>1G$.@[$CV9P--,Y<4JT+;91UYM</2;:DBMOST-<;=:/Y$5>0
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M$? @W+.&UO3.:/V]F,?0[X^DXG&?= LJ>E@'/Z70%O%)2K:4.RG.+X3FN[\
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M6HO>AQ@2XJGC>%LZAQW$DQD]Q^NN:'4N5<HP/**R.%[@^%L:_6:I<M%;E1?
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M2""9?$I*VFWQV&DR,H77D:O[:KTU?EY/0U[4=U=;L2)*W=PH-,TB9W>,'2^
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M'&XWY_1O+3:'H([E0@1-<A_=I)740G&G+1ZEKP@R=.S]9;0J(BI!E7+*F)W
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M=BM?)7N$N("LPS&_Q3"#Y2%!LD,]*RFPD.2PC94F++8)='@3]D[IN_)@S0]
MP@<:HQ3,!8;#$'E(; 2<E&Z/@"2F'.3MOEC%*_D.?8<KC_'^*Y72X:,  !P6
M CV>\+K!);&*"**%77]H(7,AM_]2)/!/%/!A*%R]Y"EP0V"[4$XH"'QV/!@6
M/$EK09&JD#S%1P,@$!30XY]J<*4;V&MQ+H-)5N[I!>/Z0+8**,6*N%9%F+<;
M.X,=Z[S*<"!+BB!V^E,+D<KPN4@8/J05;OQ4#+T1A=%0W:65+CL@CC9N)BH1
M(\LUE2(Q*+6(?5E5L@?G&J0MXN?"]8&3=["Q?Y%2EV5'84^5Q-#B=W8EGW:O
MVKM2BG"%;JR I)%D))Y) H1$<_)VL^H09WQML.1'1R3._ 4MZ*Y8WG!)G9JQ
M( 69(+>Q@ /KMF04/H<C&AD!!F"%H5=#_-Q#%27-[V7!K,_/],48B#_SZ!B:
MJA7<.TZ59M2Y*1MYXR[U4/BF8UVG"JYUSIN064>>^76;0U3:K$J<.]:Y#(X?
M27U=POOE'/.178(DG457P)B)5H[\GVT$9BT_4=C99"(GPHE6*/D(%4OA )R!
MDC]//C3HZ0%ZP1Y!@F0[E.:>2P+\19TMR'FQE/&M'8OK.8/&;FGOBZA]4[;<
MCVE-)/96$>\T4K.T'0WHBX3E3*7IZ*$Z2A ,"SO%++533$1>;%#:OL@GR5.#
M+88(RO:X+.?\K7L,'LUJ_? W3/#WK%@?,M88(1- ,";TFN)L68:)+/L]7#AC
M- 9/4?:-/-5$YQ4J-DSRC+@3%ZL>P=J=S3L[!%I[,Q^6J-FPL>>49E%=W:II
M903+ID=F^AV:!FF"^,4(J*6XD 8_7^/F'\-,?8D<U9<1%)6F#TK400^>#<]2
MV>G5$2BKVRU<,W4X9ZX(M4EB#.[TPRJFH[TE2XRF)E,W?3%.DJT'@XF@.+L#
M_OG=/5;FDZ0'.*OVUM@Z<Z_ID@74BQ"WMKCJ6 Z^R3?1 <\&N8LTI7N+@'>J
M1*GRP42"QV\M2S:''EONB=3R;ZP>, O?'SS6;?+G<*[2KF*083PNCA!HHV%O
M1=&0R -F;O6!VJ 4G]@QDE[F32X!V!^@A!L VY__!6HNV@":)$0P.&<5IHZ%
M"T)XII0  $(*D@C7 ?,#$CE44"@F)E7B!I3LZ1GQ]5]#17:T@&B/)CXGW[W[
M3.7=&IZ?$Y"[T3^H=$$?'K]"L(41(R M 'D0[.JJ <(5<#,,;2?XG5,)A\V@
ML ^_,2.P!^S1@6A2MY.009-,H G0T(D2A'<0FCP6=.E[]I^-I?Y%J 3%P@4/
MJ>50J^:'74I-<Z4N37/92[ZIM3.KLW5W%5KK74^4Y7\F)EBK:!>-]@^I)*38
M\7#Q,_"-#Z=B>GP$4FBI/!_OOUT<EGS0S*EG+:W1],EON,:RT$%Q0=R=X!L1
M;%3YB>SGFTZIF0P&"XOS)]YOTA-B<6JU%^R&6Z9MQX?*3C2VBGDWZV^!I]PR
MK-<O$NI]ADW&&GGR"%*BO9\H?GYZUH%2Y;=B.H+8620D^-*/L!%;#B(_%U<E
M+F1*T$D5%% ==5Y#GAF/W[TP6@4CU7GT.YVOW#W>$ JRTV]=*J1[O*WM0JJ,
MEJ+%,P<F'AH[<L]6Z,)S#?@<AEC$%ADI7O&A:W7PH,7\>?=F-4>T>?K\%VE*
M:QN):O/=0YN*%/,,[[35RKK!&D33<)HQW0F#L;#4"[DNJ90Z__4VY#=DJQ[*
M/Z$/.*^Q^9A _> >64GO/9YR5HCRIO* 8<)A&-^VS1\@.X:;^G4C]N#;&_W?
M#3A"/EG?0-UMA[E234'SC !J)@@B^(IS?[R7%=83*<*TV&E7^])]FFU*_4;_
MXGYC!6OE>[-5ZP_%7A6QK,9%*\IO-41I'U.T4:I QKATQ]E5KZJT1*TD258N
MK/=#]R,6;10+$[.26YV#@\K)ECZ#+,KTYH6%Y[AOY1XS,72IP^G.+'8ON;V*
M1N6<1&65^97"Q^(H1L3Z\S5QX<LFRNGM7F^[S9XPWQ*S'J[)%&'S62Q1Y#C/
MZOQ>L?XM$>L6DV#9QZ1#LI?&M/U:E6(_]X% E;,>A\"U/ NQ8B:P&[L?L]B7
MB1FG#!F:_R&H?>^SL!]N,?KBX'Y&H]'.[=:F+#(=)^5I'9.GCD]17?:?#VZ*
M%Y64\J6@8N72Z(30@'.ATJ(3A&WS:C#OVX1(O/5I!&/6#T8^ EO+<P\KQB<[
M+0]K%EZQSRYR&[:?)US+WELI7;/E&4)B@B;9WXS#QM$=?NJGOH:-$M4. YU3
M&+.3M8/O6=*(K[=,=F=8APD#L^OOJ*6AB5_I3Q(ZGK^^B ^<K .)I6C?V74I
M#J0.N?P#//0>[;R^ZW16]0O6U$/'K)ENEC ;['.RV9H0[IC9;OVDSJAI47^_
ME@$JGO/@2^9CO637M:J]:7Y^[AQ)U^$$Y<3U(P/>'+PG?8[O9>!*F=[3Q2XG
M3:E>N;#%^PL?XHW1$4>/[UT$F]D<N":9T67"/KG4CGV\__IC;\NGQ:KXP,!1
MC=A'[K,NLQL-^=).G#!*RHSN^0&6@>]?0A@VQJP?$D6)DKZF-$\Z)]Z2S^^K
MTZZ!;LDQ;DG%\"3/V()@;Z\O)UED_U<-*>(VQ%AI.)C5TN+BHXGCYEG(G(NR
M;KFI8WWI"#Z_ 5MDR,3Q F&"AW#CLK'R>MT[U#3NEJ)]MCH:#$ZGBV2-A"H9
M7^6)>WK.[5:,#7?.UE^+!Z<VLDCS!GJMC_.]/BCQ[9M3(\M,J6=VKZ,>VN0&
M_! B_O=(CJA%)V8)1@.+2;CQ,=GTE$/+AU[TYL$W0S -^\OSI1EO'?ZY$^D9
M:/BT*-,?OOJJ,C63V%TBZRPC W-9+O"HJK_+^KKK1:CJ:NW<Q(\)S:(#5T^&
M@2U,Z:I'ON)%@N&I4])&BNB1@X//=.\@Z=2B=>Z\"+T_9F2,[[,I)BK*\;Z5
M]@L&U%!UVTB[Q8EH6^C*I:)W;TA6QORA7H7[J*=UUX?L6==?3KK2RJ-LPOWB
M-[/VF>*E^64ILJ1+AAU]%F!CNCWPM:6#PG:/,IGA,18RG6\$+CJ9!HA#_)W\
M5MW'%V46+9H>JO>A1_[!<1Y'%C4U[]?ZA;Y@C+DT:^,C_2*5-M+J^,)44IKK
M_;9($@>FZ:34%2PKUJRT(OU9;AR%O%M\.'T85"#?$-IG[J,Y)9[[D&K;6B23
M"WHXR%9;(R[IE9_Y"J6CE'&'W6:J+B 9HT;U"6S"^YH?M9NW]: 6EO.-B9=1
M\<'/Y=/K).:#$@]8<<.;^JEUKX" !D=T)"6F?MOZ256 \S"SPIRQFM3D2-I'
MFW".'.]=!P.?N-K=?OUW3QR,J\4/ZRC5NGS4SCM GS8.R@_MF3)+5_Q[+B]_
M!W:%B+R6?"J ^/'-+;V);0%TJQA"&U!683GSF,OIF?EM$__@F6)_:VV4O/W[
MD)5&JL#>AQ.[O^BN?O]0)JGR^+5I-NABO\WI8?_(Y]0G'^';D' $"2W4(K/3
M83)J3,QU1BGEA8MYS_[3_%A;T]''AN=@UG*WJH=OG2%6]?*C!M;T?&INQ?W2
MM>WZP:<4;T6K)3_]!Q'CL0CGM!6CBQZG75EZUV6/TNA'=?%H,<V@9<=*80O2
M(K2W^)TW_O^(N3#=CS^MEQ+C(++X[@)?Z)Q[<1["*]JL1E_S=1+J[I3MY=PH
MKQSG$="1_$"X=DJ5"C^"J9*TU93IZ;B]J*M270@RLS?5V1UU*=.!@R/%$"J>
M!^QI U3-&JUCH!AKLYK?:P6S:QTOV>(YM:VK"_+*TD\X$Q=ORIC+;)/4=,DD
M]N7?SF2]9"-%B:7&%:LJZ(1/ :(>RA>>'K]ICC7B7O0U1:XOO_\:<"0;E4NO
MF"W:)2IJH@NSQN!C6QEW1;_<JPNR9X+7G\\*YFAAI3M_71O\FSKQ?19"[-%V
MZ;O 8A<%B$D7+A?AC'6P&8DF^9$#?A;OX\XKE8D-RM_8$UNW>.%>M-5)'E&(
M&2N:3B-A2<L_R@+O//M?ZD'^8PJ9 8+E/A<2\**"$Z5S6KF;*D895!YD2NGI
MK)A@.DZ0@1J35#@9E+$C#OH7ZY6P$+@2HQ+CJR^O 2'$7]0G42G58+08I'F%
M[@,#N%@$A9J@X<YV"=HX9X"(C#RR4'X#.PE=Q,5I$)!:J8>\0\G/X+Q+6GMP
M..\I)TCE_W"1D2BFKDGL$PUWRTGJV'ZW^VY+>P):2?*#6$24*6@7K)/2$5,O
MO:8E8G, <"Q):<GA!#R4%>CIP4*,_@!./U#1O[KJ';]+_+0/Z_4,W&-@?2V!
MR\%Z$]!$$P(\6N&$N[0T<L ,/5H"B$4BY!6ZU7$ 4%#18&J4T0LECZQ&HL&\
M<X:2-V;4R9'DY,E6< %P,JG[8#<".$_5-@T"! 'R&8,M.H"@$$44<3$)'7-@
MDDD"*VOH&6=\."8CBUN.K"JDO+(D*CZ3$X3<XVR\9=9AD!6[^+OY<F&;SH!@
M*I6Q0I["A"0&EK@B;GR8 ?.)"\ 8Q,ECE./8L6C9#TO$RR.O?N5\Z,$6#Z+(
M<(P=D:OBQ*???\ 0+)&L (*8PK$%1E1H J9=%]@H1_;+1Z;2T8+V>;J]B*.I
MA*KY;@*P,\'3*4.)UX?"XKNQ?<3K!B88+/&'*2[ ZUZ,4>NE^#+M97#7?$%,
M6_%$JO9+@>WU35_6RORJ,^R6\./L:D@U7@U$99-V3%QHY9.MW\9./MY98=T@
M#JYO=>%_M+K!GTPIN"[C\IE>$GY9]P=X=->7@Y^7?7=:1>.1Y-&+VOM[,EZ5
M6N"Z1NNWTSQYL[O?:3-U9H/3-;U,]Y:,R>10 ;8 R6,.%M;E*F8]'3"WYOBD
M'OVS/,0DYT]^H0_E2[$)I'NR<+!2M2T=@5CQ[[XDIP(;A;=YE%GRT'M/9!0Z
M5%-Z9[Y--N;XWDW-N7V?V$$N@#2S$'-BY8$:Y_WD$?X2K=,>>%-@!W7K;HK?
MVD9QY9J_B43Z[,Y_RWS]F?]_4$L#!!0    ( .X]?%17S>ILJ7T  ):0   3
M    :6UG,34X,C$U-3$X7S$X+FIP9^R[95A<P;8MNM F:""X!Y?@$B!H$MP]
MN&OC[I;@%B! :-S=:5R"6_ &DL:"6R"-$_1F[WWTG7?NV??(_?&^5_W-/VNM
M7EVCJN:<8TH_?GO\ 3Q5D)&7 9"0 0#ISP=X7 +> !CHZ"!T- P0"/3D"08F
M-B$.-A86-AG!,SQ"*G(::BIR2DI:!DYF6KH7])24+"]97W#S\//STS +BPGQ
MBG+R\?/^Y25(3YX\P<;")L7!(>5]3OF<]_]X/'X!\#&0_%$]49#H &1\)!1\
MI,<!@.;//-&0_CJ ?QA(R"BH:.@@C">86'\>@#X%D)%04)!14=#04%'_W W\
M<Q] Q4<C>,XCA?Y,W0Q$YTK(&YJ4CT'_NKZ72&,&P<!G[A;V!).8A)2,G)&)
MF865C5] \*60L,B;M](RLG+R"II:VCJZ[_3T+2RMK&UL[>S=/3R]O'U\_=Y_
M"(^(C(J.24[YE)J6_CD#4E!85%Q26E9>T=#8!&UN:6UK[^L?&!P:'AD=FYV#
MS2\L?OL.7]_8W-K>V=W;/S@Y/3N_N+RZ_GWS%UQ(  K2/X[_5USX?W AHZ*B
MH(+^@@L)V?LO#^"CHCWG02>04@>9N3ZCXPW%('R=E%_?^X2>3P-!9.XV@TG,
MP+_.>/(7:']%]O<!"_M/(?LG8/^,"PY@HR#]V3P4?$ "N+IA*0C!_/_E?R.#
MI'G(,3PR+$!!G'H,P%)(:/[O7F0$.(@(&XIX1!-<RGA5H39VW<_G/"U8&EKU
ML$V"J<KJ:I*JI2WTKS,5.]L@JQ3AOG2C+J^T94Z&/C3P4M1A9E'CZ7N9[T;/
MJFM7US[O#&4.[1^Z"RLI'Z[=GSVH+I%UB3CR&\ZQ>Q<P,E^0 1GO.*'.L"HK
M#A_L*^X_UY043-OI(DHINXY4GBU*>-41+IMRG*@?<3NHKY)-QS@QHN.Y7 C/
M_MPVTR9M:=?-,'MAIZ23SG:*MRY*#N-(@.6\5Q:+G-%;U)](S5X6;%2JY!_&
M:-N:#U0<@!NG"D4<;VMH\+64(V=_=J>WCBD18']CRO5A]-*\H_/K24QQR1]$
M\S7D6(JIOB#$.5,L]X[,!.&GUB+N_WC%_NZ+_\5=W.(0M>L8TA5A7'8=)F]+
M($/:JOL9!%U<3)O*IW+6/Y%(.5U=FF0,'0;1MVS*;0QIE>.JVG1=_BK^Z97F
M]W.1FKUG-D=H@<+V?239Z%2UU<M83T>- Y\[L:+JKT\%%W)TX:0WF .(P(NA
MQ@T<';MTJ_'OOHX/B$V!TA\X*F/#\JUSOY@35@^>?&M7Z)6_VGD/R:'3]M45
M2'%;G+,$O_-).]V5A3&WSS$T=31J*(A[\5!'U%R;Z*8;3=/"F./IDU__J/!8
MCWI(U;@RFH,&XNDD#/U0FG[=BQ#:\U_@"B]>H$,0YWC8TD(T7W0,# ,X1[/O
M;1=<R])?\F[[>\Y[O0R0K9TJ-+'C?D/HU-*"S,R15<: *R%B0G38N">HT]A+
MZ,;?@H6/EX,$NF-//?$[\ :O;_6<'CD7=2RU/_N808LLD:USXA59MI_6K&ET
MZ+XFLZA0($P"4/L>2L4[*&L?"6LVM#CROW)^>@V9DX1^S4C>GVY2*QMU=M]C
MA035EAT$$<1J0)NC?UEJZ+Q8EU])@-H8MH0W@4>_RED;6*MM^Z)0\6G=83T"
M=-:Y#X?!>S(9\WX)/?1^_(_ &_2KP2"VN>.C:B?^3"FQ<<<$ ;>!!YDF*!?A
M@8U>ZYR'D8!349/:(NZO$+%P7<34G:JH;L6A6_PHRCUD28P0=_/NJD*_4\+Z
MQ/,GQ+B#.->57ZI&P^-'B$B8WZRP\$%%P('3Q%+Q4<WBG.XU1?,#3W-F7R.8
M"X5=TDL>W1<ORT(BWL;@>ERGI:-!I/MC\Z7W5V)6_%.MG(P_<ZVX)I#S^(5]
MX+U80SYWA-V['(A YTMT5ZG[Z%.JUSPO@%7&<7[K-9&=X=J6:&TF.6_?&$>>
MWGECMZ9S5^5]KB[-M_ _;;B>GA=-B&0. AKSP5O/O!\!P\S?NA_WO(,1B;];
M++854ZVH=[J2CVF:X,KHKEV8.ZV'B<"P:_$2O'.-G]<9YWJ^M[AM2H<@I5TX
M$=N PE%C_YO9=FC6@\#,M81*0\>TT\.,,T4*O65#W$)5$"&^2=?81+_T]E'5
M>##:@=<HP].#6JK..$6VVWG!#/Q2EM0[YK)X/H6%ESRW8I7UB;G;AG$DS0L1
M2P/L;CBWRVF?O+^I*IPK)J++WH?QC^O%H ?."A\\M%6F^*@J9<J#GSN2IU!_
M6?<%+:1.KPC7WR3&>*QP+F#%IJ4X')!Y<8*G I3HYT65%J<MHW[HI=#G0/?:
M!2/2R-\2Z_H[*;U!RK*)*9<(W\PTR#FOPQ\'I6R'SD8U97C2L])/7BP5+Y88
MG(Q)JH,6H% )B0>">(F?"^6NS!][Z,^K.X*1BINC&:,R=WP_9-YWL3G*]I'H
MDH=W;1>?A,D5/OG(UC:3V) 4:3G[9M/6$E:=-OH]V"L)E[S=/Y?2[NF$6)M=
MP%[HR#?7W&HIJW6R'JA%#ZPVY^!=]XX?YI[U[,\:E"<<YJ_:LPN9\IL<,4;I
MQXJ[(\Y,YB[\8Z%<#-^>Y%Z C9I[2AC2TE_>>%:1D*3(1MCL8B4TI:^BS]5P
M'EF%,42;!W[-"SPP4NR[<C.&#F4&78[3^3I3^PQ#!6?8"'3;1E:-Z.Z$FF)F
MO@_#!17P: 1]:1269HO])?#?]0>7]E(VO!;-H"/],NRWJ K2KXT(;GA)T[7C
MFWUU _-3#:\QG:?K@G'IK^<9U>-)R?+6?6* B"S/SMGU-8J$Q;#\,=#_MZ6\
MPAY_7U][_JZ0U9E"3K8&I+!^L6)A%+'63_P(P!%VC0?*](8J)V%E@L>8O($G
MDM216D<>E:_8ES);GW\7&UUAM\P>ZKSVR=2?<[Q[8P\?K*E9\ ,;2_NBFOJJ
M3N*',%!G$,G<FBR>.^,.UP3WV948CY131@SFJUESQ.7!W7-\-D*%2N; %K-'
M'LKBXVHY-_!OLJX2-T.H9]<>90)<6'OM30^!1Q_<%%=ZV50709#=75C FPUE
MZX/^MQWO%9OKWPT.G$KO=,B-=YB2_2'1*?KZC@_0HGWR3SE,3X7JT38[(S$Y
MGW*ZZ5ZKVF-XV+6>ME;ZD4_;MGO6Y#*&=Q6Y&LAA>*B\M(%="'!FE^KOZ\C;
MV)"D(Q-HNZGPNODM<OPP>7H CTN'!'5'0<+8C/JA+N2K4JDWJ<*:YZ5PGTB]
MMI-3NW1B"8LY?;ALE)Q4LD85^F9BNQ@:&HOTJR(/;[AT6K% 4XO+[T2'#;F$
M#<$6PY/S0HU9!ZAM8<PEC0"]*UW\@%ED$'L.S!/OZ=H!>79)R,*8J4_>&1,9
M/L'+5YO74:BNO^378X_L:? /](FK@W$++VTMLCG-8\?96Y/J(Y5.(*C[O:N'
M@9,U/O1M+3Z,1C,BJ5871$3Q\<W95E3954&&^&%$;BJOKFI\?,(V^@<A1^%W
M,8YY]8JWQMQ> 6.;:]B%9U4X-$/D7\6)3U#AO9IEWP=:B)<T*9*UT'D2M@1U
M$7DUVOY+FIUS_)D<U*"((1JVEXX_>554-]7L@RAG/3.2#6X9TM[^$%3(\J.D
M!D<N#L>=C_!GI S4LW:UA<UO"H;\Y!2WR+IY;S24 BY_9Y< R2G@.D:R)HCZ
M$.!%2DBP+S6<5.PTD"["E.U=PIG)T7 ?[QKU,9728U^OWH>BOTXI>=@4I1!=
M<^<E:I" 09\Q"WEJ=GCU>3&4_7/Q9S0EUK>!77[>1 */0*('#N^ L='RR$?H
MTG=D.G.EBB?T@$U]7H9:,;.OM$32[(QA=<^ "8[AGJY^^ZI<VF4#1HG\<ZM4
MPW.C#S;,4#[5DYK<C1$!+ F\Y0GJ8D>\C.:-[REF8KRDN*UYL$/;JA44'2/W
MUTTP;='F#'&?LRM*E_'KI])V:DC2A/]C@OP*[?5P'IG F,EUP0[6N]V64"/K
MS/%8YMHN#Y$\K]GC#\'!XT(U*#I:*7WMW-:64B\GQ^=]2T+V'3V7]B[DJJ 4
M'IJ\V^1\N9-YT$7/>.D:_<F%9X2\A+\3F8F2L'5F?,+&C$1VP"WT#IF_,=DX
M^/H77U["LZ97IYQ?YBRIJR"56H*DG3=&)E,%OIXX0IA/OUIT^&L&-T,S/1,V
M#GJ#OFZYY/I*57'13R .,/*L6IL^\Q\FF% =YF<."II/TCO%B_X*>3Y,?ZCP
M16) _+F(*#<_=T912G)VWY5 Z7TA,*=SW6S.0I$0C+DEW5U><YBNJW-+'\-P
M&C;R*FG"UD>L)&)A5[;;:%9?SBM9R(K_'18$%#5G$';L%=5/B:N[<YBHW]T^
M"?FI932DPK<(=8-K.;0[1\OTM7DO#4,E^5MU^OM]/D384-OT4.TUH#0F:C9
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M3>9*14DM6JXPFRZ/OWET;<V2=WP$#H[1HLGFQL$*4&E^^#=<TVL\:7%N$_Q
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MZ7\$<.XXUH>?Z=LEC7O#5HR"+C4"W58DL'75"=5[":0)V&1"V"KB ) DZSF
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M&75R3O5L]-0^PZ<PM$9(Z\:SV(-%I=V!VY1K<;[=$ =X"@3&AAN0I0K75-N
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M!.4'Y;.SB'*XC/-J@Q?NB;Z,SUIEZU-**K&Y!1P20#L]_1O5$BY;"-F'_R?
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MZS2[+VKHB,6.7#N U?8%,*/1'.9>A1/<%+$L]F#)C@J!6M%04,M\,)GW\10
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M*(QL9*W;W7S$VT2L/V_DD024JZ+;0=(P03Y5JKVNU5NGJ3;&N'T+5Y300](
ML&==(8FQ7+$S[>7=UMP6<9]="5F.%S*R4R<4](H733G&_3]^4BY;Q5BLAFH>
M@P#6FI=E9F2+J'\I4U),39^GL,>J52\_,L_A$>C"*NBWH$/;#6ICM.GM:T;:
M7_!"\P!>*=H/RZ/XBP:8C V-MFH0B*WLJHYOH"%&>-@20Z><M-^KZ_23S%=4
MS>V0PID/!"^WRVVN]V V'F_HPC\I1GR*_I#[ZT-5O8)Z6GKK)O9OX"@NB%RD
M=D)O*Q;D>&BO_(.Q\^D>QUA!"&JQ4U,&S'P^,1/JH!4QU\.GIVF=(D0I1\$
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M2?#_T<,__V_Z'X8BM[/_#U!+ P04    " #N/7Q4RQ+9,%P/ 0"<1 $ $P
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M#NRJEF<Y!A]S-,W-=&D-L4CL@EUC#QI7.9  ;M^[OQZF[)$C@<\9"-(47D0
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M'Z167)PSFED^NE W3!1361.DD#S\+5DJDC?2J=T2_4?7"T; 9I;'2758$.P
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MC9F/M35!W8.0_& \0K;!QQTP-<(W9VH5_;"5P<6++[4_*G(YQ1(<,95'JOO
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M.L26YQL='<.0#+6JJIHXT>J.MSA0J0?T1A^3(ED>?-GS5,U%<W@:Y[N.!&;
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M6GN%;AZPW:Y>3TS\?2)M/3.TNJ0OMSY3QY(VUE->^L)I5O&T![3%-=[J6_4
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M]U_Y4\V2QU2O(::>=AA]H/#6,?R7TN0EV]^@1B"GNF]/^H6+7TE]L6-NX7@
MIB%DXW"2UG2(@J^MAWDLL3/)F<:ES;1FOG7C>LW>+D+=2=W="4(3R%L968(W
MQJMJ?AOF5:IAAN#[:=/->5I@V'QG? Y4Q_'&.K.M3AR2P>[<7RRH'[?RL5F+
M?&WL_465_&T/L[J#=Z;U6;Q,UTDW&8*6^/T28'>1A6D@V1"Q;S%>(Q"02'>R
MZHZXSC*V=L8] ^&6%^(-(LU+N?D=KW#@_N)\=[S2]0' E\[66X#=1]B9J8]F
M.N0 D9^C%"?7!?WR'$98E\-'N2L3F0N>:4X%"-D_KYCP>S6GVTD]RDQ3.W['
M5K318G307@4J,N;DQB'6HGXKNQK0>KZZ,UW;PS1H&KGH09L+'/S<07U94^6Y
M C9G^G(@.G6\_B35-^U9[\)C=WWL#01:'I!];9<B&A59'"34)$SP;U]I[5,V
M'&W990S/_.I3[8WA]H5O)\W2Q,0'DFYPS%_<L_,.UJ=ZC/I?B<<!Z2$1ZP<@
M<J]T.6W4::P.YJ<>TO_TYG0\0.@0?>?7+@E/RX ,I 713$DW; 9"="6_8AIZ
MXH^QUP%KP"D7N%:B]"-GFFD\RT*L!8W":3UB7/8917@%FIN&5<)QRA_!M^,#
M0 K7]>-9>#_[2K0@[#B3R(--Y_ASV.;$WD&6O#<-MGC3R9 T,_^2Z1@R*.O*
MI//&+Q.A&@I>,X]P?A5%6[\[JJ0]>!68"VK,RTNH#>2<K;9O"(^U?8O\_G:C
M-JOA\QMHJ0T-.MW':6IAB_K1J=IDDQ1FF; ^!X?5,&!P_,<D583%Q(%ZYH"Z
MQ\]K"83^E\E@+F;:>&(\=_7KS]LJ YLCEBF<6YH9_.WGI<'+W_!64,Z+B&$?
MXZP!AQQR_I=SRL@)'DW+-U>=*P3=PTW5['8J+IH;E B#WII96R0]4?X_]+;\
MR.OE/Y='#3!QX=2[C$+!\@5;G-ON=<[M] D$0WFYS[$6]15%&E>:#52AK@88
M=Y()U5&\^/7&A"+X+WMK!;*>^[%-U,PC:II"R_)K,(M[^$?&'+R-6S1_)FEG
M5"RO"68E"N7Y"!',UIM ;Z;RT_/SAK-U0(*^]<D?L)W;W)!U)U*Z;V%;FDJY
M>UI4NDRV(W/NO5Y QS%RD&V9SULX54.<4R=:%#,97MTBV73L58'N+\4<,Y!%
M\4#B13+_^[ZBQ'[138@BD\:NSM0Y!>8B:Y[3(/I!MBRM\8^D68+5RPMG+;UF
M+E:BE^Q.*%E8Q<*$Q_02QZ811N8GDJXDR]3?G9:P6GH)?LW(%Z=N:QP;GZ#>
M_]8O%ME=9P/ZN?TXH22_V6/,D-?X:1Y)Q]3QSHMI7&Z'H5!U8M',3"\@T76>
M] <05(#8 $EVC<(":?-]R=3HJGA#WF^99T?\4\ &8=M H?M5@M-@I ?E&H77
MBBCE+DPQ.7\0J<2F\N?VEZ!"EKBTU<>."L$R()>0KLUTVS\N0>[A"Q*$\Q2\
MOH?^!61[/ #MBT084C-GM?PZ&B<KZ'XF%.H4 2LM04KG;*-'F>OBQ'[X#T",
MDMP# #&%JU=\A/^G\+_47^"[ELQPS^->7-!JQ*)H2VH0/PU,^?F2;H+-;C@A
MKQ(VREQ$IN")<RWZ=D\NE/BV'I&J\5NJ)80EKS:=KYLQP76$$\-L5] OO):/
MD"0L_AO#/I404Z@^H95:/9]175R:\C,5W[+1PE2&5"59%F-95GEJ'-:53M31
M_HX,Q8/ZPAH,=_6@5;50)DNUO15$/%LK&4US]+V2(,?P)3]7BM_-KT6305Z_
MFC5^U47S$1N;T[;NA3GH9#@LW4R"]3<[R]-EK'$][0F:577C%XB5\<J+])W3
M5NVY$:38<*RAVEH+6;6\K?XSFW3(SUIM\Z[MH]W;T9U[R4%*;QLG#R#G"-Z.
M%B)IK%0A2X$YQJN'%JPSB(&9NE#J\6;1Q@AP"M/S[]FGJJ^8EB=XG5;YG>,R
M4^F%IT*31-,I&X,58\AT1OK9WRK.8!*%W]Q-(!COXW<W6<XG;!Z7$&COB25%
M2\U!B#;_:76M;]W37.VK+>(23%GL$ND%Q$O398^=&@PF_"./-DD8C<'D92>/
MJG%;O[C8V;E-(TZ @YF$;*^3*6"$F:?G;/?G>I\[;[^6\3R'"$K%V1B6K:8Y
MZQ8DYST HRVC]W<4R_J?EX:IIF#=/$)N\:2YZV3!=4@MNCX_2##X87#IJ"2I
MW&/4(CV6<PLU27S-D4S%?Y75QC_*F#^O8&$_ $;4 G6GZD96D:3D*$1;OM;9
M5Q40BUO>5'/:]$W+[-/!=[F,!^8V9=+KFA!A/I"_JS-/UR4KO4*&5MQZ5+3B
M O_(,\'#SJEISNIMGNZ6_J1AK15#8E)214Z4=C+#Q^$QLWL:)R^5Y9,E[1R=
MYP83"6?M^(_:F(Q5?C _C\[4M,*G"T<:YI!5EU3O *'*5421!AZR#,):D"5X
MM;DE%%\UEDJ.@YV>WH'R1,DQ6'6[E2)*?H*5-;NET5%@4/*5:DXX@#FWA!G,
MC?##A11%PK'9U 2LI#QWW_T ^'SX.Q =VJPF-\E]Q2Q<Y")#'V,>SQWQZEFK
MVT9+Z1GD245MO;>[:5UR_"@KV@_*NXT6YDJ.!.GAV98H)MZT'#E6D5N#'VWW
M58\/<:SICV>J=M1^.AL\9-;^]F8R[D(><GV>";]/$>U_G*9%'^'X8I7^8F7!
MXK'_AL=+&,3L$6A#3GC::EW:;@AMVPYW5?ZVI4J__[A*>H:U;7/*__;"\N+#
M+9SMKG-6?>^/QY:TX[*W"&D7JM.XY5CG6CDB*"YM6N(!0 D->0#$KQX +CA/
MR-'.:^.P!V#H*Y2U?B'7(NR J;U'/8U)CCVNKD3T&Z)4NAQ._ IDJREAK]2V
M>M?(W@H[C%(6C;$;7_.Y;5/5+UE)K<?11L;H7PZMR>RC1NB/&D;$5ERQX$%G
MHU^@L_VY'[6H<Q9'_9%G3)#9HI=B18.%I]^L8&%LBS*4ZY";C^G.E@9)OMVK
M-QI;EQ'9"0U9PGI^9;TWOZW]3GD.)Y")2XCA@EE1# U8RDUVL2??@5,;XY+J
MJ;,<9(X34R/2_^9=',D;#_3_2D('88R]"6G9[__9/Q.-[[](J9D]=V4@U50W
ML931K\_R/K1)=?AVG"/RSH6<T6S,I:NULEE''6_FK6&=H=+!V"HU<:^1.-G+
M."O7%PET>4NC!#IE<<DT@FX%:)7ONF('=+'[$$:1\]Z (-H&N_H8T^>D'J4V
M%G491($/@#I!/_73EP'8F!BN@I\[#9!W4N*L";T(FN:J[-Q4^\AN*H,0[B3M
MYK=@MA?Q+DTEI)XV:)]NA2A_ ]N!L_@(@SY2C=5)LA7ED3*+JO4MGV!2I<_7
MV&D#=@.XAMT&TW-$'(>=85B!PES+J4D-XR[?#>N-HK@3W1#'7M!3A+A\ #3^
MNFR_^)=E^[K=S/'ZX_]8Q6?;@?IFC&BU;<;;TZ^A0IB.GL];BQ)G3'E_-6YM
M=$L=MO,P=FC-TG0\?K(C;_ ,%/>V2Z;6#C\R*T,,[$'XN5D3LF7_9-@3EQ(5
M+_GS\![7EB7B%L9+V$I'NV%K=#\3+_\:6I(J"\B("=:,/1JDOGZ;-9UZ)=\C
MRC@A['9QTUT=_5O&39(B*3!R2*1EM][;P[6(;8]UL(KZ\*T: @?4SFOL&7^-
M%1MUW3/\*KKK%_2D/XP67X:6*#F#"H=@UKNXUQ6=\-(BH.&V@,8)A C'3G>7
M;6R>3'3F;ACX,O(1 LUSF2IQ;5)HG9ABYC9M74<(-@GRW4*,A5:S86^WV374
MSVUP4P\XQW:W<$Q5NH"E#MLOD_A2/LE=V.42Y8LH06J\6*O,+N9?'1ZPKH=W
MXL2(VSR%9/BHEPRO,,WJ<'N:RGSX$N__0DE5 ? 6"Q*E>P/1Y4G[1?-L38@&
M72YSI.Y.HJP=Y$I6;LU$$5]:A?G['/+\"/+Y7&F?J(OWD.PC\0=$-[^:JF*K
ME/3]O0I9O-+DWY55FP[;4/XL-%&Q8_W4LIW75@74,MC .!-%VLVXE2BIYX\@
M73,!AQE&>2] "$M"+RJTE4 Z5S?_1[%.,GNG,?79_NQ4DP[3<_.)#(88R4H.
M*I9<P#<",+ZBD44QFR#(^RJZ&S.F?B_1X63=L2&S&8[DD\/W5@CMU[@-Y>DA
MS4>Z6C=S<9V#M#/J%JLWN:DLE#"I4::#.=T&5>>I 'X0%HITCK[V#N&TO^
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M$?9,G[1CBLB<E2F*A4)6O$FM8"M,6A_-17837<F=6EH38#MP]*3]BF'NO>[
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M'<M. X>H7QW]HYUC+__Y14G_"A,JA=('"ZIK=ZE9!T*H>[X2A7:O$IK^]H:
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M!0.PM==$9%Z:ZG3I)LQ?:1(3#[8[N*10#?($%T9&9M9 ( \J<S&!"(#F=B6
M_-^KL&^ZX0$F'OW#2G\OSQ6="5SK?P#TUA^ L6'?)UXD)Q@O9CM&\YGT%_3R
M^A,-.)0=L+[/\T/DF8OZ59KX"A24V'CS=U3#%%B\FEPX'$08?IZ5E>SYH3\
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MJ-TU]>LC54&FQZN?**9JN,<_$,5GVBIU[AL=7QKIH[:U*9YD0:3*^5PT,8L
M9Z*'BH,!;.;E>Q[5IH 84HUF1?Z$@TVH,LAB[]U=]H^UMB?<)PATOK4LDX)C
M;%- [7US*5@C7"6#<4HF3,KN:PASX%WWA/C48EDWJRNC."\]$14F,W,&/!^R
M72;.2?FI-[&V##55[/H\R( +CA/4MF'YXC*Z'1S,=HPL=HM9FYR5R+EG+"ZX
MK.5KYQ'6:8H7HQB9#G@D"KO,#"7B2'U%&__L9)G\N7T!@9F77CG&8RO2_4*S
MI2 )9.D3G)B(9U)"-@=C>9LZVAQY8DBQSX?:;GRR'F=KGSZ.=>4:8IK98VGN
MF@^\M197W."]S_W=$C5(CGYB67J?#=+6(48!:LI7=S35IQP<1 M]%CPPX^0\
M8M'PTEY7/Z7)Z'2CK5);DT9PB\VS&LK<T&-^[Y@!NU@_[B&3X>4JA>=TN*W(
M6,:!Y+S?/ [72T0^F]MQ@5(.PCW5\?A /*2.0VLC'^.79J_,CV;1LE"^M:XH
MR;#?VJ&Z"KT^,H$)V8E;96U/47!9U.,S"#M'-OW>7E7=UK'(_]EJ(;I6W-S:
M0<VT:NNY,\$:S$^SP";@]SA_<E?KU3&&,P/&*?L]LK7K>E".$I3TG=[C"]9V
M!\$,K_J.P'NO%I^/&YK]5@2"O\@^Q4<Z0-(R+<#>R, HI84ZCR<9V>U3G1'Y
MF-'/HUADV7Q@J2AJFZ?WDS(Y81?IFLJ+GFX7& >]&BZE]*D%RT%7>!@B[)SD
M,<,'C5(A(JF[+,M%E1SG2<'/YMN5F'SE SG.=.^37HS[FO7LGTEVH_;4B2AG
MV#0[T=8G00QXO;G@SLMC&&P<*X\",;E.-JD4FT7TXVO5"$_2"_I\>Q"?^+>F
M^2]S5KG"Y])4Y.?VT7*<9/6&P*]R6/>M/Q98\RZ^0-IS1L;)QVEXPZ#1L#[P
MHN8K9<VZ>KR?],YIT^UJ26S.>I9M/4\_+61[*5@@&>L/(3%"S\@ Q9XI+GJ3
M 1^?1*KF"V992PF"&#$0M[;B(IOYBF[IG\#M/0=UTSJ.V\C8 SJXBZ=T]8AO
M  @RX#,-Z^7>W Z)K]MC&(ATX8S7"T0HIOD&P*[P*UQI& 4&=OURI2 P,CV6
M5&AU<7\_Z973EKI=^8OMPPV?9J]&4 X;0W4I6_U1Q\N1P,K9385X#R.P<Y"N
M&#P-3#Q%M'0+CR"/XV$BC\8DV$5A"?/N7E\_P>8/SBD&J\2JF:LTQ$Y<#2-9
M1-!4T^ZB2'ZM4('^GYE7T&3.=.Y:7J"] 2S^K;'AD ;Z;XVQNF=_'OTP6Q _
M]SHGKI!WYB %0)F?EP4=5NA8L+*.NB'&\K*W-3\B- YP5"7",GC*:AXB[B5Y
MK1?;Z2YFA+5$I H!Q\,]A)TD^Q*D*5M&"*\L2TM3DQ#L+2$ 0-:OA$"'=QH'
M0K6J%"2!I='W++VW5ZQ59B[Z:WJQOKO>;)5?JTV]ZC37^BG@3MG-R>>^P7\@
M"0-D;$Q;;TMD!W'F*@3^P '\ )$]RZ@;ZD9Q&D].S2^QT9B?0_MN!/G2O8?.
MIP/\'"()TP#(SM4%.$HO^.*'[T>U2LLXT84!&#\,L:[W>QC-QNO-8(T#J#MQ
M^+PH!\R4"?L% /+03(-LF%7BI-OQZ(=BHFH%:5##64B-TW1K:?1C=R)1,T69
MJ)@F1LG-?+B.VE!VW @1^]#%64A/A'P0(]/DF$C&?-5\;2-7DN*>N8_::>\5
MAL_ RL9S7^I%">H!%O!K-Q9 03X9@Z\=0KTYK\X.A"8KBM 8P9LQ@GB\"!H6
M+2U!*C >2D505&8024%$F;@7I7_C1G.G4CPV_DV9"/"SQ^>2ROQO_ A+_'^?
M_.O&NS\#6D!]=G>N#+G-9)7'C\81+A7?L%HKZD!-I$?UE^UNA+*4-&[8@:=H
MA_!J54"#:C'!?D.;6*U T U6(Y()^RD:)?D!@2'6R%IWT:#SYX51[:6'"_RH
MFM664HK$+L_4W]'X-O:">#^[MYT9ZKT:]YAQ84SX.6PFW&\&L3X"E>3#/L2.
MO Z,C75)D=12UI!,;D -CGE$B_Z@T6.#CYC/R%LP@7F=?,>%2 9KO<X/?FJW
M[Y<N-;]*OJFW3,T/,H.D#5VPCO8V_"#="==#XQIL!YAK %7FZ5-.#P?)=TDB
M#)%BLI6[>FS(GJGED,T4S>1'$?'?142EK*R.N/!>'MBON=U6:.<TNUEUU290
M*& LL:*UB#%13"QQ+2<<X5R7^\#UT[I';%_:&,I]@=DWUL/SFFP*O]G!)8N,
MAYK5'LKA2]M-@)RI6.!7WL ==4X4_!.R<U*_BY(V\%B!"::G&YXGC<'PR'*A
M=-#3/.I>[K_S+,S_QK.8?Q:H:JKCF/E>@GX;:&S7%9-V7;'1] 8(UKV$;AI\
M?B;>I:DJ&F2_P&AV<Y=&1GR/J: 5;/;/#HF&?>8ZGPHZG.Y]MM9I^A\[&EK2
M:@;H]D;<;+"Y#%,>V9(<L&YP*K_:^DUYY9CG7""OB:G2"HO!*65J'.:R8<ZZ
M-"6/WJ_VNF0BT]=!#'M;4E_*\Z@-HH,X!QRO(2K>5",K'87;'PJC#+57!RXI
M"D!Y40LMY2Q;!0FV18.NQ1:N[B$A_M62OGE1.LU$\^V@2H#F?:[*+$/*#:2C
M.R(F3R^H>W)[INZV6E'5M5&>ZOE[[:_O][;%$>PKG,PA47LDBO($CE$6VVT<
MMJ#D5SRZ^O2@$"?S'*\KN:_$Q:,<V<3;.IL>QK9%RS*FKFB)'^)SLP^%*IF2
MMNHLOC347GQYZ4BEL?'0;O4C2AYZ54[GCMFK:_43D0"V?3PO@7B*8E44VM@P
MV<(HAJ(/'WZ 3+(E@3YX*ON<;Y_FU\TXC0,&R@GK#)D9*<*=NY\M9RGN7;-'
MMSKOQ;#(I16"U(5&@U]?O2Q3@[= _&E6;,3HF^NKI#&V*.QYXM4#LA8[BMC[
M'FM(-%ZPBWW$,'6:;O4\'A]R3&-AF[R*!AWM+'GDY]KLM].I4>\EG$KI5,5\
M"P835+X-BO:BI+DOY@R>]\K$=2O<6[P>:89LQV0@^F83,7MQ1VGTR_V,E2%P
M20D.JT=,9X,G7;29]ILRI7A04M8OWTAZ+8/5[><37E2[5\^S4&DXAE'BCA<$
M+#&*34/ZW7T",=C.,Z(5?IA,8+A$%NJ5$)&>\Z=6 E7X )_J_0$=(F(L59%I
MK@7W%-V36T]4Y9G**<\20K"B*V@H748+BO'://1;3AP#HK.GWW6/860:CR-I
MAOAA\\OB+&MDT2O#<[\\6!=RO5@N'X_7=P9\4EUI6XF,*5D#,T]()I#BQ\<M
M$H2;)'"))_2W:B$C?GA&S-NPC 6/VMXVY;AV2%Q*RCN(<1NR#9JU9'16'KJ'
MOV+/L'KA?Z,CB95L-NTZ(,NPAT1:-I\/]D:0];H;0RK ]'L=PDDLH[W,&;U3
M*LA1W4,G&9;.%T19K,F:CLL4(_A+:5</RL5"NKIM*)K;2<]Q4=@^B^QO@"ED
M)V+H$^LWP#9B1[.9H;E)DY$)3>P/RJY'!TN/WDWDK//;I#+SJ2/%8=NB[.^L
MADQ&Z(.\YY::W1GHO[I7/H+MM=M'VB*^WLH71G,.;LOFJ]73\"T1J9]7C@4K
M7X2M(C$+OFI$]GT,F[M')TQ+42F[#/ 8B/^ >-G/M,E_LPP4[T(#RJG,5>YT
MQ&YM>NTZ 1BX;LJT#;=N\A=*^5YC2M?-Q;;B:.WI]\AO!LDP]Q0Q'%0WND2*
MB1$T@![]'[9U22S\UU]G2.F:D*[N36>:Y8)#04'GQCUF*]Y1? $U$A0>A;T9
M7,@G<%(WQ!_NX23/"]+MK3\=%]L$T5/\1AKBXPMTY!" S5$_A8T#(:[S3VSM
M2QOC)_WY.':.I=@^F^*_;!G<NXIV3/-CW]?0I/Z2S(IE/G])T2>MA./C=BFO
M]$^1^04D@\1JB'SI2Y+]'NF;F81S#-:FB_)U&F?I;O0FJ'$CDRX:&;7;9*GF
MF[Q7WH0#Z@C FWW(%W581*AA>0AOE>.?9RE)T\XX07ZDS&D>^'NQ!$7N,S&M
MA*$!<06)4S(QE\.L.*WA"[;';W$=R;A!VX20AC%IPEQRQD%<0$SX%$SI-HY1
M*S9'HX.V%"Z*#JOV2"$).]SX_6QPH J O[]H;14+Z5<=C75HI!12I._U==$-
M,89V#@]8)?&."KFH.:'@=Q94T \DJMWP%+T+E#(#6M95%;//ZJ> 9DZ$7A*&
MT>'!"LIW)QTXM8DR;#^'<@9]L]X Y81V&[F\+Q9C[M+T%;9[;8GRK6U%OP%D
MDUIHS#YX@S\'[+4WY2QMK9,:-\GS4P'?2E#$"1KYX$ 6MTGE.MK:O<A[\79T
M<_Q>K>+TEZJ1^'X__;E-?-EL7/498==WV/A$_J,M]^^2KS\8[V,A_6]K_(G$
M$\D#Z29R"S'7C+3%5J*$*T@VT?>T-\"HF\\UBT[!CTH5G<SB75/ZN=Q"W>GT
MQ@#64?QU<].&IF9D\U"$43S?]5:\ZY&KS*!=0JDGN%=UAJM*L;*KKR_MJ4N+
MU-)'1Y(V2PJB6 <9_[T\ ?4>DJ=ZR[(\P8)Y46=]38:US6V507XO4KZ^2L@N
M(RZ97E.6W(O2AX:"POU3YTEBI(RQ"_U0U!PAK;B@XC<1,H@8XSX.%!R3 ]8@
M7T@T[I6:,3I8CP0 W%6+4-^O%/;V;EN="EGOG=UXMW9R'V&APZ(KBV?A%"HE
M:.;EE$5'I7<0 6V5Y]LLC6U+A2CKII6CSM "AWBA,IIY%QTO&F95FL]?0JLB
MS:TQ#&QR?_&&VZ>Y5,KWP[QC%!-5JEB;@U2I/?3V8ZA9O&+X$R,#Q8X6>%S$
MFIN!C*O5$5F7<FRU%^\V0%?=&_"7= 5>>7#*X;%-  <>U982ZHIY>;@L3#UW
MI=LG\RJUL0YA3QH'/]FS:D8 BO=V)<F]FWX90T\4>K<ATOD1ZFL>%O5@I'VF
MU6+S=+A3V8Y2 IM^)M>]BS6_ ,(:6'H;O[430X)<B3=Z3_#U5NZ[%XUX+_LB
MS;E</[NM)?=:T%#X@)!5PB'/=:4;?$F_OZ^<(IR&%JK4-(AA=DR%]VG;Z:/0
M>9\HK1Q!9ON#MH1 @H$G2GU30Y3VTS>,_A9GFOW/6C<WE=K]..^RYUMB&W80
MSE^DZ.2V)_N.V]V<ABM96Z>6S<3OFLF.D#T"/\OW(D$1!25P76[60H_Q,H$V
M,8&M QG.Y6F)_$01WLX9_+)PE<7\";U@!Y%<X*2:#\Z]]]./MEAAZY"H,9A3
MSB-[?Z9)MFONDJ(>WS_K$XA999!5=6@_KE&6<%*'%85V;VKK9GXAKN@Q3J\)
MQ2NK2(:+D$P2."F;X+C5GS_>&<(K/+LZBE&;GC\5_GQ08+ELQY+""&?Q13.9
MCP.1B,/0W$' 3+KTIRUE0*F!3+#M.N%1P*_B9Z;[B"(+ZP(YMWQ=#)$>[G>.
M#S]U#OS __%?(UIMF5E )#+<ML6XSQW0H<D0K?-@0 [X' M\-=D!0!^Y7VBQ
M9:1:;MFB':ED4)SWM:3GE>FL '?6(X&#5GB/A#\H_WJ7[!@M_7C&:S)6Z@6;
M4<'JO4YD4.*CMHCB&R! 9U&J?FG4ECJ7-A+51HZ,\*BQ&U\2TMDX=GO9I[%K
M?856(<['HM,$@ ;H*?A2&ZN 2VT8<\)H2/Z'\.KOT93FC=]_-#%!_J8DMS&G
MT/\7?S'*HM3-#:L,0^*TJ"@_>6F+DG <(&GOC%R#G=#CRQVGU5&Y\_)1LI%Y
M75<<XZ<O*NW@LCC;C@":-[W6YO#7S"R:LF_1MFH..X5_ L&Q_PR;QX/5?C63
M.%E=ZL:^5M+UX(POGV9?)AY.+[.Y2D46/<=:;.ZQGXYV*7!69RY+GB'MC"?M
MVV]HOG;+ENI[?:]*H/X9>0(H0Q'F\^/OQQW"YK)OYRJY6Q"=<39X';/3-8B?
MW-BVAWV&&72@EZZ&)&_#'/TB'!P&NC9*:IE%Y&2ZG")"B+)@=#6M -%[CS^[
M&$J;0"EX6EO:X-&J5@PI% >FF"]2U-#R%6KZNORS-6NI^==FN*_&>N.X=X1^
M6:AD-1<'(59G,+9%+%G;;;LP+_SUQX\VS47=VTD+-SS653242E:N9W#9W6#U
M!A_8.OU"NHG\HF',@[M:@/AHAJ])2VG ^5EP&QU*H$.2#.8N_ X9;=^U_BHF
ME&WO!O/LC9&2J0=^]=: + [Q=[P3Z]. H@_'.G#EGMQRB+S<X=C8<,RXG^2Y
MM*YQL*;,?-#IZRQ3I5'17V\.M(]9:<;,EYHPH4Y\+P2/?YS8ZK4W1((6C%)P
M896G=O&:N# !=0H28X!=D._'M-ESJJR?0USY6>^BF3.$)BC7N&=Q_?WEA,""
M"!I9&3Y4B._IU^.=63M9L]4P2A>)ZEH]IF#89T9Y>?9"^B2W'5-^4U=-"'"_
M\^SV(W%>/5-650JL5V<]$4C'HXF+9'1WO)=_GQ,F*X%#5)?Q3=2^#LW+O!'A
MDGH@ULVHBAPR(7A$-2)5"Z?G.'(1C@#PE^%?$-W'LME(R&0(SEW3P%5'M5C-
M\>6ZUFS%[C6%O@\F;:"K>)[';YG;$WD'?_S#*'QU))7,!,E.*A*N.0L932@W
MN[LHUT&59"[K],\K#J.>9K[,/A>OA1EFKG7J_J60*[HM\(!9E_EX([>GR1:Q
MS?" Z?2WR3]62OYNR+BJ3;56*2O$]FU!*8R[6ML2Q,K88YH3(=8V03G.\L=#
M^6ZPS2KNKF*+<$M32R(,(6:)4MCK>GK7,RW6PP3"M(B-_@I2;A#BI'Z >1Z/
MBO?EVGHR265/RDEH5*_\:#4S3*LWE#O.3 6#JG#EDD]$A$P<^[A^DH06;V9$
MFYHU(-B%&"DF3K+OBW&L/0?1Z../3FZ.&S'B$.#.<$5CWRH"-#AP%E]KN]5K
M)F?'3I>/Y(RCT^./180"G@@JY>SE&F;+#3,F0)8/]/D_8BDW5)7V/Y%4XYP%
M0E;9/OW,7U+7TI8Q+V+;L4=!"NO!4I00\CL:K&2%*G1)EGE*]?\WUX12[5JK
M@<DDFBO3C?\++ROW+UZ6&YKT[\_[/]8C4:5N2JZ03<6M;4'LV9988_8RM\#?
M-,5< ()+FDIHRH$:QU6E7XSA^<$6^."'=)^?[ +!!LGZ85]C?E=%N/@[1B9,
MJ>@&7P^S>N'A4QFI$WX891")TTB(<*-2CM/4VD3&QF,*;ZQ!H,RI8?_7)@DE
MC2L)B<FHZ5[.R&VFOC--6E/O2Z@CT\O +2TLYG=36H''>YR<^7-L$1R2RM;"
MMXAZFZ[C=BRR$[?O(%@Z$X^+\KYRIO:8%\0[$3\1KAB"7S_/WS"$\'^I:>],
M\; T=D22!7[GYWRFSH6=]?*]T: 9Z< &!JO,/RN#$*V%7RU#]"A&Q+D^7.V$
MW6A0P,&90(FZB06""'5V=G2R\\9]6);$:JQ\,^/U[#7Y";@GGVF152'>)(TM
MU0_/I>2ICOV3N%KV8862Y9O280=>HJ;T[7FM6M1'['VK/A4O6R^;-EY4C][U
M!1:K;X#:LZSFY;L FP]8Z;]'YY3Y1%1FKXL"DNZB5S\?&MNQR%7/6=U0\A[3
M%%60@EO8D2AKZ[MJ14TLB#Y/7Q=_4WU,J&\+OB>/AGY0;J5YDA%#Y1_9IPFI
MC9BNTA=-KW@?1ID3_<^Y:I^A_&",B.#+?@F@K"QOT+XZ]XVBZ<,P=RBBK;N$
MNX(G+ UJZX^+K>IH5G_CE%7WJ:LA17NG'[[#%T!14P/?)2JX!?$TF$37&C>?
MH&:=\"C9/'-9.XRH@/:A]LJ8RV0!R7"":]ZYL,UJO I%FF-EBXT8R_UV_BZM
MC6I[B%6U$5DHW&CV#_/C GWN\3%:]7T7_G0%*0+Q2/I=NI4C9M!>;2R%[#/H
M<V7CS-%N^/$T#$]Y2 :9!8?LC]9=R3;TII096J2F:Z1RIY6$_,ULDSXVNNP,
M>W/A'PAG-%.5?9EC_&(/\/VXML*A5)WHI.635,V<$0?H&&-R0\0B/KZW@L8O
MGOQNQ,$U#G!2I8D.I@@F^/?J2/_?>TS N^-=O&#W(QH7T%7/6.U=[B5X#FHE
MONPX5^KS(0/I @-W&\8N5L8.9T=$J#%0)RRG1_4_S%EX1;&P%2MBYH#/?*:N
M)^$M<U7:FL/-;Q=6T0BGZ1$=-UJ.KMX P0N-GQX#P2D?R&!)H)S)>!>S5-0.
M!]A6@E;P]F;3SL&37L)AE!4L3?\R\%=R7?CTT8E-]L4 37NY/5U;<I&&9HQ*
M7 =@!5CD[RT',\B(J'51@;EBZ#(D#Q2-2H$4!>[AQ!J+RU*+B!G)HFY!M1>(
M6G.\2@+!S_B%(LYT%=^NQKRU(K,< (0UEG+=.KQM"\Z_.E&/%ZB,RU;?K2J=
M#K5?9%RG4WVQ:Z[-N5^57+P972<=G7Q2SO!<!P=N[?Q,X>79L:;HN[MK</?)
MW%^._7+UT6QK)]*K=((?^PTP_.-"8/Y/.L+-C^0SM JR?3S<?&1<J,G'S-^-
MCK*H<)@<6)&Y"SOUY$#-O'UR$-EC;'/NGFQW<@9UX+\!XGXN=&[$/2",I&'&
M=7YCF6$]PS/7* QC\.2S/?!J&8NAW^VY6(3COYE630&:]NE:WU=7@'677=!>
MTCH??RC$T/XF.R.X4F_8Q/04]P+QJ8I43Y=75( <$K,Y*'%XZP(R?E_W*^6M
MSE95N$.P]EX_W@=7R.UPG'>&UMWKM9+$F]4PVJ<129!$!A5<4/01ZC__V, ]
M3\S$6C\13-Y+.JVLVH6*4I)>&KE%S$@0=3L+X/4JVK@/LT4&)O;PT&DP-2.9
M[MF#PS.\!C6&DD#$H6VB(!X(1X^*BHYR*A:=TQ9O ('=!TP/7)W>YF-65?RM
MJ(^6*WU)+MXDTSHC^VL7S,7HPT>P'HO&"I1-K8Q_-L>\_SP6C+Q6V/A_^\T<
M7&?^9[L6UM3?-,=T_X]5F%P]IM(7N]",ET" \ISM=E5]HEN^1$XHXC 9 8S"
MW.($/\U]-D7HC9\YAFP*'F>?A53]\(V5RVW%$PBE%K8AUCQQD8:NO"Y -\<'
M'RHZS9FHJ9+GO-.O7EM<+5.^KM;2PZP;"$J*5CL'3.I10D?/8VR<*KM<P7A,
M)A9&T7G13+?Q;(UZ2%RW_BJEVM>\%KL2_XIU(F?1R= ;LEW'X9ID9J,7Y;%:
M*8I[=F1I^WV1[E1_-BB]"%&TD4BKYYB\ =6V'& AY&9)U,[34? EB$ <02S5
M=P<'WR/RAG RS+B&BFT@G:V_CK:[DK<*QK111SS?/+\SN*"-.UZ/Q=2>VBYU
MT,?P3PCTT!;O6?Q4HPO__8BQ[_2 :X!%D."9G[S](J&L5\ZVNH62F6R$/7Z2
M/,/^NJ1%U\\Y5498L]1+0FMU(JMYLYOLWOT:HOH,MWV,C"_%7/?T/+D^W+WB
M_7.F OA+E1U#,G^U[+;;9?PV0(\QMV)Z\R(+Q>5*NFUN+TY6L_GSG DYC)X+
M)2&LJ$N@M=7U* V= XYI#/K'L20X^[.P9MM2L*)&KTO-!U??#I>Q:/NUVR*V
M<O99Y9!O>!QSN;K,Q(R74+RO.!!!7(V#7R?6K.?>XX3] >'ZO=L.O0VH-FD+
MR!D_<X$5,Z>@<>3RH\\J\D_A/PE1W?LNK"/^I"[<\=ZR25;\6@PC@ZV[3GS5
M*;G;DX1 I9X5VY6R#-#IJSAZG56K%(4#:CG B1^Y*:YKM;SBD_*L<=P!QL<0
MS4Z=A.-H.8+SO*FAFF\[U",.\+>5R!?O04<MK#Y&K3&_AB8^.P\;\TGRUQ>?
ME_:!\P]Z5P*'T7F#3S+L]R1?D:;@:L(T#"[ZN7V19DRB#U@#;B&"4)R[<X:.
M!(VR/?ZN'%6%\N^,,,3=&1VXLCCUNX<F.'.S^P%T+,.">SV^!Z50P\_FU_(P
M'TWD4MB0+@A\Q7TL'!D^1R+N9%^?21$,[9CA"WVN73POC$8&L)&KPMD .;EP
M"N4!"GXRGEM0K97*67 FT;YKZ#%">MP7$UPYOF1+9)Y96S=8C'S]["DX9($4
M<5/R,+TI5IE'FW^EHN*PL?_>(O4?G5$^_]$9U;FK\.^3?]D8!6L;0E?0=GZ;
M;6V37Y (]PT:=YC N<+\6D9JXGIM@KX>:)C!A6N,?A;M9M4&P)*=$=IOL5:\
MU>2B_68L/.Y0W7$FC.S(D<'L(:UI<-55DVP2*]A[]BT6"Z$3@CX+%OR(*&DP
MA]Q[;[_GOP\CD?T>=7FD%@.?(OP4+ORZ^+2.9]NMK"&E%%JG%_[*R/$*31<X
M24Z !@49X/XQ?>3JNMC(P;XX-6AJ-5**2,)O1XW/=?1A I:/.O6HI<0LM,C'
M3(0\*2R(QBG<5LP$VL+1W\[^RCXC3QZ&G9^P+7*V%Q8TKN*!FZ?NV<Q,&CY(
M@C-93/.H'(5@[AY14.I*-R:#7"-<]0T72WH[='A%UKN0T%W%[D*L'#5V=FBW
ME-:$K6'(E:&N+)Q3&):;X.,LV]3A8B.D;%-M\WM-":DTM!6"&H80F;D @R#+
MA"-$$._NFQNY:?KH\Y%[I4N(X<8/F_=NSQ;_Z).!U;T*_09 C#S?VCF1G."+
M<$T8!H=OGM?4]P^OWDJ@\#V44TDG-.Z.E8HG?]GO9"G[ [A9Y/]?M.Y*U+8&
M.<)GRY:9>E.7V;(?)8(X19\%^=HE*^TJZ2]L_>J/;7%0/]U+@BP'!]-MR:":
M=G!QM_R9^JU%\S8:IKY/S79@JQ_RTT=I3%?NUS0(7:E7J'&>?J#(KF34EI-9
M]/YLL=A!4=<Q9YUC(F$-F0_1(D#R!>*\6+9-\=+LT!GVGQ^_4C=]LE\U-"[#
M>'EV@J$:X+.@.8,%%O:\,K0NMI$FWMEM'(PW)/C'Q*4Y" ZX'6N*2;+GT[3Z
M:/C%G(-<9CO(M33,V5,"N+% 3-^:(X)Z8#V>=I6C@@0NE9XU7W?> (?=VKK^
M=5&XR!H'*A=\;X#$V /C "O<'X\77<_("N<" 6SI'P?Y2>;.LK[5MZF@545C
M.#P<<MM+*<FEZH0@,?S,O.2ZSSSZZSQQ6L?\?*<';S+84[I"QT*>W$X[;@\K
MFMW;ZIJ09N:8&L*U_HY7M=?GTDZC\*GFSXU9S][Y#%M=$+_4O0&F FW,.E 7
MK%X9=('^EDYX3MD]$N0P:9&<Q]+;<G#'W+I]$%/-5K]/ \<^\2!!R6&<G7)+
M*K%)G1 4FAYO_+H+@7YB=/4C6)6:T-T4":R14-EGP-()2TIU/K@*J+DSIF&2
MT($O3GQT]]%W-):KHK-K WV!58[H_J=RAQ_&S#E';(^@Y.C/*2=03LNY2SW#
M@!FO6.*ATQQB,F]W!C8A]ZSSQSC5F2Z[E(Q2_8IGA;F]"\)RR&VFV3@F>\/(
M(+XLK"!D;B'*_]2GYI52K 4Y,M<V1R>*#M04X:L4V?:(!W;NA 7&B5SDO5*<
MA_@[.J%F6M*\W[T9 '8?+]1Y?LD#;GAY6^OV-?8LK/LA%O9L^W$.6OG"+:2F
MN3FM;"[XNB460]^;#KCG+_YJXV$OM78DPRDPT6NB\,^SGPUWJ3C>YMW XKA[
M RQQN$[+4*XM8-.RYQR4/.X4.(KNQUW@"R_2Y\_F_=*9/?VPBC47QHXJC!,U
M4WB.[<>F+="/G4&QL--0UY0N$3FQBJ_$YQ@I0*T4:^?JLYA%E"Z*J8K3\\])
M 4;5XJS6!$45X8S*04*%TX)8Y+.T7W^/TJ6ADM'WC..01TD9K; GVY%^-+^M
M@==T\LB!T[\A2G!O6] V5-4VV%.QO/_1/J1N"GP.1NBD'H!:;R)R@VX'N-:
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MI55E3&'4;?'LW';TMJC8?,]_UKI"J>Q?88#S*R^X &]>G8UC>OWZ5C&FL=Y
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M37(I!L-WR,7=\LQ0U\\>"]J-@3=T[&H'-:T-;GWA)R8B0>MXQ;RN0Y,[,F^
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M1[T1XVXJPIIUB31'7^),B_L")Y+<"%>+=G\/HCZ\D]L61#\F0@NZ'GB,;/9
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M18?O%!%(L+0!"&9&-3VMI\46[[KH)=K,N*H1US0Q<R,WA0US YX7,^K5-:9
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M??C;/4S%8MA9Z-]E_LF-IM5?D=AGS_,V;(B$FV,-O#K_PIG3ET(5B7SE*O8
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MQ+[;MS%=K%9P89G!Z_\%JA+>522'P 4=QM6XE$%QL:3/3I+I% CQ"?$PBW\
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M5VZ,,6JKDB35&7GSMSA-, 4^:H';W53)BF=:RMWOQ[,GV.ABJL"!!JMV+0\
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M<LSJ^,IE,4H+A!2S'R5>FH>R 0VBCO&N.4D5,GY6W\I!!O&C59$U;D0C<)Y
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M0_<K_<0[G(?QRYS?"?W8& "X)^RPP# /8>T0GG"(QU_6)1@E^,W,PV+^J9"
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MSN['3^E0V&HF=]T-*)$O3BC8LMK[X,+TL#K99+E@U6O&9/QVGE8+N4)E5=@
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M[UC2+JO$:#\PP 0^;]#""HI<% 2PFP4Y=#AQE6^C6IQJH ? ^]TDIQPP_ #
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M538P"]F8MU K7$VC+\"/-:90N]$3*YITZG:PAMUUDFC(2D0/84A,FFX/:<Y
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M:5HQLSO'N]556R3'- \*ES0KI01/@4V228[_V"I3;(DQ<3[(LYB^6=.O6%<
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M$V;Z*7^9E)TI37PA-DV=V14T4%:'2>42HK"E#KM^EZ"L/<-K,0>=T[9LB:E
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M)(H<5/6ZRI]8/F3-E3N%0K=47Y8YJS?YC]GV_<BT0S[)[K)S$'2/8,T1=&I
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M.3M/OYAFP2\W:S^:T,52)(3IY]))F\,#$YX4=,(,'YJ"#F*5N@_//Z=M" @
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M5M90SVW\.[*UNRUH039]@X6#O0QBKT+-:G(Y'%=9K4 LQY567U-12=9T:B,
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M?G&9,7M']@QP^51WTVU]]M]E=)WW:!!"^+)GY!^!V^6:[^(_GH'MG]K^?<\
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M[8J]QN7<(5['2+6 \[]Y4L#X5X/=,_%U64E"*=V_)C>B!$/%NPDP;1R\%%D
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MYJ)[I /3T'I_OWV;=&I3^H='8X+*ISV=6QBO;3C-]0?S?+Z(,2A,EV!,&:Y
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MJ_Q2399+U92ETUQF '602\I]6R!O1(5X=-TP[IZ*5$]XHQUCVJKEGY0?GS\
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M%R119!,I+SBK7G:V,O4;YV+WJA1Y+:#5#$UO=R^HXTI15PF#L2CZ\MJ?VNL
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MV:F="X[ BA=<F0M?T'156O0WJOU4 =LM14JNNVB*)?\+JVF\KPF<6+R/KUW
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M<J"6.Q+MT@R_,P7E35FR.Y>TA2O!KC?T'?=+-IUZ,8[^9!Q)Z^.;*(#KA8J
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M>/F3U;FAP\N%S2-*P[F@(=_%C-_>32$ESZ;&8!WT4<MY3FY2>167_S)1?_K
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M^)PQ=LC#Y=C4S9E\ZOP7T'[F^BRPX>Q:Q]+)]*\F$H:\J4R:__D)(T:_M'<
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MP X?)"*O^^%A4Y%T:1.5]_>?A]E)1)UZY_.6L;I!^C<'&^*(5]W%/R)N@0[
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M7!/K]DUK/OT%_.#LE7&L1.\T/M:>"8R[1V,]U_J/FQ$C>B,)&:OQA$UJ$J6
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M[2.:O[J;7V">\_:Q^'7HT +8X*PZ(;4 F@TY2<],07]@7!_EA>:XKQK7\<)
MQQIV..2LX'U56+IHY'*:?2BX;AYXJLTO**U.C)Z?PZM277V]T^15YWI>>'ES
M[1"0/K4[J/9&)<TT1^@8Z'6WCR7Y_^D[T/_YQ>#[]/\#4$L#!!0    ( .X]
M?%3@YFQJTUT  -UE   3    :6UG,34X,C$U-3$X7S(P+FIP9]2Z951<W[<E
M>I#@[@Z!"NX67$+P$(($UU1P=_?@#@$2".Y6!"U<@KN[4TAPAPH0>/SZ=O<;
M?>__O>Y[QW@?WJZQ/NTS:I^Y]EYKS;G.?EIXV@#PE.04Y0 $1 ! >/X!3\N
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MPN]S2F@C."E=J*^@_WYZ;K/@V[8H-W[#"DP\U&(8%FOMQ]15L^X9?#$DNN!
M<>$G,6F>TIJ7B\DXM]1IX8Y*-8%:Z>G1+2A!/BF7:/%J9,[Z?4_SU^%JU;.8
M*V/K_FJX58[576']MET 2"N)W(Z]L,6CH<%EE4$,I_@2(J]Z[A%1>%:&Z:>X
M9ZBMHTS-IM4"_>B"A%47BH(BC84B->YDF!DC,A[Z:?;4K0,OP&H?3__/>>M9
MV5BH9AIR"88V ([9OG=&>!'>C8N[#YU8U1\L,5\MXI:[?3?YJR:86DT5 \>E
M7Q@IO<UNPY!DT543G:\HWN%5?7/+-J_(L0F,ZMP@OEN5S+HYM=RM^% DL^WA
MUEWM0"N2L/A$AH""$-J<V>:UVR"&6^D9K79N',7>*C7!L)BA05S9M)* ^J97
MQH1$G-?[,Y63%(FM/QG<>0BSW%U_N<7K>+2LV\/U H27G)08["^=(.*-X2J)
M?:5S]7PH&V<@K8N;F7O-+59FC/08G+!).1$MBT@)IM'-OQ;:=<8XHUY6!9@>
M+<UQ.YIERC%X7YR=%_H"\.4?.-!?AJN1-B,W0%.UW7\*M!B4VRO'V/IUFE!1
MI3SP25&GMN3I>4;+92NU7TJ,2JP^ZMLYI(3@^.=H7!LR+NM,<M9E5#X!9DU?
MNAC[NI\9-^I<ZWV_,5Z]H<2Z<<VD[9M5*VUW1X'A=ZT57?HO%38N2#L,;B A
MTG/7++Y.9;_O$A8SV'S@INR5-WX;Y?V-"(TH!GLK$XC[DCA7E8QWE.,-!_.U
MRWV32_77A^\X@L@8N3TUXE@5)&A^:\V)V-5ANE"ENRT;R;B^^GN>$C^F6WUI
M_UO>$;703?,#@BS1OS!B5<VD VH)70[&^N"W?]+U*[[!I&^_;<2%B/?/!7*J
M&6D_ 9A*=X8"]I65QP;29DXE2D<Q)+MHQ?@L,1;;*[PK)WT\6M>XD:^]78R-
M!"I;TWV=C?1_A3@FCP0A# LZRE#%(/13I0-7Z6QIDV(?WNFEV\P+"HX7KX X
M'"F'(F_[(!V^/V@SJ+UZ[76L[\S+=P,LK 73LHS$QFO':FS'WQTSD7<]E"#N
M$*E)O?C_RCYY=L@\ 5^2?XD4Q540GU0N,H G)#_^E:IL9D8*=T!>7U_OA3S3
MK ,*B7+Q&,%;)SVO]]_5DGB'?))']:;\:?:7Q$\2/;!G9Y+VUZT^326\.Y5X
M77L^S]#PPFWF RI)![;KUZEK:E[1C,:C$_O>XPJGGQJFW,*KZ$@,68[.DB)1
M#F'51OMWA>WY6]AZ%WZ*X"B?2$-I_)<#LA]RI<:\^KPDBEK2F9&^&2-8:C6?
M?"_?=W>T\B!YU47R ?3)S:Q+NW/;5:(^X/W9=7O&%@=8-\Y*STYC\%*MNEZL
M?DGP=MM[KI<(8<"&%M=6X'NK-&@^32W3CF/*)"/ _24=9"7NWFM4OO3A];2;
MHEND66N+HH!D+<%D"@I)(!#3Z@9C$H:,10$;RYM^/VY$9DB]QPI=)"K.E 5F
M0L5Z/:OKTS#CNF/ 5%IQH<\LZCFVT]L>*KD%4V\$+YH,+UD1QQE> (BZ\32S
MLY/_#\[7TJHN6]'M)%2!0EO;K) _D7.FXA4$>S$QG0'IP&Q%/*&G]WJO"-62
M[,HMWO*(]@@WMY8)CON/D*Y^@3=]3T ?FQ?%@3=C^MS8@A7[J:)E?ZFV6LN9
MP/0'5 Z/#17!1TQ/2%'F%ZW=R0;D&$5[7?VAEYK83=+3J%5BT\5G-+%N;F[L
M6UXO&R\CH5SW=59?V6-:/Q.@5I$+'1J*$R&DY/_66@*]EC!(-E!VHDNU*GJ9
M.? A/P<I,,>1+?&,LYBD^ARU+^WG\JI^?F$@_JK4Q  /54B*O:PW^;X!:<AN
M5D"DA&#2[LS2$'CZ$M]QV__D/2P*.+7\+]2\?UD'!P2X"&S<_5_.V5>>6GC2
M^\!SU!?5S_7+R[P,@W^"6SI@1AV:?8G%G#FW6WT+1B(I5@_5;4$ 578.;4(.
M+GO]G)OVC.V5^0QDJ<]G6/K5>+IO)\UHH=GZ NF' "I7@6G+=K;9^2[O%X>_
MO>-JG3SLFJTXQ*KK8@!]'ZXUJO-30Z&SQSAVBAXK]^#)[!'N"&W[4P-PI:4\
MA0R!+ &K7"!K7LP+I!RDGSE8QZ@ZCRM3O9NU68,]-6]O+H_78F(T0^H29]P%
MBG7\29^ >-$GX!Y]]0GXO5LY]%_S1>#YZ^!643/3<IMY]\MAISW,N=17&KR;
M*5$O&0*58$P)Z-L8IX>H?7/['AN51NB<Q\<,/N[8XEWT_-3#X!\?D,0DM]C^
MFN\J0%K%/8KZJD]US1O#I/H9 O$C3]-_VPP]DG)^$RCOJ'X=NJ1:Z]NO4)-%
MSM/H!WM)5_7S-.K*SU@S1&Z:L:-1L2#N969"G^'"#8 !M,@ZQ9[CC"S_QJ6N
MJ4@?P7:B,# HH!>@] 1=@QH :D=KY:H(/;>4U:T5_?>IJ7V;+P98WR:]R2V0
MXDOLVL@JH  .XQR=YAMLQL70!,S@03#IRK;D]:.?:[:)<^Q>SF"$2'&12T/S
MD"I.*/640%UJFE826G'H H^ZIA!='(X,[EQ3!YHT![0GFU)68&7>GF'ZDK\+
MB79U<)%8?E^*^C^33,G6&.;6I:<?%SB8&F.]7 A0%H2H=L*K;.?"LITX9M-5
M!%I_BEKP#.5PWP6J7E:]AF_"*,<QX9^6EL8F079*<K%%"035H=U@I*;C*X$Y
M.&:/AP3[F7EVQ>KBWU2OF1,IG.F0V.'L3:&!')RD*.8<Q']G6'X^/7>28;#0
M>GWX\;O[+_JS<>XQR9UB6'%^G2=LF5.5]?$$2YQ5Q? ;[=#%X,KV3 JY+U3$
MS!M0U)G=YOM,P;&+DZ6#K550^K)'TO&#:!CE 0[JMCC;Z'Q?;#X\[ F0_>F
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M!N&^<([1MNO9BI]8I4&!JTFHPJ@"E1:V=ASJA&+3*4] :C*WN:0Z4 0[N31
M?][5A/^0 L\S5NDYM+=0<JU>C,6Y$9;(BZP;C+-[S TU_F&(B>'NI",651"+
MNK'>KJ=%6#I<&EH_O+VE^/)!97=)=T.>"-GUOH./UCD  SC\'^W9[G^7E+7^
M/=D-Q&!->2QU*/KR&M%6&""*_/8Y =CP3M3*3;$(-?O0R3V 5:BZA<U6O@!]
MK\2J8MD_*4LT\&]L(?[\>GW!EB[3P4W4ZMVDG$1_BQ4V?4@+<!GLI%=KXZT=
MWBI*?9(;P.X^Q%WED2TPYDG&X/*Z@>_]V#R2[555-K]#Y+''N<C%O-(T%Z2P
MB<W.O/;@Q<<L/B9>1-SA2\*XA5M(W&W?I6?S\3$#Z;[IA%6ZWFEK(^W5DI1[
M9_A]T^J!K*,$WL_9CDTK[FG^UQ/??T:R-^!R-Y"9D(4$7=HQ,$6M96+$OJZY
M)+2\F3FS6ZNG7_'L5GN< $X,!5?(CB;NJW0E*OM_5BZ/@F7.KFOZ/?S IE@V
MH;';.ITT00&_JB4W4=*O GKV>BE6S\3!<4YVM#MDR/&E AZJ9TRA=5!<F]S%
M2)$_24S?GH#;Z<\SSM/Z+7<!74\ W<QE=N030.R:=G:I8WGB@'42/GJ1J;'C
M9D\6B+MZG%4/S=<Y6,=GMZO/--]:V4]ZO,!$B^3&HH&T?3:1/_?-N2D/(+K*
MY-SKCC*?6O.)6$3&)J+\8C*0T=1/3IOI+D)<F9(:BTSA5ZZW!#E.J//!V(F4
MY+)WT1/Y&4-:J^7W!%0E5$+REBWG?A)9H'CAF;[[]@M7UB@:C@&[&O:1A7\/
MH/\][U1:'PB*)<> T+RKWLO=:D-L:I$ICR<V,%3.%W.OE:62L%AB>.6>*AJ!
M*K2MA;[L')<4Q5SZ'[H-%0XDQI"T37'UZV/39@6[Q73R!79[GH%//EJCG^#-
MO=>2Z =::MUBX_ROWKKO(,>X/+QZ-'C.9E%P78E4KBJ[JX%6+HK6-]H4;Y-:
MOVPCM'C2<C'%:QAE&[EM*-9[^BJZ%!\\ <LL=+4$>=8H"Z64G4/?PERNGXO3
ME1ZP(4$O0["R=,"SLJ=1T_!U85'1DE$YDCP!G. E*M79U<54#1$\6=;S<C.N
M61YIGJ1H:N$I7?MDTB[%+G'6)^B'(SK?^,RXF4)D>P3O8+_=4X\_SR=F*.RX
M!Q.(?24@_B4H87M%[:*XB=+RSZ</FP73L  NU94$I<]J]TT\8:S%5Y"C/514
ME-;+3O?FV.P>7 J9L@.VDM4O/SF<&[: [N%D)!,0%JXW<*7T/T.[  OW#2Y,
M"E-68T9 F9J3D.-XQ+&$_$]&LL&7=7R.:W0];!S*\EM4U"-N\O&M%;F.Z \O
M5AWZW2DX:USW"\P2P Q'21VV9]HAZH=&+-#IS=A3SK!LHI6WH1XK*[0*6^22
MN54XYR>9L.%3&IU!+%(2<QCB),4Q59_3)3G:!M7GK(7]]-M1S%]Z6E]V=YG3
M86J)3AS7P]\M N#DV[BF0<?O<%[K3XG)PW"QUQ?UK+(7[MQ^F<9.$ABM.J,-
M#.CT^RM*_"I_H(![^6UT'(O&:B%"/2C5*)T3\ @[NYB8@@,PKD4SOE5R9&U]
M>FO)V\,"_H-C#?E>:77WJT7GO9FF$'BG)JX@ (]\FT+8L,H.Z) E4D<B._"G
M>IRYP"DL]NL86=SQ*Q0;_;,/%1[[Y_ (KL/?,U#9/XZZQ#T!AUKU>XW!2WR@
M2WD"'&6%+JD'%8.\E(H7*M8HV4K99J.]+7GD2)WW^G0TCRFXX?1)XCA3BO80
MSL_IH)0LCQ5G30LJ'#;<GFQ\,;:B?=+E^G+%'3R)A<IM CY!;M3A!&%8>NZF
M<82[7G@8_V[=E%M&D0[!ZWOQ9%[4#TC8>\#&W%"LL86_(2=;>5:0K#.L5Z2U
MF.019S;.F[P@C.>N2;*0Z08:8_8$:&]&DTD_LEQ+9 ?W!61:')GMW%9=8J;5
MC?^A$%B_]W@")K#MYB,]C7L>16<? LJ6*1&*^CWJO* 4OE54E$3'V\=]F\FI
MA[W>3 \,60R-3T#\.+E!T+Z9&9%DN8- I355DI*ZLNPZ-(G ;)ULG!CZI1Z]
M.!$<B:_,1X5PB;&,2H=OI'&.NSF[\P2$HX?TI,=$4]K_,!J;0D>1 E@WY<6N
MCM@F?/F*UZTDJ*JGKRGK6IH:8N0L/K*UXJ"BMO-H"$FKO^=M:?F+ A4HR8O:
M(_L/W9=$(R5;,8W253UK";9PY<=)Q(O=]:/=.9;(#W)S+VZ"I4#:D/DDZ^3]
MUS0BS8F^ I:7TIZ1;"N'BO:@1/<M&7M/^WSD."<I&J@L\?;2;B''7E1]P5E7
MDG#=L')1:R,?C]6)'F$-V426^\9K)" HWA%7MTB9+HPI,8@U2B>47,Q'.UK/
MD"=]:F6U^FQY70\SDL)EYT30=@QSKS4#G?Q^[7H"4ENAY\LZS>G /^UG?F<C
MF._$L1]L">M_X:^N&_47Q^E0BEKR2Q5#*AO\C5+ES?UW"<^A&'*=.%5_;VU%
M8]$'?GCB)C7KO7K6[?&-NJCPEY75NB$P1\J[ $_O>5]_[M_0F,'BE3=HIZP*
M_0?$FGN7N?N[^DJJJUI&'6?]AENB"SG!S$8*'V.J%<-]J=BCO,'%Q%4V(JOZ
M\KR\O(T#S(NT054_'IGANU,6TX-1XN_-N[WBK<\*K"'HLIP(MK#L=W.I&; 2
M"'^YJ!^EXCPGY^<(V]J&IK=O]S)S9;AICE KA;H&[\N.?"!:1XFG/8$%6=^J
MZ,_:2S>? +A.VL]>K.I6:0ROY 9Z(;OM$)8^SP-<^Z_+M.@/4O/5KXZ/C&BA
MDMV[]3/P*[%0XCU_2OCKBC7/+7UQ,P/=-\L0,WG* <=>U2UY_IF [_XO\]QC
MH-?B3X Z/'23@XG^TKA:CEK-#&<]8=3D"?BU-L7%VTR37'&(/4&I++@0L"$?
MI%SL*VR,D[!D&!;D!LUMJ5YF^GN#OK=./ &!ENN6Z*]CC^$Y-0]]_"YUYUM\
M5?&W0&O_"3 *6]?\VHXN9RSJCS-^)B:S=1K5"O8C#@K 7?O=8%93.)"8&8+8
MM)S0"D,JA0QW&>-LGLM%%WN&]VE8D]Z.A9L5=G^#!3G+(6+1."4?:ODS>$)E
M,I2@<3YM;^;<&D,?1V0Z>]BC>J,2QX"-^1Q+D=3L@(+E07 )QXJ9,]48"'PM
M45]@W>\I_J[,]& :OC7IW*]:.\VAM?1KCM*2M, QYR-M($14?K;2'!Y>1J]G
M'36UK)?WG2Z!^67QX"=/I"QT&(2M&0)6G=B"GH=>#ZT?X&RAD56DO4IIMW)$
MNR(7HKGZ43]?RA,[[=>QV:%1G!?%@J?1/N6ZJF%Q$Y9MY5$K*C&),0@5=TIP
MTEC66U[4+VRKP)=&=*SN"?KH'^C(JL>RNM3YK&CH_F5_9KO5KU*ZT.J&9-Y]
M>MRL9.5OZJ;=E[ /A>0U&1*V._+O%R$-Y2L+2VLJ=AP];*#4*:^?U8^H70;Q
MG8GP"53*#<\'WN;,:<LE^^H7DU]0,]3"G+ZBGI0KG[@$&<[^6R<4\-9&VEAV
MK8?'PW3 C>EN^/O;BOQ%<I(MR?!8C\K88J$^T?G!->26<U=)/(NZLV%Y6R@A
M+S<W=/%-X#(F( (6XI_17\"M*,5\0?X)N!;823,B@I>7N#C!E)E1_'?JY'CB
M2PP>Z[/6T1]4'/]TS%X=;OC?+BWMFOXAY[G[>"]Q(67[( WO,MOP4YH;HM1Q
M8WFE<L'N(?I.1F@/0_ZZDLR?#>YN0\88?@QU5@CZSGZTD\#"4+25HQWC*P.W
MVV+3/V3S,61Q2/G$T:$TK:OF[,U#/OCX\6"-^LPBDK3[SBN^9T_UF0.KKF#3
M@)(X48<4A0?VM5FIJM6=M0+F3?07TQS$'"#K^U#CA7:L6?(8E9U1]\F>0!@$
M'?27Q\CPK/VP__'E.<??F+OZU=!&N=>OL2UC)G\R;+^+89&,XYEJ>W_9>=>M
M.W8!7S;Z/DN>*C3B%":T_XOPCW;F@_ 9295@6P!-&V/IBXJHS^M8:20[*_B#
MKXBXZ;(VMEV+,3 ^?&U*S>K8UM@V-%Y] I"O,8W#'JG#3-U*07=M<\X6,[M\
M+H=U#_EGQ%-_B]]/'\]BS35,Y'0:#D7E_]'FER#S-(A1L?-P%&=J3Y?^0U*.
M?@;KJDZ0#^>_\--[5F0B8S/W'2V/:'5"XV0V65@2 E,2TR21GI=\W^VQ?G<B
MD&/NXN&L*?3YL=4X1#QBQ=/!XU7_!+1P!J3I7:Z3^4J<#7OVC>;'B2HL;.GD
MKI7EO&3UUZ1SEM2[CG@0SRN:,V3LH7*[%WD"0JW4--2B%=O$1>XHZM\O=;1<
MS^Q!VED\^?6%HWM2!_YF#WH!$AL8.V*TYS;R\7(\!HI.8KM62EW$#:,Y R/H
MSLM>6*+G1D%5OT78'VG;@OT$YP<2N3?IV1(3GP"QOM.A)H<P(]+)NF6V;I(,
MBE&&;+[1*(-CG'O)N1B_%=<'2Z/QQ==#IV[SJM-W/V$#4&_?JHN59E^? )<G
M@,9;)0;I?BFL"BL@;F;-ZI]>R:NSD2SFL[4?X8DW.@\W#ZN=?]G*["B5P:G3
MMH/7W%QP#4JIR1\[=1D$ 8>KSVK@IE9?UE^R<JB!\GX]:#/6M&K-UUCAM%45
M>X0]@T:GRC?,QVXEAQG 'CO.>10XF("+=JDIO$J:&SM0>P(XN)CXH+O;<Z)P
MEO5^&0T)\NF VALOD%]Y?*NDU\Y1G_L-I.,1WQCWF250]#\^<%AI$$:D-.BY
M3DRYGBFM0(R=GS4U:6^#!%7:K]=:%[*%'!4RHQ?+&-^!C< OG[?/U1Y$13BS
M-PZU:I-^K;&DF+E%O9'PRQ'<Z ^#I6?W9*'_[)@TKY_F'Q6AC)0PYLFE9>[Z
M+8<FSI*%?R9>%)_7;U6Z?^?7V^.+_I8NE8Q:<5RX0KQ0FT;KZKCJCTZ[ 6UU
MV^KIDN2>2\'CPM03\/N5Q1,0,/]@S057<#6^PWIV)9P@&R9U=A.%QJ!8/? $
M%+L]4_2 &\;D)T"JA>L!5?6L]/8A)F QH U.912^=2S^8%'9+]A6] <\-/PM
MQH:1*#YQY(NC?].QH?;#JW8:VDN*Z@=&O;TZR? S*W]0]D<?&W?"OSM\M4']
MMTI!@UW'4<<O,LL29.OHXKY)R^SY2(XLM?QBL<RX<OI+>OW;44+B/#7Z"4"K
M'ZB=\W@OA4X$"%XFSC,$\AP;%H7[H.3G+Z\N&[;-\$)V4J60:#\!5'$IF5M5
MV-);'$)Z IE?\T$GF>\UBMGB"ZVMM)2+K2;U"MM:,<DZXU;P0O;3K>\E#\_I
MZTI$,!?+1:^M.@8#C-D,\Z)8X^C^O32J(ISC,)MZ,"Y9:2LH6K)[JV">W<TF
M4OJIC$?8_GL?[B>;)<Y7]^)UM6"/U-#SPZ#TBV]N#BB>WY;7UN'#'U0;^%TD
MDFZ?@&:M 7K>7&^D.#XIFOH/E84UH[N5K6\,]CRE?_RUMF9&E*2G9>[=D=])
M3LJ0P]W4%).W(3X-JQ?5S4VR+&Q(I&".(^]2YQ82>R0N5DGB3Q6,D\6*03,3
M[T5?P"6%ZV[$TBQKSZP%X*Z 71-SVQ$UT:A,'0<D3 _OM/-5-W#1#1KVQ<2+
M]V9-,0+>J<.5QI;(N':BB.0?)YI5.EWJE!9H"UW=K"OFQM9B2DN,5Y='S@*B
M:;&*F[-5HKLI^+Y]U"UD'H.#@N(4 3!3U+4#DE6XTIE_!G*S+XGV&V)2_&Z\
M=XTPII5K2%14Z=P/V# 7G/[6+F^&[?NT&$_)@LVE=1(\S"=18I*= Y'9)">4
MG":CO"BOYB>+P,]G/HK6>>Z>#"[;1TMK.&16W&)5_3A<(B2QL564\<N?MA$#
M-'GT:!3Z"4-^BW4WM["KM*SBPH"U=&RAZ#-R,-H8KEA4+3+]&G*$6!P1V#5&
M-WXFJSZ;WMDNO_I3,0;/%\9IE3\.#I(,A(_XV!)\&?J9<A,W%UP@P!\Y\4Z;
MHQBNT4-B]'K&OK+^>.>3/+9KD:JPOB/&!OZTU;9V@19Q5J$55V05,0@TB,S<
MP0#HZAG$P!IDW^Z_.<R=#NO_])55]]*J<O8. I.L%[CGY*J3;9*>,Y0P68?#
M-AZ+"D)ZE_B3(BR:;%C&'VK:8CK7X3<(#]CVFB[+76[X45MD.S'7ND3<#[%6
MPZ]J[\=4;>2,J3@>21VZUL^J4ZH,55!2'>P$B*&:K)@OY+16.MTD]6:#0'$O
M%,WYA Y??D!_0"7N@L]WNI.*\"D6!>0T#Q3FQR02?3<1-OI./F9C/?^+0%^O
M%SBG@=[78?;^"NK/6=8M5<U<]6<R^+UI1($C(-"R)G)U4/4G4P#<Y5/2WL01
M$PNN >F2<1[?ZR2(WG]T@,L6/ &YT09/0&?*$[!EDU9[9G ./[C8$9/W1 O5
M-<,ITN)(K*_AENHO+B3\,:T5O\4N2(O-/+-;4J?G4^63/V4)";AGZN$)*#NG
M<Q1AOV$.^$C_E2OZTQ.0VBS025,]2"Y92EPL>O!]^-JR(ZS >*V#/W8ND9!R
M55N<UTFI L);@'^ [34?5]4J0QJ>>>**B8K12?DE>>PB3%Y4*<8"T%I+JSRH
MMDK=4D5;Z?KZ(FEU"P-]>U,942+3FMAL!.;0E4DP;%XB5Y/D8>>KMG\ITJPR
M_,.>_&X.]P%TE'U81VV&>R_8\@1<$=BD3?NJ%A@^O+4!3=F_M(AA%:LF=OM*
MT)-RP(MK;.U<2335OCTU;#,3LV-A6;YO<9<5+TND59SUO]R%"8=QR!TJG)E7
ME^A:'&O=)(F]Q3HV$7FD#L!8*1JD4"'L967K._B8$B:#-(,O1248OT492S]O
MH/]EULW3UGXK"M\!O^E'>"39'E4")F%6Y_SK7/B6D 0=O.8,[M)3@_GM*#!,
MG&=)H2$_/C,@7!@VC]*FK3K-[IIA7&MU4ZTOD[3,8("5=1V>K[^O"#/&6].S
MGEA96^-H'K<N,,=ET?7S&COQ8T;BE8R\<<YO]2<[UZ^P'=IQ37NI<( KAJ\F
M?PY^E_:>(L:?YEQTX=M#EW.S/ME0@(^[4[SWR:?Z8*)$ADC\S^8>@.-(/RB[
M4H8DQ13G*W]CY4ME!-JO'+\>,GAB&Z]R<"3VM@I#$R)6/1UZN=$+=3Y=NA89
M7KQ>54L>IOF5M4Y826"YZ8 )KS9+((AP35OI! N1[_W3 "-U)TG;0O!PH/J%
MGNH)A;@K=+B%Y]+4,RS_NL4?.R]-I>NBBM.DLJ UP!T*% J%%YO<QINW4YXK
M-L<BQZ--97OG@E#8?@0JB-U3^ 80VIE9D4@^+[+$N$AG^&I0KE-([,Q1^D'6
M'1-LG?XE[="!K"5)('(7\Y*7!<0B$9C\9R91OQMIZ%RN9%KR^TND4T'$[?M-
MJ0=FI&#CZ"49*[M22.B63'&)N4UN$?0K8A(ZQP]':=1]]15?S>FCX[FMO>XL
MEC 2,S50N@9K4L\+<J92$,)A^J&VS-2TO-U+6XZ^'P=#<UVHJ3($.N"5I "*
MP7..]A3(@DJ^1/F+\D4QTN3 SF])PDBQW0S $0-C(*\9O-04>X6D!N[0R[.R
M8L_=LZ2!FFPY;$<^V,D@M*]*2VCW[A@XZXC&&LI=DCQ*6R%*0F 01T>]$)C6
M:XB'M$$J;>VJ*!::NQR_@<E-PX&;,13K,VBHO=&V7)Z%;&Q!_RMI$-8=8O\E
M/T*/]/G[7P>*,.C9>I29C\?%KLY5,9C2A+H"86,C).10P9]U?VM,N7MSG"A:
M9_;[KHB&[8>F%64+ (OJSF3>R@YL8\$QTG!SWOMJ),MV)#J$80.[?V8# :Y.
M+3%:\>JGX"2EXL<Y!?>'"EK1()H_PG?/:N4)P'S??53]S+U>;V77#M9^[EA4
MK8?BD:(*"8/ \_21[2P+^BK(?/] 5W;L?2D_]8.<#%'A@RH3D"6*<?38974C
M5/$X3KN8M[C3"]TQ_$+<>4,'WI?MC:V<[:V[7.X'-4 ^!RTZ@S]A)(GCH-/&
M DXA6YE![3;XFQU$&?4Q2B:/0WZ;Z'2"*WODR!9+$>VL.JIN3C:X80\:KWJ;
MU,04"WDLH5B0S1\Q<7(VM20D(6IV4OI]7!0O,56ANSS!"@9WGY/ALY@M;:C=
MMTFKJZ,69B[^TDGR)I6"78&*)T0F%O6 B^ 30%QW6,[GX;"Y3J1B^]K<\JKA
M,Z4B]H#01C!N$38I+?'5LCZ/E]/SK(RU^Y85?X.F: 3F)>%S4?7>UJH*.W;U
MPQCP_&"=8+ARD@[&Q*-.U;9"6TY>? (X;=SWWE6W_20A%:Q6MA3\1&I0LB1M
M)!Z!_!S52<E;=A6J!(J; 20,2LL,V 5"G L<0>-,&*H3%*;/\<*5.O#L5/KC
M?-X*VD75UAPZDN4?,!#6_;P#"%\%Q 6R'L<\C4D<$IQJHH&;TT:6C(;F6[.5
M4'J.;KTUU;UYZ$)'AOCQ(CS'1+QJY%R2,NB?A?@38=[8KP8-+GCY^JQ2UXF.
MN+3DZI^/DH7.MN6/WD+1%VY"9D)B>)X,]>Z##E@NP[QRY>R-EU0X^DA(DDIF
MF:%%64F5A:V.[#5U4\@&]HEQNO%-SV=R^-SB7<C[Q\F,[D>FN'Z3Y&.NPI_Q
MIK^7:V.HXJPN'S1^-G@2!&##BY@: SB)_5AF!A:8K+<O'-$[KR#M=DRJ35,!
M-46U8<I(9-%'1TTJ(7FPZ2!E'QM3^FX7'R*0+D^6, @)+Z& !!6*?"E%]9@,
M.^30-H!.42K,'7%"&+SH'R>JN=F^  WH8C"&2PBDB?(P$_%6:ZI5QVWY<_VT
MEH^)!R)DZLO&CS,I QA5B.%G9] DJ%JDU3XWY>LVMS@:/W#P[_0].;^R&._;
M/TL'FK")F(\<HF^GK]I$EOJ6%L4R+.>$ADLX0LG(Q4<M__N%4.(Q>+%NZW31
MY)$M!?.)FVBM/6.J^"$9?DLRE(%IN]_HFB86QH:9C64E4E3I9@,6N*(Q[T\&
M$KOMQFV?%2%0OQD O^QX GYFKC_&6:] N+JSV,\>2-)^&9H/HL_8?[/_AA7"
MAN?_K=(!KM+*M>/5<99@M6;$UW&,":5I&N.1HIS1PC\O#GL3)G*3'1)#*^[H
M,A4",\9B8VUH*PYS:,8ZP/03W@U\;5G!!5<1XZ9BNKG);HT)O9P'></X\_O\
MR4%!D 4"D7AQ9V8DYZA?QA3P3^^.YNMNNEC=QXJ1W:B]I[AB6SDG_T1O80OG
M]WE$A[+%0RR1O*-^.5# 30&+^;IKY$!, V9R<=&)-?ZS7\38558'.IO2F7*J
M.7OIP&K>SR=@D^]L;*-CN8$R8DSL>HP%-=:7>VQ X%BL&>8<.<\@SLO7"]A/
MZBC#5+&$3=)OLGK?SRV+_*"5&4=)?B0TQHP8"3>>;D!(6K<T0+@>!:S6K5*]
MD\I6>W=9KR@C:'-O2C>"12VUR(+0VA! CT75^GUKI H/??-7.^\EP(XY+M,_
MIN-C'G@+D" +B.]1+(Q4V-A6BH6%+J#%8.<RQI3B?J%,]LHY$Y=6.22+0]V.
MLW1/$R&9*JO[@0%C<6=Y")_4LV\QOU+<9!E@I5S.TST[39=;_:N[^3%QF)C%
M9BH(V[US8V/+;6-:^WEASX?>^:O=>,BY8X&_5Y%B8<E^@K43&H3&,:2LET\^
M&S+%-U4,#;++T4G9=I2,TN9<_[Y;'?_L7OI+U0C^31J^UA7.%>\]H5XVS_EN
M#$W!MN)2<.C( :\?JMA43=NP&P@VL)89N]0=_[[5F*"]:*Z!3NP-XF;\]SH>
MX?LV+RH?=5H*N(E([GS=V7%FF87!#[?.4=JS=#AXY.()@-;]A:]"QPU@\^3[
M,K'][\N+T@T_QBZQH?M:;8:SDQI-+Y1V(_R;VT//J\*H/1@[BGDO>*$8\M0^
MTWRO+4OL.(^KCNE;:K.$CW<,)X<)4;1I<N+RBO[7"_:M>[_2<<K_KVJ^*JH-
M[M\R-!1W=V@3I+@7UR+!W0*%-KB[5H"VE"*A! C% A1W#<&+0XM;<"ANQ8L4
MZWQW9MUYN?\[:^;AKIEYV*_GX9RU]OGM<_;>#FM0Q?KY099 ]GD%]X-PQ)^S
MLO[ZOP#Z'X0**3M3_QX4F_&/9]QP^!^>D; Q8'&Q0%6%4-!KY![AQ=T1K]+L
M]5K1/PMV]["1MV2;G<3L6KU%IL-3Z/H!.'+WL+HXU ;ES)1YT;@22_][ <&O
MV=;MC1CDLNS-JCBECF2C,HT+0M:^I!+U;T(PG54+24+ JA=J(GF)3;6/=2OF
M B% GR5E Z\-'L;PY).5$Y(0L%"1 @1\V"GURD+</+ZZ-/C]88H.KD(3Y(AF
M!(N<\4:,;.W(R\RXES.J/L%E4V;==08.BQ^1NTK>\V/B/;AO^*UJOFFG,AAZ
M72A3588>+O6MN/^NTL[GSXU$XB0HHW0%_ADW-8>*"[Z$XQOI @3^C3C4_+=D
M+:V5)E-47N7WV<+?@4FR_8S&E=@L[Q)+!>ONZMC20B^>E&=TLR0FU$N%P1AE
M%9O+52)V1^7=,,>.&0%Y5T(:DU7J@A4'(+CIB'>'K]C!!.8_!A[^9_#AP%8-
MC<V-$&2R6%XV%!=3N7G^M),1?T?SUK4OJVA^URJ@[4.R"I];<(]/CG0'K6.=
M'(1S0X%^NF"RFWFJ-JVBZ_SL 6OCK8\2Z43]=P%W+X]#HK^ ?!MK+4GVGXES
M']??&6BL0@EN:?\1_<6(]5_L,$GH(+G8"YM_."J37;^KZ5L4 IEJ#%\V2]*W
MX,\B\-WC<O:3)*\,1,CK5X0^!!BD0C"I.@W5CDG?,<&L!"#I3].I<J$YPQIO
M<^?W9$922G4F8N-%-H,?5!/I1!MB2/PZ+RID>("2NE18?2KE2F3J@?=\V]?B
M%W4PT1HP3/H'_/PE,8'=E&"5P;<,7PHI[HAZ"I$_TZ4\0#'UL0-_GB.C\8(7
M(2$"OU PX">PQQ >8%V>MSUKU8U4J$OQ.%[I+(.=2S-(%L@UPZ\OU?<&-M^P
MDT,6U-M,.X+^.F\Y)_YBM1V=F08%VON6/56> 6"C2KY:[<V$.O1V:U456=^5
M4KP'V,*XF$&)40I99:-RFA+RBKWM3\+X;KX?VG9[R?'81NM_4:*,F 0$[*?O
MO&%O=4 7EV^<B0\</J8KL&XFZ?IPD7WYB7LQ';"'ZN*>?C1%^%:&QSY"_8U-
MY4"_PA_EZVDW :*)?IMIB>AT8[\2?CYAQX<:R07FSOTL(J-<]3LY)$O<JNCQ
MPJF"!A=+-'%#:\:0G?>OTGQ!0$=7@A7<EFQN>#4LF[QNB/^0 [$T*[Q,VXF/
MSS Z%&:&IL&)+PUV[#<_[A@3?.[C2,>Y& =<DS1[[@,O%NNU;:Z..0V3MA=D
MFO!2D"^*7&"4ONC.GJ@P5&*LW4'67L%7;!Q3#PRLOKN6,KCS_"J',(SXYGVK
M,*P?]\PY.2RJ:-&X@&80"(SAR6) FGKJ,J^ZVQ3[9*)2"JZ,KB^MSDC?:S$]
MBY^S4DU$XQ%P<P-9R4+66I%;'NKR9'CM68_5)]'$@P0<C8L-,^K/A+O*R06+
M%\GFI'+(/>JK8WY OS\6M-KS4M#MS_,P75\@X%/4.6Z+2EE571T,RIQC*(CU
MJQ;Z1$RWS7 /@O,930U@O1GKMKY,M;_V&=958@A2H)D\;*63XSWR%C]Q1KZ8
M_IA68\(CW2<6+FN:I:V"GG:<V&QT477!/-YCC<.S!@DRP]49KLVR:'#2@G+G
ME_?G/6OXM 3]-](>$74\H?I V@C+;A89R+LAFKRG>K=&.G%7/4<LT!(U*O3F
M=IUQ1+_"95R)L=GLDUO>HJLQ5+Q\/GZNY9\S4O(M;;0FPZ,)G0HU>^?UU?EL
M]T(?!$;H2CK8Z>TR9OX&QM7TH]W,\=?5:V-[9 2&VR8J2VCO2@>I=%YM?<B,
M+V[JFX L]?.2RY$ O*[$-)O&Y)CS=Y]&B?FYN-=HPJ2M$U24*N9/CX#6-I"U
M1N)!D(TVZ9]IFB:PS&($V<DMMZ?*[_7Y-O5_;4KM/LGW$HHXGUU3#V'JLBO-
M V=]!! M?@V7T]9_K4#(?RY$N)-ZS"S ]J(T0UL2+:;0.YOG&S[A]1T?OT"C
M<#_],"5W+WVV%>M97I]Q)0B"GQ<(R=<G>@3\Z4+B+(! \:U$ETQYI2YT,L/-
MT#V*M%P(G;[0D(.9@S1S.(?PJ)0T#<XFT_K5._6/7:?Z96Y!3Q_//7=C=LQD
MW'):7&DSL7=W<M;HZ#BPX>X95H%J'*^QJIK6H!M;_9L]Q#&9QC]@<3S@G]=
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MQV@K50W/GN@3 SS/-L0 ";G]1RAA'Q.I9TCN_&W^NGUKGAK8)'<_?(''!0/
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MP_:#$!]WCL_C-14VLK@?7J3HO>2CLDSC7EC?_R1GNJCG?(_0Y<LK*WLO>]<
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MI2O=5?6OE^VNAU^543 4%%#Y30:JQHU:9?<P]*BS*)<4'>K2^$9VT?@A!JA
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MU<=FJII$HR6!-L!1%,VZ21C/D9?K8,K:K<7P@79%LAXV@1PQC;,VN%E?ZHI
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M$E<C8F4I7]2!#B+&(A[$U.=&?BN/VIH<:I&^T\AUZ$C$@(]W\(,HN4?4[=[
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M^*_^,/&>T2==3Y0S2M]+(Z'+7HO$6PEZ=&_/<RM#E.CWR,)_J).]HV=45?Y
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MV'.Z3*$(X38J&%4*1++LFQ4D*WQJ=S3YB?K-'C6#R81..N'@1J[2YBB/T[B
M0>E[ARE"T>&1C7B>="QB14[LUYX1U8Q=><+?DEWF]UJ0>NOL[6KG[)Z@:R?H
M-5$1_\K!58AKVBGIQW-!"R3S"G5@)10/7.^#*EB;EPEC5:OH^\GV\^26@@SG
M7Q#."(Y;FI5G='[Z7C/,(XG6 PL#L]8,*YO3DD&(]LD@LR$.@>2%:M?YU#0Y
MAT5XE3<U&I!.NXK#[/1/I?6TT2LWUX-K%.Y_U HS)XTR)DVVJ*A;TVF?S+$'
MX].?J3+H!;2L.2#*KGV[,;!:I8/,L2 *BH.LV"A.,JJIU8=/FM/P9"\5F>6O
M^397I60A:V3A0^'>1K"FLVF85P=O).?B.V!C_WU$9@X"KYRYPPF<OOED3C6O
MJJW7RW>$3[Z\3$Q>JA<T[,MP->(\Y[ESGMJ6HRM2.PG.-Q#VX>XK*UM2765\
MVZZ$?+_,K8LRPX5).P[<D_E)Q(1_BV!;SN9O0?Q;([CPY:8IJ3<G%,H1,'C3
M3K969M8Q20'#*K5ET/*WHN?F@%465$R:0W\,:DODT*E-*YOL(V97XM,(I];M
MW&->JF*W)UQDK9Z1DOF=.;5%=D29F-GG#2P5F1(@86]:-]Y^U'[SE(N7AP"C
M8NR(&]6--@[482XDQ$CKKN6!TG3<ZX[@PRB 5JMG%0.-4D6B+>V4S:,\D.Y@
M;UG'7P017 W+K'+=7'6NQX,<*>NS(;-'<\6/*]K'PFR4Y_;F#7=WF(^@#IO
MFKES*?.RPE7P$!HPK8!NZC@M#U9?3'W@#FP%V58\F%PVS#=?(C^AN7+21E%
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MFR9"*4).C:>:NG&G,2.KR\_:J:8@C1<3!"KTD#;CQ8S[G5<IIRI5FZ,U?M<
M7@^UD#,9$1TFZ\%>)6M7F<\E.9/!XDF=:;:'XZW$T123>4.'3YH<-9GQGD@Q
MI5ZQR[;!R:#\'#[B+'H5P7>9(1P,#_M@E^SL9(C\R2(T9;!X<L>T[!=".=HZ
M('?7(;J8O2.T FT/^RFPUUQM%JU1Q3^^J#2H.>XA^_(#72X!O5,'"=U6 /FX
M \?.F^I8YM!&ZI%/>$++A.PYX[#P<-#MOA*96-H/U60?WW@X3A%SIRXCH?RH
M09+3P2\_%Z;+A]#XC:5>00<MZRQ )(?Q%:XV)^G*^YHU1]+5]S6K3B$M7.-B
M>D27\^T.U+7F=U?8"?=F4U>C<YU!=R$K7N.@[4&5*ZJ$T@-]C+A[QMD21DGO
MK_Y1DI6]>_^0SUGM]),W(=:&XY9 V^>@8U*C::,GSM> )QT0Q"%DXW%S367'
M5<9+MFN U3!K5MBJ<'\?%'4):3]7?\*!0/O#%]&%]P.9P0FV3PJU Y^0[XV/
M*._^WP6GN33X?PM.'V<-84!F:$CLMPLUK* &5OPA9ZGY=V%R.IE/V//DTL7^
M  >6]<OJB%EER_.1;E,**VZ#OB1L]0JCNXSS[(P04K!J!*>[]<J7&8.G.MJ,
MUKCOO_^ ?/ L?<'SW$<5+P.EJ(Y!()MW3P>"]1_5^]\Y;+V2*I8@_<IW#2#=
M!COTX:;+U\J0T'[G&#MX.+F7M.@/DIM@@5?SLO?GOK8([OSM:+X^8[!H(IN&
ML9(D[DKEIKM9#J71*Q :P"!R]_BYEX>BS!NK>HL[@4>!W^.CE;E1DX*?=N<0
MKP[&[SO>EX7I"JIZE$F["3 0CI9P3FZ<G_$^[86U[TWYOP44-_SX:%=ZE;++
M\SK#RG][-8;'_Y D%V"K SQ8QDAO1U]<.EW=8"\OF25[53-LGSXYL>KF3?BA
M5TKX(?%W[*6)7@/X-3"S6$ZG$+\$0H=/7@-.3N$7.)/KIQ10-!-P6L)\WN97
ME:-,OQD]=\9D6NE&XM1)''A6K.#3PQBJ4+R'I#- ,* =*5,:T# ;%6[VMB;#
M1G5(F"XB[CF(:[)P6X(V:DBAKG'"?7LZ+C:#@_Z &OF]E47LE&)T6X*A'*%V
M:^IY'*C^F14A7JYJS8%$+,'^YQG#>W>,J^7KN(8!K#BT\MAQ9^B-V<D8;""Y
M?0WHSC7!;$,V'-3!*-O1L9<9<O)E-'/V*U6<BZE6>%2[FSK5 Q(<[,K!O;<]
MPAZ^2'J8+B^V0 (&U/XKF4-_K>X,(YWG*2 K*;;SIUU8E_S$2F<A*5OD +BO
M">\$#M R_'7@\E>)TU\'.>TG9!=E^*\!X5PZYQ_)U33-?Y-N7K6=)"C=C);I
M:\!#9<@*;>KN-2 OH_,:4#F)UQJ]2[+K8'7)O@-WN+QWV#+1V'<-T*V?K4W_
MNCG7$EHR;8BC4#F1-\'QS.3=H=OA:MRC6J]NL:!687H?Q(NR>KIG[-@SZI0^
MC<<>&\ZXRQ5]DM(4F<%2<W7EZ[ YH',-"*O=F3_"O93]M7P-2&_TN[H&-)W]
MJLKW.UFJ+2CQ;@HVBT;)8<:&3G5B3S_Y>*<TI64TG,[#]SVZE&VY4,5B49 *
MOWUFX/EV[<#LY3Z*>+YQ7MRK=(IU[1"'"@L^BNO(J_A5[ZJ3(T%O7X@KEF3/
MGEV:Y?)BV*"LD&[:_L/=(TPM[='E-: =Z HO=523?4Z5C[GOW^5T*C.+H!KZ
M>@99#5G&GM1HJ<W\-(-]QA3$Y!#]I<8_)<!O!B@H"@\1FIZG'K!64UC WLF'
M8M-+7.CH%@ 6V#9!QZRV^>&[^0? B#?(LC1:@12/-GKM6YL]EZBS[=]:S]C6
M^MEDVOK4AC<!_<T<UJ9MSE2>C)V'M8#CJ?%PWP5L;J8G3&Z)^-<4YQOH&LDP
MU=2]I OS?7]EY\Y/ >S:)UT'W^I_ *<_\2VVT=9E'HE==A?CR6!Z_QJE;^)0
M-@3U2E%_)YKVPD%Z43L!QUOAF_(#<8E3B3 V8(C1S4DTR_* C&]W?_*;:B^.
MLH@BS_>/*6A=Z]Z2V#L?%[>W8]@.+.$%LRBC083FZ FUWWIEHAI9QWK9J!S5
M^N'N#]N5Y1+3BX?LJ+S>^?8,"C&6@DUGCNKDU$K]6::7MMT\[YF([YY? Y C
MKP^BPBT*T-K(R-W9)HT4X9A73PQ;]<XL L6L[D9<3J;'+T+O;<]QP9!<8<NU
MU?H4C_M4@LYVS="OO\=F?%L)&J.;/TC\6&B3SH-TOUJM3;(K4"&8:CEQ>LZ)
M/B"6G:-WEN]AA?D[7 1]+)T&;X)HT?SB.7<)C/1[XT-_#%\#V /E@"$K;).Y
MR.SV9.UB[WP5BZ+JR:HFXAYR"T5V"B:++FH*SPXCX 07AMG+3J<&-F]B'L7Y
MY(C<GD5H(34].Y-_9EQ8IO=B R_)JW),<X+?B1@U+SOZ0*=2\?G\KZ-EEY!;
M[\UB4Y]OIE)0*,QW&)$AF@QSY(MM?$)"8'UZ@1_!W#3=\E0ZHBXR+L(XA>O)
MVV):^5YE](YCX(.)X3K=F"Z))+%<TQC7(V+)V:%:J3UV8JR%(B%1[AP<_+./
MQV3&2AREVW?K]')CHGHU8T! J%#IXS$%K)5DNEY$%3&CVHMFC3=$HFH94L.)
M2F$P>/*C!;_5@,;0BTM\%0I;G>2\;[FV#5Q!L$LB]1^KYKQ80*S<CVY(RTZ?
M]37W+&LW.AALSO-J1>LL2CF)(4A#H?96#N]4G]_0&*:[L=F]'\<&K$1= SHN
MFJ-/(^P6!WBFI)AZ[#P8]*X!OWH9,@Q\CH*4%$3XI^$;-[!.^PRS,'_)[SP'
M1+ST&NL0F3T+YG=PV9CE>][<#$VNZ<X);.FB DKMV0W#R]VY4/KSTW#+:\ G
MIU.KV'4G8WBCT'3:?!2W7CS*LP-#AI3(+D)ISTVKE8]G#-25)ZN1,:7&:47A
MJ4/$S )M9-2F>VX$.NYS8IBLP8.Q"U=."OTMTI<]IMUQ,BM$ T%1//(LPPP3
MQ0N-[ Z0):X(?D-E\OJZRJ9+CMIDP3NQ>HA K\%[ 2VPPEQ=U#08*5U36%8W
M4KTMZ;$Y62O:OP-IT5R(6(:.T<6K&GM!.EIHD Z8QD5]7_\7"(UVPY]*K!&?
M\)#L]_%<(&1="G3Q9TZE\%+)C:%WQ\Y+7] O"9UN376,B+R$F7VY)S57MP[=
M$&?_BK+!!4UC^"34+<4M54.LSV76-C<U;&CP/O$/44U[Q7<<M)K01]@GUMSK
M6Z/+6++$PT-LX>4_.SB-7XHF0LWK$N2^=,_>JMUU0=B]+1H.?A:P*2PNN3F5
MO0,+"+1 BXV93'*(N>;-0(KJX8G,$E]G>%'N^5[ZG2[6QO@G7M [AB\EO9^=
MIN\H,Z)YL#3I1NE\2#IP@H\]@U0BUVZ%8RUS3-*OTV%#?GV5A=YWDN03AF$K
M.2-Z4E\NY/1V]C.R+=U8V0$&%X'X^-@-$@Z= 6KYO..1H-@RL"%*8T$ZMY+Z
M_K9F&LU.=)/?=X/WV,-K:9Q[ENJ+VRE7#6O(  E/SCEP _1#QER,HW33Z\5=
M)QOA5%Z60$HOVV7Y.)4G*23D7P:[C$(8TJ(K^/ND_)$ONE0,^3; _BO(_,2&
MI*GQISM4WQ[&HTARG_"SGL\W!Z8LWM]*G*-M'#NA9=_6W=U+V0GW)I"9TR ,
MY$7@@=+<YKBQ^ <TQN*?0Q<FW#:Z]4(B/VO#CKBJ2*E@OGM-WB+N12LOFCV]
M_6("?G]*I<!+1Z<2IL*SM-1KG?4ZJ/[K'1R6H)Y]O9Y\]64QZ'<14%19$UG^
M0+97UE2?BA-O;ZWO*Y<OL4$KA2PL+%"?S>.A$)\/F(>P2;0.M*74U7JZ=%'W
MG4PD0F@3@1<H@O\+Y9EC;&V$.^8VJT#R> \HV!_M4\/+7KXJ3W]GWU!:2P'Z
M]:=LE%<>0J,)M6Y%'%M0EN%C+Z$8'"I';G)TF$XL(\T5 5DT0=FVB3;.DS=/
M?AZ\OZ8O*K><>,\W*.AX<'' K=:(;B('-6 !S<USJ]OI5P%]215 4$VGS7;9
M[D(Y'L(KDP>WGB3.F7-W1PA9,.)JN-]?_;6!!UI0(I,>00L2;,2+]S_XDK:7
M(^RM&Y4_1L\]G7X.91RIWG24P)<HM.7VSK'-.V2FEU1-@;_,0!'YD+1?X75(
MD$[PT]]?F\T?)HSD2)A/_E!XS)[6SCA=(%%?&$"# E_*'7!,1I=->7,Y\S4N
M'5$<T;)!M9A\QM;4'.8N,MF\X&KAG7V+XO?']][K)G YDM,MS=Y>(D&<E\HN
MWL/[H4(5]/UP&:.HA+);*+5Z.;'G>#*^-$A28=/14&/*.3C0*K02U71HI]/>
M IQX)L'LE:13#_MEXA/*L7I$OL](O4 7%5) +DB>JK%Y$<32"3]GINGZ W$:
MF42\AZ_(#H-V:/\P?U#H]VJ4"S9_TQ;LF(*7X2F8L-K5K".40'7801QX5JI"
M!%;)1^G(53:H<"[-]5+EOGX/2P P,K[OWM4S]!7UCNB"H_P79_4[>;9](E0\
MW38RI_L><K," !Y!Z;,]=,G+3>Y9NB@RK6&T_.*&].=2KYHSRH,X2O,WR@)7
MY%'BLCY3DV+\2_0D/UQ1V6TQTW,$XW>]37AW9F0D+$PE=[<1XJYJ7"%^*LO
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M+.U9IF9N2*9GD:T;OT\Y=5CL8'#YUC;_(WS%!4ERY0:ZH"XZV$Q_<E =7Y9
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MBA.BP$K_)Z:5]$>AG?_G-,! IC^VIRN:_&T<\P%4?=2D-B6)=E^+/[W"CF+
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M>>4+EYD1D!Y=K-?8$T-2OWRJ#7CW7&K?2*7,QBEGRT4_QJ_2\]5<D0_DH\^
MU=:%=$N%]9M4DQ#N;CQ6R)#M4=6S!Y.%E_#[V&&FPMYUI0YM/FC&CK]#,+N*
MUK!3=9*$G_2W(;*'O1D':#N>%HE<X;&D9Q-?3ZNWVDJ\%_;>A;%UIGV<_":8
M8(?3BQ4I47CCQQ3<X?'56K_4X\+6XBL?!U-S,LN9OC@4GBH2B3>JRM[<SMU\
M"XZ@5$MB;&10LO3R;.?>Q.=D87^R2"_[BN']_%P#S453,>!@<[P0"6H%/DI9
MX^[H4<\_@'9^)%<S:EVB8XEVZ&ZJKN_J'?ER#6#,V#9R6#)\O*P'JPJ;7=(.
MWF5Q>AZ#'^@:@3/$O\?P<!0.J_[ZT,"[[Z@#,D4/9Y#VUL^69939TAJ/Z?5Y
M)XK%XYATX(/=;(3618;)Y_%@%KP=BS'9\^QHR!T%?@Z7-6'3:5^<W(;[ 3)O
M!2F7HV3MD>#BG!D2O&N N5/T+M#LN6//KT9'WE0KX$?[$2,_I+N5HQ4,CC,:
M3/R9J[<6OES8-XMRN5AO%[&,7/M>2";#.>WJU]W\ CD$%=I4,_9Z/ JL,MA0
MD[7SQ=U^://$I01/U35CU="!?#FRE#X]R7&6_O*,61?_/BIA-@ZNY5#Z,[GW
M=D/SNUO4-O0Z0 VC'@.6=]4><0M;KIR,T>R4D$^-&>WHX[*]EO=,F9LC[D].
MX4Q^<[ZAD0J]J0%#:VUAWXJV3AND:U/>7@.X+V.A<V:[!@RY2[L*YV&=++],
M=RH8()3;YZ8-2.](.H&XB5-9!A(.:-A95BG#SG$#^P_S=+T4M[C&VF)NYKS:
M<:@#%:UO??:ICA"Z>%#OV*F$[^0:$.CC%&+AP&:W>0W /<5G#QU!.UY.TJM)
M:72EO\?UE\1D)'A4=,?]J)1I'0G6^KQ":M1"^T"1C'8,PID?&=8ZV=:7F'5^
M3"]-KB/?^Q>PP7D?*TU^PU+8\ZW/-4 DKE K-&?F^6\O 8G_!;X2_J\I9O_#
M)OLL108/K$?W^/*T*"?.Q><?AMQN,S1;B:EWEOQ\*NB134)U#4@<\32&8AGE
M5JDHP:6_PJ!HL141;72GRK>S8OZA.1M/L,/VE@];(== YU<A/7_$"'QH'"<S
MJ\IMP'%,\]:]:IVG'8F'D67YFW/5!7_4N5C %<-?WX?U.+$X@%[>]$V/,X#T
M"<F6^28#VB?$A$T*O#[:NXTBY7#DW9D5BZSR<4]8:NP@[33\@R$.S@YBL=V1
MS,?F+&-X#X\WV$[C<U_F@K]D6\;IB*XFM!Q'SB3#_^D51L8I8W_S"S&>'ITF
M0\M*#)1M36.^74#44D5Q:*XB*DYN+I$&YK386?4MJ[Z[R2%'[CMW^J,MY#4@
MB+_6!F(#8;C4#UU50]BL^,O::E;PV3:^D(\JHVRF\(FQ\?EM<:"9]7^*YH2]
M]BL=@ZEH%G7PF#N(^ZKB5O^;*(ZL MO=' PI:AC'/-[[^P:;R&^CLV?<3S[/
M)D)=K[97I.O>C"RBO$1>#'+/:79SKV]K]".H&T%O$$ 3OYHZ@;D&=.]F)YD6
M<UI+3>^A!W^$K7*@/2T8;SC;\>GMY0@!>QO8Q5^,J88/5*<],;I48=P2"1N-
MXOSH\+2'5P0E<LQ?2 DO6TUFS6H@?O.W\9Y!/Z7%>K[-]+T) KV*'AR,'E E
MO]G5?9?IMOH=7(8[XMNIXWX/\N>XXV:31U_^NJV!.;\&X!B+1O;DK*R';(^A
MH_.^6SFK:2+I1:X!7]?Y='18 D\ \XT--18GIM^Q'EE#'X7OTKXK6%%T1OK4
M[&*I"99H.EW+LN(#Y6_-#8#TKS!&KL::12HVTMU2BU/R 7U$@Z[B;]35X>RZ
M$)(BWAQ?3.QR296/RC@L]>>\Z4577 -(VJJW9_L.<Z4N%1KZ#L4(^P2]0B_9
MP+)0SVO ;V3Y5(5P!6VX>-9LO$OPBD.$4"[094LTVAE=' 2U+:$W;DL42>'K
M2?%]W^-&QWU&L6@IK%',HAVU[SYS05@EI&E:@/AE?\E@)>WF*7%WPL1L]8Z5
MT;0QWDGG2^#[DWPA.PL5CP3(-_Y%,>(GHKZ"9T#)*D)VG=/P_>?%9I+#N9..
M/Z3T-4%-D WQ[<RQ)OR"-B69!0G0ZF<#D@Z$X:TF[?)GSV4J?F3C%SV_Y>/U
M+-TE+LW_@6/)8<6O6:'.=I+B_1'B*+XP_BA^_+";15&!^.X41J<7\RHU=N&%
MKYRCC7(N;LP@1FNIV)OO2^C):"0DEB:REN&I(SO'2S14(J2 5F^IHQ>' V"?
M_CH,TI1</\= /**4/D 73LKO#0/VGR2S]W&@54KTG[/[[(D_:;<Z6FM(^T^!
MD.KV-93/4,(EM+^/--[4NLQBGXOK4"3N!BYIC,][O2J4IUR]Z:BN=/QXGL:Y
M:?7%B%'$9EM6]6A ?@H^[&ECFY*/M;GLHC\E,V'-'3G,$2])=_)8\)W29=+V
M^S+OL[("00IQV>E+[+H,-BNZRU*)EF+X7T9SY8VX%5=-\\&E.C;R?6N_GE"T
M;Z4+QW[-'C/%;Q;[=5O^@@19%N!T;^M(8&V<!;@G,')AVC3U:Y(AI=J)2RE:
M/4KV4T%]KO7%GD\GQ:JJ5[QN[1MMC/9IS#ZPU"U9)^J^C"Z,]8,Y<EUV#$D/
MQW?C3167[>/R1)C:K7Q)5DP6B#N<WQ.E6?>36O2"F3IR]+9[1LE?5OK[7VUG
MRNJ1&E+QE'=;".-J% ^7RJ1YN2@9,CC@GSP_6L_;&7K4,KKO]@M_5K_)3(@H
MHO""(4&Y.2?P^[L;> 7\6M6EPM.NNN JGR^:&:M&]*]#C&>'5/C\;W$^&CN+
M0?2D2].IOUY\+.,I3B$C7U8L?6#1L5=E*]E.8LP.$O7W!Z5YJNFW CJ>=U$=
M2^.<:R:T )GR\0:TCKS=A)'")^#8U9QZOS.SQY\>?3+]=/,Q(5O0=_*^QH*2
MTB?U7Y:$QBL*BQ.1$R/A"L&SRF*;/'.+WAASG?RPTAU6A:P-^&(T^UW9;8IE
MI1/(P3I%X1;O5M*0N_!J%(4OZ\XMC9)=3RU,YT@9/PG+X*$'9M]C9O7=2>M)
MR3C27F519C*RD+AT-<4!O3\;6-]5)\Z^-$$SD02#[>U">/<,?<B!E<TE4*<G
M5SYI]!2#8%2TZCB?HH-,N_2E5$*J&,16\[ MU8K)-9F/A'2+9C'8),M;@%.7
M-@/&[O 0N/B=)1U$PW"_1#-G-^\">G1X?GQGF;57+0S>7#1R#4A*;VY(HW=/
M)YR<(HC-&SP/UKC,4IEU4OF&@8 /=P4[1[9$?EL9W)R[;>"QE(MY]]=XZN]=
M^>)V^5&R89IQ FP;K9^C.K0_K^K< O/:#AW)N)O)TK]0#6] ?]TEU]0>(PC7
MS:=GDEQ&4A?:[8XI&0)QQY3[L:[%]"]P(8)%!7"4TG)Z5H;F1%B,++@Z@M[E
M/_?M_=^3#O+T+N"^C_HX68ORR'0I0&;'L-*F^I]8J68J,21_J\[NBS/K9=6C
MJ64LY-)D\ET#[NF637,HT]9US2IVB+:DA# WX+/BX%V^[+!IMXX1!G8D*=Q
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M4,OP9O&<%[.;0.+NA)D-5\+R*4RH8E=J<,J+6XPMT 4[YRC>).>('):NDB@
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M[+_G^W$R43.=5#ZT>$N8I]9R:IE)2DD<N6,CY3J ) F#Z B \_/8;S_+VR[
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MC,VA#!5R@R'RS('[Y=^G ^N:;H9G&L1VK-L9I_:]N* /S$$6->"OZY3,1+J
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M-9U TVR%6BH,X M.98T@Q5]SME3"'/D(IHJQ#1PILCQI?]* E$&Q%/2<501
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MAE[ZXS#G5=J+WGF!),#*./^2.U"=)+'$+'KX:WD/T<GU)O6+EZ1:4"=X,K7
MV$&I'_,^_ 6G$*FMD ?/&'=MI"'M7N24IW\(N^_KM/7;-NW=QL5G"$ @% '
M4IB KL[W7_/&[P=93-\R<YD.)W\F"6\#TZ@KFX+!!&UXT;@[=W"&*1VV=6]*
MS7,/FA7NL?EQOQ])JS35O4VXU,1)[+XEI4XAIAGERAH^N?:<3-HS@]-NCD>?
M+:Y'M.RS6!'S^+Z;O%=+9MMN?:$N$IOWPX/4W':[1K2N5&<F89[=+&'&ZZ-H
MYY25;42"0^$V\[VVPS-_F[&(S]0#==F1[0[Y>T!&892S;4W)<440KGTPYJ;
MY_J DU<8DU\+\BRB2CZY[_'S;<KI2&Q@O,FY*#J;;QTR%?#X?#XNBRH/W$7E
MPI9%JXH2M/8*J>XOM_7@/L3>AN*X2:"/A1KG:/:@:Z@7-07@,ST0Q\4.&[A6
MVR[4DZ->\DU9EJ^M\SF9>)EL%-CK!'=HFN*GABF8=XR?).JK'50&<5ON].2L
MCB8-0@K<TDR.ENQ)8R5?T=,L?R-()8CS\'2(@_EG5XS%2 [958R4HSQ)9(K]
MQ-$<^YUEA4+!(* XY<+[^IULCTX@;_'(AP36MOPJ]UI?-6]<XE<;X/##QUYD
M%+Q5H^4X]$HC9=/3=G)3KEUK8E36W>W?HZ@;^0H5T#9E(:YYY@]-D6__N(2V
MJCI:O2J,P.8'^;0EO9>GNSF981=T^^H2L$_41][H[T;/-<1B+>7(*5C\79&*
MGV9T&OBXPS%K?OOY%'=%H$5F:DU8@ZL/N:94R).!B/Y,I<.&S]RS.BT.PY,]
MMD;/9F9VU*?RORU;DZ/P$4;=^N=++^[:?C_J$&S_LC?,EH@7?;A"&)Q,=!^S
M8WA"1>89$P(PEF*.!&%(CLYD2YZY'EE<OV0D[$JI6L-IM$K=Z?N"C6#"^XH/
MY0A V46ZXL!JQ9%110#_8D3O#'UP%<O=N^Q.^WIV5]R%>[%WDS&\[:&[&HQD
MS6>N8>9?J6V?/ *T%''LGA0B&<##-QL=LN-V7\_U7L*R/ZA\7%)["MJ/P;;>
MEVMFG;2'UWJ-F)*LGQWI]9-7QD#N#$^W/+N=<Y*_Y^7EE1!RRZQ76D9.)XPG
M5C),31GH]/$Q_-C>\")<85F;^U.A^UTDC%#^[8I_+J20HG,1WW*N_:;]29]N
M!QWG:M6JSO'M<^;58"F%FB%[TL![$T$:#_BE5)#TT\]M?'QT??X1'!B*/P4U
M,^M,5_>RKLR>>@#%0@!,'4!>9YLM8RMNL/=TH4D,V=)D7[H/98+"J0F-##YF
MV*,[<$V=^/_U!++;"")DPEX&'?%CYZ73^F\ 4K#*=D76U48@.RQ+SW7E%Q]*
MV4"SZ]T5%MU1YUM$@.5#"TT<1<96H#'^Z[Y+^-<BE<7LEL/%>/U=80F"K=(B
MU-.C!P@ WG5']8VP[8;]VA*S;8-:L302<'5;L*,9*MWZAB^'.G ]WM_DN?QU
M3(U+T13ESUD@&?\5V 'T$VR99BNBDOP:QAFA^S4SI S%Y6^I\Q?/%HQ,5@(4
M]5?=0*7MU_D9J.PN:LY4S-U'#*A,O][R"IQFD[7 "5\I@/WUMYPJ4<%(?M#%
M'K@@PUA#N2 URA>3FC(@IR<J"Z.#0$-L60$/Y"NDXIS]P"UXSK@6N.1?K=_S
MQ;VIR*/^T[#&RSL$:MOW]#GJQH$,&\)RAI]AV 2STB>"['Q,7Z<.4V4=+YZM
M!I+JT_)674Z?$#Y.M44 6)!/IPZ:J55;]?C0R/VX.:"=)ER:GZ[N0\.G0S4]
MILJ>JYW0PGZ.R*.=YSWLM=-S'OIK5Y<N_MK:[C^DPM?#SJ'-I69B3-^]/PJ0
MG!XZF2Z9\<FN;KE5:'U5_?Z.T!0RZJ@_-O>^_+0RD>(4* !/*V&V&%O0?4EZ
MX7>?*3H54EPW F2VI_"M2RC%9U)QTIX^00#8CD22/Y=L.<4Q<S9OQ9W7"]Y4
M0 ^()0,88&X7WHY-<=)C-P99FKLLP0)U7^%+-WU7:/IJXZ$WCPZ6I0CG/UM0
M=WP5Z?_P:C>A%J\5Y8+D#/O86F4ML9;@8P!#D<%O&6PRO-!W!KG:?:%1J5,B
M*1&W$LZ.@1"+9^\'W3[31$I!2;N*[T'T5I938%:'#M'V.)1=)&M@VS4&\E?P
MI[=0[&.92Z$V69Q@>]:&_+WB,WYP"#-JKKY:^O5>* _\^PCU&XO'%;$I95Z+
MQ6+$EY]":YFWK)LZ"NW&SX8;6XX_?'LU?.N#WXTI:S'%UZ$[+B5AH]HAGQX(
M-H%NC]N6)*$2C(2[9C7"Y!JD2/-UYOL7=DFE/DY9TPZ)$>RN1JSDJ'59REN/
MDV_=JR?5'#P59E.]-MQZA_%XEXS'BYB*TKMYG1+JX\BE1&:75JVL/@9W/-[,
M?IN$^LCMA_S6V%%E=+_>RI>7)E4AM,0F5BGN\LR3/^O,97'O%52R@&PAQR:C
MM7C;%QKIXY5A@]:93*&['G[>R6,J^23@'=C/]J/G>/]<U'O+*5.-Q>J.5@B[
MM[ <@(>OXL@% 6"*_FUW&^WYKSZTK#W2N[6\@#*]3,&*SM3V-U=+P9(0+.=2
MJ55$\Y-A(/_3&L..^=,YW^Q?P_^>-'^B/WEC/S?^N0"*+DIBFZ(X2 +$>)OK
MEPEX.7IOI$^Q'B#ZERZT1Z06 M"Q PT]XD*!_8X?BT;!OCP_EE]"P,=M@5S8
MZ$:*=P28-#[!F#MS<OY@ ^%#.(U273C[2U&MV!  6BX78(LY(G0)-X8RP-8D
MMR-;EC*8FYBUV*(U 2UA!=6IBRC?Q2]PEZ5<FFO:E5Q<N=9'7($\Z.G-%Q<+
M&D^LDVV-KF??[;@T,)9"'SU+7>P#*@[NT_L8CZ;XBA8,5JWX!G<H[>%(0V B
M\4N-Y+IZ?;;<(8GD&?ZH%;N>S;(?E*VPA,[Z0.]WK00#F)\H'PI'QRQV<G<M
M58&U/DDH$<J&<A)UTN N"XVI):4*W+P>6TC:$S.^FTSPD??+I:EMCV'*U4@.
M3Q&&OH0-SB&^G*QQ/817@T2''4V)I\H;?8'WS;3M/$1GI,[,.!ML(J5#+GET
MWJ4U)OA*?$\\2:I7P#!A.:?=[)K? 4V>]?$4VP.%0N9N"Y-*'0=ER>]YTNCW
M382NQH+5XW;:LKD7RJN^?+YI0F4X5B">0J$T.81Q'X0&3.$\ASX ZT]'2 OW
M3[:OWYU?C\"FEINX8^W=4<0I)]:EBZ>25LHM[# NW3 ,H0]Y'Z'XM>5A$"IA
M<7(\C?5)G['<<CQW?4-IQ= I>#J0^+5M9F&5>Q5@[\<"NXTHN9.0:H[T#H:2
MA.W^LC"QFZ!EH7^&*]CW:/%E4"Q-!,V'>^,.8C=YE3=TWV1Q5JA?C[*6$T%N
M3DJ3[F@9O5ZV<6M[A0'CNJ2=P,TJ+JKC!KO"IK?&>35*XFTH2"5CSC$7WO*]
M=M]S6:MFI6^%N"X(,VVKNYMCR8U@6A@82U8YV :1'0/?\2V7VUW%!$)8N*6&
M*4L:1RP-Q6@&-9O)6K.SEEZA"?O:*H0K.8A:#NI.7ZQ+*N#Q5&A#2Z4$IGM]
MA:3O10/\5((,A:[M^AY[<)54C[(6T ^?"CZI[9\TJJN<B'AK@FWSBF\='3M)
MV@$M(ZT:#*/0U"F?EL@VCU&/#AF<T=.9]O5]WN@:_CW!D9)D$[(>L#7%_%E7
M2#G%SF#V52<H"I?5XF=E_E=_!YZ\(1ZDFA>%VD>CX?UJ:+<.(M+N:%X(0*K]
MU;@7V.5N[N+TLEF>MG!=<K,"T_*H3BI0YFHJ7W]SS*4P?DI_JLW6XM8P2AP/
M-CY7P_B.%H<B1PY(J:2W7N3V<-@B-G/0,J/$L#^"_5AE ]<1KX.[>0N()?3F
MG4*,,<X2WE)EK,+&!"C3H;V>WYXPA"1@-KY)C\&KHM'OE HZ4>$(3.&26&@D
MD!'5Q]LRO+TVT5]CEG<Z1\,.V+-# #XE/6LP/F9)+16_<<1G WY<@4?-FNJC
METVK:]GG3[+IOKUD#WT&2@4YP8D*5O427'Q"*0;M<%1:>=.&9<O"G?EF1)M3
M3@T'L,\;46^X2P[R"E<79>M50T^_7CX]0_H\(HTR.W:W/#TR93HZ]S0+4_3\
M'_D ;VW5\P.*J%0&37V_*$D(4YML#H]5MW.ARF-H)_%]/)J)<Z$4Z]#7MO_[
M>"$) Q?@S^$5Y5\/^@%, NRY5')0<'X]UF>._[\C+H#ZWP$Q=&7Q) WO3;5.
MRH71*7!:U3JL$*":EG18XAJJ;?S+CUG-X]>1N"FENF<-"6TYB-:)XAKK+RG
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M'X'?]:1,B\Q5^<@A+4H&#((_V4RB-V.#$&EN07I>Y1_)0*?U]:W[B\ MY0@
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M*I4G\Z#R5R*[IIQN]JTLST?_4@1>$6L#*_NS[EG'F"=U6O8#W/6C7'33^CL
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M#[MS08L$G,3U6^]Y!$!22N]4USXM79 ZND#5V BYH(V,_BED66LD14Y6%FE
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M?[Z/+EN-ZK7I"19Q7JN.S4K2B%9?39)DZ=B2 QG3C7/BF2#_".LTBV#XJ1]
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M9P/I@AP?(L03#).G%$4\(GL+&&"<U6&U-<F_[4B3.8-Z$71M%6K[U[<#9QQ
MR[*!IP%F;."U HR6LO$R"HJC\_;87!F#_=7]J(+_7?:*\N5_XVO\)]]_)%]-
MX\^LN_E3:4H5*6Q KP8766#-0W2EYKH=58E^0+JS;E[:KFMK%+A8'CWQ89ZC
M_G3^7XO3Z+W4S+<V5[I_(,UU[O@TK!A]XZ&@T' F&]@'+9TW31C6WRDE[!N\
MA,0 YQ_!I>=/C%E2?C SS:6?5;UYK0P?6G<F1Q^3LY*[F)U=0"+=[[/<'^?W
M&+XG=O;\EB!S<O5.*4%:,!%Y9[/VHQL\"^5CJ53U(GD:_/-Z4IU8Q;-,R*F<
MDY8-T; Q_!D819CSA/A7F]_RH1*\H#GY=;N[S3*>\F;Y!!,H8N.<^[DA=>);
MKAK^ZT2Z^U9T2#'5MW#N&C[YINXA$=MI[@O NBYNHMD%9FV%O1D&45IAR&^H
M3O_X+EC?F@3.=FCU"YM[#/3N;EJ!+D]_^S7^?Z-W)/]',KM1[:.6&!;@Y4J7
MBSWPKI>7=]*!YTS4:-7>83^?JW%$ W<WXPFS0V+O3\V>>,<R=6NP>#*>D&W9
M>NUX@O1 P?4;X<T)5V)UED4@[887H3^0#K05G"X(OSAZ<G\$N L,NU;O/+*W
MC+&NIF@IYWIZ^S:7FKK[8'*Z8%[4V')K\$;_!>N]UE%J91[TU @: B2R 4O1
M+@[X>$K*=)7Z,O2O/'/$Y[O^>(#8NN?%I\2)^RBG)+I* VQ9ZA4'+7VXZI<G
M+Z/XLK4EBL)<3@F;MK+.0,AX9FSAW^1^)$3CMC/O64FE'M4RM^&>SS&RG\(<
M=DE_!U\+>LY3EO%"M45JYZG@."<-G-CWK_>U%^AE41OWP_T;;\_4I;S"YUOV
M3A=;UMM#7Q?QI_%=!X7HJI#^=JN74VD_?:=29"F<!K]/8.B;]:CM<T7MEGOP
M; C[4G-_PV1"R F9E<VKZ8+-46-@B>85-J!#=V/PVK#D7GE3 VR?G=VH'_5J
MDISP2]@4$F*?SI.C"LG4]5CMPT1HGB5"$]NF5OGKC2X:!S31=L#7%Q!0;"'-
M:5RL1S9J#97P2CQ3&RN^ <#>I0LV1+WNPFJ>\O*UZUCQ_0%W;8MPAMD<Z:2^
M5X]8\"%"CYMW5\_EBTK!2SB^\ F)0!QD4L3,+L8EW[)1OKLHL\(3GFBX:6[?
M!L3"^]]F>)N'#4[[K]4K?V_EZ&]*QG5<:B)'6(>,!%Q9V-7KS=2W-\J1Q57:
MVPEMI?ZHWY)XI!O?MJ:G^%9-.3Q8CG(;GNL;8)*R:.HNKI3I,"J^@)?Y:85U
MH=7;9H=KZ5YBJ#LJWV*OY6K*?E6XE.].E<9S*XW7NP+LXL=C4C30UN>-;V>;
MZAV]45U >K>R1_%-E0KE%]9.9<&/TT/]&'NZ7N)B31/!=7=L98._O[GS9S80
MAJ%$TFZIH>8PI2XQ\<WT']^/^GQ88CP/TXO#5^8\+]Y]6%96)G]0;\.SFH1,
MB]3U+8QD P>W<#Q@:\[ ;K>KSBM\O-ZY:'],9?N*HRZ:T8Y:X%>L#U8%W[4_
M90,D969:=5X$,>6\UNT:L8^&.69K$X3F-[JB8P0)<-2R$YSAN M7G7P.-HD=
M<'\$%IC'[.UCHHPRJDXB:4?D<I[V3ALZUQZOP,?ZQ&!]K9OW[L6O$JU,6+PD
MGR)^W\\TI&697_H#1M; 6*VZ^,^A2Z5E(T-XM3BL#$GS>O*0YLN'F<?OYA/E
MI[M3^KWZGA?Q4 ?CF974Z*E@\,$J1@ZF8C='J)08D88]N<[Q1.ZR@5R.H2(#
MTJ])]KF4[AX<O+0XJZ;AGN#$*$2<],03,K5BH]Y2[MT%R:*490U47TWW6"4^
M=6SVPTA:,NQ#5>:PBC6M<9AW51*S% /]1.'5)R/QBZ8;4>5=[E$NSKT3M9\S
M(XH.>6 J"M>Q[3[%\][FJ8'B).@0V<^[24K%<=%6![;8N@B?*0LVO3,,AD+U
M:TH*05?[RRB_469\(22H$L\2;R0C^_!;Y/,37XB0(Q+X5]0M_!T^L8%WJ_Z*
M$S">0'6.Q4;4+Z]B==.E'AQ/*)EEV<U#/MP4LB",8*7IO'62(AT,-@";[6G/
M22UQ71@Z?J*I<>(B\[)5U0<-_R<H^<PY9J@S6F]M#9UH/A\P)V(>Q9!A W&W
MBCA=J0!;=L#F0"_*KVD.0,7ZC7*-5D<1&P.K>?(9./7_4(5TU3>3I1L#9Y6E
MD KNB8#OBI]S'M0N;8G(3CG4=D>-U<=' NR2 X5JDM6)A; ':L[U_H\U"*'>
M,[W^6GVN5HO8TD4!;\E= ,WHM?#]*^J\T\YAU/-)T+L!JPXH!M(UY^*(E7OA
MT2,T5T;QE/8^L0B^^,8^$=1[I\HNR=27X&MS>ZN%*)QSZEAIE^IL4$W36H,0
M-;:,"7MB_DOC#>'&$H-7%:45:,E=XIIT<(6J+5H%TI]F#<#KJ .!H3ZSX"/1
MCR0Q$?,T)1+6[5EI7#^BQ(5Z.%- T;YSFO?5EAL/(6]HV,+.A@WC"UENWOLE
M+9K6$"T^4Q8VSE0\DV>92)]D U2?U.'*7N^%O5/F7O.+&:$J+N):%C@"^=(D
MN,P9V<&$C65(MLH0+.S'?L-8^?E67,WE^C6X0+1GP.5R4,#*-UL3YE3A\R0T
M\0Z8V!%?QIA07[\;2-)A5ML73N[)_[C^*(I7H-JC6T!R&QMX\',CJP^<;$C?
MKJ':M_RR6>T7Y[/W(6./^&32UD=)"L]:L/7#J!W@E?Z^UE3,X/IH=" QVE-K
MIBT_CI+#B$Z38P-%"6R@+2M]^PTQJ&+ 9.)&"PII!/JV%P_PXM\[;[<(H+$.
MU/9=]T!X*[%T'S)RQJZO[2NQ9KKOZ<EVRV+HAB].W'R82#MY!G7H[4;;UJ(^
MA@L;T&:JL#9@#&O$,$(9)&^N"*B+/?DR2N9"S61+B$?3',?9K7W3Q@:F)EA,
M<&7FS/9*J>\GDQ!"R:/0R0L5G\-?JS.."@!(\KL.90''?*E/QR8;I\^@IO4=
M]-T$FJ^G[1X[-^'\W!:#=H[N*/T8J.RJBG7MN78!L6/@3.4#DFJKL1FFGH5.
MRCQUM%\E/&VJ*R]$T(,9Y"G/4V[*_]0$ %[SE'JD27 >W1*: 2[OMP[=@:VN
M<G\J>T4[I+CI]>YQCL(3!-^M%P7#-G:D"W;\4</R[PM[^ >H")2(FR(=J6<5
M#_N@<GE%1S \<E%:2(M7@7R#\LDZFF3DUI'I%C0)C1H&PRNJ\1$V-I2PMMM^
M$I7:4BV'&A=<M+9!PU]@Q;W..*(;L4G=69/=;TV2E+4*!DG6Q-/4K81K9.P!
M?:2!\JCTH>&?MA\YN!MX@+%)5ZL-A/<45.E07CA9!%3V(SUO(9\:WZ^3%"HK
M4 @4IO(VB"52:6FS.HZ[[)5E['G*3>[='K(RMQ\!^0:L&-"[.FU*FIT\#=+1
M[_)N%!DA=Z@,9A@]'E$ZC%TZE@T7",M'KD49CU<ZTG/]TT R9JOOC!%ECF.^
M#MN\[&W.JA?JS]&_X\$[9OIZ5#)AR%?JK>3AMA5D)$.G$'2PK#HI?6_.LZ44
MS_/X!. NI-;@F&)?_TGJ_%W4B[M-I:'">UQQUS<AIA%:B,+X6@*EA$"6Q7%4
MQ5V6C@T,PP8DAP9<"%[C]'Y_$R.$VGPEBQ>M87KH3'9>IP?)KAQ+</D GF8#
M\;>K..A;P@8F2]#=:(4"&K+QV""L2VUN4Z.CWZ.WL%1(\X,[BY5!_E'%;$ L
MA\&,S7L\\.-C-#.Z^)'#Y>K'9 O^=N1%9T^A&*E%50=PI84-V!<Y%4G3PLC*
M(K1P??[QCL8YL9\N/B]W.R;3K[R9<H'G@[^' 5@_Q5%95Y[JUWJZ*ML<<+(E
M1]:VASJ].3&XEH"W+R8E,CPX$NZFSQG?1.:#_!<4&X8,IM>%&[:-$:HYWKA!
M*+]U;R70AUA].="4,HX=UM_9/(3 T<\56RWX+ G_5'F6^!Z.=39;S)J-/;PI
MYKM D]&"M+7.!0W4-NXR[%.P5V.(#>AB_6"_G"VCS65GP0/@7@X2@KW7KFQX
M&?=]#+3%%=^NW7+$\M2>MWO"<>L&WT'2JB <3/45(K>N)F!A$8&GW$NFE<H:
M;JTEV'TN.7Z#8WOUZ#=G1)M8K)R<:D@4-'5N+KCFW6%XTW_M!!O8]W'(26IW
MZ[-4KU7GCX$)X2ZSJ7M;).;1<+(EC%)4(PNV<2XG01'#DDMJ2-M)#2+6*7"[
MP%U'/!P\MC]\&V3=NJ9:]R #C5E:U2 F*""3M3;V.>&R?X[+-DK!F:ZG5!-/
MO4J9J!W<NFOF.,RQO/B578K-$<Q[V\>!K;>]7H]7V;P./M;!T"J83JDI$1VK
M7YG@;SN#C6DM;SK\-K=QS#J\]!E#IZ<*J+!>22[KLJ]24E^Z=.[G=%$I!6"L
MG V$+/55$ 5INTYW5IVT=0[*=%P3<]RQ-)K2I[Z[?*SFLJ [@J>7OSWW S()
M>?-$;M=;\G.3U59$Z\?%TI>D^>N+]S;1HEK.T](7+T0>Z%A1L!!%:!O=^F"P
M@T_B&"\ZO#J_?FA1=H:P*LB!KG87*[$ZF[OF8O&.I#21#NQPRH$6U1O#)W@O
M8[N^FX R%2NZ?NCR06T:M&QQ+C$N[\R*21^LTFM_@%=O."Y97J]A^- D_5VC
MZ5.TMX?(4+S^=,$:..X!XR&,6G81OMBE%F]HK1)Q-"(\5NRC8O^AS*LQ!5>O
M2T3-LD1]O<PH@Y$!;OD602D776]FK$>L6Z?;CQWL* D^X(NT(@7:9ME,O8(&
ME58YR()J8HX[=_K:;:9.&9&5+V6ZZ$\-*QSN\_%+^K'BDZ7KN U#<2'29ODX
M&QC3FV #D7DV6Z_$*8O/"+^GCR'MS*_'EX?^$A^/)J-M*0NU%N-A(P)H-F!4
MO*A4*.VQ:_UY?^1]X=IBZ7L6.?!$#X_R!,UZ4FU/#-ID%NNL.$-+P^B*F!M^
M_J,&SK<++5GZNZ$ET[*=(B<W5;8[_FJ6=51_CZ&N?UTZ^=;O8/XCZ/<=S-N)
M(3M^BV"?\9NGF;X=]\_^1.GOFUS$08Z:Y!MFZ^$@/_SODXN9S#Z'=#X7?P+9
M[% UGB,%]7^Y=!;T4]OFJQSSO/3T,N1BK@MLA J3&G6\8.@$Z^BDLDP@N?\"
M7SO]GZ23<4>;[]<N5^-N:/!L8P^0KM %06H+J*GE?)U:H!KUL0$L;+YMR^]O
M\/BO1RJNX,C4EP[/>.+%&9K*W(!J(I!#71F9AD:Q#X&OYMU??&"3[\7"@97G
M1.CW5C*G]$4@2@0J2U3K%"\U6%2-V_&&V@+/TG C/??;-NL;OLB->/[(8,M-
MD5=OF0HPJ;'SMKIE]<W!L.80U6\]F_P/(55#;;YS\4S+( %HZL$!MZ?I_-I&
MPP_YK0QXCACU"PUBLH^+RI;5W9W2_M[AGWVI?P,1RZ2FN/TL8CPA17#C@+U\
M.N_SW"UJNIK\@&]VEDCU)*3K5V PPS O;1CK(HYOO%E^=DN;+TYC)_1A!Y$Y
MSI@:3W& A W1Y]8[D4W,U:_GT8L@\0QC*GN4#:3=8P-!QJW'0J25#S*60?ID
MI_@HBPX.F2IQ$$$VBT4/]MDK#JL96NL^']#EHKUCU\&U?M;&LZ])_M9'NL I
M.G$!SUQ!<),)8R.#S7[QG-8Z[G!J+*EN&&I_]QXSY/:^L^3KN05P[R@81%!!
M)G.8/H$FADASBS]$<Z]M6D]^DR;W8/)+7E;&GX7_ 853-Q'<WV4<T-K!D8R%
M/ -NHA$DG[YUGB-)7/'$<VJP@9K<+ASPZ6L=Z\4OB8_(;QF.CE^$% 'W!R)P
MG$;HTRD6**Y<&J6<TA;^GBN2G5\:FC9&: N[<L_;OX@@0A> ?SD0Y^9U/?Q5
M?O\L_,\ME+O*@3V[[*ST;4M?0"OYJQB:X!Y")*]RP='$[JMH&;7Q\'P1WC=<
MH/0FZ\D# E^ ,2?\ZU\,%(9# "[8<J67_!O<[MERPF#30CS+'\9<=CS5Q :T
MI%@;&0^_YAV?T)/D<)_050+D;W*Y4K[ >,9C>8C?09GX\R*WT^1YV!__"U!+
M P04    " #N/7Q4[KN4S=@\ 0#3@P$ $@   &EM9S$U.#(Q-34Q.%\U+FIP
M9^R[=51<3[0FVD@@2" $=Q(@. 0-WB0$#^Z>X-#!73M D. 2(#C!O8,T;L$E
MN+N[=:.-=3]^]\Z][]YY\]9[,^^?F?6F>NU>==:I7:>^JEU[?_MT%VH.M09X
MKBBK( M 0P< T!X_ -0B0!KP% L+&^O)4VQL;!R<I[CX),_P\?#P*5\0$Y+0
M4M'3T5+1T# P<;,PO.)DI*%A?<O&^8970$" GD5$0IA/G)M?@.^?3M!P<'#P
M\? IGCVCX'M)\Y+OO[N@.@!$3]$%L%LPT%X!T(G0,(C04-T ^L=Q/D'[EP+X
M+P4-'0/S"1;V4QQ<O,<&T.< =#0,#'1,C"=/,#$?[_H_W@=@$CUY\9+W'1:Q
M^F?L5\XD?('QOYXROJ_Z0ZHQ#F/B-W,)PL$E(Z>@I&)^S<+*QBX@*/166$14
M^H.,K)R\@J*FEK:.KIZ^@;F%I96UC:V=JYN[AZ>7MT_PMY#0L/#O$0F)/Y*2
M4WZFIN7FY1<4%A67E%;7U$+KZAL:FSJ[NGMZ^_H'!B<FIZ9G9N?F%]8W-K>V
M=W;W]@_@9^<7EU?7B)O;?W"A 3#0_JW\-W$1/>)"Q\3$P,3^!Q<:NN<_#8@P
MG[SDQ7KQ3AW[LS/Q*[[ IR3OXW]5_<%AY-> D9JYC..2,0FL,\/_@?8OR/[?
M 0OZ'T+V[\#^3UP+ 'P,M,?%PR "  '7\0,=!;SUQ?G2=W\TU3 E-7TB5)D?
M9%1E +IGIE/J6^VETQ&LZ.UQR#*Y1[GYMXN;\2U@*=+=+ ( ^:?BYDUXT)ZI
ME_N5X^:?"IWT+617AS4'%_E/Y7\K_J^B.+[57EQ&HH9)IW0;8<K6*J,L Y#9
M?K0-2XZHJ6F2OI,Q=*NH27ZE-("'+4[^\&L;M'4<2DSU[;?%17W73R2_,IP9
M_F,QQ25[CX]2NJUX?&[%_PJP_[?B_R?%?[EX7&Z>!&1N4>ZC%9A.:=PH'[#;
ML:*_I/:)L!&4T,'Z2I]F]"^68S3A+O!MC/"O9"T !>!JE6'YL9);^*]*_]MT
M_G^G^%],)\+T7T..]*,K*3A;G-*J5<.44=P4L$K6O+9-S<&,0EYH1Y01/9Q-
MEP)8<R/^@S2>DB-*5SO3U!K<SAVLF#^%"2_):?B'T?\L3'3H3QUY$_DC*WS/
M!O(RV!"16KJ( MC,2PW9K?*5OGN.":ZFWV'<-R8,]/.4;/5\G53:765'5,(^
M6.#WUW]-MX80OA\QH661-&+@M>":$)W6-FN8>4RBKD\;*$.BAO;?%-)=272X
M;$V%5Y%&S12/^*&7N4>T>+[1\S4"*>Q?I5'4RE=\)09O?GQ"CN]-Z68@.'JH
M1B";_IHJ;2WG]@PQ.C% -G);?5(Y!HRQM L[%FQR*Q*0;*UW+HFZC$*QN@P)
M0%W&->U9=D3%I5*J8*O*S,[ CQO>SAR^S"[*&_(ZWS1;8R(V_0+[D9B(S:,6
MAX6PF"W8A=#G5]_ZJS\>)UN92HD2CE2[MY. A,#$Y;5>/$)Z"DSL<&]Y%VK*
MK2@DU.Y'>OW?7KU2._$A;5^_4=G<" [^_/\TV1!LU>^2K)'J6,9R?X-$WKG=
MB?L5.\B^WUUH=>PQ6+V2^^8H*&:KI;!-^!)&^'<.5TK"9Q=682FK;BM9Q,QI
M+UKU(^EATB/BC ?#:[+;H#VRXHL@]3E7<UZR-#XHXR5C7,ZM=K3)[H9[XJHQ
MQ]'O;P,,7PQIJ_ S-B'O+@OW:H\67@OO*=+ (T&32)R#6MW(O044H#OV^3NF
M6^/1;!K[JM$4AP;A43B:<1ND\J"-#N%1GY88,J./J?^2\%1!?,VO!3];A4TQ
M4656NBCJV\;NX(3BM<V1#805)A<CV PAD2X"U9M8>*H'[ G(_S3#8+N1.@#^
MK#SL-0B925KGN#MD\RO[F:0H.38WA#86)$JE4;C)3&8LKL6NZ4XV=#JVG-OB
MJ#@C^1KD ;2?+#H_OB9=K9[WIO5BH)J U<<*-MQ_3"/_SO@WH2&<-XJQ=[=0
MJH,!?K-3,I[05CPH?.MB![>52#>@*Y AT6%Q4C=QA?/W4(V&G0H@+II':\JK
MFH7/XL_>4=QUS.9I"PLDGECBCF=L/VFQ1X20Z&;?J\"Y(>NG1Y"CLO::&Z1C
MZEVM_Z*'^2E&3&&XS,#\$[NJ/&R1+[%2N;]J/9)'<&BVTP3-_!5(!15*/7$Y
M,'J0KTUQ]X;\[*.[Q'-)I!9E-RBVLE5_3$A[EX':<$//59+QE%4.2+V60]5Q
M&"6D/4;-M0>/ T)5:KTSR"HXYO98RR&$?\H7;<TD/$ZHRY:W4E\"N%>Z3B!G
M%0;*^BGD?R&@)R3J\CFY$:R _RC%#@1"2$'!=Z[WP&B [#-NVZ\3.U]ITVP%
MK-*4 0:1#WHE[*S@:2XEJ4?M_SE%$ZM2^[D-NI2MZT>L% % _@3;S>P!&\XC
MC>ZYC0 TL-FRV0#^:]3_DP@Z)0H0!B_$4&E TO?F87U]VC[+LWE?NJP9]N"#
M! Y6_F>O9B(&MXQJXYHXWF9Z=^4.O)Z*HKY ;XUH,/TN293=3?9F9>[UW:*:
M7,K*!_$UW^#)V=?0/*:BDKZ8(K8Q.]',SE=]5+T1I"2 4E$ >V;]E5I;AL%#
MN/&)I&=2_=]1_[E=H,'9$#C"9R333.!NF$D!3!4^HX#WLG^3\^< ,+R")TR2
M:BI_A@4N64/S7: YZM6[4"O'%L01;\?MI%N&IHM%'R55391MV?49=25"9V&S
MFUPW@!W^D<UFWN9SC%H"*\M7TIJOV(6N^J:$/ M]?2[[.KIG1OL)-Q$AU1A/
M,,L^78CK"&5=I:E^YPF+$DAO/DQAL0M2X+.&J#?0FX#D.JV/4 #23[;EX!H=
M^QT.*XJY"DIV(&> X-CDMNWAKYU>V^FHW/(;Z H*\"9A\% 3456\?U4?:^-@
M%<^<#&QAQ'!%N^QE:WLUD0_#CKBXGH"<Z"F22>^\&;CY+6T."+ZHX*)'*H7,
M/KBGHP!2 GZ&*$!\HCP*4&EZ)\&T*AJK1*!FTNLN6F)[G1+PTF[V-BR"4YS#
MTN4*_M&<F"_#P=J!/R8'GT9K=]U_)04,<E\_=C#T5+&T'5&0_"/[5!P&-@C>
MH(L'%R'2NGITA(Z=25[S\Q6/S,CVCX@1!68[%BCS](AERNXLK';=,EV_J+^=
M2O4>S3V6D!C=5FMLU'V]K/+=EP<$=/1=5;XZX[A7AC_[ZY.4_+6^<&9YG.[$
M:SI,,R8X \ ?F+';ZK+PK8DE##GLOPXD6A[RJL2L&J"N/"%09<<2LQ<Y- 9V
MV^.I(2<F6^23.5RJ\LU.E@AYM7_LQL=H[=**^4XY([HZKUW_/ D+-&],1;B1
MQ5NJW@EC V/8?^5KQT>[+=NZ-DNFM")UV/V4IE  J)LC[H$\N@!<Z25&7$7X
M&1 C[<B/92W2G\_7WV7G[&!7,YEK@I+F"_YF!K[%)6.B$:2G(2^TKZN$M'0A
M1Z$*O1A=_,;:@3Q&HFSZ"W"+WAX%,$JYP1UQL4NK3YV634MF=_"!#EW/*<O"
MW1[X3BY37!8[S^(/2!6025LF%+#[52++]JG+5L5=HH8/\N$=3-916P#A-=S+
M9=EA]V=\)P/I=DOOX<1[E/)(Z&-[..8J05'[I&"KZ.Z7&%HZ!A$&\ZBUYUZ[
M B6F26<G.OPI"UT+]U2WIG^/6GA_V:T0U$PQ30G*-/^.84D0QMK0=13!O.BG
M"5QI69FX4X3+/"R?1D(7T\VSEZ3QOW182[PI!] X1Z5=J#Y#!.O ?_A\(_>1
MKYUD_KZI%/4;^!;@>AU#R/1)%R]/R78M4_:LKT>2WK#6BLZH=YE)W/HD>2WX
M\MC@_772]9E(V=G9Y!9"<.7J!AG:WC7Z7,%^8Z"6 HK#<S$@_9"FP/>4_:T%
MUI83@1Q$8#1D]4P,!+P<5'V@X"B 6145'.H.2V1_8YSLEOIY2O:TXZ+C$]H
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M%DT!145V*1!7CK@SQ4T/>'"<K/"5".3SQ(G)M7QU4QS@7"KA#2V?%O']X6@
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MOUE3"N5>D44HLI']]T_&O^2YTQ$57H]9VE<&D@.;(C4T98'-CP)H+JL/[Y'
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MY ^O\\[;$>A&IM"Y:LUYQ7HTF=RYNI-T@A<376A"VJ[!OEDFCB^.;].YQ]0
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MLGW-LMKJ46-^$G, 9#\44,6TT:7#A.I_60-%ELFD5AKY'1PU!SZ;0LO*%*Y
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MJ-L*_83CEP#ZOH*E=]4P0\50B8, ,T,,ALV&4T7-6C=_Q0*9IN\CP,\.32A
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M_5.UREX6#H^DI?"X318.\H)"8^M^C(.:C:*.L"+_XE.I/1]>%#*P4T&H718
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M.*O\*48KH6Q@F'LIW03C:FLV[G!9>LCGB<TLP\]JJJWNBJGT?3& @, STM[
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M?S.GCD%4C7NC%G]>D"P7^2R2K)T 43R2#JJHC-T1P^=%,D *P*B (AI"@62
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M*TI7JL5ZLCGJ8[;@,FE+GDD_KNY3#,'<X.1 F;^92%!^DTA@6?-'(D%!J#.
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ME1\V2\7 +V4@]>Z4:ME/Z+L("YQCF2;8<VGNK0SOQ[WHCE%#@-CP*;KHJQ+
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MR"NL\?73P!.\1S1#]=? =XZ)D KFSS6282]?JI>\[?M_F'OKL+:^;6TTE+9
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M&[<(P[L@N 5T%GPG(&VY"8A4Y;QK0?E%/4F17/HG9;$8193G]:@HO1I[I1@
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MF]0<IT@2SF'6U[O2\U'Q\76OI^YK"YEF)VKC<%>R<]T"4-AB*9L]T^YXIEV
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M<9VJCU[.G522D=W,\#19AFQ]JIT!]ZN_.B?/$;)H'!1FV>(6^SCVD>CG+6!
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MUK%\&3I>): ^.]::D;*V?=[.^5EU.4JZ-&K";S@#]OYKP14KS#'-@KLV.='
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M:B*^'^)"<<*56(6?ENS&CH^6)::@'4\$XV*<LSUFI;\W2O!HIF-VZRTE2L@
MMNB[A#;^/U0 *=- 6-\@OP&N&'.F(9-91*$S"@_R&=&<7VPG1!F+;\ !5_3W
MR;_]"S&][P,?(5'1R_8&BJFY_Q3>&!A+LP@&3GFSEH<TR(J<OTL/*>C>NMLR
M+WYR@/;K(X7R?X8,F]1'2PC[997!14OA7ZWF;]B8^9ZBS]P"*C9 P&)'\XYO
MKIF6HE^VX2H+%12'\^'CTN$G#6]$K'\8:.+? O+(H?L0QJ-[,NS&U-%V4OO2
M>\," B4FAM%M*S&RL*0V QH]G;YK'?(GQ%H>4?,%>RA#T'>\PPS<$#/]6*,
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MO9;ATO6[]'_;B7_T5I^?0UMF TAX9'C!TNE#(/LR&,;G'1P7/$4V!(,7;&W
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M*#R7NM;'P>,\]C)G@??SN)JS!CYE5474U4Y>_.L@054";U?H"KA2%]_LH0P
M+U$4;IF[I5ZKK$)O;D10R-NDZ0CK"LJVL /JXG@UXBYGM>/&*93M7;F+/>V5
M6>*+=[0[#<D[DK*U-^'M+9[2(*5I4?J.RW_XFCMBEQR*DB@X*[1$%&YO"2:W
M.TT27F(=C;.B/ \!3/&9U[5+)QQWW@":L M<$\9LR[S#=GOLIAD6/__PG;"C
M<JE$R0)\X=SL-31*?&;;O6O5+%UYP9JM%<,VXYK!J8!Q \A%TB/L ]6,CP,P
ML>DI1IZY:];YR\,>IKO?KVZVMJ7KR =\R%WY8CG_,%/YD@]U/)\^=@F58S7
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MF.8L*M>URR@GZ=_6A><W+^[Y@"K*$DMG,DS!CPSZ11$&>LNUOJQ[8E(F2T=
MWSAN/::)%&%>O5TQ%J]>/D42\9+Q0OG07<]WD9!W[9I3@^1[4K(6U7%08FH^
MNFDE?#%TB6TM#:$J2.+C^*<X_EJQ;BV#,,":B';_M=\2''TZ[[*F\$VTQ>(G
MG:S;RC@T%4^'FL6$FD6IPU)W\'!T8MGO"IV<\V"G<TA(Y@<!@%?CPW*HMNQP
M4JZ+BK KZC*C5ZQ9R9KVA@@O%WPU0/6JQW>#;WV!:7>NEE%MH R$KL.:D&-
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M;,[.NIM/J;&5Q'K/B&)X\VWFRWMO"C\(%[L2(G;(W)[DE?T-UDKR/4 !\A\
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M)].E,90TP%ALU!I"EL;U,IL(16F,V-+(P72:DG0&8[.>!9W%UU^;5VI&L&X
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M(GI_1T\;86XEUHLW '3)3'5R&1HN*DQ/E?"@%L4^8PPK9]+-X4CQ3%$[\%*
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MT9K[<G+J6AI%X3 6F03T%]-]YQ$53'/H;,\G6YYH>&N&M[LQ:1$'[!X'/W'
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M3X+/&+!6853<^=>"$_,@/S>*J9FM[:MH^D*YI[F0Z0E/-17R9U;BZT2>==;
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MG]E\"LP9*2X:EJ?AEBYVOY<;:)+SXG$)/R0U</%%T)$^97@FU8*,5MPS>M4
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M6-=@L-G<\:;Q2]I%B(3DCDZJ:G4-JSPT"#^TW?V!<^2+54C>GG+J0@-8TY>
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M:T=@=!UN;QCA+ZYR [@/2JKF@/591I48]K= !^Q@C9+)&YX<V=N53Y;&\F\
M\;T184XYV=AI*>'=%L/3-X 'XT%REVJ(SBLWI1M &M5<(^VZ0N8IC]X(DV$O
M=IWO#<!U"T@?U%QTT3:[SXX)1XM"UY\@?9>4,'"!I_CX9MJ*!5,/D=KM$OIP
M7A5B5/%#VLWNEMQZII'CE; K;A#,R+*1*=A:]J!CT$*E_BN\<6CYVA+XQN-
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MI)9JA:X^QMP 9*B4U:(5A&P@+$NXQ*'9+.1]FY.6*./!XB)#UYAFU'1B;]%
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M>1%IPQNL+T8M(4E* "VD&"*M>\_[Q>!\SJ6 3+V.=D*Y5P'I-.9<@MSBTNT
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M=4$0UC<>A[;=?VPVF?R]'X>6:-DH#&2J%YRGA)S@RR0*@E+U5&VY')8F4D3
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M%GGT7Y'_%?D?(O)_VNI_TVBDX5 5.UY*A:G\,8]<ED=5<W[CZ6GW_(75</4
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M[%^%9+B_F0GW5,A4GS_@4@"1W;J9^!]02P,$%     @ [CU\5&/W;#>0[@
M\% ! !(   !I;6<Q-3@R,34U,3A?-BYJ<&?LO =84]O2/QQZ1[I2#5U"[U*E
M]QH"*$4%$B! @)"$(J+TIB"]]]Y5.@@J2"]*1YI2I$@11$'%]@4L1\\Y][[E
MWN]][O]Y6+BS]YI9,[]9LV;-[+WSF*]/O\X#J'0TM#4 .#BX.#XX/@# URWZ
M\T:.;F@WE*.;.U!<2 1P5D5;'Q\?@&WT\O<A4G]T ;8L.!8 /&9NS9]G7
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M;O\Q[>N"$J,C&NTN*RSLBA*R.7R0$+)S0PA[V[@+BPJ)" /DSWF[V]@YP]!
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M4\M_QHI)B?Y7F^Q?7+%?"_?QBKDJVKFY'GX=\3]8-2R.#?96%^:!4K3W<$,
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M48>2"Y?>R.F62&J.+7E$R3O.V!;H$:-'^Q2[^EM@_'"FTONB9^CJ$U[J6.E
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MUWMBU7O0_,P^R]FT@JFPDO"6JRBRO7%D)EK'JI2\@940S(28B&?C2GJ.+YR
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M(;+(4[)IV2'05,/Q/),MI8J]I[,;_+$W<I?J@.ZF'[(FZ\"6B(1:JM;P@E3
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MYA35M]6[B]A@<KEG5I1^WS(VZT6E:J[5)*("1/?^,=][#VZF<@3#O/PN3_1
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M,[BJX#X[6L6\>)<L7'3>[%59!K%K3P@3?]^N+3*Z; 4GF9_2$7#K/"MYG!8
M!R7:Y5IU4T$$>%+M<7X?AYQIRC:>'/LZ5[^'0J^/9MT&>EJ>+"WTT=L&._-"
MR]J0(4=4H?R6>,*=%T[>-@W#]/IBB[G=:*FI$]SK7P$84>X!)(P&'DA4LM;$
M\Z5UY5T,HM-DWP)5OLT@=#+JNOE]>;H:'RBLW,^"(2K>TEH98BF&8((I"'JX
M*EJ..;8DG4IIR!<\X81[44XPA[N#B$D0GELO%0J$^&DD28[S2DAT-]HWW$?
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ME_"T19MWF^3=E=8KG_*62]U-B\U-E/1]16Y/?[KA%Y'0C!H-88_9:N4NMWZ
M[/#D$ZCOCU)P''*B<>#B?FDJ.38';N*J7^BN^5AL&70!)85X!?UR]P&_!RZ
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M%MFZS(KUR:;H$9^4!PX>S7UZ-HSVHZ4K'.C7NW5S'?<.:Y.E>43*>O6W8DA
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M63#VXD)KW0PJW!DJ>7.*-$^,\D]!X7;"2#6WXC/Z%%^]%.[6;U1OU_3P?H^
M= SR2CL5S.8598A6]_INP20]\P\BTOR2JC[R!73KURX7QI)\FOZ_6ROZ9F6G
MM1M.(TO\<M"4GJ7]FNM8C?>=2_S:[:BQAJ:,6VU4R>@S1J<5YJ.VP+QY'%8(
M-^GM[^X+J3,#UWGZ>D\7!_4O;6>FVD!CH$BW(X**PS"[9^$Y[849,Y3.V8.#
MNQY/F!P.J@@'?O-9"?0W&X4N0IE*[J3Q-K(@,TOXLKQ7KW JNUU$>CE_ZM'V
MQ$_8GE3-=SK)AHT6SX5^!.='\&J,PET]DB !G[;P60UO0B/MX2AC,/K:@^M9
M#!&9(8%C>&/\_1]@LK(D559$ .0D<^D=Y];2>FA[;! ?5<)?R"A% Y3B5]"?
MJUER:"&O],N_3D-6'/6+1?,",2$Y A[S\(IUGPT]'D(25Z+GF''&:M<90C[F
MZKB3B>Q<!4[ZU:J.UR3J^!(_BOD9[7RO\R)3IAJN:#VI[*B',=$F/;(S75-=
M<T4,T0"4=3=T5<;YX66CHFNT# XNPEMXAMDNW=[R4O@"=CU-PWAW[!:GUV A
MI:++DEH)K3D0?K3S- .5%JW!\O9.=.ENC)ZL)4. ZP/0':@\GY4W$@^ 8LAF
MA32-DDRM*5!39D)<@^D7\V8\F<$J5>'X_GX C&GGH.NXAJN7EE?FG]CBFQ^
MP"U%/H&#&$50BM)52;!J,&)]?FIJ"?(4@PV9[;<X[&9:!54=TZT?M54\7:KG
MI7^R8G.J9NS*1(!0S>F&W%2$AVUX-HL@'7?7]D$+\.2F%;)S-M-1!EO@*_GG
M$22J[);^RTW1GPSYD/KN^PV/7<JO38)\(6 '>G*Q^5&:\#GZ;/44_*FR44!"
M20;A[*$TGH_JO9NOJWVZ6N%1R9R9=-VGJ*)I4:L,H3MNI,8.T3&C](<@,.1[
M*],G=J#4/&JR5IRU-I6S5#*6@6BT9V-)VX8/;MT@IX4/*H^00(OUTA7F@E?S
MWRP><6-.*FK/1R6 0_G>J9[;8Y[3":4)&6<LOR.7(GU_IJ[2%Y@'&1<*&W96
M,<&83R0T., 7B JNFA,=<O#XYYW"$> ""R>-*!F>@#5V'PRDL?O<M/_NTR(1
M:=R*6%TN'5>[,9A!D4+*M#97=O12U 4'6I: F"BESBDH:(=PKJK!IV?)/<.;
MOGY]F4);7YO Y[Y S8(]B4RJ4: V6ZI)>2/K_O1MO?QS%-TX[#25T)A3B+A6
MH<ESCJS%2S\SM1XFI#&#*5\_K-YK<!!Z^2]+JF7]#5!XXZLJH2I@/T LSE^#
M4C%&+";SX!LJJ_0I)S=-Q77H B=XH'AZ_&^ \]_@5]1$RM*L7G 3>5:R_7OT
MAOI,CX;O96*4EI8!AXZ:ROB?N&V)6ZK.6)KC^29^2 :S>;T;W:^O34)\Z+L2
M#D7+HV0JIF*%\I-U[-(6.B2'7QC$.)C\7.AI\:4.;-]Q/1JH!0M6);65'/#]
MG=C\/#X%SU14/&V^QS<8KF;>]I[O(80_>BH8![N%(F2,C9T0F$;2.-\A17OH
M$OE<)*,,Q&EF-&_>M%@W45&LC6K$-%T=*]-:@S@0Q>8-**6&R JGY2-/+7W>
M%(>7;JL_@S7[YSB.%TV\R54K3IB+M#FFD0Y,*[(;'<CX:4@+>4=TH$O3& W:
M?X*$6Z3;E#T,UVS._?<++'M/[,@=^^N5"N0LV>?H4=7WWQR1<=YD69;E)WH[
M"ME&2@R$GE4;Y(O85[^K66A/!5S 3_2<MI7+0XF59DI.A&J4[#<_&8SBU$<>
M0Q 7OK=OK0&#:^_7>_MVJA^7W77U"*AO#]6\\#,"J"ML-&>]RKFL_.O^$6*S
M2\\.!"F5TU,/-;1SN#.0JU36MJHW(IJYEF(:E/OG?&^H5"I>I7+?E(\1?U2R
MQ?87^<PQF^%$QEY305\P];[)@*;(6S3$N>KV&$+\A]E+>YMN-M=H:U E;HG&
MQA V!HI66VM@.X06(\0,#U>U;+_Z'/4P4P$3*68_XP;#G0S/.I:XZ-*U^$'$
M3IYLODE<9/!3 :2@ VX0IQQBO:XE:I9U!QW);&DY_4J;QV&907_;4D_GD"N7
MC:VZR4K-CM,XO^(^SI8T81QA/\?0G/=OE$':0Z<+:]O5IGC0'U:N>!Q32I<E
M$(^F['NE04.W-C2!44=%%S#^MU/#R7CRD72SW$D/QI9JHA;,04VM,]HJ>9$Y
MP4FK4*;T3,70:.-.A)VM$0JI\XB;"-JW(RN.\XC3< <=)VT*9WT.BIP#<3M@
M,?$2,2[";PTB:N4Y3'WDC;A@&V2//FH^.#H);*.82>4R&PR:GNO3YN9T>I15
MJ&% :SJ)(&A+:*\R#E3BT[C<]X/.R^;B Y"J-CVW]T(WI#8GK'-F&)?<L/X!
M>(HO+!VY5_M/8 _U5YNV#\ -K;Q6\BF(6EG]S:X^1$Y_Q>L#L*^45/EU212;
M+[+7CO#59N5U-]JP<P8$3S3M >/K,M$%)Q</.GWU;"ZE &,3ORZO'KSH_3B8
M/.:)GX0Z$*149)4I6H*-)S)9=%W4GV\I+7#5@9KK??6ZC;C6ZOA/G?":_\GS
MH/^?%U*2RP(_;UA]2FAK^*\!(9-)_V=-"#V JN"<X /PQ<LU))LY?P_/V?F1
MM^ 2J_*,#/Q-LA57C7@N(WY,8;/FNHCYY]Z<%P?8.7SOF$&S$&H8C2[829-Q
M2;VUN75WH'3._(I&HHZYT7 >6T4\:C@?1W#RSTR-C@R7O)(!XIWH#IB-+Y1)
M 'L\)NP/#4><<IBP2@T[/9/UG;]0OFRD^P^54@[K]B%/Q<W2O)D*O9G]M2HF
M60>&N'@5T#H'EVXDC;$RSY%+<N:W,/*N4>_Q0L4SJ*>"B34F\ZC6SBR?IQ:"
M*!;#/![33#[_YDP7/8Y? ZZDP47*]BD=;,C4X!B-/TD^A@/5BQ6#=4X88?$Z
MGF;J?>QSV*UC3)&_*84*<LGYA?8;2S3ZB5N[(+6!KMV$:H6]X?O!VLWL,X=.
M;&32DFE?':9="7_VU9S,#US  :,L9CZ7+.3+SN%G%P*+O8VF=?=E".01]ZDZ
M0\ZSSB=0TE X0O%'WM'B@-]"F:OSSEK[K;GP0'N[O9P[9@;\DEIE"73T5*<S
M,T7##1'9, ZN>H+[N5&E$2Y2D$]&Z>8X]15^GP34;7Y@NN.,_A'0'+Z%M-RV
MD9XQQ09UIB5:G$&]LI?@$/R%]>.CE$WHY";;MRH"UNNNO*V2X"HT,GGO["*<
M>RGBTLO6.WWRR\?9\U;5*OKU.& ;L!XNJ_0G/I?J,-=ZT\*[(ACPL%?Z,\^!
MNCG0Y&U#_=.\ *) <CDD6^:TY/$1G!5%D&@60&?"7(P4Z@M'W9#.0_)+K P_
M<\,6MWI[+.9OX^9C+<;!)%2C$Q$<.7C.W8+OTQAL\4M*\F<HF/-",NC,%3A(
MJ+_3\M2?2E@8FD+\?QT'L]2YT6:!G&Z,.7P'3OO<8Y$,D)9U!%9.]WJ0H%<.
MV[FA!*^^Z.OUEF(%OMCV!7+]I%$L32F59>EETMEII3V:8$P\R:6#$8OO(!BQ
M4LFO?1A!@BP=.W/^L<J2X90R:UH,J<_(LTC'0[?E0W,5)-18\0EW37J=+?[Q
MMSLM)!&'-_"3]L*NK:M@=)D>O(DFO"T/G!LMA+M[2SW<1;GUU4\,M,+*L/JC
MKA9?5KRF.'&Y$1UQ#*H$LX3O!X*>LWMFA1&+8F5C/XSEMKT"DPO?]XH@WJVE
M/P%Z5#Q<HE6LN-#/Y6TM&_E)6+:V[Q/+<U>VIK_UD;.HSPKNPPW'#9S%P8(W
MF,KE%1FA_;OGT_8-N9VE"K9#@[0SBI[\!/2SHV*:H!/N8%[Z[_A9V;_'RN(
ME.?32+0&A8CWI\2UTI9&#)/%EW#HND1+U,LI=Q%M^D5^?'?Z3-=OI"PO;36I
M43G/$\56,X78]%55U>/#VW!\ZFOI2;\P'"CF5SK6BK><YVPW"HL&-]^+3C3<
MZ$KL5_#_)$K+LYEC)!7"I+; Q>LLB](M3<7GR<*2%HVZX!HT9%'-4A0AMUFJ
M+Z(5Z\CF]O  FN)9').B5-E83Y5S5>4MS\^1,^4R46>[5"J_-]^VB!ST[H;_
M$.'SW-J7B2M#;G1S"I[C@[#%_6W??-PV%O%G$2BU8JU7B\?ZQ=N7\'=,5NHD
MUPO!9X)6A%I'VLKDO.%\RW6_QVRZ4KN0+XHQ9-J+4*&^JTC&FR^*=OX^* M%
M[%FT<WZ-::O?VE+1^&AK=8N3_5=2T]^<ZMG^']/X++"))=%K2UMN:GFSI21H
MC\(U!A!I:_;U!J-*ZSE*:=]?YOL^)71?8^*XG.64(-(>EV?E$2&=-N1^A=K5
M!:XNNC^\,A5:U8M6NW+";0Q -->KO2@\&+Z@EG3\%2=#88LY"QNIL[\T8Y]
M\&&%>D^ZUR0D[PD^N6C ;6V#8'K9\Y'+NJAC AQ740:;IN?W.W;T4V;Q(1NJ
MV-1.G,E$.KG]=?BKB4AY_Y7]]LG"X-(I^ Z<+\)??$L6!*J20GF[#:"1, 0
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ME>Z?^.I\'(7EP]#<1N0<]49T/SN/+NF49./IM\QLY%-6R%%0--,H-:5R::?
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MLA[=\> 1] $(A7P 5M15736*2ZZ;9 AGSIMG]"-25VVSY:9>IM8B-F;KG(H
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M F/4$4*R7$NW)EHQ&I'Z+Y2)K Z(G!P)YS>P#F"/%);1O3FZ4&B+E%^PAS;
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MSJH<ZZ_P1+1Y?,@2:<!"=-+\$$[3N=(F(N-G9X\._U7F+V3<E>.?WTD4@GQ
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M6V>^ZWY?1D0Z>_M7&>P/@C8,<MSK8F;SBAFJ+8HD3W(79)+G?,(FL \?S,!
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M1L,(_FPI/3G"];G,R(;H329/NVH3Y&VGM]4GW^' &B!OQAHO-\\X)JWRT4K
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MYI[L]UKKOC? JNQZ)=5\GXQXW0X]4=[+8&5;XMP*_;7HNS/TN8#2@!/IX:+
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M5[21B[N*]6F@'\L=":"E)BQU\)9MFY7%8 [Z1FU\4XNYM%U*F2!%-M*("'"
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MV['Y[AUPX0CS-IC:7WUP:_L.N#]K[FG0>@>PT5J0.C6<77):I$ 2>UX']7Z
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M]A-6@D$DQ>"6G>WE9OE\LV6C%9./:6C'14:'X&\<O,J.1C\T\<6:XJH>H4\
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M7:%.Z2RW0]BN31QQWI/]'.]5F>M+/>#S5V:/Y66DAR[)#[D]B@UYL;X/YB5
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MVE^1# 2RX*1\ L.OQK8"\6*'P<FB!H%(V"UW-T"AK?2?+@8<V\Y0VOR*V_4
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MV*9V;5+E7I#>;O7J!."V^*0T.%*F]CB\J%6*IKN:K"ULQZZU.6%%>E#';B=
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MPM]LH>))O_/,"%]N% VZ__8C56#R02?Q\(#DX8PB[[$SCHDC[8X.6K40D?E
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M#]KU9A.L=EARZ+5:(CYP=&["/A8N+SE#$%;F$5SXP.MT@@.YE\;<J><]GU&
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M79Y^'AY793,V_N6AI.17?<]I<^\X.=ZU-,/7>5B/]C1W,^BS(XKD._'"WUW
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M7A>8]/1,HQR<&Q%(R/4G]<&*)(*3/F/^SVCP,US/VTRSE0/Z9[>OKL[NX8E
MU7AC M)UWXLD+RU#DKRV\ 75ZTD[][<.4M.Z421V64?UCZYY^WMH:2:V?>%<
M^%RC?Y7_[?XCXW'1Q*=4^6[34F\1=TH;+=I.7R_?U-.JKFV\?[]SL:W4.#@S
M-WY-GLN:")SE0%D>4:XV'[3!,08U*$AT/3A:1H$RSLKJ3;=(Z_,$??.HZKON
MBF!%,_$V5WHL<Z]"'=<E/VI_GTT>OU1!*XX,AJYA96"CRCIKS*[--SD)CL%_
M1]NHUTM_?MLDU*7+]X#F$TLT; JDT.]O3SZ]_*NZA<B?9-K1>NY:K<6(T\?P
M5EF(25%F/YQB6D1"<SY:406RGDE,M'B-[FUG1X0/[Q,!'8SK/CY_U.%;;>8W
M_4DU'F8>[PV2*L4HP0YSLYEA5N-[O<>6#-/+]9[13>9Y8M^#$SRJ./.\V'B6
MRKS E#)VQ= 0S='=&'=KL?R\3]P.Z5M2]"IR>4S<LMA7-'I_XA@E7UL''-$?
M?B7"I)GX?R43KOMY[@?^U5P/V39OZ1P25%H&K-O7?C+&LC^KQ\$.S8%#JLJ\
M+&@>U#F+E=_[-F)Y.QG#?C)E@&%=^_[;J0,MB"#"=QKKLY",68SW"'A:)X(Y
M0]!620S 5(G-N<DZI>!?-W]+)[75ZE3S+DOY<6LNX8H_0 1&Q4@25"J#Q=?5
M*)!&'7P-]K-2^0K^6>T^/R "TZCE:-ZZ7;OU#1+;RRHCL;W98PVG+_Q_03^6
MHB3NY9-:&D!+PCXO7OTW4!I& PU=Z8BJ])XR4^?>EC4&7TE=T%HD@![@6,L^
M[8+4WQ^Q]W!DC[K'G37?&:V3P@?B$3KC,1J$G7@-Y=II]0VH*,%:MK]WL/:W
MNLA"%[]S#X2AY$D&,MRANXA35>,BU."PM1P-^DEL[-F'XO7T'8KO^+.\K7-B
M;VX,-U(KC8G,,@<,#CDVL6N,B[V_(>BB>ZM$F+9=5M986<N\:91L4^3':SRC
MW?*R@I,C <PT.6JB'<S@.%D]EO^M_NNBQD[)5R':R@1WL;!^37]?0YHV[-)0
MTR5L>QL[;%LC/T_8Q^=QJ.>#XH#FFZ )IA$GR$D2,@L-7C-"(R)<JMAN?!!6
MHD] 9F0P/9#GRS@_H3,'#D_S#A*X(1.1U]!<?^&K^4>A@76056*VA_QY\/K,
M<CU7HV.'S] ,M]!6<"VX. V!EM3HCD4Z^[/T/1ZA+97B'*X#ORKK<YKK>.<T
M45_X#*;A_1J/S*Y6H$\HR[I_1F@N(^/\7GEOR\RI$1SU:[C=_89/VY!4V8Y
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M?$JXRBXQ)F/BP[C#:*+YE_K/!VG\_1"4+Q1$"*XD G,\S3@-TV'"32B_\9C
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M=Q!@V/5!F*JKYY"K>UJ]J;3@E[PO2_5%DZP/OJ$IE<_Q]S6QKY*<M#76QZ<
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M?M@,&KEW5VYI(('C#5\#%SY<09X9>19=BO4P@],Z^79,]K_3ZXUU$'Z>PKK
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MU+R0'A C?B&8O9==X $:YP$:!6=[ZJT\^\FI' W0>R)/6\4#GO0!;V&?C_F
M#GK$WD@73Y2>'\K;#X7IXN[3]'U11K9>7NX'$IJ>* <'3S^/[^?[1Q5WY'Z?
M_$#7R"5P7T+9!;6O\X=-!^1)A(>#L:J9\0^P0P5]I)>7HY$#RL];S];5#D,F
M ?0!)."%^>,(0  CP %  7Z ]X$*D?</Z>]FE-U1GM\\(K'U<W%'N7@>F,3T
M"0^D573-M0^'0F9?'HO_EX@I?XI8SQOEXN7IBZ'2'<3EC?+\'@0F2%ODCXZA
MDZ_N'QRDI\H?'4_4'QT=6W??'YV33BC_'QU5#W?XCPXFCW^85K9S<_J6B$,'
M 4-U917, ?O@W!X"L??RLU7TF@:^-W6DYU]HRNY_E5-&VAN;>*+4V W=4<!/
M3=G='O([NJ&O.^J KA_HKG@J]#N9R-_!#N6%A"-0B!]5H>^D[_N]*O;/OQU5
M#I+@X(CZG7ECS"3Y'=W(SOV0KH^T4S3_0:; 3 /O4\X.F,'%C)>+I]/WC)'M
M,PPQ/BE[H5!>'NY>GD[?5$B^<_9=^(E.^IUNZ.+D_#.#^#L#X]L/\G[E8+\Y
M] '[\:X8@ 5@?3\>5!77 8_LCP@40K]I;1PF#+,T'+1#*@[I 75_'3B<HPP_
M^BP'6N\/^H3?K8$.M+@IOMGZ5A2'V-A;!^<:@("C(X;CCOG&^Z9T2"G(ROY!
M$3[X/HWY_DX1._CF_X-R8//3P;GW=Z__W+"7]MG_?MY!+@@.\WS@%X"E>/CY
MQF/YD:?#_K'],VRQ']X?AH#A8^'^2-U?VT^T?3D0SC\0^-'^6"X 3S_W_;+#
MVH>U]?+SM/?]TVRU0PE]=W._Q'\J+^!/=0@H_ZC70S<,?Y3C00AXONXN=@Z^
MINXZ^Q,*] L.[@$/<T*)^> ?=#3A/]G&=T)Z^7G_0L+S0KHXN?Q8*U6-]I7T
M#FB8/BG"#^6E[N#I@$2@'.P/O _R_K[4$QT*[U/V.9H>3I#_@?BQ_9#NOVP8
M!\G_E:+KZ_3KIH*'<$<9(YQ^H9'9.6#T' )1FKX:QKHZWY<M@N_D7X0)G;V0
MP4KN+D[?,T5^&+S&=_)^=NT='!%^!^L6H;\#$O4;<=/OY%_%B6V=5+S<O9 _
M)1=\J*"L_H.Q[\9)+\_](R'*RQNS.?DZ_)PX(G=,(O]");$]6 #_0B=&[B]S
M?R(?S"">0[W]<E9X!_Q!!Q^<@@Y7'ASJ@][^ .$>]$D.4GKC6\+R,1]]S.DT
M &3LTY,!>@"T-[KW!B!1LO>R=;!6T06P]M8 LH,>8!^ZK[<W#D0") 0$!(0$
M)(2$)&!B(F(P#3D)"3D-/145#145/9CDH'T[_+Z!2(F)2<E(*<C(**C)R,BH
M][_(J ]5P/^,@;U& $R <3X?&P0%L, @;#!H;Q(3*-%>*T@!XR4NZ*!]2R,V
M ,+"P<7#)R D(@;]F0G"[ G?F128:@9A8^%@X>+C$>!BDXA@F&!L'#9*(5PE
M P05U"=,&(\ZN>"V,CL'C6&3K8@H,KQ/!9\SQ>C=S+J=KQAMX9T(+GBJL;UJ
M<Q%*G*[?9-9AHSJR9<!O[KT:=UIQU-WTUL'YS6LU;4,+6Z:._M$9);7MPXL?
M)-1/.07$7"Z]]V3DU4<P@(6%\1;GP"=\/%RQ Q?8A"AQ,![X0*EPA<.2J?<]
M:#+L>R?"83N##$]1,:*Q\Q5=Y\3;=P"?2ZRY'^-$$9V]JHDXRF'VAPM_[P'W
M'R[LO0!(L \PP8 "L(R$-=A/X-8"?.=(U[Z^"N$E'^G8 [2=/J_M 9W<G;OI
M(3L>5[=.JI@CN9X^-!79>ON#R?GZY6[&L_>3>T"*OB:QW."SGQ1_X9W8YSW^
MRG_U5?T>P''Y5LBVA<*S@(]EOH55OC?90\GK]36X??'D7UUX_Z*]AN)L1Q3T
MB^H>L%RY!\B]_,SQJ"]DVPTCOZNILZ#0[^?A[+A(U!W#F?\(M&LZ+NYER!"J
MOG3B0Y-G+JO+U3?NZGI3IX;H;GU7$3BS!VS6AN2]W4DY"_.X2$HC7'?)-^@Y
M> _0),4ZRVBDL,\?=MFY%S*?LA^:[J'[T/,WULUBQ3Q>*(7[UU1^[/"UVJ3T
MM\A=O+]5]09'W0YFMW5U:O-#B&<KZNOLK8I#(P<@9QZI'P2WJTGO6.>R?%?8
MR;D?[X/U\J5/<EM?63]ITR":<3XD'W?"I"?[,#W:F,R('6:FN/O#J>4,L3<I
M:FNM%^^\W.G4'<O)LUZJDDS19 *.VE$[:D?MJ!VUHW;4CMI1.VI'[7]-VYM1
M9'!&H;RE!00\?6&(_1L*,#LO#X% A+> $$Q0 )!5"/1&V+DYH""V#DXNGG+0
MM_6/H1 7>SGH*3%=05UO%0=G%XU@I(-1\$ECNV W.RE[J((\D6R@=*"'MX<#
M"@$)]'#W])4.E(,>&)?&G.^3!:"0 Q&4FQSTX#8&Q$Q7'Z+BA72 B,%$^.T$
MA80@XN(P(5$Q<7$A/HBPH)"P@"#FKSB_D*BTF+BTL 3D6X/*$V&^99'VCM*&
M<+5O<)B>'/1;7 $! ;  $9@7TDE 2$I*:M^,L# _1H+?-\@3A0CD]_1E/S3R
MW0[<P=<.Z7+PY *RWT?8>OFAY*!0(LA/[5M<'MX_@'Z;P!^6]XUCI*55D X(
ME!?2V,O+7?XP\C^><*D8B4-X3KEXVGL%^/+*"OQ9_$^6=+WL71R#X B4@[RP
MH+ 0OZ 4O["DL:"DM*"4M)#("4$Q:1'!0R,_2?[.&X>_V)"0%A:2%I+ZV<9/
MDG_V S.>]@@4XI_RY&?9[SD7^%/2_ZN#X?W3J/\R&!@&9C!$?AT,#%%:'^EE
M[V?G@)17LD-ZV2)0$+B++\K%W=T!"1$2A G!A'X9CU\T_MW.V]O]\-W;#^E^
M4*_V=@(.[@[[3R1],?X+_>J_O9TTR@7E_O-P?(=5<D?]2OW.<'?91Y-V1W@Z
MR4$#^;_=1(7*_Y<?B1Z&[^[R)R<$_NJ%K,!O'-X/PNZPPG\3AI&#S]^%(?_]
MB>X_<N!7_0,'_@JV[X(C)B0$2M[% ^'D(.#@[>MX(/N-^N\>:,PTT-7]QXN&
MAX? [S1]4:K^J'^LZ;M_LUO T,'7RP]IYZ#JCQDY]M^;,G3XF\GR>U,8<?8_
MKV6ZNM*:GKXHA.?^DQ)Y# 'FXF(OK:8D*BX,%U(3%!,65%41$E(6%1&'JZFJ
M2(I(J4BJ*L,/%H)?5?]B%NYEY[=?==_,VF/,"HD)"BE)PI4$A?^QV9]4_V+V
M\-$,POU?,/\;$W^!T< L(E[(H/]<11^4C3<"Z7OP3$@.^CWQT+\H[.L<E((T
MPNZ@$'T1_@[VL@*_T/Y>R>6O0_8?!_\7U;^W'^#LX/GG;4#LI\WD)ZF_-[*_
M%@4@D Y*3I@<_T?[Y.]4_MZTG3-F;7.PEQ?XKOB=\)>!^>W2\K]CQ-2D_J-)
M]B^.V,\;]]&(><K;>7GN/Y;\3XP:!@>!N=1U0/K*.R*]/" (;V]W%SO$OI:
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M#F'%$$$ZKG85^A$R)TY]FS0+FXQ#$88]=0AS!"RK!+6O7G"0U-!^BED>C;N
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M'Y6V7Z!LU]@F_+U3LMYM0"6^CJGOS[_K#,$G+;G+SG><^FE=PR]>4-GXF'I
ML4K.OQ97C$,0&[.3JH\;C=DHE!\MD*\]V7RY5)+4LL ;S99[4EOK#!@BPHM7
M2BE2*>9'9ZT2D3E 2>95H4+I3Y>)M](QV/VD5&!GUG4/^')%:'?:*V$/T&;=
MXN?646C"FFD.&5'Y^K+*$BVKN@?<\?K@LS.KL#IH/16S1$<04L&,O5)AAVZV
MB0OG(LB$_OVA6'P&-+=F<=^G#M\WA'[M7;0HVY9M\3SXT;WZ%;3B,!A,!J$
M4<R23@-T9#!!,IFWM2(D!K>O1=(EU;1DQ0G1;(JU#M]&8R/J+M;?HY@#&-=W
MOGS$A]CPVE(/@M4)8PWI6V[;@"*QI@7)U =Q2'VU^N9:TYH!+C#Q2[^/9.O$
M%V/\/E5"F$%1O-1!^L44<$3L, A:T>M4*;E=\5:P9PVG9G5D,!QWCH4=;PTF
M.&G#LI3X=62-G.5U,'LXONB[*OZ;G54"M0\7E"V,<SM< V2Z2:]A/9G" [/
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M1,7$8SD;T5;&*<KS4A<3/[,F-[#A$S^W=^0*S\O$>F7.J!H-ML!JBB_C8><
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MP=34R2F2=45<E#COX3"SD4J9,(X(WD(L0)O>CHLMASIL!&+M)CMTS%JR3$W
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MX!GFX81E63K>N$IBQG4$+S[M5C<S2:4H-9W1;2(S[M-750=#Z!/XZ2%5+-7
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M_WP>QX>@["(SGV $E(4^%#0_9Z'9Q-:MT%=42D&D(=*#XE#-@BX\J6@,;6?
MFKH>&\NQV%#A."FX!_ ZZX?>.*V_%06FWZ59%:D("GC=J2Y0JRFL)F,JU47$
M\U6$WH0,C%(U.!&&JZA.4M1U 9\)/[4=.5JV/ V-/JX@(214 8%27':?Y7+U
M1<C$\,3$AQ7V)M)KV!%RA,\TN8\U+-)GUU0V4\ENO""<4N=K6.<8*''N/&9:
M+L7.0>0<(ZQV_VI)3FTD/A!+X(:&W%:W5"P9JII;>AYDU"C*';%L.R.M89<_
M/;HAK2$[N-V $/AR!T*'8.^OY5W*QH>J# ,,4GGE&2+NTT/2U?WF#S6-:!*N
MR1DL8I\N1&=$E-G.6;<9Q0MK97D)EY7%?7!1R__LERY>>/)IG F$&@9ELIN;
M?LO[282]NX==(#$O.I6[R[FL_-PP5T&TY!FE,"J8 RS_/E,%6#/;%N_2,!"K
MK?R%'CYG&;\*&SUC< IUX;1C-EIG\=@6-9UARN:X^<:=#.]FR41]:7?&=$Z+
MA%@.HUB:"WB--SJNH?V,*7,[SSW%G7E$-KU&AR;RI$M4D"[LZ@%GLD>2"4?S
M#<>(S0 92;X.=Y@*P=1S3Z,RX7T4'*XX!&U&2315--<)5[;E)=0USSU&F$)7
M*M1%@ROM4TT-8YG]-<7MCI%EPZYS+>?;,>-:B6(3<>,YQQY/.1[6QZT%8YA^
M(,"]L49VZ<0<+^^=LO($>];33*OOX)4V+?HPK-$NMEFX5(NLFA]MK]?X4XA(
M5ERW&5#QN3['>,I>KEM*_)H;L_B:?*ZU"(>J6%AAJOYQ =KL& A6XW73RC!U
MWE6TCXP4[>D6[R>IT3M%TSUW6$B+"V/IBSJ79DIB4]:9\C+08>/6Y<K,F1U5
MG!H;L>Q08;(@; 7K2N;$>^EA+]QU+?S5I39Z%[T<W;O\> FQ3R^<=76%&=LY
M)&13PL/5.#H;7'-$I]("E;7=>XP3C)*T;"^Y6Y[?#N'9("F*DK0AB '3X1D8
MZ,.?;'<XYX<K!'[1T$ABMZ!@-M C9]6FB!\2#2H4)HF+U.A0A8I8>^B8UG2[
MUER32/L<IF,*?CJIPF'L6EE_8;TX0NWI8M>=RHXB*DDVOL$N:LNTF"&I*T#2
MPAL55HF(.JW$2V%U)^,C&T51CBGRY"(XZA0<M7?FXX@J:N[POD#S:*2=1'!D
M^+!+V!*CHVQK.I^8J^-+KV3JW*G@J6AG)+M3P?1$*E0E@82K[A(]/?QA3\CQ
M:R7%I<7HC-0/A1S1\ROK0^7G/B6BX/4KP2L[Y3Z]#OXL$0K+'XB_FBCL+IZ_
MM+P'].E]A8=L#NX!7WQN!>#O 98A#RY$!=Y=W -R3<SW )^2QQ.Z[W;30E;X
M'A>R?JVCGF$=CR]AG8E"\JS3[78^'GORWGD/J#8("6;-/V/VG_A'-8*Q9MBO
MEEY^;4&SSW[U]R&? *-O0-W7PZ,:6^IPX/R>;RD^ I+;%SQUE*%=LY'-G-B/
MK8QD$&)OADQ%FCAD=VNK72GUZ[Q <P"C=>('QI?GZSZ>^S W]\2LW'G4H'\/
M,%<C*+QYIYD_!8OJ[FF.&GIH0LI,:^P5'2<KQ8R,!Z_U24?J\ <F*!Z_]UR;
M9M* %L9FRQ;$)FR/FXU9/+/N<PS%TDT@WL2>56I#VC,"H0&2.[(1[:#./6 N
M_IA@GPI%.&&?_O;SI*$LMP!'?!>1<5]R!BJII&0/AT<C)X? 56:*19UV/H%J
M(W67:'<%U(0T-5-3VPWN,9*JQB@./FD1<W/$+SM6\N9.H<(55;C83?8)QK?$
M!.N>LR#P+)D0L!;[$?_J%2/)1-";2$6U8Y:6G<,XW2:;!K%9)%L:C&\-! D^
M"=0I7D!,8;?3OFQS^Z08L TM$'URZ5HRA8D9%5Z(5;C."F6(JR[D>%8JGJ-K
M[>EK%$, !>-'&)-EP,++QTOOK%D"IXLX#-%-6.6"N!V>I:.Z< C2S&QK;.?C
M9AGNEYPO5R2V!1H"G]37"0WSM#$P*.6$J3J]H1OK!%9/]Z*?%<;FJHW?ET\F
M?X4I%PT[:B=Y0QSTP@!$^N33PEYT[QP-  :81^H(K$,&IM?(Q)ZHJ%OO 4BX
M.#'3ZM"'6D?*#3P+:4ZI[):3U9P4=<<F<L^=86&;[!*??QQ!>5Q:B;"H8/=.
MHG<$+]PLL?N*CEH11V^LZY=/-W3=/$D;9>ZKG[]'MKNT-AE2E!#TN89G:YFA
M*2"/NPU-H6J33_IF I@"><J_8O4?F?^\)K/^2"$ALLG^)F3RT> 5>'W@KNLY
M!#6..^NS@("(#[/-A!"B7B./I?)13XDI]FZ;N<^?;G@*OVQ*4%?2L7/6Z4QV
M6KIQL;K6@2HPZKYDA-^]CVI?[KW$'"Z<;]-,ZV]35ZU 0S2'GZ\!YOSAQ6!C
MB\(JRTV]=]LEA8RA 6\?34].SJXEOO[DT0^1"9<M3(SFIC%<"UJMS(N VD<+
MDP:OTG2?*3<5NS@#)FT$/6GS:'%[^242.V7XW69I:1?[)<'=+1+]W<%7A%%7
MQLW]7V=Y"P47K[B1=-+D95\Z,T1,7SN[%HO_9J[V3<OC>/^9=D31M<+BHH!T
M^@;7<:\^QP3:"ONZNL!L@.!EXIQ-'=X[QH_8]:VLXF_)A,@9=7'9A+?:KI4*
ME%ZT@D:&OV?WG/2S$+A9NA49T5]M$%KO;8IUG^E*6-J(*XP067*'_^W]]INW
M=>MCIX![SL*KA;$^ F9!KJD,7?8F4C0Z_F[+P<6Z=L93#S*E-\PF^VH:0QK4
M9NH" H$ LC6E]WM JWZB4(31]HN.)&ZK\WJ;1$YMGC/AF3 (%I8X8^(T&=L4
M4\"]WK-O'WXDP"U IPA\*F!/%WGK-!C\RN).I\^=VW)^DAF%#@-E%65U)G<Z
M8>AHS>836!<O<[:A3!]]E(F4 @)(/Q*LU>')J.AIJG-E+N.96#J*28Y!4E_C
M&PSQNI(T#@U?\UYH>4+&+&O>??EX+A/LP:L98EAA(X28[]$,5M2MK].,[]X_
ML+Q^HIN'%U[&YFM^(ZMC>9P?Z> ;V82<OCP\>^.D'CRS0]>(@M1J%KL!;UHF
M,O >N?_,Y,M'<XG>MSO+ROEBLZ]!53'[O'9E.,SK0:YD^$18HCWFXFV%9QJ=
MWC[KN;2.']T(L%_0]2IMI+]K)\_.*G[ZH4U5W<6'KJROGI\P,E/QC@TE;87+
M1+1+@!^MZ<ZTM26&2VO8]K(^TE$VB8U'E]JY)9>GXZDF-N/UPLGQW?(!TO81
MK#6@ZF5 Q/+\-M;HZY7VOOYJ_;K@5\18_K6P5=H(ANP(;<NM\YI7U3JLC>%>
MWLQ[@.Z3^,OQE_8 '2UI,^=E6T&ZZ#QL)FX+,&)T>-2,QTW8=<'(_+,^SZ7G
MV&W>:Q_E)&I:8L_6S2@+IVIJMEUH!:OF;8T/U=3D>\^;F\GXO;ULI>D#'JXB
MP)L!/Z;KO2#XZ%U-Y-F")_$T,'-<#N,Q2>@QD2PJ6NGJ*)O0>?34$[*P;,\O
M#+?O(3,E6R[%A_@^ KV;FIM8^TH_<IU97LLNUY%(Q:(ZQ6]UQ0_.<7M0\\[
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M S1-M(>D;VRZ*3&P 3?RRBR&D'MMV!-X2X0FA3OT&^5/FCV?-)D(*.L! +P
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M5KN7BY85)W))KXG QR"4@D5S&V0C!35P_.BKR$!N^J2#Q\$OWPT*RSRZ,;(
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M!E[UW&K9C!0<*SU=;X$@]=N#[N3K86.K:G "WC5OK(DUGS_917Y,@8F67?R
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MF&FIE.WK^[G1O:XL#+JD-4*+K3]'L&S+FKO\E@%HWO YTO-X(L"#]U*(PVI
MWN)V:$60ACPM6J-61?\JOS1AS)^?Y+]IL'E",ZD[ B?%M9/H>]4_S]#!.T_
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M.2+YA&9*B-P0#\5!^3V@_-\LR0TW+H[A'LHT2JKDAJDA_<@IF45F&6V0I$N
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MGSLDKU/T[]A<S&D,>3\3PXP;P>O*_>I^T1<<RP)K"'/M#[L[>/O\7'"7>-*
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M+HVVRN!!SY-!^[*J?E7L%-T%GH0KECJ0V9=CBB@;IJZM"70$OA*W/3]1VK7
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MS-HRM >9!I0L"I^IB ?4KGMEJ?O,2+44A-":9%[6%)WG@R)@((5,L08"F0!
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MRI8 =QT#'&:;,14]=N$"ZXG4+1J4YN;E/*G>M2CV>!%AKQQ.0L(<-+U[DW'
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M?DR1>N:B^*<5? Z*-PP[QK92[ZHD3Y\9/BK+X]83T=@*TWL1K)EW/4FI\[/
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M]5(&&),*%W>X*!PFN;FGAH+N($1Q4KK&QNHH:/.&:((;(VTP/Y3=>M"D]+"
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MS_ A<^^,T8YAFX="H2IRNM>'PHI-7M&/5VHI6*]\$QA1G;=)4WGJ0[YA;55
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M'?EL (&SL*8%TC;;^C[HK7!*39 \'YM;C,(T>!,R+Q)-U<JO/#C22T.:9V=
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MJ0[[[(8PEE3TNLUB.6=[UW5\EAL<^BK.7>2;84_2+3U;7KW+P[4<20,R0.@
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M?W6#^L_4"1S._:W_)?.;\C] */XS(NP&E2M-,(G6VI@/$.(##\-/ 0=) BF
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MXJ.I3-<L=D\9!ED.1(P(>5S:L-S^2/5WC4P^>Y" F<H\[B3%,^WHDA"=46N
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MP\/UY&WU/\09N\5'>N:TOEVOB-NB%[Y;[U?.;/?789T7DI =I&JB"[W\Z-]
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M98,[$B[##]7+NO=[Z.H]W\@I<3O";N$A(EI['UM+N6_-L')-(N@ BD^8Q/F
M UQJY;[ -U"L"E6%5^%GXVE]<.TXZ6D-&ZHL1H[$;X F7*-R[K,6 J)1PB+6
M)UHD\?1N9?0?!#%:P3A:*4HR"]?(=%8)^E\\8_C":OL[K)&D2FDDY\'J<-_H
ML8^>*"5.6K!F(,E*LVWE>7]@*3%=^%NY: 3BQX&T^&K=TCO6WQ%)#_?(L:?3
MS9=!Q5A."NSJMQ:*E$1KGZ>7S80[#<#\1),?0+>?,A,DVN$6E5C18#)(/$?>
MI3R^UBAEE$V-(9&6MGDF46+U";")[49)C?0T%(4!J_E1WI()D@_['/G0N=9.
M<KW[/ UYI\+Y,Y\ON!3Z17_J/8?R!_J00:A8)UC)$BR[$ABF^A\TI89/;,G=
M,#SMH#[ Z,4[KM9X7[F(IW2;[S8A\[Z=8=>A;]BEN#==G3>YQJXN,%%=#$IC
MN%#\77 IV30IVVA,+HQ2^6ZK56TD;IQ!.3J3V?6E57G$:6;[&D].D,-J9<B=
M=/ G- 6R;+L4<5RQ!-;=0B(Y/DB?:>>*@%ILW;'/B;!C.+G-3CG*K5I,4HG1
M>-^G-=$=T-_*N-X]Q=!LS&'!!2K;8,D;.@*.L#X5R'5Z=(YJG'L$H;(:V=+
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M_A:(*#9&J60][':$4,ZKI@ZXFE-!(IX#8L!(,,AYIQQ6B=MR*QIL3U+-!D,
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M<@?P+]OH $Y48I6D18+EWLE4A!Q!1I!,E$7O&-CKQ9KD&W< WY2YXEQ!;-V
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M0=+B(NFOG9B\G:8[L8)AQH"3\2@05S3D^ZS<#<W02$2,DA5G')84XG9/E\1
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MO?DTB2=]V;(?B*C^V-G;>;Y3*2IS5\0?\\[/MKFH3^PF0*8K7"35[>%0 P=
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M[[U=<5818U'9XHN%]D;!\I %RU@X:10LEPB6L2W9#00+^^ 'WONAS6PU1[8
M3]Y.#]52BKQ;W<DYD?&^M6""# $\CQ>Y:8-7JWH-;P4#!? S.JT>M!BA8\/[
M48Q<(D;&KF8W$"/\PU%;3WU]9"<?[&DR[X<4MS3;[.UR-RN9RM4KV,U0]"*V
MQ[4?D\\>MIR0]RXGQNC.,;JS $E=1D3*UC/5,;KS@?'->XSN/-[:X,[_N'^E
M:;LP/W+BAZ/>EH&_T=?QO?LZQDYG-_!UB _QTT'MZEEW67W/K71WO%QLZ$+U
MM=-:G]6>/XAA/AE='@_;Y7'_O=U'<5'4D1C$Q=BB[ ;B0N9*"7U*P)\?NODA
M3'*RE3+B%<Q7$8S^5NT-NQA%P0,6!>RK49SP7^LFL?_S2R#]7]\,4;)Q1OIE
MZ*P/BJ4!=0J-[W;3!Z?B_\CNQX$ZD4U 6D_MY*,]Z9X]JIY\O^ I9=-GW.ZV
M>4OO'_S6 -!!>.2HS]_ NFBSG9&;RW35;M<U8';D.)V^1O2;>5O],N\ ,EU7
M**B+\]&5#IQR)%P^76YQNJJZJ[JY^T?TLVK65-/Y880U=M7A\H!FL[BOFEBU
M_5'MBT*=-/.J.VCFDU"Y6-F/MHWY5+N8*V/!LW\.Y<RK>GH<NUEO1H,>5N<N
M?CO5^X/8Q<5L^<$0.]_6#L[^87XZS2>3DUP_?5# =_/$LP-8YNYT.L\4$X^:
M=I9+IY^I93&W=9K #$/?0/\LDU7URO9)FSO#E^'9N3?74S^9A_BXLH<-++;?
M8O<8W@0K:":3YB-LX>E(>Y?2WN7$U^M%IZ<==-;8]N_.@,3/^E_1Q,+1F3U-
M]:<8GGVLP^P 7ME#</$ ;&-BC[KXM(M'-B?4+BSL%0/\&,Z1JR?U[.3I<O0E
M9O@P.=\QE/RO#*O+5/1A# .M65XQ!N\83:\88T QUN=?MNH_6-- .&4(WXG)
M>.OZR3<89R/L1]B/L!]AOSG8;\Z!_#WCJ(R[XQ%'VV'> .JX&3GA2&4/$$?E
M4-G?8V^\VPKF'"Q[,,GS^_=/JER[PTY/!E^6K2;U89U=6\U1S#<Q8&V#.0^6
M^<E.!;,<V.-831N8IPESGR_BC^#/8QB?FC9/=1C;_DJ^LQ,PUQ?#9]5^G.;I
M8%Q^55^E>@ZV>]L<+J?JGQ@N]@_M236%(6WE(DP9\Y!4]S;II1=\V^;M'ZW_
M+UC_>!/6/U R7\?ZOS!HM/X+TL1'V(^P'V$_PGZT_K<-1Z-=4CZ.RK%+1NM_
MI+*'BJ-RJ&QIM]=3/V];L,$[6'.= ,K3&1C:LVK2=!T\T\& 6#7S-H^,1SD,
ML[?'85B=BPS,XA!0\#%6'^O)I,IM>^MLQ\^:8>[E1-D7,-S-M[&+L3<VTWPV
M;T?[_4';[_QJ\YUMZO)^--_+5:5'V(^P'V$_PGXTW[<-1Z-A43Z.RC$L1O-]
MI+*'BJ-RJ.SO"W-[&L%T!U.[M747<QY EZO]]6'_ .!LK<.?"18,P-ZI7J=L
MI^=;__FTMQ9/G_3VJ)[!T(\'<=I/FF_[VQRC/XOM85=9GXW_Y3/S[G%O\"_S
M!\"F]\,Z0@03\W'5QC#/;H.VBCEV8)K=!%V^M6]2[TM8WN^'>!PGS5&?7P#?
M[;<6WG4N:*#^[S[ULXH)7C+K1E_!0_857!GI3W>,&>_Z2V"%H]$TPGZ$_0C[
MAP/[T5FP;;K-:,9LNQDS.@M&*GNH."J'RDYC]/OX^6X.MGS7#5GZ.=!_$I<Q
M^!Y@DF%?S7+E@"'P_F/L8^_=JL\@-&#-]S?Z^:FE,>]A>!W #NSR0PO3?N>T
M/]J9Z3^8^=D-T<VR$P-^S#D(RY>O.@7.A_[;<)S[,N<E7#9Z= X\9.> WHQO
M *_C&Z"C;Z!8/7V$_0C[$?8C[$??P+;A:+1:RL=1.5;+Z!L8J>RAXJ@<*GMS
MT21/C9]W^?9_VH?KKQKCV8)?5@C(U?;L49P#/H;8_B,[JV%0-]0,R+G]/:HF
M)S!% G#V\02NAM>V?X)]&-KZ.$ZSS\#W9?M@>_X@US*T%<Q;!W@N'C>3X[X.
M(9R _/+.U[G#[=#\-B^N+S1@X;E%5,-LJ%N8/11UYYO>90!#%WNH0CO?[^LE
M3N&GR07?PB3:/H+AM'@!++=?ZV .+XL;C#Z&[]S'H#;E8QCC#\K5]T?8C[ ?
M83_"?O0Q;!N.1NNG?!R58_V,/H:1RAXJCLJALLO2#LY%(1S#+G+@P.-34[UO
M6N#ZN($V[L\G-E<;7-CF.:-AR!& W>;<@%#;_6G3 =JJ6>QF@S]B-<U@)3*A
M+U;0QG_.Z[;/3QAR&,[R#28YU&$:4ST;*A'".@^&61_WZ0R?CF+;>R'.%4SH
MTQYR2X(J--D#T36/EX$3N=(AG*X)0&NH?S#OJR2<%D4\:F9QR-CHVR3D_@:?
M+WOT.CQDK\,Z:0_KN!W62GN0H]NA6!-@A/T(^Q'V(^Q'M\.VX6@TB,K'43D&
MT>AV&*GLH>*H'"I[ODP1N*S:0#W-T06YN4 UB=/]V<%)[W/(]OVTJX][(SP[
M*!XO>B!,JWF.5!@R&>:SW()@IZI>S=L<"/&X]S;TA107.0MG5OU0X[#J[4"W
M:&3=7>H9."NI&)8^B-'P?]"&_QANL"U<;;1_1MB/L!]A_W!@/]K]VZ;:C!;)
MMELDH]T_4ME#Q5$Y5/9Z.HMM??BX@LVCO.TA80#>,-0B;$^J8&=VN-_/AOO2
M1+]0_6#9U\!.I\U\.I0S/)J[2=T=#,_.X-4YEJ'_;[;H_8&=[L,#8-\W,.$B
M)6)XVZ)MH3VV]:2W1OLN"FU?M/$?T<_ZH@;---6PY>PC@$7/0SUX$^"0])$&
M?27$WC$18,&+%?H^@@$^SB?9K0$+R=N';0RKZ:,2^L"#.M>"S&L9G0K?N5-A
MG3H)=!VG AZ="L4J^"/L1]B/L!]A/SH5M@U'H[E3/H[*,7=&I\)(90\51^50
MV;O>ONX&PS_:=G)RKF9A-P-C'1[YK,AA[WCX+ LAV_WY^G\:<XR!;>MANE#[
M68X]&#(!%C9]/^DD&_67OC&_X:+G8KU5+/M!^.S@R*$(1Y/L8XCGWGWJ),E[
MKK^PAC5WW8=.M-^VE\>7%J \ESVR".MX?%7"2#_[2F.)^(4<D=$]\I#=(_BJ
M9 L&O'%##2G)A9>-_I&";)41]B/L1]B/L!_](]N&H]%R*Q]'Y5ANHW]DI+*'
MBJ-RJ&QP):R41UB41 "[.]0IU7X^F=5GP0A@X\_J(9XA5U68MF"Y+6M,GE:2
MA+&?>0.RR=Y&'^NC?NS2@7)RF=7?+6(CW&(U0U%'V/0Q3!_#:.<_9#M_C3 (
ML:G<BK&F0KDJ]PC[$?8C[$?8CV;^MN%H-$#*QU$Y!LAHYH]4]E!Q5 Z5O?ER
MN@28UK.#IHO+:(!E.82F_;P&0M,.)1"R*9[O_U=**=H :(-9>B.]ZZ,DNABG
MR^"!U; !F'G:3"^-(A@F7Z9$V*JS*<[Z5I6ISB$$9XD3]?0 S,K9I5$#IRT@
M*NM]/)KUS2=A>[GKY5G,PT,,'[@5_>B[W?3!J19X9/?CP*B03;/8/K63C_:D
M>_:H>O+]@J?D38_^M2_XUZ[RG6TRS6ALQUH<W8Z:VPC[$?8C[$?_VM;B:+3\
MR\=1.9;_Z%\;J>RAXJ@<*MO+-4*^Z%JJ#N&;G#Z38V0.LN.@3VP9>J?F0J1#
MEY6%YVV22XR>ZV<:4XI#AM'0OK6.W5 ;93ZK^X28H3&J _3D+B:39B@Y<MJ>
M];Q7;1].0L[D@6^B;?W!:J_5/I9G**::W['B7*N[;GZ^=$D?F[,2F7/J?WL\
M1 \-G5Q[C]M\^N>T^=C'#,VGJ_523[V&_0X?A@]N=#U<W_6P3MG4M5P/8]G4
M<LV $?8C[$?8C[ ?70_;AJ/1*"H?1^481:/K8:2RAXJC<JCLK$MKCKE95MH8
M:FKTEGB=5GP,9QU/AQ$ ^<?+OJKA\F2<+W=E[8M\?*PGD_[5+IZ^_5RYCGX1
M_:B5A)Z<([0RJ%_&EU[2-Y6%W^Q@:^87[,=IS#9I'XDTG<?3^9=55"<G57UX
M9/.N1J?"37E"P3Z%*WNPLAW,QEXL);#,T;@:83_"?H3]PX']Z%38>M5FI*,M
M,W=&I\)(90\51^50V?N#6#53M-_D>(+G;_[C]0M$3 5+#?&P]KU%;ZNNAJ=M
MN_)U/*K/!H IV"-IR+P!B[\/8FCF78X-B+:+C_O A!6+O6^M,D0$Y$]]3$!O
M^;MY!Z#ONE-70&Z*,LVN@]."IT.5T!R7X.V\B[ \>$L[/^IKE>1F+P?Q7)##
MF =TK9R/0MT 8T?6;>%QHS4TPGZ$_0C[AP/[T0LPVB??!X[*L4]&+\!(90\5
M1^50V=^'RJ!#D],VV^39ECZHVP V?]O7!1VZG_8F])=;LC[.K54_QLDD_[>>
M'L=N5N_G, -8<C/MFAQZ\.5>*)>U/P%KOHL7EA*:H>K(:H\1;]N<@3"?Y2?J
M-J]UUEH_F^>6JO-9GTCAF\,C&/JQGAVL!D L@B(.^W(FN:)(C+,%.&).?K A
M'X2S1B<70B"N:&K2M&OU-#EU>)QZ0$Y+HW9SU\UR+D7O.CFP[>$8ZO!]YT]L
ML /*Z.0HV. 883_"?H3]"/O1R;%M.!K-K_)Q5([Y-3HY1BI[J#@JA\K^'D^]
M H,/X+Q7(?7U4;.)/YVG[#EHOU;H(37G2YVN1AQD4_[,G9+?6>?,!?@[-%77
M],^>>4&RCV2Z_UGST[ZPPT[U_J#NLD>F'DJ;7O3*U%/?Y@B+;N@)6W=_#H4;
M5M,U#NQQ=B+D'B^Y;4OUSWEV)LS.]X6]N+_F]-O^[V[N#U8?M'F7RZ*KV8;V
M33=;5J%8J1KQ^+1F1,Y/Z?,T^C>>"]!H/]]XKA/1M&.=B(?MY^!W6*)R]'.4
M:W.,L!]A/\)^A/WHY]@V'(T66/DX*L<"&_T<(Y4]5!R50V4YI>.\EV!^!!;U
MQX/F,/L%^O".I;.CFQ_ED(BF#[0 >[ZO/7F48PQ@4?,>,Q7@HHUAZ/C:5Y!L
MY_NG+H-9DT,4YMU0Z>%+L0WM$/;0-=D*A;^&+BW#RX>R#_GUDZ;K5KJW#*$?
M_: ZMLN B)56-(MHB'-A$Z/#X*;T7CIP'GR7$Y^;'[?E\A<Z-L\9C]77CI5K
M)N%;0?=[,XO5N[AOV[ZR\:NF_0A_HE^;YL_\>6\&@J2/T"L4NAMCX]<!WO8Q
M\7*X677VO_ZN97<ZS3&C[^)1T\[RA0L<Q<.*8/2W_B;'UM,N7^ZT.41SN-,
M[21DA:H_L)/%@>U.#VQ_UU1/A[NE:',AKJS=[/4YLM.*JMVE^@5?S=OA?F77
M]XFKQ##6Q]1:F"K$,.A*IX^2EY<\^O*3/[#3_;@R!U^=H_HA/_"O__*)8N*?
MK8X>O@O/?MRI_@ZZ>3?<^L"3__HOC#\[J^;=/>Z_&+Y>7F^=_PXTM=4O#NW)
MZD< 5O3V_V?O3;O;MK(VT;^"E:Z\5UH75#18'N)[LY8BEU/NBAVUK73UMW>!
MP"&)& 18.(!DUJ_O/9T!("@/<2R0.KWZK5@D"!R<88_/?K9N.C?BC%GGHQPD
M5IEU/EH52=G]  2'8&/]CZ<*EN6F.U2MU/ON(W63+_LOM$)C-VW\CQK8X,I\
M@BMPD]0Y,Z^S'0O3=$LSAE^::FG9)7056L#\-K  8#/G>!CSV9I_NWWSP,(5
MS:)JYPLF?2N*NW::;%"QG,TS\"(:W9$5JP._-;QR\S:I8:D59P<%YKU2]0Q/
M%^8@J7:[)ECR'R;%"4X<8:!S#1,<M:5\T%C^^D3K=KGB&:,$)5'4Y9B31+)Z
MN(=,^W.FL,,=$D>"WS:5WPB^QM^HVJ\EG]7@UW!C2YEQYM(WFXP]$_0I:*[=
M*Q]%[^Z>?!KD-*'[E;9=)N]3P[MOMQ"])O@^?_#AA+^GB$9'WP1$;ZN;FLO>
MC:."-?$EV$OXI/]'1[1?9S);9C[]65LF&0QF33=TOXQM,\V\3(LV@TF;MHU=
MS *V8D,[+O;?JS9Z]D>C3>\[7;GCB<I/Y)[[I$3E<4A4CLV,#R&P,/=A[L/<
MAT3ESJY12*&,?XW&$Q0(B<IPRO9UC<9SRC .E9=YPZ&4. )/FNCAP8N>U^0B
MB^<O7G&E+9O;UI9V]-MDZ>JIC=N.?YMHAH?;UDV;Y>*];Q2SLT_="PI8YYD"
M;SQF')9[$X/E7A6*_L00D3P&TZY<]H[7U*J@YG@P(')4L7@<-MO[F&Z]4G5>
MP=NU-45P3 ]!&PZ1T)_<3WCQ4^Q/F-PD>8&^LJ/4_^B$W6E[[$KB]*&QX86X
MQ*Y(W>"?A;D/<Q_F?G_F/L0E@L?T,-9H/!Y3B$N$4[:O:S2>4]9K06<:W/NN
M\Q#*69D*ZV(=';C0 0&KLQO$3A@^>M__]FNN2Q-24,0X9Q <N<H.]\(]#X70
MP8_?<2D5_)DP]V'NP]SOS]P'/W[73)O@8>RZAQ'\^'#*]G6-QG/*?#_>U!C;
M<A'T[#M4;\A*AI7-0K>>.DA_W]'O$,_WB>!:;'?797AS"7_$!D0%5I. JH7O
M%%]IV<_XU_E,*.3!_PQN?W#[@]M_[T(MN#]A[L/<A[G?G[D/;O^NF3;!(=EU
MAR2X_>&4[>L:C>>44<+=<_L1&0_S24W5I'R Z-$F2(^VAO&C+S?/TXA<-G#V
M$(BO.]3M6]'SQ)C&O!L$YJ>$?[5!<=[K\[894PA^?O#S@Y]__U(L^#MA[L/<
MA[G?G[D/?OZNF3;! ]EU#R3X^>&4[>L:C>>4]6#ZTH=]!B-#+YQZK\,5U4K5
M0M58*DS;)_6:?7NJSU?P@QHI!S<ZN&WV)-O>+>V X04)L@/FW,\M3?0BIO^-
ML+_\35)8 G68]?=*7%7'VTD%_*JDCUL*/^"K^.\ =T7RP5(;OH)DE3=)P1]F
M.<$8.LWL83R%2G2#U),5\[VKM()?+I)BAJ]S>GSZ*)06A-A#B#V,0+(&'RS,
M?9C[,/?[,_<A]K!KIDWPBG;=*PJQAW#*]G6-QG/*AF,/[-SGW(2A5O.V8$X_
M1O.#I[XU@A!\\."#!Q_\_B5,\$7"W(>Y#W._/W,??/!=,VV"=[#KWD'PP<,I
MV]<U&L\IZ_G@?KY>^6ZV#A7UP=,.GO;(Y$CP.,+<A[D/<[\_<Q\\[5TS;8(/
ML.L^0/"TPRG;US4:SRDCXKPZ1^=.^M;ERVE;:TMH/YS4#GYW\+N#WSTRJ1+\
MCS#W8>[#W._/W >_>]=,F^ 1[+I'$/SN<,KV=8W&<\K0[\ZQ3!W][$X-^K35
M.1':+:M,%=SFW1'9K8JDU+8"WEX;J.>"8QX<\[&*G>"@A+D/<Q_F?G_F/CCF
MNV;:!)=AUUV&X)B'4[:O:S2>4T94:FFU4NB/@TO=J)2\\UL5)36RSX,KV%21
MTNCWY7K1K0Q'QQS^J8H"?M8F!=YAI9"+GM9#1]1N'I/MH5@\>.S!8Q^K/ J>
M2YC[,/=A[O=G[H/'OFNF3? E=MV7"!Y[.&7[ND;C.67@BN=+XFJ7#/JL);YT
M0Z@>6S9UGT&=$^MX>:E41HX[K@/Z^G#E+"^3$MW%X) 'ASPXY/<O;H)C$N8^
MS'V8^_V9^^"0[YII$UR%77<5@D,>3MF^KM%X3AG5E%<-3$X.KO14E6J6-^2=
M#S5DQ^1Z,J^5<<M[W&_PH:JYR]F67\.=X1=UG93SOFOOW2=IX->8:^]T@K_-
MFX7?'B[N<+L/MHK#L )L&7 L]R$T\)?8.&-ZZ90VT'@/RUEOWA;6&%PE<\7R
M:I+,X!U^3(K;9*V??Q?],*H9?I#;ZKZU9 BSA3#;SKF\8>[#W(>Y#W,?PFR[
MMD8A ##^-1J/3Q/";.&4[>L:C>>4"<S%Q<XXFM4L\CJ+P'-K<OA!7D9I59:F
MB(4O4 -A+:YVZ96C4 @L*==1!3^J+>&C;;^P%R&PX+8'MWW'A5)P7\+<A[D/
M<[\_<Q_<]ETS;8)#L>L.17#;PRG;US4:SRDC@@FXFGQK&-(MN.0.+0-N.%X
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M9*L#HG&]"5=5@SP0\% )T.'M6WV$8X=?I3##4Q65591HW=8)W)5)&P?O2G?
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M<MC*U.F:R/-O*-0C%TIQ/IF-[RY>Q]*-Q*#N1$+BA5D%PQ+IA7U5%,+],"V
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M-_CAR8+K3[:PX"S=J$6>%LJ82M8\$N(V,HV.[@Y6W&D6>9T<2S.?S@*BC6&
MY(2@((/,FD%,POO))F,<_=>\>8X]L3>-?U\@;@!+96#,2;+Q6[,G[%)C$Z*$
MWM559C4+D%&+JN!2*=MZ8C]DS[.]$SV?,W7C%8]WN< G0UP]&MZCKK"@KJ<I
M$8\]8?7JL!?E4$7:)B7T)FQ[H\Q?_-=]39_^A;IYV):'(6PQYLTWV_G03D^^
M)O/L@[/F!PP2T)0S+E35\4<)LM!,W4#"#AX^JE@X/]XT%SK$7[:W*-\ %R*9
M(Z6"3I#9T@&P2J^<X>3TT%2;97[KK6F.-5^5HTIP#9?UYS0RN<=>#C0+M9JC
MRV"2,I-'C[Z/H\F3I]_3]$^>/?[>F"W>*A$5?T8Z'QP>)\.N7OR?P9E/0=TG
MX,!5:5*G>0D#B)F&C1[29V*#WZV,R-P/J^ !IC'.0QHCE,5]0R/N]"XC;E!O
MD$[RQ5]^1XX\X-E"Z/E;A)[!&=EFKIY\W%P]^XKFZK?Q9+^]DSK.?;$#RN8^
M<^;W9R5?6#L7^U+9X#O&0*UV:38LZ8& 0-<B_N7GURZ[<';(.5:F'1(2' F]
MI=B:NJ[T*D=3>U:TX(8<7+Y[>1AA/XN;A!B*D)N'85;^SQ$]SFPRJYHY>(1V
MB(B/3(,+ZA+8EOF_6XQ0P*]S1FB9W#+2OA$Y!C6L<$5:U8I"?AC#6X';HS!G
MW.M9:3I>?81!&=[GS;M#KZ4R3@[.!WR,;%.);HAE"BD4*5_2>8*NBMP\9ZP5
M8>%T[Y E>;8#G?L&[<&_U/[%;^%<CG2O?=2L.MUJ5IT.%5T^\[LB/'D6"(!W
MX:7'P:7YW4]7!2;3/>+!I@;5J?>@Q_<#[&Y!X5[;.!DIG*_ 3 ,U\<-I-,MK
MC9,G5A8M,W$>"G:%;)X!+D@/_0ZBNN(F7FMNSOTQ2^H &7B,JGID82G89WXE
M^\Z+1(-\GV'ZB4;2EF!,@4&5T:;$)MYDO97J5OJ((2,E#J)68E>":=@00:?2
ML6>?20>-\:O)[WZ"OW%^BYQBSIMQ:+(S0:_%8P:,PO%-#,&I[BSO[4)Q9W9D
MS:RE?QQNEIZ9+AL*6X8T\,9)G>$>3/$GNDT7>-O75V_>75-76P_Y:_9]K[+T
MMJK?NR:_WF[%]K],[Y>#0F8&4!I3I,JZ*HJE\58^NL^9#; $26'@'GAP-#@]
MJDSQJX,WO[P+?)*[*5>O%XQ)B11RS?+2KDBL$N6IE9\ZF2GD8#1DC>]AAIH\
MU7&?OA&9SG=!',&),&2V(Q<X&\JHJ)BI/LEN\-1GB(D2Y]SU3")L>+FVBF-M
MJ>=(.AA@V5'T$H0!DT0;/)35C*0T5XW!4G8HFTFT=/>(L.<R07"'=M3F>^UH
M)C9;JS[ M*/; V)SJ3W=1F(P-BKN4]4'0=I6":CZ F&H=I D]*+$FX]D7E::
M)JQ:5#4+0^$_9E%-8"A2S-A=?.Z,!G;IYF0G) Z*!=> ."_ B<.WQP?MPD'@
MR<AGT;2NDJS+8B+@LZ/HEQQ;&%'VO;-]HBI-6Z8^.#G^'J?PY/Q[>GNRPT0K
MT3(LDS6O-9I%<"$'D 8V!"^'CJ;C/I=4ZHB[UI(U]J!ZSCHE<S0HR!V./;_B
M)24W YE ZX8E[.GQZ2F!Q*.7+RZ8YUW:[[UZ(_4^FSN!1-6\3DHTLEXB</2Z
MAO<5&T_:@U2V2<FXCP$X9NCMX(#!KR+*E-X[=YWOKF+ *W=!2&J55MR;Q5_Y
M<:\,Y19 XI+366'2 [4</ #=@#*IUV+4T7:T>IN@5[AQNXO$.W^1%#-Y^3-D
MML)6<C4&)Y?4@>$#JF[#F$.$5SF<B"RZF->*6M3LB0P\.SH/"=D L#( J\<!
M8!4"U]\N*_;(XJM>#D4]=;I0RR2 I$8@>A\ 2.IL:S;O;*A"]^FY!Y)Z]OAK
M8OK_NN;N8\QLO<%A>N%8+F-Y9<D(0Y+I2ZBR),JANL4/68:)>>*)E$!<M*I6
MIF)S,V[N1ST2 @!AZ2"&M#RH/MRR:NN4\SR4S*(5G&&?,+"KE82C"!. ) _M
M2M5Y57N]VNG!CK-)VN;$W<+13CL)-/21_"GB/E!9A9%]<A.84'=P3]G"U0XS
M+?H1KBFAUTN>8D2M9B=0)TL5+56Z2,I<+RDDR4S4B<UM3-O&9/:\LH9E54L'
M^Z;3!TAUBTU@VC;0$3!O.#T=9)4W[Z:[$(:C$HQ\"C #ZSBY)MNKHF2ZC59O
M=*[CN?1N>W?_=TV/,]'%!)8NX[I1V+>J;;AF17W8$_?H88:(+DIP@-5RA22M
MY #C[NP?*7*'-9QD//<:Q<RX8PA&"(*TV'XDA_:[7W-N\(O"7?-Q*MW88\K>
MC0JN5TAYY[<BPR:=*?PDP:;!\P@V]L(R3UC2AVX5? ^7ZJ$I;8$<AQKM-NO@
MRQX_^:@0HN(\,PK^R")?S^\_@QOM@?P9EZL(IV?84'1*W6XFH]TWR$XL=+%S
M:$4%GYP^'6@*".J=J5D8L."H&[QS'=S!/70''VUU!Q\-N(/G9[X[^/@T@#M#
MH= N'H8QJH7O?CIY$N+2^QV7OC][U_.MA]P<%RD@UY[Z ;O"I0H[:9,[X7IM
M-XN$_7GRD#;\ <.5Q!BF:*V:S_*AQW,HHU>S3C3"BZ)@A,6&&1A3)3BLNZ<8
MN>8(,$/U8XOU"I$U.O=0-X6D@%?@EE;(PK7U;FBY;5\%F)-T(:WBP5%IBT:X
MOL'9HYXG^--., C>GQPBC/RLX/$?L/IM%QPZQ-:>G!*@B:#AS6)/VB$]L#@Y
MHO%54F.TT]N7 EH(A2"[MIS7'*+M-XE]:%/WA5AOF3PB%I3C  XZX_M1=$L
M/,MUBJ$BX414J(T(H+LJDF8&CQ9%D.,T([TBW*UNYW/*D/ ]I(%?5A%1T_O<
ML:IQV"G+0?$U6,>-\7]00H@%39JF3D!3R5/Y2@SG*PQ K%'7+RFL+P]>P\WA
M)?JC1+4FSS_(#RD#0TD#0U/)(37#T(K<K/ #*I>@R-Q!GA\:*+.AZ>3WA3=
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M)YQX08B"TM8;4/T&NL1\:/*TKE1YD]=52=#;Z*UJD+W$DJ<:CF-;K&'3^9@
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M:!W!(.7&,]>)6*UCT7=42;XE%D+N0NQWE$F\>S,HV;N/7U)%H1JZYP_>O7;
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M4)UHMHTV-K>5M<I,*)+[$FJ[B28VBHE7V\M< $9N;*5'V"F[N5.0J61KGLA
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M0I4+AIXR4-66^L,%BY)JMV.2(:6TW<;^04MJCBI=Y%P@U @+D!-P"4@CCV'
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M 9(F1:_>O(@ELBBV+KFU-KIL+-G^.6&C=FX*8<5,;E=<O964);>8Q"]OD0?
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M[2T5,^,5Y?_(OB_ESK9D9=><,>0XXA 8H(Z$9]Y1#KW"?"D-'GX10 -?K[?
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M"^^=;UV O !RZ(AV4V'0*(=TE?X=%*N4  '$C' U^IMJ]2<0;I4#V2QR8?W
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M@L[ND/XR2L/W\&URRO"Q@J3,7C#1H=0EAU\X6>*7&3]57^@G53*]]R&.TBA
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MT!93+&+/4'_<=EOU5-&B.SOO_#H6)M\@A$7WY/2!_;H_5IY3!ARUE/1H/4)
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M%_)HM*V$.0DKZ-*> )*6<@*3970IS0'M$1T*]&,[U1+P$Q^:Q,+LUM62/6>
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MGF1U8Q7'=&'=Z?%@LM1:="!()*X=/ZSL&SFIL!&[O+@DWM_8(*BW)?<(GHB
M1@D&I<D:)*G _)/=7@<3C5F8W8FEG?!T7_'1VC$ZEFC7:4 9"T1CM!2H52QL
MP6,-A"5X),8/])^#AC1\A,Q.G9EE.R7^#"9.>41_AM8]$EW&XQ(GC!_<%DD4
M/Q<YG<W4ZNQ=(CEC$!M_!D';I]L73[CJ0MA][A"3?9)%406L0M#<G'#-1TA
M:$5(BST^LR6<"N=<$'B7=$UL'WYYK*P3J9QE.T9*5[[B)=R\2#I"R9^&04;$
M=Q.6';B*_'92KU=R-[SR2,-'X<;D#G)^Y<*-+4H27FP.PJQZ"5*!5X,=0\D1
M_Y?VE3(_4C/LECTV5Q'(.X@:A#SAFEDH=7IZ%N+SJ(-,Q^B7@2W]?L*6WL9U
M=7.=_3_\^>&O__WDT<EI?V7=Y*F;ULL-<%O0;ZAK9T9"!!#,T+;V5JHMD@UL
MNP7J4-1YONL6/JA4_0U* *K<1F@T$C;V,O3%446#=0:DZ6EX;V'EGM55PLM'
M3;?<= 9LK)"G*RNB#)AJ<S-W49<7H9H!'0/FUG8BHDH%I@*U1L!M^0FY<PDY
M*'!4^R^#:AO.-+.6"L>TC)T<$H:#S6II(!08F-92.9E$]&LT#%!5EVX%K##<
M?F0 O>M-Z3!@?:A 2_[[\!408;Q_9>AQS V1?YBZBZ*!Z!Z_IA9/[,IUIAE*
MHYN!N=#I3V?7QS<)U^2EB]0F8#*)]"82MSWYY5&BMH4TE; ^:-VM:+@.W>PY
MFO).[[V0*>:^OZ/L*.K:8DVM^A<9=?9NSO&.2%&E'>A)L_#.F30_)+A[H'I7
M07 D)!1#+YRVS>FB)RGA,C\ 7A17&_8E( 24\/;W63<Y;K;H]BKD2=5HD[:4
MI*OPS^!]A"5%/:DYXEVC/48W;6/&5<ONL4*:QZ9(72@/G_\Z&W0#2/\ I@@2
M+DB:6XW@1%/ HIZ4VI3()9*5,OKTGSPJF'WR 7SZ(=RBP_F&>22G]^<//L)3
MOZ?%\!9K0>?H%J29;N?D?'DQ]==WIYCZ(UBD#]68-2M6_^</_E&W_W.:_P]4
MQOY'_.D;&FX_N=$X7+>=G9[-9\_]/,Y^XGF\5F[_P?ST_OT;879O5I@\5DM]
MPCJ[S%I&P#S2W2.*_*)"! H'EM+NTIX!CQA+>S[[_^H.F@)@!0?,@_D[0@<
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M Q[D!7>=HO>5.XTHZX:TA;3#:L+)SQYJR?O K6/,XR<O"4]AR7MU06D!T3Z
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M8C3XW5C:Z8@Z-H=G:940L'DT@,"F2&,%F=:5-R$->RG^>SEG-H*49N&#P/P
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MZH+DO=?N=CNE[8NE_$#%@=I?*.O?]52%T5ME9N2@C/&/'N@'YF YC#F%"-U
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M9+IBK#Q[%&OAF0C 8N+FY<P^<WP/DX;BRJ,A5:[T(_KTW_#:>]G46.#XX)\
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M:!\W;<W%AN'!H7/;M2Z(7UVS!T_?/\'A^G93=2-N=.-Z1E$.2N#^RNNQT/.
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M.^3;SER+.C32$6A$I@'9?$*>]0GYDU"OW(3=;VR='X=?; W[F$1%#0@Z*UO
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M4_!Y_R05,,(P]]#O.T@)AKBH9GKKI[I&WYOE1\I1*V9!) %%<?+\JK2R)K1
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MKU\4 1]7[;GQ)0LE&S9*ZS3>;BAH#8W2MOV%QB/LX8Q+&8XZ@?$K&QS2A\F
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MT\S[Y,O>)Q:",SXB NK()".*X/; PZ"&*%"[\X*FG@W@N>#[5 >[\K.!ZTD
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MBU=)_X7X-R/'@Y )$QT(23_9">4^V>8\6O__*_>/'H\>"GV9+7\;3\RPTRV
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MNM5,;OPTM^-[DQO+F@[2&::2@MD#+8TCNBW=A(-M1'3TXSVL_(A5[7?B@;
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M-!206_LW*/+9G!R2JFMLWB\MX\3N2J'M=%JO*F^=#EUZRBZI4A1(QB&M'9
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M*-<LPB](WX*&BBFDWZXKOW3]J=GAS4=.79FT\IY"'="AK%<=4.[DOBU9C_A
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M4.'R&V^.&*WL:A*;X*A&ED@S9/<2SGZ1O>F<B3JY^P-U I5^2[Y:!%8P!:!
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M&I^%[["V,2Q-7RS=B6J5<C4*XQTCL-!SS<6]N+)4@0\@6R2J8/0-)4@JE,$
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M0!E,!#Q6=__L1)1DF$@ZN)2#=9GRL!LZT\U$+<HTD9=O@X7E@;K:9<PGC_:
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MZB55,&A 4;J4I.<;H6%UH[@;>RN/<%'*(S7",E']*&WS]%T6U9(8OY;W[X$
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MY#J<JN(^Q6!VL0%"C#/-C)[$T1LV6)9HMLXM4_:R)&[2!(()BI'W0D6S@ID
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M%_EK)JB(?D.F$HOMJNP:TG!143@U75=R3S!UA&R]O"Y!F: X?-%MN\8L>&S
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MR8)T\ B8R.8W9-O7Q;LNW@_KSQ>1MN"P<8E9%J*H'Q"@^.C-*>\+SO_E5Y_
M(IT1"XJ0E5$3UJ;9[88V8V@>-SBY#MB*%DA[7%N<_!)Z[CV-CV^P^9=__WO9
MO>XV?R\JD.8&#^[/X.%#9OCO1L_W$7N WMO;?>X&XOVT3Z4J">JNT\]"QDA*
MXJC!W9( V&%>Z9VY'>LB 25M]DW!.+QCD=<3CH!4)"R*:3_^O@@7$CC4VJ3V
M--?LVRJ*B'"&D=_,+ 1:*86T3*,F!DXO(TNF[$N8-];Q(B4NYKPHWK"BJ5^;
MR*\<D+:G$I*PV_!"1-E)M.QFEN)\!4\B"G1I@TJ_3R^=D).-RGU7:G6Q'P8B
MM;-Z88H 5 ZU66I:>'_26'V$.P"N6[>_YC3:"&QH(JS'@<C3B07K+,H31FX$
MOJU:!$#2C>AD6%26>&:#1U7HJ@1'$VX]\X7D$<9ZY5XX9!].L'.71::P1(T$
M3S_X9F]\GM4-X"])M;+G67'<>U:!]*3%\6VE1"PR77@:)J&:?Q+5D682I%B]
MU *27H\8B]$,P8N&DBQSL\GB"B$JO2YTJ9G99;&&_9PH:UNP'"M3VE8Z"M<1
MN6R']?+D1<K5%>=MW\;,#L:T4E$7<]AYM>Q"AO$1:JE##9VUH8E2\M?B4;[_
MP/G)DZ]\O9*OO#/YRAKN+LWA+^*]/DQS)=5^7^F?N[_P5TW]53!3H:BC%'%-
M*R?2@Z[QW-!COL<HXUR^9W00V96@N-)%)Z0;T<5Z2> _??MR TVG;FFF\^D\
M9R*V,SFW4K=&C_W4O8'[ 1>*[\+'5!2I9;Q@=*LX'W%L/*O@9$31:W%'^,MD
M0EB"YI8RO,P*F@X+'@0X+EDK+CG666^+U;*X35XTF8A*H&SVG7&0]JB%<_GO
M.MA$8<V%.$G3%;.^I>_.<CGINJG-T^WZ <S[!(U*O5^"=(U_)7 U;JB<751:
MW0F1VTG.Z^7W.!>7;?Y:4UL52=BK6NZ"2^B6(V86.O=&YHDL1=YUS:Y$H@(>
M%BU*_3KN=!P3($<O>68V9U8LK[IMH6MN#\<QC/FX'=J.L75"DUSB:Y//*D8-
MIB/E8J:I(#5MR&EDRNR[BV:&\;3!>]J+@ESPY[P2!/NA,$;* .7(^VPF?A6N
MTR>8C)M+) @W;%<4KR,-M-@49OS*HUY(*LT]?_1E:)HT70O:X!ID,'8G7C13
M5G2E\MHWV>1#$R8".M-(*S"-?3!@'X'*;E\3-T]S];XU*ZDZ"\9@K+71&6/;
MT%E(^FL]G8 PKLA2A.4>EOK0I=KG3*HCMC9+SG=F?7,8:9<8*(_XQE% .I0J
M8IEYRQ75)G5# V>5>E[?Q8(7<4#>(-F-P8VX=X-22E2F@JYYW4AR26^+<!S?
MHIJ=5Q>@[N@W2D(/!!U]1UF2F4D^VP1WXT9\"&:[5BG#Q '!>1KV,U_-J*?)
MB2F@\)<^P.CLF9""T\")V(AIF(G/NRV$$3H<S\&/.LG99$11K:*G5$(TO6$8
M=<]T2[/N9#CSG#G:%E59W!9I$]2,R]=MP@>OB3DQIO/\JZ'?X;[C1;"CU92,
MM^P]R5-^[QNW>$)!P"78_35Y)6F0/5R2BVRE%XV@:Q&\IF"\9*1V&\^\7<3K
M7H9O2JM8^ ,];_1\*?](QP&([<?+01<?-O@T7+)[T2#$@PUK]P56FUYD=]XQ
M*3"#.U=OY4G8^_?OK33MB6S1OAVN)YZ*YE'O\5)<'GU+(M.N>A0Y7X9Z%G>V
M#2;]4/;3@&%A3&/]FIC!C%4!PRJ'_; Z+4]S$;^U?CV='V.9RPU"^,+Q[7W8
M97U?X0=A8Q+7CI?LM CUW=""(2GU9VC<G02UE6H+=$<*M4_A1Q!&-"<3Y<L[
M_\#A</@O:.31'7_@WW]+$P$1^7D'*N>I(IG=.IF\<(:S8&D\Z3GV%6EF<@G#
MWUH"U07/ HKSZ/@R8 I7JL(5KL-^;Z&GS'KN>U;UG3X0'*;B3OVDK[X(*^N+
M+ZB'->SK_<!UJ7K I>8S,"P9,GMAO9J&8+/E06ZD8V%*D-;X9B NBS@B P;1
M=EB;@DTT&Z6NKY5YE!J!V^OR:J%"B3S$[)/-+VRRA#T8( 6?#NB[XH3"*J0/
M4+J&._K"@CF=FK8?:EZ]M-38=SH,K!S2-W?!+QUGH[A.%U91_L91?V$E#R$<
M>'$H2/*1N*&?1VUHS>$O0M:X-QQB4;69*5J1_.\P\E?-4?3GL\UPLA0VNCU#
M5.-3O-]]_S**T^![/;FBM.S$0GU/NC8E>;H_2@HMTU3VTIH'1SGEDCD ]-VR
MM!-A0PWQ:U9+P[E]F5_735>"D;801QLJ1!;FAJM4Y:%XT=\@]UM+J_ONIFVP
M)V#*4*CE?G>S>IUPD],O@;1I8$YR$NUBU,.7;(5"O-<)PH"GE4NTIE06+$\7
MKMTQ@?0YQ*?AQ$%\.#O\+!T_@C[BJY"#ZG_"XW_6M)MI4+X=Q^/BG#&)&*6Z
M^8&*_>=C?2W_1LC*(\K@9^!7<-G,9Y.ISR>3GVG*83SQ%!M*,@*9?WY!:6*"
MC'J=.3X#-8DJR3W45?D:W/>T9M@TR_+EH]#>D<U9-Q", :=,F*A_#AWD7>@;
ML:64*^>:V!B=#W1AF'K=8._-O@-0$$]3KC:LYOG78I[_K,Z4D%A'1P,DG8OK
M*&E9DY1RY_ALYDH^NF_) =M%/UH<.S8STZRT-S*4W.$%+,GGF.>*M4$7NF4F
MU,A=J9VYK3*4<)ZP!\6#Y-(B5[9F,5SV#%U^C,,BJS!Z*';H2OH0AIC1L(H3
M]BXHSTD<T(NA<XK-(7_DT2@AB"P89-B746C]^"-VO(;/4CWJ9^BNV=38]><^
MK;4N11.1UE/Y1J_OUTD4%#D61<_SNPNA3+AXS@G%A05$33>'\<N-=I!9W\/)
M@;E0!9-I<"YNM8R!+6=9[%>K]*RMTG<Q[6O@B[B,_.NW2MAR$(Z5X[^C-2PK
M"8PD!F8J *+^PT0E3=0WB 5^*]C>Y# C\2_SQ*ESU60S+*G#8;\FNY2?*,Z:
M^[:[8_0?J?P7!DHF\O"BRK=%=;7![+*^[3A*[T8E%S*5=*_$W'N$1F('%Y[!
M@4IV36V&6")>ECYU1D C14I5#+!2K978V</J;HCP+X*!VXP]XX@'1B+O-=P<
M4,<\!W.PX@NG^,+?KOC"#R_N]HD>,L$6]6VY'2P'('F^70CS$4LIZHI*?Y;B
MW"<&4X\2!54L'5,Q_>DM=B[$64QIC;*J+^HN^<ERLSB2Z%;Y>N7<6 KGU@KK
MRJQ'J1ANRD8Z\\VV>ESLYW0-UY1Q$#DW[RZGB\$=E(QMM-!RX0CR(UFZSI5Y
M\@YRT2XZ_N^!1.+Z\QCR1S6AX']*R%SL$7'+"^T<0'\IO2S#4=\_B8+L1,MY
MY,>F+-CQ=%+8]QQ&R$BTQ8DHV0 ;-#:S^];?#PM^<UV4&")@=D7=35)6"#J:
M.4 ._R7UWMO-M45N,9SQ)>9R BF]!]^S^0>0KI>64)9<-FW2+VZ!+)H'+'7B
MR2A::?F#69*"7P#\%O4_FW-:4,0BHZ15<M=?A2^Q"ORAEOIR Q>BOPECO+X1
M!_N<K%,D4G.BZ&W#PR1_$N&!8!DC?-KG+9T^Z-PJ7\32N>V<7;;Q!+R7C[ N
MAMHHZUT+HP>/F]*3Y4W3B);ZO</DS:%;:P&B/BT[K37S)[EKWL[D>*!'_O".
M >RJ.=X3E!-\;O8R.%1=41>G1KC<M@3URLZ<)2T&D#JN(&'1J7?<ENIY  +B
M0;(X-[F6X"Y)IT,L0&OZ/WQ@4K*9=1RX$Z&@G%Y-:7JK<Q:$3J1F1W'CO+<T
M>2RNHA_#\0(80J*'ZR&-H,8KWI1=+YE_R0<T=?*H/H1VQ9@P8Z>F9"4G2>_[
M&\6J"?LNX;(AZF_)TRRH@I=TV3H;Q8TD2WK'D>W<^=! $4[>?\E=#\$$YCN;
M7"H##K4ZPMNBOU/F=#0$:'[DU!#QNOJ%4F0.6^JFJ$Z03 ,SE515CN37%N95
M!L_KAB$=,T\GS3O4YG%DV6<XF<-Q6[2)EWFJ\ATW5X3U:YD(>'D-6=#KL*_(
M:?EQ.E&7S(P[;6*_<? Y$[3C&,.'%I7=KJB(R8.N;OT3W_HCKEO:UF7GT7T.
M\ME84!#V\F[7M%3LIRK"#&+SWOS<4MYX?\GX1C"4LLNA=<KY^'"4$DQ5?72%
M=D)G8NPB<KP7SD&4$3.M0!?E24J(%QF]V183BQ -"CISS,=S?.:,]UA.EP(,
M"SXLZE9]#?WT ,S./9A/IH16ST!B+)7LCM>)RVT4#.L;OJ@!@2*VBK;=/3O>
MOT.-,'?<Q4,%U(5^_+3R(. 9RWO2E/"MU7+04X>GWY5B,4;%"']+6)!8N\'%
M:( S[P;>D?1-24BV5A]^'>X.$SJ0S[/@_C_LYT@C@_ CPG<X;'[^VY__^,4?
M$.3>451J$<-#089>B"NL876W/1]!7WWQU5?@)L@MC3\!2XP@$??Y.1/GQH[%
MY(C,^]S[+-T(3$L!S7[?$K9RJ(_$5$#('.I@1'Z&QU5V'N+G#W*\@1/1*QS
MD# W-P^U)2RT(>"V28WYO70:3"][1R^]=E;VW S1PM"X[X2=@FV/[SN83VW,
MST.B$4VPPK:$Y_E.)\V]70,_.Y--#L*^S>^6%C#G/F52O1.< GZB/>\&8 JY
M 17+S,2L9QVT,+ P;\?@ALX/@".$F0Z&](!P_3D18S9VJ-PD/ <C_W >Z.NK
MWSUK$__^6QGF_.7'Z%QNADZCA&0IS5Z70H^[_'RU(2]Z^N>',DRC,47^@7M4
M."]).\TGD.>ZE.!K]Q=FFMXRQ;1FDY[FWGL/V:2/LM=>VI6DSI6<X[/?Y4,,
M3E3W*/<I=BM(PRH*0$5.'Z7VIEAH06XGO\W+BNM?&B"-PB^B%R/: I\NHNY"
M(P )HPLSUUS3'S3C8WDSZS\X;Q2E2NAG<LWZ>+HJ:A?@FG#!F-1*KB<HE/ T
MY-UPEJC4"F;9$B:W[3"O(4C<EON26W'##STHPE$9^^OWWV>7#2]YRO"U2"8^
M'GAXQ33-KKQWL%<9XTTA\["699=#$D>ZM>;(^055M$1<'EY.N!*_AST4E5Y(
MUH=PBJ>FZU_$JNN(E0.N5"?DZ<2!3G9/"#N4G0(T8X6UM>T'RL2$%4L^WFAQ
M&,Z&]TYUC@^9IS.RN-)IIX^8XYAF!;QE7,GM%%C)[&I".DP9PN _[BR !J3Z
M(*&Y23=5^5"'KZ85W"6'=VZ(CW)W+SW(,DD0W/O"[92SYG/RZT%I%Q['<B@)
M4\FOPDW\!*%'OUNA1[\ ]&@M0Y-#^;/Z^(I)C\J "P1,( ^B8X%%_2(_5&LL
MSAW;ON B&#M2/4&+:(6%;7/Y/]9M=5]+*U*RNW#(7T<HJC%QNA-[]=N?YJ)]
M.XLXNT@?X@>+HI*H P*A$(YL2@NB5A:5QPY#ZQ<\G<';LC'9C;,AK(-S1ZX/
M&%^#?]0(1.M0[,G1Y@5*((00X(9UOM#9ZZ0O\=>KGZXVKYKZF@;&&VFGW85>
MI_/:Z-*QN_A'N LRI$R8^2AW?/%S G24/&M8B\'Y:T.L\I,J9PKYTH3)=G;W
M<EJZ55*UQ2J\J$4XB]#-<"D[ F%/([<]>P4*!L2[_AJ>L08Q )%/;9N]2'^R
MZ3#<8$):+)>?<941"#8IK?&]T!7UK:?^7VX+2,R?>]$,(;Q+1T;O>@@.7R6H
MQP++\3A4UUKCJXKZNK\IEL!R+NN*RVZ8]R9&$&; ':F?,EE;3H6>TUMOZ:+6
M3(Z:Y)2@,O8<<%TT+,6P=GJ%QDT6E,WO(\\&!,,R$H\Z0 !D%T7ST_SYA*CM
MKN"0>%?<APZ,??"834U8H\2JH,WTS8]?N1$W)V3+(W;'^,['U,\A1.F:S)$[
M^)'8E%(Q(MC4DFB11VW%"V5-7;.I"A$M'3GT?1W9%_G'>3F-J"6GCI#\KG#R
MVEQZ8*LL!,V$"B!>;8X5Y4[89;8$]_R6::V7(^]DAK\HVKK[O9#E-27>!2WT
MZNP(O97X-,:<([9K#9JGS)BC55TDR2;/;#U+))NC,EQ1%U%=$]B78,._)FZC
MU2,G5_&OM25UE,G"U8?8!_KINU?.-8 +$?V#:'!<JVG3>H[<.7K4Z$-YSA?4
MO]RUNYN!4NYW-7.4"+*M[-KAQ'N,D2)D1V04FAIUHCZ9;*6;4EE>RF0'W= Q
MQ3X>6O!>%V?8=U&-C4_.Y -U45D?/@Y0\QC@D17M;;DKA-)N6P!/QQ: ;4JR
M)?<S.\T>%-8K\O@W[BE%(IT/529-H)T467["NXQ6B%-8]&YL4B:T0&QRJW.:
M\)JW/N]?96L->YY&V*.[(J+>LK?:TPGOX]X:*9/=HJV=PI-!7G9.!-5H.B$.
M!E!X).;!68;ML"=5"#[&V&XA#**0Y_ZM;;O80(,G3N2>\K,>TL3- Q((P9O7
MM/3!IDA/FF#5 1UIP@(\JUL:W+LP3*ITN'X4Q'"3H&%A]N"L'*J!]*"%QYH2
MMF%LW)GNW);@RCASZ.X1S989C0CVJ9J["/Z*U!L'4#'>S7D$W/?##\3"&+^Q
M$(5?7KS,S.&@9N5NE$?/I<[QE+3[WI,5^>,G:462*HU;"+I)Q;*D+L6L-Z'G
M%JT-I] 7#RI/%==H?R'=A[9&V">43R $J,\"$E99O8[.TXPSIBO8#;C0%L4:
M&5M9WQ12:0H;LV1IF*&6!""9Q%_+NGWNG)]O-WOS5G0N4?W<S&FJ?H'B.],1
M=#T85RB7R,>*)0C='<%5HUZX?5Y.-(HPA1QR)@,1FR_&30QA]TO^\(;3*"%^
MKH"6)F@\=B F?]%*%.%AFK-FLKJP;.,WXQX7J&B84R0']N/( H\$/5'FM)J3
M$W6%WJES!,/!OKOS=BPO,"0'/"33D'0=595%XD1KS@])VV[^Q,F&3./WF:=2
M4;'YE$&^D\Q),'G#MD);CNET*1%)7'^[_$0N-G+=+2(H\,@%DUS9'RF]P D'
MR0*E5GNUC<_9-OY4D-??X]#MB#IM\SU.UZ^^^.H+L,19-, =%^'[82M29PJE
MVV!2 0"O2/F# $+<0!06]DU#J."AT!/XU0__^Z_?OOCRC\$7#^_D6.XBTL.X
M^>Z:]C43;L(%#A8W3%5/C2_=T-X695514C6C0H/Y <>F+L,FC(HZ#OKAAPD0
MD$!A$9YO\ZX,6V[S$Q[[9?A318_]93JN6"I0RBM_4400;+#(-0'_HC5_458R
MC&+05 7CO$@8AM(!P91B7S.-(7?PH0M$ Q1)ZKM,;L.0=;)^/]37#6:JS:E
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M::_S6CJ%L(W8/J!)SS:0EM.X/R\L_[8HC]LA^.XF"E\7=U%H9)] R3,/\Y0
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ME"557N@X>YRH4,8>PCX8#S(*=]2LS$[9/L'V,,;9"N-E?:B&0GCPI7!US-'
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MOLOT?4> >2NT.^Q+[)2=MV1<XD0;Y"PY_T/V2+HGZ]NFNL5)1:PX4"+FS*3
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MDP37V?3WR,DOZBX7")RRB\#])_*"065P.RV4O:'/1Q@+KSC!:F"/E)'L+0J
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MZ$TZM*+SJ:M8SSW1_AAU.:DVO(B>QW8SZ>([BCM'1U=!ZA&[/AS:P8?S=Y7
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MD\(MU$_RCS1*,#V2%(1>(''06ANVV/P3%2/RM52FIQ4<-4BO\MP@4U.Q97W
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M&6($RM; KH)LBWG6U_K81BERLV71&MI_8_(PWZ[J4^QTJE!G/O!5_9IAY^I
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M.!;NNIH 1"??^X9),.-/U!]":+ 3Q259<2"OA,_-B"Y\F/EB(B(!L.*"0;"
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MXA']YY#B )\^__;UT-?,BH&!?)V!2(;]]O7=)^1[)7#DN<@C4<NHA7-*V:N
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M4P&;E%X?6.*GSV?O1L3^^*_Q'IZ\1!SB/BB@*^/U763+M@6#C+N(0#1U>=U
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MH3L./0VF&99Q8;1'.D"_JD1E04Q1M"!<1$F4%UCC<>&@E;JC75S7\U,FOS,
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M(^[K$]5NCR'HOX# 5E3'A/]8HD#UO4OES8,+Y9U3GK@@>8R]IRA*$P'#5?G
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M+D!X5MY.,'U/-&ZI!'S<X<HL[9(<OLKRTN+??01>!BMM(.QP95 NH^=%GG]
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MN>LDWK@JJ\+_+4C9]D]K<ZVYL172$K2/F*U\\V.[3]8="I;&(#[Q*S(LS09
MB8 E>RQ207:RO8ER-F:KV-<S>J"!3*J4/  L_<F**<CKY8ZB\2RL=Y"Y"XI$
M4L6@I(@4-92+U0*:EFM_.B!]Z@;=9E5&QP6@PUO4#)V,! 2C%!1P@Q]DJJ9Y
MCCY>[QP,OK6[,W!H;;+I^#O[FHX_ 1#7<:'FUGU+SNLE]-P-A6:+.5!K",2]
M@'99*(J51A=QC'HM(N!;0*18&:?7%9R 8@5 IK]4R:16QU\:K/]\LFB3 ^S
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ML#-*"<'.X<?PZWI[<%<FR_G69? 49F/D%_,C'BP1<9/>8@LV&A0HSEE<^ML
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MIOA?C5<]3Z:U[.'>.L.U]T"DPQIGA[??O#J[J3%V>]@VR27/ V:UA"JO5S5
MVR#.[>JOO+KL6G^K<=2U"T;][O9>Q%B!_=__=7#8<<'B12Y&?U#6YA\JPZ%!
M!-..FC[=#W4^!V6:LC!>U<#L-B)TE2MPG++3H/-H*/ZC]J[^X=H,_&$RESM+
M3HBREWT_&/3.M4BP-0>_@!VI$Q5S2B*YCMY2BX\2AV//V<$5HD4;(GG),UYC
M]*Z']A.;&KD'P<C]\D;NET,L8J08(/U#*=519OGVXMW[Z-6K5QW)93.L\A:9
M-!S\X49'_N'ZW?R1LS7>V;24KJMX\!S(2P/7WG)4EF.JEWD!1@GZ>7^BRED,
MF7:#"-<ASM?R&7Q:R*,;,-Q*9QU.@A_G:9K?T%0366KC&+/]4#S[S_I'?I2C
MHL+\?7:/[),/#Y[/;&R@.9RV[JIEN4Q759JO*FY-[X3E!M&PXM'9R;[_?RH[
M'^5%(@O:"(#YV>"<?K^7BD5>E<_&ZJ-,SKF1\=DI0LX\'V,5Z%S+9UIB-+G$
M1L7P=GB]4X:NE58C&L#]S#YM'H*G$@<'6GO_K+^_?XJ=D?_?W\IDS4-P#0?'
M=SXSP [4MSZSWS^^:YE!_^3PY,YG#L[.[GSF='#WL08GAW<\<]P?#N[:S]%1
M_^3DZ,'P@;\4[:NS>,^3W)8O[5[<Y@8PA97A9ZP2XP?GU(,U%JDA#2 XBU)6
M9/0' WAK1&4249-9P;;7T;0E%J*>T_O0]& K3+V6!#N]CYTG9K[X7XD-7_D&
M_84!E-V_RL\C*N]S6Y$-%%ENWKXQV I^_[_?[7_WV/2W FA=N<2OYS;8@"+Y
M:OW_7DS6D^CC7W@@USMS0QZ-6L--!,;YS3#.MZ9UY<ZH,_<S-[M*E@_*GEM!
MEK?9&H?]DX?8&H/#WO[!Z1?CGH]U3]V)<SS'(6R%B'Z7(TRG>MU_T=^0"G?T
MJKXF2=TEZL(%/!I/>Z"JL>%=;*I ?(V[>8@&,3P[@?.#Y#P\_<H>Z>.CSV!P
M!4K:>DH*=_$E+*@=O8SNJ&-O"ZFIX*]W>X5N*K3&S $7-E[%]6[3PP_ZIU_!
MYQ\N_KX7_P*S?--41,]E_ $^^KJF<-?OJ4O<,ES MJ@.&][%KBCACY<6<GCP
M>%&/+MW6MTY)X2XZ%,;H^F5T1Q=;4VSZ4!4[N+J[=:T7*>SJYTI@^X.WT^#H
M[C S#!>P+9I!<'0_DJ/[\"PXN@,EA;L(CNZM5,98Q[Z*%3>WBS=5LOE=]U6R
MW4G#C7[V&WTMBCAZ5R5Y6O[53"1Y-':PYO\VT_MW#W>^2'%2@.B7A>B]9=C#
MH;LK2OEC<+^CTT>^L1I G;FS E?9+1+I$GAWCP%U';K=83>L/K^6"4+PZ^C.
MP2;ZXCD@>35)A8Z>BZ)8!.=TEU35 -<O+R^"+_FQ?,E'^YVXO:#"!K#O.-B[
M!.1N*T,_R4P6U*"ZRK1,;3XT#@9)%4T+:B1$N]Y85S(N),X'#AG1VXT %ZG\
MJ$ 9S@NE-]6&=_22NA13"Q>P+0'FD []2.G01X.0#ATH*=Q%2(?>2D5LN=C0
MC.01ZDN7'08KZPO?[3^E3N4BNA3I%+83?*-=98?A K9%-PA.[,=R8A\'MUZ@
MI' 7(2%Z*S4QHV5OW-#C@=6&P6KZTNYK4>19]$)<*QV<UUWE?^$"MD49",[K
MT,LC4%+PEW;B+L)E;(T:]M4[Y05#Z0O?Z#NIDNCGBMI5AS8>G>:#X0*V12D(
M7NO'\EI_CMR00$E;3TGA+H+7>@N5L4_U6H>DZV[=YVN1EC)Z*T%RZD^:!K.C
M-]4E-A@N8%MT@N"\?JS,Z\_1)"]0TM934KB+X+S>0FW,.J^_5E)(,)>^N'H=
M2_A'.9792!:3,&^QVZPP7,"VZ 7!?QWF+09*"B[33MQ%N(RM4<@>I&'#GV*4
M2OKK.OC^\&#P#K>CJ=<C'GJXOSE2?0[?TRA/DX?";VENIPZPW)1,^6'<V3-5
MPJ;C\UOGUG?W(" ;ID)'6A;7,HG@;WE51&[DJZFJ7CWU52ML>80]UJ?1_F!X
MTH]>%'T^/:TYDC*+1/0O6*<J9/16%&6&O9'*Z/U4%0EL(/Y@O]7MU8[ZN(MK
ME5<Z7?2\E>N=7LE,Y47T+]A,O>->]"9#X$T6T?M"9#H5I<HSD7)C4D#27O1K
M?@U;43H:%_D,WC4XB\J<WME;NU@O^NGJ'^X'1_P#^"'"YVV1CZ76.=ZY>0E]
MCNVB0 SJ7O1;!G KM"H743Z.WLHLTXOT6F1*\)+#L[-#L^11&XKFO'D6@8D>
MC7(!D(-%$B,<-/[CG;S.TPH/ZG8 ;WV5Q?WHR:\75R\N_N]9].Y?KU\\[<%]
MC%1>RGB:,9#B? :X">=C^%_,"Y4B+$Y[T8_Y)'H[%8!3^#/XXAJ;6<'/Y_1A
M+"L2\NTEWL"V</.\" +BS=M_1Q?QGY4"". >L3-6/WI5[^W-SQ<7M#<]ES3>
M;%X5\UP#&+U?K7W-_M"'&8!%*L*0Z'G_JA\I>-]4SI0NBP7M!B@129,ACS!M
MWL[O0D]5-BGSK!?= /Q%Y(@!EE)H "$ZS=Q-E]&_1=I8!=\REFF:W^!/7$=<
MBY?P"WSM"Y&)Z$?@&;#I2^P>5L"-Z5*552GQ,$ _J9) ;_79_JR U8P54 L@
M"R$&X@52+./%2&A&E2D\# !DP#V$J'OTTU2*!,XR5?-(?IS+0DF$./X,OP4^
M+3.-/_*^5 8_E[ #Q$B%L.\'8?,YA<VZX<S=/<5*2;-FKJ&A\2LY+^7,,!-F
MMLV?$SFJV=IEB,8]AG2,A'-130 C:4D4,BA#X-/_Y"H#NH\JX)P:,'E>Y-=
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M!WSX6W?P/*TDR'T0&4ZM<&TM<76WE^=O7U_27B9I/L*MP"*P!5X<H+"D9[P
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M+6YU++BTX5%_9];)USZMKKV2P,8H]_H*=I__U<QLKK6&P[I'72,WWKV5MH$
MN *$XG]1?9>@E';,6L%4G9]%1J4!AB>]J+._U_=<>.VU.K-U6_TV3I ()GY;
M2A%/O7X5,\K\KW.VTR:/?NZW.%A9=O1:J.RO7O231.<L=I!QAW>(=^4W:RA)
M]H#H6-6T !V@>0&T R(?Y))(L+F=;H0XC;CR6TUPPZ-__"0NK)5L"[CJ7A;8
M)2*&VY(EH'@#/@TI]R*W[W%@<,+MQT(J[_0@5^3A>0DZ4@&W[$& <G 0"PLN
M6FN#S23MO14)7!>H-L#,S*^> [!!V:*_-E>U'GY/340/+:Z=**PI0R2I_#?
M&Z>"]%%1LB-WQ0W??:%+O>X8:E:H>C*U8>N;D.B*(M/;S?H@.+^6X%PQ5Z*W
M%0KL V2GGY]#]:3NP$2@<]<*!RGA[1BV4-S=+6U%"=3J\F$D8RM^?L^+-+G!
M?#;[% D#,9;EPJ6[FN ]MM%8+T51;#A18']I.P*9EIZKDW7PERO%(%7"FFU=
MC,="%9PMP1!9>MO@U+SM>(5Y:Z'8 C?7/>T?F4142BD0"0@6T6NG)XY%C.Y%
M9I++[.F]_ @09ZW?52]=4B E8JYT>$[Y"1<@10 ,=+I_"0RL C<L_=7LF?G7
M2RA"X4#3*=1LI3::N$2*^/ATH8&="I./V'C,&%4-!:0N"^8L"<+>O=AE2JR5
MQ>U6I?VHO6.OK^]]\GFOP";/_Y+9'6G_6/X7HUYB@WRFPA#_F135)(*3)BH1
MI>U\"O8A.FR K&9Y4E%30#(. 0/FHIS>"-=HCG.?]CE5^J)*<XT:A_$ >WUM
MT\4>:2]J-JNR?"^W(&SUK?/IO0V;AIBGV,":S%Z_CIJ36YL-:9$7_1ME[ZT6
M;F]ML?@Z2;P:1ZTGW2L,OZ5KK;.1[VQ96T.FMH^=B&ZUE6W4#M3)-BC(@QS_
M>F5I/](7=3DE.D<"-#=7)-Z3(,=DABR/^"D@4P^XD9CEQ/(6UFGNL<^BD7G/
M'?L#<F^,W&\ NLO)-@&>FZ/WF]6:,99>*^Z=#.8_NG P0(Y)KA.)6<PQ#CB1
MS?*0'B>&HNN@C@/#8P *9OIYYJP^7L^L F9KR3\365918W;)>;E,3Y1EALFI
MY+\3_+/F?F]4FH+DBDBKD(EIRD-OV4-E,@)1RI[7*HZE9 6LH>;@!UK,S*9
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MZ.#@A_-OR7Q_))_%<']SO-\_.NK9_Q]NB/VC/$T>!C]^&/?U3)6PY1@VBY5
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M/EC/@<IV]8ZZ0V5:IC*FQB9^!Y1617&FJ[046<DIWCQ[%G]R,Y54\X[_D9'
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MXIGB;-]"EC9S&3<_E2(U>'HCTS$N, ))-%8E5\7THPM,+^+@#I9Z%2*1[!0
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MEKKO6QVUJL_&22^2XS$\2.C6-$+"=7_NZSZCZWYG&2JH5&-<"%B<Y3="3]F
M0W&+W)/U'12U:YB#7N?KS+.]EW]6JEP KT=#"'_S%J>]^\[.ID.3^!_(7JGC
M0C$+-UQB!GR^0-X+?\RT_13L2^#MLVA>%;H2;-.R16P$B,<]48<S)PJ(]=E]
MYH.G;38RSPOD(I8/?#_L'9P-\.*0X8.,!=U-9G*LT*4.XO?[@][^D/VIJ1H#
M/HG9_!RT,"U&*D4D@NW.5#73+,$0(?%Z4:\C%SS^$&YY)*<B'>-KG H9;ONS
MW_;PSML^[!WLK[[M7O3]?N_T^ B_G(+^ 9I5 Q%6W[[*=%60+D;(<M0['AS@
M"O(C4CAL$.]_/LTS:=5X7FV:SRRGJI\-&/3H&+3_R?QBV#O;/_F,_,+7:\*%
M?_8+/_@TEC'L'9\>WN>V"3<.>R<G^U^:/02$^:((<_C)'&*_-Q@<?U8.89R6
M7;[MX?YV7O?1U^0/!_\_>V_>W$:.I ]_%41/>W[R&R6:Q4,DI=V-D&5WCW?;
M;47;,Q/[UP18!8H8%ZO8=4CF?OHW$T =I(HB14DDBLJ-[;%(U@'D\>0!(-/I
M[@,?'B,N+[]R<FC)&$>!_UBY>,2&&2+R[NKW3\QOQB*9J]RA#O=58G0I@C;1
MMK,N\1Z+6RGN5K.6*J0/ K.R*S"[JS-+*H_X8%[A$Q!,I"KA6/Y<KA-)HZ1%
MO@+^5JE>=8-./<@B]:!SP3I)63-X+PH3Z8NX;OA*SV.U*VL>)5+GN&1H$A/Q
M=Y&JU2)X#F[*7+X_$+<BR%<KBEDH(OCR5OJ8HJWD87#Q0;^N3+P@\'@IUZ_%
M24;C?^N,6:)YX8L$YH&7SR+X&E/B!;7Q6^Y-)0R#)5. U%,=945@DC"7@FS/
M@M2@&B9;S<3&(DGA;[@&_DCR&:@\WQ0T&1BD'L0KCT)@EL7F IUOQL1A0<@*
M:!:@6-6+/8H\LP,O&NF<?:G7?Y 3T!&93-5Z[I(6:,E(A7"4T/@B4(LX2L15
MGK^X@('JIUR&2_>?QB)0ET^R4*]_%,O"5\8&2[7-)EB8E5]V'4N\(BI'A:A@
M%AQJ![8&&&;<7[G'%YY,U"#N:G!S+9PU2.#VNW_"DDG;IF7_G(K2_JU;F:L*
MYCK#K'4NC.X*_*T5?Z"8P-")W8!;'>=V+)7J?;G=<YA>*(AP4<@7\"1?P?U4
MQOXI;NM:H%?N3=$LPFMYL$BEIXR0#-'&:9LI?Q@_OAP)?*[L '',+K)E4U48
M<U(FVR=MFS)]62OY3";@V4J8(]RIP!P]0?3UT,3X B5/AK7&(W=M5[V[B@O[
MP'NUNZQE'")5+TO0B87A\AN!/E2YN J.-^C?JF>JC ^^5_='^5B\W;1'*3WO
MPNMD48KKL>#J:1]OS9TM]CY7\G0*+\Z'5SB@F&+![V*A,2'EWY% X"U&:MM$
M%NHM"!.N;:@Z$\'X.+HU=G8-25(#>4D]K04XLO>I7.=(VK/%<DN2*[("7@,I
M %+7S/^A^XWW4>/ *#&8@PR!0ZX%LN:B4@#7LZ<4R&*@^@H<.\00$A=I08?T
MR^H>911E=0ZY,4.)CK+TP7F:<SC;,_UPF/.@]D^YV="4P9QC#%715PUO0/GU
M%ID\#04TXRHZ10JKW4M@"3&64G(%Y,*PE7'_5B;:X>6@J!BZ8?2F0L.;, ^U
M2]VI"^R-;H> 04J=ZYW>%ON@MU$56]+U=LDU[C->\(#& X* LR_\>W.^1F^>
M?18+F*3.YEV#=P&.";@SO_UVA7$R6" 1W]O-9TAE=@,HNJB=)6OF#C*;8BR[
MG), \8T1.NO(9&BJ9@;2A,E)(]LZ%X![TGC%X[GG=!7DSD/B^X9#/5SO="Q"
M[_O$;6VDDLZB)N:68)'#1#TW6I6H"241J;'A#<X#CT-)% D:$K07I;OH"9UM
M25)T'949^YTG/O^309BF9#PIMLYI(NN=2+[.4:A=9DI15*8!"&(BR(+OOO3U
M;CB.O,?H$'Z<!-)35^<YC1?,0 P;G("P_\Q"A\XL'$N8L']URTGTJE<)'K\4
MHR_&<95]&9=.)MLA=(<F[&Z0IM8]PQ"7 I97-XSE7Y=25.EZDZT!VY['JL)W
M<A_<-W&%69C19VAPD0(N'R\>LMW@!D:QKP.+XA+Q\'!,C"+QY& J$QW]+9:6
M-]!]@;OTND1U.8!=UA% KT>DZ#:H7#%.2KF[X ;_, %Q%!HW8'FS_,/96"=?
M5S:!/8[Y.^Z*Q^C344LN,  8,5P8!69QJ4@.X)HR#$_'R>5H<W]N+8&F_+;*
ML+'0X2X#KT:M$X&C)@3>&PIP@Q-<Z$0?-DUC(*49@DJ.EXM')@F=9(JW0'\>
M #E6\V.J*$8N_D9EU(8$"#^BB['BM))K(,=Y^T)=?AKP!807YXK2%W?23Z?G
MPQ&JL+D>G5\^3\1Y(G!Y+!6Y,JKR+/K1/ZVVW05W7--O<9[??W&_^ZY^6W?4
M&O8[;U!]ZPJHZ(OZK>[@;,,U;NNLW]MP3;LU</L;KNFXK5%O] P/ZK<&O4T#
M>K9!MULC]]'/>:!ELC:W6[=,7H;5K0K::#3/Y:QP*/IM>#%+H@#\^V5@WK;T
MS7 ;B]., ETK-GP;'^AWP*4=JQ*](!.KSP9JVL_-#9[Z-IS84-0+*(^__.=/
MW9\L4*X:<MC"GOT%JSNHFTJ0E4[R@IW\O&M!R+VJ7^/X_?(*^5+<L8BTA'0-
ME'Q[D,Y=1;J3#H%=X\#N :_?9#*V=OM?OH[E=OFC9GCSNR6.WO-X#)&W/J7F
ML,^M#ZT==>Z%*TX?BE4ODE2WJYHK:8&]5:=)[/=8=WH?Q#Y<X>FM>-8;N<Z9
MQ96G21_(O!Z:K@T167M A<SK$8D]F=<G:((IJTWZL%=]>,:<Q Z9I8:PP!XE
M^<!#*8* YZ4Q]I<$)(^)5, *%=C58SI>WC18[,EC>H(FF$8!I ]'H ]-,*_V
M2/Z)N\?ESX9(O3W<(0M]#(A$%OH9+/2(+'2C<QK'FU:R1TDNL6RYJN7GL.LI
M[;*PS7:0#MCK,ATO;QHL]N0R/<5E&G2=8?N,].$(](',ZZL667M A<SK$8D]
MF=>G;&+4K35)'PZ2D8!_\?"_]95CJ,7OHU)S^UWYN-<!7;6N5 5D=1V/VH;?
M*^W_= ,&$>L/U?; JI6;_^\LJ6DM7GF>;C!8ULE<K3Q.I6IV8&Y',??>@;^Q
M\#ARL^CEF-6T7L:/6[9?)B8]L9[0FK(^98T@54P/VQ!@<;S0%#%4NK*637DM
MQ[SF^AC+@")O.9MGXT!ZP>(4--TWA7G@$E,6\EZ5'%7)U4C$[Q^_)-B:( NP
MNW>ESW:U!-%28]NRC_-J11[5TZ5\=B)J2_\ ?-R)(,!_L;P.\E4WC#1%A; )
MYE)EH=IRD&71GJ)U0J51A.I7@K5S-25P;#B?>[4@!<P/96=.#1&LT+CG*8VV
M7?-3.RC>2"=#ES'&$O%Y55:9+%4*PQ+%-R$\SY3-PNXO6) T\B1/#0KIOBBJ
M6TRE=4797:54;"#O=_W<O)8M@%M9#QDH<P? B6]*,@]+=SDEE-Y$/-!U1Q6P
MY97$#8C^/S7L6 *(>952]ZIY2DNWQ,IGJ">QU+:WK,;O1?$\PB)<IHAOT5P&
MZW&#3P1S0Z=(-PXWM6216/P6J_3"Q'P1P)RQ_>Y,<*P8##X:P^JQ>1?>*,52
MNSDV%@AFVL7H4K>3FI["IK*=NK-2P9]]B%2IUZA:.G@,@Q"Z/4["O%BJ,$TY
M%UDB3&=W'%,6HFKI;L&5X:IWJ$8_JL4Y/#FZ$:I.LBZ2EL9 X$J)==W!1A<L
M-YW"'.;'J*R5HNFJE&].3ZQO72G\>ZL*7IO^.OB#^.$)Y$@6YQ,OY<D2I\;"
M^,J22=N&<@\X<KDOMJ$/C\;(F0"$\9)USI[RY@V:@HT"V+DT89/^I=J7 Z_7
MK4+R.T2,.HUURVL].PS6EGRZ%W0W#^ RWH)3:SJ#E5");#NL$]D 92.$.6B:
M]5NN^*7G4$) 7FA5^TEHT+. &WM>MM2;<Y5H28P74H3\QA[FY=G+CEYK7)2J
M0X/>TFJ7N[*:[<,U:W4SP/M5\M'E2431X>A.@)9505(W#H,1*GIH\SZ;@8_A
MY3W*5,WYTB,XT3[E3+<NR$)ORL,;^,O7G1'PZ@4\]"V\^GW>G##.!X N48H8
M5@*GP8Q[P%-ZF-7TU\I;='LG?+YN%*A'/!:Z+2GVT\A=-!DG*?LSXS$V3S7O
MG( C$]WA\_!9QN,LOU3#+B&_''/9@4T7%58%_C7!SBF2/3P(/E?%7[?=WF?)
MWUZOU>L--U6T;0W<395QM[G&';2Z&U_6:PV'F\KG=EJCP:8ZQ=M<L^6 SMI=
MJM7;I"T!UM?JQ6TP5*C7LO*59EV:RE?NIU"O<GZ_:3_GY$TCBE=:Q&#2/]*_
MIY6/7=&_-0<HZ>1,H[(,5*'T"'<Y$EUI]ZBM@-.CC:/V,N<-8533,8KH2MAO
M*[ST"?OM94XM]E-MQT;QD&H[6FUVB*[6T)7,^=/1IMNGJD36,F?74(XPRAJ,
M(KH2]ML*+SNG\0C[FQ_*43A.)>U>N]TANEI#5[+G!XSER!;8&\L11EF#4417
MPGY;X86V9%C,G =C.2H&=IA)/Z4(RJ'.DJX>(UTZ^UQSRAS/@2=2E?"""_HL
M/U%6'%97!Z+564T]-CPWF9BCB<GY"J-\>5MWV*W7ZG>&;RY\F< K%^>30/RH
M,NJLGE%864Q.%D!5+"B2JMM.DY3'Z87BQBD0<9:<XYE,O+=68F?P17Y>J]\=
MO+&"F9LW8^>4DJ&BBB+80]<_0*HJ!0;]CCL8GO5&G>Z@-^CTWRB%^P$BT2E4
MKL+"Y5'LKTK#XXO_@.SK'>L?9.+A"?]%W>%7V^I*L--2ISKM-^K4KTSR0[[P
MER\2$%1]DEB$7I3%ZIAREM?7$Z8L"N(AL!_+U4A?'Y8VAZSAUYF A^$]>06<
MB0SP3/&GWS\DQ9GD+,UB5>B@.)#-@&XBG.)I<!_/H?N9E[*YG"M=*]-4("[F
M?TG_2?\/I_\?XNRFN=K?O:?]6*^E6AQ!53_2%1^PFM8]#$#.RS!3.LS]6U7$
M 2\RV""U$F,!*U7IJKC(9SY2SL\IQ^93T*>$%)P4W"X%OXZ%!Z-4E<@^8*V>
M:*XJFS1!U1_4]!4[O\Y<P^S 8JMR']]^_W74'N:VNY=.J]5$5-E6QM;HKRWA
MX_X.0N[&,=?MKH0VTV(Y=0Y.F,Z G/()S.*<!W=\D5S\Q-Y91>.]ANA':AA>
M!#/(/#R_>;@J\AY?4_SGIG$^H/MD'U"9CG'FP[U8H$I5[U)E-^4,R^)QL)98
M#\\4$-,EOHIZ=U4;Q#&YHTQ-[E:"FUBQN5A&#UZ^&A4N1Y.OS(4DI&@(4ER+
M:!Z(XT"'JM*:XLJQ2+(@-85#L<JF*KX9 2[(P%<= +*TK.D[R4)5 S3)=3J*
M;W@H_\^4Q<0J?66DB+_KZG6YYJM(LG#+TU@"I.A">&I <(TH((H!*(088R),
M<%T\,)6JSIX(;V4<A0I;5#T['L"?ZP!D-__*)/,;7!-]-R'Z]$"QV6I-Z*4R
MW@[3)5)SF[I4LW$&P@=&PP61+$HF5JV4NK92>1MK,<]-4=9S=B+?5AZ<&&,-
MET^E-U5"G3^_;YZOQ1V%ZD3"S7.EOW4WN/W*#46]R4H9S*2X2Z@*KR%(\VQ3
M/4LG+V$K?"#+#$M7:ZN:3D&=X)'ZUMQ.&FW1%3E!TE?2*[F)Y%Y1;_+JRS\^
M?3AU1PRDR!<SZ3WPR%73Z\$M*N6+M;I#+\C\O"8E]SP1B)A7J^&:)'E719+8
M]P6U01<3GLK8M ?!QU\!R2;LL_"57G_193#UL$QE=:SS_>GZ"\['] PIJG:J
MP6=QK)N_J%K?2L+FD>X]T\*ZQMP E1Z:7"JGGG-)%_$6NOQP48?4."X)3 0K
MADH-*&493EV.60FSJJ.H^]1H(?#KY&2YU*:NV&A8GMPOM(P/6RD:>J\R<U6A
M='%6?&]%D#6#4E2^I:$6=>3Q D-IX%IX$Y4S, 525VL,-[329'?8<@?=3049
M6\/V:-,UO59OL+%F8WO8WU@@LG-VMKF(9&]3$<EVZZRWZ3DP9M?=-/EM'M1I
M#=J;G@,3&VQZSI:#[F\JCGG_.50<T_)]*U0<T\;=>,]9G*_S L7Y'JU95)SO
M&8OS47',)NG?2Q3')/T[G/[]W C]:QS#7UXC7XH[%I&6H*Z!DF\?U%WF20<"
MNP:"'9T%;]3V?2K23"?7Z.0:%91L%FK1J>7&8Q32E0#J"3KP,^D Z< KUX'.
M6==IM_=HJ4D3B*Y-HRLA#%E9T@'2@=VM[&#@C%RRLGO4!&J.T*A\!#5'L-IH
M4"'G9A7_(LBR-X5*&&4-1I%C>YC@KA@J2?\S2?_C*4IR_Y1"$_VSW=.F)/V'
MEWZB*.&)17A"=I3D_C7*O7O6<_IG'9+^AJ5$:8L6-1DZ:EVA;:6VJ@4U1+"8
M.;2MM/$813XM;7@A'2 =>')<UZ-MI<>A"4170ACK$(:L+.G :]<!]VSH='L#
MTH3]YU"IN9_%D[9'0R^#@$UD6"T8JDO,II$JN!IR+&0K?@@O4T52(UVS%<O"
M3A@/%XXI\@[ .)/AYIJWN@)K+%(NPX1-,G@]%K&%+_!"U3\(2XDSX)>\E3Y6
M,ETJ:,JQ&'6R7-"T4HD7RZ:658"Q)&KE0952L&795U-7>L87C =)\?[ZM^D"
MO1,8413G3<YD7)E!BWW:]#Y%L!L1BI@'P0)($>C.:A$3,)%U!%=%TMW1Q5)!
M6QP!UKB%)W*<.9;EQK:+NDBJFA?^C!5_8SG.=$%N>)&J_+I:Z-5F?3DVD#AT
MR>_'U[?7%^.XSF4*0_9@L!__S%#,/IG>$8)=592>"+T[*'_!#AR*N*:GABQ(
M;!#I)N:A08V'4+JF P?\:5!+HC<KDKRF?SJ-$I$7ZD[2R/L^!2F!AU@"%,UD
MY3\%F_);K(,.)(W14P7,SY"GR129$\TU*F/Y[[#"9VQ7$$3AS2D:UF5K:GA>
MP^VQ\#@\6U?Y7GZ\ZKRRYC9XX#R.)C)EDSB:Z;+I:&)0&+08+@\@"F$.T@B*
M>LT<9H;6"*P@=OG31@W? 8]>'4QIR6 HL2<3<WM9G;WZ+;8Q2W0=?EW?'@07
MY.([?'7+@ZP06'0Q8&CJ14GN&& !>[Q :4N+ 2_0S*M/^<2,/L'CDPQ>GBH&
M C/PF>,(&U_ _;Z,A3;YT3K/IG2!X/8YD!-&#V\O=*<JH_ML]4&Z^Q3?&'L,
M++>VJ.MIH<"R5#60=%YV0KG7*/N6@V1@37WLG62:*& /!]T9HZKGV$))UC9C
MN:?$5:^PQ;XN#RC'_ KBHV;GS]B$_RQ!6#(M-^Z!A\<-(("*1#<A-I#*<<!?
MGH\!%^R=L:Q\!B1 .)!,:MKKH86/H]MB,!6@:.5M.?0S5]H:EW.%ETTB+S,8
M@5.NQ NF9XT:@A_C//,7HZM=XK&&'IZ4+3SR7A&50;?8+UF, 8-NWC"!@9QB
M*PD&PTBQ)43B386?!:(<;+(RTEC,($[*6]VHX$IU]@"R0NREC 2V4T;"83\+
M$ (9^62OG^IZE3PHXS2EUBA;V.P#+37H-ZBW-B9Y]Q5C-/F2P<-?:UKE2&VT
M1*4#B^:S^J2NRI(6N_1]U=TD?U>B;%CD>5EL^&V<"GB+*FR)<H/=F>2D^*'L
M[;:J])5&3CJ*1KDL%4*W1(GB"O2 TF/LO@PX7W+(*$ G7<S-ZU':457@$9U^
MT=D'&"[B8*'48,EFZT90/ QAD'&"_>9RW#1:LT0TOPSS6?<,<07H!(Y .E43
M3R!4"70^0W6(2I=;LDQCH;N[) #BF8K0<S#2V%?Z*F77G#HF_:*@#81)W0[_
MYNUB'N% %!D(>%62QMB%AP> -J'VI%9!0WDIX+)5_0X4T=+W4*W[(K@9_YYS
MS)-F :_T]@/A IM3M5MY6*$FII!ER1?++5(8L0 [R,#G\ ENF?*XM +EGY2&
M60)@]S(3]C>7[5%S6<K^O$AWPR]9"F :JC9@)N]S681.RC/^12;H[_XOP.GI
MQ] G4N^NR'6=P^#QB>G]INRNLAZQN $>J#;>B.05'BU[V%,1*.=199@--*_/
M&:GPX(, $SL&F]EUG6-J#.8.6V<;>UJYK?[&=E6M@;NQ=UB[U>UL:@SFMCH;
MFWZ!%&]L0N;"@X8;1]3JM=V-U[2'FYN']=TM!M3>=,U6S]F&&<\S9)"-C8W<
MMGE.MS7J;^;[9E8 WS>2$.;>[FVXIM]J;]%;[9E8L5DO1B#.R^QZX.3/X'$'
M?VQJXS8XGMWV*S[#8 LKAFW<5&QV'4,(*N?@'%R;5IU-Z/E@.9,W.,7;,.A5
M-'C; WL.UG5E&R;_JN+K#^!)D=*1TI'2[47I_F&2=5?57"7I8--TL-'MQEZ[
M#OZ>J?1%-&%?A9?A<BQ<\/=RV>'O89[=]MD7DP,_^<M;=O)1?XWYBJ-N3G8P
M 7EY#7XI[EA$V@-#8Y^@\15"X]_#IH&C12)!S@QI[*X:J[60?<S7XZ_5>OR)
MVP@=;!S3R4%I/MQ1_N08X&XN8[W2O2YY\L#"T?!Q"T?/4BVK.(]K2WMH/,PF
M)XN#;%K:ILOT09L3-Y=_+]K?^_!'L_= V!W,DXU4?7+!OCV0^G!%"K;AF/NN
MTWN'NWQ)%9JM"D15 A@[ <8E?#D"32"J6E#!E@A+P+TWX.Z/G,&H2[K0>%T@
MZ":J-H6J! )D$"TUB& /N_TAJ<*QJ(+EA+5&[D\ZNZZSDU4EB6^BQ.^Q>'4S
M.--<D2=_9_<$0*M/T7_S%8$L*E&U*50ET'Z&]?SNNTZ[4[O>1MO%FKQ=3%^+
M0RJ+4%_'(I%(+H?VC=&^,;(S9&?V9F>Z;;0SEO:0(U4@JA+ -!M@7,*7(] $
MHBIERYI'6 +NW8&[W7?:[3[I0N-U@:";J-H4JA((D$&TU2"Z/<?MD4$\&EVP
MG+#6"#YM'".)?UT2OW[CV/:56<A&'V2OT]G^#73S^-5 !".[0%1M"E4;BPOV
MX/B[SNA=I]VM73:B[4_'MOWI:BK%!.M"FBY>7W07+]H+17NAR.B0T=F?T1GB
M7@675*'9JD!4)8"Q$V!<PI<CT 2B*F5";<>:O_[E1Z?M]L@^4#;T6!&(J-H(
MJC9C[;&YA&T>X%IC)%VG,^PY[0.L&5K$HN/2!LL):XWHTZ8>DOC7)?%4#>IH
M1)Y<GIVUH-OJ[_$L)BD"652BZBNG*H'V,ZQ,#W [5.W*$6V'.K;M4#STV0<9
M"R^-: \4[8$B2T.69E^69OC.[= >A2-0!:(J 0P!#*D"494V0;U:L*%-4+0)
MZL@1B*C:"*K20@@!KJ5&<G3F.KUVCW3A6'3!<L):(_BT!8HD_G5)/-4U:JJ-
M;O7/R*>B();L E'UX-:V>;A@#8X/W[GN'C;R $_S_XY_]X<US/W 0RF"@+/W
MPOL.7^VHF*^*>8=&P1V(3;9E/R),MN61FT3;[URL7^36]@PE76B.+A!5"6%L
M1)C1.[=- ',$JD!4?4& (<(2<EN'W%VGO7,&F53!'E4@Y":J-H6J! )D#RVU
MAX..TQT,2!6.114L)ZPU<G_2W77+$UE5DO@F2OQS;'DB$WV(Y8Q6OTLNE?5;
MGL@N$%6/F*J-Q05[<+S]SL7B19W:52/:\]3D/4_Z6AS2:B^W7V3(0T_RX(F]
MW%X55QN(CV1UR.K8ATM8,:^+6Q4ZN]8Z)56P1!6(J@0P5@*,;N9&>Z&:K@I$
MU=>;I6XN80FY=T;NSM 9[%P#GU3!'E4@Y":J-H6J! )D#VVUAV=.K[]K.592
M!>M4P7+"6B/WM!>*)/YU23SMA6JHB79;.[>H?4W\:B""D5T@JC:%JHW%!7MP
M_%UGA.6?:K./S[85JIC85ES5E-R:AZYKI;Z8855?>@4/&\?2"D6A'4B$]8VB
M*F']<^Q[I1U(1Z *1%4"&!L!9D#X<A2:0%1]O:GAYA*6@'OW!=>>X[J[]MLA
M5;!'%0BYB:I-H2J! -E#2^UAK^N,1F0/CT85+">L-7)/&Y!(XE^7Q-,&I(::
MZ&ZKL_\=PLWC5P,1C.P"4;4I5&TL+EB#XR-=%N.%-R"]M,;0'B2BI\WT)$0G
M1-_CEE)L^K9/]YQ4@:C:%*H2P#P=8%S"ER/0!*(JI1EMQYJ__N5'I^WVR#Y0
MJO%8$8BHV@BJ-F-AK[F$;1[@6F,DAT/'I7H]QZ,*EA/6&KD_Z=!V&9+XUR3Q
MZ[?+O%+.-%?DR=]YPMXCJM9[!(I %I6HVA2J$F@_P[(T-GWKUL:IM-'HE6Z,
M(7H2HA.B-Q/1A^_<#FT$. )5(*H2P!# D"H056FGT:L%&]II1#N-CAR!B*J-
MH"HM.!#@6FHDN\.VTQONO_.(10PZ+EVPG+#6"#YM-2*)?UT23Y5Y&FJC1ZW^
M&?E4%,2272"J'MS:-@\7K,'QX3O7W<.&F7;/Z72'3^1M4[I96</<RP &];>,
MAS<.NYZV/K1VU,Q7Q;U#P^ .Q";CLA\1)N/R.([U]-*Z.R15:+8J$%4)8&P$
M&%TDB/"EZ9I 5'U!?"'"$G#;!MS#KN/V=UWA)56P1Q4(N8FJ3:$J@0#90TOM
MH>L,!KM6&R!-L$X3+">L-6*_>RLR,JHD\4V4^.?8\$06^A 6NM7=8YJQL?QJ
M((*172"J-H6JC<4%:W"\IS<\=6K!G#8\-7G#D[X6AW0N4QBP!^.\FDHQ85\]
M"123$^FQ+Q/X7Q'33BC:"456AZP.[80B52"J'IJJ!##/ #"$+T>@"435UYND
M;BYA";AWSRNW70> FW2A\;I T$U4;0I5"03((%IJ$$=D#H])$RPGK#5B3UNA
M2.)?E\335JB&6FC:"D5;H<@N$%6ML+;-PP5K<-S>K5#4W(OH>2ST)$0G1-]?
M/91.#[<!C$@5FJT*1%4"&#L!QB5\.0)-(*J^W@1P<PE+P+U[K#]R^MT.J4+C
M58&0FZC:%*H2") ]M-0>ND.GUQZ0*AR+*EA.6&OD?O<6<V152>*;*/&TS:BI
M)KK5[Y)+1=N,R"X050]N;9N'"_;@^+M.%[<9U2X:T3:C5[HMANA)B$Z(WE1$
M[[81T?=8L9Q4@:C:%*H2P#S/-B/"EZ9K E'U]2: FTM8 NZ=@;O;<?H'R-I:
MQ)\C405";J)J4ZA*($#VT%9[V'>ZPS-2A6-1!<L):XW<TS8CDOC7)?&TS:BA
M)MIMG>V_$7GS^-5 !".[0%1M"E4;BPOVX/B[SNA=I]VM732B;4:O=%L,T9,0
MG1"]L8@^Q&T >ZP&3JI 5&T*50E@GFF;$>%+PS6!J$II1MNQYJ]_^=%INSVR
M#Y1J/%8$(JHV@JK-6-AK+F&;![C6&$GWK.NT^SW2A6/1!<L):XW@TWX9DOC7
M)?'K]\N\4LXT5^3)X=E]?W"KO\=#CJ0(9%&)JJ^<J@3:S[ N/<"=1K7K1K33
MZ)7NC"%Z$J(3HC<3T8?OW [M!#@"52"J$L 0P) J$%5IJ]&K!1O::D1;C8X<
M@8BJC: J+3@0X%IJ)-VSD3/L[[&1,>G"JR:L-8)/6XU(XE^7Q%-IGH;:Z%&K
MO__:><WC5P,1C.P"4;4I5&TL+EB#X\-WKKMQPPS\R\>!4'^N(^N;ZL:&]C9D
M=?>^WZ*]BPBOG?1IK^6>#=Y<S+GOR_#F%$=TWK.#$FM4#%0K_\]]+BG;BJHG
M[EL$@<L@8-&$I5/!HGDJHY#Q.Q[["0MDD@J?R5#]IJ2-W8E8L)N8A_C+G4RG
M#.8G?HC8DXE@\UAZ\+\B9LF4PX7IE*=,)BR,6""2!#_KATVXC!F0\+M(V2T/
M,H$CB+(8/,S9#$:@;D]8I*_V>:HN4._%/Y+,F^I1MM@O40Q#G" %U.!C<0/?
M ^_5K?AP_3W<)O[,9+HPTW-8(@3[/8)'=V 2OO[3[; T4B/AF2]QDA,9\M"3
M/  VPCAF(&4)##-,.8B+H0Y,\3(,,[CF#S&/XA0'#N.:,;=]^C\,QJ;&LA \
M9@+DU&<?A"=F8Z!3UW48KG.V2+B?6;@[2K@[_3?L5B0IR@.?@!5B;I("NT,)
M5BOA\2(7_?PB%$ 1>HK/6O!0-D FTVFP**Y"EG;/BJ]E"+(1!%HVX&E@&_%=
M(&+9^-_"2U&F4&1DF 'SQ6P>1 OU J5!^'IX+1!S8;,8N)U&RD%7R<'G&@;V
MAO4,G$1!$-T5"+).,+;DKD&UK;G[\F;[T(P<1X'_6#9^_"&\+ 6E95= 2Q$F
M&M0O8S )-QJ4B;B[:\D_!:B 3,'*@3(H;UV9-A!LCI9S K@9B!3A4\FTX&!_
M#7"&?(927_ 'K@8G($[0,H)6A* @R"EUG[+;Y@*]ZCZZ2.YI3 :V&>8)ER;@
M'H"F&HR$U\\2!<?P7##.\-A$CT(F#SW5@:%X0:9\@C$'-R7A 2"_ RY-?".4
M-4#3/8["#)XS1P.> 3$63DZ39<=!C0#@(O3ADWD->!)C$8J)3-D\ )+-.89$
M<JZDM,4^ @4]19UL;GP:+X@2')"AXOL,/J&+!.(]!H\#[P,JB'O,J!"+W\3"
M^"-+7/D0M]@_Q1CMS^>DQ=X+[SMP60T;?_I;QA6T@6L6"QBM!T]7SE^%S7J2
M\SBZE;Y08)G,A2<G$JZ=\X5^*5YB9EW+;:XX9B:C_*]R['@YA(T<_Y6QE\V0
MH)Z X7X!O+R)@.CPDQZ 06)DG "KC==I*9BB[ILWIW$4K!M:HGPZ-;TD0SF1
M. 2/)],<MY&[\++4#%_)J:+0@Q)^)\%UGD1>IHP^>+23#+Y(0;O4 #A0,M1S
MUSR/48YBPS+#^''.^)BCXU"ZR/-(W8V$ +)!?*WEW3B3\#)PD.=&JN8@2^IG
M9#Q,1.!48<Y3#C\:.L,,EUWC\@45LLX DV!P0$CE[L,S'J* LS3J4-Q$\#QE
M+2N/U$145%$DY>L>5XL(N0@)/3<U(QXD$?.%_DE)+S[6\T0 [T2?/;?92GX2
M13<ED89DVL5/E0[C9<OJ72O)?P)"R,E"T>[10LTP%N)S& T$2.A2CH7'LP3I
M(1!N/? 1.$@RN@IKA0W&#(];:'F#2XQ,%?*C I$('KKTZF4.J7L5ZFPC8S.,
MY)(H1*/08M_@^@? Y\&Q&\%_6)M@@OI;H!7(#T"HIG'QICSJ4KX\NP'UCF'D
M,7 =01U8X05<SA0E)OP6Y@!?9>JY,81;^"[PP2J268L6>J(02XH8Z:)MCM'5
M!Z:_%>:B&"39#!P&,,SX2G SR2?<T2?4%^.XSB7X[M*#P;[G\1C$IN!$ZP.1
M]PE>X;.Y+6 :[FJU9T5Y6NSOP)&X_*+6)!1W.\QD5M2U[&-YR65Y2?$L;:X3
M$2,0) JPKJ923%@96WS16(3PB,H+Y,-;P&>4H-,U@^JT.YW"?2P]2_0X?NX/
M^DZ[W<Y=6?BJ$BX"L,K(EQX@TZT$VBAWP?]WEJ1ZT,K%A(G!70+$11I;+'BL
M1U;U6'-?RSBSRH*C24/TBEB__0:9A2:@,L+*;%;?4;JN(D_]U?JX )NW7 :Y
MFX#DS*]+ED+CTG570H,F2MUOB6K>RVZ5JQ5[7QS82BM=M[]"N6EQ<G8.;H1>
MH#E5&:AS'MSQ17+Q$WMG%8T/OU! F%]/P>LL3C),LQO-?0A:<WBX58XZ.N$(
M,U6'."G]=_!W%LS %3C?3*.H=Z$\8?W!OT! +Y$)W'4@F_9'\\MOHLB''SCX
MI<5-)P#G*OC%E^%+?4"IL%RZ6#^'M_>0RCBFD?;=1&X!E9$#_*KW3*L9A@V>
M*>*D\DX==B+?*I#71D;93)D&&,^4'FO5JIA85;];^>AW(H!K3MS.6YW)7,I=
MEF$*OFJ+=W&,EW0 A3D0$]^HX&$I4:("9Y@P/N-6IZZ+A-S26@?B?744>509
MW0I]U:,F@#,H>55CC;W(>/3X8E")F<QF141KPE"(PC#.P5%P[=H41BM_$$9,
M(L]_X%H6L%''@I4\+[OZ\OZ/2R .#U+,(F!,<2.4ZZ-([!5SK)!2?5P:5VFG
MU>#T=TJ3\$%1%O@ZXIUSJ5B59V3,>V689#J6J5($;M'> [Q*+U*9.?IY?HW!
M:V2@Y9W'@81P&<=W<OGV,2QY_[;645.^A PPHD9I0'";,XCY<(N SHX5F9E,
M>7L8E45I"1W5I]7<#<\\N7JK!P],JB:\ROM6V%-1'.UZ:1?K1-Z^+1,'^"M@
ME-O))VY8EH683UC6"HZN9!IYW\V:J0XB]2S4]Z>HN7Z>4\@%-XD"$2P4OP%Y
MS35YMF(J @62I3M,AFQW0_8I9"#86:%WM:E!7R1>+,>EJ9@C&/HZ@P5N(*A6
MG9E[.#YYR.KIO,]:*U>Q;AB$1#K?C@-X2"UY:4Q74Z)+-O)XS")G03:;8S)%
MS14-4H&D;JNOM"NI8Q/,)3SULCA6@>3]R.TDJHT^ZV*\T)"!R1GB$S [P"2R
MC.*<:/>X 00!@PI"+>*W6QOE76?Z/#;;&-XGC/+%W0J%XN0:O+AKH-!8B!!0
M:/A:G .WK?,G>['WN.U)ZUAE,8.<@&=,$'_@H11!P/,$/='6_NQP93TESP]7
MOMHR0YPOR-0G,JI+-NNRQ+\4^P ?S!+7#NVA/'&O XP[?)ZXMR9/7"7-*\\4
M-U--5Q-Z#VO"RZ3TJD+T7$F]A^9A??SR3&D][:8L)\9J >B5^[]5^=M?<JS>
M2NW? ZX=QR8?F##7TMS3)M]GJ^S3.D#>:_ZIT0C^<%ZF;?(RM<S:)@=5>Z.=
M6:CZ.3YK]HFL&UFW!ZQ;;JJJ)F&/:,_L,)4-W,AR1AM9:"/+"TG7HSW>/6=]
MJZA->=\7SOM>HNU0F[ ==CVE;<&-2/P6&^>KVX+5%ULF??6N^_7;@O7OZQ*^
M7]4Q(3F1WN9]P2NCVI3O[0[[N^=[GS7="T^ZMRU8DX62O0U4S=5D[T,:4)/J
ME5MG$A[<O:G?^ER)WO5S.'B2X'!9WAK0>>51<"EX& /O;??CJCTZS :'E5%0
M<K>AR=V'/9RM-Q;>!^"])G:;B]C;975KN+3MOL*5VUXNH_N$B=9-[X72N63&
MR(SM;L8.L$]/LX;R-<]:W.>+8L_'H*R,42WR<\&N1?QG)A-X,Q7Y><:DV-^T
M8J&"_%,$$ZQ.<(T1.-%X=^?P0Q:;^BJRNFW*>;@^!I+^@61+-8FRFFS1!NXF
MYK.DZA7E8(N_(\/0R3" [8#[.A$5J_-7/IM?,%\FW"!^>:4Q:0D,',:=*N=&
MY\@TI&+!FU-5VF53DD=Y=Q6K<K\6#F6 7D+)_Q"I(;-2;B+MDXJDH2NFZOMP
MUFN[)]_?@AP7]$WX+:A>HAT<])I6DI^E=CX$!I@8CAB:OF2R*.H)K5,=7:YF
MZ<T2XYY4UQD%%325B]2 5""D4[/\!TLA'E1Y9>/"?34.,LZ,O\U=W:O(%WG1
M-1P*J+(. .!Y/A::PGS^!)Z450J^5@<P$T)[[:LJ7WW?]Z7WM=AUCH!X[8PO
MX+_ORNT^Q9&KX1C*J.5A]>W)'P!*;_,X2H\-HQ6,D>0XT^Z@ 27-HSB:Y5"=
MHR_FTA4MP6/-T2^%R:51+%4<5@3V)A@*Y$SF%%PS?F0H0GR_K<(B'=C>J&@=
M=%S$:H+%,(':OJYNA_AM A_MD9K5EGQ "_UR'>%[//6FIS#JI?DNC62%%#@D
MY=MBV!YGB<)VPR3E\ ;\+E]Z437VD&@J./(AC@DCL&I^8>X>K&YKBJ^9,IA8
M7<F;ZIJ:*ZR95\EFL@E&//#ENCK<KF9TY6$%-=&X&2.5K+=K9)5V]N^72G;^
M(9/O[#))1)(@$A!5GV20QB#OXC:OK!=@+O &E_U6\A5+*1J3?O"+];D:32J"
MYD+^$=8A[%:%ML%KU#&RL_* U?>@7\K\2& )\+12Z4[\\(#_ZI4Q8&<H\".B
M=HS2D?+O$E=]0=EI:U=#MW8-:&L7;>UZ(>FJ0QEM_7VUY*&A;;FNYI8@IU+D
MZ.57ZVP"L:8LF0*DGJHU:KPQB,(;_2E),?]W(SU5MA8\KDMTD<%/S()4>TN1
M0K\EJ,ZK@M=/0R_4@*..'MYWDYG4I4_+TI3<QQ+V(E\M,-[,%94:?Z*W\GL4
MGG[,LRT?P!?VP-5>RD@^FU':97BVFJ0F ,<3=JYQ/YKCJBNO]W'R<#\$X2E2
M=;X1GGR-1._X4GM=:J_3BT[Y$AT.I[(4:P+!LOXS;EF3GNZ2@J\>1UB/'.91
MO'85!'0+EYPW40QC4C2&YY^W+]2OIP%?1%EZ/I$_A']Q)_UT"J15XF1N '8%
M?)Z(<[,PBWT555^BM+#P6'-9YRK.\ZO-1=6.4_KAO=:HX[Y!P:GK2J6OZ;;:
M[MF&:]JMT;"SX9J1VVH/EU^6=U/"X6_9$ZOPI_+^&T:?W+8,M^\[EM^L.E$5
MMV_;(FL[A=Y[.[+=_)]']",CVA/MB?9$^^>C?=4 Y&_,)Z.??-]R$8]6>72
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M"/S.2?.CY L).Q&5B$JNB8U(W>N/G X%D@U,B^N5B;-C7)FP1ST^\R 5[%H
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M>SH* "S'L3Q &N&1)!U:2=&AA?D9(NP>%N6(R"2]+T78![8X#E]\AZ.AO_%
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M831IV;'RR!XMXT&P0Q2-VZ6Y7@QO43#]V%.V+S_I9AZ+>5^W65\NG<GDG@=
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MKT?%M(]!(PC$B:XVQ+&$Y@?*01[@2&\#&=:4F/8H<\+V:,NWJ8Q]^.1]9_\
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M(P\5-"OCLV]__ .^K81Q=;?]>KWF3O5#&4PAMA5?KX2-Q?<*NHMP$&\!L@8
M>B!E,"\EQ'I4J\_;,:3;UA:9EP*)BW<^>*VYHGH]S@T\S?%8@F<J@E!^%['#
MKJ>M#V!*_XA %5/V3<SG^.UG]>55S.4-^YS)6,WV"CVVZXF83/)+& 97-98G
M61J&)O;=-%HF)IJ@IQH>0Q;%_ ]QB_TM0T2!6?."(#RM$QMCI/&]O&(NHRPV
MGCA\\&4,;U7^>16:0."9J(1M=?$.ZXQ08\894.QK&@N1YH:L!V$O1!W@,X=
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M+HO3_DCF(M>G\FDYX?-[UF3V>*K/?:HWP6@RPYG-8WE@(NK<L<JJ;3/ U2'
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M:E?N""%R!";.LS%H;K&[T<D%!W0%WX9_%DEQ&%7^ !9!$ S*%$2IEJ*Y=L.
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MED^J:][M $G."GFUPZ@=FL^/KQ5>I.*OL%;P&-B12M#[HC TT75W_?D4LB\
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MW@?^<:7-QJ,V.GJKK_KH:$< KW=+S3:IW@*I.N%UQ?!4CH2)&SI()OUX=&F
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MX@/(?G.&_0JI]+-<>95'KX_6-^GR-> W:?))/I!_J>5?@U7Y$,8>I>0WD-?
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M<S>999ID0O@,PF=J-9AGC('_=T^@&%@%K )6 :L@  8!L!T5QGWV_P*K@%7
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M.T+W@I4=O<G*=NR@YQ!5;M/1:ZOMZJ31^LF_I7/+T1(,/"I+\: ^REO:QZ_
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MJS8+XIAZR N(C8AP L2XDZ!8;L\3J<$8IJ*5_/CV]^.1V_/=MG;D@ :&I Q
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MJRCSR=IQ*<-.0!,64A1QUT?$)PF*$JK^C!(<!,+V@F@-*U OH/)H7-WDA9P
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M]C^T#N6O@E]6M!+E>7(T%(5<UE_RP8 6I;YY:CO:\[:C,S,=_V;W(P*=#[J
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M=@*/2G7IMJU#WZ$R?[_\<F"5<@7)1[OSFA.Y2RA.4)J [4!8(*P1A%U=ZVV
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M3-C^::?+>+>N/;5T4I QUMO:FPN<\>4X QHW#H.O 5* M'Y((:4)*<V#-@"
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M.B-,>9D,4EPPQ+DV2#N+D68*NZ 8(43M2-/K:].UO^16S2S=CIY#SZ\AZ1,
M"\ ."]@!>E1[Y+-(FF1DAB.IE$0\>H%,H!P)HA/FDGAUVV?AU%,9E4?9R="(
M4YF0L3A[+UXPS4EPNIS=_H1SV/O,P_$L_DGR 7_633%C2OF8T/O/_ 72&#II
M +  [+" !9G;I<QQQK@F"2-IJ2DR1W-4;K)X6>5Q<L[1Z+Z:S-T4N*?&XQH$
M;F_I H %8(<%+ C<3M>3>1(F68N<,3F.T\0A2T0>O& )95@XZOA-@4LZ*HZI
M1C$JAS@N[\Y*B+PWE$FEN;=TIP)7$LX*%I#WES, 6 !V6,!"22Z4Y((Q +
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M9ZWM2A+B'^7W"*W'JI(- +8^8$&5H9<O& , "\ .$EB@;Z!O, 8 %H =)+!
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MI/5#"C0--+UW!@"MIX9!/@ I0%H_I""1()$';0  *4!:/Z1 TT#3!VT  "E
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MHI^N^<EIOE1HN5V5+PG U@<L;)L:WO%,%8W0?AD#  O #@M8H&^@;S & !:
M'22PD"C?97Z'DF!B+-562I6TMX[(1L<0UI0:3(Q3DCPGO[.8G?SQ_8=X=CYO
M;'/1)\DW\C@_+9O)[.1M;";ST&_;S)?</=4^<],FI6.IY1A3L?N#88 [ %@
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MS =AN/1BMVVDNDU Q^?EUZ^T,4^--6-;VIP'+%,'RP"D &G]D$+( B'+01L
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MQED64SD[X-8Q1$]9B]LDPNV<"6BVU? /R* 6,@!0 =1A@ JRM5O9$MX9FFQ
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M(L>73<FGQ9"?'^9#'JV6A#N "JL8=9'-_M=/1NF2PX8@R8/+WA=5R,:8?:K
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M88=PJ?G@A$EDC38()\Q24B'[?;=J<+?8<OY9'M^#COO3;,P9M-8=A,I#+<C
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M.0?&:M['#QH\96!0V_IAAZ_%-)EN7*+;W4LS6NT-<Q3VNCOTKQ<6R6JV'RA
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MXK#1\<&'O/#F[*2RH9Q!:.J!4VO[N0V3EK?,G,[YZ'U9E.Y8 V 0,]D&RVM
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MW60\1M45@IP':,%,)A.VRS/1G7:Q%ZMY_N#][\^]W>ZJBATCN[%T'4;;D-4
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M<-+XC?HNB9V0'X7MYK 5E.XR8*B*,$J-%M]),?VYOFQ,)J7IGM!)((TCQ_+
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M1DM@#J1E"%Y2?#4"VW7O;L+EVNZ58Z 5&R9X:SMM]'Y+UJ<+#*N^Z!(OM@K
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MA'LR2:B,$E)2KN#),@]+GH8B2K]KM\*9I*?I5[@SN\ZU&+S(T=DO4DG(LHB
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MPOREL::6$Z"J!2G[J1H&W8YB;B5Q-HOSW$?97EIP^"C;2=H^YU*^"V#C$&T
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MSS@IHS(FN:*AA/]G,M_J</7$]4A,1^J/NFYANS)U[3XM=6\AH(NO5O+-DO&
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MP6PE_78\T>UX_+7QA/9R[Q7*O>+'*-05W@)S3!"X<X% 'PQX 7BB^](+0"\
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MC]'Y%HO9;</8=5ZVU7\>/<PDJIS,S>1TS.DCS"TRG#B$C7.1)J[\YLDI"5O
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MSK,7XF5LD0L>,VK%V)S7EW#[['->'FQ7_Q=O<G,NU]]HJ1H+&LL+A0M"@I$
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M9$OLM-@$N@AC\A4?YR,[FTRO3FXE,JXK^GN^K[749@T5WK<NE.4MXWD;<G?
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M")7WXQOD!/B_&-.DG8R4D$W_0V$ DIR=\( M/ :%7 1/)' ;$_-2A+B18CP
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M>=?/@ZK$MHSDSFJQK[W^5TK)2M'XP&J9KODP?K*C.:A$LV/+P%*;NG*&V,P
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MF(0A*L6S&VWAML)MPY^.%^8V6JAMB-3V<WLB6*&IH=I? ;H"=/V>GEX!'2U
M-U#[*T!7@*[?T],KH&,%Z 9J?P7H"M#U>WIZ G0?\J:( G/#L[Z27RWYU>%/
MQU&L'0Y.ZCWAGF_;]L>3>6/'H?E3\>?ZS2B+ K*'4 K%ZH1R##Q.6QVZS_2
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MT%MMZ=H=\6MSOOE7,>Z"FD6PPQ-L?P"FT-&==-2?R=I@@V)-!::*8(<GV/Y
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M/:OCLP2TZH0HT8\#GOJDRD>('46\1;S#%>\ F:\_9%8"FN,UC"+>(M[ABG>
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MCI@W+F?[?.XRX9'R5$E+F:%JHV/$"E8[E/TY?HHC\F'2_DT_3.VX27':O+L
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MQH'P*.3?3J: 2O"[G..MX!]-#:.WT[6AG, (_Y6_V(;_F2_PI'*V@8> K]"
MW.L$=\,()RZ/K7V3-OKJ6+(YK=[-JFAAK,Z.[-C#&,]CG%7!SN+)^DV=)."E
M+^>M7*[@1S^:A]B-%O[5$3H\]*1RT\F_( B"(8<([#^M_CV?S/)H71W@STEJ
M8S_XM06 NG#UN$LP3E(.]YJ8O]U6S60^!2&=]HAP]LTV'!.N'( P,5H!'(N
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M3T"M3$1/)F* [')4H9\WWF.1(K)48L032\AY'I V05,<&)=6/D?H]R)'TH)
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M"B41G8V:,\+4[=!8"FZYH!PQGW?L<>V1U?"'\E1)2YFA!UD<5R=,DK):\ I
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M$!9?S\=MI-!L+:. 1Y]^;*WLV*FVU^('JC3FLJ(8"4"BB"NAD(K&(*4)M2(
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M6">)')IY<9(,3N<6)\FI;\$10J/AR+%OMJ6^GA9RJRRWE:!(6JD09UXCBPG
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MCVE10.>T,^_\==U,9Z-W'\W,'U)?;EMHT:"/BG>VD]-!M<FSM;R*US*2I#(
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MA<-1;^TH#5X.1DE,&.HN#.>P_#*_"+/B.QJ<\BB$'1)ABSXN\8B[XA$:.TO
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M_.KCV$XN_$WJF>L=)#4GTZ8>>5O4JW9G61&)*"+SBLPK[N$5RG,M8WE,4JJ
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M*&TK+]6:AKNC_#^=K\K53?69[RHH #J!G-_JT:6^:MZ]*7Y,QP1>L/;!=V=
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M4B+C D%*:VN4HMH)LHO,WP'<+B4#1<M!B5EVNSV$IKTG]7*0Y<#;V-LBMLL
M2UM':!]!E1S33S6J?#Q$+9VY]8P RXMHLH=\+QWE'O]&-$=4%4H%U))7!#&C
M!*H8HXC(2@0)')4KOH^."_?QSC_AHW>?8[>+YE,X;4OOZP^Q%GC=M%]>;5S#
MZ^2TO-ZW]C,^4;LDH?N<J?VCHNG8]#,VQV>6DEG*ZYDHF:5DEM)CEF*\9=A9
MBWQ@"C&'2V08ETA@;(C5-%1\@Z4\)6CVPBR%G B:6<K1@^^#MM'#Y]A7YXZN
M:;GIXT.%?4>'\AG(:ZA'770K-KEMO)UWW09C!\.A/8^-]6*#S5L[D*;777+G
MXZ^^B>V<8E->T$W\N'[QH#C7<&?C?6P0V-[,%:&>7"RZ\5Y,YUT;Q-@4\;X&
M4TW[!1]"[#QX.9F/7&Q%V#97=W/KN]:.&]];M! ,D]IW[1TO;^^M&K=)@/CT
M]2!@<V.;U;SINA>NNE<58 ?GF_'!IW;&&G8OUP#NGCR_Q_B;[1W:M%'<!&.0
M=T$C%JQ&E?<,_ 6CE:.5%]5&DN5Y'=I.P;R6MO5Y95J_+JS@-S""]]?ZWVSH
M]L5O;][6CG$XGGMW.GOHB_T_TH?)>3U#HCETW=&B_5U/U1LV.F@;KD9JZ*(M
MPK_P)WT!+S6[:;]Z5G@-LWG1/M6/W>!)<_ !IKSLU]H]*O;A=.!9VQ%ZJV$B
M+2 E#@NNNUA,Y18DSK6#V03_S89HA4G=C'][W:/MMBO8G"UO;O"%[8T.RP=.
MHX6MZ37B]6![2[DG\XX,_"%BW*P??R1-]O@)5@_J.7?"A7K =?A$DNHA]V,G
MC#WDP@??,*T!IM$/(J&*P;G)7F+"S_V+$E%.TI72<Y.]EU+XH8NGYQ9%N471
M:W=2N9U'+YU4;E'43X^4,2UC6G)6GPZFY19%/<2T7$*K?[G%SS=2@K-),9W7
M]EPW-W.&>4_:\>U)R^+-Y6Z.>'^5]R)H31TJ'96(E95!RH2 K./$4R4TLQNU
M +!QF):,HE+:$C'&/*H4,\@Q;VSIK.*JNITO?V:6_+3-]S[KC*(:4%D.E$ID
MWU5*9GZ$N)+%F\7;7_%FKWA8KR@]P8X;BBP1 3R<PTA[(1"UG!K!I QV8]>Q
MML949<F0-\8C<)L*&4(L<I7$HE08\U*EYQ79 "LVX"R1,U,IF?FQG,5_7*0G
MQP4>H\L_O[,Q.-&X]O%.GX-7V<DJ.+@*>LB>TD&T[N@$2TZ[_3N&U-N9E@5[
M< C+*CBX"GKH18YJ#:XJ[$LN&#*AQ+ &QQY5I=6H=$%4@03%M;N]!B>JQ,H;
M6(,'(1&KE$*J% 9A2DG)J'7"D/36X/"6@XJ07#JOAS"52^<=Z]+^RV2F1SD(
MEJCSSU5F7I,B,A<[<*TXRHGTRB#NE05>12JDO"*(!^TM,1)S(W9QJO[P7"RQ
M70*9DZ4&6EF\B?B$K(A$%)&=\X&=LZHTU8HAQ;!$C'./#.4658)CY:T(I<2[
M*)%V>.?,!I13<- \.^?>@M:=E<_6:] L:Y]MK8@&7TZZZ,Q>9)C22[_<J:BG
MP>1O:%N]I'3&1_$MQ9ZOPH93?>8[^$$Z@)#?ZM&EOFK>O2E^A"M_^M%,W-7/
M_^NG'\]G%Z.?_S]02P,$%     @ [CU\5&XDA<HO&   020! !$   !T;F=X
M+3(P,C$Q,C,Q+GAS9.T]VW+C-K+O^Q4X?MEL;>3;9":)*Y,M^99UE3UR6?+N
MGJ<43$(23BA0 4C;.E]_&@"OX@4@17NH.<Q#1@:Z&]WH!M!H-,!?_O&Z\M S
MX8+Z[//!R>'Q 2+,\5W*%I\/'J>C\?3BYN;@'[_^Y9?_&HW0Y?7-%_2%O*"Q
M$]!G<DF%X_DBY 1]-[W[&_K/^<,MFCI+LL+HTG?"%6$!&J%E$*S/CHY>7EX.
MW3EEPO?" )H3AXZ_.D*C443\@A,LR]$E#@@Z.ST^/1T=?QB=_C0[_G3VP\>S
MXT^'GXY/?_S[\?'9\7$&S5]O.%TL _2=\S<DL:!MQHCG;= U99@Y%'MH&C?Z
M/;IASB$:>QYZD%@"/1!!^#-Q#S7-5^&>"2U#@/F"!%_PBH@U=LCG@XPD 68+
M/WA5,D"C)R>G'TX.$ X"3I_"@%S[?'5)YCCT@L\'(?LSQ!Z=4^)"]WI$]DL.
M(%,-^F#BS WX*-BLB<BU^?K$O4.?+XZ@^DA6RY:/1\<GH].3&).P<'6:8"48
M$O"(O :$"?KDD9$$(USUMQB=2K5K=,&#!'F.Q9-"AD(EHVSI0](2=%2.NY</
M44O')T?_N;O5=A #>Y3]42X+P'\XDM5/6) 8/!2C!<;K(BM110D[+J%YL05Q
M#A?^\Q%4*/ _?T@XAVHW*.NDXX]'NC(+2FL8!W,&2W 2Q@.V>+6PDXAXH5>B
M/CSY^>>?CU3MP:]_04C9)%VM?1X@;9JWOJ-T5\.9_&L4LS>21:.34^BO0R!V
M@%BI45?(=K0;$[%R6S&16$9;)F*-RM8_5K5;:@)6+8H8NS!:CH@7"/G7*#76
MJO:KAEI+%K*C1+,1E31AI62H-6.G. #ESY'^6:N)DJ%KW;1IHE1_"RL#+)MF
M4SXP8WZ@&I=%<>%Z3=G<UR50)LWW++;A!S)':E2?8>YPWR/U8_]HS?TUX0$E
M(CM!*@)+3N:?#^1L,XIGE=\]_'0($TL,4F@@/[!D]1&@$.\V92_&#6@@D6]E
MM4!J(HIKH#\^'PA0@A>-R7>7<\U)4SD!1<"BJ[15+>Y]!JIO0KMDWE1H0*&,
MUHM\F<#T36 '>TT%!A0G] Q*ODB!K$66U&=0C^2/QX<;XPI_%.!7G_FKC6;L
M ?[W>^P1Q_^.F7O%@*G-#4P8?*4X.D 4G"I[\)C-F-%4Y;^>',O_P/W.>.+)
M3R"&-#64(??+T3:1+?*A(.Z$_:I^;P^I"#D"J4'<TI(U7MZ<2]&BPEA=;Z#$
M*0BL_/<+7VYDJ M_NN?8DW[2=$E((#(JM  V*/!$*C A@^1N)Z6$(E)(TQJT
M5Z>]=*\*^S]_16;XE0BY1W%#CTSF, \2SHD+Q6,AH#=AA-Q2_$0]*F<L779)
M DP]<:I5W"E%@QV<JH&<;K='2+>)5*/21J)VD3]'<<NR$NEV$(8!GVD]+OXN
M8@ VSH/YV)G/+8%E14S#U0KSS61^'090> ?,K<*5JKO'&SE8Q2-S"9^LU2Z;
M+32:[NZ" 75"TV!"'PHFI-&E\>B&I>WHIE'4M@9!<>M(-8^2]F,*D14-1M3-
M"G*/.50O24!!T$;+21[38! _-%A;T'<YTG\;]-Q.STFAF,RC802UL#)<^"OH
MIJ4,SSV36U\8W8@&E QV\+'6#M)VY/20MJ16E%Q;2#8V&$:=81@U^4!<0E;X
MR2, \2QW2_ 3MJ5Z09\&OO,'J%C]N_0]F(S%U9\A>/%R&^?00!O-F[=B,*A/
M#0PJ905E>$$),TAQH8PMR\]?D>9(+CV*IV%&^JJ&5[)DO6^3!I/\\6N8Y+!H
M=K]H7F"QO/;\ET;K8XID,).?&IB))(H4U4&OYMA7LN_X@N4&8S(_#P5E1$B/
MY1P+"EK*1E^S<;"FJ 8=_US8!VFZ4J<P5%%,70UP15_69%L8]-U W\FF=DH7
MC,+$B%DP=AP_9'('>0^#RZ%$E.K;$K5>WR?'!7UGMKL9RB@EC6+:@Z;M8B+Q
MF(']P!-E2I*3[1A'*8Q!=R<%W26C,T-FT%*#\7CA>QY^\O4N;KS@1*]HI0.P
M"M:@M6*P,D<(I90&S370W#6F_%_8"\D=P?+O:KV50QJT5HP/2C)(T4%90H/2
M&BCM#O,_2" W$U/BA%P%WTMU5@IH4-D/!96E5%!*9E!8(W]EO=89>MC+QE8K
M#FD;X1G4^;'$4TF)YB.RP[%M2_WJ(XM2%495!BU]JCA'&;30R M9K6B@EA,5
MLE9N-V&56X$Z>(.^?BSQ1A)B410[0VY0HYW+;Q&]*VP!K' ,ZORIH$Z[>-V@
MUX;#TV>JWRJ'8UQOT%<QW**1!ZTTUHJ.+]^ #\#D[8M[< ?*9\M2P'H]G1;#
M)%$X.R&#%)U!8PTTEDD,*E54MMZ@GV(H))L!-&BE20B:!/*H^I[PZ1)S4AYK
MWH(Q:*<8\@ "ZD < 0FD: PZZCQLW$'XV#*,?%H,C]B'D=%W\:_A#-#2O;13
MWDQZ?6+;S6R$:U![,<321.VZC4'I[8\1RC5<#6A09S'$4G:@,"BNL_AT5G\-
MX UJ+,9@*F+5@R:["EK7*+(&W*#'8FRF-( ]:/&-(MDU2K7'-NBX&+"QBVH/
M2F\?WJ[1:P[ H+IB["9.^!]4TTWXID91->#U:OM@&\H9U+AC3*=&>T4H@]+J
MXSN#JCH(]-2HJQS2H#*;H,^@N+=+$AV[KF(9>QFW(;K0N$,":2U9@TD4HT1-
MDTL!)64@[P_%=S4'4^H\D-C8E#H@:S"EG2)/@Q&];R RO?;]0!R?.=2C2FA]
M]T"F+, _T@M[QEZ4Q/! 1,"I$Q!5E[.UK]:ZP23+$I0:F&3VCGJ>T>0^A4K'
MD#\RW*K"E%]=/]CQVTV&"=25".A*7GUY%&0>>K>P<U!KI7K'92,?) $MK=4C
M)3M/E3LT:K#:8K"PF=6FP EK2/.&%'-Z!=?L*5M-&!RLM(,3 //2W![=8#G%
M\&3I:<&PV+ZA^I-Y ?96,,H<0EQQS?U5F:J9>T_7)'KTDRUF'#.!'5DE[ VF
MXP8-)E:,CE:86&8:DKO,F#,T!];*<>14=']S?X42_E"6P<$ZN[3.3$;<) SD
MNYGR"=WQ/"!<WB&58-HC:V9&+<SVC3DQV',Q9&RVYVQ"(,KPC!33*,NU!&]A
M[(.M[X&MYU^ON>R!S6]S5&_[/Q3C[GVP_<+;/<-@Z'(P6.2TWP@1$A?LK+%M
MMIC^WX4?PT"PN[:;'PB6KVYHWI7)MQPM@_5W:/W_)O(-?>)B4!A>Q/<"Y,&'
MD-%M!XSLDGHA0+0PY>;$#799/+ QVV7,Q&BLN4AF;,7']RJ([RA[C'@9#*S+
M>^F- _-MZ!C,IGBH4W6??0@%=#;KM-!CX;Y9*QH&8R@>R[0WAI/!&G9.,(VF
MZNOX2R_Z8=L(PAT'"=*$/<B$0@[N@CIXK9M$WJ8E@V453U>JDEK3!2IA)G[0
M-V8'X2"++G<)*.$J.GD>YJ3.K+#Q,M6<BL%Z[%.BAS7JS9.E$Q?VDCP%:?'X
M&;I70E[[?(H]4F<@'9 U6(QM\G7.'98M9RJ_1TGC"%I'LOG!CCJSH\;32F,B
M!ALI'D]4V<@PI[QOZGZ:\U%V-/Z%&([DNZ-OL*#B@8!E^G\^7Z3\@/U[=18V
MV-@;V5B+K+C=:-;;TL>RIQPM;6F8GKI*AVLP<XP=AX?$O7I=$R:(3#N;!$O"
M+V 7 @0RGR.)2BJ3X-ZA38/I%4/:K::QB#L4LZ<#V9)!%/&3^TI+7#:8:?N[
M4(TG,0LT@[$4X\S)IU:&>:AS!:>9@U[\X+>JN/!%-+IKU&R!;%"VW7=U8O+R
MM_ZHCFPA^7+.H/9W^_C2&WQ[R60BQ9AQYY]>&@RHF]<'6YPWM:-E,)EB,+CV
MU<)A9>G60FR^3=+44G:E:;"88@#8,J5B,)VW>CNQU61B@VLPA?(G3Y,TLT'A
M;WZOO['F&Q,QF$ Q<%OQ!L!@#%WYIF4JS*3EQ??7].A^P=P58P< U1>M2N,>
MNQ,T&$DQ-EMI)+E,O>0JGIY/=-LH;GRPG,ZFD32LI7.;URJ"6F8U71&KMYA/
MUD^+Y,->47JS:G&PD[>TDSA=,<I6' L1KE2WBT?@>.;'5QA_XY@%E_ CS5K)
MFD5M=LS[<F"PR&)@ULHB8RY1G-:9X5/>[G11X"?W/9'B%4EF<TDU><,>$FJZ
M63+ST]03!L;D=V8)$TK4*'3>9,UL1M%@<,7@KOT4.%)MHVSC\5' 8#Q-C2?S
MQ%*3.\*V: 8S*(9]<^\U#6[U6SVZ5?W8Q>/TFK@PFWOR0YUAX/--@O8 4_?,
ME^,.L\WT:CXGT@DAN?JZ)>\]VS<87C&8O&5X]<]L/!Y.#U'$)TH8S=! DA>Y
M^D7<_E6@A-\"V&#-[2>MU) NHX <%.LTWC%S,\? NLP\G;4D:+"W8B2ZQM[B
MAI6%1"G),EB=/=2.B@?3Z>!)NU3E5Y@SRA9)3=WUJXYI&@RH&)@N>28O;T9Q
MPRG <-'JS2UH#,ZK*[L6)OHTM?/JU?%"E[CR"0RY(H1!M-IM&T<K"^NH38,%
M%N/A1@O,,I9-=(U9T^]N9)@K-]MOW49_.7H5[AE>KRFXN+(H*F#,U]RK,EE$
M= *$LHZ +5Y_K[J<]20"CIW@ #&\(I\/C& !,//YX/6)>_1,!B;9XB8@*\GB
M 1(A@%%P<0#W-^Z'ZQB0 L@!TK_7A%/?G2DR;J@;@M:II]+:@5L> BD<-1C]
M?50MF$KGRF8\;DE47=\[49+^'K]2$?._5=B":3<X<RE0$%!\\Y;LZP>]!'C!
MA#ZKDU>=4/< PPMS9WGU&F@NK@E)Q&N&E!5_Y3,8[>#VM]<:9?).>U G]1Q[
M@L2X3SKQ$/J+/-' T!EVB9&9CK!%Z$LG..!Z6O5"K$OIS)!GXODJG5RF9,5Y
MH5N]8(.P1[W 6(B]!RB[QQM).I&V6+$_4I4^=GDGW]^EP>9>\9"L*C:@6<GC
MZ>B-)V0MND'&>TS=:Y_'7[)-)=JJZ%AS]ORW4%VZRC^3=)5_7(.;I6QQI29@
M.2,3M\0UL$':J^XH>\_H'AKG,[_DR8RT1YKBY59O]:3%>XSM6M&9 L4R2L"C
M69?$2^X\7:<M /LR=1G79IV>)?G6YU)X06 2DL<)\"LC<!V0%M8-^$C^$I)S
M6?>U)ZQ"*"J?01N[$9M82GOXO=%N1J2,UW1)8)?GT-SXM8'LB]CF6>R2>'AS
MP_3IZ,R_I8YT)">\X$C?<W_!\2J_1+?%[N.J71[PSP?GH?!"=:DH]S7C?NF&
M5D]G"[G9D)E%E_29NH2YZE0^7?$KJ_=H;;^F7 21-;M@NV[H!&-G24$[8@KB
MT3DE[H5'F7RL[XYZ1 0@4.+GM4;?GWFC3,39$A?%?" +&>SR^6:\7G,?O'@P
M<_D$@;#KMQV([D]OPC3!Y<IY2?2_-ZQB8U\2 FB'VYO!:%R9B_*5>QNU75*#
M\NWTQ(/T."?S1T&45V;;&P6TWO2(_<"9S($5(0J.Z78?5,/MD=!*:S/"5_'K
MN/&V^@ZV6]*+^&]P)V+)+8&SXB]DD:K^VJ[&+0D"PB=S[2C-?%@3I%-Q[?/Q
M2@: Y>*@(@R!3)6@_TO<?]-@*<,LJ?CM*>R12:0OON2?'8K"97*#DK:N.J8)
M1A_=]3O"%P0V&@Y>TT!J+DH3=):8+<B#_"L1U08T*^-:YFQ\W1!+XL?$ETL3
M88H5^^/G%)B//#NW4KH48(^E3(^I*N7,@O1%4J-#$EV#3B-<F2\#93/&5<QR
MPI)L\K&X>@4<*L@]!V\_[92.R/5TXVPEW\P_)W>80CUE1)X4Y&2;S&>$1014
M/RQ]SR5\MH0>D3\;=>6N3?6[FZ,#,OW%>I!4'KQ,G@G_XC-'VK<B+QVCK3YK
M@+=/#D*]<!-.%^ @>@WZ(X^R1UT!BN1D'C)7DLT?1(GMXRL[V-X(;YRQOX2K
M)^D.7^*-R)P^)>)65??1 XR9W0H8;<M2J,[* I,? =^P+Z*DT:MMQZ@.HH<"
M3>:PP0;+D<D724Y5KFQ_QDP:+?&%N,"<;^8^E]=I;^F*Z@PZ\$8>1>+'-$#8
M&U>O4B;PO=94]_T4N)<@V?!#<[Q").*KV[*%"$U%WCM1;UB4?FJV\ASL'AOX
MM19'QH-2Q<DX:>:\ORG6-]H=-M9AB[\W713Y@6,A/VE$7:(E C%G2YGTH7*'
MF=Q'I;<,XY/>*>'/F8UO%Y3V9SV-I&WZH3>5Q[G58RUI]*:OS)N5Y&&[M<\R
M47PPA3B.O]4EM9#[)'@F=!&?WMRPRJ18:_">!BW*^9^\,,+%DJXSU;#U'LL@
M#)$.0SX=9T<BW7=-%Y%P%8R*+Q,EDN8+2SA7-5^=]4:?)E9'DZF$;7![,\"-
MJT :\*Z[Z&&"VAMGP?:3CZ76WA*YIZ.B7M]]UK)YU2KC_U^8TTAWJ7-7)W %
MPCZ-;2U4-IJ<+^MC//&!!-S'*FUSO%Y[U(G\I^V#XU0B6_C>:,[&@.V$FC#2
MM!\4RC?8%?H\LFEOQ%C9#MGY<L>[CH/X'+:Q(600^RC],_;"F/-\:IQ\H2-W
MP4'NM53)G>_2>21PVAV[4^K-<#'.^?'C$_EGN\:<RQP;"7J^24'B@(<,",4G
M&Y%5S"L_?SUA-ZL5#%H<$&\#WH]#U,6IPAV</G#2TUUF)%DJR3F9^_+5ZV8K
MW\YD.AWV7?BD99GEE6GJEL#[X[5.8?(1OOQ JCHLA3V$OJXS)T1G2::2&P%[
M,V-9B"W']S]55HO0[P.V' X[T]DC4RG(NGMO#?U4[4[N3J=_<VVZK%Z&7"^<
MT(#F=^R D$(=<LB+*_></L,J>\.>85K-Y<'N2J5_GF>M1#=)OO*USQ^5(.K!
MBY+WQ9G[R$B4R>=F7^NUZKIN&MJ;WE6)D+L:G2V1/5H;D]NIV9/]\GP'*]#>
MI3K,R&KM<U# +BO_CD3V9SG;$K0Z5&T!V-.P]!;G.YK"_P,C:.?0[$BD=][,
MECP=[;"[IMK[;JMS2;Z0%U5594.VR/US2A)!$A'D6,QENM2"],:A,(8'\V*T
M'@X-L;_U_JF86EO1Z.'HB*\:9?-:,E>1U 6PW)TEV+)<I*^K3N818MGEIZ33
MWK:1G@:"\U=9XK[8+MT?UV3K:@ZH2"9]P39L1A@T>;.2KX20W%ZN$4IO)A)S
M5VQ]VR=WJ)'U(/+OA(_=_PFW-KL=$.K?G+(E5&8R5,=%J^TYU1Z^?[(FB9^7
M_@K39#$M%&_/4:XJ?V/N3>\"UWRS-WJN^Y8RM6=,G]=L@I)35Q_><<Y\)*(@
M67E=[T28T@53A]<PC^H7FJ4S[H/O04N$LH7NG9AC^-,E[F_4(]A-WU,A<GY,
M!EDM3"]'W+D3+#)!S N?K_,RU0#T5B"+U-FBD V0>BOXC,,R'(VKHH1EM;T4
M)?=I@0?R3%A(\N+40?14)/E!"L*G_CQX 3]A6YSRVEZ*<@WV(T\F872,W6<J
M?"[RTM0 ]%*@K?E:IPBE-[#RPED"[X.@M8+M@2#ZF:]:<2I >BG4/VD CFN%
M.!65_10$AC_L6,\I8V0S#8#EX(9=X-43I^YB:SC9P?92S%N] /DZ(KTNZJP&
MH)\"Z4<S2A?<\KI>BE'YR%U.(!-4/T4C+GVF55->56U/19'O\U5*4EK92T'N
MPR?8O>J 4%Z*LII>BE#^%GE>F'J8OHH5)3!E/K^ATI@*HAG@>BG>%.@1,<X&
M)/-RU0#T62"+BX^E<C; Z['XYR<FA99#]%DDHT3[)M"$61AD-=1>B5:NL6JP
MG@O7<G9IB-KG3FC; ]^(^/)E&&=)=C"%5A3VH$MF+_Z.7=*,0C^[I/I3+5N2
MFP'[+6#=1;9KG_]&& FH(T]4R6M0(7LK&GO3+96?F3'WAA&UGYV0N<^Q)6-)
M32]%F,GOKL^6A.,U@98=<<.<O"AU$/T424VL4:147DIFY)S[_A\P[Y"QBL?I
M2^1Y*9LA]5/P%]"3'PK,I 17*BF'L-I3C$8H>R#T[ 4J-Z"\J]7:\S>$J(%X
M'W)G"=J[]S"KD]\>>Y^ZPEKJW@MXCP,2?:Q:Y<!L9K!,GGN@HR2&6 .Q+5(0
M5WWM'#3Y@!<+O$WTC$*:Y\-]!C\=G6!9(7%+Y-YVACE!;99]T] :7 O<*$/*
M#<Z6&YF,'#ZI/*MWR&K+R58L[[$0M9EJ.;%L(/LL*&S<W-"3+\V6?T/P(H2M
M&PLR']"+2I1LA0'<';W>CNE4Q"3]_U&0>>C=TF?YB S,5=!F(#=%R=&OJ;/:
M4^IM-\5?W$L2Z.I6.DO@W@IK$?BXI,+Q?!'RHAVTQ>YM=TS#U0KSC;QZ9/>.
MY=9S2^-Y #,%[#8E'7WGIB1#LV)0?96VO[HJ?CF2FA PHZSPK_\'4$L#!!0
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MW[E7T#W45#?3;7H*5+1#.@4*Q)J_WRJ7>)3_#41&+("E>*7T#;US-[T#4_S
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MT#@,?7$2\M_EZBR-_1#%=.N?.;%/)HG,1TR(RR3"PO-\^G\GN Y7$=YDO[Q
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M@%7I;NZ0.U#7RI5<'VWP+\(P=0**&?D@P\_$::3M^[<(NS0=^8G(KNO0I5?
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MJ,#;KW:;<,[.]PSJG81.KMKY1L+!],YA;VFR]YK",1R\$\IG;>SE11RGFQR
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MQE2%1:",3 P'/:>1)LW'NIAYGS7&48DZ^G**7]/_T"OS_OO_ U!+ P04
M" #N/7Q4Z1/8CB_:   RU@D %0   '1N9W@M,C R,3$R,S%?;&%B+GAM;.R]
M?7/C1I(G_/]]BGJ\]^S:<93=ZI[UC3T[>T&]M76G;BHDRG-SCHL)B"A*&(,
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MO4@,';>/99E',[3NW,/#IA:BVS;BS]A]07DF*%;@O%7E%U:,&A"=\",HRU%
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M5-Z!Q<\>GTNJJ-92]1C\-43-&+5DK+;LV@VUQ\Q#1B&%'P,/#WU<S$,)(V@
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M0'7H+/-PS/D; KC3"-'B3E!GYU#PDL8(H74Z"4+IX24O*B@ZCUER '0XVM]
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M__+E\__Y?P>79)U$B2,,T$VT+A:[.*'*PJ*J2,ETV^LT/!;[ QT&O,= ZS*
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M_]H!C\ K<++1P>RN*VMCCS?&91ZA\LX4]*LLOFRPK%D;>36NHZC8 6$%XPD
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M0):N@\'8T/L&;)=OO2<9>0M3F*D=#&)]9!9\:A?T%WJSI/W9TVQ/>(_)FS0
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M(/%=)U T,^*8@T_S^,-XN5[N <PX*$9L=17M]A!L01@C<7<?Q1T65/X;/<'
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M_VNV+NB?7Z\BI&LL7I!"Z[C'V_>!\P*"OWUW_OL?AB I1^\);'S\U3!Y<':
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M&0*OO@MB8FX!NZVR,-U5%* /%@^7%S*#'J%CM-9;X)IS#?,Q@ID^0<@JY&T
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MASC!EYIR<^$F3'!*P8G6+) J+HJ%1C-AG6N""Y=O]5]Q>0"IA1880Z/6?BQ
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M;'[MO_H>"+VL+NE9'0EF4XU/7N9NLZKKGZ:;D]M.\#92GQ=1UW5/9G[3 ?T
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M2)V94WR-2 >T,\47/^%0A H1^]\@+3HY5#BF>.%!=/\+C:;TG!30N-C'I_@
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M9*OE>/:O,XGZ>BT'>B@SG^ZZLKSF:B]B]=-$BO_V?O3S8@DSOMWP980W>JG
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MGHIRDJTW2R,M;0W%(UPL@\U2S#I9>D?@A(TM2U%L8W&>RDS5K3^;(2(:NN=
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MT@ 4?'-YR+B(E! FTD/?-- .SG3JZB9@Y 31V^M+=ZE0PDPG(S14%[(&$"<
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M6 K"V.X6S3'^0:*1,FXE2U>&)Q[J;B9+01@]>QX-7:774^8%4N\_ZZ.4][Q
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M]?:G0!O!G2<S@X<AAVR+$#4%CP4I#VS ]^&',Q$+/R3+@(5\+KPV72UO$(L
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M$"'8"0VA<"$,:>]UNB[^\R;TL18.3@777U!]K3@"V3^-LC@%;V9KH]O?W$I
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MH3[&TF(_H30_M;&@G2$/NJW#=24KP-".10EXYHAO 49%IIMGGF@.K5IE4KK
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M]0X8%8O!X!NJ=_IG2'F!CS$//S=C[U>MA$;MOE-5;T%578E)%OOIDAV+192
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M#AM-R;(!RZ4TE\C$]JW4TD*RBXHQ/*2G"S8?;/%\@:ZDSDUF"X]">7 CW,)
M-;8_ GN)41/\!L=VK:F>\&25=!.(DPR?;-K50GDNK+0D-+BGUJNK"F+=.*#V
M;(KAF-LH /YG,@6!V^'K%-J$/!\PBC$L^)66F.3E!YV32J?H 7N(6S2"03)R
MWBR+$K;)%[>2*,>R[4"O!.PF:PM6TGD+TTI1-MAE(T7>>1<"L^75ZKDI+--)
MP#Z8++OCB:Q0OPEXDN@_R7++TF@2<+#:7=CJ.6$KC%MA^G$"1Z=I\@J#G&2+
MTWR&=4RUU^ECXT AM;Q9\HHI#C+)<W26SS8)! ^IPA\[N.8J8J"+$<F%T;3R
MI"!&/I[4+OY33D9I9)S,P.JW7AD&2Z\$0B8B!EQ6Q54*ZWWD^F S!<=F)#D<
M5<@ZVE2M2WQ9^)*9VDPZ>%S'6:ADTHCQ#0P]%(28BD.89!@V5B'_@J,H-41I
MPQ^61?ZTG-HW[4XT1Y5"Y&!RA)F.JUGEVJ9N-W\E:D+B,8B9N/ARQ1&!&'22
MKZ3>KR)6#_]_#+=2,5%5';!"4K'L S9IP4='8"LCJ+HL-T\V8-V$2E+!7E$'
MU (]5[5=>D/N(P=,>Y2S'A7OJTY21US*;ZK2+Q6A6ZRNL#3?VN&K\KS\\#;R
M9;XE%E6XN28_(HU2'0!IZS'+:\_BF]5,//;RQ]=);*(Y,"N6%ACYLRHZ2"?C
M^:A<S&-K4BB";L?/Y9U(]179#!-*V &?<-\S%?2KLX/5 B?<M#S"M^@$3,2#
MI=$HMI(IUZDLK$=7L5]UUU#%8O7,'F(&\F*\MK1R?9! 4LQ0;R%HJ7BL9U2B
M6X/TE$?B=0$:V49Y^*5$ZBC4I&@F[PE?7!K:&B6 J@"68!,LBX !#Y0\K"06
MJ7X?VQB*I4@5U7+&NH$# VT"UA/U>H+\ 8V^E2TJ"TKR2A*\DAH$%M@RA^(M
MHK[2W&NCH:'*S5M)DUJ5^?<)ZJ1P-9%48D*(C\PEY_ECDO/ZB&#SCV5QODI1
M@)>"[*%2LW.:0@Y_<#^6V8 \N?N(+!!*/WNY*G]L;;IMU>(*8(THK[0>]#(3
M*<Q'?.0E(PH9([:7FUN@SR +'&&%/<2HPFZ%(8;$6/$Y"9B8=][W<F\)GEF3
M%PFY'3<@Z> &2_D][=>]J34I<&S*54F(E*Q!8C!]HZ3XH[S-JM2,+,\J!(4G
MO&_!D#ZVU2IQ)C<_=S@QH%[,99520\0@4_69Q^>Z4HZB]\L%<)FQK*1>DLR6
MH']+,1),GDZQW=FSO!!U/TLBRU1$A>Q]V(LK4@156,#-31F:38^Z>&(*6T^G
M8PY>E;D4.KGI^7.:/%O6SH6&%_91V;@<=+JG&1(<Z+&LMLA!5BP#DH_CZ :?
M6*4]E)S6DJVL&5U1_'.\LLEF0X$TY,6XVG=87N)/$"+&*,I?J8\_C>)Z%Y\]
MIN"4!(ZRDO*R4U $N5EPH]^6%4I3\PNT5%A@!WE%D2EB#,B:1ZUT>.B24W5+
M(SPN.=6KZ<:YY%0]J<HEIUQRZA[VJM(RJI\K+6&B3#@\7'57D^%:\=-J"!>3
M<BIWVQL*H+#BXVN> W^*T8:I2'/EER_B^97.PPI\ :TZU1+\^5QXF-.CG).8
M"'K5!!D=[O8]0@/WOG1B>P?2#OAF,8+[=[L4)L ?/.4HOEN@X/[5D__YJ)=L
M9 2AZJW0WJRV+8O49-]'-[G GA:(+,]Y?LLPQ.-7G3P^+O'@3277?&W(8O2<
MB(,,!/S(D ->5]Z9>VFD:AN-O'E\#$+3+J[>G_A4!4H$Y=S]9[C[WFMR]R^C
MB*G)\9V7AK7]RHTOB>N)GN%9;"Z,HV@*I(E9K,])<QK^X!S4,=3[$/(>3UW1
M#;)B%J$7$H#$"XP1*F$DJ5FJ$< "%^8]S%$TY21(_8_!\%2QX0P;RB288B.V
M_J-<\4=:<>-V'PV+, IS6 [51V]2PMC58$HO5@!8=<]#0G"8:2"SL&C>@MUC
M@?!^C, V9*?\+P&V/=7XR(Y!F?U7]3Z;[5PL6D5KN7#)<]JZP(0R^WF-2E3A
M0K(-E<C6-A3LZ%R-$V]K([SP7+NI0F:>:4?@SG>"DZU$;BSFM-N8!5<%,/F:
MU-5E5Q;DN\Q)2^-J12.HFAFRR>0B$4 XDAC#BRB1J>IUP'2;]^TX%3D%44((
M_U/I5* _9)2/=(C:983<->#)5!0QCSRL6<2!!.A88OQF]<3N@;[M=7JRFLAZ
MGE7NU3O &DIR_R>ZEK(*?,]JHU%@;K+QEXB^&M?16I^%[AC%AOAGXOD,D$?4
M=3F.]5@JBRSP':%_5$]9,+ :$KU/US5BU8NLJMRPBH7(Y4QDH*X",V^S&%%1
MS4CEY>FNY*)86,6_I-<@C-,M7#?0C_R#;NK)=RIU7@'7S\=9G.29/CD)H5P!
MU);\&@356'Q628D=EXBR="N:;BVBR6>16CB$JA+PUD^48#$GF#=];5C>>K[%
MB9AD"-E@AFWXTL626T[!+-E79'7U"T_6IZA4/ JA<L:TN+,K?+.YKOO;S(-X
MX :YJU?1A5C]BRH 1<4>,C8A90/P5FPF9\?YY.R5IC&18+V4G\PJ".<!1&QL
M"2TA"102Q^W[VNDTR]%$#FR%Y*H0$>?WP1,VDLV*MY>2&0N[4)PCTC*)76V!
MG/JA/\_FP$=JV(?YJ=:EKV.R1@\<Q'K;+N7A&FVK\U*=L)'3VIU"S%\I4$P5
M7J(;MF6I:,G\*0C>]8"H]]228,4\#P7UKG\%&3Z1\+!B3_;(/O4EW3"2YPPC
MV6EH4"6/2^3:X5(+T5-IX,G()N%DUR.'5J?<Z>,R\CLUW3B7D:\G5;F,O(OC
M/Q#'YZ\ICG\M50QV,R[K;7W:O;?&]=#N\EB$8NJGEBM2 >3QZ&A'VYXC)=T?
M/9/*Y,@DOZ(_F(662VR&*AGOJGJ(5%O-$[#86TZ?8D+.GL((UTK;I35XJC!W
MJI #S<,?)$976FK\$%R[(&A+5"2= -&)^K9!8)->IFP>IHU6+O=*SM7R JJG
M4A;''3UV'B:E5V.T^==U,+=+SU'F-I))VP1:Y( Q"KRI=XEBW8)-/Y$G61KP
M6 J(JIKWPC@3%6-8EL$+"?/$3S/EF\="HZ"D<NX65A+<\D#(7/!8SI%6PEW'
MAF"K*&PYB66#') 3#AHM5%_H(6H:D4A@])1\G0=!;6B;D/7:+,SF8_2J-*XK
M_(LOM[#.G\9^<#P*?:+V]!)YX[SIQ2(":PI5(61G'0_EYHD,=7. E9E.;-*C
M38P%L)3J<,2H3$!'AE0N\Q<F@*())<$0D*QPP;(EU4NM%H3F14R=:W$^]K1(
M2?*V$^$',JP9T_39ML+EDSD2_2E355E8.0*L3%.ZY"#2<H>:J5W2"U&3C'4V
MW\_=1C6)33?/EL/%5@>V%9'1M1P1#3%;0=$4*&/HUQ)E2M<RF,%[NCD =^Q6
M'JL,SFC\(QJ%6H81<,;$\X#Q7YTQ8?NK]=SV2EM"3LU1\ZI+=@7%SV7^!57O
M70BJ>N8OZ#=J+*,,L5./:(+1\ 0K:(K:ZCZPAJ(N,SWM*MA-BBC3VI+0UVXM
M66E-W"K(:,.J=":FL506%]EU6-8P'GL,]VK.AV2N+5+F(*!D590T1DC7<+;(
MQ@'B@8$O(BJF7!I?YA$VV4K!75'946%A/L?SH1F>A4 UJ4$YVJ]MQ0+;E1/F
MVA53$;'FRAZ?U+$3@>M?2+IYQ'GPA$@WE%=BSE37&Q9B[LH0D%J3QS']10'/
M\B0VFSK:^4_;N7%$7& VUU+PJ<P;TZ_@7Y.4H#WT@$_U?22_5T".:=Z CQLE
M@30#2N+0,&93@4;MQ!)@4./I(=1?H&=)8JFL0)-5WH/R"]+SKKP?KD#2'SQ=
MSB^;8JF ;J5[<$,)X#+'/VF;M!0I5WN+).*%1AM8S4[>R[I%]BP:U9)5A9>'
MP'4$7+[#QF!S+6KLC<2&F02^^@>HP6@N--"K 8Y5@!>V(+A_JEKA_0KV_\:'
M317J%O'$3];,\5(BU&HCU#R2<_:#?M'];E'1WLKQG*37)I],1D^Q6E<2+,9S
M8*\S!!K2(EK!F)A)MC*(,O4GYL>YFY7O#Y4*[+W;WF:+SN,&W+@(_YH(?[^A
M%A+80R5"E?%](-*/-)ST'&N#:VXH.>/>10JE<7^,I6)2"=:]XE>WP2^R>!$I
M()B"M@&A\L[!B3UGZ%@3ZD,OSS^>&UN@WA1K*@I,)$LCL7&*YWY1UI6<?)Y0
MW<.,;>PW>[IU.JOWJ:CIUJOA057/JNI)M-_1EMU',IT7X<T&A1I'Z5GG[4;K
MBW')HEZJ8><\H)C=AM\1G;:-3F:5M.@EAC[1Q:&CBY>@"]*'%'8@O]3+SW;3
M'4BC&+58C!P4&56!Q>D!)!1ESQ/O3B;_D*-6XS,2.3;EBS^7W=[];GOW8'<5
M,A"CD+(<61V;%JN.3^MS>-W#=O^P^O!J B)1IU*EQQ7 ]6NZ<:X KIY4Y0K@
MG/-_O_,/WO\ ;*J"=VW[K3A=1Y73-"%*<*^/5F]UJJ,&&"'H;JX!X)ZJIKIX
M;K5KEJ&XA?9EE.W;B/[?D5HRG5DS3HK\0NKD*K(/9A4+[72-.H F\<HFC5V5
M2#9$ZM@P-T:627$J@"<K!4-QAS6 &[U-Z2JB<+N034"4PJ2;5,1N*/LM[[MZ
MRJKF4^%)!GR1T# TG3*E1X^7\B)2EW?<OY55CW>QQ-E5+;(S."PYP(">4EH9
MJLD=M7!KH V^'U%:A'FG*BK,?=^-0DEC6]<_DH^[4I! Q68X#Y?NNRZJM8*B
M7LT&!HP\90%/=:@+6YUG0$54 W@G$)%HH]LK(MGGZ$5Z4)[$',;L^ T664PY
MKN"OS+N1.$XYIE%Q%1IEZ%[-X,;H/G<>21,D'!'&D1F"U P1M\88DP, ?!0H
MT\=EOUQ)0C7Y=C=;$C:1_!04R)YL,;5KB^3<@])X%KLN5TO,];J$B@!-%3&6
MG6-; ;E4!;-N:A7N/2QE33[)S+>0\ ?3#(AF2N 55.%$]39MG8>(447ZV-4?
M1J"T)AF^T?!6K>583#E._;5&69,:^L\FN^;A380!5-A\D:7^!*3R*)QTJ&Q)
M!%-4F3<21LVTV.<3S*_!H4NPGT+0-E7-)^IU^FTJLZ<ZH"65WZ2DQX!V_"\I
M(1.B1\TV]K9_,I%Y$V6R*\!S383*TZ,_K+ ^O95CG6>P3D^SCN&:2&.S5&AB
M3E2'I&RD&.)0WHJX>"J2/N%7-%M8'SXM%.VHC>[!)IO#PF8)P[B3+KS#(E>V
M88;[6/68!AE118SO 3^A"K! <1LPAE86LM=#E\/1"+>%J1@C8S-?PR*+DTP-
M"-9TO8-D+4<(*.P'>II\2<FPR*MT33X*&(L7J>(6N;NHO4I&G3P!4>$*8L-[
M2' =M+B/_A?XR67>:8]\1KT5OAF98^Z,[YG__DSV&50>1 $XJ,)A!0;<(B .
MW!98AS.XGF-PW3;#WK(]F>896[IB0\'$:"[0'B7"UT@1H M@!2O$,*J# ZX&
MSS78J!J\BSB:" ^+R>M>@F>U010&C^F1; I^I>A>L0W5CB8-@O*W!8PCBHVT
MT>#$V$B*J+]2V5AF@1^N&_&1MU=4(IMQ##AL4:=DK&MV"5]+Q4Y,D(>O!,(Q
MZD)5^A7FC*PVN#^N@(.6"H&;/)JA^G9*-_4?*#.J#M=H'Z2\>XV(.S:@<-H.
M^,)BU=3D=9'!PO$/<5:HC*7) TL$02BF,]W9/1.F75="@\&R"BR51QQE%S1\
M;EEQDKN,?[K@2Z*='*)Z0UZQ8OAAF/3?"'2=]W,AY>'+G?(8<=\NE3]8%?RL
M=M_(S*6&'TWG7A5&6;E\MZV[I=%X!!TTIR3DD>TB$P3E(X*.C2#YH7E')15+
M+]H0;L!CN]U<$[K0<('Y>5IN@5=UFA4$3V&'VTVK71\?E-@CM349$(_E(/FH
M5;#=:9%:7R-7@,"DGLT&2LH!O0^R44,(I#"Y5MK.8P2E%%:8C1S)[4TVSA)4
MBTEE$@"U7&(?I"UB1\9QE>#WJ.F#I4EDY+MF9)FYAWZ FN.[:CN$D6DV-/$!
M55 X$U(;:"XV(LCV_\N2#I:+Z79K3;F@GH/YC5*Y$'8HMOGFQ&V2(?FMVBRZ
M!W!6@^=97ODC)+Z;75:WDI['%8KMUG3C7*%8/:G*%8JYV67W1O)T#_9(SX0V
M"LR :$E #-*Y4A&I^/BWTD5%I*B2MH9S5K"LP;*8+)4Q ,L4M)[NHG%NY*V&
MNR''8E!P+(Z)WI (BS'<FH?KKBD7I)>^&M4R_C\AQFOW+<E#$SJEIC/:&O^"
M@,KH1U;8+^%S?0,:CY"'^&Q_4-NQKE/W69VZKX??&A;T>"?;QAZ.2=W#;A3J
MHS*X:*JJ?"E#^T T2,(U5L?@UK$L3OWI;2HW>VD5$Q>K/-<4L-YRM.X4=(],
MT2=K IVY!SW%1CHY($7PV.0&S,P/"@A]!4BZ$P)K*_9?CQ0HSMZIO0CX%-*@
MWEP9%O@OCRU)_+?2 *5'1*\+HN(I\6][QH(J]IT^^6;DP=$PUHD:HE(=PPN!
M%+"&][!8POLHV?;P*M;&YHJH:>B+!!01RTV?JJR=B0#G0)LF&(PU^_@B._)%
MU$TEJJF.%.<E2_(MZ1FT [Z@IM-MUW7Z?;M./8Q^(D[N2BS9E("OTAF1L/1?
M[[UBE<2)*.39[FRGLTU+H5JPDQ.1AZ@KR&85_KF*MJI+?6\C7]:P 45C/)J*
M.A%DCVHZ90!\S3L9WUQ6>17>38[WJGBY L/9HY9R,#ADLU(\_#YI9MY P["5
MWD&Z&*'JI9 ],W8"'TPJ'84O(KU1$-[ZT6.D244\74'GW6"<J[IDX+[7]"L%
MC;S;8XH$UK1ZW=/>%>CZ(FIV!^VL#*O[ENELKF=V.+P>HXLB:\WSO[[.^*I^
MR1<QPARK/:^V]?5PVC"7YW5GL:KE ]/5><DRTEG:XZ\)R(P)YZD0!?W:_IOU
M01@G!9XN!5Z5$!B$(9;9Y05X]>8I%>E<6751+_(YK#5=KX(SJ:R5A8N!!)D3
ME%[-@RE!NM7J$E9J7HHE/32(1/ZMFIM5]$.C?:F:GE2W Q'KKW^6;M1>4[I4
MC!;HL(=Z95FR5%JMJL4LQQEPTDCDK7'_\'EGX@8\1+D[%_)B/8[2AD6URC W
MO,U-Y<BM>;^OJ@*M#D%;_8Q?82>IXE%3(#I>L@]Q]!FV[KC0P'3/<%OY@C7)
MY]>ICN-QU4%[-=TX5QU43ZIRU4'.7KO?7GM5\9&\R;9<^5%[R^WQ,9)"Z#/%
M$2F"K^AW717/DRT_T67=;3/QS.R3_T#;MQ^R<J/X="7 ;-E)CXGC6L.&K!$G
M=YA[EJEF'JNDM)QB%)*=A=<%:@Q(:F:,$!@"M?6HM#@AS2).S23@.!OFQNKR
M+%W<-JT.:B *_/ES9$>JDW6/48/FJC/K\,](!;]IZJ$>$*=CZ*6Y)\J'I=$Y
MUK@6FH>"PR!C+?#D#)MUB$%KQ[&T"P'\QS^\")*![Q)$=X\\Y [VG.-E.'#1
MTS.MS&B[-N,5(Z' G!6)Q(<M=*43V:F%^$D!R$/E],J5C54-*E;G28D><ZP0
M1!SBWJV?F.?=S81"^EXE@FH"F*G&8]6Q6$Y\6,11IBV+6*KOW4$G2<] 4J@$
M7MZ[GU*/O@%$7EWM?=N ,YJ\=;3%6<#'**^C>"GGE1;R'-&3 ZX. .>9 #BE
MIE+##WF*"B3'8IVXS)F/$( 1Y>R*L!Y08EX$/%P/(T;0'(5[CT(/=HQLN]^6
M-[X(X5$,S<Q\2M/:NU5[J>\=SLOS<5Y*%+):80TZ!H<OAJD-YJ)J4/3 ,9$4
MU$-.-_\,H[M >#>"SE8*'PS&^H4N4W(.0,?P&WBOV6:>RBV(K@T)L[*Y&I9]
M!&FMB7-LX,^;T")(RS[V$QHP[+%3Y2;5W'"U.DHM<*KVT\)+EDH.(_8;_P^/
MO2A+\KU8HW&E :NLU5L_"DPPTE)VP_#6CZ,0EX$X'_PND8.0>6K&Z@(CX( "
M-$_\\!;;7V_43- 8&<8WZ7U9N("O *I:* /S: 8V%/RWUQWFUZP^M<-P+-)]
M(Y$V)IOHEK4-V3Z>"4MH*#@4E'XZ5C_%?W\V'%MYKP+@#T^0%>&H^<TCTR+.
MRZ[@DC_L,;,5QG S'7!,DLIP3Z_3K;>8*N8&BUW"6D;0$/G*M*.++STGOO2J
M DQEGS7'6#M?-&(FGY6',;K'YHJQ*$$TK& [N,Z[Y_"#]YJXX0B#\)@\P+"
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MKKM4H6&>#SPZQ.^+J_61#^8BI<-0VQ,+<+(5#K*RIYI _ 7CH-Z4WM&D[@R
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MHS:<:LL[KQXI*!_+YB_'.BVFJW0U+= "OU+8NQ+(^I= 'M9TXUP)9#VIRI5
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M"WM+F;%Z8QFT 5-ML97(T'T5C1_[UMIFX>IQ(V**'10I_+T@.)X(X<1/9S(
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M-<&;IJD\"O^T(S'II@X:,_*:49O@\K]T+&D[R;[(QB4KO9+L=T06D7*;E?D
MERGR'IF2@02(GWL3XG1<OEBO]NPB/2*A:L?(?VOZ[>@99Q'C2\[XM*5*4>4W
M;7(++$3R+'; #O8,-X B0.,SK.);J8/**,3PB!$80T ;B$@98\DW-J,OWAJY
M#L$S**2%'UV8&DZH:A> ;)_24VV5%V5%F,1:@\#&<\!L(;JB C .JZ<2G^>'
MR:L[%?%$WLY#KIDL B?N&)=;6P( PDU:WTR]V4\MV7T8A.+9B2[<!*$X3:F:
M(!13;_8]QXLL'U8TXPJLP'W005;>GRK':J58]6I5>]"3';]Z0$0=A'JIR3"G
M4UW8O%>J3ZHSS,=\O4'"=J?W?\OKLF](VD2?=RE#@VU!CQ=]O5JAZL>BM5C=
M$D][-[0Y5S/ >X9U)XN!2<@(/.Q>IL'Q.Y?BC%AO#[%.SJ0>;$<?01/)OTL=
MNOJ,!8:[FG9+@I)IJ6%!>6O@@JW^\A;!_0/=9/BW"2K\;\  L;=)Y)D?"^F<
M2?_$Z70N91:X5JY505!BK!$1LY0;F^WU=J183IV]X)T\Y-'][M//HKQ8H32K
M4)-U_Q@8U]+T8%;ZP( H$UN\Y @OTI]/Z\,HC?I'*\#I3OGS$UR,XYYG<I%X
MLAAJB(+HKQQ+^&JF1T8^TI*(7C957DA?^K7O2DR0MKV5^OH7J@6+A5+^46^F
M$' 08+(76"[!FZ"MD*]U-55SGZCAIAHXF[D>MZ#A86-Y>+O-$E'O1 7L./3S
M$JL/*3-.0?+.$"R1Z(]5C/O)GN?+LS/'YTK%G)SG.^3:>3(Y7JE+IYQ_431K
M7&FIS[T'J>M<*=T*<:$N+ F;=]^T'T H=8L;_^V43X)/VN3;MG',,D(\S UK
MX/]&#$\5$9QUZ+$)$*=LO>-$8DQ269D[0Y"I&Q@>=O/@,]-:YZ:QLI3Q>6.R
M8#E:S%> XY7JRJ*"^X'^'1[M..HS2=<G2!>(E^.K8 B/#6A;Q@E'@[XTV*<-
M[SO[IZ9E 4CO8VK/Y"*<MNR8+8,]ZWJ3(\=\3DCASMSC?VZ02*<IP5 T2!'3
ME@4F(TCQP2\VMY@MD*+:V067F[NV4$//J0O[=T5,P;]R%9#2&(W[-SO\(<(9
MY2O^)J .56HH]N%A+]^YU%9T#&W6$E29'B9(OQ;$JRN:[DPQ$ $4ZM0\;'D$
MCW;S@=L/))"(/H33I+3V 2M>MP1VV)-P'B&<=ZBN$B:4NP@828_VE.T>Z&PJ
MD$I%XF _Y)I72?Q87SY\8]WG+49-I&S\!IPM^,F8;C[MY.?OI-K(#JD$**)9
M4'D3M5NB,RN&,W+2=$BI,"GCHY:\]&N^T'Z+.SS=@*$!>[/";;?!<S.M^3%K
MCA:0M857Q&AA3600[[9\B/;#5Q:E/)\,_ITO6!6Y!V?J';9DHT*^#.2BD[9E
MJ[+E]%7>#<1EDW-%Q:Z"H%'/5$<BEFX-*BH32Q'B?I>:C1%_[IC?)R_,*"FQ
MDN:1N@8+R99G2+9L:[>B9J^4Y$L/-QXJD6HP<H,H=)A&C\K5L"/0#4738LHP
M7^E%6ETM==)0P"_?-I74:])7PC<<ID7^O;+%AV$0OCK1A9LP"*<I51,&85+6
M#REKT-:)"&3$=3>* A_#1IM97)^UNQYBIG7!7O?9-:DYE+&"'XR?U_Z1>+_)
M'LX2Z?,IJO@=1+IU._0])H"&;DRGK":("ENX;ZTC'XU:$,QYA=$"RX]+@V;0
ML_\6O\$:JD[/3R&>X[WHC_,OE@:>6 @7\(HL0::L"P@V":BII25-CH6,KU1?
MA[Q4J1!^Z>OR-(>DJN=69;YQ<E2%!K.9;BIMNS7CJVS!9>>OS9R-0!J5):3;
MF5Z03M[!LM@:5>*?WM(4,=X# R=9Y8:^;]G8X_7B)(@EQ?-G]B7] I.[Q(YP
MP08K+SB1.H-A.F *>VFZHBT7#-#IAD7'N9&.EMBRU3+9HX;UPS!-*_60\-9S
M2".^P>TFE?E"%N*E6HCS2"G.J1XX2[H@:L,R+GP6LM 5!9<R?0Z4\ =5(61<
MV//FVQYR-T]0.1SPY&[K1 A,Y(/6LZ!>Y^C(P9**VX.,&Q3PK/GJ%@[!T@0
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M 7QWMG(P:DIU%J8+ZS>"["U<T7A_#^ _^-2(0U:NO"+6]&]9 !?S_"81FO8
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M>9'P *1Q]LXP\2\[8$OP$L'"!-]:(3:<HRSV"7=Y-; X[!IA<F1T;ZVQL)D
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ML/\8A&&P)5X[#D?8UK+X7R1/7U3<JCBD;; 163>[@\A8^MNH05PTV_'F2@K
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MC6#7L,*X%>!T&=? _!]X3DA0=GA?7!PX1B4P::7J(<*GL9U"]L>$[,^W5U*
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ML&J/!K)D1UJ,L8:ZQ2A%;8V%"Q21<]UN1/7 [\YDU]G;<*BWKFC+!64 =XK
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M(2V1Y)X? @YD@H+RALOOXC9,--$1C(_3)O"9:HMM=H):0;!]-4> T,^CU:<
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M88,?694K[%KQ#'.T-F5K]=G(C.&&?SD69HIA1^K(*NF9;?1,<<O$UXDHH/V
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MD--&/1UOL4FME%KT#:SK-9ISSFJ%!1EJSEX?8'K8C"C+A <58:?[SE51$14
M["[5B(;+3%E0HL9UK:"X"KT'TY7\;XJ'J/%14%2E<3]N3-T9WU,^#G3<X,GV
M1$*6GHI!SN &H#%SP<8-7 DU&;C*^)+=,-+"OF<AU*V$(FLO+/QQ8.97KZ0Y
M#3+KO-QOR,KV=9231DK8LA]ZXJ^J&]??@3I<=KKT?V&VC<BB#M"AAV,M.6PJ
M;'JU3 TLS]H%CT8A+B>=XC&)3V,;,C&@*ZJ#DH^2['"Q,=KOG2K#D=?*GNV*
MJZ4=B'2]'FY:9:N3PR]DXTG@!0\_=A2++?M@2HAV)PI\.B=IKRCSS3]$@RR%
M;IH%S,'8J-ZM:V95P^C/V/5)Y/59/GO="UHQ[6,SGB5X#)VAMCPKRAUP]:$Z
M00FB#0YXA6(+VM"))WHB_@SDU%8.9Y$8X6(KQ5Y42#=[D<,C*[S0\]E[ZI-*
M[D(^Z^&&;*CVLH"G8?1.0H+?8[=NV.7?#/PRHYV(Z"URK[N79I5+WQL7T>,Z
M<PP'HG#W#79LM0-^>(FG^-U1\;MS[EMBV_-,"=&C$Z*Z*Y%<H62HQ&3B"V+K
M(PP[AW@HS%[VEG ?8;U(JT[O"5H[/=C5"9ND#!5'Y!8/VX)1RT!BG=RI@O<U
MS8(SX'M1AX6JTC/JH1Z5V;[!+AO#$2 P/8:UD:[3TI;,JF5P4QH,[7%#%KK[
M7.]/N6:I/)H5^ZIW$1R*L-H@GK*JVK!EJ&:S[VU^2,*)TI S")*R.&1< V]I
MG<A;VQ>P'472*+F-E<:K+4=4B2^T#?K6<+<<[O"(B29NJ*7,U'W ;UPN.QT;
MX?-MN_!752GA0.]RK(:6=./>UES8+K- 4Y094TO&PH-<B@%JTVNS15Y6Y-U2
MQ[L>&T)PRM_EO] +-8>UUYHJ"S^GLO 5EA:^>/GV_?6K7V;O7_YR_<O[V8O7
MO](_WDVZX9_5V2I$J*9YCO$;#A]A#QY=$<Y^Y@81E-&IM\E6+0<!,:<]3)MX
M5V=<+_IV(OOY$XOF>VZ.Y^ EJ"^OZQH97+XO/Q++<LVF:$2GYLQ3BZ?!&V;H
MV9BR'3AGKC=3S,'C:$E\2R5O2SG3 DQ&JV!^??4*7TD5<?8.&S&\Q>-1@1W'
M= +_'@]/>_'JC9-D'77IG2_8][^Z$Z_+F6HHIZ)]6T/I NNG+[7@_S44)B"(
M!-J<VS%Y,OU"3XK<OZ";:EG_-K KCL',(F(3/J#CJ3Q'FK%R2'J"59Q: OPP
M6,73$UVX"59QFE(UP2HF6,4^6(5O3HOQ7"'"S"FBZZJ@B0]RO:E*'\S>302/
M_O_7DJO.9JLJ7Z\I!K^JAG+)7<-OX9U%7G64Z*N'LL/G.EI.'! ^==R>S#)O
M-I2I+"6X7S<E-X!JECCFFD/1@;+3/7B%WY63NO?-4#F4 EP<EMI:OE;!O4+4
M^RL>OATB[-U]?\N,)]4R4-;2C&II[II^K*E=P*F7%KVV5 )\LDV#7U5 @M@R
MX+GAI_$E]@F2G>ZH[5'=8;N7NO>;A!T\"'10N'2%IVO%]; ]M7 .JJG6PMD3
M*TN6VO6/BBKO' _!/\!Q+KD;+,;:U9NRT.Q!HJ+,M^C"L:XY.X!!])6!46,V
M/F?X:HV)A** T]&GK*.8Y2;O-. ;AI9J$^&Y15W/'(1)8S\*3#C8=CPDY3B-
MSJ)@Y6[C;9')]".*6)R;&%SSS',&8RK=W)##[EN/4?.RTK9'*.L[6,2EW&F.
M@96/%TQQ6'=.1A2C:SUZ/>X OGC\"O;[9[5!?"T.BXZZ9ZQ5H0,;N; /CE%3
MM*N5BREP0D["((A;Z) ,@5L7,^-KU*W8[MJ<<QR*=*@OBZ'*6W<.?!T.?( >
MCLRQA&N*!_7!F$TH$]2-;6.5F$8/=?G*X%@W<IEU4?[-M2E9;#4F)[V+K]Q^
MZ+],SNI$^"/.ZJ]@K+1PA$_?3QUQ64FZN#+$?N):C@E:+G-'M]FX:P3!/'<R
MX_,H0XVQ/N>Q7[XDE3A:Y)J+#9T$  $W=WR39=Y6(!;\O%UVZ>VUFSM"3N G
MK]=@U!=@3EQW75.4_"5\S$_>IGB1MVSFD3P-5/"!)ANJ$1K$ K/^<$7"-=4B
M'7=>(&=X=^DZ-%"JW6;];%-0N:AULZ9=G3P[)/@F7C:T!-CB6M'"W.=@..'$
M$%_1>=LS6(%= J, ?;X+H(<%9*"[\B5,LUR3U0NS*XN><+6C31IOT&6R%-5A
M%U/U1+ GUJ3QG01X\(20\/OW,$HFA7TY:%$0N)B3@D4DXAKDFRT/QA_.#*$/
M;=$RT16XIR)NE6:);]AO>FDL96KE]51X-.POH!S=<+>L26$?USCNSZ.PWR.^
M!-D;G7!?\YD]=:*^7QI_N_ _^$)#1=T((0C>DI0&K!C);Z'G_#UVWZBU2>)"
M$>TBCZ9&<S=&3/[8(W-61&]7,U11SFOQV5"= PV8"3"OAB4&%0)Y*_#'VM*&
M 7C4Y!K1H$83]<!VB2BY%[L14E,HUWOOZNJOCQ_/\LLU]<_SP_?VS8%+G)JL
M-,.&:ZR%-_?W&#[##W"E SS\*WSYAEZ.5_#7?BS7&N+(6#&9/54DIU<9:8.;
MFDA1N?ADF]X8BGT$/E)!$0];L&D;WK1XG=/+ZR9X/X: 4'M0SEFZALLW8".K
M?&$JBT%W)2'P[QH_P!Z> RS:Z*-#A<JC*$S![^3EJ$4L!0**6N5(Z8=561#(
MM*< 1!:LD>!/,P[LD!CZ+'_5+!:C'C?XR0-. ')"5.8.K:,N#OVL6KH0_ <F
M/76,GEK^F?34KWE!Y-^NO.VTM=.G]-EV#;:LSA&2\C+J3ILOX$D<O;K+Y=)@
MZO)6-[!2A^J NA,*1IF6\B$2,-6]M6(?ZY/*5"B*AT\O\4I:T85'Q!4T.-VN
MD99Z.[NX^N;QG#HI20O<O6X +:1TK34S14,3!#AC;V#"_!R%^3E?+IIWL,1D
MPH'6?D5=SWX5/?YZZ)$]*3;K3B/#=DJ9U</R]5^>Z,)-^?K3E*HI7S^IG0=<
M?=+US8*YXFWR6CPJRB5S^XF13X*;*35%V+>1O3+]!9M2UIU &46&]5J*%I !
M 6NJO\<\.'ZQ>TXOL#&XG;U.57*><W]EW8O'M*GR0E+.U)02]@-L'_"8R0G,
M9@O8Z65'E7]+*B6_Q]:J^ \24#+(5E5^LVF(/4MBV%6)O K63>5TKN@XK> N
M1S;JOD!RU"8'B^SAU])G-;?T$*GP*'- \*8)&P"3N&*$7"Q,C,6D'<N,3^"N
MA[JLO0WE(ZCAT:KD"76B].4MUK.D-U%<17Z/T@GG_YM_L7$#;G6/N! YB7#
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M?=A;Z65X:PA"3Q_$750 V)G'-2;E!CU!YDV.&AB'U$H9W^DB. +<)B.O\=%
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M.U4T_I KHQM]!A33OB^2^M2)\<@4L R&*27NR0]U[=[",\/ZX+DMZ4%Y<R3
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M]EZ</_Z.(M91C>MP@<1@5;E.6M?(3,$C!(N[C-B@1WFO\P@,54/_7ZU%[M-
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MT;38,@X@I_=(@O"@*[FIP/(8O] ,)_*SYD:-$I\8KH&.6QHD81HV)(NH'7;
M8MT(-!'G=G8QQK=F?[FJFHT15#;D ?MARS+TEU)[,K<>8XE.FC#@<]]VZQZ4
M&V_;.'[BPTV:=_VL)WK[T.+: W-T.'Z7HL0^'C\=@#OQ8V^CNP6[ HEW])_R
MH(TY8;_!?<?&\) F_PC-.(NB!T].444 (O"-O+JZ@%O^PC[CS+[1_UXR05L$
MHL!V=D/=[%)[QU;Q NA3[NPOH.7,-9=0GTI=XQOMVX4X6IG?HS3E?_SII[W#
MJJ.W/8A.N&Z!?%'\]_V#1D=Z1'M?:7O#!:9\ ?AO3^=N_W!AX\(?3/W/4N':
M_-5?>VB*-8:U=3':<:/]+K60Z#@_^BWT/7"8K%MH,!S">] C)2H;2:@$&IOP
MA@-537O.5QL^#PE80 V2!$J84C+%91G.GSQZDDLI$/C@L#F3KX1,)TLL69%$
M#E"Q8-<F4@+OQT[R[X J/R@GB[^'I&0'.=,_KE=VW"!\^C57A'=,+O][VO[I
MXN/'R[^\^^'-NY^RBW>OLX\___GMFY]^NGSWE[%F^/":X9/SQR=KTSX8 '5R
M'S*@=G"YFG9<#P]>#V\H&0TY,<>;XVVA:[\7[6T.*=*$;4C,T"MX+V4_*D0[
M0?V%_U5TH%69 TP758WR;(4.3IY=;U;P&#,NA/A'ZGFF58).L& Q=,L)]TAQ
MQVE[=&L;C/2"-^^Q3RY%'48OP"=*=H4I%,@VL8H.45_DHE'721JJ*F\,L;7=
M70/,1(CD _ =(S/.O&H9#@:AB7<-"#Z9#(-CC2?E)H)@M\9^P@ TT8AHEH:0
M'X$HZ#&GF>,]?9S;1OP.I(?=.$.$JUYM'\?&0"E,D-B LQFG2"?P5#Y.G8'"
MF)X6AZG(3<JA5'3;E)H_U:XVH-AHVAGA+(E3XJ7*7D*)$1^7NF Z3H^ BE5Q
M"SL/?3'6KXGEF08M-5.H3?5E7S'ZT9@;P@0MREG<+N$R&Y JZ)F %26JDCUO
M'OU-.@PC7NB@L__)R9[]L9E_UX#\S[@:'KP:[ #"CL.N&2\+IYLM7"!F?49'
M-:6;UZ5-SW3$I]3P:1:=NPB(QJ-W>#BF>UHC</H5E.A4<4K/O![<44#B^%%>
MSXYTX$:4UW&NJA'E-0I([$K1G@I\YKWPJ+E8X=W6<^QXAM=A: 9T<"[XA)-<
MQ; 88X B+AW3TJ2)T< FX63P7YACSEW(Q^M23Y7N+6@R@Q_5Q=*P2"1*>6RY
MF)'0OV> !O27L1<S8]GCXOXG"*JHRC%Z1K"^G()Y;8J*3@4QX1-Y+Q;RWVI$
M^\C)K:W/=$=,G]"H4=I/H='"/OBJX#HOCK?X< P># 1R?5%6:\91__F-X?2Z
M;I'5>03((<!D!F^\58\T9EH 7,Q@7 (ARNOB5GQ/1\<@>M10;L9G"! UT)6^
MKD&F$OYAS59;FPWEH21]DH%N*?2>8,=,<#_LF9GDB,=$W7E:,_#Z+%OJ%R>2
MF'.N:)]%FE$W#E,7Y-AXMWVAZ=\),4&WD^>%KBU)K%.P>1>8=X .17JE$[%U
M=NK,O\1&X(H;M&(&+*\/W9/HBRR^Y%,_WV79TNKE OW01L9+T'O)XON?B7 X
M0&[D.(0\/03)1T=#\'S,#!V4&7IZLIFA86[T)[5S/L ]QZ7QX*6QFSU)M]4V
M*RY2X#EE/IEVAHIKVZB 2 >WM=:O7/4IAJ)M+O/I8.8OJ)L74M_O;<S8'#DB
M0R/F&T>;8G0Z#X)@[]G&![SKA4:@1NR02\B0^\@YE?,'9ZA5?L\^1YJ@^@L2
MJ>#B Q5>"@E%7-.%M&K0=S7OMZ., <J@KOP$"_:%+%A Q5>HB>,4@:_MK+6&
M8.#]G7V0#4@"ARM\:)_BY_$\Y[%'[81TM#. CUU$A'K;[L)>AY(/T$K!S&=5
M I,8/JSCF@QN=L9*],RBM.4*4Z#S,NE+0,Q&JD\17>G.E1(&EU*[DNJO9]K'
M8:(JJ V+*J/8Q90[$F65T=6"F KYV<@)(6:-_<@.YVM#B2/7-^9?,'Y]QCH5
M4*B32MB\L0$?B3>D]@@\O/E4 )M7GK%LM/HBCAO>'A_F_^S*S;Y-#;+_^+MH
M *SI)2UT$L?F$5^D=S;M+W^Q/V1J95+LI+2R,%QE6V#W<5'6N%S@F8-5&\@"
M#8EQ$V3U<J[@(P<N,A4RH= -RQ#\0^QZ8+6 HD2-!"PE8&M+BYP(=O'P;AS
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MK78M4-;#/0.Z$-!-=D1S+EI<@/T^>QY'BSL7;;CXXR4\M_[5;>05%I'@+7%
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MLN-5)F\+@:S;GS/@P:5N?TF&33?<6%G(<V$-.3VZ458<OXKU0;R7XQX&[F1
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ME:&@&Z"0$;&*T&AO.2.W4!_$L%O.B*$ /G7NI!"JI8C[0_\'$[)E!SQ#!+M
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M)H]%3GDV.FV64"=L,1D@N1R5X'#1<T&=4$4/F@'B'0-/F'B=ZFE$Q)83$4D
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MEBKAB 80IO+&(95F@/,P=]5)W5) X,2S)8\8!;_*7;#R;B\;SVR=6' N9 "
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M2P-P^);5@Z1,NU6?>D-6!%6E#(LH#0^!#-H,^Y; FJ;T/FV :26?(G>OVTP
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M-PPBHRJ1>(<DX@*[-8 NMM\'$'!T^ERGCG'@H(N_&% ZQ=Z1& R3N&W5V,>
MX"O(S83.*IL:T'9\)TT^;TPKKOI693?J.#HZ/9L<K_0<7#&YA0>M64-"$<D5
M*.^^[4O36FQJ?8XD&S7O?+]%:1U$_<-'[*<L<V<D]D $-B:QZJ*\@[KZ^TZ(
ME-=2*#YZJO@1BW><I15DH00M]*JEX F'SE/%.AC2E5J%OWSY[.G9<_/?BS3_
M 9K/J1)G1@O>JT<_X.W'6J2T4_MJ 50>/]RF\_KJU8NG<$;P]=B;=%VI5Y4"
M''"M* 6IWVYRE<"P1R0 K^1JODA?-3=)4WSV$SVVQR_^ 4?!]_6\YZ*G+T\>
M/3OS+M(_E.WWRO%$Z]=]XP[IN=4?2"G65Y1HA5_\L(;*A7PI$_GH^5,]=S<
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M0]@Y>C2EOJ+(/X>:.L2NR*INUWLKC$K=)&F6^-TT$S]XHP6)6I<CUT-T>U5
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M_\O+0AI<IL/$0)NPU4T#4^C53O'J3(W^<PP4!;:,.N9,.MN7P6V\']2FO1'
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M2X6>&(&63?B*0U<6>NF.3L_!P@4ETY?I!Q(]-+M0AE7'#NU(KVU&G+C9AE)
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M-Z*-ID5'E#79=J<Q!@W_KKP/\^KM7GH=(9W\,?51^QN+/DRWWM-\EBG9 %G
M0N4,#, LDAG#55*N,MM5+-\8^QH9%:H8"::PS9#2RP8H*4*5TRB31C*B_,NJ
M87XT",]#(AVS['&T2.%(DD;E*3<\I!,#80F;UN0:0Y=(C$OJ8]?4S)I-<U^Y
M0>]@>Z*PQC''<!4M(6B@7)XTN8 IIH3%NOT26[CVP,#E:#/W<3 \?G2P' P_
M%:46FU^3WU53JE$*[BT%'VRX)V0C]FQ"IFL'%3+3=WI\<9S&6"<;26NOM$FM
M36-ULCR)W=]_$G7APHBH')>\L@GD[%4.*7>*1*4%P1O!-$\KIH@& KUJ5J93
M<;UG3O$7=&//84R,H +@T09O!#9*M*3H5R':.-*#;JY'>B-Y)?U8C3Q73J]/
M\#X;RU%C(%_^)U!9(R;D*^%P@SZCUPBQ2HN:#@/4_S\7\]@']V7)M"A=IELH
MF4M*>XO^;5EHO:[/!:\O@#Z\?"QNS!\*:!O[BQ8^KF+X! 0Z'*B<@X]S)M-C
MF3@(@HF@/AGFEG7))=YVZ(X6"+RF@E=3!@YI;%J9=J,'[[O'X_1AQ^GIP1ZG
M78C1IXNWEUY4;)2->\N&8_A:XE<X\;@Y#U80KP"2$F* <7@+>(]#= <*DI/*
MZ-82 Y=X &DW'OO<ZL.FWL2B+:@6,)7 /K8 1"9DP]-FG@5 ,HIQ&]+;.OF"
MHP*^W)4RS]3'A-R4KES@?"VD:\P^2_<Y@]'C</HI0 MFK!Y>B'U?14]/SXZF
MDZ/'D[%,<6AI[/W $:<#G;@1'#%,J?I[@R/&<.:.[05K\.+ILZ/Y1&)/;T%4
M<TSK:0.X@4Y8<W0@3U^^>(9(T$0+ 3AF7DG?D-T0^((#\3Y,'.^WD\\GT1L%
M_H5X]I>02FC*C5X96Y#G%'&2!TT!A8-9&^=;#F2)R$%L@1N,+>FPZ(@J*S&L
M@OD: '.0<0HQ:S1.C6W:B01!!04HS#L8IJX-V3)+'9-TIRG*/1!VFIY[6YOP
M0%_-H%818=\MT":=P/PZ1\F$*#FE<M:OEX70%.@Q TXG'D507 9U(O_ @\59
M/RBFLLT?];UF_@,.1;M'TEW6",^_Z<2IY#U"6CL&ZB,^GKI^VC[F#B44Z J&
MC[FE+@XU'3R8JFRB&1_V9@';TL8-'SOO=GCKYBDV#L45H(DS)3I(-0U=@&R?
M#+_I"R>\F 4*"\H5-J$SL4']_5SC:801O64 P*7S%-;"24-- MT@:Y^T.E1+
MZO:>J:6HBD.;[4XS:ZA7P =#X05FQXYLEUJ[)B1CAJBKLRAF#NP+*%(Z ; #
M"2;G>I&ZBOG3]"./SB>=V#$EC.%%%H>AIQ**Y5=-Y7)K6E161[-H\3_Z<>(\
M(7&?D:LEE9EP/Q_>X+@-N/ 5"KSAVZ1OD,MRY37^@C=[>:KV6/0Z_B05RS=%
M.I=P];QHIEH"P6A,)8VE?ZF(2BJ\(UIS3YQJ',.&K'J&)BELN60*Y0M':*CB
MC2#3'#?HR$VW!*SP2L!, 9@LIHR-^K0545; *\C(U<-!\]<.J,)U1F7P([<*
M11ZL5,V)'*'34-@(,S;19?-[RW+C-N5J;I%NLT9Z?(Q!%964DJ%^Q8+M)0AI
M +A;32H4CQ=N M<->3G00 <Q"W9[R51E4 ;DI\>YTIN"JTEE"IN1(?-&;41(
MNF^S[:?]1]N&S\-P%?Y<__F0/_K1H7_TX$-,9P.=N#'$-$RI&D-,8Z9FZP:[
M^/?%Z]\N+]Y@\$A;'DG&2/^R$6I%@!)C6QAL<M. +,.A7X$G1V@LM"P+A..6
MTFP-G)(&RF*:^JHH]7CF@N%] TL8;-)]>G)&YM]>N,@SW,I_=A@QI/F&$L!Y
M=_[^S;L/G]X,.WJS5WN!<;%W3>/YIXOC7\^U8_[SVP_OH_<?3J(7SZ/+B_?G
M[R_CZ-V[U\,6@O@_IN4_D^B-]M5NP<^2H(-UG8BH87,_83G6!^'+TT'4%GTK
M&;K?.ORX>?5=2))0A/9>)+Q0/S#!",Q*K::JW&OA0F5AI[B:X\K=<^6B7W_]
M-HOW.%"G<'RJ9_UTW'C[+-]WY^\N_JU/[$]O807/WT47GR_/+R^BB__\[>WE
MVXO/>A5//I[T+2.89!Q?N>\"/NFJ33WTIW_"XCW>R\$<TN+1WOO/3Y^CUQ\^
MF57Z-2DW&7&1VCH%^!.3B<JJ[;4Z =WXQ]M 9T\.;B6BZ%!!B='WU??1>9:E
MT';DY[*87159\JTAEG<<,TCSV[K2LWZPT_[YOSYR9O#Q#]$GR =>()<PUU"?
M+Q;0B?Z[T4WY&FX*>23#ENG!>J1_WKEXKZ4^?__SA^CREXM/YQ\O?KM\^UJ;
M,&_?#]P1[1A8SM$]5+$X/&OI@$\+.*-_3,II4B;1OY0VK?<[&/X4Z^W@G"!W
M7F$?OKY*U2*Z^*)F#<(>B/-AOUC"W^HHOM]\_Y\O_S=ZBP'[Z09Q2-3X70JE
M]0<D=5.J.,J3%7=L0L)W!FF >EQMVM?9R\9DY6%_])C/_Z/S^8\'.G%C/G^8
M4C7F\__,P_R;+_Q7,UHO_OW+VQ_?7GX>9_:>AA)LG6%,WB'HZO_X?EK,-__\
M'__Q_56]RO[Y_P%02P,$%     @ [CU\5%&^>.E( @  - @   \   !T;F=X
M+65X,C-?,2YH=&W55F%KVS 0_;Y?<71LM! GMK.&XGB!-75+6.N$)&7[*BMG
M6]26A*209K]^Y[C96+N-CFZEPR!SNG>GN_<D6W'IZFKT"N(2V8K>$#OA*APE
MG[VPWPWB7FL2H'>'B#.UVNZ0&JS;5OC^P.&M\X1<H721W_7?#',EG6?%%XP"
MLK4;ULP40GI.Z2A\MYNIA$2O1%&4+@JZP7$;D[-:5-MH*6JTD.(&YJIF<A^>
M*>=4O<^P6Y55HI 1IY71# ]&<9-E7U;&^$UAU%JN/*XJ92)39.S0[^R>H^&#
MN>!HN"F%0\]JQC'2!KV-8;JM;-.6*I6I6?6PP=]5?S :3]-%DBYA>@Z3]"R9
M)320.4\N)HME,D_.8'9]>CD9PX?Q>'J=+B?I!9Q/YE=QK\D[BGOZ"83[3^5[
M<)_N"G/W<LG^A%"BP6P+7$E+%(%3X$H$(;DR6AGFA)) ?H,Y 25O7#O$' MA
MW1U@X9C#NHDGXYQ*@85W H>IZD*_W_?VVGP?'TG%/VH['/CA\<FW'?/'93VC
M0D>@<E@R62A8DE1,X]H);CLPD;S;^-3:D#@DE8,5B;""*V9X">%)!T(_#,E7
MD4:RV"N;"\DD%ZRB7N]$HVQ4/04QK9$9VTHL;*MDX'L?NS\CZ1E9@+]RNH/P
MJ<?;_[^.=\_V8&8$QPTI;4JUMCA62B-)?'DYBS,S.E76*=FA36,MXR4!G+.-
MX\==]#(^KH]B_]=4/IZWMZ^#@3^\UW1I]DMH5J"7&60W'LN)V(A5&[:U%-C\
M^]M_/MT!FMO"5U!+ P04    " #N/7Q4RN/>)Q4(  !R0@  #P   '1N9W@M
M97@S,5\Q+FAT;>V<47/;-A* GW._ I.;7.T92A8MV<Y).L^HMM)JKG$RBG+7
M5Y!<BCB#! N DM5??[L@9<F64DMMTTBVG!D[!!>+Q1+XM+N@W4UL*B__QKH)
M\ A_LJX55L)E_^=:TZ_[W9/R$@5.*HENH**9D\R9L3,)_WIMX<[61!9!9MN-
M>N--)U:9K1GQ*[1]O,YM)^5Z++*:57F[;) B@UH"8IS8-HYS5G:)>2KDK#T2
M*1AV U,V5"G/YKT#9:U**P5N3"[%.&MKTM)Y?=DE'7.; A[>CK4JLJ@6*JET
M6X\#?M3PW+_CSDJ;?]R9)L)"S>0\A':NH3;5/"_MFI:&9DJG7"[/SG>V_);M
MKR_[=XD(A&6E/TGVLGN2[[X'O^R.S>?^C[_[YXW.CLXZQ'%!_Q4+)U RVM9U
M5_WA:/!N<-4;#3[<L _OV,?AX.9J\+'W$^O_W+_Z/!K\IX_-*-$?LH^?AY\^
M]VY&;/2!#3__U&=^D]?\UA$_9B=5PUE4-:"JT8]]]@EU# >C0?\3ZKOZL7?S
M0Y_UKD9TV_]GL^6QWB?6>]^_N>Y?[^CS>YFK5D*\P[ ;>.Q[K@.N.?LO!* ]
M]KY^7?=8"-J*>,9LPFU[CSS[U993)";S,2)A<LEG[5C"W08S_%]AR)7XI!%?
MZ"GJ5C.6:]MQ\ZBAQ:EI!]P ]5T[ZQ0;IB*R2;M9;S:;;Y;=4.G?U34V]Y;(
MG&><T[92\!O^6W'+ZTN_/G]P:YY8:<.N>@IW(TOX!)B&B8 I1+C[A&&]+"NX
M9$/(E;9,9>P=ZF9^H_9OIF(VXME8L5$": $45H3&8X,LK"_6+_JA^OY@\U;+
MC#91^[Q^?GY1+:IOMY^_L)"WW])7J"_0XK"5]WLKG^[S5OX>UT!$NS6=L=M,
M325$8_#*':W+K1PI[),IR\@=7&2,9S-69%87@//AN)301[3'.4OQ2@ND0,Q#
M;-),I9BA6%7*K0AD$((Q7,]().6W@.,NZ338%J$Q.*2D*=(8)! *'18IBF78
M'2V)0#-T3Y@P4]"W1?\I:*B4T 12821FFR(;LZFP"4[0Y! Z TEOCJ:I"*<Y
MP6X1"V;+;O@FH#IM^8V6?W[_M06VWGZ=,.3 K&?!K.:S9!:P6&1(!0+,@@(>
M @O%\;9>NB^RF :W O6(+)1%A#J1-$M;WD-*"2UG#&TWQ#ABGY0+B%7\,(^&
MQD<0"5+LD40A40#)I1 O;CCC[ FY25@LU=3,L:9A+(S5' ?BU%C:C59Z2W0R
M<V-6K#T Z@"HYP.HUCX#:O1@-W]G*OA4Q0H*/U0<"[QT.WS N ;'$F2#""30
MGF> K@FD, F)DUB*H1>%7W2-C@BE,@7V(W=J)4NHY%J%$&&S84?(D @02B4H
M^G=A@BD8L![&.\-"HH2KY9T=P;'KZ@IY=%5>"JIA9B7,2#^CH&B)<25SR):-
M!XH?#!3C0#3/Q^1#"4HNVT_1;!E=M6:]U7K[II/SB(*[$G'54MK3W'#[<L\R
MWL_J%TW_3>= N%TDW%GS[/ST_.*B<=IH^!=^BW!WQ(_WF'?78/#YXOYW^=?3
M</(H-0QY83;O0CE:  B::J0RZU.%1@48&4V$<?$62D'F]%!%>!&I+4=[&B1W
MY*K2O@5]O"H2I)L"HS:TQ2@I(FZ=H8$1D>!:T 1$F9RZ^#,C386AA-&!WKCL
MTD5GR@ :9#$:I$XY+@41%I)34(G3<D8L$D_L4::QR]DW_B\ $L3GA?TA>C+.
M>WGEL0/Z]AE]P?-!W\91TPH!-X^W-@8APG,B(N(;-RKC%%AR@VRDLAE!C^MH
M#B!$HN"!D,+.*!M=-RSAV+'*8:@DZ0/1I;*;BU_OJ@GEA<X1@\9ESV&H=.0,
M< 6X,628%$ND(=Z!G#!+(D5F2^(ACD6.(>2+8=XA['M9[ OWF7W]"9>%BXT(
M#!#'$%HQP2UMUM2T, O>(,HK+]<7N!SDL"-&:*8LHP6JL%\>>Y,XE-]+ ]4(
MXZ?/ 5@PKSXZ;D/I [2G0\H/G#IPZCER*MIG3EV7(%@%"AUD5M4J=^<1K[:(
MR2C95&%8: +&4F;W0%^JC,46>C\0M9@05?Q2H/M1Z=&*<(RTPPCID5QE9HAK
MW)VXTF&L>^VBM.6XM"3AYC[UI=C*T1$B%W2ZV5<!X8Q)<0NR.GY])._] 8=L
MS<+:1=UO-1]5\*I#BKU 9./W(C+1\R%R/H9:@ _GML9C='2;RRF?&>QX.+C8
M VY6!Q=G+^G@PKT&%LWQZBUB(PK5EG&W"),(6UNDR2LU.C2*%Y&P2IO[G-0U
MH+(T%=8"K T^ X7Y+MV)!-KDNA\A#C'6,Q1+XD^J$,ZY#;\4 DUVI"ZRT!W;
M'C]Y)G%X5^T0Z.T/L)[?.41/2D9E,8&,HL-$.I8,!2!4JM3R_CQ@BI^RE"N6
M92F7+;J"FGMG;?ZBQE:HJDKWY5'NFOB*1]C1P'UXM09K50$.A9%02B-/7:IJ
M,$\U18JK'!WAIE&%KVM?9GE1:>B!2B^#2GM]1-##+#/6&*-XR AP 152QKV/
M6N'(*],VD4V4G #E;AGF N5KM;J*P2#-I9H!WITFJ@R\^ /8(9S^8!I;_^K8
MV+W7Q;;]+:UECK1PL3;WX"6ZW=D*UU0M;C/VGFO\K#Q]Z['3QNGIJU>OV-S?
M?Y'=SF,1?<JZ#\VV.T5S&-ER1B?F9-UOIFVR?/QF_?R;)PB[O5Y>T=?!O5_5
MO5>)@)CU[R LZ 2%?2@S_(.+_SP7'WTL3[+QPW;%S\=?<O3.?ZQ\XY)H]Z3\
MBQ'=$_>W)OX/4$L#!!0    ( .X]?%1Z4*+Y&0@  .5!   /    =&YG>"UE
M>#,Q7S(N:'1M[9SA<]JX$L _]_T5FK[IO60&" :2] $O,UQ"WC'O+NE0.G-?
M95O&NLB23Y(AW%]_NY())- +7%];2$AGFEA>K59KZ<?NRDDWM9FX^ ?IIHS&
M\)UT+;>"7?1_K3:#6J-[XB]!X*24Z(8JGCG)G!@[$^P_;RV[MU4N8R9MNUZK
MO^LD2MJJX7^P=@#7N>UD5(^YK%J5MWV#X))54\;'J6T'M>#4=TEHQL6L/>(9
M,^2&3<E0953.>X?*6I65"MR85/"Q;&O4TGE[T44=<YM"&MV-M2ID7(V44+JM
MQR$]JE?<O^/.2EMPW)FFW+*JR6G$VKEFU:FFN;=KZ@V52F=4+,\N<+;\E>UO
M+_KW*0^Y)=Z?*'O1/<EWRH.")2L._+PW-I_Z#_\,SNJ='9UT!.,R_2W63:A$
MO*WK+OO#T>!Z<-D;#6YOR.TU^3 <W%P./O1^)M>#FQ[\"#_=7H-$?T@^?!I^
M_-2[&9'1+1E^^KE/@B:M!JTC>DQ.RH;3N&P 5:.?^N1C__+3<# :]#^2_J^7
M/_5N_MLGO<L1W@[^W6Q52.\CZ?W2O[GJ7^WH\UN[[5_\JEVW57>'=8,*N:*2
M,R$H^9%%=]!:(1'3EB<S8E-JVWODUJ^VEF(^F8\1<Y,+.FLG@MUO,,/?"H.N
MA,<,[ )/8;>JL53;CIM'%2S.3#NDAF'?M;/.H&'*8YNVF[5FL_ENV0VE_EU=
M8'-O<>D\XYRVE8*_\-^*6]Y>!+7Y@UOSQ+P-N^HIV(HDI1-&-)MP-F4Q[#YN
M2$_*@@HR9+G2EBA)KD$W">K5_Q&5D!&58T5&*0,+6&%Y9"ID(*/:8OV"'\K_
M'VW><IGA)FJ?U<[.SLM%]?WV\V<6\O9;^A+TA9H?MO)^;^7&/F_E'V$-Q+A;
MLQFYDVHJ6#QF%;^CM=_*L8(^4EF"[J!<$BIGI)!6%PSF0V$I@8]PCU.2P97F
M0(&$1M"DB<H@.['*RZT(2!8Q8ZB>H4A&[QB,NZ330%L,QL"0 J>(8Z! Q'54
M9" FH3M8$C--P#U12DR!_RWZ3YEFI1*<0,:-@$R3RS&9<IO"!$W.(F<@ZLW!
M-!7#-"?0+2;A;-D-WP54C590;P5G#U];8.O]UPE##LQZ$<QJODAF,9)P"51
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MIDM1$3FF8:9#W<I8[/\2BRU4AF?<,2CI60G*B]:D[==5-9S@:8T\ /A 9)A
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MY^[K2L"_!Y,>,O"3@IU[V.]V0J37 I;6T<:";%8 _K5:"8U_MZJSTWEK+6]
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M@7%P&^B_U4*4M47T 9QX0Z:#2T*!_<#Y-XWNX^N28T0,@E685[!*PWL'>,1
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MBYT^FJE\_?POIX^6MBR>_S]02P$"% ,4    " #N/7Q4T!\'9>G-  #E!0$
M$@              @ $     :6UG,34X,C$U-3$X7S N:G!G4$L! A0#%
M  @ [CU\5.CSS[[(>P  &Z4  !(              ( !&<X  &EM9S$U.#(Q
M-34Q.%\Q+FIP9U!+ 0(4 Q0    ( .X]?%1BM"-F?J,  .["   3
M      "  1%* 0!I;6<Q-3@R,34U,3A?,3 N:G!G4$L! A0#%     @ [CU\
M5/LBC/1.F   ^ZX  !,              ( !P.T! &EM9S$U.#(Q-34Q.%\Q
M,2YJ<&=02P$"% ,4    " #N/7Q4!R#2S LT  "I.0  $P
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M-3@R,34U,3A?,38N:G!G4$L! A0#%     @ [CU\5!<5<P<CXP  UC4! !,
M             ( !.N8$ &EM9S$U.#(Q-34Q.%\Q-RYJ<&=02P$"% ,4
M" #N/7Q45\WJ;*E]  "6D   $P              @ &.R04 :6UG,34X,C$U
M-3$X7S$X+FIP9U!+ 0(4 Q0    ( .X]?%3+$MDP7 \! )Q$ 0 3
M      "  6A'!@!I;6<Q-3@R,34U,3A?,3DN:G!G4$L! A0#%     @ [CU\
M5%J6*,;[* $ 598! !(              ( !]58' &EM9S$U.#(Q-34Q.%\R
M+FIP9U!+ 0(4 Q0    ( .X]?%3@YFQJTUT  -UE   3              "
M 2" " !I;6<Q-3@R,34U,3A?,C N:G!G4$L! A0#%     @ [CU\5!>Y3;$-
M8   A(T  !(              ( !)-X( &EM9S$U.#(Q-34Q.%\S+FIP9U!+
M 0(4 Q0    ( .X]?%3<!L6N5!L! )!R 0 2              "  6$^"0!I
M;6<Q-3@R,34U,3A?-"YJ<&=02P$"% ,4    " #N/7Q4[KN4S=@\ 0#3@P$
M$@              @ 'E60H :6UG,34X,C$U-3$X7S4N:G!G4$L! A0#%
M  @ [CU\5&/W;#>0[@  \% ! !(              ( ![98+ &EM9S$U.#(Q
M-34Q.%\V+FIP9U!+ 0(4 Q0    ( .X]?%19%4?]1G0  *"/   2
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M+3(P,C$Q,C,Q+GAS9%!+ 0(4 Q0    ( .X]?%1Y82Q5I1   #+G   5
M          "  <[Y$P!T;F=X+3(P,C$Q,C,Q7V-A;"YX;6Q02P$"% ,4
M" #N/7Q4"2!S9OP_  #%ZP0 %0              @ &F"A0 =&YG>"TR,#(Q
M,3(S,5]D968N>&UL4$L! A0#%     @ [CU\5.D3V(XOV@  ,M8) !4
M         ( !U4H4 '1N9W@M,C R,3$R,S%?;&%B+GAM;%!+ 0(4 Q0    (
M .X]?%0XJ>_UB%L   U-!P 5              "  3<E%0!T;F=X+3(P,C$Q
M,C,Q7W!R92YX;6Q02P$"% ,4    " #N/7Q49X2WF3Z< 0# S@X $
M        @ 'R@!4 =&YG>"UE>#$P7S$T+FAT;5!+ 0(4 Q0    ( .X]?%11
MOGCI2 (  #0(   /              "  5X=%P!T;F=X+65X,C-?,2YH=&U0
M2P$"% ,4    " #N/7Q4RN/>)Q4(  !R0@  #P              @ '3'Q<
M=&YG>"UE>#,Q7S$N:'1M4$L! A0#%     @ [CU\5'I0HOD9"   Y4$   \
M             ( !%2@7 '1N9W@M97@S,5\R+FAT;5!+ 0(4 Q0    ( .X]
M?%2 @/F$P 0  $T@   /              "  5LP%P!T;F=X+65X,S)?,2YH
M=&U02P$"% ,4    " #N/7Q4V@D2];X$  !,(   #P              @ %(
M-1< =&YG>"UE>#,R7S(N:'1M4$L! A0#%     @ [CU\5&5&ZH?C$P  5KP
M  X              ( !,SH7 '1N9W@M97@T7S(N:'1M4$L%!@     B "(
*@ @  $).%P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
